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Summary 
This thesis summarises a selection of forty-two studies [1-42], published by the author 
during the period 2000-2012, investigating the conceptual basis of Insomnia Disorder, 
and its evaluation and treatment, principally using cognitive and behavioural 
interventions.a The work reflects a range of research methodologies including 
experimental, psychometric, qualitative and population-based studies, and randomised 
controlled trials. Important theoretical contributions to the literature published in this 
period are also included and reference is made to major textbooks, position papers, and 
influential chapter contribution.  
The Research Diagnostic Criteria (RDC, 2003) for Insomnia Disorder refer to persistent 
difficulty with initiating and/ or maintaining sleep with associated daytime consequences 
[11]. Despite the latter symptoms being important ‘drivers’ of clinical complaint, they 
have been relatively neglected. Therefore, proposed refinements of clinical and RDC 
criteria, in the Diagnostic and Statistical Manual of Mental Disorders (5
th
 edition: DSM-5, 
due 2013), have been evaluated in large scale field trials. Our studies have revealed that 
the daytime sequelae of Insomnia Disorder comprise two statistically robust principal 
components; daytime performance deficits (in concentration, productivity and 
sleepiness) and compromised interpersonal and social functioning (low energy, mood, 
relationship problems) [41].  Alongside such night-time and daytime symptoms, people 
                                                           
a
 The thesis specifically excludes other works by the author, during the same period, on sleep disorders in 
special populations (e.g. learning disabilities/mental retardation, acquired brain injury, pain), on other 
sleep disorders (e.g. sleep apnoea) and on other disorders (e.g. epilepsy). The thesis also excludes 
published studies where the author contributed as a co-investigator to work initiated by international 
collaborators. On all included data-based papers the author is first, second or last named in the authorship 
list. 
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with insomnia exhibit reciprocally interacting behavioural, cognitive and emotional 
concerns about poor sleep which perpetuate the disorder and adversely affect quality of 
life [28]. Indeed, contemporary thinking about the aetiology and maintenance of 
persistent Insomnia Disorder incorporates variants of the ‘psychology’ of sleep [35]. The 
International Classification of Sleep Disorders (second revision; ICSD-2, 2005) certainly 
emphasises such phenotypical features, particularly in relation to Psychophysiological 
Insomnia, the most common form of insomnia in adults. We have reported sensitivity 
and specificity characteristics for this (and other) forms of insomnia, showing that 
cognitive behavioural features may be an important target for clinical intervention [9, 12, 
21, 37]. Indeed, our Psychobiological Inhibition Model of insomnia [PIM: 6] and its 
presumed Attention-Intention-Effort Pathway [A-I-E: 16] have been at the forefront of 
understanding insomnia as a disorder of sleep preoccupation, and difficulty in down-
regulating arousal at bedtime and during the night. Importantly, experimental studies 
using novel computer-based paradigms of selective attention bias have provided 
confirmatory data of the PIM/A-I-E model [13, 15, 19, 25]. Likewise, our qualitative and 
psychometric scale development studies have yielded reliable and valid instruments to 
capture cognitive/ attributional data for both descriptive and treatment outcome 
purposes [1, 2, 10, 14, 24, 29], such that many of our measures are recommended by 
international review groups [18].  Further studies have pointed to the reactivity of people 
with Insomnia Disorder to naturally occurring and experimental stimuli [21, 32]. A logical 
extension of all these findings has been to apply randomised controlled trial (RCT) 
methodology to investigate the efficacy and clinical effectiveness of cognitive 
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behavioural therapy (CBT) for insomnia. We have developed and tested a novel mode of 
community nurse-delivered, small group CBT across two relatively unselected primary 
care samples [3, 22] employing a treatment as usual (TAU) control group, to reflect real 
world evaluation. This manualised CBT programme ensured robust levels of treatment 
standardisation, and findings demonstrated statistically and clinically significant benefits 
to sleep pattern and daytime wellbeing that were maintained at 6 to 12 month follow up 
[3, 4, 5, 22]. One consequence of this work has been a demand for dissemination of CBT 
methods, both to clinicians and direct to the public. Collaboration with a Canadian 
colleague, therefore, led to the publication of a clinician’s handbook in 2003 [8], which 
was subsequently translated into Italian and Mandarin; and publication of a ‘self-help’ 
book in 2006 [20] which is now available in French, Italian and Danish, with other 
translations in progress. The RCT methodology was then extended in a further trial 
where cancer patients with persistent insomnia were treated by cancer nurse specialists 
who had been trained in CBT [23]. Again, very favourable results were obtained at post-
treatment and follow-up, and this work was subsequently recognised as the Best Patient 
Support Initiative at the UK National Oncology Awards in 2009, and received the Pfizer 
Prize. Recent systematic reviews by international peer groups have highlighted these 
three trials [3, 22, 23] in their evidence-based guidelines for clinically effective insomnia 
therapies [17, 33]. So Insomnia Disorder is a very common and durable disorder [39], 
which can be effectively treated with CBT, however, a major obstacle in practice 
continues to be the paucity of services available, to provide an alternative to 
pharmacotherapy. This is despite the evidence that a CBT approach would be preferred 
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by most patients [37].  Our further response to this situation has had several research 
strands. First, to suggest how services might be delivered in a cost-effective way using a 
stepped care model [26]; second, to explore abbreviated CBT by investigating its 
component strategies and their efficacy [7, 27, 34]; and third, to simplify the self-help 
proposition by publishing a very brief guide to CBT for insomnia [36] and using web and 
mobile technology to deliver CBT online. In relation to the latter, we recently published a 
placebo controlled RCT of a rich media, online CBT programme where the intervention 
was delivered by an animated virtual therapist. [40, 42]  Results from this trial mirror the 
effects and effect sizes typically obtained in face-to-face therapy for sleep variables, 
daytime benefits and sleep-related attributions and thinking styles, thus suggesting that 
online CBT could (at least) provide an effective entry level treatment for a stepped care 
service. Finally, we have endeavoured to strengthen the dissemination of knowledge and 
good practice about Insomnia Disorder through overview papers in selected influential 
textbooks [30, 31] and through planning and co-editing the Oxford Handbook of Sleep 
and Sleep Disorders [38] which is a 900 page reference book that was published in 2012.  
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Spiegelhalder), Italy (Dr Chiara Baglioni) and the Netherlands (Ilja Croijmans) and to 
support clinicians in training, most particularly Consultant Neurologist Dr Ian Morrison. 
Other clinicians too have made a notable contribution to the research including Drs Rod 
Duncan (neurology), Brian McKinstry and Phil Wilson (general practice), Aline Russell 
(clinical neurophysiology) and Breda Cullen (clinical neuropsychology). At the time of 
writing I am very proud to say that two postgraduates have just been awarded their PhDs 
(Dr Chris Harvey, Dr Megan Crawford) and a third (Chris Miller) has successfully 
completed the second year of his PhD as part of a Cotutelle Studentship arrangement 
with the University of Sydney. Louise Beattie (supervised in her PhD primarily by 
Stephany Biello) has also been an integral part of the work at UGSC.  
I have been very fortunate over the years to have had excellent administrative support in 
my NHS and university positions. Anita McClelland above all deserves special mention, 
having worked with me not only in the NHS in Ayrshire but also as my departmental 
administrator in Psychological Medicine and latterly as the Business Manager of UGSC. 
Anita has been a tremendously loyal colleague, as well as a good friend. In recent years 
Louise McFadzean joined the team and has proven to be a thoughtful, diligent and 
enthusiatic PA. I am very grateful to Louise and also to Shona Currie who has become the 
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‘voice’ of UGSC by dealing so capably with telephone enquiries and initial screening/ 
recruitment to our studies.  
I have always believed in the virtuous link between research, teaching, and clinical 
practice. With this in mind we developed the online Masters Programme in Behavioural 
Sleep Medicine. Dr Jason Ellis, Dr Marina Malaffo and Anita McClelland helped me to 
develop the concept and the proposed curriculum, and Asha Ginda and Drs Chris Harvey 
and Megan Crawford helped make it a reality.  This has been an interesting journey! At 
the time of writing the MSc (MedSci) has attracted health professionals from 12 
countries around the globe. Asha has been an inspiration in marketing and student 
support, and Chris and Megan have done a great job in advising and encouraging this 
interdisciplinary group of postgraduates. 
Of course, research these days is also an international affair and I would like to 
acknowledge and thank my collaborators, near and far. In the UK in particular I would 
mention Prof Kevin Morgan (Loughborough University), Dr Alice Gregory (Goldsmith’s 
College, London; external examiner to our Masters programme), Dr June Brown (Institute 
of Psychiatry, London), Prof Niro Siriwardena (University of Lincoln), Prof Sir Neil Douglas 
(University of Edinburgh), Dr Brian McKinstry (University of Edinburgh) and Dr Leslie 
Samuels (NHS Grampian and University of Aberdeen); plus colleagues I have not 
previously mentioned at the University of Glasgow – Prof Jim Cassidy (Oncology), Prof 
David Morrison (Public Health), and Dr Michaela Benzeval and Prof Kate Hunt (MRC-
SHPSU). Further afield it has been my honour to collaborate with Prof Charles Morin and 
Dr Annie Vallières (Université Laval, Quebec City) on grants funded by the Canadian 
Institutes of Health Research, with Prof Ron Grunstein and Dr Delwyn Bartlett [University 
of Sydney: National Health and Medical Research Council (Australia)] and with Prof 
Michael Perlis (University of Philadelphia: NIH collaborative R-01 grant). Other key 
collaborators and senior colleagues whose support I have valued include Prof Jack 
Edinger (University of Colorado, Denver), Prof Allison Harvey (University of Berkeley, Ca), 
Prof Dick Bootzin (University of Arizona), Prof Rachel Manber (University of Stanford, Ca), 
Prof leoon Lack (Flinders University, Adelaide), Prof Bjørn Bjorvatn (University of Bergen), 
Prof Eus van Someren (University of Amsterdam) and Prof Dieter Riemann (University of 
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Freiburg). All of these international figures have also become firm friends, and along with 
a cast of others, we have enjoyed many stimulating and productive discussions and 
debates at congresses and work groups worldwide. 
As well as contributing to the scientific literature on insomnia, I have written or edited a 
number of books on sleep and its disorders. I am grateful in particular to the editorial 
teams at Kluwer Academic/ Plenum, Constable & Robinson, and Oxford University Press 
for their advice support and direction, and to their marketing teams for promoting these 
works. My closest professional collaborator, and dearest friend in the professional 
sphere has been Prof Charles Morin. I first met Charles at a conference in 1988, and since 
then we have worked closely together on many projects including our co-written 
clinician’s textbook (2003) and our co-edited Oxford Handbook published in 2012. I am 
grateful to Charles for this friendship, and for his outstanding leadership in the field. 
I have enjoyed participating in the work of national and international societies. I am 
grateful to Prof Mary Morrell (Imperial College, London) for all the support she gave me 
in my role as Conference Chair when the British Sleep Society hosted the European Sleep 
Research Society (ESRS) Annual Meeting in Glasgow in 2008. I am grateful also to the 8 
members of the ESRS Scientific Committee who served with me when I was Chair of that 
committee leading up to the ESRS Paris meeting this year (2012).  I have been privileged 
to work on the editorial boards of several journals and acted as Associate and then 
Deputy Editor for the Journal of Sleep Research (Editor: Prof Derk-Jan Dijk, University of 
Surrey) and the American Academy of Sleep Medicine journal SLEEP (Editor: Prof David 
Dinges, University of Philadelphia). Thank you Derk-Jan and David for your support and 
mentorship. 
In the past few years some of my research took on a new and unanticipated direction 
after being contacted by Peter Hames.  Peter is a graduate in Experimental Psychology 
from the University of Oxford, but he has built a reputation as an entrepreneur in the 
online business sector. Together we have developed Sleepio, a 100% online CBT 
programme delivered by a virtual sleep expert, the Prof. Our collaboration has brought 
together high quality research and first class digital expertise. This has proven to be a 
tremendously productive working relationship as well as great fun. We share a passion 
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for making CBT available – one of the biggest challenges of our times. Peter has injected 
expertise in the execution of health behavior change into Sleepio, and his unrelenting 
focus on optimizing the user experience complements my clinician/ researcher 
perspective upon best patient care.  I am particularly grateful to Peter and to the team 
(including Rob Mildenhall, Brandon Paluzzi, Rosie Gollancz and Sapana Agrawal) we have 
built at Sleepio for making these past few years amongst the best in my professional 
career. 
In ‘retirement’ now from Glasgow University (2012) I am proud to be an Emeritus 
Professor of Clinical Psychology; but equally proud to be starting (again) in February 2013 
as a Professor in the Nuffield Department of Clinical Neurosciences at the University of 
Oxford. The Sleep & Circadian Neuroscience Institute funded there by The Wellcome 
Trust and the University of Oxford promises much. I hope that I can go some way to 
helping Professors Russell Foster, Guy Goodwin, Daniel Freeman and many others deliver 
on that promise. 
Finally, I want to acknowledge and thank the people who mean the most in the world to 
me. Without my family all this would be meaningless. My wife, Audrey is my best friend, 
stronghold and soul-mate. She is also a better clinical psychologist than I am! My children 
Craig, Carolyn and Robbie are the best that any dad could ever hope for. I am more 
proud of them than words can express; and our grand-daughter Mia is certainly the 
cutest 1-year old ever. Thank you too mum and dad for supporting me, all those years 
ago, in the idea that psychology was a good career choice, when others had their doubts!   
 
Example is not the main thing in influencing others.  It is the only thing.   
[Attributed to Albert Schweitzer (1875–1965); lived by Alexander S. Espie (1925–1975)] 
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1. General Introduction 
1.1 What is insomnia? 
Insomnia is characterized in diagnostic nosologies by persistent difficulty in initiating 
sleep, maintaining sleep, or waking early, or by sleep which is chronically non-restorative 
despite adequate sleep opportunity (cf. DSM-IV, ICSD-2). The clinical presentation is 
commonly that of a frustrated patient with a racing mind, trapped in a vicious circle of 
anxiety and poor sleep, reporting having “tried everything,” and generally being unable 
to down-regulate arousal levels in bed. Insomnia also causes daytime impairments, 
including fatigue, inattention, and mood changes, and negative effects upon cognition 
and performance. Research diagnostic criteria (RDC) for insomnia emphasise the 
importance of assessing both night-time and daytime symptoms. Indeed, concerns about 
daytime functioning and wellbeing are common drivers for help-seeking behavior. The 
presence of excessive daytime sleepiness (EDS), however, is relatively unusual in 
insomnia. When EDS is a prominent complaint, investigations for other sleep disorders 
should normally be considered, including obstructive sleep apnoea syndrome (OSA), 
narcolepsy, periodic limb movement disorder (PLMD), and restless legs syndrome (RLS).  
 
Table 1 Differentiation of insomnia phenotypes in ICSD-2 (adapted from Espie & Bartlett, 2009) 
 
In ICSD-2, specific insomnia phenotypes are proposed (Table 1), with Psychophysiological 
Insomnia being the most common ‘primary’ form, presenting in clinical practice, with 
Paradoxical Insomnia and Idiopathic Insomnia much less common. The diagnosis of 
Inadequate Sleep Hygiene is seldom used. It should be noted, however, that 
contemporary thinking (cf DSM-5) reflects the use of the single term ‘Insomnia Disorder’ 
(rather than primary vs. secondary) because of mounting evidence that sleep disruption 
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is more often co-morbid with medical or psychiatric disorders (rather than caused by 
them). Indeed, insomnia is now a recognized risk factor for the evolution of, or relapse 
into, disorders like depression. 
1.2 How common is insomnia? 
Community psychiatric morbidity data show that sleep disturbance is the most common 
symptom of mental disease, regardless of age, sex, or ethnic group. Indeed insomnia is 
more common than worry, and twice as common as anxiety or depressive symptoms. 
Insomnia affects one-third of adults occasionally, and 9–12% on a chronic basis. It is 
more commonly reported in women, shift workers, and patients with medical and 
psychiatric disorders. Among older adults, prevalence has been estimated at 25%, 
although co-morbid conditions and hypnotic drugs are factors in this increased 
prevalence. Typically, insomnia is associated with impaired work productivity, reduced 
quality of life and relationship satisfaction, as well as increased ill health. The importance 
of insomnia to public health is illustrated by national annual costs ($92 to $107 billion 
USD in USA), and its cost per untreated case ($5,000 CAD in Canada). 
1.3 What is the aetiology of insomnia? 
Many patients report having been marginal light sleepers before developing insomnia. 
Sleep disturbance often arises during life change or stress, and such adjustment sleep 
disorder may represent a normal transient disruption of sleep. However, secondary 
factors, such as anxiety over sleep and faulty sleep–wake conditioning, may exacerbate 
and maintain the insomnia as a chronic problem when sleep itself becomes a focus for 
concern. People with insomnia may be hyperaroused relative to normal sleepers, for 
example having higher levels of cortisol and ACTH, and also find it difficult to ‘down-
regulate’ their arousal at bedtime. 
1.4 What is the course of and prognosis for insomnia? 
There has been relatively little research on the natural history of insomnia. However, 
untreated Psychophysiological Insomnia (PI) can last for decades, and may gradually 
worsen over time. Indeed, there is a normal developmental trend for sleep patterns to 
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deteriorate, with increasing age. On the other hand, delayed sleep-phase syndrome 
(DSPS: a circadian rhythm sleep disorder) and insufficient sleep hygiene can be 
associated with developmental stage and/or lifestyle factors and may ameliorate as 
these are resolved. Although certain insomnias tend to persist if untreated, prognosis 
with effective treatment can be very good. 
1.5 How can insomnia be treated? 
1.5.1 Pharmacotherapy 
Traditionally, insomnia has been treated pharmacologically. Barbiturates were 
superseded by benzodiazepine (BZ) compounds during the 1960s and 1970s. These drugs 
were safer in overdose, were thought to have fewer side effects, and to be less addictive. 
Controlled studies have demonstrated that a considerable number of BZ, of short to 
intermediate half-life, are effective hypnotic agents. However, from the mid-1970s 
potential problems became apparent, both during administration and withdrawal. 
Longer-acting hypnotics were prone to carry-over effects of morning lethargy, and 
shorter-acting drugs to ‘rebound insomnia’. Furthermore, tolerance develops, leading 
either to increased dosing or switching to alternative medication. Although BZs used for 
short periods/intermittently can maintain effectiveness, these are not the treatment of 
choice in chronic insomnia, and are contraindicated in older adults and where insomnia 
may involve sleep-related breathing disorder because of their potentially depressant 
effects on respiration. A number of BZ compounds have been removed from the market 
in the United Kingdom, United States, and elsewhere. Contemporary hypnotic therapy 
has extended to include BZRAs (benzodiazepine receptor agonists; often referred to as 
the ‘z’ drugs), and more recently melatonin receptor agonists (MeRAs) have been 
introduced. Whereas the place in therapeutics of MeRAs has yet to become established, 
the BZRAs are often thought to offer more sustained benefit for insomnia, and to have 
fewer adverse effects. Nevertheless, there remains uncertainty about the effectiveness 
of BZRAs in chronic insomnia. 
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Table 2 Summary of CBT components for the treatment of chronic insomnia (adapted from Espie 
& Bartlett, 2009) 
 
1.5.2 Psychological Therapy 
Psychological treatment for chronic insomnia, primarily in the form of cognitive 
behavioural therapy (CBT), has been extensively investigated in over 100 controlled 
studies during the past 20 years. Five meta-analyses and numerous systematic reviews 
have demonstrated that CBT is associated with large effect size changes (measured in 
standardized z scores) in the primary symptom measures of sleep latency (difficulty 
getting to sleep) and wake time after sleep-onset (difficulty remaining asleep). Around 70 
per cent of patients with persistent sleep problems appear to benefit from CBT and 
effects are maintained to long-term follow-up. It is thought that CBT achieves these 
outcomes because it tackles directly the dysfunctional thoughts and maladaptive 
behaviours that otherwise maintain insomnia. Recent controlled studies have shown that 
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CBT may be effective in general practice settings with nurses delivering the intervention 
according to a standard protocol. Despite the superior efficacy of CBT relative to 
medication for insomnia, and these recent demonstrations of CBT working in real-world 
settings, practical problems remain in making CBT widely available. Within the CBT 
model, a number of strategies have strong empirical support. Behavioural procedures 
such as stimulus control and sleep restriction, and cognitive strategies such as 
paradoxical intention and thought restructuring have been extensively investigated and 
are outlined in Table 2. 
1.5.3 Melatonin, light therapy and exercise 
The pineal hormone melatonin has been the subject of highly publicized claims. 
However, controlled scientific research has been more limited. Several studies support 
its sleep-promoting effects, especially as a chronobiotic for phase advancing sleep-onset. 
Several MeRA products are now licensed, and more may be available soon. Bright light is 
a potent marker for human circadian rhythms, and has been known for some time to 
enable the resetting of such rhythms in advanced sleep-phase syndrome and delayed 
sleep-phase syndrome. The results of studies investigating the efficacy of bright light 
against psychological treatments for psychophysiological insomnia are somewhat 
preliminary, but nonetheless promising, as is the combination of CBT and light therapy 
for insomnia. However, a limiting factor to the value of light therapy is that continued 
treatment may be required to maintain therapeutic effects. Athletic people sleep well, 
although this may be more to do with behavioural patterning than aerobic fitness. 
Nevertheless, there is evidence that exercise can have positive effects upon sleep quality, 
particularly if taken late afternoon or early evening, and in otherwise relatively fit 
individuals. Morning exercise can also be an effective modality to encourage the same 
waking time and early morning light exposure; which help to reset sleep patterns on a 
daily basis. 
 
1.6 What is Behavioural Sleep Medicine? 
As defined by the American Academy of Sleep Medicine (AASM) the domain of 
Behavioral Sleep Medicine (BSM) comprises the behavioural dimension of normal and 
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abnormal sleep mechanisms and the prevention, assessment, and treatment of sleep 
disorders and associated behavioural and emotional problems through the application of 
established principles of behaviour change. From this definition it should be clear that 
BSM is more than CBT, and that BSM relates to all aspects of sleep disorder, and not just 
to insomnia. 
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2. Introduction to the Published Work 
2.1 Work included in and excluded from the thesis 
The thesis comprises a selected body of work (42 outputs), published during the period 
2000-2012, investigating the conceptual basis of Insomnia Disorder, and its evaluation 
and treatment, principally using cognitive and behavioural interventions. On all data-
based papers the author is first, second or last named in the authorship list. The thesis 
specifically excludes other works by the author, during the same period, on sleep 
disorders in special populations (e.g. learning disabilities/mental retardation, acquired 
brain injury, pain), on other sleep disorders (e.g. sleep apnoea) and on other disorders 
(e.g. epilepsy). The thesis also excludes published studies where the author contributed 
as a co-investigator to work that was initiated by collaborators. 
2.2 Methodological approaches 
The work is selected to reflect a range of research methodologies including experimental, 
psychometric, qualitative and population based studies, and randomised controlled 
trials. Important theoretical contributions to the literature published in this period are 
also included and reference is made to major textbooks, position papers, and influential 
chapter contribution.  
2.3 The structure of the thesis 
In Chapter 3, papers are first presented within sections pertaining to each of the 
following 4 major themes:  
a. Pathophysiology and conceptualisation of insomnia (section 3.2) 
b. Clinical and psychometric appraisal of insomnia (section 3.3) 
c. Cognitive behavioural treatment of insomnia (section 3.4) 
d. Dissemination of evidence-based practice (section 3.5) 
At the start of each section, the inter-relationships between the various papers included 
in the section are summarized, to help place the work in the context. Papers are then 
introduced in turn along with a brief synopsis of their impact (see 2.4 below).  
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Chapter 4 provides a reference list relating to selected citations and Chapter 5 comprises 
reproduction of the full papers in published form. These papers are of course self-
contained, with an abstract, a methods section which describes the approach taken, a 
results section which describes the data and a discussion which puts these specific 
findings in context at the time of publication. 
2.4 Evaluation of the contribution of the published work 
The approach taken was to identify papers which subsequently cited each of the 
individual outputs. This was achieved by conducting a citations search on the ISI Web of 
Knowledge website on 10 August 2012. Of course, for some papers, particularly those 
published recently, there had been relatively little change in the literature since the 
publication. However, many of the papers in the thesis have been extensively cited. In 
particular, examples are reported of current or recent citations to demonstrate the 
enduring impact of the published work.  
It should be noted that background knowledge, relevant to placing each published work 
in context, is summarized briefly, but is not specifically referenced. This is for two 
reasons. First, it is not the purpose of this evaluation of the published work to present a 
comprehensive overview of the sleep/insomnia literature; this is available elsewhere 
[e.g. Morin & Espie, C.A. (2012) The Oxford Handbook of Sleep and Sleep Disorders]; and 
second, including such references could obscure the cited references that are provided 
as examples of the impact of the work. 
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3. The Published Work 
3.1 Citation Search  
Results from the Web of Knowledge search indicated an Average Citation per Item of 
39.8 (range 0 – 215) when taking into account citable papers, across the first three 
themes. The impact of the fourth theme (on dissemination) is evidenced in other ways. 
3.2 Pathophysiology and conceptualisation of insomnia 
This section comprises a series of 10 papers investigating behavioural, mental, emotional 
and physiological aspects of insomnia, and the inter-relationships between them.  
Average Citation per Item for papers in this section was 32.5 (range 0 – 122). 
Studies are theory-testing or theory-building in nature, with the general aim of improved 
understanding of aetiological and maintaining factors for insomnia disorder. There is a 
particular focus upon factors that might be modifiable through cognitive behavioural 
intervention; and the exploration of novel candidate mechanisms for targeting 
assessment and treatment. Here and elsewhere in the thesis, papers are largely 
introduced in chronological order of their publication. 
3.2.1 Wicklow, A. and Espie, C.A. (2000) Intrusive thoughts and their relationship to 
actigraphic measurement of sleep: towards a cognitive model of insomnia. 
Behaviour Research and Therapy 38, 679-693 [Cited 78 times] 
Cognitive factors seem to be particularly important in the maintenance of insomnia, and 
perhaps also in its aetiology. Certainly patients presenting clinically complain that falling 
asleep is, in large measure, a mental obstacle. CBT, therefore addresses not only the 
behavioural aspects of sleep scheduling (the ‘what to do’), but also these cognitive and 
emotional challenges (how to deal with the mind).  Traditionally, such data have been 
gathered retrospectively on a questionnaire or self-report rating scale, or prospectively 
on some kind of thought record or diary. However, it is important to validate the content 
of wakeful thinking in insomnia with ‘real time’ data; sometimes referred to as ‘hot’ 
cognitions. Moreover, model-building for insomnia requires us to investigate the 
temporal association of such thoughts and with the sleep initiation problems reported by 
people with insomnia. 
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In this study, therefore, we developed a novel approach to measure mental events. 
Participants kept a voice-activated audiotape-recorder at their bedside and were asked 
to speak aloud what was going through their minds during periods of wakefulness. These 
thoughts were then content-analysed, themed, and related to objective estimates of 
sleep, using actigraphy.  The actigraph is a small device worn like a wristwatch on the 
non-dominant hand. It contains a micro-processor/ accelerometer unit that detects and 
stores movement data in 1-minute bins (epochs). Because movement is a good proxy for 
wakefulness, and absence of movement for sleep, proprietary software can estimate 
periods of sleep and wakefulness and so construct an objective profile of the main sleep 
parameters. Another practical advantage is that actigraphy is relatively non-instrusive.  
This study has been cited 72 times and continues to be well cited, even 12 years after 
publication. For example, recent studies exploring pre-sleep cognitive arousal include 
Tang et al (2012), Wuyts et al (2012) and Suh et al (2012).  Indeed, interventions are 
increasingly targeting such intrusive and worrisome thinking. Jansson-Fromark et al 
(2012) investigated whether a constructive worry (CW) intervention added to the effects 
of behaviour therapy (BT).  A randomized, controlled design was used including a 2-week 
baseline, a 4-week intervention phase (sleep restriction and stimulus control [BT] or 
sleep restriction and stimulus control plus constructive worry [BT + CW]), and a 2-week 
follow-up. Compared to BT, BT + CW led to a larger decrease in insomnia severity at all 
three time points (d= 1.10). In comparison with BT, BT + CW also resulted in a larger 
reduction in worry at two of the time points (d= 0.76). The work has been influential not 
only in reports of adult populations but also in studies exploring mental factors across 
the lifespan e.g. work on repetitive negative thoughts in children and adolescents 
(Broeren et al, 2011; Alfano et al, 2010) and cognitive style in older adults aged 65-84 
years (Willis et al, 2011). 
3.2.2 Espie, C.A. (2002) Insomnia: Conceptual issues in the development, persistence 
and treatment of sleep disorder in adults. Annual Review of Psychology 53, 215-
243 [Cited 122 times] 
This invited paper posited the Psychobiological Inhibition Model (PIM) for the first time. 
The PIM is an explanatory and testable conceptualization of insomnia, contrasting 
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insomnia with normal (involuntary) sleep. Good sleepers seem to sleep without any 
difficulty. They are not good sleepers because they are (actively) good at sleeping. 
Rather, they seem passively to allow sleep and circadian drive to do its work. People with 
insomnia, on the other hand seem to have a highly activated sleep intention. The PIM 
explains how attentional processing in relation to sleep, and failure to sleep, dysregulates 
the normal sleep process – much in the same way that concern about breathing causes 
respiratory dysregulation or anxiety about sexual response promotes impotence. 
The PIM draws on the experimental cognitive literature on selective attention to derive 
objective computerized tests of attentional bias, and to lay out a research agenda to 
evaluate the model. Our first experiment adapted the emotional Stroop task to 
investigate attentional bias in people with acute versus persistent insomnia secondary to 
cancer (Taylor et al, 2003: not included in this thesis). Our subsequent studies employed 
other task such as the Inducing Change Blindness [ICB: Jones et al, 2005 (3.2.3); Macphee 
et al, 2006 (3.2.4), Dot Probe: MacMahon et al, 2006 (3.2.6), and Modified Posner: 
Woods et al, 2009 (3.2.8) paradigms]. A further conceptual piece followed [Espie et al, 
2006 (3.2.5)] and a large C-R01 (collaborative) grant from the National Institutes of 
Health (NIH) was awarded (2007-2012) to take this work forward. The data from this 
extensive study are being collated at the time of writing. 
The influence on the field of the PIM model is evident in that the paper in Annual Review 
of Psychology has been cited 122 times. Other research groups have investigated the 
model directly using similar attentional paradigms (e.g. Spielberger et al, 2008) and 
indirectly with other methodologies such as Event Related Potentials (ERP: Bastien et al, 
2008a) and the examination of sleep EEG microstructure (Bastien et al, 2008b). The 
paper has also been widely cited not only in ‘primary’ insomnia but also in studies of 
insomnia associated with co-morbidities, and in animal models of insomnia (Cano et al, 
2008). To illustrate the influence of the paper, even 10 years after publication, studies 
citing the model in 2011-2012 include work on insomnia related to osteoarthritic (Von 
Korff et al, 2012) and other chronic pain (Tang et al, 2011, McCracken et al, 2011), 
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myocardial infarction (de Zambotti et al, 2011), cancer (Kim and Oh, 2011), anxiety, 
depression and bipolar illness (e.g. Maroti et al, 2011; Stone et al, 2012; Harvey, 2011). 
3.2.3 Jones, B.T., Macphee, L., Broomfield, N.S., Jones, B.C. and Espie, C.A. (2005) 
Sleep-related attentional bias in good, moderate, and poor (primary insomnia) 
sleepers. Journal of Abnormal Psychology 114, 249-258 [Cited 21 times] 
This study was the first in the field to use the ICB paradigm in insomnia research. The 
task is essentially ‘spot-the-difference’, where the dependent variable is the number of 
flickers (transitions between the original stimulus screen, a mask screen, and the 
changed screen) it takes for the participant to notice which object is missing from the 
array. The hypothesis is that people with insomnia will have a selective attentional bias 
towards sleep-related objects, and so will spot a change in one of those objects more 
quickly than good sleepers, for whom sleep objects are essentially neutral. This study 
confirmed that people with insomnia display selective attention towards sleep cues, and 
so lent support to the underlying PIM/ A-I-E model. 
The paper has been well cited, for example, by a group in Germany who have engaged in 
a series of experimental replication and extension studies over several years 
(Spiegelhalder et al, 2008, 2009, 2010). The paper has been shown to be sound 
methodologically, and has been included in a major review of sleep misperception 
(Harvey and Tang, 2012) and a meta-analysis of daytime performance in insomnia 
(Fortier-Brochu et al, 2012). New variants of the ICB have emerged e.g. its adoption in 
repeated measures experiments (Moss et al, 2011) and the paper is cited in the 
development of structural equation approach to insomnia (Schmidt et al, 2010) and the 
emergence of new priming (Ree and Harvey, 2006) and clock monitoring paradigms 
(Tang et al, 2007). 
3.2.4 Macphee, L.M., Biello, S.M., Broomfield, N.M., MacMahon, K.M.A. & Espie C.A. 
(2006) Who is pre-occupied with sleep?: A comparison of attention bias in 
people with Psychophysiologic Insomnia, Delayed Sleep Phase Syndrome and 
Good Sleepers using the Induced Change Blindness paradigm. Journal of Sleep 
Research 15, 212-221 [Cited 22 times] 
In this second ICB study we were concerned to test our PIM/ A-I-E model of insomnia 
against a clinical comparator condition (DSPS). Perhaps selective attention bias to sleep 
37 
 
cues is an epiphenomenon of having any sleep problem or concern about your sleep, 
rather than something specific to insomnia? Our results indicated that people with 
insomnia (a psychophysiological condition) did exhibit selective attention bias, whereas 
those with DSPS (a chronobiological condition affecting the timing of sleep engagement) 
did not. These data then supported our hypothesis. 
This paper, like Jones et al (3.2.3) has been cited by other research groups who have used 
our paradigm. Repeat citations will not be mentioned here. Rather, it is noteworthy that 
this paper led to our work being recognized also in the field of circadian physiology and 
the treatment of circadian elements of sleep disorders (e.g. Lack and Wright, 2006; Auger 
et al, 2011). In parallel with our work on objective evaluation of attentional bias, other 
groups have worked on new self-report measures that may be used in parallel with our 
computerized tasks [e.g. the Sleep Associated Monitoring Index (SAMI); Chan et al, 
2012]. Finally, this study and our broader programme of work have been recognized as 
contributing to inter-disciplinary developments in cognitive science (Jensen et al, 2011). 
3.2.5 Espie, C.A., Broomfield, N.M., MacMahon K.M.A., Macphee, L.M. & Taylor, L.M. 
(2006) The attention-intention-effort pathway in the development of 
Psychophysiologic Insomnia: a theoretical review. Sleep Medicine Reviews 10, 
215-245 [Cited 57 times] 
This paper was a sequel to our 2002 paper on the PIM (3.2.2), and it articulated in some 
detail what we had begun to refer to as the Attention-Intention-Effort pathway from 
acute/ transient insomnia to persistent psychophysiological insomnia. In brief, the paper 
describes how normal good sleep becomes upset at times of stress. There is a natural 
hyperarousal response at that time, which probably confers evolutionary survival value, 
making the person more alert/ responsive, and thereby also having symptomatic 
insomnia. The person’s focus of attention remains selectively on the perceived source of 
the stress (e.g. illness, work problems, uncertainty about a specific situation or outcome). 
This then equates to a transient or adjustment form of insomnia. However, upon 
resolution of or adaptation to the stressor, sleep may not immediately recover, leading 
to the person (already primed to be in response mode) to become aware that they are 
not able to sleep. This switch in attention to the sleep process is then regarded as 
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challenging the ‘Achilles heel’ of sleep regulation (that it works well automatically but 
poorly when we try to sleep). A vicious cycle may then quickly evolve where increased 
concern about sleep leads to not only attention but to explicit intention and effort to 
sleep. 
The paper, published in Sleep Medicine Reviews, has been cited 57 times; that is 
approximately 10 times per year since publication. Indeed, it remains influential, with 12 
citations of the A-I-E model appearing between January and August 2012. One example is 
the study by Mitchell, Mogg & Bradley (2012) investigating relationships between 
insomnia, negative emotionality and attention control. They found that insomnia was not 
only associated with negative emotionality (combination of worry, somatic anxious 
arousal and rumination), but also with the interactive effect of poor attention control 
and negative emotionality. Thus, they concluded that poor attention control may further 
contribute to sleep difficulties in individuals with high negative emotionality. Hamilton et 
al (2012) have also leaned heavily on the A-I-E pathway in presenting their Sleep and Pain 
Diatheses model of fibromyalgia (FM). They propose that a wide range of biopsychosocial 
stressors can set the stage for FM by activating diatheses for sleep disruption and pain 
sensitivity. They say that sleep disruption, in those most sensitive to pain, initiates a 
cascade of symptoms that are codified as FM. Once this process is initiated, the 
symptoms of FM are perpetuated and aggravated by increased vigilance to a broad range 
of threat-related biopsychosocial stimuli. Thus, it is proposed that sleep is integral to the 
etiology of FM and also energizes a cognitive feedback loop that maintains or amplifies 
symptom severity over time. 
 
3.2.6 MacMahon, K.M.A., Broomfield, N.M., Macphee, L.M. and Espie, C.A. (2006) 
Attention bias for sleep-related stimuli in primary insomnia and delayed sleep 
phase syndrome. Sleep 29, 1420-1427 [Cited 12 times] 
Having utilized the ICB task in two studies, here we investigated attentional bias using 
the Dot Probe paradigm. This is another ‘standard’ methodology found in the 
experimental cognitive literature that we were the first to adapt and instrument for the 
insomnia field. The Dot Probe overcomes some of the methodological criticisms that 
have been leveled particularly at the Stroop task. The paper provided further evidence 
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for the specificity of selective attention mechanisms at work in the aetiology of insomnia, 
because we also included a DSPS clinical comparison group. Like our previous studies this 
paper was well received, and contributed further evidence in support of the PIM/ A-I-E 
model. 
An indication of the influence of our work on selective attention bias, using cognitive 
probe tasks such as in this paper, can be found in a recent comprehensive review 
published in Psychological Bulletin. Harvey & Tang (2012) carefully evaluated no less than 
13 possible explanations for what they called the puzzle of sleep mis-perception. They 
concluded that worry and selective attention toward sleep-related threats was a strong 
contender explanation for why people with insomnia might consistently overestimate 
night-time wakefulness and underestimate total sleep time, relative to objective 
measures. An example of a more experimental study is that of Ellis, Gardani & Hogh 
(2010). This group investigated whether asking participants about their sleep 
experiences, prior to testing for a perceptual bias, affects responses on a sleep-related 
ambiguity task. A multivariate analysis showed that the order in which participants 
completed the task affected the responses on the Insomnia Ambiguity Task with those 
given the DBAS-10 and Insomnia Severity Index first, showing greater insomnia-related 
interpretations than those given the Insomnia Ambiguity Task first. This effect was 
evident only for poor sleepers, consistent with there the notion of a priming effect. 
 
3.2.7 Robertson, J.A., Broomfield, N.B. and Espie, C.A. (2007) Prospective comparison 
of subjective arousal during the pre-sleep period in primary sleep-onset 
insomnia and normal sleepers. Journal of Sleep Research 16, 230-238 [Cited 9 
times] 
According to Hyperarousal Theory, people with insomnia have higher arousal levels 
(somatic and cognitive) than normal sleepers, as a steady state condition on a 24-hour 
basis, in the peri-sleep-onset period and/or during sleep itself.  The Stimulus Control 
Model suggests that the bed and bedroom environment serves as a discriminative 
stimulus for wakefulness, rather than for sleep, raising the possibility of insomnia 
representing a form of conditioned arousal.  Despite the prominence of the stimulus 
control over the past 40 years, there has been virtually no research investigating changes 
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in arousal associated with the pre-sleep period.  In this study, participants with insomnia 
were compared with a good sleeper control group across 3 time-points (3 hours prior to 
bed, 1 hour prior to bed, and in bed).  They completed the somatic and cognitive sub-
scales of the Pre-Sleep Arousal Scale (PSAS) at each time-point, so that we could 
investigate gradients in experienced arousal across this time-course.  The study was the 
first to demonstrate that, whereas arousal in normal sleepers steadily declines in the 
evening and particularly during the 1 hour preceding going to bed; in people with 
insomnia, arousal fails to decrement during this latter transition, with some evidence 
that it may in fact increase.  We suggest that this attenuation in de-arousal measured 
using the PSAS may reflect difficulties that people with insomnia have in down-regulating 
their levels of alertness, and so could be associated with greater problems initiating 
sleep. 
The paper has been cited in a wide range of articles including longitudinal work 
(Fernandez-Mendoza et al, 2011; Keller & El-Sheikh, 2011), treatment trials (Cortoos et 
al, 2010; Harris et al, 2012) and psychometric reports (Gieselman et al, 2012) as well as 
being cited in influential reviews (e.g. Lack et al, 2008; Bootzin et al, 2011). 
3.2.8 Woods, H., Marchetti, L.M., Biello, S.M., Espie, C.A. (2009) The clock as a focus 
of selective attention in those with primary insomnia: an experimental study 
using a modified Posner paradigm.  Behaviour Research & Therapy, 47,231-236 
[Cited 1 time] 
This study describes the fourth experimental task that we have developed for 
investigating cognitive bias in insomnia. The modified Posner paradigm permits greater 
exploration of components of the attention system (shift, engage, disengage) and so 
helps to address one of the allocation of attention e.g do threatening stimuli (sleep cues 
and their emotional salience to a person with insomnia) attract attention by modulating 
engagement and/ or do they hold attention by modulating the disengagement 
component. 
At the time of writing it is perhaps too early to evaluate the impact of this work as it has 
only been cited on one occasion. 
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3.2.9 Baglioni, C., Lombardo, C., Bux, E., Hansen, S., Salveta, C., Biello, S., Violani, C., 
Espie, C.A.  (2010) Psychophysiological reactivity to sleep-related emotional 
stimuli in primary insomnia Behaviour Research and Therapy, 48, 467-475 [Cited 
2 times] 
As an extension of our work on selective attention bias, where the dependent variable is 
cognitive/performance based (i.e. a variant of reaction time or response speed), we 
wanted to investigate physiological reactivity to sleep salient stimuli.  This work involved 
the adaptation of paradigms that have been used in, for example, the anxiety literature, 
where photographic images are presented on a computer screen and concurrent 
measures taken of physiological responses.  The International Affective Picture System 
(IAPS) provides normative ratings of emotion (pleasure, arousal dominance) associated 
with photographs that represent a set of normative emotional stimuli for experimental 
investigations of emotion and attention.  
We selected items from the IAPS for this study, and developed an additional set of sleep 
positive and sleep negative images as specific probes. The physiological parameters of 
particular interest to us were the corrugator and zygomatic facial muscles (groups which 
are activated by the frown and smile response respectively).  Thus the study developed 
and instrumented a new paradigm for the investigation of reactivity to sleep related 
stimulus. 
This paper has so far been cited twice, including meeting criteria for a systematic review, 
‘Sleep America: Managing the crisis of adult chronic insomnia and associated conditions 
[Kraus & Rabin (2012), Journal of Affective Disorders]. 
 
3.2.10 Espie, C.A., Barrie, L.M., Forgan, G.S. (2012) Comparative investigation of the 
psychophysiological and idiopathic Insomnia Disorder phenotypes: 
psychological characteristics, patients’ perspectives and implications for clinical 
management.  SLEEP,  35, 385-393 [Cited 1 times]  
This paper is the first ever published to compare the psychophysiological and idiopathic 
Insomnia Disorder phenotypes in this way. Insomnia in clinical practice is a rather 
heterogeneous condition, so in order to understand its nature it is crucial to establish 
and compare different phenotypical features. Idiopathic insomnia refers to lifelong poor 
42 
 
sleep, or at least poor sleep since early childhood. One might expect such individuals to 
differ from people who were good or normal sleepers when young, but who somehow 
‘acquired’ insomnia in their adult years. Any such differences may also have important 
implications for treatment, not least which CBT or other psychological [e.g. mindfulness 
based stress reduction (MBSR) or acceptance and commitment therapy (ACT)] strategies 
to employ. This study systematically, across two component experiments, investigates 
psychological characteristics and patient perspectives in these two insomnia groups. 
Published in March 2012 this paper has so far only been cited once. 
 
3.3 Clinical and psychometric appraisal of insomnia 
 
This section comprises 13 papers on the clinical and research evaluation of insomnia at 
both the symptom and syndrome level. Average Citation per Item for papers in this 
section was 40.0 (range 0 – 215). 
Studies include psychometric scale development papers to test and validate new self-
report instruments, qualitative studies of the patient experience of living with insomnia, 
and longitudinal evaluation of the persistence of insomnia over time. 
3.3.1 Espie, C.A., Inglis, S.J., Harvey, L., and Tessier, S. (2000) Insomniacs’ attributions: 
Psychometric properties of the Dysfunctional Beliefs and Attitudes about Sleep 
scale and the Sleep Disturbance Questionnaire. Journal of Psychosomatic 
Research 48, 141-148 [Cited 71 times] 
People with insomnia complain that they are unable to fall asleep because of a ‘racing 
mind’. That is they attribute insomnia to mental events, more than physical ones (like 
tension). Therefore, it becomes very important to have valid, reliable and sensitive 
measures with which to measure attributions, beliefs and attitudes about sleep. Such 
cognitive phenomena likely play a central role in the maintenance of insomnia.  
This paper has been consistently cited since its publication in 2000. It reports further on 
the psychometric characteristics of two scales, the Dysfunctional Beliefs and Attitudes 
about Sleep scale (DBAS: Morin, 2003) and the Sleep Disturbance Questionnaire (Espie et 
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al, 1989) and provides a validated short form (10 items) of the former (DBAS-10), as well 
as confirmatory principal components analysis (PCA) of the SDQ.  
Edinger and Wohlgemuth (2001) conducted a replication of our study, exploring an 
abbreviated version of the original DBAS (of 30 items). They showed that the DBAS-10 
correlated highly with the full DBAS, had respectable internal consistency, effectively 
discriminated normal sleepers from insomnia sufferers, and detected cognitive changes 
resulting specifically from CBT intervention. They also found through PCA, three 
conceptually meaningful DBAS-10 subscales. Their subscale structure varied somewhat 
from our previous PCA findings, but overall the Edinger and Wohlgemuth report 
confirmed the validity and clinically utility of the DBAS-10. In a parallel study, they also 
demonstrated that the DBAS-10 was sensitive to treatment-related change (Edinger et al, 
2001). Likewise, Smith & Trinder (2001) reported that the DBAS detected insomnia 
complaints in a young adult population.  
Recently, Chieng-Min et al (2011) explored the association between dysfunctional sleep 
beliefs and vulnerability to stress-related transient sleep disturbance. One hundred 
thirty-two good sleepers and 307 poor sleepers were included in this study. They found 
that poor sleepers showed more dysfunctional beliefs than good sleepers on the DBAS-
10, and that, even in good sleepers, DBAS-10 scores positively correlated with 
vulnerability to stress-related sleep disturbance as measured by the Ford Insomnia 
Response to Stress Test. Their results, therefore, suggested that dysfunctional sleep 
belief is not only a perpetuating factor for chronic insomnia, but that it may also serve as 
a risk factor for stress-related transient insomnia. The SDQ (and the DBAS) are regarded 
as recommended research tools for the evaluation of insomnia (Buysse et al, 2006). 
 
3.3.2 Miller, A. Espie, C.A. and Scott, J. (2004) The sleep of remitted bipolar 
outpatients: a controlled naturalistic study using actigraphy. Journal of Affective 
Disorders 80, 145-153 [Cited 35 times] 
It has for long been recognised that sleep and circadian function is adversely affected in 
psychiatric disorders.  In Bipolar Disorder (BD), people have episodes of depression, but 
also at times episodes of mania or hypomania.  In both of these phases of this disorder, 
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sleep may be disturbed.  However, there was a question at the time we conducted this 
study as to whether or not sleep patterns normalised during euthymic periods; that is, 
when patients were clinically well and free from either depressive or manic symptoms.   
We compared a group of patients with diagnosed bipolar illness during this euthymic 
period, with normal good sleeper control subjects, and obtained objective estimates of 
sleep-wake pattern using actigraphy.  As previously explained, an actigraph is a device 
worn on the non-dominant wrist, which measures body movement sensitively in one-
minute epochs.  Data gathered over many consecutive days provide a very good estimate 
of circadian rhythm, and also of the stability (or instability) of sleep-wake function during 
the monitored period.  The study was the first to report the finding that, even during 
periods when patients were at their best in terms of mental health, there was 
considerably more variability in their sleep-wake patterns than normal controls. This 
raised the possibility that lack of normalisation of sleep-wake function may be a 
vulnerability factor for recurrent depressive or manic episodes.   
This paper has been cited 35 times. It continues to be well cited in studies exploring the 
euthymic state in BD (Sylvia et al, 2012), and in studies investigating risk factors (Leopold 
et al, 2012; Jones et al, 2006) and early intervention (Gruber et al, 2009). Harvey’s group 
(University of California, Berkeley) have an international reputation for their work on 
sleep and BD. They first conducted a replication of our study in 2005 (Harvey et al, 2005), 
as did Jones et al (2005), and they continue to refer to the influence of our work in 
clinical studies (most recently, Talbot et al, 2012) and in review articles (Harvey et al, 
2008). Our work has been cited also by groups interested in molecular and genetic 
aspects of affect regulation (e.g. Yang et al, 2009; Etain et al, 2011). 
3.3.3 Harvey, K.J. and Espie, C.A. (2004) Development and preliminary validation of 
the Glasgow Content of Thoughts Inventory (GCTI): a new measure for the 
assessment of pre-sleep cognitive activity. British Journal of Clinical Psychology 
43, 409-420 [Cited 10 times] 
This paper exploited the novel methodology we had developed in a previous study 
[Wicklow & Espie, 2000 (3.2.1)] and reported further data on the ‘live’ cognitions that 
people with insomnia experience during periods of night-time wakefulness. The paper 
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goes on to report on the construction, validation, and PCA of a 25-item scale; named the 
Glasgow Content of thoughts Inventory (GCTI).  The GCTI is both a research tool and a 
clinical tool, to identify the types of thinking that people engage in whilst unable to sleep. 
Its component structure for example identifies rehearsal and planning thoughts (where 
people reflect on the day past and think ahead), problem-solving thoughts (where people 
engage in analysis of life situations; past, present and future), sleep-related and self-
monitoring thoughts (where people have heightened self-awareness of themselves, their 
sleep and its consequences) and thoughts that relate to their immediate environment 
(e.g. sounds outside). This knowledge and awareness of what people are thinking about 
during wakeful periods in bed then helps with the tailoring of suitable cognitive 
interventions. 
The scale continues to be cited and used, for example, by the Stanford group (led by 
Manber) to explore cognitions across insomnia sub-types (Su et al, 2012) and has met 
criteria for systematic reviews of robust sleep self-report measures (Martoni & Biagi, 
2007; Wells et al, 2009). The GCTI is one of the instruments that we included on a CD-
ROM of requested scales and measures attached to our clinical handbook (Morin & 
Espie, 2003). 
3.3.4 Edinger, J.D., Bonnet, M.H., Bootzin, R.R., Doghramji, K., Dorsey, C.M, Espie, 
C.A., Jamieson, A.O., McCall, W.V., Morin, C.M., Stepanski, E.J. (2004) 
Derivation of Research Diagnostic Criteria for Insomnia: Report of an American 
Academy of Sleep Medicine Work Group. Sleep 27, 1567-1596 [Cited 215 times] 
RDC are required to standardize research in any given field. This brings numerous 
benefits, including increased homogeneity within and between studies and the 
possibilities of combining data. The process of the RDC work group, however, is also 
valuable in its own right. Evidence may be consensual, or it may be data-based, so the 
future research priorities as well as the extant research knowledge become clearer. This 
AASM commissioned work group, led by Edinger (then of Duke University, North 
Carolina) published RDC for the insomnia field. 
Unsurprisingly perhaps, this 2004 paper has been cited 215 times, and has influenced 
individual researchers, research groups, companies and policy-makers toward greater 
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recognition of insomnia as a disorder worthy of attention in its own right. Although RDC 
do date over time, and these ones will likely be updated in the next year or two, this 
paper remains influential in defining insomnia for the purposes of epidemiology (e.g. 
Leger et al, 2011; Sivertsen et al, 2009; Greendale et al, 2010; Joffe et al, 2012), 
differential and co-morbid diagnosis (Budhiraja et al, 2012), psychometrics (Jansson-
Fromark et al, 2012), and pharmacological (e.g. McCall et al, 2009: Joffe et al, 2010; Roth 
et al, 2011) and behavioural clinical trials (e.g. Manber et al, 2008). 
3.3.5 Kohn, L. and Espie, C.A. (2005) Sensitivity and specificity of measures of the 
insomnia experience: A comparative study of psychophysiologic insomnia, 
insomnia associated with mental disorder and good sleep. Sleep  28, 104-112 
[Cited 21 times] 
Sensitivity refers to the capacity of a measure to identify index cases of a disorder; 
normally the people you are trying to select for a research or clinical purpose. Specificity 
refers to the usefulness of a measure to identify non-cases; that is those who do not 
have the disorder of interest whom you may be trying to exclude. This paper, 
investigating the psychometric properties of several scales commonly used in insomnia 
research and clinical practice, has been influential in the ongoing debate about what 
characteristics of sleep and sleep-related concern are specific to insomnia in its primary 
form, relative to insomnia in the context of co-morbid psychiatric disorder.  It has been 
cited on a number of occasions by several, leading research groups. The group led by 
Kessler for example, who have pioneered the America Insomnia Survey and developed 
the Brief Insomnia Questionnaire continue to refer to the paper in journals ranging from 
Biological Psychiatry (Hajak et al, 2011; Roth et al, 20111) to SLEEP (Kessler et al, 2010).  
Likewise, Edinger’s group (with Carney) have conducted follow-on studies exploring cut-
off scores on measures of worry, rumination and psychopathology as potential predictors 
of insomnia disorders (e.g. Carney et al, 2010, 2011). The paper has been cited also in 
influential topic reviews (e.g. Manber & Chambers, 2009) and in a systematic review in 
Journal of Affective Disorders aiming to evaluate systems for classifying insomnia and 
reviewing theoretical models regarding the aetiology and maintaining factors of chronic 
insomnia (Kraus & Rabin, 2012). 
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3.3.6 Broomfield, N.M. and Espie, C.A. (2005) Toward a reliable, valid measure of 
sleep effort. Journal of Sleep Research 14, 401-407 [Cited 15 times] 
Our A-I-E Model suggests that the end state of persistent psychophysiological insomnia is 
a sleep pre-occupation and sleep effort syndrome.  That is, people get caught up in a self-
defeating focus upon sleep and vain effort to achieve sleep.   We wanted to have a 
simple self-report scale that would capture this notion of sleep effort.  This paper 
describes the development and validation of the 6-item Glasgow Sleep Effort Scale 
(GSES).  With most scales that measure psychopathology, one expects to find a 
significant difference between the normal and clinical populations. For example, people 
with an anxiety disorder will score much higher on an anxiety scale, but nonetheless the 
normal population will have some level of resting anxiety. Our A-I-E model, however, 
would suggest that normal good sleep does not involve any effort whatsoever. 
Therefore, not only should this scale discriminate people with insomnia from good 
sleepers; good sleepers would score close to zero, because for them they simply go to 
bed and fall asleep – nothing else.  Our results confirmed these findings. 
 ‘Third wave’ therapies have become of interest to insomnia researchers over the past 5 
years.  Unlike CBT, such approaches address the relationship that the person has with 
their problem. One might, therefore, regard a ‘mindful’ approach as the opposite of an 
effortful one. Some of the recent citations have explored this fresh perspective. Howell 
et al (2011), for example, found that mindfulness mindfulness predicted well-being both 
directly, and indirectly, through association with self-regulation of sleep. Likewise, Ong & 
Sholtes (2012) have clinically tested a mindfulness-based therapy for insomnia (MBT-I). In 
a 12-month follow-up study they showed improvement in sleep associated with MBT-and 
demonstrated that persistent sleep effort on the GSES was associated with having 
further episodes of insomnia during follow-up (Ong, Shapiro & Manber, 2009). 
 
3.3.7 Buysse, D.J., Ancoli-Israel, S., Edinger, J.D., Lichstein, K.L. and Morin, C.M. [on 
behalf of co-authors including Espie, C.A.] (2006) Recommendations for a 
standard research assessment of insomnia. Sleep, 29, 1155-1173 [Cited 171 
times] 
This paper was the product of the Pittsburgh Consensus Conference held in 2005, when 
around 20 leading clinical researchers gathered for a 3 day meeting to agree upon a 
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standardized approach to data collection. The rationale was that international 
consistency in the use of clinical tools would advance the field by enabling comparison 
and replication of studies, and ultimately lead to the pooling of data to answer important 
research questions relating to the insomnia phenotypes.   The fact that the paper has 
been cited more than 25 times per year since publication indicates that there has been a 
strong and positive response from the research community. 
 
3.3.8 Waine, J., Broomfield, N.B. & Espie, C.A. (2009) Development and validation of 
the sleep metacognitive beliefs scale. Journal of Behaviour Therapy & 
Experimental Psychiatry, 40, 15–23 [Cited 1 time] 
With the development of cognitive research and therapy, there has been growing 
interest in the concept of meta-cognition. In this paper, we suggested that two 
metacognitive belief types might operate in response to the intrusive thinking that is 
characteristic of insomnia: (i) beliefs concerning the meaning of the intrusions (e.g. 
thinking in bed prevents me getting to sleep) and (ii) plans that guide and shape the form 
that cognition takes (e.g. before I fall asleep, I should try and switch off my thoughts). In 
other branches of psychopathology, measures have been developed to evaluate meta-
cognition, and in this paper, we brought this concept into the sleep field, and developed 
an insomnia-specific measure of meta-cognitive beliefs.  
This paper has been cited by Barclay & Gregory (2009) in a study which showed that poor 
sleepers possess a 'perseverative iterative style' which may predispose them to 
catastrophize, regardless of content or affective valence; a style previously found to 
occur more commonly in worriers compared to others. 
 
3.3.9 Kyle, S.D, Morgan, K., Espie, C.A. (2010) Insomnia and health-related quality of 
life Sleep Medicine Reviews 14, 69–82 [Cited 22 times] 
In this paper we argue that Health-related Quality of Life (HRQoL), which has become an 
important construct in contemporary medicine and health care, needs to be actively 
measured in insomnia, to guage disorder burden and the evaluation of interventions on 
various aspects of functioning, in a standardized manner. We reviewed the literature on 
the measurement of HRQoL in insomnia populations, and the extent to which insomnia 
treatment improves domains of HRQoL, and concluded, from the relatively small 
49 
 
literature available, that insomnia impacts on diverse areas of HRQoL, and that both 
pharmacological and non-pharmacological interventions can produce, to varying 
degrees, improvements in domains spanning physical, social and emotional functioning.  
The paper contained a call to increased research, and we have been gratified to see that 
it has been cited 22 times in the past two years. It was cited, for example, in the report 
on the international Consensus Sleep Diary (Carney et al, 2011) and has been referenced 
in epidemiological work (Zhang et al, 2012), in studies of sleep and work performance 
(Swanson et al, 2010)  and in pharmacological treatment studies (Perez-Lloret et al, 
2012). Other researchers and guideline groups developing measures for use with kidney 
transplant patients Burkhalter et al (2011) and functional disability (Gradinger et al, 
2011) have also cited the paper. 
 
3.3.10 Fleming L, Gillespie S, Espie CA. (2009) The development and impact of insomnia 
on cancer survivors: a qualitative analysis. Journal of Psycho Oncology 19, 991-
996 [Cited 3 times] 
The clinical trial that we conducted with the support of the CR-UK grant led us to 
recognise the important part that sleep played in the wellbeing of people who had 
cancer.  Although, at one level, we knew that to be the case, and it was part of our 
motivation for conducting the trial, we were nonetheless impressed by the informal 
comments that many of our participants made to us.  People told us that being able to 
sleep well again had been crucial to getting their lives back on track.  It was reported to 
us for example that one person had said to her Professor of Oncology that “CBT for 
insomnia knocks your chemotherapy into a cocked hat”!  In order to explore patients’ 
personal experiences more fully, we obtained a grant from the National Cancer Research 
Institutes (NCRI) to conduct some qualitative studies on patient experiences.   This paper 
summarises some of the data from that work.  In turn, this has led to a 3 year grant from 
the Breast Cancer Campaign (ongoing at the time of writing) to study the natural history 
of sleep and sleep disturbance.  By completion of that grant in 2013, a total of 250 
women will have been followed up from diagnosis through to 1-year follow-up, and we 
will have novel data on the co-variation of symptoms of insomnia, fatigue, and mood. 
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This paper has been cited three times to date, including two studies developing protocols 
for internet CBT for insomnia in cancer survivors (Ritterband et al, 2012; Garland et al, 
2011). 
3.3.11 Kyle, S.D., Morgan, K., Spiegelhalder, K., & Espie, C.A. (2011) No pain, No gain: 
An exploratory within-subjects mixed-methods evaluation of the patient 
experience of sleep restriction therapy. Sleep Medicine 12, 735-747  [Cited 0 
times] 
People with insomnia characteristically say that they have “tried everything” to solve 
their sleep problem.  This clinical anecdote alone speaks of the resistant nature of 
insomnia once it gets established.  Scientific data on the natural history of insomnia also 
bear this out, because more than 70% of people with insomnia still have insomnia one 
year later.  This is in marked contrast, for example, to depression, which is a more 
naturally remitting disorder.  In this context, it is encouraging that CBT is a durably 
effective treatment for persistent insomnia, and it seems likely that this is because it 
helps people achieve lasting behavioural, cognitive and attitudinal change.  At least this is 
true for approximately two-thirds of people in clinical trials; but it also raises the 
question of why some people improve, whereas others do not.  This paper on “No pain, 
no gain” investigated the possibility that home adherence to treatment guidelines (in this 
case Sleep Restriction Therapy) is crucial to therapeutic benefit. The paper has yet to be 
cited. 
3.3.12 Green, M., Benzeval, M., Espie, C.A., Hunt, K. (2012) The longitudinal course of 
insomnia symptoms: inequalities by gender and occupational class among two 
different age cohorts followed for 20 years in the West of Scotland.  SLEEP 35, 
815-823 [Cited 0 times] 
In the early 2000s, there was opportunity to introduce formal measurement of sleep 
quality into a large ongoing longitudinal study being conducted by the Medical Research 
Council (MRC) team at the Social and Public Health Sciences Unit (SPHSU), University of 
Glasgow.  The Twenty-07 Study was set up in 1986 to investigate the reasons for 
differences in health by socio-economic circumstances, gender, area of residence, age, 
ethnic group and family type. Over 4,500 people were followed up for 20 years. The 
initial wave of data collection took place in 1987/8 when respondents were aged 15, 35 
and 55 years. The final wave took place in 2007/8 when respondents were 35, 55 and 75 
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years old. Thus the Twenty-07 study provides unique opportunities to investigate health 
and life change over a 20 year span. 
This paper is the first output from this study that reports data on sleep quality.  Latent 
Class Analysis (LCA) is used to determine the underlying sleep quality sub-groups that 
exist in the general population and their trajectory of stability/change over time. It has 
not yet been cited. 
3.3.13 Espie, C.A., Kyle, S.D, Hames, P., Cyhlarova, E., Benzeval, M. (2012)  The daytime 
impact of DSM-5 Insomnia Disorder: comparative analysis of insomnia subtypes 
from the Great British Sleep Survey (n=11,129) Journal of Clinical Psychiatry 73, 
e1-e7 [Cited 0 times] 
The workgroup for DSM-5 has recommended a paradigm shift towards the diagnosis of 
Insomnia Disorder, whenever diagnostic criteria are met.  Thus, in this new nosology (due 
2013), Insomnia Disorder may be classified alongside a concurrent mental disorder, 
physical disorder, or other sleep disorder.  Another important feature of DSM-5 is clear 
specification of daytime impairments that must accompany sleep disturbance.  To meet 
criteria for Insomnia Disorder, therefore, a patient must also complain of significant 
effects upon energy, mood, interpersonal functioning, concentration, productivity or 
ability to remain awake. 
In this paper, we report on a large sample (n=11,129) of respondents to the Great British 
Sleep Survey (GBSS).  The GBSS was designed to profile DSM-5 Insomnia Disorder, 
including these six daytime symptoms.  The paper compares the daytime impact of 
Insomnia Disorder, and Insomnia Disorder associated with the various above co-
morbidities, with normal sleep. At the time of writing this paper is just published.  
 
3.4 Cognitive behavioural treatment of insomnia 
This section comprises a series of 12 papers investigating non-pharmacological treatment 
of insomnia, using cognitive and behavioural methods. Average Citation per Item for 
papers in this section was 45.2 (range 1 – 167). 
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The majority of studies reported are primary outputs from randomized controlled trials, 
exploring the efficacy and clinical effectiveness of multi-component CBT in insomnia, and 
insomnia associated with co-morbid health problems. The studies also deal with different 
methods of CBT delivery (individual, group and online) 
3.4.1 Espie, C.A., Inglis, S.J., Tessier, S., and Harvey, L. (2001) The clinical effectiveness 
of cognitive behaviour therapy for chronic insomnia: Implementation and 
evaluation of a Sleep Clinic in general medical practice. Behaviour Research and 
Therapy 39, 45-60 [Cited 93 times] 
Traditionally, CBT is provided a) by a qualified clinical psychologist/psychotherapist, b) on 
a one-to-one basis in a clinical setting, and c) it is tailored towards the needs of the 
particular patient.  In practice, however, this level of resource may be neither feasible 
nor necessary.  This trial was the first in a series of studies, where we explored the 
clinical effectiveness of nurse-delivered, small-group CBT, delivered using a standard 
protocol, in the form of manualised therapy.  Consistent with the clinical effectiveness 
tradition, the CBT intervention was compared with treatment as usual (TAU). Moreover, 
participants were patients attending primary care practices, and thus relatively 
unselected in terms of other co-morbidities.   
This study, funded by the Chief Scientist Office, Scotland (Novel Health Services 
Initiative), has been highly cited (93 times over the past 11 years).  Our approach has 
been associated with an interest in increasing access to CBT and a proliferation of studies 
which have explored new and ways of delivering insomnia treatment.  Examples of 
citations include the short-term training of GPs in the Netherlands to improve primary 
care treatment approaches (Backhaus et al, 2002), the use of CBT in general practice to 
reduce long-term dependence on hypnotic drug use in England (Morgan et al, 2003) and 
to encourage medication tapering in Canada (Morin et al, 2004), the early development 
of internet-based treatment of insomnia (Sweden; Strom et al, 2004), the development 
of a comprehensive sleep education programme for dementia patients in the US (USA: 
McCurry et al, 2005) and group CBT for insomnia secondary to breast cancer (Canada: 
Savard et al, 2005).  The study was also cited in numerous influential reviews in the early 
years after publication, including the Lancet (Sateia and Nowell, 2004) and JAMA 
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(Schenck et al, 2003) and NEJM (Silber, 2003).  The study is still well cited in review 
papers, e.g. a meta-analysis by Belleville et al (2011) in Clinical Psychology Reviews, 
Bootzin et al (2011) [Annual Review of Psychology] and Babson et al (2010) [Psychiatric 
Clinics of North America].  In the US, dissemination of CBT to non-sleep specialists has 
been nationally funded under a Veteran’s Health Administration (VHA) programme also 
cited this work (Manber et al, 2012).   
Our early emphasis upon the importance of clinical effectiveness (rather than efficacy) 
studies has also been supported by others, both conceptually (e.g. Haynes et al, 2010; 
Morin, 2003) and procedurally through the development of other novel interventions, 
such as brief behavioural therapy for insomnia (Buysse et al, 2010). 
3.4.2 Espie, C.A., Inglis, S.J. and Harvey, L. (2001) Predicting clinically significant 
response to cognitive behavior therapy (CBT) for chronic insomnia in general 
practice: analyses of outcome data at 12 months post-treatment. Journal of 
Consulting and Clinical Psychology 69, 58-66 [Cited 40 times] 
This paper was a secondary analysis of the data from the above trial, the purpose of 
which was to determine reliable predictors of who might respond to this form of CBT for 
insomnia, and who might not.  As such, the analyses reported in the paper extend the 
theme of clinical effectiveness, because the questions that arise for most clinicians are 
not only “does this treatment work?”, but also “is this treatment likely to work for this 
particular patient?” 
This paper was probably the first of its kind to be published in the insomnia field, and it 
has been well cited.  Since publication, similar analyses have been conducted on trial 
data from other studies, including predictors of treatment response to CBT for insomnia 
secondary to chronic pain (Currie et al, 2002), predicting long-term outcomes following 
psychological treatment for hypnotic dependent insomnia (Morgan et al, 2003). 
Recently, the paper continues to be influential, being cited in relation to pre-therapy 
dispositions in treatment outcome in older adults with insomnia (Edinger et al, 2008), 
predictors of the effect of CBT for insomnia co-morbid with breast cancer (Tremblay, 
2009), and predictors of outcomes on sleep daytime function and health-related quality 
of life in medical settings (Van Houdenhove et al, 2011), along with further work on 
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predicting adherence to sleep intervention to breast cancer chemotherapy (McChargue 
et al, 2012).   
3.4.3 Harvey, L., Inglis, S.J. and Espie, C.A. (2002) Insomniacs’ reported use of CBT 
components and relationship to long-term clinical outcome. Behaviour Research 
and Therapy 40, 75-83 [Cited 26 times] 
This study followed up participants at one year post-therapy to investigate which parts of 
the CBT programme people had been using, which parts they had found helpful, and to 
explore the relationship between these factors and a structured evaluation of long-term 
clinical outcome.  Interestingly, it was found that it was not always the things that people 
preferred that helped them most.  Indeed, sleep restriction therapy, which is a 
particularly challenging behavioural regime, was most strongly related to good long-term 
outcome.   
Since 2002 when this paper was published, factors associated with adherence to CBT 
have been more widely studied, and this paper has been cited in a good number of 
reports.  For example, recently, adherence to CBT for insomnia among women following 
primary breast cancer treatment was reported by an American team (Matthews et al, 
2012).  Likewise, also in breast cancer patients, Trembley et al (2009) found that “at 6 
month follow-up, subjectively assessed sleep improvements were best predicted by 
adherence to behavioural strategies.”  Vincent et al (2008) explored barriers to 
engagement in sleep restriction and stimulus control, and Arnedt et al (2007) adapted 
CBT to the particularly challenging scenario of sleep disturbance during alcohol recovery. 
3.4.4 Broomfield N., and Espie, C.A. (2003) Initial insomnia and paradoxical intention: 
an experimental investigation of putative mechanisms using subjective and 
actigraphic measurement of sleep. Behavioural and Cognitive Psychotherapy 31, 
313-324 [Cited 16 times] 
Paradoxical intention is a psychotherapeutic technique which addresses performance 
anxiety problems. It has been used in the treatment of insomnia for many years (for an 
overview see Espie, 2010). This paper fulfilled criteria for inclusion in 2 subsequent  
systematic reviews (Morin et al, 2006; Smith et al, 2008) and an associated practice 
parameter paper on the non-pharmacological management of insomnia, published by 
the American Academy of Sleep Medicine (Morgenthaler et al, 2006). It was also recently 
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cited in a meta-analysis on the treatment of insomnia and concomitant anxiety disorder 
(Belleville et al, 2011). The paper has encouraged the development of a novel technique 
that targets the refocusing of thoughts during the evening in order to improve sleep 
(Gellis, 2012). 
 
3.4.5 Morin, C.M., Bootzin, R.R., Buysse, D.J., Edinger, J.D., Espie, C.A. & Lichstein, K.L. 
(2006) Psychological and behavioural treatment of insomnia. Update of the 
recent evidence (1998-2004) prepared by a Task Force of the American 
Academy of Sleep Medicine. Sleep 29, 1398-1414 [Cited 170 times] 
This review group was set up to reconsider the evidence for the efficacy and 
effectiveness of CBT for Insomnia based upon additional data published in the period 
1999-2005.  Thus the paper provides an update from an earlier review, also published 
under the auspices of the AASM in 1999.  An expert international panel reviewed all 
studies that met clinical trial criteria, and the resulting review paper was used as a basis 
for the AASM Practice Parameter Statement on the Non-Pharmacological Treatment was 
published in the same issue of the journal (Morgenthaler et al, 2006). 
As might be expected, an authoritative review of this type has been very highly cited, and 
has become a standard reference for people working in the field of clinical insomnia 
disorder. 
3.4.6 Espie, C.A., MacMahon, K.M.A., Kelly, H-L., Broomfield, N.M., Douglas, N.J., 
Engleman, H.E., McKinstry, B., Morin, C.M. Walker, A. & Wilson, P. (2007) 
Randomised clinical effectiveness trial of nurse-administered small group CBT 
for persistent insomnia in general practice. Sleep 30, 574-584 [Cited 45 times] 
This paper is the primary output, from a second major grant-funded study (Chief Scientist 
Office, Scotland), evaluating our nurse-delivered small-group CBT model.  Again, nurses 
working in general practice settings, primarily health visitors, were trained to 
competently deliver manualised CBT during the course of 5, weekly, 50 minute sessions, 
working with small groups of 5 or 6 patients.  As in the previous study, treatment 
benefits were maintained at follow-up, and the study provided further convincing 
evidence for the clinical effectiveness of CBT as a first-line insomnia treatment. 
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The influence of this paper can be evidenced by the fact that in 2011-1012 (4-5 years 
after publication) it is still being cited by research groups working in the USA (Epstein et 
al, 2012; Manber et al, 2012; Buysse et al, 2011; Bootzin et al, 2011), Canada (Morin & 
Benca, 2012), Norway (Bjorvatn et al, 2011), Australia (Harris et al, 2012; Fuller et al, 
2011; Kippist et al, 2011), China (Lee et al, 2011) and Japan (Okajima et al, 2011).   
3.4.7 Espie, C.A., Fleming, L., Cassidy, J., Samuel, L., Taylor, L.M., White, C.A., Douglas, 
N.J., Engleman, H.E., Kelly, H-L. & Paul, J. (2008) Randomized controlled clinical 
effectiveness trial of Cognitive Behavior Therapy versus Treatment as Usual for 
persistent insomnia in cancer patients. Journal of Clinical Oncology 26, 4651-
4658 [Cited 50 times] 
During the early 2000s, interest grew rapidly in the application of CBT for insomnia in 
people with co-morbid medical and psychiatric disorders.  Hitherto, the dominant 
wisdom was that insomnia was likely a secondary consequence of other health problems.  
However, epidemiological data pointed to insomnia as a risk factor for the development 
of and relapse into depression; and a foremost concern of people with cancer as they 
tried to re-adjust to normal living after active treatment was completed.  Indeed, our 
PIB/A-I-E model would predict that insomnia symptoms, ‘incubated’ during times of 
extreme stress, could become a psychophysiological disorder, self-perpetuating in its 
own right (Espie, 2002; Espie et al, 2006).   
We were encouraged, therefore, to apply to CR-UK for a trial grant to investigate the 
effectiveness of CBT delivered by cancer nurses to people with persistent insomnia in the 
aftermath of cancer treatment.  The primary output from this research was this paper 
published in the Journal of Clinical Oncology.  Our work was highly regarded, and the 
research team was awarded the Pfizer Prize for the Best Patient Support Initiative in 
Cancer Care in 2009, presented at the British Oncology Association annual meeting. 
Subsequent work in the cancer field has cited this paper 50 times since 2008. These 
citations have been widespread methodologically, in other RCTs (e.g. Ritterband et al, 
2012; Morin et al, 2009; Berger et al, 2009), in meta-analyses (e.g. Kwekkeboom et al, 
2010), in papers recommending developments in cancer care (Richardson et al, 2011; 
Luckett et al, 2010; Berger et al, 2010; Mortimer et al, 2010), in descriptive and 
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longitudinal studies (e.g. Savard et al, 2011; Shocat & Degan, 2010; Beck et al, 2010) and 
in conceptual pieces (e.g. Innominato et al, 2009: exploring the clustering of circadian 
disruption fatigue and anorexia in cancer patients). 
3.4.8 Espie, C.A. (2009) ‘Stepped care’: a health technology solution for delivering 
Cognitive Behavioral Therapy as a first line insomnia treatment.  Sleep, 32 (12), 
1549-1558 [Cited 29 times] 
There is a substantial evidence base for CBT for Insomnia, yet CBT is very seldom 
available.  This paper analyses the challenges associated with delivering CBT to the 
community on a large scale, and proposes “stepped care” as a health technology that 
would be capable of achieving this, whilst making best use of resources.  It is suggested 
that CBT can be disseminated simply and effectively in self-help format, for example, 
using booklets and the internet.  This would be the least restrictive and (at least 
minimally) effective intervention that has an evidence base.  A hierarchy above this is 
proposed, requiring progressively greater levels of expertise and resource, for example, 
manualised small-group therapy through individualised therapy, to highly specialised 
evaluation and treatment that might require expertise in behavioural sleep medicine.   
The paper has guided thinking about how best to develop and deliver services. For 
example it is cited in a paper recommending  standard procedures for adults in 
accredited sleep medicine centres in Europe (Fischer et al, 2012), published by the 
European Sleep Research Society. Likewise it has been cited in studies exploring the 
practical treatment of insomnia in general practice (Katofsky et al, 2012; Logue et al, 
2012) and in clinics for people with arthritis and heart disease (Rybarczyk et al, 2011) and 
cancer (Savard et al, 2011). The stepped care model has also been applied to student 
populations (Kloss et al, 2011) and to sleep health awareness screening programmes 
(Fuller et al, 2011). 
3.4.9 Mooney, P., Espie, C.A., Broomfield, N.M. (2009) An Experimental Assessment 
of a Pennebaker Writing Intervention in Primary Insomnia.  Behavioral Sleep 
Medicine 7, 99-105 [Cited 4 times] 
Many people with insomnia complain of rehearsing the day that has passed, and 
planning ahead when they lie awake in bed at night, either initially, or during a 
subsequent night-time awakening.  Such thoughts can be experienced as intrusive and 
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unwelcome, yet they are not necessarily dysfunctional.  Indeed, thinking things through, 
evaluating events and making sensible plans would be regarded as a good thing.  With 
this in mind, in the late 1980s, we developed a cognitive control strategy, whereby 
people spent some time in the early part of the evening “putting the day to rest”.  The 
more recent work of Pennebaker, working with patients with anxiety disorders and 
chronic worry, has highlighted the importance of processing emotion that is associated 
with events and thoughts, and not merely dealing with the thoughts and behaviours per 
se.  He developed what has become known as the Pennebaker Writing Task: a way of 
helping people to fully express their feelings.  In this paper, we brought the Pennebaker 
Writing Task into the field of insomnia for the first time.   
The paper has been cited 4 times to date, in relation to clinical populations (e.g. Jansson-
Fromark et al, 2012: an RCT of a constructive worry intervention) and to college student 
sleep (Arigo & Smyth, 2012). 
3.4.10 Wilson, S.J., Nutt, D.J., Alford, C., Argyropoulos, S.V., Baldwin, D.S., Bateson, 
A.N., Britton, T.C., Crowe, C., Dijk, D-J, Espie, C.A., Gringras, P., Hajak, G., 
Idzikowski, C., Krystal, A.D., Nash, J.R., Selsick, H., Sharpley, A.L. and Wade, A.G. 
(2010) British Association for Psychopharmacology consensus statement on 
evidence-based treatment of insomnia, parasomnias and circadian rhythm 
disorders. Journal of Psychopharmacology 24, 1577–1600 [Cited 20 times] 
The British Association of Psychopharmacology (BAP) set up this review group.  The 
approach taken was unusual in two respects.  First, it was decided to review evidence for 
both pharmacological and non-pharmacological approaches; and second, it was decided 
to broaden the scope of the guideline to include not only insomnia, but also circadian 
disorders and parasomnias.  The resultant paper is broad in its reach, and is an excellent 
source of information, particularly for clinicians.  It is part of a BAP Guidelines series 
intended for that purpose.  Although published only recently, this paper has already been 
cited 18 times, indicative of the impact of the work. Citations include practice guidelines 
(e.g. Fischer et al, 2012; Lingford-Hughes et al, 2012) and therapy option reviews (e.g. 
Buford & Nemeroff, 2012; Thorpy, 2011) and pharmacological treatment studies (e.g. 
Coe & Hong, 2012; Wichniak et al, 2011). 
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3.4.11 Espie, C.A., Kyle, S.D, Williams, C., Ong, J.C., Douglas, N.J., Hames, P., Brown, 
J.S.L. (2012) A randomized, placebo-controlled, trial of online Cognitive 
Behavioral Therapy for chronic Insomnia Disorder delivered via an automated 
media-rich web application.  SLEEP 35, 769-781 [Cited 2 times] 
Prior to publication of this paper, there were several smaller scale RCTs of online CBT for 
insomnia.  Results from those studies were encouraging, but the approach had not been 
tested in a placebo controlled trial; nor on a sizable sample.  This paper was also ground-
breaking in presenting an online intervention that utilised the full range of rich media 
(automated interactions, animated therapist, full web and mobile support) and social 
networking (community) support that is now typically part of the online technology.  The 
results of the study suggested that this form of online CBT (Sleepio; see 3.5.8) may 
achieve effect sizes that are similar in magnitude to face-to-face therapy, across a range 
of sleep and daytime function measures.  The paper was selected as a rapid publication 
in the journal SLEEP, and there was an associated commentary in the same issue 
(Ritterband et al, 2012).  The paper was only published on 1
st
 June 2012, and so there 
have been no further citations at the time of writing, other than a commentary in The 
Lancet (Moore, 2012). 
3.4.12 Espie, C.A., Kyle, S.D, Miller, C., Williams, C., Ong, J.C., Hames, P. (2013) 
Randomized, placebo-controlled, trial of online Cognitive Behavioral Therapy 
for persistent Insomnia Disorder: therapeutic impact upon attribution, cognition 
and psychopathology Journal of Consulting & Clinical Psychology (in press) 
[Cited 0 times] 
This paper reports secondary outcome data from the above randomised placebo-
controlled trial of online CBT for Insomnia (3.4.11).  Nevertheless, these outcomes are 
important because thoughts, beliefs and emotions associated with sleep are very 
important in the aetiology and maintenance of Psychophysiological Insomnia.  In 
comparison to the primary paper, which reports sleep and daytime function outcomes, 
modest placebo effects were observed on attribution, cognition and psychopathology.  
However, moderate to large standardised effect sizes in favour of CBT were observed for 
the CBT–placebo, demonstrating that CBT also has marked effects on people’s 
psychological and emotional approach to sleep over and above the placebo response.  At 
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the time of writing, this paper is “in press” in the leading American Psychological 
Association journal. 
3.5 Dissemination of evidence-based practice relating to insomnia 
This section comprises 8 outputs which illustrate professional contributions to the 
dissemination of good evidence-based practice.  The majority of these are books, but 
exemplar chapters in influential textbooks are also provided.  As such, these outputs 
were not subjected to a citation search. In addition to the text outputs, the section also 
refers to a web-based programme delivering CBT for insomnia. 
3.5.1    Morin C.M and Espie, C.A. (2003) Insomnia: A Clinical Guide to Assessment and 
Treatment. Kluwer Academic/ Plenum Publishers, New York [200 pages] [ISBN 
0-306-47750-5] 
This clinical handbook was co-written with Charles Morin PhD (Universite Laval, Quebec 
City) in response to frequent requests for access to our assessment and treatment 
materials. Written particularly with clinical psychologists and psychological therapists in 
mind, the book is divided into sections covering clinical assessment and treatment, and is 
accompanied by a CD-ROM of commonly used clinical tools and procedures. Translations 
in Italian and Mandarin have also now been published. 
Morin C.M and Espie, C.A. (2004) Insonnia Guida alla valutazione e all'intervento 
psicologico. McGraw-Hill Publishing Group Milan [ISBN 88-386-2798-3] [Italian 
translation] 
 
Morin C.M and Espie, C.A. (2008) Insomnia: A Clinical Guide to Assessment and 
Treatment. DK Vision [ISBN 978-986-191-123-6] [Mandarin translation]  
3.5.2   Espie, C.A. (2006) Overcoming Insomnia and Sleep Problems: A Self-Help Guide 
Using Cognitive Behavioral Techniques. Constable & Robinson Ltd., London 
[ISBN13: 978-184529-070-2/ ISBN10: 1-84529-070-4] 
This is a single-authored book that provides ‘guided self-help’ directly to adults who have 
an insomnia problem. It is part of a highly regarded series of books written by expert 
authors/clinicians and published by Constable & Robinson. The aim of the series is to 
make effective CBT (for a wide range of disorders) more directly available to the general 
public.  The book is sub-divided into a background section and a therapeutic section; the 
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latter following a session-by-session approach, to mirror clinical consultations. It will be 
available as a Kindle edition from November 2012. It has also now been published in 
French, Danish, and Italian with a Swedish translation in progress at the time of writing. 
Espie, C.A. (2008) L’insomnie et les Problemes de Sommeil. InterEditions, Dunod, Paris 
[ISBN 978-2-10-050115-1] [French translation] 
 
Espie, C.A. (2011) At Overvinde Søvnløshed. Forlaget Klim, Aarhus [ISBN 978-87-7955-
801-4] [Danish translation] 
 
Espie, C.A. (2013) Superare L’insonnia. Eclipsi SRL, Florence [Italian translation] 
 
The book has been well received by the public. For example on www.amazon.co.uk there 
are 20 reviews; 13 of which give it a 5 star rating (average rating of 4.5).  In the media, 
the book has been described as "A sensible lucid description of the leading treatment of 
insomnia by an internationally renowned expert." Allison G. Harvey PhD, University of 
Berkeley" 
 
3.5.3 Espie CA, Bartlett D.J. (2009) Insomnia, in R.P. Lisak, D.D. Truong, W. Carroll & R. 
Bhidayasiri (eds) International Neurology: A Clinical Approach. Wiley-Blackwell, 
Oxford, pp. 554-556 
This chapter illustrates contributions made to dissemination to the knowledge and 
training other health professionals; in this case clinical neurology. 
3.5.4 Espie, C.A. Bartlett D.J. (2009) Clinical syndromes of adult psychiatry: Insomnia 
in M.G. Gelder, J.J. Lopez-Ibor and N.C. Andreasen (eds) New Oxford Textbook 
of Psychiatry (Vol. 2) (second edition) Oxford University Press, Oxford, England, 
pp. 933-938 
Similar to 3.5.3, this chapter was published in the major textbook of psychiatry and 
illustrates contributions made to psychiatry and the broad mental health field. 
3.5.5 Perlis M.L., Shaw, P., Cano, G., Espie, C.A. (2011) Models of Insomnia In MH 
Kryger, T Roth and WC Dement (eds) Principles and Practice of Sleep Medicine, 
5th edition. Elsevier Saunders, NY, pp. 850-865 
Principles and Practice of Sleep Medicine (now in its 5th edition) is the most influential 
textbook in the field, and is read by sleep specialists worldwide. This chapter (senior 
author) provided an overview of the most influential thinking on insomnia disorder, and 
featured prominently our Psychobiological Inhibition Model, incorporating the Attention-
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Intention-Effort pathway. The text is linked to web-site supplementary material where CE 
is featured as one of the ‘Pioneers in Sleep Medicine’.  
3.5.6   Espie, C.A. (2011) Introduction to Coping with Insomnia & Sleep Problems.  
Constable & Robinson Ltd., London [32 pages] [ISBN 978-1-84901-620-9] 
As a result of demand for the self-help guide (3.5.3), this brief version was commissioned 
as a booklet that primary health care practitioners, and mental health services could 
hand out to patients in clinical settings, providing a practicable alternative to offering 
prescription medication. It is also now available as a Kindle edition. 
3.5.7   Morin, C.M. & Espie, C.A. (2012) The Oxford Handbook of Sleep and Sleep 
Disorders (Oxford Library of Psychology) Oxford University Press, USA [928 
pages] [ISBN 978-0-19-537620-3] 
In response to a request from the commissioning editor for the Oxford Library of 
Psychology, my colleague Charles Morin PhD (Université Laval, Quebec City) and I edited 
this substantial handbook. It is intended to provide a comprehensive, knowledge-based 
curriculum for the emerging field of behavioural sleep medicine. The handbook 
comprises over 900 pages and xx chapters, each provided by an eminent world expert 
incorporating current research and clinical developments in normal and abnormal sleep.  
The handbook is in three sections: Section I covers the basics of normal sleep, its 
functions, and its relationships to emotions, cognitions, performance, psychopathology, 
and public health and safety issues. Section II addresses abnormal sleep, including 
disorders like insomnia, parasomnias, circadian rhythm disorders, and sleep apnea. An 
informed classification of sleep/wake disorders is presented along with a protocol for 
assessing sleep-wake complaints and evidence-based treatment options. Section III 
provides a developmental perspective on sleep and sleep problems in childhood, 
adolescence, and in late life, and a discussion of sleep disturbances in selected special 
populations. 
This first edition was published in 16 March 2012 in print format. An electronic version of 
the handbook will be available shortly. 
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3.5.8   www.sleepio.com 
The internet provides a pervasive milieu for healthcare delivery. Sleepio is a novel web-
based cognitive behavioral therapy course delivered by an animated virtual therapist 
(The Prof). The program comprises a fully automated media-rich web application, driven 
dynamically by baseline, adherence, performance, and progress data. At the start of each 
session, The Prof conducts a progress review with the participant, explores the diary data 
submitted during the week, the participant’s current sleep status and pattern, and 
progress achieved against goals previously set. Underlying algorithms feed the delivery of 
information, support, and advice in a personally tailored manner. CBT content is 
consistent with the literature, and covers behavioural (e.g., sleep restriction, stimulus 
control) and cognitive (e.g., putting the day to rest, thought re-structuring, imagery, 
articulatory suppression, paradoxical intention, mindfulness) strategies, as well as 
additional relaxation strategies (progressive muscle relaxation and autogenic training) 
and advice on lifestyle and bedroom factors (sleep hygiene). The intervention is based on 
validated manuals and has been evaluated in a randomized placebo-controlled trial. 
The Sleepio programme is available directly online at www.sleepio.com or through Boots 
stores in the UK.  
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Intrusive thoughts and their relationship to actigraphic
measurement of sleep: towards a cognitive model of
insomnia
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Abstract
Although cognitive over-arousal has been hypothesised as a causal factor in sleep-onset insomnia,
relatively little is known about the specific pre-sleep intrusions which delay sleep. To investigate this
relationship adequately ‘live’, verifiable, unobtrusive and independent monitoring of thought process and
sleep pattern is essential. This study was designed with these requirements in mind. Voice-activated
audiotape recordings of spontaneous thoughts, and actigraphic data from which to estimate sleep
parameters, were obtained over three consecutive nights from 21 participants (63 subject nights).
Content analysis of transcribed audiotapes yielded eight categories of pre-sleep intrusion. Results from
correlational and regression analyses indicate that thinking about sleep and the anticipated consequences
of poor sleep, along with general problem-solving are the strongest predictors of objective sleep latency.
Principal Components Analysis suggests that intrusions can be subsumed under one of three factors:
‘active problem-solving’, ‘present state monitoring’ and ‘environmental reactivity’. Implications for
cognitive models and treatments of insomnia are discussed. 7 2000 Elsevier Science Ltd. All rights
reserved.
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1. Introduction
Insomnia, defined as diculty initiating or maintaining sleep (American Sleep Disorders
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Association, 1997), presents in 30% of the adult and older population occasionally, and in 10–
15% on a chronic basis (Foley et al., 1995; Gallup Organisation, 1991; Oyahon, Caulet &
Guilleminault, 1997). Clearly, insomnia is a severe and widespread complaint. However, its
origins are only partially understood.
1.1. Cognitive arousal and insomnia
Investigation of the relative influence of cognitive and physiological arousal, consistently
associates the former more strongly with sleep disruption, and ‘having an overactive mind’ has
been the attribution of poor sleep rated most highly, both by insomniacs and non-insomniacs
(Broman and Hetta, 1994; Espie, Brooks & Lindsay, 1989; Evans, 1977; Lichstein &
Rosenthal, 1980; Nicassio, Mendlowitz, Fussel & Petras, 1985). However, there have been
conflicting conclusions from studies investigating the relationship between pre-sleep cognitive
activity and dierent measures of sleep latency. Van Egeren, Haynes, Franzen & Hamilton
(1983) found that cognitions were significantly correlated with subjective sleep latency, but not
with electroencephalographic (EEG) sleep; whereas Borkovec, Grayson, O’Brien and Weerts
(1979) and Kuisk, Bertelson and Walsh (1989) reported more frequent cognitive activity in
objective insomniacs (i.e. sleep disturbance confirmed by EEG data) than in subjective
insomniacs. Sanavio (1988) reported a very low product–moment correlation (r = 0.09)
between pre-sleep intrusion and self-reported sleep latency, and furthermore, found no specific
advantage of a tailored cognitively focused program in the treatment of sleep-onset insomnia.
The possibility, therefore, remains that cognitive arousal is simply an epiphenomenon of night-
time wakefulness (Freedman and Sattler, 1982; Morin, 1993).
Support for a cognitive model has also come from studies where significant sleep diculties
have been induced through the experimental manipulation of cognitive intrusions in the pre-
sleep period (e.g. Gross and Borkovec, 1982; Hall et al., 1996). However, Haynes, Adams and
Franzen (1981) exposed insomniacs and non-insomniacs to brief cognitive stressors and found
a decrease in subjective and objective sleep-onset latency among insomniacs on stress nights.
They concluded that a mental processing task which disrupts sleep-related cognitive events
may, as a result, decrease sleep-onset latency, implying that the nature of the intrusive
cognitions may be a critical factor in the final eect upon sleep. It seems possible, therefore,
that failure to dierentiate thought content could result in limited comparability betwen
studies.
1.2. Nature of pre-sleep cognitions
Insomniacs tend to have more negative thoughts than good sleepers at bedtime (Kuisk et al.,
1989; Nicassio et al., 1985; Van Egeren et al., 1983) and such thinking processes remain part of
their experience even when wakened from light sleep (Borkovec, Lane & Van Oot, 1981). There
is evidence that the thoughts of insomniacs may be dependent on emotional state. In a study
investigating the relationship between worry and insomnia, Watts, Coyle and East (1994)
found that much of the pre-sleep mental activity of ‘worried insomniacs’ revolved around
work-related issues and general mental activity. In contrast, thoughts of ‘non-worried
insomniacs’ tended to focus on problems they were having with the sleep process itself.
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Insomniacs also feel less in control of their thinking (Watts, East & Coyle, 1995). Gendron,
Blais and Morin (1998) have reported that insomniacs with co-morbid Generalised Anxiety
Disorder (GAD) had higher levels of cognitive activity at bedtime than insomniacs without
GAD, evaluated their thoughts as more intrusive and worrisome and attempted cognitive
avoidance strategies more frequently.
Espie and Wicklow (1999) have proposed a treatment model for insomnia, comprising four
pre-requisites for successful cognitive de-arousal. First, a reduction of the ‘business/work’ of
the mind; second, a reduction of ‘eort/control over sleep’ itself; third, a reduction of ‘aect/
anxiety’; and fourth, a reduction of ‘mental acuity/thought readiness’. Morin (1993) similarly
has argued that dysfunctional beliefs and attitudes about sleep play a critical role in the
maintenance of night wakefulness. However, the available literature concerning the actual
thought content of insomniacs during sleep-onset is insuciently detailed to test such models.
Formal analysis of sleep-interfering cognitions has been reported in only three studies. Coyle
and Watts (1991) used an extended 30-item version of the Sleep Disturbance Questionnaire
(Espie et al., 1989), and reported two distinct cognitive factors. One was labelled ‘sleep
attitudes’ and reflected anxiety about the sleep process; the other was labelled ‘mental activity’
reflecting non-specific cognitive activity. Six factors of night-time intrusive thoughts, i.e. mental
activity and rehearsal; thoughts about sleep; family and long-term concerns; positive plans and
concerns; somatic preoccupations; and work and recent concerns, were identified in a later
study of young adults by Watts et al. (1994). An extensive study by Fichten et al. (1998) of the
thoughts of older adults (mean age 68 years) during wakeful periods in bed yielded a three
factor solution of generalized positive thinking, generalized negative thinking and thoughts
related to sleep. They suggested that insomniacs may use positive thinking as a ‘buer’ in an
attempt to combat more negative intrusions.
1.3. Methodological issues in previous research
In many studies cognitive arousal has been measured by self-report questionnaire (e.g.
Gendron et al., 1998; Sanavio, 1988) such as the Pre-Sleep Arousal Scale (PSAS; Nicassio et
al., 1985), or by checklists of thought content (e.g. Watts et al., 1994). However, such measures
may not adequately assess intrusions for two reasons. First, they limit responses to a
predetermined set of items; and second, they are retrospective reports completed the following
morning. Sleep Diary estimates of sleep (e.g. Fichten et al., 1998; Gendron et al., 1998;
Sanavio, 1988) also present problems; first, due to their limited reliability as indices of
underlying sleep pattern; and second, because of their inherently subjective nature. They are of
course also retrospective measures. However, apart from issues of validity and reliability with
these measures when considered separately, the main problem arises when comparing
information on intrusions and information on sleep. It is simply not possible to regard these
data as suciently independent to make reasonable judgements concerning relationships
between them. Clearly, what is required is some form of ‘live’ and verifiable independent
monitoring both of thought process and of sleep pattern.
Some workers have attempted to gather direct information on thought content and objective
data on sleep. Van Egeren et al.’s (1983) subjects provided thought reports in response to a
random series of tape-recorded beeps, and Kuisk et al. (1989) conducted brief interviews at
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4 min intervals during the pre-sleep period. Although attempts were made in both these
laboratory-based studies to be minimally intrusive, the procedures had limited ecological
validity. Polysomnography (PSG) is the recognised ‘gold standard’ for measuring sleep, and
has been employed in studies of pre-sleep cognitive activity (e.g. Broman and Hetta, 1994;
Kuisk et al., 1989; Van Egeren et al., 1983). However, for this purpose PSG may introduce an
experimental eect. First, PSG is physically intrusive involving electrode placement. Second, it
introduces the subject to a dierent environment (even if home recording is possible the
stimulus environment is altered). Third, and most importantly, PSG may influence reported
thought content towards situational/procedural rather than internal factors. An alternative
method for assessing sleep parameters, which is reliable and minimally intrusive, is the wrist
actigraph. The actigraph is a small device attached to a wrist strap. Internal motion sensors
record the wearer’s movements and these data can be downloaded for analysis. Although the
actigraph solely measures activity, it is increasingly recognised that movement is a good
predictor of wakefulness and lack of movement a good predictor of sleep (American Sleep
Disorders Association, 1995; Sadeh, Hauri, Kripke & Lavie, 1995). Measures derived from the
wrist actigraph have been found to correlate around r = 0.80 to 0.95 with PSG measures
(Kripke, Mullaney, Messin & Wyborney, 1978; Mullaney, Kripke & Messin, 1980; Sadeh et al.,
1995).
In this study, cognitions were obtained as they arose using voice-activated audiorecording
and sleep was measured using the wrist actigraph. It was considered that this methodology
would be minimally intrusive, clinically and ecologically valid, being carried out in the subject’s
own environment, and yet being self-administered, would eliminate other extraneous influences
on sleep. The purpose of the study was, firstly, to determine the nature and content of pre-
sleep cognitions reported by people who complain of significant disturbance in falling asleep;
and secondly, to investigate their eect (both in terms of amount and content of thinking) on
subjective and objective measures of sleep.
2. Method
2.1. Subjects
Subjects were recruited through advertisement in a University sta newsletter, and notices
placed in the Department. Subjects were included if they were aged between 16 and 65 years,
and if they complained of clinically significant problems in falling asleep, according to
International Classification of Sleep Disorders criteria, i.e. sleep latency of 30 min occurring on
four out of seven nights, with or without disruption to other sleep variables (American Sleep
Disorders Association, 1997), and scored in excess of 5 on the the Pittsburgh Sleep Quality
Index (Buysse, Reynolds, Monk, Berman & Kupfer, 1989). Subjects were excluded if they were
receiving treatment for sleep diculties; suering from medical conditions known to impact on
sleep; suering from a psychopathological disorder; or if they suered intermittent awakenings
without a diculty in getting to sleep. Potential subjects completed a telephone screening
interview to determine eligibility for inclusion. Twenty-one suitable participants were identified
(14 female, seven male) with mean age of 36 years and average duration of sleep disturbance of
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10 years (Table 1). Prior to investigation, subjects received an information leaflet on the study
to which an informed consent slip was attached, and several intake questionnaires, including a
Sleep History Questionnaire (from Morin, 1993) to complete and return.
2.2. Measures
Four main measures were used in this study:-
1. The subjective assessment of sleep consisted of a Sleep Diary which is a well-documented,
retrospective, self report measure and is completed upon rising (Espie, 1991). This provides
a summary record of parameters from the preceding night’s sleep.
2. An objective measure of sleep was obtained using wrist actigraphic recording on the
‘Actiwatch’ (Model AW21 Cambridge Neurotechnology Ltd). The period of time the
actigraph accumulates activity counts, before saving the sample and resetting the counter to
zero, is referred to as the epoch length. For this study the epoch length chosen was 1 min
(for sleep analysis, an interval of 1 min or less is recommended). A recording epoch is
scored as ‘sleep’ or ‘wakefulness’ according to criteria determined by the program’s
algorithm. The actigraph also had an event marker button which, when depressed, marked
the date and time.
3. The cognitive sub-scale of the Pre-Sleep Arousal Scale; a self-administered, eight item
questionnaire, was completed each morning (Nicassio et al., 1985). This provided a
description of the subject’s level of cognitive arousal as they fell asleep. Subjects rated on a
five point scale (‘not at all’–‘extremely’) how intensely they experienced each of the
symptoms as they attempted to fall asleep.
4. Subjects were provided with a voice-activated audiocassette recorder (Sony Cassette
Recorder TCS-580 V) to place at their bedside on each night of investigation. This provided
a ‘live’ measure of the content and nature of intrusive thoughts experienced as the subject
attempted to fall asleep.
Table 1
Summary descriptive information on sample (n=21)
%
Sex Male (n=7) 33.3
Female (n=14) 66.7
Marital status Married (n=8) 38.1
Single (n=10) 47.6
Divorced (n=3) 14.3
Bed partner 47.7
Occupational situation Working 85.7
Student 14.3
Age (years) Mean Range S.D.
36.0 19–60 10.8
Duration of sleep problem (years) 10 1–40 8.2
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2.3. Procedure
The procedure for the direct monitoring of intrusive thoughts was developed after piloting
the use of the voice-activated recorder on a small group of volunteers. Once set to record,
subjects were instructed to leave the recorder at their bedside while they attempted to fall
asleep. When having diculty in falling asleep, they were instructed to say aloud whatever was
going through their mind. No directive guidelines were given on what should be recorded in
order to minimise performance anxiety and to allow subjects to express themselves freely.
Subjects were also supplied with a wrist actigraph and instructed to wear it continuously for
three nights. If the actigraph had to be removed, for example in wet activities, then a record
was kept by depressing the actigraph’s event marker button, which was also used to mark
‘lights out’ and ‘rising time’. The Sleep Diary and Pre-Sleep Arousal Scale were completed
upon rising after each night of investigation. Subjects were instructed to go to bed as normal,
following their usual routine. The actigraph was removed upon completion of three nights’
wear and returned to the investigators along with the completed forms and audiotape.
3. Results
3.1. Content analysis of pre-sleep cognitions
Data were available for three nights for each of the 21 subjects, i.e. 63 subject nights. The
following procedure was adopted for the content analysis.
1. Tape-recorded material was transcribed.
2. Transcripts were segmented into a series of single ideas or statements which could stand
alone.
3. The segmented transcripts were independently studied by the authors to generate descriptive
themes.
4. Themes were then discussed and those sharing common content were grouped into
categories, and then into sub-categories. The model of cognitive, somatic and environmental
arousal proposed by Espie (1991) was useful here.
5. Detailed criteria for the coding of segments to categories were agreed (available from the
corresponding author).
6. Segments were then categorised and an independent reliability check was conducted on a
proportion of the transcripts.
This procedure generated over 1,000 thought segments. Derived thought categories are
presented in Table 2 and brief definitions are provided. Reliability of coding to category was
found to be satisfactory with 93% agreement between independent raters using a sample of
four subjects, i.e. 12 transcripts. Agreement did not vary substantially across categories.
Since aect may also be an important factor in the pre-sleep experience, a numerical global
rating of emotion was assigned to each subject night according to the dominant emotion
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expressed on the tape, taking into account the tone and content of speech. A 10 point Likert
scale ranging from ÿ5 (extremely unpleasant) through 0 (neutral) to +5 (extremely pleasant)
was used. Since this was an assessment of perceived emotion, reliability was again investigated
using a sample of four subjects, i.e. 12 tape recorded nights. Agreement was deemed acceptable
if numerical ratings, independently assigned, were either the same or within one integer of the
same value. Concordance between raters for aective state was found to be reasonable at 80%.
Table 2 presents a profile of the nature and frequency of occurrence of each category of
thought. As can be seen, by far the most commonly reported thoughts concerned rehearsing,
planning and problem-solving (43% of total). Thoughts relating to the sleep process and its
consequences were also quite common (20%), followed by non-specific ‘thinking about
thinking’, and thoughts relating to arousal status (12% and 9% respectively). The remaining
four categories together comprised the remaining 16%. Friedman two-way analyses of variance
for related samples were used to test for systematic variations across the three nights. These
showed that there was no significant dierence between nights, and in particular, no ‘first night
eect’. Therefore, data from each night could be included in subsequent analyses.
3.2. Sleep pattern
Actigraphic and Sleep Diary data were obtained from 21 subjects for a total of 63 nights,
from which the following measures were calculated: sleep onset latency (time taken to fall
Table 2
Categories of thoughts derived from content analysis of audiotape-recorded material with examples for each coding
category
Thought category Sample content n of
thoughts
% of
total
Rehearsing/planning,
problem-solving
Thinking about the past day, past experiences, next day, things to
do, planning things, forthcoming events, work-related and social
issues, friends and family
465 43
Sleep and its
consequences
Thinking about need/desire to sleep, eorts/time/expectancy to fall
asleep, ease/diculty of falling asleep quickly, importance of sleep,
consequences of not sleeping, having a sleep problem, past
experience of sleep
217 20
Reflection on quality
of thoughts
‘Thinking about thinking’, mind buzzing, thoughts rushing, darting
thoughts, visual imagery, random/dream-like thoughts, reference to
own type of thinking, uncontrollability, unpleasantness
129 12
Arousal status Thinking about feeling exhausted, experiencing sleepiness,
preoccupation with physical tiredness
93 9
External noise Thinking about the wind, wood creaking, trac, clock, telephone
ringing
69 6
Autonomic
experiences
Thinking about heart rate, headache, tension, body movement,
feeling cold, hot feet, breathless, itching, restlessness
67 6
Procedural factors Thinking about procedure of the research itself, need to press
actigraph button, thinking about what to say aloud
35 3
Rising from bed Thinking about getting up, putting the light on 15 1
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Table 3
Means, ranges and standard deviations for actigraphic and sleep diary data with results of two-tailed t-tests for paired samples and product-
moment correlations (63 subject nights)
Actiwatch Data Sleep Diary Data
Minimum Maximum Mean S.D. Minimum Maximum Mean S.D. t-test Pearson
Sleep-onset latency (min) 0 157 29.6 34.49 0 240 57.69 48.55 t=4.801 p<0.001 r=0.419 p<0.001
Sleep eciency (%) 55.1 95.4 76.59 9.38 38.3 96 71.82 12.25 t=2.719 p<0.008 r=0.194 p<0.128
Total sleep time (min) 278 539 383.17 55.42 180 540 359.71 69.19 t=3.010 p<0.004 r=0.526 p<0.001
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asleep); total sleep time; and sleep eciency (the percentage of time spent asleep relative to
time in bed). Table 3 presents means and standard deviations for actigraphic and sleep diary
data, and the results of two-tailed t-tests for paired samples. Pearson correlation coecients
were computed to evaluate the relationships between variables. Table 3 confirms that the
subjects had significant sleep problems. Objectively measured sleep eciency was 77%, well
below the criterion cut-o point of 85% which defines clinical problems. Subjects typically
slept around 6.5 h per night. Comparison of actigraphic and subjective measures demonstrated
that, although moderately correlated (r = 0.42–0.53 for principal measures), mean scores
diered significantly. Subjects overestimated sleep latency by around 28 min and
underestimated time slept by a similar margin.
3.3. Relationship between sleep and cognitions
Correlational data on the relationships between derived thought categories and objective and
subjective measures of sleep disturbance are presented in Table 4. It is noteworthy that the
patterns of association were generally dierent for actigraphic and diary measures of sleep.
Actigraphic sleep latency correlated modestly but significantly with three derived thought
categories, including the two most frequently reported i.e. rehearsal/planning (r = 0.33) and
sleep and its consequences (r = 0.37), along with autonomic functions (r = 0.29). By
comparison subjective sleep latency did not correlate with any specific thought category.
However, subjective sleep eciency correlated inversely with sleep and its consequences
(r=ÿ0.28) and general arousal (r=ÿ0.37). Both measures of sleep-onset correlated with the
total number of thought segments, although for the sleep diary measure this correlation was
Table 4
Correlations between actigraphic and sleep diary measures of sleep disturbance and tape-recorded cognitions. p<
0.05 p<0.01 p<0.001
SOL actigrapha Eciency actigraphb SOL diarya Eciency diaryb
Rehearsing/planning, problem-solving 0.326 ÿ0.183 0.239 0.043
Sleep and its consequences 0.372 0.002 0.186 ÿ0.278
Reflection on quality of thoughts 0.034 0.220 0.194 0.089
Arousal status 0.040 ÿ0.088 0.153 ÿ0.370
External noise 0.140 ÿ0.081 0.010 ÿ0.094
Autonomic experiences 0.289 ÿ0.043 0.156 ÿ0.152
Procedural factors ÿ0.010 0.005 ÿ0.029 0.115
Rising from bed 0.050 0.029 0.040 ÿ0.045
All thoughts 0.334 ÿ0.095 0.261 ÿ0.163
PSAS cognitive subscale 0.173 ÿ0.049 0.424 ÿ0.495
Rating of emotion ÿ0.293 0.019 ÿ0.193 ÿ0.033
F I ‘active problem-solving’ 0.319 ÿ0.160 0.222 ÿ0.044
F II ‘present state monitoring’ 0.232 0.074 0.244 ÿ0.317
F III ‘environmental concerns’ 0.136 ÿ0.066 0.079 ÿ0.060
a SOL: sleep onset latency; bsleep eciency: % of time in bed spent asleep.
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relatively weak. Thoughts relating to external noise, procedural factors and rising from bed
were unrelated to any sleep measure, perhaps due to their infrequency.
The cognitive subscale of the PSAS was not found to be associated with objectively
measured sleep, whereas highly significant correlations were observed with diary measures of
both sleep latency and sleep eciency ( p<0.001). In contrast, unpleasant emotional state was
found to correlate with objective but not subjective sleep latency.
3.4. Interrelationships between thought categories (Principal Components Analysis)
In order to develop an explanatory model, a principal components analysis was performed
on the eight derived categories of thought intrusions. Varimax rotation yielded a three-factor
solution, each with eigenvalue greater than 1 and explaining more than 10% of variance
(Table 5). Factor I comprising problem-solving thoughts, thoughts about feeling tired and
about the experimental procedure itself, explained 33% of variance and was labelled ‘active
problem-solving’. Factor II explained a further 17% of variance and was labelled ‘present state
monitoring’ since it comprised reflective thoughts relating to sleep, bodily functions and general
introspection. Factor III explained 13% of variance and was labelled ‘environmental reactivity’
since it comprised responses to or awareness of external stimulation disrupting sleep. The total
explained variance of this solution, therefore, was 63%. Inspection of factor loadings in Table 5
suggests a relatively ‘pure’ factor structure.
Factor scores were then calculated and correlated with sleep measures. The results of this
analysis are presented in the lower half of Table 4. As can be seen, ‘active problem solving’
was positively correlated with actigraphic sleep latency (r = 0.32). ‘Present state monitoring’
just failed to reach significant correlation with objective ( p=0.06) and subjective sleep latency
Table 5
Results of Principal Components Analysis comprising derived factors, and factor loadings (significant values in
bold)
Extraction Eigenvalue % of variance Cumulative % %Explained variance
Factor I 2.636 32.95 32.95 52.22
Factor II 1.386 17.33 50.28 27.47
Factor III 1.025 12.81 63.09 20.31
Rotated Factor Matrix Factor I
‘active problem solving’
Factor II
‘present state monitoring’
Factor III
‘environmental reactivity’
Rehearsing/planning,
problem solving
0.760 0.340 0.106
Sleep and its consequences 0.111 0.743 0.134
Quality of thoughts 0.462 0.545 0.270
Arousal status 0.608 0.390 ÿ0.039
External noise 0.036 0.224 0.785
Autonomic experiences 0.044 0.676 ÿ0.128
Procedural factors 0.821 ÿ0.223 0.141
Rising from bed 0.147 ÿ0.179 0.845
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( p= 0.055), but was inversely correlated with subjective sleep eciency (r=ÿ0.32). Factor III
‘environmental reactivity’ was unrelated to any sleep parameter.
3.5. Validation of derived factors
The cognitive sub-scale of the PSAS, although limited by its retrospective and global nature,
has been widely used in previous research. Similarly, aect-laden cognitions have been reported
to be more strongly associated with sleep disruption than non aect-laden thoughts (see
introduction). Therefore, the PSAS sub-scale and the independent rating of emotion used in
this study, were correlated with the derived factors for the purpose of preliminary validation.
Correlations with the PSAS were for Factor I (r=0.209; p=0.099), Factor II (r=0.427; p<
0.001) and Factor III (r= 0.223; p= 0.078) suggesting that ‘present state monitoring’ is more
similar to the measurement properties of the PSAS than is ‘active problem-solving’ or
‘environmental reactivity’. Correlation with emotional state was strong both for Factor II
(r=ÿ0.420; p = 0.001) and Factor III (r=ÿ0.419; p = 0.001) suggesting that emotionality is
more negative with higher levels of ‘present state monitoring’ and greater ‘environmental
reactivity’. The non-significant correlation with Factor I ‘active problem-solving’ (r=ÿ0.189; p
= 0.138) implies that this form of mental activity is less aect laden. It should be noted that
PSAS scores and emotionality ratings were somewhat independent of one another being
modestly inversely correlated (r=ÿ0.301; p=0.016).
3.6. Regression analyses
To further consider potential explanatory models, all measures of pre-sleep cognitive activity
which correlated significantly with a sleep measure (Table 4; p < 0.05) were entered into a
stepwise linear regression on that particular sleep variable. The results af these analyses are
presented in Table 6.
An equation combining ‘rehearsing and planning’ thoughts with those concerning ‘sleep and
its consequences’ explained around 16% of variance (adjusted R 2=0.161) in actigraphic sleep
Table 6
Stepwise linear regression of explanatory pre-sleep cognitive variables upon actigraphically and subjectively reported
sleep disturbance
Outcome variable F ratio p R 2 Adj. R 2 Explanatory variables
(beta; prob)
Actigraphic data
Sleep-onset latency 6.97 0.0019 0.188 0.161 ‘sleep and its consequences’ (0.300;
p=0.017) ‘rehearsing/planning problem
solving’ (0.235; p=0.048)
Sleep eciency – – – – no predictors
Diary data
Sleep-onset latency 13.36 0.0005 0.180 0.166 PSAS cognitive sub-scale (0.424; p=<0.001)
Sleep eciency 19.77 0.0001 0.244 0.232 PSAS cognitive sub-scale (ÿ0.495; p<0.001)
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latency. By comparison, subjective report of sleep-onset was predicted only by scores on the
cognitive sub-scale of the PSAS (Adj. R 2=0.17). Actigraphic sleep eciency had no significant
predictors, and for subjective sleep eciency, only the cognitive sub-scale of the PSAS entered
significantly (Adj. R 2=0.23).
4. Discussion
This study investigated systematically the relationship between independently gathered,
objective data on mental activity and sleep pattern. There has been increasing emphasis in the
insomnia literature both upon cognitive models of aetiology and maintenance, and upon
cognitive mediation of treatment eects. Therefore, the results of the study are of particular
relevance at this time.
The use of voice-activated audiotape recorders made it possible to gather information ‘live’
while subjects lay awake in bed during the pre-sleep period. Informal reports indicated that
they found this procedure, and wearing the wrist actigraph, relatively non-intrusive. This is
supported by content analysis of the tape-recordings where only 15 out of 1090 thought
segments (3%) related to the research process itself. Also, there was no evidence of the ‘first
night eect’, common in EEG studies of sleep, either in terms of volume or content of thought
intrusion. Significant dierences were observed between actigraphic and subjective assessment
of sleep pattern. Indeed, diary reports overestimated objective sleep-onset latency by 100%,
while still achieving modest correlation (r=0.42). Such findings are entirely consistent with the
literature, and underline the potential importance of considering subjective and objective data
as separate factors in explanatory models. We would argue, therefore, that the data gathered in
this study are both valid and reliable for their purposes of assessing cognitions (volume and
content) and sleep (objective and subjective).
Categorisation of transcribed audiotape material achieved highly satisfactory levels of
concordance between independent judges. Thus, the derived content analysis appears to be
reasonably robust. ‘Rehearsing, planning and problem-solving’ thoughts formed the largest
component of pre-sleep cognitive activity. Approaching half of all mental activity was of this
type, comprising reflection on the day past, preparation for the next day and consideration of
personal and work-related matters. It cannot be assumed, of course, that these thoughts were
necessarily worrisome to the subjects, or that they caused delayed sleep. Certainly, a modest
but significant correlation was observed with actigraphic sleep latency (r= 0.33) suggesting, at
least, that the longer subjects were awake the more rehearsal and planning occurred. The
Principal Components Analysis (PCA) loaded thoughts about physical tiredness and about the
experimental procedure itself, along with these problem-solving thoughts into Factor I. This
factor also correlated with objective sleep latency (r = 0.32). Interestingly, however, Factor I
was the only factor which did not correlate significantly with the rating of emotional tone
implying that ‘active problem-solving’ is a less aect-laden form of cognition. In relation to the
model proposed by Espie and Wicklow (1999), it may correspond to the pre-sleep cognitive
‘load’ or ‘business’ of the mind where mental arousal primarily reflects activity rather than
concern.
Thinking about ‘sleep and its consequences’ represented the next most frequent form of
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thinking, comprising around 20% of all thought segments. Typically, subjects reported
preoccupation with being unable to fall asleep and the anticipated impact which poor sleep
might have on daytime performance and mood. This category again correlated with objective
sleep latency (r = 0.37). PCA factored ‘sleep and its consequences’ along with ‘reflection on
quality of thoughts’ and ‘autonomic experiences’ into Factor II ‘present state monitoring’. This
label was chosen in consideration of common factor variance which appeared to be concerned
with self-awareness and self-monitoring. Although Factor II did not correlate significantly with
actigraphic sleep latency, an inverse correlation was found with emotional tone, i.e. the greater
the state monitoring the more unpleasant the perceived emotion. Insomniacs have long been
regarded as introspective and prone to worry, and this factor seems most closely associated
with this disposition, as well as the with the concept of aect-laden thinking. It is also
noteworthy that concern about sleep and its consequences has previously been proposed as
central to the dysfunctional beliefs and attitudes which insomniacs have about their sleep, and
as an important target for change using cognitive therapy techniques (Espie, Inglis, Harvey &
Tessier, 1999; Morin, 1993; Morin, Stone, Trinkle, Mercer & Remsberg, 1993). ‘Autonomic
experiences’ was the only other type of thinking from the content analysis to be specifically
correlated with objective sleep latency, and as mentioned above, this category appears
associated with more general internalised focussing (Factor II).
It is particularly striking that none of the derived categories or factors of intrusive thinking
correlated significantly with subjective perception of sleep latency. The Sleep Diary is the
standard assessment tool in clinical practice with insomniacs and yet, in this study, it was only
objective measurement which demonstrated significant association with discrete cognitions.
Self-report was, however, quite strongly associated with scores on the cognitive sub-scale of the
PSAS (r= 0.42), whereas actigraphic measurement was not (r= 0.17). This divergence implies
that self-report and objective indices may reflect diering facets of sleep phenomenology.
Inevitably, the PSAS is a global index and it might be expected to correlate better with another
summary, retrospective measure such as subjective sleep eciency. The PSAS is probably most
useful in dierentiating, i.e. high versus low arousal, insomniacs versus non-insomniacs or
cognitive versus physiological hyperarousal. Although an association was found between
Factor II and the PSAS (r= 0.43), only the thought categories of ‘sleep and its consequences’
and ‘rehearsing, planning and problem-solving’ contributed significantly to the prediction of
objective sleep latency. The PSAS was the only measure to predict subjective latency and
subjective sleep eciency. There are two clear implications arising from these findings. First,
diary assessment of sleep may not be suciently accurate for investigation of explanatory
models of objective sleep pattern; and second, where cognitive models are under consideration,
particular care needs to be taken to avoid ‘globalising’ the cognitive phenomenon itself.
Numerous reviews and meta analyses have confirmed that cognitive–behavioral treatment
for insomnia is eective in treating sleep-onset insomnia (Edinger and Wohlgemuth, 1999;
Morin, Culbert & Schwartz, 1994; Morin et al., 1999; Murtagh and Greenwood, 1995).
However, it now seems important to understand their influence on cognitive processes per se.
Presumably, if falling asleep more quickly, a treated insomniac will have fewer pre-sleep
thoughts. However, the eects of specific treatments upon specific types of thoughts may tell us
something both about the nature of insomnia itself and the mechanism of action of
psychological treatment. Similarly, a comparative study with normal sleepers would be
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valuable. The present study may provide a useful methodology for further research. It is
suggested (a) that actigraphic monitoring of sleep merits further application in this field; (b)
that methods of ‘live’ recording of intrusive thoughts should be developed further. In
particular, more consideration might be given to the type and degree of emotional expression
and how that can be rated from audiotape material; and (c) that the categories derived from
content analysis and the factors derived from PCA in this study might be helpfully
incorporated into a rating scale format for further validation.
The advantages of tailoring treatment for insomnia, although intuitively appealing, are less
persuasive from empirical evidence (Edinger and Wohlgemuth, 1999; Espie et al., 1989;
Sanavio, 1988). This reflects a mismatch somewhere within the matrix of presumed and actual
causes/maintaining factors of insomnia, and presumed and actual mechanisms of action of
interventions for insomnia. Additionally, however, is the suggestion from this study that the
sources of data for the appraisal of outcome may be crucial, i.e. objective/specific versus
subjective/global. Clarification of this overall matrix is the ultimate research goal which will
deliver the most ecient and eective treatment.
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n Abstract This paper critically reviews the evidence base for previously reported
conceptual models of the development and persistence of insomnia. Although a number
of perspectives have some empirical support, no one approach emerges as preeminent.
Importantly, the efficacy of any particular psychological intervention cannot be taken
as confirmation of presumed, underlying mechanisms. An integrated psychobiological
inhibition model of insomnia is developed that accounts for the research data. The
model views insomnia as arising from inhibition of de-arousal processes associated
with normal sleep. It is proposed that sleep homeostatic and circadian factors are
compromised by impairment of the automaticity and plasticity associated with good
sleep, and that cognitive/affective processes activate the clinical complaint of insomnia.
Common pathways for the action of cognitive-behavioral interventions are identified,
and a research agenda is set for further conceptual and clinical study.
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AN INTRODUCTION TO INSOMNIA
The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) defines
primary insomnia as a complaint lasting for at least 1 month of difficulty initi-
ating and/or maintaining sleep or of nonrestorative sleep (Am. Psychiatr. Assoc.
1994). The International Classification of Sleep Disorders-Revised (ICSD-R)
uses the term “psychophysiologic insomnia” for such a complaint and associated
decreased functioning during wakefulness. (Am. Sleep Disorders Assoc. 1997).
ICSD-R regards insomnia of 6-month duration as chronic. Both systems differen-
tiate insomnia from circadian rhythm disorders, in which timing of the major sleep
period is out of alignment with the local clock; from parasomnias, in which behav-
ioral events occur in association with sleep (e.g., sleepwalking, night terrors); and
from secondary insomnias, in which psychiatric, neurologic, or medical problems
present. Disorders such as sleep apnea, with associated respiratory impairment, and
disorders of excessive sleepiness (e.g., narcolepsy) are also classified separately.
Conservative estimates for chronic insomnia range from 9–12% in adulthood
and up to 20% in later life, and women present about two times more than men
(Bixler et al. 1979, Mellinger et al. 1985, Ford & Kamerow 1989, Gallup Organi-
sation 1991, Foley et al. 1995, Hoch et al. 1997). Sleep disturbance is a common
complaint in general practice (Shocat et al. 1999) and once established may persist
over many years (Mendelson 1995). Insomnia therefore constitutes a considerable
public health problem. The direct costs of assessing and treating insomnia were
approximated as $14 billion in the United States and FF10 billion in France in
1995 (Walsh & Engelhardt 1999, Leger et al. 1999).
Polysomnographic assessment (PSG) comprises monitoring of the electroen-
cephalogram (EEG) along with muscle activity, eye movement, respiration, and
blood oxygen saturation levels. However, PSG is not required unless clinical pre-
sentation raises the possibility of disorders such as sleep apnea (Gillin & Byerley
1990, Douglas et al. 1992, Reite et al. 1995, Am. Sleep Disorders Assoc. 1995a).
Actigraphic assessment is helpful to identify disorders of circadian function. The
wrist actigraph provides data on body movement over extended periods (typically
1 minute epochs for several weeks) and is a reliable index of sleep parameters
(Sadeh et al. 1995, Am. Sleep Disorders Assoc. 1995b).
In practice, structured interview is recommended (Buysse et al. 1989, Morin
1993, Spielman & Anderson 1999, Espie 2000), supplemented by a sleep diary
completed upon waking, comprising information on sleep-onset latency (SOL),
A
nn
u.
 R
ev
. P
sy
ch
ol
. 2
00
2.
53
:2
15
-2
43
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
by
 G
la
sg
ow
 U
ni
ve
rs
ity
 o
n 
10
/0
3/
12
. F
or
 p
er
so
na
l u
se
 o
nl
y.
30 Nov 2001 10:40 AR ar146-09.tex ar146-09.sgm LaTeX2e(2001/05/10) P1: GJC
CONCEPTUAL ISSUES IN INSOMNIA 217
wake time after sleep-onset, and total sleep time (Espie 1991). Time in bed (TIB)
is calculated by subtracting rising time from bedtime, and the sleep efficiency
index is computed as the ratio of total sleep time to TIB expressed as a percentage.
A sleep efficiency index of 85% is the upper limit for poor sleep (Frankel et al.
1976, Coates et al. 1982), and a minimum SOL or wake time after sleep-onset of 30
minutes per night is a threshold for clinical significance (Espie et al. 1989a, 2001a).
Baseline values in outcome studies, however, are typically twice this level (Morin
et al. 1999b). With medication, alcohol, and ratings of sleep quality commonly
included, the sleep diary quantifies sleep experience and permits study of night-to-
night variability, which is important because unpredictability of sleep is a feature
of insomnia (Coates et al. 1982, Roth et al. 1976).
The American Academy of Sleep Medicine (AASM) has published practice
parameters for the assessment (Chesson et al. 2000) and nonpharmacological treat-
ment of insomnia (Chesson et al. 1999). The latter were derived from systematic
review (Morin et al. 1999b) following meta-analyses demonstrating the efficacy
of cognitive-behavioral treatment (CBT) for adults (Morin et al. 1994, Murtagh
& Greenwood 1995). Another review came to similar conclusions (Edinger &
Wohlgemuth 1999). Furthermore, clinical effectiveness studies have produced
comparable results (Espie et al. 2001a,b), and CBT with or without pharma-
cotherapy compares favorably with pharmacotherapy alone for older adults (Morin
et al. 1999a). CBT, therefore, may be the treatment of first choice for chronic in-
somnia (Espie 1999). The role of hypnotic medication has been debated (Kripke
2000, Kramer 2000, Buysse 2000), there being little evidence of long-term effi-
cacy for any drug. Recent textbooks also provide useful discussion: Lichstein &
Morin (2000) focus on late-life insomnia, and Pressman & Orr (1997) provide
an overview of insomnia in medical patients. Finally, an AASM working group
on research diagnostic criteria will report in 2002 (Edinger et al. 2002). Thus,
there is a sizeable, systematic, and practitioner-oriented literature on insomnia.
The conceptual foundations of insomnia, however, have been more neglected, and
it seems timely to review models of the development, persistence, and treatment of
insomnia, to evaluate explanatory mechanisms, and to propose an evidence-based
integrated model.
THE CONCEPTUAL BASIS FOR THE DEVELOPMENT
AND MAINTENANCE OF INSOMNIA
A wide range of factors may play some part in insomnia. It may be helpful to
consider each of these before presenting a proposed integrated model.
Normal Sleep in Human Development
Wakefulness is not pathological. On the contrary, it might be considered the pre-
ferred state because a primary function of sleep is to ensure wakeful cortical
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function (Horne 1988). Prolonged wakefulness reliably induces sleep, and failure
to obtain at least a core amount (sleep deprivation) leads to impaired function.
Two processes interact in normal sleep (Borbely 1994). The sleep homeostat
“drives” the sleep-wake schedule toward a balanced requirement because pro-
longed wakefulness accrues “sleep debt” (Carskadon & Dement 1981) and sleep
pays off the debt; the circadian timer regulates the biological clock in approxima-
tion to the 24-hour clock (Borbely 1994, Moore-Ede et al. 1982). These processes
also regulate type of sleep (Dement 1960). Thus, young children have longer
sleep periods than adults and have higher proportions of rapid eye movement
(REM) and “deep sleep” (non-REM stages 3 and 4). Similarly, insufficient sleep
induces recovery sleep comprising proportionately more REM and deep sleep. The
sleep of older adults is more fragmented and lighter (Bliwise 1993, Carskadon
et al. 1982), and homeostatic drive declines with age (Buysse et al. 1993), when
disturbances of the sleep-wake schedule are less well tolerated (Webb 1981,
Monk et al. 1992). Thus, increasing age represents a vulnerability factor to sleep
disturbance.
Quality of Sleep
Investigations of PSG and self-report generally reveal modest positive correlation.
Poor sleepers overestimate sleep disturbance relative to objective criteria (see Espie
1991, pp. 17–18). However, insomniacs have reported being awake when roused
from light sleep (Borkovec et al. 1981), and modified EEG criteria are associated
with greater accuracy (Coates et al. 1982). There is debate over whether insomni-
acs are sleepy in the daytime (Seidel et al. 1984, Mendelson et al. 1984, Chambers
& Keller 1993, Lichstein et al. 1994). However, sleep should not be considered
only in terms of chronobiological “fitness for purpose.” The quality of the sleep ex-
perience is important. Indeed, ratings of sleep quality do not necessarily correlate
highly even with subjective reports of sleep pattern. Unpublished analyses from
our recent clinical cohort (Espie et al. 2001b; n D 139) reveal modest inverse asso-
ciation of SOL and wake time after sleep-onset with ratings of “sleep enjoyment”
(r D ¡0.30 and ¡0.31) and “restedness after sleep” (¡0.22 and ¡0.19).
Predisposing, Precipitating, and Perpetuating Factors
How then might insomnia develop? A useful conceptualization comprises pre-
disposing, precipitating, and perpetuating components (Spielman & Glovinsky
1991). Both DSM-IV and ICSD-R report familial association with light, disrupted
sleep, and ICSD-R reports anxious over-concern with health as predisposing. In-
deed, insomniacs appear prone to introspection and worry (e.g., Kales et al. 1984,
Edinger et al. 1988, Lundh et al. 1995, Schramm et al. 1995). Research suggesting
elevated autonomic and metabolic rates also implies a vulnerability factor (Bonnet
& Arand 1995, 1997a). However, predisposing factors alone are unlikely to create
imbalance in sleep homeostasis or circadian timing, although they might impair
sleep quality and, potentially, lead to sleep state misperception (see also Bonnet &
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Arand 1997b). Reduced “plasticity” (see below) might also be a predispositional
factor.
Transient sleep disorder is a likely context in which to identify precipitating
factors. ICSD-R defines adjustment sleep disorder associated temporally with acute
stress, conflict, or environmental change, and shiftwork schedule disorder as a
transient phenomenon relating to work schedules. Because the homeostat and timer
regulate natural variation, it can be hypothesized that there is generally sufficient
plasticity to absorb the impact of such events, and to survive more prolonged
change. The severity and impact of events may need to be greater to precipitate
sleep disturbance in the absence of predisposing factors. Nevertheless, studies
investigating the onset of chronic insomnia have commonly found that stress or
life change was a factor at the time (Healey et al. 1981, Kales & Vgontzas 1992,
Morgan & Clarke 1997). Presumably, some other mechanism accounts for the
persistence of a sleep problem. Why only some disturbances develop into chronic
insomnia when others spontaneously remit, and why good sleep can persist during
chronic stress are important questions requiring further study.
To summarize, predisposition may interact with precipitating factors to create
temporary sleep disruption, but in the absence of perpetuating factors, the plas-
ticity of the sleep-wake schedule would drive toward homeostasis and reestablish
good sleep. The literature has focused primarily on presumed factors maintaining
insomnia.
Mental Disorder
A common misconception is that insomnia is a symptom not meriting treatment
in its own right. However, insomnia can be either a symptom (e.g., a complaint
of difficulty falling asleep) or a disorder (i.e., complaint plus significant distress
and functional impairment) (Harvey 2001a, Lichstein 2000). The misconception is
particularly evident in the mental health field but is unsupported by the literature.
Ford & Kamerow (1989) reported on 8000 respondents, revealing that the risk
of developing depression was much higher in those with preexisting insomnia.
Similarly, Eaton et al. (1995) reported that having a sleep problem was the highest
precursor in terms of attributable risk, identifying 47% of new cases of depression
the following year. Other longitudinal studies have confirmed such findings. One
report on 262 older adults suggested that frequency of depressed affect related to
poor sleep, even when age, sex, and health status were accounted for (Rodin et al.
1988). Breslau et al.’s (1996) work on 1007 21–30-year-olds found that gender-
adjusted relative risk for major depression in people with a history of insomnia was
4.0 (95% CI 2.2–7.0). Weissman et al.’s (1997) epidemiological survey reported
an odds ratio of 5.4 (95% CI 2.6–11.1) for first-onset depression in 414 people with
insomnia and no psychiatric history. Insomnia was also an independent risk factor
for panic disorder and obsessive compulsive disorder. Finally, the Johns Hopkins
Precursors Study found that insomnia in young men was indicative of greater risk
for depression and psychiatric distress that persists for 30 years (Chang et al. 1997).
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Thus, insomnia cannot be accounted for simply as presumed mental disorder.
Furthermore, sleep disturbance often fails to resolve upon recovery from depres-
sion. However, the possibility that insomnia shares some psychobiological diathe-
sis with anxiety and mood disorder is worthy of further investigation.
Faulty Conditioning
Since first proposed by Bootzin (1972), an understanding of insomnia as the prod-
uct of maladaptive sleep habits has had considerable appeal. Good sleep is seen as
coming under the stimulus control of the bedroom environment, which acts as a
discriminative stimulus for sleep (Bootzin et al. 1991). Difficulty falling asleep may
result either from failure to establish discriminative stimuli for sleep or the pres-
ence of stimuli incompatible with sleep. Poor stimulus control, therefore, might
compete with sleep drive by strengthening conditioned arousal, and with circa-
dian timing by doing so at normal bedtime. The insomniac may also nap in an
armchair and so strengthen associations between sleep and nonsleeping environ-
ments. Stimulus control treatment instructions comprise lying down to sleep only
when sleepy, avoiding using the bed for activities other than sleep (sexual activity
excepted), getting up if unable to sleep quickly (within 15–20 minutes), repeating
rising from bed as necessary throughout the night, getting up the same time every
day, and avoiding napping (Bootzin 1972, Bootzin & Epstein 2000).
Only a few studies have investigated conditioning in insomnia. Haynes et al.
(1982) compared student insomniacs and noninsomniacs on 12 sleep-incompatible
behaviors, but found only one that differentiated the groups. Furthermore, duration
of engagement in sleep-incompatible activity was unrelated to SOL. They had pre-
viously reported that the number of sleep-incompatible behaviors was not related
to sleep difficulty (Haynes et al. 1974). Although over half the chronic insomni-
acs in Espie et al.’s (1989a) outcome study reported reading or watching TV in
bed, there was no comparison group of good sleepers. Tokarz & Lawrence (1974)
separated situational (reestablishing bedroom cues for sleep) from temporal com-
ponents (regularizing sleep routines) and found both reduced SOL in their student
sample. Zwart & Lisman (1979) conducted a study of 47 undergraduates assigned
to stimulus control (all instructions), temporal control (lie down only when sleepy,
rise at same time each day, do not nap), noncontingent control (a fixed number of
risings within 20 minutes of retiring), countercontrol (sit up in bed and read, watch
TV etc. if unable to sleep), or no treatment. They found countercontrol as effective
as stimulus control, suggesting that it may ensure contingent disruption of bed
and bedtime as cues for mental arousal. Davies et al. (1986) used countercontrol
with older adults and found it moderately effective, although their 30% reduction
in wake time after sleep-onset is less than typically reported in this population
(Morin et al. 1999c).
In spite of equivocal evidence for the mechanism of effect (i.e., is it a stimulus
control paradigm?), there has been little recent work on the conceptual basis of
stimulus control. Harvey (2000a) reported that primary insomniacs did not differ
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from good sleepers on daytime napping, variable sleep scheduling, whether they
stayed in bed or got up when unable to sleep, or on engagement in sleep-incompa-
tible activities. Nevertheless, significantly lower sleep efficiency is typical of
insomniacs, and this may evidence the need for improved stimulus control. In-
terestingly, Bootzin has reported that stimulus control reduces sleep anticipatory
anxiety as well as improving sleep (Bootzin et al. 1999). More research is re-
quired because stimulus control interventions have consistently been found to be
efficacious in meta-analyses (Morin et al. 1994, 1999b; Murtagh & Greenwood
1995). Indeed, they are the only procedures recommended by AASM as comprising
“standard” nonpharmacological treatment for insomnia (Chesson et al. 1999).
Poor Chronobiological Timing
In sleep phase disorders people sleep relatively normally, but during the “wrong”
hours. In Delayed Sleep Phase Syndrome (DSPS), for example, in which the sleep
period is phase delayed, subjects experience sleep-onset insomnia if they attempt
to sleep before they are ready to sleep, and in advanced sleep phase syndrome
sleep-onset is early and the phase advance results in early waking. In primary
insomnia there may be an element of chronobiological dysfunction. For example,
some insomniacs go to bed early and spend excessive time in bed either habitually
as in the case of older adults, or as a response to having slept poorly on previous
nights (Morgan 2000, Morin 1993). This contributes to poor sleep efficiency, which
is affected both by TIB and total sleep time (see above), and can be improved
by spending less time in bed, sleeping longer, or by a combination of the two.
Similarly, napping reduces nighttime sleep drive in adults. The literature may
have failed to discriminate adequately between circadian disorders and primary
insomnia (Morris et al. 1990, Lack & Wright 1993). In particular, DSPS may not
have been identified in studies involving younger populations. Research diagnostic
criteria require clarification (Edinger et al. 2002).
It is suggested that, in the absence of competing factors, good sleep is associated
with optimal, stable, and accurate circadian timing. Stimulus control instructions
contain elements of temporal adjustment (see Lacks 1987, pp. 51–53; Espie 1991,
pp. 51–55) and may provide zeitgebers (Aschoff 1951) for healthy sleep. Sleep
restriction is another technique that may act both as a circadian harmonic and a
reinforcer of homeostatic drive. Patients are encouraged to reduce bedtime hours
(by staying up late and/or rising earlier) to approximate TIB closer to actual sleep
duration (Spielman et al. 1987). Sleep restriction compresses sleep toward greater
continuity, reduces wakefulness in bed, and increases sleep efficiency. Once the
sleep pattern is improved, TIB may be extended, at a rate of 15 minutes per night
per week, until the patient no longer gains further sleep or sleep efficiency is at
risk of being reduced. Wohlegemuth & Edinger (2000) reviewed empirical findings
on the efficacy of sleep restriction, and the AASM support sleep restriction as a
“guideline” intervention for insomnia (Chesson et al. 1999). The synergy between
stimulus control and sleep restriction is evident, and they are often presented
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together. We use the term “sleep scheduling” for the combination (Espie et al.
1998, 2001b).
Recent interest in using appropriately timed bright light exposure to entrain
circadian timing also focuses attention on possible chronobiological explanations
of sleep disorder. Early evening bright light shifts the circadian rhythm of core
body temperature and improves PSG-defined sleep in sleep-maintenance insomnia
(Campbell et al. 1993), and morning light reduces SOL (Lack et al. 1995). Light
exposure may also have a role in managing sleep disturbance in dementia (e.g.,
Satlin et al. 1992).
Physiological Hyper-Arousal
In 1967 Monroe conducted an influential study comparing 16 good sleepers with 16
poor sleepers, suggesting that poor sleepers exhibit heightened autonomic arousal
(higher rectal temperature, vasoconstrictions per minute, perspiration rate, skin
conductunce, body movements per hour) both prior to and during sleep. This work
has been partly replicated (Stepanski et al. 1989), but other studies have failed to
demonstrate arousal differentials. Higher levels of hormones indicative of adreno-
cortical activity have been both supported (Johns et al. 1971, Adam et al. 1986)
and denied (Frankel et al. 1973). Other early work reported less rapid decline in
heart rate associated with sleep in insomniacs, but others found no significant rela-
tionship between sleep-onset and heart rate or frontalis electromyography (EMG)
(Haynes et al. 1974, Good 1975, Browman & Tepas 1976). Now that heart rate
variability in the progression through sleep is better understood in normal subjects
(e.g., Baharav et al. 1995, Bonnet & Arand 1997a), further comparative study seems
warranted. Freedman & Sattler (1982) found that, prior to sleep-onset, insomniacs
had higher frontalis and chin EMG than good sleepers, and the literature on relax-
ation and/or biofeedback treatments (e.g., Borkovec & Weerts 1976, Borkovec &
Sides 1979, Freedman & Papsdorf 1976) might appear to support muscle tension
as a problem in insomnia. However, there is limited evidence of tension reduction
as the active mechanism, and posttreatment changes in EMG, heart rate, or res-
piration have proven elusive (see Espie 1991, pp. 43–45; Bootzin & Rider 1997,
pp. 322–26 for review).
Interest in physiological arousal has been rekindled by evidence that insomni-
acs display measurable neurobiological differences from normal sleepers. Bonnet
& Arand (1995) compared 10 objectively defined insomniacs with age-, sex-, and
weight-matched controls and found they had significantly increased oxygen use
both day and night. They suggested that increased 24-hour metabolic rate could
be magnified by stress or viewed as a “higher arousal set point.” In a complemen-
tary controlled study, 9 subjects with sleep state misperception (SSM) were also
found to have increased metabolic rate, but less so than the primary insomniacs
(Bonnet & Arand 1997b), raising the possibility that SSM is a mild version of, or
precursor to, psychophysiological insomnia. Hyper-arousal has also been investi-
gated in PSG studies. Early reports suggested insomniacs had more beta and fewer
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alpha frequencies in their EEG (Freedman 1987, Freedman & Sattler 1982). Re-
cently, Merica et al. (1998) compared spectral characteristics of 20 insomniacs and
19 controls. For all frequencies below beta, insomniacs had slower rise rates and
reached lower levels, whereas beta power was increased. In REM, insomniacs
showed lower levels in delta and theta bands, whereas power in faster bands was
increased. These findings are consistent with slow wave deficiency in insomnia
accompanied by hyper-arousal of the CNS, suggesting that insomnia may result
from increased cortical activation. They noted, however, that homeostatic control
of slow wave activity appeared to be intact in the patient population. A study
by Loewy & Bootzin (1998) also investigated hyper-arousal and found that event-
related EEG activity, as measured by auditory evoked potentials, provided evidence
of information processing during sleep.
Importantly, however, not all objective poor sleepers complain of insomnia, and
not all subjective insomniacs have poor sleep (Edinger et al. 2000), suggesting that
physiological arousal alone is an insufficient explanation.
Cognitive Hyper-Arousal
It was first reported 25 years ago that poor sleepers complain of mental alertness
more than physiological arousal (Evans 1977). Other studies have consistently
associated cognitive arousal more strongly with sleep disruption, and “having an
overactive mind” has been the attribution rated most highly, both by insomniacs
and noninsomniacs (Lichstein & Rosenthal 1980, Nicassio et al. 1985, Broman
& Hetta 1994). Espie et al. (1989a) reported that the cognitive items of the Sleep
Disturbance Questionnaire (e.g., “my mind keeps turning things over,” “I am
unable to empty my mind”) were the most highly rated; Harvey (2000b) recently
replicated these findings. The Sleep Disturbance Questionnaire has been found to
have modest internal consistency (fi D 0.67) (Espie et al. 2000). Although there
is no gold standard measure of cognitive activity, the Pre-Sleep Arousal Scale
(Nicassio et al. 1985) is widely used and has satisfactory internal consistency
for its somatic and cognitive subscales (fi D 0.81 and fi D 0.76, respectively).
These constructs have some degree of independence (74% unshared variance). The
cognitive subscale of the Pre-Sleep Arousal Scale has also demonstrated modest
(r D 0.35) validity compared with voice-activated recordings of presleep thoughts
as a criterion measure (Wicklow & Espie 2000).
Population survey confirms that people dissatisfied with sleep report mental
activity near bedtime (Ohayon et al. 1997). However, there are conflicting con-
clusions from studies of the relationship between cognitive activity and sleep
latency. Van Egeren et al. (1983) found that audiotape-recorded cognitions were
significantly correlated with subjective sleep latency, but not with polysomno-
graphic (PSG) assessment sleep, whereas Borkovec et al. (1979) and Kuisk et al.
(1989) reported more frequent cognitive activity in insomnia confirmed by PSG.
Sanavio (1988) reported a low correlation (r D 0.09) between presleep intrusion
and self-reported sleep latency, and furthermore, found no advantage of a tailored
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cognitively focused program in the treatment of sleep-onset insomnia. The possi-
bility, therefore, remains that cognitive arousal is an epiphenomenon of nighttime
wakefulness (Freedman & Sattler 1982, Morin 1993).
Support for a cognitive model has also come from studies involving experimen-
tal manipulation of presleep cognitive intrusions (e.g., Gross & Borkovec 1982,
Hall et al. 1996). However, Haynes et al. (1981) exposed insomniacs and nonin-
somniacs to brief stressors and found a decrease in subjective and objective SOL
among insomniacs on stress nights. They concluded that a mental processing task
that disrupts sleep-related cognitive events may decrease SOL, implying that the
nature of the intrusions may be critical to the effect upon sleep. Therefore, fail-
ure to differentiate thought content could result in limited comparability between
studies.
Dysfunctional Thinking
The importance of emotional arousal has been stressed, because affect-laden cog-
nitions are more likely to interfere with sleep (Espie 1991, Morin 1993, Haynes
et al. 1981, Coyle & Watts 1991). Beliefs about the negative experiences and con-
sequences of insomnia may foster the clinical complaint. This parallels research on
“worry,” posited as a generic trait (Barlow 1988, Meyer et al. 1990), and studies on
unwanted intrusive thoughts (Rachman & De Silva 1978, Reynolds & Salkovskis
1992). Negative and distressing cognitions are likely to contribute to the devel-
opment of obsessions; however, it is not the thoughts per se that are untypical or
pathological, but the meaning and concern attributed to them (Clark & Purdon
1993, 1995). The conceptual relatedness of nighttime and daytime intrusions,
therefore, appears considerable.
Insomniacs have more negative thoughts than good sleepers at bedtime
(Nicassio et al. 1985, Van Egeren et al. 1983, Kuisk et al. 1989), and such think-
ing is reported even when wakened from light sleep (Borkovec et al. 1981). The
thoughts of insomniacs may be dependent on emotional state. Investigating the
relationship between worry and insomnia, Watts et al. (1994) found that much
of the presleep mental activity of “worried insomniacs” revolved around work
and general mental activity. In contrast, thoughts of “nonworried insomniacs” fo-
cused on the sleep process itself. Insomniacs may also feel less in control of their
thinking (Watts et al. 1995). Gendron et al. (1998) reported that insomniacs with
comorbid generalized anxiety disorder had greater cognitive activity at bedtime
than insomniacs without generalized anxiety disorder, evaluated their thoughts as
more intrusive and worrisome, and attempted cognitive avoidance strategies more
frequently.
Morin (1993) has argued that beliefs and attitudes play a critical role. He devised
a 30-item questionnaire to identify irrational, affect-laden thoughts that intrude
prior to sleep-onset (dysfunctional beliefs and attitudes about sleep scale) (Morin
1993, Morin et al. 1993). This scale comprises misconceptions about the causes
of insomnia, misattributions or amplifications of the consequences of insomnia,
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unrealistic sleep expectations, diminished perceptions of control, and faulty be-
liefs about sleep-promoting practices. It has satisfactory psychometric properties
and sensitivity to change after cognitive-behavioral treatment (CBT) (Espie et al.
2000, Morin et al. 2001), and may help identify subgroups of the insomniac pop-
ulation (Edinger et al. 1998). Furthermore, those with subjective insomnia report
more dysfunctional sleep-related cognitions than do those with objective insomnia
(Edinger et al. 2000), consistent with the view that cognition/affect may influence
sleep report and perhaps mediate insomniac complaint.
Formal analysis of sleep-interfering cognitions has been reported in several
studies. Coyle & Watts (1991) used an extended version of the Sleep Disturbance
Questionnaire (Espie et al. 1989a) and reported two distinct factors: “sleep atti-
tudes,” reflecting anxiety about the sleep process, and “mental activity,” reflecting
nonspecific cognitive activity. Six factors of nighttime intrusive thoughts, i.e., triv-
ial topics, thoughts about sleep, family and long-term concerns, positive plans and
concerns, somatic preoccupations, and work and recent concerns, were identified
in a study of young adults (Watts et al. 1994). Extending these findings by using a
good-sleeper comparison group, Harvey (2000b) reported that presleep cognitive
activity of insomniacs could be distinguished by being more focused upon worry
about not getting to sleep, general worries, solving problems, the time, and noises
in the house, and less focused upon “nothing in particular.”
A study by Fichten et al. (1998) of the thoughts of older adults during wakeful
periods yielded a 3-factor solution of generalized positive thinking, generalized
negative thinking, and thoughts related to sleep. They suggested that insomni-
acs use positive thinking as a buffer to combat negative intrusions. Also recently,
Wicklow & Espie (2000) obtained voice-activated audiotape recordings of sponta-
neous thoughts and sleep actigraphic data from 21 poor sleepers over 3 consecutive
nights. Content analysis yielded 8 categories of presleep intrusion, and a regres-
sion model indicated that thinking about sleep and the anticipated consequences
of poor sleep, along with general problem-solving were the strongest predictors of
objective SOL. Intrusions were subsumed under one of 3 factors: active problem-
solving (e.g., rehearsing/planning events), present state monitoring (e.g., thinking
about sleep/not sleeping) and environmental reactivity (e.g., attending to external
noises).
Paradox and Ironic Control
This model of insomnia proposes that anxiety responses may be conditioned not
only to external, situational cues but also to the individual’s behavior (Ascher &
Turner 1979, Espie & Lindsay 1985, Espie 1991). Fear of performance failure
(insomnia) and of anticipated negative consequences of that failure is described as
performance anxiety. In paradoxical treatment counterproductive attempts to fall
asleep are replaced by the intention of remaining passively awake or by giving
up any direct effort to fall asleep (Ascher & Turner 1980, Fogle & Dyal 1983).
This rationale is supportable in that good sleepers do not use any strategies to
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fall asleep. Paradoxical intention has demonstrated efficacy in controlled trials
(Turner & Ascher 1979, Espie et al. 1989b) and is an intervention that reflects a
“moderate degree of clinical certainty” according to the AASM (Chesson et al.
1999). Paradox continues to be used within multicomponent CBT (e.g., Espie et al.
2001b) and may be particularly useful with patients who are resistant and reactive
to therapeutic suggestions (Shoham et al. 1995).
Further evidence for this type of mechanism was provided by Ansfield et al.
(1996), who explored the effects of different sleep-onset instructions in good sleep-
ers under high or low mental load. Paradoxical wakefulness was found amongst
those attempting to sleep while listening to marching music. This was interpreted
in terms of Wegner’s (1994) theory of a self-loading system that suggests that
under certain conditions the thwarted attempt to control a particular mental state
can yield the opposite of what is desired. They hypothesized that failure to fall
asleep on a few occasions could occur when sleep is attempted under transitory
mental loads, such as at times of stress. Eventually, a person’s thoughts about
being unable to sleep could constitute a debilitating mental load, which when
combined with the continuing frustrated desire to fall asleep, could lead to chronic
insomnia.
Harvey (2001b) has explored the effects of suppressing presleep cognitive activ-
ity on sleep-onset latency. A cohort of insomniacs and good sleepers were allocated
to either a suppression condition (“suppress the thought most likely to dominate
your thinking as you get into bed”) or nonsuppression condition (“think about
anything as you get into bed, including the thought you would most likely think
about as you go to sleep”). Suppress participants reported longer sleep latencies
and poorer sleep quality, regardless of whether they were insomniac or not. Harvey
concluded that thought suppression appeared to have the opposite effect in that
it prevented sleep-onset, in a manner consistent with Wegner’s theory of ironic
mental control.
There are parallels between Wegner’s theory and the performance anxiety model
that gave rise to the adaptation of paradoxical intention from the work of Frankl
(1960). Indeed, Ansfield et al. (1996) propose that their results are consistent with
theories of cyclic escalation of anxiety disorders (Ascher 1981) and worry about
sleep (Borkovec 1982).
AN INTEGRATED PSYCHOBIOLOGICAL MODEL
OF NORMAL SLEEP
There are, thus, differing explanations of insomnia, each having some empirical
support. The rest of this paper attempts to integrate this evidence into a conceptual
framework. A model of the normal sleep process is presented first, because a
perspective on the pathway to sleeping well is likely to inform understanding of
the development, maintenance, and treatment of insomnia.
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Figure 1 A psychobiological model of good sleep. Insomnia is proposed as
resulting from chronic inhibition of one or more of the component processes.
Figure 1 summarizes hypothesized processes and interactions in normal sleep.
The model proposes good sleep as the natural state of the human organism—its
default state. That is, homeostatic and circadian processes, under normal circum-
stances, default to good sleep, not to insomnia. The core of the model is involuntary,
harmonious interaction between homeostat and timer, which is associated with the
self-perception of good quality sleep. Like all neurobehavioral systems, good sleep
is assumed to have both functional plasticity and automaticity. These are presented
as protective properties, “defending” the core.
Plasticity refers to the “absorb and readjust” capability of the sleep-wake system
to accommodate living in the real world where situational and personal factors pro-
voke variance and challenge normal, stable functioning. Night-to-night variability
is tolerated but minimized by the good sleeper, for whom the sleep homeostat drives
sleep-related behaviors effectively. In acute insomnia the norm would be recovery
of sleep pattern, again reflecting the system’s plasticity in function and default
regression towards good sleep. Automaticity refers to the involuntary nature of the
well-adjusted schedule, to the habitual, conditioned associations that are part of its
stimulus control paradigm, and to the implicit expectations and assumptions the
good sleeper has about sleep continuity and sleep quality. It is tempting to think of
the model as the good sleeper’s list of ingredients for good sleep, but that would be
misleading. The good sleeper is not thought of as following a recipe to produce the
perfect sleep. Rather, the good sleeper is regarded as essentially passive because in-
ternal and external cues act as automated setting conditions for sleep. Endogenous
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cues to sleep such as physical and mental fatigue interact reciprocally with exoge-
nous cues in the home environment. The good sleeper sleeps just as he walks, or
talks—without thinking about it. This, presumably, is the insomniac’s ambition.
The defensive properties of the good sleep paradigm, therefore, are seen as
maintained by four interacting subsystems: sleep-stimulus control, physiological
de-arousal, cognitive de-arousal, and daytime facilitation. In a reciprocal way, sleep
homeostasis, circadian timing, and sleep quality serve to reinforce and maintain
these behavioral, cognitive, and biological processes. That is, good sleep begets
good psychobiological preparation for sleep, which begets good sleep.
The model predicts that the good sleeper accurately interprets physiological and
mental signs of sleep readiness and, once in the bedroom, the stimulus environment
there further reinforces de-arousal. Regular sleep habits for retiring and rising
constitute a good predictive framework that exhibits both sensitivity and specificity.
In terms of the former, a high percentage of nights that follow this pattern is
associated with efficient sleep. In terms of the latter, sleep is highly specific to the
bedroom and wakefulness to other environments; i.e., the good sleeper is less likely
to lie awake in bed or need to sleep in the day or evening. Effective stimulus control
reinforces not only circadian timing and sleep homeostasis but also contributes to
cognitive de-arousal because high sleep efficiency precludes cognitive intrusion
in bed. Both physiological and cognitive de-arousal are presumed to occur in
parallel. Active information-processing recedes as the wake system disengages
and the sleep system engages. The good sleeper is less likely to use time in bed for
problem-solving or anxious thinking, nor have time to do so because sleep-onset
is rapid, and nervous system adaptations proceed unhindered because the good
sleeper has few inaccurate expectations or worries about sleep or wakefulness.
Crucially, the good sleeper experiences little affect associated with sleep. Affect
regulation, which represents an interaction between cognitive and physiological
processes, is proposed as functional when affect is essentially neutral. Dysregula-
tion would occur with strong (negative or positive) emotions, both of which are
arousing. Similarly, the good sleeper is seen as having few conscious expectations
of sleep and puts no direct effort into the sleep process. Daytime attitudes and
behaviors may also facilitate sleep. The good sleeper may make fewer attributions
of daytime mood and performance to the preceding night’s sleep. For example,
when irritable or fatigued, he may be more likely to associate these with proximal
events (e.g., pressure of work) than view them as contingencies of sleep pattern or
sleep quality. Also, the good sleeper may be more effective at managing state/trait
symptoms and/or may put less pressure on sleep to compensate for any excessive
daytime routines.
Thus, the common pathway in the maintenance of sleep homeostasis, circadian
timing, and sleep quality is proposed as an involuntary process of psychobiological
de-arousal within which there is insufficient mental, behavioral, or physiological
inhibition to impair the automaticity and plasticity of sleep. Implicit in the model
is the expectation of regression towards normal sleep because of its fundamental
importance both developmentally and functionally.
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UNDERSTANDING INSOMNIA WITHIN THE
PSYCHOBIOLOGICAL INHIBITION MODEL
At the simplest level, insomnia may be seen as a failure of automated sleep activa-
tion and maintenance. More specifically, insomnia may arise from acute inhibition
of one or more of the processes normally contributing to good sleep (precipitating
stage), perhaps in predisposed individuals, which may become persistent when
chronic inhibition develops, preventing the natural recovery of good sleep (per-
petuating stage). This conceptualization seems consistent with the lack of pathol-
ogy or fundamental disorder of sleep-wake function in primary insomnia. Insom-
nia is proposed, therefore, as persistent loss of expression of normal sleep. The
conceptualization is also consistent with evidence that chronic insomnia is amenable
to cognitive-behavioral intervention (Morin et al. 1994, 1999b; Murtagh &
Greenwood 1995). CBT may act to overcome inhibitory mechanisms and reestab-
lish adaptive mental and situational “setting conditions” for the restoration of
normal sleep.
Automaticity and plasticity would be weakened by inhibitory feedback from
one or more of the attendant psychobiological processes (Figure 1 and Table 1).
For example, poor stimulus control represented by sleep-incompatible behavior,
diminished sleep-wake sensitivity and specificity, and irregular sleep habits could
inhibit sleep and maintain insomnia. Similarly, affect-laden thinking would un-
dermine cognitive de-arousal. The notion of “inhibitory sufficiency” is introduced
because good sleepers do not necessarily observe all the rules of sleep preparation;
e.g., good sleepers may read, drink caffeinated beverages, spend time anxiously
reflecting on the day while in bed, be poor daytime copers, etc., without ever be-
coming insomniac. It helps to account for those individuals who are under chronic
stress but who apparently still sleep well. Inhibitory sufficiency, therefore, rep-
resents the critical mass of inhibition required to outweigh the stability of an
individual’s default sleep pattern. Theoretically, it would need to be higher where
there is strong sleep homeostasis and/or circadian timing, and less where there
is predisposition to insomnia, strong precipitating factors or limited protection
afforded by plasticity and automaticity.
Table 1 presents detail of the elements of the model and how they may be-
come inhibited. Poor sleep-related stimulus control would be observed where the
bedroom becomes a conditioned focus for waking activity and where the sensitiv-
ity/specificity of the sleep-wake schedule is compromised, primarily by remaining
awake in bed, but also by sleeping in the daytime. Attempting to sleep longer
on recovery nights and spending too long in bed could also inhibit the continuity
and automaticity of sleep by reducing sleep efficiency. Stimulus control and sleep
restriction treatments may be effective because they counteract the process of inhi-
bition (stay up until sleepy, compress time in bed, etc.) and reinstate default sleep.
The instruction to get up if not asleep within 15 minutes may also attenuate the
inhibition associated with effort to sleep, as it can be likened to a “give up trying”
instruction.
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TABLE 1 Insomnia within the psychobiological inhibition model.
Insomnia: factors inhibitory to sleep homeostasis and circadian
Factors contributing to timing, and to the protection of good sleep afforded by
good sleep automaticity and plasticity
Sleep stimulus control
Sleep-compatible conditioning Conditioned association of sleep-incompatible, waking activities (e.g.,
reading, watching TV, eating, talking, problem-solving) with bed and
bedroom environment; keeping the light on
Sleep-wake Environmental latitude in sleep and wake behaviors: lying awake in
sensitivity/specificity bed either presleep or upon wakening, sleeping in the day, sleeping
elsewhere than in bed
Regular sleep habits Variable and/or reactive patterns: changing times for retiring and
rising, extending time in bed to catch up on sleep, sleeping in at
weekends, spending longer in bed than current sleep requirement—
reduced sleep efficiency
Physiological de-arousal
Sleep system engagement Not feeling tired at bedtime, in bed too early, keeping the light on,
sleep-incompatible activities, anxiety, trying too hard to sleep,
tension, heart rate variability
Wake system disengagement As above; active thinking and problem-solving, self-monitoring of
internal (bodily and mental) cues, hypervigilance, poor sleep hygiene
Good sleep hygiene Stimulants (e.g., caffeine, nicotine) in excess/near bedtime; alcohol
withdrawal symptoms during the night; active exercise late evening;
bedroom stuffy, hot, or cold; bed uncomfortable
Cognitive de-arousal
Minimal cognitive drive Rehearsing/planning/problem-solving thoughts in bed, thinking about
events the previous or next day, preoccupation with sleep/
sleeplessness, “stimulus hungry” mind, mind racing, unable to
“switch off ”
Accurate sleep-wake attribution Dysfunctional beliefs and attitudes about sleep and consequences of
not sleeping, not expecting to sleep, catastrophic thoughts, concern
about next day well-being and coping
Affect regulation
Minimal affect Worry, anxiety, frustration, negativity or excitement, intensity in
emotional tone associated with above cognitive or physiological
processes
Minimal effort to sleep Sleeplessness preoccupying: trying to control sleep/overcome
insomnia, attempts to suppress thoughts/suppress affect, self-
monitoring of alert/sleepiness state, performance effort to fall
asleep, performance anxiety
Daytime facilitation of night sleep
Accurate wake-sleep attribution Attribution of impaired daytime mood, attention, performance to
quality of sleep; expectation that sleep should compensate; blaming
problems on insomnia; fatigue seen as pathognomic of insomnia;
perception of self as insomniac
Effective coping skills Experiencing time pressure; problems relaxing; worry, frustration,
low mood; active late into evening; poor wind down
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Some insomniacs report not being tired at bedtime, which undermines physi-
ological de-arousal, and evidence of wakefulness when aroused from light sleep
suggests slower engagement of the sleep system. Studies revealing elevated au-
tonomic symptoms in poor sleepers suggest that inhibition of normal arousal
is problematic. Sleep hygiene is traditionally regarded as a behavioral strategy.
However, its components are primarily physiological in terms of the model of
sleep inhibition. Excessive use of caffeine and strenuous exercise delay sleep
onset, presumably through heightened arousal. Indeed, in one experimental study
400 mg of caffeine three times per day for one week produced increased arousal on
metabolic measures and reports typical of insomniac complaint (Bonnet & Arand
1992). Similarly, environmental factors (temperature, humidity, light) could in-
hibit sleep physiologically. Use of alcohol may lead to dehydration or provoked
awakenings because of ethanol metabolism. Observing good sleep hygiene, there-
fore, would remove some potential inhibitors of sleep. Similarly, relaxation-based
treatments may either reciprocally inhibit autonomic activity (Wolpe 1958) and
thus counteract the maintenance of physiological arousal or, perhaps more likely,
facilitate mental (and physiological) de-arousal.
Problems with cognitive de-arousal appear central to insomnia. Insomniacs re-
port intrusive thinking; some of this is reflective, but much is also worrisome.
The active mind is likely to inhibit de-arousal, particularly where accompanied by
negatively toned affect. The insomniac typically becomes concerned about sleep-
lessness and its immediate and longer-term negative consequences. This gives rise
to emotional upset, ironic urgency, and performance anxiety associated with failed
efforts to regain perceived loss of control over sleep. Indeed, the development of
attentional bias for sleep- or insomnia-related thoughts may help to explain the
maintenance of sleep disorders even after proximal sources of transient sleepless-
ness (e.g., stress) have passed. The fact that attempts to suppress thinking produce
sleep disturbance even in normal sleepers is further evidence of insomnia arising
from cognitively mediated sleep inhibition. Insomniacs often try too hard, thereby
obviating passive acceptance of sleep, which is a hallmark of the good sleeper.
The success of cognitive strategies for insomnia may depend, therefore, upon the
extent to which they disable sleep-interfering mentation and affect. The central
paradox is that deliberate efforts to do so fail to emulate the automatic nature
of sleep-onset in good sleepers and may exacerbate preexisting sleep inhibition.
The less direct mechanisms of behavioral interventions such as stimulus control
upon cognitive processes therefore merit further attention, as do techniques using
paradoxical instructions.
It is specious, of course, to set up physiological and cognitive arousal in direct
competition. The psychobiological inhibition model presumes interaction between
physiological, cognitive, affective, and behavioral subsystems, and indeed between
daytime and nighttime variables. These relationships are represented by arrows in
Figure 1. Their interaction contributes positively to the maintenance of good sleep.
The corollary, however, is that interaction would also compound inhibitory effects.
Indeed, Born et al. (1999) have demonstrated that normal sleepers, told that they
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would be woken at 6 A.M., had significant increases in adrenocorticotropin during
the hour preceding waking. This suggests that some form of cognitive priming
may be linked to sleep-related biological responses.
Less attention has been paid to how daytime factors could contribute to in-
somnia. Good sleep may be inhibited by daytime preoccupation with impairments
perceived to result from poor sleep. Just as attributional (sleep-wake) error can
contribute to sleeplessness during the night, so it may form dysfunctional sleep-
related schema during the day (wake-sleep). Self-perception of being insomniac
may influence interpretation of everyday experiences, such as feeling fatigued or
irritable, in a manner comparable to obsessional disorders in which special mean-
ing is attributed to common thoughts and behaviors. Just as some people differ
from controls only in respect of their interpretation of events, some insomniacs
have normal or close-to-normal sleep, but perceive it to be abnormal. Insomni-
acs have been characterized as prone to worry and internalizing of anxiety. Such
traits may be reinforced in the day, not only during the night. Furthermore, failure
to manage daytime concerns effectively may put pressure on sleep when, in the
absence of other stimulation or distraction, the insomniac spends time thinking,
rehearsing, planning, and worrying. The model, therefore, includes poor coping
skills and disturbed daytime affect as factors that may undermine preparation for
sleep and may contribute to behavioral and cognitive sleep inhibition.
It may seem counterintuitive or even arbitrary to talk in terms of inhibition of
de-arousal rather than excitation (hyper-arousal). However, the definition of in-
somnia as failure of expression of an essentially normal underlying sleep process
is defensible. To remain awake the insomniac does not need to be hyper-aroused
any more than one needs to be hyper-aroused at any other time to remain awake.
Hyper-arousal is a sufficient but not necessary precondition to wakefulness. Fur-
thermore, even if hyper-arousal were to occur initially to delay sleep it would not
follow that remaining hyper-aroused would be necessary to stay awake thereafter.
By comparison, if an individual is becoming sleepy (de-aroused) but subsequently
becomes wakeful, it only seems necessary to infer that there has been attenuation
of the de-arousal, and that explanation also seems sufficient. It is not being ar-
gued that hyper-arousal never occurs, but rather that inhibition of de-arousal does
always occur. Inhibition is the lowest common denominator that can be reliably
deduced. It is suggested that insomnia as a disorder of initiating or maintaining
sleep is at its core a disorder of sleep engagement, not a disorder of excessive
arousal.
Nevertheless, the model does account for hyper-arousal in insomnia. Hyper-
arousal clearly would inhibit sleep, but it is hypothesized that there is within-group
variability in insomnia (i.e., not all insomniacs are hyper-aroused). Variability
between populations of insomniacs studied might explain apparently discrepant
results reporting both physiological and mental measurement. Physiological hyper-
arousal may be a distinct subtype of insomnia. De-arousal, however, is suggested
as the reliable correlate of good quality sleep; anything else at or above a level
sufficient to inhibit sleep may be associated with insomnia.
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Why then has cognitive arousal been more strongly associated with insomnia
than physiological arousal? It is suggested that cognition is invariably symptomatic
of insomniacs’ subjective nighttime experience, whereas physiological arousal is
less invariably so. Accordingly, when asked to rate or attribute sleeplessness, in-
somniacs are likely to stress mentation and/or affect rather than physiological
symptoms. There may be interpretation bias, and the possibility that cognitive ac-
tivity is simply an epiphenomenon of sustained wakefulness or a by-product of
the measurement process cannot yet be excluded. However, the cognitive/affective
component of primary insomnia does seem to be a sine qua non in clinical practice.
Like physiological arousal, cognitive arousal may represent a continuous dimen-
sion from de-arousal to hyper-arousal, exhibiting individual variability, but once
again, de-arousal appears to be the correlate of good sleep. This helps to explain
the common finding that insomniacs consistently appear hyper-aroused, relative
to good sleepers, on measures such as the cognitive subscale of the Pre-Sleep
Arousal Scale. It cannot be stated with conviction that they are hyper-aroused in
any absolute sense, but it may be reasonably inferred that they are not de-arousing.
It should be noted that the model can also be applied to sleep-maintenance
insomnia. This subtype is more commonly associated with mid- to late-life, when
a propensity to lighter, more broken sleep develops and automaticity and plasticity
may be compromised. It is suggested that in sleep-maintenance insomnia there
is inhibition of the rapid, automated de-arousal response to the brief wakeful
experiences typically found in older good sleepers. This results in more conscious
processing of arousals, more frequent arousals, and times of extended wakefulness
with difficulty returning to sleep. One way in which inhibition might occur would
be through attentional bias for arousal and threat-related cues. The insomniac
may selectively attend to brief arousals in the night and interpret these by means
of established schema as evidence of inability to sleep. This could then set up
the pernicious cycle of inaccurate attribution, affect, effort to sleep, physiological
arousal and engagement of the wake system.
It is proposed, therefore, that the common pathway in insomnia is inhibition
of the expression of normal sleep. It is further suggested that, whereas any of
the subsystems may contribute to inhibition, it is cognitive/affective factors that
serve as the “activating agent” for the phenomenology of insomnia and presen-
tation of clinical complaint. This is evidenced by the consistent association of
intrusive, affect-laden cognitions with primary insomnia and by the fact that some
self-reported good sleepers sleep as poorly as insomniacs, but without experienc-
ing concerns about sleep (Edinger et al. 2000). In the psychobiological inhibition
model such cognitions are presumed to pervade nighttime and/or daytime think-
ing. A corollary to the suggestion of activation is that, if CBT intervention is to
be effective, it must somehow close this cognitive/affective gate. This again is
consistent with the proposition that stimulus control may achieve its effects by
fostering cognitive de-arousal. Similarly, sleep restriction might be regarded as a
paradigm involving behavioral experiments to evaluate assumptions about sleep
requirements and their consequences. The circadian readjustments that form part
A
nn
u.
 R
ev
. P
sy
ch
ol
. 2
00
2.
53
:2
15
-2
43
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
by
 G
la
sg
ow
 U
ni
ve
rs
ity
 o
n 
10
/0
3/
12
. F
or
 p
er
so
na
l u
se
 o
nl
y.
30 Nov 2001 10:40 AR ar146-09.tex ar146-09.sgm LaTeX2e(2001/05/10) P1: GJC
234 ESPIE
of both stimulus control and sleep restriction may, of course, take place without
synchronous cognitive conceptual shift, but if that is the case it is suggested that
insomnia complaint is likely to persist.
Relationship of the Psychobiological Inhibition
Model to Other Models of Insomnia
Espie (1991, pp. 39–56) proposed a framework in which insomnia was conceptual-
ized as mediating from activation of nervous system (central, autonomic), psycho-
logical (cognitive, emotional), or environmental (situational, temporal) arousal.
These elements can all be accommodated in the current model, although the em-
phasis is now upon inhibition, impairing the automaticity of normal sleep. Daytime
factors are also factored into the new model, and further detail of the cognitive
dimension (from Espie 1992, Espie & Wicklow 2001) is presented in the cognitive
de-arousal component.
Morin (1993, pp. 46–60) also presented an integrative conceptualization of in-
somnia. He suggested that hyper-arousal (emotional, cognitive, physiologic) is the
central mediating feature of insomnia, which interacts with dysfunctional cog-
nitions, maladaptive habits, and perceived consequences of insomnia. Although
the psychobiological inhibition model makes no requirement of hyper-arousal,
Morin’s emphasis on cognitive factors parallels the cognitive/affective activation
agent presented here. The role of dysfunctional thoughts and beliefs in the psy-
chobiological inhibition model is consistent with Edinger et al.’s (2000) inter-
pretation that these influence self-perception of insomnia and insomniac report.
Morin also stressed the bi-directional influence of the components, such that con-
sequences often become causes and vice versa, similar to the proposed reciprocal
interaction of the elements of the psychobiological inhibition model.
Perlis et al. (1997) discussed discrepancies between PSG and subjective ap-
praisal of sleep. They suggested that inconsistencies may be explained by the
presence of high frequency EEG activity in insomnia around sleep-onset, which
interferes with the development of mesograde amnesia, and results in insomniacs
having blurred phenomenological distinction between sleep and wakefulness. The
psychobiological inhibition model can accommodate such an association but would
suggest that cortical arousal represents a failure to de-arouse, with hyper-arousal
presenting only in some insomniacs. The reciprocal interaction between main-
tained physiological and psychological processes would inhibit both the transition
to slower EEG activity and the experience of sleep-onset, but the model would sug-
gest that it is cognitive/affective inhibition that is the more likely activating factor.
It is also noteworthy that the psychobiological inhibition model is consistent
with Spielman’s (1991) model of insomnia acquisition (presented above) and with
Edgar’s (1996) “opponent process” model. The latter proposes that circadian tim-
ing promotes wakefulness and opposes sleep drive, and that prolonged wakefulness
leads to compensatory sleep responses. The psychobiological inhibition model
assumes such an interaction between homeostat and timer, but also describes how
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such an automated interaction may be inhibited by thoughts, emotions, and behav-
ioral changes.
Some Implications of the Cognitively Activated
Psychobiological Inhibition Model
This model raises testable hypotheses and suggests mechanisms for treatment ef-
fects. It is only possible to touch upon some of these. The central premise is that
in insomnia the expression of normal sleep is chronically inhibited. Therefore,
further study of sleep-related de-arousal in good sleepers is required. The model
predicts phenomenology comprising attitudinal passivity towards sleep, with neu-
tral expectations, compared with the negativity and worry of the insomniac. In
terms of automaticity, it is suggested that the good sleeper is like the experienced
car driver who executes a complex series of operations with minimal attentional
load. In comparison, the insomniac is like the anxious learner driver: vigilant, de-
liberate, and errorful. The concept of automaticity in human learning has long been
discussed as part of information-processing theory (Shiffrin & Schneider 1977).
Its application to sleep and insomnia could be fruitful. The ability to automate
is, presumably hard-wired in order to overcome problems associated with an oth-
erwise limited-capacity information-processing system. Theories of paradox and
ironic mental control are interesting because they emphasize allowing events to
take their natural course, and de-emphasize the need for control and success. Effort
to sleep and suppression of wakefulness, and its associated mental activity, may
disengage automaticity.
Study of within-subject as well as within-group variability may lead to greater
appreciation of how similarly or differently good sleepers and insomniacs respond
to good and bad nights, in terms of their expectations, affect, and behavior. Fur-
thermore, because cognitive/affective activation is seen as central, insomniacs may
be differentiated not only from good sleepers, but also from noncomplaining poor
sleepers. It seems important to identify this latter group for formal study and to
consider degree/severity of complaint as a correlate of mental arousal/concern.
The latter may be an inverse correlate of automaticity. Good sleepers and non-
complaining poor sleepers may make more benign attributions after a bad night,
leaving automaticity intact. It is further suggested that sleep state misperception
(SSM) may represent cognitive activation and perceived severity equivalent to
that found in primary insomnia, thus differentiating SSM from good sleepers and
noncomplaining poor sleepers, but not from insomniacs. Longitudinal study of
SSM is required to investigate whether or not objective sleep disturbance develops
over time. There is a need, however, to develop better measures of sleep quality,
with sound psychometric properties, and to investigate the interrelationships be-
tween sleep quality, cognitive arousal, dysfunctional beliefs, attributional error,
attentional bias, and affect, both in SSM and insomnia.
Comparison of the relapse patterns of various subgroups after bad nights or peri-
ods of poorer sleep would be interesting from another perspective. The interaction
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of sleep homeostasis and circadian timing is thought to demonstrate impaired
plasticity in insomniacs, who present sleep pattern variability. Their sleep-wake
rhythm may be more brittle, and the repayment of sleep debt may not function
as efficiently. Unfortunately, research data are usually analyzed as weekly mean
values, thus concealing within-subject and within-group variability in sleep. In-
dividual raw score variance has been reported only occasionally in insomnia, but
further work using such data would be valuable. Theoretically, stability in sleep
pattern would be displayed by small raw score standard deviations, and plasticity
would be demonstrated by regression from higher values (e.g., at times of acute
insomnia) to lower values. The time taken to accommodate and adjust from above
to below some threshold value might be a useful measure of plasticity.
The “setting conditions” for insomnia are potentially wide-ranging, and further
study employing experimental manipulation of situational, autonomic, mental, and
affective variables would be valuable. The model would predict that only manip-
ulations with a cognitive/affective activating component would lead to subjective
sleep concern, which can vary independently of sleep disruption. The concept of
inhibitory sufficiency requires investigation, and methods need to be developed to
titrate experimental “doses” so that outcomes can be related to inputs. For exam-
ple, if an experiment was conducted on the countercontrol procedure, it would be
helpful to use standard stimuli (e.g., text to read, TV program to watch) validated
for emotional valence, intrusiveness, imagery potential, etc. It should be borne in
mind, of course, that disturbance of a single night is not insomnia, but only a bad
night. Care must be taken, therefore, also to consider inhibitory sufficiency from
the clinical perspective of generalized and enduring sleep disturbance where, pre-
sumably, retrospective experience influences response to prospective experimental
factors.
The proposed model suggests that maintained arousal is the necessary and
sufficient precondition for insomnia. Clearly, this hypothesis requires validation,
and a between-group repeated-measures model utilizing daytime, pre-bedtime,
presleep, and early-sleep measures of physiological and cognitive arousal in in-
somniacs and good sleepers would seem appropriate. This would also identify
cases of hyper-arousal, proposed as a subpopulation of insomnia. In terms of in-
tervention, the model suggests that cognitive behavioral strategies may act via the
common pathway of disengaging mechanisms inhibitory to de-arousal, and facili-
tating reestablishment of automated normal sleep. Given the proposed importance
of cognitive/affective de-activation, it would be particularly useful to investigate
stimulus control and sleep restriction as de-activating in this context e.g., attitu-
dinal shift, relinquishing control, precluding worry from bed. Their contribution
to circadian timing and homeostatic drive, along with such de-activation, may
explain the positive clinical outcomes achieved using these procedures. Specific
cognitive interventions need to be explored in terms of direct versus indirect ac-
tion upon sleep-related variables. Automaticity would predict that indirect (e.g.,
paradoxical) methods would be more efficacious than those that focus attention
and intervention directly upon sleep or upon sleep-related thoughts.
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CONCLUSION
Although there are a number of perspectives on the etiology and maintenance of in-
somnia, each of which has some empirical support, the conceptual basis lags some
way behind treatment methodology and the evaluation of efficacy and effective-
ness. An integrated psychobiological model has been proposed that differentiates
insomnia from normal sleep in terms of inhibitory mechanisms and processes. It
is hoped that the hypotheses raised here will stimulate interest in further experi-
mental and clinical study, and that the resultant research process will improve both
understanding and management of this common condition.
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Sleep-Related Attentional Bias in Good, Moderate, and Poor
(Primary Insomnia) Sleepers
Barry T. Jones, Lauren M. Macphee, and
Niall M. Broomfield
University of Glasgow
Benedict C. Jones
University of Aberdeen
Colin A. Espie
University of Glasgow
Evidence was sought of an attentional bias toward a highly representative object of the bedroom
environment in good, moderate, and poor (primary insomnia) sleepers. Using a flicker paradigm for
inducing change blindness, the authors briefly presented a single scene comprising a group of bedroom
environment and neutral objects to participants and then briefly replaced this scene with an identical
scene containing a change made to either a bedroom environment or a neutral object. In a 3  2 entirely
between-participants design, change-detection latencies revealed a sleep-related attentional bias in poor
sleepers but not in good sleepers. A possible bias in moderate sleepers was also revealed. It is suggested
that attentional bias has a role in the perpetuation and possibly precipitation of primary insomnia.
Keywords: attentional bias, insomnia, charge-detection, sleep disruption, circadian
Sleep disruption is not unusual. Although good sleep usually
returns, either through the disappearance of the precipitating agent
or through the operation of mechanisms that appear to combat
sleep disruption (the sleep homeostat or the circadian timer; Bor-
bely, 1994), sleep disruption sometimes persists. When it persists
for longer than a month (and is not a side effect of other medical,
neurologic, psychiatric, or psychological disorders or the result of
a circadian rhythm disorder), it is called primary insomnia
(Diagnostic and Statistical Manual of Mental Disorders, 4th ed.
[DSM–IV]; American Psychiatric Association, 1994). This report
explores a possible role for attentional bias in the perpetuation and
possibly the precipitation of primary insomnia. An attentional bias
toward a particular class of stimulus (e.g., sleep-related) is said to
have developed when disproportionate processing resources ap-
pear to be automatically allocated to exemplars, as compared with
other otherwise equivalent stimuli—producing a disproportionate
impact on current cognitions. This article is based, first, on a
framework that has been helpful in addressing many other clinical
disorders and, second, on an extension of this framework to
encompass subclinical features of sleep disorder. This extension
derives from research on attentional bias in relation to understand-
ing alcohol consumption variability along the entire alcohol use–
misuse–abuse–dependence continuum, not just at the clinical pole.
First, support has been found implicating attentional bias in the
perpetuation of a wide range of anxiety-related psychological
disorders and concerns (see Mogg & Bradley, 1998, for a review).
Support has also been found implicating attentional bias in the
perpetuation of a family of substance abuse and dependence dis-
orders: for example, with alcohol (Sharma, Albery, & Cook,
2001), heroin (Franken, Kroon, Wiers, & Jansen, 2000) and nic-
otine (Waters & Feyerabend, 2000). Principally, through the use of
the emotional Stroop paradigm (Williams, Mathews, & MacLeod,
1996), the extent to which attention is captured by disorder-related
stimuli as compared with neutral stimuli has been revealed. Gen-
erally, but not exclusively, an attentional bias has been found in
those who have a clinical diagnosis but absent in those who have
not—this would be more completely termed a differential atten-
tional bias. Finding such a differential attentional bias has helped
explain why disorders (e.g., Mogg, Mathews, Bird, & MacGregor-
Morris, 1990) and abuses and dependences (e.g., Drummond,
Tiffany, Glautier, & Remington, 1995) are frequently self-
maintaining and why relapse so frequently occurs after initially
successful treatment. In explanations such as these, attentional bias
is conceived as an involuntary (i.e., unconscious, implicit) process
but (important to note) gives rise to voluntary (i.e., conscious,
explicit) processes. These cognitions feature as part of the disorder
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and can contribute to subsequent behavior decisions. Franken,
Kroon, and Hendriks (2000); Franken, Kroon, Wiers, and Jansen
(2000); and Ingjaldsson, Thayer, and Laberg (2003), in particular,
related attentional bias and craving with risk of relapse in sub-
stance abuse and dependence.
Williams et al.’s (1996) model of emotional Stroop performance
(extending Cohen, Dunbar, & McClelland’s, 1990, network model
of the standard Stroop effect) accounts for attentional bias at the
clinical pole of disorders, such as those mentioned above, through
the increased responsivity of network input units representing
disorder-related concepts—an increase caused by “a history of
association with [anxiety-generating] threat or loss and thereby
subject to neuromodulatory control affecting the responsivity of
those units” (Williams et al., 1996, p. 17). As noted earlier,
attentional biases, which reflect discrete changes in the direction of
attentional focus in response to “threat,” have been revealed in the
anxiety disorders (e.g., Keogh, Dillon, Georgiou, & Hunt, 2001).
We would argue that attentional bias may also be a strong candi-
date model for the perpetuation of primary insomnia. Sleep is a
fundamental life process much like eating or drinking. Thus,
inability to sleep can be conceptualized as a significant threat as
well as an anxiety generator (Espie, 2002). We believe that atten-
tional biases favoring sleep-related stimuli will, during an acute
insomnia phase, lead to persistent insomnia in two ways: by
promoting sleep preoccupation and by driving heightened sleep
effort. This hypothesis is consistent with the reported association
between insomnia and both excessive presleep cognitive activity
(Wicklow & Espie, 2000) and effortful attempts to control sleep
onset (Broomfield & Espie, 2003). Together, these two processes
are likely to prevent successful cognitive and somatic de-arousal,
which will inhibit the recovery of normal sleep (Espie, 2002).
Harvey (2002) makes parallel predictions. In her cognitive model,
worries regarding inability to sleep, and the consequent daytime
impact of sleep loss, are thought to promote autonomic arousal and
anxiety that in turn drive selective attention toward internal–
external sleep-related threat cues. Again, it is proposed that sleep
disturbance is maintained by an attentional bias favoring sleep-
relevant cues.
Second, although differential attentional biases have generally
been sought between those who have a diagnosed disorder and
those who do not, efforts to understand alcohol consumption
variability show that a systematically changing differential atten-
tional bias toward alcohol-related stimuli might be present along
the consumption continuum (of use, misuse, abuse, dependence),
not just at its clinical pole. For example, a differential attentional
bias has been found with (a) “alcoholic” drinkers (using “nonal-
coholic” controls; Johnsen, Laberg, Cox, Vaksdal, & Hugdahl,
1994), (b) “problem” drinkers (“nonproblem” controls; Sharma et
al., 2001), (c) “heavy” social drinkers (“light” social drinking
controls; Bruce & Jones, 2005), and (d) “frequent social” drinkers
(“occasional social” drinking controls; Townshend & Duka, 2001).
Moreover, even at the clinical pole itself, Ryan (2002) and Jones,
Bruce, Livingstone, and Reed (in press) have shown that the extent
of attentional bias exhibited by problem drinkers in treatment is
positively related to their problem severity. Applying Williams et
al.’s (1996) model to the anxiety generated within the context of
the negative expectations (or expectancies) of future consumption
held by those at the clinical pole (B. T. Jones, 2004; B. T. Jones,
Corbin, & Fromme, 2001) helps explain this differential bias.
Moreover, it has been found in social drinkers, using explicit (e.g.,
Lee, Greeley, & Oei, 1999; McMahon, Jones, & O’Donnell, 1994)
and implicit (Gadon, Bruce, McConnochie, & Jones, 2004; Gadon
& Jones, 2002; Leigh & Stacy, 1998) methodologies, that the
number, range, and severity of negative expectancies increase as
consumption increases along the continuum from infrequent and
lighter to frequent and heavier drinker—predicting a systemati-
cally changing attentional bias along the continuum. It is important
to note that the progressive increase in negative expectancies
would not necessarily restrain consumption (a macrobehavior)
until a threshold was exceeded (B. T. Jones, 2004; B. T. Jones &
McMahon, 1998) but that while subthreshold, it would progres-
sively impact on microbehaviors such as emotional Stroop perfor-
mance. While subthreshold, consumption would be driven by
positive expectancies (e.g., Goldman, Del Boca, & Darkes, 1999)
and because an attentional bias would prime positive expectancies,
the apparent paradox is resolved that at levels of social drinking,
increases in anxiety caused by increases in negative expectancies
would increase consumption.
Little comparable research (either at the clinical pole or along
the sleep-problems continuum) has been carried out on sleep-
related attentional bias, which is surprising because interest in the
control that sleep-related objects might have over sleep behavior is
long established (Bootzin, 1972). For example, within a condition-
ing framework, bedroom environment objects might become dis-
criminative stimuli for sleep (e.g., Bootzin, Epstein, & Wood,
1991), but when the bedroom–sleep contingencies are broken, they
might become discriminative stimuli for wakefulness. Meta-
analyses have suggested that treatments for insomnia that purport
to modify the stimulus control the bedroom environment has over
sleep are indeed effective (Morin et al., 1999; Murtagh & Green-
wood, 1995; Smith et al., 2002)—to the extent that they are
recommended by the American Academy of Sleep Medicine as the
standard nonpharmacological intervention (Chesson et al., 1999).
Yet, evaluations of the principles of stimulus control within the
sleep environment have produced inconsistent data (see Espie,
2002, for a review), which raises the possibility that considerations
of stimulus control extend beyond the conditioning framework and
that treatments might have other active ingredients.
In an effort to more fully understand the impact that the bed-
room environment might have on sleep, this article goes beyond
the conditioning framework described above (which addresses one
form of stimulus control) to a framework of attentional bias (which
addresses another). Two previous studies have explored sleep-
related attentional bias using a textual Stroop paradigm. In one,
Lundh, Froding, Gyllenhammer, Broman, and Hetta (1997) found
that individuals with primary insomnia showed no effect. In the
other, Taylor et al. (2003) found an attentional bias in cancer
patients with persistent insomnia (12–18 months) as compared
with cancer patients with acute insomnia (0–3 months). In the
former study, however, only one fourth sleep-related words rep-
resented bedroom objects and, in the latter, only 3/20; conse-
quently, although informative, neither study addressed the possible
influence of the bedroom environment on sleep.
Rather than use the textual Stroop paradigm, we explore sleep-
related attentional bias with digitized objects using a flicker par-
adigm (Rensink, O’Regan, & Clark, 1997; Simons & Levin, 1997)
featuring a perceptual phenomenon called induced change blind-
ness (ICB; Rensink, 2002; Simons, 2000; Simons & Rensink,
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2005). This research reveals that when a change is made to a visual
scene (and the process of change is hidden from view), it is more
difficult to detect than might be expected. Normally in this para-
digm, a single feature of a visual scene is changed between
successively repeated brief presentations until the change is de-
tected. Change-detection latency is explained by a change’s “grab-
biness” (O’Regan & Noe, 2000), and this depends not just on the
object’s physical features that carry the change but also on the
viewer’s history in relation to that object. Using this technique,
researchers (B. C. Jones, Jones, Blundell, & Bruce, 2002; B. T.
Jones, Jones, Smith, & Copely, 2003) have found differential
attentional biases between two levels of social use of alcohol and
cannabis. Here, we extend their approach to explore differential
attentional biases along the sleep-problems continuum.
We postulate that a systematically changing attentional bias will
be found (at different points of the sleep-problems continuum) to
exist toward changes made to bedroom environment objects as
compared with changes made to other objects. We predict it will be
greatest in poorest sleepers (having primary insomnia diagnosed),
reduced in moderate sleepers (not having a clinical diagnosis but
having more sleep problems than good sleepers), and absent in
good sleepers (having no or few sleep problems). We propose that
(a) anxiety is a mediator of sleep-related attentional bias at the
clinical pole (Espie, 2002; Harvey, 2002), just as with alcohol-
related attentional bias at the clinical pole of the consumption
continuum, and (b) that different subclinical points of the sleep-
problems continuum will generate different levels of anxiety, just
as with subclinical levels of alcohol problems. Through Williams
et al.’s (1996) model, we predict an increasing sleep-related atten-
tional bias toward bedroom environment objects from good
through moderate to poor sleepers. We use a highly representative
set of bedroom objects and test this hypothesis with a change
carried by the one most representative.
Method
Participants
Students, staff, and visitors on the campus of a large city university were
asked to take part in a 15-min experiment in a nearby quiet room. Each of
the opportunistically recruited 302 volunteers were tested singly. Using the
procedures described below, we selected 192 for analysis (M age  32.1
years, SD  12.6).
Measures
Each participant completed a computer task that measured his or her
visual change-detection latency (the dependent variable) to changes in
photographic scenes described below. They then completed three question-
naires (used for participant exclusion and retrospective group assignment
with age-matching). First, the Beck Depression Inventory (BDI; Beck &
Steer. 1987) was given, followed by the Pittsburgh Sleep Quality Index
(PSQI; Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). The PSQI
provides a global measure of sleep quality by aggregating the scores on a
0–3 subscale (3 is the negative pole) of seven different areas of sleep:
subjective sleep quality, sleep latency, sleep duration, habitual sleep effi-
ciency, sleep disturbances, use of sleep medication, and daytime dysfunc-
tion. The PSQI is a widely used, internally consistent (Cronbach’s alpha 
.83) screening instrument for the detection of significant sleep disturbance
(using a threshold score of 6). Recent, independent study has validated this
cut-off and confirmed reliability (Cronbach’s alpha  .85, test–retest r 
.84; Backhaus, Junghanns, Broocks, Riemann, & Hohagen, 2002). Finally,
a local questionnaire was given that collected information on age, gender,
and whether individuals had suffered from any psychopathology or other
illness known to affect sleep or had any sleep complaint.
The global PSQI score has been shown to be effective in discriminating
between nonclinical (0–5) and clinical (6–21) sleepers (e.g., Backhaus et
al., 2002), and we use it for this purpose. In addition, however, we seek to
explore the possible continuity of attentional bias along the sleep-problems
continuum by using the PSQI’s continuous measure of sleep problems to
further classify nonclinical sleepers using the end regions (0–2 and 4–5) of
the nonclinical PSQI range (0–5). We identify participants as “good” and
“moderate” sleepers, respectively, discriminating them from “poor” sleep-
ers and thereby creating three points on the sleep-problems continuum that
can be compared. We acknowledge that our concept of moderate sleeper
has, perhaps, more limitations than good sleeper, but we justify inclusion
of this group for two reasons. First, epidemiological data clearly demon-
strate that prevalence of insomnia varies depending on the question asked.
Whereas 25–30% of the adult population report dissatisfaction with their
sleep, the true prevalence of the clinical disorder is around half that rate,
10–15% (Ford & Kamerow, 1989; Gallup Organization, 1991; Oyahon,
Caulet, & Guilleminault, 1997). Second, because (a) there were clear
criteria for establishing a poor sleeper category, (b) the distance between
the poor sleeper and good sleeper category was substantial, and (c) we
wished to test the hypothesis that there would be systematically modified
attentional bias across the sleep-problems continuum, we felt that the
conceptual delineation of a middle category would be appropriate.
Design
The hypothesis tested was that participants with PSQI-indicated sleep
problems will detect a change made to one of a collection of sleep-related
objects quicker than a change made to one of a collection of neutral objects,
as compared with participants with fewer PSQI-indicated sleep problems.
An entirely between-participants design was adopted with the following
three factors: nature of change to be detected (two levels: sleep-related and
neutral), gender (two levels: male and female), and PSQI-indicated sleep
quality (three levels: good, moderate, and poor). The dependent variable
was change-detection latency.
Sleep problems approximately double from adulthood to later life, and
women present about twice as often as men (e.g., Espie, 2002; Ford &
Kamerow, 1989; Li, Wing, Ho, & Fong, 2002). Accordingly, groups were
matched for age (on an individual basis rather than a group-mean basis),
and gender was included as a factor in the design.
A target of approximately 300 participants was estimated to be necessary
to allow for the application of the exclusion and matching procedures
described below. Each participant was given the flicker ICB change-
detection task followed by the BDI, the PSQI, and a local questionnaire.
Once recruited into the experiment, participants were randomly assigned to
one of four groups generated by crossing the factors of nature of change
and gender. Group sizes of 75 or 76 were planned. For each of the four
groups, participants who (a) self-reported an illness known to affect sleep
(i.e., 2), (b) scored above 9 on the BDI (10–18 indicates moderate-mild
depression [Beck & Steer, 1987]; no participants were found to be in this
category), or (c) failed to satisfy the task requirements (i.e., to correctly
identify the change to which they were exposed—9 participants) were
excluded from the analyses. For analyses purposes, the remaining partic-
ipants of each of the four groups were retrospectively assigned to one of the
three levels of the factor of sleep quality, on the basis of their PSQI scores:
good sleepers (PSQI score 0–2 inclusive), moderate sleepers (4–5 inclu-
sive), and poor sleepers ( 5). Assignment to the newly formed 12 groups
(2  2  3) was constrained by matching for age (to within 4 years) and
the goal of equal group sizes (to obtain the best estimate of between-groups
variation). Retrospective group assignment was blind to the dependent
variable of the analyses: change-detection latency. Unmatched participants
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were excluded from the analyses. Analyses were carried out on the 192
remaining participants, with a group size of 16.
Apparatus and Stimuli
An Apple iBook (MacOS 9.1) and the experiment-generation package
SuperLab 1.75 (Cedrus Corporation, San Pedro, CA) were used to imple-
ment the flicker paradigm. Photographic stimuli were presented centrally
and almost filled the iBook’s 28-cm (diagonal) screen. The viewing dis-
tance was approximately 65 cm normal to the screen.
A different flicker pair of stimuli were used for each of the two levels of
the nature of change factor (sleep-related and neutral). Each of the two
pairs contained the same original stimulus (OS) shown in Figure 1. The OS
was a full-color photograph (1280  960 pixels) taken in natural daylight
of seven sleep-related objects and an equal number of neutral objects
arranged in two collections on either side of the scene midline. The second
stimulus of each pair was identical to the OS but for one small change: a
sleep-related change was introduced for the “sleep” level of the nature of
change factor (stimulus conditioned stimulus [CS-S]) and a neutral change
for the “neutral” level of the same factor (stimulus CS-N). The two
changed stimuli are shown in Figure 1 along with their common originating
stimulus. Within a flicker paradigm, the two stimuli of a pair (OS/CS-S for
the six sleep change groups and OS/CS-N for the six neutral change
groups) are presented in continuous succession (each replacing the other, in
register, on the iBook screen) until the change from the original to the
changed stimulus (or from the changed stimulus to the original stimulus) is
detected (see Figure 2). In the current experiment, following usual practice
to suppress visual transients produced by the change process, a mask
comprising a rectilinear matrix of Xs was presented on the screen between
the OS and the changed versions (CS-S or CS-N). The OS and either the
CS-S or the CS-N were presented for 250 ms, and the mask was presented
for 80 ms with no other interstimulus interval and no intertrial interval
(B. C. Jones et al., 2002; B. T. Jones et al., 2003).
Precautions were taken to ensure that the seven sleep-related objects
included in the OS were highly representative of the sleep environment and
that the object carrying the sole sleep-related change to be detected
throughout the experiment was the most representative of the seven. This
was done in three stages. First, by asking 60 students (50% female) to list
at least 5 objects that they would associate with “going to bed to sleep.”
Their lists were compiled to identify the 12 most listed objects. Second,
examples of these objects were photographed singly, and the set of 12
objects were embedded in another set of 12 photographs of neutral objects
(thought not to be bedroom and sleep-related by the experimenters and
none of which had appeared in the 60 lists of sleep-related objects collected
earlier). This created a 4 6 matrix of photographs of 12 sleep-related and
12 neutral objects. Finally, another 30 students (50% female) were asked to
rate the 24 photographs of the objects on a 1–10 “sleep-relatedness” scale
(1 highly sleep-related, 10 not sleep-related at all). The 7 objects with
the highest mean sleep-relatedness score (mean range  1.2–5.8) were
selected for the sleep-related collection of objects in the OS, and the 7 with
the lowest mean score (all had means of 10) were selected for the neutral
collection. The sleep-related objects were teddy bear, pajamas, pillow,
alarm clock, hot water bottle, hand cream, and pair of slippers. The pair of
slippers had the highest sleep-related score. The neutral objects were
rucksack, journal issue, files, bottle of ink, office tray, telescoped umbrella,
and pair of gloves. The CS-S was made by removing one of the pair of
slippers (the most representative sleep-related object) from the OS and
photographing the remaining scene, and the CS-N was made by removing
one of the pair of gloves from the OS. (In the absence of differential
sleep-relatedness scores in this group, this object was chosen because it
was physically most similar to the object carrying the sleep-related
change.)
In earlier applications of the flicker paradigm to explore attentional
biases in the social use of alcohol and cannabis, B. C. Jones et al. (2002)
and B. T. Jones et al. (2003) used both normal and mirror-reversal versions
of the original and changed stimuli as a between factor. This was done to
control for possible carry-over effects from, for example, lifelong reading
practices generating side preferences in visual processing. In the four
studies they reported, however, B. C. Jones et al. (2002, B. T. Jones et al.,
2003) found no significant main effects for or interactive effects implicat-
ing the factor of normal/mirror-reversal. For this reason, mirror-reversals
of stimuli OS and CS-S/CS-N were not included in the current experiment.
Procedure
Potential participants were approached throughout the campus and asked
to take part in an experiment. Care was taken during the recruitment period
Figure 1. Gray-scale versions of the full color stimuli used: original
stimulus (OS) and the two changed stimuli for each of the two levels of the
nature of change factor—sleep-related change (CS-S) and neutral change
(CS-N).
Figure 2. A flicker paradigm for inducing change blindness illustrating a
change cycle or single “flicker.” os  original stimulus; cs  changed
stimulus.
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to ensure that the sleep-related nature of the experiment was not apparent.
Those who agreed to take part were taken to a nearby quiet room and asked
to read the instructions on an iBook screen on what they should expect.
Participants were then asked to press the space bar when they were ready,
at which time they would see a visual scene presented on the screen for less
than a second. It would keep appearing and disappearing for as long as it
took them to spot a small change made to the scene between successive
presentations. When they had spotted the change, participants were asked
to immediately press the space bar, which would be recorded by the
computer, and then to say what the change was. Participants were then
asked to complete the BDI, the PSQI, and the local questionnaire. It would
only have been through reading the contents of the PSQI and the local
questionnaire (given after the flicker paradigm) that participants would
have been explicitly exposed to the sleep-related nature of the experiment.
Once the questionnaires had been completed and passed to the experi-
menter, the true purpose of the experiment was explained. Participants
were also provided with contact information in case they wanted to be
informed of the outcome of the project when it was completed.
Results
As indicated earlier, age and BDI-indicated depression associ-
ates with sleep problems. Consequently, two analyses of variance
(ANOVAs) were carried out prior to the main analyses. A
matching-check for age across the 12 groups was carried out using
an ANOVA that was identically structured to the main analysis,
that is, a three-factor between-participants ANOVA (N 192, n
16) but with age as the dependent variable and with the following
factors and levels: nature of change (sleep-related, neutral), gender
(male, female), and sleep quality (poor, moderate, good). With age
as the dependent variable, there were no main, two-way, or three-
way interactive effects. This indicates a good degree of equiva-
lence in age between the 12 different groups. A second identical
ANOVA was carried out with BDI scores as the dependent vari-
able; this analysis also showed no main or interactive effects
(overall BDI score: M  3.1, SD  2.1), indicating a correspond-
ing equivalence.
Analysis 1: ANOVA
The number of flickers to correct change detection for each
participant was entered into a three-factor between-participants
ANOVA (structured as above; N  192, n  16). There were no
significant main effects. Sleep-related change-detection latencies
were no different from neutral change-detection latencies (Ms 
17.7 and 19.0, respectively; SDs  12.3 and 11.1, respectively),
F(1, 180)  0.51, p  .05; womens’ change-detection latencies
were no different from mens’ (Ms 18.2 and 18.5; SDs 7.9 and
9.4, respectively), F(1, 180)  0.07, p  .05; and there were no
differences between the change-detection latencies of poor, mod-
erate, and good sleepers (Ms  18.4, 16.9, and 19.8, respectively;
SDs  7.8, 7.1, and 9.7, respectively), F(2, 180)  1.35, p  .05.
Of the one 3-way and three 2-way interactions, only the Change
Sleep Quality interaction was significant, F(2, 180)  7.12, p 
.01 (see Figure 3). The interaction was interpreted using tests for
simple main effects. This was done in two ways.
First, for the neutral change, no differences in change-detection
latency were found between the poor, moderate, and good sleepers
(Ms  21.9, 18.4, and 16.5, respectively; SDs  12.1, 10.9, and
6.8, respectively), F(2, 180)  1.69, p  .05. By contrast, differ-
ences in change-detection latency were found between poor, mod-
erate, and good sleepers for the sleep-related change (Ms  14.5,
15.5, and 23.1, respectively; SDs  9.4, 10.7, and 7.6, respec-
tively), F(2, 180)  6.59, p  .01. These differences were located
using t tests. It was found that poor sleepers detected the sleep-
related change significantly more quickly than good sleepers (M
14.5 vs. M 23.1; SDs 8.5 vs. 7.6), t(191) 3.33, p .01, and
moderate sleepers detected it significantly more quickly than good
sleepers (M  15.5 vs. M  23.1, SDs  9.1 vs. 10.1), t(191) 
2.90, p  .01. There was no difference in the change-detection
latency for the sleep-related change between poor and moderate
sleepers, however (M  14.5 and M  15.5, respectively; SDs 
9.4 and 10.7, respectively), t(191)  0.34, p  .05.
Second, poor sleepers detected the sleep-related change signif-
icantly more quickly than the neutral change (Ms  14.5 and 21.9,
respectively; SDs  9.4 and 12.1, respectively), F(1, 180)  7.11,
p  .01, displaying a sleep-related attentional bias. Although
moderate sleepers showed the same difference direction as poor
sleepers, the difference between sleep-related and neutral change
detections was not significant (Ms  15.5 and 18.4, respectively;
SDs  10.7 and 10.9, respectively), F(1, 180)  1.29, p  .05. By
contrast, good sleepers detected the change within the neutral
objects significantly more quickly than within the sleep-related
objects (Ms  16.5 and 23.1, respectively; SDs  6.8 and 7.6,
respectively), F(1, 180)  6.21, p  .05, showing a bias toward
neutral rather than sleep-related objects. The effect size for poor
sleepers (see Figure 4) was significant and “moderate” using
Cohen’s (1992) classificatory scheme for effect size comparisons
(Cohen’s d  0.60; 95% confidence limits of 0.07 and 1.06) as
compared with a “small” and nonsignificant effect size for mod-
erate sleepers (d  0.21; 95% confidence limits of 0.17 and
0.51). The effect size of the opposite bias shown by the good
sleepers was significant and “large” (Cohen’s d  0.91; 95%
confidence limits of 0.41 and 1.46).
The foregoing is consistent with poor, moderate, and good
sleepers, together responding equivalently to the neutral change
but responding differently to the sleep-related change. Further, no
difference between the neutral and sleep-related change is found
for the moderate sleepers but for the poor sleepers, there is a
decrease in change-detection latency whereas for good sleepers,
there is an increase.
Analysis 2: Regression
Two hierarchical regression analyses were carried out for the
two different levels of the nature of change factor (sleep-related
and neutral) in order to test the relationship between change-
detection latency and a continuous representation of the global
PSQI score (rather than a categorical representation, as was used in
the ANOVA). With change-detection latency as the dependent
variable, age, gender (for reasons outlined earlier), and the BDI
score were first added to the regression model and then the PSQI
score. Although BDI scores above 9 represent the severity of a
clinical diagnosis associated with increasingly poor sleep, this does
not necessarily mean that the BDI score range 0–9 can be used to
represent states increasingly proximate to a clinical diagnosis (and
with commensurate associations with sleep quality). Nevertheless,
entering the “subclinical” BDI score into the regression model
prior to the PSQI score appears to be a sensible precaution. The
incremental variance explained when the PSQI score is added to
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the model already containing age, gender, and the BDI score is the
critical test of the relationship.
In both models (sleep-related change and the neutral change),
there was no significant variance explained in change-detection
latency when age, gender, and the BDI scores were added. When
the PSQI score was added to the model for the sleep-related
change, however, the model deviated from the null, F(4, 92) 
2.51, p  .05. The incremental variance explained on the basis of
adjusted R2 was 10.6% ( p  .05), and the beta for PSQI was
0.310 ( p  .05). For the neutral change, the model did not
deviate from the null when the PSQI score was added, F(4, 92) 
2.29, p  .05.
Thus, there is no relationship between PSQI-indicated sleep
problems and change-detection latency for the neutral change, but
for the sleep-related change, change-detection latency decreases as
sleep problems increase.
Discussion
Espie’s (2002) and Harvey’s (2002) models of primary insom-
nia identify attentional bias toward sleep-related concepts as con-
tributing to the perpetuation of primary insomnia. In both models,
the heightened arousal accompanying insomnia and the belief that
the night’s sleep problems will negatively impact on next day’s
activities generate anxiety. Williams et al. (1996) postulated that
anxiety raises the resting activity level of network inputs repre-
senting concepts with which the anxiety temporally occurs. The
raised resting activity level is the basis of the attentional bias we
predict will be found for bedroom objects in primary insomnia.
This means that representations of the bedroom environment will
be more likely to enter current cognitions, generate anxiety, and
disrupt sleep.
Our results support this prediction, showing an attentional bias
toward a representative bedroom object in sleepers who satisfy the
minimal criteria for primary insomnia (our poor sleepers); change-
detection latencies in poor sleepers were quicker when the change
was made to the sleep-related object than to the neutral object.
There was also found a marked differential attentional bias be-
tween poor sleepers and the good-sleeping controls. However,
whereas the poor sleepers showed a bias toward the sleep-related
object as predicted, the good sleepers showed a bias toward the
neutral object. This part of our prediction, therefore, does not
appear to be supported—namely, that because good sleepers would
be reporting few if any sleep problems, there would be little
anxiety generated within the sleep-problems context, negligible
changes in the resting activity levels of the sleep-related network
input units, and therefore a negligible sleep-related attentional
bias. There are two explanations why the good-sleeping compo-
nent of the differential attentional bias might occur.
First, it is possible that the good sleepers’ choices are driven by
the physical properties (physical saliencies) of the sleep-related
and neutral objects themselves, rather than semantic saliencies.
Particularly in complex stimuli (e.g., real-world objects collected
Figure 3. Mean sleep-related and neutral change-detection latencies (number of flickers to detection) in poor,
moderate, and good sleepers. PSQI  Pittsburgh Sleep Quality Index; SEM  standard error of the mean.
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into a scene), values of the objects’ physical properties will com-
pete for attention resources and contribute to, or even drive, what
is attended to and what reaches consciousness. Physical properties
such as object size, color, brightness, complexity, and overlap as
well as relative positional and configurational aspects will be
important in this respect. This means that any single attentional
bias measure (e.g., the comparison between the change-detection
latencies of the group of good sleepers given the sleep-related
change with the other group of good sleepers given the neutral
changes) is ambiguous because it confounds the sleep salience
manipulation (i.e., the sleep-related change vs. the neutral change)
with a range of other nonsleep saliencies. If the good sleepers have
comparatively problem-free sleep (a group assignment feature of
the design), there will be little associated anxiety and, conse-
quently, negligible sleep-related attentional bias. In addition, in
such a case, any attentional bias would be driven by the physical
saliencies of the grouped objects. We would conclude, therefore,
that either the group of neutral objects in which the neutral change
was embedded, or the neutral objects that carry the neutral change
had more “grabby” physical properties than did the corresponding
sleep-related objects; this would explain the neutral attentional
bias shown by the good sleepers. When measuring differential
attentional bias, however (i.e., the difference in attentional bias
between poor sleepers and good sleepers), we are able to control
the physical saliencies (and any other nonsleep semantic salien-
cies) through giving the poor and good sleeping groups the same
Figure 4. Effect size (Cohen’s d) and 95% confidence limits of net attentional bias in poor, moderate, and good
sleepers (net attentional bias calculated as sleep-related minus neutral change-detection latencies). PSQI 
Pittsburgh Sleep Quality Index.
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stimulus presentations. The interaction representing the differential
attentional bias between poor and good sleepers is, therefore, the
properly controlled measure of the effect of the PSQI-derived
sleep-problem manipulation on sleep-related attentional bias. In-
deed, it follows from this explanation that the apparent sleep-
related attentional bias shown by the poor sleepers will be an
underestimate of the real sleep-related attentional bias and will
only be provided through the measure of differential attentional
bias.
Second, there is an alternative explanation for the neutral bias
found in good sleepers that makes no reference to physical salien-
cies. It is possible that our good sleepers were low in anxiety-
sensitivity (Reiss, 1997), given that, using a dot probe paradigm,
Keogh et al. (2001) have shown that participants with low anxiety-
sensitivity under some circumstances orient away from threatening
stimuli rather than toward them—in which case, our good sleepers
should orient away from the set of bedroom objects if they were
low in anxiety-sensitivity. If this occurred, it would assist neutral
change detection but hinder sleep-related change detection and
explain the bias toward the neutral set of stimuli that good sleepers
show. Although there might be grounds for suggesting that good
sleepers might indeed be low in trait anxiety (because this dispo-
sition might either contribute to or derive from their good-sleeping
status), there is less to suggest that they might be low in anxiety-
sensitivity and, as Keogh et al. noted, it is the latter rather than the
former that would be an important feature of this type of expla-
nation. Nevertheless, it remains a possibility.
However the differential attentional bias between two poles of
the sleep-problems continuum is explained, it remains that the poor
sleepers appear to attend to a sleep-related object more than a
neutral object. If our finding with one sleep object generalizes to
others, the attentional bias that it represents will feed the processes
that maintain or perpetuate primary insomnia described by Espie
(2002) and Harvey (2002). There is some indication that atten-
tional bias might be an agent for not just the perpetuation of
primary insomnia but also its precipitation—this possibility is
raised through a consideration of the moderate sleepers’ perfor-
mance. On the surface, the moderate sleepers do not appear to
show an attentional bias toward the sleep-related object as com-
pared with the neutral object. If, however, the explanation of the
performance of the good sleepers is indeed based on physical
saliencies (as described above), then the good-sleepers perfor-
mance represents a baseline condition against which the perfor-
mance of the moderate sleepers can be judged, with all nonsleep
saliencies controlled. When this comparison is made, good and
moderate sleepers do not treat the neutral change differently (and
neither do poor sleepers); by critical contrast, however, the mod-
erate sleepers detect the sleep-related change significantly more
quickly than do the good sleepers. The apparent lack of attentional
bias in moderate sleepers, derived from comparing only their
detection latencies to the sleep-related and neutral change, should
not obscure the fact that a differential attentional bias is revealed
from good to moderate sleepers when more appropriately con-
trolled comparisons are made. If moderate sleepers do indeed
exhibit a sleep-related attentional bias—generated by the anxiety
accompanying acute sleep problems, not diagnosed as the more
chronic primary insomnia—it could help maintain these sleep
problems in much the same way as Espie (2002) and Harvey
(2002) suggested that attentional bias maintains primary insomnia.
If sleep problems are maintained beyond an acute phase by atten-
tional bias, however, and if the length of time satisfies the criterion
for primary insomnia, it suggests that attentional bias might not
only be implicated in perpetuating primary insomnia but also in
precipitating it.
Our study is the first to report a sleep-related differential atten-
tional bias between good and poor sleepers and a possible corre-
sponding differential bias between good and moderate sleepers. It
also identifies a likely source perpetuating primary insomnia and a
possible precipitating factor. We find only partial support for a
continuity of sleep-related attentional bias corresponding to the
sleep-problems’ continuum, however, because of the failure to find
a differential attentional bias between the moderate and poor
sleepers.
Our findings and conclusions are limited by a number of con-
siderations. First, the clinical pole (primary insomnia) was repre-
sented by participants with PSQI scores greater than 5. The incor-
poration in future research of an additional “primary insomnia”
group with a higher inclusion threshold would provide an addi-
tional opportunity to compare more distant clinical and subclinical
points on the sleep-problems continuum as well as points within
the diagnostic category—providing a more extensive test of the
hypothesis of continuity of attentional bias. Second, only a single
sleep-related change and neutral change were used, and this might
compromise generalizing the findings and conclusions to other
bedroom and neutral objects. Care was taken, however, to ensure
that all the objects used were either highly representative of the
bedroom environment or not representative at all. Further, the most
representative bedroom object was chosen to carry the sleep
change. Finally, Bruce and Jones (2005) have recently shown with
social drinkers that change detection performance in a flicker
paradigm is almost entirely driven by the set of different objects in
which the single object carrying the change (also a set member) is
embedded rather than by the single object itself. If this finding
extends to our sleep study (which uses similar stimulus configu-
rations), this limitation is reduced because seven sleep objects
make up the sleep set and another seven make up the neutral set.
Nevertheless, our finding requires replication, and future research
should extend the range of objects used. Furthermore, we do not
have anxiety and anxiety-sensitivity data, and the possibility that
good sleepers low in anxiety sensitivity might be orienting away
from the sleep-related objects cannot be evaluated. Future research
needs to pay attention to this potential explanatory source by
collecting anxiety data.
Although it is some 30 years since stimulus control was pro-
posed as offering an explanatory, and potentially modifiable, par-
adigm in insomnia (Bootzin, 1972), contemporary sources agree
that its role in the development and amelioration of persistent
insomnia remains unclear (Edinger & Wohlgemuth, 1999; Espie,
2002; Morin et al., 1999). In large part, this is because research
effort has focused on treatment efficacy derived from stimulus
control intervention rather than on experimental studies. We are
now in the position where a psychological rather than pharmaco-
logical approach is seen as the treatment of choice for persistent
primary insomnia (Espie, 1999; Smith et al., 2002) and stimulus
control instructions meet American Academy of Sleep Medicine
criteria for “standard treatment” (Chesson et al., 1999). The
present study, which uses a novel experimental approach well
suited to the systematic investigation of the stimulus control par-
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adigm, illustrates one way forward for research in this area. Evi-
dence presented of attentional bias toward the bedroom environ-
ment, and our previously reported evidence of attentional bias
toward textual representations of sleep and sleeplessness (Taylor et
al., 2003), raises the possibility that dysfunctional stimulus control
in insomnia develops from the conditioning of nonverbal and
verbal signals as threat cues that impact on selective attention
through the principles of Williams et al.’s (1996) model—starting
a vicious cycle. The feasibility of objectively and accurately mea-
suring this bias, therefore, yields new opportunity for both exper-
imental and clinical investigations of the development of primary
insomnia during remission and treatment response.
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SUMMARY Cognitive models of insomnia suggest that selective attention may be involved in
maintaining the disorder. However, direct assessment of selective attention is limited.
Using the inducing change blindness (ICB) paradigm we aimed to determine whether
there is attentional preference for sleep-related stimuli in psychophysiological insomnia
(PI) relative to delayed sleep phase syndrome (DSPS) and good sleepers (GS). In the
ICB task, a visual scene, comprising both sleep-related and neutral stimuli, ﬂickers
back and forth with one element (sleep or neutral) of the scene changing between
presentations. Therefore, a 2 · 3 totally between-participants design was employed.
The dependent variable was the number of ﬂickers it took for the participant to identify
the change. Ninety individuals (30 per group) were classiﬁed using ICSD-R criteria,
self-report diaries and wrist actigraphy. As predicted, PI detected a sleep-related change
signiﬁcantly quicker than DSPS and GS, and signiﬁcantly quicker than a sleep-neutral
change. Unexpectedly, DSPS detected a sleep-related change signiﬁcantly quicker than
GS. No other diﬀerences were observed between the two controls. These results support
the notion that there is an attention bias to sleep stimuli in PI, suggesting that selective
attention tasks such as the ICB may be a useful objective index of cognitive arousal in
insomnia. The results also suggest that there may be an element of sleep preoccupation
associated with DSPS. Results are discussed with reference to other experiments on
attentional processing in insomnia.
k e yword s attention bias, cognitive arousal, delayed sleep phase syndrome, inducing
change blindness ﬂicker paradigm, insomnia
INTRODUCTION
Insomnia is, in part, characterized by mental arousal (AASM,
2004, 2005). Indeed, having an overactive mind has been the
attribution of poor sleep rated most highly, both by insom-
niacs and non-insomniacs (Bootzin et al., 1991; Espie and
Tweedie, 1991; Lichstein and Rosenthal, 1980; Nicassio et al.,
1985). Cognitions interfering with sleep typically form part of
a dysfunctional belief system, and reﬂect a tendency towards
problem-solving, worry, and heightened self-awareness both in
bed and during the daytime (Harvey, 2000; Harvey and Espie,
2004; Morin et al., 1993; Neitzert Semler and Harvey, in press;
Watts et al., 1994; Wicklow and Espie, 2000). Such studies
have relied on subjective methods to index the mental
component of insomnia. Self-report is, of course, appropriate
because it reﬂects the experience of insomnia. However, there
are clear advantages to objective indices, when they are
available.
In this context, it is interesting that the notion of preoccu-
pation with sleep maps neatly onto the concept of selective
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attention. Psychologists interested in information processing
have researched human attention extensively (Allport, 1980;
Broadbent, 1958; Deutsch and Deutsch, 1963; Posner, 1980;
Shiﬀrin and Schneider, 1977). In short, stimuli that are salient
are likely to attract attention, because of an information
processing bias or attention bias. Such biases can be measured
objectively using computerized cognitive probe tasks where
information processing speed is taken as a proxy for selective
attention. These tasks use salient and neutral word or picture
stimuli within an experimental test paradigm.
Support has been found implicating attention bias in the
perpetuation of a wide range of anxiety-related psychological
disorders (see Mogg and Bradley, 1998; Williams et al., 1997)
and habit/dependence disorders (Jones et al., 2003). Generally,
an attention bias has been found in those who have a clinical
diagnosis, contributing to the explanation of why such
disorders are frequently self-maintaining, and why relapse
often occurs after emergent treatment response (Drummond
et al., 1995; Mogg et al., 1990). It is thought that attention bias
in anxiety is conveyed by threat monitoring (Matthews and
MacLeod, 1994), whereas in the addictions it may be due to
craving (Lusher et al., 2004).
So is it reasonable to consider attention bias a proxy for
cognitive arousal in insomnia? If so, the possibility emerges for
objective measurement of the mental concern associated with
poor sleep. This topic has been recently reviewed (Espie et al.,
in press), however, a brief synopsis may be helpful.
Harvey’s (2002) cognitive model of insomnia proposes that
the anxious state generated by excessive worry, negative
thoughts and autonomic arousal triggers selective attention
towards and monitoring of internal and external sleep-related
threat cues. Likewise, Espie’s (2002) psychobiological model
emphasizes the inhibitory inﬂuence of attention and intention
upon normal sleep engagement. It is argued that such
processes are dysregulatory because they contravene the
automaticity of normal unattended sleep engagement (Espie,
2002). These theories are consistent with ICSD-2 (AASM,
2005) text describing just how marked the attention to sleep is
in psychophysiological insomnia (PI) – Concerns about sleep
grow progressively over months or years as sleep gradually
deteriorates until the desire to obtain a good night’s sleep
becomes the person’s major concern (p. I-6). This statement
conveys both a sense of incrementing distress associated with
sleeplessness (cf. threat), and a preoccupying longing for sleep
(cf. craving) that might serve as preconditions for attention
bias.
To date, three studies have applied cognitive probe tasks to
insomnia. Lundh et al.s (1997) study was a pioneering piece of
work because it translated the emotional Stroop task into the
insomnia ﬁeld. The Stroop task involves target (salient) and
control (neutral) words being presented at random in diﬀerent
ink colours. Subjects are asked to respond quickly to the
presented colour by pressing the corresponding coloured
button on a response box. They are instructed to ignore the
actual meaning of the words. Response latencies for colour
identiﬁcation are automatically recorded for each stimulus.
Longer response latency is thought to suggest increased
attention bias because automatic processing of word meaning
for salient words is likely to interfere with (slow down) colour
naming relative to response time for the neutral words: the so-
called interference eﬀect.
Lundh et al. (1997) found that people with insomnia had
prolonged response latency for sleep-related words. However,
this eﬀect was also evident in a control population of good
sleepers (GS), and there was no group diﬀerence on the Stroop
interference index; a result inconsistent with the attention bias
hypothesis. Lundh et al. (1997) suggested that sleep-related
words might have emotional valence irrespective of sleep
problems. However, the extensive literature on the Stroop task
would not predict experimental eﬀects in normal control
groups. Of course, recruited GS may have a particular interest
in sleep, and this might yield a bias. Also, no measure of
aﬀective state (known to inﬂuence Stroop ﬁndings) was taken,
and diagnostic criteria were not reported for the insomnia
group.
Taylor et al. (2003) also used the Stroop task, selecting a
cancer population because the primary purpose was to
investigate the development of insomnia associated with stress
in people who had previously been GS. None of the partic-
ipants had insomnia prior to diagnosis; that is they were a
true secondary insomnia population rather than people whose
(pre-existing) insomnia had been exacerbated. Two groups of
people with cancer and insomnia, 0–3 and 12–18 months after
cancer diagnosis, completed the task comprising cancer-
related, sleep-related and neutral word cues. Both groups
demonstrated attention bias for cancer-related words but only
the persistent insomnia group demonstrated attention bias for
sleep-related words. The fact that interference eﬀects were
absent at 0–3 months but evident at 12–18 months, therefore,
suggested that selective attention bias towards sleep may play a
role in the transition from adjustment insomnia to PI.
There has been debate over whether the Stroop task
measures increased vigilance or simply reﬂects the impact of
heightened arousal interfering with information processing
when salient stimuli are presented. The dot-probe task has
been posited as one solution to this problem (MacLeod et al.,
1986). In this task, words are simultaneously presented to two
areas on a computer screen. The ensuing distribution of visual
attention is measured by recording detection latency for a
visual probe that could appear in the spatial location of either
word, immediately after the display of that word has termin-
ated. The trials providing the data of interest are those in
which one of the words is salient. By examining the impact of
sets of such words on relative probe detection latencies in the
two spatial areas, it is possible to determine whether visual
attention has shifted towards or away from such stimuli.
MacMahon et al. (unpublished data) used the dot-probe
task with 63 young adults across three experimental groups
[PI, delayed sleep phase syndrome (DSPS) and GS]. The DSPS
group was employed as a further, clinical, control sample of
people who, like PI participants, had sleep-onset problems, but
who would not be expected to exhibit cognitive arousal as an
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explanatory mechanism for their continued wakefulness.
Results supported the predictions, with those in the PI group
showing a signiﬁcantly greater processing bias towards sleep-
related words (in comparison with neutral words) when
compared with the GS and DSPS groups. Notably, the GS
and DSPS groups did not diﬀer from each other, suggesting
that the underpinning mechanism maintaining DSPS is not an
attention bias. This is consistent with DSPS as an endogenous
circadian problem.
It is also possible to explore attention bias with digitized
objects (i.e. pictures, rather than words) using a ﬂicker
paradigm featuring a perceptual phenomenon called induced
change blindness (ICB: Rensink, 2002; Simons, 2000).
Research reveals that when a change is made to a visual scene
(and the process of change is hidden from view), it is more
diﬃcult to detect than might be expected. A single feature of a
visual scene is changed between successively repeated brief
presentations until the change is detected – essentially the ICB
is a ‘spot the diﬀerence’ task. Change-detection latency,
measured by the number of ﬂickers it takes for the change to
be identiﬁed, is explained by object salience. For example, in
the alcohol ﬁeld, problem drinkers take fewer ﬂickers to detect
an alcohol-related change and are faster to detect such changes
than control subjects. Interest in the control that sleep-related
objects might have over sleep behaviour is long-established.
Within a conditioning framework, bedroom environment
objects might become discriminative stimuli for sleep (Bootzin
et al., 1991), but when the bedroom-sleep contingencies are
broken, they might become discriminative stimulus for wake-
fulness. In that regard the ICB paradigm may be well suited to
investigating the inﬂuence of the bedroom environment on
sleep.
Jones et al. (2005) suggested that if attention is implicated in
the development of persistent insomnia it might be expected
that a systematically changing attention bias might be
observed, not just at the clinical pole. In their ICB study,
192 participants (mean age 32 years) were selected for this
totally between-subjects experiment. Participants completed
the 15-min ICB task, after which they were assessed for sleep
quality. Importantly, therefore, retrospective group assign-
ment was blind to the dependent variable of the analyses,
change detection latency. Jones et al.s results revealed
signiﬁcant diﬀerences in change detection latency between
poor, moderate and GS for the sleep-related change. Only the
poor sleepers, who detected sleep-related change quicker than
neutral change, demonstrated selective attention bias for sleep
salient stimuli. Moderate sleepers showed a trend in the same
direction. By contrast, GS detected the change with the neutral
objects signiﬁcantly quicker. Hierarchical regression was then
applied to test the relationship between change detection
latency and a continuous representation of the global PSQI
score. This evidenced a systematically changing eﬀect of sleep
quality upon attention bias, independent of age, gender and
depressive symptom level.
Thus, three of the four available experiments suggest that
attention bias probe tasks may index and discriminate cogni-
tive arousal in insomnia. It seems plausible then that this
paradigm could be a useful research tool.
METHODS
Aims and hypotheses
The current study extends research in this ﬁeld in two ways.
First, this ICB experiment used novel sleep-related and sleep-
neutral objects to undergo a change in the sequence. Jones
et al. (2005) measured the response to one sleep-related change
and one sleep-neutral change; we wanted to rule out the
possibility of an idiosyncratic eﬀect and to improve general-
izability. Second, an additional, clinical control group of DSPS
was included, in keeping with the MacMahon et al. protocol.
DSPS involves initial insomnia, similar to sleep-onset PI, but
with no presumed psychological mechanism. Comparison with
normal sleepers, without a clinical control, leads to problems
in testing the speciﬁcity of insomnia phenomena. Therefore,
the DSPS group allowed us to assess diﬀerences in selective
attention between sleep disorders that are behaviourally
similar in terms of sleep initiation problems.
We hypothesized that (1) people with PI would detect a
sleep-related change signiﬁcantly quicker than would GS or
DSPS participants; (2) with a neutral change there should be
slower response in PI, because their attention would be
drawn to the sleep area of the visual scene, and would have
to shift to notice a neutral change; (3) there would be no
signiﬁcant diﬀerence between detection latencies to sleep-
related versus sleep-neutral changes by the two control
groups, GS and DSPS; and (4) there would not be
diﬀerences in detection latencies between GS versus DSPS,
at either level of change.
Design
A 2 (experimental condition) · 3 (group) entirely between-
participants design was employed. The necessary conﬁrmation
process (making explicit the semantic nature of the stimulus
carrying the change) means that a within-participant factor
cannot be implemented in ICB experiments. This is because
any explicit knowledge carried over by participants as a result
of the conﬁrmation process would compromise the main
objective, exploring their implicit knowledge of the stimuli
contained in the scene (Jones et al., 2003). Therefore, each
group (GS, PI, DSPS) was split in half at random (n ¼ 15) to
represent the nature of the change introduced in the photo-
graphic image (sleep-related or sleep-neutral).
Allocation of sleep-related stimuli to the left and sleep-
neutral to the right side of the visual ﬁeld was chosen at
random. This orientation of the stimulus presentation was kept
constant in all conditions. Including mirror reversal to control
for diﬀerences in scene processing, due to left–right placement,
was not considered necessary because no diﬀerences have
found between normal and reversed scene processing in
previous ICB ﬂicker paradigm experiments (Jones et al., 2003).
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Participants
Data were derived from students and staﬀ at the University of
Glasgow. Appraisal of individual sleeping patterns was con-
ducted in three phases. Phase 1 of the screening phase was
based upon the information gained from an initial mass
advertisement email, which, after giving a brief introduction
about the Glasgow Sleep Laboratory asked ﬁve speciﬁc
questions: (1) Are you someone who struggles to sleep at
night? (2) Once asleep do you regularly wake during the night?
(3) How many hours on average do you sleep per night? (4)
Would you describe yourself as a lark or an owl? (5) Are you a
good sleeper, who falls asleep as soon as your head touches the
pillow and wakes up feeling refreshed in the morning? The
email concluded by stating if you feel you would gain from
being part of a sleep experiment and would like to learn a little
more about your sleeping patterns, and ways to improve them,
we would like to hear from you. Please send information about
your sleep pattern based on the questions above.
In total, 253 individuals responded to this email. Of these
253 respondents, 189 reported symptoms similar to PI and
DSPS and were subsequently emailed for a second time (phase
2) to obtain further details of their sleep patterns. This second
email asked more speciﬁc questions: how many minutes does
it take you, on average, to fall asleep at night, once asleep do
you wake at regular intervals throughout the night, How long
do you predict you are awake during the night, On average
how many hours of sleep do you get per night, Do you view
your sleep as a problem, What time do you get up in the
morning , Do you feel refreshed?.
From the 189 individuals emailed in phase 2, 157 responded
and 97 were assessed as potentially suitable and subsequently
completed the ICB procedure. The third and ﬁnal phase, after
the experiment, applied rigorous criteria and prospective diary
and actigraphic assessment to conﬁrm allocations; 90 of the 97
tested were included in analyses. The main advantage of the
third screening phase occurring post experiment was that it
further limited the priming eﬀect upon participants. Further
details of recruitment and assessment are provided as part of
the procedures for the investigation.
Inclusion/exclusion criteria
Participants met combined DSM-IV and ICSD-R criteria for
primary insomnia of the PI type or DSPS, and those with PI
were required to score >6 on the PSQI. PI exclusion criteria
included active psychological or drug interventions for sleep
problems, or when sleep disorder was suspected as being the
result of substance misuse or physical ill health. The same
exclusion criteria applied for DSPS. Good sleepers were
required to score <5 on the PSQI, report themselves as being
good sleepers, and meet no criteria for a sleep disorder at the
present time or in the past. For all three participant groups,
scoring above the cut oﬀ markers for depression (BDI SF-4)
resulted in exclusion from analyses. Actigraphy was used to
conﬁrm participants subjective account of their sleeping
complaint and to aid in the diﬀerentiation between PI and
DSPS in those reporting sleep diﬃculties.
Experimental protocol and apparatus
The ﬂicker ICB paradigm was employed. An originating
stimulus (OS) was presented for 250 ms – then a mask for
80 ms – then the changed stimulus (CS) for 250 ms – and
ﬁnally a mask for 80 ms (Fig. 1). This four-presentation cycle
was repeated seamlessly until change-detection. Thus, the
combined number of transitions between OS–CS and CS–OS
(the ﬂickers to change-detection) was the dependent variable.
Sleep-related stimuli were chosen from a questionnaire
distributed, randomly, to 60 individuals. This questionnaire
was devised for the Jones et al. (2005) study. People were
asked to list ﬁve or more objects that they associated with sleep
and going to bed. Evaluation of the lists yielded a top 12 most
commonly suggested items. These items were photographed
and embedded in a collection of 12 neutral, individually
photographed objects. A further 30 individuals were then
asked to rate all 24 photographs on a 1–10 sleep-relatedness
scale (1 ¼ highly sleep-related, 10 ¼ not sleep-related at all).
In this study the item with the second highest rating (teddy
bear, 5.6) was used, and paired with an entirely sleep-neutral
item (a mug).
A diﬀerent ﬂicker pair of stimuli was used for each of the
two levels of the factor; nature of change (sleep-related and
neutral). Each pair contained the same OS comprising seven
sleep-related objects and an equal number of neutral objects
arranged in two collections on either side of the scene midline.
The second stimulus (CS) of each pair was identical to the OS
but for one small change: a sleep-related change (removing the
teddy bear) or a neutral change (removing the mug). The two
stimuli of a pair were then presented in continuous succession
(each replacing the other) until the change was detected. A
brief mask was inserted in between the ﬂicker pairs to
suppress visual transients. The experiment was implemented
using a Dell optiplex GX270 laptop and the experiment-
generation package SuperLab Pro 2.02 (Cedrus Corporation,
San Pedro, CA, USA). The size of the screen was 28 cm
diagonal with stimuli positioned centrally; the viewing distance
OS Original stimulus
Original stimulus
Changed stimulus
OS
MASK
80
250 ms
A change cycle or
single flicker 80
80
250
250
MASK
MASK
CS
Figure 1. A ﬂicker paradigm for inducing change blindness illustrating
a change cycle or single ﬂicker. OS, original stimulus; CS, changed
stimulus.
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was approximately 45 cm. Stimuli were full colour photo-
graphs (1280 · 960 pixels) taken in natural daylight. Fig. 2
shows the OS, and the two changed stimuli; one with the sleep-
related change (the teddy bear is taken away) and the other
with the sleep-neutral change (the mug is taken away).
Procedure
As described previously, contact was ﬁrst made with partic-
ipants by email, inviting individuals to contact the ﬁrst author
with details of their sleeping patterns in answer to a brief set of
questions. These questions enabled the experimenter to screen
and select the responses that best resembled the traits of the
various sleep groups involved in the study, invite the suitable
candidates to give more speciﬁc information about sleep
quality and subsequently invite them to take further part in the
study. Thus, group allocation was largely known to the
experimenter before testing commenced.
Participants were ICB tested in an assessment room in the
Department of Psychology, University of Glasgow. To ensure
an equal distribution of participants across the experimental
conditions (sleep and neutral), assignment to conditions
alternated consecutively. Thus, if one participant completed
the sleep condition, the following would complete the neutral
condition. Furthermore, an identical instruction protocol was
presented to participants upon arrival, regardless of their
group allocation. To begin, participants pressed any button on
the response button box to display instructions which said that
(when they pressed it again) they would see a scene on the
screen that would be switched on and oﬀ repeatedly – each
appearance and disappearance lasting less than a second.
They were instructed that they had to spot a change made to
the visual scene at some point in the series of ﬂickers and to
indicate this detection by immediately pressing the button on
the response box. After the participants had detected and
responded to the change, they were asked to conﬁrm what the
change was. Only those who had correctly identiﬁed the
change were retained as having completed the task (all
participants who completed the ICB ﬂicker paradigm identi-
ﬁed the correct change in the scene). They were verbally asked
if they understood the instructions and were invited to
continue (without additional practice). The experiment then
commenced. After completion of the ﬂicker task each parti-
cipant immediately underwent the second and detailed assess-
ment phase. This comprised three components.
First, each participant was interviewed to evaluate his/her
general sleeping patterns. The interviewer proposed questions
relating to the DSM-IV and ICSD-R criteria for PI and DSPS,
using our laboratory’s structured interview format (Espie,
2002; (Morin and Espie, 2003).
Second, several questionnaires were administered. The
Pittsburgh Sleep Quality Index (PSQI; Buysse et al., 1989)
provides a reliable, valid and standardized measure of sleep
quality; to discriminate between good and poor sleepers. A
PSQI global score >5 indicates that a subject is having severe
diﬃculty in at least two areas, or moderate diﬃculty in more
than three areas of sleep quality. This global score conveys
information about the severity of the subject’s problem, and
Original stimulus, OS
Neutral changed stimulus, CS-N
(mug removed)
Sleep-related changed stimulus, 
CS-S (teddy bear removed)
Figure 2. Grey scale versions of the full colour used; original stimulus (OS) and the two changed stimuli for each of the two levels of the nature of
change factor – sleep-related change (CS-S) and neutral change (CS-N).
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the number of problems present, through a single measure.
Recent, independent study has validated this cut oﬀ and
conﬁrmed reliability (Cronbach’s a ¼ 0.85, test–retest
r ¼ 0.84; Backhaus et al., 2002). The revised version of the
Spielberger State and Trait Anxiety Inventory (STAI; Spiel-
berger et al., 1983) is a reliable and valid scale. Alpha
coeﬃcients (STAI-S a ¼ 0.93 and STAI-T a ¼ 0.90) reﬂect
strong internal consistency. Construct, concurrent, divergent
and convergent validity have been demonstrated (Spielberger
et al. 1983). Finally, the Beck Depression Inventory (BDI:
(Beck and Steer, 1987) is a 21-item self-report form covering
symptoms of depression. The BDI demonstrates high internal
consistency, with a coeﬃcients of 0.86 and 0.81 for psychiatric
and non-psychiatric populations, respectively. The 13-item
short form, adopted for this experiment, has shown similar
reliabilities (Beck et al., 2000).
Third, participants wore an actigraph and completed a
standard sleep diary (Espie and Tweedie, 1991) for seven
nights following the experiment. The actigraph is a small, non-
intrusive watch-like device, which records objective rest/
activity periods based on wearer movements. For the use of
actigraphy in insomnia patients, epoch by epoch agreement
rates range from 78% to 90% (Jean-Louis et al., 1997; Sadeh
et al., 1995). The inclusion of actigraphy was to help determine
the sleep/wake (circadian) patterns of each participant (Sadeh
et al., 1995) rather than to estimate sleep continuity variables.
Therefore, this measure assisted diﬀerential diagnosis of PI
and DSPS and conﬁrmed group status. In particular, we used
Van Someren et al. (1999) non-parametric circadian rhythm
analysis (NPCRA) to calculate the L5 component (onset of the
ﬁrst 5 h of lowest movement period) which gives an estimate of
circadian sleep phase onset.
Upon return, 1 week later, the participants had opportunity
to discuss their sleeping patterns and were oﬀered a copy of
The Good Sleep Guide [Prepared by Colin A. Espie for
guidance report (National Medical Advisory Committee,
1994) and now recommended by the British Sleep Society].
RESULTS
Descriptive and clinical data
Inspection of subjective and objective sleep quality data
revealed that seven of the original participants did not meet
inclusion criteria for PI, DSPS or GS; four cases due to
sleeping disorders other than PI or DSPS, one case due to the
patient receiving medical intervention for sleep disruption and
one due to lack of sleep caused by a broken collar-bone. On
ﬁve occasions, individuals believed to have PI from the general
information given in response to the email advertisement, were
subsequently re-allocated to the DSPS group on the basis of
the more thorough interview, questionnaire measure and
actigraphy data. The experimental population as a whole
consisted of 45 females and 45 males with an average age of
22.8 years. Table 1 shows the demographics of the experimen-
tal population for each sleep quality group.
Table 1 also presents summary scores for the other clinical
questionnaire data. There was a signiﬁcant eﬀect of group at
both levels of STAI; Trait: [F(2,87) ¼ 30.12, P < 0.0001],
State: [F(2,87) ¼ 23.43, P < 0.0001]. Scheﬀe post hoc tests
revealed that PI were generally (trait) and situationally (state)
more anxious than GS, P < 0.0001 and P < 0.0001, respec-
tively. Similarly, on both STAI scales, PI scored signiﬁcantly
higher than DSPS P < 0.001 trait, P < 0.001 state, respec-
tively. DSPS scored higher on the state measure of anxiety,
P < 0.001, than GS, but were not signiﬁcantly diﬀerent on
trait measures of anxiety, P ¼ 1.92. There was no signiﬁcant
main eﬀect of group for the BDI data, which revealed low
mean scores in all groups [F(2,87) ¼ 3.04, P ¼ 0.053],
although the trend in the data was for PI to score higher than
either GS or DSPS.
Sleep data
Table 2 summarizes mean and standard deviation data for the
PSQI, and selected sleep diary and actigraphic measures.
Analyses revealed a signiﬁcant eﬀect of group at the level of
PSQI [F(2, 87) ¼ 61.07, P < 0.0001]. Scheﬀe post hoc analyses
revealed that PI scored signiﬁcantly higher than both GS
P < 0.0001 and DSPS P < 0.0001, and DSPS scored
signiﬁcantly higher than GS P < 0.01.
On the sleep diary, total sleep time (TST) was signiﬁcantly
diﬀerent between the three sleep quality groups
[F(2,87) ¼ 41.22, P < 0.0001], with PI participants reporting
less than 5 h sleep, compared with greater than 8 h for DSPS
and GS (P < 0.0001 and P < 0.0001, respectively). There was
no diﬀerence in TST between GS and DSPS groups. Sleep-
onset latency (SOL) was also signiﬁcantly diﬀerent between
Table 1 Demographic and clinical summary data
Primary insomnia
(n ¼ 30)
Delayed sleep phase
syndrome (n ¼ 30) Good sleep (n ¼ 30)
Between-group
analyses (P-value)M SD M SD M SD
Age 22.5 2.81 22.7 3.56 23.2 1.69 NS
Gender (% female) 51% – 49% – 50% – NS
STAI state 37.2 7.83 32.8 8.74 24.3 5.35 <0.0001
STAI – trait 48.1 10.52 37.9 11.40 27.3 9.15 <0.0001
BDI – short form 4.7 3.52 2.3 3.32 2.9 2.36 0.053
STAI, State Trait Anxiety Inventory; BDI, Beck Depression Scale.
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groups [F(2,87) ¼ 88.36, P < 0.0001], with PI taking signiﬁ-
cantly longer to fall asleep than DSPS (P < 0.0001), and GS
(P < 0.0001), and DSPS taking signiﬁcantly longer to fall
asleep than GS (P < 0.05).
Analysis of actigraphy data using NPCRA software
revealed a signiﬁcant main eﬀect of group on L5 data
[F(1,58) ¼ 45.81, P < 0.0001], with DSPS lowest peak of
activity beginning signiﬁcantly later than PI. These data
indicate a sleep-onset phase delay of 2.9 h in DSPS relative
to PI.
Change detection data
Table 3 summarizes the reaction time means (number of
ﬂickers) and standard deviations for each sleep group. To test
our hypotheses, a stimulus change/sleep quality (2 · 3)
between participants anova was carried out. As predicted the
stimulus change/sleep quality interaction was signiﬁcant
[F(2,84) ¼ 51.7, P < 0.0001] with a signiﬁcant eﬀect of change
[F(1,84) ¼ 70.3, P < 0.0001] and quality [F(2,84) ¼ 3.5,
P < 0.05]. There was a signiﬁcant main eﬀect of change at
the level of PI [F(1, 84) ¼ 171.5, P < 0.0001] that was not
present at the level of GS [F(1,84) ¼ 0.004, P ¼ 0.95] or DSPS
[F(1,84) ¼ 2.2, P ¼ 0.14]. Signiﬁcant main eﬀects of quality
were revealed for both the sleep change [F(2,84) ¼ 28.6,
P < 0.0001] and neutral change [F(2,84) ¼ 26.7, P < 0.0001].
Fig. 3 illustrates the tests for simple main eﬀects that permit
the following interpretation of the stimulus change/sleep
quality interaction. PI participants detected a sleep-related
change signiﬁcantly quicker than a sleep neutral change
[t(15) ¼ 13.10, P < 0.0001]. No such diﬀerences were ob-
served in either the GS [t(15) ¼ 0.06, P ¼ 0.95], or DSPS
groups [t(15) ¼ 1.5, P ¼ 0.14]. For the sleep-related change,
responses of PI were signiﬁcantly quicker than GS [t(15) ¼ 7.5,
P < 0.0001] and DSPS [t(15) ¼ 4.8, P < 0.0001]; and re-
sponses of DSPS were signiﬁcantly quicker than those of GS
[t(15) ¼ 2.66, P < 0.01]. By comparison for sleep-neutral
changes, responses of GS and DSPS were signiﬁcantly quicker
than PI [t(15) ¼ 5.7, P < 0.0001; t(15) ¼ 6.8, P < 0.0001],
respectively. No diﬀerence was observed between GS and
DSPS.
These main eﬀects and simple eﬀects appear consistent with
our hypotheses that sleep-related stimuli would be more salient
to PI, and thus detected quicker than sleep-neutral stimuli, and
that PI participants would detect changes more quickly than
DSPS or GS participants.
DISCUSSION
Insomnia research is constrained by the absence of reliable
objective markers of the phenomenology of poor sleep. Mental
arousal is a hallmark feature of insomnia. It is also a symptom
of other psychopathological conditions – in which context it
has been captured using techniques adapted from experimental
cognitive psychology, based on the measurement of informa-
tion processing speed to target stimuli. This experiment is one
of a series from our laboratory in Glasgow that suggests that
attention bias, measured by computerized probe tasks, may be
Table 2 Sleep summary data
Primary insomnia
(n ¼ 30)
Delayed sleep phase
syndrome (n ¼ 30) Good sleep (n ¼ 30)
Between-group
analyses (P value)M SD M SD M SD
PSQI 9.5 2.4 4.8 3.2 2.6 1.7 <0.0001
Diary TST (h/min) 4.83 1.83 8.33 1.81 8.27 1.46 <0.0001
Diary SOL (min) 47.63 17.85 17.57 9.09 7.9 4.57 <0.0001
ActigraphyL5 (24 h clock) 01 : 10 0.9 04 : 00 1.9 N/A N/A <0.05
PSQI, Pittsburgh Sleep Quality Index; TST, total sleep time; SOL, sleep-onset latency; L5, onset of lowest 5 h of motor output.
Table 3 Reaction times (RT) on the ICB change detection task. Data
represent ﬂickers to change detection
Sleep change,
mean (SD)
Neutral change,
mean (SD)
Collapsed
mean RT
Primary insomnia 4.7 (2.14) 18.2 (1.64) 11.6
Delayed sleep
phase syndrome
9.7 (3.50) 11.2 (3.14) 10.5
Good sleep 12.4 (2.99) 12.3 (3.10) 12.4
Collapsed mean RT 8.9 13.9
Nature of change
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Figure 3. Mean sleep-related and sleep-neutral change detection la-
tencies for the three sleep quality groups.
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a useful index of cognitive arousal in insomnia. Based on our
accumulating data sets, we propose that attention bias is a
cognitive process, involved in the maintenance, and perhaps
the development, of PI from adjustment insomnia, and
detectable after the onset of the complaint.
This study applied the ICB ﬂicker task to investigate the
hypothesis that people with insomnia exhibit an attentional
monitoring preference for sleep-related objects. This hypothe-
sis was conﬁrmed. Taken along with the results of our previous
ICB study, which used diﬀerent sleep-change stimuli (Jones
et al., 2005), we suggest that this is not an idiosyncratic
ﬁnding. These are the ﬁrst experiments to apply a visual
attention task to insomnia, and then show that people with
insomnia are selectively attentive to common environmental
sleep cues. Indeed, we would point out that the sleep stimuli
were incidental and innocuous (this study: a teddy bear; Jones
et al.: a slipper). They were simply objects that people associate
with sleep or preparation for bed, and because people with
insomnia have a heightened interest in this domain, they
respond selectively to such stimuli when they are presented
experimentally. Therefore, although not designed for the
purpose of testing conditioned responses, our results lend
weight to models of sleep-related arousal conditioning in
insomnia (Bootzin, 1972; Perlis et al., 2001) whilst emphasi-
zing the importance of the cognitive component.
It is also important that the objects used were not
intrinsically commanding of attention, nor were they emotive
or threatening. The literature on attention bias in psycholo-
gical disorders is based on a threat-monitoring model, whereby
words and images are presumed to grab attention because they
are emotionally salient. Through conditioned association this
may indeed be possible, even with everyday objects, and
Harvey’s (2002) model of insomnia is based largely on
responses to perceived threat. However, we think it is too
early to judge what may be motivating attentional processing.
Studies need to be conducted that speciﬁcally manipulate the
emotional valence of presented stimuli. We suggest that both
threat (of sleeplessness) and craving (for sleep) are good
candidate explanations that require further testing, and we
have discussed this model, and potential methodologies,
elsewhere (Espie et al., in press).
Attention bias is conceived of as an initial involuntary
(unconscious, implicit) process that gives rise to voluntary
(conscious, explicit) processes (Shiﬀrin and Schneider, 1977).
In other words, pre-attentive processing guides the early,
automatic capture of relevant information even when con-
scious access to the information is not available. A good
illustration of this phenomenon was a study by Ohman and
Soares (1994) that successfully elicited both psychophysio-
logical reactivity and subjective fear in phobic participants to
pictures of their feared objects when they were presented
beyond their conscious awareness. It is not possible using an
ICB study to address the level at which processing begins,
because the dependent variable is deﬁned by awareness of the
change. However, we noted that after completing the experi-
ment many of our participants, including those with insomnia,
were unaware that the experimental stimuli were particularly
related to sleep or sleep disorder, yet experimental eﬀects were
found. The exploration of implicit processing and the trans-
ition to explicit processing is an important research topic
(Espie et al., in press). Our study using the Stroop paradigm
(Taylor et al., 2003) indicated that attention bias to sleep word
cues was absent in acute/adjustment insomnia but present in
persistent insomnia, and this further reinforces the importance
of exploring how, and when, attention bias develops in relation
to the complaint of insomnia.
In this study, we used DSPS as a control condition for our
sleep-onset insomnia group. We feel it is important that our
hypotheses were conﬁrmed, not only in comparison with
normal GS, but also against these clinical controls. This result
replicates our ﬁnding, using the dot-probe task, of attention
bias in PI relative to GS and DSPS (K.M.A. MacMahon et al.,
unpublished data). Insomnia is undoubtedly a multifactorial
disorder, and one that can present heterogeneously. Separating
out PI from circadian disorder in relation to diﬃculty initiating
sleep, helps to ensure good discrimination on the independent
variable. In addition, however, the contrast between PI and
DSPS is that of disorders that are primarily seen as psycho-
logical and circadian, respectively. It is interesting, therefore,
that in the present study we observed signiﬁcant diﬀerences
between GS and DSPS, with the latter exhibiting greater
attention bias to the sleep stimulus change. We did not ﬁnd
this eﬀect in our dot-probe experiment.
Several factors may account for the DSPS eﬀect in this
study. DSPS, particularly in younger people, may comprise
two sub-populations, a socially driven DSPS and an inherent/
genetic DSPS, whose responses to attentional measures may
diﬀer. The mechanisms that trigger DSPS in some individuals
are often precipitated by life or social events and the eﬀects of
DSPS may lead to increased pre-sleep arousal when individ-
uals with DSPS try to reset their clocks by attempting to sleep
out of phase. This could theoretically precipitate symptoms
of, or the onset of PI (Lack and Bootzin, 2003). Conversely, of
course, when individuals with PI are unable to fall asleep, they
may inadvertently entrain their sleep to a later time, resulting
in an element of DSPS. Our results may also depend on
whether our DSPS participants were sleeping in phase or out
of phase at the time of the experiment. In the latter case one
might expect more insomnia symptoms. With this information
in mind, we retrospectively assessed data from our DSPS
group. Variations were evident with respect to the length of
time the individuals, who were all university students, reported
onset of the complaint. Some reported disorder onset in
childhood and several reported a family history of DSPS, while
the majority had suﬀered the disorder for as little as a year,
and many of these reported problems occurring at the start of
university. Furthermore, during the experimental period there
was variation within and between DSPS subjects in terms of
sleeping in and out of phase. Consequently, our results are
likely explained by a combination of social, genetic and
sampling frame factors, but we have insuﬃcient numbers to
separate our participants into subgroups for the purposes of
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analysis. What is clear from our ﬁndings is that there may be a
degree of overlap between psychological (PI) and circadian
(DSPS) factors in young adult populations.
Several limitations to our methodology need to be raised.
First, because this was a recruited population, our ﬁndings
may not be generalizable to the clinical pole. Attention bias
studies, therefore, require replication with clinical samples.
Nevertheless, it should be noted that non-clinical populations
do display cognitive overactivity at bedtime, excessive worry
about sleep, distorted perception, and characteristic safety
behaviours (cited in Harvey, 2002). Besides, processes detected
at any stage of sleep disruption, particularly before the clinical
extreme, may provide crucial evidence about the mechanisms
involved in the maintenance/enhancement of the disorder
proper. Second, this was not an intervention study. We do not
know whether attention bias in insomnia reduces as a result of
eﬀective intervention, as it has been shown to do following
cognitive behavioural therapy (CBT) for anxiety disorders
(Matthews et al., 1995; Mogg et al., 1995). Demonstrating that
established psychological treatments such as stimulus control
or multi-component CBT impact attention bias in PI would
add strength to the argument that such biases play a critical
role. Third, our results suggest an important pathway in
insomnia, but cross-sectional comparison of the type reported
here cannot test aetiological factors. The work of Harvey and
colleagues is leading the way in this regard by emphasizing the
application of controlled experimental methods to tease out
causal pathways associated with sleep associated monitoring
(Neitzert-Semler and Harvey, in press; Tang et al., in press).
One other limitation concerns the possibility that our results
may be inﬂuenced by experimenter bias. Although allocation
on the independent variables (sleep status and ICB condition)
was known to the experimenter, our experimental methodo-
logy followed a rigorous written protocol for participant
throughput and task instructions on the PC screen were
identical for the ICB task. These features of experimental
control make such bias an unlikely explanation for our
ﬁndings.
In conclusion, the results of this study are consistent with
other recent experiments in suggesting the potentially import-
ant role of selective attention bias in insomnia. A computerized
cognitive probe paradigm, using tasks such as the ICB, may
oﬀer insomnia research a much-needed objective index of
sleep-related mental arousal. However, at this stage we cannot
say whether such attention biases are due to a generalized
cognitive arousal in insomnia, to disease-speciﬁc distress or to
preoccupation with disease-speciﬁc markers. Indeed, as we
have acknowledged elsewhere the construct of arousal in
insomnia remains poorly deﬁned (Espie, 2002; Espie et al., in
press). Our hope is that by developing and instrumenting
measures of selective attention bias, as one facet of the
cognitive process, we can help to move the ﬁeld down-speciﬁc,
testable lines, and away from exclusive reliance on generic self-
report phenomena. Of course, we cannot yet conclude that
attention bias is of primary importance in the aetiology of
insomnia. It is entirely plausible that an information process-
ing bias of this kind could arise simply because sleep is
persistently disturbed, and so selective attention to sleep may
be a secondary characteristic of chronic insomnia. This is one
of the reasons that research purporting to explain critical
pathways in the aetiology and maintenance of insomnia needs
to include not only control samples of GS but also comparison
groups with other forms of chronic sleep disorder.
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THEORETICAL REVIEWThe attentionintentioneffort pathway in the
development of psychophysiologic insomnia:
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* Corresponding author. Tel.:C44 1
E-mail address: c.espie@clinmed.gSummary Psychophysiologic insomnia (PI) is the most common form of persistent
primary insomnia. Its ‘behavioral phenotype’, comprising elements such as
conditioned arousal, sleep-incompatible behavior and sleep preoccupation, has not
changed markedly across several generations of diagnostic nosology. Moreover, a
substantial outcome literature demonstrates that PI can be treated effectively using
a range of psychological interventions. It seems evident that behavioral and cognitive
factors play a part. What is less clear is exactly how PI develops and what are its
crucial maintaining factors. This paper proposes an explanatory model, that we call
the attentionintentioneffort pathway. The argument is that sleep normalcy is a
relatively automatic process. Consequently, it is vulnerable, and may be inhibited,
by focused attention and by direct attempts to control its expression. Drawing upon
parallels in the literature on adult psychopathology, and upon recent clinical and
experimental studies on insomnia, the evidence for this pathway is considered and a
research agenda is outlined. In particular, computerized tests of cognitive bias are
seen as offering an objective means of appraising mental processes in insomnia.
These may be applied concurrently with somatic measurements in future studies to
better understand this common psycho-physiologic condition.‘Sleep (is like) a dove which has landed near one’s hand and stays there as long as
one does not pay any attention to it; if one attempts to grab it, it quickly flies away’
(Viktor E. Frankl (1965, p. 253): [Frankl VE. The Doctor and the soul. 2nd ed. New
York: Knopf; 1965.] cited in Ansfield, Wegner and Bowser (1996) [Ansfield ME, Wegner
DM, Bowser R. Ironic effects of sleep urgency. Behav Res Ther 1996;34:523–31.]
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In this paper, we propose a possible pathway for the
development and maintenance of persistent psy-
chophysiologic insomnia. Our thinking is guided by
predictions from recently described insomnia
models, by the relevant literature, including work
undertaken in other disorders, and by recent
experimental data.Psychophysiologic insomnia
Psychophysiologic insomnia (PI) is the most com-
mon insomnia sub-type, found in 1–2% of the
general population, and in 12–15% of all patients
seen at sleep centers. According to clinical
nosologies3–5 and research diagnostic criteria,6 the
central pillars of PI are heightened arousal and
learned sleep-preventing associations, with
patients exhibiting an excessive focus upon and
anxiety about sleep. A number of models has been
proposed, each placing somewhat differing
emphases upon these features of insomnia, never-
theless, all appear to endorse the validity of the PI
phenotype7 for a comprehensive review). Many
studies evaluating psychological interventions
have also been generated, and there is now
substantial evidence that cognitive behavioral
methods, either singly or within multi-component
therapy, yield sustained reductions in insomnia
complaints.8–10
In spite of this progress, there is much that
remains to be done. Not least, there is an out-
standing need to investigate the mechanisms and
processes underlying the development of insomnia;
and to establish what are the critical components of
behavioral insomnia therapies and how they
achieve their effects.11 A timely call has been
made to adopt experimental psychopathology
paradigms for the purposes of testing and develop-
ing theories in relation to insomnia.12 This approach
has been fruitful in other areas of mental health
research, most notably in anxiety and depressive
disorders.
In recent times, we have established such an
experimental program at the University of Glasgow
Sleep Research Laboratory. The invitation to write
this review arose from a presentation made on some
of this work by the first author at the 17th Congress
of the European Sleep Research Society in Prague,
October, 2004. In this paper, we propose one
candidate process, in still an early stage of
conceptual development, that seems to meritfurther experimental and clinical research evalu-
ation in PI.The attentionintentioneffort pathway
This idea has its origins in the psychobiological
inhibition model of insomnia (Espie, 2002),13 which
differs from most other conceptualisations in that it
takes as its starting point a perspective upon
normalcy rather than pathology. The model con-
siders what it takes to upset the course of normal
good sleep, and to prevent (inhibit) its recovery.
Lundh and Broman (2000)14 similarly reflected on
the importance in insomnia research of having “a
sufficiently adequate understanding of how the
(sleep) process typically unfolds normally” (p. 303).
It is of course known that prolonged wakefulness
reliably induces sleep, and that failure to obtain at
least a core amount of sleep (sleep deprivation)
leads to impaired function. Within the ‘two
process’ system (process S, sleep homeostatic
drive, process C, circadian variation), the sleep
homeostat drives the sleepwake schedule toward
a balanced requirement in that prolonged wakeful-
ness accrues ‘sleep debt’, and the circadian timer
modulates sleep propensity on approximately a 24 h
cycle.15,16 We suggest, however, that there is an
implicit ancillary process that is associated with the
automatic regulation of sleepwake patterns in
good sleepers. The concept of automaticity13 refers
to the largely involuntary nature of the well-
adjusted sleep schedule, and to the over-learned
associations that may form part of a good sleep
stimulus control paradigm.17 In other words, we see
the good sleeper as essentially passive because
internal and external cues act as automated setting
conditions for sleep, and these are further
reinforced by rapid sleep-onset. Endogenous cues
to sleep, such as physical and mental fatigue, are
presumed to interact reciprocally with exogenous
perhaps classically conditioned cues, in the bed-
room environment; so that the good sleeper
approaches sleep, just as s/he walks or talks—
without thinking much about it and without a
consciously explicit plan.13
Just as homeostatic and circadian mechanisms
play a central role in understanding some sleep
symptoms (e.g. excessive daytime sleepiness,
phase disorders), this ‘third process’ of automati-
city may be central to PI. We hypothesise that
because the sleepwake process is essentially self-
regulatory, de-arousal and sleep engagement may
be particularly vulnerable if for any reason the
process is switched out of its natural automated
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switching,13 for two reasons. First, our focus is upon
factors that might be preventing the expression of
normal sleep and preventing its natural recovery.
Second, we do not assume that PI is associated
causally with any particular sleep pathology.a Rather
we are inclined to the view that people with PI have
the potential to sleep normally if inhibitory factors
can be overcome. In this context, Cognitive behavior
therapy (CBT)methodsmay be effective inPIbecause
they serve to overcome inhibitory mechanisms and to
re-establish setting conditions for normal involuntary
sleep. To the extent that any CBT method enables an
individual to abandon personal agency over sleep and
to return to reliance upon involuntary sleep it may be
likely to achieve a good therapeutic effect.13
More specifically, we now propose that sleep–
wake automaticity can be inhibited by selectively
attending to sleep, by explicitly intending to sleep,
and by introducing effort into the sleep engagement
process. We call this route into PI the attention–
intention–effort (A–I–E) pathway.Selective attention
Introduction
We can go back as far as William James18 for a
definition of selective attention:
“Everyone knows what attention is. It is the
taking possession by the mind, in clear and vivid
form, of one out of what seem several simul-
taneously possible objects or trains of thought.
Focalisation, concentration of consciousness are
of its essence. It implies withdrawal from some
things in order to deal effectively with others.”
Psychologists interested in information proces-
sing theory have researched human attention
extensively. In short, we now know that stimuli
that are salient to an individual are likely to attract
attention. That is, there is an information proces-
sing bias toward salient stimuli. If you are engaged
in the process of buying a new car of a certain
model you will likely begin to notice other vehicles
of that same type. It is not that more of these cars
have appeared on the roads; but simply that you
have developed an attention bias to something that
has become a relevant stimulus.a This is not to say that there is no neurobiological substrate to
insomnia, but rather to suggest that such ‘arousal’ may be part of
the expression of the A–I–E pathway itself.Support has been found implicating attention
bias in the perpetuation of a wide range of anxiety-
related psychological disorders and concerns
including panic disorder, hypochondriasis, eating
disorders, obsessional disorders, generalized
anxiety disorder, and PTSD19,20 for reviews). In
this field, attention bias toward potentially threa-
tening stimuli has been of particular interest.
Indeed, it has been argued that attention bias
toward threat may have a causal role in anxiety
disorders.21 Evidence favouring attention bias in
depression has been more equivocal,22 with some
studies demonstrating effects and some not. Some
recent evidence, however, suggests that if
depressed individuals do selectively attend to
negative material it tends to be a more delayed,
and possibly a more controlled, process than in
anxiety disorders.23
The classic Beck cognitive model of emotional
disorders assumes attention biases (as well as
mnemonic and interpretive biases) are driven by
negative beliefs stored in long-term memory.
When activated these ‘schema’ guide information
processing, including attention, toward stimuli
congruent with them. Conviction in negative
automatic thoughts is thereby increased, and
hypervigilance is promoted. The anxious individ-
ual, therefore, remains preoccupied with danger
and threat, and the depressed individual with
failure and loss.24 However, one of the limitations
of schema theory, and the account of attention
bias it offers, is that it views beliefs in a static
rather than dynamic way by failing to acknowledge
the top down influence of self-knowledge.25 So-
called ‘metacognitive’ models like the Self-Regu-
latory Executive Function model (S-REF)26 account
for cognitive self-regulation of attention, percep-
tion and memory, and, thus, may offer a more
holistic, dynamic account. Psychological disorders
are, according to S-REF, associated with a ‘cogni-
tive-attentional syndrome’ that maintains atten-
tion focus on threat, promotes ruminative worry-
based processing, and activates negative self-
beliefs. Alternative processing routines are denied,
adaptive self-knowledge is blocked and maladap-
tive self-knowledge is maintained. This S-REF
approach is somewhat closer to our line of thinking
about PI than ‘classic’ cognitive theory because
S-REF helps to explain how intrusive, worrisome
thought (and attention bias) may persist in
insomnia.
It is very important to observe, however, that
attention biases do not operate only in the context
of threat. For example, expertise and personality
have also been shown to mediate selective
attention.27,28 Likewise, in the illustration
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type on the roads would be unlikely to be
motivated by threat. Rather, cognitive bias would
probably be influenced by a more positive interest
in making an eventual purchase! It is instructive,
therefore, to look beyond the psychological
disorders to consider how attention bias has been
implicated in the perpetuation of habit/depen-
dence disorders, including alcohol, heroin and
nicotine. The stimuli that have been used in
experiments on these disorders are clearly salient
(related to the dependence) but if anything they
tend to be reinforcers rather than threats. To take
the example of alcohol, selective attention bias to
behaviorally relevant word or picture stimuli has
been found in alcoholics and problem drinkers, but
not in social drinkers.29,30 It seems that problem
drinkers are more likely to notice alcohol-related
stimuli in the environment, that this attention bias
‘reminds’ them of drinking, and that it may even
mediate the maintenance of their addiction by
producing ‘craving’.30 We will come back to ways
in which both threat and incentive may be relevant
to PI in conceptualization of selective attention in
relation to PI.
Generally, an attention bias has been found in
those who have a clinical diagnosis, contributing to
the explanation of why anxiety disorders31 and
abuses/dependences32 are frequently self-main-
taining, and why relapse often occurs after an
emergent treatment response. In explanations such
as these, attention bias is conceived as an initial
involuntary (unconscious, implicit) process that
gives rise to voluntary (conscious, explicit) pro-
cesses.33 In other words, pre-attentive processing
guides the early, automatic capture of relevant
information even when conscious access to the
information is not available. A good illustration of
this was a study that successfully elicited both
psychophysiological reactivity and subjective fear
in phobic participants to pictures of their feared
objects that were presented beyond their conscious
awareness.34
The human attention system is clearly complex
and intriguing. So what might happen to sleep if itTable 1 Comparison of potential ‘drivers’ for sleep-relate
Incentive
Sleep is a primary reinforcer
Sleep is at top of the ‘hierarchy of needs’
Sleep ‘deprivation’ produces craving
Hunger, thirst, oxygen as a model
Goal directed behavior is to obtain sleepbecame subject to such selective monitoring and
scrutiny?Conceptualization of selective attention in
relation to PI
Attention biases reflect discrete changes in the
direction of attention focus, in response to stimuli
that are, in some sense, salient. Sleep is certainly
salient to people with PI. Contemporary ICSD-24
diagnostic criteria for PI include:-
“Excessive focus on and heightened anxiety
about sleep” (Criterion C1)
The accompanying ICSD-2 text describes just
how marked the preoccupation with sleep can
become in PI:
“Concerns about sleep grow progressively
over months or years as sleep gradually deterio-
rates until the desire to obtain a good night’s sleep
becomes the person’s major concern” (p. 1–6)
Interestingly, this statement conveys both a
sense of incrementing distress associated with
sleeplessness (cf. threat), and a preoccupying
longing for sleep (cf. craving) that might serve as
preconditions for attention bias. We have summar-
ised in Table 1 what may be some of the key
features of this incentive-threat comparison.
In 1943, Maslow published his influential paper on
human motivation suggesting that a ‘hierarchy of
needs’ act as motivators for human behavior.35
According to Maslow’s theory, basic needs are
physiological; for example, hunger, thirst, sleep,
etc. When these are satisfied they are replaced by
safety needs reflecting the desire for protection
against danger or deprivation. In this context, we
can think of sleep as a primary reinforcer, reflecting
basic physiological processes necessary for physical,
intellectual and emotional well-being (Table 1).
Thus, the A–I–E pathway in relation to sleep may
parallel Maslow’s commentary on hunger.d attention bias in Psychophysiologic Insomnia
Threat
Inability to solve sleeplessness is threatening
Safety needs come after primary physiological
essentials
Sleep ‘deprivation’ produces worry
Fear, anxiety as a model
Goal directed behavior is to avoid being awake
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hungry, no other interest exists but food. He
dreams food, he remembers food, he thinks
about food, he emotes about food, he perceives
only food and he wants only food (.) For our
chronically and extremely hungry man, Utopia
can be defined simply as a place where there is
plenty of food. He tends to think that, if only he
is guaranteed food for the rest of his life, he will
be perfectly happy and will never want anything
more. Life itself tends to be defined in terms of
eating.” (p. 374)
Similarly, we suggest that the person with PI
experiences sleep disruption, sleep loss and per-
ceived sleep inadequacy and so becomes atypically
motivated by sleep, which is increasingly incenti-
vised in proportion to the preoccupation associated
with it. Just as food is more of a reinforcer when we
are hungry, in PI we might expect that a much higher
than normal value would be placed upon sleep. Of
course, sleep would be a primary reinforcer for any
individual, but presumably its reinforcement value
might increase in relation to sleep requirement/
deficit or perceived sleep requirement/deficit. The
desire for sleep of good quality, therefore, may in
this sense become a ‘craving’.
However, consistent with the second level of
Maslow’s hierarchy, the perceived inability to sleep
may also be conceptualised and experienced as a
significant threat. Sleeplessness may be threaten-
ing. Bedroom arousal may develop in PI as a result
of the conditioning of non-verbal (environmental)
and verbal signals (e.g. thoughts about sleepless-
ness) as threat cues which impact on selective
attention. But there is also another sense in which
being unable to sleep might be experienced as a
threat. Taking our principle of automaticity into
account, people who sleep well do not usually know
how they do so. Ask any normal sleeper what they
do to sleep and they will probably appear rather
bewildered. Sleep is not in this sense an enacted
operant (cf.17), but rather it is passive and
effortless. On the assumption that the person with
PI started out as a normal sleeper, one can
understand that to have apparently lost the
capacity to sleep, not really knowing how you
managed to sleep successfully before, might be
rather threatening.
Harvey’s model of insomnia36 represents an
adaptation of the cognitive perspective on psycho-
logical disorders, and finds common ground with
the selective attention component of the AIE
pathway. Harvey suggests that insomnia is main-
tained by a cascade of cognitive processes that
includes selective attention and monitoring ofthe internal environment (e.g. alertness, bodily
sensations) and external environment (e.g. clock-
watching, environmental noise) that interact with
negative beliefs, worry, misperception of sleep and
the negative daytime sequelae of insomnia and the
engagement of counterproductive ‘safety beha-
viors’. Anxious people, for example, have been
found to exhibit characteristic ‘safety behaviors’.37
These are overt and covert strategies that people
develop in order to avoid feared outcomes.
However, they generally prevent disconfirmation
of catastrophic beliefs, and so in fact make feared
outcomes more likely. For example, a social phobic
fearful of spilling a drink in public, might grip the
glass more tightly, thus (a) preventing unambiguous
disconfirmation of the belief that spilling the drink
is likely, and (b) increasing the likelihood of actually
spilling. In insomnia, classic safety behaviors might
include things like going to bed early or clock-
watching. According to the Harvey model,
increased monitoring for, or attention to sleep-
related threat cues increases the chance of
detecting such cues and thus establishes a mutually
maintaining vicious cycle.36
So, it seems conceivable that selective atten-
tion to sleep-related cues might arise because of
salience (unspecified), because of threat monitor-
ing, because sleep is a reinforcer, or, of course,
because of a combination of the latter reasons.
Attention bias may be a signature of classically
conditioned arousal in PI. In this respect, it would
seem timely to re-consider the stimulus control
model of insomnia in terms of classical/associa-
tive learning as well as its conceptualisation in
terms of operant/instrumental learning.17 It may
also be worth considering which sleep parameters
would be associated with different components of
the AIE process. We suggest that increased
sleep–onset latency (SOL) and wake time after
sleep–onset (WASO), as the symptomatic represen-
tation of insomnia, could be indicative of con-
ditioned arousal responses to intrinsic and
extrinsic threat cues; whereas reduced sleep
efficiency (SE) may reflect sleep craving through
increased time in bed (TIB) (sleep opportunity) in
the effort to increase total sleep time (TST). The
contrast between good sleepers (GS) and those
with insomnia is even clearer in the sub-group of
GS who by choice mildly restrict their bedtime to
6–7 h/night on a fairly chronic basis. This applies
to those busy people who accept the mild cost of
some increased daytime tiredness for the choice
of spending more time at work, with family, being
entertained, etc. The attitude of these people
towards sleep is not craving as the PI, nor even
neutral as with the GS, but it may even be
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sleep may be seen as deserving relatively little
attention.
Further relating attention bias to the concept of
automaticity, we suggest that the good sleeper is
like the experienced car driver who easily executes
a complex series of operations with minimal
attention load to the process. By comparison the
person with PI is like the anxious learner driver—
vigilant, deliberate and errorful.13 The concept of
automaticity in human learning has long been
discussed as part of information-processing the-
ory.33 Some authors have suggested that the
development of explicit, conscious processing is a
relatively recent development in evolutionary
terms.38 Essentially, prior to humans gaining
conscious thought, all learning would have flowed
through an implicit acquisition process without the
need for conscious, verbal reflection. Explicit,
verbal learning may provide a means to ‘short-
cut’ the development of some skills, such as
driving; with the process of automatisation occur-
ring as the skill is consolidated.
Paradoxically, it has been demonstrated, that
proficient motor skills, may degrade if individuals
are asked to verbalise their actions and turn their
attention inwards towards the mechanics of their
actions.39,40 Perhaps, the most eloquent demon-
stration of this is paying attention to, and
attempting to take conscious control of, the
actions of your feet as you run downstairs. This
is not to be recommended at the top of a flight of
stairs. Thus, the development of sleep processes
may be seen in much the same light. Setting
conditions for sleep, responding to sleep cues,
developing a sleep pattern are all part of infant
training and should lead the development of sleep
process that does not enter the realm of
consciousness. However, if one encounters diffi-
culties with sleep and attempts to ‘take control’
of the situation by directed attention, the
disruption to the automaticity of the sleep
process may parallel the difficulties encountered
in consciously controlling one’s legs whilst
descending stairs. Respiration is another example
of a similar phenomenon, although in this case
there is no learned component. Respiration like
sleep engagement, is normally an unconscious,
passive, simple process. Yet, during a panic
attack, thinking that not enough oxygen is being
obtained induces hyperventilation that exacer-
bates the sensory dysphoria, light headedness,
feelings of insufficient oxygen, which induces
greater panic and a vicious cycle, at times leading
to final unconsciousness.Evidence of attention bias in PI
We have recently suggested that individuals with PI
are characterised by high levels of metacognitive
beliefs and plans for processing, which predispose
them to appraise thoughts, experiences, and bodily
states negatively.41 This ‘cognitive architecture’,
we hypothesise, promotes worry, rumination and
attention bias in the pre-sleep period. We would
predict, therefore, that metacognitive beliefs that
promote negative appraisal of nocturnal intrusions
(e.g. ‘thinking at night keeps me awake’) charac-
terise the person with insomnia, as do associated
metacognitive plans for processing, including
those, which promote attention bias (e.g. to
sleep, I must focus on how sleepy I feel).
Evidence of information processing bias in
insomnia can be drawn from several sources, using
differing methodologies. The most direct evidence
comes from experimental studies specifically
measuring or manipulating aspects of selective
attention. We will review these studies after
consideration of the less robust, but nevertheless
interesting, descriptive literature comprising quali-
tative data, questionnaires and rating scales.Phenomenological/descriptive studies
Many measures used in insomnia research contain
items that reflect the person with insomnia’s
tendency to pre-occupying worry about sleep.
These include the pre-sleep arousal scale (e.g.
item 1 ‘worry about falling asleep’),42 the dysfunc-
tional beliefs and attitudes about sleep scale (DBAS)
(e.g. item 4 ‘I am worried that if I go for 1 or 2 nights
without sleep I may have a nervous breakdown’),43
the sleep disturbance questionnaire (e.g. item 12 ‘I
worry that I won’t cope tomorrow if I don’t sleep
well’)44 the self-statement test: 60C (e.g. item X
‘if I don’t get to sleep soon, I will feel very tired
tomorrow’)45 and the anxiety and preoccupation
about sleep questionnaire (e.g. item 1 ‘I worry
about the amount of sleep I am going to get each
night’).46 Interestingly, Watts et al. conducted a
study comparing ‘worried’ and ‘non-worried’
insomniacs on pre-sleep mental activity.47 The
former group appeared preoccupied by work-
related issues and general mental activity. In
contrast, ‘non-worried insomniacs’ tended to
focus on problems they were having with the
sleep process itself. This direct focus on sleep is,
of course, of particular relevance in relation to
attention bias.
In a prospective study of pre-sleep mentation,
Wicklow and Espie obtained voice-activated audio-
tape recordings of spontaneous thoughts, and sleep
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consecutive nights.48 Content analysis of over 1000
thought segments yielded eight categories of pre-
sleep intrusion, and a regression model indicated
that focusing on sleep and the anticipated con-
sequences of poor sleep, along with general
problem-solving were the strongest predictors of
objective SOL. Thought content was subsumed
under one of the three factors; ‘active problem-
solving’ (e.g. rehearsing/planning events), ‘pre-
sent state monitoring’ (e.g. thinking about-sleep/
not sleeping, autonomic experiences, your own
thinking) and ‘environmental reactivity’ (e.g.
attending to external noises). Thirty-eight percent
of thought segments represented present state
monitoring.
The qualitative component of this study was
partially replicated in a further investigation which
also had a psychometric phase, leading to the
development of the Glasgow content of thoughts
inventory (GCTI).49 The GCTI was found to have
good internal consistency (aZ0.87) and testretest
reliability (ICCZ0.88) and a score of 42 discrimi-
nated PI from GS groups with sensitivity of 100% and
specificity of 83%. A principal components analysis
of the GCTI found that present state monitoring
emerged as an important factor accounting for 38%
of explained variance.
Harvey conducted some parallel research.50
Using a semi-structured interview, five areas of
attention focus were investigated. It was found
that people with insomnia relative to GS were
more likely to attend to sensations of falling asleep
and to worries/concerns, trying to solve problems
and listening to noises. Good sleepers on the other
hand were more likely to attend to ‘nothing in
particular’ during their (relatively shorter) wake
times. Neitzert-Semler and Harvey then reported
two related studies. In the first of these, students
meeting criteria for primary insomnia were
compared with a GS control group using a semi-
structured interview of sleep-related threat, nega-
tive thoughts, and safety behaviors.51 People with
insomnia reported more frequent monitoring, night
and day, and they engaged in more safety
behaviors. A path analysis suggested that monitor-
ing may act as a driver for negative thinking in
insomnia. In the second study reported in this
paper some evidence emerged for the general-
izability of these findings to a clinical insomnia
sample.
This work was extended through the develop-
ment of the sleep associated monitoring index
(SAMI).52 This 30-item scale of sleep-related threat
monitoring shows good reliability (aZ0.87) and
positive correlation with the Pittsburgh sleepquality index (PSQI132). Importantly, moderate
correlation (rZ0.36) with the Penn state worry
questionnaire suggests that the SAMI score is not
simply an index of generic aspects of worry. An
eight component solution was obtained following
principal components analysis on a large sample
(nZ400) of university students and staff. These
components included monitoring for body sen-
sations (daytime, pre-sleep, and on waking, each
loaded as separate components), clock time and
the environment. This study also explored the
relationship between the SAMI (monitoring) and
two other constructs used in attentional theory.
Both ‘amplification’ (the tendency to experience
somatic sensation intensely) and ‘self-focus’
(awareness of internally generated information)
correlated with the majority of the SAMI subscales,
excepting calculation of time and pre-sleep clock
monitoring.
Summarizing this work, it seems that question-
naire data are broadly supportive of the notion of
attention bias in PI. However, two notes of caution
seem appropriate.
First, mental arousal associated with sleep may
not be as crucial to the conceptualisation of PI as
some of the psychological theories suggest. In a
recent comparison of PI, delayed sleep phase
syndrome (DSPS) and GS, we found that several
self-report measures of the construct of cognitive
arousal were elevated in both PI and DSPS,
relative to GS.53 This raises the possibility that
such arousal may be epiphenomenal to wakeful-
ness in PI (rather than causal). DSPS is presumed
to reflect an endogenous phase delay so there is
no need to infer any psychological process. On the
other hand, the mechanisms that trigger DSPS are
often precipitated by life or social events and the
effects of DSPS may lead to increased pre-sleep
arousal when individuals with DSPS try to reset
their clocks by attempting to sleep ‘out of phase’.
This could theoretically precipitate symptoms of,
or the onset of PI. Conversely, when individuals
with PI are unable to fall asleep, they may
inadvertently entrain their sleep to a later time,
resulting in an element of DSPS.54 Of course,
worry and rumination are transdiagnostic phenom-
ena that present across a range of psychiatric
disorders.55 Also in many medical disorders, worry
is an associated feature. What the research
literature needs to determine is which features
of cognitive arousal are directly involved in the
genesis and maintenance of persistent insomnia.
Second, the studies reviewed so far were not
designed specifically to test attention bias within
the context of a controlled experiment. However, a
number of such studies has emerged recently,
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Oxfordb and from our own laboratory in Glasgow.Real world experiments
Harvey’s innovative work stems from her cognitive
model of insomnia in which the importance of
monitoring of sleep-related threat was posited
(outlined above). This research team has conducted
a series of controlled experiments, involving the
manipulation of attention in order to test its causal
role in increasing or decreasing insomnia symptoms.
Neitzert-Semler and Harvey56 attempted to test
the hypothesis that monitoring for sleep-related
threat during the day would trigger a cycle of
subsequent negative thinking, perceived impair-
ment, and subjective sleepiness. Young people with
insomnia were randomly assigned either to a
condition involving monitoring of body sensation
(to be closely aware of the feelings and sensations
and to focus attention on internal reactions), to a
condition involving distraction from such monitor-
ing (focusing upon external environment and
activities) or to a no instruction control group.
Results largely confirmed the prediction that the
monitoring group would report higher ratings for
negative thoughts, safety behaviors and daytime
sleepiness than the control condition. Daytime
functioning, however, was not different between
groups and, unfortunately, the no monitoring
manipulation was less well designed and so was
relatively unsuccessful. Nevertheless, this does not
detract from the findings for the monitoring group.
Neitzert-Semler and Harvey57 assigned 51 par-
ticipants meeting DSM-IV criteria for insomnia to a
self-focus group (viewing themselves on a TV
monitor), to a monitoring group (similar to above
but also focusing on thoughts and mood) or to a no
instruction group. Participants were then exposed
to a 60-min neuropsychological test battery. The
purpose of the study was to index the effect of
attentional focus on real versus perceived perform-
ance. As hypothesized, no differences were
observed in the former comparison. However, the
self-focus group perceived their performance as
significantly worse on the majority of tasks than the
no instruction group, providing confirmation of the
potential role of self-focusing as a contributory
factor to the perceived daytime impairments of
people with primary insomnia. By contrast, the
monitoring condition did not differ from the no
instruction group on any subjective performance
rating. The authors suggest that the self-monitoringb Now at Sleep and Psychological Disorders Laboratory,
University of California, Berkeley.condition, unlike the video-TV condition, in this
experiment may have resulted in insufficient self-
focused attention.
Tang et al.58 considered the importance of clock
monitoring in insomnia. In a first experiment, good
and poor sleepers were instructed to monitor (or
not) a clock as they were trying to get to sleep.
Clock monitors, whether poor or good sleepers,
reported a higher worry rating and had longer SOL
as indexed by sleep diary and actigraphic data. A
second experiment was conducted with a clinical
sample, where monitoring per se was controlled by
using a digit display monitoring task to isolate the
specific effects of clock watching. The degree of
worry and SOL overestimation demonstrated by the
clock monitoring group was greater than the control
condition, thus, lending further support to the idea
that attentional bias, in the form of clock watching,
is not conducive to sleep.
To summarise these real world experiments, it
seems that insomnia is associated, at least in terms
of self-report, with sleep-related self-monitoring
tendencies.
One of the challenges for research in the area of
attention is to separate out sleep-specific effects
from heightened generic responding. For example,
research on the ‘orienting response’, indexed
physiologically by skin conductance levels, suggests
that people with insomnia exhibit a general
tendency to increased attentiveness. That is they
are more responsive, particularly to emotional
stimuli and stress, and take longer to habituate
than do good sleepers.59–61 Although, so far,
psychophysiological measures have not been taken
in parallel, studies employing reaction time as a
dependent variable have now gone some way
towards establishing responses to sleep stimuli
over and above heightened orienting per se.
Computerized experimental studies
Several studies have explored selective attention
bias in insomnia using measures of information
processing speed (Table 2). These studies used
computerized experimental protocols where both
salient and neutral stimuli were presented to
investigate any systematic processing differences
between good sleepers and people with sleep
disorder. The paradigm in such attentional tasks is
that stimulus salience interferes with response time
because of the ‘grabbiness’ (uncontrolled pro-
longed attention capture or focusing) of sleep-
related word or picture stimuli relative to neutral
stimuli. An advantage of this experimental
approach is that it does not rely on self-report,
but rather posits objective reaction time differen-
tials as a proxy for cognitive arousal. Before
Table 2 Experimental studies investigating attention bias in insomnia using information processing paradigms
Authors Participant characteristics Paradigm Findings
Lundh et al.68 40 adults between ages of 20 and
65 and gender matched across two
experimental groups (primary
insomnia and good sleepers)
Stroop task Repeated measures ANOVA examined the effects for each of the 3 stimulus types
[i.e. sleep, physical threat and physical control words; and colour names versus a
control sequence of letters (XXX.)]. Both the insomniacs and the controls
responded more slowly to the sleep words, physical threat words and colour
names, than to their matched control stimuli. There was no main effect of group
with regard to any stimulus type and no significant interaction between group and
sleep words [F(1, 37)Z0.21)].
Taylor et al.69 33 Adults (23 F/10 M; mean age 47
years) with sleep-onset insomnia
subsequent to cancer diagnosis.
Mean time since diagnosis for the
acute insomnia group was 2.0
months and was 14.3 months for
the persistent insomnia group
Stroop task Independent samples t-tests indicated no significant difference between the two
groups for the cancer interference index (tZ0.91, pZ0.37) but there was a
significant difference on the sleep interference index (tZK2.44, pZ0.02). Both
groups demonstrated interference for cancer words relative to neutral words, but
only the persistent insomnia group exhibited interference for sleep words. Groups
did not differ significantly on pre-sleep cognitive or somatic arousal (PSAS) and
they used similar thought control strategies (TCQ: distraction, re-appraisal, social
control)
MacMahon et al.70 63 adults (35 F/ 28 M; mean age 25
years). Across three experimental
groups (primary insomnia (PI),
delayed sleep phase syndrome
(DSPS), good sleeper (GS)).
Dot probe Orthogonal contrasts of PI versus DSPS and GS indicated a significant difference
(tZK1.88, pZ0.03), suggesting that participants with PI showed a greater
attention bias to sleep related words than those with DSPS or GSs. A further
contrast between DSPS and GS did not indicate a significant difference between
these groups (tZK1.27, pZ0.10), thereby supporting the hypothesis that
attention bias plays a fundamental role in the disorder of PI. The possibility of an
underlying trend in DSPS responses needs to be further investigated
Jones et al.72 192 Adults (50% F; mean age 32.1
years) age and gender matched
adults across three experimental
groups (poor sleepers, moderate
sleepers good sleepers)
Flicker ICB Independent samples t-tests revealed that Poor sleepers and Moderate sleepers
detected the sleep-related change significantly quicker than Good Sleepers (tZ
3.33 and 2.90, both p!0.01). There was no difference in this change detection
latency between Poor and Moderate sleepers. Poor sleepers detected the sleep-
related change quicker than the neutral change [F(1180)Z7.11, p!0.01]
displaying a sleep-related attention bias. For Moderate sleepers this difference
was not significant, and Good sleepers detected the change within the neutral
objects significantly quicker than within the sleep-related objects [F(1180)Z6.
21, p!.05] showing a bias towards neutral rather than sleep-related objects
(continued on next page)
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C.A. Espie et al.224reviewing the literature on the application of these
experiments in insomnia research it may be helpful
to describe the tasks themselves.
Attention bias tasks. Three different methods have
been applied to the study of insomnia.
First, the emotional Stroop task, which has been
described as the hallmark measure of attention,62
has been used to assess selective attention bias in a
wide range of conditions. The Stroop task involves
target (salient) and control (neutral) words being
presented at random in different ink colours.
Subjects are asked to respond quickly to the
presented colour by pressing the corresponding
coloured button on a response box. They are
instructed to ignore the actual meaning of the
words. Response latencies for colour identification
are automatically recorded for each stimulus.
Longer response latency is thought to suggest
increased attention bias because automatic proces-
sing of word meaning for the salient words is likely
to interfere with (slow down) colour naming
relative to response time for the neutral words:
the so-called interference effect.
There has been debate in the literature over
whether the Stroop task actually measures
increased vigilance or simply reflects the impact
of heightened arousal interfering with information
processing when salient stimuli are presented.63
Thus, Stroop data alone may be insufficient to
conclude that attention bias is present in PI. A
second test of cognitive bias toward semantic
material, the dot-probe task, has been posited as
one solution to this problem.63 In this task, words
are simultaneously presented (typically for 500 ms)
to two areas on a computer screen. The ensuing
distribution of visual attention is measured by
recording detection latency for a visual probe that
could appear in the spatial location of either word,
immediately after the display of that word has
terminated. Thus, the task bypasses limitations of
the Stroop, by using a neutral response (a keypress)
to a neutral stimulus (a ‘dot’). The trials providing
the data of interest are those in which one of the
words is salient. By examining the impact of sets of
such words on the relative probe detection
latencies in the two spatial areas, it is possible to
determine whether visual attention has shifted
toward or away from such stimuli.
There are, however, some limitations to
research on attention bias that uses word stimuli.
As Yiend and Mathews64 and others have pointed
out, although words can be unequivocally negative
in valence it is far from clear that they constitute a
severe or highly salient threat. For this reason
attention bias studies investigating state and trait
The attentionintentioneffort pathway in the development of psychophysiologic insomnia 225anxiety sometimes use picture stimuli (e.g. weap-
ons, corpses, dangerous animals) that are known to
evoke both subjective and physiological
reactions.65 Pictures of this kind are fairly generic
threatening stimuli, but ones that nonetheless elicit
greater attentional responses in anxious individ-
uals. In the context of insomnia, it is somewhat
difficult to represent sleeplessness through objects
in this graphic way. Besides, we are not committed
at this point to an explanation for attention bias in
insomnia that is motivated solely through threat
monitoring.
Nevertheless, it is possible to explore attention
bias with digitised objects using a flicker paradigm
featuring a perceptual phenomenon called induced
change blindness (ICB).66,67 Research using this
third method reveals that when a change is made
to a visual scene (and the process of change is
hidden from view), it is more difficult to detect than
might be expected. Normally in this paradigm, a
single feature of a visual scene is changed between
successively repeated brief presentations until the
change is detected—essentially the ICB is a spot the
difference task. Change-detection latency,
measured by the number of flickers it takes for
the change to be identified, is explained by a
change’s ‘grabbiness’ and this depends not just on
the object’s physical feature that carry the change
but also on the viewer’s history in relation to that
object. So, for example, in the alcohol field,
problem drinkers take fewer flickers to detect an
alcohol-related change within the visual array than
a neutral change and are faster to detect such
changes than control subjects.
Experiments using computerized tasks
The first study to be published was that of Lundh,
Froding, Gyllenhammar et al.68 This was a pioneer-
ing piece of work because it translated the
emotional Stroop task into the insomnia field.
Lundh et al. found that people with insomnia had
prolonged response latency for sleep-related words
(Table 2). However, this effect was also evident in a
control population of good sleepers, and there was
no group difference on the Stroop interference
index; a result inconsistent with the attention bias
hypothesis. Lundh et al. suggested that sleep-
related words might have emotional valence for
people that may or may not be directly related to
sleep problems. However, the extensive literature
on the Stroop task would not predict experimental
effects in normal control groups. Of course,
recruited controls who are good sleepers may
have a particular interest in sleep, and this might
yield a bias. Also, in this study no measure of
affective state (which is known to influence Stroopfindings) was taken, and diagnostic criteria were
not reported for the insomnia group.
Lundh et al.’s pioneering work in Sweden,
therefore, yielded somewhat equivocal findings.
However, since then, our research group in Glasgow
has completed four experiments using each of the
three attention bias paradigms described above
(Stroop, dot probe, Induced Change Blindness) that
generally indicate the presence of selective atten-
tion bias in insomnia.
In our first study, we also used the Stroop
paradigm, selecting a cancer population because
our primary purpose was to investigate the
development of insomnia associated with a stressor
in people, who had previously been good sleepers.69
None of the participants had insomnia prior to their
cancer diagnosis; that is they were a ‘true’
secondary insomnia population rather than people
whose (pre-existing) insomnia had been exacer-
bated. Insomnia is common in cancer populations,
so this seemed to be a valid population group to
study. Two groups of people with cancer and
insomnia, 0–3 months and 12–18 months after
cancer diagnosis, completed the computerized
emotional Stroop task comprising cancer-related,
sleep-related and neutral word cues. Both groups
demonstrated attention bias for cancer-related
words but only the persistent insomnia group
demonstrated attention bias for sleep-related
words (Table 2). The fact that interference effects
for sleep words were absent at 0–3 months but were
evident at 12–18 months, suggests that selective
attention bias towards sleep may play a role in the
transition from adjustment insomnia to psychophy-
siological insomnia.
According to ICSD-24 the essential feature of
Adjustment Insomnia is
“.the presence of insomnia in association with an
identifiable stressor. The sleep disturbance of
Adjustment Insomnia has a relatively short dur-
ation, typically a few days to a few weeks” (p. 1–3)
In Fig. 1 we have illustrated how persistent
psychophysiologic insomnia may evolve from
Adjustment Insomnia following the experience of
a series of stressors (such as illness). It is assumed
that experiencing stress is associated with both
psychological (mental, behavioral, emotional, etc.)
and physiological (autonomic, cortical, metabolic,
etc.) responses. These are likely to inhibit normal
sleep-related de-arousal, and so produce transient
sleep disturbance. If cognitive and physiological
arousal becomes sustained, insomnia may persist as
a symptom. If not, then the insomnia symptoms
would dissipate and normal sleep would return. Our
C.A. Espie et al.226assumption, consistent with the Taylor et al.
data,69 is that attention bias (whether implicit or
explicit) during Adjustment Insomnia is selective
towards the perceived source of the stress. Indeed,
because of that selectivity, the insomnia symptoms
per se are unlikely to grab attention whilst the
stressor is active.
However, continuing the description of Adjust-
ment Insomnia from ICSD-2:
“.the sleep disturbance resolves, or is expected
to resolve, when the specific stressor resolves,
or when the individual adapts to the stressor”
(p. 1–3)
Consistent with this statement, we suggest that,
close to the point of normal resolution of the
adjustment insomnia, selective attention upon the
stressor might reduce markedly. However, in
circumstances where insomnia symptoms still per-
sist, there could be an increased risk that an
attention bias towards sleep-related cues might
develop. That is, attention might shift from the
resolving stressor to any persisting sleep disturbance
at this point. Furthermore, the transition to sleep-
related implicit attention bias could be prepared by
the frequent prior conditioning of sleep cues with
sleeplessness during preceding weeks. Thus we may
have the start of the AIE pathway as a self-Figure 1 Proposed evolution of psychophysiologic insomniaperpetuating persistent PI, even when the original
stressors have resolved or diminished.
The Taylor et al. study, however, was of a cross-
sectional rather than a longitudinal design and we
did not have a control group of good sleepers
without medical problems. Moreover, the paradigm
employed presented word stimuli for the standard
supraliminal 500 ms duration. Thus it is not possible
to determine to what extent the bias was pre-
attentive/automatic, i.e. occurred involuntarily
without intention or conscious control. The results,
therefore, need to be interpreted with some
caution.
We have recently completed another attention
bias experiment study using the dot-probe task.70
Sixty-three young adults across three experimental
groups (PI, DSPS, GS) participated (Table 2). PI and
DSPS participants met ICSD criteria for their
respective disorders following extensive assess-
ment comprising clinical interviews, the use of
self-report scales, and sleep diary and actigraphy
monitoring. The DSPS group was employed as a
further, clinical, control sample of people who, like
our PI participants, had sleep-onset problems, but
whom we would not expect to exhibit cognitive
arousal as an explanatory mechanism for their
continued wakefulness. Rather, circadian factors
are presumed to explain the emergence and
maintenance of DSPS. Consequently, those withfrom adjustment insomnia following the AIE pathway.
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processing bias to sleep-related stimuli. Results
supported our predictions, with those in the PI
group showing a significantly greater processing
bias toward sleep-related words (in comparison to
neutral words) when compared to the GS and DSPS
groups (Table 2). Notably, the GS and DSPS groups
did not differ from each other, suggesting that the
underpinning mechanism maintaining DSPS is not an
attention bias to sleep-related stimuli.
Finally, we have conducted two experiments
using the ICB task. Interest in the control that sleep-
related objects might have over sleep behavior is
long-established. For example, within a condition-
ing framework, bedroom environment objects
might become discriminative stimuli for sleep,17
but when the bedroom-sleep contingencies are
broken, they might become discriminative stimulus
for wakefulness. In that regard it is interesting that
less than one-quarter of the sleep-related words in
our Stroop and dot probe studies were objects.
Consequently, we felt that the ICB paradigm may be
better suited to investigating the possible influence
of the bedroom environment on sleep. We were also
interested in the fact that, using this technique, a
differential attention bias between two ‘levels’ of
social use of alcohol and cannabis has been found.71
In the insomnia context, we wanted to extend this
approach to explore differential attention bias
along the sleep problems continuum. If attention
is implicated in the development of persistent
insomnia we might expect to find a systematicallyFigure 2 (a) Greyscale versions of the full color stimuli use
changed stimuli for each of the two levels of the factor, na
change (CS-N) and (b) a Flicker paradigm for inducing changechanging attention bias, not just at the clinical
pole.
In our first ICB study, 192 participants (mean age
32 years) were selected for this totally between
subjects experiment72 Table 2). Participants com-
pleted the 15-min ICB task, after which they were
assessed for sleep quality and other characteristics.
Importantly, therefore, retrospective group assign-
ment was blind to the dependent variable of the
analyses, change detection latency. A different
flicker pair of stimuli was used for each of the two
levels of the factor, nature of change (sleep-related
and neutral). Each pair contained the same original
stimulus comprising seven sleep-related objects
and an equal number of neutral objects arranged in
two collections on either side of the scene midline.
The second stimulus of each pair was identical to
the original stimulus but for one small change: a
sleep-related change (removing one of the pair of
slippers) or a neutral change (removing one of the
pair of gloves). The two changed stimuli are shown
in Fig. 2 along with their common originating
stimulus. The two stimuli of a pair were then
presented in continuous succession (each replacing
the other) until the change was detected. A brief
‘mask’ was inserted in between the flicker pairs
to suppress visual transients. We selected the sleep
stimuli using a comprehensive process designed to
identify objects associated with ‘going to bed to
sleep’. Clearly none of the objects is intrinsically
threatening, and slippers emerged with the highest
mean sleep-relatedness score.d in ICB experiment 72 Original stimulus (OS) and the two
ture of change-sleep-related change (CS-S) and neutral
blindness illustrating a change cycle or single ‘Flicker’.
C.A. Espie et al.228Results revealed significant differences in change
detection latency between poor, moderate and GS
for the sleep-related change.Only thepoor sleepers,
who detected sleep-related change quicker than
neutral change, demonstrated selective attention
bias for sleep salient stimuli. Moderate sleepers
showedatrend in the samedirection.Bycontrast, GS
detected the change with the neutral objects
significantly quicker. Hierarchical regression was
thenapplied to test the relationshipbetweenchange
detection latency and a continuous representation
of the global PSQI score. This evidenced a system-
atically changing effect of sleep quality upon
attention bias, independent of age, gender and
depressive symptom level.
In simple terms, when competing for attentional
resources with matched neutral stimuli, poor
sleepers appeared to prioritise sleep-related stim-
uli. The findings for GS (of relative prioritisation of
neutral stimuli) may be explained by differences in
the physical saliencies of all the stimuli in the
scene. That is, the neutral half of the scene may
have been more salient in general, or may have
included one highly salient single item, as well as
relative positional and configurational aspects.
Because all sleep quality groups were presented
with the same complex scene, we suggest that an
attentional force that is greater than existing
physical saliencies is likely to have driven the
responses of poor sleepers.
We have recently completed a second ICB
experiment to replicate and extend the above
work.73 In this study, we improved diagnostic
methods by including a clinical interview and
actigraphy in the protocol, and strengthened the
primary analysis by incorporating DSPS as a clinical
control group. In this experiment we used different
change stimuli; respectively, a teddy bear and a
mug, to rule out the possibility of idiosyncratic
effects to previously used stimuli. A 2 (experimen-
tal condition) by 3 (group) between-participants
design was employed. Participants (nZ90) were
within one of three groups (PI, DSPS, GS) and each
sleep quality group was consequently split in half at
random to receive the sleep-related change, or a
sleep-neutral. Group allocation was not fully known
to the experimenter until the ICB experiment was
completed. As predicted, the stimulus change/
sleep quality interaction was significant and PI
detected the sleep-related change significantly
quicker than the sleep-neutral change. No such
difference was observed between the sleep-related
and sleep-neutral changes for either DSPS or GS
participants (Table 2). Post hoc testing also
revealed that, for the sleep-related change,
responses of PI were significantly quicker than GSand DSPS, and that responses of DSPS were
significantly quicker than those of GS. By compari-
son, for the neutral change, responses of GS and
DSPS were significantly quicker than PI and no
difference was observed between GS and DSPS.
The results of this experiment provide further
evidence of attention biases to sleep-related
stimuli in insomniacs. However, unlike our dot
probe study70, we also found that DSPS participants
detected a sleep-related change significantly
quicker than GS. We propose several possible
explanations for this effect. First, DSPS, particu-
larly in younger people, may comprise two distinct
sub-groups, a socially driven DSPS and an inherent/
genetic DSPS, whose responses to attentional
measures may differ. Second, results may depend
on whether DSPS participants were sleeping in
phase or out of phase at the time of the
experiment. In the latter case one might expect
more insomnia symptoms. Third, and as we
previously discussed54, suggest that PI and DSPS
may often share overlap symptoms. Sleep-onset PI
may facilitate phase delay, and phase delay may
contribute to anxiety and preoccupation about
sleep initiation.
To date then, our work has shown that attention
bias presents in individuals with persistent PI. The
extent to which such biases are maintaining of PI, or
merely epiphenomenal, remains unclear, as does
whether attention bias can predispose to PI.
Although some of our data suggest that attention
may shift from stressor to sleep as adjustment
insomnia becomes chronic, longitudinal work will
be needed to confirm this. Sleep-related attention
bias may be a common factor in all sleep disorders
or it may help to differentiate insomnia subtypes,
e.g. psychophysiologic insomnia from insomnia due
to mental disorder. Again further work is needed on
this.
Evoked potential studies
Two recent insomnia studies employing event–
related potential (ERP) measurement of cortical
arousal also merit consideration. Devoto
et al.130,131 have shown, in participants with PI,
that cortical hyperarousal is not constant in poor
sleepers. Rather it fluctuates depending on the
quality of the previous night’s sleep. Variation in
P300 amplitude is thought to reflect neuroelectric
activity related to cognitive processes such as
attention allocation and immediate memory;
larger P300 amplitudes being associated with
poorer nights of sleep. These data, therefore,
are important because they further evidence an
association between disturbed sleep and atten-
tion processes. They suggest that P300
The attentionintentioneffort pathway in the development of psychophysiologic insomnia 229measurement may be of potential benefit in the
further study of attention bias. Would, for
example, biased attention to sleep cues in a
Stroop paradigm map onto enhanced ERP activity?
There is already psychophysiological evidence to
this effect, on attention to emotion cues.29
In summary to this point, we suggest that there is
a developing body of evidence that supports the
proposition that sleep-related attention bias may
be implicated in the development and persistence
of PI. This evidence comes from both qualitative
and quantitative studies. Recent experimental data
from studies manipulating attentional variables,
and from studies investigating information proces-
sing speed and evoked potentials, offer the most
direct evidence and such data are consistent with
clinical impressions of sleep preoccupation, and
possibly of sleep-related conditioning, in PI.Explicit intention
Introduction
We propose that the next stage of the inhibitory
AIE pathway is that of developing an explicit
intention to sleep. That is, an attention-for-action
mechanism associates attentional focus upon sleep
and sleeplessness, with intentive actions designed
to deliver sleep and to eliminate wakefulness
(Fig. 1). We will argue that these intentions are
antithetical to the behavior of good sleepers, as
they are with those seeking skilled performance in
other domains,39,40 that they further inhibit the
automaticity of normal sleep (beyond the effects of
attention/monitoring alone), and that, because
they are usually ineffective, they lead to the
engagement of sleep effort.
So far we have considered the process of
attention. Now it seems helpful to consider its
purpose. Why is selective attention so important?
There seem to be two, related answers to this
question. One is that attention has to be selective
because the brain is a limited capacity processor.
The other is that selectivity actually confers
distinct advantages, irrespective of capacity.
At any given time, only a small proportion of
information available in the environment can be
selected and identified for conscious processing.
Optimally, this selection should be based on the
information necessary for the execution of current
and planned behavior. Thus, it is adaptive to focus
upon a threat, so that you can take avoidant action.
Likewise, it is adaptive to focus upon an unmet need
(to crave), so that you can develop a plan to meetthat need. It is less urgent and less important to
focus elsewhere.
Allport74 pointed out that the majority of
research in this area considered the limited
information-processing capacity of the brain as
the fundamental constraint underlying all oper-
ations of attention. Thus the selection function of
attention arises necessarily from the notion of
limited capacity. However, diverging from the idea
that attention operates primarily as a mechanism
for coping with central limited capacities of
cognitive processing,75,76 Allport also emphasized
constraints in preparation and control of action.
The idea behind this attention-for-action perspec-
tive is that integrated actions require the selection
of particular aspects or attributes from the
environment that are relevant to the action at
hand. At the same time, any information irrelevant
to the action should be ignored. Thus, attentional
processes may be seen as the selection of action-
relevant events or stimuli relying on particular
action plans. This echoes the concluding phrase of
James’18 definition, presented earlier, that
“(selective attention) . implies withdrawal
from some things in order to deal effectively
with others” (present authors’ emphasis).
Likewise, Posner77 reflects upon an early meta-
phor that:
“Thinking, like swinging a bat, has a “point of no
return”— once committed in a particular direction,
thought is ballistic in that it cannot be altered.” (p. 3)
It seems then that specific aspects of the
environment are overtly and covertly selected and
become integrated in goal-directed action plan-
ning. This is what we mean by ‘intention’. We
attend so that we can intend. For the majority of
human behavior this works well as an active
process. Focusing and directed, purposive behavior
is helpful, and it generally improves performance.
However, there are certain circumstances where
explicit intention is counter-productive. These
arise, not least, with bodily functions that are
designed to operate automatically.
A good example of this is the human sexual
response. Erectile responsivity is not essentially
purposive, and it can be inhibited by attention and
intention, particularly when fuelled by anxiety or
worry about performance failure (threat) or by
desire to respond normally (incentive). There is a
considerable literature demonstrating that the
human sexual response is undermined by self-
monitoring and self-observation, and that it is
promoted by focusing away from, rather than
directly upon, physiological ‘performance’.78,79
C.A. Espie et al.230Techniques such as ‘sensate focus’ have been
applied successfully for 30 years or more to reduce
this maladaptive self-referential monitoring of
sexual response. Using this approach involves
focusing upon (selectively attending to) sensory
experiences (of touch) and away from overtly sexual
experiences (sexual arousal). The explicit intention
of responding sexually is, thereby, removed, permit-
ting arousal to re-emerge spontaneously.
There is a long tradition of psychological theory
and practice, dating back to the work of Victor
Frankl1 involving techniques such as paradox and
dereflection.80,81 These have been applied to
situations where there is excessive concern about
the frequency of a response occurring too often
(e.g. blushing, excessive sweating) or not often
enough (e.g. sexual response). This literature
illustrates that attending to, and intending to
produce, a desired behavioral goal can be inhibit-
ing; and that, in turn, that by instructing patients to
intend the opposite, the original desired goal may
be achieved more easily.Conceptualisation of explicit intention in
relation to insomnia
To re-iterate, we propose that a dysfunctional
explicit intention to sleep develops in the context
of an attention-for-action mechanism that associ-
ates sleep/sleeplessness with behavior specifically
designed to deliver sleep/eliminate wakefulness
(Fig. 1). Thus, the automaticity of normal sleep
initiation is further challenged by the emergence of
a specific purpose-to sleep. Again it is instructive to
think of sleep normalcy.
We suggest that normal sleepers do not exhibit a
well-developed explicit intention to sleep. Rather
their intentions may be more implicit than explicit.
That is, it is implicit in going to bed, putting the
light out, adjusting body position and so on that the
purpose is to sleep. We have previously referred to
these as automated setting conditions. Such pre-
paratory behaviors certainly reflect an implicit
intention—they are not indifferent to or neglectful
of sleep—but they are not done with the express
purpose of sleep. Indeed, exception to the general
principle that good sleepers lack intentive purpose
associated with bedtime behavior, may arise when
their explicit intention is, in fact, to remain awake.
The notion of ‘abandonment of wakefulness’ seems
more apposite to normal good sleep.
Take the example of reading in bed. Good
sleepers read in bed, so why should we discourage
people with insomnia from reading in bed, as per
stimulus control instructions?17 Is reading in bed asleep-incompatible behavior, or is it not? This may,
of course, depend more upon the nature of
conditioned behavioral associations, than upon
the behaviors per se. However, another explanation
of the essential difference between good sleepers
and people with insomnia in relation to reading, is
that good sleepers are more likely to have the
explicit intention of remaining awake, in order to
read; whereas people with insomnia are more likely
to read, with the explicit intention of falling asleep.
Therefore, the situation may arise that the good
sleeper gets to the point of quitting reading in order
to sleep, simply because they are already lapsing
into micro-sleeps from time to time. Indeed, they
may fight sleep off for a while before giving in
(passively) to sleep. By comparison the person with
insomnia is more likely to be filling wakeful time,
hoping that this (or another) strategy might work to
help them sleep. The contrast, therefore, is that for
the good sleeper the precursor to sleep is abandon-
ing wakefulness; whereas, for the person with PI it
is trying to initiate sleep.
It also appears from the diagnostic schedule that
explicitly intending to sleep is problematic for the
person with PI. Although ICSD-24 criteria for PI are
based in part on expert clinician evidence and await
scientific validation, they do suggest PI patients fall
asleep when they do not intend to. One of the PI
criteria is:
“Difficulty falling asleep in bed at the desired
bedtime or during planned naps, but no difficulty
falling asleep during other monotonous activities,
when not intending to sleep.” (criterion C2; p. 1–7)
The implication is that desire, planning and
intention are counterproductive in PI. There is
also the implication that people with PI may more
readily fall asleep when they do not have the
explicit intention to do so. This is consistent with
the literature on paradox.
By definition, people with PI have difficulty
falling asleep and remaining asleep, and by
convention in insomnia research and in clinical
practice we ask people to record these difficulties
in a sleep diary. This raises an interesting point in
relation to the measurement of sleep intention.
Sleep-onset latency (SOL) is usually taken as the
length of time it takes to fall asleep, after settling
down with the intention of sleeping (after lights
out). This fits with the insomnia model, because this
is what they do. However, it would be interesting to
know, from normal sleepers, on what proportion of
nights they fell asleep before they ever intended to.
We lack data on this, but our prediction would be
that the true SOL values for some good sleeper
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the above definition of SOL literally.
The fact that we routinely ask patients to
monitor sleep pattern on diaries raises another
important point. According to our A–I–E model, to
pay directed attention to the involuntary response
that is sleep may impair its very automaticity. As
therapists then, are we not likely to exacerbate
patients sleep problems merely by asking them to
complete diaries? Successful completion does
require directed attention to sleep. This could be
examined, experimentally, by comparing one group
of PI patients on standard diary completion with a
second PI group, whose sleep is monitored using a
method not requiring direct participant involve-
ment with their sleep data. We might expect
however that the strongest inhibition of sleep
would occur with direct monitoring of sleep during
the sleep-onset period.
We would also note at this point that we believe
the A–I–E pathway may be equally applicable to
sleep maintenance problems. WASO is the primary
measure of sleep (dis)continuity, representing the
cumulative time taken to re-initiate sleep after
night-time arousals. Our model would suggest that
the selective attention process may be active
before sleep, that it may remain active after
sleep-onset and that it may re-activate during
sleep, particularly during light sleep and its
associated arousals. Because selective attention
may be represented as a conditioned involuntary
response to arousal, it does not require the person
to be conscious or fully conscious. Indeed, the
literature on evoked potentials suggests that the
brain’s capacity to discriminate the intrinsic
significance or semantic content of a stimulus may
persist in stage 2 and REM sleep.82 More specifically
then, in relation to WASO, it is possible that the
vigilant scanning associated with selective atten-
tion becomes switched on during light sleep
producing vulnerability to arousal and accentuating
‘pre-existing’ normal and transient nocturnal arou-
sals. Consequently, arousals may be more likely to
extend into consciousness and to frank awakenings.
Whereas, it has been known for some time that
even in normal sleepers there is significantly shorter
awakening latency to meaningful stimuli presented
during sleep,133 it remains unclear from the
research literature available at this time whether
or not PI is associated with increased frequency of
awakening from sleep.134 Further research in this
area is required.
However, once awake, somewhat less controver-
sially, we propose that the person with sleep
maintenance PI is then in exactly the same position
as the person with sleep-onset PI. We are not thefirst to suggest that a central component of sleep-
maintenance insomnia relates to a problem of re-
initiating sleep rather than solely a disorder of
intermittent wakening per se.83 The explicit inten-
tion to get back to sleep would then apply during
the night inhibiting de-arousal in the same way as at
(the first) sleep-onset.
In summary, then we suggest that explicitly
intending to sleep is (a) not what normal good
sleepers do, (b) it is dysfunctional because it
inhibits normal de-arousal, and by extension of
these points (c) that normal sleep may be restored
when intention to sleep is neutralized.Evidence of explicit intention in PI
There are few studies that directly address sleep
intention in PI. However, evidence from a number
of sources is suggestive that explicit intention to
sleep plays a part in PI.
The multiple sleep latency test (MSLT) is not
routinely recommended for insomnia, partly
because people with PI generally have daytime
sleep latencies in the normal range or even
longer.84,85 This has been taken as support for a
variety of different positions—that PI has no true
daytime consequences, that people with PI are
hyperaroused around the 24 h clock, and that people
with insomnia find it difficult to sleep in labs or when
observed or when trying to sleep. We would develop
this last point by commenting that it may be
important that, in the MSLT, people are explicitly
trying to sleep. The typical task instruction is:
“Please lie quietly, keep your eyes closed and try
to fall asleep”
(p. 1418)86
This could be why people with PI are unable to
sleep under MSLT conditions. You might then
wonder why explicitly trying to sleep would not
inhibit people with other sleep disorders from
sleeping during MSLT naps? Our suggestion here
would be in terms of our concept of inhibitory
sufficiency.13 An explicit intention to sleep simply
may not be sufficient to inhibit sleep in someone
who has strong homeostatic pressure to sleep (e.g.
narcolepsy) or who is otherwise sleep deprived (e.g.
sleep apnea). However in PI, homeostatic pressure
to sleep may be relatively weak (until sleep
restriction is applied) or at best it may be highly
variable; and people with PI are not objectively
sleep deprived. Further experimental work varying
the instructional set for the MSLT would therefore
be informative. Similarly, a comparison of GS and PI
C.A. Espie et al.232on the maintenance of wakefulness test, or simply
using a non-instructional condition (e.g. ‘We just
want to calibrate the equipment for a few minutes
with your eyes closed while you are laying there
awake‘) could prove informative about potential
underlying mechanisms.
The inhibitory properties of explicit intention in PI
arealso supported indirectly byabodyof researchon
paradox and ironic control in insomnia. It has been
suggested that anxiety responses may be con-
ditioned not only to external, situational cues but
also to the individual’s behavior.87–89 Fear of a
performance failure (insomnia) and of anticipated
negative consequences of that failure is described as
performance anxiety. In the treatment known as
paradoxical intention, counter-productive attempts
to fall asleep are replaced by the intention of
remaining passively awake or by giving up any direct
intention to fall asleep.90,91 This rationale is
supported by the fact that good sleepers do not use
any strategies to fall asleep. Typical instructions for
paradoxical intention therapy have been summar-
ised as follows by Morin and Espie (pp 95–97)92
1. When you are in bed lie in a comfortable position
and put the light out.
2. In the darkened room, keep your eyes open, and
try to keep them open ‘just for just a little while
longer’. That’s your catch phrase.
3. As time goes by congratulate yourself on staying
awake but relaxed.
4. Remind yourself not to try to sleep but to let sleep
overtake you, as you gently try to resist it.
5. Keep this mind set going as long as you can, and if
you get worried at staying awake remind yourself
that that is the general idea, so you are
succeeding.
6. Don’t actively prevent sleep by trying to rouse
yourself. Be like the good sleeper, let sleep come
to you.
The emphasis, therefore, in paradoxical inten-
tion is upon natural sleep initiation and the patient
is encouraged to take a passive, accepting role.
Setting conditions for sleep are established (bed,
comfortable, dark) but the explicit intention is to
remain awake, thus obviating attempts to sleep. It
is, of course, consistent with the view of wakeful-
ness as accruing sleep debt that one of the most
reliable ways to guarantee sleep is to remain
awake. Paradoxical intention therapy takes advan-
tage of this principle by prescribing wakefulness as
a precursor to successful sleep. Paradoxical inten-
tion has demonstrated efficacy as a single therapy in
controlled trials,93,94 and is regarded as anintervention that reflects a ‘moderate degree of
clinical certainty’ according to AASM practice
criteria.95,96
Of course treatment outcome studies are not
designed to test mechanisms of action, so data from
such sources must be regarded as preliminary.
Rather, both experimental comparison studies
(GS, PI) and experimental manipulation studies12
(in GS) are required to look at specific causal
mechanisms. Four experimentally-based studies
have been published that yield some evidence
about the role of intention.
First, Gross and Borkovec97 allocated good
sleepers to one of three experimental conditions.
All participants were instructed to ‘go to sleep as
quickly as possible’ (p. 113) during a daytime nap
opportunity. However, in one group they were told
that they would have to make a speech at the end of
the experiment on an unspecified subject, and in
another that the speech had to be on a specific
topic. The third group was a control condition with
no manipulation of pre-sleep mental content. They
found that the speech plus topic group had the
longest mean SOL, suggesting that trying to sleep in
circumstances where cognitive arousal/anxiety was
increased led to greater sleep difficulty. In the
Gross and Borkovec experiment it was not possible
to separate out the effects of intention and
cognitive task demands.
Second, Ansfield et al.2 explored the effects of
different sleep-onset instructions in good sleepers
under high or low ‘mental load’. This was an elegant
study where two factors were systematically
investigated. Good sleepers were instructed to fall
asleep either “.as quickly as possible . in record
time” or “. whenever you would like” (p. 526)
under conditions of either “. stirring . marching
band music” or “sleep-conducive. music contain-
ing restful, outdoor sounds .”. Paradoxical wake-
fulness was found amongst those actively
attempting to sleep while listening to the sleep-
inhibiting music. This result was interpreted in
terms of Wegner’s98 theory that the thwarted
attempt to control a particular mental state can
yield the opposite of what is desired. Ansfield et al.
hypothesized that failure to fall asleep on a few
occasions could occur when sleep is attempted
under transitory mental loads, such as at times of
stress. Eventually a person’s thoughts about being
unable to sleep could constitute a debilitating
mental load which, when combined with the
continuing frustrated desire to fall asleep, could
lead to chronic insomnia. Interestingly, Ansfield
et al. also found that explicit intention to sleep plus
sleep-conducive music did not delay SOL,
suggesting the importance of the interaction of
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more, this group actually fell asleep more rapidly.
This finding could reflect an experimental treat-
ment effect where a relaxation response to calming
music counteracted the explicit intention to sleep
and delivered a sleep-promoting benefit. That is,
although Ansfield et al. intended the calm music to
be a neutral condition relative to the impact of the
marching music, it seems plausible that it had a
converse therapeutic effect.
Third, Harvey99 has explored the effects of
suppressing pre-sleep cognitive activity on SOL.
People with insomnia and good sleepers were
allocated either to a suppression condition (‘sup-
press the thought most likely to dominate your
thinking as you get into bed’) or a non-suppression
condition (‘think about anything as you get into
bed, including the thought you would most likely
think about as you go to sleep’). Interestingly,
‘suppress’ participants reported longer sleep
latencies and poorer sleep quality, regardless of
whether they had insomnia or were good sleepers.
Harvey concluded that thought suppression, whilst
attempting to turn off pre-sleep intrusive thoughts,
appeared to have the opposite effect in that it
prevented sleep-onset, in a manner consistent with
Wegner’s theory of ironic mental control.98 Wegner
uses the terms ‘intentional operating process’ to
refer to the search for mental content that will
yield a desired state (e.g. drowsiness), and ‘ironic
monitoring process’ to refer to the search for
evidence of failure to achieve a desired state (e.g
alertness). There are clear parallels here with
Harvey’s views on the negative impact of sleep-
associated monitoring36,52 and also with our con-
cept of present state monitoring13,48 that we now
suggest forms part of the A–I–E pathway.
Before considering the final experimental study
relevant to explicit intention, it is interesting that
several preliminary findings show that thought
control strategies may characterise people with
insomnia. Harvey has examined beliefs about pre-
sleep worry using the utility of pre-sleep worry
questionnaire.100 Relative to good sleepers, people
with insomnia endorsed more positive belief
statements about worry (e.g. ‘worry in bed helps
me get things sorted out in my mind’). The number
of negative belief statements endorsed was not
different between the groups. Harvey using the
Thought Control Questionnaire for Insomnia also
reported that people with insomnia used more
reappraisal, worry and thought suppression strat-
egies to control pre-sleep intrusions, relative to
good sleepers.101 Similarly, Ellis and Cropley found
worry and punishment strategies to be the strat-
egies most commonly used by people withinsomnia.102 Such attempts amongst people with
insomnia to control their thoughts (so that they can
clear the way for sleep), therefore, may fuel
further intrusions, and so maintain sleep disturb-
ance. We suggest that the motivation for thought
control may be because, unlike normal good
sleepers, people with insomnia are actively
engaged with intentional sleep.
Fourth, Lundh and Hindmarsh103 described a
clinical experiment that has relevance to this
thought control literature, and to what we have
previously described as metacognition. Forty par-
ticipants were instructed simply to monitor, but not
to respond to, their thoughts and emotional state
during the pre-sleep phase. This ‘meta-cognitive
observation’ task was found to significantly reduce
sleep latency. Although lacking a comparison
group, the study provides a demonstration of the
potential benefit to sleep of this ‘mindfulness’
approach, which in turn may mimic normal pre-
sleep cognition.
Taking the body of available evidence as a whole
then, we suggest that there is preliminary evidence
to support both the presence of explicit sleep
intentive processes in insomnia, and the utility of
neutralizing/normalizing strategies to counteract
their effects.Sleep effort
Introduction
The third component of the proposed A–I–E pathway
is what we have called sleep effort. Because, this is
a developmental pathway, we conceive of A–I–E as
comprising not so much discrete components as
overlapping stages. Consequently, there is not a
point at which intention ceases and effort com-
mences (Fig. 1). Rather, we regard effort as a
further development of intention, to the extent
that the ‘end state’ of persistent PI (leaving aside
the potential for depression to develop) could be
described as a sleep effort syndrome.
Indeed, for the past century the Yerkes-Dodson
Law has suggested that high physiological arousal
can be disruptive to intended behaviors presumably
by an excess of neural noise interfering with the
sequences of choice points necessary in initiating
behaviors. The decreases in signal to noise ratios at
all these choice or decision points result in
disruptions to skilled behaviors or voluntarily
directed behaviors. Anxiety clearly increases arou-
sal level, but so does any ‘effort’. Whereas a certain
amount of arousal can be a constructive behavioral
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to work against the organism. Because increased
arousal in response to effort is an extremely well-
learned response, we would argue why should it be
different with increased effort to fall asleep?
In evidence of explicit intention in PI we
illustrated explicit intention and how it interfered
with sexual responsivity. An analogy for effortful
preoccupation and its inhibitory consequences
would be the phenomenon of stammering. It is
rare for people with speech impediments of this
type to have specific physiological or motor/
mechanical disorder, although the ‘causes’ of
stammering are best regarded as multi-factorial.104
Deliberate and effortful speech production is
typical, and automatic, fluent speech appears to
be inhibited or compromised. Particular difficulty is
evident in responsive speech to concrete questions
where awareness of the correct answer and
attempts to produce it lead to blocking and
stammering on letters or syllables. Also, like sexual
dysfunction and insomnia, there is marked frustra-
tion at being unable to accomplish what seems like
a relatively simple thing—in this case to articulate
words fluently. The automatic, over-learned nature
of competent, fluent speech is so unremarkable
that comment would seldom be made on successful
everyday conversation. Consequently, difficulties
with speech are of magnified concern to the
stammerer. However, the ‘good speaker’, like the
good sleeper is entirely unaware of the process, and
exhibits no qualities or special competencies that
are immediately obvious.
Attention to speech, intention to speak and
effort to control spoken output seem to character-
ize the problem. This contributes to what may be
one hallmark feature of effortful preoccupation,
performance anxiety. Performance anxiety is found
in a wide range of symptoms and disorders,
particularly where psychological and physiological
factors interact. Other examples include blushing,
where social context triggers vasodilation but
attentional and controlling responses exacerbate
the symptoms, and psychogenic urinary retention
where self-observation and active efforts to urinate
restrict sphincter relaxation.80 The criterion of
performance is clear in each case (e.g. erection,
speech, social encounter, urinating) thus making it
easy for the person with the problem to identify
inadequate performance or performance failure.
The impact of effortful processes has also been
shown in experimental studies. For example,
Wegner, Broome and Blumberg demonstrated using
electrodermal measurement that trying to remem-
ber a 9-digit number during progressive muscle
relaxation increased skin conductance level,whereas skin conductance decreased with relax-
ation alone.105 This combination of intention to do
one thing (relax) in the face of oppositional factors
(mental load) parallels our concept of effort arising
out of intention. ‘Striving’ would be a good synonym
for our concept of effort.
It is also instructive that successful treatment for
disorders where effort and conscious control are
part of the problem does not involve reinforcement
of effort as a strategy. On the contrary, disrupting
the inhibition of what in our terms is the A–I–E
pathway can yield good outcome. Many of these
strategies are in fact paradoxical in nature. For
example, in stammering, delayed auditory feed-
back disrupts self-observation and forced speech,
and distractor or rhythmic procedures are used to
enhance natural fluency rather than emphasising
speech production per se.106 At a more generic
level, there is emerging evidence of the health
value of the principle of acceptance (e.g.107). Of
course, this is not a new idea because many
philosophies and world religions embrace the
importance of accepting certain situations instead
of struggling against them. The principle has been
particularly well articulated in what has become
known as the mindfulness approach (e.g.108). where
cognitive/emotional processes are observed with-
out any ambition to change them. Although mind-
fulness is a much wider system of thinking and
therapy than is actually required for the present
purposes of understanding PI, it does lend further
construct validity to intention and effort as
maladaptive strategies.Conceptualisation of sleep effort in relation
to insomnia
Our suggestion is that the development of PI follows
a pathway from an implicit information processing
bias (pre-attentive perceptual) to an explicit
processing bias (conscious mental), then to an
explicit intention (responsive mental) and then to
an effortful preoccupation (responsive/proactive
behavioral). If selective attention is scanning mode
and explicit intention is planning mode, then sleep
effort is performing mode. Sleep effort is seen as
comprising two, related processes—one that is
direct (e.g. actively trying to sleep) and one that
is indirect (e.g. increasing sleep opportunity).
This conceptualisation therefore characterises
the development of the behavioral response to
the developing PI problem and is illustrated in Figs.
1 and 3.
A mechanical analogy may be helpful. We
propose that good sleep is fully automated, in the
Figure 3 The development of psychophysiological insomnia following the attentionintentioneffort pathway and its
impact on automaticity.
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selective attention partially impairs this automati-
city. We suggest that it is then further impaired by a
crucial switch towards ‘manual’ operation during
the intentive stage. However, the lasting damage,
resulting in persistent PI, may be done when a
compelling need to take control and fix the problem
develops. We suggest that this stage is more
emotionally driven and so it will be particularly
associated with evaluative considerations. This is
what we mean by using the term performing mode
(Fig. 3). Sleep has now become an enactment that is
observed, analysed and performance reviewed.
Dissatisfaction in these circumstances is likely to
undermine not only sleep but also self-efficacy.
Fig. 3 also illustrates notionally the cumulative
effect of the AIE pathway upon the impairment
of automaticity of the healthy sleep process.
Returning to ICSD-24 descriptions of PI, the
following segments seem relevant to the concept
of sleep effort.
“Learned associations are marked by over-
concern with the inability to sleep. A cycle
develops in which the more one strives to sleep,
the more agitated one becomes, and the less
able one is to fall asleep” (p. 1–6)
“. individuals with insomnia characteristically
demonstrate effortful preoccupation with both
the consequences of and the potential solutions
for their sleep problems” (p. 1–6)
“A sense of repeated failure to resolve sleep
problems often leads to intermittent periods ofresigned helplessness and help-seeking beha-
viors” (p. 1–7)
We suggest that the sleep effort response
presents in two ways; first, as increased direct
effort to get to sleep, or to get back to sleep when
awake in bed; and second, as increased indirect
effort to sleep by manipulating the setting con-
ditions for normal sleep. Furthermore, ‘efforts’
may be both cognitive and behavioral. We will
briefly describe these ideas.
Direct behavioral effort may include things like
trying to force sleep to come, tossing and turning
to find a sleep position, lying particularly still as
if asleep, and being unwilling to ‘give in’ and get
up when not sleeping. We have previously
mentioned reading in bed with the express
purpose of sleeping in this context, and people
tiring themselves out by exercising vigorously is
another example. Examples of direct cognitive
effort include thought management, counting
sheep, suppressing thoughts and distraction tech-
niques. As will be apparent, direct efforts to
sleep may also include well-intentioned strategies
that have some basis in behavioral sleep medi-
cine, e.g. the use of relaxation exercises as a
sleep-inducer. Our point is that, to the extent
these activities involve the direct effort to sleep,
they may actually contribute towards the main-
tenance of PI, rather than towards its resolution.
It is anecdotal, but nevertheless typical, of the
person with PI to report that they have ‘tried
everything’ to help them sleep!
Indirect sleep efforts may be particularly
important in PI. This would be where maladaptive
steps are taken to influence the probability of
C.A. Espie et al.236sleep. In terms of our model, this not only upsets
the default setting conditions for good sleep, but
also reduces the statistical probability of sleep. At
the cognitive level, people with insomnia often try
to manage or contain levels of mental and
emotional stimulation so that they are likely to
sleep better. Sleep becomes such a priority that it
is anticipated throughout the waking day. The
most common behavioral responses are to increase
sleep opportunity by going to bed earlier, staying
in bed later, and trying to ‘catch up’ on lost sleep.
We emphasized earlier how craving for sleep might
result in increased time spent in bed. So,
ironically, in an indirect behavioral effort to obtain
more sleep, the net effect is to reduce sleep
efficiency.
To illustrate this, consider the data presented in
Table 3. This is a fictional case of a person averaging
63 min of wakefulness and with sleep efficiency of
85% based on 7 h in bed (week A). This sleep pattern
is at the margin between normal sleep and
insomnia, but let us suppose that the person is
concerned about their sleep and its consequences,
and so increases time in bed by 1 h per night for the
next 7 nights. The data in week B assume that this
actually results in some benefit to sleep duration
(illustrated by a stable increase in sleep of 15 min
per night). However, the impact on sleep efficiency
reduces the average to 78% (range 66–86%).
Although, this is only a modest 7% reduction from
the week A value, for the homeostat to return
efficiency to the 85% value, based on the new
behavior of spending 8 h in bed, would require an
average sleep of 408 min (480!0.85). Inspection of
the raw data over the 14 nights in Table 3 show that
this length of sleep was only ever obtained on 1
occasion, and that, in spite of sleeping a little
more, average sleep in week B is some 36 min below
that target.
Direct efforts to initiate sleep we suggest are
more likely to be affect laden—e.g. lying awake
trying to get to sleep. Indirect efforts such asTable 3 Comparison of 2 weeks of fictional sleep diary dat
by 1 h
Night 1 Night 2 Night 3 N
Week A TST 380 360 390 3
TIB 420 420 420 4
SE 90 86 93
Week B TST 395 375 405 3
TIB 480 480 480 4
SE 82 78 84
TST, total sleep time (min); TIB, time in bed (min); SE, sleep efficiincreasing sleep opportunity may be less affect
laden. Indeed, they may initially reduce anxiety
because they offer the reassuring possibility of
more sleep, and may actually deliver some.
However, as well as undermining automaticity,
they have the capacity to exacerbate insomnia
symptomatology and place sleep efficiency outwith
the range within which it can spontaneously
recover.
Most commentators regard stimulus control/-
sleep restriction as the core components of an
effective CBT programs (e.g.92). One of the fore-
most reasons for this is that these interventions
quickly and effectively tackle the problem of
extended sleep opportunity. We cannot say at this
stage by what means these procedures achieve
their effects,13 however, it should be noted that
these, essentially behavioral, approaches are not
inconsistent with the A–I–E pathway. Both stimulus
control and sleep restriction therapies involve (a)
establishing setting conditions for sleep that are
largely determined by sleep needs, rather than
sleep desires; (b) strengthening homeostasis and
circadian timing, rather than personal agency over
sleep; and (c) precluding the need for, or quickly
abandoning, direct attempts to sleep, rather than
trying to initiate sleep. Consistent with sleep
normalcy, stimulus control and sleep restriction
help to re-engage the ‘two process’ functions of
sleep drive and timing. Consistent with the A–I–E
pathway they also reinforce the implicit third
process of automaticity.Evidence of sleep effort in PI
Evidence of sleep effort in insomnia can be drawn
from several sources.
In the context of paradoxical intention therapy,
the outcome literature that we reviewed in the
section on Explicit intention, includes three studies
that provide some evidence of effortful processes
and mechanisms.a illustrating the impact of extending sleep opportunity
ight 4 Night 5 Night 6 Night 7 Mean
20 350 400 300 357
20 420 420 420 420
76 83 98 71 85
35 365 415 315 372
80 480 480 480 480
70 76 86 66 78
ency % (TST/TIB!100).
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to delivering paradoxical instructions. They found
that the instruction to ‘give up trying’ to sleep was
just as effective in treating insomnia as the more
explicitly paradoxical ‘try to remain awake’
instruction. In other words, ceasing to try may be
the essential element in the paradoxical approach,
which would be consistent with reversal of the
effort component of the A–I–E pathway.
Our own early work using paradox yielded some
unexpected findings. We found that it could be a
very effective treatment for insomnia,94 yet for
some individuals the paradoxical directive seemed
to re-focus performance anxiety and lead them to
quite literally remain awake.88 We interpreted this
as an interaction between the performance focus of
the individual (initially upon sleep) and the demand
characteristics of the therapeutic environment,
where they were being asked to stay awake (instead
of to sleep), such that they tried too hard (to
implement therapy). In other words, effort gets in
the way. There may be parallels here with Lundh
et al.’s suggestion that perfectionistic traits may be
predispositional in some people with insomnia.109
Recently, we have completed another study on
paradox.110 This was an experimental trial that
examined the effect of paradoxical intention on
effort to sleep, on sleep performance anxiety, and
on both objectively-estimated and subjectively-
estimated SOL. Sleep effort was measured by a
rating of ‘When I went to bed last night, I tried
really hard to get to sleep’ ranging from 0 ‘not at
all’ to 6 ‘very much’, and performance anxiety
about sleep was rated using a preliminary version of
the Glasgow sleep effort scale (GSES).c Following a
seven-night baseline, 34 participants (mean age 25
years) with persistent sleep-onset insomnia (mean
duration 6 years) were randomly allocated to
fourteen nights of paradox, or to a control (sleep
as usual) condition. The intervention period was
deliberately short because we were primarily
interested in the impact of paradoxical instruction
upon sleep effort. Consistent with this model,
participants allocated to paradox, relative to
controls, showed a significant reduction in sleep
effort and sleep performance anxiety. A developing
trend for significantly lowered subjective (sleep
diary) SOL in PI participants was also demonstrated
within the brief treatment period. The important
finding here was the observation that paradoxical
intention appeared to operate by reducing sleep
effort/anxiety. Effort change significantlyc The final version of the GSES is described in greater detail
below.correlated with SOL change when sleep anxiety
was partialled out (rpZ0.42, pZ0.016). In con-
trast, when effort change was partialled out, sleep
anxiety was not associated with SOL change (rpZ
0.08, pO0.1). This further supports the model of
explicit sleep intention as inhibitory.
Some rating scales that are commonly used in
insomnia research and in clinical practice contain
items that suggest that an effortful approach to
sleep might be implicated in PI. The dysfunctional
beliefs and attitudes about sleep scale43 is designed
to measure cognitive distortions and thinking errors
in insomnia. DBAS Item 7 (‘When I have trouble
falling asleep or getting back to sleep, I should stay
in bed and try harder’) forms part of a constellation
of mental symptoms that Morin111 originally related
to ‘faulty beliefs about sleep-promoting practices’.
This item was retained (as Item 4) in a recent
psychometric analysis of the DBAS that produced a
shortened 10-item version comprising beliefs that
demonstrably changed in response to CBT interven-
tion.112 A Principal Components Analysis (PCA)
loaded this item on Factor III ‘beliefs about the
need for control over insomnia’.
Three of the 12 items in the Sleep Disturbance
Questionnaire (SDQ) are also relevant to the
concept of effort. In the original study using the
SDQ the items ‘I try too hard to get to sleep’, ‘I get
too “worked up” at not sleeping’ and ‘I worry that I
won’t cope tomorrow if I don’t sleep well’ were
used to select patients for paradoxical intention
therapy because they were felt to reflect sleep
effort and sleep performance anxiety.44 Further-
more, Principal Components Analyses have demon-
strated that these items do load together on the
same construct.44,112 However, the lack of a
specific validated measure of sleep effort led us
to develop a new self-report measure— the glasgow
sleep effort scale (GSES).113
Work on the GSES began in the context of a study
investigating the sensitivity and specificity of
commonly-used insomnia research tools in discri-
minating PI, insomnia associated with mental
disorder (I-MD) and GS.114 Fifty-four adults (mean
age 40 years; nZ18 per group) participated by
completing a set of six psychometrically robust
insomnia self-report instruments, along with the
Beck Anxiety Scale and the Beck Depression Scale.
Although the experimental groups differed on the
majority of these measures, logistic regression
analysis indicated that ‘effortful preoccupation
with sleep’ (as measured by the GSES) discrimi-
nated PI from GS (with 100% sensitivity, and 94%
specificity) and the GSES also discriminated I-MD
from GS (100%, 100%). Furthermore, only depress-
ive symptomatology (on the Beck Depression
Figure 4 A preliminary working model of direct sleep effort in persistent Psychophysiologic Insomnia (reproduced
from113).
d That is direct sleep effort. Indirect sleep effort (e.g. by
increasing time in bed) is best measured behaviorally, on a sleep
diary, rather than on a Likert Scale.
C.A. Espie et al.238Inventory (BDI)) discriminated I-MD from PI. No
other variables entered any of the regression
models.
These results not only suggest that sleep effort is
an important concept in PI, but also that other
mental and behavioral measurements may be less
specific to PI as a disorder. Furthermore, the fact
that these findings held also for insomnia associated
withdepression raises the interestingpossibility that
a continuum may exist across ‘primary’ and
‘secondary’ insomnia (at least where it is associ-
ated with depression/anxiety). This possibility is
supported by other recent work on symptom
reports in severe chronic insomnia which have
found that ‘depression-related insomnia’ and PI
were separable only by characteristic symptoms of
depression.115 On the other hand, Broman andHetta116 reported that cognitive and somatic pre-
sleep arousal was not correlated with insomnia
associated with affective disorder. Clearly, further
work in this area is required.
We were encouraged by these results to conduct
a formal validation study of the GSES.113 Therefore,
a working model was developed, integrating what
we felt were the seven core subjective components
of sleep effortd and each component was assigned a
single item (Fig. 4 and Table 4). Fig. 4, thus,
represents the final stage of the A–I–E pathway and
illustrates what we mean by performing mode (cf.
Figs. 1 and 3 and associated text). This proactive
Table 4 The Glasgow sleep effort scale113
The Glasgow sleep effort scale
The following seven statements relate to your night-time sleep pattern in the past week. Please indicate by circling
one response how true each statement is for you
1. I put too much effort into sleeping when it
should come naturally
Very much To some
extent
Not at all
2. I feel I should be able to control my sleep Very much To some
extent
Not at all
3. I put off going to bed at night for fear of not
being able to sleep
Very much To some
extent
Not at all
4. I worry about not sleeping if I cannot sleep Very much To some
extent
Not at all
I am no good at sleeping Very much To some
extent
Not at all
6. I get anxious about sleeping before I go to
bed
Very much To some
extent
Not at all
7. I worry about the consequences of not
sleeping
Very much To some
extent
Not at all
Relationship of Items 1–7 to components A–G in Fig. 4: 1–F; 2–G; 3–E; 4–C; 5–A; 6–D; 7–B.
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the problem of sleeplessness. Each core component
was allocated one item in the GSES and we field-
tested the scale on 89 insomnia patients and 102 good
sleepers. The GSES was found to have good internal
consistency (aZ77) and discriminant validity. Mean
total GSES score for PI was 7.06 (SDZ3.58) and for GS
was 1.22 (SDZ1.35) [tZ15.27, p!0.0001]. Impor-
tantly, sensitivity/specificity analysis found that a
cut off score of only two correctly identified 93.3% of
insomnia patients, and 87.3% of good sleepers. This
result is supportive of the concept of automaticity in
normal good sleep. GS simply do not endorse the
items because the idea of trying to sleep is quite alien
to them. There was also evidence of the construct
validity of ‘sleep effort’ because PCA yielded a single
principal component (EigenvalueZ4.38) accounting
for 62.6% of total variance, and each of the seven
items loaded similarly and significantly on this factor
(range 0.64–0.85).
Further work is clearly required on the GSES.
Nevertheless, it has the potential to be a quick
screening method to identify people with PI in the
community, and used alongside other measures, to
contribute to further research investigating diag-
nostic components of PI.Discussion
In this paper, we have argued for an expansion of
experimental cognitive research on insomnia, and
have focused upon evidence relevant to the
appraisal of what we believe may represent (for
Psychophysiologic Insomnia at least) one criticallyimportant sleep inhibitory process: the attention
intentioneffort pathway. Consistent with our
starting point of understanding how PI differs from
sleep normalcy,13 we have suggested that the
involuntary and automatic nature of the ‘two
process’ sleep system is first compromised by
selective attention to sleep, then imperilled by
explicit intention to sleep, and finally dysregulated
by a destructive combination of direct and indirect
sleep effort. Therefore, PI in its end state as a
‘sleep effort syndrome’, may be characterised by
attention bias, sleep preoccupation, and a panoply
of mental and behavioral strategies designed to
deliver sleep and to avoid sleeplessness, none of
which would be typical in good sleepers. Of course,
we must bear in mind that the true end state of
insomnia may lie, not in intractable insomnia alone,
but in the dysregulation of affect, because insomnia
is an independent risk factor for depressive
disorder.117,118
Evidence to support an A–I–E model is only
beginning to emerge and there is much work still
to do. Indeed, for now, whilst there is reasonable
support for the attention component of the model,
there is less evidence for the second and third
components. The information processing literature
on anxiety disorders emphasises attention bias
toward emotionally threatening stimuli. This con-
cept of ‘sleep cue as threat’ may apply to PI,
although salience may be conferred on sleep cues
for other reasons, not the least of which might be a
‘craving’ for sleep. Because, we are interested in
the specificity of attention bias in insomnia, it will
be important to partition and compare responses
(within subjects) to threat words (e.g. tired,
C.A. Espie et al.240wakeful, restless) and non-threat words (e.g.
rested, relaxed, sleeping) using a verbal attention
bias paradigm. We have also argued that attention
is first ‘allocated’ to sleep cues as part of an
unconscious process, akin to conditioning. This
implies that people may be already incubating an
insomnia response before they are aware that sleep
and sleeplessness are grabbing their attention, as in
the transition from acute/adjustment insomnia to
persistent insomnia. Exploration of attention bias
at the implicit or pre-attentive level is therefore
required, and can be achieved using subliminal
variants of attention bias probe tasks.119
The selective element of attention is also
important to consider, because inevitably as
attention is focused more in one direction, it is
focused less in another direction. Posner has
suggested that the attention system is not unitary,
but comprises measurable cognitive components
(shift, engage, disengage),77 which are sub-served
by specific, neural sub-systems120,121 and, which
are open to modulation by negative emotional
stimuli.29 In recent years, anxiety researchers have
begun to apply Posner’s attention model to
determine whether salient threat stimuli attract
attention i.e. modulate the engagement com-
ponent of covert attention, and/or hold attention,
i.e. modulate the disengage component.122 Most
findings for anxiety emphasise slowed disengage-
ment from threat, i.e. a holding function.123,124 In
insomnia research, it would be useful, therefore,
to determine which components of attention
comprise the bias for sleep words that we have
observed. Use of a modified cue-target paradigm
would be appropriate for this purpose.
Similarly, we have reprised the notion of
‘attention for action’.74 That is selective attention
has a purpose. In general terms, it confers
evolutionary advantage by prioritising and
directing activity through intention and goal-
directed behavior. However, sleep may not be a
response that is facilitated by such direct action;
rather it may be inhibited. It remains to be
demonstrated through experimental study that
threat of sleeplessness and/or desire for sleep
would drive explicit intention to sleep, although
the idea is consistent with clinical experience and
with contemporary diagnostic criteria for PI. The
glasgow sleep effort scale, however, includes
items that may span the A–I–E construct and reflect
this ‘dynamic’ force of attention for action. The
GSES has some encouraging sensitivity/specificity
data113,114 and may prove to be a useful measure
for identifying individuals with PI. Ideally, how-
ever, sleep intention and sleep effort should not be
measured solely by a self-report instrument. Someadditional measure of mental/behavioral response
tendency is desirable. We have illustrated how
extending sleep opportunity by increasing time in
bed could be a behavioral correlate of indirect
sleep effort, leading to homeostatic dysregulation.
In parallel, direct sleep effort (trying to force sleep
to come) is likely to increase cognitive and
emotional arousal.
The interrelationship between attention, inten-
tion and effort in the emergence and persistence
of PI also needs to be studied. For example,
researchers might consider exploring whether
sleep intention and sleep effort can be reliably
induced, experimentally, in good sleepers through
manipulation of sleep monitoring instructions. It
may also be possible to study, longitudinally,
following an acute stressor event, the pattern of
sleep change and associated development of
attention, intention and effort, in individuals
predisposed to PI. Extending the cross-sectional
paradigm employed by Taylor et al.69 in cancer
patients would be useful here. Importantly, the
work of Harvey and colleagues is leading the way
by emphasizing the application of controlled
experimental methods to tease out causal path-
ways in insomnia.56–58 Computerised experimental
tasks seem complementary to this work because
they offer an objective index of sleep-related
cognitive arousal.69,70,72,73
Related to these matters is the question of
whether psychological treatment impacts upon the
A–I–E pathway. For example, attention biases
reduce following CBT therapy for anxiety dis-
orders.125,126 Demonstrating that established
psychological treatments such as stimulus control
or multi-component CBT impact attention bias in
PI would add strength to the argument that such
biases play a critical role. We are currently
gathering data considering the impact of CBT on
attention bias in individuals suffering sleep dis-
turbance secondary to cancer, and will also have
some outcome data on the GSES from other clinical
trials.
We have suggested that, to the extent that any
CBT method enables an individual to abandon
personal agency over sleep and to return to total
reliance upon involuntary sleep it may be likely to
achieve a good therapeutic effect. This might
result from a cognitive manipulation, aimed at
changing the person’s perspective upon sleep.
Mindfulness approaches, which have recently
been applied to insomnia treatment,103 and other
‘acceptance’ based approaches, are of relevance
here, as are attention-retraining methods (already
used in the treatment of anxiety disorder127), and
the more established cognitive and paradoxical
Research agenda
1. Prospective, longitudinal study of the A–I–E
pathway is required to investigate its role in
the etiology of insomnia.
2. Further studies are required to investigate
the specificity of sleep-related attention
bias to Psychophysiologic Insomnia, as
opposed to other forms of sleep disorder.
3. Investigation of the somatic correlates of
attention bias is required to understand
insomnia as a psychophysiologic disorder
with autonomic, cortical and cognitive
Practice points
1. Computerized information-processing tasks
offer a novel objective method for apprais-
ing mental arousal associated with insom-
nia, particularly the sleep-related attention
and monitoring component of arousal.
2. The A–I–E pathway offers a framework for
evaluating the development of psychophy-
siologic insomnia as a persistent disorder
following acute, stress-related sleep dis-
turbance.
3. The Glasgow sleep effort scale is a brief
measure that discriminates psychophysiolo-
gic insomnia, and operationalises this com-
ponent of sleep preoccupation. It may be
useful for diagnostic purposes.
4. The A–I–E pathway suggests that targeted
CBT intervention to modify the attentional,
the intentional or the effortful processes,
which maintain insomnia may be sufficient
to reduce sleep disturbance and to restore
normal sleep.
5. The A–I–E model as a pathway suggests that
novel interventions may be applied early to
prevent the development of severe and
persistent insomnia.
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insomnia.92 However, we would point out that
simple behavioral manipulations might be
expected to achieve the end-point of involuntary
sleep more quickly. Both sleep restriction and
stimulus control (particularly the quarter of an
hour rule) involve resisting or giving up efforts to
initiate sleep and replacing them with an ultimate
abandonment of wakefulness due to sleep press-
ure. This seems typical of normal good sleepers.
Finally, it seems important to examine the
physiological substrate of the A–I–E pathway. In
general, few studies have collected psychophysio-
logical data associated with attention bias mech-
anisms.122 Most employ only reaction time, despite
the direct measurement potential of autonomic
indices such as heart rate, skin conductance, as
well as gaze direction. Additionally, examining
attention allocation in PI using bedroom based
(ambulatory) autonomic measurement would bet-
ter explore conditioned arousal patterns in associ-
ation with attention bias. Several studies have
shown that differential attention responses can be
activated by differing sensory and affective proper-
ties of the cue, and can be indexed using autonomic
measures such as heart rate.65 For example,
deployment of attention towards sleep cues in PI
may give rise to an orienting response associated
with cardiac deceleration, whereas rapid deploy-
ment away might be associated with a defensive
response accompanied by cardiac acceleration.128
Importantly, this cognitive-psychophysiological fra-
mework should extend to exploration of the
relationship between cognitive and cortical arou-
sal, with data on the latter indexed from the EEG
power spectrum (cf.129). If the attention bias
paradigm provides a direct measure of cognitive
arousal, and skin conductance or heart rate
variability offer a parallel measure of autonomic
function, then comparisons of such data with
quantitative EEG parameters could prove particu-
larly informative in exploring the underpinnings of
the PI phenotype.components.
4. Future studies need to consider the com-
ponents of attention (e.g. engagement,
disengagement) that comprise selective
attention bias to sleep cues in people with
insomnia.
5. There is need to investigate the impact that
psychological intervention has upon the A–I–
E pathway. In particular, to consider
whether measures of sleep-related infor-
mation-processing bias and sleep effort
reduce following CBT.Acknowledgements
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INTRODUCTION
INSOMNIA IS A FREQUENT HEALTH COMPLAINT, WITH 
UP TO 33% OF THE GENERAL POPULATION REPORTING 
SLEEP DIFFICULTIES AT ONE TIME OR another and 9% re-
porting insomnia on a regular nightly basis.1 Insomnia can occur 
as a secondary consequence of physical or mental illness but also 
as a primary disorder in itself.2,3 Primary Insomnia (PI) is char-
acterized as a disorder with the main complaint of disturbed or 
unrefreshing nocturnal sleep and associated daytime impairment, 
unrelated to a medical or mental disorder. 
 An interplay of psychological and physiologic factors have 
been implicated in the development and maintenance of PI, for 
example, higher metabolic rates, increased nocturnal melatonin 
secretion,4,5 heightened cognitive arousal, and dysfunctional be-
liefs about sleep in those with PI.6,7 Given that sleep disturbance 
may be seen as a considerable anxiety generator to an individual 
with PI, behavioral formulations of PI suggest that repeated epi-
sodes of sleep difficulties may lead to the poor sleeper developing 
conditioned arousal to the bedroom environment, thus exacerbat-
ing existing sleep difficulties. Recent cognitive models of PI8-10 
have taken this notion further and suggest that the poor sleeper is 
selectively vigilant for internal stimuli indicative of wakefulness 
(when trying to sleep) and symptoms of fatigue (during daytime 
activities11). Any indication of difficulties in either of these areas 
serves to heighten anxiety about sleep difficulties and their con-
sequences,12 thus leading to a redoubling of efforts to sleep and, 
paradoxically, reduced probability that sleep will occur.13,14 
 Selective vigilance, or “attention bias,” has been a focus of 
investigation in psychopathology for several years and is well es-
tablished as a maintaining mechanism in several disorders, such 
as social phobia or panic disorder.15,16 However, at present, there 
are only 3 published studies that examine attention bias in PI, 
with equivocal findings that provide only limited evidence that 
sleep-related attention bias is present in those with PI.
Attention Bias in PI
 Lundh et al,17 using the emotional Stroop task, found that par-
ticipants with PI took relatively longer to name colors in trials 
containing sleep-related words, in comparison to neutral words, 
indicating an interference effect of sleep-related stimuli. How-
ever, they also found equivalent effects in “normal sleepers,” sug-
gesting some degree of priming across the groups, or the presence 
of sleep difficulties in the “normal sleepers.” Taylor et al18 found 
a relatively heightened interference effect on the Stroop task for 
sleep-related words in a population with persistent insomnia (12 
to 18 months), in comparison with a group with acute insomnia 
(up to 3 months). However, both of these groups were recovering 
cancer patients, and no control group of good sleepers, without 
medical problems, was employed. 
 Nonetheless, perhaps the most compelling evidence of atten-
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tion bias in PI was provided in a recent study by Jones et al.19 
They used a novel “flicker” paradigm,20 involving repeated brief 
presentations of a visual scene with a single feature (either sleep 
or neutral) altered on each alternate presentation. Participants 
defined as “poor sleepers” (> 5 on the Pittsburgh Sleep Quality 
Index [PSQI]21) detected a change in a scene related to a “sleep” 
object (1 of a pair of slippers), significantly quicker than a non-
sleep object (1 of a pair of gloves). Furthermore, a significant 
correlation between PSQI and detection latency for the sleep-re-
lated change was observed. There are some drawbacks with this 
study, most notably the use of a between-subjects design, with no 
assessment of whether individuals showed relatively greater bias 
toward the sleep-related change. Jones et al19 also used only a 
single object, rather than several exemplars of a class, and classi-
fication of poor sleepers as suffering from PI was inferred purely 
on the basis of PSQI scores, with no clinical interview to confirm 
diagnosis. Although studies in the addiction literature suggest that 
the flicker task is a valid measure of attention bias,22 there is little 
in the general psychopathology literature on its use at the present 
time. 
Overcoming Limitations of Previous Work
 The study reported in this article attempted to establish whether 
attention bias is associated with PI by overcoming some of the 
limitations of previous work in this area. Firstly, the dot-probe 
paradigm, a well-established “hallmark” measure of attention 
bias, was employed.23 In this task, pairs of words are simultane-
ously presented, 1 above the other, on a computer screen, and the 
ensuing distribution of visual attention is measured by recording 
detection latency for a visual probe that appears in the spatial lo-
cation of either word, immediately after the display of that word 
has terminated. Thus, the task bypasses limitations of the Stroop 
by using a neutral response (key press) to a neutral stimulus (vi-
sual probe). The trials providing the data of interest are those in 
which 1 of the words has emotional salience. By examining the 
impact of such a word on the relative probe-detection latencies in 
the 2 spatial areas, it is possible to determine whether visual atten-
tion has shifted toward or away from such stimuli.
 In order to address the difficult question of whether attention 
bias is associated specifically with PI, and not simply with sleep 
disturbance, a control group of individuals with delayed sleep 
phase syndrome (DSPS) was employed. DSPS is, like PI, charac-
terized by difficulties in initiating sleep.24 Although the cause of 
this difficulty, in PI, is presumed to involve psychological factors, 
DSPS is believed to be the result of a circadian timing disorder. 
Because there is no presumed cognitive pathway to explain the 
emergence or maintenance of DSPS, it was predicted that those 
individuals who suffer from DSPS would not show attention bias 
to sleep-related stimuli. 
 A further limitation of previous studies in the sleep disorders 
literature has been a lack of clear differentiation between partici-
pants with PI and those who may have a mixed pattern of DSPS 
and PI.25,26 Thus, objective (actigraphic) assessment of circadian 
sleep parameters has been used in tandem with subjective (self-
report sleep log) assessment to differentiate between DSPS and 
PI in poor sleepers. Many sleep studies also define control partici-
pants as not “obvious” sufferers of insomnia,17 possibly leading 
to the inclusion of “noncomplaining” poor sleepers. Therefore, a 
further control group, who actively describe themselves as “good 
sleepers” (GS), rather than those who report “no sleep difficul-
ties,” was used.
Aims and Predictions
Aims
 This study examined whether individuals with PI show an at-
tention bias toward sleep-related stimuli on the dot-probe task in 
comparison with control groups of GS and those with DSPS. 
Predictions
(1) Participants with PI will show attention bias toward sleep-re-
lated stimuli in the form of reduced latency in dot-probe reaction 
time to sleep-related words, in comparison with neutral words.
(2) Neither DSPS nor GS will show an attention bias toward 
sleep-related stimuli in the form of increased latency in dot-probe 
reaction time to sleep-related words, in comparison with neutral 
words.
Ethics
 Ethical approval for the study was sought from, and granted 
by, Greater Glasgow Primary Care Trust NHS Ethics Commit-
tee.
METHODS
Participants
 An e-mail message sent round the student e-mail system re-
quested those with “sleep problems,” “night owls,” or “good 
sleepers” to contact the first author. An initial, informal, screen-
ing process by e-mail or telephone was used to assess whether 
respondents were likely to meet necessary criteria. Seventy-nine 
individuals appeared to meet criteria and were invited to take part 
in the study.
 Participants met Diagnostic and Statistical Manual of Men-
tal Disorders, Fourth Edition2 and International Classification 
of Sleep Disorders-Revised3 criteria for either PI or DSPS, and 
those with PI were required to score > 6 on the PSQI. Exclusion 
criteria included active psychological or drug interventions for 
sleep problems or when a sleep disorder was suspected as be-
ing the result of substance misuse. GS scored < 5 on the PSQI, 
reported themselves as being “good” sleepers, and met no criteria 
for a sleep disorder at the present time or in the past. Actigraphy 
was used as an aid to differentiate between PI and DSPS in those 
reporting sleep difficulties. All participants had normal vision or 
corrected to normal vision.
 Final allocation of participants to groups for the purposes of 
analysis did not take place until all sleep-assessment data had been 
collated. No formally screened participants were excluded due to 
either psychological or drug interventions for sleep or because 
of substance misuse. However, 15 participants were excluded for 
the following reasons: failure to return all questionnaire measures 
(4); error score (making an upper key press for a lower target 
word and vice versa) on the dot-probe task above 5% threshold 
(1), “good sleepers” with PSQI scores > 4 (6), sleep difficulties 
were a combination of PI and DSPS (2), and “poor sleepers” who 
did not meet threshold of > 6 on the PSQI (2). One further par-
ticipant (a “good sleeper”) was excluded as an “outlier” because 
her results fell more than 2 standard deviations from her group 
mean.
 This left a total of 63 participants who met all relevant criteria 
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and completed all measures and who were classified into PI (n = 
21), DSPS (n = 22), or GS (n = 20) groups. A power calculation 
(using data from previous studies of attention bias17,18,27) carried 
out prior to the study suggested that 21 participants would be re-
quired in each of the 3 groups (PI, DSPS and GS) to detect statisti-
cally significant differences at a power of .8 with an α level set at 
.05. 
Apparatus
 The dot-probe task was run on a Dell (Bracknell, UK) Optiplex 
GX270 computer, with software developed by the first author on 
the experiment-generating package, SuperLab Pro (Version 2.02; 
Cedrus Corporation; San Pedro, CA). The size of the screen was 
28 cm (diagonally), with stimuli in 14-point Times New Roman 
font in white lettering on black background, positioned centrally, 
on a vertical plane; the viewing distance was 45 cm. Millisecond 
timing was made through SuperLab Pro and an external response 
box (Model RB-400; Cedrus Corporation; San Pedro, CA) to 
avoid timing errors associated with standard keyboard or mouse 
input.
 Actigraphy was facilitated by the Cambridge Neurotechnology 
(Cambridge, UK) Actiwatch system. This comprises wrist-worn 
actigraphs (Model AW-2), roughly the size of small wristwatches, 
and sleep-analysis software (Actiwatch Sleep Analysis v 1.06), 
capable of automatically calculating sleep parameters. There is 
general consensus that wrist actigraphy provides an accurate ob-
jective measure of circadian sleep and wake parameters.28
Materials
 A stimuli list comprising 88 words was developed for this study 
(see Table 1). Firstly, 8 neutral, non–sleep-related practice words 
were divided into 4 pairs (leisure/gallant; poetry/joyful; welcome/
capable; prizes/secure). Secondly, a list of 20 sleep-related words 
were matched to 20 neutral words. The 20 sleep-related words 
were originally used by Taylor et al18 in their study of insomnia 
in patients recovering from cancer. Taylor et al18 developed these 
words from Wicklow and Espie’s29 study of the content of pre-
sleep cognitions, and, thus, they have a high degree of salience 
to individuals with sleep difficulties. Finally, 60 further neutral, 
non–sleep-related words were selected and divided into matched 
pairs. Although each pair of words was used on 2 occasions in the 
study, repeated word pairs have been used before in this paradigm 
with no priming effects found.30 
 Matching of words into pairs was carefully done to ensure 
equivalence in length and frequency of usage in the English lan-
guage. The latter was achieved by consulting frequency tables con-
structed from the British National Corpus, a representative sample 
of present-day spoken and written British English31(http://www.
comp.lancs.ac.uk/ucrel/bncfreq). Analysis-of-variance (ANOVA) 
across the 4 sets of word pairs for frequency of occurrence in the 
British National Corpus showed no significant differences (F
3,76
 = 
0.025, p = .995).
Self-Report Measures
Demographic Measures
(1) Beck Depression Inventory-Short-Form (BDI-SF32) to assess 
for symptoms of depression.
(2) Spielberger State and Trait Anxiety Inventory (S-SAI/ S-TAI33) 
to assess levels of state and trait anxiety.
(3) National Adult Reading Test (NART34) to provide an estimate 
of reading vocabulary and ensure that participants’ reading level 
was sufficient for the stimuli used in the dot-probe task.
(4) Caffeine Intake Questionnaire, an idiosyncratic questionnaire, 
to assess usual and actual recent intake of caffeine, comprising 3 
questions examining caffeine intake in beverages in past 24 hours, 
the day so far, and usual caffeine intake. Intake was divided into 
units according to the caffeine content of these beverages.
Table 1—List of Words for Dot-Probe Task With Frequency of Oc-
currence per Million in the British National Corpus 
Sleep Words Frequency Neutral Words Frequency
Tired 41 Clubs 38
Exhausted 15 Impatient 7
Fatigue 5 Paddock 2
Dream 46 Grass 41
Bed 159 Red 149
Sheets 24 Models 53
Wakeful 0 (20) Shufﬂe 3
Silence 3 Texture 9
Pillow 7 Scents 2
Naps 0 (14) Pear 2
Dark 135 Hour 113
Alert 16 Linen 10
Snoring 0 (25) Consist 12
Overactive 0 (22) Quantiﬁes 0 (11)
Arousal 4 Reforms 0 (30)
Sleepy 4 Absurd 10
Night 365 Money 374
Restless 7 Youthful 0 (5)
Tossing 2 Empower 1
Lethargy 1 Kinetics 2
Mean ± Sd 41.7 ± 87.95 Mean ± Sd 41.4 ± 87.96
Neutral Words Frequency Neutral Words Frequency
Graft 19 Males 22
Featuring 9 Scrubbing 2
Cushion 5 Specify 13
Meals 24 Chord 6
Led 154 Lot 246
Stairs 36 Mirror 39
Invoice 5 Prodigy 1
Playful 2 Tramped 1
Margin 15 Pencil 12
Tops 10 Laps 3
Book 248 News 145
Habit 23 Steel 37
Sandals 3 Potters 1
Attendants 2 Speculates 0 (27)
Invents 0 (20) Drafted 7
Graft 2 Disarm 1
Point 402 Water 350
Thankful 4 Entrants 5
Vaccine 4 Embrace 10
Wriggles 0 (1) Fixation 2
Mean ± Sd 48.4 ± 103.45 Mean ± Sd 45.2 ± 93.81
Note: When frequency of occurrence is less than 1 per million, as 
with several of the chosen sleep words, the range of sections in the 
British National Corpus (out of a maximum of 100) in which the 
word occurs is taken as a measure of frequency of usage; this range is 
given in parentheses in this table.
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Sleep Measures
(1) PSQI21 to assess for presence and severity of sleep distur-
bance.
(2) Anxiety and Preoccupation about Sleep Questionnaire 
(APSQ35) to assess for specific worry about sleep difficulties. 
(3) Morningness-Eveningness Questionnaire-Reduced Form 
(MEQ36) to assess preference for “morningness” or “eveningness” 
as an aid to classification of sleep disorder as PI or DSPS.
(4) Stanford Sleepiness Scale (SSS37) to quantify level of alertness 
during testing. 
PROCEDURE
 Following recruitment and screening by e-mail or telephone, 
potential participants were met at the University. All testing was 
conducted in a quiet private room in the Department of Psychol-
ogy. Subjects were given a brief written summary outlining the 
purpose of the study, stating that it was to “understand some of 
the reasons why people have difficulty sleeping.” No other details 
on the purpose or hypotheses lying behind the study were given 
at this stage and what would be required of them if they agreed 
to participate. Informed consent was then obtained. No financial 
remuneration nor course credits were offered for participation.
 Participants were then asked to complete the dot-probe task. 
Each participant viewed a set of instructions, on screen, and the 
task was explained verbally to ensure that it was fully understood. 
Following this, participants completed 4 practice trials, followed 
by the remaining 160 experimental trials. Pairs of words were pre-
sented in a random order, with rerandomization of the order for 
each participant, to ensure that order effects did not confound re-
sults. Each trial consisted of the following events: a fixation cross 
appeared in the center of the screen for 500 milliseconds, fol-
lowed by the pair of words for 500 milliseconds; the words then 
disappeared, and a dot-probe, consisting of an asterisk, appeared 
in either the upper or lower position; this remained on screen until 
the correct response key (upper or lower) was pressed. Half of 
the trials contained a sleep-related word, and there was an equal 
probability that the probe would replace the sleep-related or the 
neutral word. The relative positions (upper or lower) of each pair 
of words were also counterbalanced within the experiment. An 
intertrial interval of 1000 milliseconds followed each trial.
 A brief screening interview was then conducted to assess sleep 
history and general psychological state. This was done after the 
experimental task to minimize priming for sleep difficulties on 
the dot-probe. The screening interview covered items in Diag-
nostic and Statistical Manual of Mental Disorders, Fourth Edition 
and International Classification of Sleep Disorders criteria and the 
differential diagnosis of alternative sleep disorders, such as sleep 
apnoea and general mood state. Participants then completed the 
NART, the MEQ, and the SSS with the experimenter and the S-
SAI and CIQ by themselves. All participants then completed the 
PSQI, APSQ, BDI-FT, and S-TAI at home and filled-out a sleep 
diary each night over the next week. Those who reported sleep 
difficulties were also asked to wear an Actiwatch day and night 
for this week. 
 On their return visit, approximately 1 week hence, participants 
were fully debriefed as to the purpose of the study, and their sleep 
data was reviewed. All participants were given a copy of the Good 
Sleep Guide,38 and those who complained of either PI or DSPS 
were given some general advice, based on the Good Sleep Guide, 
in managing their sleep difficulties.
RESULTS
Participant Characteristics
 Mean age across all participants was 24.4 years (SD = 7.44 
years), with a total of 35 females and 28 males. In terms of group 
differences, ANOVA and post-hoc testing with the Tukey Hon-
estly Significant Differences (HSD) test demonstrated that the GS 
group was significantly older than the DSPS group (see Table 
2 for data). Given this finding, further analysis between groups 
used analysis-of-covariance (ANCOVA), with age as a covariate, 
followed by Tukey HSD test. ANCOVA and Tukey HSD across 
the 3 groups revealed significantly lower mean levels of state-
anxiety, trait-anxiety, and depression in the GS group (28.7, 31.5, 
and 0.5, respectively) in comparison with those with PI (37.9, 
47.7, and 3.6, respectively) or DSPS (35.6, 46.1, and 4.0, respec-
tively). No statistical difference was present between the PI and 
DSPS groups on these measures. No significant differences in vo-
cabulary level emerged between any of the groups. No difference 
between groups in either regular or actual recent caffeine intake 
was reported either (all p values > .3). 
Sleep-Related Questionnaire Measures
 The GS group scored significantly lower on the PSQI and 
APSQ than either the PI or DSPS groups. Individuals in the DSPS 
group were rated, by the MEQ, as significantly more “evening” 
type than the other 2 groups (lower scores on the MEQ reflect 
a greater tendency to “eveningness”). On average, participants 
in the PI and DSPS groups report themselves to be significantly 
less alert (as measured by the SSS) than their GS counterparts. 
Table 2—Participant demographics within the PI, DSPS, and GS 
Demo- PI DSPS GS F
2,59
a/  p Value
graphic (n = 21) (n = 22) (n = 20) χ2 (2)
Age  23.6 ± 6.9 21.8 ± 2.2 28.2 ± 10.1 4.50 ‡† .02
(years)
Sex, male/ 7/14  12 /10  9/11 1.96 ‡† .38
female 
BDI-FT 3.6 ± 3.1 4.0 ± 3.6 0.5 ± 0.7 5.90 ‡† .005
S-SAI 37.9 ± 8.3 35.6 ± 7.3 28.7 ± 7.1 5.95 ‡† .004
S-TAI 47.7 ± 11.4 46.1 ± 9.7 31.5 ± 5.7 15.54 ‡† < .001
NART 13.5 ± 7.7 10.8 ± 3.7 11.4 ± 4.7 1.38  .26
PSQI 9.8 ± 2.4 7.4 ± 2.4 2.6 ± 1.9 46.60 ‡† < .001
APSQ 56.9 ± 17.7 53.9 ± 15.5 20.2 ± 11.1 30.78 ‡† < .001
MEQ 11.5 ± 3.5 8.6 ± 2.6 13.8 ± 4.4 7.55*† .001
SSS 2.9 ± 1.2 2.8 ± 0.9 2.1 ± 0.8 5.04 ‡† .01
Data are presented as mean ± SD unless otherwise indicated. 
aAge df
2,60 
PI refers to primary insomnia; DSPS, delayed sleep-phase syndrome; 
GS, good sleeper; BDI-FT; Beck Depression Inventory-Fast Track; 
S-SAI, Spielberg State Anxiety Inventory; S-TAI, Spielberg Trait 
Anxiety Inventory; NART, National Adult Reading Test; PSQI, Pitts-
burgh Sleep Quality Index; APSQ, Anxiety and Preoccupation about 
Sleep Questionnaire; R-HOMEQ, Horne and Ostberg Morningness-
Eveningness Questionnaire; SSS, Stanford Sleepiness Scale
*Indicates signiﬁcant (p < .05) difference between PI and DSPS with 
Tukey posthoc Test.
‡Indicates signiﬁcant (p < .05) difference between PI and GS with 
Tukey posthoc Test.
†Indicates signiﬁcant (p < .05) difference between DSPS and GS with 
Tukey posthoc Test.
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However, SSS scores did not correlate directly with the dot-probe 
performance measures.
Sleep Data
Sleep Diary
 ANCOVA, with age as a covariate, across groups for subjective 
bed time, arise time, sleep-onset latency, wake after sleep onset, 
and total sleep time all revealed significant (p < .05) differences 
across the groups (see Table 3 for data). Posthoc testing with the 
Tukey HSD test confirmed that the DSPS group reported going to 
bed and rising from bed significantly later than the other 2 groups. 
Both PI and DSPS groups reported longer sleep-onset latencies 
than did the GS group, although they did not differ between them-
selves. WASO and number of nighttime awakenings were sig-
nificantly greater in the PI group in comparison with only the GS 
group. Total sleep time was equivalent across all 3 groups.
Actigraphy
 Actigraphy aided in making the diagnosis between PI and 
DSPS in individual cases. Furthermore, nonparametric circadian-
rhythm analyses39 of L5 (time of onset of lowest 5 hours of ac-
tivity) and M10 (time of onset of highest 10 hours of activity) 
confirmed that the phases of lowest and highest activity were, on 
average, significantly delayed (by around 2 hours) in the DSPS 
group, in comparison with the PI group (see Table 4 for data). 
Preparation of Response-Time Data
 Response times (RTs) from trials with errors were excluded, 
and those more than 2 SD above the mean were discarded as outli-
ers.15 As detailed earlier, 1 participant had an error rate above 5% 
and was therefore excluded from all analyses, and 1 further par-
ticipant was excluded as an “outlier,” with her results lying more 
than 2 SD from her group mean.
 ANCOVA, with age as a covariate, confirmed that the groups 
did not differ significantly (F
2,59
 = 1.97, p = .15) on error rate (1.5% 
of total data) or in outliers (F
2,59
 = 1.62, p = .21), which comprised 
a further 3.1% of the remaining data (see Table 5 for data). How-
ever, significant differences between the groups (F
2,9670
) = 151.17, 
p < .001) were evident on mean RT, with posthoc testing confirm-
ing that the PI group responded more quickly to all stimuli than 
the GS group who, in turn, responded more quickly to all stimuli 
than the DSPS group (see Table 5 for data).
 Table 5 also details mean RT for each stimuli combination (po-
sition of sleep word and position of probe). In order to assess 
whether systematic differences were present between groups and 
stimuli combinations, an attention bias score was calculated, in 
accordance with general practice in this literature.40 The attention 
bias score was calculated using the following equation: attention 
bias score = [(SleepUProbeL+SleepLProbeU)-(SleepUProbeU + 
SleepLProbeL)]/2 where Sleep = sleep-related word; U = upper; 
and L = lower e.g., SleepUProbeL represents the mean RT when 
the sleep-related word is in the upper position and the probe is 
in the lower position). The attention bias score summarizes the 
interaction between sleep-word position and probe position on 
RT, providing a measure of the relative speeding of RT to probes 
that appear in the same location as sleep-related words. Positive 
values reflect vigilance for sleep words relative to neutral words, 
whereas negative values reflect avoidance. 
 Mean and SD attention bias scores were +3.9 ± 9.4 for the PI 
group; +1.1 ± 8.3) for the DSPS group; and -2.5 ± 9.70 for the GS 
group. 
 It was predicted, a priori, that a greater degree of attention bias 
to sleep-related stimuli would be shown by the PI group in com-
parison with the DSPS and GS groups. Orthogonal contrasts, with 
an assumption of equal variances, on attention bias scores sup-
ported this prediction (t
60
 = -1.88, p = .03).
 It was also predicted, a priori, that the DSPS and GS groups 
would show an equivalent degree of attention bias, ie, no sig-
nificant difference would be observed. This prediction was also 
upheld (t
60
 = -1.27, p = .10). 
 Finally, the Pearson product-moment correlation coefficient 
was calculated between attention bias score and PSQI score to 
establish whether an underlying association existed across all 
participants. Although a positive correlation emerged, it did not 
reach statistical significance (r = +.19; p = .13). 
DISCUSSION
 Recent cognitive models of insomnia8,10 predict that individu-
als with PI, in comparison with GS, will demonstrate heightened 
vigilance for sleep-related stimuli. Results from this study pro-
vide support for this prediction. Those with PI, in comparison 
Table 4—Actigraphy L5 and M10 parameters for PI and DSPS 
Parameters PI DSPS t
41 
p value
 (n = 21)  (n = 22) 
L5 2:26 (61.7) 4:22 (70.6) -5.73 < .001
M10 11:40 (131.9) 13:11 (136.9) -2.22 .03
Data are presented as mean 24-h clock times with SD of minutes 
in parentheses. PI refers to primary insomnia; DSPS, delayed sleep-
phase syndrome.
Table 3—Sleep-Diary Parameters for the PI, DSPS and GS Groups 
Para- PI DSPS GS F
2,60 
p
meters (n = 21) (n = 22) (n = 20)   value
Bed  00:38 (46.1) 02:40 (83.0) 00:24 (55.5) 24.71*† < .001
Time
Arise  09:18 (51.3) 11:10 (72.7) 08:32 (87.1) 21.48*† < .001
Time
SOL 40.0 ± 20.8 31.1 ± 15.3 10.2 ± 8.8 15.37*† < .001
WASO 21.5 ± 29.0 18.7 ± 18.1 3.9 ± 5.3 5.58‡ .006
TST 442.0 ± 80.2 468.0 ± 65.8 474.1 ± 57.6 1.73 .19
Awake- 2.2 ± 2.1 1.33 ± 1.0 1.0 ± 1.2 5.28‡ .01
nings 
Data are presented as mean ± SD except for bed time and arise time, 
which are presented as mean 24-h clock times with SD of minutes in 
parentheses
PI refers to primary insomnia; DSPS, delayed sleep-phase syndrome; 
GS, good sleeper; SOL, sleep-onset latency; WASO, wake time after 
sleep onset; TST, total sleep time; Awakenings, number of awaken-
ings during the night
*Indicates signiﬁcant (p < .05) difference between PI and DSPS with 
Tukey posthoc Test.
‡Indicates signiﬁcant (p < .05) difference between PI and GS with 
Tukey posthoc Test.
†Indicates signiﬁcant (p < .05) difference between DSPS and GS with 
Tukey posthoc Test.
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with GS, showed relatively greater vigilance, as measured by the 
dot-probe task, for sleep-related stimuli. Although a positive cor-
relation between attention bias score and PSQI score (a measure 
of sleep quality) was demonstrated, it did not approach statistical 
significance. Nonetheless, results provide support for the specific 
prediction, from cognitive models of PI, that suggest attention 
bias is a component of this disorder.8,10 
 Two other findings emerged. Firstly, participants with DSPS, 
in comparison with GS, did not show significant evidence of at-
tention bias, as predicted. A second, notable, finding was the sig-
nificantly shorter RTs from the PI group, in comparison with GS 
and, in turn, with DSPS (see Table 5). There were no significant 
differences in overall error rates that might explain this as a speed-
accuracy trade off (indeed, overall error rates were low; see Table 
5). It is possible to speculate that those with DSPS are less alert 
(as shown by their higher SSS scores) than their GS peers, but this 
is unlikely to explain slowing because SSS scores per se did not 
predict dot-probe data. However, the speeded responses (in spite 
of their equally high SSS scores) of the PI group may be a reflec-
tion of increased arousal levels in this population, something that 
has been demonstrated in studies of physiologic aspects of PI.4,5 
 Self-report ratings in the DSPS group are also of some interest, 
with unexpectedly high levels of state-anxiety, trait-anxiety, and 
worry about sleep (see Table 2). Although differentiated, in this 
study, on a case-by-case basis from those with PI, there is clearly 
some overlap between the disorders. This raises the question of 
whether those with DSPS can form a “pure” enough control group 
against which to compare those with PI on psychological factors.41 
Indeed, some authors have suggested that circadian dysfunction 
may act as a precipitating mechanism in PI.42 Interestingly, in this 
study, there does appear to be some degree of phase delay in the 
PI group, with a relatively late L5 onset of 2:26 AM (see Table 4), 
although it should be borne in mind that the use of a relatively 
young University sample suggests that social factors may be a 
causal factor in this late L5. Perhaps future studies would be best 
served by screening more carefully for DSPS but still exercising 
caution in the interpretation of results from this group, with the 
assumption that some overspill of PI may be inevitable.
 There are several limitations in the current study that should be 
considered. Firstly, the sample was drawn from a university popu-
lation, thus narrowing the age and education range of the partici-
pants (see Table 2). Furthermore, students have greater flexibility 
to adjust work schedules than do those in regular (9:00 AM to 5:00 
PM) employment.43 Thus, failure to sleep at night, or perform at a 
set time of day, may pose less of a threat to (and hence less of a 
focus of attention for) both the PI and DSPS groups, than would 
occur in a comparative sample with regular employment. Thus, 
potentially, this study may underestimate the degree of atten-
tion bias in both of these groups. However, participants met both 
Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition and International Classification of Sleep Disorders-Re-
vised criteria for PI, and the mean PSQI scores for PI and DSPS 
groups were well above the mean for the GS group (9.8 and 7.4, 
respectively, versus 2.6). Furthermore, mean APSQ scores are 
comparable to those of a recent study on PI44 and indicate a sig-
nificantly greater degree of worry about sleep in the PI group and 
DSPS groups in comparison with the GS group (56.9 and 53.9, 
respectively, versus 20.1). In this case, the comparative levels of 
concern about sleep in the DSPS and PI groups are not reflected 
in the degree of attention bias, further supporting the argument 
that cognitive factors may play a role in PI, whereas physiologic 
factors may underpin DSPS. 
 Secondly, although this is a positive finding, discrepant find-
ings are not uncommon in the attention-bias literature, with the 
role of mood state often implicated in this.45 For example, in a 
study using the dot-probe task, Mogg et al46 failed to find evi-
dence of attention bias to exam-related stimuli in a high trait-anx-
ious population when testing was conducted out with the exam 
period. However, when exams were imminent, the processing 
bias appeared. Again, it is feasible that a larger effect would have 
been seen in our study if participants were tested at a time when 
sleep loss was a salient threat; for example, in the evening prior 
to an examination or other important event the following day. A 
testing laboratory in the middle of the day, with no cost attached 
to “poor” performance on the experimental task, may fail to acti-
vate dormant schema. However, when loss of sleep is imminently 
threatening, such as in the early hours of the morning, or when 
performance on a task is particularly valued, increased vigilance 
for indicators of sleep readiness (at night) or negative consequenc-
es of sleep loss (in the daytime) may be observed. This leads to 
a further limitation of the present study. It was not possible, for 
both practical and theoretical reasons, to adjust time of testing for 
participants’ circadian rhythms. Testing on the dot-probe task was 
conducted at the first available opportunity; hence, actigraphic 
assessment (which could potentially have provided information 
to set testing times according to individual circadian rhythms) 
followed the testing session. To wait until actigraphic assessment 
had been completed and then set specific testing times would 
have significantly increased the demands on participant time and 
would also have raised the possibility of priming to sleep-related 
Table 5—Overall Response Times, Error Scores, and Response Times for Word-Pairs
 PI (n = 21) DSPS (n = 22) GS (n = 20) F
2,59
/ F
2,9670
 p value
Errors 3.5 ± 4.1 2.0 ± 1.8 2.0 ± 2.1 1.97 .15
Overall RTs 384.2 ± 71.3 410.8 ± 75.4 397.1 ± 72.4 151.2*†‡ < .001
SleepU ProbeU 384.8 ± 73.7 410.1 ± 77.3 402.5 ± 75.9  
SleepU ProbeD 388.5 ± 66.6 409.1 ± 73.5 394.0 ± 66.9  
SleepD ProbeU 386.0 ± 68.7 410.9 ± 74.8 397.0 ± 72.7  
SleepD ProbeD 380.5 ± 75.2 410.1 ± 74.8 394.2 ± 69.1  
Data are presented as mean ± SD unless otherwise indicated. All response times (RT) are shown with errors ﬁrstly removed. PI refers to primary 
insomnia; DSPS, delayed sleep-phase syndrome; GS, good sleeper.
*Indicates signiﬁcant (p < .05) difference between PI and DSPS with Tukey posthoc Test.
‡Indicates signiﬁcant (p < .05) difference between PI and GS with Tukey posthoc Test.
†Indicates signiﬁcant (p < .05) difference between DSPS and GS with Tukey posthoc Test.
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stimuli. Nonetheless, this is something that would be of value to 
consider in future studies. 
 One potential limitation of this study was the inclusion of 
sleep-related words that might not be considered “sleep-threaten-
ing,” such as “pillows” or “nap.” However, the words used in this 
study were taken directly from previous work that elicited pre-
sleep cognitions of individuals with PI.29 Thus, it was predicted 
that they would be selectively processed by individuals with at-
tention bias to sleep-related stimuli. Indeed, even if the word sets 
used in this study were not considered to be sufficiently “threat-
ening,” this suggests that a magnified effect could be detected if 
alternate word sets were used. At the time of study development, 
this word set, taken directly from presleep cognitions, was felt 
to provide the most ecologically valid option. Furthermore, the 
DSPS group reported sleep difficulties equal to those of the PI 
group (as evidenced by PSQI scores, see Table 2), yet did not 
show equivalent attention bias scores, suggesting that the word 
set used in this case appropriately discriminated by sleep disorder, 
rather than simply reflecting the degree of “interest” expressed by 
individuals in sleep problems. 
 Alternate grouped categories of neutral words (eg, household 
items or animals) have been used in some studies of attention bias 
to limit the possibility that bias is shown as a result of target words 
falling into categories, rather than actual category itself being dif-
ferentially processed. The lack of categorized neutral words is a 
noted limitation of the present study. However, no effect of either 
neutral or sleep-related word lists was seen in the GS group, sug-
gesting that the systematic bias seen in the PI group is unlikely to 
have been purely the result of using a category in itself. Nonethe-
less, future studies utilizing this paradigm should consider devel-
oping matched categories for neutral word lists.
 Furthermore, although considered a relatively pure measure 
of attention,16 the dot-probe task has also been described as a 
“relatively fragile index of anxiety related attentional biases in 
non-clinical studies, particularly when using word stimuli that 
have relatively mild threat value.”47 A possible lack of emotional 
salience in the word-based stimuli may minimize the vigilance 
effect in the present study. Future studies might consider the use 
of a pictorial dot-probe paradigm to maintain the degree of ex-
perimental control available from the dot probe but maximize the 
possibility of uncovering processing biases by increasing the sa-
liency of stimuli.48 Furthermore, because RT is an indirect mea-
sure of vigilance, a future study might also consider the use of 
psychophysiologic measures of attention, such as heart rate49 or 
eye tracking,50 in order to add credence to results. 
 Notwithstanding these limitations, using a “hallmark” measure 
of attention bias and a carefully screened sample, our results offer 
evidence of attention bias in young people with PI; this is consis-
tent with cognitive models of PI.8,10 In particular, the results are in 
keeping with the attentional component of a proposed “attention-
intention-effort pathway” in the development of psychophysi-
ologic insomnia.9 Our findings also provide some support for the 
neurocognitive model of PI.51 This model suggests that those with 
PI have greater cortical arousal, something that may be reflected 
in the speeded RTs recorded in the present study. Notably, Perlis 
et al51 did not make recourse to attention bias as a maintaining fac-
tor in their model. However, our results would suggest that both 
aspects may operate, possibly in a complementary fashion, during 
the development of PI. 
 Finally, if attention bias is to be considered as a key element in 
the development or maintenance of PI, and not merely as an as-
sociative factor, further work to demonstrate a direct link between 
attention bias and PI is necessary. For example, the repeat admin-
istration of the dot-probe task at intervals when sleep difficulties 
are waxing and waning might demonstrate a concurrent increase 
and decrease in attention bias. Perhaps of even more interest 
would be to determine whether increasing attention to sleep-re-
lated material would lead to an increase in sleep difficulties, as 
has been suggested in parallel studies in the anxiety literature.52 
Furthermore, measurement of attention bias following successful 
and unsuccessful treatment for PI would be helpful, particularly 
with regard to the impact of sleep medication (effective in the 
short term) in comparison with the relatively enduring effects of 
cognitive behavioral treatment.
 Further work, utilizing pictorial stimuli, additional psycho-
physiologic measures, and carefully screened participants, is still 
necessary before definitive conclusions can be drawn on any po-
tential role of attention bias in PI. However, if further evidence 
emerges to support the findings of this study, it would be an im-
portant step in finding an “objective” measure of PI. At present, 
the cognitive arousal reported by those with PI is only measured 
by self-report; attention-bias tasks may offer the possibility of ob-
jective measures, sensitive to the experience of PI. 
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SUMMARY Psychophysiological insomnia (PI) is the most common insomnia subtype, representing
12–15% of all sleep centre referrals. Diagnostic guidelines describe PI as an intrinsic
sleep disorder involving both hyperarousal and learned sleep-preventing associations.
Whilst evidence for the ﬁrst component is reasonably compelling, evidence for learned
(conditioned) sleep eﬀects is markedly lacking. Indeed, to date no study has attempted
to capture directly the conditioned arousal eﬀect assumed to characterize the disorder.
Accordingly, the present study explored variations in subjective arousal over time in 15
PI participants (sleep onset type) and 15 normal sleepers (NS). Self-report measures of
cognitive arousal, somatic arousal and sleepiness were taken at three time points: 3 h
before bedtime (early to mid-evening); 1 h before bedtime (late evening); and in the
bedroom at lights out (bedtime) across four, 24-h cycles. Fluctuations in mean arousal
and sleepiness values, and in day-to-day variation were examined using analyses of
variance. Participants with PI were signiﬁcantly more cognitive aroused and signiﬁ-
cantly less sleepy relative to NS, within the bedroom environment. These results
support the tenet of conditioned mental arousal to the bedroom, although competing
explanations cannot be ruled out. Results are discussed with reference to extant
insomnia models.
k e yword s cognitive, conditioned arousal, psychophysiological insomnia, sleepi-
ness, somatic
INTRODUCTION
Insomnia, the most widely reported psychiatric symptom in
the UK (Singleton et al., 2001) and the main reason for
benzodiazepine prescribing in primary care (NICE, 2004),
disrupts sleep initiation and/or maintenance and promotes
daytime fatigue, decreased mood and general malaise (Ameri-
can Psychiatric Association, 1994). Presenting in 30% of
individuals occasionally, and 10–15% chronically (Foley et al.,
1995; Gallup Organization, 1991; Ohayon et al., 1997),
insomnia may be symptomatic of several disorders. When
contributing medical, sleep and psychiatric disorders are ruled
out, psychophysiological insomnia (PI) is usually diagnosed
[International Classiﬁcation of Sleep Disorders, second edition
(ICSD-2); American Academy of Sleep Medicine, 2005]. PI is
the most common insomnia subtype, representing 12–15% of
all referrals seen at sleep centres. Despite its prevalence,
underlying mechanisms for PI remain at best only partially
understood (Espie, 2002).
There is at least general acceptance as to what comprises PI.
For a diagnosis to be made, patients must exhibit (i) heightened
arousal and (ii) learned sleep-preventing associations, in the
context of diﬃculty initiating and/or maintaining sleep despite
adequate opportunity, with associated daytime impairment.
Heightened arousal may be physiological in nature, or reﬂect a
more cognitive hypervigilance pattern. Learned sleep-prevent-
ing associationsmay be in response to either internal cognitions,
or external stimuli. This notion, that PI is a disorder of
hyperarousal and conditioned sleep diﬃculty, has stood the test
of time, featuring in the original (ICSD: American Sleep
Disorders Association, 1990) and subsequent classiﬁcation
systems [ICSD-R (revised): American Sleep Disorders
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Association, 1997; ICSD-2), as well as in Research Diagnostic
Criteria for Insomnia (RDC-I; Edinger et al, 2005).
People with PI may be more aroused autonomically (Bonnet
and Arand, 1992, 1995; Freedman and Sattler, 1982; Monroe,
1967; Stepanski et al., 1989), or cortically (e.g. Freedman,
1987; Freedman and Sattler, 1982; Merica et al., 1998) than
either good sleepers (e.g. Merica & Gaillard, 1992; Lamarche
and Ogilvie, 1997) or patients with insomnia secondary to
major depression (Perlis et al, 2001). There are also data
suggesting elevated metabolic (Bonnet and Arand, 1995) and
higher adreno-cortical function (Adam et al., 1986; Johns
et al., 1971) in insomnia. Furthermore, data from thought
sampling (e.g. Broman and Hetta, 1994; Lichstein and
Rosenthal, 1980; Nicassio et al., 1985; Wicklow and Espie,
2000) and experimental cognitive manipulation studies (Ans-
ﬁeld et al., 1996; Gross and Borkovec, 1982; Hall et al., 1996),
indicate that PI is associated with elevated arousal in the form
of ruminative pre-sleep cognitive activity. Essentially, this is
what patients describe as a racing mind.
However, it remains unclear whether such cognitive and
somatic hyper- arousal are learned responses. Outcome data for
Stimulus Control therapy (SCT), arguably the most eﬀective
component of behaviour therapy for PI (Murtagh and Green-
wood, 1995; Morin et al 1999), only indirectly support sleep-
related conditioning in PI. Although SCT is based on the
premise that conditioned cues associated with successful sleep
should be separated from activities incompatible with sleeping
(Bootzin, 1972), there is little evidence that good sleepers and
insomnia patients actually diﬀer in their sleep (in)compatible
activities (Harvey, 2000; Haynes et al., 1974, 1982). Moreover,
the treatment eﬀectiveness of SCT cannot be taken as a reliable
demonstration of a presumptive underlying process. There is
also experimental clinical evidence that the temporal compo-
nents of SCT [regularizing sleep routines] are as eﬀective as the
situational (conditioning) components [re-establishing bedroom
cues for sleep] in reducing latency to sleep (Tokarz and
Lawrence, 1974), and that a countercontrol directive (sit up in
bed and read, watch TV etc. if unable to sleep) may also be
eﬀective (Zwart and Lisman, 1979). Such data present a
challenge to the conditioning model.
Even at the experiential/phenomenological level, we are
unaware of any study that captured directly self-reported
arousal changes associated with sleep preparation in PI relative
to normal sleepers (NS). This would seem to be a logical
starting point to consider whether or not PI patients de-arouse
in some respect diﬀerently from NS. In the present study,
therefore, process data on subjective arousal and subjective
sleepiness were gathered from PI and NS participants at three
time points: three hours before bedtime (early/mid-evening
after dinnertime); one hour before bedtime (late evening, quiet
wakefulness); and in the bedroom at lights out (bedtime).
These times were speciﬁcally chosen to track changes in
arousal as bedtime approached, and when entering the
bedroom environment.
Relative to the NS group, we hypothesized that PI
participants would report (i) greater cognitive and somatic
arousal (across time points), consistent with general hyper-
arousal, and (ii) elevated arousal and (iii) reduced sleepiness
speciﬁcally in the bedroom, consistent with the potential
situational conditioning eﬀects associated with the bedroom
environment.
METHOD
Participants
Participants (‡18 years) were recruited via email (University
and National Health Service), a local newspaper advertisement
and a Sleep Clinic waiting list. Potential participants were
screened for eligibility using UGSRL’s comprehensive sleep
interview schedule, and questionnaire measures of sleep
(Pittsburgh Sleep Quality Index [PSQI] – Buysse et al., 1989;
Epworth Sleepiness Scale [ESS] – Johns, 1991), sleep beliefs
(Dysfunctional Beliefs and Attitudes about Sleep Scale -10
item version [DBAS-10; - Espie et al., 2000) and depression
[BDI-II] - Beck et al., 1996).
For inclusion in the PI group, participants had to have PI of
sleep-onset type that was chronic (>6 months in duration)
(ICSD-2: American Academy of Sleep Medicine, 2005). In
addition PI participants had to score >6 on the PSQI, a
recognized cut-oﬀ for identifying signiﬁcant sleep disturbance
(Backhaus et al., 2002; Buysse et al., 1989), and <10 on the
ESS. NS participants did not meet criteria for PI, and reported
satisfaction with their sleep, and being typically good sleepers,
including during the past month (c.f. RDC-I criteria for NS).
NS also had to score <5 on the PSQI.
Similar to previous studies (e.g. Bonnet and Arand, 1997,
1998), exclusion criteria for both groups were (a) symptomatic
evidence of another sleep disorder (e.g. sleep apnoea, restless
legs syndrome or periodic limb movement disorder); (b) sleep
disturbance attributable to a psychiatric/medical condition, (c)
signiﬁcant depressive symptoms (>23 on the BDI-II), (d)
being on medication (for sleep or otherwise), or (e) receiving
psychological treatment (for insomnia or otherwise). Follow-
ing screening, four PI participants were excluded based on
BDI-II scores, one due to drug usage, and one due to
signiﬁcant medical problems.
A ﬁnal sample of 30 participants met inclusion criteria (15
PI, 15 NS), ranging in age from 18 to 53 years old, with an
average of 29.2 years. Sixteen were female and 14 were male.
All participants completed the study.
Measures
Arousal and sleepiness
The following measures were selected to capture the experience
of cognitive and somatic arousal, and sleepiness.
• The Pre-Sleep Arousal Scale (PSAS; Nicassio et al., 1985) is
a brief self-administered measure in which participants rate
the intensity of experienced arousal. Internal consistency for
somatic (8 items) and cognitive (8 items) subscales are
satisfactory (a ¼ 0.81 and a ¼ 0.76) respectively.
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• The Stanford Sleepiness Scale (SSS; Hoddes et al., 1973) is a
seven point Likert-type measure. Respondents provide a
rating to match the set of descriptors that best describes their
feeling of sleepiness at a given moment. The reliability of the
SSS has been reported as r ¼ 0.88 (Hoddes et al., 1973).
• The Neutral Cognitive Activity Scale (NCAS: Tang and
Harvey, 2004) is a 7-item self-report scale validated to
measure the intensity of neutral cognitive activity, i.e.
making no assumption about the content of individual
pre-sleep cognitive activity. The original scoring scale of 1–
10 was amended to a common 5-point scale, in order to be
consistent with other measures. According to our own data,
the NCAS was internally consistent in this revised format
(Cronbach a ¼ 0.921).
• The Arousal Level as Present State (ALPS) rating scale was
devised by the authors to yield point in time ratings of mental
arousal/alertness, physical tension, and sleepiness, utilizing a
common 5-point scale (1-not at all to 5-extremely).
Sleep
Participants completed a daily sleep diary (Espie, 1991) each
morning upon rising after the experimental night allowing
calculation of: (i) sleep onset latency (SOL), (ii) total sleep time
(TST), (iii) wake time after sleep onset (WASO), and (iv) sleep
eﬃciency (SE) ([total time slept/total time in bed] · 100),
Actigraphic data were also gathered as an objective estimate of
sleep, using Actiwatch AW4 units  (Cambridge Neurotech-
nology Ltd.). Actigraphy is a simple, non-intrusive measure
which estimates sleep parameters based on body movement
(Sadeh et al., 1995). Participants wore the Actiwatch continu-
ously on their non-dominant hand except during wet activities.
An event marker was depressed at lights out and upon rising.
Epoch length was 1 minute with sleep and wakefulness
determined by the programme algorithm; (i) SOL, (ii) TST,
(iii) WASO, and (iv) SE data were computed as per sleep diary
data.
Design and procedure
The study was designed as a mixed models anova with two
levels of the between subjects factor Group (PI, NS) and three
levels of the within subjects factor Time [three hours before
bedtime (T-3), one hour before bedtime (T-1), at bedtime (in
the bedroom) (T)]. Participants completed all measures at
home and were advised to follow their normal personal
schedules and routines, across a 4 night/day experimental
period. The duration of the study period (four 24-hour cycles)
was deemed suﬃciently long to capture any patterns in the
data being collected, while remaining manageable for partic-
ipants to adhere to. The experimental period occurred during
weekdays (Monday-Thursday), as it was postulated that
participants would be more likely to have a regular/consistent
bedtime than at a weekend. Potential participants were asked
at screening about their regular bedtimes, and were advised to
adhere to these during the study. After the study period,
questionnaire measures and actigraphs were returned, and a
single global compliance rating was completed. This comprised
the general question to what extent did you comply with the
instructions (relating to sleep diary completion at speciﬁed
times, arousal measure completion at speciﬁed times, and
actiwatch use) given to you at the start of the study? which
was rated 1 – not at all, 2 – slightly, 3 – moderately, 4 – a
lot through 5 – fully. Participants were debriefed, thanked,
and provided with a copy of The Good Sleep Guide (National
Medical Advisory Committee, 1993).
Data handling
All data were examined for normality of distribution and
logarithmic transformations (log to the base of ten) were
applied to skewed data. A ﬁrst set of anovas used mean values
for each time point across the four nights of the study, with
Bonferroni corrections applied to follow-up analyses (alpha
level set at 0.017). A secondary analysis was conducted using
standard deviation values for these means to investigate
variance (day-to-day variability) in relation to evening de-
arousal. BDI-II scores were entered into two analyses (ancova),
because of observed linear correlations (mental alertness rating
on the ALPS, SSS).
RESULTS
Participants
There were eight women and seven men in each experimental
group and mean ages were similar [PI ¼ 30.7 yr. (SD 10.7);
NS ¼ 27.7 yr. (SD 7.05)]. Descriptive clinical and sleep
information is presented in Table 1.
Table 1 Descriptive clinical data for the Psychophysiological Insom-
nia (n ¼ 15a) and Normal Sleeper (n ¼ 15) groups
Psychophysiological
Insomnia
[Mean (SD): medianb]
Normal Sleeper
[Mean (SD):
medianb]
PSQI 10.47 (2.2) 2.93 (1.28)
ESS 4.73 (2.94) 3.21 (1.72)
DBAS-10 4.24 (1.43) 3.21 (1.72)
BDI-II 7.27 (6.66) 2.13 (3.16)
SOL (diary) 61 (39.7): 53 11 (5.86): 10
WASO (diary) 37 (42.1): 23 4 (3.91): 3
TST (diary) 348 (79.4): 366 438 (49.5): 445
SE (diary) 78 (11.7): 80 97 (1.59): 97
SOL (actigraph) 30 (23.0): 21 12 (9.95): 9
WASO (actigraph) 56 (25.8): 50 59 (26.7): 54
TST (actigraph) 354 (61.8): 352 374 (56.8): 381
SE (actigraph) 80 (6.41): 82 84 (7.58): 85
PSQI (Pittsburgh Sleep Quality Index), ESS (Epworth Sleepiness
Scale), DBAS-10 (Dysfunctional Beliefs and Attitudes about Sleep
Scale – 10 item version), BDI-II (Beck Depression Inventory –II), SOL
(Sleep-Onset Latency: min), WASO (Wake time After Sleep-Onset;
min), TST (Total Sleep Time; min), SE (Sleep Efﬁciency, percent).
an ¼ 14 for actigraphy data.
bfor sleep data.
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Clinical characteristics
Neither group demonstrated clinically important daytime
sleepiness and there was no signiﬁcant between group diﬀer-
ence on the ESS. There was a non-signiﬁcant trend for PI
subjects to score higher than NS on the DBAS-10 (P ¼ 0.086).
PI participants had a higher PSQI index (10.5) than NS (2.9)
(t ¼ 11.47, P ¼ 0.0001) and more depressive symptoms on the
BDI-II (t ¼ 2.70, P ¼ 0.012). Nevertheless, both group means
were within the 0–9 BDI-II range, indicating minimal
depression.
Sleep comparisons
Subjective report
Mann-Whitney comparisons indicated that PI and NS partic-
ipants diﬀered on subjective SOL, WASO, TST, and SE (all
P < 0.001), with PI as expected reporting poorer sleep.
Actigraphy
One participant’s actigraphic data was lost due to faulty
equipment, therefore, these analyses were based on 14 partic-
ipants in the PI group. Again PI and NS diﬀered signiﬁcantly
in the expected direction on the primary sleep variable of
interest, SOL (P ¼ 0.008), with a near signiﬁcant eﬀect also on
WASO (P ¼ 0.063). There were no diﬀerences on the other
actigraphic sleep measures.
Arousal comparisons
Results for each of the four sets of dependent measures (PSAS,
SSS, NCAS, ALPS) are presented with associated graphical
illustrations (Figs 1–4).
Pre-sleep arousal scale
Analysis revealed a main eﬀect of Time (F (2,56) ¼ 53.77,
P < 0.0001), a main eﬀect of Group (F (1,28) ¼ 16.43,
P < 0.0001), and an interaction eﬀect of Group X Time (F
(2,56) ¼ 10.92, P < 0.0001) for the PSAS cognitive sub-scale
(see Fig. 1a). Signiﬁcant diﬀerences were found between the
groups three hours before bedtime, at T-3 (t (28) ¼ 2.63,
P ¼ 0.014), one hour before bedtime, at T-1 (t (28) ¼ 3.84,
P ¼ 0.001), and at bedtime, T (t (28) ¼ 5.08, P < 0.0001). On
this measure, therefore, PI participants were signiﬁcantly more
cognitively aroused than the NS group during the evening and
in the bedroom. Comparable results were obtained for a
secondary analysis using individual participant standard
deviation values to represent the variance around the mean.
Main eﬀects were signiﬁcant for Time (F (2,56) ¼ 66.98,
P < 0.0001), Group (F (1,28) ¼ 16.43, P < 0.0001) and
Group X Time (F (2,56) ¼ 13.80, P ¼ 0.004) and signiﬁcant
diﬀerences were observed between groups at all three time
points. Inspection of Fig. 1a shows that cognitive arousal
decreased in both groups over time, but that PI de-aroused less
than NS group, and the rate of change during the period T-1 to
T was greater in NS than in PI (P ¼ 0.023). Figs 1–4 also
display error bars, and it can be seen in Fig. 1a that the group
variance around the group mean also reduced over time in NS
relative to PI.
Analysis of the PSAS somatic sub-scale revealed a main
eﬀect of Time (F (2,56) ¼ 5.66, P ¼ 0.006) with non-signiﬁcant
trends for Group (F (1,28) ¼ 3.65, P ¼ 0.066) and for the
Group X Time interaction (F (2,56) ¼ 2.59, P ¼ 0.084). Like-
wise, analyses using standard deviation scores to represent
individual variability yielded a signiﬁcant Time main eﬀect
only (F (2,56) ¼ 7.37, P ¼ 0.011). Mean PSAS somatic sub-
scale scores can also be observed in Fig. 1b. There was a
greater reduction in somatic arousal from 1 hour before
bedtime to bedtime (T-1 to T) in NS relative to PI (P ¼ 0.014).
Stanford sleepiness scale
Results for the SSS comparisons are presented in Fig. 2.
ancova (with BDI-II as a covariate) revealed a main eﬀect of
Time (F (2,54) ¼ 78.78, P < 0.0001), and a Group X Time
interaction (F (2,54) ¼ 11.17, P < 0.0001) but no main eﬀect of
Group (F (1,27) ¼ 0.90, P ¼ 0.351). As can be seen in Fig. 2,
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Figure 1. (a) Mean arousal scores of the PI and NS groups at each
time point as measured by the cognitive subscale of the PSAS. (b)
Mean arousal scores of the PI and NS groups at each time point as
measured by the somatic subscale of the PSAS.
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there were no signiﬁcant diﬀerences between groups three
hours (t (23) ¼ 0.12, P ¼ 0.903) or one hour before bedtime
(t (28) ¼ 1.31, P ¼ 0.201). However, at bedtime the PI group
was signiﬁcantly less sleepy than the NS group (t (28) ¼ 3.14
P ¼ 0.004). These results suggest that the progressive incre-
menting of sleepiness displayed by the NS participants was
somehow curtailed in the PI group once they were in the
bedroom, although increases in sleepiness from T-3 to T-1
(P ¼ 0.027) and from T-1 to T (P ¼ 0.003) were both
signiﬁcantly greater in NS compared with PI.
Neutral cognitive activity scale
On this measure, anova revealed a main eﬀect of Time (F
(2,56) ¼ 60.23, P < 0.0001), a main eﬀect of Group (F
(1,28) ¼ 7.29, P ¼ 0.012), and an interaction eﬀect of Group
X Time (F (2,56) ¼ 13.32, P < 0.0001) for the mean data. No
signiﬁcant diﬀerences were found between the groups three
hours (t (28) ¼ 0.95, P ¼ 0.348) before or one hour before
bedtime (t (28) ¼ 2.44, P ¼ 0.021) [when strict Bonferroni
adjustments were applied]. However, at bedtime (t (22) ¼ 4.57,
P < 0.0001) PI participants reported signiﬁcantly greater
neutral cognitive activity; see Fig. 3. Analysis of night-to-
night variability scores as the dependent variable also yielded
main eﬀects for Time (F (2,56) ¼ 74.76, P < 0.0001), Group (F
(1,28) ¼ 8.40, P ¼ 0.014), and an interaction eﬀect for Group X
Time (F (2,56) ¼ 16.62, P < 0.0001). The graphed pattern of
results for the NCAS appears similar to the PSAS cognitive
sub-scale data (c.f. Fig. 1a). Again the standard error of the
mean in the NS group is much lower than that for the PI group
at bedtime, and there is a signiﬁcantly greater reduction in
cognitive activity in the NS group from T-1 to T (P ¼ 0.011).
Arousal level as present state
For the ALPS ratings of mental alertness, ancova (with BDI-II
as a covariate) was applied. Main eﬀects of Time (F
(2,54) ¼ 27.75, P < 0.0001), Group (F (1,27) ¼ 8.53,
P ¼ 0.007), and Group X Time (F (2,54) ¼ 12.07,
P < 0.0001) were obtained. PI participants were signiﬁcantly
more alert than NS during late evening (t (22) ¼ 2.88,
P ¼ 0.009) and in the bedroom (t (28) ¼ 4.44, P < 0.0001).
However, no between group diﬀerence was found in mental
alertness three hours before bedtime (t (28) ¼ 1.24, P ¼ 0.23)
(Fig. 4). Consistent with this was the ﬁnding that reduction in
ALPS mental alertness was greater from T-1 to T in the NS
than in the PI group (P ¼ 0.001). In terms of physical tension,
anova revealed a main eﬀect of Time (F (2,56) ¼ 19.9,
P < 0.0001) but no main eﬀect of Group (F (1,28) ¼ 1.22,
P ¼ 0.278), or Group X Time (F (2,56) ¼ 0.88, P ¼ 0.419).
There were no signiﬁcant reductions in physical tension in the
NS group relative to the PI group during either the T3 to T1,
or the T1 to T periods. The ALPS sleepiness rating revealed a
main eﬀect of Time (F (2,56) ¼ 114.40, P < 0.0001), and an
interaction eﬀect of Time X Group (F (2,56) ¼ 8.18, P ¼ 0.001)
but no Group main eﬀect (F (1,28) ¼ 2.10, P ¼ 0.159). No
signiﬁcant diﬀerence was found between groups three hours
(t (23) ¼ 0.35, P ¼ 0.733) or one hour before bedtime
(t (22) ¼ 0.82, P ¼ 0.424). However, at bedtime, NS had
higher sleepiness ratings than PI (t (24) ¼ 3.34, P ¼ 0.003) and
the increase in sleepiness from T1 to T was also signiﬁcantly
greater in normal sleepers (P ¼ 0.010). These results closely
parallel our SSS data, with PI participants appearing to be less
sleepy in the bedroom than NS.
Compliance with experimental instructions
Participants in both groups reported high levels of compliance.
The mean global compliance rating scale score was 4.53
(SD ¼ 0.51) out of a possible 5, with no signiﬁcant diﬀerences
between PI and NS. Importantly, these data indicate that
participants reported completing the arousal measures (our
dependent variables) at the stated times as directed by the
research protocol. The scale provided space for participants to
report any particular areas of non-compliance. Few completed
this section at all, presumably due to high reported compliance
in both samples. Amongst those who did give free text
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comments, several reported that they had forgotten to press
the actigraph event marker button on one or more occasion.
DISCUSSION
As far as we are aware, this is the ﬁrst study to examine
systematically the process of self-reported de-arousal, during
the pre-sleep period, in people with insomnia relative to
normal sleepers. In particular, we compared people with PI
(sleep-onset type) with normal good sleepers, across three
evening time points, to test the conventional wisdom that
arousal diﬀerences between groups would be, at least in part,
situation dependent, consistent with a conditioned arousal
model of insomnia.
Our results, ﬁrst of all can be interpreted in terms of general
hyperarousal theory regarding insomnia (e.g. Bonnet and
Arand, 1995). For example, on the cognitive subscale of the
PSAS, the PI group had elevated scores at all three time points.
This higher level of mental activation, present at least 3 hours
prior to bedtime and in the living areas of the house rather
than in the bedroom, is suggestive of cognitive hyperarousal in
PI relative to NS. Concurrent validation that this ﬁnding was
robust at one hour pre-bedtime (but not at three hours) was
obtained using a novel present state rating of mental
alertness.
Interestingly, our parallel subjective measures of somatic
arousal (PSAS somatic sub-scale, ALPS physical tension
rating) demonstrated only a Time main eﬀect. That is, the
groups were similar at each observation and reductions were
observed over time in both NS and PI, but not at diﬀerential
rates. Objectively gathered data have shown arousal diﬀer-
ences between insomnia and good sleepers, on numerous
physiological dimensions (see Introduction, this paper), so it
may be that using self-report alone is insensitive to this arousal
domain. Alternatively, there may be validity problems with
either the PSAS or the ALPS, or both, as measures of self-
reported somatic arousal. Consequently we calculated corre-
lation co-eﬃcients to estimate concurrent validity. These
demonstrated satisfactory validity 3 hours before bedtime
(r ¼ 0.788), 1 hour before bedtime (r ¼ 0.759) and at bedtime
(r ¼ 0.795). In practice, clinicians work primarily with the
phenomenology of insomnia, and our data (showing that
mental measures at least are sensitive) are consistent with the
replicated ﬁnding that people with PI generally complain more
about cognitive than somatic symptomatology (see reviews by
Espie, 2002; Harvey, 2002).
However, we found stronger evidence consistent with
arousal conditioning to bed-time itself and/or to the bedroom
environment. Four out of seven analyses showed signiﬁcant
eﬀects in support of less de-arousal at bedtime in the PI group.
Furthermore, analyses of change scores consistently found that
there were more sizeable reductions in cognitive activation,
and greater increases in sleepiness, in normal sleepers in the
period from 1 hour prior to bedtime and bedtime itself than
there were in people with insomnia. There is also evidence
from inspection of standard error bars of considerable
homogeneity in such de-arousal responses in normal sleepers.
Although such results appear to be broadly supportive of the
conditioning model of PI, we cannot discriminate from our
data between bed-time and the bedroom environment. Our
third and ﬁnal time sample was taken, at bedtime within the
bedroom. A future study may better discriminate these factors
by taking an additional time sample at bedtime, but prior to
participants entering the bedroom environment. Nevertheless,
relative to NS, people with PI were signiﬁcantly more aroused
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on measures of neutral cognitive activity once in the bedroom,
and they were signiﬁcantly less sleepy, in the context of there
being no group diﬀerences at the earlier time points. This may
suggest that there is a link between going to bed and the
individual’s arousal gradient. However, PI participants were
not more alert once in the bedroom compared with NS. Rather,
both groups appeared to de-arouse in the lead up to bedtime,
but PI de-aroused to a markedly lesser extent. In terms of our
subjective sleepiness data, a similar pattern (although in
reverse) was observed. That is, both groups showed increased
sleepiness over time, but the PI group less so. This is consistent
with the idea that failure to de-arouse may be typical of
insomnia (Espie, 2002; psychobiological inhibition model).
Compared with the NS experience, it seems possible then that
the process of retiring to bed failed to act as a discriminative
stimulus for further de-arousal (and ensuing sleep) in the PI
group (c.f. Bootzin, 1972; stimulus control model).
Further research is required with detailed deﬁnition of
arousal changes over time. We only had three data points;
insuﬃcient to clarify, for example, whether linear changes in
de-arousal occur over time. Liberal interpretation of the
graphs might suggest that the rate of de-arousal between T-1
and T was not merely a linear extension of the de-arousal
between T-2 and T-1, as might be expected if only Process S
and C were operating. Rather, the apparent increase in de-
arousal (and sleepiness) at bedtime may suggest that an
additional mechanism such as conditioned de-arousal is indeed
operating. Another advantage of using multiple time points to
obtain a ﬁne grain picture would be the opportunity to
examine highly speciﬁc situational eﬀects that might be crucial
to the stimulus control model (e.g. entering the bedroom,
getting into bed, putting the light out, watching television,
talking in bed etc.).
Of course, competing explanations unrelated to condition-
ing should also be considered. The ﬁnding regarding elevated
neutral cognitive activity may reﬂect a cognitive arousal
anticipation eﬀect, or heightened sleep eﬀort (Broomﬁeld
et al., 2005; Espie et al, 2006; attention-intention-eﬀort path-
way). It is possible that PI participants became preoccupied
with sleep once they have decided when to go to bed, resulting
in cognitive arousal. Indeed, PI patients reﬂect on their sleep
(problem) at any time of the day or night (Harvey, 2002;
cognitive model). It could be that such anticipation and
monitoring simply becomes more focused proximal to bed-
time. The observed group diﬀerences on sleepiness level in the
bedroom could be inﬂuenced also by circadian timing.
Whereas we attempted to screen out participants with explicit
circadian phase delay, it is possible that circadian physiology
may play some role in insomnia, just as insomnia factors may
be problematic to separate from the clinical presentation of
circadian rhythm sleep disorders (Lack and Bootzin, 2003).
Clearly, our ﬁndings should be taken as preliminary.
Further work is required using similar prospective methodo-
logy, with concurrent psychophysiological measurement (heart
rate, skin conductance) alongside self-report data. Cortical
arousal (as measured by qEEG methods) may be particularly
fruitful to explore because this has been posited as the primary
feature of conditioned arousal in PI (Perlis et al., 1997:
neurocognitive model) and because cortical activity might be
reasonably regarded as the neurobiological substrate of
cognitive activation. We also relied heavily upon self-reported
sleep to deﬁne our samples and future studies might include
polysomnographic screening to objectively exclude possible
occult sleep disorders other than insomnia. Interview and self-
report screening measures cannot reliably achieve this, and
although we used actigraphy, which partially conﬁrmed
subjective sleep problems in our sample, the role of actigraphy
in insomnia assessment continues to be a matter of some
debate (Ancoli-Israel et al., 2003).
We attempted to measure compliance, but this was retro-
spective and likely to be subject to experimental demand
characteristics. We suggest, therefore, that palm pilot tech-
nology might be useful to time lock the self-report data to
simultaneous assays of somatic data. Our sample, though
carefully screened, was small in number. Replication of the
eﬀects we have demonstrated is also required in treatment-
seeking individuals with PI. Finally, there are pros and cons to
exploring arousal phenomena in natural settings (the bedroom
at home) versus experimental settings (in lab). Home-based
study maximizes ecological validity; whereas lab studies
improve reliability of measurement. There is relatively little
evidence to support the view (stated in diagnostic criteria) that
PI patients sleep better away from home. Consequently, we
suggest that methodological reﬁnements of the type suggested
above should be undertaken ﬁrst of all under rigorous
laboratory conditions, where direct measures of somatic
arousal can also be achieved, and then generalized to the
home environment.
In conclusion, arousal and sleepiness data from the present
study are consistent with hyperarousal and conditioned
arousal in insomnia. These are not mutually exclusive per-
spectives. It appears that diﬃculties with the normal process of
bed-time de-arousal may characterize the experience of PI.
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Espie and colleagues [(2006). The attention–intention–effort pathway in the development of psycho-
physiological insomnia: a theoretical review. Sleep Medicine Reviews, 10, 215–245] propose a route into
psychophysiological insomnia along the attention–intention–effort pathway which focuses on the
inhibition of sleep-wake automaticity. A contributing factor to this is selective attention to sleep
(alongside explicit intention to sleep and effort in the sleep engagement process). Following on from
previous work on selective attention to sleep [Marchetti, L. M., Biello, S. M., Broomﬁeld, N. M., Mac-
Mahon, K. M. A., & Espie, C. A. (2006). Who is pre-occupied with sleep?. A comparison of attention bias in
people with psychphysiological insomnia, delayed sleep phase syndrome and good sleepers using the
induced change blindness paradigm. Journal of Sleep Research, 15, 212–221; MacMahon, K., Broomﬁeld,
N., Macphee, L., & Espie, C. A. (2006). Attention bias for sleep related stimuli in primary insomnia and
delayed sleep phase syndrome using the dot-probe task. Sleep, 29, 11] and considering the importance of
monitoring both internal and external cues in the maintenance of insomnia, as highlighted in the
cognitive model of insomnia [Harvey, A. G. (2002). A cognitive model of insomnia. Behaviour Research and
Therapy, 40, 869–893], a cognitive probe task was employed to investigate further the role of the clock as
a focus of selective attention in those with primary insomnia.
A 2  2 between participants design comparing reaction time of individuals with primary insomnia
(n ¼ 22) and normal sleepers (n ¼ 22) on a modiﬁed Posner paradigm. Responses obtained from
a computer task presenting times which fall within a normal sleep period were analysed.
Individuals with primary insomnia demonstrated delayed disengagement to the clock (F(1,84) ¼ 6.9,
p < 0.05) which is taken as further support for previous research demonstrating that individuals with
primary insomnia exhibit an attentional bias to sleep related stimuli.
These results lend support to the attention–intention–effort model (Espie et al., 2006) and the cognitive
model (Harvey, 2002) both of which recognise the importance of selective attention towards salient
stimuli in the maintenance of insomnia. Possible clinical implications of attentional bias to sleep as
a marker of psychopathology progression and treatment efﬁcacy are discussed.
 2008 Elsevier Ltd. All rights reserved.Introduction
Insomnia
Primary insomnia (PI) is reportedly found in 3% of the pop-
ulation in western industrialised countries (Ohayon, 1996, 2002).
According to diagnostic criteria, heightened arousal and learned
sleep preventing associations form the foundations of this disorder,
with patients exhibiting excessive focus upon and anxiety aboutgy, University of Glasgow,
s).
All rights reserved.sleep (American Sleep Disorder Association, 1997 & 2005, DSM-IV;
American Psychiatric Association, 1994). Numerous authors
contend that PI is the result of a number of psychological factors,
such as maladaptive beliefs about sleep or excessive pre-sleep
intrusive thoughts (Harvey, 2002; Espie, 2002; Morin, 1993).
Espie, Broomﬁeld, MacMahon, Macphee, & Taylor (2006)
propose a route into PI along the attention–intention–effort
pathway which focuses on the inhibition of sleep–wake automa-
ticity. In their conceptual paper, the authors propose that inhibition
of sleep–wake automaticity can be attributed to three processes;
selectively attending to sleep, explicitly intending to sleep and
introducing effort into the sleep engagement process. This model
has been developed by drawing on parallels in the anxiety disorder,
H. Woods et al. / Behaviour Research and Therapy 47 (2009) 231–236232alcohol and drug abuse literature as well as recent clinical and
experimental studies on insomnia. The cognitivemodel of insomnia
(Harvey, 2002) likewise highlights the importance of monitoring
both internal and external cues in the maintenance of insomnia.
Selective attention to sleep
An attentional bias is said to have developed when the attention
system becomes sensitive or selective to a particular theme and
impacts on the individual’s cognitions. Espie et al. (2006) suggest
that the attentional systems of individuals with PI are particularly
sensitive to sleep. Several studies have now been carried out
establishing a selective attention to sleep in PI using the ICB ﬂicker
paradigm and sleep related objects (Marchetti, Biello, Broomﬁeld,
MacMahon, & Espie, 2006), using the dot probe task and sleep
related words (MacMahon, Broomﬁeld, Macphee, & Espie, 2006)
and in a cancer population who have developed sleep onset difﬁ-
culties (Taylor, Espie, & White, 2003).
Clock monitoring
There is widespread evidence that individuals with insomnia
attribute their difﬁculty with sleep to excessive pre-sleep worry
with PI being 10 times more likely to attribute their sleep distur-
bance to cognitive arousal compared to somatic arousal (Lichstein &
Rosenthal,1980). The items implicating cognition as themajor cause
of the sleep disturbance (e.g. ‘My mind keeps turning things over’)
on the Sleep Disturbance Questionnaire are the most highly rated
(Espie, Brooks, & Lindsay, 1989; Harvey, 2001). Therefore, we ﬁnd
ourselves at the juncture of having established that pre-sleepworry
contributes to PI but still unable to identify a trigger for such worry.
From clinical practice it is proposed that PI selectively attend to
and monitor for sleep related cues such as body sensations which
are consistent or inconsistent with falling asleep and the environ-
ment for signs of not falling asleep (Harvey, 2002). One of the sleep
related cues associated with the stress of not falling asleep is the
bedside clock. Subjective reports highlight two types of clock
monitoring in PI; how long the individual has been in bed without
sleep and how many hours are left before they have to start their
day (Bearpark, 1994; Harvey, 2002). Following from this, Tang,
Schmidt, & Harvey (2007) investigated the association between
clock monitoring, pre-sleep worry and sleep. Thirty-eight PI were
instructed to either monitor a clock or a digital display unit as they
were trying to get to sleep. The clock monitoring task was rated as
more worry provoking and interfered with sleep more than the
digital display monitoring task. The clock monitoring PI reported
more pre-sleep worry and longer SOL on the experimental night
compared to baseline. Hence, in the clock displaying sleep times,
we have an ecologically valid stimulus which is relevant in both the
perspective of the patient and clinical research but also within
everyday life. Most people would be able to recall at least one
occasion where sleep eluded them while being aware the time to
rise was approaching.
Cognitive probe task
The aim of this study was to investigate further the role of the
clock in the development and maintenance of PI, by bringing
together the work discussed above with selective attention in PI
and the real life experimental and clinical work carried out previ-
ously which provided valuable subjective reports of the impact of
the clock and time monitoring on sleep in PI.
Although the paradigms previously used to establish an atten-
tional bias to sleep in PI are recognised as legitimate measures of
attentional bias, it was felt that using a modiﬁed Posner paradigmwould enable a purer measurement of engagement and disen-
gagement to particular cues presented to the participants.
Posner has suggested that the attention system comprises
measurable cognitive components (shift, engage, disengage; Pos-
ner, 1980), which are subserved by speciﬁc, neural sub-systems
(Posner & Petersen, 1990) and which are open to modulation by
negative emotional stimuli (Stormark, Laberg, Bjerland, Nordby, &
Hugdahl 1995). In the original Posner cue-target paradigm,
participants responded to a target appearing in the same (valid) or
opposite (invalid) location as a previously presented cue. Results
indicated faster detection of targets on cued trails, particularly at
short (<200 ms) cue-target intervals. This facilitation effect was
taken as evidence of the time-cost of disengaging attention from
the cue to the target on invalid trials (Posner and Petersen, 1990;
Posner, 1988). Over recent years, researchers have begun to apply
Posner’s attention model to develop a paradigm which can deter-
mine whether threatening stimuli can attract attention, i.e.
modulate the engagement component of covert attention, and/or
hold attention, i.e. modulate the disengage component (Broomﬁeld,
Gumley, & Espie, 2005).
Methods
Aims and hypotheses
The aim of this study was two-fold. First, by presenting a picto-
rial representation of an ecologically valid stimulus, to obtain
objective evidence of the inﬂuence upon attention of monitoring
the clock when set at sleep times and therefore the suggestion of
the clock and sleep time as a precursor to pre-sleep worry. Second,
to explore systematically, with regard to the components of the
attentional system, whether participants would take longer to
categorise the target on invalid trials with PI having the longest
reaction times due to delayed disengagement from this salient cue
compared to normal sleepers (NS).
Design
A 2  2 between-participant design was employed for this
experiment comparing NS and PI on validly and invalidly cued
trials. All subjects recruited completed the computer task followed
by the questionnaires detailed below. On completion of these,
subjects were preliminarily assigned to either NS or PI group. Thus,
it is important to note that the sleep quality for each participant
was not known to the experimenter until the computer task was
completed as well as any priming effect on the participants being
minimised.
Participants
Participants were recruited through advertising online within
the University of Glasgow, a poster campaign around the university
campus and through advertising on the psychology department’s
undergraduate student portal for students to obtain course credits.
Each individual was given an appointment time to come into the
department but was given no further information on the nature of
the experiment, other than that it involved a computer based task.
Sleep quality assessment
The sleep quality assessment had three components:
 an interview structured around the ICSD-2 statement of criteria
for psychophysiological insomnia and the DSM-IV statement
of criteria for primary insomnia;
H. Woods et al. / Behaviour Research and Therapy 47 (2009) 231–236 233 a self-report component where participants completed the
Reduced Horne and Ostberg Morningness–Eveningness Ques-
tionnaire (MEQ-RF) and the Pittsburgh Sleep Quality Index
(PSQI);
 actigraphy to conﬁrm or discount information gained from the
Horne and Ostberg questionnaire.
After completion of the computer task, those subjects meeting
PI criteria were given an actiwatch to wear and sleep diary to
complete for 5 days. These measures helped to conﬁrm diagnosis of
PI and to discount any circadian disorder based on data obtained
from the MEQ-RF alongside the PSQI such as delayed sleep phase
syndrome. Normal sleepers were not given actiwatches due to the
conﬁrmatory nature of the actigraphy within this study. Actigraphy
was conducted by the Cambridge Neurotechnology ‘Actiwatch’
system. This comprises a wrist worn unit ( model AW-4), roughly
the size of a small wristwatch, and sleep analysis software (Acti-
watch Sleep Analysis v 1.06), capable of automatically calculating
sleep parameters. There is a general consensus that wrist actig-
raphy provides an accurate, objective estimate of circadian sleep
and wake parameters (Tyron, 2004).
Inclusion/exclusion criteria
Participants met combined DSM-IV and ICSD-2 criteria for
primary insomnia as well as scoring >6 on the PSQI. PI exclusion
criteria included active psychological or drug interventions for
sleep problems or when a sleep disorder other than insomnia was
suspected. NS were required to score <5 on the PSQI, report no
problems with their sleep and have no history of sleep problems.
For both groups, scoring above 20 on the Beck Depression Inventory
– Short Form (BDI-SF4) resulted in exclusion from analyses. The
Spielberger State and Trait Anxiety Inventory was used to provide
a comparative measurement of anxiety between NS and PI but was
not used for exclusion purposes.
All participants had normal vision or corrected to normal vision.
Final allocation of participants to groups for the purposes of anal-
ysis did not take place until all sleep assessment data had been
collated. No formally screened participants were excluded due to
either psychological or drug interventions for sleep or because of
substance misuse. However, eight participants were excluded for
failure to return all questionnaire measures.Fig. 1. Presentation sequence and times of the modiﬁed Posner paradigm. The trial is valid
clock showing a sleep time. The trial is invalid when the target is presented on the opposi
attentional engagement while an invalid trial provides a measure of attentional disengagemA total of 44 participants were left that met all relevant criteria
and completed all measures, 22 classiﬁed into PI and 22 into NS.
A power calculation carried out prior to the study suggested that 21
participants would be required in each of the groups to detect
statistically signiﬁcant differences at a power of 0.8 with an alpha
level set at 0.05.
Apparatus and stimuli
A Tiny Mediabook 380 and the experiment-generation package
SuperLab 2.1 (Cedrus Corporation, San Pedro, CA) were used to
implement the Posner paradigm. The size of the screen was 38 cm
(diagonally). Millisecond timing was recorded through SuperLab
Pro and keyboard input.
The sleep related stimuli presented was a photograph of
a digital clock showing a time which is usually associated with
sleeping in a normal sleep pattern, e.g. ‘02:00’ (see Figs. 1 and 2
for diagrammatical representations of stimuli and paradigm). The
stimulus set consisted of 20 digitised pictures of single stimuli.
Twenty pictures were presented on the clock in the left hand box
and 20 in the right hand box. Target stimuli were either two
horizontal dots (..) with a diameter of 0.3 cm or two vertical dots
(:) with a height of 0.3 cm. Cue and target stimuli were presented
inside two boxes (6 cm high and 10.6 cm wide) and positioned
2.0 cm to the left and to the right of the central ﬁxation point
(cross shape). These boxes were continually presented on the
screen. Participants were given four practice trials to ensure they
were comfortable with completing the task.
Procedure
Individual trials consisted of a ﬁxation cross, presented for 1 s,
followed by the clock picture displayed for 250 ms. Targets were
then presented in the same or different box (central to where one
of the pictures was positioned) and remained on the screen until
response. If the participant saw a target which was vertical, they
were instructed to press C on the computer keyboard, if the target
was horizontal, then they were instructed to press M. When the
target is presented in the box on the same side as the stimuli, this
is considered a valid trial. However, if the target is presented in
the other box on the other side of the computer screen, this is
considered an invalid trial. Latencies to detect these targets werewhen the target is presented on the same side of the screen as the pictorial cue of the
te side of the screen as the cue (as shown above). A valid trial provides a measure of
ent.
Fig. 2. Enlarged image of the clock showing a sleep time. This is an example of the stimulus used as a cue in the modiﬁed Posner paradigm.
H. Woods et al. / Behaviour Research and Therapy 47 (2009) 231–236234used to index the extent to which the groups show an attentional
bias. Participants were asked to complete the task as quickly as
possible and to remain ﬁxated on the central cross at all times
(Figs. 1 and 2).
After completion of the task and the questionnaire pack, the true
purpose of the experiment was explained. Participants who were
thought to meet criteria for PI were then asked to wear an acti-
watch and to complete a sleep diary for ﬁve nights following the
experiment.
On return of the actiwatch and sleep diary 1 week later, each
participant was given a copy of the Good Sleep Guide [prepared by
Professor Colin A. Espie for the National Medical Advisory
Committee (1994) and now recommended by the British Sleep
Society]. Participants were also provided with contact information
in case they wanted to be informed of the outcome of the project
when it was completed.Results
The experimental population was equally split between males
and females with a mean age of 24 years. Table 1 shows the
demographics for each sleep quality group (PI and NS) along with
clinical data.
BDI and trait anxiety scores were not signiﬁcantly different but
PI participants had higher state anxiety (F(1,42) ¼ 4.92, p < 0.05)
which could viably reﬂect an increase in arousal due to presenta-
tion of a ‘negative’ cue.
Table 2 presents summary scores for self-reported sleep data.
Analyses revealed a signiﬁcant effect of group at the level of PSQI
with PI having poorer sleep (F(1,42) ¼ 160.2, p < 0.0001). Total
sleep time (TST) was also signiﬁcantly different (F(1,42) ¼ 22.34,
p ¼ 0.0001) with PI reporting around 5 h of sleep compared to NS
7 h. Sleep onset latency (SOL) was also signiﬁcantly different
(F(1,42 ¼ 165.88, p ¼ 0.0001) with PI taking approximately 45 min
to fall asleep compared to 9 min for NS.
Fig. 3 showsmean (SE) reaction times on both valid and invalid
trials for PI and NS. To assess whether PI was associated with an
attentional bias towards sleep related times, we conducted a 2
(group: PI and NS)  2 (cue location: valid and invalid trial) ANOVATable 1
Demographic and clinical data.
PI (n ¼ 22) NS (n ¼ 22) Between group
analyses
M SE M SE
Age (years) 24.4 2.1 23.7 1.8 NS
Gender (% female) 50 50 NS
BDI 2.1 0.47 2.2 0.4 NS
STAI 47.9 2.48 44.6 2.6 NS
SSAI 38.2 1.8 32.2 2.0 p < 0.05
BDI, Beck depression inventory; STAI, Spielberger Trait Anxiety Inventory; SSAI,
Spielberger State Anxiety Inventory. Signiﬁcant differences were found between NS
and PI on the state anxiety measure which suggests an increase in arousal due to
presentation of a salient cue. NS and PI did not differ in mean age, gender split,
depression or trait anxiety scores.of the RT data. This revealed a signiﬁcant result for cue location
(F(1,84) ¼ 10.53, p ¼ >0.01) as well as a signiﬁcant two way
interaction between group and cue location (F(1,84) ¼ 8.98,
p ¼ >0.01). We did not obtain a signiﬁcant result for group
(F(1,84) ¼ 0.51, p ¼ 0.48).
In order to break down the interaction we then examined the
data for sleep quality (NS vs. PI) and cue location (valid vs. invalid)
separately. Scheffe tests were carried out to make comparisons
between means for selected factors. Signiﬁcant results were found
between NS and PI for invalid trials (F(1,84) ¼ 6.9, p < 0.05) and
between invalid and valid trials for PI (F(1,84) ¼ 19.5, p < 0.00001).
These results suggest that PI were slower to respond on invalid
trials than NS suggesting a delayed disengagement from the clock
cue. There was no signiﬁcant difference between valid and invalid
trials for NS or between NS or PI on valid trials.
Discussion
The purpose of this study was two-fold. First, by presenting
a pictorial representation of an ecologically valid stimulus, our aim
was to obtain objective evidence of the inﬂuence upon attention of
monitoring the clock, when set at sleep related time, and therefore
the suggestion of the clock as a precursor to pre-sleep worry.
Second, we aimed to explore systematically, with regard to the
components of the attentional system, whether participants would
take longer to categorise the target on invalid trials, with PI having
the longest reaction times due to delayed disengagement from this
salient cue compared to NS.
In line with our hypothesis we found PI showed delayed
disengagement from sleep related times. With reference to Fig. 3,
we can see that PI show a speeding effect on valid trials and
a delayed response on invalid trials. The salience of the alarm clock
cue is holding the attention of PI which enables them to process the
target faster when it appears in the position vacated by the cue. This
results in a delaying effect on invalid trials as it slows the move-
ment of attention towards the target on the opposite side of the
screen.
The lack of effect that the sleep related time cue had on NS
reaction time should be considered. Fox, Russo, & Dutton (2002)
used the Posner paradigm to compare high and low trait anxious
people when presented with angry, happy or neutral faces. With
the low anxious group, there was still a main effect for cue validity,Table 2
Sleep summary data.
PI (n ¼ 22) GS (n ¼ 22) Between group
analyses
M SE M SE
PSQI 10.8 0.5 3.0 0.4 p < 0.0001
Diary TST (h/min) 5.4 0.2 7.2 0.3 p < 0.0001
Diary SOL (min) 44.8 2.6 9.3 0.9 p < 0.0001
PSQI, Pittsburgh Sleep Quality Index; TST, total sleep time; SOL, sleep onset latency.
Signiﬁcant differences were found between NS and PI on all sleep measures.
Alongside a higher score on the PSQI indicative of poorer sleep, PI took longer to fall
asleep (longer SOL) as well as having less total sleep overall (lower TST).
Fig. 3. Reaction time (mean  SE) on valid and invalid trials of NS and PI. Signiﬁcant
differences were found between PI and NS on invalid trials and between valid and
invalid trials for PI.
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expected with longer reaction times for invalid trials compared to
valid trials. This would appear to show the ‘normal’ time course of
attention to move from one location to another. However, in the
present study, we do not see any effect of cue location in the NS. In
the Fox et al. study, the valence of the face presented as a cue will
still be salient to an extent independent of the anxiety level of the
individual. However, sleep related timesmay not have an impact on
NS and therefore do not affect the movement of their attention in
anyway. All participants were instructed to keep their eyes ﬁxated
on the cross in the centre of the computer screen. This suggests the
sleep time cue was either not registering or was having very little
impact on the attention of normal sleepers which is in direct
contrast to PI who were very much affected by the sleep time cue.
Here we present stimuli which are causing a very different reaction
in individuals with a particular psychopathology compared to those
without, who are displaying no effect at all.
By conﬁrming our hypothesis that PI show a delayed disen-
gagement from sleep related times presented on a clock, we have
provided evidence for an attentional bias towards sleep related
times. These results support previous work carried out using other
paradigms to demonstrate an attentional bias towards sleep related
stimuli (Jones, Macphee, Broomﬁeld, Jones, & Espie, 2005;
MacMahon, Broomﬁeld, Macphee, & Espie, 2006; Marchetti et al.,
2006). However, this study is novel in two ways. First, by focusing
on sleep related times the present study provides objective
evidence for a cognitive process which is argued to be fundamental
in the maintenance of insomnia (Tang et al., 2007).
Second, we used a paradigmwhich directly measures attention
to a familiar yet clinically relevant stimulus. By selecting a modiﬁed
Posner paradigm, we obtain a measure of time taken to disengage
from the clockwhich can therefore be attributed to attention rather
than response preparation as the location of the cue is not associ-
ated with the correct response. Also, the information required to
make the correct response can only be obtained from the cue itself.
This study moves insomnia research forward by objectively
validating the clock as a salient sleep stimulus which impacts on
attentional processing in PI and therefore impacting on sleep. By
establishing an attentional bias to sleep we are able to investigate
further the validity of attentional bias as a marker of disorder
severity and conversely as a marker of treatment efﬁcacy. Other
areas of research such as sleep in cancer patients (Espie et al., 2008)
and smoking abstinence programs (Waters, Shiffman, Bradley, &
Mogg, 2003) have shown attentional bias towards the relevant
salient stimuli to change in accordance with reported treatmentsuccess. Bearre, Sturt, Bruce, and Jones (2007) report a relational
attentional bias in clients engaging in a heroin harm reduction
service, i.e. attentional bias towards heroin increases as frequency
of use increases which suggests attentional bias as a potential
indicator of disorder progression.
However, there are methodological limitations to this study.
First, because this was a recruited population, our ability to
generalise to the clinical population may be limited. Attention bias
studies, therefore, require replication with clinical samples.
Nevertheless, it should be noted that non-clinical populations do
display cognitive over-activity at bedtime, with clock monitoring
among themost common (Harvey, 2002). Processes detected at any
stage of sleep disruption, particularly before the clinical extreme,
may provide crucial evidence about the mechanisms involved in
the maintenance/enhancement of the disorder proper.
In conclusion, we used a cognitive probe paradigm to provide
objective evidence for sleep related attentional bias in PI. This
provides support for the previous research done in this ﬁeld (Jones
et al., 2005; MacMahon et al., 2006; Marchetti et al., 2006) and
further supports the role of attention in the attention–intention–
effort pathway into PI (Espie et al., 2006) by impeding the
automatic passage to sleep. Also, by using the clock and sleep time,
further objective evidence is provided for the role of clock moni-
toring which has been implicated as a trigger to the cognitive
arousal widely reported by those with PI. The establishment of an
attentional bias in PI provides valuable insight into the develop-
ment and maintenance of insomnia, however more research is
needed to understand the role of threat and craving as the
underlying mechanisms for selective attention towards sleep and
attentional bias as an indicator of psychopathology progression.Acknowledgements
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a b s t r a c t
The present study examined psychophysiological reactivity to emotional stimuli related and non-related
to sleep in people with primary insomnia (PPI) and in good sleepers (GS). Twenty-one PPI and 18 GS
were presented with ﬁve blocks of neutral, negative, positive, sleep-related negative and sleep-related
positive pictures. During the presentation of the pictures, facial electromyography (EMG) of the corru-
gator and the zygomatic muscles, heart rate (HR) and cardiac vagal tone (CVT) were recorded. Subjective
ratings of the stimuli were also collected. We found that only PPI exhibited greater inhibition of the
corrugator activity in response to sleep-related positive stimuli compared to the other blocks of stimuli.
Furthermore, PPI rated the sleep-related negative stimuli as more unpleasant and arousing and showed
higher CVT in response to all stimuli as compared to GS. Results were interpreted as indicating that PPI
exhibit craving for sleep-related positive stimuli, and also hyper-arousability in response to sleep-related
negative stimuli, as compared to GS. Our results suggest that psychological treatment of insomnia could
beneﬁt by the inclusion of strategies dealing with emotional processes linked with sleep processes.
 2010 Elsevier Ltd. All rights reserved.
Introduction
Insomnia as a disorder is deﬁned as difﬁculties in initiating/
maintaining sleep and/or non-restorative sleep accompanied by
decreased daytime functioning persisting for at least four weeks
(American Academy of Sleep Medicine, AASM, 2005). Aetiological
theories (Espie, 2002; Espie, Broomﬁeld, MacMahon, MacPhee, &
Taylor, 2006; Harvey, 2002; Lundh & Broman, 2000; Morin, 1993;
Perlis, Giles, Mendelson, Bootzin, & Wyatt, 1997; Riemann et al.,
2010) consider heightened levels of autonomic, cortical, cognitive,
and emotional arousal as relevant maintaining factors of insomnia.
Although widely recognized as important (e.g. Espie, 2002; Lundh
& Broman, 2000; Morin, 1993; Riemann et al., 2010),
investigations of the aetiological role of emotional arousal in
insomnia have been classically based on indirect evidence. These
have involved studies showing that neurotic temperamental traits
are associated with insomnia (e.g. Espie, 1991; LeBlanc et al., 2007),
studies investigating the content of intrusive thoughts experienced
by people with insomnia during the pre-sleep period (e.g. Van
Egeren, Hayness, Franzen, & Hamilton, 1983; Wicklow & Espie,
2000), and studies demonstrating signiﬁcant comorbidity with
clinical anxiety or depression (e.g. Chang, Ford, Mead, Cooper-
Patrick, & Klag, 1997; Ford & Kamerow, 1989; Riemann, 2007).
Considering the dimensional approach to the study of emotions
(e.g. Bradley, 2000; Lang, 2002, chap. 14), the emotional experience
is described as referring to two main dimensions: the valence
(positive vs negative) and the arousal (from low to high). Based on
this, the majority of research considering insomnia has largely
focussed on the dimension of arousal, but not on the dimension of
valence. A small number of studies have investigated the rela-
tionship between positive (e.g. excited, enthusiastic) and negative
(e.g. hostile, upset) affective states and poor sleep quality using
self-report questionnaires (e.g. McCrae et al., 2008; Norlander,
Johansson, & Bood, 2005; Scott & Judge, 2006). These studies
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showed that people with insomnia report heightened negative and
diminished positive emotional states as compared to good sleepers.
Three studies have examined the relationship between emotions
and sleep measuring psychophysiological responses to visual
stimuli validated both for the dimensions of arousal and valence. In
two studies, Franzen, Buysse, Dahl, Thompson, and Siegle (2009)
and Franzen, Siegle, and Buysse (2008) measured pupillary
responses to high arousing positive and negative emotional
pictures and low arousing neutral pictures in sleep-deprived
participants as compared to control groups. Main results showed
that responses to negative pictures were larger in sleep-deprived
participants as compared to controls. In a functional magnetic
resonance imaging (fMRI) design study of sleep deprivation, Yoo,
Gujarm, Hu, Jolesz, and Walker (2007) presented pictures ranging
from emotionally neutral (neutral valence, low arousal) to
increasingly aversive quality (negative valence, high arousal). The
sleep deprivation group displayed enhanced activity in the amyg-
dala and reduced functional connectivity between the amygdala
and the medial prefrontal cortex (MPFC). These results were
interpreted as an increased neurobiological response to emotional
stimuli and a reduced inhibitory inﬂuence of the MPFC on
emotional reactivity after sleep deprivation. Taken together, these
studies show that sleep deprivation alters emotional responses to
negative stimuli, thus, sleep seems to be important for maintaining
adaptive emotional processes. However, as these studies focussed
on sleep deprivation, no data about emotional reactivity in
insomnia are available up to date. In fact, insomnia is a condition
which differs from sleep deprivation because it implies chronic
sleep difﬁculties (more than four weeks), primarily subjective
complaints, impairments in sleep quality and not necessarily in
sleep quantity, and adaptation processes. Moreover, the studies
aforementioned did not speciﬁcally considered the valence
dimension. In fact, Yoo et al. (2007) did not use positive stimuli, and
Franzen et al. (2009, 2008) used pupillary responses which are
indices of more general emotional information processing. Bradley
(2000) has indicated that facial electromyography (EMG) measures
speciﬁcally the emotional valence. The activity of the corrugator
muscle (knits the eye brow into a frown) is both potentiated by
unpleasant pictures and inhibited by pleasant pictures when
compared to neutral stimuli. In contrast, the activity of the zygo-
matic muscle (pulls the corners of the mouth back and up into
a smile) increases in response to pleasant pictures, while
unpleasant stimuli elicit no inhibition (e.g. Larsen, Norris, &
Cacioppo, 2003). The aim of the present study was to evaluate
facial EMG responses to positive and negative emotional stimuli
related and not related to sleep in people with primary insomnia
and good sleepers. We assumed that the presentation of symptom-
relevant emotional stimuli would enhance responses in the group
with insomnia due to a greater attention directed to this material
and due to personal relevance.
The following predictions were considered. As compared to
neutral stimuli and as compared to good sleepers, people with
primary insomnia should exhibit enhanced corrugator activity in
response to sleep-related negative stimuli. Additionally, they may
show diminished corrugator activity and heightened zygomatic
activity in response to sleep-related positive stimuli. With respect
to stimuli not related to sleep, people with primary insomnia
should present enhanced responses in the corrugator activity to
negative stimuli. Additionally, two alternative predictions were
considered with respect to positive stimuli. Diminished responses
to positive stimuli in the zygomatic muscle have been reported for
individuals with dysphoria compared to healthy controls (Sloan,
Bradley, Dimoulas, & Lang, 2002). As insomnia is a condition
highly linked with depression and with a waking complaint of
negative mood changes, we may see a reduced response in the
zygomatic muscle to positive stimuli in individuals with primary
insomnia. Alternatively, this reduced response may be unique to
depression as primary insomnia is an independent diagnostic
entity from mood disorders (e.g. Perlis et al., 2006; Riemann &
Voderholzer, 2003).
In addition to these hypotheses, we also expected that people
with primary insomnia would respond with higher autonomic
arousal to all stimuli. Thus, numerous studies have demonstrated
increased levels of arousal in people with primary insomnia when
compared to good sleepers (for a review see Riemann et al., 2010).
Additionally, Lundh and Broman (2000) suggested that people with
insomnia are characterized by an increase in the levels of arousal in
response to sudden, new or emotional stimuli (hyper-arousability).
In the current experiment, we also recorded heart rate (HR) and
cardiac vagal tone (CVT) during the presentation of the visual
stimuli. As an increase of the heart rate is linked to heightened
arousal stimulation (Witvliet & Vrana, 1995) and higher CVT has
been associated with greater reactivity to stimuli (Movius & Allen,
2005), we predicted alterations in these measures.
Finally, subjective ratings of the valence and the arousal of the
pictorial stimuli were also collected. We predicted that people with
primary insomnia would demonstrate an altered valence and
arousal ratingsof sleep-related stimuli as compared togoodsleepers.
Method
Participants
Participants were 39 (31 F, 8M) university students, including 21
individuals with primary insomnia and 18 good sleepers (Table 1).
Their age ranged between 18 and 30 years (mean age  standard
deviation sd¼ 22.4 y 2.96). Participants with primary insomnia
(PPI) met the Diagnostic and Statistic Manual of Mental Disorders,
Fourth Edition (DSM-IV, American Psychiatry Association, APA,
2002) criteria as measured through screening questionnaires and
a clinical assessment interview. These criteria include: duration of
the symptoms of at least one month, and complaints of decreased
functioning at work and/or in social and personal life. Additionally,
PPI met quantitative criteria of insomnia as reported by Lichstein,
Durrence, Taylor, Bush, and Riedel (2003) which indicate
a frequency of the symptoms of three or more nights per week.
Controls participants (good sleepers e GS) met the Research Diag-
nostic Criteria for normal sleepers indicated by Edinger et al. (2004).
This study arises from a collaboration between the University of
Glasgow Sleep Research Laboratory (UGSRL) and the Department of
Psychology of the “Sapienza” University of Rome. Nineteen partic-
ipants were recruited and recorded in Glasgow, 11 PPI (all F,
20.54 y  1.69) and 8 GS (5 F; 3 M, 23.25 y  3.06). Twenty
participants were recruited and recorded in Rome, 10 PPI (8 F; 2 M,
23.7 y  2.49) and 10 GS (7 F; 3 M, 22.4 y  3.68).
Table 1
Study participants.
PPI GS X2/F p
Women/men 19/2 12/6 X2(1,N¼39) ¼ 3.37 0.07
Age (in years) 22.8  3.31 22.0  2.64 F(1,37) ¼ 0.58 0.45
ISI 12.09  3.32 1.33  1.53 F(1,37) ¼ 159.86 <0.001
STAI-T 44.09  8.53 36.11  6.99 F(1,37) ¼ 10.01 0.03
MEQ 43.14  8.71 47.72  7.72 F(1,37) ¼ 2.97 0.09
KSS 5.00  2.15 4.39  1.65 F(1,36) ¼ 0.95 0.34
Note. Data are presented as mean  sd. One-way ANOVAs and chi-squares were
computed. Abbreviations: ISI: Insomnia Severity Index; STAI-T: State-Trait Anxiety-
Trait version; MEQ: MorningnesseEveningness Questionnaire; KSS: Karolinska
Sleepiness Scale; PPI: People with Primary Insomnia; GS: Good Sleepers.
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The duration of insomnia was 51  42 months (mean  sd),
ranging from 1 to 120 months. Five participants out of 21 reported
difﬁculties exclusively in sleep onset, indicating difﬁculties in
falling asleep within 30 min. All others participants reported mixed
symptoms (difﬁculty in falling asleep within 30 min, difﬁculty in
maintaining sleep during the night with a total time awake longer
than 30 min, and wakening up in the morning at least 60 min
before of the wanted time and with less than 6 h of sleep). Quality
of sleep was also assessed in GS using questionnaires and the
clinical assessment interview.
None of the participants reported the use of sleep medication,
any relevant psychiatric conditions or other medical problems as
assessed by both the questionnaires and the clinical assessment
interview.
Written informed consent was obtained prior to the onset of the
study. The research was approved by both the Ethics Committees of
the NHS Greater Glasgow and Clyde, UK and the Department of
Psychology of the “Sapienza” University of Rome, Italy.
Screening measures
1) Sleep Disorder Questionnaire (SDQ, Violani, Devoto, Lucidi,
Lombardo, & Russo, 2004). The SDQ is a brief self-report cate-
gorical questionnairewhich evaluates the presence of insomnia
according to the DSM-IV (APA, 2002) and the quantitative
(Lichstein et al., 2003) criteria. Respondents are classiﬁed into
three categories: Good sleep; Clinically signiﬁcant insomnia;
Subthreshold insomnia. The SDQ has been validated as a brief
and valid instrument, useful for the screening of insomnia
(Violani et al., 2004).
2) Insomnia Severity Index (ISI, Bastién, Valliéres, & Morin,
2001). The ISI scale assesses the severity of insomnia during
the previous two weeks. Respondents are classiﬁed into
four categories: No clinically signiﬁcant insomnia (score
between 0 and 7); Subthreshold Insomnia (score between 8
and 14); Clinical insomnia e moderate severity (score
between 15 and 21); Clinical Insomniae severe (score between
22 and 28).
The order of SDQ and ISI was counterbalanced across subjects.
In the current study, participants were included in the GS group
if they were classiﬁed in the category “good sleep” at the SDQ and
scored below 8 on the ISI. With respect to the PPI group, partici-
pants were included if they were classiﬁed in the category “clini-
cally signiﬁcant insomnia” at the SDQ or scored above 14 on the ISI.
Consequently, participants classiﬁed in the category “subthreshold
insomnia” at the SDQ and scoring between 8 and 14 on the ISI were
not selected. Moreover, participants classiﬁed in the category “good
sleep” at the SDQ and scoring above 8 on the ISI were not selected,
as those classiﬁed in the categories “subthreshold insomnia” or
“clinically signiﬁcant insomnia” at the SDQ and scoring below 8 on
the ISI.
3) State-Trait Anxiety Inventory-Trait version (STAI-T, Spielberger,
Gorsuch, & Lushenne, 1970). The STAI-T uses a 20-item scale.
Respondents are asked to rate how they generally feel on a
5-point frequency scale ranging from 1 (almost never) to 4
(very much so). The STAI-T is a widely used measure of trait
anxiety. The total score ranges from 20 to 80. Sesti (2000)
indicates 2 cut-off scores: 40 for “moderate anxiety”, 60 for
“clinical anxiety”; scores below 40 are considered low anxiety.
In the current study, participants were included if they scored
below 60.
4) MorningnesseEveningness Questionnaire (MEQ, Horne &
Ostberg, 1976). The MEQ is a 19-item questionnaire which
assesses the circadian preference. The MEQ categorizes
responses into ﬁve possible groups: “deﬁnitely morning types”
(score between 70 and 86), “moderately morning types” (score
between 59 and 69), “neither types” (score between 42 and 58),
“moderately evening types” (score between 31 and 41), “deﬁ-
nitely evening types” (score between 16 and 30). The MEQ was
used in order to exclude those participants with a problem of
insomnia due to advanced or delayed phase syndrome. As our
sample was a student sample, advanced or delayed phase
problems could be frequent due to irregular life-style times.
Only participants classiﬁed as “neither types” or “moderately
morning or evening types” were included in the study.
5) The Edinburgh Handedness Inventory (Oldﬁeld, 1971). This is
a self-report questionnaire which identiﬁes the hand prefer-
ence of the respondents. Participants are asked to report with
which hand they do a list of actions (writing, drawing,
throwing, scissors, toothbrush, knife, spoon, broom, sticking
a match, opening a box). To calculate the score, the difference
between the score related to the right hand and the score
related to the left hand is computed. This difference is then
divided for the total score and the value is multiplied for 100.
Thus, the score ranges from 100 and þ100, positive values
indicating a tendency to right handed. In the current study, as
asymmetry for specialization of brain hemispheres with
respect to emotion processes have been reported (e.g. Zhou &
Hu, 2006), only deﬁnitely right-handed participants
(score > þ40) were included.
All questionnaires have both the Italian and the English versions
validated in samples independent from the one of the present
study.
Procedure
All potential participants were approached by email or
around universities sites (e.g. library, campus, lectures halls,
etc.). One hundred and ten persons accepted to ﬁll out the
screening measures in Glasgow and 134 in Rome. Of those, 41
participants proved to be eligible in Glasgow, 20 GS and 21 PPI.
Thirty-two participants proved to be eligible in Rome, 17 GS and
15 PPI. Both in Glasgow and in Rome, participants of the two
groups were further selected to be matched on the basis of
STAI-T and MEQ scores, and on the basis of hand preference. In
total, 19 people were selected in Glasgow (8 GS, 11 PPI) and 21
in Rome (10 GS, 11 PPI). Based on questionnaires responses,
selected participants were invited to the sleep laboratory for
the experimental session, which was preceded by a clinical
interview conducted by the ﬁrst author (CB). One of the
participants recruited within the Italian PPI cohort was excluded
after the clinical interview because insomnia criteria were not
satisﬁed.
Selected participants received detailed instructions for the
experimental section and had electrodes attached as described
below. A Trackit ambulatory Electroencephalography (EEG)/
polygraphic recorder (www.llines.com) was used for acquiring
data in both laboratories. The sampling rate was 256 Hz. Facial
EMG over the corrugator and the zygomatic muscles on both
sides of the face was recorded using 6 mm surface silveresilver
chloride (Ag/AgCl) electrodes. The EMG electrodes were con-
nected to the Trackit's bipolar channels. The “Guidelines for
Human Electromyographic Research” (Fridlund & Cacioppo, 1986)
were followed for the placement of the electrodes. Electrodes
were attached with the GRASS adhesive paste (www.
grasstechnologies.com). A single channel Lead II Electrocardio-
graphy (ECG) was recorded, using two AmbuRNeuroline 720
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Single Patient Surface Electrodes (www.ambu.com), one placed
just below the right clavicle, one on the left side of the torso.
A third surface electrode placed over the forehead was used as
ground electrode. Heart rate (HR) and cardiac vagal tone (CVT)
were derived from the ECG ReR interval using the Neuroscope
software (www.mediﬁtgroup.com). The non-invasive index of
CVT is deﬁned as ‘pulse-synchronised phase shifts in consecutive
cardiac cycles’ (Little, Julu, Hansen, & Reid, 1999), and is
measured in arbitrary units of a linear vagal scale (LVS) (Julu,
1992). The least value in this scale is zero, equivalent to full
atropinisation of human subjects (Julu, 1992).
A biocalibration was provided to check the recording: partici-
pants were asked to frown as if they were very angry and then to
smile as if they were very happy. Before starting with the image
viewing, participants were asked to sit on a chair in front of the
computer screen at a distance of 60 cm. The size of the screen was
17 inches. The chair height was adjusted so that the centre of the
computer screen was at the eye level of the participant. Images
were presented in ﬁve different blocks: neutral, negative not
related to sleep, negative related to sleep, positive not related to
sleep, positive related to sleep. Blocks were counterbalanced within
a Latin square in 5 different sequences.1 Each sequence started with
2 neutral stimuli which were not considered for data analysis, but
used for adaptation. At the end of each block the participants were
asked to rate the valence and the arousal of all the pictures of the
block using a subjective scale, the Self-Assessment Manikin (SAM,
Bradley & Lang, 1994). Pictures were presented with Superlab,
version 2.1 (www.cedrus.com).
While viewing the visual stimuli, the room was only illumi-
nated by a table lamp shining on the wall, while during the rating
the full room light was lighted. Participants were instructed to
keep their head still while watching the stimuli. In order to
increase the emotional impact of the stimuli, before starting with
the presentation of the pictures, participants were asked to read
a paragraph describing the experience of a night with insomnia
taken from “Overcoming Insomnia and Sleep Problems: A self-help
guide using cognitive behavioural techniques” (Espie, 2006, p. 62).
During the task the experimenter stood behind the participant. A
qualiﬁed psychologist and an advanced undergraduate psychology
student conducted the experiments. Good sleepers received
payment of 10 euros (or 6 English pounds) for their participation,
while PPI additionally received a self-help booklet dealing with
the Cognitive-Behaviour Treatment strategies of Insomnia (CBTI)
developed at the Department of Psychology of the “Sapienza”
University of Rome and adapted for an Italian and an English
version.
Control measure for levels of sleepiness during the experimental
session
The Karolinska Sleepiness Scale (KSS, Akerstedt & Gillberg,
1990). The KSS is a commonly used measure assessing state
levels of sleepiness. It uses a 9-point scale ranging from 1 ¼ “very
alert” to 9¼ “very sleepy, great effort to keep awake, ﬁghting sleep”.
Participants are instructed to rate their sleepiness in the 10 min
prior to taking the test. The KSS was administered immediately
before the presentation of the pictures. A score of 7 or more indi-
cates excessive sleepiness.
Subjective ratings of the stimuli
The Self-Assessment Manikin (SAM, Bradley & Lang, 1994). The
SAM is a non-verbal pictorial assessment technique that includes
manikins differing in facial expressions and aiming at measuring
the dimensions of valence and arousal on two continuous 9-point
scales. The scale used for assessing the valence dimension ranges
from a smiling happy man to an unhappy, frowning man. The scale
used for assessing the arousal dimension ranges from an excited,
wide-eyed ﬁgure to a relaxed, sleepy ﬁgure.
Picture stimuli
Negative and positive stimuli not related to sleep as well as
neutral stimuli were selected from the International Affective
Picture System (IAPS, Lang, Bradley, & Cuthbert, 2001).2 This is the
most widely used collection of visual stimuli for inducing emotions
in laboratory tests. It includes colour photographs with a known
valence and arousal evaluated through the Self-Assessment
Manikin. All selected stimuli had low to medium levels of arousal
(<6). Twelve neutral stimuli (valence between 4 and 6; mean
valence 4.97  0.35, mean arousal 3.45  0.62), 10 positive stimuli
(valence > 6; mean valence 7.64  0.60, mean arousal 4.39  0.35),
10 negative stimuli (valence < 4; mean valence 2.46  0.82, mean
arousal 5.10  0.60) were selected. No stimuli representing socially
desirable situations (e.g. weddings) were chosen.
Stimuli related to sleep3 were 10 negative (valence < 4; mean
valence 3.18  0.50, mean arousal 4.60  0.42) and 10 positive
(valence > 6; mean valence 7.47  0.57, mean arousal 1.90  0.21)
pictures, which valence and arousal were previously assessed
through the Self-Assessment Manikin. The validation of the sleep-
related stimuli was tested on a different sample of 30 volunteers
college students (18 F, 12 M) of the Faculty of Psychology of the
“Sapienza” University of Rome, aged between 18 and 30 years. The
same procedure used to validate the IAPS stimuli (Lang et al., 2001)
was followed in the validation of the sleep-related stimuli. Negative
sleep-related stimuli included pictures of people awake in bed at
night-time. Positive sleep-related stimuli included pictures of
people sleeping in bed at night-time. A statement congruent with
respect to the valence of the stimulus was added to each picture in
order to maximise the emotional impact of the stimuli. It was
assumed that stimuli affectively congruent enhance the activation
levels and facilitate responses that reach a threshold level that is
necessary for identiﬁcation. This assumption is consistent with the
model proposed by Fazio, Sanbonmatsu, Powell, and Karders
(1986), which assumes that all affective concepts with the same
valence are linked in semantic memory and their combination
facilitates the affective response and categorization. All sentences
were derived fromvalidated questionnaires, namely the statements
for the IAPS positive pictures were taken from the State-Trait
Anxiety Inventory (STAI, Spielberger et al., 1970), the statements for
the IAPS negative pictures were taken from the Fear Survey
Schedule (FSS, Wolpe & Lang, 1964) and the statements for the
sleep-related pictures were taken from the Glasgow Content of1 Sequence 1: neutral e positive not related to sleep e negative not related to
sleep e positive related to sleep e negative related to sleep; Sequence 2: positive
not related to sleep e negative not related to sleep e positive related to sleep e
negative related to sleep e neutral; Sequence 3: negative not related to sleep e
positive related to sleep e negative related to sleep e neutral e positive not related
to sleep; Sequence 4: positive related to sleep e neutral e positive not related to
sleep e negative related to sleep e negative not related to sleep; Sequence 5:
negative related to sleep e negative not related to sleep e neutral e positive not
related to sleep e positive related to sleep.
2 Numbers of the IAPS stimuli selected: X: 2038, 2102, 2372, 2383, 2385, 2480,
2487, 2493, 2516, 2595, 2840, 7550; P: 2050, 2070, 2154, 2311, 2352, 2395, 2510,
2530, 7325, 8497; N: 2276, 2490, 2795, 3180, 3350, 6562, 8231, 9221 9435, 9594.
3 Sleep-related stimuli are distributed on CD-ROM and can be obtained on
request from the authors.
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Thoughts Inventory (GCTI, Harvey & Espie, 2004).4 The statements
for the neutral stimuli consisted in the description of the picture. All
statements were formulated in the ﬁrst person. Examples of
statements for each valence category are: 1) positive not related to
sleep stimuli: I am happy (IAPS picture number: 2070); 2) negative
not related to sleep stimuli: I fear weapons (IAPS picture number:
6562); 3) positive sleep-related stimuli: I am good at falling asleep;
4) negative sleep-related stimuli: I worry about not sleeping well;
5) neutral stimuli: I am working (IAPS picture number: 7550).
Stimuli were balanced with respect to complexity, brightness,
contrast of the image, and number of words in associated
statements.
Results
Data preparation and analyses
Statistical analyses were conducted using the STATISTICA soft-
ware (version 6, www.statsoft.com).
1) Description of the sample. Groups were compared using one-
way ANOVAs (with respect to age, sleepiness, anxiety and
severity of the insomnia symptoms) and chi-squares (with
respect to GENDER).
2) Facial electromyography (EMG). The Spike-2 software, version
5 (www.ced.co.uk), was used for preparing the EMG data. Raw
data were high-pass ﬁltered for eliminating the DC signal. Data
were then rectiﬁed, smoothed and transformed into logarithm
to normalise the distribution. According to the “Guidelines for
human electromyographic research” (Fridlund & Cacioppo,
1986), most psychophysiological research using EMG has
focussed on some variations of EMG signal amplitude as the
dependent measure. Commonly, reﬂexes are often quantiﬁed
using peak-to-peak EMG amplitude and onset latency (phasic
responses). However, the guidelines also underline that it has
been suggested that maintained EMG activity represent
muscular contractionmore accurately than a simple amplitude.
Research has used, thus, also the mean of the rectiﬁed,
smoothed, and ﬁltered EMG signal (tonic responses). In this
study, we have considered both phasic and tonic responses to
analyse the EMG responses to the stimuli.
Phasic responses: Changes in the phasic responses were
obtained as the difference between the peak-to-peak
amplitude of the EMG recorded during the presentation of
each block of pictures and the peak-to-peak amplitude of the
EMG recorded during the second before the stimulus onset.
Two mixed design factorial ANOVAs were computed using
the GROUP as between subjects factor, the VALENCE and the
SIDE OF THE FACE (left vs right) as within subjects factors,
and the mean changes of activity recorded in the corrugator
and the zygomatic muscles respectively as dependent
variables.
Tonic responses: Tonic EMG activity was obtained as the
mean values recorded during each block of pictures (10
neutral, 10 negative not related to sleep, 10 negative related
to sleep, 10 positive, 10 positive related to sleep). Two mixed
design factorial ANOVAs were computed using the GROUP as
between subjects factor, the VALENCE and the SIDE OF THE
FACE as within subjects factors, and the mean activity
recorded over the corrugator and the zygomatic muscles
respectively during each block as dependent variables.
3) HR and CVT. Mean heart rate (HR) and mean cardiac vagal tone
(CVT) were calculated for each stimulus block. With skewness
and kurtosis < 1, the distributions of the means were consid-
ered normal. Data were analysed within two mixed design
factorial ANOVAs using the GROUP as between subjects factor,
the VALENCE as within subject factor and respectively the
mean HR and CVT as dependent variables.
4) Subjective measures. Two mixed design factorial ANOVAs
GROUP  VALENCE were computed using the GROUP (PPI vs
GS) as between subjects factor, the VALENCE (neutral vs
negative not related to sleep vs negative related to sleep vs
positive not related to sleep vs positive related to sleep) as
within subjects factor, and the subjective valence ratings
(pleasant vs unpleasant) and arousal ratings (low vs high)
respectively as dependent variables.
5) Cultural differences. As our sample was recruited half in Scot-
land and half in Italy, we consider possible cultural differences
in the emotional responses. Descriptive analyses and the same
mixed design factorial ANOVAs analyses aforementioned were
repeated considering as between subjects factor the PLACE
(Glasgow vs Rome).
When a signiﬁcant principal effect or interaction was found,
speciﬁc hypothesis were tested through planned comparisons.
Findings
Means  standard deviations are reported in the text in
brackets.
1) Description of the sample. A summary of the descriptive results
is provided in Table 1.
The PPI group included a marginally signiﬁcant higher number
of females, reported higher scores on the STAI-T and had higher
scores on the ISI compared to the GS group. There was no difference
between the two groups due to the time of day of recording (X2(2,
N¼39) ¼ 1.48, p ¼ 0.48). Nine PPI and 8 GS were recorded in the
morning (between 9:00 and 12:30), 9 PPI and 5 GS at lunch time
(between 12:30 and 15:30) and 3 PPI and 5 GS in the afternoon
(between 15:30 and 18:00). Two good sleepers and 4 people with
insomnia reported scores higher than 7 on the KSS, however no
difference between the groups was found, as shown in Table 1.
2) Facial electromyography (EMG). Results are summarized in
Table 3.
No signiﬁcant effects were evidenced for phasic responses of the
corrugator muscle. Phasic responses of the zygomatic muscle
showed a signiﬁcant main effect for the factor VALENCE. Planned
comparisons evidenced that both groups presented heightened
activity in response to positive stimuli (related and not related to
sleep) compared to negative stimuli (related and not related to
sleep) (positive not related to sleep: 1.17  1.77; sleep-related
positive: 1.61  2.03; negative not related to sleep: 2.01 1.49;
sleep-related negative: 1.98, p ¼ 0.03; F(1,21) ¼ 12.17, p ¼ 0.002).
Additionally all participants presented increased zygomatic activity
in response to positive stimuli related to sleep compared to negative
stimuli related to sleep (F(1,21) ¼ 7.60, p ¼ 0.01). Finally, all partici-
pants displayed different responses toneutral stimuli (1.882.03)
as compared with all the emotional stimuli (F(1,21)¼ 5.53, p¼ 0.03).
4 Item numbers: Positive not related to sleep (from STAI): 2, 5, 10, 15, 16, 20, 21, 23,
26, 27, 30; Negative not related to sleep (from FSS): 5, 22, 41, 47, 48, 51, 56, 66, 61, 67;
Positive and Negative sleep-related (from GCT): 4, 6, 8, 9, 10, 13, 15, 18, 20, 24, 26.
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When tonic responses of the corrugator muscle were analysed,
a signiﬁcant interaction GROUP  VALENCE was found. Planned
comparisons showed that GS presented similar responses to all
types of stimuli (neutral: 0.03  1.39; positive not related to sleep:
0.09  1.38; negative not related to sleep: 0.02  1.36; sleep-
related positive: 0.10  1.37; sleep-related negative: 0.0005  1.36;
F(1,36) ¼ 2.30 p ¼ 0.14). In contrast, corrugator activity in PPI
decreases signiﬁcantly in response to positive stimuli related to
sleep (0.239  1.325), compared to the activity produced in
response to all the other types of stimuli (neutral: 0.0685  1.34;
positive not related to sleep: 0.099  1.40; negative not related to
sleep: 0.0645  1.37; sleep-related negative: 0.1205  1.345;
F(1,36) ¼ 5.426, p ¼ 0.03). The interaction is shown in Fig. 1.
When tonic responses of the zygomatic muscle were analysed,
a signiﬁcant main effect of the VALENCE was found. Planned
comparisons showed only that both groups displayed heightened
activity in response to positive stimuli (related and not related to
sleep) compared to negative stimuli (related and not related to
sleep) (positive not related to sleep: 0.66  1.42; sleep-related
positive: 0.55  1.48; negative not related to sleep: 0.41  1.40;
sleep-related negative: 0.37  1.37; F(1,36) ¼ 16.34, p < 0.001).
Additionally, a marginally signiﬁcant main effect of the GROUP has
to be noted, showing that PPI display enhanced reactivity to all
stimuli as compared to GS.
3) HR and CVT. Results from HR and CVT responses are presented
in Table 4.
No signiﬁcant effects were evidenced for HR responses. When
CVT was analysed, a signiﬁcant main effect of the GROUP was
found. People with primary insomnia (8.12  2.93) displayed
increased CVT in response to all stimuli compared to GS
(5.027  1.315).
4) Subjective measures. The results from the subjective ratings
of VALENCE and AROUSAL are presented in Table 2.
Valence: Results showed a signiﬁcant main effect of the
VALENCE and a signiﬁcant interaction GROUP  VALENCE.
Planned comparisons showed that both groups rated posi-
tive stimuli (related and not related to sleep) as more
pleasant as compared with negative stimuli (related and not
related to sleep) (positive not related to sleep: 7.83  1.35,
sleep-related positive: 7.15  1.48, negative stimuli:
3.13  1.47, sleep-related negative: 4.44  1.65;
F(1,37) ¼ 181.03, p < 0.001). Moreover, both groups rated
positive stimuli related to sleep as more pleasant compared
to negative stimuli related to sleep (F(1,37)¼ 79.37, p< 0.001).
It has to be noted that neutral stimuli (6.42  1.50) were
differently rated by all participants as compared with all the
emotional stimuli (F(1,37) ¼ 12.17, p ¼ 0.001).
With respect to the interaction GROUP  VALENCE, planned
comparison evidenced that GS rated negative stimuli not
related to sleep (3.17 1.42) asmore unpleasant compared to
negative stimuli related to sleep (5.11  1.23; F(1,37) ¼ 24.30,
p < 0.001). In contrast, PPI rated negative pictures related to
sleep (3.76  1.73) as unpleasant as negative pictures not
related to sleep (3.10  1.55; F(1,37) ¼ 3.33, p ¼ 0.08).
Arousal: The mixed design factorial ANOVA showed a main
effect of the GROUP, and a main effect of the VALENCE.
Additionally, it has to be noted that a marginally signiﬁcant
interaction GROUP  VALENCE was detected. People with
primary insomnia (4.49  1.93) rated all stimuli as more
arousing compared to GS (2.788  1.40) regardless to the
valence. Planned comparisons evidenced that both groups
rated negative stimuli (related and not related to sleep) as
more arousing than positive stimuli (related and not related
Table 2
Results related to facial EMG data.
SOURCE OF VARIATION Corrugator Zygomatic
df Sum of
squares
df error Mean
square
F p Observed
Power
df Sum of
squares
df error Mean
square
F p Observed
power
Phasic responses
GROUP 1 5.179 17 5.179 0.520 0.48 0.11 1 34.626 21 14.876 2.327 0.14 0.142
SIDE 1 0.016 17 0.016 0.003 0.96 0.05 1 13.712 21 13.712 1.469 0.24 0.212
VALENCE 4 9.548 68 2.387 1.521 0.21 0.45 4 22.359 84 5.590 4.197 0.004 0.909
GROUP  SIDE 1 2.505 17 2.505 0.490 0.49 0.10 1 0.905 21 0.905 0.097 0.76 0.060
GROUP  VALENCE 4 5.550 68 1.387 0.884 0.48 0.27 4 4.808 84 1.202 0.903 0.76 0.275
SIDE  VALENCE 4 3.131 68 0.783 1.479 0.22 0.44 4 3.426 84 0.856 1.539 0.20 0.457
GROUP  SIDE  VALENCE 4 2.382 68 0.596 1.125 0.35 0.34 4 1.114 84 0.278 0.500 0.74 0.164
Tonic responses
GROUP 1 1.551 36 1.551 0.117 0.73 0.06 1 51.143 36 51.143 3.758 0.06 0.471
SIDE 1 2.703 36 2.703 0.590 0.45 0.12 1 21.330 36 21.330 3.388 0.74 0.433
VALENCE 4 0.287 144 0.072 0.631 0.64 0.20 4 3.976 144 0.994 7.562 <0.001 0.996
GROUP  SIDE 1 0.014 36 0.014 0.003 0.96 0.05 1 0.116 36 0.116 0.018 0.89 0.052
GROUP  VALENCE 4 1.137 144 0.284 2.502 0.04 0.70 4 0.297 144 0.074 0.565 0.69 0.185
SIDE  VALENCE 4 0.272 144 0.068 1.027 0.40 0.32 4 0.009 144 0.002 0.048 0.10 0.059
GROUP  SIDE  VALENCE 4 0.376 144 0.094 1.422 0.23 0.43 4 0.355 144 0.089 1.828 0.13 0.545
Table 3
HR and CVT.
SOURCE OF VARIATION HR CVT
df Sum of
squares
df error Mean
square
F p Observed
power
df Sum of
squares
df error Mean
square
F p Observed
power
GROUP 1 82.087 21 82.087 0.274 0.60 0.08 1 228.49 20 228.49 7.538 0.01 0.74
VALENCE 4 16.464 84 4.116 1.011 0.41 0.31 4 5.864 80 1.466 2.255 0.07 0.64
GROUP  VALENCE 4 19.265 84 4.816 1.182 0.32 0.36 4 0.608 80 0.152 0.234 0.91 0.10
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to sleep) (negative not related to sleep: 4.949  1.89; sleep-
related negative: 4.462  2.08, positive not related to sleep:
3.359  2.12, sleep-related positive: 2.564  1.54;
F(1,37) ¼ 34.09, p < 0.001). Moreover, both groups rated
negative stimuli related to sleep as more arousing compared
to positive stimuli related to sleep (F(1,37) ¼ 30.33, p < 0.001).
Finally neutral stimuli (3.10  1.99) were differently rated by
both PPI and GS as compared with all the emotional stimuli
(F(1,37) ¼ 10.88, p ¼ 0.002). With respect to the interaction
GROUP  VALENCE, planned comparison showed that GS
rated negative stimuli not related to sleep as more arousing
as compared with negative stimuli related to sleep
(F(1,37) ¼ 4.04, p ¼ 0.05). They also rated as equally arousing
negative and positive sleep-related stimuli (F(1,37) ¼ 3.40,
p¼ 0.08). In contrast, PPI rated negative stimuli not related to
sleep as arousing as negative stimuli related to sleep
(F(1,37) ¼ 0.01, p ¼ 0.92). Moreover, PPI rated negative stimuli
related to sleep as more arousing than positive stimuli rela-
tive to sleep (F(1,37) ¼ 37.61, p < 0.001).
5) Cultural differences.
We found no statistical signiﬁcant differences between the
group recruited in Rome and the group recruited in Glasgow with
respect to gender (X2(1,N¼39) ¼ 0.51, p ¼ 0.38) and with respect to
age (Rome: 23.05  3.14; Glasgow: 21.68  2.67; F(1,37) ¼ 2.14,
p ¼ 0.15).
The results from the mixed design factorial ANOVAs applied
considering the PLACE (Glasgow vs Rome) as between subjects
factor evidenced the following:
- Main effect of the PLACE: The sample recruited in Rome, as
compared to the sample recruited in Glasgow, presented
enhanced tonic EMG activity in response to all the stimuli both
in the corrugator (Rome: 0.30  1.33; Glasgow: 0.52  0.99;
F(1,37) ¼ 5.56, p ¼ 0.02) and in the zygomatic (Rome:
1.08  1.42; Glasgow: 0.09  1.02; F(1,37) ¼ 11.78, p ¼ 0.001)
muscles.
- Interaction PLACE  VALENCE: A signiﬁcant interaction was
detected with respect to the subjective ratings of the arousal
level of the stimuli (F(4,48) ¼ 2.60, p ¼ 0.04). Planned compar-
isons showed that the sample recruited in Rome (4.10  2.25),
compared to the sample recruited in Glasgow (2.58  1.71),
rated the positive stimuli not related to sleep as more arousing
(F(1,37) ¼ 5.62, p ¼ 0.02).
No other statistically signiﬁcant differences were observed.
Discussion
The results of our study suggest that people with primary
insomnia, as compared to good sleepers, present: increased phys-
iological craving response for positive sleep-related conditions,
enhanced physiological hyper-arousabilty in response to all stimuli,
and enhanced subjective hyper-arousability for negative sleep-
related conditions. In fact, we found an inhibition of the tonic
activity of the corrugator muscle only in people with primary
insomnia in response to sleep-related positive stimuli as compared
to the other blocks of stimuli. Consistently with the atten-
tioneintentioneeffort theory proposed by Espie et al. (2006),
people with insomnia perceive sleep requirement/deﬁcit and
become increasingly motivated by sleep. The perceived inability to
sleep would be experienced as a signiﬁcant threat, and conse-
quently sleep-related stimuli would enhance the arousal levels
necessary for monitoring the threat. On the other hand, and not
mutually exclusive with the response to the threat, people with
insomnia could show speciﬁc sensitivity for good sleep which
represent a desired condition for them. The desire for sleep of good
quality may become a “craving” (e.g. Espie et al., 2006). Consis-
tently with the craving response, sleep-related positive stimuli
elicited also greater responses in the zygomatic muscle in people
with primary insomnia compared to sleep-related negative
responses, thus, suggesting that these stimuli induce a positive/
craving response in people with insomnia. Additionally, the result
related to the zygomatic muscle was found also in good sleepers,
indicating that sleep of good quality is a pleasant experience for
everybody.
Results related to our physiological measures showed no
signiﬁcant effects with respect to responses to negative stimuli
(both sleep-related stimuli and not). It is possible that, although the
IAPS was developed following the dimensional approach to
emotions which do not refer to discrete emotions, certain speciﬁc
content effects can inﬂuence the emotional response. As Hamm,
Schupp, and Weike (2003) note, pronounced corrugator activity is
related mainly to disgust-eliciting stimuli. Indeed, the IAPS stimuli
generally used for inducing negative emotions associated to an
increase in the activity of the corrugator muscle are rated as highly
arousing and induce predominantly the emotion of disgust (e.g.
photographs of amputations, tumours, skin infections, etc.). In
Fig. 1. Tonic responses for corrugator muscle: interaction GROUP  VALENCE.
Table 4
Subjective responses.
SOURCE OF VARIATION Valence ratings Arousal ratings
df Sum of
squares
df error Mean
square
F p Observed
power
df Sum of
squares
df error Mean
square
F p Observed
power
GROUP 1 7.329 37 7.329 1.962 0.17 0.28 1 139.531 37 139.531 22.251 <0.001 1.00
VALENCE 4 593.784 148 148.446 86.256 <0.001 1.00 4 143.838 148 35.960 16.716 <0.001 1.00
GROUP  VALENCE 4 22.748 148 5.687 3.305 0.01 0.83 4 19.961 148 4.990 2.320 0.06 0.66
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order to control the dimension of arousal and tomatch the negative
stimuli from the IAPS with the negative sleep-related stimuli, these
high-arousal and disgust-eliciting pictures were not used in this
study. It is also possible that the presence of the experimenter
during the task inﬂuenced the outcome. Although the experi-
menter sat behind the subject, some data suggests that observa-
tions by others can reduce facial activity (Fridlund & Cacioppo,
1986). This appears to be especially important when the
emotions expressed are not desirable emotions (i.e. negative).
Moreover, some studies have used relaxation techniques before the
presentation of the stimuli to the participants (e.g. Fridlund &
Cacioppo, 1986). These techniques could induce a lower level of
activity in the muscular activity at the beginning of the trial, which
could facilitate the detection of an effect. As these factors may
represent confounds within this experiment, they should be taken
into consideration when planning future studies.
In our study, there was no relation between primary insomnia
and impairment in the emotional processing of pleasant stimuli, as
was found in dysphoric individuals (Sloan, Bradley, Dimoulas, &
Lang, 2002). The positive stimuli elicited greater zygomatic
activity in both groups compared to unpleasant stimuli. Thus, this
result suggests that decreased emotional reactivity to positive
stimuli is a speciﬁc feature of depression.
Our ﬁndings show that, compared to good sleepers, people with
primary insomnia respond with increased levels of arousal to all
stimuli, consistently with the hyper-arousal (e.g. Riemann et al.,
2010) and the hyper-arousability hypothesis (Lundh & Broman,
2000) for insomnia. This result was evidenced by enhanced
cardiac vagal tone and zygomatic activity in responses to all blocks
of pictures by people with primary insomnia compared to good
sleepers. Although the effect for the zygomatic muscle was only
marginally signiﬁcant, the observed power of 0.47 is below the 0.80
level, which suggest that the result could be signiﬁcant if the
number of participants was increased.
In addition to these results, considering the subjective ratings of
thevalenceandof thearousalof thestimuli, inour sampleonlypeople
withprimary insomnia rated sleep-negative stimuli asmore arousing
compared to sleep-positive stimuli. The levels of arousal of the sleep-
positive stimuli, instead, were rated similarly by the two groups. This
result could suggest that for people with primary insomnia it is not
just the sleep-related stimulus in general (e.g. the bed) to be associ-
atedwith high arousal, but only sleep-related stimuli associatedwith
the experience of wakefulness during the night. Peoplewith primary
insomnia subjectively rated negative and sleep-negative stimuli as
equally unpleasant, while good sleepers rated negative stimuli as the
most unpleasant compared to all other types of stimuli. This suggests
that good sleepers do not view symptoms of insomnia in as negative
light as those individuals with primary insomnia.
In addition to the results related to the main hypothesis of this
study, our ﬁndings evidenced cultural differences both with respect
to physiological and subjective measures of emotional responses.
Our Italian sample responded with increased physiological activity
to all stimuli and rated the positive stimuli not related to sleep as
more arousing compared to the sample recruited in Glasgow.
Further investigation is needed to deepen the role of different
cultural and social norms in the affective experience. The cultural
component of the emotional responses should be taken in
consideration when investigating emotions in different contexts.
As expected, people with primary insomnia reported higher
trait levels of anxiety on the STAI-T compared to good sleepers.
Nonetheless, all participants were under the clinical threshold for
clinical anxiety (Sesti, 2000) and reported no psychiatric condition
at the clinical interview. Additionally, the two groups did not differ
with respect to the level of subjective sleepiness before the
recording. Furthermore, groups did not differ with respect to
medications use. Thus all the differences in the emotional
responses to different conditions seen in the present study could
not reasonably be attributed to the presence of a psychiatric or
psychological disease or to excessive subjective sleepiness.
Some points of strength and some limitations of the study have
to be addressed. The use of validated sleep-related material
allowed us to evaluate speciﬁc emotional responses in people with
insomnia. In addition, this study is the ﬁrst one to differentiate
negative and positive stimuli related to sleep in insomnia
research. Furthermore, we used facial EMG which has the
advantage of detecting muscular activity that would not be
observable with the naked eye (Ekman & Rosenberg, 2005).
However it has the disadvantage of being obstructive and intru-
sive. Thus, participants are aware that their face movements are
being measured which, of course, is different from the natural
conditions in which emotions are generally expressed. Results
could have been inﬂuenced by gender differences between the
two groups, as the group with insomnia included more women
compared to the control group. Women are generally more facially
expressive and demonstrate greater stress induced changes in
heart rate than men (Heponiemi, Ravaja, Elovainio, Näätänen, &
Keltikangas-Järvinen, 2006).
While none of the stimuli had a high level of arousal (all val-
ues < 6), there were still differences in the arousal levels between
the types of stimuli: negative stimuli not related to sleep had the
highest levels of arousal compared to all other types of stimuli, and
sleep-related positive stimuli had the lowest levels of arousal. The
arousal dimension of the stimuli should bemore closely matched in
future studies. Moreover, the ratings of the sleep-related positive
stimuli could have been also inﬂuenced by intrinsic aspects of the
SAM. In fact, the ﬁgure which represents the low extreme of the
arousal dimension is deﬁned as a “relaxed, sleepy ﬁgure”. Indeed,
both good sleepers and people with primary insomnia rated the
sleep-positive stimuli with low levels of arousal.
This is the ﬁrst study evaluating physiological responses to
emotional stimuli considering the valence dimension of
emotions in insomnia. For this reason, conclusions about the
relevance of the processing of the emotional valence of
symptom-related stimuli in insomnia have to be drawn carefully,
and more investigations are needed. Since responses in the
corrugator muscle did not show sensitivity to symptom-rele-
vant-negative stimuli, further investigations are needed using
different physiological techniques and measures (as for example,
neuroimaging studies). Moreover, new studies could use
dynamic stimuli (i.e. ﬁlms), instead of static stimuli (i.e. pictures)
to contrast the reduction of spontaneous facial activity due to
intrinsic proprieties of the EMG recordings. Additionally, this
study was conducted on an undergraduate sample. The ﬁndings
from this sample may, therefore, not generalize to other pop-
ulations, such as children, adolescents, elderly adults, patients.
Indeed, the ﬁndings need to be replicated in a treatment seeking
sample. Furthermore, investigations are needed to conﬁrm the
presence of a craving effect for positive sleep-related stimuli in
people with insomnia. Indeed, an excessive focus on the bene-
ﬁcial effects of a good night of sleep would be consequently
related to worries and negative thoughts about the conse-
quences of not sleeping well. If our results will be conﬁrmed by
further research, they could suggest that psychological treatment
of insomnia can beneﬁt from the inclusion of strategies dealing
with emotional processes associated to sleep disruption. Since
the occurrence of isolated insomnia symptoms for a period of
more than two weeks predicts increased risk of developing
depression within the following three years (Riemann &
Voderholzer, 2003), the understanding of the speciﬁc nature
and mechanisms underlying affective regulation in primary
C. Baglioni et al. / Behaviour Research and Therapy 48 (2010) 467e475474
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insomnia can help in improving the quality of treatment and in
delineating preventative programs for possible consequent mood
disorders.
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contrast, IdI is a lifelong complaint with a chronic course and 
few periods of sustained remission. It has been suggested that 
IdI may be resistant to treatment.6 There is a limited amount of 
research literature on IdI, perhaps because the condition is rela-
tively uncommon and affects fewer than 10% of those present-
ing with insomnia complaints.1 Moreover, conceptualizations 
of insomnia development and maintenance seem to fit more 
closely with PI than they do with IdI.7-11
IdI is partly defined by the absence of precipitating and 
maintaining factors, and patients appear to exhibit only minor 
psychologic abnormalities. The use of denial and repression 
as coping strategies has been suggested, and there may be an 
association with neurodevelopmental disorders.12,13 Higher lev-
els of “arousability” have been reported in patients with IdI,6 
and it may be that IdI represents the extreme of an insomnia 
continuum, where there is less of a psychologic and more of a 
physiologic characteristic. Somatic hyperarousal may be pres-
ent in all insomnias,14,15 but may be a particular feature of IdI. 
In this regard it should be taken into consideration that con-
ditioning of arousal also may be a factor in IdI, although this 
possibility has not been investigated. On the other hand, some 
research has found no major differences between IdI and PI 
on either polysomnography (PSG) recordings or psychologic 
measures.16 This finding is consistent with the Diagnostic and 
Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) 
Work Group conclusion that, although the PI and IdI classifica-
INTRODUCTION
Insomnia is a prevalent disorder that is challenging to man-
age,1,2 partly because of its inherent heterogeneity and the limit-
ed data available on the benefits (or disadvantages) of matching 
treatment to clinical presentation.3,4 The International Classifi-
cation of Sleep Disorders, 2nd Edition (ICSD-2) provides diag-
nostic criteria for several primary insomnia subtypes, including 
psychophysiologic insomnia (PI) and idiopathic insomnia (IdI).5 
The goal of the current study was to compare the way that adults 
with each of these subtypes perceive their insomnia, and to con-
sider any resultant implications for clinical management.
According to ICSD-2, PI develops in adulthood, may be 
linked to identifiable precipitating events and/or stressors, and 
comprises both psychologic and physiologic features such as 
conditioned arousal, sleep-incompatible behavior, sleep preoc-
cupation, and excessive focus on and anxiety about sleep. In 
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pression Inventory (BDI-II)20 and the Beck Anxiety In-
ventory (BAI)21) were used to assist evaluation of mental 
state and to describe and compare the final samples.
All assessment procedures were carried out by final-year, 
doctoral-level clinical psychology interns who were trained 
and supervised in behavioral sleep medicine by the first author 
(CAE). Consistent with current clinical assessment practice for 
such patients, PSG was not conducted.
Design
Cross-sectional, two-group comparison of PI and IdI.
Hypotheses
Consistent with a model of arousal conditioning, people with 
PI will exhibit greater sensitivity to threat (in general), and 
greater attention to sleep and sleep effort specifically, than will 
their IdI counterparts.
Measures
Behavioral Inhibition/Behavioral Activation Scale: Based 
on Gray’s seminal work, the Behavioral Inhibition/Behavioral 
Activation Scales (BIS/BAS) were developed to assess a person’s 
dispositional sensitivity to threat (behavioral inhibition: avoid-
ance of negative outcomes) and to reward (behavioral activation: 
pursuit of positive outcomes).22-24 BIS sensitivity (also known as 
threat sensitivity) underlies the experience of anxiety.25,26 Conse-
quently, we were interested in the possibility that, based on their 
differing historical experiences with sleep/insomnia, PI and IdI 
might express behavioral sensitivity in different ways.
The BIS/BAS comprises 24 items across four subscales: BIS 
Sensitivity (7 items: e.g., “criticism or scolding hurts me quite a 
bit”; “if I think something unpleasant is going to happen I usu-
ally get pretty “worked up”), and BAS Sensitivity, namely BAS 
Drive (4 items: e.g., “I go out of my way to get things I want”; 
“if I see a chance to get something I want I move on it right 
away”), BAS Fun Seeking (4 items: e.g., “I will often do things 
for no other reason than that they might be fun”; “I often act on 
the spur of the moment”) and BAS Reward Responsiveness (5 
items: e.g., “When I’m doing well at something I love to keep 
at it”; “it would excite me to win a contest”). Responses are on 
a 4-point scale, ranging from 1 (“very true for me”) to 4 (“very 
false for me”), with higher scores indicating greater sensitivity. 
The scales have good psychometric properties in other popula-
tions. Internal consistencies in our own sample were also ac-
ceptable (Cronbach α = 0.77, 0.76, 0.78, and 0.70, respectively).
Glasgow Sleep Effort Scale: According to ICSD-2,5 IdI “is 
not associated with specific precipitating or perpetuating fac-
tors” (p. 12), whereas the related notions of sleep preoccupation 
and striving for sleep are regarded as “essential features” of 
the acquisition and maintenance of PI, i.e., “Learned associa-
tions are marked by overconcern with the inability to sleep. A 
cycle develops in which the more one strives to sleep, the more 
agitated one becomes, and the less able one is to fall asleep….
Concerns about sleep grow progressively over months or years 
as sleep gradually deteriorates until the desire to obtain good 
sleep becomes the person’s major concern” (p. 6). Indeed, such 
selective attention to sleep is now recognized as important in 
several contemporary models of insomnia.8-11 Consequently, we 
wanted to compare PI and IdI on this dimension.
tions offered some clinical value, there was limited empirical 
support to propose their distinction.17 Perhaps because of the 
relative paucity of additional studies on idiopathic insomnia 
in the period between major editions, the DSM-5 committee 
appears to be taking a similar view in classifying a single in-
somnia disorder without subtypes being specified. (For further 
information see: http://www.dsm5.org/ProposedRevisions/
Pages/proposedrevision.aspx?rid=65).
Clearly more research is warranted to better understand why 
PI and IdI appear to be (at least) clinically distinctive. The pur-
pose of this study, therefore, was to compare how people meet-
ing diagnostic criteria for PI and IdI conceptualize their own 
sleep difficulties. The study objective was to investigate simi-
larities, and potential differences, in patients’ personal perspec-
tives, that might inform how we should approach management. 
Here we report two comparative studies, each having a sepa-
rate clinically defined IdI sample, with its own PI comparison 
group. We first present the methods and results of each study, 
followed by an integrated discussion.
STUDY 1: COMPARATIVE INVESTIGATION OF AROUSAL 
CONDITIONING AND SLEEP EFFORT IN PI AND IDI
Methods
Participants
Eligible participants (18-65 yr) were recruited from the Uni-
versity of Glasgow Sleep Centre (UGSC) outpatient clinics 
and through local media advertisement, with most participants 
(approximately 75%) located via the media source. Rigorous 
clinical inclusion criteria for PI and IdI applied to all potential 
participants were as follows:
1. Initial telephone screening using the UGSC screening 
interview.
2. In-person, clinical evaluation against generic DSM-IV 
and specific ICSD-2 (PI and IdI) insomnia criteria, in-
cluding detailed sleep history review.
3. More specifically, PI participants had to have developed 
persistent insomnia during adulthood, with no prior his-
tory of sleep disturbance; IdI participants had to have 
persistent and unremitting sleep problems since child-
hood.
4. Evidence of a current complaint of insomnia, verified by 
review of a minimum of 1 wk of sleep diary records; 
scores > 5 on the Pittsburgh Sleep Quality Index (PSQI)18 
and > 8 on the Insomnia Severity Index (ISI).19
Exclusion criteria were as follows:
1. Anyone developing insomnia between the ages of 12 and 
17 yr (to reduce overlap and increase the specificity and 
homogeneity of the samples).
2. Any symptomatic evidence of narcolepsy, sleep apnea, 
restless legs syndrome/periodic limb movement disor-
der, circadian rhythm sleep disorder, or parasomnia us-
ing the UGSC sleep diagnostic interview.
3. Any history or present-state diagnosis of psychopatho-
logic disorder; somatic disorder related to the onset and/
or course of insomnia; evidence of substance abuse; tak-
ing medications known to influence sleep; or unstable 
medical condition. The Beck inventories (the Beck De-
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Behavioral sensitivity
Table 1 also summarizes between-group comparisons on 
the BIS/BAS scales. As can be seen, the PI group scored 
higher than the IdI group on the BIS scale (t (38) = 4.04, 
P < 0.001) indicating higher levels of threat sensitivity in PI. 
Given that historical differences are crucial to testing of the 
group factor (PI versus IdI), we repeated this analysis, con-
servatively correcting for age as a covariate, because it had 
been found to correlate with some of the dependent variables. 
The model remained significant when age was in the equa-
tion (F(2,37) = 7.98, P = 0.001). There were, however, no 
significant differences between PI and IdI on any of the three 
BAS dimensions.
Sleep effort
An omnibus, multivariate test (again with age as a covari-
ate) was conducted across the 7 items of the GSES. This 
test revealed a significant between-group multivariate effect 
(F(7, 31) = 3.40, P = 0.008). Subsequent univariate compar-
isons revealed that this effect was accounted for by 4 GSES 
items differing between the PI and IdI groups (Table 2).
Specifically, PI endorsed “putting too much effort into sleep-
ing” (F(2) = 4.41, P = 0.019), being “anxious about sleeping be-
fore going to bed” (F(2) = 3.87, P = 0.030) and “worrying about 
the consequences of not sleeping” (F(2) = 3.34, P = 0.046) more 
strongly than did IdI. Conversely, there was a nonsignificant 
trend for the IdI participants to endorse being “no good at sleep-
ing” more strongly than PI (F(2) = 3.01, P = 0.062).
The results from Study 1, therefore, broadly confirm the hy-
pothesis that people with PI exhibit greater levels of threat sen-
The Glasgow Sleep Effort Scale (GSES) is a short (7-item) 
scale specifically designed to assess effortful preoccupation 
with sleep.27 The GSES can be used to support a diagnosis of 
primary insomnia, particularly psychophysiologic insomnia,27 
and it also differentiates people with insomnia associated with 
mental disorder from normal sleepers.28 A cutoff score ≥ 3 cor-
rectly identifies 93% of insomnia patients and excludes 87% of 
normal sleepers, representing a likelihood ratio of +7.3 (4.39-
12.20) for insomnia patients relative to -0.08 (0.04-0.17) for 
normal sleepers. The GSES has a single factor structure with 
acceptable internal consistency (Cronbach α = 0.77) and re-
spondents score each item on a 3-point Likert scale ranging 
from 2 (“very much”) to 0 (“not at all”).27
Results
Sample demographics and sleep characteristics
Forty eligible participants (29 female) with a mean age of 
46.1 yr (standard deviation (SD) 14.5) were recruited (Table 1). 
There were no differences between groups on descriptive de-
mographic, sleep, or mental health dimensions. PSQI and ISI 
mean scores were indicative of clinical insomnia of moderate 
severity, whereas BAI and BDI scores suggest mild anxiety and 
minimal depressive symptoms. These results confirm that the 
groups were well matched
As expected, IdI and PI group allocation was supported by 
the IdI group reporting significantly younger mean age of in-
somnia onset (younger than age 5 yr compared with age 34 yr: 
t (38) = 9.1, P < 0.0001) and longer insomnia duration (37 yr 
compared with 16 yr: t (38) = 5.01, P < 0.001).
Table 1—Demographic, mental health, and sleep characteristics of Study 1 
samples; and between-group comparisons on behavioral sensitivity scales 
Psychophysiologic
insomnia
(n = 20)
Idiopathic
insomnia
(n = 20)
Demographic
Age (yr) 49.95 (12.7) 42.15 (15.4)
Sex [n (%)]
Female 15 (75) 14 (70)
Male 5 (25) 6 (30)
Mental health
Beck Depression Inventory II 9.6 (6.64) 5.65 (7.24)
Beck Anxiety Inventory 12.75 (11.12) 8.2 (7.46)
Sleep
Age of onset (yr) 34.33 (13.8) 4.7 (4.1)
Insomnia duration (yr) 16.33 (11.0) 37.15 (14.2) 
Pittsburgh Sleep Quality Index 13.11 (2.95) 12.85 (3.88)
Insomnia Severity Index 17.39 (4.67) 15.25 (5.77)
Behavioral sensitivity
Inhibition sensitivity 22.85 (2.71) 18.65 (3.77)
Activation sensitivity - drive 10.25 (2.93) 9.5 (2.52)
Activation sensitivity - fun 10.60 (2.74) 11.85 (2.83)
Activation sensitivity - reward 15.95 (2.01) 16.0 (3.03)
All data represent mean (SD), unless otherwise stated.
Table 2—Between-group comparison of Study 1 samples on items from 
the Glasgow Sleep Effort Scalea
Psychophysiologic
insomnia
(n = 20)
Idiopathic
insomnia
(n = 20)
Glasgow sleep effort scale
1.  I put too much effort into 
sleeping when it should come 
naturally
1.10 (0.79) 0.70 (0.73)
2.  I feel I should be able to 
control my sleep
1.15 (0.59) 0.90 (0.64)
3.  I put off going to bed at night 
for fear of not being able to 
sleep
0.50 (0.61) 0.75 (0.72)
4.  I worry about not sleeping if I 
cannot sleep
1.35 (0.59) 1.05 (0.76)
5. I am no good at sleeping 1.20 (0.69) 1.70 (0.57)
6.  I get anxious about sleeping 
before I go to bed
0.80 (0.69) 0.30 (0.57)
7.  I worry about the 
consequences of not 
sleeping
1.40 (0.68) 0.90 (0.64)
aAll data represent mean (SD), unless otherwise stated.
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elicit individuals’ beliefs in relation to having personal control 
over their illness (high subscale score indicates perceived lack 
of control: e.g., “I have the power to influence my insomnia”) 
or if they believe a treatment might be effective in curing their 
illness (high subscale score indicates low treatment expecta-
tions: e.g., “There is nothing that can help my condition”).
Participants responded to each item using a 5-point Lik-
ert scale ranging from 0 (strongly disagree) to 4 (strongly 
agree). Several previous adaptations to particular health pop-
ulations have yielded good internal consistency (Cronbach 
α = 0.70-0.90).30 We obtained similar values across the sub-
scales in the current study (Cronbach α = 0.68-0.89).
Illness Cognition Questionnaire: Similar to the IPQ-R, the 
Illness Cognition Questionnaire (ICQ) was developed for use 
in chronic diseases,34 and can be worded specifically to the “ill-
ness” in question. We included the ICQ because it evaluates 
two important components of mental state, in our case in rela-
tion to insomnia. One scale measures the cognitive construct of 
“acceptance” (6 items: e.g., “I think I can handle the problems 
related to my insomnia, even if the insomnia gets worse” and “I 
can cope effectively with my insomnia”). A high score is indic-
ative of low acceptance. The “helplessness” scale then provides 
an additional measure of impact/sense of control (6 items: e.g., 
“my insomnia controls my life” and “my insomnia limits me in 
everything that is important to me”). A high score indicates less 
helplessness/more control.
Items are rated ranging from 1 (agree) to 4 (disagree) (sub-
scale score range = 4-24) The ICQ is reported as a reliable and 
valid assessment of perceptions of patients with a chronic dis-
ease (Cronbach α = 0.84-0.91).34 In our study, subscale inter-
nal reliabilities were Cronbach α = 0.81 (acceptance) and 0.77 
(helplessness).
Coping Style (Brief Cope): We also wanted to compare 
how people with PI and IdI perceive that they typically respond 
when confronted with difficult or stressful events. The 28-item 
Brief Cope profiles 14 coping styles: active coping, planning, 
positive refraining, acceptance, humor, religion, using emotion-
al support, using instrumental support, self-distraction, denial, 
venting, substance use, behavioral disengagement, and self-
blame.35 Responses are scored ranging from 1 (“I usually don’t 
do this at all”) to 4 (“I usually do this a lot”). Some examples 
of items include “trying to see it in a different light, to make it 
seem more positive” (positive reframing), “turning to work or 
other activities to take my mind off things” (self-distraction), 
and “making fun of the situation” (humor). The Brief Cope is 
said to have psychometric properties consistent with its origi-
nal 60-item version (Cronbach α ≤ 0.90).35 We did not check 
the internal consistency of this short-form version because each 
subscale comprised only 2 items.
Treatment Acceptability Scale: Finally, we included a 
scenario-based assessment of patients” perceptions by adapt-
ing the treatment acceptability/preferences paradigm by Morin 
et al.44 to include a novel treatment descriptor on acceptance 
treatment. In this regard it should be noted that there is growing 
evidence that acceptance-based strategies may be associated 
with better emotional adjustment across a range chronic health 
conditions.58,59 The traditional Treatment Acceptability Scale 
(TAS) incorporates a behavioral treatment and a pharmacologic 
treatment scenario, each of which participants rate for treat-
sitivity in general and a more pronounced sleep-related focus 
than people with IdI.
STUDY 2: COMPARATIVE INVESTIGATION OF ILLNESS 
PERCEPTION, COPING STYLE, AND TREATMENT 
ACCEPTABILITY IN PI AND IDI
Methods
Participants
Eligibility criteria and recruitment procedures were identical 
to those used in Study 1 with 2 exceptions. First, the conserva-
tive exclusion zone for age of insomnia onset was set slightly 
larger, between the ages of 10 and 18 yr. No one whose insom-
nia started within this age range was accepted into the study. 
Second, anyone with previous or current experience of psy-
chologic treatment for insomnia was excluded, and none of the 
participants was on pharmacotherapy for insomnia at the time 
of the study. Also in this study, the Dysfunctional Beliefs and 
Attitudes About Sleep Scale (DBAS-16)29 was added to give a 
further descriptive profile of the samples.
Design
Cross-sectional, two-group comparison of PI and IdI.
Hypotheses
People with IdI will regard their insomnia as more perma-
nent and will be more accepting of it than will people with PI. 
Both groups will rate a behavioral treatment as preferable to 
pharmacotherapy, but the IdI group will also consider an “ac-
ceptance treatment” in preference to pharmacotherapy.
Measures
Illness Perception Questionnaire-Revised: Acknowledg-
ment that IdI (in particular) is an unrelenting condition suggests 
that it may be worthwhile considering patients’ perceptions 
from a “chronic symptom” perspective. Pain and fatigue come 
to mind as parallel, poorly understood psychophysiologic con-
ditions often displaying poor treatment response,31,32 and being 
associated with clinician frustration and helplessness (“com-
passion fatigue).33 The Illness Perception Questionnaire-Re-
vised30 (IPQ-R: 21 items) has proven valuable in such disorders 
to investigate patient perspectives, so it was selected as a suit-
able measure to explore illness perceptions of IdI relative to PI. 
Moreover, the IPQ-R is validated to permit the word illness to 
be replaced, in this instance with insomnia, to make it a disease-
specific scale.
The IPQ-R includes a timeline: acute/chronic subscale (6 
items), which measures perceptions of permanency (high sub-
scale score indicates permanence: e.g., “my insomnia is likely 
to be permanent rather than temporary”; “I expect to have this 
insomnia for the rest of my life”) and a timeline: cyclical sub-
scale (4 items), which measures if an individual perceives his or 
her illness to be variable, with either a cyclical nature or being 
constant and unrelenting (high subscale score indicates vari-
ability: e.g., “I go through cycles in which my insomnia gets 
better and worse”; “my insomnia is very unpredictable”). The 
two other IPQ-R subscales are also of interest. The personal 
control subscale (6 items) and treatability subscale (5 items) 
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perceived their insomnia to have greater permanency than did 
the PI group (t (59) = 2.18, P = 0.033). There were no signifi-
cance differences between groups on the variability, personal 
control, or perceived treatability subscales. It should be noted, 
however, that mean scores suggest that both groups tended to 
view their insomnia as variable and outside of their control, and 
had doubts about its treatability.
Illness cognition
Both PI and IdI groups scored in the midscale range on the 
ICQ acceptance subscale, indicating moderate levels of insom-
nia acceptance/lack of acceptance (Table 4). However, there 
were no significant differences between participants with PI 
and IdI. Likewise, there were no differences between groups on 
the ICQ helplessness scale (both P > 0.05).
Coping strategies
A comparison of profiles of use of the 14 different strategies 
measured by the Brief Cope is also presented in Table 4. Inter-
estingly, the top three endorsed strategies (interpreting mean 
scores from highest to lowest) for PI were acceptance, active 
coping, and planning. Acceptance and active coping were 
also the two top-rated strategies in the IdI group, but with the 
use of humor scoring equal second. Between-group compari-
son showed that patients with IdI rated using humor to cope 
significantly more often than those with PI (t (59) = -2.73, 
ment acceptance (2 items), willingness to comply, suitability 
for sleep onset, and for sleep maintenance problems, perceived 
effectiveness (2 items), and side effects.36 Each dimension is 
rated ranging from 1 to 6, giving a possible range of 8-48 per 
scale. We added an Acceptance Therapy scenario to explore 
this additional perspective to the way adults with PI and IdI 
might conceptualize insomnia treatment. The treatments were 
described in three ways.
Behavioral treatment is a nondrug treatment method aimed at 
teaching individuals a set of skills to help overcome their sleep 
problem. It provides specific guidelines for changing poor sleep 
habits and for regulating sleep schedules. Education about sleep 
hygiene factors (e.g., bedroom environment) is also provided. 
Pharmacologic treatment consists of taking a prescribed pill at 
a specified time. The prescribed medication is a naturally-oc-
curring hormone that is essential for sleep. The specific dosage 
would be based on the nature and severity of the patient’s sleep 
problem. Acceptance treatment is a nondrug treatment method 
aimed at encouraging acceptance of insomnia. It is designed to 
develop strategies for overcoming the effect of insomnia on a 
patient’s life (e.g., engaging in increased activity or reducing 
distress caused by insomnia-associated thinking).
We modeled the pharmacologic treatment on a melato-
nin receptor agonist (mRA) for three reasons. First, previous 
studies have already indicated that a conventional sleeping 
pill is not particularly favored by people with insomnia, with 
behavioral treatment receiving higher ratings36,37; second, we 
wanted to “match” the novelty aspect of acceptance therapy, 
as a new(er) approach; and third, how people might respond to 
an mRA proposition was in itself interesting. In our study, all 
three TAS achieved satisfactory reliability (behavioral: Cron-
bach α = 0.88; pharmacologic: Cronbach α = 0.82; acceptance: 
Cronbach α = 0.92).
Results
Sample demographics and sleep characteristics
A total of 61 adults with insomnia (48 females; mean age 
36.6 (15.1) yr) participated. There were no differences between 
PI and IdI groups on sex or age, or on educational or relationship 
status (Table 3). Likewise, the groups were well matched on 
health status (Short Form-36)39 and alcohol consumption, and 
had at most minor anxiety and/or depressive symptoms. Both 
PI and IdI groups reported sleep disturbance, in the moderate 
range on the PSQI and ISI, with no significant between-group 
differences. Average duration of insomnia was 7 years for the 
PI group and 26 years for the IdI group, yet dysfunctional think-
ing about sleep did not differ between groups, either in terms 
of Dysfunctional Beliefs and Attitudes About Sleep (DBAS-16) 
total score (Table 3) or on its subscales. None of the partici-
pants had received previous psychologic treatment. Some in 
both groups reported occasional previous use of prescribed and 
nonprescribed medication for insomnia, although none was tak-
ing prescribed medication at the time of assessment.
Illness perception
Both groups perceived their sleep difficulties to be relatively 
chronic, scoring above the mid-point on the IPQ-R permanency 
subscale (mean item scores: Table 4). However, the IdI group 
Table 3—Demographic, health, and sleep characteristics of study 2 samplesa
Psychophysiologic 
insomnia
(n = 31)
Idiopathic
insomnia
(n = 30)
Demographic
Sex [n (%)]
Female 24 (77.4) 24 (80)
Male 7 (22.6) 6 (20)
Age (yr) 38.52 (14.5) 34.63 (15.7)
Education [n (%)]
Secondary completed 14 (45.2) 10 (33.3)
Tertiary completed 17 (54.8) 20 (66.7)
Relationship status [n (%)]
With partner 13 (41.9) 14 (46.7)
Living alone 18 (58.1) 16 (53.3)
Health
Alcohol (units/wk) 6.67 (5.85) 6.8 (6.66)
BDI II 12.39 (6.67) 10.41 (5.88)
BAI 7.74 (3.98) 8.35 (5.8)
SF-36
Physical 76.37 (15.34) 82.73 (12.51)
Mental 63.18 (18.37) 66.37 (17.92)
Sleep
PSQI 10.25 (3.76) 10.90 (3.38)
ISI 14.74 (5.29) 16.23 (4.7)
DBAS-16 76.28 (25.76) 74.73 (29.34)
aAll data represent mean (SD), unless otherwise stated. BAI, Beck Anxiety 
Inventory; BDI, Beck Depression Inventory; DBAS-16, Dysfunctional 
Beliefs and Attitudes About Sleep Scale; ISI, Insomnia Severity Index; 
PSQI, Pittsburgh Sleep Quality Index; SF-36, Short Form-36.
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(behavioral (rho = -0.054); acceptance (rho = 0.026); pharma-
cologic (rho = -0.164); all P > 0.40).
Treatment acceptability scores for the PI and IdI groups are 
also presented as centiles in Figure 1. Related t-tests indicate 
that behavioral treatment was the highest rated both within 
the PI group (behavioral versus pharmacologic: t (31) = 3.30; 
P = 0.003; behavioral versus acceptance: t (31) = 5.03; 
P < 0.001] and the IdI group (behavioral versus pharmaco-
logic: t (30) = 3.45; P = 0.002; behavioral versus acceptance: t 
(30) = 2.79; P = 0.01). Despite the visual impression that the PI 
group rated pharmacologic treatment higher than acceptance 
treatment, and that the IdI group rated acceptance higher than 
pharmacologic treatment, neither effect was not supported sta-
tistically (both P > 0.30).
The results from Study 2 lend some support to the hypothesis 
that IdI participants regard their insomnia as somewhat more 
permanent than PI. Whereas neither group regards insomnia as 
acceptable, an acceptance treatment was considered more fa-
vorably by IdI than by PI participants. Behavioral intervention 
was preferred to pharmacotherapy by both groups.
DISCUSSION
Despite some early interest in comparing and contrasting 
the insomnia phenotypes of IdI and PI, scientific progress 
has been limited. Although ICSD-2 retained the subtypes 
proferred in the original ICSD,38 due to limited research data 
they were not included in DSM-IV and they seem unlikely 
to be in the DSM-5 nosology (expected publication in 2013). 
Nonetheless, their “clinical utility” has been recognized (com-
passion fatigue, DSM-IV). Therefore, we took this consensus 
clinical framework to conduct two consecutive studies, with 
the purpose of comparing and contrasting the patient perspec-
tives and insomnia treatment preferences of people with IdI 
and PI. We endeavored to make clinical differentiation both 
valid and robust; e.g., by excluding anyone whose sleep prob-
lem developed during their teenage years, and by matching 
the IdI and PI groups on demographic factors, insomnia se-
verity, and associated (but minimal) psychopathology. Thus, 
we recruited two relatively homogeneous insomnia subgroups 
P = 0.008). The only other strategy that differentiated between 
group was self-distraction, which also was used more often 
by patients with IdI than by those with PI (t (59) = -2.72, 
P = 0.009]. These findings fail to achieve significance after 
conservative adjustment for multiple comparisons (critical 
value: P < 0.004).
Treatment acceptability
Table 4 also summarizes between-group comparisons across 
the three treatment scenarios on the TAS task. Mixed-model 
analysis of covariance (with age as a covariate) revealed sig-
nificant effects of group (F(1) = 5.34, P = 0.025), treatment 
type (F(2) = 3.11, P = 0.049), and a near-significant group by 
treatment interaction (F(2) = 3.73, P = 0.059). There was no 
significant difference between PI and IdI in patient ratings of 
behavioral treatment or pharmacologic treatment. For the ac-
ceptance-based approach to insomnia, however, there was a 
significant effect, with the IdI group rating this intervention as 
acceptable relative to the PI group’s lower ratings (t (61) = 2.40, 
P = 0.02). To consider the possibility that treatment acceptabili-
ty covaried with duration of insomnia (independent of subtype), 
we correlated insomnia duration in the PI group with ratings for 
each treatment scenario. No significant effects were observed 
Table 4—Between-group comparison of study 2 samples on illness 
perception, illness cognition, coping style, and treatment acceptability scalesa
Psychophysiologic 
insomnia
(n = 31)
Idiopathic
insomnia
(n = 30)
Illness perception questionnaire
Permanency 3.44 (0.68) 3.84 (0.69)
Variability 2.99 (0.97) 2.78 (1.11)
Personal control 3.04 (0.65) 2.83 (0.72)
Treatability 3.24 (0.53) 3.25 (0.57)
Illness cognition questionnaire
Acceptance 14.4 (4.67) 15.7 (4.21)
Helplessness 16.5 (4.42) 17.2 (4.50)
Coping style (Brief Cope)
Active coping 5.33 (1.45) 5.85 (1.35)
Planning 5.27 (1.41) 5.69 (1.54)
Positive reframing 4.63 (1.45) 5.38 (1.81)
Acceptance 5.67 (1.37) 5.92 (1.74)
Humor 4.33 (1.94) 5.85 (2.20)
Religion 3.67 (2.14) 2.92 (1.87)
Emotional support 4.23 (2.05) 4.69 (2.22)
Instrumental support 4.70 (2.00) 4.28 (1.65)
Self distraction 4.73 (1.48) 5.73 (1.22)
Denial 2.83 (1.39) 3.19 (1.58)
Venting 4.63 (2.61) 4.28 (1.45)
Substance use 2.70 (1.29) 2.92 (1.29)
Behavioral disengagement 3.10 (1.54) 3.23 (1.73)
Self blame 4.23 (1.98) 4.12 (1.95)
Treatment acceptability scale
Behavioral therapy 41.3 (7.63) 42.19 (8.84)
Pharmacotherapy 32.9 (9.34) 34.17 (7.23)
Acceptance therapy 30.2 (9.74) 36.20 (8.80) 
aAll data represent mean (SD), unless otherwise stated.
Figure 1—Between group comparison of Treatment Acceptability centile 
scores for Study 2 samples.
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insomnia, with approximately two thirds of patients making a 
sustained response.44-47 Therefore, there is a rationale for using 
CBT with both PI and IdI patients. From the data in this study, 
we can see that PI and IdI have common psychologic features 
that may form part of an insomnia-specific (e.g., dysfunctional 
beliefs about sleep) and a generic (e.g., sense of helplessness) 
focus for CBT. Moreover, both groups rated CBT highly, pre-
sumably because they thought that it would be (most) relevant 
to their situation.
By the same token, however, we know from the literature 
that one third of patients do not respond to CBT. Therefore, it 
seems reasonable to consider two things. First, what character-
izes a nonresponder; and second, what pragmatically might be a 
“second line” therapy for those who fail to respond to adequate-
ly delivered CBT, as the behavioral treatment of first choice. 
Research has shown that it is difficult to predict, either a priori 
or a posteriori, who the responders and nonresponders might 
be48; although, importantly in relation to the current study, it 
seems likely that poor definition and subtyping in insomnia re-
search studies could be one important factor.49
From our findings, we speculate that there is a rationale for 
considering an acceptance-based therapy as a second-line in-
tervention for PI patients who have not responded to CBT; and 
potentially, as a first-line treatment for IdI. Perhaps the integra-
tion of aspects of acceptance into CBT is worth considering, al-
though we note that the evolution of multimodal CBT over and 
above its components (e.g., relaxation, stimulus control, sleep 
restriction) has not been accompanied by greatly improved 
outcomes.3 On balance, therefore, we would recommend that 
controlled evaluation of acceptance as a stand-alone therapy 
against a CBT comparator would be valuable, especially if pa-
tients can be stratified by insomnia subtype so that treatment × 
phenotype interactions can be reported. Such research would 
address two important clinical caveats: if a sleep problem can-
not be eliminated, then failing to reduce its effect and associ-
ated distress would amount to poor quality care; and if a sleep 
problem can be solved, then living with insomnia in a contented 
way would be a suboptimal therapeutic solution.
To encourage more research, we note that the therapeutic 
value of acceptance is becoming influential across a range of 
other chronic medical and psychologic disorders. Contempo-
rary “third wave” techniques such as mindfulness-based stress 
reduction, mindfulness-relaxation, and ACT,50 raise the ques-
tion of whether a person’s relationship with their symptoms 
could change (rather than focusing on symptom reduction). In 
insomnia, this would translate into addressing concerns about 
lying awake in bed, rather than addressing directly the fre-
quency or duration of lying awake in bed. There are several 
small or uncontrolled studies on acceptance and mindfulness 
approaches to insomnia in the literature,51-57 and this work is 
very much welcomed. It is worth bearing in mind, however, 
that people may be less likely to endorse acceptance of a prob-
lem if they are participants in a study based at a center where 
they are actively seeking a remedy. In this study, most partici-
pants completed measures at home. Nevertheless, the study was 
clearly associated with our clinical research center. Therefore, 
there may be methodologic advantages in also evaluating ac-
ceptance with non-treatment-seeking samples and in explicitly 
community settings.
that differed primarily, and categorically, on their history of 
poor sleep experience.
In relation to results, the first thing to be said is that we 
observed many similarities between IdI and PI, across the 
psychologic measures that we applied. Both groups reported 
helplessness and that their insomnia felt out of control, and 
they expressed doubts about its treatability (ICQ and IPQ data). 
Also trying to accept their situation and to cope with it actively 
rather than passively seemed characteristic (Brief Cope). They 
also endorsed similar levels of dysfunctional thinking (DBAS-
16) and both groups had a clear preference for a behavioral 
approach to insomnia intervention (TAS). Nevertheless, some 
hypothesized between-group differences were supported.
In Study 1, people with PI exhibited higher levels of behav-
ioral inhibition or threat sensitivity (BIS), consistent with an 
etiologic model of vulnerability to conditioned arousal in PI. 
This vulnerability might find its expression during an insom-
nia acquisition phase, perhaps at a time of stress.8,10,40 Like-
wise, analysis of sleep effort data (GSES) appears consistent 
with the ICSD-2 account that people with PI characteristically 
strive hard to sleep, and worry excessively about the conse-
quences of not sleeping.10,11 By way of contrast, there was a 
trend for people with IdI to endorse the notion that sleeping 
is just something that they are not any good at; perhaps not so 
much a learned performance failure, as a fundamental (life-
long) inability. This would be consistent with a trait hyper-
arousal perspective on IdI.
In Study 2, whereas both groups perceived their sleep prob-
lems to be chronic, and possibly permanent, this belief was held 
more strongly by people with IdI (IPQ). It is interesting, there-
fore, that as hypothesized, participants with IdI rated an accep-
tance treatment highly, an approach that seemed in comparison 
relatively unacceptable to people with PI (TAS). So we might 
speculate that there are phenotypical differences between IdI 
and PI in their readiness to adapt to a “living with insomnia” 
perspective. IdI participants were also more likely to use humor 
as a form of coping (Brief Cope). Humor is integral to some 
psychotherapeutic traditions, including Frankl’s logotherapy 
approach,41 from which paradoxic intention therapy for insom-
nia was first derived,42 and also in what has become known as 
Acceptance and Commitment Therapy (ACT).43 Perhaps humor 
provides some relief from the effect of symptoms on the person 
with insomnia, rather than directly influencing their occurrence 
per se? This would be consistent also with the comparatively 
higher use of self-distraction as a coping strategy in IdI.
We also replicated previous TAS experimental findings that 
behavioral therapy is highly rated by people with insomnia 
(here in both PI and IdI) and that it is generally preferred to 
pharmacotherapy,36,37 in this case, to the scenario of an mRA 
compound, although we did not specifically mention melatonin 
in the study. However, our data also hint (nonsignificant trend) 
that people with PI might prefer pharmacotherapy to accepting 
that they have a chronic problem that they might need to live 
with (TAS).
Taken together with the cognitive-behavioral literature on 
insomnia and its treatment, what might our results imply for 
research and for clinical practice?
We know that cognitive behavioral therapy (CBT) is an ef-
fective intervention for (largely undifferentiated) persistent 
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9. Espie CA. Insomnia: conceptual issues in the development, persis-
tence, and treatment of sleep disorder in adults. Annu Rev Psychol 
2002;53:215-43.
10. Espie CA, Broomfield NM, MacMahon KMA, Macphee LM, Taylor LM. 
The attention-intention-effort pathway in the development of psychophys-
iologic insomnia: a theoretical review. Sleep Med Rev 2006;10:215-45.
11. Harvey AG. A cognitive model of insomnia. Behav Res Ther 
2002;40:869-93.
12. Hauri PJ. Olmstead EM. Childhood-onset insomnia. Sleep 1980;3:59-65.
13. Hauri PJ. A cluster analysis of insomnia. Sleep 1983;6:326-38.
14. Bonnet MH, Arand DL. Hyperarousal and insomnia. Sleep Med Rev 
1997;1:97-108.
15. Nofzinger EA, Buysse DJ, Germain A, Price J, Miewald J, Kupfer D. 
Functional neuroimaging evidence for hyperarousal in insomnia. Am J 
Psychiatry 2004;161: 2126-29.
16. Philip P, Guilleminault C. Adult psychophysiologic insomnia and positive 
history of childhood insomnia. Sleep 1996;19:3;16–22.
17. Reynolds CF, Kupfer DJ, Buysse DJ, Coble P, Yeager A. Subtyping DSM- 
III-R primary insomnia. a literature review by the DSM IV work group on 
sleep disorders. Am J Psychiatry 1991;148:432-38.
18. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pitts-
burgh sleep quality index: a new instrument for psychiatric practice and 
research. Psychiatry Res 1989;28:193-213.
19. Bastien CH, Vallieres A, Morin CM. Validation of the insomnia sever-
ity index as an outcome measure for insomnia research. Sleep Med 
2001;2:297-307.
20. Beck AT, Steer RA, Brown GK. Beck depression inventory. New York, 
The Psychological Corporation, 1996.
21. Beck AT, Epstein N, Brown G, Steer R. An inventory for measur-
ing clinical anxiety: psychometric properties. J Consult Clin Psychol 
1988;56:893–7
22. Carver CS, White TL. Behavioral inhibition, behavioral activation, and 
affective responses to impending reward and punishment: the BIS/BAS 
scales. J Pers Soc Psychol 1994;67:319-333.
23. Gray JA. The neuropsychology of anxiety: an enquiry into the functions 
of the septo- hippocampal system. Oxford, Oxford University Press, 1982.
24. Gray JA. The neuropsychology of emotion and personality. In: Stahl SM, 
Iversen SD, Goodman EC, eds. Cognitive Neurochemistry. Oxford, Ox-
ford University Press, 1987.
25. Campbell-Sills L, Liverant GI, Brown TA. Psychometric evalua-
tion of the behavioral inhibition/behavioral activation scales in a large 
sample of outpatient with anxiety and mood disorders. Psychol Assess 
2004;16:244-254.
26. Bijttebier P, Beck I, Claes L, Vandereycken W. Gray’s reinforcement sen-
sitivity theory as a framework for research on personality-psychopatholo-
gy associations. Clin Psychol Rev 2009;29:421-30.
27. Broomfield NM, Espie CA. Towards a valid, reliable measure of sleep 
effort. J Sleep Res 2005;14:401–7.
28. Kohn L, Espie CA. Sensitivity and specificity of measures of the in-
somnia experience: a comparative study of psychophysiologic insom-
nia, insomnia associated with mental disorder and good sleep. Sleep 
2005;28:104-12.
29. Morin CM, Vallieres A, Ivers H, Bouchard S, Bastien CH. Dysfunctional 
beliefs and attitudes about sleep (DBAS): validation of a briefer version 
(DBAS-16). Sleep 2003;26:29.
30. Moss-Morris R, Weinman J, Petrie KJ, Horne R, Cameron LD, Buick D. 
The revised illness perception questionnaire (IPQ-R). Psycholog Health 
2002;17:1-16.
31. Van Damme S, Crombez G, Van Houdenhove B, Mariman A, Michielsen 
W. Well-being in patients with chronic fatigue syndrome: the role of ac-
ceptance. J Psychosom Res 2006;61:595.
32. McCracken LM, Eccleston CA. Prospective study of acceptance of pain 
and patient functioning with chronic pain. Pain 2005;118:164-9.
33. Figley CR. Compassion fatigue: psychotherapists’ chronic lack of self 
care. J Clin Psychol 2002;58:1433-41.
34. Evers AWM, Kraaimaat FW, Van Lankveld W, Jongen PJH, Bijlsma JWJ. 
Beyond unfavorable thinking: the illness cognition questionnaire for 
chronic diseases. J Consult Clin Psychol 2001;69:1026–36.
35. Carver CS. You want to measure coping but your protocol’s too long: 
consider the Brief COPE. Int J Behav Med 1997;4:92-100.
36. Morin CM, Gaulier B, Barry T, Kowatch RA. Patients’ acceptance 
of psychological and pharmacological therapies for insomnia. Sleep 
1992;15:302-5.
In conclusion, we wish to acknowledge important limitations 
to our studies. We used clinical interview criteria to establish a 
working diagnosis. Whereas this appears valid for the purpose 
of the study, and PSG would be unlikely to be informative about 
the PI/IdI discrimination, we cannot be certain that other sleep 
disorders were excluded. For example, it is possible that mild 
obstructive sleep apnea and/or periodic limb movement disor-
der could be present in either or both of our insomnia phenotype 
samples, Also, although we reviewed diary records, actigraphy 
may have been useful, for example, to confirm stability of poor 
sleep in IdI compared with night-to-night variability in PI. We 
also cannot completely exclude the possibility that the differ-
ences between PI and IdI reported here relate solely to the length 
of time that people have had problems with insomnia. Bivariate 
correlations of duration of insomnia with TAS scores in the PI 
group suggest that this was not a factor, and we included age as 
a covariate in all our major analyses. However, this is a research 
question that should be specifically addressed in the future. We 
would also point out that our description of acceptance treat-
ment was necessarily brief (40 words) to match previously pub-
lished behavioral treatment descriptions,36 and possibly left the 
descriptor open to misinterpretation (e.g.,a coping strategy rath-
er than a treatment). It is problematic to convey the therapeutic 
value (of any treatment) in so few words,and a further study 
should consider comparing more detailed outlines. Finally, we 
recognize that what people think and believe is not necessarily 
the best guide to what should be offered in the way of treatment, 
or to what will actually work for them.
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Abstract
Objective: Mental overactivity has been widely implicated ture than the original scale (three relatively “pure” factors ex-
plained 55% of the variance). The derived subscales achievedin the development and maintenance of insomnia, making the
accurate and valid measurement of cognitive variables of some satisfactory internal consistency, and the DBAS-10 demon-
strated treatment-related measurement sensitivity. Theimportance. The purpose of this study was to investigate the
psychometric properties of two existing attributional scales. DBAS-10, nevertheless, correlated highly (r 5 0.826) with the
DBAS. A four-factor solution for the SDQ is also presentedMethods: Data are presented from 178 clinic attending insom-
niacs who completed the Dysfunctional Beliefs and Attitudes (61% explained variance) with a 5 0.67. Internal consistency
of these subscales ranged from 0.59 to 0.82. The associationabout Sleep Scale (DBAS) and the Sleep Disturbance Ques-
tionnaire (SDQ). Standard procedures for the psychometric between the SDQ and DBAS-10 was modest (r 5 0.28), sug-
gesting that the scales have some independence. Conclusions:evaluation of scales were adopted. Results: The internal con-
sistency of the DBAS (30 items) was reasonable (Cronbach’s The scales offer potential for clinical and research work on
insomnia and possible applications are discussed. Ó 2000a 5 0.72); however, a revised ten-item short form (DBAS-
10) demonstrated a more robust principal component struc- Elsevier Science Inc. All rights reserved.
Keywords: Insomnia; Sleep; Beliefs; Scales
Introduction It was first reported more than 20 years ago that poor
sleepers complain of mental alertness in bed more than
Insomnia, defined as difficulty in initiating or main- physiological arousal [16]. Similar conclusions were
taining sleep [3], is reported by up to 30% of adults and drawn in later studies with insomniacs [2,13]. However,
older adults, although prevalence for frequent, severe this may be a general rule, because, in one study, having
insomnia is closer to 10% to 15% [4–7]. There is evi- an overactive mind was the attribution of poor sleep
dence that such problems can persist relatively un- rated most highly, by insomniacs and noninsomniacs.
changed over many years [8]. Both groups also rated cognitive aspects of their pre-
A substantial body of psychological research has sleep state as being more difficult to control than somatic
yielded important evidence on the genesis and mainte- ones [17]. Furthermore, experimental study has found
nance of insomnia, and models and methods of cognitive that manipulations aimed at increasing cognitive intru-
behavioral treatment have emerged [9–12]. Investiga- sion led to significantly longer latency to sleep onset
tion of the relative importance of cognitive and physio- [18,19]. Tape-recorded presleep cognitions [20] and pre-
logical arousal has found the former to be more strongly sleep mental arousal in psychophysiological insomnia
associated with sleep disruption [13–15]. Certainly, [15,21] have also been associated with delayed sleep
there is good evidence that attitudes, beliefs, and mental latency. Indeed, one recent survey has reported that
arousal are central to the complaint of insomnia [12,25]. people dissatisfied with their sleep often report engaging
in mental activity near bedtime [22]. Conversely, mental
processing tasks that disrupt sleep-related cognitions* Corresponding author. Tel.: 0141-211-3903; fax: 0141-357-4899.
E-mail address: c.espie@clinmed.gla.ac.uk (C.A. Espie) appear to decrease sleep-onset time [23]. Thus, the na-
0022-3999/00/$ – see front matter Ó 2000 Elsevier Science Inc. All rights reserved.
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ture of the thoughts may influence the effect upon sleep. quences of insomnia; unrealistic sleep expectations; di-
minished perceptions of control; and faulty beliefs aboutWe have recently studied the relationship between
sleep-promoting practices. However, the componentthought content and actigraphically measured sleep and
structure, reliability, and validity of the DBAS scalefound that thoughts related to problem-solving, rehears-
have not been formally evaluated.ing and planning daytime events, and concern about
The aim of the present study was to investigate fur-feeling tired (but not sleeping) were the best predictors
ther the psychometric adequacy of two of the threeof delayed sleep onset [24].
aforementioned scales, namely the SDQ and the DBASThe importance of emotional arousal also has been
scale. Opportunity arose to undertake this work, onstressed, reflecting the finding that affect-laden (emo-
a large patient sample, in the context of a controlledtionally charged) cognitions are the ones most likely to
outcome study of cognitive-behavioral therapy in gen-interfere with the sleep process [11,12,25,26]. Thus, it
eral medical practice [33]. The results, therefore, derivemay be the insomniac’s beliefs about the negative expe-
from a methodologically sound protocol, although theriences and consequences of insomnia that foster the
insomniac sample was clinic-presenting. It was hopeddevelopment of the clinical complaint. This work on
that statistical appraisal of the scales would lead to moreinsomnia appears to parallel studies on “worry,” which
knowledgeable future application, both in clinical prac-has been posited as a generic trait, measurable in a
tice and for research purposes.wide range of neurotic conditions [27,28], and studies
on unwanted intrusive thoughts, which are in fact com-
Methodsmon in nonclinical populations [29,30]. Negative and
distressing cognitions are the ones most likely to contrib- Subjects
ute to the development of obsessions; however, it is not
Table 1 presents summary information on the sample,the thoughts per se that are untypical or pathological,
which comprised 178 adults consecutively selected intobut the meaning and concern attributed to them [31,32].
an out-patient program for treatment of chronic insom-The potential conceptual relatedness of nighttime and
nia. The assessment protocol incorporated extensivedaytime intrusions, therefore, appears considerable.
screening for other disorders of sleep such as sleep ap-In spite of considerable evidence of the importance of
nea, periodic limb movements, parasomnias, and circa-thoughts and beliefs in insomnia, there is no recognized
dian disorders. Clinical interviewing and history-taking“gold standard” measure of cognitive activity. The Pre-
was supplemented by the use of sleep diaries [11]; acti-Sleep Arousal Scale [14] was published by Nicassio and
graphic assessment of sleep pattern [39] (particularlycoworkers in 1985 and demonstrated satisfactory inter-
useful to identify sleep phase disorders); and, wherenal consistency for both its somatic and cognitive sub-
warranted, on the basis of interview information, polys-scales (r 5 0.81 and r 5 0.76, respectively). These con-
omnographic assessment in a sleep laboratory [40]. Thestructs were found to have some degree of independence
treatment program, which involved cognitive-behav-(74% unshared variance) and acceptable face and con-
ioral therapy with the gradual withdrawal of hypnotics,struct validity. In a recent study, the cognitive subscale
has been described elsewhere [33,34]. The present co-of the PSAS demonstrated modest (r 5 0.351), but statis-
hort appears representative. The majority of patients
tically significant, validity against “live” tape-recordings
was female (68%), and the average age of the sample
of presleep thoughts as a criterion measure [24]. was 50 years. Almost 60% had insomnia of .5-year
The Sleep Disturbance Questionnaire (SDQ) [2] was duration and half were regular users of hypnotic drugs.
developed by Espie and coworkers in 1989 to guide the Table 1 also demonstrates the severity of subjective
tailoring of cognitive-behavioral treatment in a major sleep complaint (from sleep diary records). Mean sleep
controlled outcome trial. The factor structure of the latency was 62 minutes and mean wake time after sleep
SDQ was investigated by principal components analysis, onset (wakeful time in bed after sleep commenced) was
which yielded a three-factor solution, accounting for 78 minutes. Thus, these patients represented both initial
68% of total variance. Factor 1 “mental anxiety,” com- and sleep maintenance problems and appeared typical
prising 7 of the 12 items, accounted for the greatest of the clinical population. Patients either presenting
proportion of explained variance. Validity and internal with, or in active treatment for, clinically significant
consistency were not investigated. depression or posttraumatic stress disorder were ex-
In 1993, Morin published his Dysfunctional Beliefs cluded. Thus, data from standard measures of emotional
and Attitudes about Sleep Scale (DBAS) [1,12]. The state revealed generally mild depressive and anxiety-
DBAS scale is extremely useful in clinical practice as it based symptomatology as the norm with generally low
helps to identify particular, salient, irrational, and often levels of daytime sleep tendency.
affect-laden thoughts that intrude prior to sleep onset.
MeasuresIt comprises 30 analog-scaled items and the author de-
scribed five subscales: misconceptions of the causes of Subjects completed the DBAS and SDQ at baseline
entry to psychological treatment. For the purposes ofinsomnia; misattributions or amplifications of the conse-
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Table 1 DBAS
Descriptive summary of demographic, sleep, and psychopathology
Internal consistency of the DBAS was investigateddata for the insomniac sample (n 5 178; unless otherwise stated)
by calculation of a coefficients (Cronbach’s a). TheseDescriptor Values n Percent
are presented in Table 2. The a for the total scale was
Gender F 121 68
reasonable at 0.72. Alpha if item-deleted mean was 0.71M 57 32
(range 0.68 to 0.75). However, only two DBAS subscalesOccupational status Working 70 39
At home 57 32 achieved satisfactory internal consistency. Subscale 2,
Retired 51 29 “misattributions or amplifications of the consequences
History of sleep ,2 years 38 22 of insomnia,” had an a 5 0.77 and subscale 4, “dimin-
problem (n 5 172) .2 and ,5 years 34 20
ished perceptions of control and predictability of sleep,”.5 and ,10 years 33 19
a modest a 5 0.41. “Faulty beliefs about sleep-promot-.10 and ,20 years 33 19
.20 years 34 20 ing practices” (subscale 5) achieved internal consistency
Use of sleep Not in past month 91 51 of only 0.34 (range 5 0.24 to 0.35), and “unrealistic sleep
medication Less than once per 11 6 expectations” (subscale 3) had a low negative value,
week
indicating a degree of inverse relationship among items.Once or twice per 11 6
Subscale 1 (“misconceptions of the causes of insomnia”)week
Three or more 65 37 consisted of only two items, therefore, a was not com-
times per week puted. In light of these results, an exploratory principal
Mean sd components analysis (PCA) was conducted to consider
other possible factor structures for the DBAS. However,Age (years) 49.8 17.9
Sleep-onset 61.5 55.1 PCA failed to achieve convergence. It seemed likely,
latency (min) therefore, that some amendments to the DBAS scale
Wake time after 77.63 75.74 would be required.sleep-onset (min)
Total sleep time (hr) 5.83 1.57
Development of the DBAS-10Epworth Sleepiness 5.79 4.47
Scale [35] As the starting point for redevelopment of the scale
Beck Depression 12.21 9.30
we decided to examine the measurement sensitivity ofInventory [36]
each of the original 30 DBAS items. It was felt thatState–Trait Anxiety
Inventory [37] items that demonstrated significant posttreatment and
State 36.70 13.06 follow-up changes over baseline would be important to
Trait 43.53 12.84 retain in a new version of the scale. Such items couldPenn State Worry 47.69 14.97
be regarded as valid because they would represent aQuestionnaire
[38] (n 5 172) durable, treatment-related shift in attitudes and beliefs.
A series of paired t-test comparisons was made and a
conservative criterion value of p , 0.01 was selected
for the comparisons. The results of this analysis revealedevaluating measurement sensitivity in this study, the
that ten items could be regarded as significantly lowerDBAS was also completed at posttreatment and
at posttreatment (range of p 5 0.009 to 0.0001; df 53-month follow-up on smaller samples (n 5 91 and 60,
90) and at follow-up (p 5 0.007 to 0.0001; df 5 59).respectively). The DBAS comprises 30 statements re-
flecting beliefs and attitudes about sleep. Subjects are These items were retained, therefore, for further
asked to place a mark for each statement on a 10-centi- analysis.
meter horizontal line with poles labeled “strongly The ten-item scale (DBAS-10; see Table 3) was found
agree” and “strongly disagree.” The SDQ has 12 items, to have internal consistency of 0.69 (Table 2). Investiga-
each on a 5-point scale (“never true,” “seldom true,” tion of its structure by means of PCA yielded a factori-
“sometimes true,” “often true,” “very often true”). Sub- ally “pure” solution, explaining 55% of total variance.
jects are asked to rate items in relation to typical nights Three factors had eigenvalues .1 and these accounted
when they do not sleep well. for 54%, 27%, and 19% of explained variance, respec-
tively (Table 3). Factor I comprised five items from the
original scale (statements 1, 2, 10, 12, 21) and was labeled
Results “beliefs about the immediate negative consequences of
insomnia.” Factor II, “beliefs about the long-term nega-Data on internal consistency and measurement sensi-
tive consequences of insomnia,” comprised three of thetivity, and from factor-analytic studies, are reported.
original statements (5, 8, 17), and factor III, “beliefsThese will be presented for each measure in turn fol-
about the need for control over insomnia,” comprisedlowed by correlational analyses of the interrelationship
of the DBAS and SDQ. two statements (7, 22). It should be noted that statement
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Table 2 4). Similarly, the SDQ factors correlated significantly
Internal consistency of the SDQ, DBAS and DBAS-10 scales and with the SDQ total (0.31 to 0.88). As would be expected,
their factor scales (N/A refers to factors with two or less items) the strength of relationship between factor and total
(n 5 178)
scale score reflected the proportion of explained vari-
a if item ance associated with that factor. Intercorrelation among
Scale Coefficient a deleted (range)
DBAS-10 factors was modest (all r , 0.30). Similarly,
DBAS total 0.717 0.684 to 0.748 SDQ factors appeared relatively independent with five
DBAS subscale 1 N/A N/A
of the six correlations being less than r 5 0.20. SDQDBAS subscale 2 0.773 0.706 to 0.783
factors I and II did, however, demonstrate a stronger,DBAS subscale 3 20.233 20.856 to 0.219
DBAS subscale 4 0.411 0.302 to 0.567 positive association (r 5 0.38; p , 0.001).
DBAS subscale 5 0.343 0.240 to 0.351 Intercorrelation among DBAS-10 and SDQ factor
DBAS-10 total 0.693 0.629 to 0.719 scores is also presented in Table 4. A modest, but sig-
DBAS-10 factor I 0.733 0.650 to 0.716 nificant, relationship was found between total scores on
DBAS-10 factor II 0.600 0.264 to 0.739 the DBAS-10 and SDQ (r 5 0.28), and there were few
DBAS-10 factor III N/A N/A
strong relationships between the measures at the factor
SDQ total 0.674 0.614 to 0.727 level, suggesting that the DBAS-10 and SDQ are some-SDQ factor I 0.586 0.477 to 0.698
what independent of one another. “Beliefs about theSDQ factor II 0.818 0.714 to 0.767
SDQ factor III N/A N/A long-term negative consequences of insomnia” (DBAS-
SDQ factor IV N/A N/A 10 factor II) correlated positively, but relatively weakly
(r 5 0.30), with “attributions concerning restlessness/
agitation” (SDQ factor I) and “attributions concerning
22 loads inversely on factor III, thus representing belief consequences of insomnia” (SDQ factor III). “Beliefs
in the need for active control over thought processes. about the need for control over insomnia” (DBAS-10
All factor loadings were greater than r 5 0.45, with the factor III) correlated more strongly (r 5 0.49) with “at-
majority being greater than r 5 0.68. Internal consis- tributions concerning mental overactivity” (SDQ factor
tency for factors I and II was calculated as 0.73 and II) and “restlessness/agitation” (r 5 0.37; SDQ factor
0.60, respectively (Table 2). Because factor III had only I). DBAS-10 factor I (“beliefs about the immediate,
two items, the a was not computed. negative consequences of insomnia”), which accounted
for the greatest proportion of variance in the DBAS-SDQ
10 scale, did not correlate with any of the SDQ factors
The internal consistency of the 12-item SDQ was (r 5 20.13 to 0.12).
calculated to be 0.67, indicating satisfactory reliability
(Table 2). PCA was again used to investigate structural
properties and this yielded a four-factor solution ex- Discussion
plaining 61% of total variance (Table 3). Factor I, “attri-
In spite of an increasing emphasis upon cognitivebutions concerning restlessness/agitation,” accounted
factors in understanding and treating insomnia, therefor the greatest amount of explained variance (46%).
are few suitable, tested measures available in this field.It comprised six items from the original scale (1, 3, 4,
Those that have been introduced in the literature have5, 8, 9), with internal consistency of 0.59. Factor II,
not generally been subject to further rigorous scientific“attributions concerning mental overactivity,” com-
study, although they may have become part of commonprised three items (2, 6, 10), and had high internal relia-
usage in clinical practice. The DBAS and the SDQ arebility (a 5 0.82; Table 2). Factor III, “attributions con-
two promising measures that have been available forcerning the consequences of insomnia,” and factor IV,
the past 5 to 10 years. The results of this study indicate“attributions concerning lack of sleep readiness,” com-
that each has some structural and psychometric strength.prised two items (11, 12) and one item (7) respectively;
therefore, a-values were not computed. Loadings on DBAS and DBAS-10
factors II, III, and IV were all greater than r 5 0.77,
and on factor I were in the range r 5 0.41 to 0.68. Although the DBAS scale had good overall internal
Inspection of Table 3 demonstrates that PCA provided consistency, further analysis proved somewhat disap-
a relatively “pure” solution. pointing. Only one of the five suggested subscales dem-
onstrated sound internal consistency and DBAS failed
Relationships between the scales to achieve convergence during principal components
analysis. Thus, it was not possible to confirm Morin’sThe DBAS-10 total score was found to correlate
putative factor structure [1,12]. However, a shortenedhighly and significantly with the original DBAS total
ten-item scale emerged that had many of the qualities(r 5 0.826). Each of the DBAS-10 factors correlated
with the DBAS-10 total score (range 0.48 to 0.86; Table required of a rating scale instrument.
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Table 3
Results from principal components analyses of DBAS-10 and SDQ comprising derived factors, loadings (significant values in bold), labels
and item content (n 5 178)
Variance Cumulative Explained
Factor Factor label Eigenvalue (%) (%) variance (%)
DBAS-10 factor I “Beliefs about the immediate negative 2.947 29.5 29.5 53.7
consequences of insomnia”
DBAS-10 factor II “Beliefs about the long-term negative 1.487 14.9 44.3 27.2
consequences of insomnia”
DBAS-10 factor III “Beliefs about the need for control over 1.055 10.5 54.9 19.1
insomnia”
SDQ factor I “Attributions concerning restlessness/ 3.434 28.6 28.6 46.8
agitation”
SDQ factor II “Attributions concerning mental 1.568 13.1 41.7 21.4
overactivity”
SDQ factor III “Attributions concerning the consequences 1.263 10.5 52.2 17.2
of insomnia”
SDQ factor IV “Attributions concerning lack of sleep 1.065 8.9 61.1 14.6
readiness”
Rotated factor matrix Item content Factor I Factor II Factor III Factor IV
DBAS-10 01 (item 01)a I need 8 hours of sleep to feel refreshed and 0.686 20.113 0.145
function well during the day
DBAS-10 02 (item 02) When I don’t get the proper amount of sleep 0.699 20.077 0.087
on a given night, I need to catch up on the
next day by napping or on the next night by
sleeping longer
DBAS-10 03 (item 05) I am concerned that chronic insomnia may 0.163 0.774 20.046
have serious consequences on my physical
health
DBAS-10 04 (item 07) When I have trouble getting to sleep, I should 0.103 0.147 0.873
stay in bed and try harder
DBAS-10 05 (item 08) I am worried that I may lose control over my 0.125 0.816 20.021
abilities to sleep
DBAS-10 06 (item 10) After a poor night’s sleep, I know that it will 0.709 0.316 0.014
interfere with my daily activities on the
next day
DBAS-10 07 (item 12) When I feel irritable, depressed, or anxious 0.617 0.399 20.101
during the day, it is mostly because I did
not sleep well the night before
DBAS-10 08 (item 17) When I sleep poorly on one night, I know it 20.056 0.477 0.038
will disturb my sleep schedule for the
whole week
DBAS-10 09 (item 21) When I feel tired, have no energy, or just 0.707 0.144 20.298
seem not to function well during the day, it is
generally because I did not sleep well the
night before
DBAS-10 10 (item 22) I get overwhelmed by my thoughts at night 0.113 0.404 20.454
and often feel I have no control over this
racing mind
SDQ 01 I can’t get into a comfortable position in bed 0.642 0.003 0.041 0.110
SDQ 02 My mind keeps turning things over 0.104 0.884 20.084 0.067
SDQ 03 I can’t get my sleep pattern into a proper 0.412 0.056 20.032 20.087
routine
SDQ 04 I get too worked up at not sleeping 0.681 0.095 0.202 0.171
SDQ 05 I find it hard to physically let go and relax 0.590 0.202 20.018 20.291
my body
SDQ 06 My thinking takes a long time to unwind 0.235 0.804 20.079 0.079
SDQ 07 I don’t feel tired enough at bedtime 0.016 0.084 0.049 0.898
SDQ 08 I try too hard to get to sleep 0.598 0.098 0.081 0.508
SDQ 09 My body is full of tension 0.654 0.358 0.104 0.240
SDQ 10 I am unable to empty my mind 0.075 0.831 0.332 20.025
SDQ 11 I spend time reading/watching TV in bed when 20.076 0.019 0.796 0.041
I should be sleeping
SDQ 12 I worry that I won’t cope tomorrow if I don’t 0.251 0.036 0.774 0.043
sleep well
a Item number in original DBAS.
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Table 4
Intercorrelation of DBAS-10 and SDQ scales and subscales (n 5 178)
DBAS-10 DBAS-10 DBAS-10 SDQ SDQ SDQ SDQ SDQ
factor I factor II factor III total factor I factor II factor III factor IV
DBAS-10 total 0.858** 0.674** 0.477** 0.279** 0.264** 0.164* 0.206* 20.021
DBAS-10 factor I 0.286** 0.191 0.034 0.051 20.044 0.124 20.132
DBAS-10 factor II 0.214* 0.342** 0.300** 0.149 0.273** 0.134
DBAS-10 factor III 0.402** 0.372** 0.487** 0.108 0.017
SDQ total 0.882** 0.649** 0.469** 0.309**
SDQ factor I 0.383** 0.192* 0.136
SDQ factor II 0.157 0.105
SDQ factor III 0.134
*p , 0.01; **p , 0.001.
First, items in the DBAS-10 demonstrated measure- causal attributions concerning the perceived sources of
the sleep problem. In this regard it should be notedment sensitivity to cognitive-behavioral treatment. This
that the two scales were only modestly related to onesuggests that the DBAS-10 will be useful not only as a
another, as evidenced by the generally nonsignificant,means of descriptive quantification of “thinking errors”
or otherwise low, correlation coefficients. The strongestprior to treatment, but also as an outcome measure of
correlation between the scales was for DBAS-10 factortreatment-related cognitive change. Second, PCA
III, “need for control,” and SDQ factor II, “mentalyielded a factorially “pure” solution comprising three
overactivity.” It seems reasonable that insomniacs at-factors that form conceptually meaningful subscales. Be-
tributing sleeplessness to mental alertness would en-liefs about the immediate (next day) negative conse-
dorse beliefs concerning control. This would typify thequences of insomnia can be discriminated from beliefs
“performance anxiety” previously reported in some in-about long-term consequences (e.g., to health) and from
somniacs [11].beliefs about needing to actively control the process of
In this study, patients were not reassessed on thegetting to sleep. Third, DBAS-10 and its factor scales
SDQ because it was not regarded as a likely outcomedemonstrated satisfactory internal consistency, sug-
measure. Nevertheless, two principle conclusions maygesting some stability in measurement; finally, DBAS-10
be drawn from the statistical analyses.total score correlated highly (r 5 0.83) with the original
First, the SDQ also yielded a robust factor structureDBAS total scale score. This indicates that the overall
with relatively high factor loadings across its 12 items.thrust of the DBAS has been maintained in the DBAS-
Factor I appears to comprise elements of perceived10 while its structural integrity has been improved.
physiological arousal combined with poor “stimulusIt should be observed that the item content for factors
control” [9,11]. Factor II represents a particularly pureI and II of the DBAS-10 (respectively, beliefs about the
factor of mental overarousal and corresponds stronglyimmediate, and the long-term, negative consequences
with the first factor extracted in a previous analysis of theof insomnia) and Morin et al.’s [12] DBAS subscale of
SDQ [2]. Factor III represents attributions concerning“misattributions or amplifications of the consequences
perceived consequences of insomnia to both daytimeof insomnia” only partly overlaps (i.e., items 5, 12, 21).
and nighttime behavior, and factor IV, “lack of sleepOf course, Morin [12] derived his subscales conceptually
readiness,” preeminently relates to the principles under-rather than statistically. It is of interest, therefore, that
lying “sleep hygiene” [10]. Second, the SDQ was foundconceptual similarities seem to exist between the DBAS
to have sound internal consistency. Item deletions didand the DBAS-10 in relation to beliefs about the conse-
not greatly affect a-values, which again indicates stabil-
quences of insomnia, but the item content is less consis- ity and measurement.
tent. Likewise, both versions of the scale identify the The original factor structure of the SDQ yielded a
importance of beliefs about “control.” However, in the three-factor solution [2] compared with the four factors
DBAS-10, item 22, concerning control over nocturnal in the present study. Nevertheless, there are some repli-
thoughts, loads along with item 7 concerning beliefs cated findings. The present factor II, “mental overacti-
about the need to try harder to sleep (on factor III), vity,” comprises the three items (2, 6, 10) that had the
whereas, in the DBAS, this latter item is placed within highest factor loadings on a factor we originally labeled
a category of beliefs about sleep-promoting practices. “mental anxiety.” Also, factor I, “restlessness/agita-
tion,” incorporates the three items (1, 5, 9) that com-SDQ
prised the “physical tension” factor in the earlier report.
The SDQ is a different type of measure from the
Application of the scales
DBAS-10. Whereas the latter identifies beliefs and as-
sumptions concerning insomnia, and particularly the It is suggested, therefore, that both the DBAS-10
and SDQ have a credible scientific basis and may beperceived effects of insomnia, the SDQ seeks to identify
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[6] Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB,useful in further studies on the cognitive basis of insom-
Blazer DG. Sleep complaints among elderly persons: an epidemi-nia and its treatment. Both scales appear to have concep-
ologic study of three communities. Sleep 1995;18:425–433.
tually sensible factor scales that will be useful both to [7] Ford DE, Kamerow DB. Epidemiologic study of sleep distur-
describe insomniacs’ perceptions and attributions of bances and psychiatric disorders. JAMA 1989;262:1479–1484.
[8] Mendelson WB. Long-term follow-up of chronic insomnia.sleep problems and, in the case of the DBAS-10, to
Sleep 1995;18:698–701.evaluate changes in underlying beliefs and assumptions.
[9] Bootzin RR, Nicassio PM. Behavioural treatments of insomnia.The original DBAS scale will continue to be useful at
In: Hersen M, Eisler RE, Miller PM, eds. Progress in behaviour
a descriptive level, especially on an item-by-item basis modification, volume 6. New York: Academic Press. pp. 1–45.
to guide treatment. [10] Lacks P. Behavioral treatment for persistent insomnia. New
York: Pergamon Press 1987.As a measure of causal attribution, the SDQ could be
[11] Espie CA. The psychological treatment of insomnia. Chichester,compared in further studies with the Pre-Sleep Arousal
UK: John Wiley & Sons 1991.Scale [14] (see Introduction). In particular, it should be
[12] Morin CM. Insomnia: psychological assessment and manage-
noted that SDQ factors I and IV might be primarily ment. New York: Guilford Press 1993.
related to physiological activation on the PSAS and [13] Lichstein KL, Rosenthal TL. Insomniacs’ perceptions of cogni-
tive versus somatic determinants of sleep disturbance. J Abnormfactors II and III to cognitive activation. The effective
Psychol 1980;89:105–107.targeting of patients to therapy and/or tailoring of ther-
[14] Nicassio PM, Mendlowitz DR, Fussell JJ, Petras L. The phenome-apy to meet presenting need continues to be a matter
nology of the pre-sleep state: the development of the Pre-Sleep
of both research and clinical interest and these scales Arousal Scale. Behav Res Ther 1985;23:263–271.
may provide a valuable starting point. It is also notewor- [15] Broman JE, Hetta J. Perceived pre-sleep arousal in patients with
persistent psychophysiologic and psychiatric insomnia. Nord Jthy that the DBAS-10 and SDQ scales, being 10 and 12
Psychiatry 1994;48:203–207.items in length, respectively, can be completed quickly
[16] Evans FJ. Subjective characteristics of sleep efficiency. J Abnormin the clinic (within 3 to 5 minutes) and, therefore, can
Psychol 1977;86:561–564.
be recommended to the busy clinician. Finally, both [17] Watts FN, Coyle K, East MP. The contribution of worry to
measures require further, independent study by other insomnia. Br J Clin Psychol 1994;33:211–220.
[18] Gross RT, Borkovec TD. Effects of cognitive intrusion manipula-research groups. Reports of test–retest performance and
tion on sleep-onset latency of good sleepers. Behav Ther 1982;relationship to presenting characteristics of insomnia
13:112–116.would be particularly welcome.
[19] Hall M, Buysse DJ, Reynolds CF, Kupfer DJ, Baum A. Stress
related intrusive thoughts disrupt sleep-onset and continuity of
sleep. Sleep Res 1996;25:163.
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The sleep of remitted bipolar outpatients: a controlled naturalistic
study using actigraphy
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Background: Several sleep laboratory studies suggest sleep abnormalities in bipolar disorder. However, this is the first study
to compare remitted bipolar subjects with controls on actigraphic and subjective sleep parameters in a naturalistic setting over 5
nights. Methods: Nineteen subjects with Bipolar I Disorder and 19 age- and gender-matched healthy controls were included.
Objective sleep parameters were estimated using wrist actigraphs. Subject-rated sleep diaries and mood ratings were also
completed. Sleep data were averaged for each subject across nights, and raw score standard deviations were calculated as a
measure of within-subject variability. Results: Multivariate analyses of variance found significant group differences for both
actigraphic (F(4,33)=3.80, P=0.012) and subjective measures (F(4,31)=3.18, P=0.027). Univariate analyses identified reliable
differences in sleep onset latency (subjective), sleep duration (subjective), and variability of sleep duration and night wake time
(actigraphic). Binary backward stepwise logistic regression demonstrated that a combination of three sleep measures correctly
predicted disorder status in 84% of cases. Limitations: Failure to match on sociodemographic and employment status is a
limitation that may provide an alternative explanation for some findings. Furthermore, in the bipolar group 18 of 19 subjects
were in receipt of psychotropic medication, compared to none of the healthy control group. Also, no information was recorded
about family history of mental disorders in the control group. Conclusions: The study suggests that the sleep of remitted bipolar
outpatients measured in naturalistic settings is characteristically different from controls: bipolar subjects sleep longer, report
longer onset latencies, and display greater variability across nights.D 2003 Elsevier B.V. All rights reserved.Keywords: Actigraphy; Bipolar affective disorders; Manic depression; Sleep disturbance1. Introduction
Bipolar disorders (BP) are common, severe and
persistent disorders, which affect 1.3–1.7% of the
population (Kessler et al., 1996). Hyposomnia and0165-0327/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/S0165-0327(03)00055-7
* Corresponding author.
E-mail address: c.espie@clinmed.gla.ac.uk (C.A. Espie).hyperactivity are two defining features of mania,
while reduced activity and hypersomnia characterise
bipolar depression (Leibenluft et al., 1995). The
pervasiveness of sleep disturbances in BP suggests
that they are not merely symptomatic, but may be
central in the aetiology of symptoms.
There is evidence that changes in sleep and activity
may act as sensitive markers for relapse in BP, with
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with the onset of a manic episode (Barbini et al.,
1996; Klein et al., 1991, 1992; Leibenluft et al., 1996;
Nowlin-Finch et al., 1994). There is also compelling
evidence that sleep abnormalities are trait markers of
mood disorder, which persist even when subjects are
not in an episode. The evidence is more clear in the
case of unipolar (UP) depression, where it has been
shown that reduced REM latency is a stable sleep
characteristic in those with a history of UP depression,
even when remitted (Rush et al., 1986; Giles et al.,
1990, 1993).
In one of the few studies exploring sleep character-
istics of remitted BP subjects, Sitaram et al. (1982)
reported an increased density and percentage of REM
sleep in remitted BP patients (n=14) compared to a
control group. The study also found that the patients
were more sensitive to the effects of arecoline, an
acetylcholine agonist that can reduce REM latency.
Knowles et al. (1986) undertook electroencephalo-
graphic assessment of remitted BP patients on five
consecutive nights. In many respects, the sleep of the
10 remitted patients was similar to that of 10 controls.
However, the BP patients had a higher percentage of
time in stage 1 sleep, and more disturbed sleep than
controls.
The above data are consistent with the view that
BP patients may have characteristic sleep disturban-
ces. However, a major limitation of this research is its
reliance on polysomnography (PSG). For logistic
reasons polysomnographic studies are usually con-
fined to one or two nights. In addition, the artificial
nature of the sleep laboratory may disrupt natural
rhythms. For example, the fact that subjects are woken
at predetermined times may lead to underestimation of
sleep duration in hypersomnic subjects (e.g., Wehr et
al., 1985). A potential solution to these problems is
offered by actigraphy, which employs a small motion-
sensitive device, worn like a wristwatch, that can
sample physical activity levels continuously for pro-
longed periods (Sadeh et al., 1995). A range of sleep-
related variables is calculated from raw movement
data (e.g., sleep onset latency, sleep duration, amount
of wake time during the night, and ‘sleep efficiency’).
Although actigraphy is less precise than polysomnog-
raphy, and does not discriminate sleep stages, com-
parative studies have reported 80–90% agreement
between PSG and actigraphic recordings with respectto determination of sleep and wakefulness (Sadeh et
al., 1989). The practical advantage of actigraphy is
that recordings of daytime and nighttime activity can
be made with minimal disruption to a subject’s normal
life. Actigraphic measurement has been utilised suc-
cessfully in group comparisons where stability of the
sleep–wake cycle is of particular interest (e.g., Gruber
et al., 2000). This capacity for naturalistic measure-
ment makes actigraphy the obvious choice to study
underlying circadian abnormalities in BP subjects.
The present study compared a group of euthymic
BP I subjects with age and gender matched controls
on a number of actigraphically estimated, and subjec-
tively estimated sleep variables over a 5-day period.
The study also explored the relationship between
sleep variables, and mood ratings to determine wheth-
er objective and subjective sleep parameters and/or
daily mood ratings can be used to classify subjects as
cases or controls.2. Methods
With ethical approval, a two-group design was
employed that compared subjects with a confirmed
psychiatric diagnosis of BP I with healthy age- and
gender-matched controls on a number of sleep param-
eters. Cases and controls all gave informed consent to
participate in the study. No participant was involved
in any other research study.
2.1. Subjects2.1.1. BP subjects
Subjects with BP were recruited via community
mental health teams, and psychiatric outpatient clinics
in Glasgow and Renfrewshire. All subjects fulfilled
DSM-IV criteria for BP I (American Psychiatric
Association, 1995), according to case note informa-
tion and recorded psychiatric diagnosis. Two research-
ers (AM & JS) independently confirmed each case
diagnosis. Information about the current mood status
of subjects was provided by the referring psychiatrist
or key mental health worker (e.g., Community Psy-
chiatric Nurse), and independently validated by AM
using DSM-IV diagnostic criteria, and the subject’s
self-reported mood at initial interview. Only those
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for an episode) were included.
Subjects who met criteria for a major psychiatric
disorder other than BP I and/or those being treated for
drug or alcohol problems were excluded. Shift work-
ers were also excluded.
2.1.2. Control subjects
Control subjects were recruited on a voluntary
basis via personal and occupational links. Controls
were gender- and age-matched with BP subjects. An
effort was made also to recruit from diverse occupa-
tional and social class groups, and to match on socio-
economic factors. Controls participated in a screening
interview to exclude current and lifetime history of
major psychiatric disorder, and sections of the SCID-I
relevant to affective disorders were administered
(Structured Clinical Interview for DSM-IV Axis-I
Disorders: Clinician version; First et al., 1997). Shift
workers were excluded.
2.2. Measures
Background information on psychiatric history and
current prescribed medication was recorded for all
participants, followed by sleep and any history of
sleep problems using a Sleep History Questionnaire
(based on Morin, 1993). A number of measures were
recorded in both groups over a 5-day period.
Actigraphy was used to obtain objective estimates
of sleep over the 5 days. Each subject wore an
‘actiwatch’ on their non-dominant wrist for five
consecutive days and nights. The Actiwatch-R Model
AW2 was used (developed by Cambridge Neurotech-
nology). Raw actigraphic data was then downloaded
using the SLEEPWATCH* software programme, and
the following parameters calculated: sleep duration,
‘sleep efficiency’ (the percentage of time in bed spent
asleep), sleep onset latency, and wake time during the
night.
Subjective measurement of sleep was obtained for
the same period using sleep logs (Espie, 1991), which
participants completed each morning on rising. The
sleep log allowed calculation of the same sleep
parameters as measured by the actigraphs.
In order to consider the relationship between sleep
and mood all subjects were asked to provide a mood
rating twice daily (morning and evening) for the sameperiod, using a simple visual analogue scale (VAS) of
mood rated 0–100 (on a 100-mm line), from 0—
‘‘most depressed/down I’ve ever felt’’ to 100—‘‘most
high/manic I’ve ever felt’’; with a ‘well’ range defined
from 35 to 65 mm (Whybrow and Guylia, 1995).
2.3. Analyses
Mean values for actigraphic and subjective param-
eters of sleep were calculated for each subject across
the five nights. In addition, because night-to-night
variability in sleep was of interest, the raw score
standard deviation over the five nights was also
calculated for each variable. This was shown to be a
useful measure by Gruber et al. (2000). The two
groups were compared on objective and subjective
sleep parameters using separate multivariate analyses
of variance (MANOVA) for each set of sleep meas-
ures. These analyses tested the hypothesis that there
are group differences in the sets of sleep measures,
while controlling for multiple comparisons. Four
MANOVAs were therefore conducted: on averaged
actigraphic sleep measures, on night-to-night variabil-
ity of actigraphic measures, on averaged subjective
sleep measures, and on night-to-night variability of
subjective sleep measures (using the summary varia-
bles described above, and following the protocol of
Gruber et al., 2000). In keeping with the assumptions
of MANOVA the distribution of subjects responding
on all parameters was assessed using the Shapiro–
Wilks test of normality. In cases where the distributed
data were not normal, natural log transformations
were conducted prior to entry of the variable into
MANOVA testing. Three actigraphic variables (aver-
aged onset latency, standard deviation of onset laten-
cy, and standard deviation of sleep efficiency); and
four subjective sleep variables (averaged onset laten-
cy, averaged night waking time, standard deviation of
onset latency, and standard deviation of night waking
time) were log transformed. Following each MAN-
OVA, univariate comparisons were conducted for
each sleep measure using one-way analyses of vari-
ance (ANOVA). Given that sleep abnormalities may
be associated with variations in mood state, the above
analyses were then repeated using mean daily mood
rating as an additional covariate.
Finally, the relationship between sleep variables,
mood ratings and diagnostic status was explored,
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techniques.3. Results
3.1. Description of the groups
Thirty-two BP subjects were identified for poten-
tial inclusion. Eleven chose not to take part and, of the
21 who consented to participate, two subjects dropped
out within the first day of the study. The BP group
comprised eight males and 11 females; their ages
ranged from 26 to 68 years (mean=47.3 ,
S.D.=10.61). Time since diagnosis ranged from 1 to
35 years (median 15 years) and time since last episode
ranged from 1 to 96 months (median 12 months).
Eighteen BP subjects were receiving psychotropic
medication, 17 of whom were in receipt of polyphar-
macy (more than two medications). Ten individuals
were on lithium as the only mood stabiliser. Two
individuals were taking other mood stabilisers, and
three individuals were taking lithium in combination
with another mood stabiliser. Eleven subjects were
being prescribed antidepressant medication and 10
were receiving antipsychotic medication (two as
depots). Two other subjects were receiving night
sedation. One subject was not receiving medication.
Nineteen age- and gender-matched controls were
recruited. Ages in the control group ranged from 27 to
67 years (mean 45.8, S.D. 10.93). There was no
significant difference between BP subjects and con-
trols in age (t=0.42, df 36, P=0.68). Similarly, there
was no significant difference between groups in terms
of marital status (v2=2.9, df 2, P=0.23). Despite
efforts to match for occupation, the groups differed
in employment status with a smaller proportion of BP
subjects in part- or full-time employment (37%) than
the control subjects (95%; v2=14.2, df 1, P<0.001).
3.2. Comparison of groups on sleep history variables
The Sleep History Questionnaire revealed consis-
tent between group differences. All 19 BP subjects
reported longstanding sleep disturbance, compared
with only four of the control group (21%). There
was an associated difference in how the groups rated
the stability of their sleep pattern (from month tomonth, and year to year) on a four-point scale (from
1=‘very stable’ to 4=‘very unstable’) with the BP
group reporting less stable patterns (v2=21.2; df 3;
P<0.0001). A larger proportion of the BP group
reported having at some time used sleeping pills (74
vs. 16%; v2=14.3; df 1; P<0.001) or alcohol to aid
sleep (47 vs. 5%; v2=9.4; df 1; P=0.002).
In contrast to these long-term differences, the
groups did not differ significantly in their reported
recent use of sleeping pills (BP=16%; Controls=11%)
or alcohol to aid sleep in the last 4 weeks (BP=11%;
Controls=0%). Similarly, there was no difference
between their ratings of sleep quality over the last 4
weeks (v2=1.69; df 1; P=0.64).
3.3. Comparison of groups on averaged mood
measures and mood variability
On the 0–100 VAS, the BP group (mean 43.2; S.D.
10.5) rated themselves as significantly more depressed
than the control group (mean 50.0; S.D. 5.1; t=2.6;
df 36; P=0.015). However, the variability of subjec-
tive mood across the 5 days did not differ significantly
(BP mean 1.8, S.D. 0.96; Control mean 1.3, S.D. 0.74;
t=1.7; df 36; P=0.10). These data suggest that, even
when BP subjects do not fulfil criteria for an episode,
they remain depressed compared to controls.
3.4. Comparison of groups on objective and subjec-
tive sleep measures
3.4.1. Actigraphic sleep variables
The MANOVA comparing groups on combined
averaged actigraphic measures of sleep duration, onset
latency, sleep efficiency, and wake time yielded a
significant overall group effect (F=3.80; df 4, 33;
P=0.012), suggesting that the objective sleep pattern
of remitted BP patients differed from healthy controls.
Results of separate univariate ANOVAs for each sleep
measure, did not find any significant group differ-
ences. However, there were trends towards the BP
group sleeping longer, taking longer to fall asleep, and
sleeping less efficiently than controls (see Table 1).
The MANOVA comparing groups on variability in
sleep duration, onset latency, sleep efficiency, and
wake time did not show a significant difference
between the two groups (F=2.45; df 4, 33; P=0.07).
However, separate ANOVAs of each measure sug-
Table 1
Means and standard deviations of bipolar group and controls on actigraphic and subjective sleep parameters (averaged and variability measures),
and results of univariate analyses
Variable Bipolar group Control group df Statistic Sig. ( P)
Mean (S.D.) Mean (S.D.) F
Averaged actigraphic measures
Sleep duration 434.2 (91.7) 387.5 (53.0) 37 3.69 0.063
Onset latencya 19.5 (22.1) 8.0 (6.9) 37 3.66 0.064
Sleep efficiency (%) 83.0 (9.2) 86.9 (3.6) 37 3.04 0.090
Night waking time 59.0 (26.0) 49.2 (17.5) 37 1.83 0.184
Standard deviations of actigraphic measures
Sleep duration 70.0 (39.6) 44.8 (24.6) 37 5.53 0.024*
Onset latencya 21.4 (28.7) 8.8 (12.2) 37 3.27 0.079
Sleep efficiency (%)a 6.6 (6.3) 4.3 (2.3) 37 .936 0.340
Night waking time 23.6 (15.1) 15.4 (8.1) 37 4.33 0.045*
Averaged subjective measures
Sleep duration 473.5 (112.9) 411.7 (56.1) 35 4.19 0.048*
Onset latencya 40.9 (45.3) 17.3 (11.0) 35 9.01 0.005**
Sleep efficiency (%) 85.7 (8.7) 89.3 (10.3) 35 1.32 0.258
Night waking timea 38.8 (40.8) 30.2 (51.0) 35 .362 0.552
Standard deviations of subjective measures
Sleep duration 91.9 (63.2) 55.6 (31.8) 35 5.19 0.029*
Onset latencya 31.2 (54.9) 11.6 (13.5) 35 4.86 0.034*
Sleep efficiency (%) 12.5 (8.4) 6.9 (5.4) 35 6.23 0.018*
Night waking timea 37.2 (39.2) 20.8 (25.3) 35 1.00 0.324
a Indicates that the variable was transformed for the purpose of analyses. In these cases statistics ( F values) are the result of analysis
conducted on the transformed variable, but means and standard deviations reported were calculated on raw (untransformed) data.
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of sleep duration and night waking time, with the BP
group showing more variability than healthy controls
(see Table 1). The pattern of the results of the
MANOVAs and ANOVAs did not change when
controlling for mood ratings.
3.4.2. Subjective sleep variables
Results of the MANOVA, which compared groups
on averaged sleep duration, onset latency, sleep effi-
ciency and wake time revealed a statistically signifi-
cant multivariate effect (F=3.18, df 4, 31; P=0.03).1
Separate univariate ANOVAs confirmed significant
differences in sleep duration and onset latency; with
the bipolar group sleeping longer and having a longer
sleep onset latency. As shown in Table 1, these1 Two subjects (one from each group) had sleep logs with
missing data, and were therefore excluded from the multivariate
analysis of subjective sleep variables.findings are broadly similar to the trends observed
in the objective sleep data.
MANOVA on variability in subjective sleep vari-
ables did not show an overall difference between the
two groups (F=1.79, df 4, 31; P=0.16). However,
univariate analyses again suggested statistically sig-
nificantly greater variability in sleep duration, sleep
onset latency, and sleep efficiency in the BP group
(Table 1). The pattern of the results of the MANOVAs
and ANOVAs did not change when controlling for
mood ratings.
3.5. Classification of cases and controls
To assess the ability to distinguish between BP
subjects and healthy controls on the basis of sleep and
mood measures, direct binary backward stepwise
logistic regression analyses were applied with group
membership (BP or Control) as the dependent vari-
able, and different combinations of objective and
subjective sleep parameters and mood variables as
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a combination of three predictor variables: one acti-
graphic (variability of sleep duration) with two sub-
jective sleep variables (average sleep duration, and
average onset latency). Averaged mood ratings over
the 5 days made a non-significant contribution to this
model.
A test of the full model with these predictors
against a constant only model was significant
(v2=23.7, df 4; P<0.0001) suggesting that this set of
predictors reliably distinguished between BP (correct-
ly assigned 15/19) and control subjects (correctly
assigned 17/19), correctly classifying 84% of subjects.
Table 2 shows regression coefficients, and odds ratios
with 95% confidence intervals (CIs) for each predictor
variable.4. Discussion
This study suggests that the more prolonged,
naturalistic measurement offered by actigraphic tech-
niques is a useful method for studying possible
sleep–wake cycle abnormalities in this disorder. It
is noteworthy that the differences in sleep parameters
between BP outpatients and controls identified would
almost certainly have been masked by the constraints
of laboratory-based methods of sleep measurement.
Using actigraphy appears to be a sensitive and
convenient way of identifying these abnormalities.
The study suggests that even in the absence of
significant affective symptoms, the sleep of BP out-
patients is abnormal relative to controls. Bipolar
subjects sleep longer than healthy controls, report
longer sleep onset latencies and display greater
night-to-night variability in a number of objectiveTable 2
Classification of cases and controls using backward stepwise logistic regr
Variables B Wald df
test
Actigraphic variability 0.04 4.4 1
of sleep duration
Subjective—average 0.02 3.9 1
sleep duration
Subjective—average 0.10 3.9 1
onset latency
Constant 5.0 0.95 1and subjective sleep parameters. They also report less
stable sleep histories, and are more likely to have been
prescribed medication or used alcohol to aid their
sleep. These findings provide preliminary support for
the hypothesis that sleep abnormalities are trait as well
as state markers of vulnerability to mood disorders.
The above findings should be interpreted cautious-
ly given the relatively small sample size, the null
findings of some of the analyses and the group
differences in currently prescribed medication and
subjective mood state. Although medication may
partly account for the differences in sleep patterns
reported, it could equally be argued that the abnor-
malities in sleep found in BP subjects remained in
spite of adequate pharmacological prophylaxis in 18
of the 19 subjects investigated. The groups also
differed significantly in their self-reported mood state
with the BP group being more depressed than the
control group. However, the mean mood ratings for
BP subjects in this study fell within the ‘normal’ range
on the VAS and when mood ratings were included as a
covariate in the MANOVAs and ANOVAs the pattern
of statistically significant differences remained con-
stant. This suggests that the abnormalities in sleep
between BP subjects and healthy controls are not
simply a function of the BP subjects experiencing
higher levels of inter-episode depression. This is
further borne out by the results of the logistic regres-
sion analysis. The combination of objective variability
in sleep duration, subjective latency in sleep onset and
subjective sleep duration correctly classified 84% of
the sample into cases and controls. Whilst the spec-
ificity of this combination of measures in predicting
BP in comparison to other mental disorders was not
tested by this study, the broad implication of this
result is that a relatively simple package of measuresession
Sig. ( P) Odds ratio 95% CI
(Exp(B))
0.04 0.96 0.93 to 0.99
0.05 0.98 0.97 to 1.00
0.05 0.90 0.82 to 0.99
0.33
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tion with a high degree of accuracy.
The suggestion of abnormal sleep patterns, and
particularly increased instability in the sleep–wake
cycle in BP is consistent with the hypothesis that
circadian rhythm disruption is crucial in the aetiology
of the disorder. This supports the ‘social zeitgebers
and biological rhythms’ model promoted by Ehlers et
al. (1988) and further elaborated in the circadian
rhythm dysregulation model described by Goodwin
and Jamison (1990). At the core of these models is the
notion that rhythmic disturbances produce symptoms
(possibly through neurotransmitter–neuroendocrine
intermediaries), which reinforce or exacerbate abnor-
mal rhythmic processes. Furthermore, genetic factors
may shorten the intrinsic period of the circadian
locomotor rhythm whilst psychosocial variables may
decrease an individual’s capacity for entrainment of
circadian rhythms. As such the methodology
employed in this study, combined with repeated
measures of other putative variables may be used to
research these models in both BPI and BPII disorders.
It may also prove helpful in reducing the misdiagnosis
of BP depression (Bowden, 2001).
The findings also have clinical implications, in
that they suggest that even during periods of remis-
sion, subjects with BP have difficulties in maintain-
ing stable and adaptive sleep–wake cycles. Given
the use of self-regulation of social rhythms as a core
strategy in interpersonal therapy and cognitive ther-
apy for BP (Ashman et al., 1999; Scott et al., 2001),
the use of actigraphy offers an excellent additional
method of self-monitoring. It could be used to
establish baseline sleep and activity levels and to
identify changes following ‘social rhythm disrupting’
or other stressful life events (Malkoff-Schartz et al.,
1998). It could also be used to enhance the effec-
tiveness of self-management techniques employed to
prevent prodromal symptoms developing into a full
blown relapse (Perry et al., 1999). This approach
would be particularly useful in individuals who find
that they have difficulty in monitoring their mental
state subjectively.
4.1. Limitations
Evidence of differences in the sleep–wake cycle of
remitted BP outpatients provided by this study shouldbe regarded as preliminary, and interpreted cautiously
given the relatively small sample size. It is possible
that with a larger sample some of the trends towards
group differences would have reached significance.
Nonetheless, it should be noted that the sample size
compares favourably with previous studies cited,
perhaps reflecting the practical difficulties of working
with this subject group.
Previous studies have utilised actigraphy with
bipolar subjects (e.g., Klein et al., 1991, 1992);
however, no study has specifically validated acti-
graphic measurement against PSG in this population.
It is possible that in an anergic sample of subjects
like BP patients actigraphic measures of sleep may
overestimate actual sleep, although this would not
explain the parallel findings in the subjective sleep
data, or the greater night to night variability in BP
subjects identified using actigraphy in the present
study.
The groups were not matched in terms of medica-
tion. The use of medication is likely to have affected
the sleep of the BP group to some extent, and many of
the BP patients included in the sample had been on
medication for prolonged time periods. It is possible
that this in itself could have resulted in modifications
to the sleep–wake cycle; however, it is unrealistic and
unethical to stop the long-term treatment of BP sub-
jects. A strength of this study is its ecological validity,
and this adds weight to the implications for everyday
clinical practice arising from this project.
The failure to match groups on employment status
is recognised as a weakness of the study that may
provide an alternative explanation for group differ-
ences in variability of the sleep–wake cycle. Diffi-
culties of matching groups on this variable reflect the
disorder status of the BP group, since many of them
had discontinued work. It would be hard to control for
this, since an age-matched healthy control group with
the same proportions of unemployment would not
necessarily provide a meaningful comparison, and
would be unlikely to have the same diversity of
occupational histories.
A further limitation relates to the method of mea-
suring current mood status. No formal observer-rated
scale was used to evaluate the current mood status of
BP subjects; instead judgements about current mood
status were based on a combination of clinical opinion
(both the researcher’s and the psychiatrist’s/key mental
A. Millar et al. / Journal of Affective Disorders 80 (2004) 145–153152health worker’s), and the subject’s self-rating of mood
on the VAS.
Finally, no information on family history of mood
disorders was collected from either the BP or the
control group. This represents a limitation, particular-
ly with regard to the control group since it has been
shown that one fifth of healthy individuals with no
current or lifetime diagnosis of psychiatric disorder,
but with at least one first-degree relative with mood
disorder, show abnormal, depression-like EEG pat-
terns during sleep (Lauer et al., 1995). However, even
given this limitation, the study identified differences
between the BP and control groups that were largely
in the expected direction.References
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Development and preliminary validation of the
Glasgow Content of Thoughts Inventory (GCTI):
A new measure for the assessment of pre-sleep
cognitive activity
Karen J. Harvey and Colin A. Espie*
Department of Psychological Medicine, University of Glasgow, UK
Objective. To develop a self-report measure (the Glasgow Content of Thoughts
Inventory [GCTI]) for the assessment of pre-sleep cognitive activity in adults with
sleep-onset insomnia.
Design. A psychometric, scale development approach was used.
Method. Over three consecutive nights, 12 people with insomnia provided ‘live’
audio-recordings of pre-sleep thought content, which were used to generate an item
pool. The results were compared to the content and categorical structure of pre-sleep
cognitive activity identified by Wicklow and Espie (2000), and commonalities in thought
content were used to generate a draft scale. Following further piloting, a 25-item scale
was developed and administered to two groups (29 people with insomnia and 29 good
sleepers), along with other self-report measures, objective (actigraphic recordings) and
subjective (diary) sleep indices, and results analysed to evaluate the psychometric
properties of the scale.
Results. The GCTI demonstrated evidence of construct validity, successfully
discriminated between individuals with insomnia and good sleepers, and was
significantly correlated with existing measures of sleep disturbance. A score of 42
yielded a sensitivity of 100% and specificity of 83%. The GCTI demonstrated good test–
retest reliability (ICC = .88) and internal consistency ( = .87).
Conclusions. The GCTI appears to be a valid and reliable instrument for use with
patients with sleep-onset insomnia.
Insomnia is a heterogeneous complaint reflecting reduced quality, duration or
efficiency of sleep (Morin et al., 1999). Primary insomnia is reported by up to 30% of
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the population, with prevalence of chronic insomnia estimated at 10–15% (Ohayon,
Caulet, & Guilleminault, 1997).
In a survey of causal attributions of insomnia, Lichstein and Rosenthal (1980) found
that individuals with insomnia were 10 times more likely to blame excessive cognitive
rather than somatic activity for their sleep disturbance. Experimental work by Gross
and Borkovec (1982) demonstrated that increased sleep-onset latency (SOL) could be
induced in good sleepers by increasing cognitive arousal (telling participants that they
had to give a presentation on wakening), with the effect occurring independently of
physiological activity (heart rate and skin conductance). Haynes, Adams, and Franzen
(1981) obtained similar results, demonstrating that estimates of SOL increased for both
objective (polygraphic) and subjective (sleep diary) measures of sleep disturbance
following cognitive arousal. Espie, Brooks, and Lindsay (1989) also found that ‘mental
overactivity’ was the most common causal attribution made by clinic-presenting
patients with chronic insomnia.
It has been known for some time that intrusive thinking may lead to increased SOL
(Van Egeren, Haynes, Franzen, & Hamilton, 1983). However, there is a limited literature
on the content of these thoughts. Watts, Coyle, and East (1994) differentiated people
with insomnia into either ‘worrying insomniacs’, whose pre-sleep cognitions focused
on various topics (e.g., trivial topics, plans, work, family and recent concerns, bodily
sensations) or ‘non-worrying insomniacs’, whose pre-sleep cognitions focused
specifically on concerns about sleep loss. Harvey (2000) analysed focus of attention,
content and process characteristics in good sleepers and people with insomnia. The
latter groups’ attention focused on solving problems, worries, concerns, reviewing
events of the day, thinking about their sleep pattern, and environmental noises. Ratings
of cognitive interference, estimated duration of cognitive activity and intrusiveness
(preoccupation and effect on sleep) were higher for those with insomnia than for good
sleepers. Wicklow and Espie (2000) used voice-activated tape-recorders to obtain ‘live’
recordings of the pre-sleep thoughts of individuals with insomnia. They identified eight
thought categories reflecting three factors: active problem-solving, present state-
monitoring and environmental reactivity. Subjective measurement (sleep diary) and
objective measurement (wrist actigraphic recordings—a device which, based on the
amount of movement, can differentiate between sleep and wake periods) of SOL were
also taken. Only the latter was correlated significantly with pre-sleep cognitive activity.
The authors concluded that the use of ‘live’ recordings of pre-sleep cognitive content
merited further investigation, and that their putative categorical and factorial structure
of pre-sleep thinking might be used to develop a scale to assess the content of pre-sleep
cognitions.
There are four existing self-report measures relevant to the pre-sleep mental state:
the Pre-Sleep Arousal Scale (PSAS; Nicassio, Mendlowitz, Fussell, Petras, 1985); the
Sleep Disturbance Questionnaire (SDQ; Espie et al., 1989); the Dysfunctional Beliefs
and Attitudes About Sleep Scale (DBAS; Morin, 1993; Morin, Stone, Trinkle, Mercer, &
Remsberg 1993); and the Self-Statement Test: 60+ (SST; Fichten et al. 1995, 1998). The
DBAS also has a 10-item short-form version (DBAS-10; Espie, Inglis, Harvey, & Tessier,
2000). Each of these was developed using appropriate scale design methods and has
adequate psychometric properties. However, they are unsuitable for descriptive
quantification of pre-sleep thinking because they provide more global assessment of
cognitive dysfunction and arousal, and fail to reflect the specific content of pre-sleep
cognitive activity such as identified by Harvey (2000) and Wicklow and Espie (2000).
The PSAS is essentially a measure to quantify arousal level and to compare somatic
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with cognitive arousal state. The SDQ is an attributional measure and, like the PSAS, is
insufficiently detailed to describe thought content. The DBAS scales come closer to
reflecting pre-sleep thought content, but DBAS items are at the somewhat ‘deeper’ level
of belief/attitude/schema (e.g., ‘After a poor night’s sleep I know that it will interfere
with my daily activities the next day’). Although the SST assesses pre-sleep cognitions, it
has only been validated for use with older adults and is not specific to pre-sleep
mentation, but to ‘nocturnal wake times’. Furthermore, items for all four measures were
obtained through retrospective analysis (e.g., thought records, diaries, semi-structured
interviews), which may be subject to low specificity of thought content, response
limitation due to pre-defined questions, and omissions or distortions through forgetting.
The development of a scale that can reliably measure pre-sleep thoughts in terms of
their nature, content and frequency of interference upon sleep would be beneficial, not
only in assessment and treatment planning, but also in monitoring and evaluating
treatment mechanisms and outcomes. Our aim, therefore, was to develop and evaluate
the psychometric properties of a self-report measure to assess the content of pre-sleep
thoughts in adults with insomnia.
Method and results
Stage 1: Derivation of an item pool
Rationale
Wicklow and Espie (2000) used ‘live’ audiotape recordings of the pre-sleep cognitive
activity of adults with insomnia to gather data. It was felt that replication of this
approach would provide the best available item pool, and permit validity analysis by
comparing results with their findings.
Participants: scale development group
Participants were recruited using the university e-mail service, requesting those with
‘current sleep problems interested in taking part in sleep research’ to contact the
researcher. Participants had to be 16 to 65-years-old; meet diagnostic criteria for
significant problems falling asleep— specifically a minimum SOL of 30 min occurring at
least four out of seven nights with or without disruption to other sleep variables
(International Classification of Sleep Disorders—Revised [ICSD-R], 1997); and obtain a
Pittsburgh Sleep Quality Index Score (PSQI; Buysse, Reynolds, Monk, Berman, &
Kupfer, 1989) of 6 or above. The PSQI adequately discriminates good sleepers from
poor sleepers using this cut-off (sensitivity = 89.6%, specificity = 86.5%; Buysse et al.,
1989). The sensitivity of a scale is the probability that an individual with the condition
will be classified correctly as having the condition; specificity is the probability that a
person without the condition will be classified as not having it (Fleiss, 1981).
Participants were excluded if they:
(1) were receiving psychological treatment for sleep difficulties;
(2) were currently taking, or had in the past three months taken, medication known
to affect sleep;
(3) were suffering from a psychological disorder;
(4) were suffering from a chronic medical condition known to impact on sleep; or
(5) scored 20 or above on the Beck Depression Inventory (BDI; Beck, Ward,
411Glasgow Content of Thoughts Inventory
Mendelson, Mock, & Erbaugh, 1961) to exclude individuals with insomnia with
significant suspected clinical depression (cf. Espie et al., 2000). A screening
interview was arranged in which participants completed the Sleep History
Questionnaire (SHQ; Morin, 1993), the Penn State Worry Questionnaire (PSWQ;
Meyer, Miller, Metzger, & Borkovec, 1990), the State-Trait Anxiety Inventory
(STAI; Spielberger, Gorusch, & Lushene, 1970), the PSQI and the BDI.
Of 19 respondents, seven were excluded (two failed to meet inclusion criteria, one
was excluded through medication use, one reported sleep difficulties due to
nightmares, two retracted from the study, and one was excluded due to missing data).
Twelve people with insomnia (nine females, three males) with a mean age of 26 years
(average duration of sleep disturbance = 12.0 yrs, SD 4.6 yrs) participated in Stage 1.
These individuals were excluded from subsequent stages.
Data gathering procedure
Over three consecutive weekday nights, participants used voice-activated tape-
recorders (Sony Cassette Recorder TCS–580 V) placed at their bedside to record their
thoughts as they tried to sleep. Wicklow and Espie (2000) reported this procedure as
non-intrusive, with no evidence of a ‘first night effect’. Participants were instructed to
say aloud whatever was going through their mind, whenever they wanted to, when
having difficulty sleeping. To minimize performance anxiety and allow participants to
speak freely, no further specific instructions were given.
Subjective and objective measures of SOL were taken to permit subsequent
comparison with the insomniac group recruited to the field-testing phase (Stage 3).
Participants completed a sleep diary each morning. This is a well-documented,
retrospective, self-report instrument. Espie (1991) cites evidence demonstrating high
test–retest reliability of diary measurement (r = .93 for poor sleepers). To provide an
objective estimate of sleep, wrist actigraph recordings were obtained over three nights
using the Actiwatch-R Model AW21 (Cambridge Neurotechnology Ltd). The actigraph
records ‘sleep’ or ‘wakefulness’ by accumulating activity counts during a specified time
interval. An epoch of 1 min was selected—the recommended interval for accurate sleep
analysis (American Sleep Disorders Association [ASDA], Report 1995]. The actigraph
has an event marker that participants were instructed to press when they went to bed
and when they got up. The main actigraphic parameters of sleep correlate strongly with
polysomnography (Kripke, Mullaney, Messin, & Wybourney, 1978). Hauri and Wisbey
(1992) did report accuracy difficulties for actigraph recordings; however, error was
only half that normally associated with sleep diaries.
Content analysis of pre-sleep thoughts
Data were available for at least two nights from all participants and totalled to 27
subject nights. These data were analysed by the first author according to the procedure
for content analysis adopted by Wicklow and Espie (2000). First, audiotape-recorded
material was transcribed; secondly, transcripts were segmented into single ideas or
statements; thirdly, segments were allocated to one of eight thought categories; and
fourthly, an independent reliability check on the allocation of thought segments to
categories was conducted of four participants’ (33%) transcripts.
Content validity
This procedure generated 423 thought segments over the 27 nights (M per night =
15.7). This is comparable to Wicklow and Espie (2000), who obtained 1,090 thought
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segments over 63 nights (M per night = 17.3). Distribution per category was also
similar, with ‘rehearsal/planning/problem-solving’ accounting for the majority of
thought segments (32.4%, n = 137), followed by ‘sleep and its consequences’
(20.8%, n = 88), ‘autonomic experiences’ (14.9%, n = 63), ‘reflection on quality of
thoughts’ (11.3%, n = 48), ‘rising from bed’ (7.3%, n = 31), ‘arousal status’ (6.9%, n =
29), ‘external noise’ (5.0%, n = 21) and ‘procedural factors’ (1.4%, n = 6). Concordance
was satisfactory, with 95% agreement between independent raters.
Stage 2: Refinement of item pool and development of scale
Refinement of the item pool and development of the scale followed a six stage process:
(1) As described above, each thought segment was allocated to one of eight
category themes. From visual inspection and discussion between the authors,
each category was broken down into subcategories to reflect faithfully the range
of thought content. Each specific thought segment was then allocated to a
subcategory, thereby forming potential scale items (e.g., thoughts relating to ‘the
length of time it is taking to fall asleep’ were a subcategory of ‘sleep and its
consequences’). This procedure, therefore, produced eight sets of items;
however, only seven sets were retained because ‘procedural thoughts’ (e.g. ‘Is
that tape-recorder on?’) were excluded from the analysis. These are unsuitable
for inclusion in a scale, and comprised less than 2% of the total (see above).
(2) An identical allocation procedure was repeated on a random sample of data
(seven participants; 16 subject nights; 345 thought segments) from the Wicklow
and Espie (2000) study.
(3) Data from these two analyses were then compared for commonalities across the
top five most frequently endorsed items within each category theme. This
process yielded 34 potential scale items which had been frequently reported by
participants from both studies, and which accounted for the majority of the total
number of thoughts reported (category range = 77.3–100%).
(4) These items were reviewed by the first author and an expert clinician, and
reworded as statements. A draft scale was then produced containing the 34
items ordered randomly. Instructions were added that requested respondents to
indicate, using a 4-point response, how often (over the past seven nights) each
thought had kept them awake. A 4-point scale (1 = ‘never’, 2 = ‘sometimes’, 3 =
‘often’, 4 = ‘always’) was selected.
(5) The draft scale was administered to a sample of people with insomnia from the
scale development group (n = 6), and a sample of normal sleepers (n = 6). A
semi-structured response sheet was provided for comment on what they
thought the scale was measuring, their understanding of how to complete the
scale, ease of completion, and views on individual items (e.g., overlap, possible
omissions). Informal interviews were conducted to expand on responses.
(6) Following feedback from this process, six items were dropped because they did
not discriminate, the wording of four items was amended, and five items were
reorganized into two items.
These procedures resulted in the final 25-item scale, the Glasgow Content of
Thoughts Inventory (GCTI), presented in the Appendix.
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Stage 3: Field testing and psychometric evaluation of the GCTI
To examine the psychometric properties of the GCTI, two groups (people with
insomnia and good sleepers) were recruited.
Participants: validation phase
Participants were again recruited by university e-mail. Over 150 responses from
individuals reporting insomnia were received. From this pool, 59 respondents were
screened using the measures described earlier (SHQ, PSQI, STAI, PSWQ, BDI) of whom
44 (75%) satisfied our inclusion criteria for insomnia (as before). Fifteen met exclusion
criteria and took no further part in the study. A lower e-mail response was obtained for
good sleepers (n = 45), 14 of whom were excluded due to failure to return screening
measures, and two due to missing data. Good sleepers did not meet ICSD-R criteria for
insomnia, and scored less than 6 on the PSQI.
The final sample comprised 29 adults with insomnia (24 females, 5 males) and 29
good sleepers (19 females, 10 males). Following checks for skewness and kurtosis,
groups were compared on participant characteristics and screening results using
independent sample t tests or Mann–Whitney tests as appropriate. The insomnia group
was also compared to the scale development group. Due to faulty equipment, missing
actiwatch data were incurred for three participants (one from the scale development
group, and two people with insomnia from the validation phase). Four participants also
failed to complete sleep diaries adequately (one from the scale development group, one
good sleeper and two people with insomnia from the validation phase). Table 1
presents summary data for each group.
Results suggest that the insomnia group did not differ from the scale development
group on age, z = 1.33, p = .195, or gender, 2(1) = 0.35, Fisher’s exact p = .719. There
were no significant differences between the insomnia and scale development group on
problem duration, z = –.26, p = .810; the PSQI, t(39) = 1.07, p = .293; the BDI, z = –.61,
p = .543; the PSWQ, t(39) = 0.45, p = .659; the STAI–state anxiety, t(39) = 0.72, p =
.473; the STAI–trait anxiety, t(39) = 0.15, p = .988; subjective SOL, t(33) = 0.46, p =
.648; or objective SOL, z = –.98, p = .339.
Similarly, no significant differences emerged between good sleepers and people with
insomnia for age, t(56) = .473, p = .638, or gender, 2(1) = 2.248, p = .134. However,
good sleepers scored significantly lower than people with insomnia on the PSQI, t(46)
= 12.70, p < .001; the BDI, z = –3.89, p < .001; the PSWQ, t(49) = 2.269, p = .028; the
STAI–state anxiety, t(56) = 2.98, p = .004; and the STAI–trait anxiety, t(56) = 3.59, p =.
001. Subjective SOL was around 60 min in insomnia compared with 14 min in good
sleepers, z = –5.61, p < .001. Objective SOL was estimated at around 30 min by
actigraphy in the insomnia group compared with 13 min in good sleepers, t(54) =
3.057, p = .003.
Table 1 also presents comparative characteristics for Espie et al.’s (2000) clinic-
presenting sample of 178 patients with insomnia. With the exception of age, the mean
scores for both the scale development and insomnia group were close to those of Espie
et al. It can be concluded, therefore, that the people with insomnia in this study are
similar to clinic patients with respect to clinical and sleep characteristics.
Measures and procedure
To examine the psychometric properties of the GCTI, participants completed the GCTI
at home along with the cognitive subscale of the PSAS (PSAS-cog; eight items,  = .76),
the DBAS–10 ( = .69) and the SDQ (12 items yielding four factors; SDQ-F2 reflects
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cognitive arousal;  = .82; Espie et al., 2000). Participants kept sleep diaries and wrist
actigraph recordings were taken for three consecutive nights (as for the scale
development group).
Construct validity The PSAS-cog is known to correlate with measures of affect and sleep-
onset, a finding congruent with the theory that increased mental arousal contributes to
sleep disturbance (Espie, 2002). The correlation between the GCTI and PSAS-cog was
computed to provide preliminary evidence of the GCTI’s construct validity (n = 58). A
strong positive correlation was obtained (r = .879, p < .001), confirming that frequency
of cognitive intrusions is associated with pre-sleep mental arousal.
Concurrent validity The relationship between GCTI and other measures of sleep
disturbance was examined for the SDQ-F2 and DBAS–10 (n = 58). The GCTI
correlated significantly with both measures (SDQ-F2: r = .815, p < .001; DBAS–10: r =
.732, p < .001). Similarly, relationships between the GCTI and sleep diary (n = 55) and
actigraph recordings of SOL (n = 56) were investigated. Diary estimates were more
strongly associated with the GCTI (r = .650) than actigraph estimates of SOL (r = .484),
although both were significant (ps < .001).
Discriminant validity The ability of the GCTI to discriminate people with insomnia (n = 29)
from poor sleepers (n = 29) was investigated. Those with insomnia scored higher than
good sleepers (M = 58.0, SD = 10.08 vs. M =/=, 35.2 SD = 8.37); t(56) = 9.40, p < .001.
Figure 1 illustrates GCTI scores for both groups. As distributional data indicate, there is
limited overlap between the highest scoring good sleepers and the lowest scoring
individuals with insomnia. Scores for good sleepers also appear to be more closely
grouped (as indicated by the box highlighting the interquartile range) than those
obtained for people with insomnia.
Sensitivity and specificity Analysis of GCTI sensitivity data suggested that a score of 42
correctly identified 100% (i.e., 29) of people with insomnia, and correctly identified
83% (i.e., 24 out of 29) of good sleepers (i.e., specificity). Using this cut-off, the total
sample was split into two groups: those experiencing ‘high frequency pre-sleep
cognitive events’ (n = 34), versus those with ‘low frequency pre-sleep cognitive events’
(n = 24). Differences between groups on the PSAS-cog, SDQ-F2 and DBAS-10 were
analysed. Participants with high frequency pre-sleep cognitive events scored
significantly higher on all three measures: PSAS-cog (M = 26.0, SD = 6.0 vs. M =/=,
13.2 SD =/, t(56) 5.1) = 8.62, p < .001; DBAS-10 (M = 53.3, SD = 15.2 vs. M =/=, 32.0 SD
= 12.0), t(56) = 5.70, p < .001; and SDQ-F2 (M = 12.8, SD = 1.8) vs. M =/=, 6.7 SD =
2.2), t(56) = 11.54, p < .001. Participants with high frequency pre-sleep cognitive
events also scored higher on subjective and objective measures of SOL (both ps < .001).
Test–retest reliability The GCTI was administered a second time, three weeks later. Test–
retest scores were available for 26 people with insomnia (89.7%). Test–retest reliability
of the GCTI using the intra-class correlation coefficient appeared highly satisfactory
(ICC = .878, p < .001).
Internal consistency
Cronbach’s alpha was calculated at .870 using the insomnia group (n = 29). Guttman
split-half reliability was similar (.851). Item-deletion alphas give an indication of the
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stability of a measure when items are systematically eliminated. These remained high,
with little variation between values (M  = .87, range = .855–.874). A criterion of .80 is
usually considered acceptable (Nunnally & Bernstein, 1994), therefore these results
appear satisfactory. The corrected item–total correlation is the correlation of a single
item with the sum of all other items (Nunnally & Bernstein, 1994) and, ideally, will be
modest (approximately r = .4) to ensure that a range of items is retained. The mean
corrected item–total correlation was .43 (range = .12–.73).
Discussion
The purpose of this study was to develop a psychometrically robust self-report measure
for the assessment of pre-sleep thought content in insomnia. We suggest that our
derived measure, the Glasgow Content of Thoughts Inventory, offers considerable
potential in quantifying the nature and frequency of such mentation. Items for the GCTI
arose directly from the prospective experience of adults with insomnia and were
validated against our previous work using similar methodology (Wicklow & Espie,
2000). The items also appear to reflect other research findings highlighting that pre-
sleep cognitive events typically focus on solving problems, worries/concerns,
reviewing the day, and thinking aboutsleep (Harvey, 2000; Van Egeren et al., 1983;
Watts et al., 1994).
A test is considered to be measuring the same attribute as existing measures if
intercorrelation is greater than .4 (Streiner & Norman, 1995). Field testing of the GCTI
using people with insomnia and good sleepers produced preliminary evidence of the
GCTI’s construct validity, as it was strongly correlated with the cognitive subscale of
Figure 1. Box and whiskers plot demonstrating the ability of the GCTI to discriminate between
good sleepers and people with insomnia.
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the PSAS, an established measure in the domain of general mental arousal. The GCTI
also demonstrated acceptable association with the cognitive arousal subscale of the
SDQ and the 10-item short form of the DBAS. It should be observed, however, that the
GCTI probes specific thought content within the general domain of cognitive excitation
and this is a unique aspect of this new measure.
Significant differences in GCTI total scores were obtained between people with
insomnia and good sleepers, supporting the GCTI’s ability to discriminate between
these groups, and exploration of sensitivity and specificity revealed that a cut-off score
of 42 yielded perfect sensitivity (100%) and good specificity (83%). Again this requires
replication. We would suggest that differentiation of people with insomnia from non-
complaining poor sleepers would also be valuable because it may be that the pre-sleep
mental and emotional experience is critical to the complaint of insomnia. We hope in
future, with much larger samples, to conduct principal component analyses of the
GCTI that might offer quantification of the factorial structure of the content of pre-sleep
thinking. This in turn would permit investigation of any specific differences in the
nature of pre-sleep thought content, as well as frequency of occurrence, between
people with insomnia and good sleepers.
We have reported a stronger association of pre-sleep thinking with subjective
estimates of sleep than with objective (actigraphic) sleep. This is interesting because it
tends to be the subjective phenomenology of the sleep experience that acts as the
‘driver’ of concern and help-seeking behaviour. This association of cognitive events
with insomnia should not be taken to imply a causal mechanism. Nevertheless, it
highlights the importance of pursuing cognitive models of insomnia where failure to de-
arouse in bed and/or hyperarousal may inhibit sleep-onset (Espie, 2002).
The reliability of the GCTI, in terms of internal consistency ( = .87), item–total
correlation values (M = .43) and test–retest reliability (r = .88) appear very acceptable.
Although the utility of the GCTI in clinical settings was not explored, the GCTI’s simple
format suggests that it is easily understood by recipients, and quick to administer (less
than 5 min) and to score. At this stage we see the GCTI as an aid to the clinical
interview process, raising issues for discussion and perhaps identifying goals for
intervention. We hope also that the GCTI will be used in both experimental and clinical
psychological research on insomnia because critical pathways in the acquisition,
persistence and treatment of insomnia remain poorly understood (Espie, 2002).
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Appendix: The Glasgow Content of Thoughts Inventory
Here are some thoughts that people have when they can’t sleep. Please indicate by placing a tick
in the appropriate box how often over the past 7 nights the following thoughts have kept you
awake.
Never Sometimes Often Always
1. Things in the future
2. How tired/sleepy you feel
3. Things that happened during the day
4. How nervous/anxious you feel
5. How mentally awake you feel
6. Checking the time
7. Trivial things
8. How you can’t stop your mind from racing
9. How long you’ve been awake
10. Your health
11. Ways you can get to sleep
12. Things you have to do tomorrow
13. How hot/cold you feel
14. Your work/responsibilities
15. How frustrated/annoyed you feel
16. How light/dark the room is
17. Noises you hear
18. Being awake all night
19. Pictures of things in your mind
20. The effects of not sleeping well
21. Your personal life
22. How thinking too much is the problem
23. Things in your past
24. How bad you are at sleeping
25. Things to do to help you sleep
420 Karen J. Harvey and Colin A. Espie
INTRODUCTION
OVER 30 YEARS AGO, THE FIELD OF PSYCHIATRY
FOUND ITSELF STRUGGLING WITH AN IMPRECISE
DIAGNOSTIC SYSTEM THAT RESULTED IN UNRELI-
ABLE DIAGNOSTIC ASSIGNMENTS ACROSS CLINICAL
AND RESEARCH SETTINGS. Largely this was due to the
absence of explicit operational criteria in the diagnostic manuals
published to aid psychiatric research and practice. As a result,
diagnostic practice was a highly subjective and unreliable pro-
cess that relied as much on psychiatric clinicians’ and
researchers’ conceptions of the diagnoses they assigned as it did
on the diagnostic manuals designed to guide their decisions.
Fortunately, this problem was effectively addressed by the devel-
opment of Research Diagnostic Criteria (RDC)(1, 2), a set of oper-
ationally defined inclusion and exclusion criteria that standard-
ized the definitions for a majority of the recognized psychiatric
conditions. These RDC dramatically improved diagnostic relia-
bility among clinicians and researchers and were quickly incor-
porated into psychiatry’s diagnostic manuals.(3-6)
The field of sleep medicine currently finds itself only slightly
ahead of where the field of psychiatry was 30 years ago. For
some time now, sleep specialists have had at their disposal diag-
nostic manuals(6-9) that describe a range of sleep disorders and
provide lists of diagnostic criteria for their ascertainment.
However, sleep disorder diagnosis has been complicated by the
existence of several distinctive nosologies that differ markedly
and often produce rather discordant classification results.(6-11)
Moreover, many current criteria sets for sleep diagnoses are
vague or lack sufficient specificity to assure reliable diagnoses
across clinical and research settings.(10-13) Recognizing this prob-
lem, work groups have convened to develop RDC-like defini-
tions for selected sleep disorder diagnoses such as sleep apnea(14)
and restless legs syndrome.(15) There is little doubt that such
efforts will benefit the field greatly by standardizing clinical
practice and research with such disorders. Nonetheless, for many
sleep disorders, research and practice remains greatly hampered
by a lack of universally accepted and precise diagnostic criteria. 
Nowhere is this problem more apparent than it is in the basic
and clinical research pertaining to insomnia. Although there has
been general agreement that insomnia per se is a symptom and
not necessarily an independent sleep disorder, there has been
great variability in how this “symptom” has been defined in the
literature. For example, some liberal definitions(16, 17) focus sole-
ly on the presence of nocturnal sleep disturbances (e.g., sleep ini-
tiation or maintenance difficulties, nonrestorative sleep), where-
as other more conservative definitions require additional features
such as associated daytime impairment(18, 19), sleep dissatisfac-
tion(20), or meeting all diagnostic criteria for a sleep disorder
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Summary: Insomnia is a highly prevalent, often debilitating, and eco-
nomically burdensome form of sleep disturbance caused by various situ-
ational, medical, emotional, environmental and behavioral factors.
Although several consensually-derived nosologies have described numer-
ous insomnia phenotypes, research concerning these phenotypes has
been greatly hampered by a lack of widely accepted operational research
diagnostic criteria (RDC) for their definition.  The lack of RDC has, in turn,
led to inconsistent research findings for most phenotypes largely due to
the variable definitions used for their ascertainment. Given this problem,
the American Academy of Sleep Medicine (AASM) commissioned a Work
Group (WG) to review the literature and identify those insomnia pheno-
types that appear most valid and tenable. In addition, this WG was asked
to derive standardized RDC for these phenotypes and recommend
assessment procedures for their ascertainment.  This report outlines the
WG’s findings, the insomnia RDC derived, and research assessment pro-
cedures the WG recommends for identifying study participants who meet
these RDC.
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described in one of the available nosologies.(21-25) In addition,
insomnia definitions have varied as a function of inconsistent use
of frequency, duration, symptom type (e.g., onset problems,
maintenance difficulties) and/or severity criteria for case ascer-
tainment.(26) As demonstrated recently by Ohayon(26), use of these
varied definitions in epidemiological studies has led to drastical-
ly different conclusions regarding insomnia’s general prevalence,
risk factors, morbidity, and costs to society at large.            
Unfortunately, such problems have not been confined to the
epidemiological literature. Variable insomnia definitions have
encumbered studies concerning the pathophysiology, clinical
characteristics, and treatment of this form of sleep disturbance.
Admittedly, the advent of consensually-derived insomnia classi-
fication schemes(4-9, 27) within the past 25 years has provided
some standardization to insomnia research by providing clinical
criteria sets for use in research sample characterization. However,
both the degree to which researchers have adhered to criteria as
well as the methods used for their ascertainment have been high-
ly variable regardless of the specific diagnostic subtype in ques-
tion. Due to this lack of standardization, synthesizing results of
multiple insomnia studies is a difficult if not impossible task.
Given this problem, the American Academy of Sleep Medicine
(AASM) commissioned a project designed to develop standard
definitions for currently recognized insomnia disorders. This pro-
ject was devoted to three Major Objectives/Specific Aims. The
first aim was to conduct a critical review of the insomnia litera-
ture to determine which of the current insomnia diagnoses appear
most reliable and valid regardless of the nosological system in
which they are defined. The second aim was to derive standard
RDC for defining each of the subset of insomnia diagnoses that
seem to have the greatest empirical and consensual support. The
final aim was to propose specific methods for documenting the
presence/absence of the specific RDC among patients and sub-
jects to which they are applied.  
In planning this project it was recognized that the status of the
available literature would set limits on what could be accom-
plished.  For example, it was anticipated that comparisons and
synthesis of results across studies would be difficult because of
the historic lack of widely accepted insomnia RDC or methods for
defining insomnia samples. As a result, it was expected that the
conclusions and recommendations derived from this effort would
likely be based, out of necessity, more on consensus than on hard
evidence.  Nonetheless, attempts were made to consider available
evidence in addressing the objectives stated above. The remainder
of this report provides a discussion of the methods used and
results derived by the group assigned to address these objectives.
METHODOLOGY
Project Planning, Direction, and Execution
In August of 1999, the AASM formed an Insomnia RDC Task
Force consisting of two representatives of the AASM Board of
Directors as well as four additional at large members with expertise
in the fields of insomnia classification and treatment. The Task Force
was commissioned to develop the scope, direction and
objectives/specific aims of the project and to serve as a liaison to the
AASM Board.  The Task Force was also charged with the naming of
an Insomnia RDC Work Group (WG) to carry out all required tasks
to address the three specific aims of this RDC project.  In November
1999 a Chair and nine additional WG members (i.e., the coauthors
of this report) were named and approved by the AASM Board to
conduct the activities leading to the results reported herein.
Literature Review 
During the first six months of 2000, a series of conference calls
and email communications among WG members were conducted
to plan the literature review strategy. Given the aforementioned
project aims and the vast insomnia literature, it was decided to
focus the literature review on articles that would most likely pro-
vide information about the reliability and construct validity of
currently recognized insomnia diagnoses. The literature deemed
relevant included: (1) articles that reported inter-rater reliability
data (e.g., % agreement; kappa values) for one or more insomnia
subtypes; (2) studies that compared one or more insomnia sub-
types with normal sleepers or controls; (3) studies that compared
two or more insomnia subtypes with each other or with other
types of sleep disorders; (4) comparisons of one or more insom-
nia subtypes with historic normative data; (5) comparisons of
treatment responsiveness of two or more insomnia subtypes
undergoing the same insomnia treatment; and (6) descriptive case
series studies of one or more insomnia subtypes that provide
information about the defining features of the subtype(s) in ques-
tion. Excluded from the literature review were treatment studies
(randomized trials, case series, within-subject designs) conduct-
ed to evaluate one or more forms of insomnia therapy with a sin-
gle insomnia subtype unless the trial in question provided diag-
nostic reliability information for the subtype being studied.  Also
excluded were articles written in a language other than English,
single case reports, and all epidemiologic studies except those
that reported diagnostic reliability data or examined differences
among diagnostic insomnia subtypes.  Finally, studies that
focused solely on circadian rhythm disorders were excluded
since the eventual development of RDC for such conditions,
while potentially beneficial to the sleep medicine field, was not a
specific aim/objective of this project.   
The literature review was conducted by a Duke University
Medical Center librarian experienced in computer-assisted library
database literature searches under the supervision of the Chair of
the WG.  Searches were conducted within both the Medline and
PSYCINFO databases for the time period between 1966 and June,
2000. Furthermore, searches were conducted for all insomnia
diagnostic categories in ICSD (the categories in the 1990 (7) and
the 1997(28) versions of the ICSD are identical; therefore, “ICSD”
will be used throughout the text to refer to these two versions) and
the 1994 version of the DSM-IV.(9) In searching each ICSD diag-
nosis, the terms insomnia and disorders of initiating and main-
taining sleep were cross-referenced with the current name of the
diagnosis and the synonyms and key words listed with the diagno-
sis in the ICSD text.  In the case of the DSM-IV subtypes, the
terms insomnia and disorders of initiating and maintaining sleep
were cross-referenced with the current name of the diagnosis and,
where indicated, a list of diagnostic subtypes.  For example, in the
case of Substance-induced Insomnia, such terms as alcohol
use/abuse, opiate use/abuse, cocaine use/abuse, etc., were includ-
ed in the search.  Full documentation of the search terms used for
all searches is available on request from the first author.  
Data Extraction Sheets
To facilitate extraction of relevant information from each arti-
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cle reviewed, the WG constructed separate reliability and validi-
ty data extraction sheets.  Both forms elicited information about
the citation (authors, title, journal, year, page numbers), the
nature of the study sample (i.e., sample selection, types of sub-
jects, number of subjects, female/male ratio, mean age, etc.),
study setting, and study results. The Reliability Data Extraction
Sheet also solicited information about the type of reliability
assessment conducted and the type of reliability index reported.
The Validity Data Extraction Sheet solicited information about
the types of group comparisons conducted, the specific measures
used, and specific findings (means, standard deviations, statisti-
cally significant group differences, etc.) reported in each article.
The validity form also solicited a judgment and supporting ratio-
nale as to whether the article should be included in an evidence
table constructed to assess the validity of the insomnia subtype(s)
considered in the article.  Finally, both forms also included a
check box to indicate that no reliability or validity data were
reported in the article listed on the form. Copies of the Reliability
and Validity Data Extraction Sheets are shown in Appendix A.
Procedure
To facilitate the final article selection process, the literature
search was conducted so that a list of citations and accompany-
ing article abstracts would be produced for each insomnia sub-
type search conducted. The search results were first divided into
the five subsets of articles pertaining to: (1) DSM-IV insomnia
subtypes; (2) ICSD intrinsic insomnia subtypes; (3) ICSD extrin-
sic insomnia subtypes; (4) ICSD insomnia subtypes associated
with mental disorders; and (5) ICSD insomnia subtypes associat-
ed with medical or neurological disorders.  The 10-member WG
was subdivided into five dyads, and each dyad was given the
search results from one of the five subsets of articles. The WG
dyads then reviewed their respective sets of abstracts and elimi-
nated articles that clearly provided no information relevant to the
aims of the RDC project (e.g. a randomized clinical trial with one
insomnia subtype). When the potential usefulness of an article
was in doubt, it was included for an initial review.  In addition,
dyads were encouraged to select relevant review articles for an
initial review inasmuch as such articles provided additional ref-
erences for consideration.
Once all dyads had completed their initial reviews and submit-
ted their lists of the articles selected for more extensive review,
AASM administrative staff obtained copies of the complete arti-
cles selected and provided members of each dyad the articles
they requested.  WG members then carefully reviewed the arti-
cles and completed both a Reliability and a Validity Data
Extraction Sheet for each one although no such sheets were com-
pleted for the review articles. Once this review process was com-
pleted, each WG member forwarded the completed data extrac-
tion sheets to AASM administrative staff members who entered
the data into a database program for subsequent analyses.
In addition to these procedures, a Ph.D. clinical psychologist
experienced in sleep medicine was hired to examine each article
selected by the WG (excluding review articles) for consideration
and extract information about the subject selection criteria and
insomnia definitions used. The specific information extracted by
the contract reviewer included all self-report (e.g., historic infor-
mation, presenting complaint, daytime symptoms, description of
typical sleep pattern, etc.), self-monitoring data (e.g., sleep diary
information), and objective measures (e.g., PSG findings) used as
inclusion/exclusion criteria in each of the articles.  Also, use of spe-
cific diagnostic criteria for subject selection was noted.  Findings
of this review process were placed into a Microsoft Excel® spread-
sheet designed to systematize the database and facilitate the subse-
quent analyses of information acquired.  A copy of the spreadsheet
can be obtained from the first author upon request.  
Following all data entry procedures, the data extraction sheets
were reviewed, and findings supporting the reliability and valid-
ity of specific insomnia diagnoses were placed into evidence
tables to help identify the most tenable insomnia diagnoses.
Subsequently, a series of tabulations were conducted using
Version 8.2 of the Statistical Analysis System (SAS Institute,
Cary, NC) to determine how frequently various inclusion/exclu-
sion criteria were used for insomnia and normal control sample
selection in all articles reviewed.  Findings from these tabulations
in addition to some additional data (e.g., PSG findings) taken
from the completed Validity Data Sheets were then considered in
the development of RDC.
RESULTS 
Articles Considered for Review and Data Extraction
Following the initial review of a large sample (N=433) of arti-
cles requested, a total of 165 articles (10, 12, 13, 20, 23, 29-188)were
retained by the WG for data extraction. Table 1 provides categor-
ical breakdowns of the total articles undergoing initial review by
the WG as well as those articles selected for data extraction. The
165 articles retained included a total of 176 samples of insomnia
sufferers and 83 samples of normal sleepers/controls. The 176
insomnia samples included a total of 9,808 subjects and the 83
control samples included a total of 20,818 subjects.  The median
size of the insomnia samples was 17.0 (1st quartile = 8; 3rd quar-
tile = 45.5), whereas the median sample size of the normal con-
trols was 20 (1st quartile = 10; third quartile = 42).
Diagnostic Reliability of Insomnia Subtypes
The review process uncovered a paucity of data concerning the
reliability of DSM and ICSD-R insomnia subtypes. In fact, only
five published studies(12, 62, 128, 138, 163) reported any reliability data,
and these studies collectively included only 440 subjects.  Two of
these studies(12, 163) were conducted solely or in part to evaluate
the diagnostic reliability of the DSM (DSM-III-R or DSM-IV)
insomnia classification system.  In the earlier of these studies,
Schramm et al.(163) examined inter-rater reliability among clini-
cians using a structured interview to differentiate 3 global DSM-
III-R insomnia subtypes.  In the latter multi-site study, Buysse et
al.(12) examined inter-rater reliability among clinicians using a
standard clinical interview to identify DSM-IV insomnia sub-
types.  Given sample size limitations, only the reliability data for
two DSM insomnia subtypes were reported in this latter study.  In
the third cluster analytic study, Edinger et al.(62) reported reliabil-
ity data for two independent raters who reviewed archival data
from a small insomnia sample (n = 31) and assigned both DSM-
III-R and ICSD  insomnia diagnoses. In the fourth study, Morin
and colleagues(128) assessed reliability for ICSD diagnoses by
comparing impressions derived from clinical interviews with
diagnoses derived independently from sleep history, psychomet-
ric evaluations, and available polysomnographic findings.
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Finally, Ohayon et al.(138) compared a computer-assisted struc-
tured interview with impressions of clinical interviewers to deter-
mine their agreement for detecting the presence or absence of any
ICSD insomnia diagnosis.  
Table 2 provides summary data taken from these five studies.
These data show that the reliability indices for DSM categories
derived from structured interviews in the Schramm et al.(163)
study are very impressive and suggest highly acceptable reliabil-
ity of these global diagnoses.  In contrast, when such global diag-
noses are derived from clinical interviews, as was the case in the
Buysse et al.(12) study, reliabilities are less impressive. The
remaining studies by Edinger et al.(62), Morin et al.(128), and
Ohayon et al.(138) suggest reasonable reliability for ICSD diag-
noses, but unfortunately, only the Morin et al. study provides reli-
ability data for individual ICSD categories.  
Diagnostic Validity of Insomnia Subtypes
Examination of the Validity Data Extraction Sheets showed
that 113 of the 165 articles reviewed included comparisons of
insomnia subtypes with each other and/or a normal control sam-
ple. However, 85 of these articles were excluded from consider-
ation due to study design limitations that reduced the usefulness
of the data reported. Many of these studies focused on samples
(e.g., Parkinson’s Disease, Alcohol Abusers, etc.) with obvious
sleep disturbance but lacked verification that individuals in these
samples actually had insomnia complaints. In other cases, insom-
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Table 2. Studies Reporting Inter-rater Reliability Data (% agreement or Kappa values) for Insomnia Diagnoses
Study Site(s) Sample size Diagnostic System Insomnia Subtypes % Agreement Kappa
& characteristics & Method Used
Schramm et al.(163) Manneheim, 68 sleep center DSM-III-R Primary Insomnia 97 0.86
Gottingen, & patients (Structured Insomnia due to a mental disorder 91 0.84
Landeck, Germany interview) Insomnia due to organic factor 93 0.86
Buysse et al.(12) Bronx (NY) 216 insomnia DSM-IV Primary Insomnia 0.40
Detroit (MI) patients referred (Clinical Insomnia due to a mental disorder 0.42
Hershey (PA) to participating interview) NR
Pittsburgh (PA) sleep centers
Rochester (NY)
Edinger et al.(62) Durham (NC) 31 insomnia clinic DSM-III-R & Mixed Insomnia (DSM-III-R) 81 0.71
patients ICSD-90 Mixed Insomnia (ICSD-90) 74 0.68
(Chart review)
Morin et al.(128) Richmond (VA) 20 insomnia ICSD-90 Psychophysiologic Insomnia 0.54
patients Insomnia due to a mental disorder 0.64
Hypnotic-dependent insomnia NR 0.70
Other mixed ICSD subtypes 0.84
Ohayon et al.(138) Palo Alto (CA) 105 sleep center ICSD-90 Presence vs. absence of ICSD 96.9 0.78
Regensburg patients (Sleep EVAL insomnia diagnosis
(Germany) interview)
Table Caption:  DSM-III-R = the 3rd edition of the American Psychiatric Association’s Diagnostic and Statistical Manual;  DSM-IV = 4th edition of the
American Psychiatric Association’s Diagnostic and Statistical Manual;   ICSD-90 = The International Classification of Sleep Disorders, 1990
Edition; NR = Not reported 
Table 1–Types of Articles Considered and Retained for Data Extraction
# requested for # retained for
Type of Article initial review % data extraction %
Review articles 105 24.2 0 0
Case reports 26 6.0 12 7.3
Case series – descriptive 60 13.9 31 18.8
Group comparisons 129 29.8 107 64.8
Inter-rater reliability studies 3 0.7 3 1.8
Clinical trials 37 8.5 2 1.2
Case series – treatment 29 6.7 1 0.6
Within-subject designs 13 3.0 5 3.0
Survey studies 19 4.4 2 1.2
Other 12 2.8 2 1.2
Total 433 100 165 100*
*Note: Cumulative percentage actually falls just below 100% due to rounding errors.
nia samples were described merely as “insomniacs” or were com-
posed of a mixture of insomnia subtypes. Since it was not possi-
ble to ascertain much about specific insomnia subtypes from such
studies, they were not used for assessing the validity of specific
insomnia diagnoses.  In a number of studies, results of
polysomnographic studies and/or sleep logs were used both to
diagnose study subjects and to compare the subtypes derived
from the initial diagnostic classification process. Given the obvi-
ous confounds affecting such group comparisons, data from stud-
ies of this nature were not included in our evidence tables. 
A review of the remaining 28 articles provided some evidence
for the validity of the DSM(4-6) subtypes of Primary Insomnia and
Insomnia due to a Mental Disorder but no group comparisons
were found concerning the categories of Insomnia due to a
General Medical Condition and Substance-induced Insomnia.
Table 3 summarizes the findings from the subset of these studies
supporting the former two insomnia diagnoses. This table
demonstrates that all studies listed in the table included a Primary
Insomnia sample and most included a sample of normal controls.
Only three of the studies included a sample of patients with
Insomnia due to Another Mental Disorder and one of these three
studies subdivided this category into the ICSD Insomnia Due to
Depression and Insomnia Due to an Anxiety Disorder subtypes.
Most of the findings summarized in the table confirm that
Primary Insomnia sufferers differ from normal controls, and the
comparisons of the two types of insomnia sufferers suggest con-
sistent differences between them. Although the data are much
more limited, the evidence table also suggests differences
between individuals who have Insomnia due to Another Mental
Disorder and noncomplaining normal sleepers. 
Twenty of the 28 articles retained included comparisons among
insomnia subtypes listed in the ICSD. Table 4 lists the studies
providing validity evidence for the diagnosis Sleep State
Misperception (SSM) (in the forthcoming ICSD-2 (189), this diag-
nosis will be called Paradoxical Insomnia). This evidence table
supports the validity of the SSM diagnosis inasmuch as the data
listed suggest that individuals with this form of insomnia can be
differentiated both from noncomplaining normal controls and
from other insomnia subtypes.  Several of the studies listed
include comparisons of SSM patients with both normal controls
and Psychophysiologic Insomnia (PSYI) sufferers. These com-
parisons suggest that SSM and PSYI sufferers have distinct pat-
terns of differences from normal controls. As preordained by
their definition, SSM groups overlap with normal sleepers on
PSG measures of sleep time, onset latency, and wakefulness dur-
ing the night whereas PSYI sufferers differ from normal sleepers
on these measures. However, several of the studies suggest some
sleep stage architectural differences between SSM sufferers and
the other groups. Moreover, as their diagnostic name implies,
SSM sufferers are distinguished from normal controls and other
insomnia subtypes by an exaggerated propensity to underesti-
mate the sleep they obtain. Finally, the table provides some lim-
ited evidence for the distinctiveness of SSM in regard to person-
ality trait measures and indices of daytime functioning.
Since most of the studies cited in Table 4 included a PSYI group,
these studies provide evidence for the distinctiveness of this diag-
nosis as well. Presented in Table 5 are some additional studies sup-
porting PSYI. The studies included in this table provide compar-
isons of PSYI with normal controls, other insomnia subtypes, and
other types of sleep disorders. The findings reported in Table 5
along with relevant data presented in Table 4 suggest that PSYI
sufferers have more wakefulness during sleep than do SSM suffer-
ers, normal controls, and groups such as narcoleptics. The two
tables also suggest that PSYI subjects differ from normal sleepers
and other insomnia subtypes on personality trait measures (e.g.,
MMPI scales). Considered collectively, these data support the
notion that PSYI is a distinctive form of insomnia that differs from
normal sleep, other insomnia diagnoses, and other types of sleep
disorders not typically associated with insomnia complaints.
Table 6 lists studies concerning other ICSD insomnia subtypes
including childhood onset (Idiopathic) Insomnia (COI), Insomnia
Related to Sleep Apnea, and Insomnia Related to an Anxiety
Disorder. The limited data listed in Table 6 along with the two
studies listed in Table 5 suggest that COI may be distinguished
from other insomnia subtypes in terms of objective and subjec-
tive sleep measures as well as the duration of complaints. Hauri’s
cluster analytic study(83) cited in Table 5 suggests COI sufferers
may be discriminated from normal sleepers on the basis of his-
toric data, presenting information, and sleep lab findings.
However, it should be noted that the study by Philip and
Guilleminault(146) listed in Table 5 showed few differences
between COI and adult-onset insomnia. Considered collectively,
these three reports appear to provide some minimal support for
the validity of COI although the information about this condition
is much more limited than it is for SSM and PSYI.
Similarly, the evidence supporting the diagnosis of Insomnia
Related to Sleep Apnea (AI) is very limited. Although the WG
encountered many studies that included a sleep apnea sample, in
most cases it was not clear that the individuals composing such
samples actually had insomnia complaints. The two studies con-
cerning AI cited in Table 6 are the exceptions to this trend.  The
first study by Roehrs et al.(154) compared an AI sample with
another sample of apnea patients who presented mainly with
complaints of excessive daytime sleepiness (AS).  The second
study by Stone et al.(173) compared a sample of AI patients with
another mixed insomnia group. The former study found statisti-
cally significant differences between AI and AS groups on PSG
sleep and MSLT sleep latency whereas the latter study failed to
find any differences on measures of daytime cognitive function-
ing. Thus, experimentally sound studies examining the validity of
AI appear to have been so limited that it is difficult to draw con-
clusions about the validity of this insomnia subtype.
The one remaining study listed in Table 6 involved a comparison
of normal controls with a group of individuals with Insomnia
Related to an Anxiety Disorder (IAD).  This study showed group
differences across a range of measures including PSG parameters,
ratings of sleep quality, diurnal motor speed and reaction time, and
measures derived from EEG mapping studies. It should also be
noted that studies (21, 152)cited in Tables 3 and 5 suggest that IAD
can be discriminated from other insomnia subtypes on the basis of
objective measures of sleep architecture and subjective sleep rat-
ings and self-report measures of daytime functioning.  Hence, IAD
appears to be a viable diagnosis on the basis of the evidence cited.  
In addition, it is noteworthy that individuals with Insomnia
Related to a Depressive Disorder (ID) such as Major Depressive
Disorder or Dysthymia were included as comparison samples in
several studies (13, 21, 29, 86, 152, 176, 180)listed in Tables 3, 4 and 5.
Considered collectively, such studies suggest differences between
these and other insomnia subtypes on measures of sleep architec-
ture, subjective sleep quality, perceptions of diurnal functioning,
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and personality traits.  Furthermore, one of these studies(21) showed
that ID could be statistically discriminated from IA and Primary
Insomnia on the basis of subjective sleep ratings and self-report
measures of daytime functioning.  As a result, it would appear that
ID warrants consideration as a separate insomnia diagnosis as well. 
Finally, since two studies(29, 176) listed in the evidence tables
included samples of insomnia sufferers with periodic limb move-
ment disorder (PLMD), this diagnosis warrants consideration.
Unfortunately, the data supporting the distinctiveness of this con-
dition appears very limited.  The studies listed suggest individuals
with PLMD differ from some other insomnia subtypes on a limit-
ed number of personality trait measures and in regard to how accu-
rately they estimate sleep time. Since there have been few com-
parisons of PLMD with other insomnia subtypes, there currently is
very limited data supporting the validity of this diagnosis.
Consensual Definitions
The evidence tables help delineate the most supportable insom-
nia diagnoses and provide some guidance as to how these sub-
types might be identified in the research subject selection process.
In addition, a review of the subject selection criteria used in these
studies should help identify consensual research definitions that
aid in the development of RDC. However, since most studies
reviewed were excluded from the evidence tables, it seemed that
much information about consensual research definitions for the
various subtypes considered would be ignored if only the selec-
tion criteria for studies included in the evidence tables were tabu-
lated. Given this consideration, the WG decided to examine the
subject selection criteria for all 165 articles retained for review.  
Tabulations of study selection criteria showed marked variabil-
ity in the types of criteria used for selection of both insomnia and
normal control samples. In fact, no single criterion or criteria set
was used for selection of as many as 50% of the insomnia or nor-
mal control samples described in the articles reviewed.
Tabulation results showed that a total of 14 distinctive types of
criteria were used for selection of at least 5% of the insomnia
samples considered herein.  Eight of these were also used with
variable frequencies for selection of the normal control samples
described in the reviewed studies.  Figure 1 shows these criteria
sets and the frequency with which they were employed in select-
ing the insomnia and normal control samples.
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Figure Caption 1–The figure shows the 14 criteria used most frequently for subject selection. Diagnostic criteria = use of published(4-7, 27, 189) diag-
nostic criteria; Duration criteria = selection on the basis of a minimum insomnia duration; Medical exclusions = subjects excluded for sleep-dis-
rupted medical conditions; Psychiatric exclusions = subjects excluded for the presence of some or any psychiatric conditions;  Medication exclu-
sions = subjects excluded for current use of psychoactive medications; Presence of DIMS complaint = subject selection on the basis of specific
complaints of sleep onset difficulties, sleep maintenance difficulties, and/or nonrestorative/poor quality sleep; Self-reported SOL, TST, etc. = sub-
jects selected who report certain predetermined mean values of certain sleep parameters such as sleep onset latency, total sleep time, etc.; Frequency
criteria = subjects selected on the basis of having insomnia a predetermined minimum number of nights per week; PSG findings = certain
polysomnographic findings needed for subject selection; Exclude circadian disorders = subjects who had evidence of unusual sleep/wake sched-
ules (e.g., shift work) or circadian rhythm disorders were excluded; Sleep-related daytime symptoms = subjects were required to have daytime
impairment related to sleep difficulties; Exclude primary sleep disorders = subjects who had symptoms/complaints suggestive of certain primary
sleep disorders such as sleep apnea, narcolepsy, restless legs syndrome, periodic limb movements, and/or parasomnias were excluded; PSG vs. sub-
jective sleep estimates = subjects selected on the basis of predetermined differences between polysomnographic sleep measures and their coinci-
dent subjective sleep estimates; Sleep diary results = sleep diary results were used for subject screening.
As might be expected, most of the selection criteria for the nor-
mal samples in the articles reviewed were designed to exclude
individuals with evidence of any form of sleep disruption.  
Typically such samples were described as individuals either
without sleep complaints or without insomnia. Almost 50% of the
normal control samples specifically excluded individuals with
selected medical disorders that commonly disrupt sleep (e.g.,
chronic pain conditions).  Approximately 42% of the normal sam-
ples excluded individuals with histories or symptoms of psychi-
atric disorders, whereas roughly 23% excluded individuals who
reported ongoing use of hypnotics or other psychoactive agents.
Roughly 15% of the samples excluded those with unusual
sleep/wake schedules or circadian rhythm disorders. Between 8%
and 9% of the samples included individuals selected on the basis
of “normal values” of sleep onset latency, wake time after sleep
onset (WASO) or total sleep time (TST) obtained either from self-
report or a screening polysomnogram (PSG). Fewer than 4% of
the samples excluded individuals with primary sleep disorders
(e.g., sleep apnea, narcolepsy, restless legs syndrome, etc).  About
50% of the normal samples included in the articles reviewed met
at least two of these selection criteria, but over 85% of these sam-
ples were selected using three or fewer of these criteria.
About 55% of the insomnia samples were selected using at least
two of the selection criteria listed in Figure 1, but slightly under
30% of these insomnia samples were selected using more than
three of these criteria.  When the criteria were tabulated individu-
ally, it was noted that satisfaction of published diagnostic crite-
ria(4-7, 27) for a particular insomnia subtype was the most frequent-
ly used entry requirement in selecting insomnia samples. This
requirement was used for slightly over 36% of the insomnia sam-
ples considered. For roughly 32% of the insomnia samples, mini-
mal insomnia duration requirements were used for sample selec-
tion; the most frequently used criterion in this regard was an
insomnia duration of six months or longer. Between 20% and 30%
of the insomnia samples excluded individuals with sleep-disrup-
tive medical disorders (29.7% of the samples), histories and/or
current symptoms of specified psychiatric disorders (26.7% of the
samples), and/or ongoing use of hypnotics or other psychoactive
medications (20.9% of the samples). Subject selection for rough-
ly 20% of the insomnia samples was based on the presence of an
insomnia complaint  (i.e., sleep initiation or maintenance difficul-
ty, poor sleep quality or nonrestorative sleep) or self-reports of an
average sleep onset latency (SOL), wake time after sleep onset
(WASO), or total sleep time (TST) that surpassed predetermined
thresholds for insomnia (e.g., SOL or WASO > 30 minutes; TST
< 6 hours).  Selection criteria for approximately 18% of the sam-
ples included consideration of insomnia frequency. The most
commonly used frequency criterion required the occurrence of
insomnia three or more nights per week. Slightly fewer than 16%
of the insomnia samples were selected on the basis of meeting a
priori thresholds (i.e., predetermined values for sleep/wake time
measures, the RDI, or PLM index) during a screening polysomno-
gram (PSG), whereas approximately 12% of the samples exclud-
ed individuals with variable sleep/wake schedules and/or circadi-
an rhythm disorders.  Less frequently used selection criteria
included the requirement of self-reported insomnia-related day-
time symptoms or impairment (9.3% of the samples), exclusions
for the presence of selected primary (e.g., sleep apnea, narcolep-
sy, etc.) sleep disorders (7% of the samples), predetermined levels
of similarity or dissimilarity between subjective sleep estimates
and corresponding PSG measures (5.2% of the samples), and a
priori thresholds for mean values of SOL, WASO, and/or TST
derived from screening sleep logs (5.2% of the samples).
To determine how these findings generalized to each of the insom-
nia subtypes listed in the evidence tables (i.e., Tables 3-6), all of the
studies reviewed that contained samples of one or more of these sub-
types were first selected. Specifically, studies were retained if they
included individuals with DSM
(4-6) Primary Insomnia and/or
Insomnia due to Another Mental Disorder as well as studies that
included samples with PSYI, SSM, COI, Insomnia due to PLMD,
AI, IAD, and/or ID as defined by either the ASDC nosology(27) or
ICSD-1.(7) Subsequently, tabulations were conducted to ascertain
how frequently each of the above-mentioned study selection criteria
was used in each of these types of insomnia samples.
A total of 61 articles that included a total of 81 insomnia sam-
ples were retained. The numbers of samples for each of the sub-
types considered are shown in Table 7 (see table caption for list
of references).  Relatively few samples with ICSD diagnoses of
IAD and ID were found. Since the forthcoming ICSD-2(189) and
DSM texts(4-6) combine these categories into a single global
insomnia diagnosis, these groups were combined with the sam-
ples assigned the DSM diagnosis of Insomnia due to Another
Mental Disorder to form one larger set of samples with Insomnia
Due to Mental Disorders. Results of the subsequent frequency
tabulations of study selection criteria used for each of these sub-
types are shown in Figures 2a-2c. Figure 2a shows tabulations for
the DSM insomnia supported by the evidence tables whereas
Figure 2b shows similar tabulation for the ASDC and ICSD sub-
types that appear most tenable. Presented in Figure 2c are the
ASDC and ICSD subtypes that received only minimal or inci-
dental support from the evidence tables.
Figure 2a shows that the research criteria most frequently used
for selecting samples of Primary Insomnia and Insomnia due to a
Mental Disorder closely reflect those features emphasized in the
DSM diagnostic criteria sets for these subtypes. In fact, DSM
diagnostic criteria were used in subject selection for two thirds of
the samples with Insomnias due to a Mental Disorder. Whereas
relevant DSM criteria were used for subject selection in slightly
under 40% of Primary Insomnia samples, exclusions for sleep-
disruptive medical problems, active psychiatric conditions, and
psychoactive medications emphasized by these criteria were used
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Table 7. Number of Samples of Various Insomnia Subtypes
Examined for Consensual Definitions
Diagnostic Category # Samples Considered
Primary Insomnia 11
Insomnia due to Another Mental Disorder 8
Psychophysiologic Insomnia 21
Sleep State Misperception 14
Idiopathic/Childhood Onset Insomnia 3
Insomnia due to Sleep Apnea 5
Insomnia due to Periodic Limb Movement Disorder 14
Insomnia due to an Anxiety Disorder 3
Insomnia due to a Depressive Disorder 2
Total Samples 81
Figure Caption: Samples were derived from articles with the follow-
ing reference numbers in the reference list: (13, 29, 43, 44, 46, 47,
51, 56-58, 63, 67, 68, 73, 75-77, 79, 80, 84, 86, 98, 103-105, 112,
113, 119-122, 128, 133, 135, 143, 145, 146, 148, 151-154, 156, 158-
162, 166, 168, 170, 172-178, 180, 183, 188)
in selecting over 50% of these samples. The figure shows that
ascertainment of an insomnia (DIMS) complaint, as well as use
of duration and frequency criteria were commonly employed in
subject selection of both insomnia subtypes.  Exclusion of circa-
dian rhythm disorders was mentioned in selecting one third of the
insomnia samples with mental disorders but this criterion was
seldom specifically mentioned in the selection of the Primary
Insomnia samples. However, since this exclusion is incorporated
into DSM criteria for Primary Insomnia, it can be assumed that
such samples selected on the bases of these criteria excluded
individuals with circadian disturbances. A similar assumption can
be made about the limited consideration of daytime impairment
as a selection criterion for either type of sample since the diag-
nostic criteria for both subtypes require evidence of such impair-
ment. In contrast, PSG findings and subjective sleep estimate via
self-report or sleep diary seem less essential since they were
infrequently used as selection criteria for these subtypes.    
Figure 2b shows tabulation results concerning criteria used for
selection of the two most strongly supported ICSD insomnia sub-
types, PSYI and SSM. These data suggest some overlap and
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Figures 2a-2b–Research Selection Criteria used for Defining Insomnia Subtypes. The definitions provided in the caption for Figure 1 apply to
Figures 2a, 2b, & 2c.
some notable differences in the research selection criteria used
for these subtypes. Specific diagnostic criteria as well as exclu-
sions for sleep-disruptive medical problems, active psychiatric
conditions, psychoactive medications, and circadian disorders
were frequently employed for the selection of both subtypes in
the studies considered. Another common finding was that insom-
nia complaints, daytime symptoms or impairment, and exclu-
sions for primary sleep disorders were seldom considered in sam-
ple selection for both subtypes, perhaps because diagnostic crite-
ria that include these considerations were used with relative fre-
quency. In contrast, the figure shows that subjective sleep
impressions (i.e., self-reports, diary results), PSG findings, and
comparisons of PSG and subjective sleep measures were much
more common selection factors for the SSM groups than for the
psychophysiologic samples. Given the nature of SSM, these lat-
ter findings admittedly are not surprising.  Nonetheless, these
consensual data imply the potential importance of such factors in
developing RDC for this condition.
Figure 2c provides findings concerning the typical research
selection/definition criteria used for the remaining ICSD diag-
noses considered in the evidence tables. As was the case for the
above two diagnoses, these data suggest some marked differences
among these subtypes in regard to the relative importance of the
selection criteria listed.  PSG findings (either apneic/hypopneic
events or counts of PLMs) coupled with DIMS complaints were
used very frequently for selection of AI and PLMD patients,
whereas specific diagnostic criteria were employed somewhat less
frequently. The remaining selection criteria were used much more
rarely for selecting and defining these subtypes in the studies
reviewed.  In contrast, insomnia complaints coupled with duration
criteria were used universally to select idiopathic insomnia sam-
ples. Diagnostic criteria and exclusions for medical and sleep dis-
orders seemed of moderate importance for sample selection/defi-
nition of this subtype. PSG data were also frequently considered
in defining idiopathic samples, but mainly as a means of ruling out
occult primary sleep disorders such as sleep apnea and PLMD.
The remaining criteria sets were used infrequently or not at all for
selecting idiopathic samples. 
Derivation of Insomnia RDC
The findings derived from the literature search provide guid-
ance in the development of a standardized definition for chronic
insomnia per se as well as RDC for specific diagnostic subtypes
and normal control samples. Since the literature review showed
frequent use of published diagnostic criteria for insomnia subject
selection, it seemed useful to begin by considering commonali-
ties in insomnia definitions contained in the most recent of these
nosologies. Both the latest DSM(6) and most recent versions of
the ICSD(7, 28) systems agree that complaints of difficulty initiat-
ing sleep, difficulty maintaining sleep, and/or sleep that is non-
restorative or poor in quality constitute the sleep-related symp-
toms of insomnia. Furthermore, both systems require associated
daytime impairment that is perceived to be the result of the noc-
turnal sleep symptoms.  These two requirements, nocturnal sleep
disturbance and associated daytime impairment, appear to repre-
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Figure 2c–Research Selection Criteria used for Defining Insomnia Subtypes. The definitions provided in the caption for Figure 1 apply to Figures
2a, 2b, & 2c.
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sent universal definitional criteria that “fit” within extant insom-
nia nosologies and apply equally well to the various subtypes
highlighted by the WG literature review. 
In contrast, other frequently used definitional criteria examined
do not appear of equal importance to a global insomnia definition.
For example, the tabulations conducted suggest that insomnia dura-
tion may be important to the definitions of various subtypes but not
for insomnia associated with PLMD or sleep apnea. Likewise, fre-
quency criteria appear relatively important to some subtypes (e.g.,
SSM) but not to others. Similar statements can be made about the
remaining definitional criteria examined. Hence, none of these can
be applied to a universally applicable insomnia definition.
A final consideration relates to the context in which the noctur-
nal and diurnal insomnia symptoms occur. Although typically not
stated, implicit to the term insomnia is the assumption that its asso-
ciated nocturnal and diurnal symptoms arise despite a consistently
adequate opportunity for sleep. That is to say, nocturnal sleep dif-
ficulties occur despite the allocation of adequate time periods and
circumstances (e.g., a quiet and dark bedroom) for sleep. In this
vein, the ICSD-2(189) will specifically mention this requirement in
its generic insomnia definition. Given these considerations, the cri-
teria shown are offered as universal RDC for insomnia. These cri-
teria have been included in the ICSD-2, and the WG recommends
their use for selection of adult insomnia samples by all researchers
regardless of the insomnia subtype in question. 
In addition to these universal criteria, additional criteria seem
appropriate for the distinctive insomnia subtypes previously dis-
cussed. Results of the literature review suggest the RDC criteria
sets should vary across the subtypes considered. The specific cri-
teria sets and their justifications are provided for each subtype in
the following discussion.
Research Diagnostic Criteria for Insomnia Disorder
A. The individual reports one or more of the following
sleep related complaints: 
1. difficulty initiating sleep, 
2. difficulty maintaining sleep, 
3. waking up too early, or 
4. sleep that is chronically nonrestorative or poor in quality. 
B. The above sleep difficulty occurs despite adequate
opportunity and circumstances for sleep.  
C. At least one of the following forms of daytime impair-
ment related to the nighttime sleep difficulty is reported
by the individual:
1. fatigue/malaise; 
2. attention, concentration, or memory impairment;
3. social/vocational dysfunction or poor school perfor-
mance;
4. mood disturbance/irritability;
5. daytime sleepiness;
6. motivation/energy/initiative reduction;
7. proneness for errors/accidents at work or while driving;
8. tension headaches, and/or GI symptoms in response to
sleep loss; and
9. concerns or worries about sleep.
Primary Insomnia: This diagnosis is specific to the DSM (4-6)
sleep disorders nosology. It is a fairly global diagnosis established
primarily by the exclusion of other primary sleep disorders, psy-
chiatric conditions, medical factors, and substance use/abuse as
causes to the reported sleep difficulty. Given its global nature, pri-
mary insomnia subsumes several of the subtypes (e.g., PSYI, idio-
pathic insomnia, SSM) listed in the ICSD. These ICSD-2 subtypes
are more specific and are defined by positive symptoms as well as
by exclusionary criteria.  As such, the utility of RDC for both pri-
mary insomnia and these more specific ICSD-2 subtypes could be
questioned. However, as demonstrated by previous studies(10, 11)
there is not perfect concordance between the more global primary
insomnia diagnosis and the more specific ICSD-2 subtypes.  For
example, some patients who fail to meet criteria for any of the
more specific ICSD-2 subtypes may meet criteria for primary
insomnia whereas some patients who meet criteria for one of the
ICSD-2 subtypes may not meet criteria for primary insomnia.  In
addition, there is a formidable treatment literature devoted to pri-
mary insomnia. Given these considerations, it seems reasonable to
provide RDC for primary insomnia as well as for the several over-
lapping ICSD-2 subtypes described later. 
DSM criteria for this condition include an insomnia complaint
as well as a number of the exclusionary criteria highlighted by the
findings shown in Figure 2a. Both the figure and the DSM texts
advocate excluding medical, psychiatric, and medicinal causes of
sleep disturbance. In addition, the diagnostic criteria require
exclusions for other primary sleep disorders (e.g., sleep apnea,
parasomnias, etc.), sleep disturbances due to unusual sleep/wake
schedules or circadian rhythm disorders, and sleep difficulties
arising from substance abuse. Along with these criteria, both the
DSM texts and the data summarized in Figure 2a highlight the
importance of duration criteria. The DSM system requires an
insomnia duration of one month or longer.  All six reviewed arti-
cles that used a duration criterion for primary insomnia required
at least one-month duration although five of these six articles
required longer durations. Nonetheless, these articles provide
consensus that an insomnia duration of at least one-month is
needed for this diagnosis. The following criteria incorporate
these considerations in RDC for Primary Insomnia.
Research Diagnostic Criteria for Primary Insomnia
A. The individual meets the criteria for insomnia disorder.
B. The insomnia noted in A has been present for at least one
month.
C. One of the following two conditions applies:
1. There is no current or past mental or psychiatric disorder.
2. There is a current or past mental or psychiatric disor-
der, but the temporal course of the insomnia shows some
independence from the temporal course of the mental or
psychiatric condition.
D. One of the following two conditions applies:
1. There is no current or past sleep-disruptive medical condition.
2. There is a current or past sleep-disruptive medical con-
dition, but the temporal course of the insomnia shows
some independence from the temporal course of the med-
ical condition.
E. The insomnia cannot be attributed exclusively to another
primary sleep disorder (e.g., sleep apnea, narcolepsy, or
parasomnia) or to an unusual sleep/wake schedule or cir-
cadian rhythm disorder.
F. The insomnia cannot be attributed to a pattern of substance
abuse or to use or withdrawal of psychoactive medications. 
Insomnia due to a Mental Disorder: This diagnosis has been
included in several editions of the DSM sleep disorders nosolo-
gy. A variety of mental disorders have insomnia as a symptom,
but this diagnosis is applied when insomnia arises from a mental
disorder and is of sufficient severity or concern to the patient as
to require separate attention in treatment.  Traditionally, the ICSD
system has included several subtypes of insomnias that can be
subsumed within this more global DSM category.  However, the
ICSD-2 has adopted the DSM approach and includes the global
category of Insomnia due to a Mental Disorder rather than sever-
al specific mental disorder subtypes described in the previous
ICSD.  As such, development of RDC for insomnia due to a men-
tal disorder has applicability to both DSM and the current ICSD-
2 classification systems.   
Figure 2a suggests strong adherence to published diagnostic
criteria for this insomnia subtype by previous researchers. The
condition’s DSM criteria include a complaint of insomnia. The
criteria and Figure 2a also highlight the importance of exclusions
for sleep-disruptive medical conditions and medications that dis-
rupt sleep. In addition, the DSM criteria emphasize the relation-
ship between the insomnia and the comorbid mental disorder and
include exclusions for substance abuse and such sleep disorders
as narcolepsy, breathing-related sleep disorders and parasomnias
as causative factors.  In regard to this latter set of exclusions,
Figure 2a suggests that sleep schedule and circadian disorders
may warrant exclusionary attention as well. Furthermore, the cri-
teria emphasize the relative prominence and importance of the
insomnia to distinguish this subtype from mental disorders
wherein insomnia is a common albeit less central symptom. 
Along with these considerations, both the DSM texts and
Figure 2a suggest the importance of duration criteria for this sub-
type. DSM-IV criteria require a minimum insomnia duration of
one month. The findings presented in Figure 2a represent five
instances in which a minimum duration criterion was used, and in
none of these cases was a duration of less than one month used.
As such, a duration of one-month seems appropriate as a mini-
mum criterion for this condition although longer time periods
may be helpful in ascertaining the association/co-variation of
insomnia and its causative mental disorder. Given these consid-
erations the criteria shown are offered as RDC for Insomnia due
to a Mental Disorder.
Psychophysiologic Insomnia:  This diagnosis is specific to the
ICSD system (7, 28, 189)and is one of the subtypes that may be sub-
sumed within the more global DSM diagnosis of primary insom-
nia. Unlike primary insomnia, PSYI is defined by positive symp-
toms reflective of somatized tension and conditioned arousal as
well as by several exclusionary criteria. Admittedly, there is
debate(190, 191) about the utility of subdividing primary insomnia
into this and other subtypes, and there is a need for much more
diagnostic reliability and validity studies to settle this controver-
sy. However, the evidence tables discussed previously provide
some limited support for subdividing primary insomnia into a
number of ICSD subtypes.  As such, RDC for PSYI and other
selected ICSD subtypes seem needed to systematize study of
these subtypes so that their utility vis a vis the DSM global diag-
nosis of primary insomnia can be ascertained.
As suggested by Figure 2b, published diagnostic criteria fre-
quently have been used to identify or select individuals for stud-
ies of PSYI.  Central to the ICSD criteria(7, 189) for this condition 
Research Diagnostic Criteria for Insomnia due to a 
Mental Disorder
A. The individual meets the criteria for insomnia disorder.
B. The insomnia noted in A has been present for at least one
month.
C. There is an association between the insomnia and a co-
existing DSM-IV-TR-defined mental disorder as reflected
by both of the following:
1. The onset of the insomnia coincides with the onset of
the associated mental disorder.
2. The temporal course of the insomnia coincides with the
temporal course of the mental disorder.
D. The insomnia is either the sole complaint or is sufficiently
severe to warrant separate clinical attention.
E. One of the following two conditions applies:
1. There is no current or past sleep-disruptive medical
condition.
2. There is a current or past sleep-disruptive medical con-
dition, but the temporal course of the insomnia shows
some independence from the temporal course of the med-
ical condition.
F. The insomnia cannot be attributed exclusively to another
primary sleep disorder (e.g., sleep apnea, narcolepsy or
parasomnia) or to an unusual sleep/wake schedule or cir-
cadian rhythm disorder.
G. The insomnia cannot be attributed to a pattern of substance
abuse nor to use or withdrawal of psychoactive medications.
are evidence of sleep-preventing associations and somatized ten-
sion/arousal that disrupt sleep. The ICSD criteria for PSYI also
incorporate the above-mentioned  insomnia definition and, along
with the findings shown in Figure 2b, highlight the importance of
exclusions for sleep-disruptive medical and psychiatric condi-
tions as the sole cause of the insomnia. Not mentioned in the cri-
teria for this condition are exclusions for sleep-disruptive medi-
cations, yet Figure 2b suggests such exclusions have been used
with relative frequency in previous studies of this subtype.
Neither the ICSD criteria nor the findings summarized in Figure
2b argue for the exclusion of co-morbid sleep disorders with the
possible exception of circadian rhythm disorders.  In fact, the
diagnostic criteria allow for coexisting sleep disorders such as
obstructive sleep apnea presumably if the observed sleep prob-
lem cannot be explained solely by this coexisting condition.
In regard to duration, Figure 2b suggests that duration criteria
have been used with relative frequency in research studies con-
cerning this subtype. In fact, duration criteria were used for the
selection of 8 of the 21 psychophysiologic samples identified in
the articles reviewed. Minimum insomnia duration required for
these samples was variable and included three months, six
months and twelve months. Despite these findings, ICSD
allowed for the diagnosis of acute PSYI in cases where the
insomnia is present for less than four weeks. Nonetheless, it
seems that some period of time would be required to allow for the
development of the conditioned arousal that defines this condi-
tion. Hence, as a compromise between research practice and
ICSD, the WG proposes requiring a minimum insomnia duration
of one-month for clear identification of established cases of this
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Research Diagnostic Criteria for Psychophysiological
Insomnia
A. The individual meets the criteria for insomnia disorder.
B. The insomnia noted in A has been present for at least one
month.
C. The patient has evidence of conditioned sleep difficulty
and/or heightened arousal in bed as indicated by one or
more of the following:
1. Excessive focus on and heightened anxiety about sleep.  
2. An inability to fall asleep in bed at the desired bedtime
or during planned naps but relative ease falling asleep
during other relatively monotonous activities (e.g.,
watching TV, reading, etc.) when not intending to sleep.
3. Being able to sleep better away from home than at
home.
4. Mental arousal in bed characterized either by intru-
sive thoughts or a perceived inability to volitionally
cease sleep-preventing mental activity.
5. Heightened somatic tension in bed reflected by a per-
ceived inability to relax the body sufficiently to allow
the onset of sleep.
D. One of the following two conditions applies:
1. There is no current or past mental disorder.
2. There is a current or past mental disorder, but the tem-
poral course of the insomnia shows some independence
from the temporal course of the mental disorder.
E. One of the following two conditions applies:
1. There is no current or past sleep-disruptive medical
condition.
2. There is a current or past sleep-disruptive medical con-
dition, but the temporal course of the insomnia shows
some independence from the temporal course of the med-
ical condition.
F. The insomnia cannot be attributed solely to another primary
sleep disorder (e.g., sleep apnea, narcolepsy, or parasomnia)
or to an unusual sleep/wake schedule or circadian rhythm
disorder.
G. The insomnia cannot be attributed to a pattern of sub-
stance abuse or to use or withdrawal of psychoactive
medications.  
condition. This duration criterion appears in ICSD-2 criteria for
Psychophysiologic Insomnia and has been integrated into the fol-
lowing RDC for this condition.
Paradoxical Insomnia (Sleep State Misperception): This con-
dition represents another ICSD subtype that can be subsumed
within the global DSM diagnosis of primary insomnia. It has
been assigned various names including insomnia complaint
without objective findings, pseudo-insomnia, subjective insom-
nia, and most recently, sleep state misperception. Each of these
terms connotes an absence of actual sleep pathology despite
the presence of an insomnia complaint. However, the origins of
sleep complaints in patients with this condition remain poorly
understood, although some recent studies(192, 193) suggest that
excessive high frequency activity in patients’ sleep EEGs may
relate to their subjective sleep dissatisfaction. Accordingly, this
condition has been renamed Paradoxical Insomnia in the
ICSD-2 to avoid the negative connotations of its previous
names.  As the evidence tables provide some support for this
subtype, RDC are offered to systematize future study of this
condition.
As reflected by Figure 2b, the types of criteria required for
this condition are qualitatively different from those required
for the other subtypes considered thus far. Published diagnos-
tic criteria7 have been used less frequently for sample defini-
tion/selection for this subtype than for PSYI. However, dura-
tion criteria, as well as exclusions for medication, medical dis-
orders, and psychiatric conditions have figured very promi-
nently in sample definition. In addition, the studies reviewed
show frequent use of frequency criteria, self-reports of
sleep/wake measures, PSG findings, and comparisons of sub-
jective sleep estimates with PSG data to define research par-
ticipants with this condition.
In the studies reviewed, duration criteria were used for selec-
tion/definition of 9 of 14 samples, and in all of these cases, a
minimum insomnia duration of six months was used. However,
ICSD allows diagnosis of acute versions of this disorder in
cases having insomnia complaints for less than one month.
Nonetheless, the WG surmised it would be difficult to be cer-
tain about this diagnosis in the acute phase. As such, a mini-
mum duration of one month was selected as a criterion so as to
compromise between ICSD criteria and previous research
practice.    
Criteria related to the frequency (number of nights per week)
of insomnia were used as selection criteria for 7 of the 14 sam-
ples with this condition. When frequency criteria were used, an
insomnia occurring > 3 nights per week was required.
However, it should be noted that the ICSD and ICSD-2 require
no specific minimum frequency of sleep difficulties for diag-
nosis of this condition. Furthermore, frequency criteria were
generally not viewed as important for the other ICSD primary
insomnia subtypes (i.e., PSYI, & COI). As a consequence, fre-
quency criteria were not included in the proposed RDC for this
condition, although it is recognized that future research may
show that these RDC can be improved by the addition of such
criteria. 
In regard to PSG criteria, both the ICSD and a review of rel-
evant studies suggest that sleep recordings show no evidence
of other sleep disorders that may account for the insomnia
complaint.  The original ICSD system (7)suggests “sleep laten-
cies of less than 15 to 20 minutes and sleep durations in excess
of 6ﬁ hours” are characteristic PSG findings among patients
with this condition. To corroborate this statement, PSG find-
ings were extracted from all reviewed studies that included
SSM samples. PSG values of SOL were reported for seven
samples totaling 73 subjects, whereas values of TST were
available for five samples totaling 48 patients. These data
were used to compute weighted averages of SOL and TST by
multiplying the mean values reported for each sample by the
sample size, summing the results of these calculations, and
then dividing the result by the total number of subjects includ-
ed in the samples considered.  Results of these calculations
produced a weighted mean SOL of 22.8 minutes and a weight-
ed mean TST of 415.5 minutes. These findings suggest that a
minimum TST requirement of 6ﬁ hours may be reasonable for
definition of paradoxical insomnia, but a 20-minute SOL may
be an overly strict requirement. 
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In addition to these measures, several articles used a mini-
mum sleep efficiency value as a defining feature of this diag-
nosis. Sleep efficiencies of > 85% or 90% were most com-
monly used for selection of subjects with this condition.  A
review of relevant articles produced mean values of sleep effi-
ciency for four separate samples totaling 33 subjects.
Computation of a weighted average produced a mean sleep
efficiency value of 92.2% for these samples. Whereas these
findings suggest either efficiency requirement could be
employed, it should be noted that the value of 85% has com-
monly been regarded as normal in the insomnia literature.(194)
Therefore, use of this more lenient cutoff may represent a more
practical requirement for defining paradoxical insomnia. 
A final consideration regarding definition of this insomnia
subtype pertains to the observed mismatch between the
patient’s reported and recorded sleep. The studies reviewed
used several different strategies to attempt to operationalize
this discrepancy. One strategy required pathologically high
values of SOL or WASO derived from self-report or sleep logs
in subjects who show “normal” PSG measures of these param-
eters. Another strategy required subjects to overestimate SOL
or underestimate TST by a pre-determined degree.  For exam-
ple, Dorsey and Bootzin(56) assigned SSM diagnoses to those
who overestimated PSG determined SOL by 150% or more.
However, the articles reviewed showed no consistent strategy
for operationalizing this mismatch. As such, ascertaining com-
plaints of insomnia and/or pathologic values of SOL or WASO
on sleep logs in individuals who meet the above described
PSG criteria may represent the most pragmatic approach for
identification of paradoxical insomnia at this juncture. The
RDC shown for this condition assimilate these various con-
siderations.
Idiopathic Insomnia:  This condition represents a third ICSD
subtype that generally may be subsumed within the global DSM
category of primary insomnia. Whereas the WG found few arti-
cles that included samples of COI, these articles provided some
guidance in the development of RDC. Figure 2c shows that use
of published diagnostic criteria, duration criteria, ascertainment
of specific insomnia symptoms (e.g., onset, maintenance, or
quality complaint), and PSG findings appear to be the most
prominent selection criteria used.  Included among the pub-
lished criteria set is the requirement of childhood onset. The
articles reviewed all included adult samples. As such, the dura-
tion criteria used in this limited number of studies appeared
designed to assure a childhood onset, and one(82) of these arti-
cles specifically required an insomnia onset before age 10.
Although ICSD criteria allowed the presence of comorbid sleep
disorders, the few articles reviewed used PSG to exclude
patients with sleep disorders such as sleep apnea and periodic
limb movements.
Figure 2c shows exclusions for medications and psychiatric
conditions were infrequently employed, but more attention was
given to exclusions for medical conditions. ICSD criteria allow
for coexisting medical and psychiatric conditions and provide no
exclusionary criteria for current medication use or use/abuse of
substances. However, these criteria state, “ No medical or mental
disease can explain the early onset of insomnia.” On the basis of
WG findings and published criteria the RDC shown here are
offered for COI.
Research Diagnostic Criteria for Paradoxical Insomnia
A. The individual meets criteria for insomnia disorder.
B. The insomnia noted in A has been present for at least one
month.
C. Nocturnal polysomnography shows a sleep time > 6ﬁ
hours and a sleep efficiency > 85%. 
D. One or more of the following applies:
1. The individual reports a chronic pattern of little or no
sleep most nights with rare nights during which relatively
normal amounts of sleep are obtained.
2. Sleep log data during one or more weeks of monitoring
show an average sleep time well below published age-
adjusted normative values, often with no sleep at all indi-
cated for several nights per week. Typically there is an
absence of daytime naps following such nights.
3. The individual shows a consistent, marked mismatch
between objective findings from polysomnography and
subjective sleep estimates. 
E. The daytime impairment reported is consistent with that
reported by other insomnia subtypes, but it is much less
severe than expected given the extreme level of sleep
deprivation reported. There is no report of intrusive day-
time sleep episodes, disorientation, or serious mishaps due
to marked loss of alertness/vigilance.
F. One of the following applies:
1. There is no current or past mental disorder.
2. There is a current or past mental disorder, but the tem-
poral course of the insomnia shows some independence
from the temporal course of the mental condition.
G. One of the following applies:
1. There is no current or past sleep-disruptive medical
condition.
2. There is a current or past sleep-disruptive medical con-
dition, but the temporal course of the insomnia shows
some independence from the temporal course of the med-
ical condition.
H. The insomnia cannot be attributed solely to another pri-
mary sleep disorder (e.g., sleep apnea, narcolepsy, or para-
somnia) or to an unusual sleep/wake schedule or circadian
rhythm disorder.
I. The insomnia cannot be attributed to a pattern of substance
abuse or to use or withdrawal of psychoactive medications. 
Insomnia Related to PLMD:  This condition is specific to the
ICSD system; no specific analogous diagnosis is included in the
DSM system. The WG found a number of studies containing
individuals whose insomnia was attributed to PLMD. It is recog-
nized that there is an unresolved debate(120) as to whether period-
ic limb movements are a cause of insomnia or merely an epiphe-
nomenon of sleep disruption or insomnia per se.  Since further
research to clarify the clinical usefulness of this diagnosis is
needed to resolve this controversy, RDC for this condition would
currently seem useful. 
Figure 2c shows that PSG findings and a specific insomnia
complaint were the two most common definitional criteria in the
articles reviewed.  In fact, these two selection criteria were cited
more commonly for subject selection than were specific diagnos-
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tic criteria.  Admittedly this finding is, in part, artifactual because
only articles that specifically linked a finding of PLMD and
insomnia were selected for review.  Nonetheless, these two com-
ponents may indicate the most salient features of this condition in
that Figure 2c shows relative infrequent use of the remaining
selection criteria.  However, it should be noted that the ICSD cri-
teria exclude medical disorders, mental conditions and coexisting
sleep disorders as explanations for presenting complaint.
Research Diagnostic Criteria for Idiopathic (Childhood
Onset) Insomnia
A. The individual meets the criteria for insomnia disorder.
B. The insomnia noted in A began during childhood (i.e.,
before age 10) without an identifiable precipitant.
C. The insomnia has been persistent and unrelenting since its
onset.
D. One of the following applies:
1. There is no current or past mental disorder.
2. There is a current or past mental disorder, but the tem-
poral course of the insomnia shows some independence
from the temporal course of the mental condition.
E. One of the following applies:
1. There is no current or past sleep-disruptive medical
condition.
2. There is a current or past sleep-disruptive medical con-
dition, but the temporal course of the insomnia shows
some independence from the temporal course of the med-
ical condition.
F. The insomnia cannot be attributed solely to another pri-
mary sleep disorder (e.g., sleep apnea, narcolepsy, or para-
somnia) or to an unusual sleep/wake schedule or circadi-
an rhythm disorder.
G. The insomnia cannot be attributed to a pattern of substance
abuse or to use or withdrawal of psychoactive medications.
PLMD should be clearly distinguished from restless legs syn-
drome (RLS), which is itself a very common cause of insomnia.
Periodic limb movements of sleep (PLMS) accompany RLS in
the majority of patients, but by definition the term PLMD is only
used in ICSD-2 when RLS is not present. In the past, confusion
between RLS, PLMS and PLMD have led to difficulty in assess-
ing the inclusion criteria of many research studies.
Individuals with Insomnia Related to PLMD have been identi-
fied primarily by specific PSG indices of periodic limb movement
activity. Methods for quantifying this activity in the articles
reviewed typically refer to the method originally suggested by
Coleman.(52) The ICSD requires a rate of 5 PLMs per hour of sleep
for a diagnosis of PLMD. The updated ICSD-2 requires a rate of
5 PLMs per hour in children and, in most adult cases, a rate of 15
per hour, but cautions that the PLMS rate must be interpreted in
the context of a patient’s sleep-related complaint. A review of the
14 articles that included PLMD samples showed specific mention
of a 5 PLMs per hour cutoff in four articles, whereas no specific
PLM criterion was reported in the remaining articles. Recognizing
that there is not adequate data to establish any absolute cut-off for
PLMS rate, and in order to assure some consistency in future
PLMD studies, a minimum of 5 PLMS per hour in children and
15 PLMS per hour in adults has been included as a minimum cri-
terion in the following RDC for insomnia related to PLMD.
Research Diagnostic Criteria for Insomnia Related to
Periodic Limb Movement  Disorder
A. The individual meets criteria for insomnia disorder.
B. Polysomnographic monitoring shows stereotyped limb
movements that:
1. are one half second to 5 seconds in duration,
2. are of amplitude greater than or equal to 25% of toe
dorsiflexion during calibration,
3. occur in a sequence of four or more movements, and
4. are separated by more than five seconds and less than
90 seconds.
C. The PLMS Index based on the scoring criteria in B
exceeds five per hour in children and 15 per hour in most
adult cases.
D. Other coexisting sleep disorders, including RLS, cannot
account either for the insomnia noted in A or the PLM activity.  
Insomnia Related to Sleep Apnea: Both the DSM and ICSD
systems suggest insomnia may be attributable to sleep disordered
breathing. However, the extent to which IA represents a useful
clinical diagnosis has been debated. Some(105) have argued that
sleep apnea is a common occult cause of insomnia complaints,
whereas others(195) report that insomnia arising from sleep apnea
is relatively uncommon. Since this controversy remains unre-
solved, RDC to allow further study the utility of this diagnosis
seem warranted.   
As was the case for PLMD-related insomnia, articles selected for
review concerning this condition were chosen because they speci-
fied a presence of both insomnia and sleep apnea in the subjects
described.  Many articles included samples of apnea sufferers, but
these had to be excluded because they were composed primarily of
hypersomnolent individuals. As a result of our selection process,
Figure 2c shows that PSG findings and insomnia symptoms were
the two universally used criteria for the few samples representing
this subtype considered.  However, the published DSM and ICSD
criteria and the findings shown in Figure 2c suggest that other
selection criteria are important in defining this subtype.
Unfortunately the PSG definitional criteria for IA were not
consistently defined in the studies considered. Only five articles
specifically examined insomnia in the context of sleep apnea, and
several of these were case reports published prior to 1980. One
such paper(77) suggests the use of a minimum of  “30 apneic
episodes per recording night”; this index appears very crude by
the recent consensus apnea definition.(14) A more recent paper(173)
used a respiratory disturbance index (RDI) of  > 10 apneas +
hypopneas per hour of sleep in selected apnea sufferers from a
group of individuals with insomnia complaints, but required an
RDI < 5 to identify insomnia sufferers with no apnea. It seems
noteworthy that an RDI = 5 is the minimum RDI listed in the
ICSD and updated ICSD-2 diagnostic criteria for sleep apnea.
Given the limited articles devoted to this insomnia subtype and
the lack of consensus regarding an RDI cutoff, this currently may
represent the best consensual criterion to use for  identifying
Insomnia Related to Sleep Apnea. Hence, this RDI criterion is
included in the following RDC set proposed.
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Research Diagnostic Criteria for Insomnia Related to 
Sleep Apnea.
A. The individual meets criteria for insomnia disorder.
B. Nocturnal polysomnographic recording shows > 5 respi-
ratory events that meet current definitional criteria for
apneas, hypopneas or respiratory effort-related arousals
per hour of sleep.
C. Sleep-disruptive medical conditions, mental disorders,
and any coexisting sleep disorders can not totally
account for the insomnia noted in A.  
Other insomnia subtypes: The literature provided little informa-
tion about other specific insomnia subtypes. Both the DSM-IV
and ICSD texts provide diagnoses for insomnias resulting from a
medical disorder and insomnias related to substance use/abuse.
The more recent DSM and ICSD-2 texts delineate global diag-
noses for labeling these two conditions. Hence, additional RDC
appear warranted for these global insomnia diagnoses.
Although WG members reviewed many articles concerning the
study of sleep in various medical conditions (e.g., Parkinson’s
Disease, chronic pain), these studies characteristically failed to
confirm the presence of insomnia complaints in the samples
examined. Similarly, many studies of sleep disturbance related to
substance abuse/exposure were found but, once again, these stud-
ies failed to document coincident insomnia complaints.
Nonetheless, the WG consensus supports the notion that both
medical conditions and use of or exposure to certain substances
may give rise to insomnia. To encourage studies of the reliabili-
ty, validity, course, and treatment requirements of these condi-
tions, the criteria sets shown here are offered as provisional RDC
for these disorders. 
Insomnia due to Medical Condition
A. The individual meets criteria for insomnia disorder.
B. The insomnia is present for at least one month.
C. There is an association between the insomnia and a co-exist-
ing medical disorder as reflected by both of the following:
1 The onset of the insomnia coincides with the onset of
the associated medical disorder.
2 The temporal course of the insomnia coincides with the
temporal course of the medical disorder.
(Note: Researchers should identify the specific medical
disorder(s) causing the insomnia)
D. The insomnia is either the sole complaint or is sufficiently
severe to warrant separate clinical attention.
E. One of the following two conditions applies:
1. There is no current or past sleep-disruptive mental
condition.
2. There is a current or past sleep-disruptive mental condition,
but the temporal course of the insomnia shows some indepen-
dence from the temporal course of this mental condition.
F. The insomnia cannot be attributed exclusively to another
primary sleep disorder (e.g., sleep apnea, narcolepsy, or
parasomnia) or to an unusual sleep/wake schedule or cir-
cadian rhythm disorder.
G. The insomnia cannot be attributed to substance abuse or to
use or withdrawal of psychoactive medications.
Insomnia due to Drug or Substance 
A. The individual meets criteria for insomnia disorder.
B. The insomnia is present for at least one month.
C. One of the following applies:
1. There is current ongoing dependence on or abuse of a
drug or substance known to have sleep-disruptive proper-
ties either during periods of use/intoxication or during
periods of withdrawal; or
2. The patient has current ongoing use of or exposure to a
medication, food, or toxin known to have sleep-disruptive
properties in susceptible individuals.
D. There is an association between the insomnia and substance
use/abuse/exposure as reflected by both of the following:
1. The onset of the insomnia coincides with the onset of
the substance use/abuse/exposure or withdrawal.
2. The temporal course of the insomnia coincides with the
exposure to, use of, or withdrawal from the substance.
(Note: Researchers should specify the substance and
whether the insomnia occurs during intoxication, chronic
use, or substance withdrawal.)
E. One of the following two conditions applies:
1. There is no current or past sleep-disruptive mental con-
dition.
2. There is a current or past sleep-disruptive mental con-
dition, but the temporal course of the insomnia shows
some independence from the temporal course of this men-
tal condition.
F. One of the following two conditions applies:
1. There is no current or past sleep-disruptive medical dis-
order.
2. There is a current or past sleep-disruptive medical dis-
order, but the temporal course of the insomnia shows
some independence from the temporal course of the co-
morbid medical condition.
G. The insomnia cannot be attributed exclusively to another
primary sleep disorder (e.g. sleep apnea, narcolepsy, or
parasomnia) or to an unusual sleep/wake schedule or cir-
cadian rhythm disorder.  
Normal Sleepers:  Current diagnostic manuals provide no
guidance for definition of normal sleeper controls.
Nonetheless, normal controls are an essential part of research
concerning insomnia subtypes. The data presented in Figure 1
highlight common research practice in regard to characteriza-
tion of these individuals. These data show that exclusions for
sleep-disruptive medical conditions, mental disorders, and psy-
choactive medications were used more frequently than other
criteria. Less frequently, PSG findings, self-reported sleep esti-
mates, and exclusions for specific sleep disorders or unusual
sleep wake schedules/circadian disturbances, were considered
in selecting normal samples. In addition, anecdotal information
from a majority of the articles suggested that a lack of any cur-
rent sleep complaint represents a defining criterion for such
samples.  Based on these observations the RDC shown are
offered as universal criteria for identifying normal sleepers for
insomnia research.
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Research Diagnostic Criteria for Normal Sleepers (Controls)
A. The individual has no complaints of sleep disturbance or
daytime symptoms attributable to unsatisfactory sleep.
B. The individual has a routine standard sleep/wake schedule
characterized by regular bedtimes and rising times.   
C. There is no evidence of a sleep-disruptive medical or men-
tal disorder.
D. There is no evidence of sleep disruption due to a substance
exposure, use, abuse, or withdrawal.
E. There is no evidence of a primary sleep disorder.   
Methods of Assessment
The final aim of this project was to propose specific methods
for documenting the presence/absence of the RDC among
patients/subjects to which they are applied. The findings summa-
rized in Figures 1 and 2 as well as procedural information pro-
vided in the articles reviewed provide ample guidance for
addressing this aim.  Considering this information along with the
precision required by the internal and external validity demands
of the research venue, the WG offers the following methodolog-
ical guidelines for insomnia RDC ascertainment.
Interview Assessment:  Use of the clinical interview to ascer-
tain insomnia symptoms and specific diagnoses was found to be
a ubiquitous practice in the articles reviewed. In most instances,
it appeared that findings and resulting opinions derived from a
single interviewer using a standard clinic interview served as the
basis of diagnostic ascertainment. Given the very modest inter-
rater agreement found by Buysse et al.(12) (Table 2) for discerning
global insomnia diagnoses by this method, it is clear that more
reliable interview methods are desirable for the research setting.
Specifically, reliable interview methods that assure consistent
RDC ascertainment across clinicians and settings are needed to
standardize insomnia research.
In this regard, the WG was able to identify two promising
approaches. The first method, derived from those studies listed in
Table 2, is that of using independent interviewers to ascertain the
presence of insomnia RDC in prospective research candidates.
One manner of applying this approach would be to select only
those study subjects who, in the mutual opinion of independent
interviewers, meet RDC for the insomnia diagnosis of interest.
Alternately, a researcher could choose to demonstrate high inter-
rater reliability between two or more interviewers during subject
screening for the insomnia RDC in question. Use of this latter
alternative would require that only a randomly selected subset of
study enrollees are used to test reliability for RDC. A second
method would involve the use of structured interview methodol-
ogy to assure that  standardized interview questions targeting
essential diagnostic information are administered consistently
across research candidates. Examples of this methodology are the
Structured Interview for Sleep Disorders described by Schramm
et al.(163) and the computer-driven Sleep Eval system described by
Ohayon et al.(138) Although neither of these instruments is specif-
ically structured to ascertain the RDC provided herein, they serve
as models for the development of an instrument for reliable
assessment of these criteria sets.  
Polysomnography: The RDC for such subtypes as SSM, IA and
PLMD require specific information from polysomnographic
(PSG) recording. The WG found that PSG was often used in stud-
ies of other insomnia subtypes to rule out the presence of occult
primary sleep disorders. Although PSG is not considered essen-
tial for the clinical assessment of insomnia(196), its use in estab-
lishing the insomnia RDC presented herein seems desirable.
Thus, the WG recommends incorporating at least a single night
of PSG into the screening process to ascertain insomnia RDC
using established methods for sleep staging and event scor-
ing.(197-200)
Sleep Diaries/Logs: Sleep diaries or logs were used sparingly
in the studies reviewed for this project. In fact, only in the case of
paradoxical insomnia/sleep state misperception were sleep
diaries/logs used commonly, most often to assess the degree of
mismatch between subjective and objective sleep measures. In
such comparisons, there appeared to be no well accepted standard
for confirming the diagnosis, but there seems to be some consen-
sus that ascertaining markedly inaccurate estimates of sleep
through logs or diaries is useful. The WG also recognizes the
reputed(201) usefulness of sleep logs or diaries for the assessment
of insomnia complaints per se. As such, they are considered use-
ful in helping to establish the presence of an insomnia disorder in
general.  However, their usefulness for ascertaining RDC for
many of the subtypes discussed will require further exploration.
Other Assessment Procedures:  The WG review identified a
number of additional objective and subjective measures used to
assess and compare insomnia subtypes. Among the objective
measures were assessments of sleep/wake motor activity (actig-
raphy), heart-rate variability, metabolic rate, and melatonin lev-
els. Subjective measures were derived from both widely used and
relatively obscure personality/mood questionnaires. Whereas all
of these measures may provide useful information about insom-
nia subtypes, their utility for differentiation of insomnia subtypes
has yet to be established. Thus, such additional instruments have
not been included as requirements for RDC assessment. 
DISCUSSION
The scientific literature includes thousands of articles concern-
ing insomnia. Nonetheless, results of the WG’s targeted literature
review showed a paltry amount of research providing support of
the insomnia diagnoses included in past and current sleep disor-
ders nosologies.(4-7, 27, 29, 189) There have been astonishingly few
studies designed to assess the reliability of any of these diagnos-
tic categories, and no reliability information is available for many
of the insomnia subtypes delineated in the most recent DSM(6)
and ICSD(28, 189) manuals. The number of studies supporting the
validity of such subtypes is, at best, only slightly more encourag-
ing. Such findings not only make the development of research
diagnostic criteria difficult, but also call into question much of
the body of literature devoted to insomnia in general. Clearly,
much more attention needs to be devoted to confirming the reli-
ability and validity of the insomnia subtypes our nosologies
describe if the field is to move forward.
The RDC proposed are not intended to limit the clinical assess-
ment of insomnia patients, and we acknowledge that alternative
approaches may be preferable to the RDC in non-research set-
tings. However, the insomnia RDC should be regarded as a start-
ing point for improving insomnia research and documenting
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whether currently recognized methods of insomnia classification
are optimal or need change. These RDC hopefully will discourage
additional studies of poorly characterized insomnia samples that
provide us little insight into the pathology and specific treatment
needs of the distinctive subtypes commonly encountered in clini-
cal venues. Furthermore, these RDC should help standardize
insomnia research and facilitate the reliability and validity studies
that are so sorely needed to determine if an alternate insomnia
classification system may be desirable.  However, the RDC should
not be regarded as eternally fixed definitions. They represent ini-
tial efforts toward standardizing insomnia research, but they may
undergo refinements as a function of both the degree to which
they prove useful and the findings of future insomnia research. 
To assist with future revisions/improvements in these prelimi-
nary RDC, it is recommended that insomnia researchers consis-
tently report the following information in their published studies:
〈 The methods of recruitment (media announcements vs. clinical
contacts) and types of individuals (research volunteers vs. clin-
ical patients) enrolled in the study. 
〈 Means, standard deviations, and ranges of common sleep mea-
sures such as total sleep time (TST), sleep onset latency (SOL),
wake time after sleep onset (WASO), and sleep efficiency for
each diagnostic group included in the study sample as well as
any quantitative cutoffs (e.g., onset latency > 30 minutes) in
such measures used for sample selection. When subjective
sleep measures are reported, the source (e.g., sleep diary, ques-
tionnaire, clinical interview) of these data should be specified.
〈 The mean, standard deviation, and distribution of insomnia
duration for each diagnostic group included in the study sample.
〈 The mean and distribution of insomnia frequency (number of
nights per week of insomnia) for each diagnostic group in the
study sample.
〈 Means and standard deviations of the discrepancies between
subjective estimates and objective measures of TST, SOL, and
WASO for samples of SSM and other diagnostic groups
included in the study.
〈 Means and standard deviations of leg movement and respirato-
ry disturbance indices for insomnia samples meeting RDC for
insomnia related to PLMD or sleep apnea.
Researchers also are encouraged to assign applicable ICSD
diagnoses (i.e., psychophysiologic, paradoxical, idiopathic
insomnia subtypes) to study participants who meet RDC for pri-
mary insomnia and report frequency, duration, and quantitative
sleep measures for each subtype separately. This information will
help determine the utility of the ICSD subtypes over the more
global primary insomnia diagnosis. 
Admittedly, there are several limitations of the methodology
used herein that should be considered. The literature reviewed
excluded most insomnia treatment studies in which the efficacy
of one or more insomnia therapies was evaluated with single
insomnia subtypes. Such studies were excluded since they pro-
vided no useful empirical information (reliability/validity data)
for addressing the aims of this RDC project. Nonetheless, the
usefulness of the RDC proposed will need to be established for
such studies if these criteria sets are to prove viable.  It is also rec-
ognized that the literature review did not include relevant studies
published after June 2000. Although the original time line for this
project would have resulted in publication of this report at a time
more proximal to that date, the complexity of the data collection
and entry process delayed this final report. Since the WG consid-
ered insomnia literature published over a period exceeding 35
years, it is not likely that the most recent publications would have
significantly altered the trends noted. Nevertheless, the findings
reported should be considered in the context of the most recent
insomnia literature. Finally, it should be noted that the proposed
RDC are, in part, based on published evidence but also reflect
consensus opinion of the WG panel of insomnia “experts.”
Whereas the limited informative literature obviated a purely evi-
dence-based set of RDC, future refinements of these criteria sets
hopefully will be made largely on empirical grounds.
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INTRODUCTION
THE DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL
DISORDERS, FOURTH EDITION (DSM-IV) DEFINES PRI-
MARY INSOMNIA AS A COMPLAINT OF DIFFICULTY initi-
ating and/or maintaining sleep or of nonrestorative sleep lasting
for at least 1 month.1 The revised version of the International
Classification of Sleep Disorders, Revised (ICSD-R) uses the
term psychophysiologic insomnia and regards insomnia of 6
months duration as chronic.2 Contemporary understanding of
psychophysiologic insomnia refers to underlying conditioned
physiologic arousal3-5 and learned sleep-preventing associa-
tions,6,7 with these components being regarded as mutually rein-
forcing (ICSD-R). However, it is also recognised that the pre-
senting complaint usually reflects mental more than somatic pre-
occupation,8-10 and so an interaction between behavioral, physio-
logic, and cognitive factors in the development and persistence of
psychophysiologic insomnia has been proposed.11-15
Sleep disturbance presenting in a psychiatric condition has been
regarded as “secondary” to (DSM-IV) or, more descriptively, as
“associated with” mental disorder (ICSD-R). The latter can be read-
ily observed, whereas causality would need to be carefully evi-
denced. To take the example of depression, there is in fact strong
evidence that preexisting insomnia is a risk factor for first incidence
and recurrence of a depressive episode.16-20 These findings are rein-
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chophysiologic insomnia by investigating the sensitivity and specificity of
commonly used insomnia research tools in discriminating psychophysiolog-
ic insomnia, insomnia associated with mental disorder, and good sleepers.
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subjects with psychophysiologic insomnia, those with insomnia associat-
ed with mental disorder, and good sleepers to psychometrically robust
self-report instruments.
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forced by recent a meta-analysis,21 and it has been suggested that
insomnia is a prodromal state of depression.20 Thus, it appears more
circumspect to refer simply to the temporal association between
insomnia and mental disorder rather than to imply causality in either
direction. Interestingly, however, diagnostic schedules for insomnia
associated with mental disorder do not refer to any of the putative
mechanisms for psychophysiologic insomnia. 
There is a sizeable literature comparing people with insomnia
and good sleepers across a range of cognitive, affective, and
physiologic measures.14 Surprisingly, however, there is little
direct evidence of inadequate stimulus control or of conditioned
arousal in bed as specific features of psychophysiologic insom-
nia. Furthermore, although there is some recent work of good
quality on secondary insomnia,22 to our knowledge, no study has
compared insomnia associated with mental disorder with either
psychophysiologic insomnia or good sleeper controls, using the
descriptive self-report measures that are commonly used in
insomnia research and practice. Thus, we do not have data on the
sensitivity and specificity of this type of measurement. Research
of this kind is important because we cannot assume discontinuity
between the insomnias. Diagnostic systems, being categorical,
tend to infer different underlying mechanisms and treatment
responses, but evidence of such differences is unavailable. 
Our aim was to investigate whether models that are applicable
to psychophysiologic insomnia might also apply to sleep distur-
bance associated with mental disorder. More specifically, we
wanted to explore self-reported behavioral, cognitive, and physi-
ologic features to see if they evidenced continuity or discontinu-
ity. This is a preliminary study of association rather than cause
and effect. Nevertheless, because there are efficacious cognitive-
behavioral treatments for persistent insomnia and effective phar-
macologic treatments for short-term use,23-26 it is possible that
insomnia therapies might be better targeted if distinctive features
of insomnia could be established. Similarly, cognitive-behavioral
treatments might be applied to sleep disturbance associated with
mental disorder if we better understood the differential diagnosis
from a conceptual perspective. 
METHOD
Design
The study comprised a between-subjects design with 3 inde-
pendent groups: psychophysiologic insomnia (PI; n = 18), insom-
nia associated with mental disorder (I-MD; n = 18), and good
sleepers (GS; n = 18). Between-group comparisons were made on
measures of self-reported (subjective) and actigraphically esti-
mated (objective) sleep and on self-report measures of sleep-
related behavior, thinking, and arousal. 
Participants
The PI group had to meet combined DSM-IV/ICSD-R criteria,
with the sleep pattern being assessed by sleep history and a self-
report sleep diary over 7 nights,13 and (a) a sleep-onset latency
(SOL) of more than 30 minutes, (b) a sleep efficiency (SE) of less
than 85%, (c) frequent or extended nocturnal awakenings totaling
more than 30 minutes of wakefulness after sleep onset (WASO),
or (d) any combination of a, b and c, in each case occurring on at
least 3 out of 7 nights per week for at least 1 month. Subjects were
excluded from the PI group if they met criteria for any axis-I dis-
order or past major depressive episode (assessed by Structured
Clinical Interview for DSM-IV axis-I Disorders (SCID-I)27 or had
any evidence on our locally derived screening measures of sleep-
related breathing disorder or periodic limb movements in sleep.
Additionally, they were excluded if they had a Beck Depression
Inventory (BDI)28 score of 20 or more,29 or had any physical or
medical problems causing insomnia (as defined in ICSD-R).
Thirty consecutive potential participants, complaining of signifi-
cant and persistent sleep disturbance, were identified through
attendance at clinical psychology outpatient services. Of these, 7
failed to complete screening, 3 failed to attend, and 2 were exclud-
ed because they did not meet insomnia criteria (final n =18). 
Participants with I-MD had to satisfy the same sleep distur-
bance criteria, meet DSM-IV criteria (SCID-I) for major depres-
sive disorder, and obtain a score of ³ 20 on the BDI. These partic-
ipants were initially intended to form an “insomnia associated
with depression” group, but, because of the high comorbidity of
depressive and anxiety disorders, a more general title has been
applied. Operationally, I-MD should be taken to mean “insomnia
associated with mental disorder (depressed/anxious).” We exclud-
ed other individuals who met criteria for other axis-I disorders if
they had medical problems causing sleep disturbance, any clinical
evidence of sleep-related breathing disorder or periodic limb
movements of sleep, or if their only sleep problem was early
morning wakening. This latter criterion was to increase compara-
bility of sleep-symptom complaint between the PI and I-MD
groups. The Beck Anxiety Inventory (BAI)30 was also applied
descriptively to assess severity of anxiety symptoms (all groups).
Thirty-two individuals were identified through mental health ser-
vices or general practice surgeries, of whom 2 failed to complete
screening, 2 did not attend, 2 failed to return measures, and 8 were
excluded (1 mild mental retardation, 1 medical complaint causing
insomnia, 4 did not meet criteria for depressive disorder, and 2
had additional axis-I diagnoses), leaving 18 in the I-MD group. 
The GS group was recruited as an opportunity sample. Eighteen
out of 20 nonclinical volunteers participated (2 excluded due to
temporary illness causing sleep disruption). All had (a) SOL < 30
minutes; (b) SE > 85%; (c) WASO totaling < 30 minutes, in each
case occurring on at least 5 out of 7 nights per week as measured
by the sleep diary; and (d) regarded themselves as a good sleeper. 
Measures and Procedure
Following screening, participants completed a 7-night sleep
diary13 while concurrently wearing an actigraph on the nondom-
inant wrist to provide an objective estimate of sleep.
Actiwatch–Râ Model AW4 (Cambridge Neurotechnology Ltd.,
Cambridge, UK) devices were used with epochs of 1 minute
selected for accurate sleep analysis.31 Actigraphs had event mark-
ers, which participants pressed when they went to bed and when
they got up. Objective estimates of SOL, WASO, total sleep time
(TST), and SE were recovered using Sleepwatchâ software
(Cambridge Neurotechnology, Ltd.), and parallel data were
derived from the sleep diaries.
A set of self-report measures was selected to best reflect pre-
sumed underlying mechanisms in insomnia. Participants completed
these measures at home and returned them with their sleep diaries
and actigraph. The Sleep Behavior Self-Rating Scale (SBSRS)32
assesses sleep-incompatible behaviors associated with a person’s
bed or bedroom and is the only published scale to quantify the stim-
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ulus-control paradigm. Test-retest correlation (r = .88) and internal
consistency data (K-R 20 = .70) indicate acceptable reliability, and
the original authors reported good discriminant validity32. However,
we revised the scale (SBSRS-R) to more fully address stimulus-
control principles. Seven items were added, based on Bootzin’s
revision of his stimulus-control instructions.7 For example, “I take
naps during the day or evening” and “If I can’t get to sleep within
about 20 minutes I get up and move to another room until I feel
sleepy again” were added, and 14 previous items that simply repeat-
ed statements, first in relation to “around sleeping time” and second
to “during the day,” were reduced to 7 by amending the instructions
for the questionnaire. The revised SBSRS-Ra, therefore, had 14
items rated, as in the original, on a 5-point Likert scale from never
to very often (α = .69 this study, n = 53). 
The Pre-Sleep Arousal Scale (PSAS)9 is a 16-item question-
naire that yields separate scale scores for physiologic arousal and
cognitive arousal. Both scales have acceptable internal consisten-
cy (PSASphysiol: α =. 84 and 0.81 for good sleepers and insom-
niacs respectively; PSAScog: α = .67 and .76). Evidence for the
construct validity of the PSAScog scale comes from studies
where presleep intrusive thoughts have been directly audiotape
recorded.33 The PSAS is rated on a 5-point scale from 1 (not at
all) to 5 (extremely), with items reflecting autonomic arousal on
the PSASphysiol scale (eg, heart racing/pounding, tight/tense
muscles) and mental arousal on the PSAScog (eg, worry about
not falling asleep, being mentally alert).
A number of other measures relevant to cognitive arousal were
also completed. These were the Sleep Disturbance Questionnaire
(SDQ)10, the Glasgow Sleep Effort Scale (GSES)34 and the
Dysfunctional Beliefs and Attitudes about Sleep scale–10-item
version (DBAS-10).29 The SDQ is a 12-item questionnaire to
identify causal attributions concerning perceived sources of a
sleep problem (α = .82). Items are rated on a 5-point scale from
never true to very often true (eg, “I am unable to empty my
mind”). The subscale “attributions concerning mental overactiv-
ity” was utilized in this study. The GSES was developed in
response to the poor face and construct validity of an existing
measure, the Sleep Anxiety Scale.35 The GSES is a 7-item scale
designed to measure elements of a general model of effortful pre-
occupation with sleep (ie, effort to sleep, attempts to control
sleep, worry over failure to sleep). It is rated on a 3-point scale
(very much, to some extent, not at all) and has acceptable inter-
nal consistency (α = .70) .34 The DBAS-10 is a short-form ver-
sion of an original 30-item scale measuring salient, affect-laden,
irrational beliefs concerning the process of sleep.36 The 10-item
version is scored on 10-cm analogue lines from strongly disagree
to strongly agree (α =. 69),29 based on items shown to be sensi-
tive to change after cognitive-behavioral therapy. The validity of
the DBAS-10 has been recently supported.37
Finally, we included a measure of sleep hygiene. The Sleep
Hygiene Awareness and Practice Scale (SHAPS)38 has 19 items,
and respondents are asked to state on how many nights per week
they typically go to bed hungry, take caffeine within 4 hours of bed-
time, exercise within 2 hours of bedtime, have their sleep disturbed
by noise, etc. The original authors demonstrated that insomniacs
practiced poorer sleep hygiene than good sleepers, and the SHAPS
has been widely used both in clinical settings and in research. 
RESULTS
Descriptive and Clinical Variables
There were proportionately more women in the PI group (PI =
4 men/14 women, I-MD = 7 men /11 women, GS = 8 men /10
women); however, this difference was not statistically significant
[χ2 (2, n = 54) = 2.11, P = .35]. Participants ranged from 21 to 64
years of age, and average age per group was late 30s or early 40s
(Table 1). Both PI and I-MD groups reported insomnia of over 9
years in duration. As expected, I-MD participants had significant-
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Table 1—Descriptive and Clinical Information for Each Experimental Group and Results of 1-Way Analysis of Variance with Posthoc Analyses
Group*
PI I-MD GS df F P posthoc
(Scheffé)
Age, y
Mean 44.39 39.94 36.06 2, 51 1.63 .21 -
SD 14.91 13.37 13.23
Duration of sleep
problem, y
Mean 9.47 9.47 - 2, 51 8.50 < .001 I-MD, PI
SD 10.39 9.06 > GS
BDI score
Mean 8.44 28.56 1.44 2, 51 87.3 < .001 I-MD > PI
SD 7.11 8.13 2.43 > GS
BAI score
Mean 5.61 25.56 2.00 2, 51 37.0 < .001 I-MD >
SD 5.36 14.09 2.72 PI, GS
*n = 18 for each group. 
PI refers to psychophysiologic insomnia; I-MD,  insomnia associated with mental disorder; GS, good sleeper; BDI, Beck Depression Inventory;
BAI, Beck Anxiety Inventory. 
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ly higher symptomatology on the BDI (mean = 28.6), 15 of 18
were on antidepressant medication (compared with 1 in the PI and
0 in the GS groups), and 15 attended mental health services (com-
pared with 0 in the PI or GS groups). PI participants scored lower
on the BDI (mean = 8.4) but, nevertheless, significantly higher
than the GS group. Recent BDI data from 139 of our clinic-pre-
senting insomniacs suggest comparability with the present PI
group (mean = 10.9, SD = 9.12).29 An independent rater listened
to a random sample of 3 audiotaped SCID-I interviews for each
group (PI, I-MD, GS), and ratings for each item in each interview
were compared. Cohen’s k showed that, overall, the ratings made
were identical (k = 1.00). Six individuals in the I-MD group had a
comorbid anxiety diagnosis of generalised anxiety disorder, 6 had
a diagnosis of social phobia, 7 had a diagnosis of panic disorder
with agoraphobia, and 2 had a diagnosis of specific phobia. Seven
participants had more than 1 comorbid diagnosis. Only 1 partici-
pant in the PI group and 2 in the I-MD group were on hypnotic
medication, and the I-MD group scored considerably higher on
BAI symptoms than did either the PI or GS groups (Table 1). 
Sleep Variables
Several sleep variables exhibited nonnormal distributions, and
the Levine statistic revealed that group variances on some mea-
sures were not equal. However, analysis of variance is relatively
robust when normality assumptions are violated, and in the case
of unequal variances, unless sample sizes are unequal.39,40
Analysis of variance models, therefore, were applicable to our
data. Multivariate analyses of variance were applied to compare
sleep-pattern variables between groups. The 4 sleep-diary vari-
ables (SOL, WASO, TST, SE) were entered into 1 model, and this
procedure was repeated for the same 4 actigraphic variables.
There was a significant effect of the factor variable (Wilks’ l) for
both sleep diary and actigraphic variables (F8,96 = 4.22 , P < .001
and F8,96 = 2.64, P < .01, respectively). Separate analyses of vari-
ance were then applied to investigate between-group differences
on specific sleep variables (Table 2).
The GS group had significantly lower diary reports of SOL and
WASO and significantly greater TST and higher SE than either
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Table 2—Sleep-Diary And Actigraphy Estimates of Sleep for Each Experimental Group and Results of 1-Way Analysis of Variance with Posthoc
Analyses
Group*
PI I-MD GS df F P posthoc
(Scheffé)
SOL diary
Mean 41.40 52.22 11.02 2,51 9.99 < .001 I-MD, PI
SD 27.24 40.47 9.14 >GS
WASO diary
Mean 60.75 55.64 4.72 2,51 6.99 .002 I-MD, PI
SD 49.48 70.28 5.04 >GS
TST diary
Mean 343.7 381.9 446.2 2,51 5.66 .006 GS > PI
SD 86.35 120.7 59.43
SE diary
Mean 77.63 75.79 95.87 2,51 13.8 < .001 GS >
SD 11.68 18.31 3.01 PI, I-MD
SOL actigraph
Mean 13.58 25.99 8.11 2,51 3.81 .03 I-MD>GS
SD 10.41 31.40 9.86
WASO actigraph
Mean 41.47 63.70 50.87 2,51 2.53 .09 -
SD 17.68 40.09 27.20
TST actigraph
Mean 417.8 388.4 376.8 2,51 1.70 .19 -
SD 81.25 75.56 43.46
SE actigraph
Mean 87.38 80.06 86.81 2,51 4.05 .02 PI >I-MD
SD 4.90 12.97 5.36
*n = 18 for each group. 
PI refers to psychophysiologic insomnia; I-MD, insomnia associated with mental disorder; GS, good sleeper; BDI, Beck Depression Inventory; BAI,
Beck Anxiety Inventory; SOL, sleep-onset latency in minutes; WASO, wake time after sleep onset in minutes; TST, total sleep time in minutes; SE,
sleep efficiency, %.
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the PI or I-MD groups. There were no significant differences
between the insomniac groups on self-reported sleep. Both the PI
and I-MD groups took more than 40 minutes to fall asleep, had
around 1 hour of wakefulness during the night, and had SEs
around 75% (Table 2). Interestingly the PI group reported sleep-
ing on average less (5 hours 43 minutes) than the I-MD group (6
hours 21 minutes), but this difference was not statistically signif-
icant using conservative posthoc testing. 
Although the omnibus multivariate analyses of variance test
also suggested significant between-group differences in acti-
graphic sleep, no significant between-group differences emerged
for WASO or TST (Table 2). The I-MD group exhibited signifi-
cantly greater SOL than the control group, and the PI group had
a significantly higher SE than the I-MD group. Product-moment
correlations were carried out to investigate the relationship
between sleep-diary and respective actigraphic variables across
groups. Only the correlation coefficient for SOL was statistically
significant for the total group (n = 54: SOL: r = .62, P < 0.01;
WASO: r = .04, P > 0.10; TST: r = .17, P > 0.10; SE: r = .13, P
> 0.10). Within-group subjective/ actigraphic association was
significant in I-MD participants for SOL (rs = .691, P = .002: n =
18), and in GS participants for TST (rs = .577, P = .012: n = 18).
Rating-Scale Variables Measuring the Insomnia Experience
One participant failed to complete the SBSRS-R, and 3 the
DBAS-10. A series of 7, 1-way analyses of variance was applied,
the results of which are presented in Table 3. Due to the multiple
comparisons made, Bonferroni correction resulted in the critical
value for significance of P = .007 (.05/7). 
No significant differences between insomniacs (PI, I-MD) and
GS were observed on the SBSRS-R, suggesting that the frequen-
cy of engagement in sleep-incompatible activities was equivalent
across groups. The I-MD group, however, did exhibit poorer
sleep hygiene practices (SHAPS) relative to both the PI and GS
groups, and, similarly, the PI group had poorer sleep hygiene than
the GS group. The GS and PI groups did not differ from one
another on PSASphysiol, but both reported significantly less
physiologic arousal than did the I-MD group. By comparison,
however, both insomniac groups reported greater cognitive
arousal (PSAScog) than the GS, although the I-MD group had
higher scores than the PI group. Both insomniac groups again
scored significantly higher than the GS group on the SDQ (attri-
butions to cognitive arousal) and the DBAS-10 (dysfunctional
cognitions regarding sleep), but the PI and I-MD groups did not
differ from each other on either of these measures. Finally, on the
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Table 3—Comparison of Experimental Groups and Results of 1-Way Analysis of Variance and Posthoc Analyses on Model-Testing Measures
Group*
PI I-MD GS df F P posthoc
(Scheffé)
SBSRS-R
Mean 34.11 38.89 33.65 2, 50 2.44 .10 -
SD 7.63 9.07 6.54
SHAPS
Mean 32.89 43.39 21.11 2, 51 16.45 < .001 I-MD > PI 
SD 9.22 14.65 10.39 > GS
PSASphysiol
Mean 11.89 20.44 8.67 2, 51 22.79 < .001 I-MD > PI,
SD 4.30 8.28 0.91 GS
PSAScog
Mean 24.94 30.83 14.00 2, 51 39.46 < .001 I-MD > PI
SD 8.19 4.29 3.80 >GS
SDQ
Mean 12.33 13.11 7.17 2, 51 28.50 < .001 I-MD, PI
SD 3.50 2.08 1.79 >GS
GSES
Mean 13.39 15.39 7.50 2, 51 71.79 < .001 I-MD > PI
SD 3.11 1.61 0.62 > GS
DBAS-10
Mean 47.73 54.85 30.07 2, 48 12.25 < .001 I-MD, PI
SD 15.92 21.88 13.71 >GS
*n = 18 for each group except for Sleep Behavior Self-Rating Scale-Revised (SBSRS-R) missing 1 case, Dysfunctional Beliefs and Attitudes about
Sleep Scale (10-item version) (DBAS-10) missing 3 cases.
PI refers to psychophysiologic insomnia; I-MD, insomnia associated with mental disorder; GS, good sleeper; SBSRS-R,; SHAPS, Sleep Hygiene
Awareness and Practice Scale; PSASphysiol, physiologic subscale of the Pre-Sleep Arousal Scale; PSAScog, cognitive subscale of the PSAS; SDQ,
Sleep Disturbance Questionnaire; GSES, Glasgow Sleep Effort Scale.
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GSES, I-MD and PI participants reported higher levels of sleep
effort than GS, but the I-MD group also scored significantly
higher than the PI group. 
The preceding analyses, therefore, indicate between-group dif-
ferences on 6 of the 7 variables studied. However, possible rela-
tionships among variables need to be considered. Therefore, a
correlation matrix was calculated comprising participants from
the 2 insomnia groups (Table 4), which also included depression
and anxiety scale scores. Inspection of Table 4 demonstrates that
pairings of scores for the majority of variables, with the general
exception of those involving sleep behavior (SBSRS-R) and
sleep hygiene (SHAPS), were significantly intercorrelated (r >
.33). It is particularly noteworthy that measures of presleep
arousal (PSASphysiol, PSAScog) and psychopathology (BAI
and BDI) were associated (r >= .56). The correlation between
BAI and PSASphysiol was r = .87. 
If we are to understand the relative influence of these variables,
and how they may interact, a multivariate model is required. This
also helps to address the fact that our measures share method
variance (self-report ratings). Thus, separate logistic-regression
analyses were conducted for each of the comparisons of inter-
est—PI/GS, I-MD/GS and PI/I-MD. These analyses should be
interpreted cautiously because of the small sample sizes.
Nevertheless, our aim was to identify which variable or subset of
variables might best discriminate between groups and, so, to sug-
gest lines of inquiry for future study. Variables were entered in a
forward stepwise model. 
For the discrimination of psychophysiologic insomnia from
good sleep (PI/ GS), sleep effort (GSES) entered on the first step
(B = 11.85, standard error B = 108.0), correctly identifying 100%
of PI (sensitivity) and 94% of GS (specificity) (χ2 = 44.67, df = 1,
P < .001). No other variable added to this discrimination. Similarly,
GSES entered as the only predictor for the I-MD/GS comparison
(B = 8.66, standard error B = 2055.5), correctly allocating 100% of
cases to I-MD and GS groups, respectively (χ2 = 44.24, df = 1, P <
.001). For the prediction of PI versus I-MD insomniacs, only BDI
score entered (B = 28.90, standard error B = 1374.4), again cor-
rectly allocating 100% of cases (χ2 = 45.48, df = 1, P < .001), sug-
gesting that symptomatic mood was the critical between-group fac-
tor here, rather than any insomnia specific variable.
DISCUSSION
Our purpose was to explore explanatory mechanisms for psy-
chophysiologic insomnia by investigating the sensitivity and
specificity of commonly used insomnia research tools in the dis-
crimination of PI from I-MD and from good sleep. We found no
between-group differences on a measure of sleep-related stimu-
lus control, and self-reported somatic arousal was higher in I-MD
than either GS or PI. Both I-MD and PI had poorer sleep hygiene
and were particularly characterized by heightened mental
arousal. Our measure of “effortful preoccupation with sleep” best
discriminated both PI and I-MD from GS, but only depressive
symptomatology discriminated I-MD from PI. These results were
drawn from a small sample in this preliminary exploratory study.
Accordingly, they should be interpreted cautiously and require
replication using larger samples and samples in which the nature
and severity of depressive and comorbid anxiety disorders can be
specifically studied.
First, our results confirm that both insomnia groups slept poor-
ly relative to GS, according to self-report sleep-diary data. Mean
SE for the PI and I-MD groups was around 77%, compared with
96% in the GS group, respectively, which are 10% below and
10% above the recognized “cut-off” for sleep disorder.41 This pat-
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Table 4—Pearson Product-Moment Correlations Between Scales for the Combined Primary Insomnia and Insomnia with Mental Disorder Groups*
Scale 1 2 3 4 5 6 7 8 9
SBSRS-R — .31 .13 .34† .20 .05 .38† .33† .20
SHAPS — .45† .20 .14 .26 .33 .45† .50†
PSASphysiol — .58† .51‡ .45† .30 .68‡ .87‡
PSAScog — .59‡ .71‡ .39† .59‡ .56‡
SDQ — .34† .39† .41† .35†
GSES — .48† .38† .21
DBAS-10 — .48† .26
BDI — .78‡
BAI
—
*All n = 36 except Dysfunctional Beliefs and Attitudes about Sleep Scale (10-item version) (DBAS-10), with 33. 
PI refers to psychophysiologic insomnia; I-MD, insomnia associated with mental disorder; GS, good sleeper; SBSRS-R, Sleep Behavior Self-Rating
Scale-Revised; SHAPS, Sleep Hygiene Awareness and Practice Scale; PSASphysiol, physiologic subscale of the Pre-Sleep Arousal Scale;
PSAScog, cognitive subscale of the PSAS; SDQ, Sleep Disturbance Questionnaire; GSES, Glasgow Sleep Effort Scale; BDI, Beck Depression
Inventory; BAI, Beck Anxiety Inventory.
†P < .05 
‡P < .01
Insomnia 305.qxp  12/30/2004  8:49 AM  Page 109
tern was reflected also in symptom measures of “initial insom-
nia,” “sleep-maintenance insomnia,” and “insufficient sleep”
(DSM-IV) because people with insomnia took significantly
longer to fall asleep (40-50 minutes compared with 10 minutes),
were more wakeful in the night (around 60 minutes compared
with 5 minutes), and slept less than GS (around 6 hours compared
with 7 hours 30 minutes). PI and I-MD groups did not differ from
each other on sleep self-reports. As expected, however, the for-
mer had higher scores for depressive symptoms on the BDI (> 2
SD higher than for PI). Mean BDI score for PI participants was
below the clinical range. Symptomatic anxiety on the BAI was
also greater in the I-MD group. Furthermore, the majority of the
I-MD group were on antidepressant pharmacotherapy and in con-
tact with mental health services. 
While these data on between-group differences suggest that
our selection and allocation to experimental groups (GS, PI, I-
MD) were valid, they also reveal an important confound that
should be taken into account in interpreting our results. The near-
ly universal use of antidepressants in the I-MD group implies that
this is in effect a “treated I-MD” group, albeit with a relatively
high mean BDI score of 28. Future research, therefore, needs to
include an “untreated” I-MD group to control for the effects of
medication use. It would also be helpful to separately consider
treatment responsive and nonresponsive cohorts in future studies.
In comparison with self-report, actigraphic data generally
failed to confirm between-group differences in sleep, and corre-
lation with diary measures was low in all 3 groups. SE was esti-
mated in the range of 80% to 87% across groups, and overall
association between subjective and objective data was r = .13 (n
= 54). Most strikingly, participants in the GS group who had no
history of sleep disorder; no current sleep complaint; and, by
their own report, slept well during the study week provided acti-
graphic data suggesting that they slept only around 6 hours (self-
report 7.5 hours) and that they had an average of 50 minutes of
wakefulness per night (self-report 5 minutes). These results, like
those from another report,42 therefore, are strongly suggestive of
validity problems with this form of measurement. 
Second, the ICSD-R suggests that in PI, sufferers engage in
sleep-incompatible behavior in the bedroom. However, our
results evidence no differences in such behavior between GS and
either PI or I-MD. It is, of course, possible that our measure of
sleep-incompatible behavior (SBSRS-R) was inadequate. More
plausible perhaps is the possibility that the same behaviors pre-
sent, even with similar frequency, but that they have different
consequences for good and poor sleepers. Thus, and for example,
reading in bed may have a sleep-preventing effect only for poor
sleepers. Nevertheless, our findings are consistent with early
reports where insomniacs and GS exhibited similar sleep behav-
ior43 and where experimental intervention, using components of
stimulus-control treatment, suggested that the bed becoming a
“discriminative stimulus for sleep” was not the active mecha-
nism.44 In the only recent study, people with insomnia were found
not to differ from GS on daytime napping, sleep scheduling,
whether they stayed in bed or got up when unable to sleep, or on
engagement in sleep-incompatible activities.45
Third, according to the ICSD-R, PI is also characterized by
conditioned physiologic arousal. This study focused upon self-
report, so no direct measurement was taken of autonomic or cor-
tical arousal. The physiologic arousal subscale of the PSAS, nev-
ertheless, is widely used, and, interestingly, we found that only I-
MD differed from GS on this measure. This suggests that somat-
ic arousal may be more characteristic of patient report where
insomnia is associated with mental disorder. It should be noted,
however, that many of our I-MD participants had symptoms of
anxiety and that we found a strong positive correlation between
PSASphysiol and state anxiety on the BAI (r = .89). The associ-
ation of physiologic and anxiety symptoms in our I-MD sample
could account for our results. Alternatively, there may be prob-
lems with the construct validity of this subscale of the PSAS, if
it is simply a proxy for somatized anxiety. Further evidence on
physiologic arousal may come from our data on the SHAPS
because it has been argued that inadequate sleep hygiene delays
sleep onset primarily through heightened arousal.14 For example,
caffeine produces increased arousal on metabolic measures and
reports typical of insomniac complaint.46 In the present study,
sleep-hygiene practice was found to differ across the experimen-
tal groups, with I-MD having higher SHAPS scores (poorer prac-
tices) than either GS or PI, and PI having higher scores than GS. 
Fourth, not all objective poor sleepers complain of insomnia,
and not all subjective insomniacs have poor sleep,47 suggesting
that physiologic arousal alone may be an insufficient explanation
of insomnia. We found that the I-MD group reported greater men-
tal arousal than the PI group on the PSAScog and that both I-MD
and PI groups reported more mental arousal than the GS.
Insomniac thoughts during the presleep period are often worried
and negative in content.48,35 Perhaps people with insomnia asso-
ciated with depression or anxiety appraise things even more neg-
atively than do psychophysiologic those with PI? It is interesting,
therefore, that the DBAS-10 results tend to confirm the PSAScog
findings. Both PI and I-MD groups scored more than 2 SD high-
er than GS on this measure, and, although the mean score for I-
MD was not significantly higher than for PI, the trend again was
in that direction. It seems then that people with insomnia may be
more prone to sleep-related thinking errors than are GS. This
finding was further reinforced by our data from the SDQ, where
both PI and I-MD groups had higher scores on a measure of
causal attribution concerning mental overactivity in bed.
Moreover, with respect to mental arousal, our data from the
GSES are particularly interesting. They reflect a similar distinc-
tion, in terms of severity, between I-MD and PI, with both groups
exhibiting higher sleep effort that the GS group. However, our
analyses suggest that an explanatory model including “effortful
preoccupation with sleep” may be of special importance in
understanding the cognitive arousal associated with insomnia.
We observed strong intercorrelations among our variables mea-
suring arousal, despite these being supposedly differing con-
structs, perhaps indicating that a common underlying insomnia
construct may exist. We then found that logistic-regression mod-
els identified the GSES as the best measure to discriminate
insomniacs from GS. Furthermore, this effect applied for both the
PI and the I-MD groups, yielding 100% sensitivity in both cases
and 94% and 100% specificity for each respectively. This result,
when coupled with evidence that I-MD and PI groups were per-
fectly differentiated using BDI scores alone, without recourse to
measures of sleep-related behavior or cognition, suggests that a
continuum may exist across “primary” and “secondary” insomnia
(at least where it is associated with depression or anxiety). This
suggestion is supported by other recent work on symptom reports
in patients with severe chronic insomnia, which have found that
“depression-related insomnia” and PI were separable only by
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characteristic symptoms of depression.49 A caveat must be intro-
duced, however, in relation to the fact that the BDI discriminated
so well. Our patients with PI were excluded for high BDI scores,
and I-MD patients were included partly on this basis. Therefore,
although valid from a diagnostic standpoint, our BDI results do
not reflect an independent observation in this study.
PI and I-MD, therefore, may have much in common. They may
have similar mechanisms associated with their persistence and
may be amenable to similar treatment, whether behavioral or
pharmacologic. ICSD-R and DSM-IV categories imply that there
are different pathways in these insomnia subtypes. This may not
be correct. Clearly, further rigorous investigation is required to
investigate “continuum versus category” hypotheses, but our
results suggest that insomnia associated with depression or anxi-
ety may simply be a more severe variant of PI. This would make
sense in the context of insomnia being a risk factor for depressive
illness.21 However, an alternative explanation is that the absence
of difference between the insomnia groups reflects an orthogonal
relationship between insomnia and depression. There may be
commonalities in insomnia just as the diagnosis of a major
depressive disorder follows the same criteria regardless of
whether it is “primary” or “associated with” other conditions.
Therefore, both the “severity continuum” and “orthogonal con-
struct” hypotheses appear to merit further consideration.
Further comparative work is required to replicate our findings
using concomitant measures of behavior, cognition, and physiol-
ogy relevant to the insomniac experience. Ideally, self-report,
observational, and psychophysiologic measures should be gath-
ered independently of one another, in order to limit the method
variance associated with using any 1 form of data gathering on its
own. In particular, we would like to highlight the outstanding
need for better measurement, and component investigation, of the
stimulus-control paradigm. The SBSRS-R may be a useful scale
to describe and quantify sleep-related behavior, but it does not
assess the critically important relationship between behavior and
consequence. Inadequate stimulus control is central to diagnostic
conceptualization of PI,2 and stimulus-control treatment is the
best evidenced nonpharmacologic intervention,25 yet we still lack
evidence that sleep and bedroom cues are actually associated
with differential conditioning in insomnia. 
Finally, if our finding is confirmed that it is primarily “effortful
preoccupation with sleep” that best discriminates people with
insomnia from GS, then perhaps it would be productive for
researchers to spend more time studying normalcy, ie, the (perhaps
relatively unremarkable) nighttime behavior, beliefs, attitudes,
efforts, and physiologic responses of GS. After all, the ultimate
goal of insomnia therapies should be to reinstate good sleep, not
simply to achieve statistically or even clinically significant change. 
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Towards a valid, reliable measure of sleep eﬀort
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SUMMARY A frequent clinical observation is that patients with insomnia strive to control their
sleep. However, sleep is an involuntary physiological process, which cannot be placed
under full voluntary control. Therefore, direct, voluntary attempts to control sleep may
actually exacerbate and perpetuate insomnia. To date, no reliable scale has been
available to test this hypothesis directly. Moreover, while sleep eﬀort is a core
International Classiﬁcation of Sleep Disorders – Revised criterion for psychophysio-
logical insomnia, clinicians lack a reliable measure with which to assess the construct. In
this initial scale validation study, we present psychometric data for the Glasgow Sleep
Eﬀort Scale based on a relatively small but representative sample of patients with
insomnia and good sleepers. The clinical and research value of the new scale is discussed
and future research directions are described.
k e yword s insomnia, paradoxical intention, reliability, sleep eﬀort, validity
INTRODUCTION
Sleep is a fundamental life process, much like eating or
drinking. Presumably therefore, inability to sleep is signiﬁ-
cantly threatening (Broomﬁeld et al., 2005; Harvey, 2002).
This may explain the frequent clinical observation that patients
with insomnia often strive to control their sleep. As sleep is an
involuntary physiological process, which cannot be placed
under full voluntary control, any eﬀort to control sleep is likely
to fail. Eﬀort to sleep may, therefore, represent a key
perpetuating factor in insomnia.
We conceptualize the construct of sleep eﬀort as multi-
component, comprising core behavioural and cognitive ele-
ments, and describe here an initial validation study of the
Glasgow Sleep Eﬀort Scale (GSES), a new self-report scale
designed to measure eﬀort.
This initial validation study is important and timely for
several reasons. First, as already indicated, the behaviour and
cognition of insomnia patients often involve heightened sleep
eﬀort. This may express itself as performance anxiety about
sleep, a need for control over sleep, and/or trying too hard to
sleep. Interestingly, and we think this is important, good
sleepers tend towards the opposite. When asked what they do
to fall asleep, good sleepers usually: (i) appear bewildered and
(ii) report not consciously delivering any behaviour. This
supports good sleep as passive and eﬀortless, and implicates
eﬀort as disruptive (Espie, 2002). Reliance on clinical obser-
vation to inform psychological theory testing is of course a
critical tradition across psychological research studies (Sal-
kovskis, 2002) and insomnia research is no exception (Tang
and Harvey, 2003).
Secondly, consensus expert opinion has for some time
recognized sleep eﬀort as a relevant aetiological factor. The
International Classiﬁcation of Sleep Disorders – Revised
(ICSD-R) and its predecessor (ICSD), both cite trying too
hard to sleep as a core factor leading to learned sleep
preventing associations in psychophysiological insomnia
(American Sleep Disorders Association, 1990, 1997). Yet we
lack the means to address, diagnostically, the presence or
otherwise of eﬀort. Several existing scales integrate relevant
single items [e.g. The Dysfunctional Beliefs and Attitudes
about Sleep (DBAS) scale (Morin et al., 1993); Sleep Distur-
bance Questionnaire (Espie et al., 1989)]. This suggests
acknowledgement of the aetiological relevance of sleep eﬀort.
Yet no dedicated measure is available.
Thirdly, previous work suggests sleep eﬀort can discrimin-
ate good and poor sleepers. Kohn and Espie (in press)
compared good sleepers with primary insomniacs and
depressed insomniacs, and measured sleep eﬀort using a pilot
version of the GSES, which had not at that time been subject
to psychometric evaluation. Eﬀort was signiﬁcantly higher
among the two poor sleeping groups and regression analyses
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selected GSES as the best discriminatory measure between
the two insomnia groups and good sleepers. A separate,
initial validation study on the psychometrics of the GSES is
now needed.
Fourthly, there is evidence that paradoxical intention ther-
apy, an empirically supported insomnia treatment (Chesson
et al., 1999; Morin et al., 1999) improves sleep by minimizing
sleep eﬀort. Insomnia patients allocated to 14-night paradox-
ical intention therapy (relax at lights out, keeping eyes open)
showed, relative to controls, reduced eﬀort and sleep improve-
ment (Broomﬁeld and Espie, 2003). This indicates that sleep
eﬀort is sensitive to change following psychological therapy
and may act to maintain insomnia. Again, the measure of
eﬀort used was a pilot GSES not subject to psychometric
evaluation. A valid reliable eﬀort measure would allow
identiﬁcation of insomnia suﬀerers particularly suited to this
therapeutic approach.
Fifthly, experimental data from the ironic cognitive control
literature (Wegner, 1994) support eﬀort as an insomnia-
maintaining factor. Good sleepers directed to fall asleep
urgently, under high mental load (listening to marching music)
show signiﬁcantly longer sleep latencies relative to good
sleepers directed to sleep urgently under low mental load
(relaxing music). Although requiring replication in insomnia
patients, these data suggest eﬀort to sleep, particularly under
experimental stress conditions, drives wakefulness in good
sleepers (Ansﬁeld et al., 1996).
Finally, there is an outstanding need for a valid, reliable
measure of sleep eﬀort. The present initial validation study
represents an important ﬁrst step in this process. We report
psychometric data for the GSES based on small, but
representative samples of good sleepers and individuals with
insomnia. As we believe eﬀort impacts sleep initiation both at
sleep onset and at times of sleep interruption throughout the
night, the sample selected here includes initial and maintenance
insomnia patients.
METHOD
Development of the pilot GSES
A pilot GSES not subject to psychometric evaluation has
been used in two previous studies (Broomﬁeld and Espie,
2003; Kohn and Espie, 2005). This pilot GSES was originally
developed following discussions involving the authors of
these papers. An exhaustive content analysis of relevant
existing scales was completed, which resulted in a working
model of sleep eﬀort, integrating seven core components of
sleep eﬀort (Fig. 1). Each component was assigned a single
item, forming the pilot GSES (Appendix 1), which we now
evaluate. All items in GSES are valenced in the same way.
And instructions make reference to sleep in the past week.
This sets up GSES as a present state rather than trait
measure. Insomnia patients sleep well at certain times and on
certain nights, a point reﬂected in formal diagnostic criteria
(e.g. ICSD-R).
GSES ﬁeld testing and psychometric evaluation
Participants
In order to examine GSES psychometric properties, insomnia
patients and good sleepers were recruited. All participants
were 18 years or older, with no upper age limit. The majority
of insomnia participants were general practitioner referrals to
a large treatment trial, the results of which are reported
elsewhere (Espie et al., 2004). The remainder were obtained via
university e-mail, as were the good sleepers.
All insomnia participants were screened using a standard in-
house protocol (copy available on request) based on the
Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV; American Psychiatric Association, 1994) criteria for
primary insomnia. This was completed at home, and consid-
ered sleep complaint (chronicity, number of poor nights sleep,
latency, wake time after sleep onset), daytime functioning, and
substance use and mood data. Sleep-disruptive medical con-
ditions (e.g. chronic pain) and suspected other sleep disorders
were also assessed. Follow-up telephone interviews clariﬁed
detail.
Inclusion criteria were a complaint of signiﬁcant diﬃculty
initiating and/or maintaining sleep, occurring 4+ nights per
week for minimum 6 months, daytime impairment (concen-
tration diﬃculty, fatigue) and a score >5 on the Pittsburgh
Sleep Quality Index (PSQI) (Buysse et al., 1989). This cut-oﬀ
discriminates good from poor sleepers adequately (Backhaus
et al., 2002). Participants who reported taking prescribed
medications to assist sleep were included. Data on speciﬁc
medication sort were not gathered. Patients with known
sleep-disruptive medical conditions, suspected other sleep
disorders (respiratory, muscular, neurological, circadian)
such as depression, or substance abuse problems were
excluded.
Good sleepers had no sleep disturbance complaint, failed to
meet DSM-IV criteria for primary insomnia, agreed with the
statement I am a good sleeper, described their sleep pattern in
a typical month and this month as good or very good, and
scored <5 on the PSQI. These conservative criteria ensured a
representative good sleeper cohort.
Measures and procedure
To examine psychometric properties, all participants
completed the GSES, the Hospital Anxiety and Depression
Scale (HADS; Zigmond and Snaith, 1983) and the DBAS
scale (Morin et al., 1993). Scales were mailed out immedi-
ately following the telephone screening and completed at
home.
The HADS-A (anxiety subscale) is a reliable, widely used
measure of clinical anxiety. DBAS is a reliable, widely used
measure of beliefs and attitudes regarding sleep. Inclusion of
these supported concurrent validity analysis, by allowing an
examination of whether GSES scores (i) merely represented
elevated general anxiety and (ii) were associated with a known
cognitive measure of sleep.
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RESULTS
Participants
A total of 89 insomnia patients and 102 good sleepers met
criteria. Mean age of insomnia participants was 50.67 years,
SD ¼ 16.17 (56 were female). Mean PSQI score was 12.10,
SD ¼ 3.60 (range 5–18). Mean age of good sleepers was
34.08 years, SD ¼ 15.98 (52 were female). Mean PSQI score
was 1.96, SD ¼ 1.30 (range 0–5).
Internal consistency
Cronbach’s a was 0.77 using the insomnia patient group. Item-
deletion alphas reveal the stability of a psychometric measure
when individual items are systematically eliminated. For the
GSES, item-deletion alphas remained high, with little variation
between values (mean a ¼ 0.75, range 0.74–0.76). Typically, a
criterion of 0.80 is deemed acceptable (Nunnaly and Bernstein,
1994). Mean corrected item–total correlation was 0.64 (range
0.49–0.73). The item-by-item correlation matrix for insomnia
patients showed a range of values (r ¼ 0.15–0.58) (Table 1).
Concurrent validity
Anxiety subscale scores from the HADS (Zigmond and Snaith,
1983) were available for 68 insomnia patients. For these, the
association between GSES and HADS-A was non-signiﬁcant
(r ¼ 0.19, P > 0.1, NS).
Impaired preparedness
 for sleep. Activation of 
 “I must sleep” schema
But sleep is involuntary.  Effort 
and control fail, causing night  
to night vicious circle of             
chronic insomnia
D. Anticipatory anxiety about sleep E. Sleep Avoidance 
General anxiety regarding 
sleeplessness, and consequences:
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C. Nighttime
F.   Performance effort 
G.  Control over sleep
Sleep performance failure.
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develop
     Period of acute insomnia
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INSOMNIA
Figure 1. A preliminary working model of sleep eﬀort.
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DBAS scores were available for 64 insomnia patients. For
these individuals, there was also a signiﬁcant moderate
positive correlation between GSES and DBAS (r ¼ 0.50,
P < 0.0001).
For all participants, a weak positive correlation was
observed between GSES and age (r ¼ 0.22, P < 0.005). This
is a small signiﬁcant correlation, accounting for approximately
4% variance.
Discriminant validity
The ability of GSES to discriminate insomnia patients
(n ¼ 89) from good sleepers (n ¼ 102) was investigated. Mean
total GSES score for insomnia patients was 7.06, SD ¼ 3.58;
and 1.22, SD ¼ 1.35 for good sleepers.
The GSES readily discriminated the groups (t ¼ )15.27,
d.f. ¼ 189, P < 0.0001). Mean scores for individual GSES
items diﬀered signiﬁcantly between groups (Table 2). Distri-
bution examination indicated limited overlap between highest
scoring good sleepers and lowest scoring insomnia patients
(Fig. 2).
Given the signiﬁcant association between GSES and age, to
be conservative discriminant validity between groups was
considered using analysis of covariance (ancova), with age as
covariate. GSES still readily discriminated the groups, with
age partialled out [F(1,182) ¼ 228.52, P < 0.0001].
Impact of medication
Sleep medication can aﬀect perception of sleep. Data on
whether insomnia patients used or did not use prescribed
medication to assist sleep were available for 70 of 89 insomnia
patients (78.6%). Thirty reported non-use, 40 reported medi-
cation use. Independent t-test analysis indicated no signiﬁcant
diﬀerences between users and non-users on GSES score
(t ¼ )0.25, d.f. ¼ 68, P > 0.8, NS).
Sensitivity and speciﬁcity
The sensitivity of a scale is the probability that an individual
with the condition will be correctly classiﬁed as having the
condition. Speciﬁcity is the probability that a person without
the condition will be properly classiﬁed as not having the
condition (Fleiss, 1981). A cut-oﬀ score of 2 correctly
identiﬁed 93.3% of insomnia patients and 87.3% of good
sleepers. Only seven of 89 insomniacs are not identiﬁed using
this cut-oﬀ (Table 3a). Using 3 as the cutoﬀ, 82.2% of
insomnia patients and 92.2% of good sleepers were correctly
identiﬁed. Only 16 of 89 insomniacs were not identiﬁed
(Table 3b).
Following Bossuyt et al. (2003), predictive value and like-
lihood ratio data were also calculated (Table 4). Positive
predictive and likelihood ratios were high. This suggests GSES
predicts the presence of insomnia well.
Finally, using a cut-oﬀ score of 2, participants were split into
two groups: low eﬀort (score of 0, 1 or 2), and high eﬀort
(score 3 or more). Diﬀerences between these groups on the
PSQI were then analysed. High eﬀort participants scored
higher on the PSQI (mean ¼ 11.01, SD ¼ 4.61; t ¼ )15.93,
d.f. ¼ 189, P < 0.0001) relative to low eﬀort participants
(mean ¼ 2.38, SD ¼ 2.59).
Principal component structure of GSES
Data from 159 insomnia patients and 120 good sleepers were
included in a principal component analysis (PCA) with
varimax rotation. To maximize numbers, the sample used
was generated from participants described here, and from two
previous studies (Broomﬁeld and Espie, 2003; Kohn and Espie,
in press). One principal component was found (eigen-
value ¼ 4.38) accounting for 62.6% of total variance. Each
item loaded signiﬁcantly on this factor (mean a ¼ 0.79, range
0.64–0.85).
Table 1 Glasgow Sleep Eﬀort Scale (GSES) item-by-item correlation
matrix
GSES item 1 2 3 4 5 6 7
1 1.00
2 0.44 1.00
3 0.34 0.24 1.00
4 0.38 0.36 0.51 1.00
5 0.27 0.15 0.40 0.51 1.00
6 0.37 0.29 0.52 0.56 0.42 1.00
7 0.40 0.33 0.51 0.58 0.39 0.57 1.00
Table 2 Mean Glasgow Sleep Eﬀort Scale
(GSES) item scores for insomnia (I) and good
sleeper (GS) participants
Mean item score
GS I t P-value
1. I put too much eﬀort into sleeping when it
should come naturally
0.12 1.04 )10.97 0.000
2. I feel I should be able to control my sleep 0.56 1.13 ) 6.27 0.000
3. I put oﬀ going to bed at night for fear of not
being able to sleep
0.07 0.71 )7.34 0.000
4. I worry about not sleeping if I cannot sleep 0.25 1.17 )10.07 0.000
5. I am no good at sleeping 0.03 1.27 )16.60 0.000
6. I get anxious about sleeping before I go to bed 0.04 0.70 )7.94 0.000
7. I worry about the consequences of not sleeping 0.16 1.03 )10.26 0.000
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DISCUSSION
In this initial validation study, GSES psychometric evaluation
was completed with 89 insomnia patients and 102 good
sleepers. Field testing revealed highly acceptable data. Internal
consistency and item-by-item correlation data were adequate.
Item–total correlations were satisfactory, indicating no single-
scale item accounts for the majority of variance. A cut-oﬀ
score of 2 correctly identiﬁed 92.1% of insomnia patients and
87.3% of good sleepers, with excellent likelihood ratios at this
cut-oﬀ. GSES adequately discriminated insomnia patients
from good sleepers, supporting previous work (Kohn and
Espie, in press). Although sleep medication can impact
perception of sleep, hypnotic users did not diﬀer from non-
users on GSES. The GSES HADS-A association was non-
signiﬁcant, suggesting the scale is not simply measuring
anxiety. Factor analysis revealed one component accounting
for 62% of variance and a moderate correlation was observed
with DBAS suggesting substantial unique variance (75%).
This sets GSES apart from existing cognitive insomnia
measures. Although requiring replication with a much larger
and more carefully deﬁned sample, these data implicate GSES
as a valid, reliable measure with considerable potential for
quantifying sleep eﬀort.
Once fully validated using a larger sample, GSES should
serve several purposes for the sleep medicine specialist. It will
identify if eﬀort is a relevant concern in a given insomnia case.
It will also provide a useful baseline cognitive screen for
dysfunctional beliefs, which may then be targeted as part of
cognitive restructuring. And it will denote potential patient
suitability for single-component paradoxical intention therapy.
This therapy as noted improves sleep by reducing eﬀort
(Broomﬁeld and Espie, 2003), so insomnia patients scoring
high on GSES may be good responders. Research is needed on
this.
Following larger scale validation, general practitioners
could also use GSES to identify a core symptom of
psychophysiological insomnia in sleep-disturbed individuals.
The scale is short, easily administered and appears to show,
at least on this initial sample reasonable sensitivity, specif-
icity and discriminant validity. Whereas we would predict
patients with other types of sleep disturbance, e.g. sleep
apnoea or circadian disorders would not score highly.
Research examining GSES with other sleep disorder groups
is needed.
Finally, the validation of GSES will allow research into how
eﬀort perpetuates insomnia. GSES appears to provide the
means to measure eﬀort reliably, so comparison between
studies is possible. Further work on putative mechanisms
underpinning paradoxical intention therapy is also now
possible. The evidence base for paradoxical intention therapy
as a single-component therapy is established (Chesson et al.,
1999), but our understanding of how it promotes sleep change
is poor. The answer will come from research using GSES to
clarify the role of paradoxical intention therapy in unwinding
inhibitory sleep eﬀort.
Several limitations of this study merit consideration. First,
sample size was relatively small for a validation study, and
insomnia participants were obtained from a large treatment
trial and from a university-based population. Recruited
participants were neither asked to record sleep data to
conﬁrm diagnosis of primary insomnia nor was polysom-
nography (PSG) employed to rule out occult primary sleep
disorders. Diagnosis was made on the basis of a sleep
complaint present 4+ nights per week for 6 months, and a
PSQI score >6. No inter-rater check on diagnosis was
made, no data on insomnia severity and type (initial versus
maintenance) were collected, and clinical interviews were not
employed for screening. Future GSES research will beneﬁt
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Figure 2. Box and whiskers plot demonstrating the ability of the
Glasgow Sleep Eﬀort Scale to discriminate good sleepers and insom-
niacs.
Table 3 Identiﬁcation of insomniacs and good sleepers
I GS
(a) Using GSES cut-oﬀ of 2
Correct 82 13
Incorrect 7 89
(b) Using GSES cut-oﬀ of 3
Correct 73 8
Incorrect 16 94
Table 4 Diagnostic test results for the Glasgow Sleep Eﬀort Scale
score >2
Positive predictive value 0.87 (0.78–0.92)
Negative predictive value 0.94 (0.87–0.97)
Likelihood ratio for insomnia +7.3 (4.39–12.20)
Likelihood ratio for good sleepers )0.08 (0.04–0.17)
Range values are given within the parenthesis.
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from such detail and from additional screening methods, e.g.
structured interview methodology, single-night PSG (Edinger
et al., 2004) and inter-rater reliability data. Test–retest data
should also be collected.
Furthermore, to test the validity of GSES, correlation was
only made to other self-report scales (HADS, DBAS).
Objective sleep assessments are needed to conﬁrm external
scale validity. This could be performed on a smaller sample.
Related to this, HADS, DBAS and medication data were
only available from the majority of insomnia patients
and data on speciﬁc hypnotic medication type were not
recorded.
Also, the insomnia and good sleeper samples diﬀered
signiﬁcantly on age. Unmatched samples are not unusual in
insomnia scale research however (e.g. Buysse et al., 1989;
Fichten et al., 1998), probably because of epidemiology
factors (Mellinger et al., 1985). As sleep eﬀort is likely to
play a role in insomnia maintenance throughout the lifespan,
research with age-matched younger and with age-matched
older good and poor sleepers will be desirable. Crucially,
while in our sample age and GSES were signiﬁcantly
associated, ancova demonstrated adequate GSES discriminant
validity with age partialled out.
Importantly, the majority of insomnia patients (83%) were
physician-referred. So the cohort is a clinical insomnia rather
than university-based population. Notably also, good sleepers
were not merely deﬁned by absence of sleep complaint. They
also described themselves as good sleepers, and reported their
sleep as good or very good both typically, and in the last
month. This exceeds research diagnostic guidelines (Edinger
et al., 2004), and is a strength rarely seen in studies that use
good sleepers to compare.
Finally, GSES item derivation relied on an empirically
untested model of eﬀort. It was, however, our intention to
do this. The approach of setting testable hypotheses extrac-
ted from clinical experience in order to inform theory is
defendable, and has assisted our understanding and treat-
ment of a range of psychological disorders in recent years
(Salkovskis, 2002). Indeed, this should be employed more to
study insomnia (Tang and Harvey, 2003). The working
model we present requires empirical clariﬁcation using
experimental methods, and GSES will assist with this.
Carefully designed single casework is needed for tracking
insomnia patients who ﬁt the model. Related research
questions include whether it is possible to induce sleep
eﬀort experimentally in good sleepers? And what is the
impact of experimentally induced sleep eﬀort on insomnia
patients? This research will extend our understanding of
eﬀort in insomnia, and provide important groundwork for
further study of paradoxical intention therapy and putative
mechanisms.
To summarize, this validation study suggests that GSES
shows good psychometric properties. It is a useful and novel
measure of clinical assessment and change, which should
screen out psychophysiological insomnia in sleep-disturbed
individuals and aid identiﬁcation of insomnia patients suited to
psychological therapies.
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INSOMNIA
INTRODUCTION
INSOMNIA IS THE MOST COMMON SLEEP COMPLAINT IN 
THE GENERAL POPULATION. RECENT RESEARCH HAS 
ADDRESSED A WIDE RANGE OF ISSUES related to this con-
dition, including epidemiology, consequences, pathophysiology, 
and treatment. However, understanding the results of the research 
and translating these results into clinical practice have been hin-
dered by the absence of standardized definitions, assessments, and 
reporting standards. For instance, a recent review of epidemiolog-
ic studies showed that the reported prevalence of insomnia in the 
general population can range from 2% to 48%, depending on the 
definition of insomnia.1 Studies examining the clinical and physi-
ologic characteristics of insomnia have used definitions ranging 
from the very broad (e.g., self-defined “good vs poor sleepers”2), 
to the very narrow (e.g., individuals with “sleep-state mispercep-
tion,” which can only be defined with polysomnography3;4).
 Reviews of treatment studies demonstrate similar problems. 
For instance, Nowell and colleagues identified 198 studies com-
paring drug therapy with placebo in insomnia, but only 22 could 
be included in a final meta-analysis.5 The authors needed to make 
several inferences regarding the diagnosis of primary insomnia 
because most studies failed to specify insomnia duration, clini-
cally significant distress, or the means by which psychiatric or 
medical causes of insomnia were excluded. Holbrook and col-
leagues6 identified 89 double-blind trials for their meta-analysis 
but excluded half of these, noting, “the methodologic quality of 
the studies was not uniform… The diversity in outcomes used and 
the methods of summarizing… prevented the pooling of many 
trials.” Likewise, Smith and colleagues initially identified 194 
treatment studies of primary insomnia but included only 21 in 
their final meta-analysis. Many primary sources were excluded 
because means, standard deviations (SD), and test statistics were 
not reported. A recent review of behavioral and psychological 
treatment studies for insomnia7 also identified a wide range of 
diagnostic methods, specific diagnoses, and specific outcomes, 
with 16 of 53 eligible studies excluded from the review for rea-
sons including the failure to document an insomnia diagnosis. In 
summary, consistent diagnostic, baseline, and outcome measures 
have not been used in published insomnia studies. Inconsistency 
of reporting methods and outcome data has further limited the 
ability to compare findings across studies.
 This paper reports the findings of an expert consensus process 
to develop recommendations for standard assessments and report-
ing standards in insomnia research studies. This process included 
a conference held on March 10-11, 2005, in Pittsburgh, Penn, 
with 25 experts in insomnia research in attendance. The specific 
aims of this process and the accompanying conference, reflected 
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in this paper, were
1. To systematically review the relative merits and disadvan-
tages of various insomnia assessment tools in 5 key domains: 
insomnia diagnosis; medical, psychiatric, and sleep disorder 
comorbidities; quantitative sleep measurements; qualitative 
sleep and insomnia measurements; and daytime symptom 
and function measures.
2. To develop consensus recommendations regarding a standard 
research assessment of insomnia to be used in both assess-
ment and treatment-outcome studies.
3. To develop consensus recommendations regarding reporting 
standards for each of the assessments.
4. To make recommendations regarding assessment areas and 
instruments that require further development in order to meet 
the needs of future insomnia research.
METHODS
 The concept for the conference and this paper grew out of dis-
cussions at the University of Pittsburgh Mental Health Interven-
tion Research Center (MH30915). An Organizing Committee, 
consisting of the authors of this paper, was charged with further 
developing goals and methods. The Organizing Committee in-
vited a group of 20 additional insomnia experts to participate, 
based on their research and publications in the field. These indi-
viduals were chosen to provide a broad representation of different 
types of insomnia research, with the recognition that many other 
qualified investigators could also have been selected. Participants 
were assigned to 1 of 5 work groups corresponding to the 5 con-
tent areas being addressed: Insomnia diagnosis, comorbidities, 
quantitative sleep, qualitative sleep and insomnia symptoms, and 
daytime function and consequences. One member of the Organiz-
ing Committee served as the leader of each work group, which 
was responsible for reviewing the literature in its specific area to 
identify the range of tools and methods used in published studies. 
This process was aided by recent review articles8-13 and review of 
primary references. The goal of this process was to develop an 
evidence-based qualitative review of available methods, focusing 
on the strengths and weaknesses of various approaches. The work 
groups did not conduct quantitative literature reviews, since the 
focus was on identifying optimal methods rather than the most 
commonly used methods or a description of study results. In sev-
eral of the work groups, individuals were assigned more specific 
areas for review. The work groups conferred by telephone and 
e-mail to discuss their methods and preliminary findings and de-
veloped a draft summary of their findings and recommendations 
prior to the meeting.
 At the conference, the work groups convened briefly to review 
their findings and discuss remaining areas of disagreement. All 
participants then met in plenary session, where the findings and 
recommendations of each work group were presented and dis-
cussed. Additional discussion focused on development of con-
sensus regarding the recommendations for general assessment 
domains and specific assessments within these domains. During 
the course of work-group and plenary discussions, it also became 
clear that recommendations were needed to accommodate the dif-
ferent goals and resources in different types of research studies. 
For instance, epidemiologic studies often need to use relatively 
brief assessments in large numbers of individuals, whereas treat-
ment-efficacy studies include detailed assessments in relatively 
smaller numbers of individuals. 
 The members of the Organizing Committee used the work 
groups’ written summaries, the results of discussions, and the 
recommendations emanating from the conference in the develop-
ment of the final paper. All conference participants had the oppor-
tunity to comment on the initial draft, which was then finalized by 
the Organizing Committee.
 As a result of all the discussions, the 5 original domains were 
collapsed into the 3 broader domains presented in this paper: diag-
nosis of insomnia and comorbid conditions, sleep measurements, 
and waking correlates and consequences of insomnia. The goals 
and rationale for each domain are presented briefly, followed by 
descriptions of specific recommended measures and tools. Rec-
ommendations for reporting standards for specific assessments 
are also discussed within each domain.
 Table 1 summarizes the recommended standard assessment 
of insomnia for 4 types of research studies: (1) Epidemiologic 
studies; (2) Mechanism and evaluation studies (i.e., studies com-
paring the clinical or physiologic characteristics of participants 
with insomnia to a reference group); (3) Efficacy studies (treat-
ment studies focusing on relatively small, well-defined samples) 
and; (4) Effectiveness studies (treatment studies focusing on 
large community samples in routine practice settings). Although 
we have described the recommended assessments for these study 
types as though they were completely distinct, in actual practice 
there may be considerable overlap in study types. In such cases, 
it would be reasonable to include a hybrid of the recommended 
assessments. Each assessment method within each study type is 
further categorized as “Essential” or “Recommended.” The de-
scriptor “Essential” is used to indicate assessments that should 
be included in every study of the type noted. “Recommended” 
assessments are those that should be included whenever feasible. 
Note that the designation of a measure as “Essential” or “Recom-
mended” varies with the particular type of research study, as in-
dicated in Table 1. The text contains more general language than 
Table 1 regarding these levels of endorsement. 
 The recommendations in this paper are not intended to indicate 
that other measures should not be used nor that other measures 
cannot contribute useful information to the study of insomnia. 
Indeed, other measures may be very appropriate for specific in-
somnia studies, and investigators should not hesitate to use them. 
The goal of this paper is to present only the minimum set of as-
sessments needed to facilitate future comparisons across studies. 
Toward this end, the shortest set that provides coverage in key 
areas was purposely selected. Thus, Table 1 is not intended to be 
a comprehensive summary of the available assessments within 
each domain.
DESCRIPTION OF ASSESSMENT DOMAINS AND RECOMMENDA-
TIONS
1. DEFINITION/DIAGNOSIS OF INSOMNIA AND COMORBID CONDI-
TIONS
a. Background and Rationale
Insomnia Definitions and Diagnosis 
 In both research studies and clinical practice, the term insom-
nia has been used narrowly to denote a set of sleep-specific symp-
toms and more broadly to refer to a heterogeneous group of sleep 
disorders. When defined narrowly, the term insomnia implies iso-
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lated sleep-related complaints, such as a difficulty falling asleep, 
difficulty staying asleep, early awakening, or unrefreshing/non-
restorative sleep in an individual who has adequate circumstances 
and opportunity for sleep. When more broadly defined, the term 
insomnia connotes a sleep-wake disorder wherein sleep-specific 
insomnia symptoms are associated with significant waking dis-
tress or impairment and, depending on the specific insomnia dis-
order, other specific symptoms. To avoid confusion arising from 
these discrepant definitions, throughout the remainder of this 
article we use the term insomnia symptom to refer to the more-
narrow sleep-specific insomnia definition and the term insomnia 
disorder or simply insomnia to denote a broader syndrome having 
both sleep and waking symptoms. 
 Even a cursory review of the relevant literature shows that a 
substantial proportion of studies devoted to the disorder of in-
somnia have included study samples selected solely on the ba-
sis of their insomnia symptoms. In some cases, researchers have 
recruited and enrolled samples with specific types of insomnia 
symptoms such as sleep-onset or sleep-maintenance difficulties. 
However, experience shows that use of insomnia symptoms for 
sample selection or characterization provides little specificity 
inasmuch as individuals with such sleep complaints comprise a 
large and very heterogeneous population. Moreover, insomnia 
symptoms, considered in isolation, confer limited morbidity and, 
thus, are of questionable clinical significance.1 Therefore, reliance 
solely on insomnia symptoms for sample selection appears to be a 
suboptimal research practice. 
 Arguably, a more defensible research practice is that of defin-
ing insomnia as a disorder with impairment of sleep and waking 
functions. Typically, such definitions have included complaints 
of insomnia symptoms coupled with waking symptoms, such as 
functional impairments,14;15 sleep-related distress,14;15 or general 
sleep dissatisfaction.16 Insomnia definitions that combine sleep-
specific complaints with these associated daytime symptoms ap-
pear to represent clinically significant insomnia disorders that are, 
in fact, associated with elevated risks for morbidity.1 However, 
individuals meeting such criteria are still heterogeneous with re-
spect to actual or presumed etiology. Use of diagnostic criteria 
for specific insomnia-disorder subtypes from one of the currently 
available sleep-disorders nosologies17-20 offers greater specific-
ity and homogeneity in case ascertainment and research-sample 
selection. Although there is limited information concerning the 
reliability or validity of most insomnia diagnoses listed in these 
nosologies,4;21;22 application of specific insomnia diagnostic crite-
ria clearly benefits research practice, particularly when research 
questions pertain to specific insomnia subtypes.
 Recently both research diagnostic criteria (RDC) for insom-
nia4 and quantitative insomnia diagnostic criteria23 have been 
proposed to improve upon previous definitions used in insomnia 
research. The RDC were developed by a specially commissioned 
work group of the American Academy of Sleep Medicine and 
consist of criteria sets for identification of individuals who meet 
general criteria for an insomnia disorder, as well as more exacting 
criteria sets for 9 specific insomnia diagnostic subtypes. In addi-
tion, criteria are provided for the identification of normal sleepers 
who may be chosen as controls for insomnia studies. These RDC 
present the opportunity to standardize research practice in regard 
to the selection or identification of research enrollees. Further-
more, these criteria have the advantage of being totally concor-
dant with insomnia disorders listed in the second edition of the 
International Classification of Sleep Disorders (ICSD-2)17 and the 
Clinical Modification of the International Classification of Dis-
eases, 10th edition (ICD-10-CM). Although their reliability and 
validity await testing, the RDC have been developed specifically 
to standardize case ascertainment, and, given this purpose, their 
use in future insomnia studies seems preferable.
 Although there is currently no consensus regarding the use of 
quantitative diagnostic criteria for insomnia, their use in select-
ing individuals who otherwise meet conditions for insomnia may 
ensure more homogeneous and seriously affected samples and 
may avoid underestimation of treatment effects due to ceiling or 
floor effects.23 Based upon modal practice in published clinical 
trials and maximization of sensitivity and specificity, the follow-
ing criteria have been suggested: sleep-onset latency (SOL) or 
wakefulness after sleep onset (WASO) of more than 30 minutes, 
frequency of at least 3 times a week, and duration of at least 6 
months.23 Applying quantitative criteria carries the potential li-
ability of limiting the generalizability of research findings to 
clinical practice, where such criteria are not generally employed. 
Moreover, quantitative criteria do not address unrefreshing or 
nonrestorative sleep, one of the cardinal insomnia symptoms. The 
quantitative criteria described above may also reflect selection or 
reporting biases in the published literature. As in other domains of 
health science, the validity of quantitative diagnostic cutoffs is ul-
timately judged by how well they actually discriminate those with 
and without clinically significant insomnia and by their associ-
ated morbidity risk. Such data for insomnia are extremely limited, 
but future research studies could determine optimal quantitative 
sleep thresholds or other indicators of insomnia severity and their 
association with graded levels of morbidity. Thus, with additional 
supportive studies, use of quantitative criteria combined with 
RDC for insomnia sample selection or characterization could be-
come optimal research practice.
 Previous studies have provided various methods for screening 
prospective study candidates to determine if they meet criteria for 
insomnia or a specific insomnia subtype. Included among these 
methods are both brief and more lengthy questionnaires,14;24-27 the 
common unstructured clinical interview,28;29 semistructured in-
somnia-focused interviews,27;30;31 and structured sleep disorders 
interviews,32;33as well as subjective and objective sleep-monitor-
ing methods. The unstructured clinical interview that includes 
a thorough sleep history has been used widely for insomnia as-
sessment and sample selection in previous studies. The lack of 
standardized questions and procedures for this method reduces 
its interrater reliability. However, when used by interviewers who 
are experienced with sleep disorders and insomnia diagnoses, 
the unstructured interview seems to be a pragmatic procedure 
for study-sample selection, particularly if combined with a pa-
tient-administered sleep-history questionnaire. Semistructured 
interviews have been developed by selected research groups to 
standardize research diagnostic practice. These instruments have 
the advantage of ensuring a more consistent and comprehensive 
insomnia assessment across interviewers, but data regarding the 
reliability and validity of these instruments is currently lacking. 
Furthermore, use of such instruments has, to date, been researcher 
or lab specific, so we currently lack a broad “experience base” 
upon which to judge any of these instruments. Perhaps most 
promising for insomnia diagnosis are the structured interviews 
developed by Schramm et al and Ohayon.32;33 Both of these stan-
dardize the interviewing process and have data supporting their 
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reliability. Unfortunately, the interview by Schramm et al results 
in DSM-III-R insomnia diagnoses rather than the insomnia diag-
noses listed in the current DSM-IV-TR. In contrast, the comput-
erized Ohayon instrument known as the Sleep-EVAL interview 
results in DSM-IV and ICSD-90 diagnoses but is not generally 
available to the insomnia research community. Thus, neither of 
these specific instruments can be recommended for ascertaining 
RDC for insomnia disorder or for specific insomnia subtypes. 
Evaluation of Comorbid Sleep Disorders
 Other sleep disorders can also be present in individuals with 
symptoms of insomnia. Extended discussion of the differential 
diagnosis of insomnia from other sleep disorders is available 
elsewhere.34 For example, even carefully screened research par-
ticipants meeting RDC for insomnia may have sleep-disordered 
breathing on polysomnographic (PSG) evaluation.35 Insomnia 
symptoms can also occur in conjunction with other sleep disor-
ders such as sleep apnea, restless legs syndrome, periodic limb 
movement disorder, and circadian rhythm sleep disorders. How-
ever, the presence of other sleep disorders in insomnia samples 
may confound evaluation and intervention data and affect con-
clusions. Thus, it is prudent to include other sleep disorders in 
the differential diagnosis and to identify subjects with comorbid 
sleep disorders. The evaluation of other sleep disorders, exclu-
sionary diagnoses, and sleep-disorder comorbidities should all be 
described in research reports.
 Methods for evaluating other sleep disorders are similar to 
those for diagnosing insomnia and include clinical interviews, 
structured sleep interviews, and questionnaires. A number of 
questionnaires have been specifically developed to identify sleep 
apnea, focusing on common clinical characteristics such as high 
body mass index, increasing age, male sex, excessive daytime 
sleepiness, and loud snoring.36 However, no current questionnaire 
specifically discriminates insomnia from sleep apnea, provides 
clear cutoff scores, or has strong sensitivity and specificity. These 
questionnaires, like clinical interviews, suffer from patients’ dif-
ficulty assessing their own snoring and daytime sleepiness and 
from the wide distribution of apnea-related characteristics among 
the nonapneic population. Given these difficulties, a reasonable 
approach is to assess the above characteristics by interview and, 
if most are present, to assume a high probability of sleep apnea. 
Additional history from a knowledgeable sleep informant and ad-
ditional data on sleepiness from measures such as the Epworth 
Sleepiness Scale (ESS) (e.g., a score >10-12) may also be useful. 
The clinical significance of periodic limb movements has been 
questioned,37;38 and this condition is very difficult to assess by 
clinical history alone. On the other hand, restless legs syndrome, 
a condition frequently seen concurrent with periodic limb move-
ments of sleep, can be assessed reliably by history and question-
naire.39;40 A high frequency of brief awakenings (e.g., >10) dur-
ing the night should arouse suspicion of periodic limb movement 
disorder or sleep apnea, particularly if it is accompanied by ex-
cessive daytime sleepiness. Ultimately, PSG assessment may be 
deemed necessary to detect apnea and PLMS for certain forms of 
insomnia research.
 Evaluation of Comorbid Psychiatric and Medical Disorders 
and Medication or Substance Use. The co-occurrence of insom-
nia and psychiatric symptoms and disorders is common10 and may 
be associated with clinically significant psychiatric disability.41-43 
The high rate of psychiatric comorbidity with insomnia is not a 
special case; the National Comorbidity Survey reported that ev-
ery psychiatric disorder is comorbid with every other disorder.44 
To give one example, generalized anxiety disorder is comorbid 
with depression in 80% of cases. However, as pointed out in the 
recent National Institutes of Health State-of-the-Science Confer-
ence on insomnia,45 the mechanisms and nature of the relation-
ships between insomnia and comorbid psychiatric conditions are 
poorly understood and may vary between individuals and within 
individuals over time.46;47 At some time points, insomnia and co-
morbid psychiatric conditions may be parallel and functionally 
independent, whereas, at other times, one may perpetuate or exac-
erbate the other. The RDC for Insomnia Due to a Mental Disorder 
require that the onset of the insomnia coincide with the onset of 
the mental disorders and that the temporal course of the insomnia 
and mental disorder coincide. In reality, the accuracy and reli-
ability of such temporal information remains very much in doubt. 
For this reason, the term comorbid insomnia, supported by the 
National Institutes of Health State-of-the-Science Conference, 
may be more accurate, even if less precise. Given the complex 
relationships between insomnia and psychiatric disorders, it is 
prudent to systematically evaluate psychiatric comorbidities, to 
assess the nature of the relationship between the insomnia and 
psychiatric disorder, and to describe comorbidities in research re-
ports. Methods for evaluating psychiatric disorders include self-
report questionnaires, clinical interviews, and structured psychi-
atric interviews.
 These issues apply equally to medical comorbidity. Evaluat-
ing medical disorders serves 3 functions: to identify comorbid 
medical disorders; to evaluate medical or physical characteris-
tics associated with increased risk of other sleep disorders (e.g., 
sleep apnea); and to determine medical eligibility criteria, which 
may relate to the safety of conducting certain insomnia inter-
ventions. Common medical conditions comorbid with insomnia 
include cardiovascular, pulmonary, neuromuscular, endocrine, 
gastrointestinal, pulmonary, and neurologic disorders.48 Cancer 
and sex-specific conditions (e.g., menstruation, menopause, and 
pregnancy) may also influence insomnia. When insomnia is co-
morbid with a medical condition, it is not necessarily caused by 
(secondary to, due to) that medical condition. As in the case of 
psychiatric disorders, comorbid insomnia may actually be a more 
accurate term. As is the case for comorbid psychiatric disorders, 
insomnia may be completely or partially dependent on a medical 
condition, may be independent, or may exacerbate a medical con-
dition, and the nature of the relationship may change over time. 
The insomnia RDC for Insomnia due to a Medical Condition re-
quire that the onset of the insomnia coincide with the onset of the 
associated medical disorder and that the temporal course of the 
insomnia and medical disorder coincide. It is prudent to evaluate 
medical comorbidities, to assess the nature of the relationship, 
and to describe such comorbidities in research. General methods 
for evaluating medical disorders include self-report question-
naires, clinical interview, physical examination, and laboratory 
screening tests.49 
 A wide variety of medications and substances may cause or 
contribute to insomnia, daytime sleepiness, or both insomnia and 
daytime sleepiness.50 These include prescription medications, 
over-the-counter medications, herbal and “natural” substances, 
and nonmedicinal substances such as alcohol and caffeine. An 
accurate current list of medications and substance use serves two 
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Table 1—Recommended Research Measures for Insomnia
Speciﬁc area Recommended Reporting Standards Epidemiology  Mechanism/   Treatment   Treatment  
 Measures  Studies Evaluation Efﬁcacy Effectiveness
    Studies Studies Studies
Diagnosis 
Insomnia  Clinical history/questionnaire Indication that clinical history was conducted; R E E R
and other for sleep disorders using qualiﬁcations of interviewer; speciﬁc methods used
sleep    International Classiﬁcation (e.g., interview, symptom questionnaires); exclusionary
disorders of Sleep Disorders 2nd ed diagnoses; # participants judged to have another 
 (ICSD-2) criteria ICSD-2 sleep disorder; insomnia age of onset,
    duration, frequency, speciﬁc complaints
   Clinical history/questionnaire  Indication whether RDC for general insomnia  E E E E
  for Research Diagnostic  disorder or speciﬁc insomnia subtypes were used; 
 Criteria for Insomnia (RDC-I) description of speciﬁc assessment methods; # 
  participants with each speciﬁc diagnosis; 
  insomnia age of onset, duration, frequency,  
  speciﬁc complaints 
Psychiatric  Structured interview (SCID I) For SCID: speciﬁc modules used; qualiﬁcations E E E E
disorders OR Psychiatric history/ of interviewer; exclusionary diagnoses; # of  
 questionnaire subjects with speciﬁc psychiatric diagnoses and  
  with RDC-deﬁned “Insomnia due to a Mental Disorder.” 
  For clinical psychiatric history or self-report 
  questionnaires: speciﬁc methods and tools used;
  other information for diagnoses described above
Medical  Medical history/  Speciﬁc methods (interview, physical examination, E E E E
disorders questionnaire questionnaires); qualiﬁcations of evaluator; mean
   and SD of BMI for sample; speciﬁc exclusionary
  diagnoses; # subjects with speciﬁc comorbid medical
   conditions and with RDC-deﬁned “Insomnia due    
       to a Medical Condition.”
Current  List of medications  Speciﬁc methods; qualiﬁcations of evaluator; E E E E
medications (history, participant- exclusionary medications/substances; list of
and substances generated list)  medications used by subjects; # participants
  using speciﬁc medications; # of subjects using
      and amount of caffeine, alcohol, and tobacco
  (mean/SD or median/range).
Sleep and insomnia symptoms
Global sleep  PSQI Global mean, SD; subscale means, SD R R E E
and insomnia Insomnia Severity  Total score mean, SD; % of participants  R R E E 
symptoms Index in each severity range
Daily self-report Sleep diary Duration, format, and information assessed in the R E E R
of sleep   diary; thresholds or quantitative criteria for insomnia
    or other sleep disorder diagnoses; mean/SD for each
   dependent measure (bed time, ﬁnal wake time, arising
   time; SOL, NWAK, WASO, TST, SE, SQ; timing 
  and duration of naps or daytime sleep episodes);
   day-to-day variability of dependent measures
Objective Sleep Screening Description of PSG protocol; AHI and PLMAI R E E R
 polysomnography levels used to establish study eligibility or diagnoses;
   other PSG criteria used for study eligibility; 
   PSG as dependent Description of PSG protocol; total recording time NR R E1 NR
  measure (and how determined); mean/SD for AHI, PLMAI,
  SOL, NWAK, WASO, TST, SE.
Rest-activity Actigraphy Description of device and scoring software; clinical R2 R E1 NR
pattern      protocol; thresholds or quantitative criteria used to
   establish or conﬁrm insomnia or other sleep disorder
  diagnoses; mean/SD for sleep onset and offset times, SOL,
        NWAK, WASO, TST, and SE; within-subject variability 
Waking correlates and consequences of insomnia
Fatigue Multidimensional  Mean/SD for total scores and subscales R E E E
 Fatigue Inventory OR 
 Fatigue Severity Scale
Mood Inventory of Depressive  Mean/SD for total scores and total R E E E
 Symptomatology OR Beck  scores less sleep items
 Depression Inventory II  
 State-Trait Anxiety Inventory Mean/SD for Trait portion R E E E
Quality of Life SF-36 Mean/SD for total and subscale scores R E E E
 and Function
E refers to a measure that is considered “essential,” i.e., should be included in all studies; R, Measure is “recommended,” i.e., should be included when-
ever feasible; NR, Not recommended for routine use; SD, standard deviation; BMI, body mass index; AHI, apnea-hypopnea index; PLMAI, the index of 
periodic limb movements index associated with arousals; PSG, polysomnography. Remaining abbreviations are deﬁned in Table 2. 
1At least 1 assessment, either polysomnography or actigraphy, is considered essential
2Recommended for at least a subset of participants
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major functions: to identify possible causes for insomnia (e.g., 
excessive caffeine and alcohol use) and to determine eligibility 
criteria (e.g., exclusion of participants currently taking hypnot-
ics). Therefore, research evaluations of insomnia must include a 
review of current medication and substance use and consideration 
of their positive or negative impact on sleep. When feasible, or 
when necessary for specific study samples, a urine drug screen is 
also desirable prior to the start of the study and during any treat-
ment. Research reports should also include a description of medi-
cation screening and entry criteria. Methods for evaluating medi-
cation and substance use include clinical interviews or history and 
self-report checklists.
 Use of Sleep Diaries, PSG, and Actigraphy for Screening. 
Sleep diaries, PSG, and actigraphy have been used for a variety 
of purposes in insomnia research studies, including screening, 
diagnosis, and differential diagnosis. For simplicity, since these 
methods may be used as both screening and dependent outcome 
measures, they are discussed in Section 2 below.
b. Recommendations for Measures and Reporting Standards
Diagnosis of Insomnia and Other Sleep Disorders
 Recommended/essential measures: (1) Sleep history (inter-
view, questionnaires) and (2) RDC for Insomnia. In the absence 
of a validated structured interview for insomnia and other sleep-
disorder diagnoses, a clinical sleep history conducted by a knowl-
edgeable clinician constitutes the basis for establishing insomnia 
and other sleep-disorder diagnoses. This history may be aided by 
locally developed questionnaires, semistructured interviews, or 
structured interviews (e.g., 28;30;31). The psychometric properties of 
most of these instruments have not been established, but the high 
degree of overlap between them indicates that different labs have 
found the same common set of information to be useful. Informa-
tion covered in the history should include the specific nocturnal 
and daytime symptoms of insomnia; daytime correlates and con-
sequences of insomnia; and the duration, frequency, and severity 
of the symptoms. Symptoms of other sleep disorders must also 
be assessed, including, at a minimum, the following: obstruc-
tive sleep apnea syndrome, restless legs syndrome, periodic limb 
movement disorder, and circadian rhythm sleep disorders. The 
recently published RDC for Insomnia4 include general criteria 
for an insomnia disorder, as well as more specific criteria for 9 
insomnia-disorder subtypes. The RDC were designed specifically 
to standardize case ascertainment in insomnia research. Further-
more, these criteria are concordant with insomnia disorders listed 
in the ICSD-217 and the future ICD-10-CM. Because the RDC 
have only recently become available, their reliability and validity 
await testing. The application of RDC for insomnia may be aided 
by the use of checklists and/or locally developed semistructured 
or structured interviews. 
 Reporting standards. For the clinical sleep history, research 
reports should document that a clinical history was conducted, 
the type of clinician who conducted the evaluation and his or 
her training (e.g., psychologist, psychiatrist; graduate student, 
licensed, subspecialty licensed such as in sleep disorders), the 
specific methods used (e.g., interview, symptom questionnaires), 
and the number of potential or accepted research participants who 
were judged to have another sleep disorder according to ICSD-2 
criteria. Reporting standards for RDC include a statement that the 
criteria were used, whether RDC for general insomnia disorder 
were used alone or whether RDC for the specific insomnia disor-
ders (e.g., psychophysiological insomnia, paradoxical insomnia, 
etc.) were also used, a description of the specific methods used 
(e.g., clinical or structured interviews, phone interviews, ques-
tionnaires) provided in sufficient detail to allow replication of 
procedures by other investigators, and the number of participants 
with each specific diagnosis. Whether a clinical history or RDC 
are used, research reports should also provide data regarding the 
mean, standard deviation, and/or range for insomnia character-
istics, including age of onset, duration of insomnia episode (see 
above), frequency of complaint, and type of symptoms (sleep on-
set, sleep maintenance, early morning awakening).
Diagnosis of Psychiatric Disorders 
 Essential measures: (1) Structured Clinical Interview for DSM-
IV (SCID), Axis I51 or (2) psychiatric history (interview, question-
naires). The SCID incorporates DSM-IV diagnostic criteria in a 
structured standardized interview that yields diagnoses for Axis I 
disorders. It is the accepted standard for evaluation of psychiatric 
disorders, and its use is encouraged whenever possible. Most reli-
ability data for the SCID derive from an earlier version designed 
for DSM-III-R criteria.52 SCID-I diagnoses generally have κ val-
ues (an estimate of interrater agreement) in the 0.6 range. For 
diagnoses relevant to insomnia, κ values in the 0.8 range are typi-
cal for major depression and generalized anxiety disorder. The re-
lationship between diagnosed psychiatric disorders and insomnia 
should be carefully explored in order to distinguish Insomnia due 
to a Mental Disorder from other types of insomnia-psychiatric co-
morbidity. Whenever possible, the SCID is the preferred method 
for ascertaining psychiatric diagnosis. However, in some cases, 
the resources necessary to conduct SCID evaluations may not be 
feasible. In those cases, a clinical history of psychiatric disorders 
should be conducted, covering all major classes of psychiatric 
disorders such as mood disorders, anxiety disorders, psychotic 
disorders, eating disorders, and substance use disorders. The use 
of patient self-report diagnostic questionnaires, such as the Patient 
Health Questionnaire53 or the Center for Epidemiological Stud-
ies—Depression Scale,54;55 may help to establish specific diagno-
ses. However, symptom severity rating scales such as the Beck 
Depression Inventory (BDI) or the State-Trait Anxiety Inventory 
(STAI)(see below) are not adequate diagnostic measures.
 Reporting standards. For the SCID, research reports should 
include which specific modules were used; who conducted the 
assessment and their specialty and training level; specific exclu-
sionary diagnoses; and, if psychiatric diagnoses are not exclu-
sionary, frequency counts for specific psychiatric diagnoses in 
the study sample. The proportion of subjects who have insomnia 
comorbid with psychiatric disorders should always be reported. 
In addition, the combination of RDC for Insomnia and SCID in-
formation should also permit reporting of the proportion of the 
sample with RDC-defined Insomnia due to a Mental Disorder. 
If interrater reliability of SCID diagnoses is assessed, κ values 
should be reported. When clinical psychiatric history or self-re-
port questionnaires are used, research reports should indicate the 
specific methods and tools used in the evaluation, as well as the 
other information described above for the SCID.
Diagnosis of Medical Disorders
 Essential measure: Medical history (interview, physical exami-
Standard Research Assessment of Insomnia—Buysse et al
SLEEP, Vol. 29, No. 9, 2006 1161
nation, questionnaires). Some form of medical history should be 
conducted in all insomnia research studies. A clinical history is 
the preferred method when feasible. The history should include 
a review of the individual’s known medical disorders, evaluation 
of other common medical disorders, and a review of systems. The 
process may be aided by the use of published checklists, question-
naires, and semistructured interviews (e.g., the Cornell Medical 
Index,56;57 Charleson Comorbidity Scale58) or by locally developed 
questionnaires. Disorders referable to all major organ systems 
should be assessed, including neurologic, cardiovascular, pulmo-
nary, musculoskeletal, renal, and endocrine systems. Systematic 
measurement of height, weight, and vital signs should also be 
conducted, and body mass index should be computed. A physical 
examination is also recommended but is not considered essential, 
since there are no pathognomonic features of the physical exam 
in insomnia nor is there any specific finding that would rule out 
insomnia. Further, a physical examination may not be feasible in 
some research settings. However, a physical examination should 
be considered essential for those studies involving pharmacologic 
treatment, assessment that has more than minimal health risks, 
and vulnerable populations (e.g., medically comprised older 
adults). In studies in which a full history is not feasible, a check-
list of common medical conditions should be completed by the 
participant.
 Reporting standards: Research reports should include docu-
mentation of the specific methods used (interview, physical ex-
amination, questionnaires), the type of individual or individuals 
responsible for the evaluation (physician, psychologist, graduate 
student, etc.), the mean and standard deviation (SD) of the body 
mass index for the sample, specific exclusionary diagnoses, fre-
quency counts of specific comorbid medical conditions, and the 
proportion of individuals having insomnia comorbid with medi-
cal conditions. If sufficiently detailed information is available, the 
proportion of subjects meeting RDC-defined criteria for Insomnia 
due to a Medical Condition should also be reported. 
Evaluation of Medication and Substance Use
 Essential measure: List of current medications (interview, par-
ticipant-generated list). An accurate listing of current medication 
and substance use should be included in all insomnia research re-
ports. Gathering medication information may be aided by asking 
the participant to bring in all current prescription and nonprescrip-
tion medication bottles. Medication and substance use noted on 
sleep diaries may also contribute to accurate information. In addi-
tion to prescription medications, it is also important to investigate 
use of over-the-counter medications, herbal and other “natural” 
products, and supplements. Nonmedicinal substances include caf-
feine (including coffee, tea, soda, and pills), alcohol, tobacco, and 
drugs of abuse. 
 Reporting standards: Research reports should include docu-
mentation of a medication and substance history, specific methods 
used, and the person responsible for collecting this information. 
Exclusionary medications and substances should be indicated. In 
addition, the medications used by participants should be listed 
(grouped by major classes or categories), together with the fre-
quencies of use within the sample. The number or frequency of 
participants using caffeine, alcohol, and tobacco should be noted, 
as well as information regarding the amount used (e.g., mean/SD 
or median/range). 
2. ASSESSMENT OF SLEEP AND INSOMNIA SYMPTOMS 
a. Background and Rationale
 Several well-established methods are available for character-
izing sleep and insomnia symptoms, including questionnaires, 
sleep diaries, PSG, and actigraphy. The assessment of sleep and 
insomnia symptoms can serve several different functions in re-
search studies: to establish or rule out specific insomnia or other 
sleep-disorder diagnoses, to document a severity criterion for 
study entry, to use as a contrast measure for individuals with in-
somnia with a comparison group, and to measure treatment ef-
fects. The utility of a specific method may vary according to the 
intended purpose. 
 Insomnia symptoms are often heterogeneous and may in part 
reflect inadequate sleep duration, quality, or efficiency. A multi-
method approach using multiple measurement systems (ie, sub-
jective, behavioral, physiological) is necessary to adequately cap-
ture these different domains or components of insomnia.13 The 
time frame and number of evaluations may vary according to the 
assessment modality and the type of research questions under in-
vestigation (e.g., epidemiology vs clinical trials). For example, 
a single retrospective measure of sleep disturbances may be ad-
equate for obtaining prevalence estimates, whereas repeated daily 
assessments are often preferable for treatment-outcome measure-
ment. Despite the inevitable discrepancies among subjective, be-
havioral, and physiological assessment modalities, they should be 
seen as complementary, since they provide different perspectives 
on the construct of insomnia.
 Global insomnia symptom questionnaires capture subjective 
aspects of sleep experience, typically over a period of time rang-
ing from 1 week to 1 month. Global questionnaires typically in-
clude evaluations of several different dimensions of the insomnia, 
including quantitative aspects of sleep (e.g., sleep-onset latency 
[SOL], total sleep time [TST], number of awakenings [NWAK], 
wake after sleep onset [WASO]), qualitative aspects of sleep (e.g., 
sleep quality [SQ], sleep depth), and daytime symptoms referable 
to insomnia (e.g., difficulty concentrating, irritability). Numerous 
self-report questionnaires are available to measure clinical fea-
tures of insomnia symptoms and insomnia disorder (for reviews 
see9;13;59). Examples include the Pittsburgh Sleep Quality Index 
(PSQI),60 the Insomnia Severity Index (ISI),30;61 the Athens In-
somnia Scale,62 and the Insomnia Severity Questionnaire.63 Each 
of these has demonstrated insomnia-control differences, changes 
with treatment or both differences and changes.
 Sleep diaries are subjective daily reports of sleep and sleep 
disturbances, typically completed upon arising, to provide an esti-
mate of the previous night’s sleep. Sleep diaries typically include 
measures of bedtime, SOL, NWAK, WASO, terminal wakeful-
ness (TWAK), TST, final awakening time, and sleep efficiency 
(SE). (See Table 2 for definitions of common sleep variables.) 
Diaries also commonly measure SQ or depth, medication use, and 
daytime behaviors, such as napping and caffeine, alcohol, and 
medication use. Means for each variable are usually computed 
based on 1 to 2 weeks of data collection.30;64 Although several 
sleep diaries have been published,30;59;65-68 there is currently no 
standard format.
 Sleep diaries may serve several functions but are most often 
used as a diagnostic tool and a quantitative dependent measure to 
contrast insomnia patients with a comparison group or to assess 
the impact of interventions. As a diagnostic tool, sleep diaries pro-
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vide more-detailed information about quantitative sleep-distur-
bance severity and variability, sleep scheduling, and sleep-wake 
patterns than do most retrospective reports65 and may be less sen-
sitive to recall biases. Diary information may be helpful for estab-
lishing a general insomnia diagnosis and for ruling out circadian 
rhythm disorders.59 Comparisons of sleep diaries with PSG may 
also be useful for identifying objective-subjective mismatches 
suggestive of Paradoxical Insomnia (sleep-state misperception).3;4 
However, sleep diaries in themselves do not completely capture 
the diagnostic criteria for specific insomnia disorders described in 
DSM-IV, ICSD-2, or RDC for insomnia. For instance, sleep-diary 
data from 1 to 2 weeks are not equivalent to 1- to 6-month diag-
nostic criteria, not all diaries evaluate SQ or satisfaction, diaries 
typically do not address the impairment and emotional distress 
associated with insomnia, and diaries cannot address historical 
information needed to establish some insomnia diagnoses.
 Considered as a quantitative dependent measure, sleep-diary 
estimates of sleep parameters yield a reliable and valid index 
of insomnia symptoms even though they do not reflect absolute 
values obtained from PSG.63;64 Individuals with insomnia tend to 
overestimate SOL and WASO and to underestimate TST in com-
parison to PSG measures.64;69 By tracking sleep over several con-
secutive nights (sometimes up to 3 weeks for representative pa-
rameters such as WASO),70 sleep diaries are more likely to capture 
the night-to-night variability that often characterizes the sleep of 
chronic insomnia. As such, sleep diaries may yield a more rep-
resentative sample of an individual’s sleep than 1-time question-
naires or 1 or 2 nights of PSG. 
 One major weakness of sleep diaries is that most forms include 
no validity check to determine whether they were completed on 
the days and times indicated. This potential difficulty can be miti-
gated by using computer-based,71 web-based, or telephone call-
in formats (interactive voice recording system72), which include 
time stamps and accurate identification of missing data. Another 
potential difficulty is that derived variables may be inaccurate. 
For instance, calculating TST based on time in bed (TIB), SL, 
and WASO depends on the accuracy of each variable, and values 
sometimes do not “add up.”
 PSG can also serve a variety of functions but is primarily used 
for screening and quantification of sleep disturbance. Instrumen-
tation and optimal recording methods for this procedure have 
been well described elsewhere in the literature.73-77 In clinical 
practice, PSG is not recommended for routine assessment, dif-
ferential diagnosis, or severity assessment.29 However, PSG is 
useful in research studies to evaluate and quantify other sleep pa-
thologies, such as apnea and periodic limb movements, which are 
often present among individuals presenting with insomnia com-
plaints.35;78;79 PSG may be used to exclude potential participants 
who exceed a certain threshold (e.g., apnea-hypopnea index ≥ 10) 
or simply to characterize the study sample. In the insomnia re-
search setting, PSG has also been used to determine whether par-
ticipants meet specific quantitative criteria, e.g., SOL or WASO 
of more than 30 minutes.80;81
 More generally, PSG sleep measures are used as dependent 
measures to quantify group differences or intervention effects. 
In this context, it is important to distinguish between insomnia, 
which is a disorder defined by a set of symptoms, and sleep dis-
turbances, which refer to quantitative measurements of sleep and 
wake amounts. Patients with insomnia who have PSG-identified 
sleep disturbances are a subset of patients meeting the diagnostic 
criteria for insomnia, ie, a set of self-reported symptoms.29;82-84 
For this reason, PSG cannot serve as the sole outcome measure in 
clinical trials studying insomnia, as defined by standard diagnos-
tic criteria,20 nor should PSG be considered the “gold-standard” 
quantitative measure of insomnia against which other measures 
are judged and validated. Furthermore, PSG is only feasible to 
conduct for 1 to 3 nights in most cases, raising the possibility that 
it may provide insufficient sampling to adequately capture the 
features of insomnia, which may not be present every night. Fi-
nally, the expense and effort involved in PSG make it best suited 
for assessment studies and efficacy trials and may be less appro-
priate for epidemiologic studies and effectiveness trials.
 Several methodologic issues can affect PSG as a quantitative 
measure of sleep disturbance in insomnia. First is whether to use 
data from the first night of PSG study, which is subject to the 
“first-night effect.” Studies vary in their use of data from the first 
night (eg81;85). These data are often used to screen out participants 
if they have other major sleep disorders or if they sleep better 
than entry criteria allow. Second, the number of PSG nights can 
influence the reliability and statistical properties of the derived 
PSG measures.70 Once again, studies vary on the number of PSG 
nights, representing a balance between lower variance with more 
nights and practical matters, such as cost with fewer nights. Av-
eraging 2 nights for each study time point is a common choice.13 
Third is whether to record PSG data in participants’ homes or in 
the laboratory. Home studies do not allow supervised dosing of 
medications, data entry, or other testing, and there is less control 
over the patients’ behavior and environment, which may increase 
data loss and variance in PSG measures.86 During home studies, 
participants do not all spend the same amount of TIB. On the 
other hand, home studies are probably more representative of the 
participants’ typical sleep and sleep-related behaviors, they may 
require less technician time and cost, and they are less influenced 
Table 2—Standard Acronyms and Deﬁnitions of Sleep Measures
Sleep  Abbreviation Deﬁnition
Measure
Number of  NWAK Number of awakenings, excluding the 
Awakenings  ﬁnal awakening before the ﬁnal arising
Sleep Quality SQ Subjective sleep quality, typically 
  deﬁned by responses on an ordinal 
  or visual analog scale
Sleep Efﬁciency  SE Percent of time in bed spent asleep. 
(percentage)  When using sleep diaries, this is 
  calculated from other self-report 
  variables: TST/TIB x 100
Sleep-Onset SOL How many minutes it takes to fall 
Latency  asleep, starting from the moment of 
  intention to fall asleep,
Time in Bed TIB Time in bed, starting from the moment 
  of intention to fall asleep and 
  concluding with the ﬁnal arising
Total Sleep Time TST Actual time slept. When using sleep 
  diaries, this is typically calculated from 
  other self-report variables (TIB–SOL–
  WASO–TWAK)
Terminal  TWAK Amount of awake time between the ﬁnal 
Wakefulness  awakening and the time of getting out 
  of bed
Wake After  WASO Total amount of time awake during the 
Sleep Onset  night, excluding SOL and TWAK
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by “first-night effects.”86 
 A final consideration is whether to employ a fixed TIB or to 
allow participants to choose their TIB, again with variable re-
ports in the literature.12;13 Allowing participants to choose their 
bedtimes is more representative of “usual” sleep and is preferred 
when assessing interventions that seek to manipulate sleep behav-
ior.12;13 However, self-selected bedtimes may increase between-
participant variability in PSG measures and limit the ability to 
identify therapeutic effects. For example, if a medication has the 
effect of decreasing wake time, such an effect could be offset by 
a participant spending more TIB. Using a fixed TIB for PSG en-
sures greater comparability between participants and across time 
points, but it may introduce therapeutic effects of its own (ie, lim-
iting TIB), diminishes ecologic validity, and requires that PSG 
studies be recorded in the laboratory, in order to ensure complete 
adherence prospectively.
 Actigraphy is the measurement of physical movement us-
ing motion sensors, typically in a small device worn on the non-
dominant wrist.87 The devices reliably detect movements and are 
cost-effective. Actigraphy can be used to collect information for 
a period of days to months in the individual’s home environment 
and during normal routines. Actigraphy data can be displayed and 
scored manually or by computer algorithms that give estimates 
of sleep-wake and circadian-rhythm parameters.88 Specific in-
struments vary according to the type of motion detector and the 
nature of the automated algorithms that estimate sleep and wake 
variables based on the measured patterns of activity and inactiv-
ity. As discussed in 3 major reviews88-90 and 2 practice parameter 
papers,91;92 actigraphy provides an objective estimate of sleep and 
the 24-hour sleep-wake rhythm and can detect circadian rhythm 
disturbances. Actigraphy can also be used to identify if patients 
with sleep disorders are being overly active near bedtime or gen-
erally inactive throughout the day.88-92 
 Several methodologic issues must be considered in using actig-
raphy in insomnia research studies. Few studies have compared 
different sensitivity settings, different devices, and different scor-
ing algorithms, raising questions about reliability and validity 
across studies. Although well validated against PSG with normal 
sleepers and in special populations, the sensitivity and specificity 
of actigraphy for identifying sleep-wake patterns in insomnia is 
less compelling. Actigraphy is less reliable for distinguishing be-
tween quiet wakefulness and sleep, and it tends to overscore sleep 
in individuals with insomnia while they are lying quietly waiting 
to fall asleep at the beginning of the night or after awakenings 
from sleep (e.g., Hauri and Wisbey).93 For these reasons, actigra-
phy is most often used in conjunction with other methods, such 
as a diary, to ascertain the time of lights out, time to bed, time out 
of bed, times the device was removed, and times the patient may 
have been sitting still for long time periods (such as sitting in a car 
or at the movies).
 Recent data (Lichstein et al., 2005) validating actigraphy 
against PSG with a large insomnia sample did demonstrate strong 
correspondence between these 2 measures for 4 sleep variables, 
NWAK, WASO, TST, and SE. Validation data for SOL were 
weak. Actigraphic overscoring of sleep remained a problem for 
individuals taking hypnotics. This study signals progress in estab-
lishing the utility of actigraphy as an independent assessment tool 
for insomnia. To repeat the caution above, the results of this study 
are specific to a particular instrument using a particular algorithm. 
Generalization of these results to other combinations of instru-
ments and algorithms remains to be determined.
 Actigraphy, like sleep diaries and PSG, has been used as both 
a screening or diagnostic tool and as a quantitative dependent 
measure. In the clinical setting, actigraphy is not indicated for 
routine diagnosis, assessment of severity, or management of in-
somnia,88;91;92 but it may be a useful adjunctive tool. In the context 
of screening or diagnosis in research studies, actigraphy is poten-
tially useful for screening participants to establish disturbed rest-
activity patterns, examine night-to-night variability, and identify 
individuals with circadian rhythm disorders.88;89 Actigraphy has 
also been used as a quantitative dependent measure in insomnia 
research studies, particularly in treatment-efficacy studies (e.g., 
Friedman et al94), and it may be used as a measure of adherence 
in behavioral treatment studies. The precise role of actigraphy 
for establishing diagnoses or measuring treatment outcomes in 
insomnia research has not been well established. However, it is 
included in this report because of its potential as an objective 
measure of sleep-wake patterns to supplement self-reports and to 
use in situations in which PSG is not feasible.
b. Recommendations for Measures and Reporting Standards
Global Sleep and Insomnia Symptoms
 Recommended/essential measures: (1) PSQI and (2) ISI. The 
PSQI60 is a self-rating scale designed to measure general sleep 
disturbances. It is composed of 4 open-ended questions and 19 
self-rated items (0-3 scale) assessing SQ and disturbances over 
a 1-month interval (although it has also frequently been used to 
evaluate disturbances for the past 7 days). The PSQI evaluates 7 
domains, including SOL, duration, SE, SQ, disturbances, medica-
tion, and daytime dysfunction. A summation of these 7 compo-
nent scores yields a global score of SQ, ranging from 0 to 21, with 
a cutoff score of 5 achieving maximum sensitivity and specificity 
for insomnia.95 The PSQI has excellent psychometric properties, 
and, although it was not specifically designed for insomnia, it has 
been used in numerous assessment and treatment studies of in-
somnia (eg,96-98).
 The ISI30;61 is a 7-item scale assessing the perceived severity of 
insomnia symptoms (initial, middle, late), the degree of satisfac-
tion with sleep, interference with daytime functioning, noticeabil-
ity of impairment, and concern caused by the sleep problem, each 
rated on a 0- to 4-point scale. The usual time frame for responding 
is the last 2 weeks. A composite score is obtained by summing 
up the 7 ratings (total score ranges from 0-28), with a score of 
14 providing the best cutoff to optimize sensitivity and specific-
ity.61;99 The following scoring guidelines can be used for quantify-
ing insomnia severity: score of 0 to 7 (no significant insomnia), 8 
to 14 (subthreshold insomnia), 15 to 21 (moderate insomnia), and 
22 to 28 (severe insomnia). The ISI can be used as a screening 
instrument or as a treatment-outcome measure. Parallel versions 
can also be completed by clinicians and significant others to pro-
vide collateral validation of outcome.
 Reporting standards for the PSQI include specifying the mean 
and SD of the global score for each group and/or time point. De-
pending on the specific research questions, means and standard 
deviations may also be reported for the 7 component scores. Re-
porting standards for the ISI include specifying the mean and SD 
of the total score for each group and/or time point. In clinical tri-
als, it is useful to report percentage of participants scoring within 
the different severity levels.
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Daily Self-Report of Sleep
 Recommended/essential measure: One- to 2-week sleep diary. 
A sleep diary is useful as a screening or diagnostic tool and as a 
quantitative dependent measure. A number of published sleep dia-
ries are available,30;59;65-68 but none of these can be recommended 
as the preferred format. The sleep diary should assess the follow-
ing daily information: times of going to bed, final awakening, and 
arising from bed; SOL; NWAK; WASO (which typically includes 
wake time after sleep onset exclusive of TWAK); TST; SE; SQ; 
and the timing and duration of naps or daytime sleep episodes.
 Reporting standards for sleep diaries include reporting the du-
ration, format, and information assessed in the diary; thresholds 
or quantitative criteria used to establish or confirm an insomnia 
diagnosis; thresholds or criteria used to establish or confirm the 
diagnoses of other sleep disorder (e.g., the average or range of 
sleep times used to support a diagnosis of a circadian rhythm 
sleep disorder); mean and SD of each of the dependent measures 
(see above) in each participant group; and, when feasible, some 
measure of the day-to-day variability of these measures (e.g., av-
erage of the within-subject range, SD, or coefficient of variation 
for key variables).
Objective Sleep
 Recommended/essential measure: Polysomnography. PSG is 
recommended as a screening tool and as a quantitative dependent 
measure. Ideally, 1 night should serve as a screening PSG in order 
to identify and quantify sleep-related breathing disturbances and 
periodic limb movements during sleep. The PSG should use vali-
dated and contemporary measures for sleep-disordered breathing 
(e.g., nasal pressure transducer, thermocouples, inductance pleth-
ysmography, oximetry) and limb movements (bilateral anterior 
tibialis electromyogram), and these should scored according to 
accepted criteria.74;77;100 One or 2 additional PSG nights should 
be conducted to derive quantitative sleep measures. These PSG 
studies would include, at a minimum, 1 centrally derived elec-
troencephalography channel, 2 electrooculogram channels, and 1 
bipolar electromyogram channel. Sleep stages should be scored 
in epochs of 20 or 30 seconds and scored according to standard 
criteria.101
 Reporting standards for PSG include a description of the PSG 
protocol and procedures; specification of the apnea-hypopnea 
index73;77 and periodic limb movement index (with and without 
arousal)74;75 used to establish study eligibility or diagnoses; speci-
fication of group mean apnea-hypopnea index and periodic limb 
movement index associated with arousals; specification of other 
PSG criteria for study eligibility (e.g., a threshold for SOL, TST, 
or WASO); actual sleep times, whether times were fixed by the 
protocol or based on participants’ preferred or habitual times, 
and how habitual times (if any) were determined; total recording 
time; SOL, NWAK, WASO, TWAK, TST, and SE. If two night are 
collected, data from each night should be reported separately; if 
more than two night are recorded, data should be reported for the 
first night individually and the other nights as an average. Means 
and SDs (in original time units) should be reported for each study 
group but may be supplemented by median, range, or other ap-
propriate measures.
Rest-Activity Pattern 
 Recommended/essential measure: Actigraphy. Actigraphy is 
recommended as an objective measure of sleep as indicated by 
rest-activity patterns, both as a screening measure and as a quan-
titative dependent measure. Actigraphy may be useful for studies 
in which PSG may not be feasible. At least 1 of these objective 
measures should be used whenever feasible. Actigraphy should 
be collected for a minimum of 3 consecutive 24-hour periods,102 
and preferably for 1 to 2 weeks, using a validated device. Raw 
data should be inspected, and validated scoring algorithms used. 
Epoch lengths up to 1 minute are usually adequate.
 Reporting standards for actigraphy include description of the 
make and model of device used; the type and version of scor-
ing software used; the specific clinical protocol for actigraphy; 
thresholds or quantitative criteria used to establish or confirm 
an insomnia diagnosis; thresholds or criteria used to establish or 
confirm the diagnoses for other sleep disorder (e.g., the average 
or range of sleep times used to support a diagnosis of a circadian 
rhythm sleep disorder); mean and SDs across the measurement 
interval for sleep onset and offset times, SOL, NWAK, WASO, 
TST, and SE. When feasible, it is also recommended that research 
reports include data on internight variability within subjects for 
key measures (e.g., average of the within-subject range, SD, or 
coefficient of variation). Note that SOL can only be determined if 
time of “lights out” is reliably recorded. Therefore, the method of 
identifying “lights out” should be specified, whether by actigraph 
event marker, diary, or other means.
3. WAKING CORRELATES AND CONSEQUENCES OF INSOMNIA 
a. Conceptual Background and Rationale 
 The clinical disorder of insomnia includes complaints of im-
paired daytime functioning, as well as sleep problems. Reported 
daytime impairments typically include fatigue, problems with 
cognitive or mental abilities (e.g., attention, concentration, mem-
ory), mood disturbances or, more generally, reduced quality of 
life (QoL). In fact, the RDC4 for insomnia disorder require some 
evidence of functional daytime impairments. 
 Assessment of the correlates and consequences of insomnia 
rely on subjective, self-rated measures, as well as on more ob-
jective and standardized neurobehavioral performance measures. 
Although insomnia symptoms are commonly associated with 
subjective reports of daytime impairments,103 there is much more 
limited evidence documenting a causal relationship.10 Indeed, 
just as there are significant discrepancies between subjective and 
objective measures of sleep-wake parameters, there are also sig-
nificant discrepancies between subjective and objective deficits 
of neurobehavioral performance.104;105 Whether such discrepan-
cies are due to a faulty appraisal mechanism, poor measurement 
sensitivity, or other factors is largely unknown. Nonetheless, such 
correlates or consequences represent important targets in the as-
sessment of insomnia because of their prevalence and salience to 
patients.
 Insomnia-Related Behavioral, Cognitive, and Arousal Fac-
tors. Physiologic and cognitive arousal, maladaptive behaviors, 
and specific beliefs and attitudes may serve as predisposing or 
perpetuating factors in chronic insomnia.106 Measures of these fac-
tors may therefore serve as valuable indicators of etiology or im-
portant moderating or mediating factors for treatment outcomes. 
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Self-report instruments that assess arousal, behaviors, and cogni-
tions relevant to insomnia include the Dysfunctional Beliefs and 
Attitudes About Sleep Scale (DBAS),107;108 the Pre-Sleep Arousal 
Scale,109 the Sleep Hygiene Awareness and Practices Scale,110 the 
Ford Insomnia Response to Stress Test,111 the Arousal Predisposi-
tion Scale,112;113 and Regestein’s Hyperarousal Scale.114;115 Arousal 
can also be assessed in physiologic terms with measures such as 
plasma or salivary cortisol116;117 to assess hypothalamic-pituitary 
axis activation; heart-rate variability to assess sympathovagal 
tone118; whole-body metabolic rate119;120; power spectral analysis 
of the waking or sleep electroencephalogram121-123; and functional 
neuroimaging, e.g., [18F]-fluoro-deoxyglucose positron emission 
tomography scans124;125 or single photon emission computed to-
mography.126
 Most measures of this sort, whether self-report or physiologic, 
are relatively narrow with respect to the particular construct they 
assess. Furthermore, the physiologic measures are often expensive 
or difficult to measure or require expertise not widely available. 
For these reasons, measures of this sort are not well suited for 
general use across a range of insomnia studies and are not recom-
mended for routine use. Nevertheless, these measures are encour-
aged in insomnia studies that address specific research questions, 
e.g., arousal in insomnia patients versus controls, or changes in 
arousal with treatment.
 Fatigue and sleepiness. Fatigue and sleepiness have been con-
sidered to be either synonymous, different states on a continuum, 
or fundamentally different concepts. For purposes of defining 
insomnia research guidelines, they will be treated as 2 distinct 
states. Fatigue is defined as a subjective feeling of physical and/
or mental weariness or tiredness but is not necessarily associated 
with increased sleep propensity.127 Fatigue is a common complaint 
among individuals with insomnia, compared with good sleepers 
(e.g., 2;103;128-132), and may be particularly important for insomnia 
characterized by nonrestorative sleep. The 2 most widely used 
and validated scales are the Fatigue Severity Scale (FSS)133 and 
the Multidimensional Fatigue Inventory (MFI).134 Several re-
cently described fatigue scales warrant further testing in insomnia 
samples. FACES129 is a 50-item questionnaire consisting of 5 sub-
scales (fatigue, energy, consciousness, energized, and sleepiness), 
which have been distinguished in insomnia patients. The Tired-
ness Symptoms Scale135 is a 14-item self-report scale describing 
physical and mental symptoms of tiredness. This scale also differ-
entiates fatigue versus sleepiness in control participants, patients 
with insomnia, patients with narcolepsy, and patients with sleep 
apnea.
 Sleepiness represents the actual tendency or propensity to sleep 
and can be measured subjectively with rating scales and objec-
tively with the Multiple Sleep Latency Test (MSLT). Subjective 
sleepiness has been demonstrated less commonly than fatigue 
in patients with insomnia.1;103;135 A majority of studies using the 
MSLT have shown no significant difference between patients 
with insomnia and control subjects, and approximately half have 
actually demonstrated increased mean MSLT values (ie, reduced 
objective sleepiness) among those with insomnia, suggesting 
heightened alertness rather than increased sleepiness.119;136-147 
However, in a review of studies prior to 2000,10 7 of 12 studies 
using the Stanford Sleepiness Scale found significantly greater 
self-reported sleepiness in patients with insomnia as compared 
with controls, and other studies have shown that approximately 
20% of individuals with insomnia may have elevated subjective 
or objective sleepiness.103;148 This suggests that some subgroups of 
patients with insomnia have increased sleepiness and that self-re-
port and objective measures may provide different results, much 
as they do in terms of nighttime sleep. 
 Mood: Depression and Anxiety. A strong relationship be-
tween insomnia symptoms and depression and anxiety symptoms 
has been documented in numerous epidemiologic1 and clinical10 
studies. Insomnia symptoms are 1 of the diagnostic criteria for 
several mood and anxiety disorders,20 and insomnia “secondary” 
to mood disorders is the most common single diagnosis among 
patients with chronic insomnia in the general population149 and in 
clinical samples.150 Minor mood disturbances in categories such 
as depression, anxiety, and irritability are commonly reported 
by patients with insomnia.103 A number of studies have assessed 
mood disturbances among patients with insomnia compared with 
control participants, but findings have been inconsistent due to 
differing methodologies. For instance, some studies specifically 
excluded individuals with clinical depression before comparing 
insomnia and control samples, whereas others did not; the latter 
studies generally find evidence for increased depression and anxi-
ety scores among the insomnia sample.10 The choice of specific 
scales has also differed. The Minnesota Multiphasic Personality 
Inventory151 was widely used in a number of early studies but has 
been less commonly used recently, whereas scales such as the 
Beck Depression Inventory152 have become more widely used in 
recent years. The BDI presents some limitations in older adults 
because physical and neurovegetative symptoms may be com-
monly experienced as a consequence of aging itself. Therefore, 
the Geriatric Depression Scale153 is widely used in studies of older 
depressed adults. Many rating scales of depression and anxiety 
symptoms include items on sleep disturbance that may contribute 
to elevated total “mood disturbance” scores.
 Psychomotor and cognitive performance. Individuals with 
insomnia commonly report impaired performance on daytime 
tasks, particularly those requiring concentration, sustained atten-
tion, and creative thinking.103 Improvements in subjective ratings 
of concentration and performance have been demonstrated with 
treatment.72 However, there is currently no standard or validated 
format for measuring or reporting patients’ self-rated concentra-
tion or psychomotor performance. Furthermore, as is the case 
with night-time sleep and daytime sleepiness, self-reports and 
objective measures often show substantial discrepancies.
 Cognitive and psychomotor performance can be objectively 
measured and quantified. Because individuals with insomnia 
complain of reduced sleep amount, most insomnia studies have 
sought to identify deficits in cognitive performance similar to 
those found following partial or total sleep deprivation (for re-
views, see10;11). These tests can be grouped into general catego-
ries, including reaction time, vigilance or attention, motor func-
tion or coordination, verbal memory, mathematical reasoning, 
logical reasoning, and memory. However, published reviews 
demonstrate worse performance among patients with insomnia 
in only a minority of studies (approximately 10%-25%). The low 
number of statistically significant findings could indicate that 
performance is not impaired by insomnia, that the tests have not 
been sensitive enough to detect subtle differences in the measured 
domains, or that relevant performance dimensions have not been 
assessed. Even considering significant differences in test results 
across studies, findings have not been consistent. For example, 
significant differences in digit span were found in 1 of 2 studies, 
Standard Research Assessment of Insomnia—Buysse et al
SLEEP, Vol. 29, No. 9, 2006 1166
short-term memory in 2 of 6 studies, long-term memory in 1 of 2 
studies, vigilance in 1 of 5 studies, choice reaction time in 1 of 3 
studies, and continuous performance in 1 of 4 studies reviewed. 
Insomnia patients had significantly worse balance in both of 2 
studies reporting the variable,154;155 which may be important in 
light of recent findings demonstrating that insomnia is a risk fac-
tor for falls and hip fractures in the elderly.156
 Overall, results of psychomotor and cognitive performance 
testing in insomnia are not consistent with the changes one would 
expect from sleep deprivation. One potential explanation is that 
objective performance impairment exists in patients with insom-
nia but is masked by elevated levels of arousal. An alternative 
explanation is that psychomotor performance impairments can 
be “unmasked” only with more-sensitive testing protocols. For 
instance, in a recent study using the constant-routine protocol, 
Varkevisser and Kerkhof demonstrated substantial performance 
decrements in insomnia participants, compared with control par-
ticipants, across a number of domains,157 even though convincing 
evidence of hyperarousal was not demonstrated. 
 Given the current state of knowledge, no specific psychomotor 
or cognitive-performance measure can be recommended for rou-
tine use in insomnia studies. However, the identification of per-
formance measures sensitive to the effects of insomnia remains a 
high research priority. When using psychomotor and cognitive-
performance measures, investigators should specify the exact 
measures used, the testing protocol, and data including means and 
SDs for each study group and each assessment time.
 QoL and global function. QoL is a construct with varying 
definitions, most of which include dimensions such as psycho-
logical health, physical well-being, occupational fulfillment, fa-
milial/social satisfaction, and standard of living. QoL instruments 
can be divided into 3 types: the first and broadest in scope were 
developed for use in general populations; a second set have been 
designed to assess health-related QoL in particular, with some of 
these (e.g., Nottingham Health Profile, Sickness Impact Profile) 
including items on sleep or related domains; a third set assesses 
disease-specific health-related QoL. Two sleep-related QoL in-
struments geared toward apnea and sleepiness have been devel-
oped and validated.158;159 The frequent coexistence of psychiatric 
and medical conditions with chronic insomnia provides a major 
challenge for the development of an insomnia-specific QoL mea-
sure.
 The most frequently used QoL questionnaire in insomnia stud-
ies is the Medical Outcomes Study Short Form-36 (SF-36).160;161 
Population- and disease-specific norms are available and provide 
the possibility of cross-disease comparisons. Most studies in in-
somnia have shown differences between insomnia samples and 
control or normal subjects on multiple scales of the SF-36. How-
ever, there is insufficient evidence to determine whether this in-
strument is sensitive to treatments for insomnia. Two disease-spe-
cific QoL scales for insomnia have been published. The Quality 
of Life in Insomniacs Scale (QOLI)162 has been described in two 
publications and awaits further validation. More recently, initial 
description and validation of the Hotel Dieu-16 (HD-16)163 scale 
has been presented; once again, it awaits further validation.
 Another means of assessing QoL is to assess job performance or 
success in patients with insomnia compared with controls, but few 
data are available on this topic. One study found that self-reported 
poor sleepers in the Navy received significantly fewer promo-
tions and were less likely to be recommended for reenlistment.164 
Questionnaire studies have shown that patients with self-reported 
insomnia report consequences at work, including significantly 
more errors, significantly more accidents, and poor efficiency.165 
Healthcare utilization has also been reported to be higher among 
patients with insomnia than patients without insomnia.166 To our 
knowledge, no psychometrically validated instruments have been 
applied to assess healthcare utilization, accidents, and absentee-
ism in insomnia. 
b. Recommendations for Measures and Reporting Standards
 Insomnia-related behavioral, cognitive, and arousal fac-
tors. As discussed above, the relatively narrow focus and/or ex-
pertise required renders these measures unsuitable for routine use. 
However, their use is encouraged in appropriate research studies. 
When such measures are used, it is recommended that investiga-
tors describe the actual instruments used and present data, includ-
ing group means and SDs, to permit comparisons with other stud-
ies.
Fatigue
 Recommended/essential measures: (1) FSS or (2) MFI. The 
relatively small number of insomnia studies using validated 
measures makes it difficult to recommend a single instrument. 
Given their widespread use among patients of different types 
and substantial validation data, the FSS133 or the MFI134 should 
be used in insomnia research studies. The FSS is a 9-item self-
report scale, with each item scored on a scale of 1 (strongly dis-
agree) to 7 (strongly agree); higher scores indicate greater fatigue. 
It has good internal consistency as indicated by a Cronbach α 
coefficient of 0.8; good test-retest reliability, as indicated by a 
correlation coefficient of 0.84; and sensitivity to change in clini-
cal state. Strengths of the FSS include its simplicity and brev-
ity. Consistent differences have been identified between patients 
with insomnia and control participants, indicating higher levels 
of fatigue among patients. Lichstein and colleagues128 have used 
a cutoff score of 5.5 as an indicator of impaired daytime function 
among patients with insomnia, representing 1 SD below the mean 
for treatment-seeking insomnia patients. Weaknesses of the FSS 
include the small number of studies that have used the instru-
ment; questionable validity, since every item includes the word 
“fatigue” without defining the term; and absence of a multidi-
mensional structure. The MFI is a 20-item self-report instrument 
with 5 empirically defined subscales representing dimensions of 
general fatigue, physical fatigue, mental fatigue, reduced motiva-
tion, and reduced activity.134 Individual items are rated on a 1 to 5 
scale, indicating how well that statement describes the respondent, 
with anchors of “Yes, that is true (1)” to “No, that is not true (7).” 
The MFI has good internal consistency, with an average Cron-
bach α coefficient of 0.84. Scores for the 5 scales are obtained 
by adding individual items and range from a minimum score of 
4 to a maximum score of 20. No global score is obtained from 
the MFI, but, when a single score is needed, the General Fatigue 
scale is recommended. Construct validity has been evaluated with 
known-groups comparisons and convergent validity supported by 
correlations with other fatigue measures. The MFI has been well 
validated in studies of various medical disorders, but it has been 
used in only a single study of insomnia.167
 Reporting standards. For the FSS, mean and SD for the total 
score should be reported for each study group and each assess-
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ment point. For the MFI, mean scores and SDs for the 5 subscales 
should be reported for each study group and each assessment 
point.
 Sleepiness. Physiologic sleepiness has not been consistently 
demonstrated in patients with insomnia, although it may be pres-
ent in subgroups, such as those with comorbid medical insom-
nia and older adults. Given the current state of the evidence, no 
specific measure of sleepiness is recommended for routine use 
in insomnia studies. However, when a specific study design calls 
for measurement of subjective sleepiness, the ESS168;169 is the pre-
ferred self-report measure of sleepiness, and the MSLT170 is the 
preferred physiologic measure of sleepiness. Neither measure is 
specifically designed to assess sleepiness in individuals with in-
somnia, and each has substantial limitations. The ESS has an in-
determinate time frame, and answers to the specific items depend 
on the respondent actually being exposed to a particular situa-
tion. The MSLT, on the other hand, provides an estimate of physi-
ologic sleep propensity on a specific day, which may be affected 
by recent events, sleep-wake history, and the specific instructions 
given. Despite their limitations, the ESS and MSLT are the most 
widely used measures of sleepiness and, until new metrics are de-
veloped and validated, the most appropriate measures for sleepi-
ness. Reporting standards include description of the testing pro-
tocol for the MSLT and presentation of mean and SD values for 
each study group and each assessment point.
Mood (Depression and Anxiety)
 Recommended/essential measures: (1) BDI-II or Inventory of 
Depressive Symptomatology Self-Report (IDS-SR); 2) Trait por-
tion of the STAI (STAI-T). The strong association of insomnia 
with depressive and anxiety symptoms and the frequent report-
ing of minor mood disturbances in insomnia patients justify the 
routine inclusion of depression and anxiety measures in insomnia 
research studies. The BDI171 is the most commonly used self-re-
port depression measure in insomnia studies, but the BDI-II has 
more favorable psychometric properties. New items bring the 
BDI-II in compliance with DSM-IV criteria for major depression, 
compared with the original version of the BDI. The BDI-II is a 
21-item scale; the items are each rated on a 4-point scale ranging 
from 0 to 3 and summed to give a single score. A total score of 
0 to 13 is considered minimally depressed, 14 to 19 is consistent 
with mild depression, 20 to 28 with moderate depression, and 29 
to 63 with severe depression. The IDS is available in both cli-
nician-administered (IDS-C) and self-report (SR) versions. The 
IDS-SR is recommended for insomnia studies. The IDS-SR is a 
30-item scale with each item rated on a 4-point scale ranging from 
0 to 3, with higher scores indicating more severe depression. It 
has strong psychometric properties, including high internal con-
sistency, significant correlation with other measures of depression 
severity, and sensitivity to change.172-174 The IDS-SR covers all 
symptom domains in the diagnosis of DSM-IV major depressive 
episode and also assesses melancholic and atypical symptoms. A 
brief version of the IDS-SR (16 items) has also been validated.174 
As noted above, the Geriatric Depression Scale may be preferable 
in some studies of older adults.
 The STAI175 is the most widely reported self-report anxiety 
instrument in insomnia studies. The STAI measures anxiety as 
both a current state (“feeling right now”) and an enduring trait 
(“generally feel”), each evaluated with 20 items scored on a scale 
of 0 (“not at all”) to 3 (“very much so”). The trait portion of this 
instrument (STAI-T) is recommended for use in insomnia re-
search studies. Scores for trait anxiety range from 20 (mild) to 80 
(severe) and are obtained by adding individual item scores. Psy-
chometric data for test-retest reliability and internal consistency 
have been described, and convergent validity has been measured 
against other anxiety rating scales. 
 Reporting standards for the BDI-II, IDS-SR, and STAI-T in-
clude presentation of mean scores and SDs for each study group 
and each assessment point. Because these instruments include 
sleep items that contribute to the score, it is recommended that 
publications report the total scores as well as scores excluding 
sleep items.
 Psychomotor and cognitive performance. As discussed 
above, the lack of consistency of findings in the literature pre-
vents a recommendation for any single psychomotor or cognitive-
performance measure in insomnia. However, further investigation 
of such measures is strongly encouraged, and identification of 
specific performance deficits associated with insomnia is a high 
research priority. When included, measures of this sort should be 
described in sufficient detail to permit replication and compari-
sons across studies. This would include reporting of the specific 
measure, time of testing, test protocol, and the means and SDs for 
all study groups and assessment points. 
Health-Related Quality of Life
 Recommended/Essential Measure: SF-36.160;176 The SF-36 in-
cludes 36 self-report items regarding daytime functioning and 
items are grouped into 8 dimensions, each scored from 0 to 100, 
with higher scores indicating better function. Population norms as 
well as disease-specific norms for the 8 dimensions are available 
and permit cross-disease comparisons. Further research using in-
somnia-specific QoL instruments is strongly encouraged. 
 Reporting Standards. Research reports should include mean 
scores and SDs for each study group and each assessment point 
on the 8 SF-36 scales.
DISCUSSION
 Insomnia research has accelerated in recent years, due to new 
developments in epidemiology, diagnosis and classification, 
pathophysiology, and therapeutics. In the midst of this bourgeon-
ing insomnia research, it is crucial for investigators to have com-
mon metrics for describing insomnia participants and research 
outcomes. These tools will allow investigators and clinicians to 
evaluate the results of specific studies as well as results across 
different studies. The recommendations presented here represent 
a first step in the direction of greater standardization of insomnia 
research assessments. We have recommended standard research 
assessments and reporting standards in 3 key areas: diagnosis of 
insomnia and comorbid conditions; assessment of sleep and in-
somnia severity; and assessment of waking correlates and conse-
quences of insomnia.
 The intention of these recommendations is to provide greater 
standardization across insomnia research studies. Therefore, we 
recommend that all future insomnia studies under development 
make provisions for including these measures. For studies cur-
rently being conducted and reported, we recommend that investi-
gators report as many of the recommended measures as possible, 
based on the actual protocol. In many cases, investigators may 
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have similar measures covering the domains specified above, if 
not the specific measures recommended. In this case, we recom-
mend that the reporting standards advocated above be applied to 
those similar measures. In particular, by providing mean and vari-
ance measures for each participant group at each measurement 
point, investigators can ensure that subsequent quantitative analy-
ses will make use of the greatest possible number of studies. The 
recommendations in this paper are intended to be adopted volun-
tarily by researchers in order to improve the quality of research 
being conducted and reported. However, they are not intended 
to determine suitability or acceptability of any specific report for 
publication or for funding.
 The recommendations in this paper are intended for use in re-
search studies and not as guidelines for clinical care. Although cli-
nicians may find that several of these recommendations will help 
to better characterize their patients and treatment outcomes, they 
should not be taken as substitutes for a thorough initial clinical 
evaluation or for clinical judgment during a course of treatment.
 Even in research practice, these recommendations are intended 
only as a minimum set of assessments to standardize reporting. 
Additional study-specific assessments not only are reasonable, 
but are actively encouraged. Such assessments, together with the 
standard ones, are an important method for advancing our un-
derstanding of insomnia. For this reason, we recognize that the 
current recommendations will need to be modified over time as 
additional data become available. We may find that some of the 
recommended assessments do not substantially improve our un-
derstanding of insomnia and its treatment, and we may also find 
that other assessments prove more useful. The specific method-
ologies related to each assessment type are also likely to improve 
over time. 
 The recommendations in this paper are presented in categories 
for 4 types of insomnia research. As noted in the Introduction, we 
recognize that these 4 categories are not, in reality, completely 
distinct. Many investigators, in seeking to increase the relevance 
of research to clinical care, attempt to balance controls for internal 
consistency with the need for generalizable results. This can lead 
to “efficacy studies” that also have elements of “mechanism” or 
“effectiveness” studies. Such hybrid designs can be highly infor-
mative and can help to bridge our understanding across research 
domains. Thus, our recommendations for the 4 types of research 
studies should not be taken in overly literal terms; hybrid stud-
ies should include a reasonable mix of assessments described for 
each prototype.
 The most controversial measure in the development of these 
recommendations was actigraphy. We recognize that the role of 
actigraphy is not well defined at present, and some of the contrib-
utors thought that it should not be presented as a recommended or 
essential measure. We have included it here for 2 major reasons. 
First, despite its limitations, actigraphy is 1 of only 2 available 
measures for objective sleep-wake measurements. Its ease of use 
makes it more feasible than PSG in many research settings, partic-
ularly large intervention studies. Second, we expect that ongoing 
studies will better define the validity of actigraphy in insomnia 
research samples. The potential utility of this method warrants its 
recommendation despite relatively little supporting evidence at 
this time.
 Development of these recommendations points to several im-
portant directions for future research. Among the most pressing 
needs are:
• Development and testing of standardized insomnia diagnos-
tic instruments. Although several research groups utilize and 
have published insomnia diagnostic interviews, these have 
not included fully structured formats along the lines of the 
SCID, and they have not been written to provide specific 
ICSD-2 diagnoses. Even less work has been devoted toward 
developing a structured interview or standardized assessment 
techniques for common sleep disorders that enter the differ-
ential diagnosis for insomnia. Structured interviews can be 
developed for sleep disorders.32 However, an ICSD-2–based 
instrument will require careful assessment of sensibility to 
participants, training requirements, ease of use for interview-
ers, and interrater reliability and validity.
• Development and testing of a standardized sleep diary. Al-
though sleep diaries are considered the gold standard for 
subjective assessments of sleep, there is currently no single, 
widely accepted format. It is a very high priority for the 
field to develop and gain consensus on such an instrument. 
Although this would appear not to be very difficult at first 
glance, a number of important design elements need to be 
considered. For instance, it will be important to consider: 
how to account for “dozing” time in the evening; whether 
and how to distinguish the time a person goes to bed from the 
time they actually try to sleep; whether to calculate TST and 
WASO from other variables, or to ask subjects directly for 
these values; whether to define SE from total TIB, or from 
intended sleep time.
• Development of neurobehavioral or cognitive measures 
sensitive to insomnia deficits. Identifying consistent mea-
surable effects of insomnia on neurobehavioral function is 
important for a number of reasons. First, it would help to 
characterize the disorder more fully and to measure sever-
ity in a functional domain. Second, it would help to develop 
and test hypotheses regarding etiology. Third, it could have 
utility as an outcome measure in treatment studies. Widely 
used measures such as the psychomotor vigilance task (e.g., 
177;178) should be investigated more thoroughly in insomnia 
disorder, given their sensitivity to sleep loss, circadian phase, 
and individual variation (e.g., 179). However, as noted above, 
such measures rely on the conceptualization of insomnia as 
a form of sleep loss, which may not be the case. Therefore, 
novel measures or measurement strategies based on different 
theoretical models (e.g., hyperarousal) remain a high prior-
ity.
• More-sensitive objective measures of insomnia disorder. 
Insomnia is currently a diagnosis based entirely on clinical 
history and subjective symptoms. Furthermore, an enduring 
puzzle of insomnia diagnosis is the frequent discrepancy be-
tween subjective and objective sleep reports as measured by 
traditional PSG. Although various cognitive and physiologic 
theories have been proposed to explain this discrepancy and 
the pathophysiology of insomnia in general; there is current-
ly no widely accepted objective measurement of insomnia. 
Although it is by no means clear that such a measure can be 
identified, some potential candidates should be further as-
sessed. These include measures such as quantitative electro-
encephalography (power spectral analysis), heart-rate vari-
ability during sleep, and endocrine measures (e.g., cortisol).
• Multisite studies of instrument reliability and validity. In or-
der to maximize the utility of diagnostic and assessment in-
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struments being developed, they should be subjected to test-
ing across centers. An insomnia research network would be 
ideal to develop instruments, test their reliability within and 
across sites, and establish their validity. Unfortunately, such 
a network currently does not exist.
 These recommendations represent a first step toward greater 
standardization in insomnia research. Implementation of these 
recommendations will undoubtedly lead to further refinements of 
research practice and, hopefully, toward better understanding of a 
health condition that affects millions of individuals worldwide.
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Patients with Primary insomnia often experience intrusive, worri-
some cognitive activity in the pre-sleep period. Metacognitive be-
liefs may explain this yet no valid reliable scale exists. The present
study, therefore, developed the Metacognitions Questionnaire –
Insomnia (MCQ-I). Following initial metacognitive insomnia proﬁl-
ing interviews, item reﬁnement produced a preliminary 60-item
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1.1. Deﬁning primary insomnia
Primary insomnia disorder involves difﬁculty initiating and/or maintaining sleep despite adequate
opportunity, in the absence ofmedical/psychiatric causes. Found in 1–2% of the general population, and
12–15% of sleep centre patients, primary insomnia is a known, independent risk factor for depressionfax: þ44 141 944 8867.
k (N.M. Broomﬁeld).
td. All rights reserved.
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erable, with fatigue, cognitive impairments and poor motivation commonly reported.
Whilst there is considerable evidence for efﬁcacy of cognitive behavioural therapy in ameliorating
primary insomnia (Morin, Culbert, & Schwartz, 1994; Murtagh & Greenwood, 1995; Smith et al., 2002),
there remains a lack of research pinpointing how speciﬁc cognitive processes might interact, to main-
tain the disorder (Broomﬁeld, Gumley, & Espie, 2005). One developing area of interest is mechanisms
that fuel intrusive and worrisome cognitive activity (Harvey, 2005a).
1.2. Pre-sleep intrusive and worrisome cognitions in primary insomnia
Intrusions are spontaneously occurring, non-volitional thoughts associated with negative affect and
which are difﬁcult to control (Clark and Rhyno, 2005). Intrusions are likely to persist if appraised as
threatening and receive attention focus, and at such times are experienced as worry and/or rumination
(Harvey, 2005a).
There is widespread acceptance that intrusive thinking at bedtime characterises primary insomnia
(e.g. Borkovec, 1982). Reports of mental events disrupting sleep are common place at clinic: ‘‘my mind
keeps racing’’. In research studies, this is conﬁrmed. Primary insomnia patients describe their pre-sleep
thoughts as intrusive, uncontrollable and negative (Harvey, 2000; Kuisk, Bertelson, &Walsh,1989), and
attribute sleeping difﬁculties to intrusions (Broman & Hetta, 1994; Espie, Brooks, & Lindsay, 1989; Lich-
stein & Rosenthal, 1980; Nicassio, Mendlowitz, Fussell, & Petras, 1985). Moreover, experimentally
induced cognitive intrusions delay sleep onset, in good and poor sleepers (Ansﬁeld, Wegner, &
Bowser, 1996; Gross & Borkovec, 1982, Hall, Buysse, Reynolds, Kupfer, & Baum, 1996).
Despite this evidence, theoretical explanations for why intrusive pre-sleep thinking characterises
primary insomnia remain lacking.
1.3. The Self-Regulatory Executive Function (S-REF) model
One possible explanatory model is Wells’ Self-Regulatory Executive Function (S-REF; Wells, 2000;
Wells & Matthews, 1994, 1996). According to Wells, S-REF is switched on when there is a threatening
discrepancy between the perceived self-state and the ideal state; for example, wakefulness when the
desired goal is sleep. Critically, at the automatic processing level, physical (body state) as well as cog-
nitive and external information is intrusive. So for the sleep-disturbed individual awake at bedtime,
noise, thoughts about sleep, planning and being awake can all be intrusive (in theory) and thus lead
to processing of the self as a wakeful person (cf. Wells, 2000).
S-REFmay, therefore, account theoretically for the occurrence of persistent intrusive thinking in pri-
mary insomnia: wakefulness being a particularly salient intrusion to primary insomnia sufferers at
bedtime, given their desired goal of sleep. Two metacognitive belief types should operate within
S-REF in response to such intrusions: (i) beliefs concerning the meaning of the intrusions (e.g. thinking
in bed prevents me getting to sleep) and (ii) plans that guide and shape the form that cognition takes
(e.g. before I fall asleep, I should try and switch off my thoughts). We have argued elsewhere these be-
lief types and their associated action plans e.g. thought control strategies, sleep effort, attention bias/
focus should characterise insomnia (Broomﬁeld et al., 2005). Importantly, although pre-sleep cognitive
activity may not always be experienced as intrusive (e.g. Wicklow & Espie, 2000), any stimulus may do
so if it clashes with a person’s metacognitive beliefs, thereby triggering S-REF processing to reach
a mental state more conducive to sleep e.g. a calmer mind.
1.4. Evidence for S-REF and primary insomnia
Several lines of evidence support metacognitive beliefs and associated action plans as characterising
primary insomnia. First, we know primary insomnia patients engage in a range of thought control
strategies at night. These include reappraisal, worry, thought suppression and punishment (Ellis &
Cropley, 2002; Harvey, 2001; Ree, Harvey, Blake, Tang, & Shawe-Taylor, 2005). These strategies are
likely to fuel further intrusions (Wegner, 1994) and maintain sleep disturbance. Primary insomnia pa-
tients also endorse more positive belief statements about worry (Harvey, 2003a).
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trol sleep onset (Broomﬁeld & Espie, 2005), and selectively attend to salient internal and external
threat cues. Both questionnaire based (Semler & Harvey, 2004a) and experimental work (e.g. Espie,
Broomﬁeld, MacMahon, & McPhee, 2006; Jones, Macphee, Broomﬁeld, Jones, & Espie, 2005; Marcetti,
Biello, Broomﬁeld, MacMahon, & Espie, 2006) conﬁrm the latter.
Finally, thought control, sleep effort and attention bias/focus have all been linked to delayed sleep
onset latency (SOL) (Ansﬁeld et al., 1996; Harvey, 2003a; Semler & Harvey, 2004b). Such cognitive ‘ac-
tion plans’ feature in the metacognitive S-REF hierarchy (Wells, 2000), and support metacognitive be-
lief structures as guiding intrusion appraisal.
1.5. Aim of present study
Metacognition has received very little attention in the insomnia literature. No scale exists which can
directly assess presence of metacognitive beliefs. The aim of this exploratory study was, therefore, (i) to
explore the presence of metacognitive beliefs in primary insomnia, (ii) to develop a metacognitive be-
liefs of primary insomnia questionnaire and, (iii) to gather initial data on psychometric properties of
the scale, using primary insomnia and normal sleeping participants. The exploratory nature of the
work meant we did not identify ﬁrm hypotheses.
2. Methods and results
Methods and results are combined, for the purposes of clarity.
2.1. Stage one: derivation of items for the questionnaire
2.1.1. Rationale
Metacognition is under-researched in primary insomnia. Therefore, initially, ﬁeld interviews with
individuals with primary insomnia and normal sleepers were conducted to gain direct insight into sa-
lient metacognitive beliefs held by poor sleepers, and to develop a preliminary item pool.
2.1.2. Participants
Participants for ﬁeld interviews were recruited via University e-mail. Individuals with ‘difﬁculties
sleeping at night’ or ‘good sleepers’, interested in assisting sleep research, and between 16 and 65 years
old, were asked to contact the investigator and given information and consent forms.
Primary insomnia participants were not treatment seeking per se, but met strict research diagnostic
criteria for primary insomnia disorder (Edinger et al., 2004): (i) difﬁculty initiating and/or maintaining
sleep or non-restorative sleep (ii) with at least one associated daytime impairment (iii) for at least 1
month (iv) in the absence of a sleep disruptive medical/psychiatric condition, substance abuse
(v) and/or other sleep disorder. Primary insomnia participants also had to complain of sleep difﬁculties
at least three nights a week (Morin, 1993) and report a minimum SOL of >30 min on these nights. This
follows clinical convention for diagnosing primary insomnia sleep onset type (Morin & Espie, 2003). All
primary insomnia participants scored >6 on the Pittsburgh Sleep Quality Index (PSQI; Buysse, Rey-
nolds, Monk, Berman, & Kupfer, 1989). Scores over 5 on PSQI reliably identify clinically signiﬁcant sleep
disturbance with 90% sensitivity and 87% speciﬁcity (Buysse et al., 1989). Additionally, participants
were only included if they scored mild/normal on HADS depression and anxiety (Hospital Anxiety
and Depression Scale; Zigmond & Snaith, 1983) and did not meet DSM-IV criteria for major depression.
Any participants currently receiving any psychological treatments were also excluded.
Normal sleeping participants met RDC criteria for ‘normal sleepers’ (Edinger et al., 2004): (i) no
complaints of sleep disturbance or daytime symptoms attributable to unsatisfactory sleep (ii) evidence
of a routine standard sleep/wake schedule (iii) in the absence of a sleep disruptive medical/psychiatric
condition, substance abuse (v) and/or a sleep disorder. Normal sleepers scored<5 on PSQI, and viewed
themselves as ‘good sleepers’, described their sleep typically as ‘good’ or ‘very good’, and reported
a mean SOL of <30 min. These conservative normal sleeping criteria ensured a representative cohort.
HADS and DSM-IV depression criteria were per the primary insomnia group.
J. Waine et al. / J. Behav. Ther. & Exp. Psychiat. 40 (2009) 15–2318Participant suitability was determined using telephone screening. Of 23 respondents who returned
consent forms, ﬁve primary insomniac participants were excluded (one withdrew, two failed to meet
inclusion criteria, one had migraines which disrupted sleep, one had sleep paralysis and delayed sleep
phase syndrome [DSPS]). No normal sleepers were excluded.
Nine primary insomnia sufferers (three males, six females; mean age¼ 25.3 years; mean sleep dis-
turbance duration¼ 7.9 years, SD¼ 6.5; mean PSQI¼ 11.4, SD¼ 3.5), and nine normal sleepers (four
males, ﬁve females; mean age¼ 28.8 years; mean PSQI score¼ 2.6, SD¼ 1.0) comprised the sample.
No stage one participants took part later in the study.
2.1.3. Measures and procedures
Telephone screening followed receipt of consent. Individuals meeting inclusion criteria attended
a face-to-face meeting where remaining screening measures (HADS and PSQI) were completed, and
the ﬁeld interview conducted. This was tape-recordedwith the participant’s permission and was based
on a pre-existing metacognitive proﬁling interview (MPI; Wells, 2000), adapted for primary insomnia.
In line with the original MPI, our adapted version examined recent periods of distress in the pre-sleep
period in order to pinpoint salient cognitive processes. Thus, whilst the interview followed the struc-
ture and format of the Wells (2000) MPI, it was expanded to include aspects of the pre-sleep period
considered intrusive to delineate relevant metacognitive beliefs/processes. Questions pertained to par-
ticipants’ experience of pre-sleep intrusions, the meaning and appraisals attached to intrusions (neg-
ative metacognitive beliefs about intrusions) and the metacognitive beliefs governing response
(positive metacognitive beliefs about cognitive strategies). Speciﬁc coping strategies and cognitive pro-
cesses employed to manage intrusions were also examined. The same areas were covered for each par-
ticipant, the detail of which depended on the perceived relevance to each person. Interview format
information is available from the senior author.
To further assist item identiﬁcation, participants completed the MetaCognitions Questionnaire-30
(MCQ-30; Wells & Cartwright-Hatton, 2003) and the Utility of Pre-Sleep Worry Questionnaire
(UPWQ; Harvey, 2003b). Finally, participants were debriefed and provided with a copy of the ‘‘Good
Sleep Guide’’ to relay information on basic cognitive behavioural principles of good sleep (National
Medical Advisory Committee, 1993).
An initial item pool was then generated through consensus discussion amongst the authors who have
considerable expertise, not only on the psychological basis of insomnia, but also on models of psychopa-
thology in general, including S-REF. The interview materials were available in literal, typed transcript
format, and provided the primary source of information. That is, we identiﬁed and marked direct quotes
whereverpossibleaspotential itemstems.Wesought toachieveabroad representationof issues thatwere
raised by our primary insomniac participants. Where speciﬁc parts of the interview content were similar
and terminology appeared synonymous, we sought to construct items that faithfully representedwhat it
was that participants were saying, and what we felt they were meaning by their words. In this context,
interview information from normal sleepers provided important comparative data to help us recognise
the differences in experience between people with primary insomnia and normal sleepers.
In addition to these rich interview data, our discussions were informed by data from other sources,
so that we could effectively ‘triangulate’ and so conﬁrm the validity of items. In this regard, we exam-
ined individual participant responses to the MCQ-30 and UPWQ. These questionnaires already contain
generic (MCQ-30) or speciﬁc (UPWQ) items that are relevant to a metacognitive perspective on insom-
nia. Finally, we reviewed other existing insomnia questionnaires, from the perspective of metacogni-
tion (e.g. metacognitive beliefs arising from cognitive intrusions about sleep), and so tried to take
into a further body of knowledge already available in the ﬁeld (Glasgow Content of Thought Inventory
GCTI, Harvey & Espie, 2004; Sleep Associated Monitoring Index SAMI, Semler & Harvey, 2004b; Glas-
gow Sleep Effort Scale GSES, Broomﬁeld & Espie, 2005; Thought Control Questionnaire – Insomnia Re-
vised TCQI-R, Ree et al., 2005; Pre-Sleep Arousal Scale, PSAS, Nicassio et al., 1985).
2.1.4. Data management
To ensure consistencywith S-REF (Wells, 2000;Wells &Matthews,1994,1996) and Broomﬁeld et al.
(2005), derived items were then categorised by the consensus group according to metacognitive belief
type (negative beliefs about danger and threat related meanings or positive beliefs about cognitive
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vironmental factors, or feelings) in a two by ﬁve matrix (cf. Rust & Golombok, 1999).2.2. Stage two: reﬁnement of the item pool and construction of the questionnaire
Duplicate items were removed from the matrix. The authors and two behavioural sleep medicine
experts considered the remaining items, which were also discussed with a patient with primary in-
somnia meeting RDC/clinical criteria. In this way, what were felt to be the most appropriate items
for each matrix cell were pinpointed. Metacognitive beliefs in response to intrusive thoughts (e.g.
Not being able to rest my mind in bed means I won’t perform well the next day; Before I fall asleep, I should
try and switch off my thoughts) and wakefulness (e.g. Being awake in bed means I have lost control of my
sleep; When awake in bed, I should stay in bed and try harder to sleep) were designated a higher number
than other categories, since from interview data these were most relevant to participants. Fifty-four
ﬁnal items were agreed. A ﬁnal discussion with authors and experts ensured clarity of statements.
Lastly, resulting from further discussion and reﬂection upon the qualitative data, appropriate stem
statements were added that appeared consistent with the way in which participants reported their in-
somnia problems at interview, and with the clinical experience of the authors (e.g. Thinking in bed
means I won’t get to sleep, Before I fall asleep I must get things sorted in my mind).
A draft scale was created by randomly ordering the 54 items. Instructions asked participants to in-
dicate agreement on a four-point Likert scale (1¼ ‘‘do not agree’’, 2¼ ‘‘agree slightly’’, 3¼ ‘‘agree mod-
erately’’ and 4¼ ‘‘agree verymuch’’) prior to falling asleep at night (cf. MCQ,MCQ-30). No reverse items
were included, to avoid potential confusion of respondents.
This ﬁrst draft was then sent to the N¼ 9 primary insomnia participants from ﬁeld interviews. A
semi-structured response sheet invited feedback and general comments. Based on responses, one
item was dropped and seven items added, resulting in the 60-item preliminary Metacognitions
Questionnaire – Insomnia (MCQ-I).2.3. Stage three: MCQ-I ﬁeld testing and psychometric evaluation
To investigate preliminary psychometric properties of MCQ-I, further primary insomnia and normal
sleeper participants were recruited. Power calculation based on mean differences data from
Cartwright-Hatton andWells (1997) suggested that 21 participants per group were required assuming
a 0.05, power at 0.8 and a large effect size.
2.3.1. Participants
The same criterion was applied to select groups. Of 67 ‘poor sleepers’ who returned consent forms,
33 were excluded: 12 withdrew; 7 did not meet inclusion criteria for primary insomnia; 7 met DSM-IV
criteria for depression, 2 had Delayed Sleep Phase Syndrome; 3 were substance abusing; 2 had chronic
medical conditions. Of 51 normal sleepers who returned consent forms, 14 were excluded (12 did not
meet inclusion criteria, 1 met DSM-IV criteria for depression, 1 participant returned incomplete data).
The ﬁnal sample comprised 34primary insomnia participants and 37 normal sleepers. Primary insom-
niacs andnormal sleeperswere equivalent onage andgender (bothp> 0.05). Peoplewithprimary insom-
nia had signiﬁcantly longer SOL and sleep disturbance (both p< 0. 001), and higher PSQI, higher HADS-A
and higher HADS-D scores (all p< 0. 001), than normal sleepers. Summary data are presented in Table 1.
2.3.2. Procedure
Following telephone screening, PSQI, HADS, MCQ-30, and MCQ-I were sent to participants for com-
pletion. Three weeks later, participants were sent the MCQ-I again, for test–retest purposes, and re-
ceived the ‘‘Good Sleep Guide’’ (NMAC, 1993).
2.3.3. Data analysis
All continuous data were checked for normality of distribution, using the Kolmogorov–Smirnov
(K–S) test. If the ﬁndings were signiﬁcant, data was transformed using Log transformation. The
Table 1
Participant characteristics and screening measures (stage 3)
Primary insomnia group
(n¼ 37) Mean (SD) median
Normal sleeper group
(n¼ 34) Mean (SD) median
Age 30 (9.2) 31.0 29 (9.2) 27.0
Problem duration (years) 10.2 (7.4) 7.5 0.0 (0.0) 0
PSQI 11.0 (2.7) 11.0 2.5 (1.0) 2.0
Subjective SOL (estimation
in minutes from PSQI)
76.7 (45.4)a 65.0 9.6 (5.9)b 8.0
HADS (anxiety subscale) 7.6 (3.3) 8.0 3.6 (2.7) 3.0
HADS (depression scale) 3.7 (4.6) 4.0 1.1 (1.5) 1.0
a Primary insomnia group – missing data for subjective SOL¼ 2 (excluded from analysis).
b Normal sleeper group – missing data for subjective SOL¼ 1 (excluded from analysis).
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used accordingly.
One-tailed tests were employed and are reported here assuming directional hypotheses, with the
exception of test–retest validity.
2.3.4. Face validity
The scale has good face validity because items were derived directly from participants who were
also involved in the iterative three-stage process.
2.3.5. Concurrent validity
A signiﬁcant positive correlation was found between the MCQ-I and MCQ-30 (r¼ 0.69, p< 0.001)
corrected for attenuation. This association represents 47% of explained variance.
2.3.6. Construct validity
MCQ-I (total score) and estimated SOL (from PSQI) were positively associated (r¼ 0.60, p< 0.001),
as were MCQ-I total score and PSQI total score (r¼ 0.59, p< 0.001).
2.3.7. Discriminant validity
As is evident in Fig. 1, the median value for primary insomnia participants (124.5) is higher than for
normal sleepers (90.1). There is minimal overlap between lowest scoring primary insomnia partici-
pants and highest scoring normal sleepers.
MCQ-I discriminated primary insomnia (mean¼ 123.2, SD¼ 27.6) from normal sleepers
(mean¼ 90.1, SD¼ 20.0) (t¼5.838, df¼ 69, p< 0.001), representing a medium effect size r¼ 0.58.
A linear relationship between MCQ-I and HADS-A for primary insomniacs (r¼ 0.47, p¼ 0.003) and
normal sleepers (r¼ 0.34, p¼ 0.02) was observed. Therefore, ANCOVAwith HADS-A partialled out was
conducted. This was to establish whether differences between types of sleeper could be explained
solely by anxiety levels. This indicated primary insomniacs and normal sleepers still differed signiﬁ-
cantly on MCQ-I (F(1,68)¼ 10.74, p¼ 0.001). Sleeper type explained 14% of variance.
2.3.8. Sensitivity and speciﬁcity
A cut-off of 110 on MCQ-I correctly identiﬁed 71% of primary insomniacs and 92% of normal
sleepers. Using this cut-off, participants were separated into: ‘high endorsement of metacognitive be-
liefs’ (score¼>111) and ‘low endorsement of metacognitive beliefs’ (score¼<110). Mann Whitney U
tests examined differences between groups on estimated SOL (n¼ 68) and PSQI score (n¼ 71). High
endorsers had signiﬁcantly longer SOL (U¼ 142.5, p< 0. 001) and higher PSQI (U¼ 172.5, p< 0. 001)
than low endorsers, representing medium to large effect sizes (r¼0.62, 0.60, respectively).
2.3.9. Test–retest reliability
Test–retest data for 25 normal sleepers and 18 primary insomnia participants were available (mean
interval 28.9 days). Intra-class correlations for all participants (ICC¼ 0.82, p< 0.001), normal sleepers
(ICC¼ 0.63, p< 0.001) and primary insomniacs (ICC¼ 0.93, p< 0.001) were all signiﬁcant.
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Fig. 1. Box and whiskers plot demonstrating MCQ-I’s ability to discriminate between normal sleepers and primary insomnia
participants.
J. Waine et al. / J. Behav. Ther. & Exp. Psychiat. 40 (2009) 15–23 212.3.10. Internal consistency
Internal consistency data were not calculated due to the high number of items in the preliminary
version of the scale relevant to the N of participants (N¼ 60; cf. Cortina, 1993).3. Discussion
The present study investigated the presence of metacognitive beliefs in primary insomnia through
the reﬁnement of a novel scale (MCQ-I), and reported initial MCQ-I psychometric data.
Using thepilot scale, signiﬁcantly higherMCQ-I scores amongst primary insomniacs relative to normal
sleeperswere observed, an effect that remainedwhenHADS-Awas partialled out. This is the ﬁrst attempt
to describe and differentiate metacognition in primary insomnia, and conﬁrms the probable relevance of
S-REF to this sleep disorder. A range of metacognitive beliefs may shape pre-sleep cognition in primary
insomnia (cf. Broomﬁeldet al., 2005;Harvey, 2005a), althoughmorework isneeded.Metacognitivebeliefs
may reﬂect a stable trait of primary insomnia – a hypothesis supported by the large correlation (r¼ 0.82)
between the ﬁrst and second MCQ-I completion for primary insomnia participants. This was lower for
normal sleepers (r¼ 0.63), suggesting items were less consistently meaningful to this group.
The current data cannot implicate metacognitive beliefs as a primary insomnia maintaining factor.
Following further MCQ-I reﬁnement, an important progression will be to test links between different
S-REF components, using experimental methods. It should be possible, for instance, to induce
J. Waine et al. / J. Behav. Ther. & Exp. Psychiat. 40 (2009) 15–2322metacognitive beliefs/plans for processing in primary insomnia and normal sleepers, noting effect on
pre-sleep intrusions and SOL. MCQ-I would provide a helpful manipulation check in this context.
MCQ-I should also prove fruitful in strengthening primary insomnia assessment. Unlike existing
scales, MCQ-I can identify metacognitive beliefs in primary insomnia, of relevance for cognitive treat-
ment approaches. Individuals high on MCQ-I may suit a package of cognitive therapy (e.g. Harvey,
2005b), or more tailored cognitive treatment emphasising attention retraining (Wells, 2000), mindful-
ness (Heidenreich, Tuin, Pﬂug, Michal, & Michalak, 2006) or metacognitive belief restructuring (Wells,
2000). Treatment approaches such as these, which directly or indirectly disengage S-REF processing,
are in our view likely to be productive for certain primary insomnia patients.
The validity of the aforementioned work is strengthened given the reasonably promising prelimi-
nary psychometric properties of the MCQ-I. The MCQ-I correlated signiﬁcantly with MCQ-30. Signiﬁ-
cant associations were observed between MCQ-I and both SOL and PSQI scores. MCQ-I readily
discriminated primary insomnia sufferers and normal sleepers (mean scores primary insomnia¼
132.2, normal sleepers¼ 90.1; effect size r¼ 0.58), even with anxiety controlled out. A score of 110 of-
fered reasonable sensitivity (71%), and good speciﬁcity (92%), suggesting MCQ-I may usefully exclude
normal sleepers from future research studies. Using this cut-off, high endorsers of metacognitive be-
liefs showed higher SOL and PSQI scores, relative to low endorsers. Lastly, test–retest reliability was
highly acceptable although validation using a larger sample is now necessary.
Wewould acknowledge several limitations. A larger sample size would have enabled more rigorous
psychometric examination, including exploration of factor structure, and computation of internal con-
sistency data for subscales. Primary insomnia sufferers were not treatment seeking. However, mean
sleep problem durationwas over 10 years, and all participants met strict clinical and research diagnos-
tic criteria (Edinger et al., 2004). Parallels can, therefore, be made with poor sleeping individuals
approaching their General Practitioner for help. The inclusion of 1–2 nights of sleep data (diary and
actigraphy) would have clariﬁed more precisely the relationship between MCQ-I and SOL. And lastly,
the MCQ-I refers only to the pre-sleep period; metacognitive beliefs may also relate to nighttimewake-
fulness after sleep onset. However, the majority of primary insomnia cognitive research to date has ex-
amined pre-sleep processes, making it a logical starting point here.
Finally, we sought to include obstructive sleep apnea patients, as a highly rigorous control group.
Unfortunately, high levels of psychopathology necessitated their exclusion. Future MCQ-I research
should endeavour to include a sleep speciﬁc control cohort, perhaps snorers, who would be less likely
to show such elevated depression.
The present study was a preliminary scale development study. Future psychometric research of
MCQ-I is required, using a substantially larger sample size, additional ancillary measures of cognitive
activity, inclusion of a sleep speciﬁc control group e.g. snorers andmeasures of sleep. Arguably, bymax-
imising MCQ-I sensitivity, the clinical utility of the scale will be augmented. And if ﬁndings remain as
promising as ours, consideration should also be given to development of a speciﬁc metacognitive
model of primary insomnia, similar to that for generalised anxiety (Wells, 1995) and obsessive–
compulsive disorder (Wells & Matthews, 1994). Certainly, the MCQ-I, the ﬁrst scale able to directly
measure metacognitive beliefs in primary insomnia, shows promising psychometric properties.References
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Health-related Quality of Life (HRQoL) has become an important construct in contemporary medicine and
health care, permitting assessment of disorder burden and evaluation of interventions on various aspects
of functioning, in a standardized manner. Here we review literature on the measurement of HRQoL in
insomnia populations, and the extent to which insomnia treatment improves domains of HRQoL. It is
concluded from the relatively small literature that insomnia impacts on diverse areas of HRQoL, and that
both pharmacological and non-pharmacological interventions can produce, to varying degrees,
improvements in domains spanning physical, social and emotional functioning. Limitations of the current
literature are identiﬁed; with particular emphasis on measurement and conceptual shortcomings.
Suggestions aremade in relation to improving the quality of future research, and how to further shed light
on the impact of insomnia – and treatment thereof – on both HRQoL and global quality of life.
 2009 Elsevier Ltd. All rights reserved.‘‘Sleep, like insomnia, is not just about what happens at night:
it’s about what happens to the day’’.1(p 48)Introduction
Despite Insomnia being recognised as a ‘24-hour disorder’ in
both the major sleep nosologies,2,3 historically, there has been lessy; CPAP, Continuous Positive
Manual of Mental Disorders,
or Research and Treatment of
ed Potentials; ES, Effect Size;
essment of Cancer Therapy –
ionnaire; CGI, Clinical Global
alth Related Quality of Life;
ers, Second Edition; IRQoL,
verity Index; MOS, Medical
AW, Number of Awakenings;
pact of Sleep Questionnaire;
PSG, Polysomnography; PSQI,
d Life Years; Q-LES-Q, Quality
, Quality of Life; QOLI, Quality
Life Inventory; QSQ, Quebec
ial; SAQLI, The Calgary Sleep
6, Short-Form Health Survey
ncy; SWS, Slow-Wave Sleep;
ASO, Wake-time After Sleep
le).
All rights reserved.interest in the daytime aspects of insomnia compared with night-
time symptoms and sleep parameters. Recent recommendations
from leading researchers in the ﬁeld4–6 encourage further investi-
gations into the waking consequences and correlates of insomnia.
Indeed, clinical research in general, across a wide spectrum of
illnesses, has moved towards a more holistic approach; looking
beyond proximal symptoms, and viewing the patient within their
wider psychosocial context.7
The purpose of this review is to: 1) give a brief overview of the
known daytime consequences and morbidity associated with
insomnia; 2) review work on the deﬁnition and measurement of
quality of Life (QoL), or more speciﬁcally, health-related quality of
Life (HRQoL), as it relates to insomnia; and ﬁnally, 3) outline
a prospective research agenda, focusing on further understanding
and measuring the extent to which insomnia, and it’s treatment,
impacts HRQoL and individual QoL.Insomnia: daytime consequences and associated morbidity
Impairment in daytime functioning attributed to disturbed and/
or poor quality sleep, features as one of the core diagnostic criteria
for insomnia disorder.2,3,8 Clinician reports of patient consulta-
tions,9 and cross-sectional10 and prospective questionnaire
studies,11,12 reveal that individuals with insomnia report consistent
decrements in mood and cognitive abilities (concentration,
memory, attention), coupled with elevated levels of anxiety, fatigue
and physical pain/discomfort, relative to normal sleepers. Such
impairments persist in those diagnosed with primary insomnia
S.D. Kyle et al. / Sleep Medicine Reviews 14 (2010) 69–8270(PI), after screening and excluding co-morbid pathology.11,13–16
Evidence for subjective (and objective) sleepiness, on the other
hand, remains equivocal,17,18 with surveys revealing approximately
25% of PIs report excessive daytime sleepiness.19
Although reviews of earlier studies failed to ﬁnd reliable
unequivocal differences in objective, neuropsychological func-
tioning,17,20 more recent controlled work, using sensitive measures
that vary in task complexity and cognitive load, appear to be isolating
and capturing speciﬁc impairments in attention and vigilance.16,21,22
The heterogeneity in ﬁndings may be explained by both methodo-
logical (e.g., sample size and composition, assessment tools, time of
testing), and theoretical factors (e.g., ‘negative cognitive set’,
compensatory effort, and cortical arousal).22–25 Further work is
needed to tease out the contributing roles of each. Interestingly
though, a recently presented meta-analysis26 of all studies assessing
neuropsychological performance in well-deﬁned PIs, revealed
signiﬁcant impairments (small to moderate effect sizes) in aspects of
attention, episodic and working memory, and executive functioning
domains. Other groups have focused on the known relationship
between sleep and consolidation of newly encoded memory traces.
Speciﬁcally, PIs show an attenuation of the normal overnight sleep
enhancement effect on tasks probing declarative27 and procedural
memory performance,28 relative to normal sleeping controls.
Recent structural and functional imaging work may also shed
light on the neural underpinnings of the cognitive dysfunction
experienced by insomniacs. For example, Riemann et al.29 reported
decreased bilateral hippocampal volume in a small sample of PIs
(n¼ 8) relative to controls, and, more recently, Altena et al.30 found
decreased gray matter volume in the left orbitofrontal cortex, in
a larger sample (n¼ 24) of elderly insomniacs. Furthermore, the ﬁrst
published functional MRI study in PIs revealed hypoactivation of
medial and inferior prefrontal regions during a verbal ﬂuency task –
a pattern which reversed/normalised post-behavioural therapy.31
Although this imagingwork is still in its infancy (and issues of causal
ordering remain to be resolved), such atrophy, and functional
alterations, may map onto reported daytime impairments in mood,
memory, and reduced cognitive ﬂexibility. Daytime event-related
potential (ERP) data, though relatively sparse, also point to potential
impairments in aspects of attention and processing speed32,33;
though again,morework in this area using sophisticated paradigms,
and large, well-deﬁned samples is required. Recent ERP studies
assessing sensory and cognitive processing pre-sleep, during sleep,
and on awakening,34,35 over multiple nights, are beginning to tease
out the relationship between sleep quality and cortical arousal,
which may have implications for better understanding daytime
insomnia phenomenology.36
Large survey and population-based studies further reveal
a number of increased morbidity markers in those suffering from
insomnia, including: increased rates of health care utilization
(physician visits, medication prescriptions) and chronic health
problems,37–39 elevated work absenteeism rates, reduced work
productivity, and greater frequency of motor and non-motor acci-
dents.10,40,41 Such impairments may be moderated, in part, by co-
occurring illness; however, workplace studies controlling for both
mental and physical co-morbidities still reveal signiﬁcant negative
effects of insomnia on objective absenteeism, self-report work
efﬁciency,40 and work disability pension claims.42 Longitudinal
epidemiological studies also indicate that isolated sleep distur-
bance, measured at time point one, can independently predict the
development of a new depressive episode 1–3 years later (for
a review see 43). Recent work also conﬁrms insomnia as a predictor
of future clinical anxiety.44
Crucially, perceived impact on daytime functioning serves as an
important factor in driving help-seeking behaviour among indi-
viduals with insomnia, rather than simply perceived sleep loss.45For example, Morin et al.46 found, in a large epidemiological study,
that four out of ﬁve of the most commonly cited reasons for seeking
a sleep-related consultation with a health professional, were
daytime consequences of fatigue, psychological distress, physical
discomfort, and reduced work productivity. Thus, once a threshold
of noticeable daytime dysfunction is reached, individuals feel
motivated to seek medical advice – ultimately with the hope that
successful treatment will restore the particular functional impair-
ment back to ‘normal’ status.47
Quality of Life (QoL) and Health-related Quality of Life
(HRQoL)
In recent years there has been a shift towards assessing the
overall impact of illness on aspects of QoL, through the measure-
ment of HRQoL.48 QoL and HRQoL have become well established
terms in the medical and health literature – indeed, a pubmed
search reveals that published work with the term ‘Quality of Life’ in
the title or abstract has risenmore than fourfold in the last tenyears
(1998–2008: 62,641), relative to the previous decade (1988–1998:
14,428). This has occurred mainly because of the recognition that
objective changes in pathology rarely correlate with, or predict
improvements in, functional capacity or patient experience, and
that what the individual desires when seeking treatment is, put
simply, a return to pre-illness well being. Similarly, with increasing
life expectancy and medical technology advancement, the
emphasis has shifted to chronic illness management (the quality of
life) rather than simply the extension (quantity) of life. HRQoL has
thus become a variable that can help policy makers decide on
which treatments should get resources and service provision,
relative to competing others (through cost-effective analyses and
health technology assessment).
One effect of this increased attention to quality of life
measurement has been the tendency, criticised in recent reviews
and commentaries,49–51 for researchers to include QoL and HRQoL
scales in intervention and epidemiological studies without paying
much attention to the concept they are purporting to measure. That
is, QoL has become an ‘umbrella term’52 for a number of different
concepts and deﬁnitions. The distinction between QoL and HRQoL
is an important one, yet much of the health/medical literature
seems to use these two terms interchangeably. QoL is widely
regarded as a complex phenomenon: some argue it encompasses
both objective and subjective indices of well being,53 whereas
others suggest it is a purely subjective impression of ‘life satisfac-
tion’.50 Factors relevant to quality of life may thus range from
emotional functioning and happiness, through to material well-
being and education; it is therefore difﬁcult to measure, not least
with a single generic instrument. The World Health Organization54
deﬁnes QoL as:
‘‘An individual’s perception of their position in life, in the
context of the culture and values in which they live and in
relation to their goals, expectations, standards, and concerns’’
(WHOQoL study group).
A more contemporary deﬁnition proposed by Ruta, Camﬁeld, &
Donaldson,55 based on seminal work by the economist-philoso-
pher, Amartya Sen, views QoL in terms of a ‘gap hypothesis’:
‘‘Quality of Life is the gap between what a person is capable of
doing and being, and what they would like to do and be; in
essence it is the gap between capability and expectations’’
(p. 402).
Inherent in both these approaches is the importance of the
individual in the assessment of QoL. The role of relativism and
subjectivity in QoL assessment is perhaps best illustrated by the
c LeBlanc et al. used the SF-12 in their Quebec population-based study.
S.D. Kyle et al. / Sleep Medicine Reviews 14 (2010) 69–82 71‘disability paradox’56: individuals who may have society deﬁned
functional/health impairment (e.g., cancer sufferers, amputees, the
physically disabled), can report satisfactory, or in some cases,
enhanced, quality of life.50 Thus, health is just one of the many
components implicitly factored into the quality of life equation.
Simply put, having poorer health status does not necessarily mean
that one has a lower quality of life, than say someone in impeccable
health.57
HRQoL assessment, on the other hand, is concerned with
isolating the impact of disease or illness on prominent aspects of
functioning – ‘.the radiating impact of pathology on the patient’s
wider world’.7(p578) In clinical medicine the ‘pathology’ has both
immediate, proximal symptoms (for example, in the case of
insomnia, an increased sleep latency, or reduced total sleep time),
and more ‘downstream’, distal consequences (such as reduced
work performance, and social impairment). It is these latter, more
psychosocial, variables that are the target of HRQoL assessment,
capturing impairment relevant to patients’ everyday functioning.
Because health impact is easier to quantify than global QoL, most
generic HRQoL instruments typically focus on similar aspects of
functioning: covering physical, psychological (emotional) and
social well-being.58 Subsumed under these functioning domains
are isolated symptoms, such as mood, memory, and fatigue. The
various ‘levels’ of measurement have been likened to a pyramid59:
the top of which can be thought of as overall subjective well-being/
quality of life; the second level representing a collection of func-
tional domains; and the third, foundation level, consisting of
a number of isolated symptoms. Disease-speciﬁc HRQoL scales will
tend to be tailored to aspects of impaired functioning that are most
salient within a particular population, covering a mix of global
functioning domains and relevant symptoms (e.g., fatigue, pain,
and physical functioning in cancer patients). Table 1 provides
descriptions of the scales used to assess HRQoL and QoL in
insomnia populations.
Does insomnia negatively affect HRQoL?
Given the reported daytime symptoms attributed to poor
sleep2,3,8 it is reasonable to assume that individuals suffering from
a chronic sleep problem may have a somewhat reduced ‘down-
stream’ HRQoL. Indeed, about two decades ago, the ﬁrst studies
began to appear focusing on the relationship between insomnia
and HRQoL. Rombaut et al.60 created what they call the Quality of
Life of Insomniacs (QOLI) questionnaire, a 59-item scale designed
from the amalgamation of three other questionnaires (Leeds sleep
evaluation questionnaire, the Jenkins sleep evaluation scale, and
the Psychological well-being index) and 22 additional items, to
assess functioning across ﬁve broad domains: quality of sleep,
physical well-being, mood and mental state, and social and
professional/work relationships. The scale therefore measures both
sleep and non-sleep variables. The initial pilot study revealed good
discriminant properties between untreated insomniacs and normal
sleeping controls, with insomniacs showing statistical impairments
on each domain. However, the scale has not been widely used
since; only a few early studies have employed it,61,62 or variants of
it.63 This is likely to be because of poor face validity (i.e., items are
not grounded in the words of individuals with insomnia), the
simultaneous evaluation of both sleep and daytime variables,
varied response formats, and the exhaustive number of items.
Nevertheless, the limited data on the QOLI do indicate sensitivity to
impairment in a number of HRQoL domains, relative to normal
sleepers.
The bulk of published studies focusing on HRQoL and insomnia
have used a generic health status measure, the Medical Outcomes
Study short-form health survey 36 (SF-3664). The SF-36 is a genericinstrument, initially designed for assessment of health status across
different disease states. Eight dimensions (36 items) assess aspects
of functioning (emotional role limitations, energy and vitality,
social functioning, physical functioning, physical role limitations,
bodily pain, mental health) and perceived general health, yielding
two component summary scores for mental and physical well
being. Scores range from 0 to 100 – with lower scores indicating
greater impairment in health status, or HRQoL. Short forms of the
SF-36, the SF-12 and SF-8 have also been published and validated.
The ﬁrst studies to use this instrument with insomnia pop-
ulations consistently demonstrated lower scores on all domains,
relative to normal sleepers.39,65,66 Several large survey studies have
also now reported a graded trend with insomnia severity; that is,
those with more ‘mild’ or occasional insomnia symptoms show
greater impairment on all eight domains relative to normal
sleeping controls, whereas individuals (typically) satisfying criteria
for insomnia disorder score signiﬁcantly lower than both
groups.39,67–70,c Such associations continue to hold after controlling
for both physical68,70 and mental health co-morbidities.67,70
Although these studies differ in terms of what they classify as ‘mild’
or ‘severe’ insomnia, the linear pattern between HRQoL and
insomnia severity consistently emerges.
More recently, Dixon et al.71 analyzed baseline SF-36 data
(n¼ 209) collected during a randomized trial of Cognitive Behav-
ioural Therapy (CBT) to reduce hypnotic intake (cf.72), and
compared them with UK normative values. In this study, the
authors stratiﬁed domain scores by age, creating three groups (30–
49, 50–69, 70–100 yrs), and compared them with their corre-
sponding age-matched reference values. Similarly, it was found
that those meeting minimum criteria for insomnia disorder (DSM-
IV), in the ‘young’ category (ages 30–49), had signiﬁcantly lower
scores on all domains of the SF-36; the middle category (50–69 yrs)
were impaired on all but two domains (emotional role limitation,
physical role limitation); and the elderly categorywere signiﬁcantly
impaired in four out of the eight domains (pain, vitality, mental
health, physical functioning), relative to reference values. The high
degree of co-morbidities, particularly chronic illness and pain
interference (anxiety and depression scores were in the normal to
mild ranges), may mediate, to some extent, the magnitude of
impaired dimensions.
In contrast to themore clinical and effectiveness based approach
of Dixon et al., Walsh et al.73 collected SF-36 data in the context of
a multi-centred RCT of nightly Ezopiclone for a six-month period,
on a large sample (n¼ 830, 21–64 yrs) of well-deﬁned PIs (sleep
parameter inclusion and DSM-IV criteria). Comparison of pre-
treatment SF-36 scores with US normative reference values,
revealed signiﬁcant impairments in vitality, social functioning and
the overall mental health summary component. The more selective
decrements are likely to be explained by the stringent level of
screening/exclusion and the nature of recruited versus referred
populations.45,74
In a similar vein, Omvik et al.75 recently published baseline data
on daytime functioning and QoL variables from a randomized trial
of CBT versus zopiclone (cf.76). SF-36 scores from 46 elderly indi-
viduals (>55 yrs: mean age 60.9 yrs) with DSM-IV criteria
insomnia, who had undergone rigorous screening (including PSG),
failed to reveal any signiﬁcant evidence of impairment relative to
normative values. The authors do not, however, report data for each
of the eight dimensions; instead using the mental health and
physical health component summary scores for comparison. This
may obscure differences at the dimension level. Nonetheless, data
collected on another generic instrument, the Quality of Life
Table 1
Instruments used to assess HRQoL and QoL in insomnia populations.
Concept measured Instrument Brief description Comments
Generic health
status/HRQoL
SF-3664 36 Items covering 8 dimensions of functioning: physical functioning,
physical role limitation, bodily pain, vitality, mental health, emotional
role limitation, social functioning, health perception. Can calculate
dimension scores, and two component summary scores for mental
and physical well being. 12 and 8-item versions are also available.
Appears sensitive to insomnia
impairment and treatment.
Extensive normative data and
disease norms available.
NHP80 38 Items assessing impact of illness across 6 dimensions (sleep, energy,
pain, physical mobility, social isolation, emotional reactions). Combined
weighted values of individual items make up total dimension scores (0–100).
Simplistic dichotomous response
format. Focus on extreme ill health.
SIP95 136 Yes/no items grouped into 12 categories (body care and movement,
ambulation, mobility, social interaction, alertness behaviour, emotional
behaviour, household management, recreation and pastimes, communication,
eating, work, sleep and rest). Items are completed with reference to ’today and
because of health’. Global proﬁle score, category scores, and summary physical
and psychosocial scores, can be calculated.
Exhaustive number of items.
Quality of Life QoLI77 Based on a model of ‘life satisfaction’, covering 17 domains (health and non-
health) identiﬁed from the literature as being important for overall ‘life
satisfaction’: health, selfregard, philosophy of life, standard of living, recreation,
learning, creativity, social service, civic action, love relationship, friendships,
relationships with children, relationships with relatives, home, neighbourhood,
community.
Total score is based on domains
only regarded as important and
relevant by respondents.
Q-LES-Q
(short form)101
Contains 16 item-domains (health & non-health). 14 of these single item-domains
make up the total score (physical health, mood, work, social relations, ability to
function in daily life, ability to get around physically, household activities, family
relationships, leisure, sexual drive, economic status, living or housing situation,
vision, overall sense of well-being).
Sensitive to treatment outcome
in depression and anxiety.
Disease-speciﬁc
HRQoL
QOLI60 52 Item scale encompassing three questionnaires (Leeds Sleep evaluation
questionnaire, Jenkins Sleep Evaluation Scale, Psychological well-being index)
plus additional item questions, grouped into ﬁve domains: quality of sleep, quality
of waking, physical well being, mood and mental state, and relationships.
Varying response formats.
HD-1681 16 Item scale, covering ﬁve core domains (physical role, energy, cognitive, social,
and psychological well-being). Global and domain scores can be calculated.
Items generated by insomnia
patients and experts.
HD-16, hotel dieu-16; Q-LES-Q, quality of life enjoyment and satisfaction questionnaires; QOLI, quality of life of insomniacs questionnaire; QoLI, quality of life inventory;
NHP, Nottingham health proﬁle; SF-36, short-form health survey; SIP, sickness impact proﬁle.
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the normal range. The QoLI is based on a conceptual model of
general ‘life satisfaction’, asking patients to rate the importance of
17 pre-determined domains deemed important for an enjoyable
life, and thus covers a wide-range of items not necessarily speciﬁc
to health. It is perhaps not surprising that the composite score of
this measure failed to detect insomnia-relevant impairment. It is
worth pointing out, however, that the key strength of this scale is
that composite scores are calculated only on items that are rated as
important/relevant by the individual.
Another study,78 again focusing on older adults (58þ years),
compared well-deﬁned PIs (n¼ 82), normal sleepers (n¼ 61), and
those with ‘secondary’ insomnia (n¼ 46) on dimensions of the SF-
36. Only one difference was found for the comparison between PIs
and normal sleepers; with PIs scoring lower on the vitality
dimension. Those with ‘secondary’ insomnia were signiﬁcantly
impaired on seven of the eight dimensions (except role-emotional)
relative to both the PI group and normal sleepers. The reduced
sensitivity of the SF-36 to HRQoL impairment in elderly insomniacs,
especially those with primary insomnia, seems to be a recurrent
ﬁnding. It is unclear what may be mediating this trend. Perhaps
elderly individuals, who have had their sleep problem for a long
period of time, adapt and ‘recalibrate’ in a way that limits the
impact of insomnia on aspects of functioning. Conversely, norma-
tive reference values for this age group may be low anyway, given
the high level of co-morbidity and reduced functional abilities
associated with normal ageing – subsequently obscuring potential
differences.
Researchers have also used a variety of other tools to assess
HRQoL. For example, Philip et al.79 compared those with insomnia
(n¼ 986), and normal sleepers (n¼ 586), on the Nottingham health
proﬁle (NHP80). The NHP, similar to the SF-36, measures salientareas of health functioning, comprising 38 yes/no statements under
six main domains: energy level, pain, sleep, social isolation,
emotional reactions, and physical abilities. Individuals with
insomnia were characterized according to DSM-IV symptom
criteria, and had to report difﬁculties at least three times per week
for the last three months; daytime functioning was not assessed.
Signiﬁcant differences were observed on all domains, with the
insomnia group evidencing signiﬁcant impairment. This pattern of
impairment was similarly found in a selected sub-group (n¼ 442)
of the insomnia sample, screened for both organic sleep-
complaints (using the Epworth Sleepiness Scale; ESS) and depres-
sive symptoms.
Leger et al.81 recently published the Hotel Dieu-16 (HD-16),
a disease-speciﬁc measure designed to detect quality of life
disturbance relevant to insomnia. Items for the HD-16were initially
generated from interviews with 20 patients and through expert
consensus opinion. Factor analysis on an initial list of 43 items
resulted in the ﬁnal selection of 16 items, subsumed under ﬁve
categories: physical role; energy, will to do things; cognitive
(concentration, attention, memory); social (relationships with
others); and psychological well being. Good sleepers (n¼ 391),
‘mild’ insomniacs (n¼ 422), and ‘severe’ (n¼ 240) insomniacs,
were selected from SOFRES, a French polling institute. Mild
insomniacs were deﬁned as those with ‘occasional’ sleep difﬁcul-
ties; whereas those in the severe group had at least two insomnia
complaints for the last month, and suffered impaired daytime
functioning as a consequence. Initial screening excluded those with
depressive or anxiety proﬁles; those with other medical co-
morbidities were not identiﬁed or excluded. A linear trend was
again found, similar to studies using the SF-36: mild insomniacs
scored signiﬁcantly lower on all dimensions, and global score,
relative to good sleepers; severe insomniacs scored signiﬁcantly
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Thus, prima facie, the HD-16 does look sensitive to the functional
impairments experienced by those with insomnia, and has good
face validity given that items are grounded in words of sufferers. A
further strength is the ability to conﬁgure a total score, which may
be useful in outcome studies, as well as clinical settings. Despite
being a relatively brief measure, however, dimension calculation
looks to be a rather complex and arduous process (based on
weighted coefﬁcients from the factor analysis), and so this may
preclude it from being used on a regular basis in clinical settings.
Further studies are required to assess psychometric properties and
sensitivity to change.
The HD-16 was principally devised because of the absence of
a widely used insomnia-speciﬁc HRQoL instrument, as compared
with, for example, the sleep apnea ﬁeld, where there are three - the
Functional Outcomes of Sleep Questionnaire (FOSQ82), the Sleep
Apnea Quality of Life Index (SAQLI83), and the Quebec Sleep
Questionnaire (QSQ84). The implication being: generic measures
like the SF-36 may not pick up impairments relevant to those with
insomnia.85 Nevertheless, the main strength of the SF-36 is that it
permits comparisons with other illnesses; which of course is vital
in order to document the relative burden of insomnia. In this
context, Katz and McHorney70 found, in a cross-sectional analysis
of data from the medical outcomes study (MOS), that those with
mild and severe insomnia (deﬁned in terms of frequency of
symptoms over a 4-week period) scored signiﬁcantly lower on all
domains of the SF-36 relative to a mild hypertension reference
group. More importantly, however, the magnitude and distribution
of HRQoL decrements of the severe insomnia group were compa-
rable to individuals with clinical depression and congestive heart
failure (see Fig. 1), even after controlling for 16 co-morbid condi-
tions, and various other demographics. This pervasive nature of
insomnia ﬁts well with what patients report: sleep disturbance has
a knock-on effect on nearly every aspect of daily functioning,13
whereas many other conditions are more selective in their
consequences.
One ﬁnal line of evidence to support the view that disturbed
sleep can have a bearing on aspects of HRQoL comes from studies
looking at the additive effect of poor sleep on existing conditions. In
a recent study, ‘poor sleep’ (measured using the PSQI) was found toFig. 1. Deviations in SF-36 scores for Insomnia, depression, and congestive heart
failure, relative to hypertension reference group. Scores plotted from70. BP, bodily pain;
GHP, general health perception; MH, mental health; PF, physical functioning; RE, role-
emotional; RP, role-physical; SF, social functioning; VT, vitality/energy.be a signiﬁcant independent predictor of mental and physical
health component scores (from the SF-36) in patients withmultiple
sclerosis.86 Fortner et al.87 again using the PSQI, categorized breast
cancer patients into ‘good’ and ‘bad’ sleepers; ﬁnding that ‘bad’
sleepers scored lower on six (role-physical, bodily pain, vitality,
social functioning, role-emotional, and mental health) of the eight
SF-36 dimensions. Other studies using more concrete deﬁnitions of
insomnia reveal a similar pattern. For example, Caap-Ahlgren and
Delvin88 reported that Parkinson’s disease patients with insomnia
had impaired HRQoL on every dimension of the SF-36, relative to
those without insomnia symptoms. Rumble et al.89 also demon-
strated lower scores in lung cancer patients meeting criteria for
insomnia on the ‘global health/quality of life’ 2-item subscale scale
from the European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC QLQ-C30),90 a cancer-
speciﬁc HRQoL questionnaire, relative to a control group of cancer
patients without insomnia.
Overall, cross-sectional studies highlight the pervasive impact of
insomnia on aspects of functioning and HRQoL, and this relation-
ship holds, to varying degrees, after controlling for co-morbidities.
Well-screened PIs appear to have more selective impairments
relative to those individuals in the population based and clinical
studies, which might be expected given the reported (and unre-
ported) co-morbidities in the latter groups. There is some evidence
to suggest that individuals with co-morbid insomnia experience
greater/entrenched daytime functioning impairments relative to PI
patients.78 Crucially, both disease-speciﬁc and generic instruments
appear to be sensitive to HRQoL impairments.
Does improving insomnia also improve aspects of HRQoL?
Because health-related functional impairments are prevalent
within insomnia populations, and enshrined in the diagnostic
criteria, treatment should ultimately target and alleviate such
impairments. That is, improving sleep should improve functioning
(this of course is based on the notion that impaired sleep is causally
related to reduced HRQoL). Surprisingly, very few controlled
studies (see Table 2) have included assessments of HRQoL (see91 for
a review of more general daytime parameters), and only two have
speciﬁed HRQoL as the primary outcomemeasure. Table 2 speciﬁes
the following: all controlled studies of insomnia treatment that
include an HRQoL or QoL measure; two additional uncontrolled
trials of insomnia treatment, specifying HRQoL as one of the
primary outcome variables of interest; and ﬁnally two large RCTs of
CBT in those with insomnia and cancer (selected only as examples
of how treating insomnia can modify HRQoL variables pertinent to
the co-occurring illness). All papers were sourced by searching
major search engines (PubMed, ISI Web of Knowledge, ScienceDirect),
and through hand-picking citations from existing published
articles.
Cross-sectional and uncontrolled studies
Leger et al.92 conducted a cross-sectional study, selecting
patients with insomnia who had been on zopiclone for at least
twelve months, and compared themwith a matched group of good
sleepers, on a study speciﬁc QoL instrument. ‘Quality of life’ was
assessed using questions tapping ﬁve core domains: work, rela-
tionships, safety, domestic activities, and leisure activities. The
groups did not differ in terms of sleep disturbance, except that the
Zopiclone patients had ‘occasional’ difﬁculties falling asleep. It was
also found that both groups had comparable scores for each QoL
domain. Similarly, using a cross-sectional design, Zammit et al.65
compared recruited treated insomniacs with a matched group of
untreated insomniacs, on the SF-36. They, however, found no
Table 2
Insomnia treatment studies assessing Health-Related Quality of Life as an outcome variable.
Study Methods/intervention Sample size/
characteristics
Instrument used Sleep outcome HRQoL outcome
Uncontrolled Hajak et al. (2002)93 Multi-national
randomized trial of
zolpidem 10 mg 5 nights/
week (remaining 2 nights
were given placebo)
versus nightly use, for 14
days.
789 PIs (DSM-IV) free
from medication at
intake.
SF-36 th discontinuous and
ntinuous groups had
ilar numbers (59 v.
%) rating ’much
proved’ or ’very much
proved’ on the CGI-II
Improvements on all SF-
36 dimensions were
similar between groups.
No within-subject
statistical testing
reported.
Verbeek et al. (2006)94 Compared individual CBT
with group CBT.
32 PIs (Individual CBT)
versus 74 with mix of PI
and co-morbid insomnia
(group CBT).
Three sub-scales from
the SIP (social
interactions, alertness/
intellectual functioning,
and recreation) and four
‘sub-scales’ from the
RAND-36 (‘general
health’, ‘problems at
work’, ‘social occupation’,
and ‘feeling’).
th groups had
niﬁcantly improved
L, WASO, TST, and SE,
lative to baseline
Composite ratings on
both scales signiﬁcantly
improved at 9-month
follow-up, for both group
and individual CBT.
Prospective randomized
controlled trials
Goldenberg et al.
(1994)62
Multi-national RCT of
zopiclone 7.5 mg versus
placebo taken nightly for
2 weeks, and on demand
for 6 weeks thereafter.
231 received zopiclone;
227 received placebo.
Participants had to report
two insomnia symptoms
for inclusion, and were
excluded for co-
occurring illness or CNS
affecting medication.
QOLI piclone group had
niﬁcantly greater
provements in the
ep domain
2 month follow-up: both
groups improved on the
psychological wellbeing
domain and overall score,
but treatment group had
signiﬁcantly greater
improvements on
activity, social, and work/
profession domains.
Walsh et al. (2000)97 RCT of zolpidem 10mg
versus placebo (3–5
nights per week for 8
weeks).
163 PIs meeting DSM-IV
criteria
SF-36 eatment group
niﬁcantly improved on
tient global ratings and
ary measures of SOL,
T, NAW, and sleep
ality
No signiﬁcant group
differences at any time
point (4,8 weeks).
Morin et al. (2005)102 Randomized placebo
controlled trial of
valerian-hops and
diphenhydramine.
184 ‘mild’ insomniacs,
experiencing initiation
and/or maintenance
problems for between 2
and 4 times per week for
at least a month.
SF-36 th treatments had
ild hypnotic effect at
o-week assessment
lative to placebo
Small but signiﬁcant
improvement on the
physical component
summary score for
Valerian compared with
placebo group at 4-week
assessment point.
Savard et al. (2005)107 RCT of CBT versus wait-
list control.
57 females who had
undergone treatment for
breast cancer, and
reported signiﬁcant
insomnia for 6 months
(DSM-IV/ICSD-2 and
standard quantitative
criteria).
Sub-scale assessing
‘health/global quality of
life’ taken from the
EORTC QLQC30.
niﬁcant CBT
provements on
easures of SOL, WASO
d SE post-treatment
lative to wait-list
ntrols.
Signiﬁcantly greater
improvements on global
’health/quality of life’
scores for the CBT treated
patients at post-
treatment. Pooled data
for both groups revealed
maintenance of
improvements at 12
months, compared to
baseline.
Scharf et al. (2005)100 RCT of Eszopiclone 1 mg,
2 mg or placebo nightly
for 2 weeks.
231 Elderly PIs (age range
65–85) meeting DSM-IV
criteria.
Q-LES-Q niﬁcant treatment
ects for 2mg on SOL,
ASO and TST relative to
acebo.
2mg treatment group
demonstrated
improvements in ﬁve
domains (physical health,
mood, household
activities, leisure time
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Dixon et al. (2006)71 RCT of group CBT versus
‘no additional’ treatment
in a general practice
clinical setting.72
209 Hypnotic users
meeting diagnostic
criteria (DSM-IV) for
insomnia.
SF-36 CBT group had
signiﬁcantly decreased
PSQI global score and
lower percentage of
group on hypnotics,
compared with controls.
CBT group signiﬁcantly
improved on physical
functioning, emotional
role limitation, and
mental health, relative to
control group (6 month
time adjusted means).
Espie et al. (2007)99 RCT of group CBT versus
TAU in a clinical setting.
201 Individuals meeting
DSMIV/ICSD-2 and
quantitative criteria for
insomnia.
SF-36 CBT group signiﬁcantly
improved on measures of
SOL and WASO at 6
months relative to TAU
group
At 6 months: signiﬁcant
improvements in energy/
vitality and mental
health dimensions (small
ES) for CBT versus TAU.
Walsh et al. (2007)73 Multi-centred RCT of
Eszopiclone 3 mg versus
placebo, nightly for six
months.
830 PIs SF-36 SOL, WASO, TST
signiﬁcantly improved
relative to placebo at six
months (medium to large
ES).
Vitality (small to
moderate ES), social
functioning, physical
functioning, and bodily
pain (small ES) were all
signiﬁcantly improved
relative to placebo group
at 6 months.
Espie et al. (2008)105 Pramgatic RCT of CBT
versus TAU
150 Cancer patients
undergoing active cancer
treatment, and reporting
signiﬁcant insomnia
(meeting standard
quantitative criteria for at
least three nights in last
three months, and
daytime functioning
impairment).
FACT-G (functional
assessment of cancer
therapy). sub-scales
cover physical,
emotional, social and
functional well-being.
CBT group signiﬁcantly
improved on measures of
SOL, WASO and SE (large
ES), relative to TAU.
At 6 months, CBT group
signﬁcantly improved on
the physical and
functional domains (large
ES).
Soefﬁng et al. (2008)98 Randomized trial of
three-component CBT
(stimulus control, sleep
hygiene, relaxation)
versus sham biofeedback.
47 Hypnotic-dependent
older adults.
SF-36 CBT signiﬁcantly
improved on SOL, WASO
and SE (medium to large
ES) relative to sham
control group.
Neither group improved
on any dimension of the
SF-36, at 4 weeks.
Omvik et al. (2008)75 RCT of Zopiclone 7.5 mg
versus group CBT versus
pill placebo for 6
weeks.76
46 Elderly (mean
age¼ 55) adults meeting
criteria for PI.
SF-36 & QoLI Post-treatment: CBT
signiﬁcantly improved
relative to placebo and
zopiclone groups on
(objective) WASO and
SWS; both treatment
groups had improved
objective SE compared
with placebo (PSG). CBT
group more improved on
objective (WASO, SE,
SWS) and subjective
(WASO) parameters
relative to zopiclone
group at 6 months.
No evidence of
improvements between
or within groups, post-
treatment or at 6 months
follow-up (placebo group
not included in analyses).
CBT, Cognitive Behavioural Therapy; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; ES,
Effect Size; FACT-G, Functional Assessment of Cancer Therapy - General; CGI-II, Clinical Global Impressions Scale; ICSD-2, International Classiﬁcation of Sleep Disorders, 2nd Edition; ISI, Insomnia Severity Index; NAW, Number of
Awakenings; NHP, Nottingham Health Proﬁle; PI, Primary Insomnia; PSG, Polysomnography; PSQI, Pittsburgh Sleep Quality Index; Q-LES-Q, Quality of Life Enjoyment and Satisfaction Questionnaire; QOLI, Quality of Life of
Insomniacs Questionnaire; QoLI, Quality of Life Inventory; RCT, Randomised Controlled Trial; SE, Sleep Efﬁciency; SF-36, Short-Form Health Survey; SIP, Sickness Impact Proﬁle; SOL, Sleep Onset Latency; SWS, Slow-Wave Sleep;
TAU, Treatment As Usual; TST, Total Sleep Time; WASO, Wake-time After Sleep Onset.
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validated questionnaire in the Leger et al. study, and the poor
characterization of patients in the Zammit et al. investigation,
coupled with the cross-sectional nature of both papers, means
these data do not provide strong enough evidence to help elucidate
the relationship between HRQoL and treatment of insomnia.
As part of a multi-national study, Hajak et al.93 compared
continuous versus non-nightly zolpidem in a large sample of
insomniacs. Both groups had a similar number of ‘responders’, as
determined by the clinical global impression improvement score,
and SF-36 improvements were also similar for both groups across
all dimensions (non-signiﬁcant group x time effect). However, there
was no appropriate placebo/control group, and within-group
analyses were not reported on the dimensions; it is therefore hard
to tell if and how treatment affected speciﬁc domains of HRQoL.
Verbeek et al.94 reported data from both individual (n¼ 32)
and group CBT (n¼ 74) on primary outcomes of both sleep and
HRQoL parameters. Across treatment modalities, sleep-onset
latency (SOL), wake after sleep-onset (WASO), sleep efﬁciency
(SE), and total sleep time (TST), signiﬁcantly improved and
remained robust at the 9-month post-treatment assessment. To
sample HRQoL domains relevant to those with insomnia, the
authors selected items probing four domains (‘general health’,
‘problems at work’, ‘social occupation’, and ‘feeling’) from the
RAND-36d, a practically identical scale to the SF-36, and three
subscales (social interactions, alertness/intellectual functioning,
and recreation) from the 136-item sickness impact proﬁle (SIP95).
Both treatment groups showed comparable improvements in
‘global’ scores of the RAND-36 and SIP, with the SIP demonstrating
the most robust effects, at 9-month follow-up. The authors,
however, did not detail scores for each subscale, in either the
RAND-36 or SIP, making it impossible to identify what speciﬁc
HRQoL components were most sensitive to the CBT intervention.
The lack of a control group also prevents ruling out non-speciﬁc
effects; it is noteworthy that the intermediate phase before
receiving therapy (i.e., between baseline and post-waitlist) had
signiﬁcant positive effects on both sleep and HRQoL measures.
The authors believe sleep hygiene advice, provided at the ﬁrst
screening interview, may account for this, although the current
literature on sleep hygiene recommendations for insomnia would
perhaps argue against this interpretation. A relevant control group
seems essential for an accurate interpretation of HRQoL
outcomes; the placebo impact of sham CPAP, for example, has
been documented in OSA patients, where ‘active’ and control
groups can show comparable improvements across a number of
functioning and HRQoL domains.96
Prospective controlled trials
A number of prospective controlled trials have included a vali-
dated instrument to assess QoL or HRQoL domains. Goldenberg
et al.62 conducted a multi-national RCT of zopiclone versus placebo.
Two hundred and thirty one patients were randomized to receive
14 days of zopiclone (and on demand for six weeks thereafter) and
227 received placebo. All patients completed Rombaut et al.’s QOLI.
At two weeks, both groups showed improvements in the psycho-
logical well-being component and overall global ‘quality of life’
score, but the zopiclone group demonstrated signiﬁcantly greater
improvements in the sleep, activity, social, and work/profession
domains. Relative improvements remained for activity, sleep and
social domains at the two-month follow-up.d The Rand-36 is an exact replica of the SF-36 in terms of content, but has
different scoring algorithms for the Bodily pain and General Health sub-scales.Walsh et al.97 conducted an 8 week RCT of zolpidem 10 mg
versus placebo (3–5 nights per week) in 163 PIs. Although sleep
parameters improved signiﬁcantly post-treatment in the experi-
mental group, there was no corresponding change on any
dimension of the SF-36. Dixon et al. in their analysis of SF-36
outcome data from 209 individuals on hypnotics (with continuing
insomnia) randomized to either CBT or control, found simulta-
neous improvements in sleep and HRQoL, relative to a control
group. PSQI global scores signiﬁcantly decreased, as too did the
percentage of hypnotic users in the experimental group. Time-
weighted mean adjustments across the 6-month follow-up period
revealed signiﬁcant improvements in physical functioning,
emotional role limitation, and mental health, relative to the
control group. On closer inspection however, these ‘improve-
ments’ do appear to be largely mediated by declining functioning
in the control group (e.g., up to a 16 point decrease for the
emotional role dimension). Regardless, the data show an overall
tendency for the CBT group to improve, albeit marginally, and the
control group to experience further impairment. CBT improve-
ments, in this particular population, might then be argued to act
as an important buffer, preventing further (likely) decrements in
HRQoL.
More recently, Soefﬁng et al.98 reported data from a randomized
trial of a three-component cognitive behavioural intervention
(stimulus control, relaxation, and sleep hygiene) or sham biofeed-
back (psychological placebo), in a small sample of hypnotic-
dependent older adults (n¼ 47). At post-treatment, signiﬁcant
effects were found for the CBT treated group in terms of subjective
sleep parameters (SOL, WASO and SE; medium to large effects) but
there was no corresponding improvement in SF-36 scores (mean
dimension/component scoreswere not reported). Indeed, therewas
no improvement in any of the other daytime assessments probing
sleepiness, fatigue, anxietyormood. The ratherearlypost-treatment
assessment could perhaps undermine improvements, particularly
using the SF-36 instrument which has a 4-week recall period.
Espie et al. 99 conducted an RCTof CBT versus treatment as usual
(TAU) in general practice, using trained nurses as CBT therapists. At
the 6-month follow-up, small to moderate effect sizes were found
for SOL and WASO relative to controls; and a medium effect size
(ES) for improvement in sleep efﬁciency. Sleep improvements were
also accompanied by small, but signiﬁcant improvements in the
energy/vitality and mental health subscales of the SF-36, relative to
the TAU group. Noteworthy however, these follow-up improve-
ments are still substantially lower than normative reference values,
which again is likely to be mediated by the ‘real world’ clinical
context.
Walsh et al.73 in their large RCT of Eszopiclone versus placebo,
assessed HRQoL and daytime functioning as primary outcome
measures. Changes in sleep parameters were signiﬁcantly larger in
the treatment group for SOL, WASO and TST (medium to large ES)
relative to the placebo group at the 6-month follow-up, and 50%
scored7 on the (Insamna severity index comparedwith 19% in the
placebo group). In terms of HRQoL, SF-36 domains of vitality, social
functioning, physical functioning, and bodily pain were all signiﬁ-
cantly improved relative to the placebo group at six months (small
to moderate ES for the vitality domain, and small ES for the rest of
the domains). Although the authors report ‘no change’ in terms of
sleep variables during the discontinuation period (i.e., sleep gains
were maintained), they do not report data on HRQoL parameters.
This is likely to be because of the short 2-week interval, coupled
with the SF-36 recall period; nevertheless, it would be interesting
to see if these improvements are maintained beyond ‘active’
treatment.
In the original study by Sivertsen et al.76 the authors showed
that PI patients treated with CBT improved in both objective and
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group, and that these relative improvements remained robust at 6-
month follow-up. In a recent follow-up report on daytime func-
tioning measures from this trial, Omvik et al.75 failed to ﬁnd any
evidence of impairment (at baseline) relative to normative values,
using the SF-36 and the QoLI. Not surprisingly, then, they also failed
to ﬁnd a signiﬁcant group interaction effect, with neither treatment
improving mental or physical health component scores (a possible
ceiling effect), at post-treatment follow-up. Again, however, they
did not report dimension values, and so subtle component effects
may be masked. One interesting ﬁnding, when groups were
collapsed, was a signiﬁcant association between pre-post increases
in QoLI scores and increases in slow-wave sleep. This does point to
a potential relationship between objective sleep and relevant
quality of life variables.
Another study100 used a generic QoL measure, the Quality of Life
enjoyment and satisfaction questionnaire (Q-LES-Q101), comprising
16 separate dimensions (both health and non-health). Scharf and
co-workers reported signiﬁcant improvements in ﬁve domains
(physical health, mood, household activities, leisure time activities,
and medication) in a group of elderly PIs treated with Eszopiclone
2 mg, relative to a placebo group. These were accompanied by
improvements in SOL, WASO and TST compared with placebo. Final
assessment was however short at two-weeks, and the authors
do not present baseline or post-treatment means, preventing
comparison with norms or other clinical groups.
Morin et al.102 conducted a randomized-placebo controlled
trial of valerian-hops and diphenhydramine, on a group of ‘mild’
insomniacs (n¼ 184; experiencing difﬁculties in initiating and/or
maintaining sleep for between 2 and 4 times per week, in the last
month). Relatively mild hypnotic effects were found with both
treatments, particularly at the two-week assessment. In the
comparison between valerian and placebo at four weeks, the
valerian group showed a small but signiﬁcant relative improve-
ment on the physical component summary of the SF-36. Dimen-
sions scores were not presented and the mental health
component summary failed to reveal any improvements. The
limited and short-lived improvements in sleep may account for
the marginal improvements in HRQoL, coupled with the fact that
patients were not required to self-report daytime dysfunction on
study entry, perhaps creating a ceiling effect, and subsequently
making it harder to detect noticeable changes in functioning post-
intervention.
In line with contemporary conceptualizations of insomnia as
a potentially ‘co-occurring’ phenomenon, and not merely
a secondary ‘nuisance’ symptom,103,104 recent studies have exam-
ined the impact of treating insomnia within the context of other
disorders on aspects of HRQoL. For example, Espie et al.105 recently
conducted a pragmatic RCT of CBT versus treatment as usual (TAU)
in cancer patients (n¼ 150), who had completed active cancer
treatment but also reported signiﬁcant insomnia. At 6-months
follow-up, the CBT group evidenced signiﬁcant improvements in
measures of SOL, WASO, and SE, with corresponding large effects,
relative to the TAU group. The authors also included a measure of
cancer-related Quality of Life, the Functional Assessment of Cancer
Therapy-General (FACT-G),106 assessing physical, emotional, social
and functional domains of the cancer experience. At 6-months the
CBT group demonstrated signiﬁcant improvements in both the
physical and functional domains (large effect sizes). The potential
limitation of this scale, in the context of insomnia and HRQoL, is the
inclusion of sleep items, which interestingly feature only in the
subscales that showed statistical improvements. The authors also
note that changes in SE and changes in statistically signiﬁcant
HRQoL domains were low. Results from a similar study,107 adopting
an efﬁcacy approach, comparing CBT with a wait-list control, alsodemonstrated strong improvements in sleep parameters. The
authors included the ‘global health/quality of life’ subscale from the
EORTC QLQ-C30, which revealed signiﬁcant and enduring
improvements in treated patients from baseline to 12 month
follow-up. Other sub-scales of this measure were not reported
(including social, emotional, physical and cognitive functioning).
Reﬂections on existing insomnia-HRQoL treatment literature
From the limited treatment studies it is clear that improving
sleep, in some cases, can lead to statistical improvements in aspects
of HRQoL. However, what is far from clear is whether these
improvements are clinically meaningful: do they really matter to the
patient? For themost part, improvements are small and/or fall short
of normativevalues, though thismaybedependenton theparticular
population under investigation. Follow-up assessments have typi-
cally been short, with most occurring about 6-months post-treat-
ment - it is possible that improvements in functioning become
apparent well after sleep parameters have stabilized, particularly
with CBT. The converse may also occur in those treated with
hypnotics: initial improvements may not be sustained after
discontinuation. Relationships between sleep parameter changes
and HRQoL improvements are rarely assessed (or reported), and no
study has yet documented adequate improvement in HRQoL in
primary insomnia patients, using Cognitive Behavioural techniques.
Moreover, to our knowledge, no comparative controlled study of
CBT versus hypnotics exists that demonstrates superior HRQoL
outcomes in favour of a particular treatment modality (only one
relevant RCT75,76 has included a HRQoL measure). Comparative
treatment studies (and intervention studies more generally),
probing changes in HRQoL, are important because of their impli-
cations for cost-effectiveness and utility models. HRQoL scores are
typically used in the calculation of Quality Adjusted life Years
(QALYs) – a weighted product of life expectancy and quality of
remaining life years – which can then be combined with inter-
vention costs to produce a cost-utility ratio. This cost/QALY ratio
(i.e., the difference between the costs of two interventions divided
by the difference in QALYs gained) then helps establish costs per
QALY for a particular insomnia intervention, relative to say non-
treatment, competing insomnia treatments, and other interven-
tions for other common medical problems.108 The idea being that
relatively inexpensive interventions (i.e., low cost per QALY) are
then prioritized in terms of resource allocation, over more expen-
sive ones. With the contemporary focus on the burden of insomnia
it is clear that future intervention research must include, and pay
attention to, the HRQoL concept, in order to document associated
morbidity as well as utility of treatment.109,110
However, as a ﬁeldwealso need to strive for amore sophisticated
understanding and conceptualization ofQoL andHRQoL, as it relates
to insomnia. From the studies reviewed, only a select few actually
deﬁned what they were attempting to measure (and these were
typically cross-sectional or scale development/validation studies).
Moreover, many refer to assessing or improving ‘quality of life’when
they were actually measuring aspects of HRQoL, using a generic
health status measure. It may well be true that treating insomnia
does improve ‘quality of life’, butwhere specialisedmeasures such as
the SF-36, NHP, SIP, or even the HD-16 are used, it may be more
appropriate to emphasise the measurement of health-related QoL.
The key strength of generic measures, like the SF-36, is the ability
to compare scores across disease states and with normative
community reference values, in a standardizedmanner. Such data, of
course, are vital for cost-effectiveness analyses when, for example,
comparing treatments, and assessing whether patients return to
‘normal’ status. The sacriﬁce, however, is the poor speciﬁcity to
a particular disorder. The inclusion of non-speciﬁc domains may
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especially true when only summary scores are reported. Future
studies should report both overall summary scores and dimension
scores, particularly in lightof literaturequestioning the independence
of the mental and physical health components and their represen-
tation of individual proﬁle scores (e.g.,112). Indeed, for these reasons it
is recommended that intervention studies include both disease and
generic HRQoLmeasurement – with the former typically beingmore
sensitive to change than the latter.113 This approach has achieved
some success in the sleep apnea ﬁeld114; and is the recommended
perspective by recent insomnia expert consensus workgroups.4
Currently, there is no widely used insomnia-speciﬁc measure;
attempts to pilot and develop new instruments, and investigate the
validity/sensitivity of the recently published HD-16, should be
considered an important research goal. In the absence of speciﬁc
measures, researchersneed to considerusingvalidatedscales that tap
dimensions relevant to the insomnia experience. Qualitative work
from the Pittsburgh group115 and more recently our own group,13
reveal the nature of insomnia-related functional impairments –
speciﬁcally in aspects of cognition, occupational functioning, social/
interpersonal relationships, and limitations in goal attainment. It is
interesting that the SF-36 does not adequately assess any of these
dimensions; even the social functioning scale of the SF-36 simply
probes the extent and frequency of interference without detailing
what that interference may be. In the case of insomnia this interfer-
ence is likely to be multi-factorial – from rescheduling activities,
failing to schedule or commit in the ﬁrst place, cancelling at the last
minute, or not enjoying social interactionwhen present.
Another related issue, again concerning the SF-36, is the
construct validity of the energy/vitality domain. This dimension
resonates best among sleep-disordered patients, particularly indi-
viduals with insomnia, capturing fatigue-related symptoms
common to sleep loss/fragmentation. This however is the problem;
the dimensionmay simply bemeasuring fatigue. Scale development
and evaluation studies typically use the vitality sub-scale as a check
for concurrent validity, revealinghigh correlationswith instruments
such as the fatigue severity scale.116 The danger of course being, that
studies (cross-sectional and treatment) may confuse assessing or
improving HRQoL impairment, with modiﬁcations in levels of
fatigue. This may prove problematic when, for example, collapsing
scores into a physical component summary, subsequently leading
the author to conclude that ‘x treatment improves HRQoL’. A solu-
tion to this issue is to always document all measured dimensions,
and include, and correlate, validated measures of fatigue with the
vitality dimension, to see if there is a substantial overlap in variance.
A ﬁnal note on generic measurement concerns the explicit focus
on ‘health’ and ‘illness’ state terminology. The SF-36 probes the
limiting impact of ‘health’ on aspects of functioning; it is, after all,
a health status measure. It is not clear if those with insomnia,
particularlyprimary insomnia, actuallyconsiderpoor/disturbed sleep
to represent a change or variation in health state (it’s not uncommon
for an individual with PI to proclaim, when searching for an under-
lying causal factor for why they can’t sleep, that they are ‘healthy’ and
otherwise have a good life). In comparisonwith other disorders, that
perhaps have amore direct health-link, insomnia impairmentmay be
more difﬁcult to reliably document, and thus show improvements
post-intervention, using generic health status tools. Thismay explain
HRQoL discrepancies between clinical, pragmatic studies, and those
where PIs are recruited through media adverts.
Beyond generic measurement: future directions
Many questions remain unanswered about the nature of HRQoL
in insomnia. The more basic ones, such as what are the predictors/
mechanisms of HRQoL impairment and subsequent improvementwill become apparent as researchers increasingly investigate
insomnia as a 24-h disorder. Some possible targets include: sleep
parameters; daytime symptoms like fatigue, mood, and neuro-
cognitive impairment; dysfunctional beliefs; cognitive biases; and
objective markers of the stress system. Longitudinal studies on the
natural evolution of insomnia, and the transition between states
(i.e., good sleepers, acute insomnia, chronic insomnia), will also
prove helpful in better deﬁning causal relations between insomnia
and HRQoL.
In relation to assessment and measurement, the scope of this
review, a prospective research agenda should be initiated on
adapting and creating new instruments that adequately probe the
insomnia experience. One potential avenue, in addition to generic
measurement, is to adopt a supplemental modular approach117 to
functional HRQoL assessment. That is, consider important domains
that are commonly reported tobeaffectedby insomniacs, but arenot
necessarily dealt with comprehensively by generic instruments. For
example, occupational functioning is cited as a potential daytime
consequence in the diagnostic criteria, yet little work has actually
focused on this domain speciﬁcally. Encouragingly, David and
Morgan118 recently created and validated the Occupational Impact
of Sleep questionnaire (OISQ), a scale that probes the impact of sleep
quality on a number of work related areas. Initial data collected on
the OISQ shows it has good discriminant ability to distinguish
between PIs and good sleepers, and, more recently, signiﬁcant
correlations were found with global sleep quality (as measured by
the PSQI) and sleepiness (ESS) in aDutch sample of ofﬁceworkers.119
In this context, two recent pharmacotherapy studies are also
worth mentioning.73,120 Walsh et al.73 assessed work limitations,
using the work limitations questionnaire (WLQ121), in an RCT of Esz-
copiclone versus placebo. Baseline data showed lower scores on all
domains of the instrument (time demands, physical demands,
mental-interpersonal demands, output demands, and work produc-
tivity loss) relative to normative values, and somewhat comparable
scores to those suffering from clinical depression. Importantly, all
domains showed a relative improvement in the treatment group
versusplacebo, across the six-month treatment phase. Ermanet al.120
similarly assessed workplace functioning in PI patients (n¼ 752)
taking part in a randomized controlled trial of Zolpidem versus
placebo. The authors analyzed data from two components of the
WLQ, the ‘time’ and ‘output’ sub-scales. Again, baseline values were
more impaired (approximately three times greater) than normative
healthycontrols. Signiﬁcant effectsof treatmentemergedafter just12
weeks, which were sustained at the 6-month follow-up, and
improvements were related to global sleep changes. These data are
important because they not only highlight the burden of insomnia on
the workplace beyond traditional measures of absenteeism – con-
ﬁrming qualitative reports122 and population based studies41 – but
also demonstrate the ability to achieve simultaneous improvements
in sleep and occupational functioning. Cognitive behavioural inter-
ventions should include a similar assessment of occupational func-
tioning in future treatment trials.
As well as the development and use of relevant instruments,
researchers should also consider the merit of applying newmethods
and approaches to assessing insomnia-related impairment. For
example, the use of ecological momentary assessment11,12 to collect
daily diary ratings of common insomnia symptoms might provide
a new way to track daytime outcomes during treatment, and post-
treatment, as well as establishing relationships with nightly sleep
parameters. There is no reason why this method can’t be adapted to
assess, for example, social functioning, or subjective workplace
performance. A ‘signiﬁcant other’ perspective (qualitative and/or
quantitative) would also be a useful source of information to gauge
how sleep, and appropriate treatment, affects domains of HRQoL. To
our knowledge no study has used this resource to probe daytime
Practice points
- HRQoL and QoL are not synonymous constructs.
- Insomnia negatively affects diverse aspects of HRQoL
- The limited treatment data tentatively suggest that
successfully improving sleep, using both pharmaco-
logical and non-pharmacological interventions, can lead
to significant improvements in domains of HRQoL.
- There is a great need to standardize measurement use
and reporting of scores to facilitate future comparisons
and meta-analyses across studies and treatment
modalities.
- HRQoL measurement contributes to cost-effectiveness
models and therefore plays a pivotal role in service
provision and development.
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relationship functioning and insomnia. It has been reported that
individuals with insomnia have less satisfying interpersonal
relationships,10 and although it is unlikely to follow a simple cause-
and-effect model (for a review see123), sleep quality may exert
a mediating effect. It would be interesting to see if treating insomnia
can also improve marital/relationship quality; certainly, improve-
ments in marital satisfaction have been reported in sleep apnea
patients after initiation of CPAP therapy.124
Global quality of life has been viewed pragmatically in the liter-
ature as a multi-dimensional construct, assessed using commonly
reported domains deemed important. The likelihood, however, is
that QoL means different things for different people – a uniquely
personal perception49 – making it difﬁcult to accurately measure at
the group level, and especially through modular assessment. One
rather simple, but valid method might be to ask individuals to rate
their quality of life on a likert item or visual-analogue scale. It could
be argued that onmaking this judgment, individuals are factoring in
all the domains/life areas that are important to them. This single-
item format has proved sensitive when documenting, for example,
how many people within a sample of insomniacs report a ‘very
good’, ‘good’, or ‘poor’ quality of life, compared to those without
sleep-complaints.10,66 A similar approach could be tested alongside
generic and modular assessment in treatment studies; single item
visual-analogue scales have been shown to be valid, reliable and
responsive to change in patient groups.125 A relatedmethodological
approachwould be to tailor items asking patients to report whether
they think their QoL has improved as a result of treatment; instead of
simply trying todemonstrate reductions in functional impairments, as
generic measures typically do. The Patient Global Impression
improvement scale, developed from the Clinical Global Impressions
scale,126 is used for a similar purpose, allowing patients to report the
extent to which their overall illness symptoms have improved post-
treatment. Such an instrument could be modiﬁed to assess
perceived improvements in focused areas of functioning as well as
subjective perceptions of global quality of life.
It may also be worthwhile directing efforts towards gathering
basic qualitative data on the individual experience of treatment.
We13 and others115,127 have successfully applied qualitative
methods to understanding the daytime insomnia experience,
revealing novel insights on the nature of functional impairments.
Similar methodologies (semi-structured interviews, audio-diaries)
could be applied to assessing treatment outcomes, as well as the
treatment process itself. The SAQLI83 includes a section looking at
negative side effects of CPAP treatment in OSA patients; it is not yet
clear what, if any, impairments in HRQoL are incurred during CBT
for insomnia (stimulus control and sleep restrictionwould be likely
candidates for study). While clinicians may be familiar with how
sleep improvements inﬂuence patient well-being, systematic study
of the patient narrative may prove helpful in understanding the
treatment process (side effects, locus of improvement, mechanisms
of change, adherence), and the net impact of treatment on daytime
functioning and subjective quality of life (at different time-points).
The importance of measuring items that are relevant, not just
to the disorder, but to the individual has been noted in the QoL
and HRQoL literature,49,57,128 and, more recently, by sleep
researchers.75,114 We are currently piloting a mixed method,
patient-centred approach129,130 to the assessment of insomnia-
related quality of life (IRQoL) at the Glasgow sleep centre. By
IRQoL we mean ‘the impact of insomnia on aspects of life that are
most salient to the individual, as reported by the individual’.
Speciﬁcally, patients are asked to generate, using their ownwords,
the most important areas of their life that are affected by sleep
disturbance. These areas are then ranked in terms of importance,
and rated in relation to extent of interference over a deﬁned timeinterval. Items can be assessed pre and post-treatment, within-
and between-subjects. This idiographic approach permits assess-
ment of areas that are important to the individual, which is likely
to be a lot more sensitive to change given that we are enhancing
the signal (relevance) and reducing the noise (non-relevance)
associated with generic instruments. Moreover, it has been com-
mented previously4,85,114 that the major obstacle to creating an
insomnia-speciﬁc QoL questionnaire is the high degree of co-
morbidity. This is certainly the case when conducting pragmatic
effectiveness trials, or in clinical settings, where other illnesses
may mediate scores on HRQoL instruments. The strength of our
individualized approach is that it emphasizes the attribution to
sleep, and therefore, it should be theoretically possible to isolate
the subjective impact of an intervention on sleep only, even in the
context of other illnesses.Conclusion
It is clear that insomnia does have ameasurable negative impact
on domains of HRQoL, and that these impairments are not simply
limited to obvious domains, like vitality and energy, but also extend
to other aspects of mental, social, and physical functioning.
Comparisons with other illnesses, linear trends with insomnia
severity, and additive effects of insomnia beyond a primary/co-
occurring illness, all support and strengthen this perspective.
Although research into HRQoL is in its infancy within the insomnia
literature, there is already emerging data that successful treatment
can improve functioning across a number of domains. Of course, to
what extent groupmean improvements are important to individual
patients, and their daily lives, remains an unanswered question.
Future research in this area should attempt to approach the issue of
how insomnia treatment improves functioning and individual
quality of life, by using new innovative methods and instruments.
Such a task is not a trivial undertaking; the impact of insomnia on
the individual13 and society131 is very real, and authors have sug-
gested that the pathway between insomnia and depression, for
example, may be mediated, in part, through reduced HRQoL.132
In order to improve the quality of future research, outcome
studies should include a generic measure of HRQoL as well as other
measures that are relevant to the insomnia experience, and have
proven sensitivity. When reporting results, authors should specify
baseline scores and their relationship with normative values, detail
each proﬁle score as well as component/global summary scores,
and make some attempt at investigating the relationship between
sleep improvements and HRQoL changes (i.e., correlation analysis
and/or responders versus non-responders, based on ISI category
change, or quantitative sleep variables).
Research agenda
- Include measures of HRQoL in future cross-sectional,
natural evolutional, and interventional studies.
- Compare different symptom (initiating, maintenance,
mixed) and diagnostic (idiopathic, psychophysiological)
sub-types of insomnia on measures of HRQoL.
- Compare different treatment modalities on HRQoL
primary outcomes within the same study.
- Consider assessing domains that are under-researched,
yet part of the insomnia experience, such as social,
occupational and relationship functioning.
- Follow-up HRQoL outcomes for longer durations and
consider using new informative methods that capture
the patient perspective e.g., qualitative research
methodologies.
- Investigate relationships between sleep parameters
(objective and subjective) and HRQoL dimensions.
- Identify non-sleep predictor variables of HRQoL
impairment and change.
- Consider the effect of the insomnia treatment process
on HRQoL.
- Measure the impact of treating insomnia in the context
of co-morbid illness (e.g., cancer, depression, pain), on
HRQoL.
- Develop and validate measures of insomnia-related
quality of life that are grounded in the words of patients.
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Abstract
Objectives: To conduct the ﬁrst qualitative analysis of the development and impact of insomnia
on a cohort of cancer survivors.
Methods: Twenty-one cancer survivors with a history of chronic insomnia contributed to four
focus groups held at the University of Glasgow Sleep Research Centre. Participants’
perceptions of the onset, evolution and eﬀects of insomnia were elicited and qualitatively
explored using content analysis.
Results: Most participants reported insomnia onset following cancer diagnosis. Participants
who had a pre-existing insomnia reported that cancer diagnosis signiﬁcantly aggravated their
sleep complaint. Active cancer treatment was a major contributor to poor sleep quality due to
the disruption of normal daily routines. This poor sleep pattern became persistent once active
treatment had ceased and participants reported becoming particularly concerned about their
sleep when they were discharged into follow-up cancer care. The impact of insomnia was
signiﬁcant for all participants in the study and six major areas emerged as being particularly
aﬀected; mood, physical health, relationships, sleep quality, sleep-related behaviour and
cognition.
Conclusions: The majority of cancer survivors in this study developed disturbed sleep as a
result of cancer diagnosis and their sleep disruption was exacerbated by active cancer
treatment. Insomnia also had a signiﬁcant impact upon quality of life and these eﬀects persisted
long beyond the cessation of active anti-cancer therapy. Early identiﬁcation of insomnia
symptoms in cancer care settings must be a priority to ensure that sleep disturbance is not
overlooked or poorly managed.
Copyright r 2009 John Wiley & Sons, Ltd.
Keywords: cancer; oncology; insomnia; sleep; qualitative
Introduction
Insomnia is among the most distressing, debilitat-
ing and frequently reported problems experienced
by cancer survivors both during and after comple-
tion of active treatment [1–3]. Prevalence estimates
suggest that 30–50% of newly diagnosed or
recently treated cancer patients express diﬃculty
sleeping [4], with 19–30% meeting diagnostic
criteria for chronic insomnia [3,4]. Sleep patterns
commonly become disrupted around diagnosis.
Recent studies on treated prostate and breast
cancer groups demonstrate that almost half of
patients with sleep problems report insomnia onset,
which follows cancer diagnosis [5,6]. However,
sleep disruptions can persist long beyond the
cessation of active treatment [7,8]. One-quarter of
cancer survivors experience chronic insomnia that
negatively aﬀects daytime functioning and quality
of life. In a study of 982 respondents, 75% of
cancer survivors had a chronic insomnia disorder
that lasted six months or more [3]. This pattern of
persistence is seen commonly in oncology popula-
tions with 25% of cancer survivors on long-term
hypnotic medication [3]. However, this long-term
pharmacotherapy is particularly undesirable to
cancer patients [9–11]. Evidence demonstrates that
cognitive behaviour therapy (CBT) is the treatment
of choice for insomnia [12–17] and patient accept-
ability of this non-pharmacological intervention is
high [18]. However, CBT is rarely available to
cancer populations resulting in the majority resort-
ing to self-management strategies.
Insomnia disorder contributes additional risk for
experiencing persistent fatigue after cancer treat-
ment [4]. Fatigue aﬀects approximately 70% of
patients receiving chemotherapy or radiotherapy
treatments [19–21] and like insomnia is typically
viewed as a temporary reaction to anti-cancer
therapy. However, research has found that fatigue
can persist for months following the termination of
active treatment [22–24]. Results from a recent
clinical eﬀectiveness trial of CBT for insomnia in
cancer patients demonstrated that CBT for insomnia
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signiﬁcantly reduced fatigue in these patients at
post-treatment [17]. Further work is needed to
clarify the directional relationship between insom-
nia and fatigue in this population.
Alongside fatigue, untreated insomnia also leads
to an increased risk of depression [25]. Psychiatric
epidemiology indicates that insomnia is an inde-
pendent risk factor for the development of ﬁrst-
episode depressive disorder [26] and a study on
depressed and non-depressed individuals demon-
strated that sleep disturbance was associated with
immune downregulation and decreased activity of
natural killer cells [27]. These cells play an
important role in anti-tumour immune responses,
suggesting that insomnia may impact on cancer
course and survival rates [28].
In general, insomnia in cancer patients is
frequently overlooked and poorly managed [4,11]
leading to it being greatly under-reported. Indivi-
duals with cancer often develop disturbed sleep
following diagnosis, which commonly evolves into a
chronic insomnia syndrome resulting in diminished
quality of life [29,30], impaired mood [31], heigh-
tened pain and reduced energy levels [4]. Insom-
niacs report a higher frequency of health problems
and employ greater utilisation of medical and
mental health services relative to good sleepers
[32,33]. Yet insomnia is a neglected problem.
Despite the wealth of evidence surrounding its high
prevalence and potentially negative health costs,
little time and attention is devoted to cancer-related
insomnia research. This paper attempts to ﬁll gaps
in the existing literature by reporting on the ﬁrst
qualitative study to describe the development and
impact of chronic sleep disturbance in a cohort of
cancer survivors with co-morbid insomnia.
Participants and methods
Participants for this study were recruited between
October and December 2007 from a database
established during a prior clinical eﬀectiveness trial
[17] and criteria for inclusion in this study were
established during this previous trial. This included
(i) participants who had been diagnosed with
breast, colorectal, prostate or gynaecological can-
cer, (ii) participants who satisﬁed diagnostic
criteria for chronic insomnia (mean value
430min for complaint of delayed sleep-onset
latency (SOL) and/or wake time after sleep onset
(WASO), occurring X3 nights per week for
X3 months and aﬀecting daytime function) [34],
(iii) participants were at least 1 month post cancer
treatment with no further anti-cancer therapy
planned (thus excluding acute insomnia and any
transient eﬀects associated with cancer treatment),
(iv) participants were aged 18 years or over. The
exclusion criteria were as follows: (i) short term or
acute insomnia, (ii) evidence of other sleep
disorders (e.g. sleep apnoea), (iii) evidence of drug
misuse. All participants in the current study had
received CBT for insomnia during their participa-
tion in the previous trial [17].
In all, 54 potential participants were contacted
by letter asking if they would like to take part in a
small focus group to discuss the ways in which
insomnia aﬀects quality of life. A patient informa-
tion sheet was also enclosed providing details
about the purpose and nature of the study. A total
of 21 individuals responded, providing written
consent, which indicated that they wished to
participate and 33 failed to respond (these 33 were
contacted on a second occasion by follow-up letter
but when there continued to be no response, no
further contact was made). Participant demo-
graphic details are given in Table 1.
Procedure
As this was an exploratory study, the use of focus
groups was an appropriate approach. Alongside
being an eﬃcient means of data collection, focus
groups permit participants to identify topics that
are important to them and to utilise their own
frames of reference for discussion. This approach
permits direct access to patient experiences and
perceptions. Our focus groups were held at the
Glasgow Sleep Research Centre in the Southern
General Hospital (a location familiar to all
participants) at a convenient time. The focus
groups lasted an average of 90min and participants
were randomly allocated to one of four groups.
Each focus group was facilitated by L. F. (a
research psychologist) and S. G. (a medical
student) and consisted of only one session. Both
L. F. and S. G. attended a one-day training session
on ‘how to run eﬀective focus groups’ in order to
ensure their suitability as facilitators. The topic
schedule was developed using published literature
Table 1. Participant demographics (all data is frequency
except ‘mean age’)
Mean age (years) 62
Gender
Male 7
Female 14
Civil status
Partner 16
None 5
Occupational status
Employed 8
Not employed 13
Cancer diagnosis
Breast 9
Prostate 6
Bowel 5
Gynaecological 1
Mean time since cancer diagnosis (months) 34
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and our previous experience. Participants were
asked to respond to the following questions:
(i) When did your sleep ﬁrst become disturbed?
(ii) What do you think caused your insomnia?
(iii) What impact did insomnia have on your life?
All participants were given the opportunity to
respond to each question and any discussion was
encouraged and supported. At the end of the
session, the facilitator provided a verbal summary
of the main topics and issues highlighted during the
session and asked the participants to conﬁrm that
this was an accurate account of their discussion.
Immediately following each of the sessions, the
facilitators held a debrieﬁng meeting in order to
discuss and record the main themes that emerged
during the focus group. The facilitators then
generated summary sheets of the content of the
focus groups and these were sent to each of the
participants, the purpose of which was to ensure
that the summary notes were an accurate reﬂection
of the focus group discussions. These summary
notes were checked, agreed, signed and returned by
all participants.
Analysis
Focus groups, data collection and analysis were
concurrent and data saturation was achieved. All
the focus group sessions were audio-taped and
were transcribed verbatim. Content analysis was
used to systematically analyse the data produced
from each of the focus groups and the data analysis
followed established criteria for quality and rigor
[35–37]. The transcripts of the focus groups were
examined independently by three readers: the two
facilitators and a clinical psychology trainee. The
readers were from diﬀerent disciplines and only one
had prior knowledge of the area of research,
enhancing the reliability of the ﬁndings. The
readers were asked to familiarise themselves with
the transcripts and record any general themes that
emerged from the data. The readers were then
asked to read through the transcripts again, copy-
ing units of analysis (deﬁned as words or phrases)
onto individual pieces of paper, ensuring the
context was retained. This was repeated several
times to ensure that no detail was overlooked.
These units of analysis were subsequently allocated
to each of the themes to provide conﬁrming
examples illustrative of each. This distribution
was re-assessed and units of analysis moved
between themes if deemed appropriate. Within
each of the general themes, sub-themes were
created. The sub-themes aimed to cover all
information generated in each of the focus groups
in greater detail. Again, the units of analysis were
distributed between each of these, providing
representative quotes. The readers met on several
occasions to discuss their results until an agreement
was reached. Inter-rater agreement was 0.72.
Results
The majority of participants (n5 19) reported that
the onset of their sleep disturbance followed their
cancer diagnosis. Only two participants stated that
they had an existing problem with sleep prior to
diagnosis, however, both of these remarked that
their cancer diagnosis signiﬁcantly aggravated their
insomnia.
The ‘experience of being a cancer patient’ was
described by ﬁve participants as the cause of sleep
disturbance. Further discussion around this led to
many participants describing ‘suppressed stresses’
as being the main contributor to poor sleep. Eleven
participants blamed a lack of daily routine as the
cause of their insomnia with four of these
participants referring more speciﬁcally to the fact
that they could not work as a result of their anti-
cancer treatment. Other participants commented
on the ‘bad pattern’ which develops as a result of
lack of daily routine. Speciﬁcally, daytime naps,
late retiring and rising times and lack of physical
exercise were all reported to contribute to a poor
sleep pattern. Cancer treatment was also described
as a major cause of sleep disturbance with six
people reporting that chemotherapy and/or radio-
therapy led to a signiﬁcant deterioration in their
sleep quality. Nine participants found adjuvant
hormone therapy to be the most signiﬁcant
contributor, with speciﬁc reference made to night
sweats induced by tamoxifen in breast cancer
patients and nocturia in prostate patients (Table 2).
The impact of insomnia was signiﬁcant for all
participants in the study. Interestingly, the majority
of contributors (n5 16) described the eﬀects of
poor sleep as much more overwhelming than the
eﬀects of cancer treatment. From the analysis, six
major categories emerged: mood, physical
symptoms, relationships, sleep quality, behavioural
modiﬁcations and cognitive consequences. Each of
Table 2. Participants’ qualitative reports on the causes of
insomnia
‘I put my sleep problems down to the fact that I’d had cancer or I was
on cancer drugs or something and eventually I thought, you know, I
can’t remember the last time I slept properly’ (Participant 4: female)
‘I found it was the cancer treatment rather than the cancer diagnosis,
but I suppose we are all different in how it affects us psychologically’
(Participant 11: female)
‘It was almost three years ago I was diagnosed and I’ve forgotten about
it (the cancer), but the sleep problem is still there’ (Participant 6: female)
‘I had an existing problemybut I got much worse after I was diagnosed
with cancer’ (Participant 14: male)
‘It was either just the stress of the diagnosis catching up with me that
caused my sleep problem or the diagnosis and I didn’t recognise it at the
time’ (Participant 1: male)
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these categories contained several sub-themes
(Table 3).
Mood
Changes in mood were one of the most signiﬁcant
aspects of sleep disruption. Participants reported
that change in temperament and feeling ‘diﬀerent
from normal’ (participant 20: male, 64 years) was
common after a poor nights sleep. They lacked
enthusiasm for life, were highly irritable and felt
considerable frustration at their inability to control
their sleep pattern. This led to feelings of help-
lessness and loss of conﬁdence. A number of
participants experienced high levels of guilt about
feeling tired during the day. Once they had
completed cancer treatment, they felt considerable
pressure from family/friends to ‘get back to normal’
(participant 18: female, 52 years). When they were
unable to achieve certain milestones like returning
to work or re-establishing their social lives due to
poor sleep patterns, participants felt incredibly
guilty about continuing to fulﬁl an ‘illness role’.
Physical symptoms
Participants reported various physical symptoms, the
most pronounced being feelings of fatigue and
tiredness. The physical eﬀects of sleep loss were
described as similar to ﬂu-like symptoms and
included nausea, headache, heavy eyes and heigh-
tened levels of pain. Participants described engaging
in a process of ‘internal scrutiny’, frequently mon-
itoring for signs and symptoms of cancer returning.
The physical symptoms of sleep loss resulted in some
individuals’ catastrophising about recurring illness.
Relationships
Sleep disturbance had a signiﬁcant impact upon
inter-personal relationships. Participants avoided
making plans due to the erratic nature of their sleep
and their inability to predict how they would feel
the next day. This resulted in half of all participants
restricting social interactions and postponing daily
tasks. Social isolation was compounded by feelings
of intolerance and diﬃculty relating to others.
Sleep quality
Poor sleep quality resulted in several participants
sleeping in a diﬀerent room from their partner in
order to minimise disruption. Such an alteration to
sleeping arrangements had a considerable impact
on relationships and intimacy and as a result, some
participants reported that relationships had broken
down completely.
Behavioural modifications
In an attempt to combat the eﬀects of disturbed
sleep, participants made several modiﬁcations to
their usual sleep behaviour. Most reported a cycle
of trying to ‘catch-up’ on lost sleep by employing
early retiring and late waking times, daytime naps
and unusual ‘ritual-like’ bedtime routines. How-
ever, this level of attention and eﬀort is widely
known to disrupt sleep patterns further.
Cognitive consequences
Cognitive consequences of sleep disturbance were
common and included catastrophising about the
eﬀects of poor sleep, cognitive intrusions about
sleep, memory deﬁcits and loss of concentration.
These consequences were so severe for one
participant that she felt unable to continue in
employment and sought early retirement (Table 4).
Table 3. Themes and sub-themes generated from the question
‘What impact did insomnia have on your life?’
Theme Sub-themes Frequency
Mood Irritability 4 (19%)
Change in temperament 7 (33%)
Guilt about tiredness 3 (17%)
Frustration 2 (8%)
Helplessness 4 (19%)
Loss of confidence 2 (8%)
Lack of enthusiasm for life 3 (17%)
Physical symptoms Feeling tired/fatigued 12 (58%)
Feeling nauseous 3 (17%)
Head thumping 4 (19%)
Heavy eyes and body 3 (17%)
Heightened pain 2 (8%)
Hyper-arousal 3 (17%)
Relationships Difficulty relating to others 2 (8%)
Intolerant 2 (8%)
Poor conversation skills 3 (17%)
Restricted social interactions 10 (50%)
Rescheduling activities/putting things off 10 (50%)
Feeling misunderstood 3 (17%)
Withdrawn/reclusive 4 (19%)
Sleep quality Easily disturbed 3 (17%)
Concern about disturbing partner 5 (25%)
Restlessness 3 (17%)
Frequent night-time awakenings 14 (67%)
Behavioural
modifications
Daytime naps 9 (42%)
Early retiring time 2 (8%)
Lie-in 5 (25%)
Sleep in different room from partner 5 (25%)
Altered bedtime routine 3 (17%)
Cognitive
consequences
Memory deficits 5 (25%)
Lack of concentration 2 (8%)
Cognitive intrusions about sleep 3 (17%)
Catastrophising 9 (42%)
Lack of control 5 (25%)
Pressure to be ‘normal’ 7 (33%)
Worry about next nights sleep 5 (25%)
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Discussion
Insomnia commonly follows cancer diagnosis, is
exacerbated by anti-cancer therapy and has sig-
niﬁcant consequences for physical and psychological
well-being [3,4]. However, there is a lack of
qualitative research investigating the speciﬁc eﬀects
of insomnia co-occurring with cancer. Our study
directly accessed perceptions and experiences of a
group of cancer survivors in an attempt to identify
the development of insomnia and its impact on
quality of life. Most of the participants in our study
reported that they developed disturbed sleep as a
result of cancer diagnosis and that this sleep
disruption was exacerbated by active cancer treat-
ment. We also established that insomnia signiﬁ-
cantly impacts upon an individuals’ quality of life
and that these eﬀects are stable and persistent.
The early identiﬁcation and treatment of insom-
nia symptoms should be incorporated as an
important part of cancer symptom management.
Neglecting insomnia symptoms might lead to the
onset of a syndrome-level sleep complaint with far-
reaching implications for psychological, physical
and social well-being. CBT has been previously
validated as the treatment of choice for insomnia
within oncology populations [5,17], hence treatment
options are available to prevent the development of
chronic sleep complaints within cancer groups.
Participants described a shift in focus from cancer
to sleep, around the time of discharge into ‘follow-up
cancer care’. They reported increasing anxiety over
disturbed sleep as ‘normal life’ was expected to return
at this time. When sleep continues to be disrupted, it
becomes a focus, a behaviour which is known to
perpetuate and exacerbate insomnia. It seems appro-
priate therefore, to provide sleep information/advice
at this vulnerable stage in the ‘cancer journey’, which
may help prevent the development of a chronic
problem with sleep. Further research is required to
evaluate the most suitable point to provide insomnia
intervention during cancer treatment.
All participants voiced great concern over the
absence of sleep-related information or advice during
cancer treatment. This is alarming as the high
percentage of cancer patients burdened with insom-
nia has been demonstrated by various studies [1–4].
Insomnia is poorly managed within cancer treatment
and rehabilitation [4,11] as Oncology staﬀ have
neither the time nor the necessary expertise to deal
with insomnia complaints. Insomnia assessments
should be incorporated into cancer rehabilitation,
particularly at the highly vulnerable periods of
diagnosis and post-treatment/discharge.
Our sample was not representative of all
individuals with cancer and sleep problems; there-
fore, these ﬁndings are not necessarily generalisable
to the cancer population as a whole. Neither was
our sample representative of all participants who
met eligibility criteria as only 39% of the total
number of eligible participants took part in this
study. A selection bias in favour of people who feel
comfortable discussing their experiences and who
are highly motivated to co-operate is assumed.
The data generated in each of the focus groups
were based on patients’ self-reported experiences of
cancer and sleep problems providing a purely
subjective account. However, several studies have
demonstrated that self-reports of medical status
have acceptable concordance with physical or
medical records, with subjective ratings reﬂecting
physiological measures [38].
Qualitative methodologies were deemed to be the
most appropriate for such an exploratory study,
but we acknowledge that researcher bias and
preconceptions may inﬂuence our ﬁndings. Various
measures were put in place to minimise this;
multiple readers studied the transcripts indepen-
dently and were guided on how this was to be
carried out following a systematic method [35]
aiming to maximise reliability and validity [36,37].
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Objective: To explore the patient experience of Sleep Restriction Therapy (SRT) for insomnia, with partic-
ular focus on elucidating possible side-effects, challenges to adherence and implementation and percep-
tions of beneﬁt/impact.
Methods: To fully investigate the patient experience of sleep restriction therapy for insomnia we designed
a within-subjects mixed-method study, employing sleep and daytime functioning questionnaires, assess-
ments of sleep-restriction-related side-effects, prospective qualitative audio-diaries and post-treatment
semi-structured interviews. University of Glasgow Sleep Centre. Eighteen patients with Primary Insomnia
(mean age = 42; range 18–64). Patients took part in a 4-week brief sleep restriction intervention,
involving two group sessions and two subsequent follow-up phone calls in the home environment.
Measurements and results: Sleep diaries and global measures of insomnia severity and sleep quality, as
expected, demonstrated robust improvements at both post-treatment and 3-month follow-up (all large
effect sizes). Daytime functioning/health-related quality of life variables similarly evidenced strong
treatment effects (moderate to large effect sizes). Reported side-effects were common, with P50% of
patients reporting impairment in 8 out of 12 listed symptoms as a consequence of initiating treatment.
The four most common side-effects were ‘fatigue/exhaustion’ (100%), ‘extreme sleepiness’ (94%), ‘reduced
motivation/energy’ (89%) and ‘headache/migraine’ (72%) [Mean number of symptoms per patient = 7.2
(2.4); range 3–11]. Intriguingly, both side-effect frequency and ratings of side-effect interference were
associated with baseline to post-treatment improvements in sleep quality. Qualitative real-time audio-
diaries during week 1 of treatment and post-treatment interviews provided rich accounts of side-effects
associated with acute SRT implementation; general challenges surrounding treatment implementation
and adherence/non-adherence; and modiﬁcations to sleep parameters, daytime functioning and
perceptions of sleep/sleep period.
Conclusions: This work has important implications for the delivery of SRT, particularly concerning aware-
ness of possible ‘adverse events’ and likely implementation/adherence challenges. Findings also pave the
way for testable hypotheses concerning possible mechanisms of action involved in sleep restriction
treatment.
 2011 Elsevier B.V. All rights reserved.
1. Introduction
Cognitive behavioural therapy for insomnia (CBT-I) is widely ac-
cepted as an effective intervention for improving core insomnia
symptoms. Indeed, CBT-I is a standard, recommended treatment
[1], and is commonly regarded as the treatment modality of choice
[2,3]. Remarkably, however, despite over two decades of CBT-I
investigations, no single study has asked patients about their expe-
rience of CBT-I. That is, similar to the dearth of qualitative data on
the subjective experience of insomnia (see [4]), there also remains
a gap in the literature describing the patient perspective on treat-
ment. Such fundamental work is long overdue, and has potentially
important implications.
Firstly, although there are a number of plausible explanations as
to how CBT-I exerts its therapeutic effect [5–10], there are few
experimental studies that shed light on candidate mechanisms.
Tracking the subjective narrative account of treatment, longitudi-
nally, may prove fruitful in conﬁrming, as well as discovering,
factors associated with CBT-I response.
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Secondly, it is often presumed that psychological therapies, in
contrast to pharmacological interventions, are devoid of ‘side-
effects’ [11,12]. This may be naïve, particularly in the context of
the behavioural treatment of insomnia. Stimulus Control and Sleep
Restriction therapies can lead to signiﬁcant (acute) decrements in
total sleep time, and, therefore, possibly induce daytime dysfunc-
tion over and above baseline difﬁculties. The presence of ‘side-
effects’ are yet to be described, systematically, beyond anecdotal
report [6,13]. Fittingly, in their recent review, Riemann and Perlis
[2] asserted ‘‘the question of adverse events has not been properly ad-
dressed up to now in research on psychological/behavioural methods,
possibly taken it for granted that no such risks exist. . .research on ad-
verse events for psychological treatments needs to be intensiﬁed’’ (p.
213). The NIH state-of-the-science conference statement (2005)
[3] came to similar conclusions: ‘there is no evidence that such treat-
ment produces adverse effects, but thus far, there has been little, if any,
study of this possibility’ (p. 1056).
The lack of investigation of CBT-I side-effects can be contrasted
with approaches in other areas of medicine, such as pharmaceuti-
cals, where there tends to be rigorous recording of ‘adverse events’
during active therapy. Adverse event proﬁles are then used as cau-
tionary notes to inform patients when initiating treatment. This is
also the case for sleep apnea patients undergoing continuous posi-
tive airway pressure (CPAP) therapy, where side-effects have been
associated with drop-out rates and non-adherence during clinical
trials [14].
Thirdly, the beneﬁt of prospective qualitative monitoring may
be a contribution to our understanding of adherence to behavioural
instructions. To date, there are only a handful of published studies
investigating adherence to stimulus control and/or sleep restric-
tion, using a variety of adherence measures – from session atten-
dance and therapist ratings to sleep diary data. Nevertheless, this
small literature indicates that: (1) consistency of bed/rising times,
though not necessarily sleep reduction, may be predictive of out-
come [15]; (2) questionnaire ratings of retrospective global adher-
ence moderately relate to outcome [16]; and (3) pre-treatment
sleepiness, dysthymia, lower self-efﬁcacy, perceived barriers to
treatment engagement, and CBT-related sleepiness are all associ-
ated with reduced adherence and implementation of behavioural
guidelines [16–19]. Crucially, although questionnaire data indicate
that behavioural aspects of CBT-I strongly relate to outcome at one
year follow-up, they remain among the least liked and used com-
ponents of CBT-I [20,21]. Qualitative data tracking patients’ imple-
mentation of behavioural instructions could shed light on factors
relevant to therapy adherence, and potentially help reﬁne the fu-
ture delivery of CBT-I.
Fourthly, post-interventional functioning/health-related qual-
ity of life (HRQoL) has been inadequately investigated in the
CBT-I literature (for a review, see [22]). Indeed, given the small
and mixed literature on functional assessment and outcome,
some authors have questioned whether improving sleep in those
with insomnia will in fact modify self-reported daytime func-
tioning (e.g. [23,24]). Explanations for this apparent incongru-
ence include concerns with measurement [22], and theoretical
interpretations surrounding physiological arousal (e.g., [24,25])
and dysfunctional cognitive processes (e.g., [26,27]). One poten-
tial way to shed light on sleep and functioning (treatment) rela-
tionships is to simply ask participants to describe, in their own
words, the impact of insomnia treatment on domains of
functioning.
Qualitative methodologies are increasingly being recognised for
their ability to explore topics that are poorly dealt with using con-
ventional quantitative tools. Some recent examples in medicine
and health care include: understanding adherence/non-adherence
to medical regimes [28,29]; experience of illness (e.g., chronic pain
[30]); the phenomenology of emotional (blunting) side-effects of
antidepressants [31]; and factors that prompt/delay patients in
seeking medical advice (e.g. breast cancer patients [32]). Although
slow to ﬁlter into sleep medicine, perhaps given the infancy of the
ﬁeld, qualitative methodologies have also been applied to the
treatment of sleep apnea, providing important information on
inhibitory and facilitatory factors related to CPAP adherence [33].
In light of the aforementioned potential beneﬁts of qualitative
inquiry, we designed a within-subjects mixed-method study to im-
prove understanding of the implementation, experience, and
impact of a condensed sleep restriction intervention. Sleep restric-
tion therapy (SRT) was chosen because of its strong relationship
with outcome, relative ease of administration, and reliance on
adherence to prescriptive guidelines. Combining common quanti-
tative measures with qualitative techniques, it was felt, would
provide a more holistic and pragmatic picture regarding patient
experience and attributions, capturing strengths of both inductive
and deductive research.
The treatment process was investigated using: (1) audio-
diaries, to capture in vivo proximal reﬂections, and (2) post-
treatment face-to-face semi-structured interviews, to provide a
global experiential account. In addition to exploring the subjec-
tive experience of sleep restriction, our design permitted the
evaluation of self-reported changes in daytime functioning, form-
ing a secondary aim. Although single-component sleep restric-
tion [34] and sleep compression [35] interventions have proven
successful in terms of modifying sleep parameters, comprehen-
sive assessment of daytime functioning impairments is lacking.
Thus, we also sought to evaluate whether our brief intervention
could improve daytime as well as (predicted) sleep outcome
variables.
2. Methods
2.1. Participants
Individuals meeting research diagnostic criteria (RDC [36]) for
primary insomnia (PI) were recruited into the study. Participants,
therefore, reported difﬁculties with initiation and/or maintenance
of sleep, lasting for at least a one-month period. Individuals were
excluded if they had a co-morbid active psychiatric disorder, or
medical disorder that was related to sleep disturbance (i.e. partic-
ipants could have co-morbid medical ailments but they had to
show temporal separation, and attributional independence, from
the insomnia disorder). This was ascertained using the Glasgow
Sleep Centre screening interview schedule, based on a template
set out by Morin and Espie [9]. Additionally, in keeping with diag-
nostic criteria of insomnia as a 24-h disorder, participants had to
report at least one daytime impairment attributed to disturbed
sleep [36].
Participants were aged between 18 and 65, and recruited
through two avenues: (1) those completing non-interventional
University of Glasgow Sleep Centre (UGSC) projects; and (2) those
responding to local and national adverts, seeking individuals with
sleep disturbance to take part in UGSC research. Finally, those tak-
ing prescription sleep medication were accepted into the study
only if they maintained a stable regime, i.e., they had not under-
gone a modiﬁcation to treatment strategy in the four weeks prior
to treatment initiation. The study was approved by the Greater
Glasgow and Clyde NHS local ethics committee.
2.2. Treatment protocol
Treatment was conducted in groups of three or four and deliv-
ered by the lead researcher. Following a seven-day baseline period,
treatment took place over four weeks, comprising two group
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sessions and two individualised phone conversations (see Fig. 1 for
session time-line). Sleep restriction therapy content was based on
Morin and Espie [9] and the Glasgow Sleep Centre protocol for CBT
[37], and delivered using PowerPoint™ presentation slides in
group format. Speciﬁcally, a calculated sleep window was based
on the average total sleep time for the baseline period, and was
positioned according to the individual schedule of each patient
(accounting, also, for circadian factors). If the patient felt that their
calculated window was unachievable, then there was some negoti-
ation to try to facilitate adaptation and adherence.
The sleep window was titrated in the following ways: if sleep
efﬁciency for the week wasP90%, then the sleep window was in-
creased by 15 min; if sleep efﬁciency was <85%, then the sleep win-
dow was decreased by 15 min; and if values fell between 85% and
89%, then there was no change to the schedule. Downward adjust-
ments were not made until the end of the second week. The min-
imum possible sleep window duration was set at 5 h.
2.3. Outcome questionnaire measures
The following measures were completed at baseline, post-treat-
ment (four weeks), and three-month follow-up. As well as consti-
tuting an outcome variable, sleep diaries were completed each day
throughout the treatment phase to guide implementation and
titration.
2.3.1. Sleep
Participants completed a daily sleep diary (based on a template
set out by Morin and Espie [9]), the Insomnia Severity Index (ISI
[8]), the Pittsburgh Sleep Quality Index (PSQI [38]), and the Glas-
gow Sleep Effort Scale (GSES [39]).
2.3.2. Daytime functioning and side-effects
To assess aspects of daytime functioning and insomnia-related
quality of life, participants completed the Occupational Impact of
Sleep Questionnaire (OISQ [40]), the Glasgow Sleep Impact Index
(GSII [41]), the Daytime Functioning and Sleep Attribution Scale
(DFSAS [42]), and the Short-Form Health Survey 36 (SF-36 [43]).
The OISQ is a 24-item scale assessing the impact of sleep quality
on various aspects of work-related tasks and productivity (range
0–96; greater scores reﬂecting more impairment). The tool dis-
criminates between those with insomnia and good sleepers and
has high internal consistency (Cronbach’s alpha = .95) [40]. The
GSII was developed to quantify insomnia-related impairments rel-
evant to each individual patient. Participants write down in their
own words the three most important aspects of their life impacted
by poor sleep. These are subsequently ranked in importance (1–3)
and rated on a 100 mm visual analogue scale (0–100; lower scores
reﬂecting greater impairment). The GSII has demonstrated good
concurrent validity, relating moderately with several SF-36 dimen-
sions [41]. The DFSAS is a two-part scale developed to assess
impairments in a range of symptoms commonly associated with
insomnia disorder (part 1, range 0–36; higher scores indicating
greater impairment). Part 2 of the scale asks participants to rate
each item again, though this time in relation to how much poor
sleep was responsible for the impairment reported in part 1 (range
0–48; higher scores reﬂect greater poor sleep attribution). Preli-
minary data indicates good discriminant and concurrent validity,
and high internal consistency (Cronbach’s alpha = .81 for part 1,
and .89 for part 2) [42].
Participants also completed a newly-developed side-effects
checklist and interference scale. This scale asks patients to check,
from a list, symptoms experienced as a consequence of sleep
Baseline: 7-day diary
(~ 45-60 minutes)
week 1
(~ 30-45 minutes)
week 2
(~ 5-10 minutes)
week 3
(~ 5-10 minutes)
week 4
Session 1, Sleep Centre: Treatment rationale & instructions
          (keep audio-diaries)
Session 2, Sleep Centre: Review & planning
Session 3: weekly phone call to monitor progress/titrate
               Session 4: weekly phone call to monitor progress/titrate
Final meet, Sleep Centre: semi-structured interview & debriefing
    3 month follow-up: complete questionnaire pack
Fig. 1. Session time-line.
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restriction therapy. Owing to the lack of an existing tool speciﬁc
for CBT-I ‘adverse events’, items were generated spanning a mix
of somatic and psychological domains, that may be perturbed by
sleep deprivation and alterations to sleep timing. Checked symp-
toms are rated in terms of their interference with daytime func-
tioning (0–4 scale: ‘not at all’ to ‘very much’), following a similar
format to existing published side-effects questionnaires used in
pharmacological assessment (e.g. antidepressants [44]). Addi-
tional space at the end of the scale also allows patients to qual-
itatively report domains of impairment not listed. The scale was
completed during session 2, one week after the commencement
of treatment, to align with audio-diaries and to capture initial
acute impact.
2.4. Qualitative methodologies
2.4.1. Audio-diaries
Handheld dictaphones (Olympus™ WS-200s) were utilised to
track subjective experiences during the ﬁrst week of treatment.
Participants were asked to make two entries per day, according
to open-ended semi-structured guidelines. In brief, on awakening
(within 30 min), participants described their experience of
implementing treatment instructions for the preceding sleep peri-
od. Similarly, in the evening, approximately 2 h before going to
bed, participants were instructed to reﬂect on the course of the
day and how their previous night’s sleep (with reference to their
new schedule) affected their ability to function, ‘‘for better or
worse’’. Thus, evening entries were completed sufﬁciently prior
to the sleep-onset period to avoid creating excessive sleep pre-
occupation, or pre-sleep anxiety, proximal to sleep-initiation.
Guidelines were purposely kept open to facilitate recording of rel-
evant and interesting topics.
The study rationale was presented to participants as an investi-
gation into the experience of sleep restriction. There was no prim-
ing in terms of what information we were particularly interested
in; rather, it was emphasised that we wanted to know as much
as possible about the experience of SRT implementation (good or
bad), from the individual perspective.
2.4.2. Semi-structured interviews
Four weeks after treatment initiation, participants were inter-
viewed by the lead researcher on their overall experience of treat-
ment. The interview format and schedule was based on published
guidelines [45] and consisted of open-ended ﬁxed questions, with
supplementary prompts – again permitting exploration of addi-
tional interesting and relevant topics. Core questions covered the
following areas: treatment understanding and expectations;
implementation of sleep schedule; and impact on sleep and day-
time functioning.
2.5. Data preparation and analyses
2.5.1. Treatment outcome variables
Dependent variables were screened for extreme outliers and as-
sessed for normality using histograms and boxplots. Logarithmic
transformations were performed to correct skewed distributions.
The trial aspect of the study was viewed as an intention-to-treat
analysis; hence, the last observation carried forward (LOCF) meth-
od was used to impute missing data values. Imputation was almost
exclusively conﬁned to the three patients lost between post-
treatment and follow-up assessments.
Changes in sleep diary variables (sleep-onset latency, SOL;
number of awakenings, NAW; wake-time after sleep-onset, WASO;
total sleep time, TST; sleep efﬁciency, SE; sleep quality, SQ), sleep-
related questionnaires (ISI, PSQI, GSES), and daytime functioning
measures (GSII, DFSAS, OISQ, SF-36) across the three time points
were assessed using repeated measures ANOVA. For those vari-
ables failing to meet the sphericity assumption, degrees of freedom
and corresponding probability were adjusted using the Green-
house–Geisser correction [46]. Signiﬁcant main effects were subse-
quently followed up using paired t-tests. Cohen’s d [47] is reported
to provide an indication of effect size (ES) magnitude for baseline
to follow-up changes.
2.5.2. Audio-diaries and semi-structured interviews
Audio-diaries and interviews were transcribed verbatim,
including pauses, laughter and false starts. Audio-diaries and inter-
views were analysed separately and according to the framework of
thematic analysis [48]. Structured guidelines establish thematic
analysis as a ﬂexible method in its own right, unconstrained by
theoretical and epistemological underpinnings.
Analysis was a recursive process involving several stages [48].
First, transcripts were read through several times to gain a sense
of the whole phenomenon under investigation. On subsequent
readings of individual transcripts, signiﬁcant words and/or phrases
were highlighted and bullet points were entered in the margins,
creating preliminary coding schemes. After several further reviews
of the transcripts, initial notes and codes were collated into
themes. Themes were compared across individuals, looking for
common recurrent themes as well as inconsistencies and con-
tradicting cases. Themes were reﬁned throughout the analytic pro-
cess via discussions with another insomnia researcher (also a
clinician) and from feedback during data presentation at lab
seminars.
Given that the focus was on generating descriptions of the Sleep
Restriction Therapy experience, emphasis was initially placed on
identifying themes at the semantic or explicit level [48]. These
were then subsequently related to, and interpreted in light of, con-
temporary literature on the behavioural management of insomnia,
as well as additional questionnaire ﬁndings from the present study.
3. Results
3.1. Participant demographics
Participant (n = 18) demographics are presented in Table 1. The
mean age of the sample was 41.9 (standard deviation: 13.2), with
a range of 18–64 years. Five participants were male (13 female),
and the average insomnia durationwas 17.0 (14.4) years. Three par-
ticipants had problems initiating sleep only, 3 had difﬁculties with
maintaining sleeponly, and the remaining12 suffered fromboth ini-
tiation and maintenance difﬁculties. Finally, 2 participants (11%)
were on prescribed sleep-promoting hypnotics at treatment intake.
3.2. Sleep outcomes
Table 2 provides an indication of main effects of time, post hoc
comparisons between assessment points, and related statistical
signiﬁcance.
Table 1
Participant demographics.
Demographics PI patients (n = 18)
Age (years) 41.9 (13.2)
Gender 5 male/13 female
Insomnia duration (years) 17.0 (14.4)
Insomnia sub-type
Inititiating 3
Maintaining 3
Mixed 12
Medication 2/18 (11%)
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3.2.1. Sleep onset latency (SOL)
There was a signiﬁcant change over time in mean subjective
SOL. As is evident from Table 2, mean SOL for the group de-
creased signiﬁcantly by 21 min, from 41 min pre-treatment to
20 min at the post-treatment assessment. This improvement
was sustained, and remained signiﬁcant, at 3-month follow-up
(ES = 0.80).
3.2.2. Total sleep time (TST)
Subjective TST remained similar from baseline (320 min) to
post-treatment (323 min). At 3 months, mean TST signiﬁcantly im-
proved, relative to baseline ﬁgures, by 47 min (ES = 0.67).
3.2.3. Number of awakenings (NAW)
Number of nightly awakenings signiﬁcantly decreased from
baseline (3.0) to post-treatment (1.4). This effect was maintained
at 3-months (M = 1.7; ES = 0.69).
3.2.4. Wake-time after sleep-onset (WASO)
A signiﬁcant effect of time was again found with mean WASO
values. Mean WASO of 72 min at baseline signiﬁcantly reduced
by 43 min to 29 min at post-treatment. These improvements were
sustained and remained signiﬁcant at 3 month follow-up
(ES = 1.06).
3.2.5. Sleep efﬁciency (SE)
Mean SE signiﬁcantly increased by an average of 21%, from 64%
at baseline to 85% post-treatment. Three month average SE (81%)
values remained highly signiﬁcant relative to pre-treatment
assessment, with a net improvement of 17% (ES = 1.18).
3.2.6. Sleep quality (SQ)
Small but signiﬁcant improvements were recorded for subjec-
tive sleep quality, from baseline to post-treatment. These beneﬁts
were statistically maintained at 3-month follow-up (ES = 1.07).
3.2.7. Insomnia Severity Index (ISI)
Baseline mean ISI values (17.2) indicated the presence of clin-
ical insomnia of moderate severity, according to scale cut-offs.
Post-treatment reductions in ISI scores were signiﬁcant (mean
of 9.7 – ‘sub-clinical insomnia’), and were maintained at 3 month
follow-up (ES = 1.41). In terms of clinical signiﬁcance, 6/18 (33%)
participants scored in the ‘no insomnia’ range (‘remitters’) at
post-treatment. The number of ‘remitters’ at follow-up increased
to 8/18 (44%). Treatment ‘response’ rates were calculated based
on recently published minimally important difference data for
the ISI [49]. The number of individuals evidencing a change of
at least six ISI scale points at post-treatment was 66.6% (12/
18). This rate of treatment response remained the same at fol-
low-up (66.6%).
3.2.8. Pittsburgh sleep quality index (PSQI)
Similar to the ISI, mean PSQI scores signiﬁcantly decreased from
baseline (13) to post-treatment (8). This improvement was also
sustained at the three month assessment point (ES = 1.52).
3.2.9. Glasgow sleep effort scale (GSES)
Mean GSES score changes between baseline (9) and post-treat-
ment (5) were highly signiﬁcant. Again, this pattern remained ro-
bust at three-month follow-up (ES = 1.09).
3.3. Daytime functioning/HRQoL outcomes
Table 3 provides an indication of main effects of time, post hoc
comparisons between assessment points, and related statistical
signiﬁcance.
3.3.1. Daytime functioning and sleep attribution scale (DFSAS)
Mean scores on part one of the DFSAS signiﬁcantly reduced
from baseline (18) to post-treatment (12). Comparisons between
post-treatment and 3-month follow-up indicated further reduc-
tions in associated daytime impairment, which again reached
statistical signiﬁcance, above and beyond post-treatment effects.
Effect size magnitude for baseline to follow-up change was large
(ES = 1.42). Concerning part 2, the attributional component, re-
peated measures ANOVA indicated a main effect of time. Mean
values signiﬁcantly improved post-treatment, which were found
to be most robust at follow-up (ES = 0.99).
3.3.2. Glasgow sleep impact index (GSII)
Both GSII ranks 1 and 2 indicated main effects of time. Post-
hoc testing for rank 1 revealed signiﬁcant effects at post-
treatment and follow-up, with effects being most pronounced
at ﬁnal assessment (ES = 1.21). Rank 2 similarly demonstrated
improvements across the three assessments, though effects
achieved signiﬁcance only at the 3-month follow-up (ES = 1.04).
There was no within-subjects effect for rank 3, with mean values
remaining quite stable over the assessment points.
3.3.3. Occupational impact of sleep questionnaire (OISQ)
The OISQ was completed by 16 (89%) working participants in
the study. Mean OISQ values signiﬁcantly improved at
Table 2
Treatment effects and post hoc comparisons for sleep diary and questionnaire variables.
Baseline Post-treatment (4 weeks) Follow-up (3 months) df F P
M (SD) M (SD) M (SD)
Diary
SOL (mins.) 41.1 30.6 19.7** 13.8 21.3** 17.3 (1.3, 21.9) 13.08 .001
TST (mins.) 319.8 75.3 323.1 48.8 367.1**,a 65.6 (2, 34) 7.03 .003
NAW 3.0 2.2 1.4*** 1.2 1.7*** 1.4 (1.4, 24.5) 22.50 <.001
WASO (mins.) 72.0 55.6 29.0** 35.9 26.3*** 25.2 (2, 32) 17.21 <.001
SE (%) 64.2 14.4 85.3*** 10.5 80.9*** 13.9 (2, 34) 23.44 <.001
Sleep Quality (0–4) 1.4 0.6 2.1*** 0.7 2.2** 0.9 (2, 34) 15.38 <.001
Questionnaire
ISI 17.2 3.8 9.7*** 5.2 10.1*** 6.1 (1.5, 25.8) 24.45 <.001
PSQI 12.6 3.00 8.0*** 2.0 7.8*** 3.4 (2, 32) 27.73 <.001
GSES 9.3 3.3 5.3*** 2.5 5.6*** 3.5 (2, 34) 18.47 <.001
** Indicate post hoc signiﬁcant changes from baseline: p < .01.
*** Indicate post hoc signiﬁcant changes from baseline: p < .001.
a Contrast with post-treatment mean signiﬁcant at p < .05.
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post-treatment by, on average, 16 points. This effect remained ro-
bust and signiﬁcant at three month follow-up (ES = 0.74).
3.3.4. Short-form health-survey 36 (SF-36)
Three dimensions of the SF-36, ‘vitality/energy’ (VT), ‘mental
health’ (MH), and ‘role-physical limitations’ (RP) evidenced main
effects of time, while ‘role-emotional limitations’ (RE) just nar-
rowly missed signiﬁcance at the 5% alpha level (p = .055). Both
RE (ES = 0.48) and MH (ES = 0.67) dimensions achieved statistical
signiﬁcance at 3 months (relative to baseline values), whereas RP
evidenced statistically signiﬁcant improvements at the post-treat-
ment assessment point only. For the Vitality dimension, both post-
treatment and 3 month values (ES = 0.82) indicated signiﬁcant
improvements relative to baseline levels. There was no effect of
time or trends for the other four dimensions.
3.4. Treatment side-effects
Impairments as a consequence of SRT initiation were common.
Indeed, for eight out of the twelve listed domains, P50% of the
sample reported sleep restriction-related impairment (see Table 4).
The mean number of endorsed side-effects for each patient was 7.2
(SD = 2.4; range = 3–11). The four most commonly reported symp-
toms were ‘fatigue/exhaustion’ (100% of sample), ‘extreme sleepi-
ness’ (94%), ‘reduced energy/motivation’ (89%) and ‘headache/
migraine’ (72%). Subsequent ratings of the extent of ‘side-effect’
interference revealed that ‘fatigue/exhaustion’, ‘extreme sleepi-
ness’, ‘feeling irritable’ and ‘changes in hunger/appetite’ interfered
‘somewhat’ to ‘much’ (mean ratings 2–3) with everyday function-
ing (Table 4). Six (33%) participants added, qualitatively, additional
domains of impairment. These spanned the categories of: pain/dis-
comfort, temperature regulation, word-ﬁnding difﬁculties, social
interaction impairment, greater illness susceptibility, ‘hangover’-
like effects, problems with concentration and fatigue at unusual
times.
We also carried out exploratory correlation analyses between
number of experienced side-effects, relative daytime interference
ratings for side-effects [i.e. (interference score for checked symp-
toms/total possible score for checked symptoms)  100], and sleep
improvements (baseline to post-treatment). It was found that a
higher frequency of side-effects was associated with a greater
magnitude of change on the PSQI (r = .51, n = 17, p < .05; see
Fig. 2) and, to a lesser (non-signiﬁcant) degree, sleep efﬁciency
(r = .44, n = 18, p = .065) and ISI (r = .33, n = 18, p = .185) values.
Other measures of sleep continuity were weakly and non-signiﬁ-
cantly related to side-effect frequency. Greater relative side-effect
daytime interference ratings were signiﬁcantly related to both
improvements in PSQI scores (r = .54, n = 17, p < .05) and reduc-
tions in sleep effort, as measured by the GSES (r = .48, n = 18,
p < .05). Relationships between side-effects and three-month sleep
outcomes were weak in magnitude and non-signiﬁcant.
3.5. Qualitative results
At the outset of the study, it was our intention to recruit approx-
imately 50% of the total sample into the qualitative component of
the trial. Participants were initially selected based on random allot-
ment, within each treatment group, but because of time constraints
Table 3
Treatment effects and post hoc comparisons for daytime functioning and HRQoL variables.
Baseline Post-treatment (4 weeks) Follow-up (3 months) df F P
M (SD) M (SD) M (SD)
DFSAS
Part 1 17.9 5.3 12.1** 5.8 9.9**,a 5.9 (1.4, 23.4) 11.94 .001
Part 2 24.8 10.2 18.9* 12.1 14.4** 10.7 (2, 34) 8.59 .001
GSII
Rank 1 31.4 17.3 53.3* 24.6 57.3** 24.9 (2, 32) 8.07 .001
Rank 2 36.0 18.0 51.0 26.1 57.1** 22.3 (1.5, 24.9) 6.03 .013
Rank 3 47.4 19.6 52.0 23.1 55.5 25.0 (2, 34) 1.35 .274
OISQ
42.8 18.4 26.8* 13.2 26.7** 24.8 (2, 30) 4.66 .017
SF-36
PF 91.1 10.1 91.4 9.5 91.3 8.7 (2, 34) 0.02 .985
SF 69.5 25.8 74.3 24.4 77.1 24.3 (2, 34) 1.21 .312
RP 76.8 21.8 86.4* 12.7 83.9 15.5 (2, 34) 3.78 .033
RE 73.2 21.3 77.8 16.7 82.6* 18.3 (2, 34) 3.15 .055
MH 62.8 15.0 68.3 13.5 73.3* 16.4 (2, 34) 5.05 .012
VT 39.7 12.9 46.5* 16.8 53.0** 18.8 (2, 34) 6.77 .003
BP 75.8 23.8 78.9 26.9 78.5 27.6 (2, 34) 0.13 .878
GH 63.8 16.7 66.5 18.8 69.4 14.9 (2, 32) 1.47 .244
PF, physical functioning; SF, social functioning; RP, role-physical limitations; RE, role-emotional limitations; MH, mental health; VT, energy/vitality; BP, bodily pain; GH,
general health perceptions.
* Indicate post hoc signiﬁcant changes from Baseline: p < .05.
** Indicate post hoc signiﬁcant changes from Baseline: p < .01.
a Contrast with post-treatment mean sig. at p < .05.
Table 4
Side-effect frequency and average daytime interference rating for checked symptoms.
Symptom % of sample
reporting symptom
Daytime functioning
interference rating (0–4)
Low mood 61 1.55
Fatigue/exhaustion 100 2.56
Extreme sleepiness 94 2.58
Feeling agitated 50 1.78
Bodily pain 33 1.17
Headache/migraine 72 1.31
Euphoria/intense
increase in mood
39 1.29
Reduced motivation/
energy
89 1.88
Changes in hunger/
appetite
72 2.00
Blurred vision 22 1.00
Dizziness 28 1.40
Feeling irritable 61 2.09
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and recruitment difﬁculties all participants within the ﬁnal few
treatment groups were selected to take part. Hence, 14 (78%)
participants (4 male; 10 female) completed both audio-diaries and
interviews, which was slightly more than predicted from the
outset, though within standard limits for qualitative research.
3.5.1. Audio-diaries
In week one of SRT, participants, in total, recorded 179 diary en-
tries. Transcription produced 29,100 words of data. Thorough
analysis of both morning and evening entries revealed three major
themes, each with respective sub-themes/categories. Selected di-
rect quotes are presented as examples to support generated
themes and pseudonyms are used to protect patient identities
(see Table 5).
3.5.1.1. Daytime side-effects: ‘it’s made it worse’. Participants de-
scribed, on the whole, feeling and functioning worse during week
one of therapy relative to pre-treatment, making strong causal
attributions to SRT. A reduction in sleep opportunity typically
translated into less total sleep time, which had implications for
the remainder of the day. Although impairment perhaps indicated
that the therapy instructions were being followed and possibly
beginning to work – in the sense that sleep pressure was being ap-
plied – this was clearly not without consequences. Indeed, these
consequences were conveyed on awakening, proximal to the
sleep-period, with common references to ‘zombie’ or ‘hangover’-like
states.
No. of side-effects
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Fig. 2. Scatterplot of relationship between PSQI change scores (baseline to post-
treatment) and number of experienced side-effects.
Table 5
Major themes/sub-themes from thematic analysis of audio-diary entries and supporting example patient quotes.
Theme Sub-themes Example quotes
Daytime side-effects: ‘it’s
made it worse’
On awakening ‘‘. . . I feel like I’m drunk at the moment, my head’s quite swimming, and not thinking very straight at all, I
ﬁnd it quite hard to write in this bit of paper too’’ (Bill, 68–70)
‘‘ In terms of sort of quality of sleep, I actually feel this morning as if I’ve got a hangover, and I didn’t drink
anything last night, I’ve got a headache and actually I feel quite sick’’ (Jennifer, 23–25)
Throughout the course of the
day
‘‘Woke up bright and breezy, half six, Tuesday morning, raring to go, got into the car. . . and within twenty
minutes I was absolutely exhausted, so bad that I swear I was nearly falling asleep all the way to work. It
was torture, I was cross-eyed, eyes drooping, driving’’ (Sarah, 122–126)
‘‘Hi, it’s Sunday night, about ten o clock and I’m absolutely exhausted, I’ve had a really bad day and never
left the house the whole day, just felt so bad, I don’t know if I can stay up till one o’ clock. I just feel totally,
at the moment, terrible’’ (Gillian, 58–60)
‘‘The restrictive programme has affected my ability to function, it’s made it worse forme working, its been
very hard at work to focus and be as sharp as you should be’’ (Bill, 187–188)
Adjustment to new sleep
schedule
Challenges to adherence ‘‘. . .this regime would be quite easy to do if you didn’t have any social life, as soon as you’re going out late,
or drinking, or whatever, it does sort of seem to go to pot a bit. I’ll certainly restart it again tonight. I think
that’s the difﬁculty come the weekend, it all goes a bit haywire, so whether that’s undoing any good that
it’s done through the week, I possibly would think so. . .’’ (Jennifer, 196–198)
‘‘Em, just talking about the experience of implementing my new bedtime routine, I feel it’s just been really
negative so far, and although I can understand that it probably will work eventually, at the moment I just
feel really bad. I’ve had about an hour and a half to two hours sleep last night, and just feel really bad
today, and already just worrying about how on earth I’m gonna stay up till one o clock this morning’’
(Gillian, 65–71)
‘‘ I’m not driving tomorrow, but frankly in order to function at work tomorrow, I’m seriously considering
going to my bed probably about twelve tonight, that’s about as late as I can cope (with), because I can’t do
another, morning I suppose like today – that was really grim, it was absolutely dire. . .’’ (Sarah, 132–135)
Coping strategies to help
facilitate adherence
‘‘I made a point of staying with a friend to keep me awake for a while tonight. . . they’re off work. . . it’s
made me stay awake and not be tempted to go to bed earlier than I should do’’ (Jim, 55–57)
‘‘ I put more lights on than I normally would cos normally I would have it sort of quite dark in the lounge
but I reckon more light is probably a good thing, just to keep me awake – and I think it’s working’’ (Sarah,
39–41)
Evolving changes to the
sleep experience
‘Unusual’ feelings of sleep
pressure
‘‘these napping situations, it’s not like I’m sitting down wanting to nap but it’s just that I’m tired and I’m
watching the telly and I’m drifting off and that’s so unlike me’’ (Hannah, 118–119)
‘‘this afternoon I was very dosey and sort of quite tired because I had sort of struggled a little bit with sleep
last night, I got about three and a half hours all in, and this morning found it quite hard to get up. Which
(is) a little bit unusual for me’’ (Jim, 46–48)
‘‘I got really tired about three o’clock but not the usual tired that I get – just can’t be bothered doing
anything – but more I could fall asleep at my desk and my eyes really gritty tired’’ (Lisa, 49–50)
Changes to sleep quality:
could this be working?
‘‘I’ve got to admit, despite being up twice during the night, I’m having a deeper sleep than I normally get
and that’s been the same for the last couple of nights, although it’s shorter, it’s actually deeper’’ (Maria,
60–62)
‘‘I do feel that the quality of my sleep last night was better than before I started the programme’’ (Sarah,
142–143)
‘‘I’m feeling quite good today, and I had a good sleep last night, I didn’t wake up at all during the night, and
I went out like a light at twelve thirty which was very unusual for me, but I think it was because the whole
night I was craving sleep’’ (Hannah, 144–145)
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Sleep restriction therapy negatively impacted on numerous
daytime functioning domains. On an elementary level, participants
reported feeling exhausted and fatigued, experiencing difﬁculties
with concentration and memory, as well as depressed mood. These
symptoms, combined, had the net effect of impairing aspects of job
performance and ability/effort to interact socially. Furthermore, 5/
14 patients (36%) made reference to impaired driving abilities at
least once during the course of the week. These references, in some
cases, reﬂected difﬁculty maintaining wakefulness during driving,
but more typically focused on compromised concentration and slo-
wed reactions to ongoing changes in the driving environment.
3.5.1.2. Adjustment to new sleep schedule. This theme captured the
practical experience of implementing set threshold and rising
times. Participants reported a number of issues that made adhering
(rigorously) to the programme incredibly challenging, and which
frequently led to non-adherence. Such factors included: spending
extended amounts of time on own, particularly at weekends; run-
ning out of activities to do during extra hours (boredom); inability
to stave off sleepiness until set bed time; fear of disrupting partner
by entering the bedroom after they had initiated sleep; staying out
late, drinking and socialising; feeling pressure to ‘perform’ when
going to bed so late, and having a short period of time to obtain
adequate sleep; and, ﬁnally, no indication of re-bound sleep over
several nights of adherence, in parallel with accumulating daytime
difﬁculties.
A sub-theme captured strategies that patients put in place to
facilitate adjustment and promote adherence to sleep restriction
instructions. These again were numerous and varied, but included
the following: sleeping in a separate room from partner; partner
staying up late to accompany and motivate the participant to ad-
here; scheduling activities or making modiﬁcations to activity lev-
els to promote alertness, and to fend off sleep prior to set threshold
time; reducing alcohol intake and late nights out; and seeking out
other people’s experiences of sleep restriction via the internet for
additional reassurance/motivation.
3.5.1.3. Evolving changes to the sleep experience. Finally, participants
reﬂected on how sleep quality, feelings of sleep pressure, and
views on sleep, were beginning to change. These comments were
made, in nearly all cases, towards the end of the ﬁrst week as
improvements in sleep became apparent. Changes in sleep pres-
sure were conveyed with reference to the perceived ability to sleep
longer than usual (past set rising time), and, in particular, ‘unusual’
feelings of ‘tiredness’ and involuntary napping.
Table 6
Major themes/sub-themes from thematic analysis of post-treatment interviews and supporting example patient quotes.
Themes Example quotes
‘At the end of my tether’ ‘‘. . .just my mood and kinda temperament and it affected my everyday life, I thought, quite badly. . . and I thought things could
be better if my sleep was better, and it seems to be working’’ (Ross, 6–7)
‘‘I’ve tried herbalism. . . yeah just trying herbs and things, potions, but as I say I think it’s a whole lot of rubbish. . .somebody told
me it would work, it worked for them, so you go and try it, it didn’t work’’ (Bill, 41–43)
‘‘I had a wee bit of a fright about a few months ago, I didn’t fall asleep at the wheel, I would say I did, but it was almost too
quick. . . I was just really tired, and I remember the music was blasting, window was down, and I must have felt drowsy, and
then for a second my head was down and then I woke up, and I touched the kerb with the car, and I think I got a fright and I just
thought I have to do something about this’’ (Hannah, 24–27)
‘This is a sleep restriction
programme’
‘‘. . .the sort of limited amount of sleep that you were giving us in the ﬁrst night sounded pretty horriﬁc, and it was, the ﬁrst
week was really tough, eh, but I think I could see the sense then, but I didn’t see it immediately you know, it didn’t hit me
immediately that it was going to work, that sort of came in the second week’ (David, 16–19)
‘‘. . .that week one needs to come with a health warning’’(Sarah, 154)
‘‘driving was a nightmare, and I’ve never ever had an issue with driving before’’ (Bill, 84)
Adherence & adjustment ‘‘I suppose rationally and logically, it did seem a good idea, but then I think the ﬁrst week of actually doing it, I felt worse, and so
you kinda, there’s a temptation there to think ‘och this is not working’, like ‘give up now’’’ (Lisa, 17–19)
‘‘my husband was determined I was sticking at it, you know, cos he, when I was sitting at night-time, and I was like almost
falling asleep. . . he kept shouting at me ‘get up’, ‘wake up, don’t go to sleep’, you know it was kinda like that, but I felt it very
difﬁcult to get up and do anything, I was actually too tired to’’ (Gillian, 135–138)
‘‘. . .there’s been a few mornings where you’re oh you’re thinking, especially like Saturday and Sunday, ‘there’s just no way I
want to get out of my bed’, but then you think ‘well no’, especially at the weekend cos then if I lie long this morning then I don’t
get to sleep tonight, it’s just going to start the whole thing again, that’s, I suppose, the motivation, the fact that you think ‘well if
this makes you sleep ﬁve hours through the night, then just get up’’ (Lisa, 273–278)
‘I actually want to go to bed now’ ‘‘I’m sleeping longer, and going into a deeper sleep, I think, when I wake during the night it’s only. . . it’s less frequent, and it’s
easier to get back over again. . . previously if I woke up during the night I’d be worried about trying to get back over again, and I’d
be thinking about it, but because you’re so tired by this sort of programme then you actually get back over much quicker and it
seems to work’’ (David, 62–66)
‘‘you’re so knocked that you don’t have the anxiety to be anxious at that time of night, really, I’m so looking forward to going to
my bed, when I get to whichever hour my times up, I say ‘Yes, times up, going to bed’ (laughs) so that’s probably the highlight of
the day’’ (Bill, 167–170)
‘‘I think I’ve altered my, I just seem to have gone onto a different plain when it comes to my attitude to sleep, another thing
though I’ve realised is that it’s possibly true that I just don’t need 8 h of sleep, or even seven and a half hours sleep, or even
seven, possibly I only need about six and a half hours sleep’’ (Louise, 78–81)
‘‘I’m not concerned, I’m not worried about not sleeping, because I know that when I go to bed I will sleep’’ (Sarah, 188–189)
Daytime functioning: a thermometer
for success?
‘‘I do feel like a normal sleeper, which is bizarre and great, this has been huge for. . . like driving, I feel like I’m calmer you know I
don’t get road rage, I don’t. . . I’m not as bad as what I was, I’m taking less risks in the car, I’m not in a rush, because I’m not as
anxious, I’m not on edge, I’m just a bit more chilled I think, and I think the sleep helps to centre yourself.’’ (Hannah, 353–357)
‘‘much more sort of. . . quite motivated for work and stuff, eh, it deﬁnitely has had a very positive effect on my sort of daily life’’
(David, 87–88)
‘‘I think now I’m more likely if I’ve planned something for after work, to do it, I’m meant to, I’ve paid for most of this year west
Dunbartonshire council money for a gym membership, that I (‘ve) never been in, so I’m now back three times a week!’’ (Lisa,
185–187)
‘‘If I can build it up to six and a half I think, six and a half hours, I’m gonna feel like I can function, right, so I guess I’m thinking in
my head that’s where my functioning range is, six and a half hours is gonna allow me to function, eh, if I can better that then I’m
hoping that’s where the energy and the zest for life is going to come from’’ (Bill, 325–329)
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This increased sleep pressure was linked to self-reported
improvements in sleep, particularly reduced sleep latencies and
less frequent and lengthy awakenings. It was thus towards the
end of week one that patients were beginning to realise that the
programme might actually be working; that the acute exhaustion
and increased wake time might be a worthwhile endeavour.
3.5.2. Interviews
The same 14 participants also took part in a face-to-face inter-
view with the lead researcher at the post-treatment assessment
point. Verbatim transcription produced 66,400 words of data.
Following strict coding, a number of themes were generated, cap-
turing impressions and experiences of sleep restriction therapy
(see Table 6 for a summary of main themes and supporting
quotes).
3.5.2.1. ‘At the end of my tether’. Participants discussed why they
had decided to take part in the sleep restriction intervention;
descriptions tended to be dominated with references to daytime
and quality of life impairments, as key catalysts. Related to this,
it emerged that patients had tried a range of other treatments,
including medication/herbal strategies, that had, for the most part,
failed to effectively alleviate insomnia symptoms.
3.5.2.2. ‘This is a sleep restriction programme’. Initial subjective
impressions of SRT were that it was ‘logical’, and ‘made sense’;
yet, for some, it did still feel ‘counter-intuitive’, relative to how they
have typically tried to cope with their insomnia [i.e. extending
time in bed/’catch-up’ sleep: ‘‘. . .telling somebody with insomnia
‘stay up late’ is like turkeys voting for Christmas, don’t be ridiculous’’
(Sarah, 432–433)]. Others, although, again, ﬁnding it logical,
thought it seemed ‘too simple’ to be effective (‘insomnia is a chronic
problem’). This perceived ease or simplicity failed to translate into
actual experience, as the ﬁrst 1–2 weeks of the programme were
described as incredibly difﬁcult, and, by some, as ‘hell’ and even
‘torture’. As noted in audio-diary entries, participants similarly re-
ﬂected on the negative side-effects encountered in the early stages
of the programme, particularly relating to extreme fatigue and
sleepiness, impairing nearly all aspects of daytime functioning,
including subjective driving ability. These impairments were of
greater magnitude than pre-treatment functioning levels.
3.5.2.3. Adherence and adjustment. Adherence to set rising and
threshold times was affected by a number of variables. These in-
cluded, but were not restricted to, the following: experiencing
pressure to sleep in such a condensed period, coupled with concern
for next-day-functioning; external ﬂuctuating stressors and com-
mitments; actual felt impact of restricted sleep opportunity on
daytime functioning; and boredom associated with extra hours of
wakefulness. Weekend adherence was particularly difﬁcult for par-
ticipants, being adversely impacted by: socialising/alcohol con-
sumption, the prospect of being alone and awake for such a
lengthy period of time and the awareness of returning to work at
the beginning of the week (catastrophizing about possible daytime
consequences and coping).
Despite these obstacles, participants developed strategies to
help promote adherence, such as refraining from going out/social-
ising late at night, not allowing self to relax in comfortable posi-
tions prior to ‘threshold time’ (to prevent ‘dosing’/napping),
keeping active and setting chores and negotiations/discussions
with partner to facilitate adjustment.
Another factor that emerged was that non-adherence (mostly
sleeping-in and napping) contributed to sleep-onset problems
the subsequent evening, when attempting to ‘restart’ the pro-
gramme. This ‘experimental feed-back’ acted as a negative rein-
forcer, helping to reduce non-adherence and motivate continued
implementation of treatment instructions.
3.5.2.4. ‘I actually want to go to bed now’. For the majority of partic-
ipants signiﬁcant changes to sleep tended to occur in the second or
third week of treatment. These related to commonly-measured
sleep parameters, such as reduced sleep latency, decreased wake-
time after sleep-onset, and decreased number of awakenings.
Changes to sleep, however, also extended to more ‘subjectively’ ex-
pressed aspects of sleep, such as quality and depth of sleep, pre-
dictability that sleep will happen, and unusual feelings of sleep
pressure and ‘craving’. Interestingly, for many participants, this
paradigm shift to ‘looking forward’ to going to bed reduced sleep
anxiety/distress and pre-occupation, both at sleep-onset and dur-
ing awakenings.
Indeed, even for those few participants who felt they had not
beneﬁted from the sleep restriction programme, they did, however,
describe changes to their attitude towards sleep, particularly sleep
need. Having encountered side-effects during restriction, they
tended to have a ‘response-shift’ to their own sleep duration;
engendering ‘this could be worse’ phenomenon, which seemed to
relieve some pre-occupation/concern with sleep.
For most participants, improvements were considered to be
ongoing, and their perceived-capacity to obtain more sleep, and
build on gains, was a prime motivator for continuing with the pro-
gramme (after formal monitoring ceased).
3.5.2.5. Daytime functioning: a thermometer for success?. Although
improvements in functioning tended not to be as robust as changes
to sleep, at least at the time of interview, many participants re-
ported positive modiﬁcations to aspects of daily living, such as
having more energy, being more organised, being less anxious, en-
hanced coping skills, adopting a more positive outlook, and even
comments by signiﬁcant others concerning physical appearance.
These improvements were typically just evolving 1–2 weeks prior
to interview, in a slight time-lag behind sleep symptom changes.
Impact on functioning was considered a thermometer by many
to gauge therapy success. The continuation of a journey, an ongoing
treatment process, was often made with reference to obtaining fu-
ture improvements in aspects of functioning. Those individuals
who considered SRT to have been unsuccessful in terms of improv-
ing night-time sleep, or that only reported minimal improvements
(at least up until the interview), voiced that functioning was detri-
mentally affected during times of adherence (both acutely and
throughout the four-week period). In extreme cases this meant a
subsequent shift towards baseline sleep schedules, accompanied
by a return to ‘normal’ levels of functioning; while others voiced
determination to commit to the programme despite negative day-
time experiences.
4. Discussion
The aim of this mixed-method study was to investigate, using
both quantitative and qualitative methodologies, the patient expe-
rience of sleep restriction therapy for insomnia. We combined
sleep-diaries, questionnaires, audio-diaries and semi-structured
interviews in an attempt to understand the impact of SRT on sleep
and functioning, and, crucially, to systematically record patient ac-
counts of treatment implementation.
4.1. Sleep-related changes
All major sleep diary variables signiﬁcantly improved from
baseline to post-treatment (excluding TST), and these improve-
ments were maintained at three months. By three months, TST
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demonstrated a signiﬁcant gain of 47 min, on average, relative to
baseline values. Overall, sleep changes were comparable (and for
some variables, larger) in terms of magnitude to those obtained
in full CBT-I interventions [2] and previously published trials of
sleep restriction therapy [34]. Moreover, global insomnia disorder
severity (assessed using the ISI) indicated mean values for the
group to be in the ‘sub-clinical insomnia’ range at post-treatment
and follow-up, relative to baseline levels in the ‘clinical moderate’
range. The clinical signiﬁcance of these changes was conﬁrmed
with 44% and 67% of patients being classiﬁed as ‘remitters’ and
‘responders’, respectively, at three month follow-up.
Semi-structured interviews with patients, post-treatment, sup-
ported these changes in nightly sleep parameters, speciﬁcally con-
cerning reduced sleep-onset latencies, decreased number of
awakenings (also reported as a reduced ability to remember awak-
enings) and decreased amounts of wake-time during the night.
Interviews also revealed changes in subjective sleep quality; with
participants providing rich descriptions of sleep as being ‘deeper’
and ‘more efﬁcient’, as well as reporting dampened mentation at
sleep-onset and during middle-of-the night awakenings. Such
‘qualitative’ changes and increased predictability of sleep are likely
related to the harnessing of homeostatic sleep pressure and circa-
dian re-alignment, both desired targets of sleep restriction therapy
[6,7,10,50].
Importantly, participants described simultaneous modiﬁcations
to how they perceived sleep. The feeling of ‘craving’ sleep – as a
consequence of it being denied/restricted – represented a signiﬁ-
cant shift from how participants typically viewed the sleep-onset
and sleep period. In turn, this led participants to describe having
reduced anxiety and worry when initiating sleep, and during mid-
dle-of-the-night awakenings. Sleep restriction may work, in part,
then, by modifying – through partial sleep deprivation – the
evolved threat value that sleep and associated bedtime routine
have come to represent in those with primary insomnia, ultimately
restoring sleep automaticity. The knock-on effect of ‘craving’ sleep,
in terms of reduced pre-sleep anxiety and arousal, coupled with in-
creased nightly sleep predictability, may well relate to the robust
decreases in the application of ‘sleep effort’ (as measured by the
GSES), a concept central to recent cognitive models of psychophys-
iological insomnia (cf. [27,39]).
Related to this, it also emerged that some patients underwent
an adjustment process with respect to their sleep need during
SRT. Firstly, functioning worse in the ﬁrst week than they previ-
ously had done, some patients began to feel perhaps their sleep
problem was not as problematic or obstructive as once thought,
which seemed to provide some level of reassurance, despite no
obvious or immediate improved modiﬁcations to sleep. Secondly,
experiencing improved sleep quality, yet in the face of overall
shorter total sleep time, led some to question their perceptions
of individual sleep need. Thus, to build on Edinger and Means’
[10] description of ‘pathways’ implicated in CBT-I response, we
also suggest, based on our participant descriptions, that SRT may
have secondary or parallel effects on both ‘inhibitory factors’ (par-
ticularly conditioned arousal) and ‘cognitive factors/dysfunctional
beliefs’, thought to be important in the aetiology and maintenance
of insomnia. This, of course, requires additional empirical testing in
the context of isolated component intervention studies.
4.2. Side-effects and daytime functioning/HRQoL
Functioning ﬂuctuated over the course of the four-week period.
Responses from our newly developed side-effects checklist indi-
cated that at least one half of participants experienced eight of
the 12 listed symptoms as a consequence of sleep restriction ther-
apy during week one. Fatigue, extreme sleepiness, and reduced
motivation/energy were the most commonly experienced difﬁcul-
ties, and, along with irritability and changes to hunger/appetite,
negatively interfered with daytime functioning (to the greatest
degree). Though difﬁcult to make direct comparisons, these acute
effects do appear to be substantially higher than rates reported
in some pharmacotherapy studies [51]. In vivo diary reﬂections
corroborated these accounts, with participants describing, at
length, impairments in occupational performance, social func-
tioning and everyday duties, citing exacerbated levels of fatigue
and sleepiness and their subsequent downstream effects on cog-
nition as responsible. Of particular prominence, more than one-
third of our sample described, during diary entry recordings,
concerns with driving ability; reﬂecting issues with maintaining
wakefulness, impairments in concentration, and slowed reactions
to changes in the ongoing driving environment. With numbers of
this magnitude, it is clear that SRT is not an intervention with
just mild and trivial effects, and it remains to be determined if
such a treatment approach (at least acutely) is associated with
a ‘spike’ in automobile accidents (as reported with hypnotic
use: [52]). Clearly, the risk exists. It would be interesting to
qualitatively track patients assigned to active hypnotic therapy
to compare patient narratives and experiences across treatment
modalities.
To the best of our knowledge, side-effects encountered during
CBT-I have not been adequately described or investigated in previ-
ous literature. Perlis and colleagues [19], in their randomised trial
of modaﬁnil as an adjunctive to CBT, indicated that during week
one of treatment, sleepiness, as measured by the Epworth Sleepi-
ness Scale (ESS), approached pathological levels (ESS = 10.5 ver-
sus a baseline of 7), an effect that was in fact attenuated in the
CBT plus modaﬁnil group. The present study is the ﬁrst to reveal,
in-depth, the descriptive nature and magnitude of experienced
side-effects that were attributed to the programme. Interviews
suggested that for the majority of participants, side-effects sub-
sided 1–2 weeks into treatment initiation as sleep parameters be-
gan to stabilize and improvements in sleep quality evolved.
One intriguing ﬁnding was that the number of checked side-ef-
fects positively correlated (small to moderate strength) with ISI,
PSQI, and sleep efﬁciency change scores, from baseline to post-
treatment. Side-effect daytime interference ratings were also sig-
niﬁcantly associated with PSQI and GSES change scores (again
moderate strength). Although it is not entirely clear why this asso-
ciation exists, we can think of at least three possible explanations
for this relationship. First, it could be that those who tend to mon-
itor bodily and mental symptoms are more likely to detect and re-
port both experienced side-effects and improvements in sleep
quality. Second, and related to this, it could be that side-effects
provide some validation that the treatment is actually working
(in a similar manner to a drug, for example), leading to a relative
coupling with acute improvements in sleep quality. This could also
help explain why side-effects related weakly to 3-month out-
comes, where this relationship could be likely inﬂuenced by many
other extraneous variables, being sufﬁciently detached from the
experience of acute implementation. Finally, it may be that side-
effects provide an index of acute adherence to set threshold and
rising times and hence mediate this relationship with the outcome;
the association with decreased sleep effort gives further credence
to this argument. Of note, however, this ‘side-effect-outcome’ ac-
count runs partially counter to the ﬁndings of Perlis et al. [19],
who found that blocking/attenuating sleepiness using modaﬁnil
did not interfere with CBT-I efﬁcacy; concluding that sleepiness
may not be essential for CBT outcome. This ﬁnding, of course, does
not rule out additive effects of modaﬁnil properties beyond its
stimulant action, such as possible mood enhancement effects
[53], as well as increased levels of activity. Interestingly, the
authors also reported a tendency for this group to be more adher-
ent to bedtime instructions. Future studies must examine the
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mechanisms of sleep restriction and predictors of response, taking
into account the acute effects of implementation.
With respect to daytime functioning outcomes, signiﬁcant
improvements were observed on the DFSAS (parts 1&2), GSII
(ranks 1&2), OISQ, and three domains of the SF-36 (role-physical,
mental health and vitality/energy; role-emotional evidenced a
trend). Intriguingly, changes were most pronounced on our newly
developed scales (DFSAS, GSII), which may suggest enhanced sen-
sitivity of these measures – both based on words/experiences of
insomnia patients – in detecting daytime difﬁculties relevant to
those with insomnia disorder. Overall, improvements tended to
be more robust at three months than post-treatment, which may
reﬂect the overlap between questionnaire reference period and
experienced side-effects during the acute stages of treatment. This
is an important consideration when assessing CBT-I gains directly
following the ‘active’ phase. From semi-structured interviews, par-
ticipants were beginning to notice improvements in domains of
functioning three to four weeks into the programme, describing
positive changes in energy levels, fatigue and aspects of work life
and social functioning.
4.3. Adherence
Our use of qualitative methodologies provided insights into
how participants adjusted and adapted to their new sleeping sche-
dule. Audio-diary entries were particularly interesting because we
were able to track experiences over time, from day 1, and gain ac-
cess to moments of adherence and, importantly, non-adherence.
Recent work by Vincent and colleagues [16] revealed that per-
ceived barriers to sleep restriction and stimulus control treatment
engagement (measured with a questionnaire post-CBT) predicted
self-report adherence; here we were able to capture the nature
of encountered barriers, in real time. Speciﬁcally, negative impact
on functioning, an inability to stave off sleepiness prior to bedtime,
and boredom and loneliness during extra hours were all prominent
reasons for non-adhering. Such factors also affected those who
were adherent, representing general challenges of sleep restriction
therapy implementation.
Side-effects interacted with going to bed late, so that impaired
daytime functioning not only made staying up until a late set
bed time incredibly difﬁcult, but also created pressure and anxiety
for participants when attempting to initiate sleep. They were faced
with both the prospect of only having x hours to ‘obtain’ sleep, and
the experience of continued, and possibly enhanced, impairments
the following day. Thus, for some, the normal catastrophizing
about daytime consequences (cf. [54]) was in fact exacerbated dur-
ing the early stages of sleep restriction, which discouraged rigorous
adherence. It would seem important, therefore, to identify those
who do not respond in the ﬁrst few days of treatment, to prevent
complete or partial disengagement from treatment instructions.
Indeed, a few participants, during interviews, did indicate that if
there were to be increased therapist contact during active treat-
ment, it would be in the ﬁrst week.
In this regard, it would also be a worthwhile research endeav-
our to extend the early work by Perlis and colleagues [19], to deter-
mine if additional stimulant therapy can attenuate daytime
impairments, improve adherence, and (possibly) enhance out-
come. Of course, activation therapies may not necessarily be re-
stricted to pharmacological intervention. For example, some
components of fatigue interventions used with cancer patients
undergoing chemotherapy could also be applied, such as speciﬁc
exercise activities [55]. Interestingly, during interviews and
audio-diary entries, participants described a number of counter-
measures they had developed, which included keeping active,
engaging in discussion, setting chores, and increasing light expo-
sure, all with the primary aim of improving alertness to promote
adherence.
4.4. Implications for clinical practice and future research
There are several implications for clinical practice arising from
this work. Firstly, patients need to be made fully aware of how dif-
ﬁcult the sleep restriction programme can be, as well as the possi-
ble risks/dangers associated with the acute stages. Our
participants’ initial perceptions of the programme when explained
– although positive and logical – were, typically, far removed from
the reality of implementation. Perhaps vignettes from real partici-
pants, like those in the present study, would give the prospective
CBT-I patient an insight into some of the challenges involved.
This also raises the issueofwhether the ‘expert patient’ (Department
of Health [56]) may have a role in treatment preparation, as a way of
reducing attrition and enhancing adherence. That is, in addition to
vignettes, participants (‘graduates’) who had previously taken part in
CBT-I (and beneﬁted) could speak with prospective patients about
the treatment experience and implementation. This could be in the
form of a recorded video clip, for example, shown to patients during
CBT-I sessions.Asimilar approach is currentlyused insomerespiratory
clinics to inform sleep apnea patients of the beneﬁts of CPAP therapy,
prior to initiation (e.g., [57]). Finally, supplementary motivational
interventions may also have a place in the behavioural management
of insomnia; preliminary data suggests motivational interviewing,
for example, is effective in improving CPAP adherence [58]. Applica-
tion to CBT-I is worthy of investigation.
Although, admittedly, a small sample, results indicate that a
brief sleep restriction intervention can, in isolation, improve as-
pects of functioning and sleep. This supports other published con-
trolled studies that have used similar brief CBT-I packages (two
sessions), documenting substantial treatment gains [59,60].
Though more work is clearly required, this literature and the pres-
ent ﬁndings suggest that a brief (low-resource) behavioural inter-
vention may be delivered as a ﬁrst line treatment in an attempt
to widen access to evidence-based non-pharmacological insomnia
treatments.
This work also has important implications for research. For
example, the ﬁnding that SRT modiﬁes sleep-related anxiety, arou-
sal and perceptions demands greater attention in future work with
a range of assessments. In particular, serial measurement of atten-
tional bias and self-report questionnaire measures of pre-sleep
mentation and applied sleep effort, over the course of sleep restric-
tion, would be a worthwhile endeavour. Furthermore, the question
need to be posed, does sleep restriction modify physiological arou-
sal prior to sleep and also during the day? And what is the relation-
ship, if any, with daytime functioning outcomes? It would also be
informative to assess objective (cognitive) functioning throughout
the intervention period, helping to establish whether acute restric-
tion is associated with measurable impairments (as our qualitative
reports suggest), and also whether therapy reverses possible base-
line neurobehavioural deﬁcits. At the Glasgow Sleep Centre we are
currently conducting an in-lab assessment of SRT to investigate
whether therapy induces acute objective (and subjective) daytime
impairment, and to establish when these impairments resolve, car-
rying out assessments on a weekly basis. A related issue will be to
determine, in future controlled studies, the number of patients
who report side-effects during active treatment compared to an
adequate control group, and if patients are prompted to seek med-
ical attention for experienced side-effects.
4.5. Limitations
The results of the present study have to be viewed in the
context of several limitations. In relation to the diary and
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questionnaire data, particularly in light of the strong results, it
needs to be borne in mind that this was an uncontrolled study with
a small sample size, and that non-speciﬁc and other placebo-
related effects cannot be ruled out without the inclusion of an ade-
quate control group. Since the study was primarily interested in
assessing the patient experience of treatment, in a valid patient-
centred manner, conventional controlled trial methodology was
not considered appropriate at this ﬁrst stage of investigation. Such
methodological rigour will be essential, going forward, to fully
probe the side-effects issue (see below).
Similarly, procedural aspects of the treatment protocol may
have impacted results in two important ways. Firstly, audio-diary
entries may have acted as a proxy for therapist contact, enhancing
motivation/support to adhere with the programme, and ultimately
moderating outcome. Secondly, post-treatment interviews were
conducted by the therapist (also the researcher: SK), which may
have created ‘demand characteristic’ behaviour on the part of
interviewees. On this point, however, it was made explicit to par-
ticipants that we were interested in their experience, ‘good or
bad’, and that all information was interesting and relevant.
It must also be made clear that our side-effects questionnaire
differs somewhat from other measures used to assess side-effects,
where the investigator will typically record adverse events and
subsequently evaluate seriousness. Here, the questionnaire
emphasis was on patient attributions to sleep restriction therapy
in accounting for experienced impairment. This may have poten-
tially lead to an over-reporting of side-effects by patients. Yet, at
the same time, it may have also lead to the under-reporting of
side-effects that were not patient-attributed to the intervention.
Given that the study was designed to understand the patient expe-
rience, we do not necessarily regard these as major limitations;
however, we would caution against comparing our side-effect ﬁnd-
ings with published rates from different treatment modalities. That
being said, we do envisage the situation where our questionnaire
could be used to prospectively compare isolated components of
CBT-I (e.g. sleep restriction, stimulus control, relaxation) with, for
example, ‘ingredient-free’ interventions (sleep hygiene, sleep edu-
cation, sham biofeedback) to ascertain patient-attributed side-
effects. One ﬁnal point, relating to the side-effects questionnaire,
concerns possible perceived synonymity between the items ‘ex-
treme sleepiness’ and ‘fatigue/exhaustion’, leading to exaggerated
rates for both. This appears unlikely in our sample given that
audio-diary entries from patients reﬂected, clearly, complaints of
both sleepiness and fatigue. Nevertheless, future questionnaire
studies should attempt to deﬁne these terms on ﬁrst presentation
to minimise ambiguity (for a good example, see the Flinders Fati-
gue Scale; Gradisar et al. [61]).
Moreover, the sample was largely white, middle class and well-
educated; important factors when considering aspects of SRT
implementation, motivation and adherence. The generality of the
ﬁndings may, therefore, be restricted. Finally, some of the ques-
tionnaire measures used in the present study were non-validated
and require further testing with larger samples of individuals with
insomnia. On this note, the side-effects inventory is currently
undergoing reliability testing in a further treatment study at the
Glasgow Sleep Centre.
5. Concluding remarks
The present study provides novel data on the implementation
and experience of sleep restriction therapy for insomnia. The trian-
gulation of quantitative and qualitative methodologies gives con-
siderable credence to the ﬁndings. This data has several
important implications concerning SRT mechanisms of action,
experienced side-effects and adverse events, factors impacting
adherence and, ﬁnally, perceptions of beneﬁt. This work underlines
the value of using mixed methodologies to explore poorly under-
stood and/or under-researched phenomena.
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INTRODUCTION
Problems getting to sleep and/or remaining asleep are very 
common in adults,1 and have long been regarded as the core 
symptoms of insomnia.2-3 In relation to mental health, there is 
firm evidence that insomnia is a risk factor for the evolution of, 
and relapse into, depression.4-6 Likewise, insomnia has been as-
sociated with a higher prevalence of physical health conditions 
such as hypertension and type 2 diabetes,7-8 with all-cause mor-
tality,9 and with other adverse outcomes such as a poor quality 
of life and problems with work performance and personal rela-
tionships.10,11 It seems important, therefore, from a public health 
perspective, to understand who sleeps well, who has trouble 
sleeping, and whether particular groups in the community are 
more or less prone to the development or resolution of insomnia 
symptoms during adulthood.
So far, however, the natural history of insomnia remains rela-
tively poorly understood. The few longitudinal studies that do 
exist suggest that insomnia symptoms tend to become chronic 
and persistent,12-14 with evidence also of remitting and recurring 
patterns.15 A 3-yr follow-up of people with insomnia symptoms 
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showed more persistent symptoms among those with more se-
vere, clinically significant symptoms,15 and a 4-mo study showed 
greater stability of symptoms among patients who reported trou-
ble both initiating and maintaining sleep,16 but few studies have 
examined symptom patterns over a period of many years.
In terms of who experiences insomnia symptoms, the prev-
alence tends to increase with age.1 A meta-analysis of cross-
sectional data by sex concluded that women were more likely 
to experience symptoms than men and that this gender differ-
ence was stronger with increasing age.17 Other cross-sectional 
research has also highlighted socioeconomic status (SES) as 
a correlate of insomnia symptoms.18-19 Sex effects are attenu-
ated but not fully explained by adjustment for socioeconomic 
factors, as socioeconomic disadvantage is associated with both 
poor sleep and being female.20-21 Longitudinally, a pattern of 
persistent symptoms over 3 yr has been shown to be more likely 
for women than men.15 Another study showed no significantly 
greater incidence or persistence in insomnia symptoms over 12 
mo for those in manual rather than nonmanual occupations,13 
and a separate 12-mo incidence study showed a higher likeli-
hood of developing symptoms for women than men, and either 
weak or no relationships for socioeconomic factors such as in-
come and education.22 The lack of an effect for socioeconomic 
factors in these longitudinal studies contrasts with findings 
from cross-sectional research where people in disadvantaged 
socioeconomic circumstances were more likely to experience 
insomnia symptoms than those who were more affluent. This 
may be because 12 mo of follow-up is too short a time period 
for socioeconomic differences to emerge. It is important to un-
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derstand how these various risk factors for insomnia are associ-
ated with long-term patterns of insomnia symptoms.
The aim of this article was, first, to identify the main longitu-
dinal patterns of insomnia symptoms across the life course, and 
second, to investigate whether experience of these patterns var-
ied by sex and occupational class. Two cohorts, 20 yr apart in 
age, were studied over a 20-yr period, allowing comparison of 
those in their mid-30s to mid-50s with those in their mid-50s to 
mid-70s. In light of previous research, it was hypothesized that 
women, older respondents, and those in disadvantaged occu-
pational classes would be especially likely to experience more 
persistent patterns of insomnia symptoms.
METHODS
Sample and Measures
The Twenty-07 Study23 has followed people in 3 age co-
horts – born around 1932, 1952, and 1972 – for 20 yrs. It has 
2 subsamples: the regional sample, a 2-stage stratified random 
sample of people living in the Central Clydeside Conurbation, 
West of Scotland, and the localities sample of people from 2 ar-
eas of the city of Glasgow. Baseline interviews were conducted 
in 1987/1988 and there have been 4 follow-ups (1990/1992; 
1995/1997; 2000/2004; 2007/2008), with ethics approval 
gained for each wave from the National Health Service and/or 
Glasgow University Ethics Committees. At each wave of data 
collection, nurses trained in survey methods conducted face-to-
face individual interviews supplemented by a suite of physical 
measurements. Because questions on sleep were not asked at 
all interviews in the 1970s cohort, only the 1950s and 1930s 
cohorts are examined here. The 1950s cohort aged from ap-
proximately 36 to 57 yr during the study period and the 1930s 
cohort from 56 to 76 yr. Baseline sample sizes for these cohorts 
were 1,444 and 1,551, respectively (original response rates were 
88.9% and 87.1%)23 and the achieved sample has been shown to 
be representative of the general population of the sampled area.24
Insomnia symptom questions were asked at all 5 interviews 
over 20 yr of the study for both sleep latency (trouble getting 
to sleep) and sleep maintenance (waking early or during the 
night). Unfortunately, the specific questions asked changed 
during the study; nevertheless, it is possible to create broadly 
comparable insomnia variables over time for both dimensions 
(latency and maintenance). In the baseline and the first 2 fol-
low-up interviews, respondents were asked 2 questions: “How 
often do you have trouble getting to sleep?” and “How often 
are you bothered by waking earlier than you would like to, or 
by waking up in the middle of the night?” Both questions had 
6 response categories: never, less than monthly, at least once a 
month, at least once a week, most days, and every day. In waves 
4 and 5, as part of the Pittsburgh Sleep Quality Index,25 re-
spondents were asked, “During the past month how often have 
you had trouble sleeping because you cannot get to sleep within 
30 minutes?” and “During the past month how often have you 
had trouble sleeping because you wake up in the middle of the 
night or early morning?” Both questions had 4 categories: not 
during the past month, less than once a week, once or twice 
a week ,and 3 or more times a week. To define the frequency 
of insomnia symptoms consistently across all 5 interviews for 
each symptom type – latency and maintenance – the questions 
have been recoded for each interview into 2 binary variables, 
respectively representing latency and maintenance problems, 
with 0 representing either no problems or a less than weekly 
frequency, and 1 representing sleep problems occurring at least 
weekly. Note, however, that the respondents were asked specifi-
cally about their sleep within the past month in the 4th and 5th 
interviews as opposed to being asked about their sleep gener-
ally in the earlier interviews. In addition, at each interview re-
spondents were also shown cards with lists of common medical 
symptoms, including “difficulty sleeping”, and asked whether 
they had experienced this symptom in the past 4 wk or 1 mo 
(yes or no). Although this question does not contain comparable 
information on how frequently symptoms occurred and makes 
no distinction between sleep latency and sleep maintenance, the 
question wording was consistent throughout the study, and so 
we took the opportunity to validate findings from the questions 
on sleep latency and sleep maintenance in separate sensitivity 
analyses using this variable, as discussed in the next sections.
Sex was coded 0 for males and 1 for females. Baseline 
household occupational class was used as a measure of SES. 
This measure is common in British health research, and repre-
sents both social standing and material resources.26-27 Here it is 
coded according to the British Registrar General’s 1980 clas-
sification28 using the higher status occupation in couple house-
holds. If neither the respondent nor their partner had a current 
occupation then the higher class from their most recent previ-
ous occupations was used. This variable was then dichotomised 
with 0 for nonmanual (I through to III nonmanual) and 1 for 
manual (III manual through to V) classes. Twenty respondents 
were excluded from the analysis because of missing data on 
baseline occupational class.
In the most recent follow-up (2007/2008), 999 of the 1950s 
cohort and 663 of the 1930s cohort took part (73.2% and 65.5% 
of the living baseline sample). Of the 445 respondents from the 
1950s cohort who were lost to follow-up by this point, 88 had 
died (19.8%), whereas 562 of the 888 respondents who were 
lost to follow-up in the 1930s cohort had died (63.3%),29 so 
mortality was the most common reason for drop-out in the 
oldest cohort. Table 1 compares sample characteristics at the 
Table 1—Comparison of sample characteristics at baseline and final interviews
Baseline
interview
(1987/1988)
Final
interview
(2007/2008)
1950s Cohort
n 1,444 999 
Female (%) 788 (54.6) 542 (54.3)
Manual class at baseline (%)a 494 (34.6) 304 (30.7)
No symptoms at Baseline (%)a 789 (57.8) 577 (59.2)
1930s Cohort
n 1,551 663 
Female (%) 849 (54.7) 384 (57.9)
Manual class at baseline (%)a 710 (45.8) 227 (34.2)
No symptoms at baseline (%)a 729 (49.9) 353 (54.0)
aThese values represent percentages of valid responses. Item missingness 
ranged from 0-1.2% for occupational class and from 1.4-5.8% for insomnia 
symptoms.
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baseline and final interviews. Loss to follow-up was especially 
likely among those who reported sleep problems at baseline 
in both cohorts and among those who were in a manual class 
at baseline, especially in the older cohort. This uneven loss to 
follow-up is addressed using maximum likelihood estimation 
as discussed in the statistical analysis section.
Statistical Analysis
This article uses a repeated measures latent class analysis,30 
which identifies clusters of categorical responses (termed la-
tent classes) across repeated measurements. It estimates the 
overall probability of membership in each latent class (class 
membership probabilities), the probability of reporting each 
sleep problem at each time point given latent class membership 
(response probabilities), and can also be used to explore asso-
ciations between covariates and latent class membership. The 
latent class analysis is depicted diagrammatically in Figure 1. 
Modeling proceeded in 2 main stages relating to the 2 main 
aims of the study. In stage 1 the aim was to identify the most 
common longitudinal patterns of insomnia symptoms present 
within the data. Although the data contained a wide variety of 
different combinations of responses across the study period, the 
aim of the latent class analysis was to identify a smaller number 
of dominant groupings, representing different longitudinal pat-
terns of insomnia symptoms. The number of latent classes was 
determined by estimating a series of latent class models, each 
with an incrementally greater number of latent classes, and then 
comparing these models on the basis of various model fit statis-
tics (for details see supplementary information, part I).
The second stage of modeling investigated whether the lon-
gitudinal patterning of insomnia symptoms varied by cohort, 
sex, and occupational class. This was done using the optimal 
latent class model identified in the first stage. There are 2 main 
ways in which longitudinal response patterns may vary in line 
with covariates. First, an entirely different set of latent classes 
might be experienced in different groups, or second, different 
groups might experience similar patterns at different frequen-
cies. It is meaningless to investigate the second type of vari-
ation unless the first type is either absent or negligible, as like 
cannot be compared with like.30 Detailed analyses (see supple-
mentary information, part II) investigating the first type of vari-
ation suggested that differences in the response probabilities 
for each latent class by sex, occupational class, or cohort were 
minor. We therefore tested for differences in the odds of class 
membership between sexes, occupational classes, and cohorts 
by adding these variables to the latent class model as predictors 
in a multinomial logistic regression of latent class membership. 
Because latent class membership was the outcome here, the 
odds ratios associated with each covariate represent the odds 
of experiencing a particular longitudinal pattern of insomnia 
symptoms over 20 yr, rather than the odds of symptoms at any 
1 time point. Because the latent classes were based on longitu-
dinal data that included symptoms from the baseline interviews, 
measured concurrently with the covariates, there is a partially 
cross-sectional element to the estimated associations and re-
verse causation is possible. Interactions between covariates 
in predicting latent class membership were also tested and re-
tained if significant at the P < 0.05 level. Age was incorporated 
into the model in 2 ways: first, differences in the experience 
of the two cohorts, 20 years apart in age, were examined by 
including cohort as a proxy for age (because respondents within 
the same cohort were approximately the same age); second, ag-
Figure 1—Latent class analysis diagram.
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Baseline Interview
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Maintenance
Latency
Longitudinal Sleep Pattern
(Latent Class)
Maintenance
Latency
Maintenance
Latency
Maintenance
Gender
Occupational Class
Cohort
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ing effects within a cohort, i.e., from 1 interview to the next, are 
represented by the probabilities of symptoms at each interview 
as predicted by latent class membership.
All analyses were performed in Mplus version 6.1.31 Maxi-
mum likelihood estimation was used, using all available sleep 
data for each respondent (n = 2,867; 1,383 from the 1950s co-
hort and 1,484 from the 1930s cohort), and hence these analy-
ses are robust to sample attrition under the assumption that data 
are missing at random.32 This assumes that the missingness of 
a variable can be predicted by the other variables in the model, 
i.e., if nonparticipation at later waves was related to later in-
somnia symptoms, but those symptoms could be predicted by 
cohort, sex, occupational class, and the sleep data from other 
waves (e.g., baseline symptoms), then the model estimates 
would be unbiased. For example, the model would be robust to 
the slightly higher rates of drop-out among those with baseline 
symptoms unless those who later recovered were more or less 
likely to be retained than those who did not recover (and then 
only if these differences were not explained by cohort, sex, and/
or occupational class). In the third wave of interviews the 2 lo-
cality subsamples only received a postal questionnaire that did 
not include the questions on sleep; however, being in the locality 
subsamples was not related to having sleep problems at any of 
the other waves (chi-square test, P > 0.05), so there is no reason 
to believe that this missingness-by-design would bias the results.
As a sensitivity analysis, the latent class modeling was re-
peated for each type of insomnia symptom separately, to ensure 
no distortions had resulted from modeling the 2 symptom di-
mensions together. For validation purposes, given the change in 
wording for the 2 insomnia symptom questions between the 3rd 
and 4th interviews, the latent class analysis was also repeated 
separately for the general question on sleep difficulty. Because 
the general question on sleep difficulty was worded consist-
ently over the course of the study, observation of similar latent 
classes for this question would suggest that the observed pat-
terns were genuine and not an artefact of the question change 
(for details see supplementary information, part III).
RESULTS
Table 2 shows the prevalence of latency symptoms alone, 
maintenance symptoms alone, co-occurring latency and mainte-
nance symptoms, and the proportion reporting no symptoms, at 
each of the 5 interviews by cohort. The co-occurrence of latency 
and maintenance symptoms was common, varying from 12.5% 
to 27.1% of respondents in the 1950s cohort as they aged from 36 
to 57 yr, and 20.7% to 35.6% in the older cohort as they aged from 
56 to 76 yr. Sleep maintenance problems were also frequently 
reported, but it was relatively rare for respondents to report la-
tency symptoms without accompanying maintenance problems. 
There was a marked reduction in the prevalence of those report-
ing no sleep problems across the study as both cohorts aged, and 
a marked increase in the prevalence of sleep problems between 
waves 3 and 4 when the question wording changed. Comparing 
the cross-sectional prevalence of symptoms at the baseline inter-
views in the 1930s cohort with that from the final interview in the 
1950s cohort, where respondents were approximately the same 
age, suggests a lower symptom prevalence in the older cohort 
(42.6% with no symptoms compared to 49.9%).
The best latent class model in terms of balancing model fit 
and parsimony identified 4 latent classes (see supplementary 
information, part I). The probabilities of problems initiating and 
maintaining sleep at each wave of the study for the 4 latent 
classes are shown in Figure 2. Error bars show 95% confidence 
intervals for estimates. Respondents in class 1 had a low prob-
ability of latency or maintenance problems at all of the study 
waves and so were labeled the Healthy class. The overall proba-
bility of membership in this class was 0.37. Those in class 2 had 
a low probability of latency problems at all time points but a rel-
atively high probability of maintenance problems. These were 
labeled the Episodic Maintenance class (overall membership 
Table 2—Co-occurrence of sleep problems over study
Interview 1 Interview 2 Interview 3 Interview 4 Interview 5
1950s Cohort
Mean age (standard deviation) 36.2 (0.8) 40.5 (0.9) 45.2 (1.2) 50.2 (1.3) 57.1 (0.8)
No symptomsa: n (%) 789 (57.8) 823 (67.4) 461 (61.4) 464 (49.8) 415 (42.6)
Latency onlya: n (%) 109 (8.0) 61 (5.0) 39 (5.2) 39 (4.2) 48 (4.9)
Maintenance onlya: n (%) 297 (21.7) 182 (14.9) 118 (15.7) 194 (20.8) 248 (25.4)
Both symptomsa: n (%) 171 (12.5) 155 (12.7) 133 (17.7) 234 (25.1) 264 (27.1)
Missing sleep data: n (%) 78 (5.4) 4 (0.3) 275 (26.8)b 49 (5.0) 24 (2.4)
Total n (% of baseline sample) 1,444 (100.0) 1,225 (84.8) 1,026 (71.1) 980 (67.9) 999 (69.2)
1930s Cohort
Mean Age (standard deviation) 56.2 (0.6) 59.6 (0.8) 64.4 (1.2) 69.1 (1.0) 76.2 (0.6)
No symptomsa: n (%) 729 (49.9) 626 (49.5) 350 (48.5) 321 (41.4) 230 (36.7)
Latency onlya: n (%) 133 (9.1) 97 (7.7) 52 (7.2) 40 (5.2) 41 (6.5)
Maintenance onlya: n (%) 296 (20.3) 267 (21.1) 156 (21.6) 139 (17.9) 142 (22.6)
Both symptomsa: n (%) 303 (20.7) 275 (21.7) 163 (22.6) 276 (35.6) 214 (34.1)
Missing sleep data: n (%) 90 (5.8) 1 (0.1) 309 (30.0)b 62 (7.4) 36 (5.4)
Total n (% of baseline sample) 1,551 (100.0) 1,266 (81.6) 1,030 (66.4) 838 (54.0) 663 (42.7)
aTo facilitate comparison across the study, percentages here are presented as proportions of those with valid sleep data. bMissingness is higher here because 
at this stage the 2 locality subsamples only received a shortened postal questionnaire that did not include the sleep questions (n = 272 for the 1950s cohort; 
n = 307 for the 1930s cohort).
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probability: 0.22). The members of class 3 had a low probabil-
ity of reporting either symptom in earlier study waves, but then 
a high probability of both symptoms, especially maintenance 
problems, at waves 4 and 5. These were labeled the Developing 
class as they appeared to be developing insomnia symptoms 
(overall membership probability: 0.24). Finally, those in class 
4 had a high probability of trouble both initiating and maintain-
ing sleep at all time points, and were labeled the Chronic Mixed 
class (overall membership probability: 0.17). Those in the 
Episodic Maintenance class tended toward a lower probability 
of trouble maintaining sleep than those in the Chronic Mixed 
class; probabilities at each wave were all approximately 0.4-
0.6, indicating that maintenance symptoms would be reported 
in approximately half of the study waves for each individual in 
this class. This suggests less stable or more episodic problems 
than in the Chronic Mixed class where the response probabili-
ties for maintenance symptoms are approximately 0.8-0.9 and 
symptoms would be reported at most interviews. Those in the 
Episodic Maintenance class also tended to experience a higher 
probability of latency problems than those in the Healthy class, 
indicating that although maintenance is the primary or domi-
nant problem in this class, latency problems also occurred oc-
casionally and with greater frequency than where maintenance 
problems were not present. The absence of other potential pat-
terns in the latent class solution, e.g., a full recovery pattern, 
or a pattern where latency symptoms were dominant, indicates 
that such patterns were relatively rare.30
Table 3 displays the odds ratios (OR) and 95% confidence 
intervals from a multinomial logistic regression of latent class 
Table 3—Multinomial logistic regression of latent class membership on 
sex, occupational class, and cohort
Odds 
ratios
95% 
Confidence 
intervals
Episodic maintenance (ref: Healthy)
Female in 1950s cohort (ref: male)a 0.78 (0.43-1.41)
Female in 1930s cohort (ref: male)a 2.22 (1.36-3.63)
Manual (ref: Non-manual) 1.28 (0.89-1.85)
1930s cohort for males (ref: 1950s)a 1.45 (0.91-2.32)
1930s cohort for females (ref: 1950s)a 4.14 (2.24-7.66)
Developing (ref: Healthy)
Female in 1950s cohort (ref: male)a 4.30 (2.65-6.98)
Female in 1930s cohort (ref: male)a 1.59 (1.00-2.51)
Manual (ref: Non-manual) 1.61 (1.14-2.28)
1930s cohort for males (ref: 1950s)a 3.55 (2.11-5.97)
1930s cohort for females (ref: 1950s)a 1.31 (0.85-2.02)
Chronic Mixed (ref: Healthy)
Female in 1950s cohort (ref: male)a 1.20 (0.78-1.85)
Female in 1930s cohort (ref: male)a 3.10 (2.15-4.49)
Manual (ref: Non-manual) 3.22 (2.46-4.21)
1930s cohort for males (ref: 1950s)a 1.61 (1.08-2.38)
1930s cohort for females (ref: 1950s)a 4.16 (2.79-6.19)
aThis odds ratio is calculated by combining the relevant main and 
interaction effects for sex and cohort.
Figure 2—Probability of latency and maintenance problems at each study wave given latent class membership.
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membership on sex, occupational class, and cohort (mutually 
adjusted). There was a significant interaction between cohort 
and sex (P < 0.05), so for ease of interpretation ORs combining 
the main and interaction effects have been calculated and are 
presented by cohort for sex, and by sex for cohort. No other 
interactions between sex, occupational class, and cohort were 
found to be significant. Women were more likely than men to be 
in the Developing class as opposed to the Healthy class, but the 
effect was larger in the 1950s than in the 1930s cohort (1950s 
OR 4.30, P < 0.01; 1930s OR 1.59, P < 0.05). In the 1930s co-
hort, but not in the 1950s cohort, women were more likely than 
men to be in the Chronic Mixed relative to the Healthy sleep 
class (OR 3.10, P < 0.01). Respondents from manual occupa-
tional classes in both cohorts were more likely than their non-
manual counterparts to be in the Developing or Chronic Mixed 
latent classes relative to the Healthy class, though the effect size 
for being in the Chronic Mixed class (OR 3.22, P < 0.01) was 
approximately twice that for being in the Developing class (OR 
1.61, P < 0.01). Men in the 1930s cohort were more likely than 
men in the younger 1950s cohort to be in the Developing (OR 
3.55, P < 0.01) or Chronic Mixed (OR 1.61, P < 0.05) classes as 
opposed to the Healthy sleep class. Women in the 1930s cohort 
were not significantly more likely than those in the 1950s co-
hort to be in the Developing rather than the Healthy sleep class 
(OR 1.31, P = 0.22), but there was an even stronger tendency 
than there was amongst men for those in the 1930s rather than 
the 1950s cohort to be in the Chronic Mixed class (OR 4.16, 
P < 0.01) rather than the Healthy sleep class.
Figure 3 is provided to aid interpretation and shows estimat-
ed probabilities of latent class membership for all the different 
combinations of these variables. Membership in the Healthy 
class was the most probable outcome for most respondents in 
the 1950s cohort, with the exception of women in a manual 
class, who were more likely to be in the Developing than the 
Healthy class. In the 1930s cohort, however, women were more 
likely to be in 1 of the symptomatic sleep classes than in the 
Healthy class, irrespective of occupational class. Women in 
the 1930s cohort who were in a manual class were particularly 
disadvantaged in that membership in the Chronic Mixed class 
was the most likely outcome for them and membership in the 
Healthy class was the least likely. Only men from nonmanual 
classes in the 1950s cohort had a greater than 50% chance of 
being in the Healthy sleep class.
Repeating the modeling for sleep latency and sleep main-
tenance problems separately revealed a 3-class solution as the 
best-fitting model for both types of insomnia symptom (see 
supplementary information, part III). In each case the 3 classes 
observed could be viewed as corresponding to the Healthy, De-
veloping, and Chronic Mixed classes from the joint modeling. 
The Episodic Maintenance class appeared to have been sub-
sumed into the class experiencing chronic difficulties when 
modeling maintenance only, and into the Developing class 
when modeling latency only. These results are therefore con-
sistent with and support those from the joint modeling.
Given the change in question wording and concurrent in-
crease in the prevalence of insomnia symptoms at interviews 
4 and 5, it is possible that the Developing class represents 
sensitivity to question wording rather than symptom develop-
ment. This issue was investigated by performing a further latent 
class analysis using the general question on sleep difficulty that 
had been worded consistently across the study, asking about 
symptoms within the past month at each interview. Because 
this question does not make the distinction between latency 
and maintenance problems, when modeling using these data it 
would be expected a priori not to find a class similar to the 
Episodic Maintenance class, but the other 3 classes, including 
Figure 3—Latent class membership probabilities for both cohorts by sex and occupational class.
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the Developing class, should be fairly replicable. Results from 
this analysis (see supplementary information, part III) sug-
gested a 3-class model similar to those observed for sleep la-
tency and sleep maintenance separately. As well as classes with 
healthy and chronic patterns there was evidence of a class with 
symptoms developing toward the end of the study, albeit with 
a smoother slope, suggesting that the Developing class is more 
reflective of symptoms developing with increasing age within 
each cohort than of measurement differences.
Latent class membership probabilities for the general ques-
tion on difficulty sleeping were also similar to those for the 
questions on sleep maintenance, with a slightly lower preva-
lence in both of the symptomatic categories. Finally, covariate 
effects were all in the same direction as in the main results, 
though there were some differences in whether or not particu-
lar effects were significant (some small differences would be 
expected with the reassignment of those in the Episodic Main-
tenance class into other categories). Overall, modeling of this 
alternative question revealed symptom patterning similar to 
that observed for the main measures used, validating the find-
ings and suggesting that instrument effects associated with the 
change in question wording were minor.
DISCUSSION
In this article we have presented longitudinal data on pat-
terns of insomnia symptoms over a 20-yr period in 2 cohorts, 
aging from their mid-30s to mid-50s and from their mid-50s to 
mid-70s, respectively. Four distinct patterns of insomnia symp-
toms were apparent over the adult life course: a Healthy class 
with only occasional experience of sleeping trouble; an Epi-
sodic Maintenance class who had episodes dominated by trou-
ble maintaining rather than initiating sleep; a Developing class 
who appeared to develop insomnia symptoms as they aged; and 
a Chronic Mixed class who had persistent trouble with both 
initiating and maintaining sleep. The only other study of in-
somnia of comparable length that we are aware of was in a co-
hort of young adults, age 19-20 yr at baseline, in Zûrich.14 Our 
study adds information on the common trajectories of insomnia 
symptoms over 2 decades among older adults and shows pat-
terning by sex, occupational class, and cohort.
Insomnia symptoms have traditionally been subtyped into 
problems with initiating sleep, maintaining sleep, or waking 
earlier than desired, though the latter may often be perceived 
as a maintenance problem. In a study examining all 3 symp-
tom types over 4 mo, each symptom type in isolation had low 
stability, with higher stability for a combination of all 3.16 A 
cross-sectional latent class analysis on data from patients with 
sleep disturbance also identified a class that experienced both 
initiation and maintenance symptoms, whereas maintenance 
problems predominated in other classes.33 In this cross-sec-
tional analysis, the class with mixed symptoms also reported 
more frequent symptoms of longer duration than other classes. 
The Chronic Mixed class we found is consistent with this pre-
vious research, particularly in associating chronicity with the 
combined experience of both initiation and maintenance prob-
lems. The Episodic Maintenance class may indicate a distinct 
vulnerability for intermittent troubled sleep. Inevitably, some 
of these individuals would also be captured as poor sleepers 
in cross-sectional studies. Differences in the social patterning 
of the Chronic Mixed and Episodic Maintenance classes sug-
gest differences in etiology that could be confounded in cross-
sectional research.
This study goes beyond cross-sectional associations be-
tween SES and insomnia symptoms18,20-21,34 by showing that 
people in a manual occupational class were more likely than 
those in a nonmanual class to experience chronic insomnia 
symptoms. Occupational class differences may be attributable 
to differences in work and family characteristics,35 in health 
behaviors such as smoking and drinking which are associated 
with poorer sleep,1 or to socioeconomic inequalities in physi-
cal and mental health, which have both been prospectively as-
sociated with later insomnia.13-14,22 Alternatively, people with 
consistently poor sleep may have experienced daytime fatigue, 
impairing work performance and making it difficult to obtain 
or retain higher status jobs. Respondents in manual classes 
were also more likely to be in the Developing class than those 
in nonmanual classes. Previous 12-mo incidence studies13,22 
found no SES differences, but this may have been due to the 
shorter follow-up period. Because occupational class preced-
ed the development of symptoms in our analysis, this finding 
is broadly supportive of a causal role for occupational class, 
though the assumption that the Developing class is primarily 
made up of incident cases may be questionable; some may be 
relapsing after prolonged remission.
Respondents in the 1930s cohort were more likely than those 
in the 1950s cohort to experience Chronic Mixed or Developing 
relative to Healthy sleep patterns. Effects for the Chronic Mixed 
class were stronger in women, and for the Developing class 
were evident in men only. Because respondents in the same co-
hort were approximately the same age, these cohort differences 
could either be interpreted as differences in the patterning of 
insomnia symptoms with increasing age or as differences be-
tween birth cohorts, the former being consistent with conclu-
sions from previous research that the prevalence of insomnia 
symptoms increases with age.1 We suggest this may be under-
pinned by the persistence of (prior) insomnia into later years in 
some, plus the emergence of other incident new cases. Compar-
ison between interviews where respondents were the same age 
suggested a lower prevalence of symptoms in the older cohort. 
Unless this is due to question wording or attrition this finding 
suggests that age differences may be underestimated due to an 
opposing cohort effect.
The common finding of poorer sleep among women17,20-21,35 
is replicated here, and is extended to show patterns of poorer 
sleep across the life course. Women appear more likely than 
men to develop insomnia symptoms in middle age (i.e. mid-
30s to mid-50s), and then to retain the disadvantage as chronic 
symptoms in old age (i.e. mid-50s to mid-70s). This is consist-
ent with meta-analytical findings that sex differences in insom-
nia increase with age.17 Other studies have shown the effect of 
sex to be attenuated but not fully explained by adjustment for 
socioeconomic disadvantage,20-21 and our findings concur, with 
distinct effects for both sex and occupational class. Biologic 
factors may also contribute to sex differences; the menopause 
transition, for example, is associated with deleterious effects 
on sleeping patterns.36 This would be consistent with our ob-
servation of high risk for women developing symptoms as they 
move into their 50s. However, insomnia symptoms around 
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menopause could be attributable to other experiences com-
mon to women in midlife such as the development of acute 
and chronic health conditions or life stresses with associated 
increases in depression.37-38
This study has various limitations. First, it examines a fairly 
restricted range of insomnia symptoms; no measures of day-
time consequences of sleep disturbance or dissatisfaction with 
sleep were used.1 The change in question wording meant that 
respondents were asked about their symptoms generally in the 
first 3 interviews, and then specifically about symptoms in the 
past month for the last 2 interviews. If people respond differ-
ently based on the timeframe of the question then this could 
result in spurious developmental patterns, but a parallel analy-
sis of another question on sleep that was consistently worded 
revealed similar findings to those presented. There may also be 
some unaddressed heterogeneity in the severity of symptoms 
reported: symptoms reported could have been anything from 
nightly to weekly sleeping trouble. Moreover, self- reporting 
biases by variables of interest may have been present; other re-
search has shown males with insomnia to be more likely to over-
report sleep disturbance than women with insomnia,39 which 
could mean the sex differences observed here are underestimat-
ed. Small studies of sleep quality using objective measurement 
provide mixed support for these findings with poorer sleep for 
those in socioeconomic disadvantage,40-41 but either no sex dif-
ferences or better sleep quality for women.39,42-43 Furthermore, 
the data were based on repeated snapshots rather than complete 
histories and so symptoms were not necessarily stable between 
interviews and might have been experienced prior to baseline 
data collection. Differential drop-out may also have introduced 
some bias. For example, if those who recovered from baseline 
symptoms were more likely to participate in later waves than 
those who did not recover, then levels of chronicity may have 
been underestimated. Finally, if occupational class has a causal 
relationship with insomnia, then observed effects here will have 
been diluted as some respondents from the manual group will 
have moved into nonmanual occupations over time (and thus 
experienced better sleep than those remaining in manual oc-
cupations) and vice versa.
In conclusion, 4 main patterns of insomnia symptoms over 
a 20-yr period have been shown among middle-aged and old-
er adults: a healthy pattern; an episodic pattern characterized 
by problems maintaining sleep; a more chronic pattern with 
trouble both maintaining and initiating sleep; and a pattern of 
developing sleep symptoms. Experience of these different lon-
gitudinal patterns was stratified by social factors, namely age, 
sex, and occupational class.
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SUPPLEMENTAL MATERIAL
Part I: Determining the Number of Classes
The objective at this stage was to find the latent class model 
that best represented the data, i.e., striking a balance between 
maximization of model fit and keeping the number of latent 
classes low (maximizing parsimony). A sequence of latent 
class models with ascending numbers of latent classes were 
computed in each cohort, and their model-fit statistics were 
compared to decide on the most appropriate number of classes 
(see Table S1). Model fit was assessed using the likelihood ra-
tio χ2 statistic, the Akaike Information Criterion (AIC),1 and 
the Bayesian Information Criterion (BIC).2 Lower values for 
the χ2 likelihood ratio indicate improvements in model fit, and 
lower values for AIC and BIC suggest a more optimal bal-
ance between model fit and model parsimony. To check model 
identification 100 different sets of random start values were 
used for each latent class model. Where the best-fitting solu-
tion occurs with a high frequency (e.g., 100 times), then there 
can be greater confidence that the solution represents a global 
rather than a local maximization of model fit. We also exam-
ined entropy,3 which indicates how distinctly respondents are 
being classified into latent classes by the models. Values closer 
to 1 are preferred as they suggest that respondents are being 
more definitively classified by the model. We stopped at 7 la-
tent classes as model parsimony (measured by the BIC) and 
identification were clearly deteriorating with additional classes 
instead of improving.
In both cohorts, additional classes were at first associated 
with large increases in model fit (signified by large decreases 
in the χ2, AIC, and BIC statistics). However, the improvement 
lessened with each additional class and the BIC, which offers 
the more stringent balance of model fit against parsimony, be-
gan to increase after a low at 4 classes. Model identification 
also decreased after 4 classes, suggesting that there can be less 
confidence in solutions that used greater numbers of classes. 
An increase from 4 to 5 classes, while only associated with a 
small rise in the BIC, also only offered a very marginal gain in 
terms of entropy. Taking all of these findings into consideration, 
the 4-class solution was seen as the best-fitting model. As this 
optimal 4-class model exhibited a very similar pattern of re-
sponse probabilities in each cohort, it was thought sensible to 
combine the 2 cohorts so that statistical comparisons of latent 
class membership probabilities could be made between cohorts 
(see supplementary information, part II). As the models with 
more than 4 classes produced patterns of response probabili-
ties with substantive differences between cohorts and were not 
well identified, models of both cohorts with more than 4 latent 
classes were not preferred despite increases in model fit.
Part II: Testing for Measurement Invariance Across Sex, 
Occupational Class, and Cohort Groups
After establishing that the 4-class model provided the best 
fit to the data, we then investigated covariate effects. The most 
Table S1—Comparison of fit statistics and identification for models with different numbers of latent classes
No. of classes
Likelihood
ratio χ2
Degrees of 
freedoma AIC BIC Identificationb Entropy
1950s Cohort (n = 1,383)
1 1,822.32 993 12,368.10 12,420.42 100 1.00
2 1,054.01 998 10,925.19 11,035.07 100 0.72
3 803.26 983 10,731.08 10,898.50 96 0.67
4 723.23 974 10,655.01 10,879.98 83 0.64
5 656.97 962 10,610.82 10,893.36 10 0.68
6 606.19 950 10,585.01 10,925.09 8 0.70
7 582.27 941 10,565.52 10,963.15 3 0.72
1930s Cohort (n = 1,484)
1 2,381.79 1,004 12,775.72 12,828.74 100 1.00
2 1,100.25 989 11,405.72 11,517.07 100 0.72
3 849.24 978 11,175.93 11,345.61 46 0.65
4 691.80 969 11,020.28 11,248.28 94 0.58
5 626.56 959 10,976.90 11,263.23 62 0.59
6 589.88 948 10,960.27 11,304.94 32 0.58
7 561.49 939 10,951.08 11,354.07 1 0.60
Both Cohorts (n = 2,867)
2 2,307.41 2,009 26,404.51 26,541.61 100 0.85
3 1,719.48 1,993 25,871.82 26,080.45 99 0.79
4 1,496.30 1,985 25,643.75 25,923.92 99 0.73
5 1,398.77 1,975 25,552.08 25,903.78 33 0.74
aThese values do not descend uniformly with the number of classes because between 4 and 20 cells in each latent class indicator table were deleted in the 
calculation of the chi-square due to extreme values. bIndicates how many times the best-fitting solution was found using 100 different sets of random starting 
values. AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion.
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parsimonious covariate model will be one in which the covari-
ates influence class membership only, and not the probability 
of responses given class membership.4 Such a condition is re-
ferred to as measurement invariance because the latent class 
definitions are constant across all levels of the covariates; that 
is, a latent class means the same thing for 1 group as it does 
for others. Measurement invariance indicates that different 
groups experience similar rather than entirely different latent 
class patterns.
Measurement invariance can be formally tested for by com-
paring a model where response probabilities for latent classes 
can vary across covariate groupings (the variant model) with a 
nested model where response probabilities for latent classes are 
constrained to be equal across covariate groupings (the invari-
ant model). This is a sensitive test, however, and it may indicate 
that differences are statistically significant where they make 
little substantive difference to the interpretation of the latent 
classes. For this reason it is important to examine not only the 
outcome of this test, but also other model-fit statistics and the 
response probabilities for the latent classes from both models. 
Where measurement invariance is statistically significant, but 
does not alter the substantive interpretation of the classes, it 
can be more parsimonious to impose measurement invariance 
anyway, allowing for like-for-like comparisons of class mem-
bership probabilities.4
Table S2 displays fit statistics and chi-square difference tests 
for variant and invariant models across sex, occupational class, 
and cohort groupings, and also for a cross-classification iden-
tifying the 8 possible unique combinations of these variables. 
Each pair of models was tested on the whole sample (i.e., both 
cohorts). In each case the chi-square test showed significant 
group differences in response probabilities for latent classes. 
Inspection of the response probability estimates, however, re-
vealed latent class patterns that were very similar and did not 
differ markedly in terms of interpretation (results not shown). 
Additionally, the invariant model was in each case better iden-
tified and had lower BIC values and the AIC was lower in most 
cases. Allowing response probabilities to vary across covariate 
groupings did not produce large improvements in the classi-
fication of respondents as indicated by the entropy statistic. 
Overall, it was thought that group differences were minor and 
imposing measurement invariance gained more in terms of 
parsimony than was lost in accuracy, or model fit. Particularly, 
this meant that like-for-like statistical comparisons could be 
made of latent class membership by sex, occupational class, 
and cohort.
Part III: Separate Modeling of Different Insomnia Symptom 
Questions
Table S3 displays information on model fit from models with 
2, 3, and 4 classes for each of the sleep variables. In each case 
the 3-class model has the lowest value for the BIC, representing 
an optimal balance of model fit and parsimony.
Figure S1 shows the item-response probabilities for the 
3-class model of each variable. As the difficulty sleeping ques-
tion does not distinguish between problems with latency and 
maintenance, it was thought better to compare it with the 2 
separate models of latency and maintenance symptoms rather 
than the combined model. Each of the 3 models shows classes 
similar to the Developing, Chronic Mixed, and Healthy classes 
shown in the main results. For the question on difficulty sleep-
ing, the increase in the probability of a positive response over 
the study in the Developing pattern shows a smoother gradient 
than for the 2 variables where the question wording changed, 
but is notably still present. This suggests that the change in 
question wording may have accentuated the incline in symptom 
patterns, but that the incline is nevertheless genuine and not an 
artefact of question wording.
Table S2—Comparison of model fit statistics for variant and invariant latent class models across sex, occupational class, and cohort groupings
Model (n = 2,867)
Likelihood 
ratio χ2
Degrees of 
freedom P value AIC BIC Identificationa Entropy
Sex
Variant 1,389.75 1,945 – 25,661.81 26,180.41 53 0.74
Invariant 1,470.16 1,985 – 25,663.02 25,943.18 91 0.73
Difference +80.41 +40  < 0.01 +1.21 -237.23 +38 -0.01
Occupational Class
Variant 1,393.25 1,945 – 25,558.11 26,076.72 73 0.73
Invariant 1,442.63 1,984 – 25,531.29 25,811.46 92 0.73
Difference +49.38 +39  < 0.01 -26.82 -265.26 +19 0.00
Cohort
Variant 1,415.03 1,943 – 25,648.23 26,166.84 61 0.74
Invariant 1,496.30 1,985 – 25,643.75 25,923.92 99 0.73
Difference +81.27 +42  < 0.01 -4.48 -242.92 +38 -0.01
Cross-Classified Sex, Class, and Cohort Groupings
Variant 2,235.43 7,792 – 33,372.18 35,464.50 1 0.87
Invariant 2,753.79 8,081 – 33,278.54 33,701.77 97 0.84
Difference +518.36 +289  < 0.01 -93.64 -1,762.73 +96 -0.03
aIndicates how many times the best-fitting solution was found using 100 different sets of random starting values. AIC, Akaike Information Criterion; BIC, 
Bayesian Information Criterion.
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Table S4 compares the overall latent class membership prob-
abilities and logistic regression effects of covariates in each of 
these 3 models. Some degree of variation would be expected 
here as those who would have been assigned to the Episodic 
Maintenance class in the main results will have been reclassi-
fied into other classes, affecting both membership probabilities 
and estimates of odds ratios. The membership probabilities for 
the maintenance and difficulty sleeping variables, however, did 
exhibit similar patterns, and covariate effects were also fairly 
consistent across all 3 models. Notably, the propensity for 
women to be in the Developing rather than the Healthy sleep 
class (relative to men) was consistent and significant across 
all models, as was the tendency for those in manual relative to 
nonmanual classes to be in the Chronic Mixed rather than the 
Healthy sleep class. Almost all of the other effects that were 
not significant for the question on difficulty sleeping were also 
not significant in either the latency-only or the maintenance-
only model. These differences may therefore have more to do 
with only modeling a single dimension of sleep disturbance 
than with consistency in question wording.
Table S3—Comparison of fit statistics and identification for models of different insomnia symptom questions
No. of classes
Likelihood
ratio χ2
Degrees of 
freedom AIC BIC Identificationa Entropy
Latency (n = 2,866)
2 161.27 20 10,376.75 10,466.16 100 0.66
3 45.82 14 10,210.03 10,359.05 82 0.56
4 13.55 8 10,186.22 10,394.85 56 0.59
Maintenance (n = 2,867)
2 126.17 20 12,548.15 12,637.56 100 0.53
3 28.12 14 12,419.76 12,568.78 90 0.51
4 13.07 8 12,410.96 12,619.60 66 0.57
Difficulty sleeping (n = 2,924)
2 98.43 20 12,163.62 12,253.33 100 0.59
3 62.27 14 12,100.46 12,249.98 63 0.51
4 25.07 8 12,052.32 12,261.64 59 0.49
aIndicates how many times the best-fitting solution was found using 100 different sets of random starting values. AIC, Akaike Information Criterion; BIC, 
Bayesian Information Criterion.
Figure S1—Response probabilities from separate 3-class models of each insomnia symptom question.
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Expected differences aside, the data from the question on 
difficulty sleeping, which was consistently defined across the 
study, produces an overall pattern of results similar to those 
obtained by using the questions on maintenance and latency, 
which were not consistently worded. This suggests that the ef-
fect of the change in question wording was minor and that the 
observed results are reflective of actual population sleep pat-
terns rather than artefacts of measurement.
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Table S4—Comparison of class membership probabilities and covariate effects for different insomnia symptom questions
Latency Maintenance Difficulty Sleeping
Value
95% Confidence 
intervals Value
95% Confidence 
intervals Value
95% Confidence 
intervals
Class membership probabilities
Developing 0.40 – 0.24 – 0.20 –
Chronic 0.19 – 0.35 – 0.28 –
Healthy 0.41 – 0.41 – 0.52 –
Odds ratios for covariates
Developing (ref: Healthy)
Female (ref: Male) 3.34 (2.11-5.29) 5.13 (2.85-9.26) 5.21 (1.95-13.94)
Manual (ref: Non-Manual) 2.06 (1.49-2.85) 1.43 (0.90-2.27) 0.99 (0.40-2.43)
1930s Cohort (ref: 1950s) 1.98 (1.21-3.25) 3.24 (1.71-6.13) 1.23 (0.44-3.44)
Female*1930s Cohort 0.87 (0.42-1.83) 0.19 (0.08-0.44) 0.47 (0.13-1.64)
Chronic (ref: Healthy)
Female (ref: Male) 0.99 (0.61-1.61) 1.61 (1.06-2.43) 1.40 (0.71-2.77)
Manual (ref: Non-Manual) 3.35 (2.50-4.50) 2.09 (1.63-2.66) 1.69 (1.33-2.15)
1930s Cohort (ref: 1950s) 1.30 (0.90-1.89) 2.04 (1.43-2.92) 1.16 (0.83-1.62)
Female*1930s Cohort 3.89 (2.16-7.02) 1.10 (0.64-1.89) 1.82 (0.93-3.57)
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The Daytime Impact of DSM-5 Insomnia Disorder:  
Comparative Analysis of Insomnia Subtypes  
From the Great British Sleep Survey
Colin A. Espie, PhD; Simon D. Kyle, PhD; Peter Hames, MA Oxon;  
Eva Cyhlarova, PhD; and Michaela Benzeval, PhD
The adoption in DSM-5 of the term insomnia disorder (ID) (M 00) reflects a paradigm shift, recommended by 
the National Institutes of Health,1 toward coding insomnia 
“whenever diagnostic criteria are met, whether or not there 
is a coexisting psychiatric, medical, or another sleep disor-
der.”2 In laying aside the DSM-IV3 perspective of “primary” 
versus “secondary” insomnia, the DSM-5 Sleep-Wake Dis-
orders Work Group has recognized that poor sleep may be 
associated with illness vulnerability.4 For example, chronic 
insomnia is a risk factor for the evolution of, and relapse 
into, depression,5 and cotreatment of insomnia improves 
depression outcomes.6,7 Likewise, insomnia has been 
associated with physical disease (eg, hypertension,8 type 2 
diabetes9) and all-cause mortality10 and often copresents 
with sleep apnea11 where, if untreated, it may exacerbate 
daytime impairment, particularly excessive daytime sleepi-
ness.12 A further development in DSM-5, consistent with 
research diagnostic criteria and contemporary data,13,14 is 
that insomnia must have a specified sequela (fatigue, day-
time sleepiness, cognitive impairment, mood disturbance, 
impaired work function, impaired interpersonal func-
tion),2 contrasting with the general DSM-IV statement of 
“significant distress or impairment in social, occupational, 
or other important areas of functioning.” 3(p557)
It seems timely to consider how these domains of day-
time impairment might associate, in nature or severity, 
with the ID subtypes of difficulty initiating sleep, dif-
ficulty maintaining sleep, early morning awakening, and 
nonrestorative sleep. Although their investigation did not 
use DSM-5 criteria, Léger et al,15 reporting on primary care 
patients (n = 3,384), found that those with a combination 
of nighttime symptoms had the most severe impairments. 
In a controlled, in-laboratory study, Roth et al16 found 
that patients with nonrestorative sleep (n = 115) reported 
daytime impairment similar in magnitude to those with 
difficulty initiating sleep (n = 56), difficulty maintaining 
sleep (n = 18), or a combination of symptoms (n = 37). 
Walsh et al17 found that nonrestorative sleep was associ-
ated with the poorest perceived health in a well-defined 
sample of US health plan members (n = 6,791). The iden-
tification of both nighttime and daytime symptoms may 
be particularly important in advancing understanding of 
how insomnia impacts mental health.18,19 Clinical history 
also requires further study. Preliminary reports suggest 
that childhood-onset insomnia is associated with more 
severe sleep complaints and a different profile of daytime 
dysfunction relative to adult-onset insomnia.20–22
ABSTRACT
Objective: To profile the daytime impact of the proposed  
DSM-5 insomnia disorder diagnosis, with and without mental  
health, physical health, or other sleep disorder comorbidities; to 
better understand how specific daytime symptom patterns are 
associated with nighttime sleep in insomnia; and to compare 
childhood-onset and adulthood-onset insomnia disorder with 
respect to daytime dysfunction.
Method: Data were derived from the Great British Sleep Survey 
(GBSS), an open-access online population survey completed by 
adults who had a valid postcode and were residents of the United 
Kingdom. The primary variables of interest were the 6 areas that, 
according to the proposed DSM-5 criteria, may be impacted 
in the daytime by insomnia disorder: energy, concentration, 
relationships, ability to stay awake, mood, and ability to get 
through work. These variables were compared for those with 
versus those without insomnia disorder and across 5 insomnia 
subtypes (difficulty initiating sleep, difficulty maintaining sleep, early 
morning awakening, a combination of these 3 core symptoms, or 
nonrestorative sleep). Clinically comorbid insomnia presentations 
(insomnia disorder with poor mental health/poor physical health/
additional sleep disorder symptoms) and insomnia disorder of 
childhood versus adult onset were also evaluated.
Results: A total of 11,129 participants (72% female; mean age = 39 
years) completed the GBSS between March 2010 and April 2011, 
of whom 5,083 screened as having possible insomnia disorder. 
Compared with those who did not have insomnia disorder, those 
with insomnia disorder reported greater impairment in all areas 
of daytime functioning (Cohen d range, 0.68–1.30). The greatest 
effects reflected negative impact on energy and mood. Participants 
with a combination of insomnia symptoms tended to be the 
most impaired (Cohen d range, 0.10–0.23), whereas no consistent 
differences emerged between the other 4 subtypes. Finally, 
individuals who had both insomnia disorder and poor mental  
health were consistently the most impaired comorbid group  
(Cohen d range, 0.15–0.65), and childhood-onset insomnia disorder 
had greater daytime impact than adult-onset insomnia disorder 
(P < .05 for energy; P < .01 for mood, concentration, and getting 
through work).
Conclusions: The severity of daytime impact of DSM-5 insomnia 
disorder varies by insomnia type. This finding has implications for 
the evaluation and management of insomnia in clinical practice.
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In March 2010, the Great British Sleep Survey (GBSS), 
an online population survey based on detailed DSM-5 cri-
teria, was launched. The survey was conducted by Sleepio 
Limited (an organization dedicated to helping people sleep 
better through raising awareness, research, and dissemina-
tion of behavioral advice), in association with Boots UK 
and the Mental Health Foundation (London, England). Our 
major objectives were to compare and contrast both sleep 
disturbance and its daytime impact (1) in ID relative to a 
reference group with no ID, (2) in the ID subtypes (diffi-
culty initiating sleep vs difficulty maintaining sleep vs early 
morning awakening vs a combination of these symptoms 
vs non restorative sleep), (3) in a comparison of childhood-
onset and adult-onset ID, and (4) across clinically comorbid 
mental health, physical health, and other sleep disorder con-
ditions (ID + mental health condition vs ID + physical health 
condition vs ID + other sleep disorder vs ID only).
METHOD
Design
We report on 11,129 respondents to the GBSS, an open-
access, Web-based survey completed by adults (aged ≥ 18 
years) who had a valid postcode and were residents of the 
United Kingdom. The strengths of this approach include 
accessibility, ease of use, time-stamping of data acquisition, 
absence of missing information, and ability to recruit a siz-
able sample of people meeting ID criteria. Our data are not 
formally sampled, because it was not our purpose to report 
population incidence or prevalence figures. Rather, we sug-
gest that the sample is valid in relation to our objectives of 
profiling the nighttime symptoms and daytime concerns 
of people who meet ID criteria, with or without comorbid 
symptoms.
Measures
The GBSS is a brief online survey comprising personal 
and demographic information; appraisal of sleep pattern, 
sleep quality, and impact of poor sleep on daytime func-
tioning; use of prescription and over-the-counter sleep aids; 
items on physical and mental health; and screening questions 
on sleep disorders other than insomnia. (Illustration of our 
methods can be viewed at http://www.sleepio.com/research, 
and the contemporary version of the GBSS is at http://www.
greatbritishsleepsurvey.com.) The GBSS incorporated items 
on sleep and daytime function to permit evaluation against 
DSM-5 criteria and to take account of quantitative insomnia 
criteria including research diagnostic criteria.13,23 Insom-
nia disorder cases were defined according to the following 
criteria:
Current complaint of sleep dissatisfaction/concern 1. 
(ie, scoring ≥ 2 [“somewhat”] on a 0–4 scale when 
asked, “Over the past month, to what extent has poor 
sleep troubled you in general?”). 
Complaint comprises 1 of the following:2. 
Difficulty initiating sleep ≥ 31 minutes, •	
Difficulty maintaining sleep ≥ 31 minutes  •	
(individual is awake for ≥ 31 minutes during the 
night after initially falling asleep; could include 1 
or multiple awakenings),
Early morning awakening (final awakening ≥ 31 •	
minutes prior to actual rise time),
A combination of at least 2 of these 3 core  •	
insomnia symptoms, or 
Nonrestorative sleep (difficulty initiating and •	
maintaining sleep and early morning awaken-
ing ≤ 30 minutes, but all other ID criteria met).
Failure to endorse “very good” or “good” sleep  3. 
quality (ie, required to score ≥ 2 [“average”] on a  
0–4 scale when asked, “Over the past month, how 
would you rate your sleep quality?”).
Complaint is associated with significant sleep-related 4. 
daytime effects (ie, scoring ≥ 2 [“somewhat”] on a 0–4 
scale; 0 = not at all affected, 4 = very much affected) 
on at least 1 of 6 domains: energy, daytime sleepiness, 
cognitive impairment, mood disturbance, impaired 
work functioning, impaired relationship functioning.
Sleep difficulty is reported to be affecting the 5. 
person ≥ 3 nights per week.
Sleep difficulty has been occurring for ≥ 3 months.6. 
The GBSS also incorporated the Sleep Disorders Screen-
ing Questionnaire, a published clinical tool for conservatively 
identifying possible cases of narcolepsy, obstructive sleep 
apnea, restless legs syndrome/periodic limb movements in 
sleep, circadian rhythm sleep disorder, and parasomnia24 (see 
algorithm at http://www.sleepio.com/research). The GBSS 
inquired about health status by means of 2 items: “For my 
age I believe that my physical health is…” and “For my age I 
believe that my mental health is…,” both rated on a 5-point 
Likert scale (0 = very good, 1 = good, 2 = average, 3 = poor, 
4 = very poor). For this analysis, poor physical health and 
poor mental health were defined by a score ≥ 3 on the respec-
tive ratings.
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DSM-5 ■  proposes to move away from “primary” and 
“secondary” insomnia, recognizing that causality is often 
hard to determine, that sleep and comorbid conditions 
interact in a bidirectional manner, and that sleep 
disturbance is associated with illness vulnerability.
The new diagnostic entity of insomnia disorder  ■
highlights that significant sleep disturbance merits 
independent clinical attention, regardless of additional 
comorbidities.
The daytime consequences of insomnia disorder are most  ■
pronounced for those with a mixed subtype (problems 
with both initiating and maintaining sleep), those  
with poor mental health, and those with insomnia  
of childhood onset.
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Items from the GBSS were also used to calculate the 
Sleep Condition Indicator (SCI; 0–10 range), on which 
higher values reflect better overall sleep quality. The SCI 
has excellent sensitivity and specificity, high internal con-
sistency reliability, and sensitivity to change following 
cognitive-behavioral therapy.25 The SCI also correlates with 
other standard measures of sleep quality (Pittsburgh Sleep 
Quality Index: r = 0.78, n = 256; Insomnia Severity Index: 
r = 0.79, n = 256).26
Statistical Analysis
Potential differences associated with expressions of the 
independent variable (sleep status) on the primary depen-
dent variables of interest (6 daytime domains) were evaluated 
using multivariate analysis of variance (MANOVA), control-
ling for age and gender. Significant multivariate statistics 
were followed up through examination of univariate F tests 
for each domain and were pursued by independent t tests 
to determine order effects in terms of severity of daytime 
impact. Comparisons were 2-sided, with P < .05 considered 
to indicate statistical significance. When appropriate, to con-
trol for multiple comparisons within and between subjects, 
a per family error rate was adopted (.05 /n of comparisons). 
Relative between-group effect sizes, expressed as Cohen d 
(M1 – M2 / δpooled),27 were applied to estimate and to compare 
the magnitude of observed effects. 
RESULTS
Characteristics of Participants  
With Versus Without Insomnia Disorder
A total of 11,129 people (8,044 [72.3%] female; mean 
age = 39 years; range, 18–93 years) completed the survey 
(March 2010–April 2011). With the application of DSM-5 
criteria, 5,083 participants (45.7%) screened as having pos-
sible ID (ID group), and 5,542 did not have ID (NO-ID 
group) (49.8%; Table 1). A small number met insom-
nia criteria with duration ≤ 3 months, reflecting acute 
insomnia (sleep disturbance 
duration < 1 month; n = 131, 
1.2%) or subacute insomnia 
(sleep disturbance duration 
1–3 months; n = 373, 3.4%). 
These individuals were 
excluded, and thus the total 
number included in the analy-
sis was 10,625. For those with 
ID, their sleep problem was 
typically chronic, with 83% 
having had insomnia for over 
1 year and 45% having had it 
for ≥ 6 years.
A higher proportion of 
the ID group, relative to the 
NO-ID group, was female 
(75% vs 69%; χ2 = 40.5, 
P < .0001). The ID group 
was also older (t10413.30 = 13.44, P < .0001) and had poorer 
mental health (t10313.16 = 26.14, P < .0001) and physical 
health (t10623 = 16.15, P < .0001). We determined index of 
multiple deprivation (IMD) scores, a proxy for socioeco-
nomic status, through residential postcodes (IMD analysis 
included English residents only). As the majority of our 
respondents were from England (n = 8,235), we compared 
IMD scores between those with insomnia (n = 3,991) and 
those without insomnia (n = 4,244), finding no signifi-
cant difference (t8233 = 0.724, P = .469). Mean IMD values 
for our available sample (20.2, SD = 14.4) were similar to 
the national average (21.7, SD = 15.5).28 Confirmation of 
sleep status allocations may be drawn from the finding that 
SCI scores for the NO-ID group were significantly higher 
(t9862.89 = 130.46, P < .0001), more than twice those of the ID 
group (see Table 1).
Daytime Impact of Insomnia Disorder  
Relative to No Insomnia Disorder
The ID and NO-ID groups were compared across the 6 
DSM-5 domains of daytime functioning. Since, by defini-
tion, the NO-ID group did not experience poor sleep on 
a regular basis, questions for these participants reflected 
the level of daytime impairment they experienced on 
their (occasional) nights of poor sleep. Formal analysis, 
with gender and age as covariates, produced an omnibus 
multivariate effect (F6,10616 = 1035.04, P < .0001) and sig-
nificant univariate effects for all domains (all P < .0001), 
with the ID group reporting greater impairment (Figure 
1). Relative between-group effect sizes were strongest 
for energy (d = 1.30), mood (d = 1.24), and concentration 
(d = 1.05) and remained large for relationships (d = 0.96) 
and getting through work (d = 0.94). Ability to stay awake 
during the day produced a smaller, though still moderate 
to large, between-group effect size (d = 0.68). This relative 
ordering of mean daytime impact for the ID group was 
paralleled by the proportions of participants who reported 
being “very much affected” on energy (30.7% of the ID 
Table 1. Comparison of Respondents With and Without Insomnia Disorder in Relation to 
Demographic and Sleep Variables
Variable
Insomnia Disorder 
(n = 5,083)
No Insomnia Disorder 
(n = 5,542)
Total Sample 
(N = 10,625)
Gender, % male/female 25.3/74.7* 30.8/69.2 28.2/71.8
Age, mean (SD), y 41.3 (14.8)* 37.6 (14.0) 39.4 (14.5)
Index of multiple deprivation score, mean (SD)a 20.1 (14.3) 20.3 (14.5) 20.2 (14.4)
Physical health score, mean (SD)b 1.72 (0.95)* 1.43 (0.89) 1.57 (0.93)
Mental health score, mean (SD)b 1.82 (1.08)* 1.29 (0.99) 1.54 (1.07)
SCI score, mean (SD)c 3.02 (1.25)* 6.95 (1.82) 5.07 (2.52)
Taking prescribed sleeping pills, % 12.0* 2.8 7.2
Taking over-the-counter sleep remedies, % 24.3* 9.8 16.7
Insomnia duration, % reporting
< 12 mo 17.0
1–5 y 38.0
6–10 y 17.0
≥ 11 y 28.0
aA proxy for socioeconomic status, determined through residential postcode. Based on English residents only.
bLower scores indicate better perceived health: 0 = very good, 4 = very poor.
cScale of 0 to 10; higher values reflect better overall sleep quality.
*P < .0001 for comparisons between respondents with and without insomnia disorder.
Abbreviation: SCI = Sleep Condition Indicator.
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sample), mood (18.9%), concentration (16.9%), getting 
through work (14.6%), relationships (8.7%), and ability to stay 
awake (7.2%).
Daytime Impact Across Insomnia Disorder Subtypes
The most common subtype was a combination of the 
3 core symptoms (MIXED; 61.3%), followed by difficulty 
maintaining sleep (DMS; 12.7%), difficulty initiating sleep 
(DIS; 12.4%), nonrestorative sleep (NRS; 9.5%), and early 
morning awakening (EMA; 4.2%) (Table 2). The MIXED 
group comprised the following symptom combinations: 
DMS + EMA (9.2% of total ID group), DIS + DMS (24.4%), 
DIS + EMA (6.7%), and DIS + DMS + EMA (21.0%). Subtype 
differences were found for gender distribution (χ2 = 16.23, 
P < .01), age (F4,5078 = 87.35, P < .0001), and, controlling for 
age and gender, self-reported mental health (F4,5076 = 10.15, 
P < .0001) and physical health (F4,5076 = 7.43, P < .0001). For 
mental health, the MIXED group was more impaired relative 
to the DMS group, and for physical health, the DMS group 
was more impaired relative to the EMA, MIXED, and NRS 
groups. There were also subtype differences with respect to 
the SCI (F4,5076 = 525.9, P < .0001) and prescribed sleeping 
pill use (χ2 = 62.63, P < .0001), with the MIXED group report-
ing the poorest overall sleep quality and being most likely to 
be taking prescribed sleeping pills.
In relation to the nature and magnitude of daytime impair-
ment, formal analysis, with gender and age as covariates, 
produced an omnibus multivariate effect (F24,17691.82 = 4.61, 
P < .0001), and subsequent univariate effects were found for 
all 6 domains (P < .05 for staying awake and P < .0001 for the 
other 5 domains). When the Bonferroni comparison method 
for multiple testing was applied, those with the MIXED sub-
type reported greater daytime impairment relative to the 
other subtypes, particularly for mood, concentration, and 
getting through work (see Table 2). The magnitude of these 
differences was small (Cohen d range, 0.10–0.23). There 
were few subtype differences for problems staying awake, 
with the exception that the NRS group was significantly more 
impaired relative to the DIS group.
Daytime Impact of Insomnia Disorder Comorbid With 
Mental or Physical Health Problems or Additional 
Sleep-Related Disturbance
We investigated daytime impairment in relation to 
whether ID presented on its own (ID-Alone; n = 1,884, 37.1%) 
or with poor physical health (ID + PH; n = 166, 3.3%), poor 
mental health (ID + MH; n = 384, 7.6%), or another sleep 
disorder (ID + SLD; n = 1,691, 33.3%). Approximately 22% 
of participants (n = 1,138) reported ID in the presence of at 
least 2 (of the possible 3) comorbid presentations, reflected 
in the following groups: ID + PH + MH (n = 148, 2.9%), 
ID + MH + SLD (n = 510, 10%), ID + PH + SLD (n = 300, 
5.9%). No participants reported having ID plus 3 comorbid-
ities (ie, ID + MH + PH + SLD). For the purpose of the present 
analysis, we focused on daytime impairment across 4 discrete 
groups, ID-Alone, ID + PH, ID + MH, and ID + SLD, reflect-
ing DSM-5 proposals for recording possible comorbidities.
MANOVA revealed a significant main effect of comor-
bidity group (F18,11636.63 = 18.9, P < .0001), and univariate 
effects were found for all daytime domains (P < .0001; Table 
3). Respondents with ID + MH were found to have greater 
sleep-related daytime impairment in relation to mood, 
concentration, and getting through work relative to every 
other group and reported enhanced levels of impairment for 
relationship functioning compared to those in the ID-Alone 
and ID + SLD groups. With respect to energy, the ID + MH, 
ID + PH, and ID + SLD groups all tended to have greater 
impairments relative to the ID-Alone group, and, with 
respect to ability to stay awake, the ID + SLD group exhibited 
the greatest impairment relative to the other 3 groups. The 
ID + MH group also had the poorest SCI score and reported 
greater usage of sleeping pills. Effect sizes for group dif-
ferences, where the ID + MH group evidenced the greatest 
impairment, ranged from d = 0.15–0.65, with larger effects 
typically reflecting comparisons with the ID-Alone group.
Daytime Impact of Childhood-Onset  
Versus Adult-Onset Insomnia Disorder
Finally, the GBSS included the simple question, “Did you 
sleep well as a child?” (yes/no) to estimate idiopathic insomnia 
(consistent with criteria used in the International Classifi-
cation of Sleep Disorders, second edition29). This allowed 
us to investigate the daytime impact of childhood-onset 
ID (n = 1,230; 24.2%) relative to adult-onset ID (n = 3,853; 
75.8%, Table 4). Those who slept poorly during childhood 
were more likely to be younger (t2193.34 = 10.97, P < .0001) and 
female (χ2 = 12.52, P < .0001) and have poorer sleep quality 
(SCI: t5081 = 5.82, P < .0001). In addition, those reporting 
childhood onset had poorer mental health (F1,5079 = 29.53, 
P < .0001) and were more likely to be taking sleep-promoting 
hypnotics (χ2 = 4.98, P < .05) and over-the-counter remedies 
(χ2 = 7.21, P < .01). MANOVA revealed a significant main 
effect of group (F6,5074 = 2.41, P < .05). Significant univariate 
effects were found for 4 domains: energy (P < .05), mood, 
Figure 1. Comparison of Respondents With and Without 
Insomnia Disorder in Relation to Negative Impact on the 6 
DSM-5 Areas of Daytime Dysfunctiona
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Daytime Impact of DSM-5 Insomnia Disorder
e5J Clin Psychiatry 73:0, Month 2012
© 2012 COPYRIGHT PHYSICIANS POSTGRADUATE PRESS, INC. NOT FOR DISTRIBUTION, DISPLAY, OR COMMERCIAL PURPOSES. 
concentration, and getting through work (all P < .01), with 
the childhood-onset group evidencing greater impair-
ment. Between-group effects were small (range of d values, 
0.12–0.24).
DISCUSSION
Our objective was to understand how daytime symptom 
patterns associate with nighttime sleep in DSM-5 insomnia 
disorder.
First, our findings validate the DSM-5 domains because 
the patterning of impact mirrored that reported by people 
in the group without ID in relation to the (infrequent) 
nights when the latter group does not sleep well (Figure 1). 
Between-group effect sizes for this comparison were large 
for energy, mood, concentration, relationships, and work 
functioning (range of d values, 0.94–1.30), with daytime 
sleepiness the least affected area, though still evidencing a 
moderate effect (d = 0.68). These results are consistent with 
other research suggesting that impairment of energy, mood, 
and cognition is characteristic of insomnia,30–32 whereas 
daytime sleepiness, while elevated relative to normal sleep-
ers, is less so.33,34
Second, we observed differences in symptomatology 
associated with the presenting subtype. The group with 
multiple core symptoms exhibited the greatest impairment, 
Table 2. Comparison of Insomnia Disorder Subtypes in Relation to Demographic Variables and  
Sleep-Related Daytime Impairment
Variable
Difficulty 
Initiating Sleep 
(n = 632; 12.4%)
Difficulty 
Maintaining Sleep 
(n = 644; 12.7%)
MIXEDa 
(n = 3,114; 
61.3%)
Early Morning 
Awakening 
(n = 212; 4.2%)
Nonrestorative 
Sleep  
(n = 481; 9.5%)
Significant Contrasts With 
Bonferroni Correction
Gender, % male/female 73.4/26.6 73.8/26.2 76.4/23.6 71.2/28.2 68.6/31.4
Age, mean (SD), y 32.3 (12.4) 46.2 (12.6) 42.4 (15.2) 40.9 (14.5) 39.7 (12.9)
SCI score, mean (SE)b 3.60 (0.04) 3.38 (0.04) 2.53 (0.02) 4.4 (0.07) 4.4 (0.05)
Physical health score, mean (SE)c 1.71 (0.04) 1.57 (0.04) 1.73 (0.02) 1.91 (0.07) 1.81 (0.04) DMS > MIXED, EMA, NRS
Mental health score, mean (SE)c 1.75 (0.04) 1.61 (0.04) 1.88 (0.02) 1.82 (0.07) 1.77 (0.05) MIXED > DMS
Domain of daytime functioning 
score, adjusted mean (SE)
Mood 2.38 (0.04) 2.40 (0.04) 2.58 (0.02) 2.35 (0.07) 2.30 (0.05) MIXED > DIS, DMS, EMA, NRS
Energy 2.83 (0.04) 2.85 (0.04) 2.97 (0.02) 2.90 (0.06) 2.88 (0.04) MIXED > DIS, DMS
Relationships 1.57 (0.05) 1.72 (0.05) 1.79 (0.02) 1.63 (0.08) 1.57 (0.05) MIXED > DIS, NRS
Staying awake 1.38 (0.05) 1.49 (0.05) 1.51 (0.02) 1.48 (0.08) 1.62 (0.05) NRS > DIS
Concentration 2.26 (0.04) 2.29 (0.04) 2.40 (0.02) 2.15 (0.07) 2.19 (0.05) MIXED > DIS, EMA, NRS
Getting through work 2.07 (0.05) 2.02 (0.05) 2.18 (0.02) 1.94 (0.08) 2.00 (0.05) MIXED > DMS, EMA, NRS
Taking prescribed sleeping  
pills, %
8.2 9.0 14.8 5.2 6.0
aRespondent had more than 1 of the core symptoms (difficulty initiating sleep, difficulty maintaining sleep, early morning awakening).
bScale of 0 to 10; higher values reflect better overall sleep quality.
cLower scores indicate better perceived health: 0 = very good, 4 = very poor.
Abbreviations: DIS = difficulty initiating sleep, DMS = difficulty maintaining sleep, EMA = early morning awakening, NRS = nonrestorative sleep, 
SCI = Sleep Condition Indicator.
Table 3. Comparison of Insomnia Disorder (ID) Presentations in Relation to Demographic Variables and  
Sleep-Related Daytime Impairment
Variable
ID + Mental Health 
Condition (n = 384)
ID + Other Sleep 
Disorder (n = 1,691)
ID + Physical Health 
Condition (n = 166)
ID Alone 
(n = 1,884)
Significant Contrasts With 
Bonferroni Correction
Gender, % male/female 23.4/76.6 29.4/70.6 18.1/81.9 22.7/77.3
Age, mean (SD), y 37.4 (13.7) 40.6 (15.1) 41.9 (15.7) 44.2 (14.3)
SCI scorea
Mean (SD) 2.75 (1.28) 3.07 (1.28) 3.05 (1.24) 3.22 (1.18)
Mean (SE) 2.72 (0.06) 3.05 (0.03) 3.06 (1.0) 3.24 (0.03)
Domain of daytime functioning 
score, adjusted mean (SE)
Mood 2.86 (0.05) 2.46 (0.02) 2.31 (0.08) 2.30 (0.02) ID + MH > ID + SLD, ID + PH, ID
ID + SLD > ID
Energy 3.02 (0.05) 2.95 (0.02) 3.02 (0.07) 2.72 (0.02) ID + MH, ID + PH, ID + SLD > ID
Relationships 1.92 (0.06) 1.73 (0.03) 1.75 (0.09) 1.55 (0.03) ID + MH > ID + SLD, ID
ID + SLD > ID
Staying awake 1.36 (0.06) 1.69 (0.03) 1.38 (0.09) 1.17 (0.03) ID + SLD > ID + MH, ID + PH, ID
ID + MH > ID
Concentration 2.57 (0.05) 2.34 (0.03) 2.20 (0.08) 2.12 (0.02) ID + MH > ID + SLD, ID + PH, ID
ID + SLD > ID
Getting through work 2.33 (0.06) 2.14 (0.03) 1.97 (0.09) 1.88 (0.03) ID + MH > ID + SLD, ID + PH, ID
ID + SLD > ID, ID + PH
Taking prescribed sleeping pills, % 18.0 10.6 10.8 10.9
aScale of 0 to 10; higher values reflect better overall sleep quality.
Abbreviations: MH = mental health condition, PH = physical health condition, SCI = Sleep Condition Indicator, SLD = sleep disorder.
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most pronounced for mood. In the group with multiple 
symptoms, concentration was also more impaired relative 
to the groups with difficulty initiating sleep, early morning 
awakening, and nonrestorative sleep, and getting through 
work was more impaired relative to the groups with dif-
ficulty maintaining sleep, early morning awakening, and 
nonrestorative sleep. These results were statistically robust, 
though small in magnitude and broadly comparable to those 
of Léger et al.15 Our data also indicate that nonrestorative 
sleep impacts functioning to a similar degree as difficulty 
initiating sleep, difficulty maintaining sleep, and early morn-
ing awakening, in keeping with emerging epidemiologic and 
experimental literature.16,17,35
Third, investigation of comorbid conditions revealed 
that in 3 domains (concentration, mood, and getting though 
work) the group with ID and a mental health condition 
reported the greatest impairment, and this group was 70% 
more likely to be taking sleep-promoting hypnotics. Unsur-
prisingly, those with ID and another sleep disorder had the 
greatest difficulty with maintaining wakefulness. Participants 
who had ID alone tended to be the least impaired, reflect-
ing research on health-related quality of life showing that 
controlling for comorbidities slightly attenuates the next-day 
impact of poor sleep.14 Nevertheless, robust between-group 
effects were evident even when we compared the group with 
ID alone and the group without ID (n = 1,884 vs n = 5,542, 
supplementary analysis: large effects for all domains [range 
of d values, 0.72–1.09] except sleepiness [d = 0.38]).
Finally, we found that those who had slept poorly as 
children (one-quarter of the ID group) had poorer sleep 
and mental health and greater deficits in energy, mood, 
concentration, and ability to get through their work. Sánchez-
Ortuño et al22 reported that such idiopathic insomnia and 
insomnia with mental health conditions clustered together 
and were associated with mood disturbance. Perhaps the link 
between childhood-onset insomnia and affective impair-
ment supports an underlying, possibly genetic, vulnerability 
to both sleep disturbance and 
depression.37
The clinical importance of 
daytime concerns as an inte-
gral component of ID should 
not be underestimated. We 
found substantial daytime 
effects for people with all 
insomnia subtypes when 
compared with normal sleep-
ers. It seems appropriate then 
to emphasize that DSM-5 ID 
can be characterized by poorer 
sleep and poorer daytime 
well-being. It seems likely 
that the combination of these 
experiences will drive clinical 
complaint.37 This interaction 
requires greater attention in 
practice, if we are to properly 
treat ID.14,38 Our data suggest that this clinical attention may 
be particularly important for patients presenting a mixed 
subtype of insomnia, those with co-occurring poor mental 
health, and those with an early history of sleep disturbance. 
A therapeutic focus on how to cope with and minimize 
daytime symptoms could enhance “traditional” cognitive-
behavioral therapy for insomnia.39
The strength of this study lies in the application of DSM-5 
criteria to a sizable population. We did not have a valida-
tion sample, using gold-standard clinical interviews, and 
our survey method is likely to have introduced error. Our 
screening of physical and mental health and our definition 
of childhood insomnia were self-reported and based on 
single items, so we urge caution in interpreting the results. 
Further work is required using face-to-face clinical evalua-
tion and/or more comprehensive self-report methodology 
to improve the characterization of respondents’ mental and 
physical health status. Our approach to data analysis inten-
tionally reflected a categorical/diagnostic view of ID, typical 
of disease classification nosologies and of clinical practice. 
Real-world evaluations of this kind are essential to consider 
the DSM-5 ID criteria. Nevertheless, we recognize that objec-
tive validation studies on nighttime and daytime symptoms 
are important. A recent report showed that slow-wave sleep 
was reduced in those with multiple core symptoms and those 
with difficulty maintaining sleep,16 so it is possible that slow-
wave sleep has a mediating effect on daytime performance.40 
Thus, there is a clear need for further work to characterize 
interactions among objectively determined sleep param-
eters, health status (including medication influences), and 
daytime functioning. Multivariate modeling would also help 
elucidate associations between sleep and daytime well-being 
and possible intermediate variables. One example would be 
that the impact of hypnotics on daytime functioning is well 
known,41 and in our study “higher risk” groups were more 
likely to endorse taking prescription sleep medication. We 
cannot, therefore, exclude the possibility that greater levels 
Table 4. Comparison of Childhood- Versus Adulthood-Onset Insomnia in Relation to 
Demographic Variables and Sleep-Related Daytime Impairment
Variable
Sleep Problems in Childhood 
(n = 1,230; 24.2%)
No Sleep Problems in Childhood 
(n = 3,853; 75.8%)
Gender, % male/female 21.5/78.5** 26.5/73.5
Age, mean (SD), y 37.3 (13.9)** 42.6 (14.8)
Physical health score, mean (SE)a 1.76 (0.03) 1.71 (0.02)
Mental health score, mean (SE)a 1.96 (0.03)** 1.77 (0.02)
SCI score, mean (SE)b 2.82 (0.04)** 3.09 (0.02)
Taking prescribed sleeping pills, % 13.8* 11.4
Taking over-the-counter sleep remedies, % 27.2** 23.4
Domain of daytime functioning score, 
adjusted mean (SE)
Mood 2.57 (0.03)** 2.48 (0.02)
Energy 2.98 (0.03)* 2.91 (0.02)
Relationships 1.78 (0.03) 1.71 (0.02)
Staying awake 1.52 (0.03) 1.50 (0.02)
Concentration 2.42 (0.03)** 2.31 (0.02)
Getting through work 2.20 (0.03)** 2.10 (0.02)
aLower scores indicate better perceived health: 0 = very good, 4 = very poor.
bScale of 0 to 10; higher values reflect better overall sleep quality.
*P < .05, **P < .01 for group comparisons.
Abbreviation: SCI = Sleep Condition Indicator.
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of daytime symptoms were in part an artifact of such other 
factors. 
Finally, we should also mention that, when the study was 
conducted, we included the 6 daytime domains that were 
listed on the DSM-5 Web site at that time (ie, the version 
dated June 2, 2010). We acknowledge that since then there 
have been some changes, including the addition of a domain 
relating to behavioral problems (eg, hyperactivity, impul-
sivity, aggression). This latter domain, however, may refer 
more to sleep problems in children and young people rather 
than adults.
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Abstract
Chronic insomnia is a very common clinical condition which may respond well to non-pharmacological
treatment. Indeed, the literature supports the efficacy of cognitive behaviour therapy (CBT). However, there
has been no substantial study of clinical effectiveness. Since insomniacs typically present in general medical
practice this is a crucial gap in the outcome research. This study, therefore, specifically investigated the
clinical effectiveness of CBT delivered by Health Visitors (primary care nurses) trained as therapists. One
hundred and thirty-nine insomniacs (mean age 51 yr) were randomised to CBT or Self-Monitoring Control
(SMC) in a controlled trial. CBT comprised six group sessions (n=4 to 6 patients). After the controlled
phase, SMC patients entered deferred treatment (CBT-DEF), allowing both treatment replication and long-
term outcome to be investigated for a sizeable, treated sample. Repeated measures ANOVAs demonstrated
superiority of CBT over SMC in substantially reducing sleep latency and wakefulness during the night.
CBT-DEF replicated similar effects and maintained improvement was observed in both groups one year
later. Furthermore, total sleep increased significantly during follow-up and 84% of patients initially using
hypnotics remained drug-free. Results suggest that CBT administered by Health Visitors offers a clinically
effective treatment for insomnia. Ó 2000 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Conservative estimates of the prevalence of chronic insomnia, defined as persistent difficulty
in initiating or maintaining sleep (American Sleep Disorders Association, 1997), range from 9 to
12% in adulthood and up to 20% in later life, making sleep disturbance one of the most common
complaints in general medical practice (Bixler, Kales, Soldatos, Kales & Healy, 1979; Foley et
al., 1995; Ford & Kamerow, 1989; Gallup Organisation, 1991; Hoch et al., 1997; Mellinger,
Balter & Uhlenhuth, 1985). One reason for this high prevalence is that sleep is very sensitive to
physical or psychological disorder. Thus, “secondary insomnia” presents in a wide range of con-
ditions (e.g. pain, respiratory disorder, depression), often enduring once a disordered pattern has
been established, even after the medical or psychiatric problem has resolved. “Primary insomnia”,
of course, refers to a sleep disorder constituting the major difficulty at the time of presentation.
Age-related developmental change contributes to the increased presentation rates from the middle
years onwards (see Espie, 1991; Morin, 1993 for review). Statistics on the prescription of hypnotic
medications (particularly benzodiazapines) also demonstrate the scale of sleep complaint within
the general population (Gallup Organisation, 1991; Mellinger et al., 1985) and insomnia is now
recognised to be associated with significant health-economic cost (Chilcott & Shapiro, 1996;
Walsh, Engelhardt & Hartman, 1995).
Although benzodiazapines used for short periods of time, or intermittently, can maintain their
effectiveness (Kales & Kales, 1984), pharmacological treatment is not recommended for primary
or chronic insomnia, or in the elderly. Indeed, the evidence against the prolonged use of such
drugs is overwhelming (NIMH, 1984; Russell & Lader, 1992). Over the past 20 yr considerable
progress has been made in the psychological assessment and treatment of sleep problems
(Bootzin & Nicassio, 1978; Espie, 1991, 1993; Lacks, 1987; Morin, 1993).
There is a sizeable literature on the effectiveness of cognitive behavioural treatment (CBT) for
insomnia. Accurate sleep information, the practice of sleep hygiene and the use of specific behav-
ioural and cognitive techniques such as relaxation therapy (see Bootzin & Nicassio, 1978), stimu-
lus control (Bootzin, 1972; Bootzin & Rider, 1997), sleep restriction (Spielman, Saskin & Thorpy,
1983) and cognitive techniques (Espie & Lindsay 1985; Morin, 1993) has been widely endorsed.
Over 50 controlled studies support the clinical efficacy of CBT, with meta-analyses reporting
significant effect sizes for improvements in sleep latency (0.87), duration of wakenings (0.65)
and sleep quality (0.94) (Morin, Culbert & Schwartz, 1994; Murtagh & Greenwood, 1995). The
majority of studies has been North American, although European trials have reported similar
results (Espie, Lindsay, Brooks, Hood & Turvey, 1989; Sanavio, Vidotto, Bettinardi, Rolletto &
Zorzi, 1990). Around 70–80% of patients seem to benefit and CBT appears equally efficacious
in older adults (Morin, Colecchi, Stone et al., 1999; Morin, Kowatch, Barry & Walton, 1993;
Morin et al., in press); important because of clear contraindications for hypnotic use in this ageg-
roup (Lader, 1992).
However, despite this evidence and the fact that CBT could be regarded as the treatment of
choice for chronic insomnia (Espie, 1999; Morin et al., 1999, in press), impact upon general
health care practice so far has been limited. Of course, the scale of the implementation task is
such that any realistic alternative to sleeping pills must be capable of being implemented not only
effectively but simply, efficiently and locally. The task is also compounded by the likelihood that
few general medical practitioners will be aware of the psychological literature; the fact that few
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psychologists have a special interest in sleep and in any case, may be in short supply; and the
continuing tendency for the doctor-patient relationship to raise the patient’s expectations of drugs.
All of these factors are essentially practical and might be alleviated by greater dissemination of
knowledge, educational opportunity for medical students and doctors, increased availability of
psychological services and changing the culture surrounding ‘medical’ intervention.
A more fundamental factor, however, is that CBT may be time-consuming, expensive and
ultimately less therapeutic to implement in general practice. There is, therefore, also an important
empirical question around the feasibility and effectiveness of delivering CBT which has not been
answered in efficacy trials, these having generally been carried out at specialised centres rather
than in routine practice. Morin et al. (1994) and recently Edinger and Wohlgemuth (1999), have
indicated that a major scientific limitation of the available evidence is the lack of any large scale
appraisal of clinical effectiveness in ordinary clinical settings. This study, therefore, was designed
specifically to investigate this research priority.
In the UK, most General Practitioners (GPs) work in group practices, often based in “health
centres”. The primary care teams have GPs, district nurses and health visitors as the core pro-
fessionals providing community health services, with paramedical staff offering sessional input.
The Health Visitor is a primary care nurse with community nursing qualifications who works
across the life span, e.g. with infants during early development, with people rehabilitating from
illness and with elderly people at home. In planning this study, therefore, we felt that training
Health Visitors in CBT for insomnia would provide the most accessible and valid approach to
managing insomnia in primary care settings, supported by a psychologist available on a con-
sultancy basis for complex cases e.g. significant co-morbidity, or differential diagnosis. Where
required, arrangements were also made for referral to a sleep laboratory. Although polysomnogra-
phy (PSG) is not usually required for the diagnosis of insomnia (Reite, Buysse, Reynolds &
Mendelson, 1995) it is invaluable in differential diagnosis of other suspected sleep problems.
2. Aims
The aims of the study, therefore, were to evaluate the medium to long-term (12 months post-
treatment) clinical effectiveness of a primary care-based insomnia service (the Sleep Clinic), using
Health Visitors as trained CBT therapists. In order to ensure validity and generalisability to typical
clinical populations, the study required a large number of consecutively referred insomniacs whose
sleep problems were both persistent and severe. The intervention was devised to test the feasibility
of a cost efficient approach involving approximately 1 h of treatment time per case.
3. Methods
3.1. Subjects
Consecutive referrals of adults presenting with chronic insomnia during a 24 month period
were received from GPs in Ayrshire. This part of west, central Scotland has both urban and
rural communities and comprises a broad socioeconomic span. Selection, based upon International
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Classification of Sleep Disorders criteria, comprised persistent difficulty initiating or maintaining
sleep, occurring 4 or more nights per week, for at least 3 months (American Sleep Disorders
Association, 1990). In addition, subjects had to score 5 or more on the Pittsburgh Sleep Quality
Index, a cut-off point regarded as identifying significant sleep disturbance with 90% diagnostic
accuracy. Furthermore, to ensure capture of the clinical population, subjects taking sleep medi-
cations were not excluded.
Two hundred and fifty-two subjects completed screening assessment of whom 91 failed to meet
diagnostic criteria. Main exclusions were transient or subclinical insomnia (n=35), suspected
Obstructive Sleep Apnoea Syndrome (OSAS; n=10), Periodic Limb Movements in Sleep (PLMS;
n=6), Major Depression (n=22), Parasomnia (e.g. sleepwalking; n=8) and other diagnoses (
n=10). OSAS and PLMS were subsequently confirmed by full PSG assessment in a sleep labora-
tory. Patients with significant depressive symptoms were referred to local services and those with
parasomnias were managed on a case by case basis by the senior author, but independent of this
study. Therefore, a total of 161 subjects was available of whom 139 (86%) completed the protocol
to post-treatment. Twelve month follow-up data are available on 109 subjects (78% of those
entering the study).
The final sample comprised 95 women and 44 men with mean age 51.4 years (S.D. 17.1; range
18-83). The majority was married and 60% were retired or ‘at home’. Over 40% reported problems
of greater than 10 years duration and more than half took hypnotic sleep medication. Mean
Epworth Sleepiness Scale score of 5.73 (S.D. 4.48) indicated minimal daytime sleep tendency.
However, 90% rated themselves as feeling tired across the daytime. (Table 1). Participants com-
pleting the 12 month follow up assessment did not differ significantly from the complete cohort
on any demographic or clinical variable.
3.2. Measures
Subjects completed the Pittsburgh Sleep Quality Index (Buysse, Reynolds, Monk, Berman &
Kupfer, 1989) and two weeks of Sleep Diaries prior to interview, when a full history was taken.
This was of standard format covering physical and mental health and diagnostic questions relating
to the International Classification of Sleep Disorders (ICSD). The Beck Depression Inventory
(BDI; Beck, Ward, Mendelson, Mock & Erbaugh, 1961), State-Trait Anxiety Inventory (STAI;
Spielberger, Gorsuch & Lushene, 1970) and Penn State Worry Questionnaire (PSWQ; Meyer,
Miller, Metzger & Borkovec, 1990) were administered to assess psychopathology. The Epworth
Sleepiness Scale (Johns, 1991) was administered as a standard assessment of excessive daytime
sleepiness; a central diagnostic symptom of OSAS and PLMS. To further improve diagnostic
accuracy of suspected OSAS or PLMS, the bedpartner was interviewed where possible and acti-
graphic data were gathered over 5 nights using the Actiwatch Ò (Cambridge Neurotechnology
Ltd.). The wrist actigraph is no larger than a standard wristwatch and is a simple, non-intrusive,
objective measure which estimates sleep parameters based on body movement (Sadeh, Hauri,
Kripke & Lavie, 1995). Motion sensors linked to a microprocessor detect and store data for
downloading and analysis on PC software. Full overnight PSG assessment was conducted only
to confirm diagnosis of other sleep disorders. It is widely accepted that PSG is not routinely
required in the clinical evaluation of insomnia (Douglas, Thomas & Jan, 1992; Reite et al., 1995).
Sleep diaries were completed each morning upon wakening for a 2 week baseline, throughout
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Table 1
Summary descriptive information on the study sample (n=139; unless otherwise stated)
Descriptor Values n %
Gender Female 95 68
Male 44 32
Marital status Married/cohabiting 86 62
Single 18 13
Widowed 23 17
Divorced 12 8
Occupational status Working 55 40
At home 41 29
Retired 43 31
History of sleep problem (n=131) ,2 yr 25 18
.2 and ,5 yr 27 20.5
.5 and ,10 yr 26 20
.10 and ,20 yr 26 20
.20 yr 27 20.5
Use of sleep medication not in past month 65 47
,once per week 8 6
once or twice per week 11 8
three or more times per week 55 39
Ratings of daytime tiredness (n=105) morning
never/occasionally 15 14
often/most days 90 86
afternoon
never/occasionally 11 10
often/most days 94 90
evening
never/occasionally 8 7
often/most days 97 93
the 6 week treatment and for 1 week at follow-up. Diaries comprised information on bedtime and
rising time, sleep onset latency (SOL), number of wakenings, wake time after sleep onset
(WASO), duration of nighttime sleep i.e. total sleep time (TST), ratings of sleep quality and
information on use of sleep medication (Espie, 1991). The Sleep Diary is the “staple” assessment
tool for appraisal of insomnia and monitoring of treatment-related effects. Although self-report
tends to overestimate sleep latency and wakefulness and underestimate time slept, studies consist-
ently demonstrate significant correlation with objective measures using PSG or actigraphic data
(Blood, Sack, Percy & Pen, 1997; Downey & Bonnet, 1992; Espie, 1991). Therefore, in outcome
research on insomnia sleep diaries are able to reflect change over time with satisfactory accuracy.
Importantly, the Sleep Diary, uniquely, captures subjective report and is the most valid instrument
for studying insomnia in general practice.
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3.3. Design
The study comprised an initial randomised treatment trial incorporating a treatment replication
phase, followed by a longer term observational study. It was felt that this design would be parti-
cularly suited to the stated purpose of investigating clinical effectiveness in a large sample of
patients to long-term follow-up.
After a minimum 2 week baseline, subjects were allocated at random either to CBT or a Self-
Monitoring Control (SMC) condition, each of 6 week duration. The latter controlled for the non-
specific effects of attention and of diary self-monitoring. It was hypothesised that CBT would
demonstrate superiority in outcome compared with SMC and that SMC subjects would not
improve. (Research has indicated consistently that chronic insomniacs do not improve when they
are not actively treated, but tend to deteriorate (Mendelson, 1995; Morin et al., 1994; Murtagh &
Greenwood, 1995)). SMC subjects then entered the treatment replication phase, receiving an ident-
ical treatment to the CBT group. SMC, therefore, became in effect a deferred CBT condition at
this point (CBT-DEF). It was hypothesised that CBT-DEF subjects would achieve post-treatment
outcomes comparable to the CBT condition. Upon completion of active treatment, both CBT and
CBT-DEF groups were followed up at 12 months post-treatment. Sixty-five of the 139 subjects
were randomised to SMC/ CBT-DEF and 74 to CBT, with 109 completing the follow-up assess-
ment.
3.4. Intervention
CBT comprised a multicomponent package, based upon established principles for non-pharma-
cological treatment of insomnia. Subjects participated in group sessions (of 4 to 6 people) once
per week, completing a six week intervention led by a Health Visitor in a local GP surgery or
Health Centre. Each of the six treatment sessions was of 50 min duration; thus investment of
Health Visitor time per patient averaged around 1 h. Six Health Visitors conducted the treatment
sessions after extensive training from a Clinical Psychologist, a senior Health Promotion Officer
and a Pharmacist. Training was conducted both by sessional teaching of the treatment components
and through experiential learning by participating in ongoing groups (further details available
upon request). The Health Visitors were also provided with consultancy advice from the project
leader (a psychologist) and from the senior author.
Treatment comprised:
Session 1. Sleep Information (nature and function of sleep, sleep needs, disorders and effects),
Session 2. Sleep Hygiene Practices (diet, exercise and environment),
Sessions 3 and 4. Sleep Scheduling (stimulus control and sleep restriction procedures, relax-
ation therapy),
Sessions 5 and 6. Cognitive Therapy (thought restructuring, managing anxiety and intrusive
thoughts).
The CBT intervention was didactic, following a standardised format with overhead projection
of prepared material but with opportunity for discussion. Participants received written notes which
collated to a procedural manual for home-based practice. Full details of these treatment procedures
51C.A. Espie et al. / Behaviour Research and Therapy 39 (2001) 45–60
are available elsewhere (Espie et al., 1998) and from the senior author. Patients who were on
hypnotic medication received support in withdrawal as part of the programme and followed a
graded reduction schedule negotiated to maximise individual compliance. However, the with-
drawal rate was not greater than a one therapeutic dose reduction per week.
The SMC condition did not contain any specific, active treatment component. However, SMC
subjects did receive a full assessment interview and completed Sleep Diaries on a night by night
basis. They were told that they would start treatment in 6 weeks time and that continuing to
record their sleep during the intervening period would yield valuable clinical information on their
sleep pattern. If they required further help in completing the diaries they were encouraged to
telephone the office for advice. SMC may be regarded, therefore, as a waiting list condition
incorporating minimal contact, attention placebo and self-monitoring elements.
4. Results
4.1. Sleep pattern data
Data were analysed by means of SPSS repeated measures ANOVAs, appropriate for the mixed
between-within subjects design of this study (Tabachnick & Fidell, 1996). Dependent variables
were weekly mean scores for the three principal outcome measures from the Sleep Diary i.e.
sleep-onset latency (SOL; min), wake time after sleep-onset (WASO; min) i.e. total time spent
awake during night-time wakenings and total sleep time (TST; h). Each variable was considered
in a separate ANOVA, with group as the between subjects factor comprising two levels (CBT or
SMC/CBT-DEF) and time as the within subjects factor comprising four levels (baseline; post-
intervention (i.e. post-CBT or post-SMC); post CBT-DEF (i.e. after the SMC group had been
actively treated); 12 month follow up). Outcome data are presented visually in Figs. 1–3 for ease
of comparison, with formal statistical analyses presented in Table 2.
Inspection of Fig. 1 reveals that mean SOL reduced from 61 to 28 min following CBT, com-
Fig. 1. Effects upon Sleep-onset latency (SOL; min) of CBT and Self-Monitoring Control (SMC) and of the latter
group’s deferred entry to treatment (CBT-DEF) across the experimental period.
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Fig. 2. Effects upon Wake time after sleep-onset (WASO; min) of CBT and Self-Monitoring Control (SMC) and of
the latter group’s deferred entry to treatment (CBT-DEF) across the experimental period.
Fig. 3. Effects upon Total sleep time (TST; h) of CBT and Self-Monitoring Control (SMC) and of the latter group’s
deferred entry to treatment (CBT-DEF) across the experimental period.
pared with a change from 74 to 70 min associated with SMC. However, after active treatment,
the latter group achieved a post-treatment SOL of 36 min. These descriptive data suggest, there-
fore, that CBT was an effective intervention as evidenced both by its initial superiority over SMC
and by the replication of a similar outcome associated with deferred treatment. Furthermore, 12
month follow up data on 109 of the 139 participants, demonstrated stability in outcomes for both
treated groups. These results are supported by formal analysis (Table 2). Highly significant main
effects were observed for the effects of group, time and the group · time interaction (all p,0.001).
Further investigation of the interaction term demonstrated that the only significant between group
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difference was at post-treatment when the CBT group had received active intervention but SMC
had not yet embarked on deferred CBT (t=5.29; p,0.001). By comparison after the CBT-DEF
phase the two conditions were no longer significantly different, but both were improved. The
overall time main effect strongly supports the graphical evidence of maintained improvement to
12 months post-treatment for both groups.
Baseline data indicate that participants in both conditions also experienced significant wakeful-
ness during the night (Fig. 2). CBT was associated with a mean reduction in WASO of around
31 min to 47 min at post-treatment compared with little change in the SMC group which remained
at over 80 min. Deferred entry to treatment (CBT-DEF) did, however, reduce WASO to a mean
of 44 min. As with SOL, post-treatment gains appear to be reasonably maintained (around 53
min) at long-term follow up. Evidence from repeated measures ANOVA again supports these
descriptive data. The time main effect and the group· time interaction were highly significant
(p,0.001 and p=0.002 respectively; Table 2). Investigation of sub-effects revealed that the only
significant between group difference was observed after CBT treatment, prior to SMC receiving
treatment (t=2.62; p,0.01). Fig. 2, supported by the significant time main effect, suggests that
treatment gains were maintained in both groups after treatment. Graphical evidence of a slight
increase in WASO for both groups at 12 months, compared to post-treatment values, proved not
to be statistically significant using a related samples t-test on the combined group (t=21.41;
p=0.160; d.f.=108).
Fig. 3 presents summary data reflecting the impact of the conditions over time upon total sleep
(TST). The most striking feature of these data is the relatively modest effect of intervention
(whether immediate or deferred) upon TST. Participants generally continued to sleep a similar
amount of time as at baseline. There appears, therefore, to be no clear superiority of CBT over
SMC on this variable. At follow-up 12 months after treatment, however, a mean increase of
around 0.4 to 0.55 h (25 to 35 min) per night is apparent in both groups. Formal investigation
of TST revealed only a significant time main effect, reflecting this increase in total sleep during
the follow up period (Table 2) and related samples t-tests confirmed that significant change
occurred only between post-treatment and 12 months (t=25.17; p,0.001; d.f.=108). It is note-
worthy, nevertheless, that the CBT-DEF group obtained slightly less sleep after treatment than
the CBT group (t=22.38; p=0.020; Table 2). This was the only statistically significant difference
between the groups across the experimental period and importantly the groups were not signifi-
cantly different at baseline. The higher mean value at each phase in the CBT condition contributed
to a near significant group main effect, however, the interaction term was not close to statisti-
cal significance.
4.2. Clinical importance of outcome
A summary of sleep pattern outcome, for subjects whose follow up data were available (
n=109), is presented in Table 3. In overall terms, CBT was associated with a sustained, mean
reduction of wakefulness from bed of around 60 min per night. Subjects typically took 30 min
less time to fall asleep and had 30 min less wakefulness during the course of the night. These
represented substantial proportionate changes in sleep pattern compared with baseline (50 and
36% respectively). It is noteworthy, however, that the mean increase in sleep duration was only
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Table 3
Baseline to 12 month follow-up changes in sleep variables (n=109)
Variable Mean nightly change from baseline Percentage nightly change from
baseline
Sleep-onset latency reduction of 30 min reduction by 50%
Wake time after sleep-onset reduction of 30 min reduction by 36%
Total sleep time increase of 34 min increase of 10%
34 min. Taken together, the results presented in Table 3 imply that subjects’ sleep patterns were
altered in part by gaining more sleep and in part by spending less wakeful time in bed.
Previous analyses demonstrate that immediate and deferred treatment groups responded equally
to CBT. In order to consider other predictors of outcome a series of demographic and clinically
relevant, potential explanatory variables were entered in separate regression equations for each
of the three sleep pattern measures. Predictor variables included were subject sex, agegroup,
marital status, occupational status, duration of sleep problem, use of hypnotic medication, medical
history and several pre-treatment measures of psychopathology (BDI, STAI and PSWQ). A meas-
ure of perceived credibility of treatment was also included (Borkovec & Nau, 1972) as was a
variable to define which of the therapists led the group. Pre-treatment baseline to 12 month follow
up change scores were computed for the variables SOL, WASO and TST to represent clinical
outcome and stepwise linear regression models were computed.
The results of regression analyses revealed that for SOL and TST no significant predictors
emerged, suggesting that outcome was largely independent of any of these potential explanatory
variables. For WASO, only the agegroup of the subject had any predictive effect and at a very
modest level (Adj R2=0.06; beta=-0.263; p=0.016). The oldest subjects (in the 60+ age range)
achieved significantly greater long term reduction in WASO than the youngest subjects (aged 18
to 44 yr) (F=4.37; p=0.015; Scheffe post hoc p,0.05). Importantly, therefore, no contraindications
for CBT treatment emerged from this analysis.
Table 4 presents baseline and post-treatment psychopathology scores. Related t-test compari-
sons reveal modest but significant reductions in trait anxiety and worry (both p,0.05). There
Table 4
Baseline and post-treatment data and paired t-test comparisons on the psychopathology of the sample (*p,0.05)
Variable Baseline mean Post-treatment mean Paired comparison p
(S.D.) (S.D.) (t)
STAI state anxiety (n=102) 35.19 (12.16) 36.00 (12.90) -0.74 0.460
STAI trait anxiety (n=106) 41.83 (12.74) 39.85 (11.49) 2.41 0.018*
Penn State Worry Questionnaire (n=76) 45.79 (13.99) 43.22 (12.66) 2.30 0.024*
Beck Depression Inventory (n=104) 10.94 (9.12) 10.67 (11.7) 0.28 0.781
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were no changes in state anxiety or depressive symptomatology; the latter remaining in the mild
range on the Beck Depression Inventory. Furthermore, of the 74 subjects originally taking hyp-
notic medication, 56 (76%) had stopped completely at post-treatment. Data on 60 of the original
74 subjects were available at 1 year follow-up (81%), of whom 50 (84%) no longer required hyp-
notics.
5. Discussion
This study set out to evaluate the clinical effectiveness of CBT for chronic insomnia using
trained Health Visitors as therapists. With 139 subjects completing a controlled trial, comparing
CBT with a self-monitoring control procedure (SMC), this represents the largest published out-
come study on the non-pharmacological treatment of insomnia conducted in general practice.
Furthermore, since the SMC group was subsequently treated with CBT, as a deferred entry to
treatment procedure (CBT-DEF), a useful replication phase was incorporated in the study design.
All subjects were contacted 12 months after completing treatment with 109 returning follow up
measures (78%), thus permitting consideration of the medium to long-term effectiveness of the
programme.
In summary of the main findings, treatment effects may be regarded as both strong and durable,
with mean reduction of time awake in bed of around 60 min per night at 12 months post-treatment.
Sleep-onset latency and wake time after sleep-onset each reduced by around 30 min per night,
representing changes of one half and one third respectively in relation to baseline values. This
equates to 7 h less in terms of sleeplessness per week for the average patient. Increases in total
sleep amounted to 34 min per night; an additional 4 h sleep per week. Clearly, not all the reduction
in sleeplessness was made up in sleep gain. It seems, therefore, that patients must have continued
to spend less time in bed after treatment compared with baseline, but to sleep a higher proportion
of the night, with less difficulty getting to sleep and remaining asleep. This would be consistent
with the concept of raised ‘sleep efficiency’; the proportion of the time spent asleep to time in
bed increasing as a result of treatment. Put more simply, the probability of sleeping in bed was
significantly raised by CBT.
These results cannot be explained by simple attention, or passage of time, effects since SMC
alone had no significant impact upon sleep, whereas active CBT was associated with marked
improvement. Also, patients in the SMC condition subsequently responded equally well once
CBT was introduced. Although the possibility of a placebo effect arising from structured CBT
intervention cannot be entirely ruled out, since this was not specifically addressed in the present
study, the results do appear similar in scale to past research, including 28 randomised placebo-
controlled trials reported since 1980 (Morin et al., 1994, 1999, in press; Murtagh & Greenwood,
1995). The main difference between previous work and the present study, of course, being that
the former was conducted mainly in specialised hospital settings and/or university centres with
highly selected, recruited participants. The present findings from an unselected, clinically-
presenting primary care population appear to provide strong validation for the CBT approach and
its routine clinical effectiveness.
The durability of treatment-related change is of particular importance. In this study the great
majority of participants completed follow up procedures, making the results reasonably reliable.
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It also emerged that 84% of those who had originally been using hypnotic medication had success-
fully stopped one year later. This is a powerful indicator not only of the clinical significance of
the improvements in sleep pattern which were achieved, but also of the ‘mind set’ of participants.
It should, of course, be noted that the period from post-treatment to 12 months was not part of
the controlled study reported here. All subjects had received active treatment, making it impossible
to determine the longer term outcome specifically associated with CBT, as opposed to the passage
of time. Nevertheless, participants in this research had lengthy histories of chronic sleep problems
(Table 1) making it unlikely that many would have spontaneously improved. Furthermore, as
noted earlier the evidence is that such insomnias are very persistent, if anything tending to deterio-
rate further over time rather than remit.
The clinical importance of the results is also evidenced by the general lack of any significant
predictors of outcome arising from regression analyses of the principal sleep measures. It might
be considered, for example, that participants who were younger, had less severe problems, less
psychopathology or more recent and less chronic sleep problems would be more likely to benefit
from CBT. However, no evidence was found to support this. Indeed, the only significant finding
on any variable was that older subjects had greater reductions in wakefulness during the night.
This is likely to be a simple reflection of lower baseline scores on this variable in younger people,
in turn a reflection of sleep norms. Importantly, therefore, older adults responded equally well
and being on sleep medication did not contraindicate successful outcome. Similarly, participants
found the CBT intervention credible and there was no differential therapist factor effect. This
suggests that the treatment package itself comprises transferable skills which can be learnt by
Health Visitors, who have no prior expertise. The modest but significant reductions in trait charac-
teristics of anxiety and worry after treatment may suggest some generalised benefit toward improv-
ing coping responses.
It seems, therefore, that Health Visitors (and potentially other nurses based in primary care
settings) may offer a practicable solution to insomnia management in general practice, for several
reasons. Firstly, in comparison with previous studies of CBT, using psychologists as therapists,
these treatment effects are at least equivalent (cf. Morin et al., 1994, 1999, in press). Secondly,
the small group approach is highly cost-efficient, enabling treatment within 1 h per case. Thirdly,
Clinical Psychologists are in short supply and are more expensive; and finally, Health Visitors
are integral to primary care services and have regular contact with their GP practice(s). On the
basis of our experience in the West of Scotland, 10 sessions of Health Visitor time (i.e. 1 whole
time equivalent, divided over say 5 staff) with 4 sessions of a Clinical Psychologist, may serve
a population of 375,000. It should be reiterated that the CBT approach described here was highly
structured and generally didactic. However, this does afford the possibility of ‘rolling out’ the
model by making use of the prepared materials i.e. session by session therapist manual, patient-
related notes and staff training materials. There is potential also to develop from the available
materials a more self-directed intervention programme (e.g. CD-rom); the feasibility and effective-
ness of which could be investigated in comparison with the small group treatment format.
There appears then to be considerable potential for the wider implementation of CBT
approaches to the management of insomnia in general practice. Further research of course will
be required to evaluate such implementation and this could usefully include health economic and
‘quality of life’ evaluation in addition to measurement of sleep parameters. The potential benefits
of improved sleep both to the individual and to society are considerable and are worthy of greater
58 C.A. Espie et al. / Behaviour Research and Therapy 39 (2001) 45–60
attention e.g. reduced prescribing, health gains, reduced accidents, increased productivity. Formal
evaluation of treatment components would also help to identify the most active therapeutic
ingredients and this could pave the way for effective early intervention.
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The clinical efficacy of cognitive behavior therapy (CBT) for chronic insomnia has been established, yet 
clinical effectiveness is less clear. This study presents data on 109 patients from general practice during 
a formal evaluation of clinical effectiveness. Two thirds achieved normative values of S30 min for sleep 
latency and wakefulness during the night after CBT. Furthermore, al!llost half of the sample reduced 
sleeplessness by 2::50%. Logistic regression revealed that initial severity did not contraindicate good 
outcome. Rather, greater sleep disturbance was positively associated with large symptom reduction, 
although lower endpoint scores were less likely. Similarly, symptoms of anxiety, depression, and 
thinking errors positively predicted good outcome. Hypnotic using patients responded equally well to 
CBT, and demographic factors were of no significant predictive value. It is concluded that CBT is 
clinically and durably effective for persistent insomnia in routine practice. 
 
 
 
Insomnia is a widespread complaint affecting a sizable propor- 
tion of the general population. At least 1 in 10 adults experiences 
persistent difficulty getting to sleep or staying asleep (Ancoli- 
Israel & Roth, 1999; Ford & Kamerow, 1989; Mellinger, Balter, & 
Uhlenhuth, 1985), and this figure doubles to around 20% in the 
older adult population (Foley et al., 1995; Foley, Monjan, Simon- 
sick, Wallace, & Blazer, 1999; Hoch et al., 1997). Not surpris- 
ingly, therefore, considerable attention has been given to the 
assessment and management of insomnia, culminating in guide- 
lines being issued for clinical practice. 
In relation to assessment, the American Sleep Disorders Asso- . 
ciation (ASDA) has published practice  parameter  statements  for 
the use of polysomnography (ASDA, 1995b) and wrist actigraphy 
(ASDA, 1995a). It is accepted that the former, comprising EEG 
measurement of the brain's sleep stages along with recording of 
muscle activity, eye movement, respiration rates, and oxygen 
saturation levels, is not essential for the diagnosis of insomnia 
(Douglas, Thomas, & Tan, 1992; Reite, Buysse, Reynolds, & 
Mendelson,  1995). Polysomnography,  however, is often crucial to 
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appraisal and differential diagnosis of other disorders of sleep. 
Behavioral technologies were first reviewed by Bootzin and 
Engle-Friedman (1981), and the wrist actigraph is seen as the most 
convenient, nonintrusive device for objectively estimating sleep 
pattern, having been validated against polysomnography in normal 
participants (Hauri & Wisbey, 1992). The actigraph is a small, 
watch-like device that records and stores movement information in 
short epochs (1  min or less) by means of an accelerometer- 
microprocessor link. Because movement correlates highly with 
wakefulness and lack of movement with sleep, an algorithm en- 
ables PC-run software to accurately estimate the  major sleep 
parameters. The monitoring of subjective sleep by means of the 
self-report sleep diary, however, continues to be the staple of both 
clinical practice and research on insomnia (Espie, 1991; Morin, 
1993). The sleep diaries are completed each morning, upon rising 
from bed, and they represent the insomniac's perceptions not only 
of sleep pattern per se, but importantly also of sleep quality. 
In relation to drug treatment, hypnotics may be appropriately 
used for transient and short-term insomnia, but their nightly use 
should be limited to 4 weeks or less (National Institutes of Health, 
1984; Gillin & Byerley, 1990). Hypnotics are not advised for the 
routine or long-term treatment of persistent insomnia, because of 
both limited evidence of effectiveness and recognized problems on 
withdrawal (Kripke, 2000; Russell & Lader, 1992; Royal Society 
of Medicine, 1992). Contraindications for the use of hypnotics in 
the elderly have been particularly highlighted due to the aging of 
the biological clock, problems of drug accumulation, and daytime 
drowsiness (National Institutes of Health, 1991; Royal Society of 
Medicine, 1992). 
In relation to nonpharmacological therapy for insomnia, it was 
only recently that ASDA [now the American Academy of Sleep 
Medicine (AASM)J commissioned an expert review group to write 
treatment practice parameters (Morin, Hauri, et al., 1999). Never- 
theless, this position article reflects the established status of cog- 
nitive behavior therapy (CBT) as a frontline treatment for chronic 
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insomnia. Typically comprising elements of stimulus control treat- 
ment, sleep restriction therapy, relaxation methods, and cognitive 
restructuring, either singly or in combination (see Espie, 1991; 
Morin, 1993), CBT has been recommended as a core component of 
intervention for clinical insomnia (Reite, Ruddy, & Nagel, 1997) 
and as the treatment of first choice for chronic insomnia (Espie, 
1999). Meta-analytic data that  support the efficacy of CBT have 
been reported elsewhere (Morin, Culbert, & Schwartz, 1994; 
Murtagh & Greenwood, 1995), and recent reviews and research 
reports have highlighted the advantages of CBT over pharmaco- 
therapy for persistent insomnia (Edinger & Wohlgemuth, 1999), 
including insomnia  in older adults (Morin, Colecchi, Stone, Sood, 
& Brink, 1999). 
Unfortunately, it is not yet possible to provide satisfactory 
guidelines for psychological therapy that answer a key clinical 
question: Who benefits most from CBT for insomnia, and who 
benefits least? For example, Murtagh and Greenwood (1995) con- 
cluded that drug-using insomniacs may be less likely to benefit 
from CBT. However, work by Morin and colleagues suggests that 
CBT may be  equally efficacious in hypnotic-using patients, and 
CBT may be useful to aid withdrawal from medication (Morin, 
Colecchi, Ling, & Sood, 1995). Espie, Inglis, Tessier, and  Har- 
vey's (2001) work supports this view. They found that hypnotic- 
using insomniacs responded equally well to CBT delivered in a 
primary care setting, and that 84% of these patients successfully 
withdrew from medication. If CBT were to be of limited benefit to 
this important clinically presenting group, then. the utility and 
validity  of the treatment would  be compromised. 
The AASM  article debates other potential  moderators  of treat- 
ment response. Whereas earlier reports suggested that younger 
participants  were  more  responsive  to  treatment  (Alperson  & 
Biglan, 1979; Lacks & Powlishta, 1989), a series of recent studies 
of  late-life  insomnia  indicate  that  when  older  adults are well 
screened for medical disorders and other sleep disorders (such as 
sleep apnea), magnitude of response is comparable to that obtained 
with  younger  patients  (Davies,  Lacks,  Storandt,  & Bertelson, 
1986; Friedman,  Bliwise,  Yesavage,  &  Salom,  1991; Morin, 
Kowatch,  Barry, & Walton,  1993; Puder, Lacks,  Bertelson,  & 
Storandt, 1983). Furthermore, there is no evidence to support the 
notion that older adults might find a psychological approach less 
acceptable. Indeed,  in a recent, randomized  controlled  trial of 
behavioral and pharmacological therapies patients (mean age 65 
years) consistently reported greater satisfaction with psychological 
therapy than drug treatment alone (Morin, Colecchi, et a!., 1999). 
It might  also be thought  that milder  sleep problems  would 
respond readily  to CBT, whereas  more entrenched and severe 
problems would be less amenable to change. Fewer studies have 
directly addressed this thought, although there has been evidence 
for 10 to 15 years that this is not the case. Lacks, Bertelson, Gans, 
and Kunkel (1983) found that categorizing participants into sever- 
ity groups did not differentiate in terms of significant outcome, and 
Espie, Lindsay, Brooks, Hood, and Turvey (1989) reported in a 
controlled  comparative  study  the  superiority  of  psychological 
treatments over placebo in patients referred with severe insomnia. 
Also, one report has suggested that patients with comorbid anxiety 
or depressive problems can achieve sleep improvements in keep- 
ing with those obtained by primary  insomniacs (Morin, Stone, 
McDonald, & Jones, 1994), and Bliwise, Friedman, Nekich, and 
Yesavage (1995) found that improvement in sleep latency follow- 
ing behavioral  intervention  was unrelated to participants'  present- 
ing personality  characteristics. 
Appreciation of any indications and contraindications of good 
clinical outcome may be difficult to establish, however,  from 
studies of clinical efficacy (which represent the majority to date). 
To meet the rigors of the scientific paradigm, characteristics of 
clinic-presenting populations (e.g., hypnotic dependence, psycho- 
pathology, poor motivation, impoverished social support) may be 
diluted. In simple terms, efficacy studies are weighted in favor of 
experimental control at the potential expense of generalization to 
real world settings (Clarke, 1995). For these reasons, Morin, Hauri, 
eta!. (1999) and Edinger and Wohlgemuth {1999) have exhorted 
researchers to consider clinical effectiveness studies because it is 
essential to establish the capacity of CBT to improve the sleep of 
unsolicited insomniacs in the general medical setting. In practice, 
of course, the distinction between efficacy and effectiveness is not 
absolute, but it reflects a continuum, with research varying along 
many dimensions such as who serves as participants and therapists, 
how treatment is implemented and monitored, and what the setting 
is in which the treatment is delivered (Hoagwood & Hibbs, 1995; 
Kazdin, 1998). 
We have recently presented treatment outcome data on insomnia 
by using a methodology more consistent with the clinical effec- 
tiveness end of this continuum (see Espie eta!., 1998; Espie et al., 
2001). Our participants comprised a relatively unselected sample 
of chronic insomniacs, consecutively presenting and treated in 
primary care. For example, people were accepted into the study 
whether or not they were currently using sleep medication, and 
whether or not they had comorbid anxiety or depressive symptoms. 
Only those who clearly had a primary disorder other than insomnia 
were specifically excluded. Effectiveness studies should also re- 
flect the realities of the health system; therefore, treatment as usual 
may be the most appropriate control condition, and deferred entry 
to (active) treatment may provide the best opportunity to demon- 
strate clinical effects in a population who is requiring help. Using 
this design, our data demonstrated mean reductions of around 1 hr 
of sleeplessness per night, which were  durable at 12 months 
follow-up, comparable with the extant literature. This article ex- 
amines potential predictors of clinical outcome, giving particular 
consideration to the variables introduced in preceding paragraphs. 
 
Method 
 
The Sleep Clinic 
 
The Sleep Clinic was developed in the West of Scotland to provide 
psychological treatment in a primary care setting  for  people  presenting 
with severe and persistent insomnia. The assessment protocol included 
stringent criteria for the identification of significant sleep-onset insomnia 
and/or sleep-maintenance insomnia (International Classification of Sleep 
Disorders; ASDA, 1990), and the differential diagnosis of other sleep 
disorders. Consistent with recommended practice (see introductory sec- 
tion), overnight polysomnography assessment was conducted where disor- 
ders of sleep other than insomnia were suspected (e.g., obstructive sleep 
apnea), and wrist actigraphy was used to identify suspected circadian 
disorders (e.g., delayed sleep phase syndrome) or sleep  state mispercep- 
tion. Sleep diaries formed the basis of outcome evaluation, and several 
psychopathology  and other measures  were applied (see below). 
Participants attended six. weekly therapy  sessions, each lasting 50 min. 
The treatment program  was administered locally to small groups of 4 to 6 
patients  by  health  visitors  (primary  care  based  nurses)  who  had  been 
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extensively trained in CBT for insomnia. Thus, the program  was highly 
cost efficient, amounting to around 1 hr of therapist time per patient. The 
treatment format was highly structured with therapists working to a manual 
and patients receiving detailed notes for each session  and  guidance  on 
home practice (see Espie eta!., 1998, for full details). In brief, the program 
comprised  the following: 
Session 1: Sleep information (i.e., nature and function of sleep, sleep 
needs,  disorders  and effects); 
Session 2: Sleep hygiene practices (i.e., diet, exercise, and environment); 
Sessions 3 and 4: Sleep scheduling (i.e., stimulus control and sleep 
restriction procedures, relaxation therapy); and 
Sessions 5 and 6: Cognitive therapy (i.e., thought restructuring, para- 
doxical intention,  managing  anxiety and intrusive thoughts). 
 
Participants 
 
To investigate pretreatment variables that might predict long-term out- 
come after CBT for chronic insomnia, only those participants from our 
study cohort who had completed a 12 month posttreatment follow-up 
assessment were included. Therefore, of the 139 insomniacs who had 
completed the treatment program, 109 (78%) participated in this study. 
There were no significant differences between the total sample and those 
completing follow-up on any clinical or demographic variable (Espie et al., 
2001). Importantly, there were no differences at posttreatment outcome 
between the two samples. Summary descriptive information on the partic- 
ipants is provided in Table 1, from which it is evident that these patients are 
typical of the clinic presenting population in having persistent problems 
(44% had over a 10-year duration of insomnia), with 56% taking hypnotic 
medication at the time of referral from their general practitioner. The 
sample was predominantly women with  an  average  age  of  52.1  years 
(SD  =  16.2). 
 
Measures 
 
Apart from the general demographic and clinical information gathered, 
the measures used in this study can be divided into two categories; namely, 
outcome variables and predictor variables. 
Outcome variables. Because the purpose of this study was to consider 
who benefits from CBT for insomnia and who does not, the outcomes of 
interest were the various sleep parameters, recorded on a daily basis on a 
self-report sleep diary (Espie, 1991). Diaries had been completed by 
participants throughout the experimental period of the original study (for at 
 
 
Table  1 
Summary Descriptive  Information  on the Presenting 
Characteristics  of the 12 Month Posttreatment  Study 
Sample (N = 109; Unless Otherwise Stated) 
least 2 weeks  during baseline, throughout  the 6-week treatment  period), 
and they were also completed for 1 week at 12 month follow-up. The sleep 
diary comprised information on sleep-onset latency (SOL: minutes), wake 
time after sleep onset (WASO: minutes), that is, total wakeful time during 
the night attributable to wakenings; number of nocturnal wakenings 
(nWAKE), that is, the number  of discrete wakenings that the participant 
recalled; and a measure of sleep quality represented by enjoyment of sleep 
(ENJOY) rated on a 5-point Likert scale from 0 (not at all) through 4 
(extremely; see Espie, 1991, pp.  80-84). The weekly mean score for each 
variable was calculated at 12 month posttreatment to represent sleep- 
pattern  outcome. 
There has been much debate about the usefulness of appraisal of statis- 
tical significance alone, particularly in studies that are evaluating clinical 
populations  and may be presuming  clinically  important effects (Jacobson 
& Truax, 1991; Kendall, Marrs-Garcia, Nath, & Sheldrick, 1999). There- 
fore, measures of change, which might represent good and poor clinical 
outcome for this population, were considered. High between participant 
variability in both baseline and outcome scores suggested it would  be 
invalid to use standard deviation scores to establish a threshold for clinical 
change. It was decided, therefore, to adopt two sets of criteria for clinical 
significance that have been used previously in insomnia research (Espie, 
Brooks,  & Lindsay,  1989). 
First, a reduction by 50% in a particular outcome variable, relative to the 
baseline score for that patient, was considered clinically significant (e.g., a 
reduction in  WASO from a mean of 80 min at baseline to 540 min at 
posttreatment). Dichotomous variables, therefore, were calculated for each 
of the four outcome measures (SOL, WASO, nWAKE, ENJOY) represent- 
ing change of  549% and change of  2:50%, respectively.  Second, because 
a minimum of 30 min of sleep disturbance, occurring at least four times per 
week, is one of the recognized diagnostic criteria for insomnia, it was felt 
that mean weekly outcome scores of SOL 530 min and WASO 530 min 
would provide two further approximate clinical cutoff points. Participants 
with this degree of sleep problem would normally be considered as sub- 
clinical, being within the range of the nonsleep-disordered population, and 
would not be accepted into an outcome evaluation. Thus, the 30-min 
criterion permits normative comparison, where clinical significance is 
defined as end-state functioning that falls within a normative range (Ken- 
dall et a!., 1999). Dichotomies  for these two variables were created, 
therefore, representing achievement or nonachievement of the 30-min 
criterion at 12 months posttreatment. A third outcome variable for SOL and 
for WASO was created representing the achievement or nonachievement of 
both sets of criteria. It was not possible to develop comparable combined 
outcome criteria for the nWAKE  or ENJOY  variables. 
Predictor variables. It was recognized that a considerable number of 
pretreatment factors might contribute explanatory variance within a pre- 
diction model of treatment outcome; therefore, a wide range of variables 
was considered. These included demographic variables [sex, age, civil 
   status (married, cohabiting or living alone), occupation (in paid employ- 
Descriptor Values n % 
 
Age M = 52.1 
SD = 16.2 
Gender Female 78  72 
Male 31  29 
Civil status Partner 73  67 
No partner 36  33 
Occupational status Working 42  39 
Not working 67  62 
History of sleep problem <2 years 18  17 
(n = 105) >2 and <5 years 17  16 
>5 and < 10 years 24  23 
> lO and <20 years 21  20 
>20 years 25  24 
Use of sleep medication Taking  hypnotics 59  56 
Not taking hypnotics 50  44 
ment or not)] and aspects of the clinical history {duration of insomnia (less 
than 2 years; 2 to less than 5 years; 5 to less than 10 years; lO to less 
than 20 years; 20 years or more)], drug use (taken hypnotics in the past 
month or not), and daytime tiredness (tired most days vs. occasionally or 
not at all). The degree of presenting sleep disturbance  prior to treatment 
was calculated by summing nightly mean scores for SOL and WASO at 
baseline and then creating an index of insomnia severity by subdividing 
patients into three groups representing one 590 min, two 91-150 min, and 
three 2:151 min of total sleep disturbance per night. Because the clinic 
routinely gathered information on psychopathology it was possible also to 
consider pretreatment symptoms of depression [Beck Depression Inventory 
(BDI); Beck & Steer, 1993], state and trait anxiety [State-Trait Anxiety 
Inventory (STAI); Spielberger, Gorsuch, & Lushene, 1970], and worry 
[Penn State Worry Questionnaire (PSWQ); Meyer, Miller, Metzger, & 
Borkovec,   1990),  as  potential  predictors.  Other  measures  available  in- 
   cluded  the  Sleep  Disturbance   Questionnaire   (SDQ;  Espie,  Brooks,   & 
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Lindsay, 1989; Espie, Inglis, Harvey, & Tessier, 2000) and a shortened 
version of the Dysfunctional  Beliefs and Attitudes About Sleep scale 
(DBAS; Morin , Stone, Trinkle, Mercer, & Remsberg, 1993; Espie eta!., 
2000). The SDQ comprises factors that correspond to participants ' attri- 
butions about the causes of their sleep problem (I, restlessness/agitation; II, 
mental overactivity; III, consequences of insomnia; IV, lack of sleep 
readiness). The DBAS comprises factors reflecting dominant attitudes and 
beliefs about sleep and sleeplessness (I, beliefs about the immediate neg- 
ative consequences of insomnia ; II , beliefs about the negative long-term 
consequences of insomnia ; III, beliefs about the need for control over 
insomnia). Finally, Borkovec and Nau's (1972) Credibility Evaluation 
Questionnaire provided a measure of perceived treatment credibility, and a 
variable to identify which of the six therapists conducted the treatment was 
included  to consider therapist  factor. 
 
Results 
 
Clinical Improvement 
 
A patient was regarded as a treatment responder if he or she 
achieved the relevant criterion on the variable under consideration 
(e.g., 50% reduction in SOL at 12 months posttreatment); other- 
wise the patient was coded as a nonresponder. Inspection of Table 
2 reveals that 41% of patients were coded as responders in terms 
of SOL reduction and 50% were responders in terms of WASO 
reduction. Almost two thirds of patients achieved the normative 
comparison endpoints of 30 min (or less) for each of these vari- 
ables. Thirty-five percent of patients achieved both a 50% reduc- 
tion in SOL and a :530-min posttreatment value,  and  40% 
achieved both of these outcomes for WASO. The number of 
wakenings from sleep (nWAKE) was reduced by half in 28%, and 
a similar proportion achieved a 50% increase in sleep quality as 
measured  by their rating  of sleep enjoyment (ENJOY) . 
 
Associations With Clinical Improvement 
 
Each variable was considered first of all by examination of its 
relationship with each outcome measure by using the statistical test 
most appropriate to the type of variable (chi-square or independent 
t test, depending on whether the independent variable was cate- 
gorical or continuous). The purpose of this procedure was to 
identify smaller  subsets of potential predictors,  which demon- 
strated some statistical effect (see Table 3). To ensure inclusion of 
 
variables with coefficients different from zero, Hosmer and Leme- 
show's (1989) recommendations for logistic regression were 
adopted. A sensitive cutoff for statistical significance of p < .10 
was selected  for bivariate analyses , in spite of the multiple com- 
parison testing, to identify any potentially important  association 
that might contribute some explanatory variance in subsequent 
regression  analyses .  A  number  of  the  results  identified  in 
Table 3 as statistically significant, nevertheless, require cautious 
interpretation. 
Notably few significant relationships were found between out- 
come and demographic factors. Mean age of treatment responders 
who achieved a WASO :530 min was 49.0 (SD = 15.8) compared 
with  nonresponders  who  had  a mean  age of  56.3 (SD  =  15.7), 
t(108)  = 2.32, p   = .022, and there was a modest effect of civil 
status on the variable ENJOY, indicating poorer outcome in terms 
of enjoyment  of sleep amongst  those  who lived  alone compared 
with married or cohabiting patients, ¥0 . N = 109) = 4.09, p = 
.043. 
As can be seen from Table 3, few sleep history variables 
demonstrated any relationship with outcome. In particular, dura- 
tion of insomnia problem and use (or not) of a hypnotic drug were 
not associated with clinical outcome . There was one near- 
significant effect in relation to daytime tiredness, in that 47% of 
nonresponders on the variable nWAKE compared with only 28% 
of   responders   experienced   tiredness   at   baseline,   ¥0.  N    = 
109)  =  3.29,  p    =  .070.  Nevertheless,   severity   of   insomnia 
emerged as an important factor for both of the criterion indices of 
SOL and WASO response. Eighty-three percent of responders 
achieving the SOL ;;::SO% criterion were in the most severe cate- 
gory before treatment  (i.e., Category  3 on the index of  severity), 
compared with 50% ofnonresponders, ¥<2.N = l3.59),p = .001; 
and 78% of responders on WASO ;;::SO% were in the most severe 
category compared with 49% of nonresponders, ¥<2. N = 9.80), 
p = .007. In other words, these results suggest that more severe 
cases do better on the 50% reduction  measure . The  :530 min 
criterion outcomes for SOL and WASO, however, seem to reflect 
the converse. Fifty-seven percent of responders who achieved SOL 
:530 min were in the most severe category at baseline compared 
with 78% of nonresponders, ¥(2, N = 109) = 5.i1, p = .072. A 
stronger statistical effect was observed for WASO :530 min where 
 
 
Table 2 
Clinically Significant  Sleep  Outcomes at 12 Months  Posttreatment  (n; %) 
According to Three Criteria (n = 109) 
 
 
Achievement  of 
 
Achievement  of 
 Achievement of 
50% reduction 
50% reduction  in 
  target  symptom•   
posttreatment  value 
S:30 min  
and  posttreatment 
value  S:30 min" 
 
Variable 
 
n 
 
% 
 
n 
 
%  
 
n 
 
% 
 
SOL 
 
45 
 
41.3 
 
70 64.2 38 34.9 
WASO 54 49.5 69 63.3 
 
44 40.4 
nWAKE 31 28.4 
     ENJOY 29 26.6 
     
Note.    SOL == sleep-onset latency; WASO = waketime after sleep onset; nWAKE = number of nocturnal 
wakenings; ENJOY = enjoyment of sleep. 
• Rather than a reduction , there is an increase relation  to ENJOY. 
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Sex .680 .834 .677 .884 .529 .836 .262 .359 
Age .189 .419 .207 .493 .022* .257 .470 .948 
Status .586 .641 .842 .502 .966 .550 .838 .043* 
Occupation .642 .905 .859 .608 .366 .444 .932 .840 
Sleep 
Duration .842 .252 .620 .487 .610 .601 .739 .200 
Drug .725 .107 .387 .399 .582 .660 .306 .128 
Tiredness .311 .608 .559 .469 .790 .846 .070 .131 
Severity .001*** .072 .022* .007** .001*** .291 .368 .399 
Psychopathology 
Depression .071 .969 .034* .035* .150 .015* .061 .844 
State .129 .698 .161 .044* .043* .018* .265 .920 
Trait .240 .386 .071 .179 .062 .111 .170 .107 
Worry .962 .417 .530 .880 .154 .649 .424 .067 
Psychological 
SDQFI .930 .801 .991 .363 .354 .608 .759 .496 
SDQ FII .906 .715 .902 .673 .353 .833 .739 .436 
SDQ Fill .116 .675 .185 .624 .209 .371 .360 .138 
SDQ FIV .847 .944 .953 .073 .743 .053 .556 .177 
DBAS FI .578 .745 .957 .529 .227 .480 .170 .057 
DBAS FII .014* .036* .013* .950 .339 .521 .837 .338 
DBAS Fill .803 .975 .960 .554 .260 .420 .688 .329 
Treatment 
Credibility .472 .607 .427 .408 .679 .808 .300 .044* 
Therapist .188 .664 .243 .213 .209 .233 .198 .140 
 
 
Table 3 
Investigation  of Associations  Between  Clinical  Outcomes and Pretreatment  Characteristics, Prior  to Entry 
Into Logistic Regression (n = 109) 
 
SOL 50%/ WASO 50%/ 
Variable SOL 50% SOL 30 min SOL 30 min WASO 50% WASO 30 min WASO 30 min nWAKE 50% ENJOY 50% 
 
Demographic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. Tabulated data are p values from chi-square (categorical variables) or independent sample t tests with significant values in boldface type (p < .10, 
following Hosmer & Lemeshow, 1989). SOL = sleep-onset latency; WASO = waketime after sleep onset; nWAKE = number of nocturnal wakenings; 
ENJOY  = enjoyment of sleep; SDQ = Sleep Disturbance  Questionnaire; DBAS  = Dysfunctional Beliefs and Attitudes About Sleep Scale; FI, Fll, and 
so on = Factor I, Factor II, and so on. 
* p < .05.   ** p < .01.   *** p < .001. 
 
 
53% of responders were in the most severe pretreatment category 
compared with 86% of nonresponders,  (2, N = 109) = 12.67, 
p = .002. Thus, the more severe cases appear to do less well on the 
30-min outcome criterion. A modest but significant effect was 
demonstrated for the combined SOL 2:50%/:530-min criterion, 
(2, N = 109) = 7.02, p = .030. Again, there was a tendency for 
more severe cases to do better. No comparable effect was  ob- 
served, however, for the combined WASO outcome. 
Table 3 reveals that psychopathology demonstrated a number of 
significant relationships with the outcome variables. It is important 
to observe, however, that the general trend in these relationships 
was for higher levels of pretreatment symptomatology to be asso- 
ciated with better clinical outcome. For symptoms of depression, 
responders on the 2:50% reduction in WASO measure had a 
baseline mean BDI score of 12.6 (SD = 10.2) compared with the 
nonresponder  mean of 9.1 (SD  = 6.9), t(l07)  = 2.14, p  = .035; 
and, for the combined WASO outcome, responder mean at base- 
line of 13.6 (SD = 10.8) compared with the nonresponder mean 
of 9.5 (SD = 7.3), t(107) = 2.47, p  = .015. A significant effect 
was also observed for the combined SOL outcome  [responder 
mean 13.7 (SD = 10.9) vs. nonresponder of 9.9  (SD  =  7.8); 
t(107) = 2.15, p = .035], although, when  taken  separately, only 
the  SOL :530-min  criterion  came close to  statistical  significance 
(p = .071). For nWAKE 2:50% reduction, the respective mean 
BDI scores were 13.4 (SD = 11.7) and 9.9 (SD  =  7.7), 
t(107) = 1.89, p = .061. It should be borne in mind, of course, that 
patients with clinical depression were excluded from this study and 
that BDI scores were relatively low. Similarly, responders who 
achieved the 2:50% WASO criterion had higher baseline scores on 
the STAI state scale [37.4 (SD = 12.7) vs. 32.9 (SD = 8.5)], 
t(107)  = 2.04, p  = .044. Also, both state and trait anxiety levels 
were higher in responders to the :530-min WASO criterion [37.4 
(SD  = 12.7) vs. 32.9 (SD  = 8.5)], t(107)  = 2.05, p  = .043, for 
state; and [44.0 (SD = 13.7) vs. 39.5 (SD = 9.9)], t(107) = 1.89, 
p = .062, for trait. Those achieving both WASO outcomes also 
had higher baseline state mean scores  [38.9 (SD  = 13.5) vs. 33.7 
(SD = 9.5)]; t(107) = 2.40, p = .018, and those achieving both 
SOL  outcomes   had   a   somewhat   higher   trait   baseline   [45.5 
(SD = 14.6) vs. 41.0 (SD = 11.3]; t(107) = 1.83,p  = .071. Higher 
initial levels of worry on the PSWQ, however, were associated 
with poorer clinical outcome on ENJOY, the qualitative measure 
of sleep satisfaction [responders mean = 43.2 (SD = 16.3), non- 
responders 49.1 (SD = 13.2)]; t(99) = -1.85, p  = .067. 
Other psychological factors demonstrated  some association with 
outcome. Higher scores on DBAS Factor II (beliefs about the 
negative long-term consequences of insomnia) were associated 
with clinical improvement on both the SOL 50% reduction mea- 
sure   [responders   mean   =  163.7  (SD   =  53.7),  nonresponders 
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mean==  133.7 (SD == 67.5)]; t(107) == 2.49, p == .014, and the SOL 
:530-min criterion [155.5 (SD = 65.8) vs. 128.4 (SD ==  63.0), 
respectively], t(l07)  = 2.12, p  = .036, and also on the combined 
SOL outcome  (167.3 (SD  = 54.8) vs.  135.0 (SD  = 68.6)], 
t(l07) = 2.52, p = .013. Lower DBAS Factor I scores (beliefs 
about the immediate negative consequences of insomnia) were 
somewhat associated with greater quality of sleep on the ENJOY 
50% outcome criterion [responders = 247.4 (SD = 110.8), 
nonresponders  = 295.0 (SD = 111.3)], t(107)  = -1.92, p  = .057. 
Similarly, lower SDQ Factor IV scores (lack of sleep readiness) at 
baseline modestly discriminated clinical response in WASO using 
the  50% reduction criterion [responders = 2.11 (SD = 1.88), 
nonresponders = 2.62 (SD = 1.53)], t(107) = -1.8l,p = .073, 
and the combined WASO criterion [2.07 (SD = 1.33) vs. 2.63 
(SD = 1.57)], t(107) = -1.96, p  = .053.  , 
As can be seen from Table 3, therapist factor did not differen- 
tiate between responders and nonresponders on any clinical out- 
come measure, and perceived credibility of the treatment approach 
achieved modest significance on only one measure. Responders on 
the ENJOY 50% increase criterion reported higher mean treat- 
ment credibility ratings than nonresponders  [25.5 (SD  = 4.72) 
vs. 23.5 (SD = 4.07)], t(l01)  = 2.04, p = .044. 
 
Prediction  of Clinical Improvement 
 
The foregoing analyses represent tests of simple association or 
difference and, as such, do not take into account any interaction 
between explanatory variables in determining outcome effects. To 
investigate conservatively the prediction of clinically significant 
outcome, we selected a logistic regression model  as each depen- 
dent measure was a simple dichotomous variable and the explan- 
atory variables comprised a mix of continuous, ordinal and cate- 
gorical data (Tabachnick & Fidell, 1996). The significant subset of 
variables (from Table 3) that had demonstrated a bivariate rela- 
tionship  was  entered  in  the  logistic  regression  model  for  that 
 
outcome measure to determine the combination  of predictor vari- 
ables which  most  accurately  identified treatment  responders  and 
nonresponders. Results of these analyses are presented in Table 4. 
Greater insomnia severity and higher scores on DBAS Factor II 
(beliefs about the negative  long-term  consequences  of insomnia) 
together correctly predicted  over half of the treatment responders 
and three quarters of nonresponders  on the SOL   50%  criterion, 
with  severity  having  the  stronger  predictive  impact.  Scores  for 
depression on the BDI, however, did not contribute significantly to 
the  regression  equation.  By  implication,  of  course,  this  model 
missed 45% of responders and 25% of nonresponders. These same 
two variables also emerged as accurate predictors of responding on 
the  normative  comparison  variable  SOL  :530  min  (88%),  but 
identified fewer nonresponders (35%) and, thereby, missed 65% of 
nonresponders.  Of the four variables considered  as potential  pre- 
dictors only higher scores on DBAS Factor II emerged as signif- 
icant for the combined SOL outcome, identifying the great major- 
ity of responders  (90%) but relatively  few nonresponders  (21%). 
Three of the four variables entered contributed  significantly to the 
prediction  of  WASO   50%  reduction.  Symptoms of depres- 
sion, SDQ Factor  IV  (lack of  sleep readiness)  and  severity pre- 
dicted  70%  and  64%  of  responders  and  nonresponders,  respec- 
tively,  whereas   STAI  state  was  excluded   from  the  analysis. 
However,  state  anxiety  entered  along  with  severity  as  the  two 
significant predictors of normative outcome on WASO :530 min, 
correctly identifying 77% of responders and almost half of nonre- 
sponders, but consequently missing 23% of responders and 50% of 
nonresponders. Age and trait anxiety failed to contribute additional 
explanatory  power.  Greater  symptomatology  of  depression  and 
lower SDQ Factor IV scores together predicted 87% of responders 
and 42% of nonresponders on the combined WASO criterion, with 
state anxiety failing to add to the equation. 
Interestingly, symptoms of depression correctly predicted  100% 
of nonresponders on nWAKE, but identified only 13% of respond- 
 
 
Table 4 
Predictors  of Clinically Significant  Outcome for  Each of the Sleep  Outcome Measures  (n =  109) 
 
Log %correct %correct 
  Outcome variable likelihood ¥ df Sig. Predictors Significance R responders nonresponders 
 
SOL 2:50% reduction 132.6 17.3 3 .0006 Severity .010 .195 55.6 74.2 
     
DBAS Factor  II .061 .106 
  SOL :530 min 133.7 13.1 3 .0044 DBAS Factor II .010 .183 
  
     
Severity .023 .160 87.7 3S.O 
SOL ;;::so%/:530 min 132.5 11.8 1 .0082 DBAS Factor II .03S .130 90.7 21.0 
WASO  ;;::SO% reduction 128.9 19.4 4 .0007 BDI .014 .17S 70.4 64.2 
     
SDQ Factor IV .032 -.139 
  
     
Severity .038 .137 
  WASO :s:30 min 123.1 23.1 3 <.0001 Severity .001 .274 
  
     
STAI state .013 .178 77.1 46.3 
WASO 2:50%/:530 min 13S.1 15.9 2 .0004 BDI .002 .231 
  
     
SDQ Factor IV .OOS -.196 86.6 42.2 
nWAKE  ;;::SO% reduction 129.9 3.4 1 .0671 BDI .068 .010 12.S 100.0 
ENJOY 2:SO% increase 95.1 11.7 3 .0085 PSWQ .014 -.201 
  
     
Status .076 -.108 16.7 94.3 
     
Credibility .090 .094 
  
Note.    Results represent logistic regression analyses comprising consideration of contributing variables from Table 3 where p < .10 (following Hosmer 
& Lemeshow, 1989). SOL = sleep-onset latency; WASO = waketirne after sleep-onset; nWAKE = number of nocturnal wakenings; ENJOY = enjoyment 
of sleep; SDQ = Sleep Disturbance Questionnaire; DBAS = Dysfunctional Beliefs and Attitudes About Sleep Scale; BDI = Beck Depression Inventory; 
STAI = State-Trait Anxiety Inventory; PSWQ = Penn State Worry Questionnaire. 
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ers. Daytime tiredness did not contribute further to this effect. 
Finally, a combination of worry, civil status, and perceived cred- 
ibility correctly predicted 94% of nonresponders in terms of 
ENJOY, but failed to identify 85% of responders. Worry had the 
greatest impact on this regression equation and DBAS Factor I 
(concerns about the immediate negative impact of insomnia) was 
excluded  from the analysis. 
 
Discussion 
 
Our results suggest that CBT is a clinically effective treatment 
for persistent insomnia. Around two-thirds  of  patients  achieved 
and maintained a sleep latency of s30 min  1 year after completion 
of therapy, and a similar proportion achieved :S30 min of wake- 
fulness during the night. In terms of normative comparisons (Ken- 
dall et a!., 1999), these results are encouraging because they 
indicated substantial normalization of sleep patterns after treat- 
ment. That is, a high proportion of our patients had sleep patterns 
similar to normal controls after CBT. Furthermore, almost half of 
the participants reduced their sleep latency and night-time wake- 
fulness by ::::::50%. Although those with greater levels of sleep 
disturbance at baseline were more likely to achieve this reduction, 
raising the possibility of regression to the mean, 35% to 40% of 
participants, in fact, achieved both of our  outcome  criteria. 
Changes in the number of wakenings per night of sleep and in 
perceived sleep quality were less pronounced, although more than 
one quarter achieved a 50% reduction in waking frequency and a 
50% increase in sleep enjoyment. 
These results  are broadly  comparable  with  the AASM  article, 
which suggested that "between 70% and 80% of insomnia patients 
benefit from treatment, 50% achieving clinically meaningful out- 
comes [italics added], and about one third becoming good sleep- 
ers" (Morin, Hauri, et al., 1999). The present results are also 
comparable with a previous study where we used the same crite- 
rion values (Espie, Brooks, & Lindsay, 1989). In the earlier study, 
40% of patients achieved a final SOL of ::::;30 min, with 71% 
responding to stimulus control treatment (two thirds responded to 
the present multicomponent CBT program). Similarly, 47%-50% 
achieved the 50% reduction in SOL criterion compared with the 
present 41%, although stimulus control specifically had achieved a 
64% patient response in the former study. It should be noted that 
the early trial excluded patients with intermittent wakenings or 
combined  onset or maintenance  insomnia. 
Logistic  regression  analyses  confirmed  that  initial  severity  of 
insomnia did not contraindicate good outcome and, importantly, 
hypnotic-using patients responded equally well to CBT. Age and 
other demographic factors were not of significant predictive value 
but symptoms of anxiety or depression and thinking  errors posi- 
tively predicted good outcome. Our results, therefore, cannot be 
simply explained by differential responsiveness across the spectra 
of insomnia severity or chronicity, or in terms of degree of clinical 
complexity. 
Neither gender nor occupational status differentiated responders 
from nonresponders. Responders achieving 30 min or less night- 
time wakefulness at 1 year follow-up were on average 6  years 
younger, but age did not contribute significantly to the regression 
equation for this variable, and it did not discriminate on any other 
variable. A significant difference was found in sleep quality be- 
tween insomniacs who had partners  and those who did not. This 
variable did enter the regression equation for the variable ENJOY, 
having a modest effect, particularly toward the prediction of non- 
responding. Perhaps insomniacs without partners are less likely to 
experience qualitative improvement in sleep, although responding 
equally well in terms of sleep pattern. 
Half of our sample took hypnotic medication, but drug use per 
se was not a contraindication for CBT. Indeed, the vast majority of 
hypnotic users (50 out of 59; 84%) were drug free at follow-up 
(Espie et a!., 2001), strongly supporting previous evidence  that 
CBT can be useful to facilitate benzodiazepine discontinuance 
(Espie, Lindsay, & Brooks, 1988; Morin et al., 1995). Similarly, 
length of history of insomnia did not discriminate outcomes on any 
variable. Daytime tiredness achieved an effect on  one variable, 
where there was a significant difference between responders and 
nonresponders on night wakenings, but failed to enter the regres- 
sion equation for nWAKE. 
Severity of insomnia emerged consistently  as a predictive  fac- 
tor; however, the results would not support the assumption that 
CBT was less effective for more severe insomnias.  Rather, asso- 
ciations between outcome and severity may simply reflect the law 
of initial values in that there is greater scope for large percentage 
of change where baseline sleeplessness is high, and to achieve the 
30-min criterion where initial values are lower. Inspection of the 
regression data indicates that severity was the strongest element of 
the prediction equation for only two of the four variables on which 
it loaded, and the fact that severity failed to contribute significantly 
to the regression equations for either of the combined sleep out- 
comes (SOL or WASO) lends further support to the law of initial 
values  interpretation. 
There was a tendency for higher levels of anxiety or depressive 
symptomatology to be associated with better responding, particu- 
larly in terms of nighttime wakefulness. It should be noted, how- 
ever, that patients with primary depressive illness were excluded. 
Nevertheless, it appears that those with relatively higher symptom 
levels responded to CBT by achieving greater continuity in their 
sleep. The fact that posttreatment BDI and STAI state anxiety 
scores were not significantly lower than at baseline (see Espie et 
a!., 2001) appears to exclude the possibility that insomnia was 
being treated as a secondary response to an underlying condition. 
Because numerous studies have found that insomniacs are some- 
what neurotic (e.g., Edinger, Stout, & Hoelscher, 1988; Lundt, 
Broman, & Hetta, 1995), it may be more likely that such trait 
characteristics are part of the enduring clinical picture of people 
prone to insomnia. 
Although only achieving significance on one variable, worry 
appeared to form a different relationship with outcome. Higher 
baseline PSWQ scores were associated with poorer sleep quality 
outcome, and worry emerged as the strongest of the three predic- 
tors of ENJOY in the logistic regression analysis. It seems that 
sleep quality improvement, but not sleep  pattern  improvement, 
may be somewhat compromised by high pretreatment levels of 
worry. Interestingly, however, our  posttreatment  data  indicated 
that PSWQ scores did reduce modestly in association with effec- 
tive CBT treatment  for insomnia  (Espie et al., 2001). 
Other  psychological  factors  were  also  investigated.  The Dys- 
functional Beliefs and Attitudes About Sleep scale revealed that 
stronger beliefs in the negative long-term consequences of insom- 
nia (e.g., "I am concerned that chronic insomnia may have serious 
consequences on my physical health") were associated with good 
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clinical response on all three SOL outcome measures. It seems 
possible that greater evidence of dysfunctional thinking may be a 
positive indication for CBT treatment of  sleep-onset  insomnia. 
This may suggest a cognitive pathway for mediating treatment 
effects, and it is supported by data demonstrating significant shift 
in dysfunctional beliefs resulting from CBT intervention (Espie et 
a!., 2000). In contrast, stronger beliefs in the immediate negative 
consequences of insomnia (DBAS Factor I; e.g., "After a  poor 
night's sleep I know that it will interfere with my daily activities 
the next day") were associated with poorer outcome  in terms of 
sleep enjoyment. However, this factor did not contribute signifi- 
cantly to the overall regression equation for the variable ENJOY. 
Only one of the Sleep Disturbance Questionnaire factors emerged 
as a significant predictor (Factor IV, concerning  a perception  of 
not be tired enough to sleep). This was associated with less 
likelihood of achieving 50%  WASO  reduction  or  combined 
WASO reduction and possibly reflects an impaired  homeostatic 
sleep drive  and/or poor  stimulus control. 
The final areas in which predictive relationships could be ex- 
plored concerned the perceived credibility  of  treatment  and  the 
role of the therapist. In relation to the latter, no differential effec- 
tiveness was observed across the six therapists who conducted the 
CBT intervention. This implies that the treatment was similarly 
applied, and that the therapists had acquired comparable, effective 
levels of skill. Treatment credibility, however, emerged as mod- 
estly important in relation to quality, but not pattern, of sleep. In 
particular, patients whose enjoyment of sleep failed to improve had 
lower initial  expectations of therapy. 
Our conclusions concerning predictive factors must be tempered 
by the fact that explained variance associated with each significant 
effect was in the region of 10%-25% per variable (R value). The 
results, therefore, represent fairly modest predictive models  of 
sleep outcome. Also, the hit rate in identification of responders and 
nonresponders varied considerably across outcomes. For example, 
greater worry combined with living alone and lower perceived 
treatment credibility correctly identified 94% of sleep quality in 
nonresponders; but it contributed little explanatory power in terms 
of positive responding. Similarly, low depressive symptom scores 
identified all those who failed to achieve a 50% reduction in 
waking frequency, but only 1 out of 8 responders.  By  contrast, 
high levels of dysfunctional thinking along with less severe in- 
somnia identified 88% of responders achieving sleep latency of 30 
min or less, but picked up only one third of nonresponders. Correct 
identification rates were more equally balanced for the other 
variables, but it must be borne in mind that the total case identi- 
fication rate only averaged  around 65% for these measures. 
Finally, it should be recognized that our analyses considered 
only pretreatment variables that may influence outcome.  Many 
other factors may play a part in the prediction of clinical response. 
These include readiness to change (the predispositional stage at 
which the insomniac is in terms of adopting a novel approach), 
motivation and compliance (the extent to which parts or all of the 
program are implemented at home),  dose  response  relationship 
(the amount of intervention required to achieve a given level of 
response), critical components  (the unpacking  of the intervention 
to establish critical ingredients), sequencing of intervention (the 
order of presentation of treatment  components),  psychological 
"set" (including psychological mindedness and self-efficacy be- 
liefs), and relapse prevention  (the assimilation  and internalization 
 
of both behavioral and attitudinal responses to cope with symptom 
recurrence). Further investigation of these areas, of course, would 
be valuable. 
 
 
References 
 
Alperson, J., & Biglan, A. (1979). Self-administered treatment of sleep- 
onset insomnia and the importance of age. Behavior Therapy, /0, 347- 
356. 
American Sleep Disorders Association. (1990). International classification 
of sleep disorders, diagnostic and coding manual. Rochester, MA: 
Author. 
American Sleep Disorders Association. (1995a). Practice parameters for 
the use of actigraphy in the clinical assessment of sleep  disorders. 
Sleep, 18, 285-287. 
American Sleep Disorders Association. (1995b). Practice parameters for 
the use of polysomnography in the evaluation of insomnia. Sleep, 18, 
55-57. 
Ancoli-Israel, S., & Roth, T. (1999). Characteristics of insomnia in the 
United States: Results of the 1991 National Sleep Foundation Survey I. 
Sleep, 22 (Suppl. 2), S347-S353. 
Beck, A. T., & Steer, R. A. (1993). The Beck Depression Inventory: 
Manual. San Antonio, TX: The Psychological Corporation. 
Bliwise, D. L., Friedman, L., Nekich, J. C., & Yesavage, J. A. (1995). 
Prediction of outcome in behaviorally based insomnia treatments. Jour- 
nal of Behaviour Therapy and Experimental Psychiatry, 26, 17-23. 
Bootzin, R. R., & Engle-Friedman, M. (1981). The assessment of insom- 
nia. Behavioral Assessment, 3, 107-126. 
Borkovec, T. D., & Nau, S. D. (1972). Credibility of analogue therapy 
rationales. Journal of Behaviour Therapy and Experimental Psychia- 
try, 3, 257-260. 
Clarke, G. N. (1995). Improving the transition from basic efficacy research 
to effectiveness studies: Methodological issues and procedures. Journal 
of Consulting and Clinical Psychology, 63, 718-725. 
Davies, R., Lacks, P., Storandt, M., & Bertelson, A. D. (1986). Counter- 
control treatment of sleep-maintenance insomnia in relation to age. 
Psychology and Aging, 1, 233-238. 
Douglas, N. J., Thomas, S., & Tan, M. A. (1992). The clinical value of 
polysomnography. Lancet, 339, 347-350. 
Edinger, J.D., Stout, A. L., & Hoelscher, T. J. (1988). Cluster analysis of 
insomniacs' MMPI profiles: Relation of subtypes to sleep history and 
treatment outcome. Psychosomatic Medicine, 50, 77-87. 
Edinger, J.D., & Wohlgemuth, W. (1999). The significance and manage- 
ment of persistent primary insomnia: The past, present and future of 
behavioral insomnia therapies. Sleep Medicine Reviews, 3, 101-118. 
Espie, C. A. (1991). The psychological  treatment of insomnia. Chichester, 
England: Wiley. 
Espie, C. A. ( 1999). Cognitive behaviour therapy as the treatment of choice 
for primary insomnia. Sleep Medicine Reviews, 3, 97-99. 
Espie, C. A., Brindle, S., Tessier, S., Dawson, S., Hepburn, T., McLellan, 
A., Renwick, E., Steele, S., & McColl, J. (1998). Supervised cognitive- 
behaviour therapy for insomnia in general medical practice-Prelimi- 
nary results from the West of Scotland programme. In E. Sanavio (Ed.), 
Behavior and cognitive therapy today: Essays in honor of Hans J. 
Eysenck (pp. 67-75). Kidlington, Oxford, England: Elsevier. 
Espie, C. A., Brooks, D. N., & Lindsay, W. R. (1989). An evaluation of 
tailored psychological treatment of insomnia. Journal of Behaviour 
Therapy and Experimental Psychiatry, 20, 143-153. 
Espie, C. A., Inglis, S. J., Harvey, L., & Tessier, S. (2000). Insomniacs" 
attributions: Psychometric properties of the Dysfunctional Beliefs and 
Attitudes About Sleep Scale and the Sleep Disturbance Questionnaire. 
Journal of Psychosomatic Research, 48, 141-148. 
Espie, C. A., Inglis, S. J., Tessier, S., & Harvey, L. (2001). The clinical 
effectiveness of cognitive behaviour therapy in the treatment of chronic 
ESPIE,  INGLIS, AND HARVEY 66  
 
insomnia: Implementation and evaluation of a sleep clinic in general 
medical  practice.  Behaviour  Research  and  Therapy, 39, 45-60. 
Espie, C. A., Lindsay, W. R., & Brooks, D. N. (1988). Substituting 
behavioural treatment for drugs in the treatment of insomnia: An ex- 
ploratory study. Journal of Behaviour Therapy and Experimental Psy- 
chiatry,  19,  51-56. 
Espie, C. A., Lindsay, W. R., Brooks, D. N., Hood, E. M., & Turvey, T. 
(1989). A controlled comparative investigation of psychological treat- 
ments for chronic sleep-onset insomnia. Behaviour Research and Ther- 
apy,  27,  79-88. 
Foley, D. J., Monjan, A. A., Brown, S. L., Simonsick, E. M., Wallace, 
R. B., & Blazer, D. G. (1995). Sleep complaints among elderly persons: 
An epidemiologic study of three communities. Sleep, 18, 425-433. 
Foley, D. J., Monjan,  A. A., Simonsick, E. M., Wallace, R. B., & Blazer, 
D. G. ( 1999). Incidence and remission of insomnia among elderly adults: 
An epidemiologic study of 6,800 persons over three years. Sleep, 22 
(Suppl.  2),  S366-S372. 
Ford,  D.  E.,  &  Kamerow,  D.  B.  (1989).  Epidemiologic  study  of  sleep 
disturbances and psychiatric disorders. Journal of the American Medical 
Association,   262,  1479-1484. 
Friedman, L., Bliwise, D. L., Yesavage, J. A., & Salom, S. R. (1991). A 
preliminary study comparing sleep restriction and relaxation treatments 
for insomnia in older adults. Journal of Gerontology, 46, 1-8. 
Gillin, J. C., & Byerley, W. F. (1990). The diagnosis and management  of 
insomnia. New England Journal of Medicine, 322, 239-248. 
Hauri, P. J. & Wisbey, J. (1992). Wrist actigraphy in insomnia. Sleep, 15, 
293-301. 
Hoagwood, K., Hibbs, E., Brent, D., & Jensen, P. (1995). Introduction to 
the Special Section: Efficacy and effectiveness in studies of child and 
adolescent psychotherapy. Journal of Consulting and Clinical Psychol- 
ogy,  63,  683-725. 
Hoch, C. C., Dew, M.A., Reynolds, C. F., Buysse, D. 1., Nowell, P. D., 
Monk, T. H., Mazumdar, S., Borland, M. D., Miewald, J., & Kupfer, 
D. J. (1997). Longitudinal changes in diary- and laboratory-based sleep 
measures in healthy "old old" and "young old" subjects: A  three-year 
follow-up.  Sleep,  20,  192-202. 
Hosmer, D. W., & Lemeshow, S. (1989). Applied logistic regression. New 
York: Wiley. 
Jacobson, N. S., & Truax, P.  (1991). Clinical significance: A statistical 
approach to defining meaningful change in psychotherapy research. 
Journal  of  Consulting and Clinical Psychology,  59,  12-19. 
Kazdin, A. E. (1998). Methodological  issues and strategies in clinical 
research (2nd ed.). Washington, DC: American Psychological Associ- 
ation. 
Kendall, P. C., Marrs-Garcia, A., Nath, S. R., & Sheldrick, R. C. (1999). 
Normative comparisons for the evaluation of clinical significance. Jour- 
nal of  Consulting  and  Clinical Psychology,  67, 285-299. 
Kripke, D. F. (2000). Chronic hypnotic use: Deadly risks, doubtful benefit. 
Sleep  Medicine  Reviews,  4, 5-20. 
Lacks, P., Bertelson,  A. D., Gans, L., & Kunkel, J. (1983). The effective- 
ness of three behavioral treatments for different degrees of sleep-onset 
insomnia.  Behavior  Therapy,  14, 593-605. 
Lacks, P., & Powlishta, K. (1989). Improvement following behavioral 
treatment for insomnia: Clinical significance,  long-term  maintenance 
and predictors  of  outcome. Behavior  Therapy, 20,  117-134. 
Lundt, L-G., Broman, J-E., & Hetta, J. (1995). Personality traits in patients 
with  persistent  insomnia.  Personality  and  Individual  Differences,  18, 
393-403. 
Mellinger, G. D., Balter, M. B., & Uhlenhuth, E. H. (1985). Insomnia and 
its treatment: Prevalence and correlates. Archives of General Psychia- 
try, 42, 225-232. 
 
Meyer, T. J., Miller, M. L., Metzger, R. L., & Borkovec, T. D. (1990). 
Development and validation of the Penn State Worry Questionnaire. 
Behaviour Research and Therapy, 28, 487-495. 
Morin, C. M. (1993). Insomnia:  Psychological  Assessment  and Manage- 
ment. New York: Guilford Press. 
Morin, C. M., Colecchi, C. A., Ling, W. D., & Sood, R. K. (1995). 
Cognitive behavior therapy to facilitate benzodiazepine discontinuation 
among hypnotic dependent patients with  insomnia.  Behavior  Ther- 
apy,  26,  733-745. 
Morin,  C. M., Colecchi, C., Stone, J., Sood, R.,  & Brink, D.  (1999). 
Behavioral and pharmacological therapies for late-life insomnia: A 
randomized controlled trial. Journal of the American Medical Associa- 
tion,  281,  991-999. 
Morin,   C.  M.,  Culbert,  J.  P.,   &  Schwartz,  M.  S.  (1994).  Non- 
pharmacological  interventions  for insomnia:  A meta-analysis  of  treat- 
ment efficacy. American  Journal  of Psychiatry,  151,  1172-1180. 
Morin,  C. M., Hauri, P. J., Espie, C. A., Spielman, A.,  Buysse,  D. J.,  & 
Bootzin,  R. R.  (1999). Nonpharmacologic  treatment of chronic insom- 
nia: An American Academy of Sleep Medicine review. Sleep, 22,  1-25. 
Morin, C. M., Kowatch, R. A., Barry, T., & Walton, E. (1993). Cognitive 
behavior therapy for late-life insomnia. Journal of Consulting and Clin- 
ical Psychology, 61, 137-146. 
Morin, C. M., Stone, J., McDonald, K., & Jones, S. (1994). Psychological 
treatment of insomnia: A clinical replication series with I 00 patients. 
Behavior Therapy, 25, 159-177. 
Morin, C. M., Stone, J., Trinkle, D., Mercer,  J., & Remsberg,  S. (1993). 
Dysfunctional beliefs and attitudes about sleep among older adults with 
and  without  insomnia complaints. Psychology  and Aging,  8, 463-467. 
Murtagh,  D. R.,  & Greenwood,  K. M.  (1995).  Identifying  effective  psy- 
chological  treatments  for insomnia:  A meta-analysis.  Journal  of  Con- 
sulting and Clinical Psychology, 63, 79-89. 
National Institutes of Health. (1984). Consensus Conference: Drugs and 
insomnia-The use of medication to promote sleep. Journal of the 
American  Medical  Association,  251,  2410-2414. 
National Institutes of Health. (1991). Consensus development conference 
statement: The treatment of sleep disorders of older people (March 26-
28,   1990) Sleep,  14,  169-177. 
Puder, R., Lacks, P., Bertelson, A. D., & Storandt, M. (1983). Short-term 
stimulus control treatment of insomnia in older adults. Behavior Ther- 
apy,  14, 424-429. 
Reite, M., Buysse, D., Reynolds, C., & Mendelson, W. (1995). The use of 
polysomnography in the evaluation of insomnia. Sleep, 18, 58-70. 
Reite, M., Ruddy, J., & Nagel, K. (1997). Evaluation and management of 
sleep disorders. Washington,  DC: American  Psychiatric  Press. 
Royal Society of Medicine. (1992). In M. Lader  (Ed.), Medical manage- 
ment of insomnia in general practice. (Round Table Series No. 28). 
London: RSM  Services. 
Russell, J., & Lader, M. (1992). Guidelines for the prevention and treat- 
ment of benzodiazepine dependence. London: Mental  Health  Founda- 
tion. 
Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970). Manual for 
the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychol- 
ogists Press. 
Tabachnick, B. D., & Fidell, L. S. (1996). Using multivariate statistics. 
New  York: Harper Collins. 
 
 
Received October 21, 1999 
Revision received June 29, 2000 
Accepted July 6, 2000 • 
Behaviour Research and Therapy 40 (2002) 75–83
www.elsevier.com/locate/brat
Insomniacs’ reported use of CBT components and
relationship to long-term clinical outcome
Linda Harvey, Stephanie J. Inglis, Colin A. Espie *
University of Glasgow, Department of Psychological Medicine, Academic Centre, Gartnavel Royal Hospital,
1055 Great Western Road, Glasgow G12 0XH, UK
Accepted 12 December 2000
Abstract
Although there is considerable evidence for the efficacy of non-pharmacological treatment of insomnia,
many of the larger trials have delivered CBT in multicomponent format. This makes it impossible to identify
critical ingredients responsible for improvement. Furthermore, compliance with home implementation is
difficult to ascertain in psychological therapies, and even more so when trying to differentiate across a range
of elements. In the present report, 90 patients who had completed 12 month follow-up after participation in
a clinical effectiveness study of CBT in general medical practice, responded to a questionnaire asking them
about their use of the ten components of the programme. Reports of home use were then entered as
predictors of clinical response to treatment. Results indicated that reported home use of stimulus
control/sleep restriction was the best predictor of clinical improvement in sleep latency and nighttime
wakefulness. Cognitive restructuring also contributed significantly to reduction in wakefulness. In spite of
being the most highly endorsed component (by 79% of respondents) use of relaxation did not predict
improvement on any variable. Similarly, sleep hygiene was unrelated to sleep pattern change and use of
imagery training was modestly predictive of poor response in terms of sleep latency. There are methodolog-
ical limitations to this type of post hoc analysis, nevertheless, these results being derived from a large patient
outcome series raise important issues both for research and clinical practice.  2001 Elsevier Science Ltd.
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1. Introduction
It is difficult to gauge the extent to which patients comply with cognitive behavioural treatment
(CBT). Generally, such interventions rely upon home practice and there is no objective criterion
by which compliance can be measured. Beneficial effects, either within or between treatments,
therefore, could be accounted for simply in terms of patterns of implementation and/or perceived
credibility. On the other hand, there may be no a priori reason to suspect that acceptability varies
amongst treatments. Early research on insomnia, comparing single component interventions such
as stimulus control, relaxation and paradoxical intention, suggested that these treatments were
equally credible, in terms of therapeutic rationale (Turner & Ascher, 1979; Espie, Lindsay, Brooks,
Hood, & Turvey, 1989), although sleep hygiene education may be less so (Schoicket, Bertelson, &
Lacks, 1988). There is very limited evidence on compliance. In a recent influential study, patients
and significant others reported similarly high levels of compliant behaviour on a rating scale
measure across CBT and pharmacological treatments, and urine screens supported their reports
in terms of benzodiazepine use (Morin, Colecchi, Stone, Sood, & Brink, 1999). However, some
work on relaxation therapies, using discreet counters in audiocassette machines, does suggest that
people over-report home practice (Lichstein & Hoelscher, 1986). Therefore, although chronic
insomniacs of all ages appear to find CBT credible and even older adults are generally accepting
of a psychological approach (Morin, Gaulier, Barry, & Kowatch, 1992), we do not really know
how this translates into action.
These issues are compounded by the clinical practice of multicomponent CBT delivery. System-
atic comparisons of single components are more typical of efficacy studies, whereas ‘package’
treatments reflect clinical practice (Chesson et al., 1999). Recent commentaries on non-pharmaco-
logical treatments of insomnia have stressed the importance of research leading to the identifi-
cation of critical ingredients in therapy (Morin et al., 1999; Edinger & Wohlgemuth, 1999). This
would be valuable not only conceptually by suggesting possible mechanisms of effect, but also
practically, in terms of the cost-efficient use of scarce resources and an understanding of the
‘dose–response’ relationship for psychological practice.
We have recently reported outcome data from a large clinical effectiveness study using multi-
component CBT for insomnia. Our results demonstrate significant and sustained improvements
in sleep pattern and sleep quality at one year follow-up, with average reductions in sleeplessness
of around 60 min per night (Espie, Inglis, Tessier, & Harvey, 2001). Up to two-thirds of our
patients no longer met criteria for insomnia at one year, and 40% had reduced sleep latency and
wakeful time in bed after sleep-onset by at least 50%. Over 80% of those previously on sleeping
pills had stopped taking them, and patients reported finding CBT highly credible (Espie, Inglis, &
Harvey, 2001). Importantly, these outcomes were obtained across the full range of clinical presen-
tation, and were not contraindicated by factors such as severity of insomnia, associated psycho-
pathology or use of sleep medication. Although our study was not designed to tease out treatment
component effects, we do have data which permit quantification of patients’ self-reported home
use of elements of the programme, and we are able to compare reported use of these components
between treatment ‘responders’ and ‘non-responders’ at 1 yr follow-up.
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2. Method
2.1. Design
The Sleep Clinic was established to conduct a controlled clinical effectiveness trial of CBT for
chronic insomnia in general practice. Patients presenting with difficulty initiating or maintaining
sleep, according to International Classification of Sleep Disorders Criteria (American Sleep Dis-
orders Association, 1990) were randomly assigned either to immediate or deferred CBT, conduc-
ted in small groups, by a Health Visitor (nurse based in primary care) who had been trained in
the use of a manualised CBT intervention. Treatment comprised six sessions, each of 50 min
duration, comprising sleep education, sleep hygiene, stimulus control and sleep restriction, and
cognitive therapy techniques. Since patients were seen in groups of 4–6 the average treatment
time per patient was around 1 h. A full description of the treatment programme can be found
elsewhere (Espie et al., 1998).
2.2. Subjects
A total of 139 insomniacs participated and were followed up 1 yr after completion of CBT.
Summary information has been presented elsewhere (Espie, Inglis, Tessier, & Harvey, 2001;
Espie, Inglis, & Harvey, 2001) but for descriptive purposes, our 12-month follow-up sample
(n=109) comprised 78 females and 31 males with mean age of 52.1 yr (SD 16.2). Two-thirds of
the sample had insomnia for more than 5 yr and over half were regular users of hypnotic drugs
before treatment. There were no significant differences between the follow-up sample and the
larger cohort who completed treatment.
2.3. Measures
These 109 subjects were mailed a questionnaire which enquired about their use of 10 compo-
nents of the CBT programme. These related to: two components of ‘sleep hygiene’ i.e. lifestyle
and bedroom factors, stimulus control/sleep restriction, naps, the pre-bedtime routine, progressive
relaxation, cognitive control, imagery, thought-blocking and cognitive restructuring (see Table 1).
The questionnaire explained that, in our further development of the Sleep Clinic, we were inter-
ested in discovering what they felt had been the most helpful parts of the programme and ones
they used to strengthen their sleep pattern. Subjects were simply asked to respond ‘yes’ or ‘no’
to each item and to return the questionnaire by mail.
3. Results
Responses were received from 90 of the 109 patients for whom 12 month post-treatment sleep
data were available (83%). This sample, which comprised 66 females and 24 males with mean
age of 53.9 yr (SD 16.1), was not significantly different from the complete follow-up cohort.
Stated use of the different treatment components revealed considerable variation (Table 1). Around
three-quarters reported finding relaxation beneficial and almost 60% avoided napping outwith the
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Table 1
Reported use (%) of CBT components at one year follow-up (n=90), and identification of potential predictors of treat-
ment responding (responders vs non-responders on seven outcome variables) for entry to logistic regression (Chi-
square: **P0.05; *P0.15 following Hosmer & Lemeshow, 1989)
CBT Component % SOL 30 SOL SOL both WASO WASO WASO ENJOY
Reporting min 50% 30 min 50% both
use at 12
mth post-
CBT
Altering lifestyle 49 *
(diet, caffeine,
exercise)
Altering bedroom 32
factors (mattress,
temperature,
lighting)
Stimulus 41 ** * * **
control/sleep
restriction (using
bed only for sleep,
reducing time in
bed)
Not taking naps 59 * *
during day or
evening
Pre-bed routine 52 *
(slowing down 90
minutes before bed,
following routine)
Relaxing (using 74
abbreviated
progressive
relaxation)
Cognitive control 21 * * *
(dealing with
thoughts/plans/worries
early in the
evening)
Imagery techniques 19 * * **
(visualisation,
imagery)
Blocking thoughts 41
(blocking and
suppressing)
Cognitive 41 * *
restructuring
(altering beliefs
about sleep)
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sleep period. Maintenance of a pre-bedtime routine and sleep hygiene practices associated with
diet and exercise were reported by around half the participants. Stimulus control/sleep restriction,
cognitive restructuring and thought blocking were identified by around 40%, with other aspects
of sleep hygiene and putting the day to rest using cognitive control reported by proportionately
fewer respondents (32 and 21% respectively). The least used technique was imagery at 19%. It
cannot be assumed, of course, that these reports reflect behaviours initiated during CBT. For
example, subjects may never have napped even prior to treatment.
Table 1 also presents comparative data for treatment responders versus non-responders. Three
criteria were used to determine clinical response, for each of two sleep pattern variables—sleep-
onset latency (SOL; min.) and wake time after sleep-onset (WASO; min.) (see Espie, Inglis, &
Harvey, 2001). Firstly, achievement of a sleep diary value (end state functioning) of 30 min;
secondly, 50% reduction in minutes of sleeplessness, attributed to that variable; and thirdly,
achievement of both of these reductions. In addition, one measure of sleep quality (rating of ‘sleep
enjoyment’ on a five point Likert scale: ENJOY) was included using the50% reduction criterion.
Thus, Table 1 shows Chi-square probabilities for use of CBT components (yes/no) associated
with improvement/non-improvement on seven clinical outcomes. The use of this number of vari-
ables appears justified because of the exploratory nature of the study. Furthermore, there was, at
best, modest intercorrelation amongst the seven outcome variables according to Spearman stat-
istics (range of r=0.08 to 0.59). Consistent with the argument presented by Hosmer & Lemeshow
(1989) and endorsed by Tabachnick & Fidell (1996) the cut-off value for detecting potential
effects was set sensitively at P0.15. This was in order to avoid Type II error in subsequent
regression analyses. Where there is inclusion of only those values which achieve high levels of
significance (such as P0.05) on simple bivariate analysis there is the possibility of bias toward
inter-correlated predictors at the expense of other predictors which might be prematurely excluded.
In contrast we wished to ensure entry of all variables with coefficients which potentially differed
from zero since the regression model itself would act conservatively at the subsequent stage.
Inspection of Table 1 suggests that stimulus control/sleep restriction may have been differen-
tially applied between responders and non-responders. For example, the likelihood of being a
responder when using this component was over four times higher for both SOL and WASO 30
min (c2=7.18, P=0.027; c2=6.59, P=0.037 respectively). Similarly, subjects using cognitive
restructuring had a higher probability (times three) of responding on WASO 30 min and SOL
50% and cognitive control was modestly associated with better responding in terms of WASO
50% reduction and ENJOY. By comparison, it should be noted that imagery was associated
with non-response to treatment for the SOL variables including the combined outcome SOLboth
(c2=7.28, P=0.022). Although only 17 of the 90 patients reported using imagery (Table 1), 14 of
these 17 (82%) were non-responders.
Patients’ use of the 10 CBT components, of course, was not mutually exclusive. There are
limitations, therefore, to focusing upon bivariate relationships, particularly since multiple compari-
sons were made. As described above, our primary purpose in conducting these analyses was to
reduce the range of possible associations to those meeting our entry criterion (P0.15) for
inclusion in a multivariate model. The results of logistic regression analyses for each of these
outcome variables is presented in Table 2.
Using stimulus control/sleep restriction but not imagery accounted for a significant amount of
explained variance in SOL 30 min. This equation predicted 100% of responders on this outcome
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Table 2
Prediction of treatment response on seven outcome variables following logistic regression analyses
Log Chi-square df sig. Predictors sig. R % %
likelihood Correct Correct
responders non-
responders
SOL 30 55.57 12.35 4 0.015 Stimulus 0.039 0.183 100.0 33.3
min control/sleep
restriction
Imagery 0.064 0.145
SOL 50% 60.53 11.25 7 0.128 None – – – –
reduction
SOL both 60.15 9.02 4 0.061 None – – – –
WASO 30 58.72 11.53 5 0.042 Stimulus control/ 0.026 0.206 78.8 50.0
min sleep restriction
Cognitive 0.130 0.065
restructuring
WASO 50% 59.81 9.30 4 0.054 Cognitive control 0.055 0.156 76.7 52.3
reduction
Pre-bedtime 0.090 0.112
routine
WASO both 65.30 8.36 4 0.079 None – – – –
ENJOY 46.41 13.54 5 0.019 Cognitive control 0.042 0.189 28.6 91.9
50% Altering lifestyle 0.056 0.167
increase
but only one-third of non-responders. Thus stimulus control and sleep restriction seem particularly
important to reduce sleep latency to below clinical threshold levels. Similarly for WASO 30
min stimulus control/sleep restriction (20% of variance), combined with the lesser influence of
cognitive restructuring (6%), predicted over three-quarters of responders and 50% of non-
responders. No significant predictors emerged for SOL 50% reduction, however, a near signifi-
cant equation (P=0.054) for WASO 50% reduction suggested that cognitive control and having
a pre-bed routine were important, again predicting responding at a higher rate than non-
responding. Neither of the combined outcome variables (SOLboth, WASOboth) emerged with
significant predictors. In terms of sleep quality, failing to put the day to rest or address lifestyle
issues appeared to predict poor response in over 90%, in terms of the variable ENJOY. It should
be noted that some aspects of sleep hygiene (bedroom factors), relaxation and thought-blocking
techniques did not predict clinical outcome on any variable.
4. Discussion
There are a number of reasons why a patient might use a treatment strategy. These include ease
of assimilation, adaptability for and comfort in home practice, perceived relevance and perceived
effectiveness. The reporting of treatment implementation of course may be subject to demand
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characteristics. Subjects may wish to demonstrate appreciation. However, with a post-treatment
interval of 12 months in this study demand characteristics might be expected to play a lesser role
since there was no continuing contact with the therapist or the research team. Furthermore, efforts
were made to enable patients freely to report which CBT elements they found useful. The fact
that there was variability in terms of reported use, implies that this goal was in some measure met.
Taking the group as a whole, relaxation emerged as the most commonly endorsed strategy
(74%). Relaxation clearly has high face validity, and it may be particularly memorable to patients.
However, consistent with the research literature being somewhat equivocal about its efficacy for
clinical populations (Morin et al., 1999), the present analysis revealed that relaxation failed to
predict improvement on any of seven clinical outcomes, including a measure of sleep quality.
Similarly, sleep hygiene, although commonly used as a precursor to CBT, has not emerged pre-
viously as an effective element of treatment. The results of our regression analysis support the
conclusion that sleep hygiene has little effect upon clinical outcome, except perhaps those compo-
nents relevant to lifestyle which may make a modest contribution to qualitative report of sleep.
The American Academy of Sleep Medicine, in its recent Practice Parameters paper, reported
stimulus control as the component treatment with the highest level of empirical evidence, rec-
ommending it as a ‘standard’ treatment for insomnia (Chesson et al., 1999). In the present study,
the stimulus control/sleep restriction component was found to be the strongest and most consistent
predictor of outcome, particularly in terms of identifying treatment responders. Patients who
reported using these behavioural procedures were more likely to achieve a final sleep latency of
less than 30 min or to spend less than 30 min of wakefulness in bed during the night. Since
patients achieving such a sleep pattern may be regarded as similar to the general population of
non-complainants, because they would no longer meet diagnostic criteria, it appears that adherence
to stimulus control and sleep restriction may be predictive of normative end state functioning
(Kendall, Marrs-Garcia, Nath, & Sheldrick, 1999). This has important implications in terms of
clinical significance of change, which is the priority in real world settings. Our practice has been to
combine stimulus control instructions (after Bootzin, 1972) with sleep restriction (after Spielman,
Saskin, & Thorpy, 1987) and to use the term ‘sleep scheduling’ with patients. Our view is that
the successful re-conditioning of strong, positive bed–sleep associations using stimulus control
complements improved chronobehavioural functioning (where the emphasis is upon improving
sleep efficiency i.e. the ratio of actual sleep time to time in bed) by means of sleep restriction.
By default, of course, sleep scheduling also reduces the probability of experiencing negative
intrusive thoughts while in bed, raising another potential mode of action.
More explicit cognitive strategies also contributed to outcome according to our analysis. It is
interesting that cognitive restructuring had some impact upon intermittent wakefulness (WASO
30 min) rather than initial insomnia. This is consistent with the results for the other wakefulness
measure (WASO 50% reduction) where better preparation for bed, both mentally using cognitive
control and behaviourally by following a pre-bed routine, was modestly predictive of response.
It seems possible, therefore, that continuity of sleep is facilitated by the development and mainte-
nance of adaptive beliefs and attitudes. Thought-blocking using articulatory suppression, however,
did not add any predictive power to outcome on any variable. The apparently negative effect
associated with imagery was unexpected. It seems that the non-use of imagery, perhaps in favour
of stimulus control, is preferable and that imagery may have potential to exacerbate sleep-onset
problems. In our CBT package subjects are encouraged to choose their own visual image, around
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the theme of a pleasant sequence of events, and to integrate it within their relaxation routine. It
may be that other instructional sets would prove more beneficial. Finally, we found no clear
predictor of positive treatment response on our measure of sleep quality, although failure to
implement lifestyle change and to put the day to rest may impair sleep enjoyment. Since qualitat-
ive data comprise an important perspective on sleep assessment and management, and perhaps
upon the persistence of complaining behaviour, further work is required to ascertain how such
qualitative outcomes may be improved.
It is beyond the scope of our data to offer any explanation as to the mechanism of psychological
treatment effects. Besides, there are many limitations methodologically to the type of post-hoc
analysis reported here. However, it is tentatively suggested that CBT which prioritises the adoption
of sleep scheduling and cognitive restructuring methods may be more likely to produce clinically
meaningful results, than broadly educational approaches emphasising sleep hygiene, relaxation or
thought-blocking methods. This conclusion appears reasonably consistent with the outcome litera-
ture. Inevitably, further work is required to validate reports of home practice since these do not
necessarily confirm actual implementation.
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INITIAL INSOMNIA AND PARADOXICAL INTENTION:
AN EXPERIMENTAL INVESTIGATION OF PUTATIVE
MECHANISMS USING SUBJECTIVE AND ACTIGRAPHIC
MEASUREMENT OF SLEEP
Niall M. Broomﬁeld and Colin A. Espie
University of Glasgow, Scotland, UK
Abstract Paradoxical Intention (PI) is a cognitive treatment approach for sleep-onset insom-
nia. It is thought to operate by eliminating voluntary sleep effort, thereby ameliorating sleep
performance anxiety, an aroused state incompatible with sleep. However, this remains un-
tested. Moreover, few PI studies have employed objective sleep measures. The present study
therefore examined the effect of PI on sleep effort, sleep anxiety and both objective and
subjective sleep. Following a seven-night baseline, 34 sleep-onset insomniacs were randomly
allocated to 14 nights of PI, or to a control (no PI) condition. Consistent with the perform-
ance anxiety model, participants allocated to PI, relative to controls, showed a signiﬁcant
reduction in sleep effort, and sleep performance anxiety. Sleep-onset latency (SOL) differ-
ences between PI participants and controls using an objective sleep measure were not
observed, although an underlying trend for signiﬁcantly lowered subjective SOL amongst PI
participants was demonstrated. This may relate to actigraphic insensitivity, or more probably
conﬁrms recent suggestions that insomniacs readily overestimate sleep deﬁcit, due to excess-
ive anxiety about sleep. Together, results help determine putative mechanisms underlying
PI, have important implications for the clinical application of PI, and emphasize the need
for further PI research within an experimental cognitive framework.
Keywords: Insomnia, paradoxical intention, cognitive-behaviour therapy, performance
anxiety, actigraphy.
Introduction
Evidence has converged suggesting pre-sleep cognitive activity is a key maintaining factor
in sleep-onset insomnia (Espie, 2002; Harvey, 2002). Despite this, research examining stand-
alone cognitive insomnia interventions remains rare. One exception to this is Paradoxical
Intention (PI). Single case (Ascher, 1975; Ascher & Efran, 1978; Espie & Linday, 1985)
and randomized-controlled studies (Ascher & Turner, 1979, 1980) support the utility of PI
in the management of sleep-onset insomnia, and its equivalence to stimulus control and
relaxation (Espie, Lindsay, Brooks, Hood, & Turvey, 1989; Ladoucer & Gros-Loius, 1986;
Turner & Ascher, 1979). Indeed, PI is now regarded as a ‘‘probably efﬁcacious’’ insomnia
Reprint requests to Niall Broomﬁeld, Department of Psychological Medicine, Gartnavel Royal Hospital, 1055 Great
Western Road, Glasgow G12 0XH, Scotland, UK. E-mail: nmb2v@clinmed.gla.ac.uk
 2003 British Association for Behavioural and Cognitive Psychotherapies
N. M. Broomﬁeld and C. A. Espie314
intervention according to APA criteria (Chesson, Anderson, Littner, Davila, & Hartse, 1999;
Morin et al., 1999).
Despite these outcome data, and its now routine use within multicomponent CBT (e.g.
Espie, Inglis, Tessier, & Harvey, 2001), the mechanisms underlying PI remain unclear. PI
is a cognitive approach, which requires poor sleepers give up voluntary effort to control
sleep. The treatment achieves this by encouraging insomniacs to relax with the lights out at
bedtime, keeping their eyes open. Paradoxically, the likelihood of staying awake is reduced
by encouragement to do so (Espie & Lindsay, 1985).
Sleep is a behaviour, which cannot be placed under full voluntary control. One hypothesis
therefore is that direct attempts to control sleep will fail, because sleep effort inhibits relaxa-
tion and sets up performance anxiety, an aroused state incompatible with sleep. Consistent
with this, Ascher and Turner (1979) have argued that by eliminating voluntary sleep effort,
PI minimizes sleep performance anxiety, thereby promoting rapid sleep-onset. Similarly,
Espie (2002) has suggested that by diverting attention away from sleep performance, PI
facilitates cognitive/affective de-arousal and promotes sleep. To date, however, these per-
formance anxiety conceptualizations remain untested. This study, therefore, is not an evalu-
ation of the efﬁcacy of PI. Rather, it aimed to clarify whether PI institutes sleep change via
sleep effort/performance anxiety reduction.
There also, at present, remains a marked lack of PI research using objective sleep meas-
ures. This is problematic. Insomniacs’ self-report sleep data can be unreliable (Carskadon
et al., 1976), and objective and subjective sleep measures may reﬂect differing response
systems (Wicklow & Espie, 2000). To date, only one PI study has employed objective
sleep measurement (Ott, Levine, & Ascher, 1983), and the method employed only estimated
sleep-onset latency (SOL) objectively to within ﬁve minutes. A second aim of the present
study was therefore to examine and compare objective (actigraphy) and subjective
(self-report diary) sleep outcome following brief (14 night) PI using a reliable sleep measure-
ment system.
A reliable and minimally intrusive objective sleep measure is the actigraph – a small
wrist attachment that records the wearer’s movements. There is recognition that movement
is a good predictor of wakefulness, whilst lack of movement is a good predictor of sleep
(American Sleep Disorders Association, 1995; Mullaney, Kripke, & Messin, 1980). More-
over, actigraphic measures correlate highly with polysomnographic (PSG) data for sleep
duration and total wake time (e.g. Sadeh, Hauri, Kripke, & Lavie, 1995; Mullaney et al.,
1980).
To summarize then, a study was conducted examining the performance anxiety model of
PI. Sleep-onset insomniacs were randomly assigned to two weeks of PI, or a control (no PI)
condition, following a one-week baseline. Voluntary sleep effort and sleep anxiety data
were collected, alongside actigraphic and subjective sleep data. A One Between (Condition:
Paradoxical Intention [PI], Control) and One Within factor (Time: Baseline, Week One,
Week Two) design was employed. Relative to the control condition, it was predicted alloca-
tion to PI would (i) reduce sleep effort after Weeks One and Two; (ii) reduce sleep perform-
ance anxiety after Weeks One and Two; (iii) reduce objective and subjective SOL after
Weeks One and Two; (iv) and raise objective and subjective sleep efﬁciency after Weeks
One and Two. Importantly, the research was not designed as a treatment study, rather as an
experimental examination of putative mechanisms underlying PI, as well as objective/sub-
jective sleep outcome following the procedure.
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Method
Participants
Participants were recruited using the University e-mail system and via notices placed locally.
The Health Authority and University granted ethical approval. Prior to participation potential
participants completed screening questionnaires assessing sleep (Pittsburgh Sleep Quality
Index [PSQI] – Buysse, Reynolds, Monk, Berman, & Kupfer, 1989; Sleep History
Questionnaire – Morin, 1993), anxiety (Spielberger Trait Anxiety Inventory – STAI;
Spielberger, Gorsuch, & Lushene, 1970), worry (Penn State Worry Questionnaire – PSWQ;
Meyer, Miller, Metzger, & Borkovec, 1990) and depression (Beck Depression Inventory –
BDI; Beck, Steer, & Brown, 1996).
Respondents were included if they were between 16 and 65 years, complained of clinic-
ally signiﬁcant problems falling asleep according to the revised version of the International
Classiﬁcation of Sleep Disorders (American Sleep Disorder Association, 1997; i.e. SOL
greater than 30 min at least 4 nights per week, with or without disruption to other sleep
variables), and scored in excess of 5 on the PSQI, the recognized cut-off for identifying
clinically signiﬁcant sleep disturbance (Buysse et al., 1989). Participants were excluded if
they experienced intermittent awakenings without sleep-onset difﬁculties, were receiving
treatment for sleeping difﬁculties, or were suffering any medical or psychopathological
disorder impacting on sleep.
Forty-six participants were identiﬁed, all meeting criteria. Thirty-four completed the
experiment (74%; mean age 25.2 years, average sleep disturbance 6.35 years). A further
seven failed to attend the initial meeting, three withdrew during baseline, and two were
excluded due to unreliable diary completion.
Measures
A daily sleep diary (Espie, 1991), completed upon rising for 21 days, provided measures of
subjective SOL and sleep efﬁciency (based on time to bed, rise time, time to fall asleep,
and total sleep time responses). Effort to sleep data were recorded in the diary using a
7-point scale (‘‘I tried hard to get to sleep last night’’; anchor points 0 ‘‘not at all’’, 6 ‘‘very
much’’).
Two self-report scales measured sleep-related performance anxiety: the Sleep Anxiety
Scale (SAS; Fogle & Dyall, 1983, see p. 26 for internal consistency data); and a specially
developed scale, the Sleep Performance Anxiety Questionnaire (SPAQ). The latter com-
prised seven components of dysfunctional sleep monitoring (sleep effort, sleep control, sleep
avoidance, bedtime worry, performance failure, anticipatory anxiety, and daytime worry).
Piloting indicated the SPAQ readily distinguished good (N = 4; mean = 7.75, SD = 0.96)
from poor (N = 4; mean = 15.50, SD = 3.69) sleepers. Cronbach’s alpha data for both scales
are presented in the results.
Wrist actigraphic recording using the ‘‘Actiwatch’’ (Model AW2; Cambridge Neurotech-
nology Ltd) provided objective estimates of SOL and sleep efﬁciency. As noted, actigraphic
measures correlate highly with polysomnographic (PSG) data for sleep duration and total
wake time (Sadeh et al., 1995; Mullaney et al., 1980), and movement is a good predictor of
wakefulness, whilst lack of movement is a good predictor of sleep (American Sleep Dis-
orders Association, 1995; Mullaney et al., 1980).
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Participants wore the actigraph continuously on their non-dominant hand except during
wet activities. An event marker was depressed at lights out, and upon rising. Epoch length
was set at 1 min. (Wicklow & Espie, 2000), with ‘‘sleep’’ or ‘‘wakefulness’’ determined
by the program’s algorithm.
Procedure
Following a telephone interview, participants were sent screening questionnaires (see parti-
cipants section), an information sheet, and an informed consent slip. These were completed
and returned by post. Participants then received a sleep diary and wrist actigraph, and were
told the next seven days was a baseline measurement week.
Seven days later, participants completed the two sleep anxiety scales (Baseline), and were
issued with further copies to be completed after seven days (Week One). Participants were
then randomly allocated to experimental condition.
PI participants were introduced to the rationale of PI, and instructed, at lights out, to stay
awake for as long as possible by keeping their eyes open. The need to resist sleep-onset
gently but persistently in an environment conducive to sleep was emphasized. The use of
active methods to stay awake (e.g. reading, physical movement) was discouraged. Patient
expectations can inﬂuence response to PI (Epsie & Lindsay, 1985). In an attempt to control
for this, half of PI participants were told to expect immediate sleep improvement (positive
demand), whereas half were told to expect sleep improvement only at Week Two (counter
demand). Control participants were told to continue wearing their actiwatch, and to continue
completing their sleep diary.
After 14 nights, all participants returned their diaries and actigraph, and completed two
ﬁnal sleep anxiety scales (Week Two), and a compliance-rating sheet. They were then
debriefed and thanked, and issued with the ‘‘Good Sleep Guide’’, a leaﬂet describing beha-
vioural advice for home practice prepared by the second author (National Medical Advisory
Committee, 1993).
Results
Participant characteristics
Participants had a mean age of 25.2 years, and mean sleep disturbance duration of 6.35
years. PI participants and controls were equitable in terms of gender (p > .10, NS), and did
not differ on age, duration of sleep problem, trait anxiety, worry, depression or sleep quality
(all p > .10; see Table 1 for data).
Compliance with experimental instructions
Participants reported correctly following experimental instructions (diary completion,
actiwatch use) on mean = 19.2 nights. Mean compliance rating (scale 0–6) was 5.03, SD =
0.79. Non-compliance included forgetting to press the actiwatch, or to replace the actiwatch
after wet activities. This was unusual.
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Using PI
All 17 PI participants said they lay awake with their eyes open when using PI. None used
active methods (reading, television) to stay awake.
Outcome variables
All data were ﬁrst examined for kurtosis and skewness and fell within acceptable limits.
Data also showed homogeneous variance, following Hartley’s Fmax test (Winer, 1971).
Analyses then relied on a Two (Condition: Paradoxical Intention vs. Control) by Three
(Time: Baseline vs. Week One vs. Week Two) ANOVA design based on weekly means.
Alpha level was set at .05, two-tailed, throughout. Means and standard deviations are pre-
sented in Table 1.
Sleep effort
ANOVA revealed a main effect of Time (F[2, 64] = 9.05, p = .0001), and a Time × Condi-
tion interaction (F[2, 64] = 6.37, p = .003). In order to clarify this, Bonferroni corrected
simple main effects analyses for Condition were completed across the Time variable (critical
p value = .017; Keppel, 1993). As is evident in Figure 1 panel A, this indicated relative to
controls, PI participants showed signiﬁcantly lower sleep effort at Week One (F[1, 33] =
7.72, p = .009; critical p value = .017) and near signiﬁcant lower effort at Week Two
(F[1, 33] = 5.55, p = .025; critical p value = .017). No differences were observed at Baseline
(F[1, 33] = 0.01, p > .1, NS).
Sleep performance anxiety
Separate ANOVAs were run for the two performance anxiety scales employed, based on
participant scores at Baseline, Week One and Week Two.
Sleep Anxiety Scale (SAS). ANOVA revealed a main effect of Time (F[2, 64] = 6.69, p =
.002), and an interaction effect of Time × Condition (F[2, 64] = 9.84, p = .0001). As is
evident in Figure 1 panel B, simple main effects indicated PI participants displayed signiﬁc-
antly lower sleep anxiety at Week Two (F[1, 33] = 8.26, p = .007), and a near signiﬁcant
trend for lower sleep anxiety at Week One (F[1, 33] = 5.41, p = .026; critical p value =
.017). No differences were observed at Baseline (F[1, 33] = 0.09, p > .1, NS).
In order to examine the internal consistency of scale data, baseline item scores across
participants were subjected to appraisal using Cronbach’s alpha. Overall alpha coefﬁcient
was 0.86, with range of alpha values, if item deleted, of 0.83–0.87. The mean corrected
item-total correlation was 0.62.
Sleep Performance Anxiety Questionnaire (SPAQ). Analysis revealed a main effect of
Time (F[2, 64] = 15.68, p = .0001), and a Time × Condition interaction (F[2, 64] = 15.48,
p = .0001), displayed in Figure 1 panel C. As is evident, simple main effects indicated PI
participants showed signiﬁcantly lower sleep anxiety at Week Two (F[1, 33] = 9.89, p =
.004), and a trend for lower sleep anxiety at Week One (F[1, 33] = 5.66, p = .023). No
differences were observed at Baseline (F[1, 33] = 0.30, p > .1, NS). Overall alpha coefﬁcient
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Figure 1. Mean sleep effort, sleep anxiety and subjective SOL for PI and control participants, as a
function of Time
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for the SPAQ was 0.70, with the range of alpha values, if item deleted, of 0.63–0.73. The
mean corrected item total correlation was 0.42.
Finally, Pearson correlation coefﬁcients were computed across participants’ baseline
scores on the SAS and SPAQ. This indicated correlation was ‘‘moderate’’ (r = 0.62, p <
.01), representing 38.5% shared variance.
Sleep
Two participants’ actigraph data were lost due to faulty equipment. Analyses were therefore
based on 16 participants per condition.
Counterdemand instructions. A series of Two (Instructions: Counterdemand vs. Positive
Demand) by Three (Time: Baseline vs. Week One vs. Week Two) ANOVAs for PI partici-
pants only, on objective and subjective SOL and sleep efﬁciency, revealed no signiﬁcant
Instruction × Time interaction effects (all p > .1, NS; see Table 2). Primary sleep analyses
therefore compared PI participants with controls.
Objective sleep (actigraphy). ANOVA for objective SOL revealed non-signiﬁcant main
effects of Time (F[2, 60] = 0.48, p > .1, NS) and Condition (F[1, 30] = 0.06, p > .1, NS).
The Time × Condition interaction was also non-signiﬁcant (F[2, 60] = 0.13, p > .1, NS).
Objective SOL remained at approximately 25–30 minutes across condition (see Table 1).
Similarly, ANOVA for objective sleep efﬁciency data failed to reveal any signiﬁcant
effects of Time (F[2, 60] = 0.53, p > .1, NS), Condition (F[1, 30] = 0.67, p > .1, NS), or
Time × Condition (F[2, 60] = 0.19, p > .1, NS). Objective efﬁciency remained at approxim-
ately 80% (see Table 1).
Subjective sleep (diary). ANOVA revealed a main effect of Time (F[2, 64] = 6.72, p =
.002), and an interaction of Time × Condition (F[2, 64] = 9.16, p = .0001), displayed in
Figure 1 panel D. Simple main effects analyses could be indicative of an underlying trend
for lower SOL amongst PI participants, relative to controls, at Weeks One (F[1, 33] = 3.36,
Table 2. Mean and standard deviation objective and subjective sleep-onset latency (mins) and sleep
efﬁciency (%) at Baseline (B), Week One (W1) and Week Two (W2), for counterdemand (C) and
positive demand (P) instructions
Objective Subjective
SOL Efﬁciency SOL Efﬁciency
Condition M SD M SD M SD M SD
BC 20.73 10.52 78.31 16.96 62.03 20.97 78.30 16.96
BP 37.10 19.15 83.15 10.00 69.03 39.96 83.15 9.99
W1 C 22.41 13.71 81.82 16.04 46.66 18.41 81.82 16.04
W1 P 28.48 18.11 89.92 4.61 37.41 20.69 89.92 4.60
W2 C 19.32 10.35 82.53 14.53 39.41 28.01 82.53 14.53
W2 P 29.61 21.59 88.70 6.36 37.19 24.26 88.69 6.35
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p = .076) and Two (F[1, 33] = 3.34, p = .077). However, test statistics on small samples
can be unstable. No differences were observed at Baseline (F[1, 33] = 1.15, p > .1, NS).
Allocation to PI resulted in a 41.85% reduction in SOL, compared to a 1.21% increase
amongst controls (see Table 1). Treatment effect size was ‘‘moderate’’ (d = 0.61; Cohen,
1988). 70.6% of PI participants reported PI helped them get to sleep quicker.
Analysis of subjective sleep efﬁciency data revealed a main effect of Time (F[2, 64] =
6.65, p = .024), although the Time × Condition interaction failed to reach signiﬁcance (F[2,
64] = 0.73, p > .1, NS).
The relationship between objective and subjective sleep measures. As inspection of Table
1 reveals actigraphic SOL at baseline was 29.92 minutes for PI participants, and 26.62
minutes for controls. At Week Two, these scores were unchanged for both PI participants
(mean = 24.47 minutes) and controls (mean = 25.03 minutes). No signiﬁcant objective SOL
change following PI was therefore observed.
Subjective SOL scores at baseline were much higher than objective SOL scores for PI
participants (mean = 65.74 minutes) and controls (mean = 54.67 minutes). This suggests all
participants overestimated SOL relative to actigraphic assessment as an objective criterion
at baseline. The discrepancy between subjective (mean = 38.24 minutes) and objective
(mean = 24.47 minutes) SOL scores reduced for PI participants by Week Two. Control
subjects showed no discrepancy reduction (mean subjective SOL = 55.33 minutes, mean
objective SOL = 25.03 minutes). This suggests allocation to PI reduced participants’ tend-
ency to overestimate subjective SOL.
Pearson correlation coefﬁcients across all participants examined the association between
objective and subjective SOL, and objective and subjective sleep efﬁciency (baseline –
week 2). Correlations were ‘‘low’’ for SOL (r = 0.25), and ‘‘low’’ for sleep efﬁciency (r =
0.17).
The association between sleep effort, sleep performance anxiety and subjective sleep onset
latency
To explore whether reduced sleep effort or sleep anxiety best predicted reduced subjective
SOL, change scores for each variable (baseline – week 2) were computed and subjected to
Pearson correlational analyses. SOL change was signﬁcantly associated with sleep anxiety
change (SAS: r = 0.36, p =.035; SPAQ: r = 0.43, p = .01), and with effort change (r = 0.56,
p = .001). Comparing explained variance (SAS r 2 = 0.13; SPAQ r 2 = 0.18; Effort r 2 =
0.31), the association between SOL change and effort change is strongest.
Since baseline sleep anxiety was signiﬁcantly associated with sleep effort (SAS; r = 0.56,
p = .001), (SPAQ; r = 0.58, p = .0001), partial correlations were computed for PI participants
only to reveal the individual effect of effort change, and anxiety change (both scales), on
subjective SOL change. Effort change signiﬁcantly correlated with SOL change when sleep
anxiety was partialled out (SAS: rp = 0.48, p = .029; SPAQ: rp = 0.44, p = .045). In contrast,
when effort change was partialled out, neither measure of sleep anxiety was signiﬁcantly
associated with SOL change (SAS: rp = −0.2, p > .1, NS; SPAQ: rp = −0.1, p > .1, NS).
This suggests SOL reduction amongst PI participants was most strongly associated with
sleep effort reduction.
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Discussion
The present study has several limitations. The sample employed was non-treatment seeking,
and the study timescale was short, only 21 nights. The effect of PI in the longer term is
therefore unclear. The design lacked a credible but otherwise inert control treatment. So the
effect of non-speciﬁc factors on the ﬁndings is unknown. Sample size was small, which
underpowered the counterdemand-positive demand comparison, and the measure of sleep
effort employed was not validated prior to the study.
Relative to controls, PI participants showed reduced sleep effort, reduced sleep per-
formance anxiety and reduced SOL measured subjectively. SOL and anxiety change were
signiﬁcantly correlated, although SOL change amongst PI participants was most strongly
associated with sleep effort change. Together, therefore, ﬁndings support a mediational per-
formance anxiety model of PI. In other words, sleep effort and sleep anxiety are mechanisms
of change in PI (cf. Ascher & Turner, 1979), and inhibitory to normal sleep function (cf.
Espie, 2002).
Findings are also consistent with Wegner’s model of ironic mental control (Wegner,
1994). As noted, there was a strong association between reduced sleep effort and reduced
subjective SOL amongst PI participants. Thus, for insomniacs high in sleep anxiety, SOL
was reduced when attempts were made to stay awake. This raises the possibility that, under
high cognitive load (i.e. sleep performance anxiety), with the intentional operating system
undermined, PI caused the ironic monitoring process to detect restful cognitions, leading to
a perception of faster sleep onset (cf. Ansﬁeld, Wegner, & Bowser, 1996; Wegner, 1994).
As well as supporting current theoretical conceptualizations of PI, ﬁndings may have
important clinical implications. If, as the data suggest, PI institutes sleep improvement by
reducing sleep effort and sleep anxiety, the approach may prove particularly beneﬁcial to
insomniacs high in these variables at assessment. There is already some evidence of a link
between elevated performance anxiety and response to PI in the social anxiety literature
(Ascher & Schotte, 1999). Research should now clarify more closely the association between
pre-treatment sleep effort, sleep anxiety, and subsequent response to PI. Clinical assessment
of these constructs is certainly feasible, and if elevated sleep effort/anxiety does predict
outcome, this raises the prospect of routine screenings for stand-alone PI.
Turning to the sleep data, recognizing the lack of PI research employing objective meas-
ures, the present study obtained actigraphic and subjective sleep data. Contrary to hypo-
theses, no signiﬁcant objective SOL reduction or sleep efﬁciency increase was observed
amongst PI participants, relative to controls. The subjective sleep data did, however, indicate
a marginal trend for reduced SOL amongst PI participants, and the treatment effect size
was ‘‘moderate’’ (cf. Cohen, 1988). One interpretation of this may relate to actigraphic
measurement error. Although actigraphic measures of sleep duration and total wake time
correlate highly with Polysomnography (PSG) data (Mullaney et al., 1980; Sadeh et al.,
1995), lower agreement rates for SOL have been reported (Blood, Sack, Percy, & Pen, 1997;
Hauri & Wisbey, 1992). The accuracy of actigraphy in distinguishing sleep from wake-
fulness has also been questioned (Pollak, Tryon, Nagaraja, & Dzwonczyk, 2001; Verbeek,
Klip, & Declerck, 2001). Perhaps quiet wakefulness in the pre-sleep phase was coded acti-
graphically as ‘‘sleep’’, lowering objective SOL scores, relative to subjective values (see
Table 1), washing out any possible objective SOL effect.
Alternatively, it is possible PI shifted participants’ perceptions of their sleep deﬁcit.
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Lower objective relative to subjective SOL scores were observed amongst both participant
groups at baseline (see Table 1). Interestingly, this apparent overestimation of SOL was
only observed amongst controls at Week 2. This raises the intriguing possibility that PI
reduced participants’ tendency to overestimate subjective SOL relative to objective criterion.
Harvey (2002) has suggested that excessive sleep anxiety, and an attentional bias for sleep-
related threat triggered by this anxiety, causes insomniacs to overestimate their sleep deﬁcits.
Perhaps by lowering sleep anxiety, PI reduced participants’ tendency to overestimate time
to sleep (cf. Harvey, 2002). This alteration in perception may also have involved reduced
activation of metacognitive sleep beliefs (e.g. ‘‘thinking about sleep means I’m a poor
sleeper’’), as the less sleep anxious PI participants experienced fewer sleep-related intrusions
(Wells, 2001). Further research within an experimental cognitive framework will be needed
to determine whether the present ﬁndings are indeed due to a shift in PI participants’ estima-
tions of SOL or arose due to actigraphic insensitivity.
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1.0 INTRODUCTION 
INSOMNIA IS A PREVALENT COMPLAINT BOTH IN THE 
GENERAL POPULATION AND IN CLINICAL PRACTICE. IT 
MAY PRESENT AS THE PRIMARY COMPLAINT or in asso-
ciation with another physical or mental-health problem. Preva-
lence estimates indicate that about one third of the adult popula-
tion reports insomnia symptoms, 9%-12% experience additional 
daytime consequences, and approximately 6% meet formal crite-
ria for an insomnia diagnosis.1 Insomnia is more common among 
women, middle-aged and older adults, shift workers, and patients 
with medical or psychiatric disorders. Persistent insomnia can 
produce an important burden for the individual and for society, as 
evidenced by reduced quality of life, impaired daytime function-
ing and increased absenteeism at work, and higher health-care 
costs. Persistent insomnia is also associated with increased risks 
of depression and chronic use of hypnotics.2-5
 The diagnosis of insomnia is based on a subjective complaint 
of difficulties falling or staying asleep, or nonrestorative sleep, 
that is associated with marked distress or significant daytime im-
pairments.6,7 Several indicators are useful to quantify the severity 
and clinical significance of insomnia. These markers may include 
the intensity (e.g., time to fall asleep, duration of awakenings, 
total sleep time), frequency, and duration of sleep difficulties. In 
the case of duration, a distinction is made between adjustment 
insomnia, a condition lasting a few days or weeks and often asso-
ciated with stressful life events or changes in schedules and envi-
ronment, and persistent insomnia, a condition lasting more than 1 
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Background: Recognition that psychological and behavioral factors play 
an important role in insomnia has led to increased interest in therapies 
targeting these factors. A review paper published in 1999 summarized 
the evidence regarding the efﬁcacy of psychological and behavioral treat-
ments for persistent insomnia. The present review provides an update of 
the evidence published since the original paper. As with the original paper, 
this review was conducted by a task force commissioned by the American 
Academy of Sleep Medicine in order to update its practice parameters on 
psychological and behavioral therapies for insomnia.
Methods: A systematic review was conducted on 37 treatment studies (N 
= 2246 subjects/patients) published between 1998 and 2004 inclusively 
and identiﬁed through PsycInfo and Medline searches. Each study was 
systematically reviewed with a standard coding sheet and the following 
information was extracted: Study design, sample (number of participants, 
age, gender), diagnosis, type of treatments and controls, primary and sec-
ondary outcome measures, and main ﬁndings. Criteria for inclusion of a 
study were as follows: (a) the main sleep diagnosis was insomnia (primary 
or comorbid), (b) at least 1 treatment condition was psychological or be-
havioral in content, (c) the study design was a randomized controlled trial, 
a nonrandomized group design, a clinical case series or a single subject 
experimental design with a minimum of 10 subjects, and (d) the study 
included at least 1 of the following as dependent variables: sleep onset 
latency, number and/or duration of awakenings, total sleep time, sleep 
efﬁciency, or sleep quality.
Results: Psychological and behavioral therapies produced reliable chang-
es in several sleep parameters of individuals with either primary insomnia 
or insomnia associated with medical and psychiatric disorders. Nine stud-
ies documented the beneﬁts of insomnia treatment in older adults or for 
facilitating discontinuation of medication among chronic hypnotic users. 
Sleep improvements achieved with treatment were well sustained over 
time; however, with the exception of reduced psychological symptoms/
distress, there was limited evidence that improved sleep led to clinically 
meaningful changes in other indices of morbidity (e.g., daytime fatigue). 
Five treatments met criteria for empirically-supported psychological treat-
ments for insomnia: Stimulus control therapy, relaxation, paradoxical in-
tention, sleep restriction, and cognitive-behavior therapy. 
Discussion: These updated ﬁndings provide additional evidence in sup-
port of the original review’s conclusions as to the efﬁcacy and generaliz-
ability of psychological and behavioral therapies for persistent insomnia. 
Nonetheless, further research is needed to develop therapies that would 
optimize outcomes and reduce morbidity, as would studies of treatment 
mechanisms, mediators, and moderators of outcomes. Effectiveness 
studies are also needed to validate those therapies when implemented 
in clinical settings (primary care), by non-sleep specialists. There is also 
a need to disseminate more effectively the available evidence in support 
of psychological and behavioral interventions to health-care practitioners 
working on the front line.
Keywords: Insomnia, treatment, behavioral, psychological, non pharma-
cological
Citation: Morin CM; Bootzin RR; Buysse DJ et al. Psychological and 
behavioral treatment of insomnia: update of the recent evidence (1998-
2004). SLEEP 2006;29(11):1398-1414.
SLEEP, Vol. 29, No. 11, 2006 1399
month and often several years. Insomnia complaints are typically 
associated with reports of daytime fatigue, problems with memory 
and concentration, and mood disturbances, impairments that may 
be the primary concerns prompting patients to seek treatment. In-
somnia can be a symptom of several other conditions including 
medical, psychiatric, substance abuse or another sleep disorder; 
or, it can be a disorder in itself as in primary insomnia.6-8
 There are several treatment options available for insomnia, in-
cluding psychological/ behavioral approaches, various classes of 
medications, and a host of complementary and alternative thera-
pies (e.g., herbal/dietary supplement, acupuncture). The present 
paper focuses on psychological and behavioral approaches to 
treating insomnia. These procedures have received increasing re-
search attention in the past 2 decades, and were noted as effective 
therapies at a recent National Institutes of Health State-of-the-
Science Conference9on the manifestations and management of 
chronic insomnia. These methods include stimulus control ther-
apy, sleep restriction, relaxation-based interventions, paradoxical 
intention, cognitive therapy, and combined cognitive-behavioral 
therapy. A brief summary of the nature of these interventions is 
presented in Table 1; more extensive descriptions are available in 
other sources.10,11 
2.0 PURPOSE
 The objective of this paper is to provide an update of the evi-
dence regarding the efficacy, effectiveness, durability, and gen-
eralizability of psychological and behavioral interventions for 
persistent insomnia. The evidence is reviewed for the treatment 
of both primary insomnia and insomnia associated with other 
medical, psychiatric, or substance abuse disorders. As with the 
initial review paper12 this updated review was commissioned by 
the Standards of Practice Committee of the American Academy 
of Sleep Medicine. 
3.0 METHODS 
3.1 Search Methods, Keywords, and Databases 
 Treatment studies selected for review in this paper were iden-
tified through PsycInfo and Medline searches for research con-
ducted from 1998 through 2004 inclusively. The following key 
words were used: nonpharmacologic, behavior therapy, cognitive 
therapy, psychotherapy, alternative medicine, stimulus control, 
progressive relaxation therapy or progressive muscle relaxation, 
paradoxical techniques or paradoxical intention, behavior modi-
fication, cognitive behavior therapy, psychological therapy, treat-
ment, intervention, behavioral intervention, treatment, cognitive 
treatment, alternative treatment, therapy, biofeedback, sleep re-
striction, sleep deprivation, complementary therapies, mind-body 
and relaxation techniques, aromatherapy, biofeedback, hypnosis, 
imagery, or meditation, relaxation, relaxation techniques, yoga, 
massage. These terms were combined with sleep disorders or 
sleep initiation and maintenance disorders, or insomnia, or dys-
somnia. The search was limited to humans, adults (18 and older), 
English or French language.
3.2 Selection Criteria of Treatment Studies
 The initial PsycInfo and Medline searches yielded a total of 
312 titles of potential interest; an additional 34 titles were identi-
fied by members of the task force through their own reading of 
the literature, for a total of 346 titles of potential interest. Of these, 
102 abstracts were read by the task force chair for initial screen-
ing and 53 articles were selected for full review by 2 independent 
members of the task force. Only peer-reviewed published articles 
were retained at this phase. Each rater used a standard extraction 
sheet to summarize information about the study including ex-
perimental design, sample (number of participants, age, gender), 
diagnosis, type of treatments and controls, primary and second-
ary outcome measures, and main findings. Data extraction was 
completed independently and discrepancies between 2 members 
of a pair of raters were resolved through discussion with the chair 
and other members of the task force. The criteria for inclusion of 
a study were: (a) the main sleep diagnosis was insomnia (primary 
or comorbid), (b) at least 1 treatment condition was psychological 
or behavioral in content, (c) the study design was a randomized 
controlled trial, a nonrandomized group design, a clinical case 
series or a single subject experimental design with a minimum of 
10 subjects, (d) the dependent measure included 1 or more of the 
following variables (as measured by daily sleep diaries, polysom-
nography (PSG), or actigraphy): Sleep onset latency (SOL), num-
ber of awakenings (NA), time awake after sleep onset (WASO), 
total sleep time (TST), sleep efficiency (SE), or sleep quality 
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Table 1—Psychological and Behavioral Treatments for Insomnia
Therapy Description
Stimulus  A set of instructions designed to reassociate the bed/
control bedroom with sleep and to re-establish a consistent 
therapy sleep-wake schedule: (1) Go to bed only when sleepy; 
(2) get out of bed when unable to sleep; (3) use the 
bed/bedroom for sleep only (no reading, watching TV, 
etc); (4) arise at the same time every morning; (5) no 
napping.
Sleep  A method designed to curtail time in bed to the 
restriction actual amount of sleep time. For example, if a patient
therapy reports sleeping an average of 6 hours per night, out 
of 8 hours spend in bed, the initial recommended sleep 
window (from lights out to ﬁnal arising time) would be 
restricted to 6 hours. Periodic adjustments to this sleep 
window are made contingent upon sleep efﬁciency, 
until an optimal sleep duration is reached. 
Relaxation  Clinical procedures aimed at reducing somatic 
training tension (e.g., progressive muscle relaxation, autogenic 
training) or intrusive thoughts at bedtime (e.g., imag-
ery training, meditation) interfering with sleep. 
Cognitive  Psychological methods aimed at challenging and
therapy changing misconceptions about sleep and faulty be-
liefs about insomnia and its perceived daytime con-
sequences. Other cognitive procedures may include 
paradoxical intention or methods aimed at reducing 
or preventing excessive monitoring of and worrying 
about insomnia and its correlates/consequences.
Sleep hygiene  General guidelines about health practices (e.g., diet, 
education exercise, substance use) and environmental factors 
(e.g., light, noise, temperature) that may promote or 
interfere with sleep. This may also include some basic 
information about normal sleep and changes in sleep 
patterns with aging. 
Cognitive- A combination of any of the above behavioral (e.g., 
behavior  stimulus control, sleep restriction, relaxation) and 
therapy cognitive procedures.
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(SQ). Studies using global measures of treatment outcome were 
included if those measures had been validated. Studies of circa-
dian disorders (e.g., phase delay or phase advance syndromes) 
and those using other nonpharmacological therapies (e.g., light 
therapy, electro-sleep therapy) or complementary and alternative 
therapies (e.g., acupuncture) were excluded from this review.
 The majority of the initial 346 titles of potential interest were 
excluded either because they were not treatment studies for in-
somnia or because the main intervention was pharmacological. Of 
the 53 full articles reviewed and rated, 16 were rejected. The main 
reasons for article rejection were: no documentation of an insom-
nia diagnosis, sample size smaller than 10, results were secondary 
analyses of other databases (e.g., predictors of treatment response) 
and used global and non-validated measures of outcome. A list 
of excluded studies with reasons for exclusion is provided in an, 
Appendix A. The 37 studies that met inclusion criteria are listed 
in Table 2. For each study, we report the study design and the 
evidence level (using the Sackett System, 1993), the sample size 
(enrolled/completed), age, gender, insomnia diagnosis (primary 
or secondary), types of treatment and control conditions, therapy 
dosage, format, setting, therapist training, treatment duration and 
longest follow-up, primary and secondary outcome measures, and 
summary of main findings. Although some studies not meeting 
inclusion criteria are discussed in the text they are not included in 
the evidence table. Based on the Sackett sytem,13 the criteria for 
grading evidence level of each study were: Randomized well-de-
signed trials with low alpha and beta error (Grade I), randomized 
trials with high alpha and beta error (Grade II), nonrandomized 
concurrently controlled studies (Grade III), nonrandomized his-
torically controlled studies (Grade IV), case series (Grade V).
4.0 RESULTS 
4.1 Descriptive Features of the Studies and Samples 
 Table 2 summarizes the main features of the 37 studies select-
ed for this review paper. The number of studies meeting Sackett 
System standards for grading evidence levels13 was as follows: 
11 studies were graded I, 13 studies graded II, 2 studies graded 
III, 5 studies graded IV, and 6 studies graded V. A total of 2246 
patients with insomnia were enrolled in the 37 studies and ap-
proximately 2029 of those completed treatment, for an attrition 
rate of less than 10% overall. With a few exceptions (studies of 
Veterans, substance abusers, internet-based treatment), there was 
a larger representation of women than men enrolled in most stud-
ies, with a typical ratio of 2:1, which is representative of insomnia 
prevalence estimates.1 Nine of the 37 studies focused specifically 
on older adults (average age > 60 years old). 
 The main sleep diagnoses of patients enrolled in the studies 
were primary or psychophysiological insomnia (28 studies), in-
somnia associated with medical (4 studies) or psychiatric disor-
ders (3 studies) or a mix of both conditions (6 studies), and hyp-
notic-dependent insomnia (5 studies). Eight studies examined 
treatment efficacy in patients with different subgroups of insom-
nia diagnoses, leading to a total number of studies greater than 37 
studies. 
 The majority of reviewed studies (n = 33) relied on prospective 
daily sleep diaries to document treatment outcome. Participants 
were typically required to complete a daily diary for a minimum 
of a 1 or 2 week baseline period, for the duration of treatment, 
and for an additional 1 or 2 week period at post treatment and fol-
low-ups. We retained 3 studies using the Pittsburgh Sleep Qual-
ity Index (PSQI) as the primary outcome.14-16 A few studies have 
also included polysomnography (n = 7)17-23and actigraphy (n = 
6)18,19,24-27 to complement subjective reports from daily sleep dia-
ries. Those studies are identified in Table 2 and in the appropriate 
subsections of the results. Primary dependent variables derived 
from these assessment methods were sleep onset latency (SOL), 
wake time after sleep onset (WASO), total sleep time (TST), sleep 
efficiency (SE), and sleep quality (SQ). Secondary outcomes in-
cluded measures of insomnia severity (Insomnia Severity Index; 
ISI,28 sleep quality (PSQI),29 psychological symptoms (Beck De-
pression Inventory, BDI,30 State-Trait Anxiety Inventory STAI31, 
and fatigue (Multidimensional Fatigue Inventory, MFI32). 
 The following sections summarize the evidence regarding the 
efficacy of treatment for primary insomnia, the generalizability 
of the evidence to different forms of insomnia (primary, second-
ary, hypnotic-dependent), insomnia in older adults, and the clini-
cal significance and durability of sleep improvements over time. 
Comparative findings of single and multifaceted therapies and of 
different treatment implementation models are also summarized.
4.2 Treatment of Primary Insomnia
 Seventeen studies evaluated the effects of treatment for prima-
ry insomnia (see Table 2). Five of those studies were randomized 
clinical trials (RCT; with grade I,17,20,21,33,34 4 of which used CBT 
as the main intervention. In a comparative study of CBT (without 
relaxation), relaxation, and a psychological placebo (i.e., quasi-
desensitization) with a sample of 75 primary insomniacs,17 CBT 
produced greater improvements on the main diary and PSG-de-
fined sleep measures (e.g., SE, WASO) relative to relaxation and 
control. More CBT patients (64%) achieved clinically significant 
outcomes compared to relaxation (12%) and placebo (8%). In an 
effectiveness trial33 conducted in primary care that evaluated CBT 
against a wait-list control group, active treatment was found supe-
rior to the control condition on most primary and secondary out-
come measures. SOL was reduced from 61 to 28 min following 
active treatment compared to a change from 74 to 70 min for the 
control condition.a Smaller improvements were noted on WASO. 
There was no significant change on TST during treatment, but 
an increase of about one-half hour over baseline was obtained 
at follow up. Of those patients using hypnotic medications at 
baseline, 76% were medication-free at the end of treatment and 
80% at the 12-month follow up. In a comparative study21 of CBT, 
medication (temazepam), and combined CBT plus medication, 
all 3 active treatments improved more than pill placebo on the 
main outcomes of WASO and SE, with a trend for the combined 
intervention to yield the greatest benefits. PSG data produced 
similar outcomes, although of smaller magnitude, but only the 
combined condition was significantly superior to placebo on the 
main outcome variables. According to PSG, more patients in the 
CBT (56%) and combined (68%) conditions achieved clinically 
significant changes (i.e., SE > 85%) relative to medication alone 
(47%) or placebo groups (22%). In another clinical trial of pri-
mary insomnia in older adults,20 sleep restriction and relaxation 
were more effective than placebo on sleep diary variables but not 
on PSG measures. Sleep restriction produced the best outcome 
aUnless otherwise stated, reported outcomes are based on daily sleep diaries. 
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on sleep efficiency but there was no evidence of improvements 
on secondary measures of daytime functioning. In a study that 
focused specifically on sleep onset insomnia,34 CBT (with relax-
ation) decreased SOL by a mean of 34 min with a correspond-
ing 14% increase of SE. Sleep improvements, which had limited 
impact on secondary mood measures, were well maintained at 
follow up. Several additional studies, including both controlled 
and uncontrolled studies, have documented treatment efficacy for 
insomnia in the context of primary care settings,14,35,36 in compari-
sons of different interventions23,37 or treatment implementation 
models,38,39 or as part of case series.40,41 Some of these studies will 
be discussed in later sections of this paper. 
4.3 Treatment of Insomnia Associated with other Medical or 
Psychiatric Disorders
 Twelve investigations have evaluated the efficacy of psycho-
logical and behavioral treatments for insomnia associated with an-
other medical or psychiatric disorder. These studies have focused, 
for example, on patients with chronic pain,25 cancer,16,42 alcohol 
dependence 26and older adults with various medical illnesses.27,43 
Only 4 of those 12 studies were RCT (Grade I or II)25-27,43 and 
the remaining were nonrandomized studies or clinical replication 
series.
 In a study of 60 patients with insomnia associated with chronic 
pain,25 CBT was significantly more effective than control on mea-
sures of SOL, WASO, and SE, but not on number of awakenings 
and TST. SOL was reduced from 55 min to 28 min and SE in-
creased from 72% to 85%. Nocturnal motor activity (as measured 
by actigraphy) was reduced in the treated group but not in the 
control group; there were no group differences on pain ratings, 
depressive symptoms, or medication use. In a study of 51 older 
adults with insomnia associated with medical illness,27 CBT and 
relaxation conditions were more effective than control on diary 
measures of WASO and SE, as well as on a measure of overall 
sleep quality (PSQI); the relaxation group had a greater increase 
in TST than CBT and controls. A higher proportion of treated pa-
tients relative to controls achieved clinically significant improve-
ments. There were no differential group effects on actigraphy, 
medication use, or other secondary measures of anxiety, depres-
sion, and quality of life. In a study of 49 older adults with insom-
nia associated with medical and psychiatric conditions,43a com-
bined intervention of stimulus control, relaxation, and education 
reduced WASO 25 min and increased SE 11% at post treatment. 
Fifty-seven percent (57%) of treated patients achieved clinically 
significant improvements on SE relative to 19% of control pa-
tients; there was no significant change on secondary measures 
of anxiety, depression, and impact of insomnia. Outcomes were 
similar for individuals with insomnia associated with a medical 
condition and those with insomnia related to a psychiatric dis-
order. A controlled study conducted with recovered alcoholics26 
showed modest but significant improvements of SOL (- 18 min) 
and SE (+10%) among insomnia-treated patients. At the 6 month 
follow-up, 15% of treated participants had relapses with alcohol 
and this proportion was not different between treated and control 
patients.
 Several additional studies (clinical replication series or uncon-
trolled group studies) have also provided evidence showing that 
patients with medical and psychiatric disorders could also benefit 
from sleep/insomnia specific interventions. Two investigations 
with cancer patients16,42 showed that CBT was associated with 
improvements of sleep and of daytime functioning (e.g., fatigue, 
energy). One case series study of 67 patients with psychiatric 
disorders and insomnia44 reported significant improvements of 
sleep, mood, fatigue, and reduced use of sleep medication, while 
a smaller study45 found no change on specific sleep parameters 
(SOL and WASO) but reported significant reductions of global 
insomnia severity as measured by the ISI. Additional evidence 
supporting the efficacy of CBT was reported in 3 clinical replica-
tions series 46-48 conducted with heterogeneous samples of patients 
presenting to sleep disorders clinics with a variety of primary 
and secondary insomnia diagnoses. Although conclusions drawn 
from these uncontrolled studies should be treated with caution 
because of the studies’ high attrition rate, the evidence suggests 
that among those who received an adequate treatment exposure 
(average of 6 - 8 therapy sessions) outcomes were comparable 
to those patients with primary insomnia enrolled in controlled 
clinical trials. Furthermore, treatment response appeared compa-
rable between patients with medical or psychiatric comorbidity 
and those with primary insomnia in one study. Baseline anxiety, 
depression, and insomnia severity did not differ among treatment 
responders and nonresponders.48 
4.4 Treatment of Insomnia in Older Adults
 Nearly 25% (9 studies out of 37) of reviewed studies were con-
ducted with older adults (average age > 60 years old). This is in 
sharp contrast to our previous review 12 that included only a hand-
ful of studies with older subjects. Three studies focused on older 
adults with primary insomnia,18,20,21 2 on insomnia associated with 
medical or psychiatric illnesses,27,43 1 included a mix of patients 
with primary and comorbid insomnia,49 2 evaluated the impact of 
psychological and behavioral interventions specifically in older 
adults who were chronic users of hypnotic medications,15,22 and 1 
study19 examined the moderating role of upper airway resistance 
syndrome in the treatment of postmenopausal insomnia. With the 
exception of the study conducted by Pallesen et al,49 all these in-
vestigations were RCT.
 In a study of 89 older adults with primary insomnia,20 sleep 
restriction and relaxation were both more effective than a psy-
chological placebo for reducing WASO; changes were identical 
(67 min to 43 min) for the 2 treatment groups at the end of the 
6-week treatment phase, but sleep restriction produced the best 
outcome at the 1-year follow up. No significant changes were 
obtained on PSG measures. All 3 conditions, including placebo 
control, showed improvements on secondary measures of fatigue 
and a measure of insomnia impact. In another placebo-controlled 
study,21 76 older adults treated with CBT, medication (temaze-
pam), or combined CBT + medication improved more than those 
receiving placebo on the main outcome measures of WASO and 
SE. PSG comparisons yielded improvements in the same direc-
tion, albeit of smaller magnitude, than those reported on sleep 
diaries. A greater proportion of patients treated with CBT, alone 
or combined with medication, achieved clinically significant im-
provements (i.e., SE > 85%) compared to those receiving medica-
tion alone or placebo. 
 In a comparison of sleep restriction, with and without an op-
tional daytime nap, to sleep education alone,18 both sleep restric-
tion conditions produced greater SE increase, with reduced time 
spent in bed, relative to the control condition. There was no sig-
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nificant group difference on actigraphy or PSG measures; TST 
was reduced for the sleep restriction conditions at post treatment 
and returned towards baseline values at the 3-month follow-up. 
There was a mild increase of physiological sleepiness (as mea-
sured by the MSLT) but no change on subjective sleepiness. In an-
other investigation,49 a combination of sleep education plus stimu-
lus control was as effective as sleep education plus relaxation, and 
more effective than a wait-list control, in older adults with mixed 
primary and secondary insomnia; there were modest improve-
ments of daytime measures for both active conditions. Two ad-
ditional studies (reviewed in section 4.3) provided evidence that 
older adults with insomnia and comorbid medical disorders also 
benefitted from sleep-specific interventions.20,27 
4.5 Treatment of Insomnia Among Chronic Hypnotic Users 
 Four investigations examined the efficacy of psychologi-
cal and behavioral interventions for insomnia in the context of 
chronic hypnotic usage, including 2 that were conducted with 
older adults.15,22 In a study of 209 chronic hypnotic users,15 CBT 
(with an optional medication taper) was associated with improved 
PSQI scores and reductions of hypnotic use at 3- and 6-month 
follow ups. A greater percentage of patients treated with CBT for 
insomnia (39%) relative to no treatment controls (11%) achieved 
at least a 50% reduction of hypnotic use relative to baseline at 
the 6-month follow up. A cost-offset analysis revealed that while 
CBT added to the initial treatment cost, there was a significant 
cost offset at follow up resulting from a reduction of sleep medi-
cation usage. In another study comparing a supervised medication 
withdrawal program, alone and combined with CBT for insomnia, 
to CBT alone,22 all 3 interventions produced significant reductions 
in both the quantity (90%) and the frequency (80%) of benzodi-
azepine use, and more patients in the combined approach (85%) 
were medication free at post-treatment than for those receiving 
the taper schedule alone (48%) or CBT alone (54%). There were 
modest changes in sleep patterns during the initial 10-week with-
drawal phase, but CBT-treated patients reported greater sleep im-
provements relative to those receiving the medication withdrawal 
alone. Several improvements were also reported on secondary 
measures of insomnia severity (ISI), anxiety (BAI) and depres-
sive (BDI) symptoms. 
 Two additional studies have examined the impact of chronic 
hypnotic use on outcome with middle-aged adults. One study50 
found a significant worsening of sleep parameters during medi-
cation withdrawal and the addition of relaxation therapy did not 
attenuate this effect. In a similar study using stimulus control as 
the main behavioral intervention,51 stimulus control produced sig-
nificant improvements on most sleep parameters relative to no 
additional treatment. There was no difference in sleep outcomes 
between medicated and nonmedicated patients. 
4.6 Validation and Comparative Efficacy of Single and Multifaceted 
Therapies 
 Although there are several distinct psychological and behav-
ioral therapies for insomnia, there was a clear trend/preference 
for investigators to combine 2 or more of these methods when 
treating insomnia. The most common combination involves an 
educational (sleep hygiene), behavioral (stimulus control, sleep 
restriction, relaxation), and a cognitive therapy component, usu-
ally referred to as cognitive-behavior therapy. Indeed, 21 stud-
ies have evaluated the efficacy of CBT, either with (12 studies) 
or without relaxation (9 studies), and 5 more studies have used 
a similar multi-component interventions but without cognitive 
therapy (see Table 2).
 There has been no complete dismantling of CBT to isolate the 
relative efficacy of each component within the same study. How-
ever, comparisons of some components revealed that CBT was 
superior to relaxation alone in 1 study of primary insomnia17 and 
sleep restriction was superior to relaxation at follow-up in another 
study with older adults.20 In another study,52 relaxation was more 
effective for sleep initiation problems relative to sleep hygiene 
education alone and a combination of stimulus control plus sleep 
restriction, whereas the latter combination had greater effects on 
sleep maintenance variables. 
 Twelve studies have isolated in a controlled trial at least 1 
therapy component such as relaxation, sleep restriction, stimulus 
control, or paradoxical intention. All 6 studies contrasting relax-
ation-based interventions (either progressive muscle relaxation or 
similar procedures) to a control condition, have reported that this 
single therapy was more effective than wait-list,27 placebo,17,20 
no treatment,37,50 and minimal sleep hygiene education control.52 
Two studies showed that sleep restriction was superior to either 
placebo20 or sleep hygiene education alone,18 1 study found that 
stimulus control was more effective than a wait-list control,51 and 
1 additional investigation reported that paradoxical intention was 
superior to a wait-list control for sleep onset insomnia.24 In spite 
of the inclusion of a cognitive therapy component in numerous 
studies, no study has yet evaluated its unique contribution to out-
comes.
 As in the earlier review paper,12 criteria developed by the 
American Psychological Association53 for defining empirical-
ly-validated psychological treatments, were used to determine 
whether additional evidence was available for each psychological 
and behavioral interventions (See Table 3). Based on the criteria 
outlined in our previous review,12 stimulus control therapy, re-
laxation training, and paradoxical intention met criteria for well-
established psychological treatment for insomnia. With the ad-
ditional evidence from the present review (indicated by studies 
in boldface in Table 3), sleep restriction18,20 and CBT17,21 would 
also meet criteria for well-established treatments. Furthermore, 
additional studies strengthened the level of evidence supporting 
stimulus control,51 relaxation,17,20,27,37 and paradoxical intention.24
4.7 Comparisons of Psychological/Behavioral Therapies and 
Medication 
 Five controlled studies conducted with primary/psychophysi-
ological insomnia patients have evaluated the impact of psycho-
logical/behavioral interventions in comparison to or as an adjunct 
to hypnotic medications. Two studies evaluated the efficacy of 
CBT, singly and combined with medication,21,34 1 used a medi-
cation alone condition as a comparator to psychological treat-
ments,52 and 2 examined the incremental benefits of adding 1 
treatment to the other.54,55
 In a placebo-controlled comparison of CBT and medication (te-
mazepam) singly and combined21 (study described in Sections 4.2 
and 4.4), all 3 active treatments were more effective than placebo 
on sleep continuity variables, with a trend for the combined ap-
proach to yield better outcomes. These results were corroborated 
with PSG measures, although the magnitudes of sleep improve-
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ments were smaller on PSG than on diary measures. Long-term 
follow-up data showed that subjects treated with CBT sustained 
their clinical gains over time, whereas those treated with medica-
tion alone did not. The combined approach showed some loss of 
therapeutic benefits over the follow-up periods, although there 
was more variability across subjects in that condition. In a similar 
study design with 63 young and middle-aged adults with sleep 
onset insomnia34 (study described in Section 4.2), CBT was 
shown more effective than medication (zolpidem) and placebo 
on measures of SOL and SE. All 4 conditions, including placebo, 
increased their TST, with medication yielding the largest increase 
in TST (69 min), though this finding was not significantly differ-
ent from the other groups. There was no significant difference 
between CBT alone and CBT combined with medication. Sleep 
changes were well maintained at the 12-month follow up for pa-
tients treated with CBT, singly or combined with medication, but 
no follow up data was available for those treated with medica-
tion alone. Data obtained from a Nightcap device showed sleep 
changes in the same direction as those from diaries, except that 
no improvement was obtained on any of the measures for the pla-
cebo condition.
 An investigation of 41 patients treated with estazolam exam-
ined the added benefits of muscle relaxation, imagery training, 
and sleep hygiene education to medication.55 There was no group 
difference on any outcome. Significant improvements from base-
line to post treatment were obtained on WASO and SE for the 
relaxation (-17 min and + 9.7% respectively) and imagery train-
ing groups (- 33 min and + 7.4%). TST was increased by 34 min 
(education), 40 min (imagery), and 65 min (muscle relaxation) 
for the same period but there was no significant group difference. 
SOL was not changed in any of the groups. Significant changes 
were obtained from baseline to follow up in all 3 groups on sleep 
measures and on secondary measures of arousal, self-efficacy, 
and depressive (but not anxiety) symptoms.
 Another study of 30 patients54 examined the added benefits 
of modafinil when combined with CBT in the management of 
primary insomnia. Although there was no significant gain from 
modafinil in terms of sleep continuity parameters, there were 
trends suggesting that the addition of modafinil to CBT reduced 
daytime sleepiness and enhanced compliance with prescribed 
bedtime. Finally, data from 53 patients with primary insomnia52 
showed that while relaxation was more effective for sleep on-
set problems and a combination of stimulus control plus sleep 
restriction had more benefits for sleep maintenance variables, 
medication (flurazepam) produced the largest improvements on 
all sleep variables during the initial 2-week intervention. 
4.8 Treatment Implementation Methods: Individual, Group, and 
Self-Help 
 Treatment was implemented on an individual basis in 22 stud-
ies (54%), in a group format in 11 studies (29.7%), and a few 
additional studies relied on self-help materials with or without ad-
ditional telephone consultations. An average of 5.7 consultation 
visits was conducted over a mean treatment period of 6.5 weeks. 
1 study directly compared the relative efficacy of CBT imple-
mented in group or individual sessions, or through self-help writ-
ten materials combined with brief telephone consultations.56 All 3 
groups produced significant improvements of sleep and second-
ary measures and there was no between group difference on any 
Table 3—Key Studies Supporting Efﬁcacy Of Psychological And  
Behavioral Treatments Of Insomnia
Treatment Study reference Evidence
Stimulus control* Espie et al. (1989)69 SC > Pla & Rel
 Lacks et al. (1983)70 SC > Pla
 Lacks et al. (1983)71 SC > Pla
 Morin & Azrin (1987;1988)72,73 SC > IT
 Turner & Asher (1979)74 SC > Pla
 Riedel et al. (1998)51 SC > WL
Relaxation* Edinger et al. (2001)17a Rel > Pla 
 Lichstein et al. ((2001)20b Rel > Pla
 Lick & Hefﬂer (1977)75 Rel > Pla
 Nicassio et al. (1982)76 Rel > No treatment
 Turner & Asher (1979)74 Rel > Pla
 Woolfolk & McNulty (1983)77 Rel > WL
 Means et al. (2000)37 Rel > No treatment
 Rybarczyk et al. (2002)27c Rel > WL 
Paradoxical  Espie et al. (1989)69 PI > Pla 
Intention* Turner & Ascher (1979)74 PI > Pla
 Broomﬁeld et al. (2003)24 PI > WL
Sleep restriction* Friedman et al. (1991)78 SR > Pla
 Friedman et al. (2000)18 SR + SHE > SHE
 Lichstein et al. (2001)20 b SR > Pla 
EMG  Nicassio et al. (1982)76 BF > No treatment
biofeedback† Sanavio et al. (1990)79 BF > WL
 VanderPlate & Eno (1983)80 BF > WL
 Freedman & Papsdorf (1976)81 BF > Pla
CBT* Edinger et al. (2001)17a CBT > Rel > Pla
 Mimeault & Morin (1999)38 CBT > WL
 Morin et al. (1993)82 CBT > WL
 Morin et al. (1999)21 CBT > Pla
 Morin et al. (2004)22 CBT > Medication taper 
 Perlis et al. (2004)54 CBT > Contact control
CBT (with Rel)* Currie et al. (2000)25 CBT > WL
 Currie et al. (2004)26 CBT > WL
 Espie et al. (2001)33 CBT > WL
 Jacobs et al. (2004)34 CBT > Pla 
 Morgan et al. (2003)15 CBT > No treatment 
 Rybarczyk et al. (2002)27c CBT > WL 
Multi- Edinger & Sampson (2003)35 MC > SHE
component† Lichstein et al. (2000)43 MC > WL 
 Waters et al. (2003)52 MC > SHE
 
Note: Citations in boldface are for studies published between 1998 
and 2004; all other studies were published prior to this period. 
BF = EMG Biofeedback; CBT = Cognitive Behavior Therapy; IT = 
Imagery Training; PI = Paradoxical Intention; Pla = Placebo; Rel = Re-
laxation; SC = Stimulus Control; SR = Sleep Restriction; SHE = Sleep 
Hygiene Education; WL = Wait-List Control; MC=Multicomponent.
a,b,cThese studies provided evidence supporting more than 1 treat-
ment. 
*Well established treatments according to APA criteria for empirically 
supported treatments. Criteria for well-established treatments require 
at least 2 between-group design studies demonstrating efﬁcacy in 1 or 
more of the following ways: I. superior to pill or psychological pla-
cebo or to another treatment; or equivalent to an already established 
treatment in a study with adequate statistical power; II. a large series 
of single case design experiments (n > 9) demonstrating efﬁcacy as in 
I; III. the studies must be conducted with treatment manuals; IV. the 
characteristics of the sample must be well-described; V. the effects 
must have been demonstrated by at least 2 different investigators or 
investigatory teams. 
†Probably efﬁcacious treatments according to APA criteria for em-
pirically supported treatments. Criteria for probably efﬁcacious treat-
ments are: I. 2 studies showing the treatment is more effective than a 
waiting-list control group, or II. 1 or more studies meeting the well-
established treatment criteria I, III, and IV, but not V, or III. a small 
series of single case design studies (n > 3) otherwise meeting well-
established treatment criteria II, III, and IV.
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measure. A similar study of insomnia in recovered alcoholics also 
found equivalent outcome between individual CBT and self-help 
CBT plus telephone consultation.26 In contrast, 1 study38 found 
that the addition of telephone consultation to self-help written ma-
terial enhanced outcomes at post treatment, but those initial gains 
tended to disappear at follow up. An internet-based intervention 
produced greater improvement in several sleep parameters rela-
tive to controls,39 but the attrition rate (24%) was higher than in 
studies using face-to-face consultation visits. While the major-
ity of reviewed studies have used psychologists or psychology 
trainees as therapist (with treatment manual), 2 studies examined 
treatment efficacy as implemented by primary care physicians36 or 
by nurse practitioners33 who had also been trained before the stud-
ies; treatment benefits were generally equivalent to those obtained 
with therapists who had mental-health training. 
4.9 Durability of Sleep Improvements
 Twenty-six of the 37 reviewed studies reported follow up data 
of at least 1 month duration after completing treatment (mean 
duration = 7.7 months; range 1-36 months). The remaining 11 
studies reported no follow-up data. As was the case in the ini-
tial review, a very robust finding across studies is that treatment-
produced changes in sleep parameters are well maintained at 
short (1-3 month), intermediate (6-month), and long-term (> 12 
months) follow-ups. One interesting finding from studies using 
sleep restriction is that total sleep time may be reduced during 
the initial intervention, but it is significantly increased at follow 
up evaluation.20 Despite fairly robust long-term outcomes, fol-
low-up data must be interpreted cautiously as there are relatively 
few studies reporting long-term (> 1 year) follow-ups (see Table 
2) and, among those that do, attrition rates increase substantially 
over time. 
5.0 CONCLUSIONS
 This updated review of treatment studies conducted between 
1998 and 2004 provides additional evidence that psychological 
and behavioral interventions represent an effective treatment op-
tion for the management of persistent insomnia. In addition to 
studies further documenting treatment efficacy for primary in-
somnia, recent studies indicate that treatment is also effective for 
insomnia associated with some medical conditions and, to a lesser 
extent, with psychiatric conditions. Treatment benefits are well 
sustained over time. There is still limited evidence of clinically 
meaningful changes beyond reductions of insomnia symptoms 
(i.e., improved daytime functioning, quality of life). 
 These findings are consistent with our previous systematic 
review12 as well as with other meta-analyses of the efficacy of 
psychological and behavioral interventions for insomnia.57-59 For 
instance, of the 17 most recent treatment studies of primary in-
somnia, 5 were randomized controlled trials,17,20,21,33,34 and all 5 
yielded additional evidence of significant sleep improvements 
with psychological and behavioral interventions. Although most 
of this additional evidence is based on daily sleep diaries, 3 of the 
5 key studies included PSG measures and 2 of them reported out-
comes that paralleled findings from diary measures. Actigraphy, 
on the other hand, was not very sensitive for detecting changes in 
sleep/wake variables in the few studies using this device.
 The treatment of comorbid insomnia has received limited at-
tention until recently, perhaps owing to the traditional notion that 
it would not respond to treatment unless the associated condition 
was treated first. The present review, as well as recent findings,60-
62 challenge this traditional notion and indicate that insomnia-spe-
cific treatment is of benefit even among those whose insomnia is 
associated with comorbid conditions such as cancer, pain, alcohol 
abuse, and some psychiatric conditions. Nonetheless, there is a 
need for additional prospective and randomized controlled stud-
ies of comorbid insomnia contrasting outcomes when sleep is or 
is not directly targeted in treatment. 
 The treatment of insomnia in older adults is another area previ-
ously neglected and for which there was limited evidence to guide 
practitioners. Nearly 25% of the studies reviewed in this paper 
focused on older adults. The findings from those studies indicate 
that older adults with primary insomnia respond to treatment as 
well as younger and middle-aged adults, although the presence 
of comorbid medical or psychiatric condition may moderate out-
comes.27,43 A recent meta-analysis 63also confirmed that treatment 
effect sizes are comparable for middle-aged and older adults. 
There is additional evidence that psychological treatment can fa-
cilitate hypnotic discontinuation in older adults who are chronic 
users of hypnotics.15,22 This is an important finding as older adults 
are more likely to be long-term hypnotic users which, in some 
cases, may perpetuate sleep disturbances. Thus, although hetero-
geneity in diagnosis makes it more difficult to compare studies,64 
such heterogeneity of insomnia samples also enhances generaliz-
ability of outcomes.
 This review highlights an emerging trend among investiga-
tors for combining multiple treatments, which contrasts with the 
earlier review describing numerous studies comparing treatment 
efficacy among 2 or more single therapies. Indeed, 26 of the 37 
reviewed studies evaluated the efficacy a multi component ap-
proaches, including 21 studies using multicomponent therapy, 
with or without relaxation, and 5 more combining behavioral in-
terventions (e.g., stimulus control and sleep restriction) but with-
out cognitive therapy. Although the reason for this shift in para-
digm is not entirely clear, the use of multi-component approaches 
is more likely, at least on a clinical basis, to address the different 
facets/perpetuating factors of insomnia.11 
 Whether CBT produces outcome that is superior to single ther-
apies remains largely unexplored. The few comparative studies 
available show that outcome is superior for CBT, stimulus control, 
and for sleep restriction relative to relaxation alone,17,20,27,49 how-
ever, there has been no complete dismantling of CBT to isolate 
the relative efficacy of each component. Furthermore, although 
some findings65 suggest that change in beliefs and attitudes is an 
important mediator of long-term outcomes, there has been no di-
rect controlled evaluation to isolate the relative contribution of 
cognitive therapy.
 Our previous review had identified 3 treatments as well-vali-
dated and 2 more as probably efficacious according to criteria 
set by the American Psychological Association.53 This updated 
review provides further evidence supporting stimulus control, 
relaxation, paradoxical intention as well validated therapies, and 
new evidence to upgrade sleep restriction and CBT from prob-
ably efficacious to well-established treatments.
 Although there is evidence supporting the efficacy of psycho-
logical and behavioral treatment for insomnia, there is still little 
information about the specificity of this treatment modality and 
the active therapeutic mechanisms responsible for sleep improve-
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ments. With a few notable exceptions using attention-placebo 
conditions,17,20 most CBT trials have used wait-list control groups, 
precluding the unequivocal attribution of treatment effects to any 
specific ingredient of psychological and behavioral treatment. 
The lack of a pill-placebo control equivalent in psychological out-
come research makes it difficult to determine what percentage of 
the variance in outcomes is due to specific therapeutic ingredients 
(i.e., restriction of time in bed, cognitive restructuring), the mea-
surement process (i.e., self-monitoring), or to non-specific factors 
(e.g., therapist attention, patients’ expectations). 
 An important limitation noted in the previous review that is still 
evident in recent studies is the limited evidence documenting the 
clinical significance of outcomes beyond insomnia symptom re-
ductions (i.e., reduced morbidity, improved quality of life). There 
is a need for broadening the scope of outcome measures66 and for 
standardizing assessment methodology in insomnia research,64,67 
Furthermore, even for patients meeting criteria for what might be 
considered a clinically meaningful change, many such treatment 
responders reach a plateau and continue showing residual sleep 
disturbances after treatment and may remain at risk for relapse. 
There is a need to develop and validate more potent interventions 
that would increase the rate of patients reaching full remission.9 
Ongoing studies are currently examining optimal treatment dos-
age, treatment combination involving medication, and mainte-
nance therapies. 
 A related issue is that most of the outcome evidence currently 
available is about improving sleep initiatiation and sleep continu-
ity parameters, with essentially no information about the impact 
of treatment on more qualitative aspects of sleep, i.e., non-restor-
ative sleep. Although this qualitative feature is part of the standard 
insomnia definition, no study has of yet examined the impact of 
psychological treatment on this variable.
 Proper implementation of psychological and behavioral ther-
apies usually requires more time than prescribing a hypnotic 
medication, which may represent an important barrier to using 
such interventions in clinical practice. Nonetheless, several stud-
ies have documented the benefits of cost-effective implementa-
tion models using nurse practitioners, group therapy, or self-help 
materials to complement therapist-guided intervention. Whereas 
such implementation models are likely to make treatment more 
readily available, adequate therapist training remains an impor-
tant consideration in using CBT effectively to optimize outcome. 
Additional studies examining the relative cost-effectiveness of 
different insomnia interventions would be warranted68
 In summary, this updated review provides additional evidence 
supporting the use of psychological and behavioral interventions 
for primary insomnia, for insomnia associated with medical or 
psychiatric conditions, and for insomnia in older adults. Addi-
tional research is still needed to develop and validate treatment 
algorithms that would optimize outcomes and reduce morbidity; 
clinical research that would examine treatment mechanisms, me-
diators and moderators of outcomes is also warranted; and, addi-
tional effectiveness trials are particularly needed to document out-
comes in unselected patients seeking treatment in various clinical 
settings (e.g., primary care). Finally, an important challenge for 
the future will be to disseminate more efficiently the available 
evidence to health-care providers and translate that evidence into 
meaningful clinical guidelines in order to ensure a more wide-
spread use of validated therapies. 
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A. Baillargeon L, Landreville P, Verreault R, Beauchemin JP, Grégoire JP, Morin CM. Discontinuation of benzodiazepines among 
older insomniac adults treated through cognitive-behavioral therapy combined with gradual tapering: a randomized trial. CMAJ 
2003;169:1015-20. [no sleep data]
B. Espie CA, Inglis SJ, Harvey L. Predicting clinically significant response to cognitive behavior therapy for chronic insomnia in 
general medical practice: analyses of outcome data at 12 months posttreatment. J Consul Clin Psychol 2001;69:58-66. [secondary 
analysis of another paper included in the review]
C. Greeff AP, Conradie WS. Use of progressive relaxation training for chronic alcoholics with insomnia. Psychol Rep 1998;82:407-12. 
[only outcome measure, sleep quality, obtained from a single 10-point rating scale]
D. Gunning M, Espie CA. Psychological treatment of reported sleep disorder in adults with intellectual disability using a multiple 
baseline design. J Intellect Disabil Res 2003;47:191-202. [sample size smaller than 10]
E. Hajak G, Bandelow B, Zulley J, Pittrow D. As needed pharmacotherapy combined with stimulus control treatment in chronic in-
somnia--Assessment of a novel intervention strategy in a primary care setting. Ann Clin Psychiatry 2002;14:1-7. [main intervention 
was pharmacological, with optional use of stimulus control procedures]
F. Harvey AG, Farrell C. The efficacy of a Pennebaker-like writing intervention for poor sleepers. Behav Sleep Med 2003;1:115-24. 
[not a clinical treatment study; no insomnia diagnosis]
G. Harvey AG, Payne S. The management of unwanted pre-sleep thoughts in insomnia: distraction with imagery versus general dis-
traction. Behav Res Ther 2002;40:267-77. [not a clinical treatment study]
H. Krakow B, Johnston L, Melendrez D et al. An open-label trial of evidence-based cognitive behavior therapy for nightmares and 
insomnia in crime victims with PTSD. Am J Psychiatry 2001;158:2043-7. [primary diagnosis of post traumatic stress disorder with 
primary outcome measures of nightmare frequency; no insomnia diagnosis] 
I. Krakow B, Melendrez D, Lee SA, Warner TD, Clark JO, Sklar D. l. Refractory insomnia and sleep-disordered breathing, a pilot 
study. Sleep Breath 2004;8:15-29. [main sleep diagnosis was sleep-related breathing disorder, not insomnia]
J. Lundh LG, Hindmarsh H. Can meta-cognitive observation be used in the treatment of insomnia? A pilot study of a cognitive-emo-
tional self-observation task. Behav Cogni Psychoth 2002;30:233-36. [no insomnia diagnosis]
K. Morawetz D. Depression and insomnia: Which comes first? Australian Journal of Counseling Psychology 2001;3:19-24. [no insom-
nia diagnosis; did not use sleep diaries or other recognized measures to evaluate outcome]
L. Morgan K, Thompson J, Dixon S, Tomeny M, Mathers N. Predicting longer-term outcomes following psychological treatment 
for hypnotic-dependent chronic insomnia. J Psychosom Res 2003;54:21-9. [secondary analysis of another paper included in the 
review]
M. Quesnel C, Savard J, Simard S, Ivers H, Morin CM. Efficacy of cognitive-behavioral therapy for insomnia in women treated for 
non-metastatic breast cancer. J Consul Clin Psychol 2003;71:189-200. [final sample size smaller than 10]
N. Riedel BW, Lichstein KL. Strategies for evaluating adherence to sleep restriction treatment for insomnia. Behav Res Ther 
2001;39:201-12. [secondary analysis of another paper included in the review]
O. Tang NK, Harvey AG. Correcting distorted perception of sleep in insomnia: a novel behavioural experiment? Behav Res Ther 
2004;42:27-39. [not a clinical treatment study]
P. Verbeek I, Declerck G, Neven AK, Coenen A. Sleep information by telephone: Callers indicate positive effects on sleep problems. 
Sleep and Hypnosis 2002 ;4:47-51. [not a clinical treatment study; no diagnosis of insomnia]
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RAPID PUBLICATION
SLEEP DISTURBANCE IS THE MOST COMMON SYMP-
TOM OF MENTAL ILLNESS, BEING MORE COMMON 
THAN WORRY AND TWICE AS COMMON AS ANXIETY 
or depressive symptoms. Moreover, in a recent UK psychiatric 
morbidity study,1 this finding held for men and women of any 
age or ethnic group in any region. Epidemiologic studies report 
the prevalence of insomnia disorder at 10% to 12%, with older 
adult rates at greater than 20%.2,3 One fifth of patients consulting 
in primary care have insomnia.4 Typically, difficulty initiating or 
maintaining sleep, or both initiating and maintaining sleep, is as-
sociated with reduced daytime alertness and productivity, poorer 
quality of life, impaired relationships, and increased ill health.5-9 
Two meta-analyses have reported preexisting sleep disturbance 
as the largest, potentially treatable, risk factor for first-episode 
depression and for recurrence of depression.10,11 
Despite such findings, persistent insomnia often goes unrec-
ognized, and care management is poorly developed.12 Benzodiaz-
epine hypnotics and sedative antidepressants are commonly pre-
scribed in clinical practice, although long-term outcome data are 
relatively sparse,13,14 and, although the benzodiazepine receptor 
agonists confer some advantages in the management of acute in-
somnia, there is thus far limited evidence that they are preferable 
for the treatment of persistent insomnia.15 In short, the manage-
ment of chronic insomnia represents a very significant gap in the 
clinical armamentarium. 
Cognitive behavior therapy (CBT) offers 1 promising ap-
proach. Insomnia often arises from psychological factors such as 
conditioned arousal, maladaptive sleep habits and sleep sched-
ules, dysfunctional thinking about sleep and its consequences, and 
sleep preoccupation.16 This behavioral phenotype may be simi-
lar whether insomnia is primary or presenting in the context of 
psychiatric problems.2,17 Although 3 meta-analyses have demon-
strated clear benefit,18-20 CBT efficacy trials have recruited largely 
among media-solicited participants, perhaps excluding patients 
with complex presentations. Such studies have conformed more 
to the traditions of clinical efficacy research, where there is an 
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Study Objectives: Persistent insomnia, although very common in gen-
eral practice, often proves problematic to manage. This study investigates 
the clinical effectiveness and the feasibility of applying cognitive behavior 
therapy (CBT) methods for insomnia in primary care.
Design: Pragmatic randomized controlled trial of CBT versus treatment 
as usual.
Setting: General medical practice.
Participants: Two hundred one adults (mean age, 54 years) randomly 
assigned to receive CBT (n = 107; 72 women) or treatment as usual (n = 
94; 65 women).
Intervention: CBT comprised 5 sessions delivered in small groups by pri-
mary care nurses. Treatment as usual comprised usual care from general 
practitioners.
Measurements and Results: Assessments were completed at baseline, 
after treatment, and at 6-month follow-up visits. Sleep outcomes were ap-
praised by sleep diary, actigraphy, and clinical endpoint. CBT was associ-
ated with improvements in self-reported sleep latency, wakefulness after 
sleep onset, and sleep efﬁciency. Improvements were partly sustained at 
follow-up. Effect sizes were moderate for the index variable of sleep ef-
ﬁciency. Participants receiving treatment as usual did not improve. Acti-
graphically estimated sleep improved modestly after CBT, relative to no 
change in treatment as usual. CBT was also associated with signiﬁcant 
positive changes in mental health and energy/vitality. Comorbid physical 
and mental health difﬁculties did not impair sleep improvement following 
CBT. 
Conclusion: This study suggests that trained and supervised nurses can 
effectively deliver CBT for insomnia in routine general medical practice. 
Treatment response to small-group service delivery was encouraging, al-
though effect sizes were smaller than those obtained in efﬁcacy studies. 
Further research is required to consider the possibility that CBT could 
become the treatment of ﬁrst choice for persistent insomnia in primary 
healthcare.
Keywords: Insomnia, sleep, treatment, primary care, psychological in-
tervention
Citation: Espie C; MacMahon KMA; Kelly HL et al. Randomized clini-
cal effectiveness trial of nurse-administered small-group cognitive 
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emphasis on sample homogeneity, the exclusion of comorbidities, 
measurement reliability, and the management of other factors that 
are known to influence extraneous variance. Consequently, we do 
not know whether it is clinically effective or feasible to translate 
CBT to primary care. Effectiveness studies, by way of contrast, 
emphasize validity and generalizability to “real-world” settings 
by accessing populations and following procedures that reflect 
more typical clinical practice. Results from a preliminary clinical 
effectiveness study have suggested that improvements with CBT 
delivered by primary care nurses may be obtained.21 The present 
report is a formal intention-to-treat evaluation of this model.
METHODS
Aims and Objectives
The aim of the study was to test the effectiveness of CBT for the 
treatment of persistent insomnia in the “real-world” primary care 
setting. The major research questions were “Is CBT superior to 
treatment as usual (TAU) in reducing chronic sleep disturbance?”, 
“Are observed changes in sleep pattern and sleep quality durable?”, 
and “Are there predictors of good outcome, or contraindications to 
the application of CBT, for insomnia in general practice?”
Design
The study conformed to a pragmatic, randomized trial design 
following CONSORT guidelines. CBT was compared with TAU, 
this being an appropriate control for a clinical effectiveness study. 
Major assessments were at baseline, after treatment, and at fol-
low-up 6 months later. 
Participants
Potential participants were patients attending an appointment 
with their general practitioner (GP), or who were on their GP’s 
prescribing list for a sleep medication, during the period June 
2001 to July 2003. One hundred and four GPs in 19 practices 
in Glasgow, West Lothian, and Edinburgh identified participants. 
Eligibility criteria are described in Table 1. Participants had to 
satisfy criteria based primarily upon International Classification 
of Sleep Disorders -revised/Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition5,6 and standard quantitative cri-
teria. Consistent with this type of trial, exclusions were limited to 
new, untreated, or serious disorders or substance abuse problems 
that would make participation impractical or clinically inadvis-
able. Patients with physical or psychological problems were not 
excluded. Similarly, being on sleep (or other) medications was 
not an exclusion criterion.
Potential participants were notified of the study by their GP and 
through posters in clinic waiting areas and explanatory leaflets. 
Some GPs conducted record searches before circulating informa-
tion to patients with known insomnia problems. All prospective 
participants were then “referred” by their GP using a simple form 
on which GPs marked (√) against each study criterion (Table 1). 
Participants had the opportunity to discuss the research with a 
member of the research team and to reconsult with their GP prior 
to consenting. All gave written informed consent. The protocol 
was approved by local research ethics committees. Based on pre-
vious work,21 a sample size of 240 would have 90% power to 
show a 0.5 SD difference between treatments at an α level of 0.05. 
This was based on CBT achieving a reduction, in minutes of total 
wake time, at least 50% more than TAU. 
After baseline assessment and anonymization, participants 
were randomly assigned by an administrator in an independent 
research group using a computer-generated random list of num-
bers. Allocation was strictly in order of completion of baseline 
data, independent of participating GP practice or location. Ran-
domization information was kept in a locked cabinet and was in-
accessible to researchers. Because of the nature of the interven-
tion, it was not possible to blind participants or therapists to CBT 
and TAU allocations.
Measures
Potential participants were screened by telephone interview. 
Data were collected on sleep history, including diagnostic criteria, 
as well as medical and psychiatric history. A comprehensive face-
to-face interview then obtained a more detailed history. Interview 
was supplemented by completion of the Pittsburgh Sleep Qual-
ity Index (PSQI),22 the Hospital Anxiety and Depression Scale 
(HADS),23 and the Epworth Sleepiness Scale (ESS).24
Subjective sleep pattern was assessed using a sleep diary,25 
completed for 2 weeks at each of 3 assessment points; baseline, 
posttreatment, and follow-up. Such diaries are the staple tool of 
insomnia-assessment practice16 and offer a valid relative index 
of sleep disturbance, particularly when used as repeated mea-
sures.26,27 Fourteen nights is an adequate sampling period.28 Items 
“how long did it take you to fall asleep last night” (sleep-onset 
latency: SOL) and “how long were you awake in total last night, 
after you first fell asleep?” (wake time after sleep onset: WASO) 
assessed the central insomnia dimensions of difficulty initiat-
ing and maintaining sleep. Participants were advised to estimate 
WASO between initial sleep onset and rising from bed. The di-
ary also inquired about bedtime and rising time, from which total 
time in bed (TIB), and then sleep efficiency percentage (SE) was 
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Table 1—Inclusion and Exclusion Criteria Based Primarily Upon 
ICSD-R/ DSM-IV
Inclusion Criteria
• Aged ≥ 18 years
• Referred by general practitioner
• Living in the community in Glasgow or Edinburgh area
• Difﬁculty initiating and/or maintaining sleep, comprising SOL ≥ 
30 minutes and/or WASO ≥ 30 minutes, 3 or more nights per 
week
• Present sleep complaint for at least 6 months
• Negative complaint of insomnia impact (eg, fatigue, impaired 
mood)
Exclusion Criteria
• Deteriorating health or dementia
• Incapacitating pain or illness
• Untreated mental health problems
• Untreated other sleep problems
ICSD-R refers to the International Classiﬁcation of Sleep Disorders-
Revised5; DSM-IV, Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition6; SOL sleep-onset latency; WASO, wake 
time after sleep-onset.
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calculated (100 – [{SOL + WASO/ TIB} × 100]). Participants 
were trained to complete sleep diaries using established accuracy 
criteria.29 
Because movement correlates with wakefulness and lack of 
movement with sleep,30,31 wrist actigraphy was used to objectively 
estimate sleep for 14 nights before and after treatment. Actigraphs 
are small nonintrusive devices that record movement information 
by means of an accelerometer-microprocessor link. In this study, 
actigraphs (Cambridge Neurotechnology®, AW-4; Cambridge 
Neurotechnology Ltd., Cambridge, UK) were worn 24 hours per 
day on the nondominant wrist. An algorithm (maximum sampling 
frequency 32 Hz, recording all movement over 0.05 g., filters set 
3-11 Hz) enabled proprietary Sleepwatch® software (Cambridge 
Neurotechnology Ltd) to estimate the sleep parameters SOL, 
WASO, and SE using 1-minute epochs. In the United States, these 
same hardware and software products are distributed by Min-
imitter Co. Inc. (Mini Mitter Co., Inc., Bend, Ore). Validity data 
are available on the following websites www.camntech.com and 
www.minimitter.com.
Several other clinical outcomes were assessed. These com-
prised global PSQI score, nighttime use of hypnotic medications, 
generic quality of life assessed using the Short Form-36,32 and 
appraisal of clinical endpoints33 (SOL and WASO ≤ 30 minutes; 
SE ≥ 85%) at posttreatment and follow-up. 
Interventions
Cognitive Behavior Therapy
Participants assigned to CBT attended 5, weekly, 1-hour treat-
ment sessions. These were conducted in groups of 4 to 6 partici-
pants in local general practice premises during the early afternoon 
or early evening. The content, aims, and objectives of each CBT 
session are summarized in Table 2 (further descriptions in Morin 
& Espie, 200316 or available from the first author of this paper). 
As can be seen in Table 2, the intervention included the common 
CBT components such as stimulus control, sleep restriction, and 
cognitive therapy strategies.
Therapists
To test a potentially generalizable model of insomnia care, 
we delivered CBT at “grass-roots” level, not in a specialized 
center or by a specialist psychologist or behavioral sleep medi-
cine expert. Accordingly, 7 health visitors were trained to de-
liver CBT. In the UK, health visitors are community nurses with 
postqualification training and certification, who are generally 
based in primary care teams. They have a specific health educa-
tion role and commonly encounter sleep disorders in their prac-
tice. We followed a model of “training-to-criterion” standards. 
That is, the health visitors had to demonstrate competence in the 
Table 2—Summary Content of the Cognitive Behavior Therapy Pro-
gram
Session 1 Sleep Information 
Aim: To learn about normal sleep processes and about sleep disor-
ders 
• to understand the need for sleep and its functions
• to understand sleep pattern and how it varies during the lifetime
• to understand sleep as a process with stages and phases
• to understand factors that adversely affect sleep pattern and sleep 
quality
• to understand the effects of sleep loss
• to understand the concept of insomnia and how it can be mea-
sured
• to understand personal sleep histories and patterns in the above 
context
• to begin to correct misunderstandings about sleep and sleepless-
ness 
Session 2 Sleep Hygiene & Relaxation
Aim: To introduce practical steps toward developing a healthy sleep 
pattern without recourse to drugs
• to create a bedroom environment that is comfortable for sleep
• to take regular exercise that promotes ﬁtness and enhances sleep
• to develop a stable and appropriate diet
• to reduce the undesirable effects of caffeine upon sleep
• to moderate alcohol consumption and eliminate “night caps”
• to learn relaxation skills to apply at home and in bed
Session 3 Sleep Scheduling 
Aim: To reshape sleep patterns to correspond with individual sleep 
needs and to strengthen sleep rhythms
• to develop a good presleep routine
• to distance waking activities (eg, watching TV) from the bedroom 
environment
• to establish a strong bed-sleep connection
• to eliminate wakefulness from bed (rising if not asleep within 
around 15 minutes)
• to deﬁne restricted parameters for the individual’s sleep period
• to increase sleep efﬁciency through scheduling sleep in relation to 
current total sleep 
• to eliminate daytime napping
• to establish a stable night-to-night sleep pattern, rising at the same 
time every day
• to encourage and support people in changing their sleep routines 
Session 4 Cognitive approaches
Aim: To learn ways of reducing mental alertness, repetitive thoughts, 
and anxiety that interfere with sleep
• to identify thought patterns that interfere with sleep
• to develop accurate beliefs and attitudes about sleep
• to prepare mentally for bed by putting the day to rest
• to learn thought distraction and imagery techniques
• to reduce efforts to control sleep and allow it to happen naturally
• to utilize these techniques to combat intrusive thoughts
• to encourage and support people in changing their mental ap-
proach
• to further adjust sleep schedules to maintain sleep efﬁciency
Session 5 Developing a strong & natural sleep pattern 
Aim: To integrate advice from previous sessions and to maintain im-
plementation at home
• to systematically rehearse elements of program
• to address implementation problems experienced
• to further adjust sleep schedules to maintain sleep efﬁciency
• to encourage and support people in maintaining their new sleep 
routines
• to encourage and support people in maintaining their new mental 
approach
• to learn relapse-prevention approaches if a sleep problem recurs
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  [Attended 5 sessions (n = 50)   
  Attended 3 or 4 sessions (n = 28)   
   Attended 1 or 2 sessions (n = 17)]   
    Did not receive allocated      
intervent ion (n = 12) 
12) 
  
 [ Did not attend/ withdrew  (n = 12)]   
    
  
Completed follow up (n = 76)   
  Lost to follow up  (n = 19)   
   [ no response/ not contactable]   
  
Completed follow up (n = 67)   
   Lost to follow up  
   [no response/ not contactable]   
  
       
  
Allocated to TAU (n = 94)   
Received allocated intervention (n =83)   
Did not receive allocated intervention  
(n = 11)  
   [ No response to contacts (n = 11)]   
      
  
Analyzed (n = 107)   
    
  
Analyzed (n = 94)   
   
(n = 16) 
Figure 1—Participant Flowchart. CBT refers to cognitive behavior therapy; TAU treatment as usual.
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delivery of the CBT program. This was ensured by using a man-
ualized therapy approach, participation in a short CBT course, 
apprenticeship learning opportunities, ongoing mentoring by an 
experienced clinical psychologist, and evaluation of audiotapes 
from randomly selected therapy sessions. Specific aspects of the 
training in CBT are summarized in the section on integrity/fidel-
ity of treatment allocation.
Treatment as Usual
Effectiveness studies should replicate real clinical practices 
and reflect validity and generalizability.34 Because we intended to 
recruit primary care patients with chronic insomnia, we expected 
concurrent physical and psychological symptoms, as well as con-
current treatments. The TAU comparison group thus represented 
normal clinical practice, in which GPs were free to offer appoint-
ments, to prescribe, and to maintain or discontinue prescriptions. 
What this meant in effect was that participants allocated to TAU 
received no additional help with their insomnia therapy, result-
ing from their participation in the study, but that their GPs were 
free to do whatever they would normally do. Indeed, in this re-
spect, CBT was, in reality, a CBT plus TAU condition because the 
trial protocol explicitly permitted GPs (and other physicians and 
health professionals) to continue their health care provision un-
interrupted with all the participants. TAU participants completed 
assessments as for the CBT condition but received no insomnia 
advice from the trial team or from our therapists. At the end of the 
protocol, the TAU group was provided with a booklet “The Good 
Sleep Guide,” prepared by the first author for the National Medi-
cal Advisory Committee.35 
Integrity-Fidelity of Treatment Allocation 
The integrity of the treatment allocations was ensured as fol-
lows: (1) Nurse therapists attended a 12-hour, 2-day course on 
sleep disorders, working with groups, CBT principles, and in-
struction on the CBT program. (2) Therapists “sat in” on existing 
CBT groups and maintained an informal peer support network. 
(3) An experienced psychologist with training in behavioral sleep 
medicine acted as a mentor/consultant but did not work directly 
with participants. (4) The CBT program was manualized, fol-
lowing a recent study.21 It comprised therapist notes, PowerPoint 
presentations (15 slides per session), worksheets for “break-off” 
times, and take-home notes with implementation guidelines. (5) 
Therapy sessions were audio-recorded, allowing appraisal of fi-
delity of CBT administration. (6) TAU participants were not seen 
for assessment at times when or in places where CBT assessment 
or intervention was operating. (7) GPs were advised of TAU al-
locations but were not provided with copies of CBT materials. (8) 
Table 3—Demographic and Clinical Information on the Sample
Characteristic CBT TAU
  (n = 107) (n = 94)
Age, ya 54.4 ± 15.4 54.1 ± 14.4
Sex  
 Women 72 65
 Men 35 29
Civil status  
 Partner 54 46
 No partner 53 48
Working  
 Yes 54 47
 No 53 47
Location  
 Glasgow 71 66
 Edinburgh 36 28
Carstairs Deprivation Category   
 1-2 37 18
 3-4 23  24 
 5-7 47 52
Insomnia duration, ya 11.6 ± 9.79 10.6 ± 12.2
Insomnia presentation   
 Constant 80 69
 Episodic 27 23b
Sleep medication  
 Yes  54 41
 No 53 53
PSQI scorea 12.7 ± 3.75 12.3 ± 3.55
ESS scorea 6.05 ± 4.69 5.00 ± 4.26
Comorbid problems  
 None 34 28
 Physical health 11 12
 Mental health 30 36
 Physical and mental health 32 18
HADS-Anxiety scorea 9.99 ± 4.10 9.63 ± 4.60
HADS-Depression scorea 6.73 ± 3.66 7.07 ± 4.58
Data are presented as number, unless otherwise noted. CBT refers 
to cognitive behavior therapy; TAU: treatment as usual; PSQI: Pitts-
burgh Sleep Quality Index; ESS: Epworth Sleepiness Scale; HADS, 
Hospital Anxiety and Depression Scale.
aData are presented as mean ± SD.
b2 missing cases.
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Figure 2—Sleep-diary changes at posttreatment and 6-month fol-
low-up, expressed as percentage change from baseline values for 
the cognitive behavior therapy (CBT) and treatment as usual (TAU) 
groups. SOL refers to sleep-onset latency; WASO, wake after sleep 
onset; SE, sleep efﬁciency; post, posttreatment; Fup, follow-up
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CBT participants were asked to not make copies of materials. To 
strengthen this instruction, all materials were prominently marked 
as copyrighted.
Statistical Methods 
Data analyses followed a conservative intention-to-treat mod-
el, with all allocated participants who provided baseline data in-
cluded in a series of 2 (group: CBT, TAU) × 3 (time: baseline, 
posttreatment, follow-up) repeated-measures analyses of variance 
(ANOVA). Missing values were replaced using last observation 
carried forward, consistent with the methodology applied by Ja-
cobs et al57 in their intention-to-treat, placebo-controlled, trial of 
insomnia treatments. This approach was preferred to HLM analy-
sis, which would have been more appropriate if the participants 
had been randomly assigned as groups (a “cluster“ randomized 
trial). Participants were randomly assigned individually between 
the therapies. Consequently, the analysis undertaken reflects the 
nature of the underlying randomization (and the associated per-
mutation test). Significant Group × Time interactions were ex-
plored posthoc by within and between sample t-tests to locate the 
effect. Percentage change over baseline and relative effect sizes 
(d = M
1
 – M
2
/ √ [{σ
1
2
 
+ σ
2
2}/ 2]) were computed to estimate treat-
ment impact.36 Consideration was paid subsequently to potential 
predictors of outcome using linear regression methods.
Role of the Funding Sources
Neither funding source (Chief Scientist Office, Scottish Execu-
tive; Dr. Mortimer and Theresa Sackler Foundation) participated 
in the study design, data analysis, or writing of this report.
RESULTS
Participant Flow
Three hundred and eighty-five adults were assessed for eligi-
bility of whom 51 (35 women and 16 men; mean ± SD age 53.1 
± 11.2 years) were excluded, largely because of unidentified or 
untreated problems (Figure 1). A further 133 (87 women and 46 
men; mean age 51.5 ± 17.9 years) did not complete the baseline 
sleep diary, leaving 201 who met criteria and were randomly as-
signed to treatment. 
Demographic and clinical characteristics of this sample are 
presented in Table 3. Participants were typically middle-aged and 
had had insomnia for more than 10 years. Two thirds were women. 
Half were on sleep medication, primarily using benzodiazepine 
hypnotics (1 in 3 of those on hypnotic medication was on a benzo-
diazepine receptor agonist). Only one third of the sample had no 
comorbid problems. Almost 60% of the participants had some de-
gree of mental health problem (most commonly depressive symp-
toms and generalized anxiety). Indeed, consistent with this find-
ing, on the HADS, 118 (59%) scored in the clinical “caseness” 
range (> 10) for anxiety and 86 (43%) for depression.23 More than 
one third of the sample had comorbid physical disorders, either 
alone (11%) or concurrent with a mental health problem (25%). 
Disorders of the cardiovascular (eg, high blood pressure), muscu-
loskeletal (eg, arthritis, pain) and endocrine systems (eg, diabe-
tes) were among the most common. Concurrent pharmacologic 
treatments, therefore, ranged through antidepressant, anxiolytic, 
β-blocker, antiinflammatory, and analgesic medications, either 
singly or in combination. 
Participants were drawn from across the socioeconomic spec-
trum. The only baseline difference (Table 3 data) was a modest 
overrepresentation of higher socioeconomic status (DepCat group 
1-2) in CBT (34.5%) relative to TAU (19%) [χ2 = 6.02, df = 2, P 
= 0.049]. Compared with Scottish population data,37,38 our sample 
had a lower representation of midband 3 to 4 (23.5% vs 45%), a 
higher representation of band 1 to 2 (27.5% vs 10%), and a simi-
lar representation of the lowest band 5 to 7 (49% vs 45%).
Nineteen CBT groups were run by the therapists. Three quar-
ters of CBT participants attended 3 or more therapy sessions. For 
missed sessions, participants “caught up” via discussion at the end 
of the subsequent attended session. The 23 participants lost from 
CBT/TAU during the treatment phase (Figure 1) did not respond 
to 2 subsequent letters or phone calls and did not differ from com-
pleters on presenting characteristics. Respectively, 80% and 81% of 
those receiving CBT and TAU provided data at 6-month follow-up. 
Thus, “drop-out” rates for CBT and TAU were similar during both 
intervention and follow-up. Baseline variables for noncompleters 
did not differ significantly from those for completers. Likewise, 
preliminary analyses of dependent variables revealed no differ-
ences across sites. Data therefore were pooled. No adverse events 
were reported anecdotally with either CBT or TAU.
Self-reported Sleep
Summary data (mean ± SD) for CBT and TAU at each assess-
ment point are provided in Table 4. Visual inspection of these 
data suggests that the TAU group slept somewhat better than the 
CBT group at baseline. However, there were no statistically sig-
nificant baseline differences in either self-reported or actigraphic 
sleep. Difficulty initiating sleep (SOL) declined more following 
CBT than TAU, the significant Group × Time interaction (F
2,198
 = 
6.64, P = 0.002) being explained by a between-group difference 
at posttreatment (t = 2.74, df = 199, P = 0.004). Differences be-
tween CBT and TAU failed to maintain statistical significance at 
follow-up (P = 0.079). Repeated-measures ANOVA on difficulty 
maintaining sleep (WASO) also yielded a significant interaction 
term (F
2,198
 = 7.12, P = 0.001). However, independent samples t-
tests revealed no significant differences between CBT and TAU 
at posttreatment (P = 0.10). SE is a measure of sleep continuity 
across the night. ANOVA yielded a significant Group × Time in-
teraction (F
2,198
 = 8.07, P < 0.001), which was accounted for by 
higher posttreatment SE in the CBT group relative to TAU (t = 
1.70, df = 199, P = 0.045). At follow-up, this difference was not 
statistically significant (P = 0.06). Total sleep time increased by 
12 minutes after CBT and by 21 minutes at 6 months, compared 
with a 5-minute reduction for TAU. These differences, however, 
were not statistically significant. The interaction terms for SOL, 
WASO, and SE remained significant after correction for multiple 
comparisons on sleep-diary measures (P = 0.05/4 = 0.0125). In 
order to be conservative, we also repeated the above analyses en-
tering baseline values as covariates. This did not alter any of the 
above findings.
Figure 2 presents percentage-change data for CBT and TAU 
at posttreatment and follow-up. These data illustrate marked im-
provement following CBT with some loss of effect at 6 months. 
Little change was observed with TAU. In the CBT arm, posttreat-
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ment SOL reduction was 39% (23 minutes; d = 0.58) and was 
31% (19 minutes) at follow-up (d = 0.36). For WASO, these CBT 
changes were 35% (36 minutes) and 19% (19 minutes), respec-
tively (both d = 0.35). This maintained effect size at posttreatment 
was influenced by an increase in WASO of 10% (8 minutes) with 
TAU. The relative SE increase over baseline was 13% at post-
treatment (d = 0.68) and was 11% at follow-up (d = 0.57) for the 
CBT group. These changes represented absolute increases in SE 
of 9.1% and 7.3% respectively. TAU was associated with a slight 
tendency to reduced SE
Actigraphic Estimates of Sleep
Data from 126 participants were available; 69 participants were 
allocated to CBT (45 women and 24 men; mean age 54.7 ± 14.6 
years) and 57 to TAU (38 women and 19 men; mean age 54.7 ± 
13.7 years). Demographic and clinical characteristics were simi-
lar to those of the full study sample. No effect of treatment was 
observed on actigraphy-derived SOL or SE (Table 4). For WASO, 
both Group (F
1,124
 = 11.84, P = 0.001) and Time (F
1,124
 = 9.55, P 
=0.002) main effects were significant, as was the Group × Time 
interaction (F
1,124
 = 5.01, P = 0.027). Accordingly, a pretreatment-
posttreatment change score was calculated, and an independent 
samples t-test conducted. This revealed a significantly greater 
reduction in WASO following CBT, as compared with TAU (t = 
2.28, P = 0.024).
Actigraphic scores for SOL and WASO were lower and, for 
SE, were higher than sleep-diary estimates. Intercorrelations of 
weekly mean data for SOL (r = 0.340, P < 0.001), WASO (r = 
0.182, P = 0.041), and SE (r = 0.275, P =0.001) were modest.
Other Clinical Outcomes
Global sleep disturbance reduced by at least 4 PSQI points 
(more than 1 SD) at 6-month follow-up under CBT, compared 
with a 1-point change under TAU (Table 5). The Group × Time 
interaction effect was significant (F
2,198
 = 3.83, P = 0.023), ac-
counted for by PSQI reductions both at posttreatment (t = 1.68, df 
= 199, P = 0.048) and follow-up (t = 2.97, df = 199, P = 0.002) in 
the CBT group, compared with TAU. There was a nonsignificant 
reduction of hypnotic consumption in both CBT and TAU (Time 
main effect F
2,198
 = 2.68, P = 0.074) but no significant interac-
tion. 
Following CBT, 32 participants (30%) achieved a SOL of 30 
minutes or less, with 35 (33%) achieving this endpoint at 6 months. 
In TAU, the comparable figures were 17 (18%) and 21 (22%), 
respectively. These effects represent a significant improvement 
following CBT relative to TAU at posttreatment (χ2 = 4.67, df = 
Table 4—Sleep Data, Before and After Intervention, and at 6-
Month Follow-Up for Cognitive Behavior Therapy and Treatment 
as Usual Groups
SLEEP OUTCOMES CBT TAU
Sleep Diary
 Sleep-onset latency, min
  Baseline 60.5 ± 50.5 54.0 ± 41.1
  Posttreatment 37.2 ± 42.9 55.7 ± 42.2
  6-month follow-up 41.7 ± 45.5 50.7 ± 33.0
 Wake after sleep onset, min
  Baseline 101.9 ± 88.2 85.0 ± 71.4
  Posttreatment 66.1 ± 50.3 76.6 ± 53.1
  6-month follow-up 83.0 ± 76.3 92.8 ± 63.8
 Sleep efﬁciency, %
  Baseline 68.0 ± 19.1 73.5 ± 16.7
  Posttreatment 77.1 ± 15.6 72.7 ± 16.7
  6-month follow-up 75.3 ± 15.7 71.1 ± 16.7
 Total sleep time, h
  Baseline 5.54 ± 1.69 5.93 ± 1.46
  Posttreatment 5.74 ± 1.19 5.91 ± 1.44
  6-month follow-up 5.89 ± 1.27 5.85 ± 1.21
Actigraphy
 Sleep-onset latency, min
  Baseline 23.3 ± 29.7 21.4 ± 23.3
  Posttreatment 22.7 ± 22.8 20.7 ± 22.2
 Wake after sleep onset, min
  Baseline 73.6 ± 37.1 56.1 ± 20.3
  Posttreatment 59.0 ± 25.3 53.8 ± 23.7
 Sleep efﬁciency, %
  Baseline 80.9 ± 9.62 84.0 ± 6.03
  Posttreatment  82.7 ± 5.71 84.3 ± 4.00
CBT refers to cognitive behavior therapy; TAU, treatment as usual.
Table 5—Other Clinical Outcomes for Cognitive Behavior Thera-
py and Treatment as Usual Groups 
OTHER CLINICAL OUTCOMES CBT TAU
Pittsburgh Sleep Quality Index
 Baseline 12.7 ± 3.75 12.3 ± 3.55
 Posttreatment 9.84 ± 4.17 11.3 ± 3.68
 6-month follow-up 8.40 ± 4.14 11.2 ± 3.24
Medication use per night
 Baseline 0.48 ± 0.92 0.61 ± 0.85
 Posttreatment 0.30 ± 0.60 0.53 ± 0.68
 6-month follow-up 0.26 ± 0.49 0.47 ± 0.70
SF-36 
 Physical functioning
  Baseline 67.1 ± 26.5 68.5 ± 24.7
  Posttreatment 71.8 ± 18.7  71.4 ± 17.9
 Social functioning
  Baseline 61.9 ± 26.4 60.3 ± 28.2
  Posttreatment 65.0 ± 20.0 62.4 ± 25.4
 Physical role limitation
  Baseline 59.8 ± 28.9 61.7 ± 27.4
  Posttreatment 62.5 ± 19.7 60.2 ± 21.2
 Emotional role limitation
  Baseline 60.6 ± 23.7 62.8 ± 24.2
  Posttreatment 67.0 ± 17.4 62.8 ± 21.9
 Mental health
  Baseline 45.0 ± 12.9 46.4 ± 14.7
  Posttreatment 50.2 ± 8.20 47.8 ± 14.2
 Energy/vitality
  Baseline 38.4 ± 16.0 42.3 ± 15.1
  Posttreatment 45.8 ± 12.0 43.9 ± 14.1
 Pain
  Baseline 57.5 ± 22.9 59.8 ± 22.8
  Posttreatment 59.1 ± 21.5 60.8 ± 19.8
 General health perceptions
  Baseline 55.0 ± 22.0 56.2 ± 20.1
  Posttreatment 60.6 ± 16.8 58.1 ± 18.1
Data are presented as mean ± SD; for medication use, this is mean 
± SD number of tablets taken per night. CBT refers to the cognitive 
behavior therapy; TAU, treatment as usual; SF-36: Short Form-36.
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1, P = 0.022; Fisher exact Test) but not at follow-up (χ2 = 2.17, 
df = 1, P = 0.094). Fourteen participants (13%) had WASO of 30 
minutes or less after CBT, with 20 (19%) obtaining this cut-off at 
follow-up, compared with 10 (11%) and 11 (12%), respectively, 
following TAU. The achievement of SE of at least 85% was also 
included as a conventional threshold value for normal sleep.55,56 
This criterion was achieved by 28 (26%) of CBT participants after 
therapy and by 21 (20%) at follow-up. For TAU, these outcomes 
were obtained by 16 (17%) and 13 (14%), respectively. These 
WASO and SE indexes of change were not significantly different 
upon statistical analysis.
The SF-36 was completed before and after treatment (see Table 
5). Higher values indicate better perceived health. Time main ef-
fects were observed in 4 domains: physical functioning (F = 5.82, 
P = 0.017), mental health (F = 12.9, P = 0.001), energy/vitality (F 
= 15.7, P < 0.001) and general health (F = 8.89, P = 0.003) (all df 
1,199). Significant Group × Time interactions, suggesting better 
treatment response after CBT, were obtained for 2 domains: men-
tal health (F = 4.29, P = 0.040) and energy/vitality (F = 7.92, P < 
0.005). A nonsignificant effect was observed for emotional role 
limitation to respond better to CBT (F = 3.43, P = 0.066).
Predictors of Outcome
It is important also to investigate if there were any factors 
specifically associated with better or poorer treatment response. 
Demographic (eg, sex, age, socioeconomic status, location of 
group), clinical (eg, comorbidities, psychopathology), sleep (eg, 
duration of insomnia, medication) and treatment-related data (eg, 
attendance rate, therapist, group attended) were available to in-
form such analyses. At the conceptual level, such independent 
variables are divisible into “moderator (present at baseline) and 
“mediator” (treatment-related) influences upon outcome. SE 
change from before to after treatment was selected as the depen-
dent variable because SE is a recognized summary index of sleep 
disturbance and because SE demonstrated the largest posttreat-
ment effect size. Stepwise linear regression revealed that only 2 
variables contributed significantly to the prediction of SE change 
for the CBT group (F = 26.12, P < 0.001). Baseline SE (a modera-
tor variable) entered on the first step (Adj. R2 = 0.433; β = 0.611; 
P < 0.001) and frequency of attendance at CBT sessions (a medi-
ating variable) contributed a small amount of additional explana-
tory variance (Adj. R2 = 0.469; β = -.218; P = 0.033). 
DISCUSSION
Insomnia is a problem with population prevalence and comor-
bidity so high that a clinical effectiveness study is required to 
establish if a promising intervention like CBT can be translated 
into a community-based treatment. CBT is normally regarded as 
a complex and specialized intervention; therefore, as well as ef-
fectiveness, there is the issue of feasibility. This study, therefore, 
investigated the impact of manualized, nurse-administered, small-
group CBT on relatively unselected “real-world” participants with 
severe and persistent insomnia.
Our intention-to-treat data offer some support for the clinical 
effectiveness of CBT for insomnia. Significant reductions, total-
ling around 60 minutes per night, in symptom measures of SOL 
and WASO were observed with CBT, and SE increased by 9%. 
TAU did not yield comparable benefits. ANOVA models sug-
gest that these posttreatment improvements were more convinc-
ing for sleep latency than for wakefulness during the night, and 
this is confirmed by effect-size data (d = 0.58 and d = 0.35, re-
spectively). Effect size was greatest for SE (d = 0.68) indicat-
ing that, under CBT, participants were reliably sleeping through 
a greater proportion of their time in bed. Global sleep quality, as 
measured on the PSQI, also improved following CBT. Follow-up 
data, however, suggest some loss of therapeutic effect, particu-
larly in WASO, although the WASO effect size was sustained, 
perhaps because TAU participants were somewhat more wakeful 
at 6 months. Effect sizes for SOL and WASO at follow-up were 
small to medium but remained relatively robust for SE (d = 0.57). 
Mean CBT reductions for SOL and WASO, in previous efficacy 
studies, have been about 30 minutes each,33 similar to our find-
ings. However, average effect sizes have been 0.88 and 0.65, re-
spectively, considerably larger than our results. This may reflect 
the more severe and complex presentation of our patient group. 
There is also some suggestion that our study may have been un-
derpowered to detect between-group differences at 6-month fol-
low up, when nonsignificant probabilities for SE ( P = 0.06) and 
SOL ( P = 0.079) were obtained. Posthoc power calculations in-
dicate that sample sizes of 235 (for SE) and 300 (for SOL) would 
have been required to achieve an α value of 0.05 at 80% power. 
We had originally planned to enrol 240 participants but achieved 
only 201. These data may be indicative of the considerably larger 
sample sizes required for effectiveness research, relative to effi-
cacy research, because of the greater within and between-subject 
variability in clinical samples. 
Nevertheless, and consistent with other recent data,39 it is 
encouraging that factors such as the chronicity of the insomnia 
disorder, the absence or presence of physical and mental health 
comorbidities, and participant age and sex did not emerge from re-
gression analysis as explanatory factors associated with therapeu-
tic response to CBT. As might be expected from the law of initial 
values, baseline SE was the main predictor of SE improvement, 
explaining 43% of variance in the treated group. Thus, baseline 
data may moderate treatment response but, from our data, primar-
ily in the sense that high baseline values provide greater room for 
improvement. Attendance rate at CBT sessions added a further 
3.6% of explanatory variance and was the only treatment-related 
mediator of outcome. People who attended more often were likely 
to do better. This too is an important finding, reinforcing the im-
portance of motivational aspects of CBT and of helping patients 
to conceptualize the program as a course of treatment. The in-
teraction of insomnia severity with the likelihood of committing 
to achieving and sustaining change in sleep-related behavior and 
cognition appears worthy of further dedicated research effort.
Sleep self-report data were not mirrored by actigraphically es-
timated sleep, either in terms of capturing the baseline complaint 
of insomnia or in terms of outcome. Only WASO data demon-
strated treatment-related impact, whereas, on sleep diary reports, 
CBT was associated with greater reduction in SOL and increase 
in SE. These findings parallel other recent work showing limited 
impact of CBT on actigraphically determined sleep.40-42 Only 1 
study, on insomnia patients with chronic pain, has demonstrated 
both subjective and actigraphic sleep improvement.43 Indeed, a 
systematic review and practice parameters statement, published 
since we began this research, suggests a limited role for actigra-
phy applied to insomnia intervention research.44,45 Studies have 
found that actigraphy consistently produces different estimates 
Treatment of Persistent Insomnia—Espie et al
SLEEP, Vol. 30, No. 5, 2007 582
of sleep time and number of awakenings and lower estimates of 
sleep latency than do sleep diaries,46,47 and correlation between 
self-report and actigraphy has been generally poor.48-50 However, 
such limited correlation between entirely different modes of as-
sessment should not be unexpected. In considering the role of 
actigraphy in sleep assessment, Tryon51 makes the point that the 
observed modest coefficients of validity of actigraphy (in relation 
to polysomnography) actually exceed those associated with many 
medical and psychological tests. Consequently, the significant 
impact of CBT upon actigraphically estimated WASO in the pres-
ent study is interesting in part because it contrasts with the sleep-
diary improvements that were observed primarily in the SOL and 
SE domains. 
We used conservative criteria to investigate clinical endpoints. 
Of CBT treated. 20% to 30% achieved these endpoints (below 
threshold for insomnia disorder), compared with 10% to 20% of 
TAU participants. Compared with absolute reductions in SOL, 
WASO, and SE complaints, these outcomes are relatively disap-
pointing for CBT and may reflect the initial severity of the sleep 
disorders in this study. That is, although CBT was associated with 
greater symptomatic improvement, many participants remained 
in the clinical range at follow-up. Certainly, if even more strin-
gent criteria were applied (eg, reduction in symptom score of at 
least 0.5 SD plus 30 minutes or less of SOL or WASO), we would 
have obtained very few responders to CBT. Likewise, although 
significant PSQI-based sleep-quality improvement was achieved 
and sustained in the long term following CBT, the 6-month fol-
low-up mean value of 8.4 remained considerably higher than the 
cut-off of 5 used for normal sleep. 
Such results raise the long-standing issue in insomnia outcome 
research concerning the relative paucity of treated participants who 
endorse becoming normal sleepers after treatment. In the context of 
this particular study, one possible explanation for the disappointing 
clinical endpoints is that there may have been insufficient treatment 
offered through the CBT-group program, at least for a proportion of 
the patients. Whereas this model of care may be sufficient for some, 
it may not be sufficient for the majority of clinical insomnia cases. 
The use of more sessions, more highly skilled therapists, tailored 
CBT interventions, or a combination of CBT and pharmacotherapy 
treatments, along with proven methods to achieve and to sustain 
high levels of patient assimilation of treatment information and 
adherence to treatment protocol may all make a difference to out-
comes in insomnia clinics. Although work is steadily advancing in 
these areas, we do not yet have the algorithms to enable us to make 
these judgements in an informed manner. 
Nevertheless, our CBT participants demonstrated more than 
mere sleep-symptom change. On the SF-36, health-related qual-
ity-of-life improvement was found in domains reflecting mental 
health and vitality. These results suggest that CBT for insomnia 
may be associated with generalized benefits to everyday func-
tioning. This is consistent with contemporary understanding of 
insomnia not only as a disorder that impairs the sleep experience, 
but also one that negatively impacts the day.5,6 Our findings of 
quality-of-life change following CBT for insomnia parallel other 
recent data using the SF-36.52,53
Notwithstanding our earlier comments about sampling adequa-
cy, our sample size (n = 201) was considerably larger than that of 
any previous report of insomnia treatment. Efficacy studies typi-
cally have comprised 40 to 100 participants.33 More importantly, 
our participants were clinically identified, and 70% had comorbid 
mental or physical health problems. Only 51 of 385 potential par-
ticipants were excluded, largely because of suspected untreated 
disorders. However, a further 133 who met criteria and consented 
to participate in the study, withdrew prior to random allocation 
to treatment. Unfortunately, we have limited data on the reasons 
for these withdrawals. Delays in processing individuals may have 
contributed to some nonresponses. Also, we suspect that many 
individuals who were routine users of hypnotics on prescription, 
who initially expressed interest when contacted by their GPs, 
thereafter withdrew. This may reflect the importance of patient 
“readiness” to adopt a CBT approach in the real-world clinical 
setting. Nevertheless, 50% of randomly assigned participants 
were on hypnotics. The personal, socioeconomic, and clinical 
profiles of our participants suggest that we did identify our tar-
get community population and that they had severe and chronic 
insomnia. Total wakefulness per night was around 2.5 hours, and 
baseline SE was around 70%.
We wanted to test a potentially generalizable model of care that 
had proven to be beneficial in a more limited previous study.21 
From our experience, it is feasible for nurses based in primary 
care to learn, and to deliver, a CBT program, and our results are 
promising for what might be regarded as a “first-line” insomnia 
intervention. By providing group treatment using a trained nurse, 
the “per patient” costs may be minimized. Crucially, however, 
the use of a manual ensured treatment integrity and fidelity, and, 
alongside training, supervision and case review, would seem a 
crucial component of any program “roll-out.” We have summa-
rized elsewhere how a skilled clinical psychologist or behavioral 
sleep medicine specialist could operate an insomnia “triage” sys-
tem, allowing nurse-led group-based CBT to complement indi-
vidual therapies.54 This model, of course, requires further evalu-
ation. Moreover, our approach would need to be tailored to the 
operational characteristics of other healthcare systems. Perhaps 
the National Health Service in Scotland is more amenable to this 
type of intervention in primary care because of the established 
health-provision role of primary care nurses (health visitors) and 
the day-to-day interactions between clinical psychologists and 
GP services. In the UK, generally, the services provided by the 
National Health Service are all government funded, using rev-
enue from the taxation system. The common co-occurrence of 
insomnia with depressive and/ or anxiety symptoms in primary 
mental health care also highlights the need for investigation of 
CBT for insomnia as an adjunct to existing community treatment 
for these disorders. The intervention described here might be 
readily adapted for that purpose.
In interpreting our findings, several factors merit consider-
ation. First, the dataset are limited to self-report and actigraphic 
estimation of sleep. Although the former in particular is appro-
priate to the clinical-effectiveness question, appraisal of effects 
upon polysomnographically defined sleep at home would be in-
formative. Second, CBT did not specifically target hypnotic drug 
use. Reductions in use were observed with both CBT and TAU. 
This may reflect an implicit focus upon non-pharmacologic man-
agement. Nevertheless, other recent work has demonstrated that 
CBT can be effectively applied to hypnotic reduction as a pri-
mary outcome.52 Third, the use of TAU as the control condition 
of choice for clinical effectiveness study also imposes limitations. 
Important among these is the fact that CBT does not control for 
the additional time, attention, and demand characteristics associ-
ated with provision of a therapy. Although such factors have been 
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controlled for in previous CBT trials, there remains the possibility 
that such nonspecific treatment factors played a part in the re-
sponse to the CBT arm of the present study. Finally, both groups 
in effect had “treatment as usual,” and, so, other factors may have 
influenced our results, even though participants were appropriate-
ly randomly assigned to a treatment group. Efficacy trials ensure 
better control over variation, whereas effectiveness studies give 
indications about potential for service implementation. Clearly, 
both methodologies are required to test the important possibility 
that CBT could become the treatment of first choice for persistent 
insomnia in primary care. 
ACKNOWLEDGMENTS
This study was supported by the Chief Scientist Office, Scottish 
Executive Health Department (CZH/4/Z) and the by the Dr. Mor-
timer and Theresa Sackler Foundation
The authors gratefully acknowledge the administrative and prac-
tical support of Colette Fulton and Lucy McCloughan (Lothian Pri-
mary Care Network), Bridie Fitzpatrick (WestNet, Glasgow) and 
Brian Rae (Primary Care Division R & D, NHS Greater Glasgow). 
We are also grateful to Simon Dixon (University of Sheffield) for 
his assistance with analysis of the SF-36 data and to Lauren M. 
Marchetti and Carolyn J. Espie for their work on data entry. Most of 
all we thank the seven Health Visitors who acted as CBT therapists 
for the study, the General Practitioners who identified participants 
and, of course, the patients who participated in the trial.
TRIAL REGISTRATION
NCT00170417
REFERENCES
1. Singleton N, Bumpstead R, O’Brien M, Lee A, Meltzer H. Psychi-
atric morbidity among adults living in private households, 2000. 
London: The Ofﬁce for National Statistics, HMSO; 2001.
2. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances 
and psychiatric disorders. JAMA 1989:262:1479-84.
3. Lichstein KL, Durrence HH, Reidel BW, Taylor DJ, Bush AJ. The 
Epidemiology of Sleep: Age, Gender and Ethnicity. Mahwah, NJ: 
Lawrence Erlbaum Associates; 2004.
4. Shocat T, Umphress J, Israel AG, Ancoli-Israel S. Insomnia in pri-
mary care patients. Sleep 1999;22: Suppl 2:S359-65.
5. International Classiﬁcation of Sleep Disorders: Diagnostic and Cod-
ing Manual, revised. Rochester: American Sleep Disorders Associa-
tion. 1997.
6. Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-
IV). Washington: American Psychiatric Associatio; 1994.
7. Morgan K. Factors inﬂuencing persistent subjective insomnia in old 
age: a follow study of good and poor sleepers age 65-74. Age Age-
ing 1989;18:17-125.
8. Dew MA, Hoch CC, Buysse DJ, et al. Healthy older adults’ sleep 
predicts all cause mortality at 4 to 19 years of follow-up. Psychosom 
Med 2003;65:63-73.
9. Roth T, Ancoli-Israel S. Daytime consequences of insomnia in the 
United States: Results of the 1991 National Sleep Foundation Sur-
vey II. Sleep 1999;22:Suppl 2, S354-63.
10. Riemann D, Voderholzer U. Primary insomnia: A risk factor to de-
velop depression? J Affect Disord 2003;76:255-9.
11. Cole MG, Dendukuri N. Risk factors for depression among elderly 
community subjects: a systematic review and meta-analysis. Am J 
Psychiatry 2003;160:1147-56.
12. Sateia MJ, Nowell PD. Insomnia. Lancet 2004;364:1959-73. 
13. Kripke D. Hypnotic drugs: deadly risks, doubtful beneﬁts. Sleep 
Med Rev 2000;4:5-20. 
14. Mendelson WB. A review of the evidence for the efﬁcacy and safety 
of Trazodone. J Clin Psychiatry 2005;66:469-76.
15. Guidance on the use of zaleplon, zolpidem and zopiclone for the 
short-term management of insomnia. London: National Institute for 
Clinical Excellence. Technology Appraisal Guidance No.77; 2004.
16. Morin C.M, Espie CA. Insomnia: A Clinical Guide to Assessment 
and Treatment. New York: Kluwer Academic/ Plenum Publishers; 
2003.
17. Kohn L, Espie CA. Sensitivity and speciﬁcity of measures of the 
insomnia experience: a comparative study of psychophysiologic in-
somnia, insomnia associated with mental disorder and good sleep. 
Sleep 2005;28:104-12.
18. Morin CM, Culbert JP, Schwartz MS. Non-pharmacological inter-
ventions for insomnia: a meta-analysis of treatment efﬁcacy. Am J 
Psychiatry 1994;151:1172-80.
19. Murtagh DR, Greenwood KM. Identifying effective psychological 
treatments for insomnia: a meta-analysis. J Consult Clin Psychol 
1995;63:79-89.
20. Smith MT, Perlis, ML, Park A, Giles DE, Pennington JA, Buysse, 
D. Behavioral treatment vs pharmacotherapy for insomnia—a com-
parative meta-analysis. Am J Psychiatry 2002;159:5-11. 
21. Espie CA, Inglis SJ, Tessier S, Harvey L. The clinical effectiveness 
of cognitive behaviour therapy for chronic insomnia: Implementa-
tion and evaluation of a sleep clinic in general medical practice. 
Behav Res Therapy 2001;39:45-60.
22. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer, DJ. The 
Pittsburgh Sleep Quality Index: a new instrument for psychiatric 
practice and research. Psychiatry Res 1989;28:193-213.
23. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression 
Scale. Acta Psychiatr Scand 1983;67:361-70.
24. Johns MW. A new method for measuring daytime sleepiness: the 
Epworth Sleepiness Scale. Sleep 1991;14:450-545.
25. Espie CA. Assessment and differential diagnosis of insomnia in 
later life. In: Lichstein KL, Morin CM, eds. Treatment of Late-Life 
Insomnia. New York: Sage Publications; 2000:81-108.
26. Edinger JD, Fins AI, Sullivan RJ, et al. Sleep in the laboratory and 
sleep at home: comparisons of older insomniacs and normal sleep-
ers Sleep 1997;20:1119-26.
27. Coates TJ, Killen KD, George J, Marchini E, Silverman S, Thoresen 
C. Estimating sleep parameters: a multi-trait multi-method analysis. 
J Consult Clin Psychol 1982;50:345-52.
28. Wohlgemuth WK, Edinger JD, Fins AI, Sullivan RJ. How many 
nights are enough? The short-term stability of sleep parameters 
in elderly insomniacs and normal sleepers. Psychophysiology 
1999;36:233-44.
29. Espie CA. The Psychological Treatment of Insomnia. Chichester, 
England: John Wiley and Sons Ltd.; 1991.
30. American Sleep Disorders Association. Practice parameters for the 
use of actigraphy in the clinical assessment of sleep disorders. Sleep 
1995;18:285-7.
31. Sadeh A, Hauri PJ, Kripke DF, Lavie P. The role of actigraphy in the 
evaluation of sleep disorders. Sleep 1995;18:288-302.
32. Jenkinson C, Layte R, Wright L, Coulter A. The UK SF-36: an anal-
ysis and interpretation manual. Oxford: Health Services Research 
Unit, University of Oxford; 1996
33. Morin C.M, Hauri P, Espie CA, Spielman A, Buysse D, Bootzin 
RR. Nonpharmacologic treatment of chronic insomnia: an Ameri-
can Academy of Sleep Medicine Review. Sleep 1999;22:1134-56.
34. Clarke GN. Improving the transition from basic efﬁcacy research 
to effectiveness studies: methodological issues and procedures. J 
Consult Clin Psychol 1995;63:718-25. 
35. National Medical Advisory Committee. The Management of Anxi-
ety and Insomnia. Edinburgh: Scottish Ofﬁce Home and Health De-
partment, HMSO; 1993.
Treatment of Persistent Insomnia—Espie et al
SLEEP, Vol. 30, No. 5, 2007 584
36. Cohen J. A power primer. Psychol Bulletin 1992;112:155-9.
37. Carstairs V, Morris R. Deprivation and Health in Scotland. Aber-
deen: Aberdeen University Press; 1991.
38. McLoone P. Carstairs Scores for Scottish Postcode Sectors from the 
1991 Census. Glasgow: Public Health Research Unit, University of 
Glasgow; 1994.
39. Espie CA, Inglis SJ, Harvey L. Predicting clinically signiﬁcant re-
sponse to cognitive behavior therapy (CBT) for chronic insomnia in 
general practice: analyses of outcome data at 12 months post-treat-
ment. J Consult Clin Psychol 2001;69:58-66.
40. Rybarczyk B, Lopez M, Benson R, Alsten C, Stepanski E. Efﬁcacy 
of two behavioral treatment programs for comorbid geriatric insom-
nia. Psychol Aging 2002;17:288-98.
41. Broomﬁeld NM, Espie CA. Initial insomnia and paradoxical inten-
tion: an experimental investigation of putative mechanisms using 
subjective and actigraphic measurement of sleep. Behav Cogn Psy-
chotherapy 2003;31:313-24.
42. Friedman L, Benson K, Noda A. An actigraphic comparison of sleep 
restriction and sleep hygiene treatments for insomnia in older adults. 
J Geriatr Psychiatry Neurol 2000:13:17-27.
43. Currie SR, Wilson KG, Pontefract AJ, deLaplante L. Cognitive-be-
havioral treatment of insomnia secondary to chronic pain. J Consult 
Clin Psychol 2000;68:407-16.
44. Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pol-
lak CP. The role of actigraphy in the study of sleep and circadian 
rhythms. Sleep 2003;26:342-92.
45. Littner M, Kushida CA, Anderson WM, et al. Practice parameters for 
the role of actigraphy in the study of sleep and circadian rhythms: an 
update for 2002. Sleep 2003;26:337-41.
46. Guilleminault C, Clerk A, Black J Labanowski M, Pelayo R, Cla-
man D. Nondrug treatment trials in psychophysiologic insomnia. 
Ann Intern Med 1995;155:838-44.
47. Wilson KG, Watson ST, Currie SR. Daily diary and ambulatory ac-
tivity monitoring of sleep in patients with insomnia associated with 
chronic musculoskeletal pain. Pain 1998;75:75-84.
48. Jean-Louis G, Kripke D, Ancoli-Israel S. Sleep and quality of well-
being. Sleep 2000;23:1115-21.
49. Dagan Y, Zinger Y, Lavie P. Actigraphic sleep monitoring in 
post-traumatic stress disorder (PTSD) patients. J Psychosom Res 
1997;42:577-81.
50. Wicklow A, Espie C.A. Intrusive thoughts and their relationship to 
actigraphic measurement of sleep: towards a cognitive model of in-
somnia. Behav Res Therapy 2000;38:679-93.
51. Tryon WW. Issues of validity in actigraphic sleep assessment. Sleep 
2004;27:158-65.
52. Morgan K, Dixon S, Mathers M, Thompson J, Tomeny M. Psycho-
logical treatment for insomnia in the management of long-term hyp-
notic drug use: a pragmatic randomised controlled trial. Br J Gen 
Pract 2003:53:923-8.
53. Dixon S, Morgan K, Mathers M, Thompson J, Tomeny M. Impact of 
cognitive behaviour therapy on health related quality of life among 
hypnotic users with chronic insomnia. Behav Sleep Med 2007:In 
Press.
54. Espie CA, MacMahon KMA, Kelly H-L, et al. Manualised CBT 
for insomnia delivered by nurse practitioners: results from stud-
ies conducted in primary care and in oncology. Sleep Med 2005;6:
Suppl 2:S29.
55. Frankel BL, Coursey RD, Buchbinder R, Snyder F. Recorded and 
reported sleep in primary chronic insomnia. Arch Gen Psychiatry 
1976;33:615-23.
56. Coates TJ, Killen JD, George J, Marchini E, Silverman S, Tho-
resen CE. Discriminating good sleepers from insomniacs using 
all-night polysomnograms conducted at home. J Nerv Mental Dis 
1982;170:224-30.
57. Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive be-
havior therapy and pharmacotherapy for insomnia. Arch Intern Med 
2004;164:1888-96.
Treatment of Persistent Insomnia—Espie et al
Randomized Controlled Clinical Effectiveness Trial of
Cognitive Behavior Therapy Compared With Treatment As
Usual for Persistent Insomnia in Patients With Cancer
Colin A. Espie, Leanne Fleming, James Cassidy, Leslie Samuel, Lynne M. Taylor, Craig A. White,
Neil J. Douglas, Heather M. Engleman, Heidi-Louise Kelly, and James Paul
From the University of Glasgow Sleep
Centre, Southern General Hospital;
Beatson Oncology Centre, Western
Infirmary, Glasgow; Anchor Unit, Aber-
deen Royal Infirmary, Aberdeen; School
of Health, University Campus Ayr,
Beech Grove, Ayr; Edinburgh Sleep
Centre, Edinburgh Royal Infirmary,
Edinburgh, United Kingdom.
Submitted November 13, 2007;
accepted February 11, 2008; published
online ahead of print at www.jco.org on
June 30, 2008.
Supported by Cancer Research UK
(Grant No. C8265/A3036) and from
the Dr Mortimer and Theresa Sackler
Foundation.
Authors’ disclosures of potential con-
flicts of interest and author contribu-
tions are found at the end of this
article.
Corresponding author: Colin A. Espie,
PhD, FBPsS, University of Glasgow
Sleep Centre, Southern General Hospi-
tal, Glasgow, G51 4TF United Kingdom;
e-mail: C.Espie@clinmed.gla.ac.uk.
© 2008 by American Society of Clinical
Oncology
0732-183X/08/2628-4651/$20.00
DOI: 10.1200/JCO.2007.13.9006
A B S T R A C T
Purpose
Persistent insomnia is a common complaint in cancer survivors, but is seldom satisfactorily
addressed. The adaptation to cancer care of a validated, cost-effective intervention may offer a
practicable solution. The aim of this study was to investigate the clinical effectiveness of
protocol-driven cognitive behavior therapy (CBT) for insomnia, delivered by oncology nurses.
Patients and Methods
Randomized, controlled, pragmatic, two-center trial of CBT versus treatment as usual (TAU) in 150
patients (103 females; mean age, 61 years.) who had completed active therapy for breast,
prostate, colorectal, or gynecological cancer. The study conformed to CONSORT guidelines.
Primary outcomes were sleep diary measures at baseline, post-treatment, and 6-month follow-up.
Actigraphic sleep, health-related quality of life (QOL), psychopathology, and fatigue were second-
ary measures. CBT comprised five, small group sessions across consecutive weeks, after a
manualized protocol. TAU represented normal clinical practice; the appropriate control for a clinical
effectiveness study.
Results
CBT was associated with mean reductions in wakefulness of 55 minutes per night compared with
no change in TAU. These outcomes were sustained 6 months after treatment. Standardized
relative effect sizes were large for complaints of difficulty initiating sleep, waking from sleep
during the night, and for sleep efficiency (percentage of time in bed spent asleep). CBT was
associated with moderate to large effect sizes for five of seven QOL outcomes, including
significant reduction in daytime fatigue. There was no significant interaction effect between any of
these outcomes and baseline demographic, clinical, or sleep characteristics.
Conclusion
CBT for insomnia may be both clinically effective and feasible to deliver in real world practice.
J Clin Oncol 26:4651-4658. © 2008 by American Society of Clinical Oncology
INTRODUCTION
Sleep disturbance is an important, common, and dis-
tressingproblem for cancerpatients,1-3 19%to30%of
whommeet insomnia diagnostic criteria,4,5 including
negativedaytimeconsequences.6,7However, insomnia
isoftenunrecognizedorpoorlymanaged8,21 and long-
term pharmacotherapy is not desirable,9-12 especially
when fatigue is problematic,13 yet 25% of cancer pa-
tients regularly take sleeping pills.5
Cognitivebehavior therapy (CBT), effective for
primary insomnia,14-19 is promisingbecause insom-
nia often arises during stress5,6,20 and is perpetuated
by behavioral andmental factors.6,15,20,21
Two randomized trials of CBT for insom-
nia in patients with cancer have been reported.
Cannici et al22 allocated 30 participants with a
range of cancers to a three-session relaxation pro-
gram or no treatment. Self-reported sleep latency
reduced in the relaxation group. Recently, Savard et
al23 studied 57 women (mean age, 54 years) with
insomnia caused/aggravated by breast cancer. CBT
comprised 8 weekly group sessions (each 90 min-
utes) led by a psychologist. Sustained reductions in
sleep latency and wakefulness were observed after
CBT relative to control. There was no increase in
total sleep but increases in sleep efficiency (propor-
tion of time in bed spent asleep) averaged 15%.
This article reports a pragmatic, intention-
to-treat evaluation of nurse-administered CBT, to
evaluate potential for real world implementation of
CBT across a range of cancer subtypes, and within
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the clinical effectiveness tradition. Treatment as usual (TAU) was
employed as the control arm.
PATIENTS AND METHODS
Aims and Objectives
Ouroverall aimwas to test the clinical effectiveness ofCBT for persistent
insomnia associated with cancer in the real world. Major research questions
were: “Is CBT superior to TAU in reducing chronic sleep disturbance and
improving quality of life functioning?” “Are observed improvements dura-
ble?” and “Are there predictors of good outcome or contraindications to CBT
as a first line treatment for insomnia in routine care?”
Participants
Potential participants (18years)were attending follow-upclinics at the
Beatson Oncology Centre, Glasgow or Anchor Unit, Aberdeen Royal Infir-
mary from December 2003 to June 2005. They had to have a diagnosis of
breast, prostate, bowel, or gynecological cancer, and to satisfy diagnostic crite-
ria for chronic insomnia;mean value longer than 30minutes for complaint of
delayed sleep-onset latency (SOL)and/orwake timeafter sleeponset (WASO),
occurring  3 nights per week for  3 months and affecting daytime func-
tion.5,24 Participants also had to screen more than 5 on the Pittsburgh Sleep
Quality Index (PSQI),25,26 a psychometrically robust instrument that identi-
fies clinically significant sleep disturbance. Thus acute insomnia and transient
effects associated with cancer treatment/adverse effects were excluded. Treat-
ment (radiation therapyor chemotherapy)had tobe completedby1month
with no further anticancer therapy planned (excepting adjuvant hormone
therapy). Participants with acute illness, estimated prognosis fewer than 6
months, confusional problems or drugmisuse, orwith evidence of other sleep
Enrollment 
Treatment allocation 
 Evaluation post-treatment 
Evaluation 6 months 
Consented
(N = 220) 
Randomly 
assigned
(n = 150)
Excluded
No response to 
contact
Not meeting 
inclusion criteria
Sub-clinical 
insomnia 
Apnea
Did not have cancer
Cancer type 
Deceased
Consented after 
recruitment deadline   
(n = 70)
(n = 31)
 
(n = 39)
(n = 9)
(n = 1)
(n = 9)
(n = 7)
(n = 3)
(n = 10)
Allocated to CBT 
Received allocated 
intervention
Attended 5 sessions
Attended 1 or 2 sessions
Did not receive allocated
intervention
Recurrence of cancer 
Too ill to attend
Moved out of the area
Deceased
 
(n = 85)
(n = 53)
(n = 5)
 
(n = 15)
(n = 6)
(n = 4)
(n = 4)
(n = 1)
Allocated to TAU (n = 50)
(n = 100)
Received allocated 
intervention
Did not receive allocated
intervention
TAU allocation
Deceased
Recurrence of cancer
 
(n = 43)
(n = 7)
(n = 5)
(n = 1)
(n = 1)
Completed post-treatment
assessment
  Lost to follow-up
  No response/not contactable    
(n = 74)
(n = 11)
(n = 67)
(n = 7)
Completed post-treatment
assessment
  Lost to follow-up
  No response/not contactable    
(n = 41)
(n = 2)
Completed 6-month 
follow-up
Lost to follow-up
No response/not contactable   
(n = 39)
(n = 2)
Completed 6-month 
follow-up
Lost to follow-up
No response/not contactable]   
Fig 1. Participant flow chart. CBT, cognitive behavior therapy; TAU, treatment
as usual.
Table 1. Demographic, Clinical, and Baseline Sleep Information
on the Sample
Characteristic
CBT (n  100) TAU (n  50)
Median IR Median IR
Demographic
Age, years 60.5 53.3-70 58 52-68
Sex
Female 69 34
Male 31 16
Civil status
Partner 72 35
None 28 15
Occupation
Working 35 22
Not 65 28
Location
Glasgow 54 27
Aberdeen 46 23
Clinical
Cancer diagnosis
Breast 60 27
Prostate 22 12
Bowel 15 9
Gynecologic 3 2
Time between cancer
diagnosis and
screening, months
23.5 10-59.5 33.5 10-83.3
No. of patients with
insomnia prior to
cancer diagnosis
48 17
HADS-A 8 4.5-10 8 5-10
HADS-D 5 2-8 5 2-7
Current treatment for
depression
Yes 13 7
No 87 43
FSI interference
subscale
3.57 2-4.96 3.43 1.87-5.43
FACT subscale
Physical 22.6 18-25 23.0 17-25
Social 22.0 16.1-25.5 20.0 15-24.5
Emotional 19.0 16-22 19.0 15-21
Functional 18.0 13-22 18.0 15-22
Total score 80.2 68-89 80.0 66-90
Sleep
Mean insomnia duration
in months
30 27
Standard deviation 12-60 10.8-60
Insomnia
Constant 68 32
Episodic 32 18
Sleep medication
Yes 22 7
No 62 36
PSQI 13 11-16 13.5 11-15
ESS 6.5 3-9.8 8 3-10.3
Sleep onset latency 41.0 20.3-64.8 27.4 22.4-50.0
Wake time after sleep
onset
62.0 40.7-107.5 51.0 30.5-82.0
Total sleep time 399.0 343.3-455.9 392.0 348.0-457.9
Sleep efficiency 80.4 69.5-85.8 82.4 74.5-88.5
NOTE. Data are categorical or median IR.
Abbreviations: IR, interquartile range; CBT, cognitive behavior therapy; TAU,
treatment as usual; PSQI, Pittsburgh Sleep Quality Index; ESS, Epworth
sleepiness scale; FSI, Fatigue Symptom Inventory; FACT, Functional Assess-
ment of Cancer Therapy; HADS-A, Hospital Anxiety and Depression Scale-
Anxiety; HADS-D, Hospital Anxiety and Depression Scale-Depression.
Baseline sleep diary data: n  84 (CBT) and n  43 (TAU).
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disorders (eg, sleep apnea; screened by reports of nightly snoring and noctur-
nal breathing pauses, plus Epworth sleepiness scale27 more than 10) or of
untreated psychiatric disorder, were excluded. Potential participants were
notified of the study by posters/leaflets in clinic waiting areas, by mailing
information to those attending upcoming clinics, or directly by staff on atten-
dance. All participants gave written informed consent and their medical con-
sultant agreed to their participation. The protocol was approved by localNHS
research ethics committees.
Sample Characteristics
Of 220 patients who consented, 31 failed to respond to further contact
(25 females; mean age, 56 years [10.2 years]) and 39 were excluded (23
females; 61 years [13.4 years]; Fig 1). The remaining 150 participants were
randomly assigned (103 females; 61 years [10.5 years]; age range, 38 to 86
years; Table 1).
Approaching three fourths had a partner, but less than 40% were em-
ployed. Breast cancer was the most common cancer type (58% of total),
comprising 87 (84%) of 103 females recruited. There were 34 men with
prostate cancer (23% of total; 72% of males). Twenty-four (16%) had colo-
rectal cancerandgynecological cancers addeda furtherfivepatients. (Recruit-
ment of these cancer types commenced very late in the protocol, hence
their under-representation.) Median interval between cancer diagnosis
and presentation of insomnia complaint to the research team was
longer than 2 years. However, there was a considerable range in these
values because some participants were recruited during first episode
illness and others after cancer recurrence.
Table 1 summarizes other information on psychopathology (Hospital
Anxiety andDepression Scale [HADS]), fatigue (Fatigue Symptom Inventory
[FSI]), and cancer-related quality of life (QOL; Functional Assessment of
Cancer Therapy Scale–general [FACT-G]). TheHADS has been validated for
use for patients with cancer to screen for anxiety and depressive symp-
toms.28,29 Median values for both subscales was 8, however, 20% (CBT) and
23.3% (TAU) of participants screened  11 for HADS anxiety suggesting a
sizeableminorityhadanxietyproblems.30Applying this criterion to theHADS
depressionsubscale revealeda smallerproportion(CBT,9.4%;TAU,7%)with
depressive symptoms. Twenty participants (13%) were receiving concurrent
treatment for depression.
The FACT-G31 and the FSI32 also have good validity and internal con-
sistency.33,34 Fatiguewasmarginallyhigher than that reported inother centers.
For example, the FSI interference score (extent towhich fatigue interfereswith
QOL) inour total samplewashigher (median, 3.57; interquartile range, 1.86 to
5.14) than in a recent validation study (mean, 1.6; standard deviation [SD],
1.8).34 Normative comparison on the FACT-G total score revealed that QOL
in our sample (median, 80; IR 66 to 90) reflected published data from several
large cohorts (mean, 81; SD, 17.0).35
All participants had insomnia longer than 6 months with group
median of 30 months, and 25% had insomnia longer than 5 years. Two-
thirds reported unrelenting insomnia and 23% took hypnotic medica-
tion  1 night of the 10-night baseline. Insomnia was typically severe
(median PSQI, 13),25 higher than in a recent cancer validation study
(mean, 8.15; SD, 4.70).26 Participants were not excessively sleepy dur-
ing the daytime. Symptomatic sleep complaint comprised both diffi-
culty falling asleep (group median SOL, 35.25 minutes) and difficulty
maintaining sleep (WASO, 58.5 minutes.). This reflects clinical insom-
nia in our patients because total wakefulness was around 90 minutes,
and total sleep time (TST) around 6.5 hours. Median SE was 80.6%,
below the 85% lower limit of normal sleep.
Experimental Design
The study conformed to apragmatic, two-center, randomized trial com-
paring CBT with TAU. Major assessments were at baseline, post-treatment,
and follow-up 6 months later. Suitable participants were allocated to either
CBT or TAU by means of the centralized computer-based registration/ran-
domization service available within the Cancer Research UK Clinical Trials
Unit, Glasgow.We stratified for center, prerandomization PSQI scores, exist-
ing treatment for insomnia, and tumor type using theminimizationmethod.
A 2:1 treatment allocation, in favor of the intervention, was selected because
this made efficient use of available CBT sessions and minimized the time a
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patient had to wait before starting CBT, thereby, reducing patient dropout.
Due to the nature of the intervention, it was not possible to blind participants or
therapists toallocation.Noadverse eventswere reportedwitheitherCBTorTAU.
Measures
Potential participants were screened by telephone, when prelimi-
nary diagnostic information and medical/psychiatric history was col-
lected. A comprehensive structured interview obtained a detailed
history, supplemented by completion of the PSQI, Epworth sleepiness
scale, HADS, FSI, and FACT-G.
Subjective sleepwas assessed using a sleep diary,12 completed for 10 days
at each of three assessment points; baseline, post-treatment, and follow-up.
Such diaries are the staple tool of insomnia assessment and offer a valid,
relative index of sleep disturbance when used as repeated measures.18 Items
“how long did it take you to fall asleep last night” and “how long were you
awake in total last night, after you first fell asleep?” assessed the central insom-
nia dimensions of difficulty initiating (SOL) andmaintaining (WASO) sleep.
The diary also enquired about bedtime and rising time, fromwhich total time
in bed, and thence SE were calculated: (SOLWASO/time in bed) 100.
Participants were trained to complete diaries against established criteria.36
Actigraphy provided anobjective estimate of sleep pattern over the same
10-day period. Actigraphs are nonintrusive devices that record movement
through an accelerometer-microprocessor link.37 Actigraphs (Cambridge
Neurotechnology, AW-4, Cambridge, UnitedKingdom)wereworn 24-hours
per day on the nondominant wrist. An algorithm (maximum sampling fre-
quency 32 Hz, recording all movement over 0.05g., filters set 3 to 11 Hz)
enabled Sleepwatch (CambridgeNeurotechnology, Cambridge, UnitedKing-
dom) software to estimate the sleep parameters SOL/WASO/SE using
1-minute epochs.43,44
Data from the FSI andFACT-G taken at each assessment provided second-
ary outcome information to evaluate the effectiveness ofCBT relative toTAU.
Interventions
CBT. Participants assigned to CBT attended five, weekly, 50-minute
sessions during the early afternoon or early evening. These were conducted in
groups of four to six at Maggie’s Center (Glasgow) and the Clan Center
(Aberdeen). These centers, run by the voluntary sector, offer an informal
environment, close tobutnot part of thehospital itself. The content, aims, and
objectives of each session are summarized in online-only Table A1 (further
descriptions inMorin andEspie,38 or fromC.A.E.). The intervention included
standard CBT components such as stimulus control, sleep restriction, and
cognitive therapy strategies.
Therapists. We trained four experienced cancer nurses, who were re-
leased on a part-time basis from oncology nursing duties, to deliver CBT.
(These were G-grade nurses in the United KingdomNational Health Service,
equivalent toward sister level of experience.) On average each nurse worked 6
hours per week on the study. We followed a model of training-to-criterion
standards. That is, these nurses had to demonstrate competence in the practi-
cal delivery of the CBT program. This was ensured by participation in a short
CBT course, apprenticeship learning opportunities, ongoingmentoring by an
experienced clinical psychologist, and evaluation of audiotapes from ran-
domly selected sessions.
TAU and integrity-fidelity of treatment allocation. Effectiveness studies
should replicate real clinical practices and reflect validity and general-
izability.39 Because we were recruiting cancer patients with chronic
insomnia, we expected concurrent physical and psychological symp-
toms, as well as concurrent treatments (except they had completed
active anticancer treatment). The TAU comparison group thus repre-
sented normal clinical practice, where physicians were free to offer
appointments, to prescribe, and tomaintain/discontinue prescriptions.
Effectively, TAUparticipants receivedno additional help for their insomnia.CBT
was, inreality,aCBTplusTAUconditionbecausetheprotocolexplicitlypermitted
normalcontinuationofhealthcare.Attheendoftheprotocol, theTAUgroupwas
providedwithTheGood SleepGuide.40
The integrity of the treatment allocations was ensured using several
procedures (Table A2, online only).
Statistical Analyses
The study was designed to have 80% power to detect a standardized
difference of 0.5 between the treatments (consistent with published meta-
analytic data)18-20 in the four primary sleep outcomemeasures (SOL,WASO,
TST, SE) at post-treatment. A significance level of 0.0125was chosen to adjust for
multiple comparisons. These criteria implied recruiting 204 participants. In prac-
tice, slow recruitment meant that a total of 150 patients was randomly assigned,
giving 80%power to detect a slightly larger standardized difference of 0.59.
The study was analyzed on an intention-to-treat basis. Comparison
between treatments in terms of sleep and QOL variables was derived
from fitting a linear mixed model using a first-order autoregressive
variance structure, incorporating baseline value and other variables
used for minimization as covariates. Data were transformed to approx-
imate normality guided by the constructed variable approach before
applying the model.45 Interactions between SE and baseline parameters
were examined in the context of this model; for this purpose continu-
ous baseline data were dichotomized at the median.
P values for QOL end points were adjusted for multiple compari-
sons within each assessment time point using the Hochberg proce-
dure.46 In Figures 2 and 3 showing median change (95% CIs) in sleep
and QOL parameters from baseline, confidence limits were derived
from bootstrap sampling. Association between changes in QOL and
Table 2. Estimates of Standardized Effects (CBT-TAU) From the Mixed Model Applied to QOL Data
Model
Post-Treatment 6-Month Follow-Up
Standardized
Effect 95% CI P
Standardized
Effect 95% CI P
HADS
Anxiety 0.57 0.96 to 0.18 .005 0.52 0.92 to 0.12 .011
Depression 0.67 1.06 to 0.28 .001† 0.59 0.99 to 0.19 .004
FACT
Physical 0.58 0.19 to 0.97 .004 0.74 0.34 to 1.14  .001†
Social 0.42 0.03 to 0.81 .036 0.13 0.27 to 0.53 .529
Emotional 0.39 0.01 to 0.78 .057 0.16 0.25 to 0.57 .444
Functional 0.86 0.47 to 1.25  .001† 1.17 0.77 to 1.57  .001†
FSI
Interference 0.81 1.20 to 0.42  .001† .82 1.22 to 0.42  .001†
Abbreviations: CBT, cognitive behavior therapy; TAU, treatment as usual; QOL, quality of life; HADS, Hospital Anxiety and Depression Scale; FACT, Functional
Assessment of Cancer Therapy; FSI, Fatigue Symptom Inventory.
Significant at 5% after adjustment for multiple comparisons within each time point using the Hochberg procedure.
†Significant at 1% after adjustment for multiple comparisons within each time point using the Hochberg procedure.
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changes in SE from baseline were examined using Spearman’s rank
correlation coefficient. Association between actigraphic and diary mea-
sures was also assessed using Spearman’s correlation. Finally, the pro-
portion of patients achieving SE higher than 85% was compared
between study arms using logistic regression incorporating the baseline
value and the other variables used for minimization.
RESULTS
Two thirds ofCBTparticipants attendedall therapy sessions, and94%
attended3. Formissed sessions, participants caughtupat the endof
the subsequent attended session. There were similar levels of attrition
during the treatment phase, 18% fromCBT (n 15), and 16% from
TAU (n 7). It is possible that the dropout rate in CBT during the
treatment phase was due to some people not liking the treatment.
However,wehavenodata to confirmor refute this. Respectively, 87%
and 84% of those receiving CBT and TAU provided post-treatment
data, and 79% and 80% completed assessments at 6 months. Those
lost to follow-up did not respond to two subsequent letters or phone
calls. Baseline variables for noncompleters did not differ significantly
from those for completers.
Sleep Pattern
Figure 2 presents a visual comparison, by treatment arm, of
median change scores (baseline to post-treatment, baseline to follow-
up) for each self-reported sleep variable. Table 2 provides estimates of
standardized effects (CBT and TAU) relating to these variables.
Atpost-treatment, CBTwas associatedwithmedian reduction
in SOL of 16minutes (95%CI, 10 to 22minutes), and inWASO of
Table 3. Sleep Diary Results Representing Median IQR Values for the CBT and TAU Groups at Each Assessment Point, and Estimates of Standardized Effects
(CBT-TAU) From the Mixed Model
Result CBT TAU Standardized Effect 95% CI P
Sleep onset latency
Baseline, median 41.0 27.4
IQR 20.3-64.8 22.4-50.0
Sample size 85 43
Post-treatment, median 19.3 27.0 0.86 1.25 to 0.46  .001
IQR 11.9-26.6 16.1-52.8
Sample size 74 40
6-month follow-up, median 19.3 22.4 0.66 1.06 to 0.26 .001
IQR 11.1-28.5 15.5-37.5
Sample size 68 39
Total sleep time
Baseline, median 399.0 392.0
IQR 343.3-455.9 348.0-457.9
Sample size 85 43
Post treatment, median 426.3 409.0 0.27 0.12 to 0.66 .167
IQR 370.1-456.8 327.3-453.3
Sample size 74 41
6-month follow-up, median 438.7 413.5 0.39 0.01 to 0.79 .054
IQR 408.6-470.6 354.0-493.0
Sample size 68 39
Wake time after sleep onset
Baseline, median 62.0 51.0
IQR 40.7-107.5 30.5-82.0
Sample size 85 43
Post-treatment, median 27.0 51.0 0.97 1.36 to 0.58  .001
IQR 14.0-57.5 33.0-93.3
Sample size 74 41
6-month follow-up, median 26.1 34.0 0.76 1.16 to 0.36  .001
IQR 12.6-59.4 22.5-78.0
Sample size 68 39
Sleep efficiency
Baseline, median 80.4 82.4
IQR 69.5-85.8 74.5-88.5
Sample size 85 43
Post-treatment, median 89.8 82.0 1.09 0.69 to 1.48  .001
IQR 81.2-94.0 73.8-89.1
Sample size 74 40
6-month follow-up, median 89.8 88.5 0.88 0.48 to 1.28  .001
IQR 82.1-94.0 72.7-91.5
Sample size 68 39
Abbreviations: IQR, interquartile range; CBT, cognitive behavior therapy; TAU, treatment as usual.
For CBT-TAU.
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38minutes (95%CI, 28 to 59minutes), the correspondingmedian
reductions following TAU were 0 minutes (95% CI, 8.5 to 6.6)
and 2 minutes (95% CI, 15 to 9). Effect sizes were moderate to
large and were both highly statistically significant (P .001). TST
also increased by a median of 16 minutes (95% CI,1 to 30) with
CBT comparedwith 5minutes (95%CI,14 to 24) after TAU, but
the difference between arms was not statistically significant. SE
increased by 10% (95% CI, 9% to 12%) after CBT; the change in
the TAU was 0% (95% CI,3% to 3%). This effect size was large
and highly statistically significant.
This patternof results generally held at 6monthspost-treatment.
Effect sizes were somewhat reduced for WASO, SOL, and SE but
remainedmoderate and statistically significant (P .001).Changes in
TST again were not statistically significant.
In summary, CBT was associated with median reduction in in-
somnia symptoms of almost 1 hour (SOLWASO) compared with
no change followingTAU.Post-treatment and follow-upSEof 85% is
commonly regarded as the lower limit of normal sleep. A higher
proportion of CBT participants achieved this criterion, 51% (51 of
100) versus 34% on TAU (17 of 50; P  .008); at 6 months this
differencewas no longer significant (44%; 44/100 of patients onCBT;
48%; 24 of 50 on TAU; P .966).
Tables 3 and 4 presents actigraphic results for the same sleep
variables.Moderate effect sizes in favor ofCBTwere observed for SOL
andWASO post-treatment (significant at P .05). A large effect was
observed on TST reflecting a reduction in sleep in the CBT arm. This
reflects the impactof the sleep restrictioncomponent.At6months,no
significant actigraphic effects were observed. It should also be noted
that the SOL and WASO changes were not significant when ad-
justed to the conservative 1.25% level of statistical significance.
Associations between actigraphic and corresponding sleep diarymea-
sures of SOL, WASO, TST and SE were modest (0.37, 0.25, 0.47 and
Table 4. Actigraph Results Representing Median Values for the CBT and TAU Groups at Each Assessment Point, and Estimates of Standardized Effects
From the Mixed Model
Parameter CBT TAU Standardized Effect 95% CI P
Sleep onset latency
Baseline, median 14.8 10.2
IQR 6.6-23.7 4.0-22.1
Sample size 84 42
Post-treatment, median 7.8 9.6 0.41 0.80 to 0.01 .046
IQR 4.9-14.9 4.5-18.4
Sample size 74 39
6-month follow-up, median 9.5 11.7 0.35 0.76 to 0.06 .092
IQR 4.6-19.7 4.5-23.0
Sample size 67 38
Total sleep time
Baseline, median 427.5 418.2
IQR 391.7-453.7 391.6-458.8
Sample size 84 42
Post-treatment, median 396.7 425.5 0.81 1.21 to 0.42  .001
IQR 367.3-430.7 397.3-453.2
Sample size 74 39
6-month follow-up 408.4 416.4 0.19 0.60 to 0.21 .351
IQR 371.7-443.0 381.2-443.7
Sample size 67 38
Wake time after sleep onset
Baseline, median 61.6 62.4
IQR 46.6-82.5 46.8-80.5
Sample size 84 43
Post-treatment, median 52.8 61.8 0.50 0.89 to 0.10 .014
IQR 37.7-68.0 44.1-88.1
Sample size 74 39
6-month follow-up, median 59.5 61.2 0.29 0.70 to 0.12 .164
IQR 39.5-77.0 45.6-87.9
Sample size 67 38
Sleep efficiency
Baseline, median 84.2 83.5
IQR 77.9-87.1 80.1-87.3
Sample size 84 42
Post-treatment, median 85.4 85.6 0.13 0.26 to 0.52 .517
IQR 80.1-88.7 80.4-88.3
Sample size 74 39
6-month follow-up, median 84.6 83.3 0.33 0.07 to 0.74 .105
IQR 79.0-88.6 78.1-87.5
Sample size 67 38
Abbreviations: IQR, interquartile range; CBT, cognitive behavior therapy; TAU, treatment as usual.
For CBT-TAU.
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0.31, respectively at baseline). However, these are typical of relation-
ships observed in other contemporary studies.43
QOL
QOLoutcomes are reported as standardized effect sizes (Table 2)
with change score comparisons graphed in Figure 3. Effect sizes were
moderate to large for five of seven comparisons, indicating that CBT
was associatedwith improvedQOLrelative toTAU, atpost-treatment
and at follow-up. More specifically, CBT participants had reduced
symptoms of fatigue, anxiety, and depression, and increased physical
and functionalQOLrelative toTAU.Correlationsbetween changes in
SE from baseline to post-treatment after CBT and changes in statisti-
cally significant QOLmeasures were low.
Dependence of Treatment Effect on
Baseline Characteristics
No statistically significant interactions were found between the
CBT effect and sex (P .640), age (P .402), civil status (P .464),
occupational status (P  .884), Functional Assessment of Cancer
Therapy (FACT)-Physical (P .471), FACT-Functional (P .186),
or FSI interference (P  .892). Similarly, baseline sleep quality
(P  .883), insomnia duration (P  .645), and psychological states
(anxiety, P .471; depression, P .887) did not mediate response.
There was a significant interaction with tumor type (P  .027) and
treatment location (P .012); in amodel containingboth these terms
only treatment location retained statistical significance. Average stan-
dardizedeffectwashigher inGlasgow(1.28; less than .0011)compared
with Aberdeen (0.64; P .002), although both were statistically sig-
nificant and indicate benefit fromCBT.
Qualitative Reports From Patients
We did not formally evaluate what patients thought of CBT.
However, around 50 attended an open evening several months after
completion of the trial. Table A3, online only, presents a sample of
their evaluative comments.
DISCUSSION
Patients with cancer report that their sleep can be disturbed during
stressful times associated with diagnosis/treatment, and persistently
after discharge after anticancer therapy. Findings from this pragmatic
trial suggest that a cognitive-behavioral approach may be clinically
effective. Our results demonstrate sustained improvements in sleep
with large effect sizes for subjectively estimated time taken to fall asleep
and nocturnal wake time, comparable to the primary insomnia
literature.17-20 More modest effects at post-treatment were observed
actigraphically. Importantly,CBTresponsewasnotattributable toany
demographic or clinical subset. Moreover, we found generalized im-
provements in QOL, fatigue, and daytime well being.
Although psychologically based, CBT was delivered by on-
cology nurses, with no prior experience nor expertise in sleep
medicine. This testifies to the potential of CBT itself, and to the
feasibility of this treatment model. Scarce specialists might
train/supervise available staff to deliver CBT as a first level
intervention. Herein we used cancer nurses but we believe the
important thing is that the program is delivered according to
protocol, by a credible professional. We did not model cost
effectiveness but extending the skills of available personnel
could be economical, and permit patients with complex sleep
problems to filter through for expert care. We also observed that
this solution-focused approach was highly acceptable to pa-
tients and professionals. Indeed, insomnia may offer a nonstig-
matizing entry point to psychological care.
Further studies are required, both in the efficacy and the effec-
tiveness tradition. The former, explanatory approach emphasizes rig-
orous entry criteria and highly controlled quasiexperimental design.
The latter, of which this study is a prototype, resembles real world
practice, and informs care delivery. These designs are complementary
and taken together will provide evidence to inform best practice for
this neglected problem.
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THERE IS COMPELLING EVIDENCE THAT COGNITIVE 
BEHAVIORAL THERAPY (CBT) IS A LASTINGLY EFFEC-
TIVE TREATMENT FOR CHRONIC PRIMARY INSOMNIA, 
and mounting evidence that it is similarly effective for persis-
tent insomnia associated with medical or psychiatric disorders.
The challenge for CBT is no longer to prove its credentials, 
but to punch its weight. For at least a decade, CBT should have 
been a contender as the treatment of first choice for insomnia. 
In reality, however, it has had very little impact on the high vol-
ume of insomnia patient care. Indeed, it has amounted to little 
more than a patchy cottage industry.
This is not a criticism of individual professionals, or of 
groups of practitioners, or of local service initiatives. People 
are doing their best; as indeed we have tried to do in Scotland. 
Rather, it is stark recognition that the challenge for CBT with 
respect to delivery is very much greater than so far envisaged.
The argument in this paper is that insomnia constitutes an 
international public health problem. As such, it needs to be ad-
dressed systemically not just clinically; that is at the level of 
care organisation. Prevalence and morbidity data alone dem-
onstrate that CBT would need to be scaled up enormously if 
it were to address population need. This will not happen soon, 
or at all, unless new horizons are scanned. There needs to be 
serious engagement with models that are capable of supporting 
regional, national and international CBT service delivery.
The principal aim of this paper is to open debate on one such 
model, based upon the “stepped care” approach. Before doing 
so, a brief review of CBT is presented to reflect upon its evi-
dence base and its suitability as a “health technology” for adap-
tation to stepped care.
The Efficacy of CBT
Nine systematic reviews or meta-analyses of CBT have 
been published in the past 15 years.1-9 To take two examples, 
the American Academy of Sleep Medicine [AASM (formerly 
the American Sleep Disorders Association of Sleep)] taskforce 
reports (1999 and 2006)4,8 comprised 85 clinical trials (4,194 
participants), and indicated that CBT was associated with im-
provement in 70% of patients, that was sustained at least 6 
months post-treatment. Importantly, there is growing evidence 
not only that sleep parameters improve, but also reports of day-
time functioning. These clinical and generalized benefits reflect 
moderate to large standardised effect sizes (ES). Moreover, the 
2006 review included 12 trials on insomnia associated with 
medical or psychiatric disorders, suggesting that CBT may be 
effective also in more complex populations.
Based on these data, AASM published practice parameters 
statements10,11 using standardized appraisal criteria12,13 endors-
ing the efficacy of stimulus control therapy, progressive mus-
cular relaxation, biofeedback, paradoxical intention therapy, 
sleep restriction and two alternative multi-component CBT ap-
proaches. It is important then to note that CBT is a treatment 
modality, just as is sleep pharmacotherapy (PCT). The latter 
comprises a range of licensed medications, and the former a 
range of (seven) proven psychotherapeutic methods. Please 
also note that “sleep hygiene” is not one of these.
In routine practice, the overwhelming majority of insomnia 
patients is treated with PCT rather than CBT. In contrast to CBT, 
this is not evidence-based for chronic insomnia.5,9,14 There are no 
data to support the long-term resolution of sleep problems fol-
lowing either short-term or medium-term (up to 6 months) PCT, 
whereas the beneficial effects of CBT are known to persist for 
months or years after the treatment course is completed. For ex-
ample, Morin et al. (1999) compared CBT, medication (temaza-
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pam), combined therapy, and a placebo control condition.15 All 
three active treatments produced short-term improvements in 
sleep, but the temazapam-only condition regressed to baseline 
during follow-up. By comparison, both groups treated with CBT 
exhibited good 12-month outcome, suggesting the durable effi-
cacy of CBT relative to PCT. Recently, Sivertsen et al. (2006) 
reported that CBT was associated with greater benefit than zopi-
clone.16 CBT was associated with a 10% increase in polysomno-
graphic sleep efficiency (SEFF) at post-treatment and 6-month 
follow-up, relative to no reliable change with zopiclone.
Based on the published evidence, the National Institutes of 
Health Consensus and State of the Science Statement (2005) 
concluded that CBT is “as effective as prescription medications 
are for short-term treatment of chronic insomnia. Moreover, 
there are indications that the beneficial effects of CBT, in con-
trast to those produced by medications, may last well beyond 
the termination of active treatment” (page 14).14
The Clinical Effectiveness of CBT
For any treatment to become a “gold standard” in routine 
care it is important to have effectiveness data as well as efficacy 
data. Effectiveness studies speak to the generalizability of ben-
eficial effects to the population at large,17 and although research 
of this type is limited for CBT (as it is for PCT), there are indi-
cations that CBT may be effective across a range of presenting 
populations.
For example, a comparative meta-analysis, comparing CBT 
outcomes in middle-aged and older adults (55 years plus), report-
ed moderate to large ES, regardless of age, in sleep onset latency 
(SOL) and wake time after sleep onset (WASO).7 Consistent with 
this, AASM also recommend CBT as a standard treatment for 
insomnia in older adults.11 Likewise, a recent randomized con-
trolled trial has found that CBT is clinically helpful in depressed 
patients with co-morbid insomnia. Manber et al (2008) compared 
citalopram + CBT with citalopram + “sham” CBT, and reported 
significant benefits not only to sleep but to depression itself, re-
flected in an ES difference of 0.24 in favour of citalopram + CBT 
on the Hamilton Rating Scale for Depression.18
We have recently reported on the effectiveness of CBT in 
post-cancer care19; reinforcing the earlier findings of Savard et 
al.20 that CBT is effective in insomnia associated with cancer. In-
deed, much of our work in Glasgow has been in the clinical ef-
fectiveness tradition, enrolling relatively unselected patients into 
our trials programme. We have randomized 490 patients across 3 
clinical trials of CBT versus treatment as usual,19,21,22 and have not 
found any consistent pattern of demographic or clinical predictors 
of poor response to CBT. In other words, our findings support the 
effectiveness of CBT, obtaining an approximate 70% treatment 
response regardless of severity or chronicity of presenting char-
acteristics.23 This is consistent with other UK data showing that 
insomnia in chronic hypnotic users also responds well to CBT.24
The Challenge for CBT
All treatment modalities evolve over time as active elements 
are identified and refined, as new interventions are evaluated, 
and as efficacy data are replicated in clinical effectiveness para-
digms. CBT methods are no exception. There always will be 
questions on treatment outcome to answer – but this is not the 
main challenge. At this point, doubts about CBT do not reside 
in its efficacy, nor even in its effectiveness, but in its feasibility. 
Can CBT really become a first line treatment for insomnia in 
everyday practice?
Figure 1 illustrates some of the dilemmas to be faced in con-
sidering how to offer CBT services to the population who may 
benefit from it. Can a CBT service delivery model be developed 
to cope with high volume of need, safely and effectively, whilst 
still being affordable?
Stepped Care as a Potential Vehicle for CBT Service Delivery
An “insomnia care pathway” is required if we are to pre-
vent nascent CBT services from being strangled at birth. Such 
a pathway would fit well with a stepped care design solution. 
We have previously suggested how a CBT for insomnia stepped 
care “triage” system might work,22,64 as have others.65 Indeed, 
the potential of stepped care has been discussed at professional 
and scientific meetings for some time. Stepped care offers a 
generic approach to care management,25 and is often concep-
tualised as a pyramid. As can been seen in Figure 2, high pa-
tient volume is managed at the base of the pyramid using low 
intensity treatments, with progressively smaller volumes, and 
greater expertise in assessment and treatment, being concen-
trated towards the top step. Certainly in the UK, an important 
part of mental health service commissioning is focussing upon 
the urgent need to increase access to psychological therapies 
for common mental health problems, with stepped care being 
proferred as part of that solution.26
Crucial, to the successful and safe operation of stepped care, 
is that the level of intervention that people receive, either ini-
tially or subsequently, is not arbitrary; rather, it should reflect 
assessed need. Moreover, the number of steps in any stepped 
care model would be determined by the number of interven-
tions or levels of intervention that are proven and available, and 
also by the upper limits of what within the healthcare system 
would be affordable.
Let us then consider criteria for selecting an “entry level” 
treatment within a stepped care system. At this level, repre-
sented by the base of the pyramid, the least restrictive therapy 
has to be identified (Figure 2). According to Bower & Gilbody 
(2005),25 this should be a:
Needs 
 
High demand for CBT 
+ 
Short supply of CBT 
 
Perceptions 
 
CBT is complex 
+ 
CBT is time-consuming 
+ 
CBT is expensive 
 
Insomnia service dilemmas 
 
CBT service would be 
impossible to develop/ deliver 
+ 
CBT service would quickly 
become overwhelmed 
+ 
CBT would have to be highly 
selective, for the few 
 
figure 1—The CBT feasibility agenda.
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readily accessible•  form of treatment,
provided at the lowest cost•  and
least personal inconvenience•  to patients, and
requiring the • lowest treatment intensity and
the • least specialist time.
Bower and Gilbody go on to suggest several important prin-
ciples or assumptions underlying stepped care. These are sum-
marized in Table 1.
First, this least restrictive therapy must satisfy what is known 
as the equivalence assumption. That is, despite being a mini-
mal intervention, the entry level treatment must be evidence-
based to provide significant health gain. That is, a deliverable 
and relatively inexpensive treatment that can benefit at least a 
substantial proportion of patients, but without risking adverse 
effects. So, for example, if a simple and easily administered 
benign treatment had been shown to lead to remission or clini-
cal response, in say 30% of patients, it would be equivalent in 
outcome for these patients to any more complex, more time-
consuming, or more expensive intervention that they might oth-
erwise (unnecessarily) receive.
Second, and extending the above argument, the efficiency 
assumption supports the use of the minimal effective interven-
tion at each step as a reality check upon the true (finite) avail-
ability of healthcare resources. That is, not only would it be 
effective to follow a stepped care approach, it would also be 
prudent. By investing resources across a spread of intervention 
steps, it is more likely that the maximum number of patients can 
be treated in an optimal way, within budget. Again, using the 
above example, the minimal intervention might meet the needs 
of say 30% of the patient population. Thus, it satisfies what 
would otherwise be a substantial demand on resources whilst 
actually consuming relatively little resource, and without detri-
ment to care outcomes. At the whole population level, this helps 
to deliver population health gain because it provides effective 
treatment quickly to many, and conserves resources (time, ex-
pertise, funds) for those patients whose effective treatment will 
require greater resource.
Third, a stepped care service must be acceptable both to pro-
fessionals and to patients. The acceptability assumption is ad-
dressed by capacity in the system both for an initial evaluation 
of need and for subsequent “self-correcting movement,” so that 
patients can shift between levels when this is deemed appropri-
ate. Supposing an individual starts off at a given level, a decision 
might be made later about discharge or about stepping up to the 
next level, based upon their progress. This might be appraised 
through review of validated data collected on their condition 
(e.g Insomnia Severity Index27,28 scores against threshold cri-
teria), or through clinician judgement that outcomes are or are 
not (yet) satisfactory. But also, the patient would be permitted 
the perspective that s/he may prefer to see someone with a high 
level of expertise and/or for longer, even though this might not 
appear to be necessary from an evidence-based perspective.
Stepped care models have proven useful for a wide range 
of disorders. It is beyond the scope of this paper to go into this 
in detail, but, for example, a good review of stepped care for 
chronic illness was published recently29 and stepped care for 
primary care patients with persistent depression has been en-
couraged for at least the past 10 years.30 It is noteworthy in this 
latter respect that three meta-analyses of brief behavioral in-
terventions for depression have been published within the past 
couple of years.31-33
Is Insomnia a Suitable Disorder for Stepped Care?
There are four main reasons for considering insomnia to be a 
suitable condition for stepped care.
First, insomnia is very common.34,35 A problem that affects 
20-25% of the adult population, and up to 10% on a chronic 
basis, requires a care pathway to be developed to manage it 
effectively. All practitioners and healthcare services operate on 
finite resources, hence the need to manage common problems 
both soundly and equitably.
Second, and related to the first, insomnia presents with 
varying levels of severity and complexity, from short-term 
troublesome symptom, through persistent primary disorder, to 
co-morbid disorder.36 The fact that persistent insomnia is an es-
tablished risk factor for mental ill-health37,38 also suggests that 
judgement needs to be exercised to determine when, and at 
what level, a patient’s insomnia should be addressed.
Third, there are pragmatic reasons to develop stepped care 
for the behavioral management of insomnia, not least of which 
is the shortage of skilled practitioners. There are relatively few 
people with sufficient expertise to treat the high volume of 
insomnia patients who might benefit from CBT. Some useful 
suggestions have been made about how numbers of behavioral 
sleep medicine specialists might be increased.39 However, the 
Table 1—Assumptions Underpinning the Stepped Care Model [adapted 
from Bower & Gilbody, 2005] 25
1. Equivalence assumption Minimal interventions can provide 
“significant health gain” 
2. Efficiency assumption Using minimal interventions reflects 
healthcare resource
3. Acceptability assumption Stepped care is acceptable to 
patients and to professionals
low 
high
“Self-correcting” 
movement between 
steps
“Self-correcting”  
movement between 
 steps
Entry step is the “least restrictive therapy” 
low 
high
VolumeExpertise
figure 2—A generic stepped care model illustrating incremental levels 
(steps) of intervention complexity. The most efficient service will ensure 
maximal throughput by stepping patients according to need, matching 
interventions to needs, and making best use of available expertise.
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that is tailored specifically to a patient’s complex sleep needs 
over numerous sessions delivered by an expert psychologist 
trained in behavioural sleep medicine would represent the most 
resource intensive approach. This may be necessary for some 
patients, but probably not for very many. This is a crucial point. 
The great majority of insomnia patients need not, should not, 
and could not (possibly) be treated by such highly qualified in-
dividuals.
At the other extreme, a sizeable proportion of patients might 
derive significant benefit from a guided self-help book, from 
participation in a CBT class in a community college or sports 
centre, or through a web-based CBT portal. There is an insuffi-
cient evidence base at present to differentiate these precisely, or 
indeed other resource combinations that might be constructed, 
but the point is that CBT is intrinsically an adaptable health 
technology.
Second, although a limited analogy, it may be helpful to think 
of stepped care as a “dosing schedule,” whereby any given pa-
tient will require the necessary amount of intervention to re-
spond (not less because it will not work, and not more because 
it will not add anything). “Dose” might be determined by the 
number of elements in the treatment, the number of sessions, 
the amount of personal tailoring of treatment, the qualifications 
and experience of the therapist, ….. and so on, as per the con-
tent of the domains in Figure 3. Consequently, entry level CBT 
should be the lowest dose proven to be associated with clinical 
improvement. Traditionally, a dose response is the relationship 
between the amount of exposure (dose) to a substance, and the 
resulting changes in body function or health (response). It has 
been suggested that the therapeutic session is the natural quan-
titative unit of psychotherapy. That is, the number of sessions 
is stochastically related to exposure to the active ingredients 
in any psychotherapy.41 Following this rationale, Edinger et al. 
(2007) have shown that a brief CBT (4 session) intervention 
is clinically effective in primary insomnia, but less so in co-
morbid insomnia,42 implying that dosing may need to reflect 
complexity of presentation. Whatever the input is chosen as the 
dosing unit, and whatever the limitations of the analogy in gen-
eral, it does seem that CBT would be a suitable intervention for 
stepped care also because there are numerous escalating charac-
teristics that might be applied to its delivery (cf. Figure 3).
Third, CBT is also suitable for stepped care because, in the 
real world, people do make choices about treatment. In one el-
egant study, behavioral and pharmacological treatment scenar-
ios were offered to insomnia patients who rated these in terms 
of their acceptability.43 Results showed that typical patient 
preference was for a behavioral treatment approach. We have 
recently replicated this preference for CBT in patients with psy-
chophysiological insomnia and idiopathic insomnia. We have 
also demonstrated that some patients with idiopathic insomnia 
would be open to a (non-curative) acceptance-based approach 
to therapy.44 Importantly, people make choices not only about 
the type of treatment that they would prefer, but they also make 
behavioural choices about home implementation of treatments. 
Such motivational processes are cognitive-behavioral in na-
ture, again indicating the suitability of CBT for insomnia. So, 
whereas the number of sessions offered or attended reflects an 
administration (exposure) dose of CBT provided to the patient, 
the “absorbed” dose taken by the patient reflects their home 
base number remains very low, even in the US where sleep ser-
vices are better established.
Fourth, insomnia is typically a chronic disorder that does 
not necessarily remit.40 Certainly, there are everyday sequelae 
of insomnia, but these are seldom novel, acute, or inherently 
dangerous. Rather, the morbidities associated with persistent 
insomnia are longer term risks to health and well-being. Conse-
quently, insomnia is a suitable disorder for stepped care, even at 
the entry level, because there may be few adverse consequences 
to providing a minimal intervention, even if a proportion of pa-
tients are initially non-responders. Besides, they would then be 
stepped up to a higher intensity treatment.
Finally, it should be noted that pharmacotherapy for insom-
nia also can be readily accommodated within a stepped care 
approach, ranging from herbal and other “medicinal” products 
that people purchase for themselves “over the counter” at one 
extreme, through primary care management, to expert prescrip-
tion and review of licensed and “off label” medications. It is 
beyond the scope of this paper to discuss PCT in any detail, but 
it is important to acknowledge that the evidence-based treat-
ment of insomnia at population level requires both CBT and 
PCT to be available and that, in practice, CBT and PCT may 
be offered to individuals in combination. Consideration of an 
insomnia stepped care pathway, therefore, does not intrinsically 
prejudice clinical practice or research study in one direction or 
the other.
Is CBT a Suitable Intervention for Stepped Care?
There are several compelling reasons for believing that CBT 
is an inherently suitable treatment modality for stepped care.
First, as psychotherapies go, CBT methods have proven to 
be remarkably adaptable, across a wide range of disorders.26 
CBT is no exception. Indeed, Figure 3 illustrates that there are 
six domains of resource intensity that might be (co-) varied to 
yield treatment solutions. So, for example, one-to-one therapy 
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Client domain 
• Individual 
• Group 
• Class 
• Community 
Product domain 
• Tailored  
• Manualized  
• Book/CD  
• Internet  
 
Practitioner domain 
• BSM specialist 
• CBT specialist 
• Trained therapist  
• Untrained 
professional 
• Self-help 
 
Content domain 
• Number/ duration 
of sessions 
• Ingredients of 
therapy 
• Credibility/ skill of 
practitioner 
 
 
 
Problem domain 
• Insomnia sub-type 
• Severity/ chronicity 
• Complexity of case 
 
 
Implementation domain 
• Preference 
• Motivation 
• Adherence 
• Stait/ trait factors 
 
 
C
B
T 
figure 3—Methods of delivery of CBT: Interacting domains reflect levels 
of resource intensity in CBT.
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PSG staff, pharmacists) could deliver manualized CBT equally 
faithfully and effectively. This has yet to be formally evalu-
ated. Taking our most recent trial as an example,19 standardised 
relative ES at post-treatment and at 6-month follow up for CBT 
were medium to large for SOL, WASO, and SEFF, with a small 
ES for total sleep time. Medium ES were also found for reduc-
tions in anxiety, depressive and fatigue symptoms, and for im-
provements in health-related quality of life, indicating that the 
benefits of CBT may go beyond sleep pattern per se.
There is then substantial evidence for manualized CBT1-8 and 
that it may be delivered in cost-effective ways.19,21,22,50 Manual-
ized CBT could be the entry level treatment in the stepped care 
model, but there may be a step below this.
self-administered CBT
“Self-help” is a rapidly growing area within mental health, 
and consistent with this, bibliotherapy, CD-ROM, televised 
media and internet-delivered CBT methods have now been re-
ported.51 Whereas the first published paper on self-administered 
behavioral treatment for insomnia appeared 30 years ago,52 it 
is only relatively recently that such approaches have become a 
focus of systematic research investigation.
A meta-analysis of 10 studies enrolling a total of 1,000 par-
ticipants concludes that minimal contact (e.g., telephone sup-
port, brief appointments) or entirely self-directed (e.g., books/ 
booklets, audiovisual, internet) CBT yields small to medium 
ES.53 Thus, there appears to be significant population benefit, 
but the effects are weaker than in individual or group treatment. 
Consistent with this conclusion are data from formal compari-
sons of self-administered vs. “face to face” CBT, where the lat-
ter has generally shown superior outcomes, although self-help 
was also beneficial.54-56 Internet-delivered CBT is relatively 
novel. Three randomized trials have been reported to date57,58,61 
and results so far are encouraging, particularly given the poten-
tial of the web to reach extremely large populations
Therefore, taking all the evidence on CBT into account, it 
seems reasonable to conclude that self-administered CBT offers 
the least restrictive entry based treatment that has satisfactory 
outcome data, with nurse-delivered small group CBT providing 
the second level (Figure 4).
What Might Constitute the CBT Stepped Care Hierarchy?
The domains in Figure 3 should assist researchers to consider 
how resource intensity of CBT might be modelled in healthcare 
services and in future outcome studies. From the present litera-
ture, we know that nurses, graduate psychologists, experienced 
clinical psychologists, and expert clinicians have all been in-
volved in CBT trials, and that there is an emerging range of 
delivery methods. Figure 4 is proposed as an exemplar of what 
evidence-based stepped care might look like, circa 2009. It also 
parallels contemporary pathways for other common mental dis-
orders.26,59
Working on this occasion from top down, at the top of the hi-
erarchy, we might have the most experienced specialists, with the 
relatively rare combination of CBT and Behavioral Sleep Medi-
cine skills, working with individual complex cases, perhaps on 
a tertiary referral basis at a sleep centre. At the next level, clini-
cal psychologists might take on individual CBT patients. Indeed, 
there may be considerable untapped potential for qualified psy-
implementation/ adherence to the therapeutic instructions. We 
know, for example, that patients who achieve more consistent 
bedtimes and rising times have improved sleep efficiency 45 
suggesting that application of advice is an important predictor 
of outcome. Likewise, it has been found in one study that only 
adherence explained variance in patients’ post-treatment out-
come.46 Indeed, the importance of choice is evident in that not 
all patients with insomnia even seek help through traditional 
clinical routes.47,48 Stepped care offers greater engagement with 
such issues by explicitly recognizing that acceptability is cen-
tral to the way people behave (Table 1).
What would be the Entry Step for CBT that is Evidence Based?
In order to construct a stepped care model for CBT, it is of 
first importance to consider what would be the minimal inter-
vention, known to provide significant health gain (Figure 2), 
that satisfies the assumptions summarized in Table 1.
sleep hygiene
In practice, the most common non-pharmacological ap-
proach is probably provision of sleep hygiene education, either 
verbally during consultation or by clinic leaflet. In terms of Fig-
ure 3, this represents self-help material, BUT with very limited 
CBT content either conceptually or therapeutically. Certainly it 
is unrestrictive (cf. Table 1), however, there is no evidence from 
trials data or from meta-analyses that sleep hygiene is an effec-
tive treatment. Indeed, sleep hygiene is not even mentioned in 
either the 2005 US NIH insomnia consensus statements, 14 or in 
the 2004 UK NICE technology appraisal on the management of 
insomnia.49 Furthermore, current AASM insomnia practice pa-
rameters state that “insufficient evidence is available for sleep 
hygiene education to be an option as a single therapy. Whether 
this therapy is effective when added to other specific approach-
es could not be determined from the available data” (p. 1417).11 
Thus, the apparent proliferation of sleep hygiene advice as if it 
were a stand alone treatment, or even as an adjunct to PCT, is a 
practice that is independent of supporting data. Sleep hygiene 
does not meet the essential criteria for a minimally effective 
intervention offering significant health gain and so cannot be 
the first step within a stepped care CBT approach.
manualized CBT
In contrast to sleep hygiene, an intervention “product” that 
does appear to be well evidenced is manualized CBT.4,8,36 This 
is where the practitioner follows a highly structured treatment 
protocol based upon therapeutically indicated CBT elements 
(content domain in Figure 3). The manual helps to ensure treat-
ment fidelity, and also consistency in clinical practice. Manual-
ized CBT has been found to be effective also across a range 
of client groups from primary insomnia to insomnia associated 
with medical or psychiatric disorder. The majority of published 
studies has utilized individual therapy, typically provided by 
a psychologist, but a substantial minority has adopted a group 
treatment approach.1-8
Our own approach involves CBT practitioners delivering 
manualized CBT over five, weekly, small group sessions.19,21,22 
We have used nurses as therapists, for professional (e.g. familiar 
with protocols) and pragmatic (largest group of healthcare pro-
fessionals) reasons. However, we believe that other staff (e.g. 
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In circumstances where a pa-
tient is subsequently “stepped up” 
to a more intensive intervention, 
particular attention would need 
to be paid to their expectations 
(which may be negative if they 
have already failed to respond), 
and to their prior knowledge 
(which on the other hand could 
be built upon). Crucially, limited 
or no response may indicate that 
the previous assessment missed 
something important (e.g., associ-
ated disorders), underestimated the 
severity of the insomnia and the 
“level” of CBT required to address 
it, misjudged the acceptability of a 
CBT approach, or that the primary 
therapeutic challenge now is that 
of motivation and adherence to 
CBT rather than CBT per se.
All of these factors indicate 
that iterative assessment and re-
view is the key to the success of 
the stepped care system (Figure 
4) and that the standardisation of 
these assessment processes would benefit not only consistent 
clinical practice but also the pooling on a large scale of research 
data to evaluate benefit.
The Evidence Base for Clinical Governance in CBT
All services offered to patients must be safe, effective and ethi-
cal. It is normal practice to have policies and procedures on how 
referrals are made, how cases are allocated, how and when to re-
view progress, and how to end episodes of care or to commence 
new episodes. Likewise, it is incumbent on all professional groups 
to know, and to work within, the boundaries of their training and 
their clinical competence, and to maintain their skills for (re-)ac-
creditation purposes. In a stepped care system it is particularly 
important to raise issues of clinical governance because of the 
relatively fluid nature of the boundaries between the steps.
At the time of writing, from an evidence-based perspective, 
about all we can say is that clinical leadership in CBT services 
can be safely and effectively provided by clinical psychology 
professionals. This conclusion is underpinned by the summary 
of points provided in Table 2, and by the available data.
In brief, CBT is undeniably a psychological theory and thera-
py, the published evidence for which has been delivered almost 
exclusively by psychology-led research.1-8,53 In this respect, it 
may be important to clarify that, in Glasgow, our nurse thera-
pists work entirely under the training, direction and supervision 
of the psychology team. Indeed, this actually demonstrates how 
a stepped care system can work, because the role of the psy-
chologist is in assessment, triage, case management and review, 
and clinical service development, and not only in direct patient 
care. This is a fairly direct parallel with the “medical model”; 
clinical responsibility in our setting rests with the supervisor 
of the CBT programme, the clinical psychologist. Table 2 also 
highlights that clinical psychology professionals are trained 
chologists who already have extensive generic training in CBT 
methods to extend their expertise to include insomnia disorders. 
Below this, a less experienced graduate student might provide 
individual therapy or a flexible version of group CBT where the 
manual could be tailored in parts to the presenting needs and 
problem formulation. A strictly manualized group CBT pro-
gramme led by a nurse (or other professional) would then sit at 
the level below, and immediately above the proposed entry level 
of a self-administered form of CBT. The three lowest tiers might 
best be provided in primary care, although there is an argument 
also for the next again (fourth) level also being in primary care. 
This may depend on the nature of local services.
How would people be allocated and move between levels of the 
stepped care CBT system?
In the general description of stepped care, presented earlier, 
the equivalence assumption would suggest that people should 
be allocated initially to an entry level treatment, providing they 
are content to accept that, and that there is no specific evidence 
that they would be unlikely to respond and no contraindication 
in terms of risk. This approach places emphasis upon skilled 
assessment, and herein lies a potential problem — of creating a 
bottle-neck of (more) people waiting to have their needs evalu-
ated, and so waiting (even longer) for treatment.
Therefore, for a stepped care system to work on a large scale 
it would be necessary for the healthcare system to settle upon a 
range of common, validated, and simple tools for initial assess-
ment of the insomnia complaint, and of associated complaints. 
There is a number of such self-report scales available, as re-
ported earlier. Indeed, consensus opinion on these is available. 
Likewise, a standard post-intervention assessment should be 
used to determine what, if any, next steps are required, coupled 
of course with clinical judgement.
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Expert CBT 
delivered by
BSM specialist
Individual, tailored CBT
delivered by a 
clinical psychologist
Individual or small group CBT
delivered by a 
graduate psychologist
Small group, manualized, brief CBT
delivered by a 
trained therapist
Assessment/allocation Review/discharge/refer on
Self-administered CBT
delivered by 
booklet, CD/DVD, internet
figure 4—An evidence-based stepped care model for CBT (c. 2009) illustrating how patients might be al-
located to resources in relation to assessed need, to achieve optimal service provision. Arrows represent 
self-correcting referral movements.
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tells us about who can deliver and who can supervise CBT, there 
will be other sources of influence. Clinical governance arrange-
ments, line management structures, issues relating to pay and 
reimbursement, may all vary nationally and locally. It is wise to 
accept that there will be vested professional interests and that 
some of these will have no genuine evidence base. Consequent-
ly, consultation, negotiation, and above all, pragmatism, will 
be necessary to find a workable way ahead. Further research is 
certainly needed to inform such debate, particularly in relation 
to cost-effectiveness for the purposes of manpower planning.
Consequently a further recommendation is:
that work should be completed urgently to consider the 4. 
advantages to patient care of developing an inter-disci-
plinary approach to behavioral sleep medicine practice. 
The knowledge-base, the theoretical orientations, and 
the competencies of the the various professional groups 
who might be involved should be seen as complemen-
tary, rather than competing, bearing in mind that cost-
effective use of people’s time and of other health care 
resource is of the utmost importance
stepped Care and the health Care system
The stepped care model helps to ensure that the right level of 
effective care can be provided to the many, not just to the few, 
and that in so doing, relatively scarce expertise is appropriately 
targeted. As we have seen, this economy of resources applies not 
only to direct treatment but also to clinical governance of the 
service. All of this seems both necessary and timely for CBT.63
Of course, each health care system will need to consider how 
it could implement a stepped care model. The application of 
stepped care is perhaps easiest to envisage in a publicly funded 
health care system, like the UK National Health Service, where 
services are funded entirely through tax revenue (from those eli-
gible to pay income tax) and where ability to pay has no influ-
ence over the nature or quality of care received. Nevertheless, 
principles such as equitability of health care provision are central 
to most health philosophies. Coupled with the CBT growing evi-
dence base for remission and recovery from sleep disorder, health 
services, whether publically funded or insurance-based, would 
do well to consider the population morbidity that is normally as-
sociated with persistent insomnia. Stepped care CBT may offer 
a feasible service model, enabling not only insomnia patients to 
be treated at the right level, but having sufficient “reach” that as-
sociated population health might improve. Indeed, the potential 
for such “down-stream” benefits may be important, persuasive 
arguments for encouraging some health care organisations (such 
as HMOs in the US) to invest in stepped care for insomnia. The 
development and persistence of insomnia is not good for people, 
who are then more likely to go on to develop (other) costly condi-
tions that potentially reduce the profits of the health care indus-
try. The early and effective treatment of insomnia may improve 
health and save money. Moreover, there is likely to be some cost 
saving associated with treating at the assessed level of need with-
in stepped care, because the majority of patients may not need to 
be seen beyond the primary care level of intervention.
Conclusions and Future Directions
There is compelling evidence that CBT is effective in the 
treatment of chronic insomnia. Moreover it appears to be popu-
mental health professionals, with generic skills in CBT methods 
(and other psychosocial interventions). Importantly, therefore, 
they are qualified to administer psychological therapies that are 
not yet invented, just as physicians are (already) licensed to pre-
scribe new medicines that come on the market. Psychologists 
are also the people most likely to develop, instrument and op-
erationalize novel psychological interventions because they are 
doctorally qualified behavioral scientist-practitioners.
None of this is to say that other professionals do not have 
generic psychological competencies or specific CBT compe-
tencies (and certainly they could develop them), but the only 
evidence that we have currently available is that CBT is effec-
tive in contexts where it is practised by psychologists or under 
close psychology supervision. It is noteworthy here that there 
are ongoing efforts being made to develop generic competency 
frameworks for different levels of CBT practice, that would be 
open to any practitioner.59,60
In consequence of these matters relating to clinical gover-
nance, it seems appropriate to assert that professional leader-
ship in behavioral aspects of sleep is essential to safe, effective, 
and comprehensive clinical practice in sleep medicine. It is rec-
ommended, therefore:
that the appointment of a suitably qualified and experi-1. 
enced clinical psychologist with behavioral sleep medi-
cine credentials should become an essential criterion for 
the accreditation of sleep centres;
that the roles of this lead person should comprise a) ad-2. 
vanced clinical practice, b) staff training and clinical su-
pervision, and c) service development;
that these roles are not restricted to insomnia, but extend 3. 
to other sleep disorders where a cognitive-behavioral ap-
proach to care is appropriate and is evidence-based (e.g. 
adherence to treatments, parasomnias)
It has to be acknowledged that there are some tricky inter-
professional issues that will have to be faced here; perhaps even 
intra-professional ones. This has been recognised both within 
the sleep field,39 and more generally.62 It is important to under-
stand that, quite apart from whatever extant, or future, evidence 
Table 2—Reasons for Suggesting that Clinical Leadership in CBT Should 
Normally Lie with Psychology
CBT is essentially psychological practice1. 
CBT is based on psychological theory & principles2. 
Psychologists have developed CBT & will continue to develop new 3. 
CBT interventions
Psychologists are trained to use advanced CBT with complex 4. 
cases
Psychologists are qualified to deliver CBT methods that are not yet 5. 
invented
Psychologists have extensive mental health expertise6. 
Psychologists are trained behavioural scientists7. 
The published literature on CBT is almost exclusively from psychol-8. 
ogy research groups
Psychologists are trained as psychometricians and are trained in 9. 
systemic working
Psychologists are developing competency frameworks for CBT 10. 
methods generally
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ognition that the assessment and review process is iterative. Peo-
ple will move (appropriately) between levels, so we will need to 
know the sensitivity/ specificity of the original, and subsequent, 
decisions about placement within the hierarchy, in terms of treat-
ment response and recovery. Moreover, mediator and moderator 
variables (e.g. patient characteristics, treatment preference, for-
mat, setting, therapist factors) that we usually try to control for, 
or at best try to evaluate post hoc, need to become the primary 
focus of research endeavour if we are to know what best works 
for whom. Above all, if we were to reach the dizzy heights, that 
the availability of CBT were no longer an issue, the single and 
combined use of CBT and PCT would need to be evaluated prag-
matically, in real world settings, in respect of both short and long-
term outcomes at each level of the stepped care model.
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Writing Intervention in Primary Insomnia
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Faculty of Medicine, Southern General Hospital, Glasgow, Scotland
This study considers the role of pre-sleep cognitive arousal, worry, and inhibition in sleep onset
difficulties. The Pennebaker writing task, which promotes emotional processing by asking people
to write about their thoughts, worries, and emotions, has proven effective in several areas of health.
Here, the paradigm’s ability to reduce pre-sleep cognitive arousal (PSCA) and sleep onset latency
(SOL) in people with insomnia was tested. Twenty-eight people with insomnia were randomized
to three nights of Pennebaker writing or a control condition, following a one-night baseline. The
outcomes of change over baseline at Day 4 in pre-sleep cognitive arousal and SOL were compared.
Writing significantly reduced pre-sleep cognitive arousal on one out of two measures, but did not
significantly reduce SOL.
The central role of cognitive arousal and worry in sleep difficulties is well-established (Espie,
2002). Converging evidence suggests the pre-sleep cognitive activity (PSCA) of people with
insomnia is excessive, uncontrollable, negatively toned, and covers a broad range of topics
(e.g., Harvey, 2000; Wicklow & Espie, 2000). Furthermore, there is evidence that decreasing
intrusive and worrisome thoughts of people with insomnia using experimental techniques (e.g.,
Harvey & Payne, 2002) can improve sleep onset latency (SOL).
Harvey’s (2002) model of the maintenance of primary insomnia (PI) draws on such evidence,
together with studies that have shown that poor sleepers inhibit and/or internalize psychological
conflicts (Edinger, Stout, & Hoelsscher, 1988; Kales, Caldwell, Soldatos, Bixler, & Kales,
1983). This model states that for poor sleepers, unwanted PSCA at night may be a consequence
of inhibition of emotional concerns during the day. Such “unfinished business” not dealt with
Correspondence should be addressed to Patricia Mooney, Elizabeth Martin Clinic, 1 Burns Square, Greenock,
Inverclyde, PA16 0NT, Scotland. E-mail: patricia.mooney@renver-pct.scot.nhs.uk
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prior to bedtime intrudes during the pre-sleep phase, fuelling PSCA and, in turn, delaying sleep
onset.
The Pennebaker writing task (e.g., Pennebaker, 1997) is purported to reverse inhibition
of emotional concerns, directing individuals to express their deepest thoughts, worries, and
emotions through writing. Meta-analyses (Smyth, 1998; Frisina, Borod, & Lepore, 2004) show
beneficial effects on a range of physical and psychological outcomes, including sleep. In a
pilot study, Harvey and Farrell (2003) randomly allocated poor sleepers to three nights of
either utilizing the Pennebaker task, writing about “hobbies,” or to a “no writing” control
group. They found that participants who wrote about problems and worries prior to bed using
the Pennebaker paradigm experienced shorter SOL compared to those who did not write.
This pilot data is encouraging but requires replication. In particular, as the authors themselves
recognize, several points of methodology require examination. First, no baseline condition was
employed. The sleep changes observed may, therefore, reflect inter-subject variability and/or
changes unrelated to the experimental intervention. Second, it may be possible that the rationale
given to the Pennebaker group informing them of the tasks benefits led to expectations of
sleep improvement. Finally, no measurement was made of whether sleep effects were actually
mediated by reduced PSCA. Clarifying these aspects should help us to better understand and
apply the Pennebaker task to insomnia treatments. In addition, this study was carried out with
a sample of poor sleepers and, as such, it is not known whether the results generalize to people
who meet criteria for insomnia.
The current study was, therefore, designed to replicate and extend Harvey and Farrell’s
(2003) work while addressing these limitations. Thus, PSCA was measured. Furthermore, given
the evidence that patient expectations can influence response to PI (Espie & Lindsay, 1985),
counter-demand instructions were given to participants, which indicated that they should not
expect any improvements in sleep as a result of their participation. Primary hypotheses were
that, following a one-night baseline, people with insomnia randomized to the experimental con-
dition (Pennebaker writing) would show reduced PSCA (Hypothesis 1) and SOL (Hypothesis 2)
compared to participants randomized to a control condition.
METHOD
Participants
Potential participants were contacted via the e-mail systems of the University of Glasgow and
National Health Service (both in the United Kingdom). Participants were aged 16 to 65 years,
complaining of clinically significant difficulties falling asleep (SOL > 30 min; 4C nights per
week for a minimum of 4 weeks, with or without disruption to other sleep variables; American
Sleep Disorders Association, 2005), and excessive PSCA. Participants were assessed initially
using a locally developed semistructured clinical interview (available from Colin A. Espie),
the Insomnia Severity Index (ISI; Morin, 1993), the Pittsburgh Sleep Quality Index (PSQI;
Buysse, Reynolds, Monk, Berman, & Kupfer, 1989), and the Beck Depression Inventory–II
(BDI-II; Beck, Brown, & Steer, 1996). All participants scored > 5 on the PQSI and > 8
on the ISI, and both recognized clinical cutoff criteria (Buysse et al., 1989; Morin, 1993).
Those receiving psychological or pharmacological treatment for sleep difficulties or suffering
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comorbid sleep, medical, or psychiatric conditions were excluded. Twenty-eight participants
met inclusion criteria (14 per group). This sample provided 80% power to successfully detect
group differences at p < :05, based on number of participants and the standard deviations of
SOL from the experimental and “sleep as usual” group of Harvey and Farrell (2003; ˛ D 0:05).
Design and Procedure
Participants were met and given instruction in sleep diary completion. Following blind ran-
domization to experimental condition, participants received four envelopes (one for each study
day) containing relevant group instructions and materials. As patient expectations can influence
response to intervention, all participants were explicitly told not to expect sleep improvement
during the experiment. All participants were directed to otherwise carry on with their normal
daytime and sleeping practices.
Sleep and PSCA were monitored at baseline (Day and Night 1). For Days and Nights 2 to
4, experimental condition participants were instructed to “spend 20 minutes writing about any
thoughts, concerns, or worries in the early evening (between 6 p.m. and 8 p.m.) outwith your
bedroom environment” (cf. Harvey & Farrell, 2003). The time was chosen to minimize potential
pre-bedtime arousal. Participants could write about the same or different concerns during each
writing session and, to encourage honest and free expression, were not required to disclose
their writings. Control participants were instructed to “complete two questionnaires about your
worries between 6 p.m. and 8 p.m. outwith your bedroom environment.” These questionnaires
were the Penn State Worry Questionnaire (Meyer, Miller, Metzger, & Borkovec, 1990) and
the Worry Domains Questionnaire (Tallis, Eysenk, & Mathews, 1992), respectively. Controls,
therefore, spent a similar time focussed on worries as the writing group, but without the
facilitation of emotional processing. Adherence, treatment credibility, and emotional processing
data were gathered at follow up.
Measures
For both groups, a daily sleep diary completed on rising each day provided subjective SOL
data. In addition, wrist actigraphy (Actiwatch Model AW2, Cambridge Neurotechnology Ltd)
was used as an objective measure of SOL. The outcomes for this measure are not reported,
as the use of actigraphy in insomnia (particularly with respect to SOL) remains somewhat
controversial. The PSAS-C (Nicassio, Mendlowitz, Fussell, & Petras, 1985) was completed
alongside the sleep diary in the morning with respect to the previous evening. Following
Robertson, Broomfield, and Espie (2007), PSCA was also assessed using the following question:
“How mentally alert did you feel last night while you were trying to get to sleep?” This 5-point
scale ranged from 1 (not at all) to 5 (extremely). Adherence to study protocol was assessed
using the following question: “To what extent did you comply with the experimental instructions
given to you during the study?” This 7-point scale ranged from 0 (not at all) to 6 (very much).
The number of nights each participant correctly followed the study protocol was also recorded.
In the writing group, extent of worry processing was assessed using the following: “I worked
through some upsetting issues while writing,” “Writing helped me organize my thoughts,” and
“My thoughts and opinions have changed regarding the subjects I wrote about.” This 4-point
scale ranged from 0 (not at all) to 3 (a lot). Writing participants rated writing content overall
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on a scale of  5 (sad-anxious) to C5 (happy; cf. Harvey & Farrell, 2003) and estimated
time spent writing over the three days. Finally, treatment credibility and utility of writing
task was examined using questions from the Therapy Evaluation Questionnaire (Borkovec &
Nau, 1972).
RESULTS
Participant Characteristics
Overall mean age was 32.89 (range D 18–60; SD D 13.96). Ratio of females to males was
18:10. Using one-way analyses of variance (ANOVA) and chi-square (for gender), no significant
group differences were found on any variable (all ps > .10, ns).
Outcome Variables
Quantitative outcome data were examined for kurtosis, skewness, and homogeneity of variance
and found suitable for parametric analysis. In this respect, the primary outcome data were
considered normally distributed according to the Kolmogorov–Smirnov Z tests of normal
distribution: D.27/ D 0:680, p D :744, ns; D.27/ D 1:019, p D :250, ns; D.28/ D
0:876, p D :426, ns, respectively. Normal Q-Q plots supported these analyses. Outcomes
of change over baseline at Day 4 were employed to account for the variability in partici-
pants’ scores at baseline. Writing task and control group values (PSAS–C, alertness ratings,
SOL) were then compared using one-way ANOVAs, the results of which are outlined in
Table 1.
The writing group did not show significantly greater reduction in PSCA relative to controls
according to the PSAS-C, F (1, 25) D 0.963, p D :336, ns. However, the writing group showed
a significantly greater decrease in PSCA according to alertness ratings relative to controls, F (1,
25)D 6.766, p D :015; effect size D 0.21. Finally, the writing group did not show significantly
greater reduction in SOL relative to controls, F (1, 26) D 1.494, p D :233, ns.
TABLE 1
Mean Scores and Standard Deviations for Outcome Variables at Baseline, Day 4,
and Change Over Baseline
Baseline Day 4 Change Scores
Measure Writing Control Writing Control Writing Control
PSAS–C 21.92 (6.59) 19.86 (6.22) 18.31 (6.03) 18.57 (6.26)  3.62 (6.06)  1.29 (6.26)
Alertness 3.15 (1.14) 2.86 (0.86) 2.38 (0.87) 3.29 (0.99)  0.77 (1.09) 0.43 (1.28)
SOL 52.86 (35.88) 84.29 (57.74) 51.07 (41.43) 64.79 (52.81)  1.79 (21.63)  19.50 (49.73)
Note. A negative score indicates an improvement in variables. Standard deviations are shown in parentheses.
PSAS–C D Pre-Sleep Arousal Scale; SOL D sleep onset latency.
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Writing
Nine of 12 writers found writing to be “at least some benefit” to work through issues, 11
indicated writing “helped them organize their thoughts to some degree,” and 7 reported that
“their thoughts had changed on the topic they wrote about at least to some extent” (data available
from Patricia Mooney). Writers reported a mean rating of  3.58 (SD D 1.98) on content of
writing. Thirteen of 14 complied with the recommended writing time. The same number would
use the task again. Mean confidence in using the task in the future and recommending the task
to a friend with insomnia were 5.00 (SD D 1.41) and 5.17 (SD D 1.40), respectively.
Adherence
On a one-way ANOVA, no significant differences were found between groups on extent of
adherence, F (1, 26) D 1.00, p D :327, ns; number of nights adhered, F (1, 26) D 1.00,
p D :327, ns; or how acceptable or sensible tasks appeared, F (1, 26) D 1.00, p D :327, ns.
However, as the outcome results indicate, one participant failed to fully complete PSCA data.
DISCUSSION
The present experiment tested whether a Pennebaker writing task would reduce PSCA and
SOL in people with insomnia. In support of Hypothesis 1, Pennebaker writing significantly
decreased self-rated cognitive arousal among poor sleepers relative to a non-writing control
task. The size of this effect was, however, small; and this arousal reduction effect was not
found according to the PSAS-C. Contrary to Hypothesis 2, there was no significant reduction
on SOL following Pennebaker writing. Despite the lack of sleep effects observed, almost all
writers stated they would use this task again, and the majority would recommend it to a
friend with insomnia. Subjective ratings regarding extent of emotional processing following
Pennebaker writing were more modest. Compliance rating data suggested a high degree of
adherence to experimental instructions, with no significant group differences, and writers also
reported writing about negative or worrisome topics.
The lack of significant sleep effects is disappointing. Harvey and Farrell (2003) did observe
SOL reduction among poor-sleeping students instructed in Pennebaker writing following only
three nights use. However, interestingly, a second writing group instructed to write about
hobbies rather than problems and concerns also responded showing similar SOL change to
the Pennebaker group. A reasonable explanation may be that the rationale given to writers
may have promoted expectation of sleep benefit in the form of a demand characteristic and,
therefore, magnified any effect of the task. Conversely, it could be argued that the effects of
the counter-demand characteristics used here may have “washed out” what could be relatively
gentle effects of this task.
Although we closely followed the original protocol used by Harvey and Farrell (2003), and
others in the wider Pennebaker literature (e.g., Rosenberg et al., 2002), perhaps the duration
of our experiment was too short. Gillis, Lumley, Mosley-Williams, Leisen, & Roehrs (2006)
examined the effects of written emotional disclosure in fibromyalgia patients and found that
sleep benefits did not emerge until later on in treatment. Further examination of this paradigm
over a longer period is required.
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More puzzling is the observation of self-rated cognitive arousal reduction following writing
in the absence of significant decreases on the PSAS-C. Three possible explanations are offered
for this finding. It is possible that the measures used here may tap into different arousal
components. The alertness rating employed is a measure of general cognitive arousal. However,
PSAS-C correlates significantly with anxiety and depression (Nicassio et al., 1985) and may
be more specifically related to negatively toned cognitive activity. Perhaps then, emotional
processing purported to accompany Pennebaker writing may decrease general alertness among
people with insomnia, without impacting on negatively toned cognitions. This seems unlikely,
however, as there is evidence that difficulties characterized by worrisome thoughts (e.g.,
physical health worries; Rosenberg et al., 2002) respond best to Pennebaker writing. As no
attempt was made to select participants whose PSCA was specifically negatively toned, the
PSAS-C ratings obtained in the current study were not as high as expected. Perhaps a more
plausible account is that the participants in the present study did not experience sufficiently
high levels of negatively toned PSCA to find this task of significant benefit. Although the data
were not available in the current study, comparing people with insomnia who display high
and low levels of negatively toned PSCA will be an important next step in examining this
paradigm. Finally, as pre-sleep worry was assessed using a retrospective judgment made in
the morning on wakening, there is the possibility that the delay in reporting this may have
interfered in some way with the rating made on the PSAS-C. Future research should consider
using “online” assessment of worry during the pre-sleep period, for example, through the use
of a voice-activated tape recorder.
Other points of relevance require brief discussion. Outcome measures were all subjectively
reported (specifically, SOL). In addition, adherence was only assessed by self-report. Therefore,
it is possible that participants did not fully utilize the task. Also, on looking at Table 1, there is a
difference between group SOL ratings at baseline and high variability within groups. This may
have lessened the scope for the writing group to improve or reduce the ability to detect effects
if present. However, alternative analysis of the data taking the average for each participant
across the three nights intervention phase was carried out with the same results.
In summary, as hypothesized, among people with insomnia, a Pennebaker writing task signif-
icantly reduced self-rated mental alertness according to one measure, although PSAS–C scores
and SOL remained unchanged. The present study therefore failed to support previous results
regarding sleep change. The brief study length, along with the counter-demand instructions,
may account for this. Further research will be needed to better clarify the potential efficacy of
this paradigm in people with insomnia.
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treatment of insomnia, parasomnias and
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Abstract
Sleep disorders are common in the general population and even more so in clinical practice, yet are relatively poorly understood by doctors and other
health care practitioners. These British Association for Psychopharmacology guidelines are designed to address this problem by providing an accessible
up-to-date and evidence-based outline of the major issues, especially those relating to reliable diagnosis and appropriate treatment. A consensus
meeting was held in London in May 2009. Those invited to attend included BAP members, representative clinicians with a strong interest in sleep
disorders and recognized experts and advocates in the field, including a representative from mainland Europe and the USA. Presenters were asked to
provide a review of the literature and identification of the standard of evidence in their area, with an emphasis on meta-analyses, systematic reviews
and randomized controlled trials where available, plus updates on current clinical practice. Each presentation was followed by discussion, aimed to
reach consensus where the evidence and/or clinical experience was considered adequate or otherwise to flag the area as a direction for future research.
A draft of the proceedings was then circulated to all participants for comment. Key subsequent publications were added by the writer and speakers at
draft stage. All comments were incorporated as far as possible in the final document, which represents the views of all participants although the authors
take final responsibility for the document.
Keywords
Sleep, insomnia, parasomnia, circadian rhythm disorder, consensus,
treatment
Introduction
Sleep disorders are common in the general population and even
more so in clinical practice, yet are relatively poorly under-
stood by doctors and other health care practitioners. These
British Association for Psychopharmacology (BAP) guidelines
are designed to address this problem by providing an accessible
yet up-to-date and evidence-based outline of the major issues,
especially those relating to reliable diagnosis and appropriate
treatment.We limited ourselves to discussion of sleep problems
that are not regarded as being secondary to respiratory prob-
lems (e.g. sleep apnoea – see NICE Guidance TA139), as these
fall outside the remit of the BAP. We also did not consider
certain neuropsychiatric disorders for which recent sets of
guidelines already exist, such as narcolepsy (Billiard et al.,
2006) and restless legs (Vignatelli et al., 2006) and also refer
interested readers to the British Sleep Society website http://
www.sleeping.org.uk. Thus the main scope of this document is
to cover insomnia, circadian rhythm disorders and the more
common parasomnias which are likely to present to
psychiatrists or primary care physicians.
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The BAP is an association of psychiatrists, psychopharma-
cologists and preclinical scientists who are interested in the
broad ﬁeld of drugs and the brain. BAP is the largest national
organization of its kind worldwide, and publishes the Journal
of Psychopharmacology. The Association started publishing
consensus statements more than a decade ago, and the ﬁrst
BAP guidelines on depression were considered a landmark
publication when they appeared in 1993 (Montgomery,
1993). That document, updated in 2000 and in 2008
(Anderson et al., 2000; Anderson et al., 2008), has become
the standard of care in many countries as it is considered an
accessible consensus to guide practising psychiatrists.
Additional guidelines have covered management of bipolar
disorder (Goodwin, 2003; Goodwin, 2009) drug treatments
for addiction (Lingford-Hughes et al., 2004), anxiety disorders
(Baldwin et al., 2005), old age psychopharmacology (Burns
et al., 2006), and attention-deﬁcit hyperactivity disorder
(ADHD) (Nutt et al., 2007) all of which use a similar style
and process. All guidelines are available via the BAP website
(http://www.bap.org.uk).
Method
A consensus meeting was held in London on 21–22 May 2009.
Those invited to attend included BAPmembers, representative
clinicians with a strong interest in sleep disorders and recog-
nized experts and advocates in the ﬁeld, including a represen-
tative from mainland Europe and the USA. The main age
groups and clinical subtypes were speciﬁcally covered by indi-
vidual speakers. Presenters were asked to provide a review of
the literature and identiﬁcation of the standard of evidence in
their area, with an emphasis on meta-analyses, systematic
reviews and randomized controlled trials (RCTs) where avail-
able. Each presentation was followed by discussion, aimed to
reach consensus where the evidence and/or clinical experience
was considered adequate, or otherwise to ﬂag the area as a
direction for future research. A draft which pulled together
the presentations and the transcript of the taped proceedings
was drawn up by SJW and DJN and circulated to all speakers
and other participants for comment. Key subsequent publica-
tions were added by the writer and speakers at draft stage. All
comments were incorporated as far as possible in the ﬁnal doc-
ument, which represents the views of all participants although
the authors take ﬁnal responsibility for the document.
Categories of evidence for causal relationships, observa-
tional relationships and strength of recommendations are
given in Table 1 and are taken from Shekelle et al., 1999.
The strength of recommendation reﬂects not only the quality
of the evidence, but also the importance of the area under
study. For example, it is possible to have methodologically
sound (category I) evidence about an area of practice that is
clinically irrelevant, or has such a small eﬀect that it is of little
practical importance and therefore attracts a lower strength
of recommendation. However, more commonly, it has been
necessary to extrapolate from the available evidence leading
to weaker levels of recommendation (B, C or D) based upon
category I evidence statements.
The costs of the meeting were partly defrayed by unrest-
ricted educational grants from two pharmaceutical companies
(Lundbeck and GSK). Observers from these companies were
invited to attend but did not participate in the summary pro-
ceedings or in drafting the guidelines. All attendees completed
conﬂict of interest statements that are held at the BAP oﬃce
according to BAP policy.
Scope of the guidelines
Our intention is to present a comprehensive statement to
guide clinicians, who are managing patients in primary or
secondary medical care.
Definition of insomnia
Insomnia is a common disorder whose deﬁnition is often not
clearly understood. A number of international organizations
with interests in sleep disorders have proposed varying deﬁ-
nitions of insomnia that share three key elements (see
Diagnostic criteria). They all agree insomnia is a condition
of unsatisfactory sleep, either in terms of sleep onset, sleep
maintenance or early waking. They also agree that insomnia
is a disorder that impairs daytime well-being and subjective
abilities and functioning, and so can be considered a ‘24-hour’
disorder.
It is important to recognize that insomnia is a subjective
disorder, and its diagnosis is through clinical observations
rather than via measurements; in this sense, it is a syndrome
similar to pain. The cause of insomnia may be known or not,
and knowledge of causation is not necessary for a diagnosis.
However, in some cases it may be possible to identify and
remedy a physical cause for insomnia (see treatment section).
Insomnia often starts with a speciﬁc problem, for example
a stressful life event such as the loss of a job or change to a
more demanding one, or through something that changes
sleep patterns such as the birth of a child or starting shift
work. In some people this acute insomnia persists into a
chronic state. Factors involved in the persistence of insomnia
are not fully established, but include anxiety about sleep, mal-
adaptive sleep habits and the possibility of an underlying vul-
nerability in sleep-regulating mechanisms. Persistence of the
precipitating stressor can also contribute. Some cases of
insomnia are precipitated by, or are co-morbid with, other
psychiatric disorders, especially anxiety and depression, or
by physical illness such as cancer or arthritis.
The nature of sleep changes with age. Older age is associ-
ated with poorer objectively measured sleep with shorter sleep
time, diminished sleep eﬃciency, and more arousals, and these
changes may be more marked in men than in women, accord-
ing to a very large study of elderly people living at home in the
USA (Sleep Heart Health Study, Unruh et al., 2008). In the
same study the association of subjective report of poor sleep
with older age was stronger in women. The higher prevalence
of chronic health conditions, including sleep apnoea, in older
adults did not explain changes of sleep parameters with aging
and age/sex diﬀerences in these relationships.
There is some disagreement about how long insomnia
should have been present for before it requires intervention
(see treatment section), but there is general agreement that
when insomnia causes signiﬁcant personal distress or
marked impairment then some form of treatment is
appropriate.
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Definition of insomnia: Diagnostic criteria
International Classification of Sleep
Disorders (ICSD) and Research
Diagnostic Criteria for Insomnia
(RDC) (Edinger et al., 2004)
A
Difficulty
– initiating sleep,
– maintaining sleep,
– waking up too early or
– sleep is chronically non-restorative
or poor in quality
B
Occurs despite adequate
opportunity and circum-
stances for sleep
C
At least one form of daytime impair-
ment
i. Fatigue or malaise
ii. Attention, concentration, or
memory impairment
iii. Social or vocational dysfunction or
poor school performance
iv. Mood disturbance or irritability
v. Daytime sleepiness
vi. Motivation, energy, or initiative
reduction
vii. Proneness for errors or accidents at
work or while driving
viii. Tension, headaches, or gastrointes-
tinal symptoms in response to sleep
loss
ix. Concerns or worries about sleep
International Classification of
Diseases ICD-10 (1992)
Difficulty
– falling asleep,
– maintaining sleep or
– non-refreshing sleep
3 times a week and
for longer than 1
month
Marked personal distress or interfer-
ence with personal functioning in
daily living
Diagnostic and Statistical Manual of
Mental Disorders DSM-IV
Predominant complaint
– difficulty initiating sleep
– difficulty maintaining sleep or
– non-restorative sleep
For at least 1 month Clinically significant distress or
impairment in social, occupational,
or other important areas of
functioning
Table 1. Levels of Evidence
Categories of evidence for causal relationships and treatment
Ia: evidence from meta-analysis of randomized controlled trials
Ib: evidence from at least one randomized controlled trial
IIa: evidence from at least one controlled study without randomization
IIb: evidence from at least one other type of quasi-experimental study
III: evidence from non-experimental descriptive studies, such as comparative studies, correlation studies and case-control studies
IV: evidence from expert committee reports or opinions and/or clinical experience of respected authorities
This categorization is most appropriate to questions of causal relationships. Similar taxonomies for other types of research question do not yet
exist and the following is proposed.
Proposed categories of evidence for non-causal relationships
I: evidence from large representative population samples
II: evidence from small, well-designed, but not necessarily representative samples
III: evidence from non-representative surveys, case reports
IV: evidence from expert committee reports or opinions and/or clinical experience of respected authorities
Strength of recommendation
Recommendations are graded A to D as shown below. We distinguish between the category of evidence and the strength of the
associated recommendation. It is possible to have methodologically sound (category I) evidence about an area of practice that is
clinically irrelevant or has such a small effect that it is of little practical importance and therefore attracts a lower strength of
recommendation. More commonly, a statement of evidence only covers one part of an area in which a recommendation has to be made,
or covers it in a way that conflicts with other evidence. Therefore, to produce comprehensive recommendations it is necessary to extrapolate
from the available evidence. This may lead to weaker levels of recommendation (B, C or D) based upon category I evidence statements.
Strength of Recommendation
A directly based on category I evidence
B directly based on category II evidence or extrapolated recommendation from category I evidence
C directly based on category III evidence or extrapolated recommendation from category I or II evidence
D directly based on category IV evidence or extrapolated recommendation from category I, II or III evidence
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Epidemiology of insomnia
What is known about prevalence of insomnia
   •  Estimates of prevalence of insomnia vary according to 
      the definition used (Ia)
   •  Prevalence of symptoms varies with age, with increase of 
      nocturnal awakenings but decrease in complaints of 
      non-restorative sleep as people get older (Ib)
   •  Prevalence is between 1.5 and 2 times higher in women 
      than in men (Ia)
   •  Insomnia is a long-term disorder; many people have had 
      insomnia for more than 2 years (Ib)
   •  Approximately half of all diagnosed insomnia is related 
      to a  psychiatric disorder (Ib)
 What is not known
   •  What is the prevalence of distress?
   •  What is the significance of duration of symptoms on 
      distress?           
Studies of prevalence of insomnia in the general population indi-
cate that one-third of adults in Western countries experience dif-
ﬁculty with sleep initiation or maintenance at least once a week
(LeBlanc et al., 2009; Le´ger and Poursain, 2005; Sateia et al.,
2000), and 6–15% are thought to meet criteria of insomnia in
that they report sleep disturbance as well as signiﬁcant daytime
dysfunction (LeBlanc et al., 2009; Sivertsen et al., 2009). One-year
incidence rates have been reported to be 30.7% for insomnia
symptoms and 7.4% for insomnia syndrome. These rates
decreased to 28.8% and 3.9% for those without a prior lifetime
episodeof insomnia (LeBlanc et al., 2009).There ismuch evidence
that insomnia is a long-term disorder. In one large UK study,
about three-quarters of patients reported symptoms lasting at
least a year (Morphy et al., 2007) and in a population-based
3-year longitudinal study 46% of subjects who had insomnia
at baseline still had it at the 3-year time point. The course of
insomnia was more likely to be persistent in those with more
severe insomnia at baseline, and in women and older adults
(Morin et al., 2009a).
There is a higher incidence of insomnia in women, and the
incidence increases in men and women as they get older. The
symptom prevalence changes with age, so that people over 65
show more sleep maintenance problems but a decrease in
reported daytime problems compared with younger age
groups, with little change in prevalence of sleep-onset insomnia.
Diagnosis
Insomnia
Insomnia is a subjective complaint. Patients complain that
sleep is inadequate, either by being too short (such as after
a long period of trying to get to sleep, or due to early waking),
too interrupted or not suﬃciently restorative or refreshing. In
many patients there is a combination of these factors. As a
consequence of the disrupted sleep daytime function
is impaired.
There are a number of ways in which sleep can be assessed.
The most simple is by asking the patient (and family member
or carer if possible) about their sleep, and a sleep diary (see
Appendix). This allows the assessment of sleep diﬃculties
over time and gauges the potential contribution of poor
sleep and lifestyle habits to daytime impairment.
Preliminary questions for eliminating other sleep disorders
as primary diagnosis are summarized below.
Eliminating other sleep disorder as primary: preliminary 
questions – see Appendix for more detailed follow-up 
questions. 
   •  Are you a very heavy snorer? Does your partner say that 
      you sometimes stop breathing at night? (obstructive sleep 
      apnoea syndrome (OSAS)) 
   •  Do your legs often twitch and can’t keep still in bed? Do 
      you wake from sleep with jerky leg movements? (restless 
      legs syndrome (RLS), periodic limb movements in sleep 
      (PMLS)) 
   •  Do you sometimes fall asleep in the daytime completely 
      without warning? Do you have collapses or extreme 
      muscle weakness triggered by emotion, for instance when 
      you’re laughing? (narcolepsy) 
   •  Do you tend to sleep well but just at the ‘wrong times’; 
      and are these sleeping and waking times regular? 
      (circadian rhythm sleep disorder; evidence also from sleep 
      diary) 
   •  Do you have unusual behaviours associated with your 
      sleep that trouble you or that are dangerous? 
      (parasomnias – see text) 
It is important to determine if another sleep disorder (see
preliminary questions above), or a physical (such as pain,
heart or lung disease), neurological (such as Parkinson’s dis-
ease or cerebrovascular disease) or psychiatric disorder (such
as depressive illness, anxiety disorder, or substance misuse) is
the primary diagnosis. In depression, however, in many cases
insomnia should be regarded as a co-morbid condition, rather
than as a secondary one. The majority of epidemiological
evidence suggests that insomnia typically predates other psy-
chiatric symptoms and may represent an independent risk
factor for the development of depression in particular
(see below).
Circadian rhythm disorder
Circadian rhythm disorders are sleep disorders where there is
a mismatch between circadian rhythms and required sleep–
wake cycle. Thus there can be sleeplessness when trying to
sleep at a time not signalled by the internal clock, and exces-
sive sleepiness when needing to be awake.
Some circadian disorders (jetlag and shift-work disor-
der) are due to an individual lifestyle, including work and
travel schedules, that conﬂicts with the internal clock.
Others are:
. delayed sleep-phase syndrome (DSPS), where there is dif-
ﬁculty falling asleep before 2–3 a.m. (sometimes later), and
on days without work/school/college the preferred wake
time is after 10 a.m., resulting in sleep-onset insomnia
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and diﬃculty waking up in the morning on days when an
early bedtime for an early start time is necessary.
. free-running sleep disorder, where there is a daily incre-
ment of sleep and wake times (getting later each day). This
is often associated with insomnia of varying severity and
daytime sleepiness.
Parasomnias
Parasomnias are unusual episodes or behaviours occurring
during sleep which disturb the patient or others; here we
addresses those that cause signiﬁcant distress and therefore pre-
sent for treatment. Assessment of parasomnia may be possible
with a detailed history from the patient or a witness but, in
general, for an adequate diagnosis referral to a specialist sleep
centre for polysomnography (PSG) and video recording may be
necessary. Violent or unusual night-time attacks may arise from
deep non-REM sleep (night terrors and sleepwalking) or from
REM sleep (severe recurrent nightmares, REM behaviour dis-
order), and treatments depend on which disorder is present.
Night terrors (also called sleep terrors) are recurrent epi-
sodes of abrupt awakening from deep non-REM sleep, usually
in ﬁrst third of the night, usually with a scream and signs of
intense fear and autonomic arousal. The patient is unrespon-
sive to comforting; they may sit up in bed and sometimes
engage in automatic behaviour associated with fear and
escape. There is usually no detailed recall, and if the patient
wakes from a terror (not common), there is confusion and
disorientation and only a vague memory of fear. Night terrors
are common in children, with about 30–40% having at least
one episode, and repeated episodes in about 5%. The peak age
for these is at about 2–7 years, with a gradual diminution up to
early adolescence (DiMario and Emery, 1987). In some cases
night terrors persist into adult life; the prevalence in adults is
unknown. Almost all adult patients have had night terrors or
sleepwalking as a child (Crisp, 1996). There is a strong genetic
component (Nguyen et al., 2008), and night terrors and sleep-
walking in the same patient is fairly common.
Sleepwalking alone probably has 15–20% lifetime preva-
lence. The main symptom is of automatic behaviour at night
with the suﬀerer unresponsive to surroundings and other
people. The behaviour is most commonly walking around, but
can include other behaviours which are highly familiar to the
subject such as dressing, washing, making tea, arranging objects
in the house, etc. Some cases of sleepwalking seem related to use
of certain drugs, for example alcohol and hypnotics, especially
zolpidem and triazolam (Pressman, 2007). It is rare for aﬀected
individuals to present for treatment, except if they have injured
themselves or a partner, have put themselves into potential
danger, or have excessive daytime fatigue because of night-
time disturbance. Another reason for presentation is anxiety
and disruption of sleep of partner, family or housemates.
Nightmares and REM sleep behaviour disorder (RBD) are
disorders arising from REM sleep, and the main diﬀerence in
presentation from the non-REM episodes is that they are
normally recalled by the patient, who wakes from them and
is aware of the episode and can describe it. RBD is a disorder,
ﬁrst described in the late 1980s, with violent complex behav-
iour at night, which is mostly recalled by the patient. There
are two sleep abnormalities; lack of atonia during REM sleep,
and increased vividness and/or unpleasant content of dreams.
The violent behaviour is described as ‘acting out of dreams’,
made possible by the lack of the normal muscle paralysis in
REM sleep. Its incidence is unknown (probably<1%), it occurs
in older people with a steady rise after 55 years of age, and has a
marked male preponderance. It may be idiopathic but much
more often is associated with Parkinson’s disease (it is seen in
up to 50% of patients with Parkinson’s disease), Lewy body
dementia (70%), and multiple system atrophy (>90%).
RBDmay be the ﬁrst manifestation of these disorders, antedat-
ing the onset of parkinsonism, cerebellar syndrome, dysautono-
mia, and dementia by several years (Gagnon et al., 2006).
Figure 1 summarizes the diagnosis algorithm for sleep
problems.
Costs and consequences of insomnia
What is known about detrimental effects of insomnia 
   •  Quality of life is impaired in insomnia (I) 
   •  There is an increased risk of subsequent first episode 
      depression, and of relapse into depression, in those with a 
      pre-existing persistent insomnia (I) 
   •  Primary insomnia is associated with poor objective sleep 
      and impaired objectively measured daytime 
      performance (II) 
   •  There is an increased risk of hypertension in insomnia 
      with objectively measured short sleep duration (II) 
   •  Absenteeism, accidents at work and road accidents are 
      increased in insomnia (II) 
What is not known 
   •  What are the potential confounding effects of medication 
      and comorbid disorders in reports of increased accidents? 
   •  To what extent do treatments rectify the health risks of 
      insomnia? 
Several large studies have demonstrated reduced quality of life,
increased functional impairment and increased healthcare costs
in insomnia (Chevalier et al., 1999; Le´ger et al., 2001; Philip
et al., 2006; Simon and VonKorﬀ, 1997; Zammit et al., 1999).
Impairments in the areas of vitality, energy, emotional and
mental health domains have been the most widely reported.
One study shows that severe insomnia is independently associ-
ated with worsened health-related quality of life to almost the
Recommendations
. The diagnosis of insomnia is primarily based on patient-
derived and family or caregiver complaints, as determined
by the clinical interview, ideally with patient diary (A).
. In some circumstances referral to a specialist sleep centre
may be necessary for other investigations, for instance:
. Diﬀerential diagnosis of circadian rhythm disorder
(actigraphy) (A)
. Other primary sleep disorder suspected including para-
somnia (polysomnography) (A)
. In the case of treatment failure (D)
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same extent as chronic conditions such as congestive heart fail-
ure and major depression (Katz and McHorney, 2002). Studies
suggest that the resulting economic burden of insomnia is very
high, with the largest proportion of all expenses (76%) attrib-
utable to insomnia-related work absences and reduced produc-
tivity (Daley et al., 2009). The incidence of road accidents is
increased in individuals with insomnia (Le´ger and Bayon,
2010), but the potential confounding eﬀects of medication and
co-morbid medical disorders have not been studied extensively.
People with a diagnosis of insomnia have subjective com-
plaints of poor daytime function. When compared with
matched controls, they show increased subjective sleepiness
but decreased objective sleepiness, due to the fact that they are
usually overaroused, but feel subjectively tired. Objectively, they
show poorer performance on psychomotor tasks, particularly
those requiring switching of attention (e.g. frontal/executive
tasks) (Edinger et al., 2008), objectively measured time awake
after sleep onset (WASO) was the best predictor of impaired
daytime performance. Likewise, Altena et al. (2008) have
reported that people with insomnia perform more poorly on
complex cognitive tasks, an eﬀect which normalizes following
cognitive behavioural therapy (CBT) intervention.
There is an increased risk of subsequent depression and anx-
iety disorder in primary insomnia. Insomnia has been associated
with: (1) an increased risk of developing subsequent depression;
(2) an increased duration of established depression; and (3)
Difficulty going to 
Patient complains of 
sleep problems
sleep or staying 
asleep with 
impairment of 
daytime functioning
Are sleep habits 
adequate?
No sedating drugs?
Sleep scheduling OK?
Advice on sleep habits, 
lifestyle, review with 
diary, consider circadian 
rhythm disorder
Excessive 
daytime 
sleepiness
Unusual behaviours 
at night, injurious 
or distressing
Refer to sleep 
specialist
yes
no
Intake of sleep 
disturbing  
substances ?
yes
Review drugs 
etc
Diagnosis of insomnia
no
yes
Heavy snoring?
Restless legs?
Sudden sleep 
attacks or 
cataplexy?
yes
no
Are sleep habits 
adequate?
Sleep scheduling 
OK?
Figure 1. Diagnosis algorithm.
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relapse following treatment for depression (Riemann, 2009). On
the other hand, sleep disturbances arewidely understood as core
symptoms of major depressive disorder rather than associated
or co-morbid disorders (Mendlewicz, 2009). Poor sleep quality
seems to correlate with high negative and low positive emotions,
both in clinical and subclinical samples. Good sleep seems to be
associated with high positive emotions, but not necessarily with
low negative emotions (Baglioni et al., 2010).
The National Institute of Mental Health Epidemiologic
Catchment Area, which interviewed 7954 adults on two occa-
sions a year apart, ﬁrst highlighted the strong association
between sleep disturbance and subsequent depression. It was
found that 14% of those with insomnia at the ﬁrst interview
had developed new major depression 1 year later (Ford and
Kamerow, 1989). This increased risk of developing depression
has been conﬁrmed in other investigations: in a survey of 1200
young adults in Michigan the odds ratio of new depression was
four times greater in those subjects who had insomnia 3 years
earlier (Breslau et al., 1996), and of new anxiety disorder the
risk was twofold greater. In a questionnaire survey of adults in
the UK there was a threefold increased risk of new depression
and a twofold risk of new anxiety disorder if subjects had
reported one sleep problem occurring ‘on most nights’ a year
earlier (Morphy et al., 2007). In a much longer study in
Norway with two surveys 10 years apart (Neckelmann et al.,
2007), the risk of having an anxiety disorder diagnosis at the
second time point increased by about one and a half times if
insomnia had been present at the ﬁrst time point, and by about
ﬁve times if insomnia was present at both time points, indicating
the higher risk of long-standing insomnia. Doctors in a prospec-
tive study who had complained of insomnia during medical
school in the 1950s and 1960s were twice as likely to have
developed depression at follow-up in the 1990s (Chang et al.,
1997).
Insomnia is associated with activation of the hypothalamic–
pituitary–adrenal (HPA) axis with increased adrenocorticotro-
phin and cortisol in most studies (Varkevisser et al., 2005;
Vgontzas et al., 1998; Vgontzas et al., 2001). When the com-
plaint of insomnia is accompanied by short duration of sleep
measured objectively, there is a three to ﬁvefold increased over-
all risk of hypertension, which is comparable to that seen with
other common sleep disorders, such as sleep-disordered breath-
ing (Vgontzas et al., 2009).
Psychological treatment of insomnia
What is known about CBT for insomnia - CBTi 
   •  CBT is an effective treatment for insomnia delivered 
      either individually or in small group format (Ia) 
   •  CBT has been found to be as effective as prescription 
      medications for short-term treatment of chronic insomnia. 
      Moreover, there are indications that the beneficial effects 
      of CBT may last well beyond the termination of active 
      treatment (Ia) 
What is not known 
   •  Are long-term effects of a short-term course of hypnotics 
      better or worse than after CBT? 
   •  Long-term effects of CBT versus optimized (e.g. 
      intermittent) use of hypnotics in the long term 
Psychological treatment of insomnia should be considered
appropriate for two reasons. First, insomnia is a ‘psychophys-
iological’ disorder, in which mental and behavioural factors
play predisposing, precipitating and perpetuating roles.
Essential features of insomnia are heightened arousal and
learned sleep-preventing associations. Arousal can reﬂect a
general cognitive hypervigilance and many patients describe
‘racing thoughts’ as a problem when they are trying to sleep.
A cycle develops in which the more one strives to sleep, the
more agitated one becomes, and the less able one is to fall
asleep. CBT for insomnia (CBTi) employs a package of inter-
ventions designed to encourage poor sleepers to think and
behave like good sleepers. The therapy is manualized, and
health professionals can be trained to administer it either
individually or in a group setting. Therapies are multimodal,
embodying techniques such as sleep restriction and stimulus
control as well as cognitive restructuring. CBT then is a treat-
ment modality, just as is sleep pharmacotherapy. The latter
comprises a range of licensed medications, and the former a
range of proven psychotherapeutic methods.
There have been many investigations of CBT in insomnia
but it is challenging to design a randomized controlled trial as
the therapy cannot be blinded, and contact with professionals
is diﬃcult to match with the comparator group. However, in
85 clinical trials involving a total of 4194 participants (includ-
ing 12 trials in insomnia associated with medical/psychiatric
disorders) 70% of patients who completed the course
achieved sustained improvement on sleep and daytime
reports, reﬂecting moderate-to-large eﬀect sizes over waiting
list (Irwin et al., 2006; Morin et al., 2006). Based on this and
other extensive published evidence, including nine systematic
reviews or meta-analyses, the National Institutes of Health
Consensus and State of the Science Statement (NIH, 2005)
concluded that a CBT package containing cognitive and
behavioural methods is ‘‘as eﬀective as prescription medica-
tions are for short-term treatment of chronic insomnia.
Moreover, there are indications that the beneﬁcial eﬀects of
CBT, in contrast to those produced by medications, may last
well beyond the termination of active treatment’’.
In the majority of studies, CBT employs a package of the
previously mentioned techniques which are designed to
Recommendation
. It is important to treat insomnia because the condition
causes decreased quality of life, is associated with impaired
functioning in many areas, and leads to increased risk of
depression, anxiety and possibly cardiovascular disorders
(A).
. Goal of treatment:
. to less suﬀering and
. improve daytime function
. Type of treatment:
. Patient-guided
. By particular pattern of problem, i.e. sleep onset insom-
nia, maintenance
. By choice of treatments with an evidence base
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encourage poor sleepers to think and behave like good slee-
pers. The therapy is usually performed from a manual, and
health professionals can be trained to administer it either indi-
vidually or in a group setting. Therapy is multimodal, embody-
ing techniques such as sleep restriction and stimulus control as
well as cognitive restructuring. Sleep restriction and stimulus
control do not prolong sleep time but result in a shortening of
total sleep time during the acute treatment period, because
patients reduce the amount of time spent in bed by delaying
bedtime or leaving the bedroom when they wake during the
sleep period. This means that improvements in sleep continuity
and quality parameters, rather than total sleep time, have gen-
erally been the signiﬁcant outcome measures in these studies.
There have been several comparative studies of CBT versus
pharmacotherapy. A recent meta-analysis (Riemann and Perlis,
2009) concludes that during the treatment period they produce
comparable improvements; that psychological therapy produces
signiﬁcantbeneﬁcial long-termeﬀects; andnotes that studiesof the
long-term eﬀects of short-term pharmacotherapy have not been
reported.A recent randomized studyof combined therapy (Morin
et al., 2009b), inwhich two groups of patients underwent a 6-week
CBT intervention, with one group also taking zolpidem nightly
during acute treatment, found an approximately 60% response
rate in both groups.After the acute phase, patients in the zolpidem
group were re-randomized to extended CBT plus or minus inter-
mittent zolpidem; combined therapy produced a higher remission
rate compared with CBT alone during the 6-month extended
phase and the 6-month follow-up period. In patients with persis-
tent insomnia, the addition ofmedication toCBTproduces added
beneﬁts during acute therapy, but long-term outcome was opti-
mizedwhenmedication is discontinued duringmaintenanceCBT.
Outside of the research environment, for example in clinical
practice in the UK, the take-up rate for CBT is not certain – for
example, in the Bristol insomnia treatment group, which is only
available on a weekday during normal working hours, and
involves considerable travel for many patients, only half of the
patients referred from a secondary care sleep clinic for chronic
insomnias agreed to attend and some dropped out before the
end of the course; making treatment more accessible in terms of
ﬂexibility of times and locations an urgent goal. Provision of
psychological treatments for insomnia in the UK is an issue, as
there are few trained therapists and insomnia is not a priority for
psychologists in the National Health Service. One approach
involving ‘stepped care’ has been suggested (Espie, 2009)
where, depending on severity, chronicity and complexity of
insomnia, people could be allocated to the various levels, with
self-administered CBT (e.g. a book) as the ‘entry level’,
manualized, small-group CBT delivered by nurses as the next
level, and involvement of more specialized professionals there-
after. This would enable this relatively scarce resource to be
applied in a cost-eﬀective way to achieve best clinical care.
Drug treatments for insomnia
What is known about drug treatments for insomnia 
   •  Z-drugs and short-acting benzodiazepines are efficacious 
      for insomnia (Ia) 
   •  Safety (adverse events and carryover effects) are fewer 
      and less serious with decreasing half-lives (Ib) 
   •  Prolonged release melatonin improves sleep onset latency 
      and quality in patients over 55 (Ib) 
What is not known 
   •  Does improvement in insomnia last after treatment 
      is stopped? 
   •  Does treatment reduce risk of subsequent depression? 
Underpinning principles – pharmacology
An overview of the way in which various drugs are thought to
work, classiﬁed according to what is thought to be their pri-
mary site of action on sleep, is given in Table 2.
The sleep–wake function reﬂects a complex balance
between arousing and sleep-inducing physiological systems.
Current research suggests that arousal and wakefulness are
promoted by parallel neurotransmitter systems whose cell
bodies are located in brainstem or midbrain centres, with
projections to the thalamus and forebrain. These activating
neurotransmitters are noradrenaline, serotonin, acetylcholine,
dopamine and histamine. In addition the newly discovered
orexin system with cell bodies in the hypothalamus promotes
wakefulness through regulating arousal ‘pathways’ (and
inhibiting sedative ones) (Samuels and Szabadi, 2008; Saper
et al., 2005). For all these arousal neurotransmitters sleep can
be promoted by blocking their post-synaptic actions, leading
to reduced arousal. For example, many over-the-counter
(OTC) sleep-promoting agents contain antihistamines,
which block the histamine H1 receptor and so decrease arou-
sal. The relatively low eﬃcacy of these compounds may be
explained by the fact that they target only one of the parallel
arousal systems. The same is true for any drug which blocks
one of the other arousal systems; they produce a degree of
sedation but are not generally eﬀective hypnotics. However,
some agents have speciﬁc actions on certain sleep parameters;
for instance, drugs which block 5HT2 receptors (such as
ritanserin or eplivanserin) can increase slow-wave sleep
(Idzikowski et al., 1988; Landolt et al., 1999) whereas the
alpha-1 adrenergic blocker prazosin is useful in post-trau-
matic stress disorder-related nightmares (Raskind et al.,
2007). Trazodone is commonly used to promote sleep and
has blocking actions at noradrenaline, 5HT and histamine
receptors; this multiple action probably explains why it is
widely used, although there are few controlled clinical trials.
Other drugs such as sedating antidepressants and antipsy-
chotics probably promote sleep in a similar fashion.
The promotion of sleep is regulated by a number of other
neurotransmitters (see Table 2); primary amongst these is
gamma-aminobutyric acid (GABA), the major inhibitory neu-
rotransmitter in the brain. The majority of brain cells are inhib-
ited by GABA, so increasing its function reduces arousal and
Recommendation
. CBT-based treatment packages for chronic insomnia
including sleep restriction and stimulus control are eﬀec-
tive and therefore should be oﬀered to patients as a ﬁrst-
line treatment (A).
. Increased availability of this therapy is required.
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produces sleep, and eventually anaesthesia. There aremany sub-
sets of GABA neurones distributed throughout the brain but a
particular cluster in the hypothalamus (ventrolateral preoptic
nucleus) can be considered to be the sleep ‘switch’ (Saper et al.,
2005). These neurones switch oﬀ brain arousal systems at the
level of the cell bodies and therefore promote sleep. GABA
receptors in the cortex can also promote sedation and sleep by
inhibiting the target neurones of the arousal system.
The inhibitory eﬀects of GABA are mediated through the
GABAA receptor, which is a complex of proteins with bind-
ing sites for a number of sleep-promoting drugs, in particu-
lar benzodiazepines, so-called Z-drugs and barbiturates, all
of which enhance the eﬀects of GABA’s actions at the
GABAA receptor. There are a number of subtypes of this
receptor which are relevant for sleep, not only because of
their diﬀerent location in the brain but also because of the
fact that some hypnotic drugs are selective for a particular
subtype. The alpha-1 subtype is highly expressed in the
cortex and probably mediates the sedative and hypnotic
eﬀects of many drugs that act at the benzodiazepine site;
zolpidem and zaleplon target this subtype preferentially
(Sanna et al., 2002). The alpha-3 subtype predominates in
the reticular nucleus of the thalamus, which plays an impor-
tant role in regulating sleep. This subtype is particularly
targeted by eszopiclone (Jia et al., 2009). Traditional benzo-
diazepine hypnotics act on four subtypes – alpha 1, 2, 3 and
5 – which may explain some diﬀerences between them and
the Z-drugs.
The other main sleep-promoting neurotransmitter is aden-
osine. Brain levels of this rise during the day and are thought
to lead to sleepiness, which increases the longer the time since
the last sleep. The arousing and sleep-impairing eﬀects of caf-
feine (Landolt et al., 2004) are thought to be due to blockade
of adenosine-A2 receptors, so attenuating this natural process
(Porkka-Heiskanen et al., 2002). Caﬀeine is a useful transla-
tional model for insomnia as its eﬀects in rodents are very
similar to those in humans and could be used to screen poten-
tial new treatments (Paterson et al., 2007).
Melatonin is a natural hormone that is produced in the
pineal gland and which has an important role in regulating
circadian rhythms (Cajochen et al., 2003; Dijk and von
Schantz, 2005). The circadian pacemaker in the suprachias-
matic nucleus (SCN) of the hypothalamus drives melatonin
synthesis and secretion from the pineal gland. Once melatonin
appears in the plasma it enters the brain and binds to melato-
nin receptors in the hypothalamus, forming a feedback loop.
The SCN contains melatonin 1 and melatonin 2 receptors, and
much research is ongoing about their role in sleep/wake regu-
lation and circadian rhythms. Melatonin has both phase-shift-
ing eﬀects (changing the timing of the biological clock), and
direct sleep-facilitating eﬀects. Administering exogenous mel-
atonin or analogues such as ramelteon (licensed in the USA)
can promote sleep onset. A slow-release formulation of mela-
tonin has been licensed on the basis of improved sleep conti-
nuity and daytime well-being in people aged over 55 years with
insomnia. Melatonin production is reported to decline with
age and to be lower in middle-aged and elderly patients with
insomnia than in good sleepers (Attenburrow et al., 1996;
Dowling et al., 2008; Haimov, 2001; Le´ger et al., 2004).
Underpinning principles – pharmacokinetics
The principles of the ideal hypnotic have been discussed for
decades and are outlined in Figure 2. All licensed hypnotics
improve one or more aspects of subjective sleep and some also
improve daytime functioning (see below – but note this treat-
ment outcome has only been seen as being important in recent
years, so many drugs have not been evaluated in this
parameter).
Kinetic aspects are important both in terms of how
quickly the drug enters the brain and how long its eﬀects
last (see Tables 3 and 4). The faster the hypnotic enters the
brain, the sooner sleep is induced. Some agents used as
hypnotics have not been active in this aspect of sleep
because of poor kinetic properties: for example, temazepam
tablets have a poorer bioavailability and slower absorption (and
thus a longer presence in the body) than the previous gel for-
mulations. Drugs that enter the brain very quickly, though eﬀec-
tive, may need to be taken in the bedroom or even in bed to
prevent people falling asleep before they are in bed (see zolpidem
Table 2. Neurotransmitters and sleep in humans
Endogenous
transmitter
Maintains
wakefulness
Promotes
sleep
Agents promoting
wakefulness
Agents promoting
sleep
Agents causing
sedation
GABA 3 antagonists (though not
studied in humans)
agonists, positive alloste-
ric modulators e.g.
benzodiazepines
agonists, positive alloste-
ric modulators
melatonin 3 M1 and M2 agonists
adenosine 3 antagonist (caffeine)
noradrenaline 3 uptake blockers releasers
(stimulants)
a1 antagonists
dopamine 3 stimulants (releasers) and
uptake blockers
Possibly agonists (para-
doxical effect !sudden
sleep attacks)
serotonin 3 uptake blockers 5HT2 antagonists, 5HTP
histamine 3 H3 antagonist ? H1 antagonists H1 antagonists
acetylcholine 3 Muscarinic antagonists
orexin 3 OR1 and/or 2 antagonists
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No memory effects
Rapid absorption
Rapid sleep
induction
No residual
effects
Induces ‘normal’
sleep pattern
Works through
the night
No ataxic 
effects
No interaction 
with other drugs 
or alcohol
No respiratory
depression
No rebound 
insomnia
No dependence
The ideal 
hypnotic drug
Safe in overdose
Specific mechanism 
of actionNo tolerance
Figure 2. The ideal hypnotic drug.
Table 3. Pharmacokinetic data for benzodiazepine receptor-acting hypnotics
Availability (%) Plasma bound (%) Time to Tmax (h) Thalf (h)
Nitrazepam 78a 87a (85b) 1.6b, 1–5l, 0.5–0.83x 26a, 24b, 20–40l, 28–35o, 15–38p, 25–35x
Flurazepam 96a 0.5–1.5l, 0.5–1v, 0.5–1x * 76a, 40–100l, 40–103o, 47–100(2.3)v,
47–100x
Loprazolam 90q 85q 2q, 2r, 0.5x 7–8n, 15o, 6–12p, 12q, 12r, 4.6–11.4x
Lorametazepam 80t, 70–80u 92b 2b 10b, 10o, 10–12p, 10t, 7.9–11.4x
Temazepam 91a 98a, 96b 1.1b, 2–3l, 0.75–1x 11a, 9.1b, 5–20l, 12o, 8–15p, 2–25x
Zaleplon 30d, 30i 60b 1.4b, 1f, 0.9–1.5g, 1h,
0.8i, 0.25–0.5x
1b, 1f, 0.9–1.1g, 1h, 1i, 1x,
Zolpidem 70d, 70l, 70m 92b, 90l, 92m 1.7–2h, 0.75–2.6m, 0.5x 2.0–2.2h, 1.5–3.2m, 1.5–4.5x
Zopiclone 70d, 75j, 80l 80b, 45j, 45–80l 1.5c, 0.25–0.5x 5.6c, 4–5j, 5l, 3.5–6.5x
Eszopiclone 52–59e 1.5c, 1e, 1–1.5w 3.8c, 6e, 6k, 6.9–7.3w
Data from aBenet et al., 1996; bNutt, 2005a, cNajib, 2006; dDrover, 2004; eMelton et al., 2005; fPatat et al., 2001; gBeer et al., 1994; hGreenblatt et al., 1998; iRosen et al.,
1999; jGaillot et al., 1982; kFernandez et al., 1993; lChouinard et al., 1999; mSalva and Costa, 1995; nClark et al., 1988; oJochemsen and Breimer, 1986; pAshton, 1994;
qwww.fda.gov/medwatch/safety/2006/Nov_PIs/Ativan_PI.pdf; rGreenblatt et al., 1976; tHumpel et al., 1982; uDe Vanna et al., 2007; vwww.fda.gov/cder/foi/label/2001/
16721s74lbl.pdf; wBrunello et al., 2008; xWagner and Wagner, 2000.
*Metabolized to desalkylflurazepam (Chouinard et al., 1999).
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summary of product characteristics (SPC)) (see http://
www.medicines.org.uk/emc/medicine/22443/SPC/Zolpidem%
20Tartrate%2010%20mg%20Tablets/NHSEvidence).
The ease of waking and the propensity to daytime carry-
over (‘hangover’) eﬀects are determined by the duration of
action – most typically deﬁned by the elimination half-life
of the drugs (see Tables 3 and 4) and the dose taken. Drugs
with half-lives of more than 6 h tend to leave suﬃcient resid-
ual drug in the brain to cause hangover in the morning. This
was particularly the case with the ﬁrst benzodiazepine hyp-
notics such as nitrazepam, which was associated with daytime
sedation and falls (Trewin et al., 1992). The rationale for
developing the Z-drugs was in part to make shorter half-life
drugs with minimal carry-over eﬀects (Nutt, 2005b). This was
largely achieved, although there is some hangover seen with
zopiclone (Staner et al., 2005). The very short half-life of
zaleplon means that it can be taken as little as 5 h before
the desired time of arising, without the risk of hangover
impairment (see SPC and Walsh et al., 2000).
A very short half-life limits a drug’s duration of action on
sleep, and zaleplon and to some extent zolpidem are not par-
ticularly eﬀective at maintaining sleep throughout the night.
A controlled release formulation of zolpidem (CR, currently
only available in the USA) prolongs its nocturnal actions and
enhances sleep continuity, though only by tens of minutes
(Greenblatt et al., 2006). Individual factors seem important
and some people are more susceptible to carry-over than
others, probably due to individual diﬀerences either in the
rate of drug clearance, which can vary by as much a twofold
between subjects, or sensitivity to drug actions.
Tolerance, dependence and withdrawal
Dose escalation above recommended doses in patients with
insomnia alone is uncommon, and tolerance to hypnotic drug
eﬀects is not a frequent problem in clinical experience; many
patients use the same dose of hypnotic for months or years
and still feel it works. However, a temporary worsening of
sleep, usually with increased sleep-onset latency, is reported dur-
ing the withdrawal period for most agents (Hajak et al., 2009;
Soldatos et al., 1999; Voshaar et al., 2004). Although there have
been no head-to-head studies addressing this question, there is
some lower level evidence in humans that subtype selective
drugs such as eszopiclone produce less tolerance and rebound
(Krystal et al., 2003; Nutt and Stahl, 2009).
Animal and human research demonstrates that brain recep-
tor function changes in response to chronic treatment with ben-
zodiazepine receptor agonists, and this takes time to return to
pre-medication levels after cessation of medication. There is evi-
dence from animal studies that chronic administration of ben-
zodiazepines produces adaptive changes in the receptor which
attenuate the eﬀects of the endogenous neurotransmitter
GABA, and so produce symptoms on withdrawal (Bateson,
2002). It may be possible to develop drugs with a lower propen-
sity to such eﬀects either through targeting speciﬁc subtypes of
the benzodiazepine receptor, by changing the chemical structure
to produce a diﬀerent interaction at the pharmacophore, or by
making partial agonists (Doble et al., 2004).
Considerations of dependence are very much contingent
on what happens when treatment is stopped. A psychological
dependence is seen in many patients and some are unwilling
to stop treatment. If they do stop there can be relapse, where
the patient’s original symptoms return, or rebound of symp-
toms, where for one or two nights there is a worsening of
sleep disturbance, with longer sleep-onset latency and
increased waking during sleep; this is commonly reported
by patients and has been documented in some research studies
(Hajak et al., 2009; Soldatos et al., 1999). More rarely, there is
a longer withdrawal syndrome. All of these can be amelio-
rated by resuming medication. The withdrawal syndrome is
characterized by the emergence of symptoms not previously
experienced, such as agitation, headache, dizziness, dyspho-
ria, irritability, fatigue, depersonalization, hypersensitivity to
noise and visual stimuli. Physical symptoms which have been
described include nausea, vomiting, muscle cramps, sweating,
Table 4. Pharmacokinetic data for other hypnotics
Availability (%) Plasma bound (%) Time to Tmax (h) Thalf (h)
Chloral hydrate (NB t1/2 is so short,
values are for the primary active
metabolite trichloroethanol)
NK 35p, 35q 0.76–0.98o, 2p, 8.2q 9.3–10.2o, 9.3–10.9p
Triclofos sodium NK 35q 8.2q NK
Clomethiazole 25–42s 63s 0.92r 3.6–5s
Promethazine hydrochloride 12.3–40t, 25u NK 4.39u 18.6u
Sodium oxybate 25y <1y 0.6–0.9w, 0.5–2y 0.57–0.73w, 0.5–1y
Trazodone 75a, 60–80b 93a, 89–95b 1–2b, 1–2c 6.5a, 6–13b, 7–15c
Mirtazapine 50d, 85e, 0.25–2c, 1.8d, 2e 20–40c, 16.3d, 20–40e
Olanzapine 60g 93g 5c, 6g 30c, 24f, 30g
Quetiapine 83h 1c, 1.5h, 2i, 2j 7c, 6h, 5.3i, 5.3j
Melatonin 15l 71.5m, 80n 0.5–0.88k, 0.87–1l 0.76–0.86k, 1l
Data from aBenet et al., 1996; bDeVane, 1994; cKrystal, 2009; dVoortman and Paanakker, 2004; eCaraco Mirtazapine PIL, 2/08; fTauscher et al., 2002; gzyprexa-pi LillyInfo
2009; hSeroquel PIL Astrazeneca; iGefvert et al., 1998; jDavis et al., 1999; kMarkantonis et al., 2008; lDeMuro et al., 2000; mRizzo et al., 2002; nDi et al., 1998; oZimmermann
et al., 1998; pMerdink et al., 2008; qSellers et al., 1978; rRa¨tz et al., 1999; sJostell et al., 1978; tKoytchev et al., 1994; uStrenkoski-Nix et al., 2000; wAbanades et al., 2006;
yhttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000593/WC500057103.pdf
NK: not known.
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weakness, muscle pain or twitching and ataxia. This syn-
drome typically resolves within a few weeks, but in some
patients it persists, and this may be related to personality
traits and cognitive factors (Murphy and Tyrer, 1991).
Hypnotic drug treatment
All licensed drugs are eﬃcacious; levels of evidence for short-
term use are given in summary in Table 5 (there is as yet no
systematic review or meta-analysis evidence for prolonged-
release melatonin). The sleep factors which each drug improves
are given in Table 6. Thus, for example, in a patient with pre-
dominantly sleep-onset insomnia, a shorter-acting drug such as
zolpidem or prolonged-release melatonin might be appropriate,
and for those with awakenings throughout the night a slightly
longer-acting drug such as zopiclone may be preferable.
Most of the licensed drugs enhance GABA function in the
brain. As well as promoting sleep these drugs are anxiolytic,
anticonvulsant and myorelaxant, and can cause ataxia and
memory problems when taken other than just before a period
in bed. If their eﬀect in the brain persists after waking up in the
morning they are described as having ‘hangover’ eﬀects, there-
fore diﬀerences in the pharmacokinetics of individual benzodi-
azepines (or Z-drugs) are of particular importance. Melatonin
does not give rise to motor or memory eﬀects. Recent clinical
trials have begun to measure daytime outcomes after hypnotic
medications, and beneﬁcial eﬀects have been reported for mel-
atonin in over-55s, zolpidem, zopiclone, eszopiclone and lorme-
tazepam. These measures have not been used in studies of other
drugs, so their eﬀects on daytime function are not documented.
In systematic reviews of benzodiazepines and Z-drugs,
adverse events/side eﬀects are less common and less severe
for the Z-drugs zolpidem, zaleplon and eszopiclone
(Buscemi et al., 2007). Controlled studies measuring cognitive
and psychomotor function (such as digit–symbol substitution
test, and memory) in insomnia patients have only shown next-
day deleterious eﬀects consistently after use of ﬂurazepam
(very long-acting) or very high doses of other benzodiazepines
(Buscemi et al., 2005). Evidence for hypnotic eﬀects on next-
day driving in insomnia patients is limited; however, epidemi-
ological studies show that road accidents are increased in
people taking benzodiazepines or zopiclone (Barbone et al.,
1998; Neutel, 1995). Studies in healthy volunteers show that
residual eﬀects of hypnotics increase with their half-life dura-
tion (Verster et al., 2006). Eﬀects of insomnia itself on driving
have not been studied, but sleep deprivation does impair driv-
ing performance (Connor et al., 2002). In a controlled study
of patients with insomnia in a driving simulator there
was next-day impairment after zopiclone and lormetazepam
but not zolpidem, when compared with placebo (Staner et al.,
2005). Transient increases in sleep-onset latency and decreases
in sleep time have been reported after stopping nearly all
hypnotic drugs, except with zaleplon, melatonin and ramel-
teon: onset and duration is related to half-life, occurring on
the ﬁrst or second nights after stopping with short half-life
drugs, and later and more prolonged with longer-acting ones
(Hartmann and Cravens, 1973; Voderholzer et al., 2001).
Table 5. Level Ia evidence of hypnotic efficacy from subjective rating of sleep or objective polysomnographic measures
Sleep-onset latency Total sleep time Sleep efficiency Wake time after sleep onset Sleep quality
Self-rated PSG Self-rated PSG Self-rated PSG Self-rated PSG Self-rated
Benzodiazepines 3 3 3 3 3 3 3
Z-drugs 3 3 3 3 3 3 3
Table 6. Effects of individual drugs (significantly different from placebo (Ib)) on sleep parameters
Sleep-onset latency Total sleep time Wake time after sleep onset
Sleep quality
Self-rated PSG Self-rated PSG Self-rated PSG Self-rated
temazepam (3)* (3) 3 3 3 3 3
lormetazepam 3 3 3 3 3 3 3
zopiclone 3 3 3 3 3 3 3
zolpidem 3 3 3 3 3 No 3
zaleplon 3 3 No No No No 3
eszopiclone 3 3 3 3 3 3 3
ramelteon 3 3 3 (week 1 only) 3 No 3
PR melatonin 3 3 Not measured No Not measured No 3
PSG: polysomnography.
*Formulation changed since studies, longer absorption time with current tablet cf gel capsule previous formulation.
Recommendations
. Factors which clinicians need to take into account when
prescribing are eﬃcacy, safety, and duration of action (A).
. Other factors are previous eﬃcacy of the drug or adverse
eﬀects, history of substance abuse or dependence (D).
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Long-term hypnotic use
What is known about long-term hypnotic treatment 
   •  Insomnia is often long-lasting and is often treated with 
      hypnotics for long periods in clinical practice (Ib) 
   •  These studies suggest that dependence (tolerance/
      withdrawal) is not inevitable with hypnotic therapy up to 
      1year with eszopiclone, zolpidem, ramelteon (Ib) 
   •  There is also evidence that dependence may be more 
      likely with some agents or with polysomnography 
      outcome measures as compared with self-report measures 
      of outcome 
   •  Intermittent dosing may further reduce the risk of 
      tolerance and dependence (Ib)
What is not known
   •  How can we predict the needed treatment duration? 
   •  How and when should treatment be discontinued? 
   •  Should dosing for longer periods be nightly or 
      intermittent? 
   •  How we detect the abuse-prone individual in the clinic? 
   •  Does hypnotic therapy affect the course of insomnia or 
      associated conditions? 
The question of long-term hypnotic treatment is one of the
more controversial areas in psychopharmacology. It has long
been stated that hypnotic medication should not be used long
term for the treatment of insomnia. This was the consensus
view of the panel of a 1983 National Institute of Health
(NIH, 1983) Consensus Conference on the medication treat-
ment of insomnia, which became a guideline for clinical prac-
tice in the USA, and later the UK Committee on Safety of
Medicines and the Royal College of Psychiatrists both recom-
mended only short-term use. While it was appreciated that
benzodiazepine hypnotic agents had a favourable risk–beneﬁt
ratio and were ﬁrst-line agents for insomnia management, all
these reports expressed concerns about the risks of physical
dependence and recommended that their use should be lim-
ited to periods of 2–3weeks. This view was not based on data
demonstrating an unfavourable transition in the risk–beneﬁt
ratio after 2–3weeks of treatment, but appears to have been
because no substantive placebo-controlled trials of hypnotics
had been carried out for longer than a few weeks. Despite the
recommendation for treatment with hypnotic drugs being only
2–4weeks, many millions of patients worldwide remain on
long-term treatment (Balter and Uhlenhuth, 1992; Ishigooka
et al., 1999; Ohayon et al., 1999; Mellinger et al., 1985).
The reasons for long-term use are complicated and diﬃcult
to research, but are probably similar to those which aﬀect
understanding of long-term benzodiazepine treatment in anx-
iety disorders. We do not know the proportions of long-term
users who have continuing insomnia requiring daily drug
treatment, or who do not need the drug at all, or who are
afraid to try discontinuing because of fear or experience of
rebound insomnia. In one study where people were successful
in discontinuing benzodiazepine hypnotics, a follow-up after
2 years revealed approximately 40% had resumed regular use
(Belanger et al., 2005; Morin et al., 2005a), which suggests
some people have enduring problems with sleep which beneﬁt
from treatment. Insomnia may have some similarities with
depression, in that both represent long-term disorders in
which maintenance treatment may be needed in many
patients (Jindal et al., 2004). A related issue is whether early
intervention at the onset of insomnia might reduce the likeli-
hood of it persisting. There is very little evidence available on
this, and it must be seen as a research priority.
Placebo-controlled trials of hypnotic treatment for durations
longer than 3weeks that can more deﬁnitely assess safety and
eﬃcacy, and determine whether dependence phenomena occur,
have been undertaken only recently. Trials of nightly dosing for
up to 6months’ duration suggest that tolerance and withdrawal
do not generally occur with some hypnotics: eszopiclone (two
studies of 6months’ duration); ramelteon (a 6-month studywith
outcome assessed with PSGbut not self report); and temazepam
(a 2-month study) (Bastien et al., 2003; Krystal et al., 2003;
Mayer et al., 2009; Morin et al., 1999; Walsh et al., 2007).
Other agents have not been studied for longer durations. The
available evidence does not suggest there is an unfavourable
risk/beneﬁt transition at 3–4 weeks for any agent.
Open-label studies of nightly dosing for periods of up to
1 year with the agents studied (zaleplon, eszopiclone, and
ramelteon) suggest that discontinuation symptoms are mild
and infrequent (Ancoli-Israel et al., 2005; Richardson et al.,
2009). Intermittent, non-nightly dosing is also an important
consideration with respect to long-term hypnotic treatment.
Many individuals do not have nightly insomnia, and treat-
ment only on the nights when drug is needed can decrease the
risks and costs of therapy and reduce psychological depen-
dence/treatment withdrawal anxiety. There is evidence from a
placebo-controlled trial for sustained eﬃcacy and safety for
6months of ‘as needed’ treatment (subjects being required to
take at least three doses per week) with controlled release
zolpidem 12.5mg (Krystal et al., 2008).
In conclusion, insomnia is often long-lasting and often
treated with hypnotics for long periods in clinical practice.
Controlled trials of longer-term use are being undertaken
and these suggest dependence (tolerance/withdrawal) is not
inevitable with hypnotic therapy up to 1 year, and is not char-
acteristic of the several agents studied. Dependence may be
more likely with some agents or with PSG outcome measures
as compared with self-reported measures of outcome. The
longer-term safety and eﬃcacy of many other commonly
used hypnotics remain uncertain.
A number of other critical issues remain unresolved. We
currently lack the means to determine who should receive
longer-term treatment and to predict the required treatment
duration. Lacking the means to determine the optimal
duration of therapy, a rational approach is to carry out peri-
odic trials of tapering and discontinuing medication to deter-
mine if continued therapy is indicated (Krystal, 2009). As
such, the duration of treatment is decided by a series of
risk/beneﬁt decisions based on trial discontinuations. This
approach provides an ‘exit strategy’ and thereby addresses
concerns that, once started, hypnotic therapy could be unend-
ing. Concomitant CBT during tapered discontinuation may
be helpful (Morin et al., 2006). Another unresolved issue is
whether to implement nightly or intermittent dosing of hyp-
notics for a given patient. In many instances this is a practical
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decision based on whether the patient can predict, when they
go to bed, whether they will have sleep diﬃculty.
Antidepressants
What is known about the use of antidepressants to 
treat insomnia 
   •  There is limited evidence for efficacy of doxepin, 
      trimipramine, trazodone, paroxetine in insomnia (Ib) 
   •  Antidepressants may affect a wide range of brain 
      receptors and have longer-lasting carry-over effects than 
      traditional hypnotic drugs – antidepressants are associated
      with increased risks of road accidents especially early in 
      treatment in depression (Ib) 
What is not known 
   •  Is the effect of antidepressants on insomnia lasting 
      (particularly as they are often prescribed for long periods)? 
   •  Are they more efficacious than traditional hypnotics? 
   •  Do they improve mood or reduce the risk of emergent 
      depression in patients? 
Tricyclic and some other classes of antidepressants have long
been used for insomnia, whereas the selective serotonin reup-
take inhibitors (SSRI) as a class generally disrupt sleep early in a
course of treatment (Mayers and Baldwin, 2005). The alerting
eﬀect of SSRIs can be oﬀset by co-administration of sedating
antidepressants such as trazodone, probably because they block
5HT2 receptors that are being overstimulated by an increase in
5HT (Kaynak et al., 2004). Other 5HT2 antagonist antidepres-
sants such as nefazodone (now discontinued) (Hicks et al., 2002)
and mirtazapine (Winokur et al., 2003) have been shown to
reduce insomnia in depression, especially early in treatment.
Low doses (sub-therapeutic for depression) of sedating tri-
cyclics, particularly amitriptyline, dosulepin and doxepin,
have been used for decades to treat insomnia. This is parti-
cularly common practice in primary care in the UK, where
amitriptyline 10 or 25mg is also used for long periods in
many patients with chronic illness, particularly those with
pain syndromes. At this dose amitriptyline is probably
acting mostly as a histamine H1 receptor antagonist,
although a degree of 5HT2 and cholinergic muscarinic antag-
onism may also contribute. There are no controlled studies of
hypnotic eﬃcacy of low-dose amitriptyline in insomnia, and
tricyclics are more likely to be lethal than licensed hypnotics
in overdose (Nutt, 2005a). Controlled trials have demon-
strated an eﬀect of doxepin in insomnia at low dose (25mg)
for 4weeks with rebound insomnia (Hajak et al., 2001), and
very low ‘microdose’ studies using 1, 2 or 6mg for two nights
in adult (Roth et al., 2007) and elderly insomnia patients
(Scharf et al., 2008) have shown sleep improvement; at this
dose the antihistamine action is paramount.
Trazodone is an antagonist at 5HT1a, 5HT2 and a1 adre-
nergic receptors as well as a weak 5HT reuptake inhibitor, and is
the second most prescribed medication for insomnia in the US.
It has a perceived absence of risk, is cheap, and there are no
restrictions on use duration, but 25–30% patients experience
diﬃculty tolerating trazodone and dropout rates tend to be
higher than for benzodiazepine or Z-drugs. Although there
have been 18 trazodone studies measuring sleep outcomes,
only two were in primary insomnia, and only one was a con-
trolled study (Walsh et al., 1998). This study used 50mg trazo-
done versus placebo, and found a signiﬁcant eﬀect on sleep
maintenance parameters at week 1 but not week2, and a high
incidence of daytime somnolence. Trimipramine is a tricyclic
antidepressant which blocks a-1 adrenergic, histamine H1,
dopamine D2, serotonin 5HT2 and cholinergic receptors
(Gross et al., 1991; Richelson, 1994). There is one controlled
trial (Riemann et al., 2002) in insomnia at doses of 50–200mg
for 4weeks which found a signiﬁcant improvement in sleep eﬃ-
ciency as measured by PSG, paralleled by subjective improve-
ments. Side eﬀects were described as marginal. Paroxetine, an
SSRI, was studied in patients with insomnia aged over 55 years,
at a median dose of 20mg for 6weeks (Reynolds et al., 2006),
there being a 50% response rate (placebo 38%) with subjective
sleep quality and daytime well-being improved. This seemingly
paradoxical action of paroxetine to improve sleep is probably
related to its good eﬃcacy in many anxiety disorders, where it
seems to reduce recurrent thinking and ruminations.
Taking SSRIs, venlafaxine, mianserin or mirtazapine
increases the risk of restless legs syndrome (RLS) and periodic
limb movements in sleep (PMLS) (Hoque and Chesson,
2010), and SSRIs are known to induce or exacerbate sleep
bruxism (Wilson and Argyropoulos, 2005).
Antipsychotics
What is known about use of antipsychotics for 
treatment of insomnia
   •  Olanzapine and quetiapine improve sleep in 
      healthy volunteers (Ib)
   •  Quetiapine improves sleep in primary insomnia (IIb)
   •  Side effects are common because of the pharmacological 
      actions of these drugs (I)
What is not known
   •  How do they compare with traditional hypnotic drugs?      
Atypical antipsychotics have become relatively widely used
in the treatment of sleep problems with very little controlled
Recommendations
. Use as clinically indicated (A).
. To stop medication, try intermittent use at ﬁrst if it makes
sense, then try to stop at regular intervals, say every
3–6months depending on ongoing life circumstances and
with patient’s consent (D).
. CBT during taper improves outcome (A).
Recommendations
. Use drugs according to a knowledge of pharmacology (A).
. Consider antidepressants when there is coexistent mood
disorder but then use at therapeutic doses (A).
. Beware toxicity of tricyclic antidepressants in overdose
even when low unit doses prescribed (A).
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trial evidence, although a meta-analysis of atypical antipsy-
chotic agents in mania indicates they all produce somnolence
(Scherk et al., 2007). Research studies have been carried out in
healthy volunteers. Increases in objective actual sleep time and
sleep continuity and in subjective sleep quality have been
reported with olanzapine (Gimenez et al., 2007; Lindberg
et al., 2002; Sharpley et al., 2000), which also improves sleep
continuity when added to an SSRI in depression (Sharpley
et al., 2005). Quetiapine at 25mg and 100mg for two nights
in healthy volunteers increased sleep time and eﬃciency and
subjective sleep quality but periodic leg movements were sig-
niﬁcantly increased after 100mg (Cohrs et al., 2004). A single
small open study of quetiapine (a 25mg dose in most patients)
for 6weeks in primary insomnia (Wiegand et al., 2008) showed
improvements in total sleep time and sleep eﬃciency, with tran-
sient adverse eﬀects of morning hangover and dry mouth.
Side eﬀects of these antipsychotics are well documented
and include weight gain, metabolic syndrome, extrapyramidal
symptoms and risk of tardive dyskinesia. There are some case
reports of abuse of quetiapine in inpatients and prisoners
(reviewed in Sansone and Sansone, 2010).
Antihistamines
Antihistamines are sedating and are sold as over-the-counter
(OTC) sleeping medications. There is limited evidence that
OTC antihistamines work, although recently some modest ben-
eﬁts have been reported after 2weeks’ dosingwith diphenhydra-
mine in mild insomnia (Morin et al., 2005b). More profound
acute eﬀects on sleep have been reported for both promethazine
and hydroxyzine in healthy volunteers (Adam and Oswald,
1986; Alford et al., 1992), but the latter is not available as an
OTC hypnotic, and both have a long duration of action so are
likely to cause hangover. Triprolidine is used in many other
European countries and may be better as it has a shorter half-
life; however, there are no placebo-controlled studies.
Antihistamines are commonly used in alleviation of insom-
nia in drug and alcohol withdrawal where traditional hypnotics
are less suitable due to the risk of cross-dependence, although
there are no controlled trials in this setting.
Special populations
Sleep in women: effects of menopause
Insomnia increases as women approach and pass through the
menopause (Bixler et al., 2009; Kuh et al., 1997; Owens and
Matthews, 1998). This is due to a variety of reasons: climac-
teric symptoms such as hot ﬂushes due to hormonal changes,
psychiatric disorders and a rise in the incidence of sleep-dis-
ordered breathing (Bixler et al., 2001). A recent study looking
at gender diﬀerences in the clinical presentation of patients
diagnosed with obstructive sleep apnoea syndrome (OSAS)
showed that at the time of OSAS diagnosis, women were
more likely to be treated for depression, to have insomnia
and to have hypothyroidism than men with similar degree
of OSAS (Shepertycky et al., 2005). In the Wisconsin
cohort of individuals followed over time, there were no sig-
niﬁcant PSG sleep architectural changes associated with tran-
sition to menopause, but there was an increase in obstructive
apnoeas (Young et al., 2003). In contrast, a recently published
US study of normal sleepers showed that women sleep more
deeply than men and that the menopause is associated with
longer sleep latency and decreased slow-wave sleep. In addi-
tion, hormone therapy appeared to protect women from these
unfavourable changes (Bixler et al., 2009).
Offer (patient choice)
Significant distress and
daytime symptoms in spite of 
good sleep habits
Diagnosis of insomnia
yes
Ensure other disorder 
adequately treated
Insomnia
persists
no
Consider 3-7 days
Z drug
no
Associated with another disorder
yes
CBTi Hypnotic drug 
Z drug
PR melatonin if over 55Availability?
Review
After CBTi In 4 weeks
Improved
? Open appointment
Not improved
Reassess
Consider alternative medication
Refer
Likely to resolve soon (eg
bereavement, short-term stressor etc)
Figure 3. Treatment algorithm.
Recommendations
. Antihistamines have a limited role in psychiatric and pri-
mary care practice for the management of insomnia (D).
. The algorithm for the treatment of insomnia is summa-
rized in Figure 3.
Recommendations
. Clinicians should appreciate that there is a rise in incidence
of sleep-disordered breathing after the menopause and that
clinical presentation, often including insomnia, in women
is diﬀerent than in men.
. The use of hormone therapy should involve informed indi-
vidualized treatment of symptoms, looking at risks and
beneﬁts in light of recent studies.
. Follow recommendations for insomnia in other sections.
Recommendation
. Side eﬀects are common because of the pharmacological
actions of these drugs and there are a few reports of abuse.
Together these indicate no indication for use as ﬁrst-line
treatment (D).
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Sleep in women: effects of pregnancy
Many women complain of poor sleep during pregnancy, with
the reasons varying depending on the trimester. In the ﬁrst
trimester, nausea, backache and urinary frequency can cause
sleep disturbance. The second trimester tends to be easier but
foetal movements and heartburn may be issues. By the third
trimester, sleep is more disturbed with complaints again of
urinary frequency and backache in addition to cramps, itch
and unpleasant dreams. Most women fall asleep easily but
wake more frequently (Schweiger, 1972).
If patient suﬀers from intractable insomnia and a pharma-
cological agent is required, it is helpful to note that zolpidem
and diphenhydramine are in FDA class B (foetal harm possible,
but unlikely; no evidence of foetal harm in animal studies); for
review see Pien and Schwab, 2004. Zolpidem is preferable as it is
short acting and does not have anticholinergic side eﬀects.
RLS is common in pregnancy with a prevalence of
11–26% and is sometimes associated with anaemia
(Manconi and Ferini-Strambi, 2004). Snoring and sleep-dis-
ordered breathing, especially in obese subjects can also occur
and aﬀect sleep quality (Pien and Schwab, 2004).
Treatment of insomnia in the elderly
What is known about treatment of insomnia in the elderly 
   •  Cognitive behavioural therapy is effective in insomnia 
      in the elderly (Ia) 
   •  Short-acting Z-drugs increase the risk of falls in elderly 
      patients (III) 
   •  Prolonged release melatonin given for 3 weeks improves 
      sleep onset latency and sleep quality in patients over 
      55 (1b) 
What is not known? 
   •  What is the long-term efficacy and safety of 
      melatonin? 
Insomnia in elderly patients responds well to CBT (see
psychological treatment section). Meta-analyses comparing
CBT outcomes in middle-aged and older adults
(55 years plus) have reported moderate-to-large eﬀect sizes,
regardless of age, in sleep-onset latency (SOL) and wake
time after sleep onset (Irwin et al., 2006; Montgomery and
Dennis, 2003).
A systematic review (Bain, 2006) and meta-analysis (Glass
et al., 2005) concluded that benzodiazepine receptor agonist hyp-
notics had an unfavourable risk/beneﬁt ratio in elderly patients.
However, the diﬀerent methods of collection and categorization
of drug-related side eﬀects in the studies included makes them
diﬃcult to interpret. Individual randomized controlled studies
with short-acting Z-drugs show little evidence of adverse eﬀects,
particularly cognitive side eﬀects in the morning. However, if a
patient needs to rise within a few hours after taking a benzodi-
azepine agonist drug there may be undesired eﬀects on motor
control. Falls are increased after sedatives and hypnotics, neu-
roleptics and antipsychotics, antidepressants, benzodiazepines,
non-steroidal anti-inﬂammatory drugs and calcium channel
antagonists (Woolcott et al., 2009) and, for example, there is a
2.5-fold increase in the risk of falls in hospital after zolpidem
(Rhalimi et al., 2009). However, in nursing homes the situation
may be diﬀerent; in a large study (Avidan et al., 2005) insomnia
itself, but not hypnotic use, was associated with an increase in
falls and hip fractures. Therefore the development of sleep-pro-
moting drugs without motor side eﬀects has been welcomed.
Prolonged-release melatonin has been shown to reduce SOL
and increase subjective sleep quality in two large trials in patient
over 55 years (Lemoine et al., 2007; Wade et al., 2007); its eﬀects
are fairly modest but it has no known motor side eﬀects.
Treatment of sleep problems in children
What is known 
   •  Most sleep disorders in childhood respond well to 
      behavioural treatments (I) 
   •  Melatonin reduces long sleep latency (following 
      appropriate behavioural interventions) in children with 
      sleep onset insomnia or delayed sleep phase syndrome 
      and learning difficulties, autism and ADHD (II) 
   •  Antihistamines may have a role in short-term 
      symptomatic treatment (II) 
What is not known 
   •  What are the long-term effects of melatonin? 
Sleep problems are commonly associated with certain genetic
and neuro-developmental problems seen in childhood
Recommendations
. Good sleep hygiene and lifestyle (D).
. Manage general pregnancy-associated complaints, e.g.
decrease ﬂuid intake, pillow support (D).
. The beneﬁts of CBT in pregnancy have not been published
but approach would appear sensible (B).
. Recognize RLS by careful history and investigations if
necessary.
. Dopamine agonists are contraindicated (FDA category
C or greater)
. Iron and folic acid supplementation have been shown
to be eﬀective in RLS. Supplementation is suggested
even if levels are not low (D)
. Keep caﬀeine low as it can exacerbate RLS (D)
. Mild to moderate exercise in the early evening, stretch-
ing, massage (D)
. If patient suﬀers from intractable insomnia and a pharma-
cological agent is required, zolpidem is preferable as it is
short acting and does not have anticholinergic side eﬀects.
Short-term use is recommended after discussion on poten-
tial risks and beneﬁts (D).
Recommendations
. CBT is eﬀective and should be oﬀered as a ﬁrst line where
available (A).
. When a hypnotic is indicated in patients over 55, pro-
longed-release melatonin should be tried ﬁrst (B).
. If a GABAA hypnotic is used then a shorter half-life will
minimize unwanted hangover (A).
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including ADHD, autism, learning diﬃculties and epilepsy.
Training and awareness of paediatric sleep disorders is poor,
and accurate diagnoses and hence appropriate treatments are
often delayed. Evidence from systematic review suggests that
most sleep disorders in childhood respond well to behavioural
treatments (Mindell et al., 2006). Appropriate sleep hygiene
measures and more speciﬁc techniques of extinction, or grad-
uated extinction, are all more eﬀective than placebo at improv-
ing sleep and reducing the number of weekly night wakes in
otherwise healthy children who regularly wake up in the night
(Ramchandani et al., 2000). These interventions hold for both
typically developing children and children with learning diﬃ-
culties and sleep problems. These interventions may not
change sleep parameters in the child, but instead improve out-
comes related to impact on parents and other carers.
The sedative side eﬀects of antihistamines may speed
up behavioural programmes over short periods (France et al.,
1991) but seem not to workwithout behavioural interventions; in
a placebo-controlled double-blind trial in infants aged 6–
27months the same authors found no signiﬁcant eﬀect of
15mg or 30mg trimeprazine tartrate, and concluded that it is
not recommended as a pharmacological treatment for infant
sleep disturbance unless as an adjunct to a behavioural therapy
program (France et al., 1999). Clinically, the short-term use of an
H1 blocker for transient or extreme insomnia can be helpful and
is frequently employed. However, tolerance can develop
quickly and some children can experience dramatic and paradox-
ical over-arousal. Nevertheless, the TIRED RCT speciﬁcally
investigated the use of diphenhydramine in infants aged 6–
15months and found it was no more eﬀective than placebo in
reducing night-time awakening (Merenstein et al., 2006).
The evidence supporting use ofmelatonin to reduce long sleep
latency (following appropriate behavioural interventions) in pop-
ulations of children with idiopathic sleep-onset insomnia (Smits
et al., 2003) orDSPS and learning diﬃculties, autism andADHD
(van der Heijden et al., 2007) is increasingly robust. However,
evidence that melatonin can signiﬁcantly improve sleep fragmen-
tation and total sleep time in this group is only weak. The major-
ity of research in children has employed supraphysiological doses
of fast-release melatonin, and although there is little evidence of
short-term adverse eﬀects, there are also only limited data on
long-term potential adverse eﬀects. Melatonin at doses between
0.5 and 12mg is commonly used as a sedative agent in children
undergoing procedures such as electroencephalography (EEG),
as an alternative to sleep deprivation that does not aﬀect the EEG
morphology. A melatonin-induced sleep EEG was as useful as a
sleep-deprived EEG, but children’s behaviour on the day of the
melatonin-induced sleep EEG recording was more acceptable to
parents (Wassmer et al., 2001).
Clonidine is an antihypertensive agent with sedative side
eﬀects that may improve sleep maintenance in some children.
The therapeutic window is narrow, both for adverse eﬀects on
sleep architecture and tolerability. Also tolerance to the sleep-
inducing eﬀects develops over time, leading to the need for
increased doses with concomitant risk of adverse eﬀects.
Despite these concerns, it is still widely used in the UK and
by as many as a third of clinicians surveyed in the USA
(Schnoes et al., 2006).
Chloral hydrate and triclofos are still popular hypnotics
for children but have a very long half-life and considerable
potential for ‘hangover’ eﬀects in children. The half-life of
chloral hydrate itself is short (a few minutes), but the half-
lives of its active metabolites are longer, being 8–12 h for
trichloroethanol and 67 h for trichloroacetic acid. Toxicity is
an important concern due to central nervous system
depressant action, arrhythmogenic potential and stomach
irritation.
Treatment of insomnia in children and adults
with learning disability
Epidemiological studies show a very high prevalence of sleep
disturbance in people with learning disability, with ﬁndings rang-
ing from 58–86% in children (Didden and Sigafoos, 2001) and
14–56% in adults (Brylewski and Wiggs, 1999) (this study
reported a 15% prevalence of parasomnias). Positive associa-
tions have been reported between sleep disturbance and sleep
breathing disorders, challenging behaviours, early childhood,
severe or profound learning disability, institutional care,
autism/ADHD, various genetic syndromes, physical health
problems, sensory impairment, epilepsy and caﬀeine intake
(Brylewski and Wiggs, 1999). Many diﬀerent aspects contribute
to aetiology, such as neurodevelopmental causes, sensory impair-
ments, chaotic or institutionalized environments, failure of learn-
ing and psychotropic medications, including anticonvulsants.
Clinical assessment should elicit any aetiological or exac-
erbating factors which can be reversed. Assessment will usu-
ally take place by direct observation initially. Carers should
be supported to keep a structured 24-h record of sleep pattern
and behaviour. Actigraphy or EEG may be useful when a
sleep disorder other than insomnia or settling diﬃculties is
suspected. A circadian rhythm disorder should be considered
in individuals with visual impairment (see below).
There is a varying degree of evidence for treatments of sleep
diﬃculties in this heterogeneous population. The relatively
small number of controlled studies in this area give support
to parental/carer education and modifying environmental fac-
tors (Montgomery et al., 2004) and behavioural regimes such
as chronotherapy, bedtime fading, extinction, distancing/
desensitization and sleep–wake scheduling (Gunning and
Espie, 2003; Wiggs and France, 2000). The use of light therapy
has been described (Short and Carpenter, 1998).
There is very little evidence for eﬀectiveness of sleep-pro-
moting drugs apart from melatonin. A recent meta-analysis
(Braam et al., 2009) shows that melatonin (1–9mg) decreases
sleep latency and number of wakes per night, and increases
total sleep time in individuals with intellectual disabilities.
There were few adverse events in the relatively short-
term studies included, and long-term safety needs further
research.
Recommendations
. Behavioural strategies should be tried in children with dis-
turbed sleep (A).
. Melatonin administration can be used to advance sleep
onset to normal values in children with ADHD who are
not on stimulant medication (A).
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Treating circadian rhythm disorders
What is known 
   •  Melatonin is effective in jet lag disorder (1a), delayed 
      sleep phase syndrome (Ib) and free-running disorder (IIa) 
   •  Light therapy is effective in delayed sleep-phase 
      syndrome (III) 
What is not known
   •  What are the best efficacy measures – subjective 
      versus objective? 
   •  Is there a need to distinguish between adults and 
      adolescents in delayed sleep-phase disorder, since sleep 
      times are somewhat delayed in normal adolescence? 
   •  Is there a need to distinguish between sighted and 
      blind individuals? 
   •  Is melatonin or light therapy more effective for delayed 
      sleep-phase disorder? 
Current understanding of circadian rhythms and sleep phys-
iology provides a strong theoretical basis for the use of mel-
atonin in some, but not all circadian rhythm disorders
(CRDs). Empirical evidence for eﬃcacy is strong in some
CRDs, but weak or absent in others. Melatonin agonists
may be promising in the treatment of CRDs but there remains
a need for RCTs in well-characterized CRD populations.
There is suﬃcient evidence to support the use of melatonin
in jet lag (Herxheimer and Petrie, 2002; Sack et al., 2007b),
but melatonin has to be taken near desired bedtime otherwise
there may undesired daytime sleepiness. An evidence-based
strategy for minimizing jet lag which includes strategic sched-
uling of sleep combined with melatonin is given in a recent
paper by Sack (2010).
In delayed sleep-phase disorder, there is both a theoretical
and an empirical basis for use of melatonin, which is eﬀective
in practice, shown in two systematic reviews (Sack et al.,
2007a; MacMahon et al., 2005); however, studies in these
reviews vary in the physiological and subjective outcomes
measured. Direct comparison with other therapies such as
timed light exposure, for which there is a little evidence of
eﬃcacy (see below), or chronotherapy, for which there are no
controlled trials, has not been reported.
In free-running disorder in sighted individuals, case reports
(n¼ 5) suggest a positive beneﬁt of melatonin. The evidence in
blind people is more compelling, where case reports and two
small, single-blind placebo-controlled studies are positive (Sack
et al., 2007a; Skene and Arendt, 2007; Skene et al., 1999).
There is no evidence of eﬃcacy of melatonin in irregular
sleep–wake rhythm, or in shift work disorder, although there
have been some reports of use in shift workers with varying
results (for review see Sack et al., 2007b).
Bright light therapy has been used eﬀectively in DSPS (for
review see Shirani and St Louis, 2009). Exposure to bright light of
2500 lux for 2h in the early morning, combined with light restric-
tion after 16:00 (dark goggles) is an eﬀective treatment for DSPS,
and a light mask oﬀering exposure to gradually increasing light
intensity through closed eyelids over the last 4 h of habitual sleep
time has been shown to be eﬀective in these patients. Despite
limited evidence, the American Academy of Sleep Medicine cur-
rently considers timed phototherapy as ‘‘a rational and eﬀective
intervention for DSPT’’ (Sack et al., 2007a).
Treatment of parasomnias
There is little high-level evidence for treatments in these dis-
orders. There are no controlled trials of treatment of non-
REM parasomnias in adults (see Harris and Grunstein,
2009). Priorities are to minimize possible trigger factors
such as frightening ﬁlms, caﬀeine, alcohol or meals late at
night, and to make sure there is a stable and adequate
sleep–wake schedule. It is important to safeguard against
harm to the patient, such as by locking windows, bolting
doors, or sleeping on the ground ﬂoor, and safety of the
bed partner or nearby children also requires attention.
Drug treatment decisions should be based on the fre-
quency and severity of events. Clonazepam in doses up to
3mg per night has been reported to be eﬀective (case series,
n¼ 69) (Schenck and Mahowald, 1996). Smaller case series
have reported good eﬀects of paroxetine (Wilson et al.,
1997) and imipramine (Cooper, 1987) (both eﬀective immedi-
ately), and there is a small case series of hypnotherapy in
sleepwalkers (Reid et al., 1981). A randomized controlled
study of 3weeks’ treatment with 5-hydroxytryptamine in chil-
dren found evidence of eﬃcacy at 6-month follow-up (Bruni
et al., 2004).
For nightmares, psychological treatments are eﬀective and
these focus on exposure – writing down dreams – or guided
imagery, pleasant images, and ‘changing the ending’ (Burgess
et al., 1998; Krakow et al., 1995). There have been a few case
series showing beneﬁcial eﬀects of the alpha-1 adrenergic
blocker prazosin in reducing nightmares related to post-trau-
matic stress disorder in both military and civilian settings
(Raskind et al., 2007). Nightmares have been reported to be
triggered or worsened by many drug treatments, including cho-
linesterase inhibitors, beta-blockers, SSRIs (especially paroxe-
tine) levodopa, and following withdrawal from antidepressants.
There are no prospective or controlled studies of drug
treatment of REM behaviour disorder, but case series suggest
Recommendations
. Clinical assessment should describe sleep disturbance and
elicit aetiological and exacerbating factors (A).
. Environmental, behavioural and educational approaches
should be used ﬁrst line (A).
. Melatonin is eﬀective in improving sleep (A).
. Treatment should be planned within a capacity/best inter-
ests framework.
Recommendations
. Clinical assessment is essential in DSPS and free-running
disorder (A/B).
. Melatonin may be useful in DSPS, free-running disorder
and jet lag (A).
. Other approaches such as behavioural regimes and sched-
uled light exposure (in sighted individuals) can also be
used (B/C).
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a good eﬀect for clonazepam 1–4mg (Aurora et al., 2010;
Boeve et al., 2004) in reducing the number of episodes and
injuries during them, although it should be used with caution
in patients with dementia, disorders of gait or balance, or
concomitant OSAS. Smaller beneﬁcial eﬀects have been
reported for melatonin 3–12mg (Gagnon et al., 2006).
Single case studies and small series have reported beneﬁcial
eﬀects of clonidine (Nash et al., 2003), donepezil (Massironi
et al., 2003) and sodium oxybate (Kosky et al., 2008).
Drugs which can worsen RBD or provoke its symptoms
include SSRIs, venlafaxine, mirtazapine, bisoprolol, and tra-
madol (Gagnon et al., 2006).
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Appendix
Suggested algorithm to screen for sleep disorder other than insomnia.
Ask the lead question, and then proceed with supplementary only if answer is ‘yes’.
Reproduced with permission of Prof Colin A Espie, Glasgow
1. Narcolepsy
a. Do you sometimes fall asleep in the daytime completely without warning?
b. Is it literally impossible to resist ‘sleep attacks’ during the day?
c. Do you have collapses or extreme muscle weakness triggered by extreme emotion?
d. Do you have visual hallucinations, either just as you fall asleep or when you wake in the morning?
e. Are you paralysed and unable to move when you wake up from your sleep?
[Possible narcolepsy: 1a¼ ‘‘TRUE’’ AND (1b OR 1c OR 1d OR 1e¼ ‘‘TRUE’’)]
2. Sleep breathing disorder
a. Are you a very heavy snorer?
b. Does your partner say that you sometimes stop breathing?
c. Do you often wake up gasping for a breath?
d. Are you often excessively sleepy during the day or fall asleep without wanting to?
[Possible sleep breathing disorder: 2a¼ ‘‘TRUE’’ AND (2b OR 2c OR 2d¼ ‘‘TRUE’’)]
3. PLMS/ RLS
a. Do your legs often twitch or jerk or can’t keep still in bed?
b. Is it very difficult to get to sleep because of repeated muscle jerks?
c. Do you frequently wake from sleep with sudden jerky movements or with a compulsion to move your legs?
d. Do you simply have to get out of bed and pace around to get rid of these feelings?
[Possible PLMS/ RLS: 3a¼ ‘‘TRUE’’ AND (3b OR 3c OR 3d¼ ‘‘TRUE’’)]
4. Circadian Rhythm Sleep Disorder
a. Do you tend to sleep well but just at the ‘‘wrong times’’?
b. Can you sleep well enough, but only if you stay up very late?
c. Are you in a very sound sleep at normal waking time and could sleep on for hours more?
d. Can you sleep well enough, but only if you go to bed very early?
e. Do you wake very early, bright and alert and no longer sleepy?
[Possible CRSD: 4a¼ ‘‘TRUE’’ AND EITHER (4b AND 4c¼ ‘‘TRUE’’) OR (4d AND 4e¼ ‘‘TRUE’’)]
5. Parasomnia
a. Do you have unusual behaviours associated with your sleep that trouble you or that are dangerous?
b. Do you sleepwalk frequently and run the risk of injuring yourself or others?
c. Do you have frequent night terrors when you are extremely distressed but not properly awake?
d. Do you act out your dreams and risk injuring yourself or others?
e. Do you have terrible recurring nightmares?
[Possible parasomnia: 5a¼ ‘‘TRUE’’ AND EITHER (5b OR 5c OR 5d OR 5e¼ ‘‘TRUE’’)]
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INTRODUCTION
Sleep disturbance is the most common symptom of mental 
illness in the UK.1 Worldwide, epidemiologic studies report the 
prevalence of a clinical insomnia disorder at 10% to 12%,2,3 
and longitudinal investigation has shown that, once established, 
insomnia disorder tends to persist.4 Typically, insomnia is as-
sociated with increased fatigue, impaired work productivity, 
reduced quality of life and relationship satisfaction, as well as 
increased ill health.5-9 Chronic insomnia may be a risk factor 
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for the development of mental and physical health problems10-13 
and is possibly associated with all-cause mortality.14-16 The im-
portance of insomnia to public health is illustrated by national 
annual costs ($92 to $107 billion USD in USA),17 and its cost 
per untreated case ($5,000 CAD in Canada).18 Despite this, 
persistent insomnia often goes unrecognized, and care manage-
ment is poorly developed.19,20
Benzodiazepine hypnotics and sedative antidepressants 
are commonly prescribed, although long-term outcome data 
are relatively sparse.21,22 Whereas the benzodiazepine recep-
tor agonists confer some advantages, there is limited evidence 
that they are preferable for chronic insomnia.19,23 On the other 
hand, there is compelling evidence that cognitive behavioral 
therapy (CBT) is a lastingly effective treatment,19,24-27 a good 
conceptual fit for psychological factors that commonly under-
lie insomnia,5,28 and an approach that many patients prefer over 
a pharmacological one.29,30
There is support for CBT being made widely avail-
able19,24-27,31,32; however, the outstanding challenge is its inher-
ent lack of scalability to meet population need.33 This is not 
untypical of the broader population interest in solutions that 
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shifts the focus from the professional to the person and from 
the clinic to home implementation.34 Traditionally, CBT is de-
livered face-to-face by a specialist psychological therapist, and 
so is dependent on a rare and expensive resource.33,35 It seems 
inconceivable that any face-to-face therapy could replace, for 
example, the 12 million prescriptions for hypnotics that are 
written each year in England and Scotland for a combined 
population base of 47 million adults.36,37 Moreover, “stepped 
care” models argue that expert professionals should consult on 
more complex cases rather than deal with routine referrals.33,38 
Although, there is evidence that nurses, trained to follow a 
CBT manual, can deliver effective treatment to small groups 
of patients39-41 and that large community group interventions 
may also be feasible,42 this approach is unlikely to offer a re-
alistic alternative to prescribing because it too relies on regu-
lar contact, and with professionals whose duties are already 
many and varied.33
A review of 9 controlled studies, where written materials 
were distributed directly to people with insomnia, sometimes 
along with other media or telephone support, suggested some 
benefit, although effect sizes were generally small.43 Six inves-
tigations of internet-based CBT offer encouraging results,44-49 
suggestive of the potential far-reaching benefits of this health 
technology. In perhaps the best-designed study, albeit on a 
small total sample (n = 45), a 16% improvement in sleep ef-
ficiency (SE: proportion of time in bed spent asleep) relative to 
baseline was observed following CBT (an absolute increase of 
12% from pre- to post-treatment), compared with 3% (2% in 
absolute terms) in a wait-list group.46 These data were mirrored 
by significant reductions in insomnia severity. Uncontrolled 
data also suggested gains were maintained. In the 2 largest 
studies,47,49 significant effects of CBT over a wait-list condition 
were also encouraging, although limited to improvements in 
sleep quality and reductions in fatigue, rather than sleep param-
eters per se,47 or showing small-to-moderate effects, with 49% 
dropout in the electronic CBT group.49
The literature on internet CBT for insomnia remains small 
and lacks a definitive study. In particular, a placebo-controlled 
trial is required if we are to be sure that reported improvements 
are not simply the result of a novel mode of treatment, partici-
pant enthusiasm, expectations, or experimental demand charac-
teristics.50 More than this, however, the intervention platforms 
evaluated so far, may not fully reflect the levels of sophistica-
tion that might be expected by contemporary internet users, for 
example, full web and mobile interactivity and the use of social 
networking.51 Indeed, offering CBT within a supportive self-
help environment may be crucial in helping people apply what 
they are learning.52
The objectives of this study were to address these scientific 
and technical imperatives by addressing the following ques-
tions: Is CBT for chronic insomnia disorder—delivered via an 
automated, media-rich web application—superior to a credible 
placebo intervention, as well as to a treatment as usual condi-
tion, in improving nighttime sleep and associated daytime func-
tioning? Are these effects durable and clinically important?
METHODS
Participants from the UK community (18+ years), who had 
completed the online Great British Sleep Survey (GBSS), and 
who met proposed DSM-5 criteria for persistent Insomnia Dis-
order were invited to take part.53,54 The GBSS utilized pre-es-
tablished algorithms to screen for: (a) a current complaint of 
poor sleep (difficulty initiating and/or maintaining sleep, early 
morning wakening, or non-restorative sleep); with (b) sig-
nificant daytime effects in ≥ 1 of 6 domains (fatigue, daytime 
sleepiness, cognitive impairment [e.g., concentration prob-
lems], mood disturbance, impaired occupational or academic 
functioning [e.g., poor productivity], impaired interpersonal/
social functioning); and (c) affecting them ≥ 3 nights per week 
for ≥ 3 months.55 People who reported being in “poor” or “very 
poor” physical or mental health, or who exceeded a threshold 
for other sleep disorders on our screening algorithm (published 
in Wilson et al.24) were excluded. Items from the AUDIT56 and 
CAGE57 were applied to identify heavy alcohol use, and cutoff 
scores on the Depression Anxiety Stress Scales provided sup-
plementary data on mental health status.58 The use of sleeping 
pills or other sleep aids was permitted. Usual care that partici-
pants had been receiving via their medical advisers, including 
medical prescriptions and any counselling or psychotherapy, 
continued in all arms. The website www.sleepio.com/research 
hosts illustrative material of the study evaluation and interven-
tion procedures.
The GBSS was launched online in February 2010 by Sleep-
io Ltd (a company dedicated to helping people sleep better, 
through raising awareness, research, and the dissemination of 
behavioral treatment advice), in association with Boots UK 
(an international pharmacy-led health and beauty group) and 
the Mental Health Foundation (a leading UK mental health 
research, policy and service improvement charity). Growth 
was “organic in nature,” driven for example by links to Boots 
WebMD (www.webmd.boots.com), Mental Health Foundation 
campaigning, and newspaper media exposure.
A total of 10,071 adults completed the GBSS from April 
2010 to 25 February 2011, of whom 6,609 provided email ad-
dresses. In total, 1,342 of this latter group (20.3%) met prelimi-
nary screening criteria and were invited by email to consider 
taking part; of these, 276 (20.1%) replied and consented to fur-
ther screening. The majority (n = 228, 82.6%) then completed 
further standardized assessments. Finally, to confirm current 
eligibility, participants completed prospectively a 7-day on-
line sleep diary, during which they had to have a mean (base-
line) sleep efficiency (SE) ≤ 79% to reflect a sleep problem of 
clinical severity on our primary outcome variable. Sixty-four 
participants were excluded during these final stages, and the 
remaining sample of 164 eligible, consenting participants was 
randomized (see participant flowchart: Figure 1).
In order to ensure real-world evaluation of the online inter-
vention, participant enrolment was confined to email contact, 
and all eligibility and baseline data were automatically ob-
tained without face-to-face verification. Ineligible participants 
were provided with a report comprising tailored sleep hygiene 
advice, and all participants were advised to contact their doc-
tor if they had concerns about any aspect of their health. The 
website also hosted a list of telephone contact numbers for 
mental health helplines. Technical support to participants was 
provided by email contact or via the online community forum, 
where there was a dedicated discussion thread for identifying 
and resolving problems.
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Study Design
The study was a pragmatic, parallel-group, randomized con-
trolled trial comprising 3 treatment arms: (1) online CBT; (2) 
online imagery relief therapy (IRT: placebo); (3) treatment as 
usual (TAU), with blind assignment to group determined by a 
computer-generated random allocation schedule, operated by 
a remote independent technical operator. The trial followed 
CONSORT 2010 guidelines.59 Consistent with the inclusion/
exclusion criteria, the study design in effect was CBT+TAU 
v. IRT+TAU v. TAU alone. Major assessments were at base-
line, post-treatment, and follow-up 8 weeks later. Participants 
randomized to the IRT placebo or TAU arm were offered the 
online CBT package upon completion of the study. All assess-
ment, treatment, and data-gathering procedures were conducted 
online, and all queries/enquiries were managed electronically. 
These procedures ensured that the trial was genuinely an evalu-
ation of a completely online CBT approach. The study protocol 
was approved by the University of Glasgow, Faculty of Medi-
cine Research Ethics Committee and all participants provided 
informed consent online (see www.sleepio.com/research).
Assessment Measures
Participants accessed an online daily sleep diary through-
out the study, to be completed each morning upon rising. 
They could set automated SMS (mobile text message) and/or 
email prompts as reminders. Such diaries are the staple tool 
of insomnia assessment.60-62 Participants completed items by 
selecting from a drop-down menu of possible values. “How 
long did it take you to fall asleep last night” and “how long 
were you awake in total last night due to wakenings after you 
first fell asleep” (each variable offered as 0 min, 5 min, 10 
min, 15 min, 30 min, and so on, thereafter in 15-min incre-
ments) assessed the central insomnia dimensions of difficulty 
initiating sleep (sleep onset latency [SOL], min) and difficulty 
Figure 1—Flow of Participants in the Trial.
Enrollment
Randomized (n = 164)
Excluded: failed screening (n = 64)
♦ physical health problem (n = 11)
♦ mental health problem (n = 8)
♦ daytime sleepiness or other sleep problem (n = 15)
♦ sub-clinical insomnia: SE ≥ 80% on sleep diary (n = 20)
♦ other: e.g. moved to different time zone, shift work, 
family illness (n = 10)
Excluded: no response to contact (n = 48)
Excluded: no response to contact (n = 1066)
Consented to further screening (n = 276)
Completed further screening (n = 228)
Potentially eligible (n = 1342)
Status
♦ completed post-treatment 
(n = 47)
♦ completed 8-week follow-up 
(n = 47)
♦ no known reasons for being lost 
to follow-up
Status
♦ completed ≥ 4 sessions (n = 48)
♦ completed all sessions (n = 41)
♦ completed 8-week follow-up 
(n = 38)
♦ known reasons for being lost to 
follow-up [internet connection 
problems (x2), pregnancy, 
ill-health]
Post-treatment 
and Follow Up
Status
♦ completed ≥ 4 sessions (n = 47)
♦ completed all sessions (n = 43)
♦ completed 8-week follow-up 
(n = 40)
♦ known reasons for being lost to 
follow up [technical problems, 
illness in family]
Allocated to TAU (n = 54)
♦ received allocated intervention 
(n = 51)
♦ did not receive allocated 
intervention (n = 3) [withdrawal 
due to bereavement (n = 1), 
never logged on (n = 2)]
Allocated to CBT (n = 55)
♦ received allocated intervention 
(n = 53)
♦ did not receive allocated 
intervention (n = 2) [never logged 
on (n = 2)]
Allocated to IRT (n = 55)
♦ received allocated intervention 
(n = 52)
♦ did not receive allocated 
intervention (n = 3) [withdrawal 
due to pregnancy (n = 1), never 
logged on (n = 2)]
Allocation 
Analyzed (n = 54)Analyzed (n = 55)Analyzed (n = 55)Analysis
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maintaining sleep (wake time after sleep onset [WASO], min). 
The diary also enquired about bedtime and rising time, from 
which total time in bed (TIB), and thence sleep efficiency (SE, 
%) were calculated; [1 – (SOL + WASO / TIB)] × 100. To-
tal Sleep Time (TST, h) was also estimated from diary data 
[TIB – (SOL + WASO)]. A sensitive rating of “overall sleep 
quality” was obtained by dragging a slider along a dimensional 
analogue scale (0–100) between the poles of “very unsatisfac-
tory” and “very satisfactory.”
Diary data yielded the dependent variables of SOL, WASO, 
SE, TST, and sleep quality, averaged across 7 nights for each 
of the 3 major assessment points: baseline, post treatment, and 
follow-up (see www.sleepio.com/research). The primary study 
endpoint was change in SE from pre- to post-treatment, and 
from pre-treatment to follow-up for 2 reasons. First, sleep effi-
ciency provides an overall index of insomnia by capturing both 
difficulties getting to sleep and staying asleep, and so was rel-
evant for all participants of whatever insomnia subtype; second, 
endpoints relating to achievement of sleep efficiencies of 80%, 
85%, and 90% reflect clinically important improvement and not 
merely statistical change.63
Importantly, because Insomnia Disorder must incorporate 
defined consequences, 6 domains of daytime function recom-
mended by DSM-5 (energy, relationships, mood, concentration, 
productivity, sleepiness) were rated on a 5-point scale at each 
assessment phase (0 = not at all affected through to 4 = very 
much affected). Principal components analysis of data from 
our UK sample (n = 11,129) suggests that these items load (r ≥ 
0.64) on 2 factors: “daytime performance,” comprising concen-
tration, productivity, and sleepiness ratings (64.9% of the vari-
ance); and “social functioning,” comprising ratings on mood, 
relationships, and energy (12.0% of the variance).55 Accord-
ingly, we used these 2 factor scores to evaluate daytime impact 
of treatment.
The Sleep Condition Indicator (SCI) is a new patient-report-
ed outcome measure, specifically based upon DSM-5 Insomnia 
Disorder criteria.53,54 It is brief (8-item) and has shown prelimi-
nary reliability in a field study of 11,129 participants (α = 0.894, 
range of α-if-items systematically deleted = 0.877–0.898).55 The 
SCI generates scores in the range 0 to 10, with higher values 
reflecting a person’s sleep being in “better condition.” SCI ≤ 
5.9 identifies 95.4% of people with insomnia disorder, whereas 
a score ≥ 6.0 correctly identifies 76.8% of individuals without 
insomnia disorder.55 The SCI also correlates with the Pittsburgh 
Sleep Quality Index64 (r = -0.78, n = 256) and the Insomnia Se-
verity Index65 (r = -0.79, n = 256).66 The SCI provided a second-
ary, clinically focused outcome measure for the study.
Finally, we selected the Depression Anxiety Stress Scale 
(DASS: 21 items)58 because it takes a dimensional view of 
symptoms, including stress, which often co-present with 
insomnia. Internal consistency for the DASS is satisfactory 
(α = 0.82-0.93). Items from the Sleep Disturbance Question-
naire (SDQ)67,68 and the Glasgow Content of Thoughts Inven-
tory (GCTI)69 were also completed to inform CBT treatment 
algorithms.
The integrity of all data was assured by the online acquisi-
tion system and supporting software application. Clear guid-
ance was provided including pop-up “tool tip” explanations for 
many items to ensure that they were correctly understood. All 
data entries were time stamped for all participants for the dura-
tion of the online course.
Treatment Groups
CBT
Participants received 6 weekly sessions delivered by an ani-
mated “virtual therapist” (The Prof). The program comprised a 
fully automated media-rich web application, driven dynamical-
ly by baseline, adherence, performance, and progress data. At 
the start of each session, The Prof conducted a progress review 
with the participant, explored the diary data submitted during 
the week, the participant’s current sleep status and pattern, and 
progress achieved against goals previously set. Underlying al-
gorithms fed the delivery of information, support, and advice 
in a personally tailored manner. CBT content was consistent 
with the literature,60 and covered behavioral (e.g., sleep restric-
tion, stimulus control) and cognitive (e.g., putting the day to 
rest, thought re-structuring, imagery, articulatory suppression, 
paradoxical intention, mindfulness) strategies, as well as addi-
tional relaxation strategies (progressive muscle relaxation and 
autogenic training) and advice on lifestyle and bedroom factors 
(sleep hygiene). The intervention was based upon a previously 
validated manual.39-41 The following illustrations may be help-
ful. In sleep restriction, The Prof proposes a new “window” for 
sleep, calculated from available sleep diary data, and engages 
with the participant to help them select the timing (onset/offset) 
of this window from a set of personalized options. An example 
of a cognitive technique, is where another animated character 
(with insomnia) presents to the Prof their concerns, dysfunc-
tional beliefs, and associated emotions. The Prof then asks the 
participant to choose some solutions from a menu of options 
and delivers this as advice to the character, who is seen to re-
vise his thinking. The Prof then reveals to the participant that 
the scenario was based upon his/her own sleep-related attribu-
tions and thoughts (from baseline SDQ and GCTI data). In this 
way the participant is helped to learn how to restructure dys-
functional thinking. Table 1 summarizes the content and fea-
tures of the intervention, permitting comparison of CBT with 
IRT and TAU conditions (with further illustration available at 
http://www.sleepio.com/research).
IRT
Imagery relief therapy was also delivered by The Prof, us-
ing the same application platform, and design and execution 
principles as for CBT, but with no known active therapeutic 
ingredient. IRT was based on a well-established and credible 
non-pharmacological placebo intervention50 used in several 
clinical trials.70-72 The term imagery relief therapy was selected 
to enhance credibility of an active and novel therapy. For ex-
ample, if participants were to enter this as an internet search 
term, they would come upon material which would appear to 
be valid for a psychological problem such as sleep. However, 
IRT contained no active components of imagery training, or of 
systematic desensitization. Likewise, it did not include detailed 
relaxation instruction or behavioral advice about what to do 
during the sleep period. The participant was trained to visualize 
neutral objects (e.g., a key) or shapes (e.g., a yellow square) in 
conjunction with thinking about sequential aspects of their eve-
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ning routine (e.g., setting the table for dinner), and was asked 
to practice these pairings for 20 min/day early in the evening. 
The rationale for this “quasi-desensitization” framework was 
that successful sleep was associated with good preparation, and 
that neutralizing unhelpful associations with evening routines 
would recondition them towards automatic sleep engagement 
and sleep maintenance. IRT participants also received e-mail 
reminders from The Prof and had access to Wikipedia-style ar-
ticles on sleep, its functions, and its disorders.
Protocol standardization
The integrity and fidelity of treatment allocations was assured 
by the online procedures which delivered the interventions. In 
addition, in session 1 of both CBT and IRT conditions, partici-
pants were invited to commit (or not) to the course following 
an explanation of the therapeutic rationale (all did so). CBT and 
IRT participants did not have contact with each other, nor did 
they have access to alternative treatment materials. Both CBT 
and IRT were scripted and automated, so support and length 
of treatment was similar. All web-based interactions were elec-
tronically stored to provide time-stamped data on participant 
activity (e.g., diary entries, session activities, engagement with 
the community, adherence to tasks).
TAU alone
In real world practice, insomnia patients often have some con-
current physical and psychological symptoms, as well as concur-
rent treatments. Therefore, to reflect validity, and to permit greater 
generalizability of findings, the protocol explicitly permitted 
continuation of treatment as usual health care for all participants. 
Physicians were free to offer appointments, to prescribe, and to 
maintain/discontinue prescriptions. Aside from this, TAU alone 
participants comprised, effectively, a wait-list group who com-
pleted measures but received no additional help for their insom-
nia. The only contact received by the TAU arm was reminders to 
complete evaluations. After the trial was completed TAU and IRT 
participants were offered access to the CBT intervention.
Data Management and Analysis
The study was designed to have 80% power to detect a me-
dium effect size (Cohen73; consistent with published meta-an-
alytic data27), based upon a 3-group ANOVA model with fixed 
effects, main effects, and interactions, on our primary outcome 
measure of SE. These criteria implied recruiting a total sample 
of 159 participants. All comparisons were planned and tests 
were 2-sided, with P < 0.05 considered to indicate statistical 
significance. Where appropriate, to control for multiple com-
parisons, a per family error rate was adopted to maintain the 
nominal error rate (0.05/n of comparisons). Analyses were per-
formed using PASW Statistics 18 (SPSS Inc., Chicago, IL).74 
Linear mixed effects models were used, to avoid imputation of 
missing data (estimated at 16.1% of those commencing the trial 
at post-treatment and 19.9% at follow-up), predicting mean val-
ues at each assessment point (baseline, post-treatment, 8-week 
follow-up) and to test our hypotheses with respect to between 
group differences. In each model, time and treatment group 
were included as fixed effects, with time and group × time in-
teraction terms. For variables exhibiting between-group differ-
ences at baseline, the baseline value was entered as a covariate. 
Clinical response to treatment was evaluated on an intention to 
Table 1—Summary of treatment conditions
CBT IRT TAU
Treatment 
content
Sleep information/education, sleep 
hygiene, relaxation, stimulus control, 
sleep restriction, cognitive techniques 
(restructuring, paradox, mindfulness, 
imagery, putting day to rest, thought 
stopping)
Sleep information/education, hierarchy 
development, imagery training, scheduled 
pseudo-desensitization, breathing control
N/A
[Advised that most effective treatment 
would be offered upon completion of trial]
Duration 6 sessions over minimum of 6 weeks 6 sessions over minimum of 6 weeks [N/A] Diary keeping only
Delivery 
context
Fully online
Delivered by animated therapist (The Prof)
No face to face contact
Fully online
Delivered by animated therapist (The Prof)
No face to face contact
Fully online diary recording only
No face to face contact
Additional 
treatment 
features
Appointment system, interactive sessions, 
dynamic feedback against personal goals, 
progress review at start of each session, 
automatic calculation of sleep data over 
time, personal case file, end of session 
quiz, 24/7 access
Appointment system, Interactive sessions, 
dynamic feedback against personal goals, 
progress review at start of each session, 
automatic calculation of sleep data over 
time, personal case file, 24/7 access
N/A
Support/
motivational 
system
Praise/reinforcement contingent on 
progress, online Wikipedia of sleep 
educational topics
Social community of users, moderated by 
experts
Support/prompts/reminders by email and 
mobile SMS
‘Graduation ceremony’ on course 
completion
Praise/reinforcement contingent on 
progress, online Wikipedia of sleep 
educational topics
Support/prompts/reminders by email and 
mobile SMS
‘Graduation ceremony’ on course 
completion
Email support only
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treat basis in relation to proportions of participants achieving 
the clinical endpoints of 80%, 85%, and 90% for SE at post-
treatment and follow-up.
RESULTS
Participant Characteristics
Information on the allocated sample of 164 (120 F) adults 
(mean age 49 y [18–78y]) is provided in Table 2. Approxi-
mately two-thirds were employed either full-time or part-
time. Post-code data provided a proxy for socioeconomic 
status by deriving an index of multiple deprivation (IMD). 
Mean IMD was 16.7 (SD 11.8); somewhat less deprived (by 
< 0.5 SD) than national norms (21.7 [SD 15.5]).75 Participants 
were in at least average health (as per selection criteria), al-
though around 30% and 10%, respectively, took medication 
for a physical or mental health problem. One in 5 participants 
sometimes used prescribed sleeping pills, and 40% made 
some use of over-the-counter (OTC) sleep aids. Twenty-nine 
people provided additional free text on the strategies they 
used to manage their insomnia. Much of this was amplifica-
tion on their medication or OTCs; however, 9 described using 
relaxation, meditation, or yoga, and 4 used devices (e.g., ear 
plugs, a heat pad).
All participants had DSM-5 Insomnia Disorder, the great 
majority being of difficulty maintaining sleep or of mixed sub-
types. Two-thirds had had insomnia > 6 years, and almost 50% 
for > 11 years. Participants randomized to CBT (n = 55), IRT 
(n = 55), and TAU (n = 54) were similar in all demographic and 
clinical respects. Eight of the 164 participants did not start their 
treatment, so the final sample receiving the allocated interven-
tion was 156 (CBT = 53, IRT = 52, TAU = 51). There were no 
significant differences on any variable between this sample and 
the allocated sample of 164.
Treatment Attrition and Integrity
Of those receiving their allocated intervention, 43 CBT par-
ticipants (82%) completed all their online therapy sessions, and 
47 (88%) completed ≥ 4 sessions. This compared to 41 (79%) 
and 48 (92%), respectively, in the IRT group. Thus, there were 
similar modest levels of attrition during the treatment phase. 
Just under 80% (n = 125) completed follow-up assessment, 
comprising similar proportions of CBT and IRT, but a higher 
proportion of TAU (CBT [n = 40, 75%]; IRT [n = 38, 73%]; 
TAU [n = 47, 92%]). This was perhaps due to the latter group’s 
anticipation of receiving active intervention immediately there-
after, as per provision of ethical approval. Reasons for with-
drawal during treatment are summarized (where known) in 
Figure 1. There were no significant differences between treat-
ment completers (defined as completing ≥ 4 sessions) and those 
who dropped out, on any variable. No harm-related or serious 
adverse events were reported.
Participants in the CBT group took an average of 50 days to 
complete the course compared with 48 days in IRT, with TAU 
participants typically taking one further week (58 days). Par-
ticipants were generally adherent in completion of diaries. The 
study generated 11,278 daily diary records, of which only 239 
(2.2%) had to be estimated by participants, upon prompting by 
The Prof, at the weekly progress review point.
Baseline Characteristics
Baseline data indicated current insomnia in the severe clini-
cal range, with an average total wake time (SOL + WASO) of 
136.5 min (SD 72.5) and mean self-reported SE of 61.3% (SD 
16.2) for the sample as a whole (Table 3). Average estimated 
TST was 5.09 h (SD 1.47). On the SCI, the overall mean score 
of 2.98 (SD 1.04) was > 4 SD below the mean for good sleep-
ers, based on our UK sample.55 Consistent with diagnostic cri-
teria, substantial impact was observed on daytime performance 
and social functioning. In descending rank order of mean (SD) 
impact at baseline, insomnia had a negative effect on energy 
(2.71 [0.80]), mood (2.50 [0.93]), concentration (2.40 [0.92]), 
productivity (2.12 [0.92]), relationships (1.72 [1.06]), and stay-
ing awake (1.28 [1.00]). There was modest symptomatology 
on the DASS, consistent with selection criteria, with stress 
scores significantly higher than depressive (7.80 [3.70] vs 5.05 
[3.01], t163 = 11.1, P < 0.001) or anxiety (2.70 [2.20], t163 = 21.0, 
P < 0.001) scores, and depressive scores higher than anxiety 
scores (t163 = 11.5, P < 0.001).
One-way ANOVA revealed differences in pre-treatment 
scores for SOL, SE, and TST (all P < 0.01), in each case ac-
counted for by the TAU group having more symptomatic scores 
(see Table 3). Consequently, baseline values were introduced 
conservatively as covariates in subsequent hypothesis testing 
on these variables.
Impact of Treatment on Self-Reported Sleep
Summary sleep diary data comprising pre-treatment, post-
treatment and follow-up actual mean (SE) values for each 
group are presented in Table 3. Change scores (with 95% CI) 
and within group effect sizes [ES: (M1-M2/δpooled)] are also pro-
vided. ES were regarded as large (d = 0.8), moderate (d = 0.5), 
or small (d = 0.3), consistent with recognized definitions.73 In 
Table 4, relative ES, representing changes over baseline ob-
served at post-treatment and follow-up, are provided for each 
comparison (CBT-TAU, IRT-TAU, CBT-IRT). For all variables, 
significant effects in favor of CBT were observed, and these 
remained significant when taking account of baseline values.
CBT was associated with an absolute post-therapy increase 
of 19.5% (95%CI, 15.3 to 23.7) in SE (a 30.8% increase over 
baseline), compared with a 5.7% (95%CI, 2.79 to 8.52) gain fol-
lowing IRT, and 6.4% (95%CI, 2.88 to 9.86) in TAU (Table 3). 
A near 20% level of improvement was sustained in the CBT 
group at follow-up (95%CI, 15.7 to 23.6), compared with 7% 
(95%CI, 4.53 to 10.1) and 9% (95%CI, 4.89 to 13.7) gains in 
IRT and TAU. The mixed effects model confirmed a main effect 
for time (F2,151 = 92.54, P < 0.0001) and a significant treatment 
× time interaction (F4,304 = 15.97, P < 0.0001), with between-
group comparisons favoring CBT at post-treatment relative to 
both TAU (d = 0.95) and IRT (d = 1.06), each representing large 
ES (Table 4). At follow-up, CBT again yielded superior out-
come relative to IRT (d = 1.00) and TAU (d = 0.69).
Substantial reductions in SOL and WASO were observed 
in the CBT group, of around 26 min and 48 min, respectively, 
at both post-treatment and follow-up (see Table 3 for detailed 
data). By comparison, a more modest (20 min) but sustained 
reduction in WASO (only) was observed following IRT. TAU 
participants reduced their SOL by around 10 min. Mixed model 
analysis supported the superiority of CBT relative to TAU and 
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IRT across time points for both SOL (F4,304 = 4.55, P < 0.001) 
and WASO (F4,306 = 8.53, P < 0.0001). At both time points for 
WASO, CBT exhibited a large ES relative to TAU (d = −0.77), 
and a moderate to large ES relative to IRT (d = −0.41). For 
SOL, there was a large effect in favor of CBT relative to IRT 
(d = −0.86) and a modest ES relative to TAU (d = −0.45). At 
follow-up, IRT was associated with lower WASO than TAU 
(d = −0.41). To further quantify these medium term improve-
ments in sleep continuity, TWT reduced by some 75 min 
(95%CI, −56.8 to −92.7 min) following CBT, exhibiting large 
Table 2—Demographic and clinical characteristics of participants (n = 164)
Characteristic CBT (n = 55) IRT (n = 55) TAU (n = 54) All (n = 164)
Age, mean (SD), y 50.7 (13.8) 47.3 (13.0) 49.1 (13.7) 49.0 (13.5)
Gender, No. (%)
Female 40 (72.7) 42 (76.4) 38 (70.4) 120 (73.2)
Male 15 (27.3) 13 (23.6) 16 (29.6) 44 (26.8)
Occupation, No. (%)
Employed. Full-time 20 (36.4) 25 (45.5) 20 (37.0) 65 (39.6)
Employed, part-time 17 (30.9) 12 (21.8) 11 (20.4) 40 (24.4)
Retired 13 (23.6) 8 (14.5) 16 (29.6) 37 (22.6)
Student 3 (5.45) 3 (5.45) 2 (3.70) 8 (4.88)
Not currently employed 2 (3.64) 7 (12.7) 5 (9.26) 14 (25.5)
Index of multiple deprivation, mean (SD)a 16.7 (11.3) 18.4 (13.8) 15.2 (10.4) 16.7 (11.8)
Civil status, No. (%)b
No Partner 20 (36.4) 20 (36.4) missing missing
Partner 35 (63.6) 35 (63.6) missing missing
Physical health, No. (%)
0 Very good 15 (27.3) 13 (23.6) 7 (13.0) 35 (21.3)
1 Good 25 (45.4) 26 (47.3) 37 (68.5) 88 (53.7)
2 Average 15 (27.3) 16 (29.1) 10 (18.5) 41 (25.0)
Mental health, No. (%)
Very good 16 (29.1) 11 (21.0) 13 (24.1) 40 (24.4)
Good 25 (45.4) 23 (41.8) 28 (51.8) 76 (46.3)
Average 14 (25.5) 21 (38.2) 13 (24.1) 48 (29.3)
Prescriptions for physical health, No. (%)
Yes 18 (32.7) 14 (25.5) 18 (33.3) 50 (30.5)
No 37 (67.3) 41 (74.5) 36 (66.7) 114 (69.5)
Prescriptions for mental health, No. (%)
Yes 4 (7.3) 7 (87.3) 6 (11.1) 17 (10.4)
No 51 (92.7) 48 (12.7) 48 (88.9) 147 (89.6)
Prescribed sleeping pills, No. (%)
Yes 10 (18.2) 8 (14.5) 15 (27.8) 33 (20.1)
No 45 (81.8) 47 (85.5) 39 (72.2) 131 (79.9)
Over the counter sleep aids, No. (%)
Yes 24 (43.6) 20 (36.4) 19 (35.2) 63 (38.4)
No 31 (56.4) 35 (63.6) 34 (64.8) 101 (61.6)
Duration of insomnia, No. (%), y
< 2 9 (16.4) 7 (12.7) 6 (11.1) 22 (13.5)
2-5 13 (23.6) 16 (29.1) 5 (9.2) 34 (20.7)
6-10 10 (18.2) 13 (23.6) 9 (16.7) 32 (19.5)
≥ 11 23 (41.8) 19 (34.6) 34 (63.0) 76 (46.3)
Type of insomnia. No. (%)
Difficulty Initiating Sleep 1 (1.8) 3 (5.4) 1 (1.9) 5 (3.0)
Difficulty Maintaining Sleep 26 (47.3) 22 (40.0) 22 (40.7) 70 (42.7)
Mixed (Initiating/Maintaining) 22 (40.0) 24 (43.6) 26 (48.1) 72 (43.9)
Early Morning Awakening 4 (7.3) 3 (5.5) 3 (5.6) 10 (6.1)
Non-Restorative Sleep 2 (3.6) 3 (5.5) 2 (3.7) 7 (4.3)
aThese data available only for postcodes in England (n = 137). bThese data were not collected, in error, from the TAU group.
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Table 3—Treatment outcomes for sleep and daytime measures. Baseline, post-treatment, and follow-up data (actual mean [SE]) are presented for each 
group along with change scores (95% CI) and within group effect sizes (Cohen’s d )
Treatment Group
Baseline 
Mean (SE)
Post-treatment
Mean (SE)
Change from Baseline to 
Post-Treatment (95% CI) d
8-wk Follow-up 
Mean (SE)
Change from Baseline 
to Follow-up (95% CI) d
Sleep Efficiency, %
CBT 63.2 (2.10) 82.7 (1.74) 19.5 (15.3 to 23.7) 1.28 82.8 (1.10) 19.6 (15.7 to 23.6) 1.37
IRT 65.1 (1.28) 70.8 (1.70) 5.70 (2.79 to 8.52) 0.55 72.4 (1.63) 7.29 (4.53 to 10.1) 0.73
TAU 55.6 (2.90) 62.0 (2.51) 6.37 (2.88 to 9.86) 0.51 64.9 (2.51) 9.30 (4.89 to 13.7) 0.59
Sleep Onset Latency, min
CBT 47.9 (5.52) 21.5 (3.12) -26.2 (-16.0 to -36.4) -0.71 21.3 (2.12) -26.6 (-17.5 to -35.7) -0.80
IRT 48.0 (4.04) 48.0 (4.85) -0.08 (6.37 to -6.22) 0.00 45.5 (3.96) -2.50 (3.42 to -8.42) -0.12
TAU 75.5 (10.1) 65.0 (8.37) -10.5 (-1.10 to -19.8) -0.31 62.8 (6.86) -12.7 (0.53 to -25.9) -0.27
Wake Time After Sleep Onset, min
CBT 76.9 (6.49) 28.5 (4.34) -48.4 (-35.5 to – 61.3) -1.03 28.8 (3.22) -48.1 (-35.4 to -60.9) -1.04
IRT 75.0 (5.10) 54.8 (5.44) -20.2 (-11.7 to – 28.7) -0.66 53.1 (5.18) -21.9 (-13.6 to -30.1) -1.01
TAU 87.1 (7.95) 79.5 (7.40) -7.56 (1.06 to -16.2) -0.25 90.6 (4.15) 3.54 (26.9 to -19.8) 0.04
Total Wake Time, min
CBT 124.8 (8.86) 50.0 (6.26) -74.8 (-56.8 to -92.7) -1.15 50.1 (3.70) -74.7 (-57.7 to -91.8) -1.21
IRT 122.9 (5.71) 102.8 (7.29) -20.1 (-9.61 to 30.6) -0.53 98.5 (7.03) -24.4 (-14.0 to -37.8) -0.65
TAU 162.5 (13.44) 144.5 (11.31) -18.0 (-3.16 to 32.8) -0.34 153.4 (12.6) -9.15 (-17.7 to -36.0) -0.09
Total Sleep Time, h
CBT 5.11 (0.18) 5.76 (0.18) 0.65 (0.36 to 0.94) 0.63 6.30 (0.14) 1.19 (0.89 to 1.50) 1.08
IRT 5.51 (0.14) 5.87 (0.18) 0.36 (0.02 to 0.69) 0.30 5.98 (0.15) 0.47 (0.24 to 0.71) 0.56
TAU 4.65 (0.26) 5.30 (0.24) 0.65 (0.31 to 0.99) 0.54 5.44 (0.24) 0.79 (0.39 to 1.19) 0.55
Sleep quality, 0–100 rating
CBT 43.2 (2.00) 56.3 (2.62) 13.1 (8.38 to 17.8) 0.77 57.6 (2.25) 14.4 (10.6 to 18.3) 1.04
IRT 45.0 (1.57) 52.0 (1.75) 7.08 (2.87 to 11.3) 0.47 53.9 (1.66) 8.96 (5.46 to 12.5) 0.71
TAU 41.4 (1.19) 44.0 (2.44) 2.57 (-0.92 to 6.05) 0.21 46.0 (2.51) 4.57 (0.55 to 8.59) 0.32
Sleep Condition Indicator
CBT 3.06 (0.14) 6.30 (0.33) 3.24 (2.64 to 3.83) 1.50 6.59 (0.33) 3.53 (2.91 to 4.13) 1.60
IRT 3.00 (0.13) 4.48 (0.24) 1.48 (1.07 to 1.89) 1.00 4.95 (0.26) 1.95 (1.38 to 2.44) 1.00
TAU 2.79 (0.16) 3.78 (0.26) 0.99 (0.57 to 1.42) 0.65 4.12 (0.28) 1.33 (0.77 to 1.78) 0.71
Impact on problems with daytime performance (concentration, productivity, staying awake: 3 × 0-4 ratings)
CBT 6.01 (0.30) 3.60 (0.39) -2.42 (-3.10 to -1.73) -0.98 2.54 (0.42) -3.47 (-3.98 to -2.22) -1.29
IRT 5.87 (0.32) 4.23 (0.41) -1.63 (-2.31 to -0.95) -0.67 3.41 (0.38) -2.46 (-3.20 to -1.86) -1.19
TAU 5.59 (0.34) 4.92 (0.38) -0.67 (-1.34 to -0.10) -0.28 4.58 (0.40) -1.01 (-2.23 to -3.19) -0.45
Impact on problems with daytime social functioning (mood, relationships, energy: 3 × 0-4 ratings)
CBT 6.74 (0.28) 3.70 (0.41) -3.04 (-3.82 to -2.25) -1.06 2.79 (0.43) -3.95 (-2.73 to -5.00) -1.37
IRT 7.21 (0.31) 5.15 (0.38) -2.06 (-2.71 to -1.40) -0.88 4.15 (0.37) -3.06 (-2.10 to -3.90) -1.10
TAU 7.02 (0.29) 5.20 (0.35) -1.82 (-2.57 to -1.08) -0.68 5.35 (0.39) -1.67 (-0.99 to -3.20) -0.74
Table 4—Relative effect sizes (Cohen’s d) for each treatment group comparison (CBT-TAU, IRT-TAU, CBT-IRT) at post-treatment and follow-up for sleep 
and daytime variables
Relative effect size (d )
Pre-treatment to post-treatment
Relative effect size (d )
Pre-treatment to 8-wk Follow-up
Variable CBT-TAU IRT-TAU CBT-IRT CBT-TAU IRT-TAU CBT-IRT
Sleep Efficiency, % 0.95 -0.06 1.06 0.69 0.15 1.00
Sleep Onset Latency, min -0.45 0.30 -0.86 0.34 -0.27 0.86
Wake Time After Sleep Onset, min -1.03 -0.41 -0.71 -0.77 -0.41 -0.67
Total Wake Time, min -0.96 0.05 -1.03 -0.81 -0.21 -0.98
Total Sleep Time, h 0.00 -0.24 0.26 0.32 -0.26 0.73
Sleep quality, 0–100 rating 0.71 0.33 0.37 0.70 0.32 0.41
Sleep Condition Indicator 1.20 0.33 0.95 1.11 0.34 0.77
Impact on social functioning, 0-4 rating -0.44 -0.10 -0.37 -0.78 -0.53 -0.24
Impact on daytime performance, 0-4 rating -0.72 -0.40 -0.32 -0.85 -0.72 -0.23
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ES compared with either IRT (d = −0.98: 24 min; 95%CI, −9.61 
to −30.6) or TAU (d = −0.81: 9 min; 95%CI , −3.16 to −32.8) 
(F4,306 = 9.56, P < 0.001).
Mixed models analysis also revealed significant interaction 
effects on TST (F4,304 = 2.81, P = 0.026). At post-treatment, TST 
was increased by approximately 40 min in both CBT and TAU 
compared with 20 min in IRT. However, by follow-up, TST had 
increased by 70 min in the CBT group compared with 28 min 
(d = 0.73) and 47 min (d = 0.32) in IRT and TAU, respectively. 
Self-reported sleep quality also increased to a greater extent in 
CBT than in either IRT or TAU (F4,306 = 4.06, P = 0.003), with 
the latter comparison representing a moderate-large effect both 
at post-treatment and follow-up (d = 0.70). Applying a Bonfer-
roni correction to maintain the 0.05 error rate across all sleep 
diary variables (adjusted P < 0.01) would result in the TST main 
effects (only) failing to attain statistical significance. It should 
be noted that, as for the primary outcome of SE, time main ef-
fects were observed for SOL, WASO, TST, and sleep quality (all 
P < 0.001) in addition to the interaction terms reported above.
Impact of Treatment on Daytime Functioning
Comparative data on daytime outcomes are presented in 
Table 3; inspection of which indicate that there was a main ef-
fect of time for daytime performance (F2,151 = 63.47, P < 0.0001) 
and for social functioning: (F2,151 = 91.98, P < 0.0001). Visual 
impression suggests that both the CBT and the IRT groups 
improved relative to TAU, and this was confirmed by interac-
tion effects for daytime performance (F4,316 = 5.73, P < 0.001) 
and social functioning (F4,316 = 3.78, P = 0.005). In relation to 
daytime performance a moderate-large effect in favor of CBT 
had developed by post-treatment for the CBT-TAU (d = −0.72) 
comparison (Table 4), and this was consolidated by follow-up 
(d = −0.85). However, a moderate-large effect was also evident 
for IRT relative to TAU by this point (d = −0.40 to −0.72). The 
ES for the CBT-IRT contrast, therefore, is important and re-
veals a small additional ES benefit favoring CBT (d = −0.23 to 
−0.32). A similar pattern of results was obtained with the social 
functioning data (Table 4). DASS total score data also suggest 
some generalized impact of CBT on participants’ (mild) symp-
toms of psychopathology, with small effects for the CBT-IRT 
comparison observed at post-treatment (d = −0.33) and follow-
up (d = −0.28).
Clinical Effects of Treatment
The SCI exhibited > 2-fold sustained improvement fol-
lowing CBT, represented by large CBT-TAU effects at post-
treatment (d = 1.20) and follow-up (d = 1.11: Table 4). The 
CBT-IRT comparison also yielded large ES at both time points 
(d = 0.65 and d = 0.77), and placebo demonstrated a small ef-
fect (d = 0.34) relative to TAU (F4,316 = 12.22, P < 0.0001). In 
terms of clinically relevant change associated with CBT, mean 
SCI score at post-treatment and follow-up was higher than our 
suggested threshold score of 6.0 used to identify normal sleep-
ers on this measure.55
To be eligible for the study, all participants had to have initial 
SE < 80%. Therefore, it was of interest to determine the propor-
tion within each group who exceeded this value (SE ≥ 80%) fol-
lowing intervention. These data are presented in Figure 2, along 
with comparisons on the more stringent clinical cutoff scores 
of SE ≥ 85% and SE ≥ 90%. Three-quarters of participants al-
located to CBT completed the course with SE ≥ 80%, compared 
with less than one-third of those in IRT, and one in 5 of the 
TAU group (χ2(2) = 33.0, P < 0.001). Likewise, 55% of CBT 
participants achieved a SE of 85% (χ2(2) = 23.8, P < 0.001), and 
approaching 40% achieved SE ≥ 90% (χ2(2) = 13.4, P = 0.001). 
These advantages of CBT over placebo and the passage of time 
alone, all represent large ES (w = 0.86, w = 0.72, and w = 0.51 
for the 80%, 85%, and 90% criteria, respectively), where w is 
the square root of the standardized χ2 statistic (ES conventions: 
w = 0.10 [small], 0.30 [medium], 0.50 [large]).73 At follow-up, 
large effects were maintained for the 80% (w = 0.81) and 85% 
criteria (w = 0.62), with a medium effect observed for the 90% 
criterion (w = 0.38).
Finally, we wish to report that 38 IRT participants (79% of 
IRT completers) and 39 TAU participants (83% of those who 
provided post-treatment data) created CBT user accounts sub-
sequent to completion of the trial period.
DISCUSSION
We compared CBT for insomnia, delivered via an automated 
media-rich web application, with a similarly delivered, credible 
placebo (IRT), and a waitlist TAU control group.
On our primary endpoint of SE, large pre- to post-treatment 
effect sizes were observed for CBT relative to IRT and TAU. 
These effects remained robust at follow-up. SOL was reduced 
by 56% (compared to 5% and 17% in IRT and TAU), and 
WASO was reduced by 63% (compared to 29% in IRT and a 
4% increase in TAU). Global sleep-wake function, assessed 
by the Sleep Condition Indicator, similarly favored CBT, and 
clinical significance of findings was confirmed by the propor-
tion of patients achieving SE values > 85% (post-treatment: 
55% [CBT] v. 17.3% [IRT] v. 7.8% [TAU]; follow-up: 42% 
[CBT] v. 15% [IRT] v. 3.9% [TAU]), as well as improvements 
in daytime functioning. Moreover, the mean sleep parameter 
scores for CBT (Table 3) were within normative values (i.e., 
Figure 2—Percentage of patients within each treatment arm achieving 
sleep efficiency (SE) clinical end-points.
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SOL < 30 min, WASO < 30 min, TST > 6 h,76 and SCI > 6)76 
at follow-up.
Such outcomes appear comparable in magnitude to therapist-
delivered CBT27 and greater than the majority of online CBT 
studies.44,45,47,49 Our findings are most similar to those of Ritter-
band et al.,46,48 suggesting that there may be benefits associated 
with the design and delivery of online CBT, such as engaging 
animations and graphics and reminder prompts. Importantly, 
we also had comparatively low attrition rates (12% to 20%), 
in contrast with some other studies, where dropout rates have 
been as high as 33% pre-to post treatment,47 and up to 49% pre-
treatment to follow-up.49
Thus, CBT delivered using advanced web-based tools, and 
tested within a placebo-controlled design, had a positive and 
durable impact. It should be noted that IRT placebo relative to 
TAU, did also show some positive effects, particularly in re-
ducing WASO, and in achieving SE endpoints for around 15% 
of participants. Such findings help to confirm that there was a 
placebo effect for at least a proportion of participants, on some 
outcomes. It should also be borne in mind that usual care con-
tinued in all groups, consistent with a real-world trial. Although 
we cannot be certain of the effects of such uncontrolled factors, 
it seems unlikely that usual care would systematically differ 
across our groups.
In contrast to substantial improvements in quantitative es-
timates of sleep, we observed more modest improvements on 
ratings of sleep quality. In the CBT group, mean scores in-
creased by around 15 points (on a 100-point scale). Although 
statistically greater than IRT or TAU, the degree of absolute 
change and the final endpoint seem low. We cannot readily ex-
plain this, given (a) the global improvement observed on the 
SCI and the generalized benefits to daytime function observed 
with CBT, and (b) the literature that suggests that sleep qual-
ity can be more amenable than sleep pattern to improvement 
with CBT.26,27 One possibility is that our dimensional, bipolar 
measure of sleep (“very unsatisfactory” to “very satisfactory”) 
was not sufficiently sensitive. People tended to use mainly the 
central area of the scale, and we did not provide definition of 
intermediate points. Also the sleep quality rating was the first 
item on our diary, when it is more usual to be near the end.77
We did not investigate the association between treatment 
and use of medication. Indeed, our website specifically advised 
people not to adjust medication without consulting their doctor. 
Twenty percent reported taking hypnotics at baseline (Table 2) 
and slightly fewer (16%) reported using them at post-treatment, 
but this appeared unrelated to group allocation. Further research 
is required to consider how, if at all, online CBT may be used as 
an alternative to prescription medication.
We would suggest that our design was particularly rigorous, 
providing the first placebo-controlled evidence that online CBT 
for insomnia can be clinically effective. We have demonstrated 
that CBT effects are not merely associated with user engage-
ment on an attractive programme, or with the demand charac-
teristics and expectations of benefit associated with receiving 
treatment. IRT was considered a credible treatment by partici-
pants, reflected in low levels of attrition, faithful recording of 
sleep diary information, and good session completion rates. 
Furthermore, we included a comprehensive assessment of day-
time outcomes, based on proposed revised DSM-5 criteria and 
research recommendations.78 We would also suggest that there 
were methodological advantages associated with our technol-
ogy. For example, treatment fidelity was likely enhanced be-
cause The Prof’s interactions and recommendations, though 
highly tailored, were all pre-programmed. Indeed, standardiza-
tion of protocols in online CBT may offer quality assurance 
that is superior to training therapists to consistently follow a 
manual. Technology offers greatly improved precision of mea-
suring adherence (e.g., time stamps of page views, entries, and 
interactions).
In addition to demonstrating reliable interaction effects, our 
data also reveal main effects of time (independent of group 
allocation). In this respect it should be noted that all our par-
ticipants started the trial in February 2011, completing in May/
June 2011. One explanation of this finding may be an under-
lying seasonal improvement in sleep (or a reduced concern 
about insomnia) from late winter through to early summer. This 
requires further systematic study because, in most RCTs, par-
ticipants are recruited sequentially, often over months or years. 
Thus any seasonal effect is likely to be randomly represented 
in the data. Of course, the time main effect may simply relate 
to spontaneous improvement over the study period. We cannot 
differentiate these possibilities at this stage. The feasibility of 
simultaneously commencing entire cohorts online affords po-
tential advantages, and disadvantages. In relation to the former, 
online recruitment and in-parallel processing of many partici-
pants may permit highly efficient use of research resources. In 
terms of disadvantages, gathering a cohort for the purposes of 
research may not reflect the real world, where patients want to 
start their treatment whenever they feel ready to do so. A large 
scale, open trial of online CBT, with participants enrolling at 
the time of signing up to the site, would be welcome to address 
this point.
This study has a number of important limitations. Subjects 
were recruited by online survey and may represent a cohort un-
usually interested in addressing sleep problems. They certainly 
all had access to, and competencies in, using the internet, thus 
restricting the sample targeted from that of the wider population 
with insomnia. We also did not, for example, include polysom-
nography in our design, and therefore, we are unable to rule out 
occult sleep disorder pathology. Further work evaluating CBT 
with respect to objective sleep outcomes would be valuable. 
We also acknowledge that our selection of SE as the primary 
endpoint could have unduly favored CBT because the sleep re-
striction component of CBT can lead to improved SE, in the 
absence of other evidence. Whereas our outcome data across 
other sleep variables do corroborate significant sleep pattern 
gains, we would advocate using SE as part of a group of sleep 
endpoints in the future.
In setting the inclusion criterion of ≤ 79% for baseline SE on 
the sleep diary, we attempted to ensure that our participants had 
a current, prospectively monitored problem with sleep upon en-
try to the trial. In so doing, however, we recognize that we ex-
cluded those with better sleep efficiency, who may nonetheless 
have benefitted from CBT. In this regard, and also in our exclu-
sion of those who reported being in either “poor” or “very poor” 
physical or mental health, our study departed from a real-world 
evaluation and limiting the generalizability of our findings. 
Future investigations with patients with active comorbidities, 
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who represent the majority of patients in clinical practice, are 
required. Finally, we acknowledge that our follow-up period, 
though experimentally controlled, was relatively short. Most 
face-to-face CBT-I studies have demonstrated maintenance 
of gains between 6 and 12 months post-treatment, with some 
showing durability up to 2 years.27 Future work should assess 
the stability of gains over longer periods.
In keeping with a real world framework for online CBT, we 
wanted to have minimal contact with participants. Communica-
tion, therefore, was by email and questionnaire completion, with 
no face-to-face contact during the trial. We feel that demonstrat-
ing robust effects in the absence of formal contact strengthens 
the ecological validity of the study as well as the applicability 
of the approach. Contacts between the intervention system and 
the participants (e.g., text reminders from The Prof) and among 
the participants (the social community) on the other hand were 
integral to the program. Of course, the community here was 
necessarily limited, to the 53 CBT trial participants. Neverthe-
less, 37 (70%) posted comments on the site, indicating that this 
element of the program was valued, and it should be borne in 
mind that social networks generally increase in perceived value 
as they expand in scale. We do, however, recognize that it will 
be important to assess the specific impact of personal tailoring 
and community support in further online intervention studies. 
Consistent with the stepped care approach,33 such work should 
bear in mind that personal preference is likely to play a role in 
motivation and adherence, such that some people may prefer to 
have personal support (regardless of whether or not they actu-
ally would “need” it). Indeed, there is recent evidence that brief 
behavioral intervention, involving only two in-person contacts, 
can be very effective.79 There would be value in comparing ef-
ficacy, preference, and satisfaction between such minimal con-
tact models and online CBT.
In conclusion, CBT delivered using an online media-rich web 
application with automated support and a community forum ap-
pears effective in improving the sleep and associated daytime 
functioning of adults with insomnia disorder. Further work 
is required to evaluate the objective changes associated with 
treatment delivered in this way. Treatment trials of insomnia 
associated with complex clinical presentations and associated 
with physical and/or mental health problems are also needed to 
establish any necessary pre-screening requirements for access 
to online, compared with, in-person CBT.
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Abstract 
 
Objectives: Insomnia patients complain that mental events keep them awake. This 
study investigates how online cognitive behavioral therapy (CBT) impacts such 
psychological processes and outcomes.  
Method: Randomized, placebo-controlled trial of 164 adults (120 F: [mean age 49y (18–
78y)] meeting DSM-5 criteria for Insomnia Disorder, assigned to CBT (n=55; 40F), 
Imagery Relief Therapy (IRT placebo; n=55; 42F) or Treatment as Usual (TAU; n=54; 
38F). CBT/IRT comprised 6 online sessions delivered by an animated therapist, with 
automated web/email support and access to ‘Wikipedia’ articles. CBT had access to a 
moderated community of users. TAU comprised ‘usual care’. Participants completed the 
Sleep Disturbance Questionnaire (SDQ), Glasgow Content of Thoughts Inventory 
(GCTI), and Depression Anxiety and Stress Scales (DASS) at baseline, post-treatment 
and 8 weeks follow-up. 
Results: The sample was characterised by “mental arousal in bed” (SDQ); ‘sleep and 
sleeplessness’ and ‘rehearsal and planning’ thoughts (GCTI) being most common. 
Treatment effects were observed for all SDQ domains (‘unable to relax’, ‘mental 
arousal’, ‘lack of routine’, ‘trying too hard’); relative effect sizes (CBT v. IRT) were most 
pronounced for ‘trying too hard’ (d=.76 at post-treatment, d=.51 at 8 weeks follow-up). 
CBT was superior to IRT on the GCTI: ‘rehearsal and planning’ (d=.62 and d=.26) and 
‘sleep and sleeplessness’ (d=.74, d=.56). Small effects were observed for depression 
and stress symptoms. Placebo effects (IRT v. TAU) were small to moderate. Changes in 
attribution and thought-content were associated with improvements in global sleep 
quality. 
Conclusion: Online CBT modifies sleep-related attributions, night-time thought content 
and psychopathology over and above a placebo intervention.  
 
Keywords: Insomnia, sleep, treatment, psychological intervention, placebo, internet 
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Introduction 
 
Insomnia is a prevalent and troublesome disorder where people find it difficult to get to 
sleep and/or remain asleep, resulting in daytime problems with fatigue, mood, 
concentration, relationships, work productivity and/or sleepiness.  According to the 
proposed criteria for DSM-5, an Insomnia Disorder should be coded when such 
problems occur 3 or more nights per week for at least 3 months, and ”whether or not 
there is a co-existing psychiatric, medical, or another sleep disorder” (www.dsm-5.org: 
June-02-2010; Reynolds & Redline, 2010). This is in keeping with mounting evidence 
that insomnia is a characteristically persistent condition (Morin et al., 2009; Green et al., 
2012) that is associated with illness vulnerability, particularly the evolution of and relapse 
into depression (Cole & Dendukuri, 2003; Baglioni et al., 2011). In its most common 
form, ‘Psychophysiological Insomnia’ comprises hyperarousal in bed, maladaptive sleep 
behavior, mental arousal in the form of a racing mind, and the evolution of a vicious 
cycle where the harder one strives to sleep, the more elusive sleep becomes 
(International Classification of Sleep Disorders: American Academy of Sleep Medicine, 
2005). There is a long tradition of psychological research on insomnia (e.g. Bootzin & 
Nicassio, 1978; Borkovec, 1982; Hauri & Fisher, 1986; Morin, 1993; Espie, 2002; 
Harvey, 2002; Perlis et al., 1997), suggesting that Cognitive Behavioral Therapy (CBT) is 
a good conceptual “fit” for insomnia. Indeed, outcome studies suggest that CBT offers 
the best long-term treatment benefit (Morin et al., 2006; Irwin, Cole & Nicassio, 2006; 
Riemann & Perlis, 2009; Wilson et al., 2010). 
Although CBT is a credible and effective therapy for insomnia, it is seldom 
available in practice (Espie, 2009). This is a concern, not least because of the 
demonstrated high population prevalence rate of clinical Insomnia Disorder of 10-12%,  
with older adult rates >20% (Ohayon,  2002; Lichstein et al., 2004), and the paucity of 
skilled therapists to offer an alternative to pharmacological treatment (Espie, 2009). 
Nevertheless, in keeping with developments more broadly in psychological therapies 
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(e.g. Bower & Gilbody, 2005; Bennett-Levy et al., 2010), a considerable amount of work 
has been undertaken on manualised CBT for insomnia, in guided self-help, and more 
recently in online CBT (Espie et al., 2001, 2008; Swift et al., 2011; van Straten & 
Cuijpers, 2009; Vincent & Lewycky, 2009; Ritterband et al., 2009). 
The first randomized placebo controlled trial of online CBT, using a rich media 
web-based programme, was recently conducted, demonstrating significant 
improvements in sleep pattern and daytime functioning (Espie et al., 2012). In this 
secondary analysis, emphasis is placed on the psychological processes and outcomes 
associated with CBT. Consistent with the formulation of insomnia as a 
psychophysiological condition, it is important to reflect not only upon the impact of CBT 
on sleep, but also its impact on a range of secondary outcomes that are likely 
maintaining factors, such as attribution, cognition and psychopathological status. 
The objectives of this report, therefore, were to address the following questions: 
Is online CBT for persistent insomnia disorder superior to a credible placebo intervention 
as well as to a treatment as usual condition, in modifying sleep-related attributions, 
night-time thinking processes and daytime symptoms of depression, anxiety and stress?  
Are these effects durable and clinically important?  
 
Methods 
The methodology for this trial has previously been published (Espie et al., 2012) and the 
website www.sleepio.com/research hosts illustrative material of the study evaluation and 
intervention procedures. In brief, however, participants from the UK community (18+yr), 
who had completed the online Great British Sleep Survey (GBSS: Espie et al., under 
review) and who met proposed DSM-5 criteria for persistent Insomnia Disorder were 
invited to take part. The underlying logic of the GBSS ensured that individuals: had a) a 
current complaint of poor sleep (difficulty initiating and/or maintaining sleep, early 
morning wakening, or non-restorative sleep); with b) significant daytime effects; c) 
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affecting them 3 or more nights per week for ≥3 months. People with possible significant 
mental or physical health problems, suspected disorders of sleep other than insomnia or 
heavy alcohol use, were excluded conservatively, using further online screening. The 
use of sleeping pills or other sleep aids was permitted. Usual care that participants had 
been receiving from their medical advisers continued in all arms.  
A total of 10,071 adults completed the GBSS during the period April 2010 to 
February 2011; of whom, 6,609 provided email addresses. In total, 1,342 of this latter 
group (20.3%) met screening criteria and were invited by email to consider taking part. 
Of these, 276 (20.1%) replied and consented to further screening. The majority of this 
group (n=228, 82.6%) then completed these further standardized assessments. Finally, 
to confirm current eligibility, participants completed prospectively a 7 day online sleep 
diary to confirm a sleep problem of clinical severity. Sixty-four participants were excluded 
during these final stages, and the remaining sample of 164 eligible, consenting 
participants was randomized into the study (Figure 1). 
[Insert Figure 1] 
Study design 
The study was a pragmatic, parallel group randomized controlled trial comprising three 
treatment arms; (1) online CBT, (2) online Imagery Relief Therapy (IRT: placebo), (3) 
treatment as usual (TAU), with blind assignment to group determined by a computer-
generated random allocation schedule, operated by a remote independent technical 
operator. The trial followed CONSORT 2010 guidelines (Schulz et al., 2010). Consistent 
with the inclusion/ exclusion criteria above, the study design in effect was CBT+TAU v. 
IRT+TAU v. TAU alone. Major assessments were at baseline, post-treatment, and 
follow-up 8 weeks later. Participants randomized to the IRT placebo or TAU arm were 
offered the online CBT package upon completion of the study. All assessment, treatment 
and data-gathering procedures were conducted online, and all queries/ enquiries were 
managed electronically, without any face-to-face contact. The study protocol was 
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approved by the University of Glasgow, Faculty of Medicine Research Ethics Committee 
and all participants provided informed consent online (see www.sleepio.com/research). 
Assessment measures 
Three self-report measures were completed at each assessment point (baseline, post-
treatment, follow-up) to evaluate different aspects of sleep-related psychological 
wellbeing. These were secondary measures which complemented the sleep diary, 
completed daily, from which our primary endpoint of sleep efficiency was derived (see 
‘sleep diary’ below).  They were included to provide a profile of participants’ attributional, 
cognitive, and psychopathological characteristics which may be important in a) 
developing a better understanding of insomnia as a psychophysiological condition, 
suited to cognitive and behavioural intervention; and in b) investigating treatment 
processes and outcomes associated with CBT. 
Sleep Disturbance Questionnaire (SDQ) 
The SDQ has been used for more than 20 years to profile the attributional beliefs of 
people with insomnia, to aid tailoring of CBT to individual circumstances, and to evaluate 
treatment-related change (e.g. Espie et al., 1989; Espie et al., 2000; Harvey et al., 2005; 
Smith & Trinder, 2001). The scale comprises 12 items; three relating to each of four 
dimensions: attribution to being ‘unable to relax’, to ‘mental arousal’, to there being a 
‘lack of routine’ associated with sleep, and to ‘trying too hard’ to sleep. Studies have 
shown that this is a relatively ‘pure’ factor structure, explaining 61% of variance (Espie et 
al, 2000). The respondent is asked to rate each item on a 5-point scale (0 ‘never true’, 1 
‘seldom true’, 2 ‘sometimes true’, 3 ‘often true’, 4 ‘very often true’) in relation to typical 
nights when s/he does not sleep well. Thus subscale scores reflect the strength of 
attribution towards a particular explanation of insomnia [e.g. ‘My body is full of tension’ 
(unable to relax), ‘I am unable to empty my mind’ (mental arousal), ‘I can’t get my sleep 
pattern into a proper routine’ (lack of routine), ‘I get too “worked up” at not sleeping’ 
(trying too hard)]. Data from the present study demonstrate that the SDQ has 
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satisfactory reliability (α = 0.82, range of α-if-item-deleted = 0.78-0.84). There was 
moderate inter-correlation between the subscale scores (average r = .40).  
Glasgow Content of Thoughts Inventory (GCTI)  
The GCTI was originally developed using an iterative process. First, a large number of 
spontaneous wakeful cognitions of people with insomnia was gathered using voice-
activated audio-recorders; and these were subjected to content analysis to identify major 
underlying themes (Wicklow & Espie, 2000). Second, a psychometric scale development 
study was conducted, on a separate cohort of patients. This yielded a 25-item self-report 
inventory of exemplar common thoughts, related to each of three themes: ‘rehearsal and 
planning’ thoughts’, thoughts relating to ‘sleep and sleeplessness’ and thoughts 
reflecting ‘heightened awareness’ (Harvey & Espie, 2004). Items are rated on a 4-point 
scale (0 ‘never’, 1 ‘sometimes’, 2 ‘often’, 3 ‘always’) in response to the lead question: 
‘how often over the past 7 nights have the following thoughts kept you awake?’ Such 
information is useful to tailor the cognitive component of CBT (cf. Morin & Espie, 2003). 
In the present study, the GCTI was condensed, to nine items: three per theme [i.e. ‘what 
happened today and what I've got on tomorrow’, ‘things that have happened in the past 
and how they worked out’, ‘what the future might hold and what I should be doing for 
things to work out well’,  (rehearsal and planning); ‘how long I've been lying awake’, ‘how 
I'm going to cope tomorrow if I don't sleep well tonight’,  ‘how out of control my sleep is 
and I don't know what to do about it’ (sleep and sleeplessness); ‘noises I can hear in the 
house or from outside’, ‘my body feeling hot or cold; or my heart beat pounding in my 
head’, ‘trivial things of no importance that go through my mind’(heightened awareness)]. 
This short-form GCTI appears to perform similarly to the original (Harvey & Espie, 2004: 
α = 0.87). Internal consistency in the present study was good (α = 0.79, range of α-if-
item-deleted = 0.75-0.80) and average inter-correlation of the derived themes was 
moderate (r = .38). 
Depression, Anxiety, Stress, Scale (DASS) 
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Finally, we selected the DASS (Henry & Crawford, 2005: 21-item) because it takes a 
dimensional view of psychopathological symptoms, and is commonly used in samples of 
participants who do not have a formal affective or anxiety disorder (as in this study). For 
example, the DASS has been used in previous insomnia treatment studies (Harris, Lack, 
Wright, Gradisar, & Brooks, 2007) and as a depression and anxiety screening tool in 
other medical conditions (Mitchell, Burns, & Dorstyn, 2008). Moreover, it has a subscale 
on stress, which often co-presents with insomnia.  Each item is rated on a 4-point scale 
(0 ‘did not apply to me at all’, 1 ‘applied to me to some degree, or some of the time’, 2 
‘applied to me to a considerable degree, or a good part of the time’, 3 ‘applied to me very 
much, or most of the time’) in relation to the past week. It has three subscales, each 
composed of 7 items: depression (DASSdep: e.g. ‘I couldn’t seem to experience 
anything positive at all’), anxiety (DASSanx: e.g. ‘I was worried about situations in which 
I might panic or make a fool of myself’) and stress (DASSstress: e.g. ‘I was intolerant of 
anything that kept me from getting on with what I was doing’) which have satisfactory 
internal reliability (Henry & Crawford, 2005: α = 0.88, α = 0.82, α = 0.90 respectively). In 
the present study these values were somewhat lower but still satisfactory for DASSdep 
(α = 0.78, range of α-if-item-deleted = 0.74-0.79) and DASSstress (α = 0.80, range of α-
if-item-deleted = 0.76-0.81). DASSanx was less reliable, perhaps due to the limited 
range of scores we obtained on this subscale (α = 0.62, range of α-if-item-deleted = 
0.48-0.69) 
Sleep diary 
Participants also completed an online diary each morning upon rising 
(www.sleepio.com/research). The diary-derived variable of interest here is sleep 
efficiency (SE, %) calculated by the formula {[1-(SOL+WASO/TIB)] x100} where SOL 
refers to ‘sleep onset latency’ (time taken to fall sleep), WASO refers to ‘wake time after 
sleep-onset’ (total time awake resulting from awakenings in the night), and TIB refers to 
‘time in bed’ (total time from retiring to rising).  Thus, SE reflects the proportion of time 
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spent in bed that the person is asleep, and the achievement of SE of 80%, 85% and 
90% reflect clinically important improvement endpoints and not merely statistical change 
(c.f. Morin, 2003). 
Sleep Condition Indicator 
The Sleep Condition Indicator (SCI) is a patient-reported outcome measure, based upon 
DSM-5 Insomnia Disorder criteria.  It is brief (8-item), and has shown excellent reliability 
in a large field study of 11,129 participants (α = 0.89, range of α-if-items systematically 
deleted = 0.87-0.90; Espie et al., under review). The SCI generates scores in the range 
0 to 10, with higher values reflecting a person’s sleep being in ‘better condition’. The SCI 
correlates strongly with other standard index measures, of sleep quality [Pittsburgh 
Sleep Quality Index (Buysse et al., 1989): r = .78, n = 256] and insomnia severity 
[Insomnia Severity Index (Morin, 1993): r = .79, n = 256] (Gardani et al., 2011). 
Treatment groups 
CBT  
Participants received 6 weekly sessions delivered by an animated ‘virtual therapist’ (The 
Prof). The programme comprised a fully automated media-rich web application, driven 
dynamically by baseline, adherence, performance and progress data, and including an 
online Wikipedia style sleep educational site, a social community of fellow users 
moderated by experts, and support, prompts and reminders sent by email and mobile 
SMS.  At the start of each session, The Prof conducted a progress review with the 
participant, explored the diary data submitted during the week, the participant’s current 
sleep status and pattern, and progress achieved against goals previously set. Underlying 
algorithms fed the delivery of information, support and advice in a personally-tailored 
manner. CBT content was consistent with the literature (e.g. Morin & Espie, 2003), and 
covered behavioral (e.g. sleep restriction, stimulus control) and cognitive (e.g. putting the 
day to rest, thought re-structuring, imagery, articulatory suppression, paradoxical 
intention, mindfulness) strategies, as well as additional relaxation strategies (progressive 
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muscle relaxation and autogenic training) and advice on lifestyle and bedroom factors 
(sleep hygiene). The following illustrations may be helpful. In sleep restriction, The Prof 
proposes a new ‘window’ for sleep, calculated from available sleep diary data, and 
engages with the participant to help them select the timing (onset/ offset) of this window 
from a set of personalised options. An example, of a cognitive technique, is where 
another animated character (with insomnia) presents to the Prof their concerns, 
dysfunctional beliefs and associated emotions. The Prof then asks the participant to 
choose some solutions from a menu of options, and delivers this as advice to the 
character, who is seen to revise his thinking. The Prof then reveals to the participant that 
the scenario was based upon his/ her own sleep-related attributions and thoughts (from 
baseline SDQ and GCTI data). In this way the participant is helped to learn how to 
restructure dysfunctional thinking. The intervention was based upon a previously 
validated manual, found to be effective in three randomized clinical trials (Espie et al., 
2001, 2007, 2008). Illustrative examples of the CBT and IRT interventions are provided 
at www.sleepio.com/research.     
IRT  
This was also delivered by ‘The Prof’ using the same application platform, and design 
and execution principles as for CBT i.e. interactive sessions, dynamic feedback against 
personal goals, progress review at start of each session, automatic calculation of sleep 
data over time, personal case file, 24/7 access, Wikipedia of sleep; but with no known 
active therapeutic ingredient. IRT was based on a well-established and credible, non-
pharmacological placebo intervention (Steinmark & Borkovec, 1974) which has been 
used successfully in several trials (Espie et al., 1989; Edinger at al., 2001; Manber et al., 
2008). The term Imagery Relief Therapy was used in order to enhance credibility of an 
active and novel therapy.  For example, if participants were to enter this as an internet 
search term, they would come upon material which would appear to be valid for a 
psychological problem such as sleep.  However, IRT contained no active components of 
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imagery training, or of systematic desensitization. Likewise, it did not include detailed 
relaxation instruction or any behavioral advice.  Rather, the participant was trained to 
visualise neutral objects (e.g. a key) or shapes (e.g. a yellow square) in conjunction with 
thinking about sequential aspects of their evening routine (e.g. setting the table for 
dinner), and was asked to practise these pairings for 20 minutes per day early in the 
evening. The rationale given for this ‘quasi-desensitization’ framework, was that 
successful sleep was associated with good preparation, and that neutralizing unhelpful 
associations with evening routines would recondition them towards automatic sleep 
engagement and sleep maintenance.  
Protocol standardization  
The integrity and fidelity of treatment allocations was assured by the online 
procedures which delivered the interventions. In addition, in session 1 of both CBT and 
IRT conditions, participants were invited to commit (or not) to the course following an 
explanation of the therapeutic rationale (all did so). Participants in different groups did 
not have contact with each other, nor did they have access to alternative treatment 
materials. Both CBT and IRT were scripted and automated so support and length of 
treatment was identical within each group. All web-based interactions were electronically 
stored to provide time-stamped data on participant activity (e.g. diary entries, session 
activities, engagement with the community, adherence to tasks). 
TAU  
In real world practice, insomnia patients often have concurrent physical and 
psychological symptoms, as well as concurrent treatments. Therefore, to reflect validity, 
and to permit greater generalizability, the protocol explicitly permitted continuation of 
usual health care for all participants. Physicians were free to offer appointments, to 
prescribe, and to maintain/discontinue prescriptions. Aside from this, TAU alone 
participants comprised, effectively, a wait-list group who completed measures but 
received no additional help for their insomnia. After the trial was completed TAU and IRT 
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participants were offered access to the CBT online intervention. The only contact 
received by the TAU alone arm was reminders to complete evaluation at baseline and 
the two follow-up points.  
Data management and analysis 
The study was designed to have 80% power to detect a medium effect size (Cohen, 
1988) consistent with published meta-analytic data (for a review see Riemann & Perlis, 
2009), based upon a 3-group ANOVA model with fixed effects, main effects and 
interactions, on the primary outcome measure of SE (cf. Espie et al., 2012). These 
criteria implied recruiting a total sample of 159 participants. All comparisons were 
planned and tests were two-sided, with p<.05 considered to indicate statistical 
significance. Where appropriate, to control for multiple comparisons, a per family error 
rate was adopted to maintain the nominal error rate (.05/ n of comparisons). 
 Analyses were performed using PASW Statistics 18 (Norusis, 2011; SPSS Inc., 
Chicago, Ill). Treatment effects were assessed using Linear mixed effects models, which 
permitted appropriate handling of missing data (cf. Olsen, Stechuchak, Edinger, Ulmer, 
& Woolson, 2012), predicting mean values at each assessment point (baseline, post-
treatment, 8-week follow-up). In each model, time and treatment group were included as 
fixed effects, with time and group x time interaction terms. For variables exhibiting 
between group differences at baseline, the baseline value was entered as a covariate.  
[Insert Table 1] 
Results 
Participant characteristics 
Descriptive, demographic and clinical information on the allocated sample of 164 (120 F) 
adults [mean age 49y (18–78y)] is provided in Table 1. Approximately two-thirds were 
employed either full-time or part-time.  Post-code data were used as a proxy for socio-
economic status by deriving an Index of Multiple Deprivation (IMD).  Mean IMD was 16.7 
(SD = 11.8) indicating that the sample was somewhat less deprived (by <0.5 SD) than 
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national norms 21.7 (SD = 15.5: Office for National Statistics, 2007). Participants were 
generally healthy, endorsing stable average or better health (as per selection criteria), 
although 51 (31%) and 17 (10%), respectively, took prescription medication for a 
physical or mental health problem.  A total of 33 participants (20%) sometimes used 
prescribed sleeping pills, and 63 (38%) made at least some use of over-the-counter 
sleep aids.   
All participants had Insomnia Disorder, the great majority being of difficulty 
maintaining sleep or of mixed insomnia sub-types. Baseline sleep characteristics 
indicated current insomnia in the severe clinical range, with average total wake time per 
night (SOL+WASO) of ~2¼ hours and mean sleep efficiency of 61% (Table 1).  Average 
estimated total sleep time was a little over 5 hours. Consistent with insomnia diagnostic 
criteria, substantial impact was observed also on daytime performance and social 
functioning. Two-thirds had insomnia for over 6 years, and almost 50% for over 11 
years. Participants randomized to CBT (n = 55), IRT (n = 55) and TAU (n = 54) were 
similar in all demographic and clinical respects, with no significant differences on any 
baseline descriptor. Eight of the 164 participants did not start their treatment so the final 
sample receiving the allocated intervention was 156 [CBT = 53, IRT = 52, TAU = 51]. 
There were no significant differences on any variable between this sample and the 
allocated sample of 164. 
Treatment attrition and integrity 
Of those receiving their allocated intervention, 43 (82%) CBT participants 
completed all their online therapy sessions and 47 (88%) completed ≥4sessions. This 
compared to 41 (79%) and 48 (92%) respectively in the IRT group. Thus, there were 
similar, modest, levels of attrition during the treatment phase. Just under 80% of 
participants (n = 125) completed the follow-up assessment at 8 weeks. Reasons for 
withdrawal during treatment are summarized (where known) in Figure 1. There were no 
significant differences between treatment completers (defined as completing ≥ 4 
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sessions) and those who dropped out, on any demographic, clinical or sleep variable. 
Participants in the CBT group took an average of 50 days to complete the course 
compared with 48 in IRT, with TAU participants typically taking one more week to 
complete (58 days). No harm-related or serious adverse events were reported by 
participants. 
Baseline characteristics 
Of the four SDQ domains, the highest baseline value was for ‘mental arousal’ (M = 9.15, 
SD = 2.75) relative to ‘trying too hard’ (M = 6.74, SD = 2.75: t(163) = 11.00, p < .001), 
‘unable to relax’ (M = 6.14, SD = 2.38: t(163) = 14.81, p < .001) and ‘lack of routine’ (M = 
5.89, SD = 2.34: t(163) = 14.30, p < .001). Reports of ‘trying to sleep’ were also greater 
than lack of routine’ (t(163) = 4.10, p < .001) and being ‘unable to relax’ (t(163) = 2.93, p 
= .004). SDQ domains inter-correlated very modestly (r = .24-.49), representing 6-24% 
of shared variance (R2). At the item level, ‘my mind keeps turning things over’ (mental 
arousal domain) was the most strongly endorsed single item on the SDQ with 77.3% 
rating this as a problem ‘often’ or ‘very often’. For the other subscales, the highest 
scoring individual items were ‘I can’t get my sleep pattern into a proper routine’ (61.8%: 
‘lack of routine’ subscale), ‘I worry that I won’t cope tomorrow if I don’t sleep well’ 
(50.0%: ‘trying to sleep’) and ‘I find it hard to physically “let go” and relax my body’ 
(44.6%: ‘unable to relax’). 
On the GCTI, participants exhibited higher baseline scores for ‘sleep and 
sleeplessness’ (M = 7.89, SD = 2.63) and ‘rehearsal and planning’ thoughts (M = 7.62, 
SD = 2.65) compared to ‘heightened awareness’ thoughts (M = 5.24, SD = 2.31) [t(163) 
= 12.83, p < .001 and t(163) = 10.74 respectively, both p < .001]. There was no 
significant difference between rehearsal and planning and sleep thoughts, and the GCTI 
factors again moderately correlated (r = .35-.43, approximate R2 = 15%).  Thinking about 
‘how long I've been lying awake’ was the item that was most commonly rated ‘often’ or 
‘very often’ (by 64.6% of participants: loading on the ‘sleep thoughts’ subscale). Thinking 
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about ‘what happened today and what I've got on tomorrow’ received the strongest 
endorsement of the items on the ‘rehearsal and planning’ subscale (58.2%) and concern 
about ‘trivial things of no importance that go through my mind’ (42.7%) was the most 
prominent of the ‘awareness thoughts’. 
 Consistent with our selection criteria, there was only modest baseline 
symptomatology on the DASS, with stress scores being significantly higher than 
depressive [M = 7.80, SD = 3.70 vs. M = 5.05, SD = 3.01; t(163) = 11.1, p < .001] or 
anxiety [M = 2.70, SD =2.20, t(163) = 21.0, p < .001] scores, and depressive scores 
being higher than anxiety scores [t(163) = 11.5, p < .001]. Compared with the SDQ and 
GCTI, the DASS subscales were more strongly inter-correlated (DASSdep/ DASSanx, r 
= .53; DASSdep/ DASSstress, r = .55; DASSanx/ DASSstress, r = .57: approximate R2 = 
30%). 
One-way ANOVA between treatment group comparison revealed differences in 
pre-treatment scores for the SDQ variables ‘unable to relax’ [F(2,161) = 4.34, p = .015], 
‘mental arousal’ [F(2,161) = 3.84, p = .024] and for ‘heightened awareness’ [F(2,161) = 
3.73, p = .026] on the GCTI, with a marginally non-significant effect for DASSanx (p = 
.052). Consequently, baseline values were introduced conservatively as covariates in 
subsequent hypothesis testing on these variables. The dependent variables exhibited no 
significant association with age, gender, socioeconomic status or any other sample 
demographic. Similarly, no relationship with insomnia duration or sleep pattern 
characteristic was observed. All ten SDQ, GCTI and DASS variables were somewhat 
associated with overall sleep condition on the SCI (range of r = -.21 to -.35, R 2 ≤ 12%). 
 [Insert Table 2] 
Impact of treatment on sleep-related attributions 
Summary data comprising pre-treatment, post-treatment and follow-up mean (SE) 
values for each group are presented in Table 2. Change scores (with 95% CI) and within 
group effect sizes (ES) are also provided. ES were regarded as large (d = 0.8), 
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moderate (d = 0.5) or small (d = 0.3), consistent with recognized definitions (Cohen, 
1988). In Table 3, relative ES, representing changes over baseline observed at post-
treatment and follow-up, are provided for each treatment comparison (CBT-TAU, IRT-
TAU, CBT-IRT). 
For all four sleep attribution variables, significant effects (summarized below) 
were observed, and these remained highly significant when taking account of baseline 
values. The mixed effects model confirmed a significant main effect for time [range of 
F(2,263) = 13.00-49.9, all p < .001] and for the treatment x time interaction for all the 
SDQ variables. These latter represent the hypothesis-testing analyses so will be taken in 
turn. 
For ‘unable to relax’, between group comparison favored CBT at post-treatment 
[F(4,263) = 3.12, p = .016] relative to both TAU (d = -0.72) and IRT (d = -0.56) (see 
Table 3).  These effects were maintained at follow-up, but with smaller standardized ES. 
For ‘lack of routine’, CBT was again superior [F(4,266) = 4.30, p = .002] to TAU and IRT 
(moderate to large ES) at post-treatment, and at follow up). ‘Mental arousal’ [F(4,270) = 
4.65, p = .001] and ‘trying too hard’ [F(4,275) = 8.45, p < .001] also exhibited significant 
interaction terms. For ‘mental arousal’, CBT was associated with stronger effects than 
TAU at post-treatment (d = -0.90) and follow-up (d = -0.54). The CBT-IRT comparison 
was also significant at each measurement point (d = -0.64 and d = -0.19). ‘Trying too 
hard’ reduced significantly following CBT compared with TAU (d = -1.15) and IRT (d = -
0.76), and similar magnitude of effects were maintained 8 weeks post-treatment (Table 
3). These latter variables also exhibited a small placebo response (IRT-TAU) at follow-
up [‘mental arousal’ (d = -0.40) and ‘trying too hard’ (d = -0.35)]. 
Applying a Bonferonni correction to maintain the .05 error rate across the SDQ 
variables (adjusted p = .0125) would result in the treatment x time interaction for one 
outcome, being ‘unable to relax’, failing to attain statistical significance. 
[Insert Table 3 here]  
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Impact of treatment on night-time thinking 
 Comparative data on the GCTI at baseline, post-treatment and follow-up are 
presented in Table 2. Main effects of time were observed for all variables [range of 
F(2,264) = 14.33-54.20, all p < .001]. The group x time interaction was strongest for 
thoughts about ‘sleep and sleeplessness’ [F(4,266) = 10.92, p < .001], associated with 
improvement in CBT relative to TAU after treatment and at 8 weeks (both d ≥ 1.00); and 
by CBT relative to IRT at these measurement points (d = -0.74 and -0.56 respectively: 
Table 3) Superior outcomes were also demonstrated for CBT on ‘rehearsal and 
planning’ [F(4,264) = 3.15, p = .015] and ‘heightened awareness’ [F(4,263) = 2.41, p = 
.049]. Moderate effects for ‘rehearsal and planning’ thoughts relative to both groups 
were maintained at follow-up particularly for the CBT-TAU comparison (Table 3). A 
similar pattern was observed for ‘heightened awareness’ with ES in the small to 
moderate range, however, it should be noted that the interaction term for this variable 
was no longer significant following conservative correction for multiple GCTI 
comparisons (.05/3; p = .017). Response to IRT, though inferior to CBT, was moderate 
for thoughts about ‘sleep and sleeplessness’ at post-treatment (d = -0.42) and follow-up 
(d = -0.60) relative to TAU. Small effects in favor of IRT relative to TAU were also 
obtained for the two other GCTI variables at follow-up. 
Impact of treatment on symptoms of psychopathology 
Main effects of time were obtained for DASSdep [F(2,322) = 16.71, p < .001] and 
DASSstress [F(2,337) = 26.75, p < .001] with interaction effects also significant on these 
two variables (respectively: [F(4,322) = 5.91, p < .001] and [F(4,337) = 3.90, p = .004]). 
Relative ES at post-treatment were generally small and favoring CBT over TAU and IRT 
(Table 3). At follow-up, ES had strengthened for the CBT-TAU and the IRT-TAU 
comparisons, with small additional benefits of CBT over IRT on DASSdep (d = -0.29) 
and DASSstress (d = -0.26). 
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Association of change in attribution, cognition and psychopathology with sleep 
improvement 
 
Sleep diary data from the trial are reported elsewhere (Espie et al., 2012) with summary 
data presented in Table 1. It was of interest here to consider how change on the 
psychological variables reported in this paper associated with the more direct benefits of 
CBT to insomnia symptoms per se. This was investigated in relation to the trial’s primary 
end-point of sleep efficiency, and with respect to the Sleep Condition Indicator score, our 
overall index of sleep health, taking into account both night-time and day-time aspects of 
insomnia disorder. Accordingly, the SDQ, GCTI and DASS change scores (baseline to 
post-treatment, baseline to follow-up: presented in Table 1) were correlated with change 
scores for the SCI and for SE.  
The results of this analysis support a stronger change score relationship with our 
global (SCI) measure than with sleep efficiency per se. Post-treatment improvement on 
the SCI was moderately associated with reduction in the SDQ subscales ‘trying too hard’ 
(r = -.49), ‘unable to relax’ (r = -.44), ‘mental arousal’ (r = -.42) and to a lesser extent 
‘lack of routine’ (r = -.28) [all p <.001]. Comparable results were obtained at follow-up 
except that the association between sleep improvement and ‘lack of routine’ had 
strengthened (r = -.45). By contrast, smaller inverse correlations were observed with SE 
(range of r = -.15 to -.21; p = .08 to .015), the strongest of these being with ‘lack of 
routine’ at follow-up. Likewise, on the GCTI, there was an association between reduced 
night-time thoughts about ‘sleep and sleeplessness’ and SCI improvement (r = -.47 at 
post-treatment, r = -.51 at follow-up) and weaker change relationships with ‘heightened 
awareness’ (r = -.31) and ‘rehearsal and planning’ (r = -.28) [all p < .001]. Again, 
changes in SE were less closely mirrored by cognitive change; the strongest association 
being with reduced thoughts about ‘sleep and sleeplessness’ at post-treatment (r = -.23, 
p = .008). Reduction in DASS depressive and stress symptoms were also associated 
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with SCI score improvement (r = -.39 and -.41 respectively) at follow-up, but there were 
no significant associations with sleep efficiency. 
 
Discussion 
Consistent with the formulation of insomnia as a psychophysiological disorder, our 
participants reported particular problems with mental arousal in bed. The 
characteristically “racing mind” phenomenon was borne out by over 75% attributing poor 
sleep to being unable to empty their mind. The next strongest attribution was trying too 
hard to sleep. Concerns about having a poor sleep pattern were also endorsed by 
almost two-thirds and a significant minority had trouble relaxing (45%). These 
attributions are not, of course, mutually exclusive, and we observed a stable though 
modest inter-correlation across SDQ item scores. Data from the GCTI complemented 
these findings with thoughts about sleep and sleeplessness (e.g. how long I’ve been 
lying awake: 65%) and rehearsing the day past and planning ahead (58%) being very 
common experiences. Some participants also reported a hyper-awareness at night 
whereby they were conscious of their environment or internal state.  
The complaint of insomnia, therefore, may be as much to do with such 
phenomena as it is to do with concern about sleep pattern problems per se.  Indeed, the 
experiences seem likely to go hand-in-hand, because the individual is both lying awake 
(measurable in minutes) and thinking or worrying (measurable by such self-report 
scales).  Importantly, CBT may directly impact upon each of these.  Sleep restriction, for 
example, may increase homeostatic pressure for sleep by extending wakefulness 
(Pigeon & Perlis, 2006; Spielman, Saskin, & Thorpy, 1987), helping to over-ride pre-
sleep arousal through the rapid induction and consolidation of sleep (Kyle et al., 2011).  
Cognitive strategies on the other hand may reduce the pressure for mental 
arousal (e.g. putting the day to rest) or obviate its effects (e.g. cognitive restructuring, 
mindfulness) [Espie & Kyle, 2009]. This approach is also consistent with the perspective 
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that people with psychophysiological insomnia may benefit from interventions that 
combat hyperarousal and/ or facilitate the down-regulation of arousal, whether 
expressed autonomically (Bonnet & Arand, 2010), cortically (Perlis, Giles, Mendelson, 
Bootzin, & Wyatt, 1997) or mentally (Espie, 2002). 
Trial methodologies do not, of course, permit firm conclusions to be drawn about 
mechanisms of treatment effect. Nevertheless our outcome data on the SDQ, GCTI and 
DASS are at least consistent with such mediation. Moreover, the fact that we had a 
quasi-desensitization placebo arm may offer greater confidence in the interpretation of 
self-reported change on what are essentially psychological variables. We will start 
therefore by considering the placebo response, which was evident for most of the SDQ 
and GCTI subscales. The relative ES for the IRT-TAU comparison were typically small in 
magnitude (mean d = -0.33).  Nevertheless, these results do indicate that non-specific 
factors were associated with some improvement. Likewise, therefore, these could have 
been a factor in other online CBT studies, without a placebo arm, where significant 
improvements were reported on psychological measures (Ritterband et al., 2009; Strom 
et al., 2004; Lancee et al., 2011; Vincent & Lewycky, 2009). Interestingly, there were no 
comparable placebo effects on self-report measures of sleep (Espie et al., 2012). There 
are several possible explanations for our findings here. Perhaps any intervention that is 
perceived to address the self-management of sleep may be likely to induce at least 
some psychological change. Alternatively, participants knew that the trial was evaluating 
psychological intervention, and so they may have been predisposed first to take part; 
and second to respond in these domains. A third possibility, and also consistent with our 
rationale for conducting a placebo controlled trial, is that the experience of our online 
medium would be intrinsically engaging and would produce some effects in its own right.  
A final possibility is that our placebo may have been neutral in relation to sleep-related 
effects, but somehow active in relation to non-specific factors. 
Turning to the CBT intervention, it is important to recognise that CBT was 
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associated with significant improvement over and above the effects of the placebo 
condition. Significant effects on the CBT-IRT comparison were consistently observed, 
although relatively small in magnitude (average d = -0.32), with the overall effect relative 
to TAU being moderate to large (d = -0.65).  From this, we can conclude that CBT 
impacted upon attribution and cognition beyond the effects of placebo alone. 
Strengthening the importance of these findings, we also show that changes in attribution, 
cognition and psychopathology were moderately and significantly related to 
improvements in global sleep quality (using the SCI), though tended to be weakly related 
to improvements in sleep efficiency. It is perhaps not surprising that such changes were 
more aligned with this overall appraisal of sleep, given that the SCI comprehensively 
captures core features of the insomnia experience (quantitative and qualitative aspects 
of sleep, as well as daytime functioning). Though not possible to determine cause and 
effect, it might be expected that improvements in both sleep (quality and quantity) and 
daytime functioning will help modify the nature of sleep-related cognitions and 
attributions. Of course, the converse direction is also plausible and the present design 
cannot permit teasing out of competing explanations. Interestingly, Edinger et al. (2001), 
in a placebo-controlled trial of face-to-face CBT-I, also found that reductions in 
dysfunctional beliefs and attitudes about sleep were more strongly related to 
improvements in global insomnia severity (r= .60) than sleep efficiency values (r= -.25).               
We excluded any potential participants who rated their mental health as “poor” or 
“very poor”.  Consequently, our data on psychopathology are limited. Nevertheless, the 
DASS is a dimensional symptom measure, and permits some insights. We found that 
depressive and stress symptoms were more problematic at baseline than anxiety 
symptoms. Unsurprisingly, therefore, we did not observe much in the way of change in 
the latter. On the other hand, both depressive and stress symptom levels reduced 
following both CBT and IRT. At the eight week follow-up point, these effects were 
moderate to large for CBT, and moderate for IRT, with the additional effects of the CBT-
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IRT comparison significant but small in magnitude (for DASS dep d = -0.29;  for DASS 
stress d = -0.26). Future studies should recruit co-morbid clinical samples, with greater 
degrees of psychopathology, to determine the extent to which online CBT has 
generalisable effects beyond improvement of sleep parameters.   
This work is not without limitation. Our sleep-related outcome measures, though 
validated with insomnia patients, have not been used in online treatment outcome 
studies; therefore, comparison with existing intervention trials is not possible. In general, 
insomnia treatment studies have tended to focus on night-time sleep parameters, 
frequently neglecting daytime functioning and treatment process measures. Future, 
adequately controlled, online (and face-to-face) CBT-I studies should incorporate similar 
measures to the present study, in addition to assessments of other relevant constructs 
(e.g. pre-sleep cognitive and somatic arousal [Nicassio et al., 1989], sleep effort 
[Broomfield & Espie, 2005], dysfunctional beliefs and attitudes about sleep [Morin et al., 
2007]).  
Another limitation is our relatively short-term follow-up. Face-to-face CBT-I 
studies often include follow-ups between 6 and 12 months and it will be important to 
determine the durability of online CBT-related treatment effects in future studies. Related 
to this, inspection of effect sizes at follow-up reveals a general weakening of treatment 
effects (CBT v. IRT, relative effects) and the emergence of small (within-subject) effects 
for the TAU group. Such patterning of data may imply a small seasonal effect on sleep 
(cf. Espie et al., 2012), with improvements being observed over the months when the 
trial was conducted [i.e. late winter (Feb) through to spring (May)].              
          In conclusion, this work indicates that online CBT for insomnia disorder modifies 
sleep-related attributions, night-time thought content and psychopathology, over and 
above a placebo intervention, and that these changes are associated with improvements 
in global sleep quality. The trial design applied herein raises the bar for what should be 
considered the “gold standard” in determining the true benefits of online CBT-I 
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interventions.    
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Figure 1. Flow of Participants in the Trial 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potentially eligible (n=1342) 
Excluded: failed screening (n=64) 
♦ physical health problem (n=11) 
♦ mental health problem (n=8) 
♦ daytime sleepiness or other sleep problem (n=15)  
♦ sub-clinical insomnia: SE ≥80% on sleep diary (n= 20) 
♦ other: e.g. moved to different time zone, shift work, family 
illness (n=10)  
 
Analyzed (n=55) 
 
 
 
Status 
♦ completed ≥ 4 sessions (n=47)  
♦ completed all sessions (n=43) 
♦ completed 8-week follow-up (n= 40) 
♦ known reasons for being lost to follow up [technical 
problems, illness in family] 
 
Allocated to CBT (n=55) 
♦ received allocated intervention (n=53) 
♦ did not receive allocated intervention (n=2) [never 
logged on (n=2)] 
 
Status 
♦ completed ≥ 4 sessions (n=48) 
♦ completed  all sessions (n=41) 
♦ completed 8-week follow-up (n= 38) 
♦ known reasons for being lost to follow up[internet 
connection problems (x2), pregnancy, ill-health] 
 
Allocated to IRT (n=55) 
♦ received allocated intervention (n=52) 
♦ did not receive allocated intervention (n=3) [withdrawal 
due to pregnancy (n=1), never logged on (n=2)] 
Analyzed (n= 55) 
 
 
 
Allocation  
Analysis 
Post-treatment and Follow Up 
Randomized (n= 164) 
Enrollment 
Allocated to TAU (n=54) 
♦ received allocated intervention (n= 51) 
♦ did not receive allocated intervention (n=3) [withdrawal 
due to bereavement (n=1), never logged on (n=2)] 
 
Status                                                                      
♦ completed post-treatment (n=47) 
♦ completed 8-week follow-up (n= 47) 
♦ no known reasons for being lost to follow up 
 
 
Analyzed (n=54) 
 
Consented to further screening (n=276) 
Excluded: no response to contact (n= 1066) 
 
Completed further screening (n=228) 
Excluded: no response to contact (n= 48) 
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Table 1: Demographic and clinical characteristics of participants (n=164) 
 
Characteristic 
 
 
CBT (n = 55) 
 
 
IRT (n = 55) 
 
TAU (n = 54) 
 
All (n = 164) 
 
Age, mean (SD), y 50.7 (13.8) 47.3 (13.0) 49.1 (13.7) 49.0 (13.5) 
Gender , No. (%) 
Female 
Male 
 
40 (72.7) 
15 (27.3) 
 
42 (76.4) 
13 (23.6) 
 
38 (70.4) 
16 (29.6) 
 
120 (73.2) 
44 (26.8) 
Occupation, No. (%) 
Employed. Full-time 
Employed, part-time 
Retired 
Student 
Not currently employed 
 
20 (36.4) 
17 (30.9) 
13 (23.6) 
3 (5.45) 
2 (3.64) 
 
25 (45.5) 
12 (21.8) 
8 (14.5) 
3 (5.45) 
7 (12.7) 
 
20 (37.0) 
11 (20.4) 
16 (29.6) 
2 (3.70) 
5 (9.26) 
 
65 (39.6) 
40 (24.4) 
37 (22.6) 
8 (4.88) 
14 (25.5) 
Index of multiple deprivation, mean (SD)a 16.7 (11.3) 18.4 (13.8) 15.2 (10.4) 16.7 (11.8) 
Civil status, No. (%)b 
No Partner 
Partner 
 
20 (36.4) 
35 (63.6) 
 
20 (36.4) 
35 (63.6) 
 
missing 
missing 
 
missing 
missing 
Physical health, No. (%) 
0 Very good 
1 Good 
2 Average 
 
15 (27.3) 
25 (45.4) 
15 (27.3) 
 
13 (23.6) 
26 (47.3) 
16 (29.1) 
 
7 (13.0) 
37 (68.5) 
10 (18.5) 
 
35 (21.3) 
88 (53.7) 
41 (25.0) 
Mental health, No. (%) 
Very good 
Good 
Average 
 
16 (29.1) 
25 (45.4) 
14 (25.5) 
 
11 (21.0) 
23 (41.8) 
21 (38.2) 
 
13 (24.1) 
28 (51.8) 
13 (24.1) 
 
40 (24.4) 
76 (46.3) 
48 (29.3) 
Total wake time, mean (SE), min 
 
124.8 (8.9) 122.9 (5.7) 162.5 (13.4) 136.5 (5.7) 
Hours of sleep, mean (SE), hr 
 
5.1 (0.2) 5.5 (0.2) 4.7 (0.3) 5.1 (0.1) 
Sleep efficiency, mean (SE), % 
 
63.2 (2.1) 65.1 (1.3) 55.6 (2.9) 61.3 (1.3) 
Sleep Condition Indicator, mean (SE) 
 
3.06 (.14) 3.00 (.13) 2.79 (.16) 2.98 (.08) 
Duration of insomnia, No. (%), y 
<2 
2-5 
6-10  
≥11  
 
9 (16.4) 
13 (23.6) 
10 (18.2) 
23 (41.8) 
 
7 (12.7) 
16 (29.1) 
13 (23.6) 
19 (34.6) 
 
6 (11.1) 
5 (9.2) 
9 (16.7) 
34 (63.0) 
 
22 (13.5) 
34 (20.7) 
32 (19.5) 
76 (46.3) 
Type of insomnia. No. (%) 
Difficulty Initiating Sleep 
Difficulty Maintaining Sleep 
Mixed (Initiating/ Maintaining) 
Early Morning Awakening 
Non-Restorative Sleep 
 
1 (1.8) 
26 (47.3) 
22 (40.0) 
4 (7.3) 
2 (3.6) 
 
3 (5.4) 
22 (40.0) 
24 (43.6) 
3 (5.5) 
3 (5.5) 
 
1 (1.9) 
22 (40.7) 
26 (48.1) 
3 (5.6) 
2 (3.7) 
 
5 (3.0) 
70 (42.7) 
72 (43.9) 
10 (6.1) 
7 (4.3) 
a
 These data available only for postcodes in England (n=137) 
bThese data were not collected, in error, from the TAU group 
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Table 2: Treatment outcomes for measures of attribution, thought content and psychopathology. Baseline, post-treatment and follow-
up date [mean (SE)] are presented for each group along with change scores (95% CI) and within group effect sizes (Cohen’s d). 
[SDQ: Sleep Disturbance Questionnaire, GCTI: Glasgow Content of Thoughts Inventory, DASS: Depression, Anxiety, Stress Scale] 
 
 
Variable 
 
Treatment 
Group 
 
Baseline 
Mean (SE) 
 
Post-
treatment 
Mean (SE) 
Change from 
Baseline to Post-
Treatment 
(95% CI) 
 
d 
 
8-wk 
Follow-up 
Mean (SE) 
Change from 
Baseline to 
Follow-up 
(95% CI) 
 
d 
 
SDQ - Unable to relax 
 
CBT 
 
 
5.45 (0.31) 
 
3.60 (0.38) 
 
-1.85 
(-2.57 to  -1.01) 
 
 
-0.73 
 
4.03 (0.41) 
 
-1.42 
(-2.45 to -0.60) 
 
-0.49 
  
IRT 
 
 
6.22 (0.31) 
 
5.90 (0.40) 
 
-0.32 
(-1.17 to 0.27) 
 
 
-0.14 
 
5.64 (0.35) 
 
-0.58 
(-1.61 to 0.70) 
 
-0.22 
  
TAU 
 
 
6.76 (0.33) 
 
6.62 (0.36) 
 
-0.14 
(-1.22 to -0.44) 
 
 
-0.09 
 
6.21 (0.41) 
 
-0.55 
(-1.31 to -0.50) 
 
-0.26 
 
SDQ - Mental arousal 
 
CBT 
 
 
8.38 (0.42) 
 
6.05 (0.52) 
 
-2.33 
(-3.30 to -1.63) 
 
 
-0.86 
 
6.15 (0.53) 
 
-2.23 
(-3.44 to -1.36) 
 
 
-0.69 
  
IRT 
 
 
9.29 (0.35) 
 
8.60 (0.44) 
 
-0.69 
(-1.61 to 0.16) 
 
 
-0.25 
 
7.72 (0.39) 
 
-1.57 
(-2.77 to -1.07) 
 
-0.60 
  
TAU 
 
 
9.80 (0.32) 
 
9.38 (0.35) 
 
-0.42 
(-0.93 to -0.17) 
 
 
-0.32 
 
8.87 (0.43) 
 
-0.93 
(-1.49 to -0.50) 
 
-0.55 
 
SDQ - Lack of routine 
 
CBT 
 
 
5.65 (0.32) 
 
3.74 (0.40) 
 
-1.91 
(-2.69 to -1.31) 
 
 
-0.85 
 
3.65 (0.38) 
 
-2.00 
(-2.71 to -1.34) 
 
-0.93 
  
IRT 
 
 
6.11 (0.34) 
 
5.28 (0.34) 
 
-0.83 
(-1.51 to -0.18) 
 
 
-0.40 
 
4.74 (0.34) 
 
-1.37 
(-1.85 to -0.62) 
 
-0.72 
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TAU 
 
 
5.91 (0.29) 
 
5.49 (0.32) 
 
-0.42 
(-1.03 to 0.06) 
 
 
-0.22 
 
5.23 (0.36) 
 
-0.68 
(-1.28 to -0.81) 
 
-0.33 
 
SDQ – Trying too hard 
 
CBT 
 
6.25 (0.35) 
 
 
3.67 (0.42) 
 
-2.68 
(-3.47 to -2.11) 
 
 
-1.22 
 
3.53 (0.45) 
 
-2.72 
(-3.66 to -2.09) 
 
-1.11 
  
IRT 
 
 
7.24 (0.33) 
 
6.40 (0.43) 
 
-0.84 
(-1.82 to -0.27) 
 
 
-0.34 
 
5.90 (0.40) 
 
-1.34 
(-2.44 to -0.74) 
 
-0.51 
  
TAU 
 
 
6.74 (0.35) 
 
6.11 (0.37) 
 
-0.63 
(-1.07 to -0.78) 
 
 
-0.37 
 
5.96 (0.39) 
 
-0.78 
(-1.32 to -0.24) 
 
-0.43 
 
GCTI – Rehearsal and 
planning  
 
CBT 
 
 
7.00 (0.39) 
 
5.60 (0.44) 
 
-1.40 
(-2.39 to -0.86) 
 
 
-0.56 
 
5.43 (0.52) 
 
-1.57 
(-2.78 to -0.82) 
 
-0.51 
  
IRT 
 
 
7.78 (0.36) 
 
7.35 (0.40) 
 
-0.43 
(-0.86 to 0.51) 
 
 
-0.20 
 
6.56 (0.42) 
 
-1.22 
(-1.96 to -0.87) 
 
-0.42 
  
TAU 
 
 
8.09 (0.32) 
 
7.94 (0.37) 
 
-0.15 
(-0.84 to 0.08) 
 
 
-0.10 
 
7.89 (0.43) 
 
-0.20 
(-0.92 to 0.28) 
 
-0.10 
 
GCTI - Sleep and 
sleeplessness 
 
CBT 
 
 
7.53 (0.36) 
 
4.65 (0.48) 
 
-2.88 
(-3.94 to -2.34) 
 
 
-1.10 
 
4.05 (0.49) 
 
-3.48 
(-4.62 to -2.68) 
 
-1.14 
  
IRT 
 
 
8.25 (0.33) 
 
6.98 (0.41) 
 
-1.27 
(-2.07 to -0.58) 
 
 
-0.55 
 
6.23 (0.38) 
 
-2.02 
(-2.89 to -1.32) 
 
-0.83 
  
TAU 
 
 
7.89 (0.35) 
 
7.47 (0.40) 
 
-0.42 
(-0.95 to 0.01) 
 
 
-0.26 
 
7.32 (0.42) 
 
-0.57 
(1.35 to 0.11) 
 
-0.23 
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GCTI – Heightened 
awareness  
CBT 
 
4.69 (0.29) 3.42 (0.34) -1.27 
(-1.80 to -0.48) 
 
-0.59 3.33 (0.34) -1.36 
(-2.02 to -0.57) 
-0.60 
  
IRT 
 
 
5.16 (0.29) 
 
4.78 (0.37) 
 
-0.38 
(-1.06 to 0.21) 
 
 
-0.19 
 
4.00 (0.30) 
 
-1.16 
(-1.83 to -0.53) 
 
-0.57 
  
TAU 
 
 
5.87 (0.33) 
 
5.81 (0.23) 
 
-0.06 
(-0.86 to 0.30) 
 
 
-0.03 
 
5.64 (0.22) 
 
-0.23 
(-1.01 to 0.21) 
 
-0.11 
 
 
 
DASS - Depression 
 
 
CBT 
 
4.98 (0.40) 
 
3.38 (0.42) 
 
-1.60 
(-0.79 to -2.41) 
 
-0.54 
 
2.30 (0.35) 
 
-2.68 
(-1.08 to -3.55) 
 
-0.85 
  
IRT 
 
 
4.81 (0.41) 
 
4.04 (0.43) 
 
-0.77 
(-0.12 to -1.42) 
 
-0.33 
 
3.81 (0.46) 
 
-1.00 
(-0.21 to -1.79) 
 
-0.35 
  
TAU 
 
 
5.53 (0.46) 
 
4.53 (0.45) 
 
-1.00 
(-0.14 to -1.86) 
 
-0.33 
 
5.47 (0.64) 
 
-0.06 
(0.93 to -1.05) 
 
-0.02 
 
DASS - Anxiety 
 
CBT 
 
 
2.32 (0.27) 
 
1.74 (0.31) 
 
-0.58  
(-0.19 to -0.98) 
 
-0.40 
 
1.34 (0.21) 
 
-0.98 
(-0.50 to -1.46) 
 
-0.56 
  
IRT 
 
 
2.63 (0.30) 
 
2.48 (0.29) 
 
-0.15 
(0.36 to -0.67) 
 
-0.08 
 
2.04 (0.26) 
 
-0.59 
(-0.13 to -1.06) 
 
-0.36 
  
TAU 
 
 
3.29 (0.35) 
 
2.98 (0.36) 
 
-0.31 
(0.32 to -0.95) 
 
-0.14 
 
2.92 (0.38) 
 
-0.37 
(0.22 to -0.96) 
 
-0.18 
 
DASS - Stress 
 
CBT 
 
 
7.25 (0.53) 
 
5.04 (0.54) 
 
-2.21 
(-1.31 to -3.10) 
 
-0.68 
 
4.36 (0.47) 
 
-2.89 
(-1.97 to -3.80) 
 
-0.87 
  
IRT 
 
 
8.31 (0.51) 
 
7.13 (0.48) 
 
-1.17 
(-0.45 to -1.89) 
 
-0.46 
 
6.85 (0.48) 
 
-1.46 
(-0.58 to -2.34) 
 
-0.46 
  
TAU 
 
 
8.08 (0.51) 
 
7.27 (0.50) 
 
-0.81 
(0.12 to -1.73) 
 
-0.25 
 
7.45 (0.56) 
 
-0.63 
(0.27 to -1.52) 
 
-0.20 
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Table 3: Relative effect sizes (Cohen’s d) for each treatment group comparison (CBT-TAU, IRT-
TAU, CBT-IRT) at post-treatment and follow-up for the SDQ (Sleep Disturbance Questionnaire), 
GCT (Glasgow Content of Thoughts Inventory) and DASS (Depression, Anxiety, Stress Scale)  
 
 
 
 
Relative effect size (d)  
Pre-treatment to post-treatment 
 
 
Relative effect size (d)  
Pre-treatment to 8-wk Follow-up 
 
 
Variable 
 
CBT-TAU 
 
 
IRT-TAU 
 
CBT-IRT 
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-0.62 
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0.08 
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-0.26 
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-0.44 
 
-0.26 
 
 
 
 
 Dissemination of evidence-based practice relating to insomnia 
Insomnia: A Clinical Guide to Assessment and Treatment. Kluwer Academic/ Plenum 
Publishers, New York, 2003 
Overcoming Insomnia and Sleep Problems: A Self-Help Guide Using Cognitive 
Behavioral Techniques. Constable & Robinson Ltd., London, 2006 
International Neurology: A Clinical Approach. Wiley-Blackwell, Oxford, pp. 554-556, 
2009 
New Oxford Textbook of Psychiatry (Vol. 2) (second edition) Oxford University Press, 
Oxford, England pp. 933-938, 2009 
Principles and Practice of Sleep Medicine, 5th edition. Elsevier Saunders, NY, 2011 
Introduction to Coping with Insomnia & Sleep Problems.  Constable & Robinson Ltd., 
London, 2011 
The Oxford Handbook of Sleep and Sleep Disorders (Oxford Library of Psychology) 
Oxford University Press, USA [928 pages], 2012  
 www.sleepio.com 
 
  
 
Morin C.M and Espie, C.A. (2003) Insomnia: A Clinical Guide to Assessment and 
Treatment. Kluwer Academic/ Plenum Publishers, New York [ISBN 0-306-47750-5] 
 
 
 
  
 
Espie, C.A. (2006) Overcoming Insomnia and Sleep Problems: A Self-Help Guide 
Using Cognitive Behavioral Techniques. Constable & Robinson Ltd., London 
[ISBN13: 978-184529-070-2/ ISBN10: 1-84529-070-4] 
 
 
 
UN
CO
RR
EC
TE
D 
PR
OO
F
Copy edited by Julie Musk
Chapter 142
Insomnia
Colin A. Espie1 and Delwyn J. Bartlett2,3
1University of Glasgow Sleep Centre, Scotland, UK
2Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia
3Royal Prince Alfred Hospital, Sydney, Australia
International Neurology: A Clinical Approach. Edited by  Robert P. Lisak, 
Daniel D. Truong, William Carroll, and Roongroj Bhidayasiri. © 2009 
Blackwell Publishing, ISBN: 978-1-4051-5738-4.
554
Introduction
Insomnia is frequently observed in a number of  medical, 
neurological, and psychiatric disorders, representing
a considerable public health concern. Insomnia is the 
repeated diffi culty in initiating sleep (greater than 
30 minutes), maintaining sleep (greater than 30 minutes), 
or waking early, which is chronically non-restorative 
despite adequate sleep opportunity. Within the neuro-
logical fi eld, insomnia may present as a hypersomnia 
such as narcolepsy and/or as a sleep-related movement 
disorder including restless legs syndrome (RLS) and 
period limb movement (PLM) (Table 142.1).
Epidemiology
Insomnia affects one-third of adults occasionally, and 
9–12% on a chronic basis. It is more commonly reported 
in women, shift workers, and patients with medical 
and psychiatric disorders. Among older adults, preva-
lence has been estimated at 25%, although co-morbid con-
ditions and hypnotic drugs are factors in this increased 
prevalence.
Pathophysiology
Sleep disruption is often unreported until insomnia is 
well established. It is unclear whether the physiological
changes associated with insomnia precede onset or 
are a consequence. High-frequency electroencephalo-
gram (EEG) activity is exaggerated in individuals with 
insomnia. These fi ndings suggest a central nervous 
 system arousal, supporting previous research that 
found increased cortisol and adrenocorticotrophic 
hormones. This could also refl ect an adaptation to 
poor quality sleep, as objective performance is not 
necessarily impaired.
Clinical features
Subjectively, sleep is non-restorative and daytime func-
tioning is impaired. Individuals are overwhelmingly 
concerned about sleep onset, returning to sleep, and the 
unpredictability of sleep. Severity is judged by frequency 
(three or more times per week), with a minimum duration 
of 1 month. The clinical presentation is commonly one of 
a frustrated patient trapped in a vicious circle of anxiety 
and poor sleep, reporting having “tried everything,” and 
generally unable to “down-regulate” arousal levels at 
bedtime.
Insomnia also causes daytime impairments, including 
fatigue, inattention, and mood changes, with anxiety and 
irritability. Less frequently, cognitive and performance 
abilities may be affected. The presence of excessive day-
time sleepiness (EDS) is unusual in insomnia. When EDS 
is a prominent complaint, investigations for other sleep 
disorders should be considered, including obstructive 
sleep apnea syndrome (OSA), narcolepsy, periodic limb 
movement disorder (PLM), and restless legs syndrome 
(RLS). Additionally, head injury or depression may be 
causes of EDS.
Insomnias due to a drug or substance can include 
hypnotic dependent sleep disorder – commonly associ-
ated with benzodiazepine (BZ) drugs, where withdrawal 
exacerbates the primary problem, reinforcing hypnotic 
dependency. Psychiatric conditions, particularly affective
disorders, have associated sleep symptomatology. When
the diagnostic criteria for DSM-IV Axis I or Axis II 
 disorders are fulfi lled, a primary diagnosis of psycho-
physiological insomnia cannot be made. Sleep distur-
bances often precede depression, being an independent 
risk factor for a fi rst episode or recurrence of depression. 
Insomnia due to medical conditions arises from an iden-
tifi ed medical cause (orthopedic, neurologic, pulmonary, 
cardiac, etc.) and may vary with the condition. The natu-
ral history of insomnia is not clear. It is known that sleep 
quality is reduced with increasing age. Circadian rhythm 
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disorders, shift work, parasomnias, and inadequate sleep 
hygiene can all be triggers for insomnia.
Investigations
A thorough history incorporating questions regarding 
mood, lifestyle, restlessness, limb movements, and breath-
ing is important. Sleep diary monitoring is a useful form 
of assessment in addition to questionnaires on beliefs and 
moods. Wrist actigraphy estimates sleep-wakefulness 
based upon body movement for up to 10 consecutive 
24-hour periods and can identify paradoxical insom-
nia, along with circadian anomalies. Polysomnography 
(PSG) is undertaken only when another sleep disorder is 
suspected.
Treatment and management
Drug therapy
BZ compounds superseded barbiturates and, although 
effective short term, were found to cause potential prob-
lems with administration tolerance and withdrawal. 
Contemporary hypnotic therapy includes BzRAs (“z” 
drugs) and, more recently, melatonin receptor agonists 
(MeRAs), which have yet to become established. BzRAs 
offer fewer adverse effects; however, long-term effective-
ness is less clear. Increasingly (off-label) sedative anti-
depressants are being used.
Melatonin, the pineal hormone, triggers sleep onset by 
lowering core body temperature and is a useful chrono-
biotic for reducing sleep latency in delayed sleep phase 
syndrome (DSPS).
Psychological and behavioral therapy
Psychological treatment with cognitive behavioral ther-
apy (CBT) has demonstrated large-effect size changes 
in primary outcomes and is maintained at long-term 
follow-up. CBT is also effective in general practice and 
can be adapted for other settings.
Management strategies
Educating the patient about sleep is an important aspect 
of treating insomnia. Understanding what sleep is, how 
sleep changes with age, good sleep hygiene practices 
(reducing caffeine and alcohol, etc.), and some facts about 
sleep loss are starting points for self-management.
Bright light is a potent marker for human circadian 
rhythm, resetting sleep-times in advanced sleep phase 
syndrome (ASPS) and DSPS. Sleep initiation insomnia 
is improved with morning light and avoidance of 
evening light.
Exercise can positively infl uence sleep quality, par-
ticularly in the late afternoon or early evening. Morning 
exercise with light exposure suppresses melatonin, 
enhancing circadian rhythm and setting a constant 
waking time. Sleeping in a safe environment includes 
minimizing disruption from external factors (heating, 
noise, violence, others) and internal factors relating to 
previous experiences.
Stimulus control
Stimulus control is a reconditioning treatment forcing 
 discrimination between daytime and sleeping environ-
ments. For the poor sleeper, the bedroom triggers 
associations with being awake and aroused. Treatment 
involves removing all stimuli that are potentially sleep-
incompatible (reading and watching television) and 
excluding sleep from living areas. The individual is 
instructed to get up if not asleep within 15–20 minutes or 
when wakeful during the night.
Table 142.1 Diagnosis and differentiation of the insomnias – International Classifi cation of Sleep Disorders (ICSD-2).
Classification Sleep disorder Essential features
Complaint of insomnia plus ⁄
Insomnias Psychophysiological insomnia Learned sleep-preventing associations, conditioned arousal, ‰racing mind„ phenomenon
Paradoxical insomnia Complaint of poor sleep disproportionate to sleep pattern and sleep duration 
Idiopathic insomnia Insomnia typically begins in childhood or from birth
Insomnia due to a mental disorder Course of sleep disturbance concurrent with mental disorder
Inadequate sleep hygiene Daily living activities inconsistent with maintaining good-quality sleep
Insomnia due to a medical disorder Course of sleep disturbance concurrent with mental disorder
Insomnia due to drug or substance Sleep disruption caused by prescription medication, recreational drug, caffeine, alcohol or 
foodstuff
Adjustment insomnia Presence of identifiable stressor; insomnia resolves or is expected to resolve when stressor 
is removed
Lisak_C142.indd   555 2/27/2009   10:03:18 AM
UN
CO
RR
EC
TE
D 
PR
OO
F
556    Part 17 Sleep disorders 
Copy edited by Julie Musk
Sleep restriction therapy
Sleep restriction relates to the ratio of time asleep with 
time in bed, and involves recording average nightly sleep 
duration. The aim is to slowly reduce time in bed to match 
recorded sleep duration, increasing sleep effi ciency and 
confi dence.
Cognitive control
Intrusive thoughts need to be addressed before bedtime. 
Setting aside 15–20 minutes before bedtime to rehearse 
the day and to plan for tomorrow allows the day to be put 
to rest. Thought-stopping attempts to interrupt the fl ow 
of thoughts via “blocking” techniques, such as repeating 
the word “the” every 3 seconds, occupy the short-term 
memory store (used in processing information), poten-
tially allowing sleep to happen. Cognitive restructuring 
challenges faulty beliefs that help maintain both wakeful-
ness and helplessness.
Relaxation methods include progressive relaxation, 
imagery training, biofeedback, meditation, hypnosis, and 
autogenic training, with little evidence to indicate supe-
riority of any one approach. At the cognitive level, these 
techniques may act by distraction.
Paradoxical intention
Attempting to remain wakeful rather than “trying” to 
fall asleep (decatastrophizing technique) strengthens the 
sleep drive and reduces performance effort.
Treatment of insomnia should include assessment for 
known extrinsic causes of certain sleep disorders includ-
ing alcohol, stimulants, and proprietary drugs, which 
interfere with sleep. Individuals need to be encouraged 
to seek advice early rather to than self-administer treat-
ment. Avoiding the use of hypnotic agents would sub-
stantially reduce the number of iatrogenic cases of chronic 
insomnia.
Further reading
ICSD. The International Classifi cation of Sleep Disorders Revised: 
Diagnostic and Coding Manual. American Sleep Disorders 
Association; 2005.
Morin C, Espie C. Insomnia: A Clinical Guide to Assessment and 
Treatment. New York: Kluwer Academic/Plenum; 2003.
NIH. State-of-the-Science Conference Statement on Manifestations 
and Management of Chronic Insomnia in Adults. State-of-the-
Science Conference; 2005.
Perlis M, Lichstein K. Treating Sleep Disorders: Principles and Practice 
of Behavioral Sleep Medicine. Chichester: Wiley; 2003.
Smith M, Perlis M, Park A, et al. Comparative meta-analysis of 
pharmacotherapy and behavior therapy for persistent insomnia. 
Am J Psychiatr 2002; 159: 5–11.
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4.14.2
Introduction
Most people’s experiences of poor sleep are memorable, because 
sleeplessness and its daytime consequences are unpleasant. There 
are those, however, for whom insomnia is the norm. Persistent and 
severe sleep disturbance affects at least one in 10 adults and one in 
fi ve older adults, thus representing a considerable public health 
concern. Sleep disruption is central to a number of medical and 
psychiatric disorders, and insomnia is usually treated by general 
practitioners. Therefore differential diagnosis is important, and 
respiratory physicians, neurologists, psychiatrists, and clinical 
psychologists need to be involved. The purpose of this chapter is 
to summarize current understanding of the insomnias, their 
appraisal, and treatment. Particular emphasis will be placed upon 
evidence-based practical management.
Clinical features
Insomnia often remains unreported, and fi nally presents when a 
poor sleep pattern is well established. Alcohol has long been a fi rst-
line self-administered sleep aid, and recent years have seen an 
increasing use of ‘over-the-counter’ preparations and ‘self-help’ 
strategies. The clinical presentation is commonly of a frustrated 
patient, trapped in a vicious circle of anxiety and poor sleep, who 
reports having ‘tried everything’.(1,2)
There may be concern about the pattern of sleep. This is the most 
quantifi able aspect of self-report relating to, for example, length of 
time taken to fall asleep, frequency and duration of wakenings, or 
total amount of sleep. A poorly established sleep pattern can lead to 
unpredictability of what sleep will be like on any given night. 
Patients often report poor quality of sleep, and subjective perceived 
quality can be a critically important outcome variable. Typical 
reports relate to light sleep and sleep felt to be unrestorative. 
Although it may be unclear how such complaints relate to EEG 
sleep architecture, the clinician should not overlook qualitative 
report as it may refl ect underlying pathophysiology. Concerns are 
normally expressed also about the daytime effects of poor sleep. 
These can be cognitive effects, such as fatigue, sleepiness, inatten-
tion, and some impairments in performance, or emotional effects, 
such as irritability and anxiety.(2)
Classiﬁ cation
The International Classifi cation of Sleep Disorders (second edition: 
ICSD-2)(3) was published in 2005 and provides the most compre-
hensive account of sleep disorders, both for descriptive purposes 
and for differential diagnosis (see Chapter 4.14.1). ICSD-2 describes 
insomnias as disorders of initiating and maintaining sleep. Patients 
may have either sleep-onset problems or wakenings from sleep, 
or both of these. Table 4.14.2.1 summarizes the principal classi-
fi cations that relate to the insomnias, along with some other sleep 
disorders where patients commonly present with insomnia 
symptoms. As can be seen, concomitant symptomatology, potential 
aetiological factors, and sleeplessness require careful assessment in 
order to reach a valid diagnosis.
Diagnosis and differential diagnosis
Severity of insomnia is judged along dimensions of frequency, 
intensity, and duration, as well as impact on daytime functioning 
and quality of life. Generally, the criteria for severe and chronic 
insomnia are a minimum duration of 6 months with problems 
presenting three or more nights per week. Restlessness, irritability, 
anxiety, daytime fatigue, and tiredness commonly accompany such 
presentations.(2) Mild and moderate insomnia may be diagnosed 
where problems are less intrusive.
Most patients presenting with insomnia have psychophysiologi-
cal diffi culty initiating and/or maintaining sleep. Usually marked 
functional effects and somatized tension associated with sleep are 
evident. The patient reports extreme tiredness while being unable 
to sleep satisfactorily and appears preoccupied with sleep and its 
consequences. This contrasts, for example, with the circadian 
disorders where, in delayed sleep-phase type, the patient may not 
feel sleepy until late in the normal sleep period, and in advanced 
sleep-phase type, may waken early and be unable to return to sleep. 
Taking a history, incorporating screening questions on restlessness, 
limb movements, and breathing can help to diagnose obstructive 
sleep apnoea syndrome, periodic limb movement disorder, and 
restless legs syndrome, although full polysomnographic evaluation 
may also be required.(4) However, polysomnography is not essential 
for the diagnosis of insomnia, for which sleep diary monitoring 
(see Chapter 4.14.1) is usually the most useful form of assessment.(2) 
Wrist actigraphy is an inexpensive objective evaluation, which 
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estimates sleep/wakefulness based upon body movement.(5) 
Continuous recordings can be made over 5 to 10 consecutive 24-h 
periods. It is useful in identifying paradoxical insomnia, and charted 
data can be inspected for circadian anomalies.
Other causes of insomnia are reported in Table 4.14.2.1 and 
should not be overlooked. In particular, insomnias due to a drug 
or substance can include hypnotic-dependent sleep disorder, asso-
ciated most commonly with benzodiazepine (BZ) drugs where 
withdrawal leads to exacerbation of the primary problem.(6) This 
can be mistaken for a severe underlying insomnia and hence rein-
force hypnotic dependency. Likewise, a wide range of psychiatric 
conditions, particularly affective disorders, has associated sleep 
symptomatology (see Chapter 4.14.1). A primary diagnosis of 
psychophysiological insomnia cannot be made where diagnostic 
criteria for DSM-IV Axis I or Axis II disorders are fulfi lled. However, 
it is very important to note that sleep disturbance often precedes 
depression. The bulk of the psychiatric epidemiological data 
indicate that insomnia is an independent risk factor for fi rst 
episode depressive illness, and for recurrence of depression, in 
adults of all ages.(7,8) Insomnia should not be assumed to be simply 
a symptom of underlying depression, even when depression is 
present. Unless the illness courses clearly co-vary it is best to make 
a diagnosis of co-morbid insomnia. Similar caveats apply to insomnia 
associated with medical disorders, both in terms of identifying a 
primary illness, and concluding that insomnia has the status of an 
associated/ co-morbid disorder (see Chapter 4.14.1).
Epidemiology
Insomnia affects one-third of adults occasionally, and 9 to 12 per 
cent on a chronic basis. It is more common in women, in shift 
workers, and in patients with medical and psychiatric disorders. 
Prevalence amongst older adults has been estimated at up to 25 per 
cent and sleepiness and hypnotic drugs are risk factors for injury 
and fracture.(9) The decline in prescription of anxiolytics has 
been greater than the rate of decline for hypnotics [taking BZ 
and benzodiazepine receptor agonists (BzRAs) together]. 
Furthermore, there is increasing use of (off-label) sedative anti-
depressants primarily to treat insomnia.
Aetiology
Many patients report having been marginal light sleepers before 
developing insomnia.(4) Sleep disturbance often arises during life 
change or stress, and such adjustment sleep disorder may represent 
a normal transient disruption of sleep. However, secondary factors, 
such as anxiety over sleep and faulty sleep–wake conditioning, may 
exacerbate and maintain the insomnia as a chronic problem when 
sleep itself becomes a focus for concern. People with insomnia may 
be hyperaroused relative to normal sleepers, for example having 
higher levels of cortisol and ACTH, and also fi nd it diffi cult to 
‘down-regulate’ their arousal at bedtime.(2,10,11)
Course and prognosis
There has been little research on the natural course of insomnia. 
However, untreated psychophysiological insomnia can last for 
decades, and may gradually worsen over time. Indeed, there is a 
developmental trend for sleep pattern to deteriorate, with increasing 
age. On the other hand, delayed sleep-phase syndrome and insuf-
fi cient sleep hygiene can be associated with lifestyle problems and 
may ameliorate as these are resolved. Although certain insomnias 
tend to persist if untreated, prognosis with effective treatment can 
be very good.
Treatment
A review of the evidence
(a) Drug therapy
Traditionally, insomnia has been treated pharmacologically. 
Barbiturates were superseded by BZ compounds during the 1960s 
and 1970s. These drugs were safer in overdose, were thought to 
have fewer side effects, and to be less addictive. Controlled studies 
have demonstrated that a considerable number of BZ, of short to 
Table 4.14.2.1 The classiﬁ cation and differential diagnosis of the insomnias within ICSD-2
Classiﬁ cation Sleep disorder Essential features, complaint of insomnia plus
Insomnias Psychophysiological insomnia
Paradoxical insomnia
Idiopathic insomnia
Insomnia due to a mental disorder
Inadequate sleep hygiene
Insomnia due to a medical disorder
Insomnia due to drug or substance
Adjustment insomnia
Learned sleep preventing associations, conditioned arousal, ‘racing mind’ phenomenon
Complaint of poor sleep disproportionate to sleep pattern and sleep duration
Insomnia typically begins in childhood or from birth
Course of sleep disturbance concurrent with mental disorder
Daily living activities inconsistent with maintaining good-quality sleep
Course of sleep disturbance concurrent with mental disorder
Sleep disruption caused by prescription medication, recreational drug, caffeine, alcohol or foodstuff
Presence of identiﬁ able stressor, insomnia resolves or is expected to resolve when stressor is removed
Sleep-related 
breathing disorders
Obstructive sleep apnoea syndrome 
Periodic limb movement disorder 
Restless legs syndrome
Excessive sleepiness, obstructed breathing in sleep, associated symptoms include snoring and a 
dry mouth
Episodes of repetitive, highly stereotyped limb movements occurring in sleep
Strong, nearly irresistible urge to move legs relieved by walking
Circadian rhythm 
sleep disorders
Delayed sleep phase type
Advanced sleep-phase type
Phase delay of major sleep episode, initial insomnia, excessive sleepiness in morning
Phase advance of major sleep episode, inability to stay awake in evening, early wakening
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intermediate half-life, are effective hypnotic agents. However, from 
the mid-1970s potential problems became apparent, both during 
administration and withdrawal. Longer-acting hypnotics were 
prone to carry-over effects of morning lethargy, and shorter-acting 
drugs to ‘rebound insomnia’.(6) Furthermore, tolerance develops, 
leading either to increased dosing or switching to alternative 
medication. Although BZs used for short periods/intermittently 
can maintain effectiveness, these are not the treatment of choice in 
chronic insomnia,(12) and are contraindicated in older adults and 
where insomnia may involve sleep-related breathing disorder 
because of their potentially depressant effects on respiration. 
A number of BZ compounds have been removed from the market 
in the United Kingdom, United States, and elsewhere.
Contemporary hypnotic therapy has extended to include BzRAs 
(often referred to as the ‘z’ drugs), and more recently melatonin 
receptor agonists (MeRAs) have been introduced. Whereas the 
place in therapeutics of MeRAs has yet to become established, the 
BzRAs are often thought to offer more sustained benefit for 
insomnia, and to have fewer adverse effects. Nevertheless, there 
remains uncertainty about the effectiveness of BzRAs in chronic 
insomnia.(13)
(b) Psychological therapy
Psychological treatment for chronic insomnia, primarily in the 
form of cognitive–behavioural therapy (CBT), has been extensively 
investigated in over 100 controlled studies during the past 20 years. 
Five meta-analyses and numerous systematic reviews have 
demonstrated that CBT is associated with large effect size changes 
(measured in standardized z scores) in the primary symptom 
measures of sleep latency (diffi culty getting to sleep) and wake time 
after sleep-onset (diffi culty remaining asleep).(14,15) Around 70 per 
cent of patients with persistent sleep problems appear to benefi t 
from CBT and effects are maintained to long-term follow-up. It is 
thought that CBT achieves these outcomes because it tackles 
directly the dysfunctional thoughts and maladaptive behaviours 
that otherwise maintain insomnia. Recent controlled studies have 
shown that CBT may be effective in general practice settings 
with nurses delivering the intervention according to a standard 
protocol.(16,17) Despite the superior effi cacy of CBT relative to 
medication for insomnia, and these recent demonstrations of CBT 
working in real-world settings, practical problems remain in 
making CBT widely available.
Within the CBT model, a number of strategies have strong 
empirical support. Behavioural procedures such as stimulus 
control and sleep restriction, and cognitive strategies such as para-
doxical intention and thought restructuring have been extensively 
investigated(2,14,15) and are outlined briefl y below.
(c) Melatonin, light therapy, and exercise
The pineal hormone melatonin has been the subject of highly 
publicized claims. However, scientifi c research has been limited. 
Several controlled studies support its sleep-promoting effects, but 
the use of melatonin continues to be controversial. At best it may 
be useful as a chronobiotic for reducing sleep latency.(18) Several 
MeRA products are currently under formal evaluation, so more 
data may be available soon.
Bright light is a potent marker for human circadian rhythms, 
and has been known for some time to enable the resetting of 
such rhythms in advanced sleep-phase syndrome and delayed 
sleep-phase syndrome.(19) The results of studies investigating the 
effi cacy of bright light against psychological treatments for psycho-
physiological insomnia are awaited. A limiting factor to the value 
of light therapy is that continued treatment may be required to 
maintain therapeutic effects.
Athletic people sleep well, although this may be more to do with 
behavioural patterning than aerobic fi tness. Nevertheless, there is 
evidence that exercise can have positive effects upon sleep quality, 
particularly if taken late afternoon or early evening, and in other-
wise relatively fi t individuals.(20) Morning exercise can also be an 
effective modality to encourage the same waking time and early 
morning light exposure; which help to reset sleep patterns on a 
daily basis
Advice about management
(a) General perspective
Non-pharmacological treatment using CBT procedures should be 
preferred over pharmacological treatment, in cases of severe persis-
tent insomnia. Hypnotic agents should be recommended mainly 
for short term or occasional use, although longer-term trial data 
are now becoming available. The practitioner should be aware of 
morning-after effects, and potential problems of withdrawal and 
dependency, not only with BZs but also possibly with BzRAs. 
Psychological intervention may also facilitate reduction or discon-
tinuation of medication in hypnotic-dependent person with 
insomnias.(21) There is limited support for the use of melatonin 
or exercise as treatments of choice, although light therapy seems 
effective for circadian disorders.
(b) Using cognitive–behavioural therapies
Brief descriptions of effective management strategies are presented 
in Tables 4.14.2.2 and 4.14.2.3. The following text provides 
explanation of underlying psychological models and further 
information on implementation.
(i) Sleep education and sleep hygiene
The simple provision of information ameliorates the sense of 
being out of control. Inaccurate attributions are challenged and 
misunderstandings corrected by understanding what sleep is, how 
Table 4.14.2.2 Summary description of sleep hygiene and education 
components for the treatme nt of chronic insomnia
Components of sleep education
The need for sleep and its functions
Sleep patterns across the lifespan
Sleep as a process with stages/phases
Factors adversely affecting steep
The effects of sleep loss
The concept of insomnia
Measuring sleep and sleep problems
Components of sleep hygiene treatment
Bedroom comfortable for sleep
Regular exercise, timing, and ﬁ tness
Stable and appropriate diet
Undesirable effects of caffeine and other stimulants
Moderation of alcohol consumption
Other common ‘self-help’ strategies
4.14.2 insomnias
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common insomnia can be, how sleep changes with age, good sleep 
hygiene practices, and some facts about sleep loss. Similarly, 
sleep hygiene provides patients with a starting point for self-
management. These techniques are best construed as introductory 
but they will not of themselves treat insomnia effectively.
(ii) Stimulus control treatment
Stimulus control increases the bedroom’s cueing potential for sleep. 
For good sleepers, the pre-bedtime period and the stimulus envi-
ronment trigger positive associations of sleepiness and sleep. For 
the poor sleeper, however, the bedroom triggers associations with 
restlessness and lengthy night-time wakening via a stimulus-
response relationship, thereby continuing to promote wakefulness 
and arousal. The model is similar to phobic conditions where a 
conditioned stimulus precipitates an anxiety response.
Treatment involves removing from the bedroom all stimuli 
which are potentially sleep-incompatible. Reading and watching 
television, for example, are confi ned to living rooms. Sleeping is 
excluded from living areas and from daytime, and wakefulness is 
excluded from the bedroom. The individual is instructed to get up 
if not asleep within 15–20 min or if wakeful during the night. 
Conceptually, stimulus control is a reconditioning treatment 
which forces discrimination between daytime and sleeping 
environments.
(iii) Sleep restriction therapy
Sleep restriction restricts sleep to the length of time which the 
person is likely to sleep. This may be equivalent to promoting ‘core 
sleep’ at the expense of ‘optional sleep’. Sleep restriction primarily 
aims to improve sleep efficiency. Since sleep efficiency is the 
ratio of time asleep to time in bed, it can be improved either by 
increasing the numerator (time spent asleep) or by reducing the 
denominator (time spent in bed). People with insomnia generally 
seek the former, but this may not be necessary, either biologically 
or psychologically. Sleep restriction fi rst involves recording in a 
sleep diary and calculating average nightly sleep duration. The aim, 
then, is to obtain this average each night. This is achieved by setting 
rising time as an ‘anchor’ each day and delaying going to bed until 
a ‘threshold time’ which permits this designated amount of sleep. 
Thus, the sleep period is compressed and sleep effi ciency is likely 
to increase. The permitted ‘sleep window’ can then be titrated 
week-by-week in 15 increments in response to sleep effi ciency 
improvements.
(iv) Cognitive control
This technique aims to deal with thought material in advance of 
bedtime and to reduce intrusive bedtime thinking. The person with 
insomnia is asked to set aside 15 to 20 min in the early evening 
to rehearse the day and to plan ahead for tomorrow; thus putting 
the day to rest. It is a technique for dealing with unfi nished 
business and may be most effective for rehearsal, planning, and 
self-evaluative thoughts which are important to the individual 
and which, if not dealt with, may intrude during the sleep-onset 
period.
(v) Thought suppression
Thought-stopping and articulatory suppression attempt to inter-
rupt the fl ow of thoughts. No attempt is made to deal with thought 
material per se but rather to attenuate thinking. With articulatory 
suppression the patient is instructed to repeat, subvocally, the word 
‘the’ every 3 s. This procedure is derived from the experimental 
psychology literature. Articulatory suppression is thought to occupy 
the short-term memory store used in the processing of informa-
tion. The type of material most likely to respond is repetitive 
but non-affect-laden thoughts, not powerful enough to demand 
attention. Additionally, this technique may be useful during the 
night to enable rapid return to sleep.
(vi) Imagery and relaxation
There is a wide range of relaxation methods including progressive 
relaxation, imagery training, biofeedback, meditation, hypnosis, 
and autogenic training, but little evidence to indicate superiority of 
any one approach. Furthermore, there is little evidence to support 
either the presumption that people with insomnia are hyper-
aroused in physiological terms, or that relaxation has its effect 
through autonomic change. At the cognitive level, these techniques 
may act through distraction and the promotion of mastery. During 
relaxation, the mind focuses upon alternative themes such as 
visualized images or physiological responses. In meditation the 
focus is upon a ‘mantra’ and in self-hypnosis upon positive self-
statements. Relaxation may be effective for thought processes that 
are anxiety-based, confused, and which fl it from topic-to-topic.
(vii) Cognitive restructuring
Cognitive restructuring challenges faulty beliefs which maintain 
wakefulness and the helplessness which many people with insom-
nia report. It appears to work through appraisal by testing the 
validity of assumptions against evidence and real-life experience. 
As an evaluative technique, it may be effective with beliefs that are 
irrational but compelling. If such thoughts, for example ‘I am going 
to be incapable at work tomorrow’, are not challenged, they 
will create high levels of preoccupation and anxiety and sleep is 
Table 4.14.2.3 Summary description of cognitive–behavioural 
components for the treatment of chronic insomnia
Components of stimulus control and sleep restriction treatment
Deﬁ ne individual sleep requirements
Establish parameters for bedtime period (threshold time and rising time)
Eliminate daytime napping
Differentiate rest from sleep
Schedule sleep periods with respect to needs
Establish 7 day per week compliance
Remove incompatible activity from bedroom environment
Rise from bed if wakeful (>20 min)
Avoid recovery sleep as ‘compensation’
Establish stability from night to night
Adjust the sleep period as sleep efﬁ ciency improves
Components of cognitive intervention
Identify thought patterns and content that intrude
Address (mis)attributions connecting sleep and waking life
Establish rehearsal/planning time in early evening
Relaxation and imagery training
Distraction and thought blocking
Develop accurate beliefs/attributions about sleep and sleep loss
Challenge negative and invalid thoughts
Eliminate ‘effort’ to control sleep
Motivate to maintain behaviour and cognitive change
Utilize relapse-prevention techniques
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unlikely to occur. With cognitive restructuring, the person 
with insomnia learns alternative responses to replace inaccurate 
thinking.
(viii) Paradoxical intention
Finally, the technique of paradoxical intention is useful in situa-
tions where performance anxiety has developed, that is, where the 
effort to produce a response inhibits that response itself. The para-
doxical instruction is to allow sleep to occur naturally through 
passively attempting to remain quietly wakeful rather than attempt-
ing to fall asleep. Paradox may be regarded as a decatastrophizing 
technique since it appears to act upon the ultimate anxious thought 
(of remaining awake indefi nitely) initially by focusing on and 
enhancing this thought (a habituation model) and then subjecting 
it to appraisal through rationalization and experience. By intend-
ing to remain awake, and failing to do so, the strength of the sleep 
drive is re-established, and performance effort is reduced.
Possibilities for prevention
There is insuffi cient knowledge of the natural course of transient 
sleep disorders. Mention has been made of adjustment sleep disor-
der and of the association of life events and stressors with the onset 
of insomnia. Systematic research is required to establish the ‘setting 
conditions’ for the secondary maintenance of insomnia beyond an 
initial normative reaction to events. Perhaps there is an interaction 
with a predisposing tendency to light sleep, or with introspection 
and worry. The instinct to increase opportunity to sleep (spend 
longer in bed to catch up) when insomnia symptoms develop 
should probably be resisted. If anything it may be better to advise 
patients to limit sleep opportunity so that their pattern knits 
together again more quickly.
The establishment and maintenance of a regular ‘tight’ routine, 
both pre-bedtime and in terms of sleep schedule, seem to be impor-
tant preventive factors. Such chronobehavioural functioning 
can be at risk of disruption by, for example, jet lag, shift work, 
weekend patterns differing from weekday, adolescent lifestyle, 
and retirement. Adherence to, and/or reinstatement of, an adaptive 
pattern seems crucial.
It is important not to underestimate the importance of attitudes 
and beliefs in the presentation of insomnia. Exaggerated or 
emotionally and mentally arousing thoughts should be dealt with 
promptly. Sleep loss can be distressing, but patients should be 
reminded that nature seeks to restore equilibrium. What they need 
to do is to provide the conditions under which sleep can occur 
rather than attempt directly to control the sleep process. 
Expectations are important also, since it is the breach of these 
which generally give rise to anxiety and dysfunctional beliefs about 
sleep requirements. More often than not sleep-related expectations 
are unrealistic and require reappraisal, even more so in older 
adults.
Finally, prevention should be extended to the known extrinsic 
causes of certain sleep disorders. Where alcohol, stimulants, or 
proprietary drugs interfere with sleep and the recovery of the 
normal sleep process, attention should be paid to these factors. 
Better still, patients should be encouraged to seek advice early rather 
than go down the path of self-administered treatment. Avoiding 
the use of hypnotic agents, both in general practice and during 
acute admissions to hospital, would substantially reduce the 
number of iatrogenic cases of chronic insomnia.
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history. A simple conditioning history, wherein a stimulus 
is always paired with a single behavior, yields a high prob-
ability that the stimulus will yield only one response. A 
complex conditioning history, wherein a stimulus is paired 
with a variety of behaviors, yields a low probability that 
the stimulus will yield only one response. In persons with 
insomnia, the normal cues associated with sleep (e.g., bed, 
bedroom, bedtime, etc.) are often paired with activities 
other than sleep. For instance, in an effort to cope with 
insomnia, the patient might spend a large amount of time 
in the bed and bedroom awake and engaging in activities 
other than sleep. The coping behavior appears to the 
patient to be both reasonable (e.g., staying in bed at least 
permits the patients to rest) and reasonably successful 
(engaging in alternative activities in the bedroom some-
times appears to result in cessation of the insomnia). These 
practices, however, set the stage for stimulus dyscontrol, 
the lowered probability that sleep-related stimuli will elicit 
the desired response of sleepiness and sleep. Figure 78-1 
provides as schematic representation of stimulus control 
and stimulus dyscontrol.
Strengths and Weaknesses
The treatment that is derived from stimulus control theory 
is one of the most widely used behavioral treatments, and 
its efficacy has been well established.8-12 The success of the 
therapy, however, is not sufficient evidence to say that 
stimulus dyscontrol is the factor, or one of the factors, 
responsible for predisposition to, the precipitation of, or 
the perpetuation of insomnia.* This is the case because the 
therapy includes active components that are not based 
solely on learning or behavioral theory. For instance, the 
treatment specifies that the patient should spend awake 
time somewhere other than the bed and that the sleep 
schedule should be fixed. These two interventions also 
influence the homeostatic and circadian regulation of sleep. 
Thus, the efficacy of stimulus control therapy does not 
necessarily provide evidence for the stimulus control model. 
In fact, one investigation found that the reverse of stimulus 
control instructions also improved sleep continuity.13
Another limitation of the stimulus control perspective is 
that it focuses solely on instrumental conditioning. That 
is, there are activities that can be engaged in that reduce 
or enhance the probability of the occurrence of sleep. The 
original model does not explicitly delineate how classical 
conditioning might also be an operational factor. That is, 
the regular pairing of the physiology of wake with sleep-
related stimuli might lead to a scenario where sleep-related 
stimuli become conditioned stimuli for wakefulness. This 
latter possibility, although not part of the classical stimulus 
control perspective, is clearly consistent with it.
Up until the late 1990s there were only two models regard-
ing the etiology and pathophysiology of insomnia. The 
relative lack of theoretical perspectives was due to at least 
three factors. First, the widespread conceptualization of 
insomnia as owing directly to hyperarousal may have made 
it appear that further explanation was not necessary. 
Second, the long-time characterization of insomnia as a 
symptom carried with it the clear implication that insom-
nia was not itself worth modeling as a disorder or disease 
state. Third, for those inclined toward theory, the accep-
tance of the behavioral models (i.e., the 3P behavioral 
model and the stimulus control model1,2), and the treat-
ments that were derived from them, might have had the 
untoward effect of discouraging the development of alter-
native or elaborative models.
Since the 1990s there has been a proliferation of theo-
retical perspectives on the etiology and pathophysiology of 
insomnia that includes ten human models* and three 
animal models. In this chapter, six models (Box 78-1) are 
described and critiqued: the classic 3P behavioral model,1 
the stimulus control model,2 and four models that are 
arguably the most influential of the modern perspectives†: 
the neurocognitive model,3 the psychobiological inhibition 
model,4 the Drosophila model,5,6 and the rodent model.7
THE DEFINITION OF INSOMNIA
Currently, insomnia is conceptualized in terms of chronic-
ity, type, and subtype. Chronicity refers to whether the 
insomnia is acute or chronic. Type refers to the forms of 
insomnia that have been identified as distinct nosologic 
entities including (for adults) idiopathic insomnia, psycho-
physiologic insomnia, paradoxical insomnia, insomnia due 
to inadequate sleep hygiene, and insomnia comorbid with 
medical or psychiatric illness. Subtype refers to the insom-
nia phenotype (initial, middle, late, or mixed insomnia). 
The formal definition of these entities, and discussion 
about their orthogonality and clinical utility, may be found 
elsewhere in this volume. What is relevant for the present 
chapter is that these diagnostic distinctions exist and thus 
must be taken into account by the various models; that is, 
each model must indicate which type of insomnia (and 
subtype, if pertinent) is being modeled.
THE STIMULUS CONTROL MODEL
Basic Description
Stimulus control, as originally described by Bootzin,2 is 
based on the behavioral principle that one stimulus may 
elicit a variety of responses, depending on the conditioning 
Models of Insomnia
Michael Perlis, Paul Shaw, Georgina Cano, and Colin Espie
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*A complete listing of theories and models, along with citations, is contained in 
Appendix 1 on the website.
†Although it is difficult to assess which models are the most influential, one 
approach would be based on a citation index metric. Using this index, it does 
indeed appear that the four contemporary models described in this chapter are 
the most influential.
*The conceptual time frame for causality in terms of “predisposition, precipitation, 
and perpetuation” was first articulated as part of the 3P model. It is used in this 
context to illustrate the complexity of modeling what “cause” insomnia.
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determine which, if any, specific stimuli are most associ-
ated with sleep continuity disturbance and whether altera-
tion of these stimuli produces enhanced clinical gains.
THE 3P MODEL
The 3P behavioral model,1 also known as the Spielman 
model, the three-factor model, or the behavioral model is 
the first fully articulated model of insomnia to gain wide-
spread acceptance. The model delineates how insomnia 
occurs acutely and how acute insomnia becomes chronic 
and self-perpetuating. The model is based on the interac-
tion of three factors. The first two factors (the predispos-
ing and precipitating factors) represent a stress-diathesis 
conceptualization of how insomnia comes to be expressed. 
The third factor (the perpetuating factor) represents how 
behavioral considerations modulate chronicity. A sche-
matic representation of this model is presented in Figure 
78-2.
Basic Description
Predisposing factors extend across the entire biopsychosocial 
spectrum. Biological factors are likely to include increased 
basal metabolic rate, hyperreactivity, and or fundamental 
alterations to the neurotransmitter systems associated with 
sleep and wakefulness.* Psychological factors include 
Box 78-1 Potential Implications for Treatment of 
Insomnia
Stimulus Control Model
One unexplored implication for treatment is that 
physically altering the sleep environment may be 
helpful (e.g., paint the room a different color)
Spielman Model
The 3P model suggests that insomnia is perpetuated 
by sleep extension and thus should be managed with 
treatment protocols that restrict time in bed (i.e., 
compress the sleep period).
One implication for treatment is that sleep com-
pression need not occur in a radical fashion, but 
could be accomplished over days or weeks.19
Neurocognitive Model
The neurocognitive model suggests that patients 
with insomnia suffer from an attenuation of the 
normal mesograde amnesia of sleep.
One unexplored implication for treatment is that 
potentiation of the normal mesograde amnesia of 
sleep via the use of more traditional hypnotics (e.g., 
benzodiazapines with effects on long-term memory) 
might serve to augment clinical gains, if not in 
general, then at least in patients with substantial 
sleep state misperception.
Psychobiological Inhibition Model
According to the psychobiological inhibition model, 
chronic insomnia is less a hyperarousal disorder and 
more a disorder characterized by the failure to inhibit 
wakefulness.
One implication for treatment is that persistent 
wakefulness may be the result of hypersecretion of 
orexin, and thus orexin antagonism might have a 
place in the management of insomnia.
Drosophila Model
The Drosophila model suggests that there may be a 
strong genetic component to insomnia that may be 
related to reduced sleep ability.
One implication of the model is that it, like the 3P 
model, suggests that sleep opportunity should be a 
major focus for treatment.
Cano-Saper Model
The Cano-Saper model suggests that insomnia repre-
sents a hybrid state, one that is, from a neurobiologi-
cal perspective, part wake and part sleep.
One implication for treatment, which has not yet 
been tested empirically, is that corticotropin releas-
ing hormone antagonist represent an alternative way 
of alleviating disturbed sleep continuity.
Implications for Current and Future 
Research and Therapeutics
Given the efficacy of stimulus control therapy, as it is 
classically rendered, it would be useful to determine how 
much treatment outcome from cognitive behavior therapy 
(CBT) owes to the manipulation of this factor. One way 
to assess the relative importance of stimulus control would 
be as part of a dismantling study. To date no such study 
has been conducted as a single, large-scale, randomized 
trial.* Alternatively, experimental studies could be used to 
*The possibility of altered neurotransmission in insomnia (e.g., reduced 
GABAnergic tone) was recently explored by Winkelman and colleagues. See 
SLEEP 31(11)2008:1499-1506.
Figure 78-1 The instrumental conditioning perspective on 
stimulus control. Left, Good stimulus control: The bedroom is 
tightly coupled with sleep and sex where, given the orthogonal-
ity and equal probability of events, the probability of associa-
tion of bedroom to sleep is 1 in 2. Right, Stimulus dyscontrol: 
The bedroom is no longer a strong associate of sleep and sex 
where, given the orthogonality and equal probability of events, 
the probability of association of bedroom to sleep is 1 in 8. The 
treatment implication of stimulus dyscontrol is the voluntary 
elimination of the nonsleep associations except for sex, which 
should result in instrumental conditioning.
STIMULUS CONTROL
Good Stimulus Control Stimulus Dyscontrol
Odds 1 in 2
Bedroom
bedtime
Sex
Sleep
Sex
Sleep
Eat in bed
Read in bed
Watch TV in bed
Work in bed
Worry in bed
Clean bedroom
Bedroom
bedtime
Odds 1 in 8
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to be very efficacious. The equivocation regarding efficacy 
represents one of the models weaknesses.
There have been very few studies evaluating sleep 
restriction therapy as a monotherapy,8,9 and no studies 
evaluating the relative efficacy of sleep restriction therapy 
(using dismantling designs) as component of CBT. It is 
therefore difficult to assess the extent to which treatment 
efficacy supports the 3P model itself. Further, even if there 
were large-scale studies showing that sleep-restriction 
therapy produces large effects, the validation of the model 
would still require empirical studies (see later).
The model (while compatible with the two-process 
model of sleep–wake regulation) does not explicitly take 
into account the influences of the circadian system and 
sleep–wake homeostasis. Further, the model does not 
provide a detailed account of how one transitions from 
good sleep to acute insomnia (i.e., how does the precipitat-
ing factor precipitate disturbance of sleep continuity?).
In the original model it is implied that the predisposition 
to insomnia varies across patients but is a trait factor (static 
over time) within the individual patient. Presumably the 
postulated between-subject variability means that some 
patients are not prone to insomnia, some are marginally at 
risk, and still others are at high risk. Although it stands to 
reason that the vulnerability for insomnia exists on a con-
tinuum (i.e., is normally distributed), it is also plausible 
that everyone is at risk for acute insomnia and that this is 
so to the extent that insomnia represents an adaptive 
response to stress (i.e., real or perceived threat prevents 
the inhibition of wakefulness; this idea is addressed by the 
Cano-Saper rodent model and the psychobiological inhibi-
tion model). The postulate of within-subject variability 
(risk being static over time) also may be open to question. 
Some predispositions may be indeed be hardwired 
(addressed by the Drosophila model) but it also stands to 
reason that some predispositions vary over the lifespan 
(e.g., new sleep environments or partners, pregnancy or 
childrearing, altered hormonal status, effects of aging. The 
newer rendition of the 3P model (reviewed in Chapter 
144) reconciles this issue by explicitly allowing predispos-
ing factors to vary with time).16
As with stimulus control, the 3P model focuses on 
instrumental conditioning. It does not explicitly take into 
account the role of classical conditioning in chronic insom-
nia, i.e., the likely possibility that the regular co-occur-
rence of wakefulness with sleep-related stimuli might lead 
to a second-order, and perhaps more virulent, perpetuat-
ing factor: conditioned wakefulness or conditioned arousal.
The 3P model does provide a conceptual framework for 
understanding types or subtypes of insomnia. For example, 
it addresses why some subjects have psychophysiologic 
insomnia as opposed to paradoxical insomnia and why, in 
either case, the insomnia is expressed as one phenotype as 
opposed to another (initial versus middle versus late 
insomnia).
Implications for Current and Future 
Research and Therapeutics
Most of the tenets of the 3P model are untested and await 
empirical demonstrations. Several avenues for research are 
possible. Family studies or medical anthropology studies 
could be used to evaluate the predisposition toward 
Figure 78-2 The classic 1987 rendition of the 3P model. There 
is a more recent representation of the model in Chapter 144. 
The reader is encouraged to compare the two versions of the 
model. The differences (e.g., allowing the predisposing factors 
to be represent as variable with time), while subtle, are theoreti-
cally important.
Premorbid Acute Early Chronic
Threshold
Perpetuating
Precipitating
Predisposing
worry or the tendency to be excessively ruminative. Social 
factors, although rarely a focus at the theoretical level, 
include such things as the bed partner keeping an incom-
patible sleep schedule or social pressures to sleep according 
to a nonpreferred sleep schedule (e.g., child rearing).
Precipitating factors, as the name implies, are acute occur-
rences that trigger disturbance of sleep disturbance. The 
primary triggers are thought to be related to life stress 
events (including medical and psychiatric illness).
Perpetuating factors refer to the actions the insomniac 
person adopts that are intended to compensate for, or cope 
with, sleeplessness. Research and treatment have focused 
on three kinds of perpetuating factors: the practice of non-
sleep activities in the bedroom, the tendency to stay in bed 
while awake, and the tendency to spend excessive amounts 
of time in bed. Stimulus control speaks to the first two of 
these considerations (as reviewed earlier).
The classic version of the 3P model focuses primarily 
on the last of these considerations. Excessive time in bed 
(or sleep extension) refers to the tendency of patients with 
insomnia to go to bed earlier or to get out of bed later or 
to engage in napping. The patient enacts such changes 
(compensatory activities) to increase the opportunity to get 
more sleep; these changes are likely highly self-reinforcing 
(in the short term) because they allow lost sleep to be 
“recovered” and the daytime effects of lost sleep to be 
ameliorated. The tendency toward sleep extension is, in 
the long term, problematic. Sleep extension leads to a 
mismatch between sleep opportunity and sleep ability.1,14 
The greater the mismatch, the more likely the person will 
spend prolonged periods wake during the given sleep 
period, and that this will occur regardless of what predis-
posed the individual to the insomnia and precipitated it.
Strengths and Weaknesses
The greatest strengths of the 3P model is that the therapy 
based on the theory (sleep restriction) is conceptually 
appealing to sleep medicine clinicians and scientists, the 
model is highly face valid for patients (especially when it 
is delivered as part of therapy), and the therapy itself 
(which is also compatible with, and a logical clinical appli-
cation of, the two-process model of normal sleep15) appears 
Kryger_6453_Ch 78_main.indd   852 8/27/2010   5:33:33 PM
L CHAPTER 78 • Models of Insomnia 853
insomnia. Stress-induction studies in good sleepers, like 
those, for example, conducted by Hall and colleagues,17,18 
could be use to produce acute insomnia and to evaluate 
how a variety of biopsychosocial factors mediate the mag-
nitude of the stress response. Longitudinal studies could 
be used to confirm whether the putative perpetuating 
factor of sleep extension does indeed mediate the transi-
tion from acute to chronic insomnia.
As for therapeutics, the 3P model has served as the 
conceptual basis for one treatment modality in particular: 
sleep restriction. This therapy, while believed by many to 
be the single most potent component of CBT, was devel-
oped to target one particular factor (of the three) and only 
as it is expressed in one particular form (i.e., sleep exten-
sion). This may explain the overall value of multicompo-
nent CBT in that the other treatment components, it can 
be argued, address other perpetuating factors (e.g., stimu-
lus control addresses engaging in nonsleep activities in the 
bedroom, cognitive therapy addresses the problem of cata-
strophic or dysfunctional thinking about insomnia, sleep 
hygiene addresses the misuse of counter fatigue measures). 
Thus, the question at hand is: In what ways might the 3P 
model lend itself to identifying alternative treatment 
targets with standard or alternative methods?19 One pos-
sibility is to develop therapies or adapt existing therapies 
to target predisposing factors. Such treatments could be 
used to increase treatment response, decrease the risk for 
reoccurrence (as an adjuvant to traditional CBT), or 
prevent first episodes of insomnia.
In the case of treatment response, depotentiation of 
predisposing factors might serve to augment outcomes to 
the extent that they are more, as opposed to less, opera-
tional. Treatment response may be boosted if the patient 
is hypermetabolic by nature by providing relaxation train-
ing, if the patient is anxious by nature by providing anxio-
lytic treatments (medical or psychotherapeutic), or if the 
patient is (for social reasons) sleeping in a nonpreferred 
sleep phase by providing some form of chronotherapy 
(e.g., progressive shifts in sleep scheduling, bright light 
treatment, or adjuvant treatment with melatonin).
In the case of preventing relapse, one could address the 
factors discussed earlier or could develop interventions to 
prevent perpetuating factors from becoming operational 
during recurrence (new episodes of acute insomnia). In this 
instance the tendency toward sleep extension could be 
considered a predisposing factor. This being the case, a 
brief behavioral intervention could be designed that spe-
cifically targets sleep extension as a means for coping with 
acute insomnia. Alternatively (or in addition), rational 
approaches to fatigue management could be developed, 
such as giving instructions on how to compensate for short-
term sleeplessness in a way that allows normal sleep homeo-
stasis. In the case of prophylaxis, it might well be possible 
to prevent many cases of chronic insomnia by replacing 
sleep hygiene with an empirically validated set of rules.
THE NEUROCOGNITIVE MODEL
Basic Description
The neurocognitive model3 is based on, and is an extension 
of, the 3P behavioral model as described by Spielman and 
colleagues.1 The central tenets of the model include:
• a pluralistic perspective of hyperarousal (cortical, cogni-
tive and somatic arousal);
• the specification that cortical arousal (as opposed to cog-
nitive or somatic arousal) is central to the etiology and 
pathophysiology of insomnia;
• the proposition that cortical arousal, in the context of 
chronic insomnia, occurs as a result of classical condi-
tioning and permits cognitive processes that do not 
occur with normal sleep;
• the proposition that sleep initiation and maintenance 
problems do not occur because of hyperarousal per se 
but because of increased sensory and information pro-
cessing at sleep onset and during non–rapid eye move-
ment (NREM) sleep;
• the suggestion that sleep state misperception derives 
from increased sensory and information processing at 
during NREM sleep or the attenuation of the normal 
mesograde amnesia of sleep.
As with the “3P” behavioral model of insomnia, it 
is posited that acute insomnia occurs in association with 
predisposing and precipitating factors and that chronic 
insomnia occurs in association with perpetuating 
factors.1 The primary perpetuating factor is a form of 
instrumental conditioning that occurs with sleep exten-
sion. The neurocognitive model posits that classical 
conditioning can also serve as perpetuating factor for 
chronic insomnia and stipulates that hyperarousal needs 
to be construed and assessed in terms of its component 
domains: cognitive, somatic, and cortical arousal. With 
these considerations in mind, it is suggested that 
repeated pairing of sleep-related stimuli with insomnia-
related wakefulness (arousal) ultimately causes sleep-
related stimuli to elicit (or maintain) higher than usual 
levels of cortical arousal at around sleep onset or during 
the sleep period. This form of arousal is not thought to 
be paralleled by somatic arousal (which is posited to be 
more characteristic of acute insomnia) and is thought to 
precede, and act as the biological substrate for and pre-
cipitant of, cognitive arousal in the context of chronic 
insomnia.
Conditioned cortical arousal is, in turn, hypothesized 
to contribute to disturbance of sleep continuity or to sleep 
state misperception via enhanced sensory processing, 
enhanced information processing, and long-term memory 
formation. Enhanced sensory processing (detection of 
endogenous or exogenous stimuli and, potentially, the 
emission of startle or orienting responses) around sleep 
onset and during NREM sleep is thought to directly 
interfere with sleep initiation or maintenance. Enhanced 
information processing (detection of, and discrimination 
between, stimuli and the formation of a short term 
memory of the stimulating events) during NREM sleep 
is thought to blur the phenomenologic distinction 
between sleep and wakefulness and thus contributes to 
sleep state misperception. Enhanced long-term memory 
(detection of, and discrimination between, stimuli and 
recollection of the stimulating event hours after its occur-
rence) around sleep onset and during NREM sleep is 
thought to interfere with the subjective experience of 
sleep initiation and duration and thus contributes to the 
discrepancies between subjectively and objectively assessed 
sleep continuity.
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Conditioned cortical arousal is hypothesized to be self-
reinforcing, and for essentially two reasons. First, because 
sleep-related stimuli (X) act as conditioned stimuli for cor-
tical arousal (Y), the pairing is self-reinforcing. That is, if 
X elicits Y, and the occurrence of Y reinforces the associa-
tion of X and Y, then pairing is self-reinforcing. Second, 
because cortical arousal permits processes associated with 
wakefulness, it is likely that the elicited arousal will, on 
each occasion, be amplified because of ongoing sensory 
processing, enhanced information processing, and long-
term memory formation. Taken together, these consider-
ations virtually guarantee that the insomnia will, in the 
absence of its original precipitants, continue unabated and 
will not be subject to extinction, as usually occurs with 
classical conditioning. See Figure 78-3 for a schematic 
representation of the model.
Strengths and Weaknesses
Strengths
In general, the major strengths of the neurocognitive 
model are that it allows a pluralistic perspective on the 
concept of arousal; it does not require that hyperarousal 
be so intense as to directly interfere with sleep initiation 
and maintenance but instead posits that arousal only be 
sufficiently intense as to permit processes that are charac-
teristic of wakefulness and can perpetuate wakefulness 
(stimulus detection, startle, orienting, stimulus identifica-
tion, intention or action, and long-term recall); it delin-
eates a mechanism beyond that of instrumental conditioning 
(i.e., classical conditioning as a perpetuating factor); it 
specifies how chronic insomnia takes on a life of its own 
(i.e., is self-reinforcing), and its hypotheses are falsifiable. 
Two lines of research (indirect and direct) provide support 
for the model.
The indirect evidence derives from observations about 
the effects of sleep on long-term memory in good sleepers 
and perceived wakefulness during sleep recorded on a 
polysomnograph (PSG) in patients with insomnia. With 
respect to the former, there is good evidence that normal 
sleepers cannot recall information from periods immedi-
ately prior to sleep,20-23 during sleep,24-28 or during brief 
arousals from sleep.29,30 Thus, normal sleep is indeed char-
acterized by a dense amnesia for events occurring at around 
sleep onset and during sleep.
With respect to the latter, there is substantial evidence 
that when awakened from PSG-defined sleep, patients 
with insomnia (as opposed to good sleepers) tend to per-
ceive themselves to be awake rather than asleep.31-38 This 
tendency, better known as sleep state misperception, is con-
sistent with the neurocognitive model’s perspective regard-
ing sensory and information processing during sleep. That 
is, if one cue for “knowing” that one is asleep is the lack 
of awareness for events occurring during sleep, and if it is 
the case that patients with insomnia exhibit increased levels 
of sensory and information processing during sleep, then 
it would be expected that the greater level of awareness for 
events occurring during PSG-defined sleep serves to blur 
the phenomenologic distinction between sleep and wake-
fulness so that patients with insomnia would have difficulty 
indentifying PSG sleep as sleep. In this instance, what 
remains open to question is whether sleep state mispercep-
tion can be correlated with objective measures of cortical 
arousal—such as by quantitative electroencephalography 
(qEEG), analyses of cyclic alternating pattern (CAP), or 
brain metabolic functional imaging—or with objective 
measures of increased sensory and information processing 
during sleep (i.e., via evoked-response potentials [ERPs]).
The direct evidence pertains to whether patients with 
insomnia exhibit increased cortical or central nervous 
system (CNS) arousal as measured by qEEG and positron 
emission tomography (PET), increased sensory or infor-
mation processing as measured by ERPs, an attenuation in 
the normal mesograde amnesia of sleep, or association 
between sleep state misperception and objective measures 
of cortical arousal or ERP abnormalities. Patients with 
primary insomnia have been found to exhibit higher levels 
of cortical arousal (in terms of increased NREM high-
frequency EEG) as compared to good sleepers39-43 or 
patients with insomnia comorbid with major depression.43a 
Figure 78-3 The neurocognitive model shown here differs 
from prior versions in several ways: Dotted lines are provided 
to highlight feedback loops; solid lines represent feedforward 
loops. The examples provided for perpetuating factors have 
been changed. The primary factor is designated as sleep exten-
sion (previously denoted as increased time in bed and staying 
awake in bed). The secondary factor is designated as sleep 
stimuli as conditioned stimuli. This is meant to represent when 
sleep stimuli become conditioned stimuli for wakefulness 
(arousal). CSs, •••; PSG, polysomnographic.
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Cortical arousal (as well as increased activity involving 
subcortical areas and circuits) has also been observed in 
patients with insomnia using PET techniques.44,45 Altered 
sensory and information processing have been observed 
with ERPs.46-47 Correlational analyses provide evidence 
that that beta and gamma activity is negatively associated 
with the perception of sleep quality17,48 and is positively 
associated with the degree of subjective-objective discrep-
ancy.43 There is some evidence that patients with sleep 
state misperception disorder (paradoxical insomnia) have 
been found to exhibit more beta and gamma EEG activity 
than good sleepers or patients with primary insomnia.49 
One study shows that patients with insomnia are better 
able to recognize word stimuli played during sleep-onset 
intervals and during early NREM sleep. This latter finding 
provides support for the hypothesis that there is an attenu-
ation in the normal mesograde amnesia that accompanies 
sleep in patients with chronic insomnia.
Weaknesses
The primary limitations of the neurocognitive model are 
its failure to adequately account for the transition from 
good sleep to acute insomnia (like the 3P behavioral model, 
it primarily describes chronic insomnia), the importance 
of circadian and homeostatic influences on sleep, and the 
possibility that cortical arousal constitutes a permissive 
factor for worry, rumination, and monitoring behavior. 
The original model does not clearly address whether con-
ditioned cortical arousal represents hyperarousal or the 
newer concept of the failure to inhibit wakefulness. With 
respect to this last point, the summary endeavors to clarify 
this issue by suggesting that chronic insomnia (versus acute 
insomnia) is perpetuated by a form of conditioned arousal 
that is more akin to alert wakefulness than to hyperarousal 
(physiologic and neurobiological states that occur with 
flight-or-fight–type stress responses). Finally, whereas the 
neurocognitive model does provide a conceptual frame-
work for two types of insomnia (psychophysiologic and 
paradoxical insomnia) and how insomnia becomes self per-
petuating (via classical conditioning), the model does not 
explicitly address how it is relevant for the other insomnia 
types or subtypes.
Implications for Current and Future 
Research and Therapeutics
There is evidence supporting the viability of the neurocog-
nitive model, but many of the model’s central tenets 
require further empirical validation. Apart from the 
research required to support the behavioral base of the 
model, further work is needed showing that cognitive pro-
cesses (sensory and information processing and long-term 
memory) are reliably altered during the sleep period in 
patients with chronic insomnia and that altered cognitive 
processing has clear neurobiological concomitants (e.g., 
altered metabolic activity in specific brain regions) and 
functional consequences (sleep continuity disturbance and 
sleep state misperception).
Novel experimental paradigms need to be developed to 
test the model’s core hypotheses. For example, if classical 
conditioning is an operative factor, experimental para-
digms could also be used to evaluate whether sleep-related 
stimuli may be conditioned to elicit wakefulness. Experi-
ments of this type will most likely need to be conducted 
in animals because they run the risk of experimental effects 
persisting beyond the conduct of the experiment itself. If 
mesograde amnesia is a primary determinant of perceived 
sleep quantity and quality, it should also be possible to 
assess the relative importance of this factor using com-
pounds that promote amnesia (with or without sedative 
properties) in combination with the manipulation of situ-
ation cues. Experiments of this type will need to be con-
ducted in humans given the centrality of self-reported 
sleep continuity.
The neurocognitive model may provide some insight 
into the potential mechanisms of action of existing thera-
peutics and also some guidance regarding potential targets 
for new treatments. In the case of existing therapeutics, 
pharmacotherapy might effective to the extent that the 
various compounds block sensory and information pro-
cessing or promote amnesia within the sleep period. This 
idea, first espoused by Mendelson,50-55 seems probable 
given the effects of benzodiazepines and benzodiazepine 
receptor agonists on arousal thresholds and memory for-
mation. Sleep restriction therapy might also work via these 
mechanisms to the extent that this treatment modality 
serves to deepen sleep (augment the endogenous form of 
sleep-related mesograde amnesia).
Potential avenues for new medical treatments include 
the assessment of compounds that have greater-than- 
normal amnestic potential for their efficacy as hypnotics, 
provided that such effects can be limited to the desired 
sleep period and the use of diurnal stimulant therapy to 
promote wake extension and thereby their potential to 
diminish nocturnal cortical arousal via increased sleep 
pressure. Potential avenues for behavioral treatment 
include inpatient protocols that use more-intensive forms 
of sleep restriction therapy to promote countercondition-
ing, such as what is now being done with intensive sleep 
retraining therapy.56
THE PSYCHOBIOLOGICAL 
INHIBITION MODEL
Basic Description
The psychobiological inhibition model15 states that stress-
ful life events precipitate both physiologic and psychologi-
cal arousal, and the consequences of this are the occurrence 
of selective attending to the life stressor and the occur-
rence of insomnia symptoms. In the case of acute insom-
nia, it is thought that physiologic or psychological arousal 
is sufficient to interfere with the normal homeostatic and 
circadian regulation of sleep (i.e., is sufficient to prevent 
the normal inhibition of wakefulness). The acute insomnia 
might resolve or be perpetuated based on the extent to 
which the stress state resolves and the patient does not 
attend to the acute insomnia. The shift of attention from 
the life stressor, implicitly or explicitly, to the insomnia 
symptoms is posited to be the critical event that transitions 
acute insomnia to a form of sleep disturbance that is self-
perpetuating. A schematic representation of the model is 
presented in Figure 78-4.
This model substantially distinguishes itself from 
earlier perspectives in three fundamental and related 
ways. First, the point of departure for the model is the 
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psychobiological framework for normal sleep that is inher-
ent in the stimulus control perspective4 and formally delin-
eated in the two-process model of sleep–wake regulation.57 
Second, it is proposed (and was the first etiologic model 
to do so) that persistent sleep continuity disturbance occurs 
in relation to a failure to inhibit wakefulness (as opposed 
to conditioned hyperarousal). Third, the model is focused 
on how cognitive factors (as opposed to behavioral or 
physiologic factors) serve to perpetuate insomnia.
Psychobiological Framework for Normal Sleep
Espie4,58 suggests that for normal sleepers, homeostatic and 
circadian processes default to good sleep, not to insomnia, 
and that like other neurobehavioral systems, this is ensured 
by plasticity and automaticity. Plasticity refers to the ability 
of the sleep system to adjust to, and/or accommodate, situ-
ational factors that disrupt normal sleep-wake functioning 
(e.g., circumstances that require that sleep be temporarily 
foreshortened or extended). In transient or acute insomnia, 
the norm would be the recovery of good sleep, reflecting 
the system’s plasticity in function. Automaticity refers to the 
involuntary nature of sleep initiation and sleep mainte-
nance. That is, that sleep is initiated and maintained auto-
matically by the well-established conditioned associations 
between sleep-related stimuli and sleep and by the two-
process system that governs the timing and duration of 
sleep and wake. Thus, under normal circumstances, sleep 
occurs passively (without attention, intention, or effort).
Insomnia as the Failure to Inhibit Wakefulness
The majority of insomnia models conceptualize insomnia 
as a disorder of hyperarousal. That is, the inability to initi-
ate or maintain sleep derives from the occurrence of a level 
of arousal that is simply incompatible with sleep, where 
such arousal occurs acutely in relation to stress and chroni-
cally in relation to behavioral factors58 or classical condi-
tioning. Espie, however, has proposed an important 
alternative point of view, suggesting that insomnia occurs 
in association with a failure to inhibit wakefulness. That is, 
the psychobiological inhibition model suggests that in the 
early stages of chronic insomnia, problems with sleep ini-
tiation or sleep maintenance can occur because of funda-
mental alteration in the functioning of the neurobiological 
mechanisms that normally inhibit wakefulness and permit 
sleep to occur. Such an alteration is likely to be systemic; 
it occurs with real or perceived threat and is part of the 
larger flight-or-fight response. This alteration, which 
should dissipate along with the resolution of the acute 
stressor, may be potentiated by cognitive processes.
Cognitive Factors Trigger the Failure to  
Inhibit Wakefulness
The failure to inhibit wakefulness (in the context of chronic 
insomnia) is hypothesized to result from three related cog-
nitive phenomena collectively referred to as the attention-
intention-effort (A-I-E) pathway.4 Each of the three 
phenomena are thought to act in concert, and in a hierar-
chical fashion, to transition acute stress-induced insomnia 
into a form of insomnia that is self-perpetuating. This is 
thought to occur as follows. First, when the person is 
unable to sleep, his or her attention is drawn to an other-
wise automatic process. The very process of attending, in 
turn, prevents perceptual and behavioral disengagement. 
Second, because a primary function of attention is to 
promote action in response to perceived need or threat, an 
intentional (purposive) process is initiated that acts to 
further inhibit the normal downregulation of arousal. 
Third, when the person is unable to sleep, active effort is 
expended trying to fall asleep, and this effort, like enhanced 
attention and intention, serves only to further prevent the 
inhibition of wakefulness.
In sum, the psychobiological inhibition model provides 
a generic common pathway to chronic insomnia. Insomnia 
occurs in a persistent fashion when there is a sufficient 
level of attention, intention, or effort to outweigh good 
stimulus control or the intrinsic drives of the two-process 
system.
Strengths and Weaknesses
Strengths
There is substantial support, in general, for the concept 
that attention bias or selective attention plays a role in 
mental illness.59 It has been found to be operational for a 
wide range of psychiatric disorders including panic disor-
der, hypochondriasis, eating disorders, obsessional disor-
ders, generalized anxiety disorder, and posttraumatic 
stress disorder.60-64 In fact, the data within these domains 
are sufficiently compelling that it has been argued that 
attention bias may have a causal role in most, if not 
all, anxiety disorders.63 The concept is that the anxious 
person is preoccupied with danger and threat and thus 
Figure 78-4 Proposed evolution of psychophysiologic insom-
nia from adjustment insomnia following the attention-intention-
effort (A-I-E) pathway.
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selectively attends to threat-related stimuli as he or she 
perceives that the danger is imminent but also potentially 
avoidable.
Attention bias has also been implicated in habit and 
dependence disorders. In this case, however, attention is 
not focused on threat-related stimuli per se but instead on 
the object of the addiction.64 For example, in alcoholism, 
patients are thought to selectively attend to alcohol-related 
cues and that this form of attention bias can moderate or 
mediate addiction by producing craving. In the case of 
insomnia, attention bias is likely to operate in a manner 
akin to anxiety and dependence disorders (attention to 
threat or object of craving), and this might account for the 
nosologic requirement that insomnia (psychophysiologic 
insomnia) include “excessive focus on, and heightened 
anxiety about, sleep”.64, p. 7
Apart from the general perspective that attention bias is 
relevant for mental disorders, there is also a significant 
amount of experimental evidence supporting the psycho-
biological inhibition model, and especially with respect to 
sleep-related attention bias and sleep-related effort. To 
date eight studies have been conducted whose findings 
reliably indicate:
• sleep-related mental preoccupation may be associated 
with the transition from acute to persistent insomnia in 
cancer patients65;
• subjects with psychophysiologic insomnia exhibit 
heightened levels of attention bias as compared to good 
sleepers and subjects with delayed sleep phase 
syndrome66,67;
• attention bias to sleep-related stimuli detected in patients 
with psychophysiologic insomnia may be driven by 
threat57,67-69;
• there are positive linear relationships between sleep-
related attentional bias and self-reported sleep quality 
and sleepiness;
• subjects with psychophysiologic insomnia exhibit 
“effortful preoccupation with sleep.”70
Another strength of the psychobiological inhibition 
model is that it allows an objective means of indexing 
cognitive processes in insomnia. In practice, insomnia 
patients complain primarily of mental events interfering 
with sleep, including intrusive thoughts, racing thoughts, 
increased worry, and the inability to disengage attending 
to environmental noise or bodily sensations. Although 
such mental events appear central to the experience of 
insomnia, their assessment has relied primarily on self-
report measures. Thus, a major strength of the psychobio-
logical inhibition model is it concepts may be operationally 
defined and tested with objective measures like the com-
puterized emotional Stroop task, the induced-change 
blindness task, and the dot probe task.
Finally, and perhaps most important, a major strength 
of the psychobiological inhibition model is the extent to 
which one of its central tenets (inhibition of wakefulness) 
is supported by both animal and human data. In the case 
of the former, Cano-Saper’s rodent model7 serves to high-
light that there is indeed a neurobiological substrate for 
the concept of the failure to inhibit wakefulness and it 
appears to be dysregulated in rodents exposed to the cage-
exchange paradigm. In humans, studies using evoked 
response potential methodology46,47 suggest that patients 
with insomnia exhibit a diminished capacity to inhibit 
exterioception.
Limitations
Much of psychobiological inhibition model and the A-I-E 
pathway that remains to be validated (particularly the 
intention and effort components). Moreover, studies con-
ducted in Glasgow now need to be replicated and extended 
by other research groups. An important consideration for 
subsequent studies will be the extent to which the psycho-
biological inhibition model and the A-I-E pathway apply 
across the range of primary insomnia types (e.g., psycho-
physiologic insomnia versus idiopathic and paradoxical 
insomnias) and the insomnia subtypes (initial, middle and 
late insomnias). Finally, and perhaps most difficult, is the 
need to create conceptualizations and measures that allow 
a clear distinction between, and an assessment of, the rela-
tive importance of the two primary concepts now thought 
to undergird the incidence and severity of insomnia: 
arousal or hyperarousal and the failure to inhibit wakeful-
ness (or function typical of wakefulness).
Implications for Current and Future 
Research and Therapeutics
As previously suggested, the psychobiological inhibition 
model offers a generic common pathway to insomnia. 
Consequently, the model can accommodate a common 
pathway explanation for the effectiveness of many existing 
elements of cognitive behavioral therapy for insomnia 
(CBT-I). The model’s potential explanatory power, 
however, is not limited to elements of CBT-I but also 
likely extends to potential mechanisms of action for exist-
ing medical therapeutics.
With respect to CBT-I, any behavioral or cognitive 
intervention that augments the inhibition of wakefulness 
should permit the reinstatement of normal sleep. Sleep 
restriction might exert its therapeutic effects via the rein-
statement of sleep automaticity. That is, sleep restriction 
serves to increase homeostatic pressure for sleep to a point 
where sleep will occur inevitably and without attention, 
intention, or effort. Stimulus control may strengthen adap-
tive and automatic dearousal associations of bed and sleep 
and thereby diminish the conditioning effects that inhibit 
downregulation. Finally, relaxation, distraction, and 
imagery methods might reduce worry about sleep, and 
paradoxical intention methods might entirely refocus the 
A-I-E pathway away from sleep preoccupation.
With respect to the medical management of insomnia, 
the psychobiological inhibition model suggests that the 
mechanisms for existing therapies reside in their capacity 
to promote relaxation, inhibit exterioception, and derail 
sleep-related attention, intention, and effort. Clearly these 
are features of traditional sedatives (e.g., barbiturates, ben-
zodiazepines, and benzodiazepine receptor agonists) but 
also might apply to the off-label use of antipsychotics (e.g., 
quetiapine, olanzapine).
Finally, the model also offers a perspective that might 
allow the development of new approaches. From the CBT 
or psychotherapeutic point of view, the psychobiological 
inhibition model clearly carries with it the suggestion that 
sensory gating training or (alternatively) mindfulness ther-
apies may be successfully used to treat insomnia. From the 
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pharmacologic point of view, the psychobiological inhibi-
tion model clearly carries with it the suggestion that it may 
be productive to antagonize wake-promoting or wake-
consolidating systems and that one such approach would 
be via orexin antagonism.
THE DROSOPHILA MODEL
Basic Description
The conceptual basis for the Drosophila model (as an ana-
logue of human insomnia) is that insomnia occurs, in part, 
in relation to predisposing factors. This fundamental tenet 
of the behavioral model suggests that chronic insomnia 
may have a genetic component and that a portion of the 
variance in the incidence of insomnia71,72 should be related 
to factors that are heritable, for example, the strength and 
plasticity of the sleep system, the trigger threshold for and 
intensity of the flight-or-fight response, or the strength 
and plasticity of sleep homeostasis and circadian processes. 
Consistent with this point of view is that insomnia tends 
to run in families and that persons with a family history of 
insomnia are more anxious and prone to stress-related 
sleep disturbances.73,74 Thus, if insomnia results, in part, 
from predisposing trait characteristics, the identification of 
the underlying mechanisms should be feasible using genetic 
strategies.
Given the complexity and number of traits observed for 
insomnia, it seems unlikely that single gene mutations will 
result in an animal model that adequately captures the 
human condition. An alternative approach is to identify 
natural variants in a population that simultaneously exhibit 
several behavioral characteristics of insomnia. The pheno-
typic variation in these individuals is likely to be the result 
of minor changes in many genes and as a consequence is 
more likely to reflect the diversity of the human disorder.75 
The natural polygenic variation can be amplified over suc-
cessive generations using laboratory selection and can be 
identified using whole-genome arrays.76 This is the 
approach that undergirds the Drosophila model.
Evaluation of a normative dataset of wild-type Canton-S 
(Cs) Drosophila indicated that they display a sufficient range 
of sleep times and activity levels to make them suitable for 
laboratory selection (Figure 78-5A, green bars). Drosophila 
that demonstrated reduced sleep time in combination with 
increased sleep latency, reduced sleep bout duration, and 
elevated levels of waking activity (insomnia-like, referred to 
as ins-l flies) were selected and bred over successive genera-
tions. As seen in Figure 78-5B, total sleep time was pro-
gressively reduced during selection and stabilized after 60 
generations. At generation 65, more than 50% of ins-l flies 
obtained less than 60 minutes of sleep in a day, and the 
distribution of sleep times was shifted dramatically to 
the left (see Fig. 78-5A, pink bars). Not surprisingly, the 
decrease in sleep time (or increase in total wake time) in 
selected Drosophila came primarily at the expense of night-
time sleep (see Fig. 78-5C). As with human insomnia, ins-l 
flies showed increased latency from lights off to the first 
sleep bout of the night (see Fig. 78-5D), suggesting that 
they have difficulty initiating sleep.77 The ins-l flies also 
exhibited difficulties maintaining sleep as evidenced by an 
inability to consolidate sleep into long bouts (average sleep 
bout duration; see Fig. 78-5E).7 The maximum episode of 
consolidated sleep that can be generated by an ins-l fly is 
only 36 ± 9 minutes versus 257 ± 22 minutes in Cs flies. In 
addition to disrupted sleep, the ins-l flies exhibit increased 
locomotor activity during waking (1.86 ± 0.03 crossings) 
compared to Cs flies (1.42 ± 0.05 crossings).
To assess the extent to which the sleep patterns of the 
selectively bred Drosophila represent a reasonable analogue 
of human insomnia (chronic insomnia), the sleep of the 
ins-l Drosophila was evaluated for chronicity (i.e., stability 
of the abnormal sleep pattern over the life span) and wake 
state of the ins-l Drosophila was evaluated for evidence that 
the altered form of sleep was associated with daytime con-
sequences (i.e., fatigue, sleepiness, impaired concentration 
or memory) or health outcomes (increased mortality). 
With respect to chronicity, it was found that the sleep 
profile remained stable in ins-l Drosophila over time. Total 
sleep for three representative ins-l flies and one Cs fly are 
shown in Figure 78-5F. These three ins-l flies obtained a 
total of 358 ± 128 minutes of sleep during their first 20 
days of life (and this appears stable with time) versus 17,567 
± 655 minutes of sleep over the same time period in the 
Cs flies (and this appears to trend downward with aging). 
Thus, the observed stability of the sleep profile of the ins-l 
flies may be viewed as chronic (i.e., the sleep disturbance 
does not spontaneously remit with time).
With respect to daytime consequences, the two types of 
Drosophila were evaluated for sleepiness, learning impair-
ment, and motor or coordination difficulties. Sleepiness was 
assessed using a biomarker for sleepiness (amylase).6 As 
seen in Figure 78-5G, ins-l flies show elevated levels of 
amylase relative to Cs flies, suggesting that they experience 
sleepiness (or increased sleep drive) during their primary 
wake period. Learning was assessed using aversive photo-
taxic suppression (APS).78 In this task, flies learn to avoid 
a light that is paired with an aversive stimulus (quinine or 
humidity). In this paradigm it was shown that APS is sensi-
tive to both sleep loss and sleep fragmentation.79 For 
example, as seen in Figure 78-5H, learning is significantly 
impaired in the shortest sleeping ins-lshort flies compared to 
Cs controls. To determine whether the selection protocol 
generated poor-learning Drosophila as a phenotype inde-
pendent from the observed sleep deficit, learning in long-
sleeping ins-l flies was also evaluated. Longer sleeping 
siblings maintained their ability to learn, indicating that 
the selection procedure did not inadvertently, and inde-
pendent of sleep, contribute to poor learning. Motor and 
coordination difficulties were assessed by quantifying the 
number of spontaneous falls in young age-matched Cs and 
ins-l flies walking for 30 minutes in an obstacle-free envi-
ronment. Cs flies rarely fall under these conditions. In 
contrast, ins-l flies often lose their balance (see Fig 78-5I).
Finally, health consequences were assessed in terms of 
mortality via a measure of lifespan duration. This approach 
derives from the epidemiologic studies in humans that 
suggest that sleep duration and insomnia are associated 
with an increased risk of all-cause mortality and reduced 
lifespan.80 Accordingly, one would predict that if the 
selected lines have insomnia or are getting less sleep than 
they need, they would have a shortened lifespan. As seen 
in Figure 78-5J, this is indeed the case. It should be noted 
that the reduced lifespan observed in the ins-l flies is not a 
result of decreased fitness.
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Figure 78-5 A, Frequency distribution of total sleep time in 60 min bins in wild type Cs flies (n = 1000) and in ins-l flies at genera-
tion 65 (n = 364). B, Total sleep time in males (n = 40) and females (n = 40) for successive generations of ins-l flies. C, Daily total 
sleep time is shown for 37 days in one Cs and three ins-l flies. D, Sleep in min/hr for 24 hr in Cs flies (n = 32) and ins-l flies (n = 
32). The gray rectangle represents lights off. E, Sleep latency is increased in ins-l flies (n = 28) versus Cs flies (n = 33). 
F, Average sleep bout duration is reduced during the dark period in ins-l flies (n = 32) versus Cs flies (n = 32). G, Amylase mRNA 
levels are elevated in ins-l flies (% of Cs expression) at ZT0-1. H, Learning in Cs flies, longer-sleeping ins-l flies (average daily sleep 
time, 347 ± 55 min), and short-sleeping ins-l flies (average daily sleep time, 26 ± 7min) (n = 10 for each group) I, Number of falls 
during 30 minutes in Cs flies (n = 20) and ins-l flies (n = 18). J, Representative survival curve of aging ins-l compared to Cs flies 
(30 flies/group). *P < .05; error bars represent standard error of the mean.
In sum, the selection procedure was effective in produc-
ing animals with reduced total sleep time, increased sleep 
latency, and shortened sleeping bout duration. These sleep 
effects were found to be persistent and were associated 
with a variety of sequelae including diurnal sleepiness, 
impaired learning, motor or coordination difficulties, and 
increased mortality. Taken together, these findings suggest 
that the Drosophila model is a reasonable analogue of 
human insomnia (chronic insomnia).
Strengths and Weaknesses
A major strength of the Drosophila model is its approach: 
a naturally occurring set of sleep parameters (parameters 
that are commonly found in human insomnia) were opera-
tionally defined for use in the fly and amplified over suc-
cessive generations using laboratory selection. Not only is 
the selection procedure an ideal one for a genetic study of 
insomnia, but also the use of multiple parameters ensures 
that the analogue condition more closely resembles the 
human expression of the disorder. Another strength of the 
model is the effort to demonstrate that the aggregate phe-
notype also exhibited daytime deficits with respect to 
sleepiness, learning impairment, coordination difficulties, 
and reduced lifespan.
One weakness of the model is the inability to establish 
(as with any animal model) the subjective complaint of 
insomnia. Another weakness is a level of insomnia severity 
that is not analogous to that seen in humans: Total sleep 
times are a fraction of the total sleep time seen in non–ins-l 
flies. This might suggest to some that the selection process 
produced a new class of sleep mutant as opposed to 
an idiopathic form of insomnia. The demonstration of 
sleepiness the ins-l flies are controversial. The consensus 
view (based on the use of the multiple sleep latentcy 
test [MSLT]) is that patients with chronic insomnia do 
not exhibit pathologic sleepiness. Finally, the method of 
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assessment of sleepiness is also somewhat controversial to 
the extent that amylase is also used as a biomarker for 
stress.81-84
Implications for Current and Future 
Research and Therapeutics
There are a variety of possible directions for future 
research. Given the complexity of insomnia, it is likely that 
independent selections would potentially yield alternative 
outcomes. That is, the genes identified in the ins-l flies 
might only represent one potential pathway to insomnia. 
Thus, a greater understanding of insomnia may be 
advanced with additional selected lines. Further, the use of 
molecular-genetic and genomic strategies such as Affyme-
trix arrays, suppressor screens, and genetic mapping may 
be useful for the identification of the genes that are associ-
ated with the various aggregate phenotypes. Given this 
latter strategy, it is important to acknowledge that gene 
profiling in Drosophila obtained by laboratory selection is 
likely to reveal two classes of genes: those that are causative 
for a given behavior and those that are a consequence of 
the behavioral change.85 Most studies have focused on 
identifying genes that are causative for a given behav-
ior.76,86,87 However, given that extended waking results in 
substantial physiologic impairment,88,89 including death,90,91 
the latter set of genes may also be particularly important 
in the context of insomnia.
THE RODENT MODEL  
OF ACUTE INSOMNIA
Basic Description
A rat model of acute stress–induced insomnia has been 
developed using a species-specific psychological stressor, 
cage exchange. The aim of this model was to identify the 
brain circuitry activated in rats experiencing stress-induced 
insomnia to better understand the neurobiological basis of 
acute insomnia.
In the cage-exchange paradigm, stress is induced by 
manipulating the social context rather than by applying a 
continual physical stressor (e.g., tone, shock).7,44 This is 
accomplished by transferring a male rat from his home 
cage, at the peak of the sleep period, to a soiled cage previ-
ously occupied by another male rat. Because rats are very 
territorial, exposure to the olfactory and visual cues of a 
competitor, even in its absence, induces a stress fight-or-
flight response including activation of the autonomic 
nervous system and the hypothalamic-pituitary-adrenal 
axis and sustained wakefulness. Several hours later, when 
the physiologic indicators of acute stress are attenuated, 
this manipulation induces a late period of disturbed sleep.
The brain circuitry activated during this late period of 
disturbed sleep was assessed by examining the expression 
of Fos, a transcription factor widely used as a marker of 
neuronal activity. Increased activation was observed in the 
cerebral cortex, limbic system, some arousal groups (locus 
coeruleus and tuberomamillary nucleus), and part of the 
autonomic system. Surprisingly, there was also simultane-
ous activation of the sleep-promoting areas: the ventrolat-
eral preoptic area (VLPO) and the median preoptic 
nucleus. This coactivation results in a unique pattern of 
brain activity that differs from those observed during wake 
or normal sleep, because the sleep circuitry appears to be 
like that in a sleeping rat, whereas the arousal system and 
the cortex show a level of activation similar to those of 
wakefulness. The high level of cortical activation (as mea-
sured by Fos) was also associated with high-frequency 
EEG activity (distinctive of wakefulness) during NREM 
sleep. The co-occurrence of high-frequency EEG activity 
and traditional sleep frequencies also appears to represent 
a novel intermediate state that differs from both normal 
EEG sleep and wakefulness.
Subsequent experiments revealed that inactivation of 
discrete limbic or arousal regions, via cell-specific lesions 
or pharmacologic inhibition, allowed the recovery of spe-
cific sleep parameters and changed the pattern of brain 
activity in the cage-exchange paradigm.7 This suggests that 
stress-induced insomnia requires the occurrence of a 
cascade of neuronal events along with the normal propen-
sity for sleep. This cascade likely includes sensory inputs 
(olfactory and visual cues of a competitor) that activate 
limbic areas, which in turn activate part of the arousal 
system that subsequently activates the cerebral cortex. 
This latter event (cortical activation) may be measured as 
high-frequency EEG activity during NREM sleep, and it 
is eliminated after inactivating parts of the arousal system, 
which supports the proposed pattern of brain activation 
represented in Figure 78-6.
The proposition that this particular stress paradigm can 
induce a novel intermediate state needs to be considered 
within the context of normal sleep–wake control,92,93 as the 
Figure 78-6 Putative circuitry involved in stress-induced 
insomnia: The olfactory signals are conveyed to the limbic 
system, which in turn activates the arousal and autonomic 
systems, as well as nonorexin neurons in the lateral hypothala-
mus. The cerebral cortex becomes highly activated by inputs 
from the arousal system and the lateral hypothalamus, which 
generates the high-frequency activity observed during NREM 
sleep. The reciprocal inhibition between the sleep and arousal 
systems would ordinarily prevent co-activation, but the homeo-
static and circadian pressure keep the sleep system activated, 
whereas stress activates the arousal system, resulting in a 
unique pattern of brain activity.
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existence of such a state represents an aberration of what 
is considered normal sleep and wake. As proposed by Saper 
and colleagues,93 in normal animals there is a reciprocal 
inhibitory innervation between the main sleep-promoting 
neuronal group (VLPO), whose neurons are active during 
sleep, and the neuronal groups that compose the arousal 
system—the histaminergic tuberomammillary nucleus, the 
serotoninergic dorsal raphe, and the noradrenergic locus 
coeruleus—whose neurons are active during wakefulness. 
The authors have proposed that this reciprocal inhibition 
provides a control system that is analogous to an electrical 
flip-flop switch. In this case, when one side is strongly 
activated, it inhibits and deactivates the other side, which 
decreases the inhibitory input to itself (disinhibition) and 
reinforces its own activity. In the absence of other factors, 
this configuration renders a bistable circuit (stable in one 
or the other state), with rapid and complete transitions 
between states and no occurrence of intermediate states 
(co-activation). The circuit is switched from one state to 
the other due to the strong inputs generated by the gradual 
buildup of the circadian and homeostatic pressures. As 
summarized by Saper:
When this pressure to change becomes great enough, the 
same feedback properties that allow the flip-flop circuit to 
resist change will suddenly give way and rapidly produce a 
reversal of firing patterns. The flip-flop switch therefore 
changes behavioral state infrequently but rapidly, in 
contrast to the homeostatic and circadian inputs, which 
change continuously and slowly.93, p. 729
In this context, the simultaneous activation of the VLPO 
and the arousal system in the cage-exchange paradigm is 
surprising. A possible explanation is that during stress-
induced insomnia, the VLPO is fully activated because of 
both the homeostatic and circadian drives, but it is unable 
to turn off the arousal system because this is being excited 
intensely by inputs from the cortical and limbic systems. 
At the same time, the arousal system cannot turn off the 
VLPO because it is highly active owing to the stronger 
homeostatic pressure caused by the fact that the stressed 
rats are partially sleep deprived. This results in the simul-
taneous activation of opposing systems that normally are 
not activated in tandem, and the bistable circuit becomes 
inherently unstable: The switch is forced into an interme-
diate position. This scenario is represented in Figure 78-7.
Strengths and Weaknesses
The rat model’s cage exchange paradigm has several 
strengths. One is the conceptualization of insomnia as part 
of, or precipitated by, the flight-or-fight response. It uses 
a psychosocial stressor (perceived territorial threat) to 
induce sleep continuity disturbance, and it successfully 
produces a form of acute insomnia that includes both 
initial and late subtypes. It identifies specific neuronal 
effects within regions implicated in the regulation of sleep 
and wakefulness and produces quantitative EEG findings 
that are consistent with those found in human insomnia. 
Its overall findings are consistent with the conceptualiza-
tion of insomnia as a disorder of hyperarousal, and it neu-
ronal findings suggest that acute insomnia is a hybrid state 
resulting from the co-activation of systems that normally 
function in bistable fashion.
Figure 78-7 During normal sleep, the circadian and homeo-
static drives enhance the activity of the sleep-promoting areas 
and simultaneously inhibit the arousal system, favoring the 
sleep state (the homeostatic effect is mediated in part by ade-
nosine acting on A1 and A2a receptors). Stress activates part of 
the arousal system via cortical and limbic inputs, and this acti-
vation opposes the direction of the circadian and homeostatic 
drives. In stress-induced insomnia, the cortical, limbic, and 
arousal activation persists, but the homeostatic pressure is 
stronger than usual because the rats are partially sleep deprived; 
the circadian drive still favors the sleep state. Because these 
two forces are opposing and strong, the sleep–wake switch is 
forced into an unstable position, allowing the emergence of an 
intermediate state in which both sleep and wake circuitries are 
activated simultaneously, but each state is unable to sufficiently 
inhibit the other to prevent it from firing. His, histamine; LC, 
locus coeruleus; NE, norepinephrine; TMN, tuberomammillary 
nucleusVLPOc, ventrolateral preoptic nucleus core; VLPOex, 
ventrolateral preoptic nucleus extended.
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The characterization of acute insomnia as part of (or as 
a consequence of) the flight-or-fight response is particu-
larly useful. This suggests that insomnia may be, as a tran-
sitory phenomenon, an adaptive response to perceived 
threat94 and is consistent with Richardson’s95 proposal that 
insomnia reflects the overactivity of systems extrinsic to 
the sleep–wake circuitry that can temporally override 
normal sleep–wake control to facilitate a more imperative 
function, the stress response. The suggestion that acute 
insomnia exists as a hybrid state represents an important 
refinement of the concept of hyperarousal and is consistent 
with the transition probability model described by 
Merica and colleagues 96,97 and with Espie’s concept that 
insomnia occurs in association with a failure to inhibit 
wakefulness.4,58
The rat model of acute insomnia does have some limita-
tions. As with the Drosophila model, it is unable to establish 
the subjective complaint of insomnia, and as an analogue 
of acute insomnia, it might not be relevant for assessing 
chronic insomnia, which many would argue is the more 
clinically relevant condition. Although there is no question 
that modeling chronic insomnia (e.g., using a conditioning 
paradigm) would be useful, the acute model might never-
theless serve as a guide for what to expect in chronic 
insomnia. For example, the model clearly identifies brain 
regions of interest and clearly delineates one kind of 
pathology that may be characteristic of both acute and 
chronic insomnia, namely, the co-activation of both sides 
of the flip-flop switch. Another limitation of the model 
may be its reliance on the Fos measure. Not all neuronal 
groups express Fos in association with action potential 
activity. Thus, this might limit the resolution of the neu-
robiological effects of the cage-exchange paradigm to 
regions that express Fos.
Implications for Current and Future 
Research and Therapeutics
Observations from the rat model might help to identify 
putative targets for pharmacologic manipulation that can 
guide the development of new therapies. One essential 
finding is that the sleep-promoting neuronal groups are 
fully active in the rat model, and the problem seems to be 
the anomalous residual activation of the arousal and limbic 
systems at a time they should be completely off. This sug-
gests that shutting down the residual activity of these 
systems might be a better approach to treat stress-induced 
insomnia (and perhaps chronic insomnia) rather than 
potentiation of the sleep system. Further, identifying the 
phenotype of these neurobiological abnormalities may be 
helpful in the search for more-specific pharmacologic 
treatments, which may, in turn, yield fewer unwanted side 
effects.
CONCLUSION
The neurocognitive model, psychobiological inhibition 
model, and the Cano-Saper rodent model share at least 
two central tenets: Stress (threat or perceived threat) is a 
major precipitant of acute insomnia, and chronic insomnia 
involves a hybrid state where there are simultaneously 
higher than normal levels of CNS activation and a 
failure to inhibit processes normally associated with 
wakefulness.
The neurocognitive model and the psychobiological 
inhibition model differ with respect to the role of cognitive 
processes as they occur in chronic insomnia. The psycho-
biological inhibition model allows mental activity and cog-
nitive processes to assume a central role in perpetuating 
insomnia: The person is awake because he or she is wor-
rying or is attending to not sleeping. The neurocognitive 
model takes into account cognitive processes but does not 
ascribe a primary role to such phenomena: One is worrying 
or is attending to not sleeping because he or she is awake. 
Thus, cognitive phenomena serve as the flame for the 
psychobiological inhibition model and wind to the flame 
for the neurocognitive model.
The Cano-Saper model differs from the human models, 
at the conceptual level, because of its mechanistic emphasis 
on the sleep switch (as opposed to functional or environ-
mental factors) and dysregulation of the sleep switch as it 
occurs acutely with homeostatic and circadian dysregula-
tion. This difference is, however, not as profound as one 
might think. The question is what happens over time? Is 
it possible that rodents can develop chronic insomnia, and 
if so does this occur in a fashion that is analogous to, or 
relevant for, the human condition ? In the absence of data, 
it stands to reason that the conditioning factors that appear 
to be operative with human insomnia are also likely to be 
operational in the rodent. If true, an animal model of 
chronic insomnia is possible and may be used to explore 
the effects of conditioned arousal or conditioned wakeful-
ness on brain function, physiology, and anatomy.
In the end, the differences in emphasis among the neu-
rocognitive model, the psychobiological inhibition model, 
and the Cano-Saper model might not be a matter of which 
is correct but rather at what point the various models are 
more or less relevant. The assessment of such a proposi-
tion awaits empirical assessment, such as a large-scale 
natural history study focused on the factors that mediate 
the transitions from good sleep to acute insomnia and from 
acute insomnia to chronic insomnia. It stands to reason 
that stress response, attention bias, conditioning, and 
altered neurobiology all play a role across the trajectory 
from acute to chronic insomnia.
Finally, there is the Drosophila model. At first glance it 
appears that this model highlights an entirely different 
component or phase of the disease process (genetic predis-
position) and as such is potentially more relevant for idio-
pathic insomnia and has little overlap with models that are 
almost entirely focused on the precipitation and perpetu-
ation of insomnia in the context of psychophysiologic or 
paradoxical insomnia. This, however, might not be the 
case.
The Shaw Drosophila model might also be relevant for 
issues pertaining to the precipitation and perpetuation of 
insomnia. This may be true because the selective breeding 
paradigm might have resulted in a fundamental alteration 
of the strength and plasticity of the sleep system, the 
trigger threshold for and intensity of the flight-or-fight 
response, or the robustness of sleep or circadian processes. 
It is also possible that the selective breeding paradigm 
(particularly the short sleep aspect) might have itself 
directly predisposed the animals to insomnia. That is, 
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Shaw and colleagues bred short sleepers without altering 
the environment (duration of the light–dark cycles) in such 
a way as to be compatible with short sleep. Thus, as with 
humans, it is possible that the insomnia was expressed as a 
result of a mismatch between sleep ability and sleep 
opportunity.
In humans with psychophysiologic (and potentially par-
adoxical) insomnia, this mismatch is posited to result from 
sleep extension (activities enacted to recover lost sleep). In 
the Drosophila model the mismatch might occur because 
the animal cannot escape the environmental imperative for 
sleep. As with the above speculation, this concept also 
awaits an empirical evaluation; in this case one where the 
light–dark cycles may be altered to match sleep–wake pro-
pensity or where an opportunity is provided for the fly to 
manipulate its environment so as to allow light and dark 
exposure on demand. Under such conditions, if negative 
consequences are attenuated, this would suggest that the 
Drosophila model is also relevant for the primary 
insomnias.
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 Clinical Pearls
While many consider theory and experimental models 
of clinical entities to be largely academic enterprises, 
this is far from the case for the models summarized 
in the present chapter. Each model clearly suggests 
one or more targets for treatment, which might 
or might not be currently addressed by current 
therapeutics.
REFERENCES
1. Spielman A, Caruso L, Glovinsky P. A behavioral perspective on 
insomnia treatment. Psychiatr Clin North Am 1987;10:541-553.
2. Bootzin RR. Stimulus control treatment for insomnia. Proceedings, 
80th Annual Convention, Amer Psycholog Assoc 1972;395-396.
3. Perlis ML, Giles DE, Mendelson WB, et al. Psychophysiological 
insomnia: the behavioural model and a neurocognitive perspective. 
J Sleep Res 1997;6:179-188.
4. Espie CA, Broomfield NM, MacMahon KMA, et al. The attention-
intention-effort pathway in the development of psychophysiologic 
insomnia: an invited theoretical review. Sleep Med Rev 
2006;10:215-245.
5. Seugnet L, Israel S, Toledo R, Shaw PJ. Evaluating a Drosophila 
model of insomnia. Sleep 2004;27:A859.
6. Seugnet L, Boero J, Gottschalk L, et al. Identification of a biomarker 
for sleep drive in flies and humans. Proc Natl Acad Sci U S A 2006; 
103:19913-19918.
7. Cano G, Mochizuki T, Saper CB. Neural circuitry of stress-induced 
insomnia in rats. J Neurosci 2008;28:10167-10184.
8. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological inter-
ventions for insomnia: a meta-analysis of treatment efficacy. Am J 
Psychiatry 1994;151:1172-1180.
9. Murtagh DR, Greenwood KM. Identifying effective psychological 
treatments for insomnia: a meta-analysis. J Consult Clin Psychol 
1995;63:79-89.
10. Smith MT, Perlis ML, Park A, et al. Behavioral treatment vs 
pharmacotherapy for insomnia—a comparative meta-analyses. Am J 
Psychiatry 2002;59:5-11.
Kryger_6453_Ch 78_main.indd   863 8/27/2010   5:33:35 PM
L864 PART II / Section 10 • Insomnia
38. Rechtschaffen A, Monroe L. Laboratory studies of insomnia. In: 
Kales A, editor. Sleep: physiology and pathology. Philadelphia: JB 
Lippincott; 1969. p. 158-169.
39. Freedman R. EEG power in sleep onset insomnia. Electroencepha-
logr Clin Neurophysiol 1986;63:408-413.
40. Merica H, Gaillard JM. The EEG of the sleep onset period in insom-
nia: a discriminant analysis. Physiol Behav 1992;52:199-204.
41. Merica H, Blois R, Gaillard JM. Spectral characteristics of sleep EEG 
in chronic insomnia. Eur J Neurosci 1998;10:1826-1834.
42. Lamarche CH, Ogilvie RD. Electrophysiological changes during the 
sleep onset period of psychophysiological insomniacs, psychiatric 
insomniacs, and normal sleepers. Sleep 1997;20:724-733.
43. Perlis ML, Smith MT, Orff HJ, et al. Beta/Gamma EEG activity in 
patients with primary and secondary insomnia and good sleeper con-
trols. Sleep 2001;24:110-117.
43a. Fernardez-Mendoza J, Vela-Bueno A, Vgontzas AN, Ramos-Platôn 
MJ, et al. Cognitive-emotional hyperarousal as a premorbid charac-
teristic of individuals vulnerable to insumnia. Psychosom Med 
2010;72(4):397-403.
44. Nofzinger EA, Buysse DJ, Germain A, et al. Functional neuroimag-
ing evidence for hyperarousal in insomnia. Am J Psychiatry 
2004;161:2126-2129.
45. Nofzinger EA, Buysse DJ, Germain A, et al. A comparison of regional 
cerebral metabolism across waking and NREM sleep between 
primary insomnia and major depression. Sleep 2005;28:A232-A233.
46. Bastien CH, St Jean G, Morin CM, et al. Chronic psychophysiologi-
cal insomnia: hyperarousal and/or inhibition deficits? An ERPs inves-
tigation. Sleep 2008;31:887-898.
47. Yang CM, Lo HS. ERP evidence of enhanced excitatory and reduced 
inhibitory processes of auditory stimuli during sleep in patients with 
primary insomnia. Sleep 2007;30:585-592.
48. Nofzinger EA, Price JC, Meltzer CC, et al. Towards a neurobiology 
of dysfunctional arousal in depression: the relationship between beta 
EEG power and regional cerebral glucose metabolism during NREM 
sleep. Psychiatry Res 2000;98:71-91.
49. Krystal AD, Edinger JD, Wohlgemuth WK, Marsh GR. NREM 
sleep EEG frequency spectral correlates of sleep complaints in 
primary insomnia subtypes. Sleep 2002;25:630-640.
50. Mendelson W, Martin J, Stephens H, et al. Effects of flurazapam on 
sleep, arousal threshold, and perception of being asleep. Psychophar-
macology (Berl) 1988;95:258-262.
51. Mendelson W. Do studies of sedative/hypnotics suggest the nature 
of chronic insomnia. In: Monplasir J, Godbout R, editors. Sleep and 
biological rhythms. New York: Oxford University Press; 1990. p. 
209-218.
52. Mendelson W, Maczaj M. Effects of triazolam on the perception of 
sleep and wakefulness in insomniacs. Ann Clin Psychiatry 
1990;2:211-216.
53. Mendelson W. Pharmacologic alteration of the perception of being 
awake. Sleep 1993;16:641-646.
54. Mendelson W. Hypnotics and the perception of being asleep. ASDA 
News 1994;1:33.
55. Mendelson WB. Effects of time of night and sleep stage on percep-
tion of sleep in subjects with sleep state misperception. Psychobiol-
ogy 1998;26:73-78.
56. Harris J, Lack L, Wright H, et al. Intensive sleep retraining 
treatment for chronic primary insomnia: a preliminary investigation. 
J Sleep Res 2007;16:276-284.
57. Marchetti LM, Biello SM, Broomfield NM, et al. Who is pre-occu-
pied with sleep? A comparison of attention bias in people with psy-
chophysiological insomnia, delayed sleep phase syndrome and good 
sleepers using the induced change blindness paradigm. J Sleep Res 
2006;15:212-221.
58. Espie CA. Insomnia: conceptual issues in the development, persis-
tence, and treatment of sleep disorder in adults. Annu Rev Psychol 
2002;53:215-243.
59. Shiffrin RM, Schneider W. Controlled and automatic human infor-
mation-processing 2. Perceptual learning, automatic attending, and 
a general theory. Psychol Rev 1977;84:127-190.
60. Mogg K, Bradley BP. A cognitive-motivational analysis of anxiety. 
Behav Res Ther 1998;36:809-848.
61. Williams JMG, Watts FN, MacLeod CM, Mathews A. Cognitive 
psychology and emotional disorders. 2nd ed. New York: John Wiley; 
1997.
62. Mathews A, MacLeod C. Cognitive approaches to emotion and emo-
tional disorders. Annu Rev Psychol 1994;45:25-50.
63. Dalgleish T, Watts FN. Biases of attention and memory in disorders 
of anxiety and depression. Clin Psychol Rev 1990;10:589-604.
64. Lusher J, Chandler C, Ball D. Alcohol dependence and the alcohol 
Stroop paradigm: evidence and issues. Drug Alcohol Depen 
2004;75:225-231.
65. Taylor LM, Espie CA, White CA. Attentional bias in people with 
acute versus persistent insomnia secondary to cancer. Behav Sleep 
Med 2003;1:200-212.
66. Jones BT, Macphee LM, Broomfield NM, et al. Sleep-related atten-
tional bias in good, moderate, and poor (primary insomnia) sleepers. 
J Abnorm Psychol 2005;114:249-258.
67. MacMahon KMA, Broomfield NM, et al. Attention bias for sleep-
related stimuli in primary insomnia and delayed sleep phase syn-
drome using the dot-prob task. Sleep 2006;29(11):1420-1427.
68. Woods H, Marchetti LM, Biello SM, Espie CA. The clock as a focus 
of selective attention in those with primary insomnia: an experimen-
tal study using a modified Posner paradigm. Behav Res Ther 
2009;47:231-236.
69. Spiegelhalder K, Espie C, Riemann D. Is sleep-related attentional 
bias due to sleepiness or sleeplessness? Cognition & Emotion 
2009;23:541-550.
70. Broomfield NM, Espie CA. Toward a valid, reliable measure of sleep 
effort. J Sleep Res 2005;14(4):401-407.
71. Heath AC, Kendler KS, Eaves LJ, Martin NG. Evidence for genetic 
influences on sleep disturbance and sleep pattern in twins. Sleep 
1990;13:318-335.
72. Watson NF, Goldberg J, Arguelles L, Buchwald D. Genetic and 
environmental influences on insomnia, daytime sleepiness, and 
obesity in twins. Sleep 2006;29:645-649.
73. Drake CL, Scofield H, Roth T. Vulnerability to insomnia: the role 
of familial aggregation. Sleep Med 2008;9:297-302.
74. Beaulieu-Bonneau S, LeBlanc M, Merette C, et al. Family history of 
insomnia in a population-based sample. Sleep 2007;30:1739-1745.
75. Greenspan RJ. The flexible genome. Nat Rev Genet 2001;2:383- 
387.
76. Dierick HA, Greenspan RJ. Molecular analysis of flies selected for 
aggressive behavior. Nat Genet 2006;38:1023-1031.
77. Andretic R, Shaw PJ. Essentials of sleep recordings in Drosophila: 
moving beyond sleep time. Methods Enzymol 2005;393:759-772.
78. Le Bourg E, Buecher C. Learned suppression of photopositive 
tendencies in Drosophila melanogaster. Anim Learn Behav 
2002;30:330-341.
79. Seugnet L, Suzuki Y, Vine L, et al. D1 receptor activation in the 
mushroom bodies rescues sleep-loss-induced learning impairments 
in Drosophila. Curr Biol 2008;18:1110-1117.
80. Tamakoshi A, Ohno Y. Self-reported sleep duration as a predictor 
of all-cause mortality: results from the JACC study, Japan. Sleep 
2004;27:51-54.
81. Granger DA, Kivlighan KT, el Sheikh M, et al. Salivary alpha-
amylase in biobehavioral research: recent developments and applica-
tions. Ann N Y Acad Sci 2007;1098:122-144.
82. Nater UM, La Marca R, Florin L, et al. Stress-induced changes in 
human salivary alpha-amylase activity—associations with adrenergic 
activity. Psychoneuroendocrinology 2006;31:49-58.
83. Dantzer R, Kalin N. Salivary biomarkers of stress: cortisol and alpha-
amylase. Psychoneuroendocrinology 2009;34:1.
84. DeCaro JA. Methodological considerations in the use of salivary 
alpha-amylase as a stress marker in field research. Am J Hum Biol 
2008;20:617-619.
85. Robinson GE, Grozinger CM, Whitfield CW. Sociogenomics: social 
life in molecular terms. Nat Rev Genet 2005;6:257-270.
86. Edwards AC, Rollmann SM, Morgan TJ, Mackay TF. Quantitative 
genomics of aggressive behavior in Drosophila melanogaster. PLoS 
Genet 2006;2:e154.
87. Sorensen JG, Nielsen MM, Loeschcke V. Gene expression profile 
analysis of Drosophila melanogaster selected for resistance to environ-
mental stressors. J Evol Biol 2007;20:1624-1636.
88. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on meta-
bolic and endocrine function. Lancet 1999;354:1435-1439.
89. Van Dongen HP, Maislin G, Mullington JM, Dinges DF. The 
cumulative cost of additional wakefulness: dose-response effects on 
neurobehavioral functions and sleep physiology from chronic sleep 
restriction and total sleep deprivation. Sleep 2003;26:117-126.
90. Rechtschaffen A, Bergmann BM, Everson CA, et al. Sleep depriva-
tion in the rat: X. Integration and discussion of the findings. Sleep 
1989;12:68-87.
Kryger_6453_Ch 78_main.indd   864 8/27/2010   5:33:35 PM
L CHAPTER 78 • Models of Insomnia 865
91. Shaw PJ, Tononi G, Greenspan RJ, Robinson DF. Stress response 
genes protect against lethal effects of sleep deprivation in Drosophila. 
Nature 2002;417:287-291.
92. McGinty D, Szymusiak R. The sleep–wake switch: a neuronal alarm 
clock. Nat Med 2000;6:510-511.
93. Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic 
control of sleep and wakefulness. Trends Neurosci 2001;24: 
726-731.
94. Perlis M, Gehrman P, Pigeon WR, Findley J, et al. Neurobiologic 
mechanisms in chronic insomnia. Sleep Medicine Clinics 2009;4(4): 
549-558.
95. Richardson GS. Human physiological models of insomnia. Sleep 
Medicine 2007;8:S9-S14.
96. Merica H, Fortune RD. A neuronal transition probability model for 
the evolution of power in the sigma and delta frequency bands of 
sleep EEG. Physiol Behav 1997;62:585-589.
97. Perlis ML, Merica H, Smith MT, Giles DE. Beta EEG activity and 
insomnia. Sleep Med Rev 2001;5:365-376.
Kryger_6453_Ch 78_main.indd   865 8/27/2010   5:33:35 PM
AUTHOR QUeRy FORM
Dear Author
During the preparation of your manuscript for publication, the questions listed below have arisen. Please attend to these 
matters and return this form with your proof.
Many thanks for your assistance.
Query  Query Remarks
References
1 Au: please define CS.
Kryger_6453_Ch 78_main.indd   1 8/27/2010   5:33:35 PM
 Espie, C.A. (2011) Introduction to Coping with Insomnia & Sleep Problems.  
Constable & Robinson Ltd., London [32 pages] [ISBN978-1-84901-620-9] 
 
 
 
 
  
 
 
Morin, C.M. & Espie, C.A. (2012) The Oxford Handbook of Sleep and Sleep Disorders 
(Oxford Library of Psychology) Oxford University Press, USA [ISBN-10: 019537620X] 
 
 
 
 www.sleepio.com 
 
 
 
 
